<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="0" size="11" family="Times" color="#ffffff"/>
	<fontspec id="1" size="26" family="Times" color="#0e2a52"/>
	<fontspec id="2" size="9" family="Times" color="#000000"/>
	<fontspec id="3" size="9" family="Times" color="#4c4c4c"/>
	<fontspec id="4" size="6" family="Times" color="#000000"/>
	<fontspec id="5" size="9" family="Times" color="#327eb1"/>
	<fontspec id="6" size="8" family="Times" color="#000000"/>
	<fontspec id="7" size="8" family="Times" color="#327eb1"/>
	<fontspec id="8" size="6" family="Times" color="#327eb1"/>
	<fontspec id="9" size="5" family="Times" color="#000000"/>
<text top="142" left="166" width="246" height="17" font="0">CLINICAL PRACTICE GUIDELINE</text>
<text top="185" left="165" width="503" height="25" font="1">2017 ACC/AHA/AAPA/ABC/ACPM/</text>
<text top="221" left="165" width="501" height="25" font="1">AGS/APhA/ASH/ASPC/NMA/PCNA</text>
<text top="257" left="165" width="399" height="25" font="1">Guideline for the Prevention,</text>
<text top="293" left="165" width="533" height="25" font="1">Detection, Evaluation, and Management</text>
<text top="329" left="165" width="444" height="25" font="1">of High Blood Pressure in Adults</text>
<text top="378" left="167" width="503" height="12" font="2">A Report of the American College of Cardiology/American Heart Association Task Force on</text>
<text top="396" left="167" width="150" height="12" font="2">Clinical Practice Guidelines</text>
<text top="471" left="63" width="40" height="12" font="3">Writing</text>
<text top="489" left="63" width="60" height="12" font="3">Committee</text>
<text top="507" left="63" width="51" height="12" font="3">Members</text>
<text top="471" left="167" width="167" height="12" font="2">Paul K. Whelton, MB, MD, MS</text>
<text top="474" left="334" width="5" height="8" font="4">C</text>
<text top="471" left="339" width="77" height="12" font="2">, FAHA, Chair</text>
<text top="489" left="167" width="219" height="12" font="2">Robert M. Carey, MD, FAHA, Vice Chair</text>
<text top="525" left="167" width="205" height="12" font="2">Wilbert S. Aronow, MD, FACC, <a href="">FAHA</a></text>
<text top="525" left="372" width="5" height="12" font="5"><a href="">*</a></text>
<text top="543" left="167" width="102" height="12" font="2">Donald E. Casey, J</text>
<text top="545" left="269" width="6" height="8" font="4">R</text>
<text top="543" left="275" width="134" height="12" font="2">, MD, MPH, MBA, FAHA</text>
<text top="541" left="409" width="5" height="15" font="5"><a href="">y</a></text>
<text top="561" left="167" width="120" height="12" font="2">Karen J. Collins, MBA</text>
<text top="559" left="287" width="5" height="15" font="5"><a href="">z</a></text>
<text top="579" left="167" width="231" height="12" font="2">Cheryl Dennison Himmelfarb, RN, ANP, P</text>
<text top="581" left="398" width="6" height="8" font="4">H</text>
<text top="579" left="404" width="48" height="12" font="2">D, <a href="">FAHA</a></text>
<text top="577" left="452" width="5" height="15" font="5"><a href="">x</a></text>
<text top="596" left="167" width="244" height="12" font="2">Sondra M. DePalma, MHS, PA-C, CLS, <a href="">AACC</a></text>
<text top="595" left="410" width="6" height="15" font="5"><a href="">k</a></text>
<text top="614" left="167" width="154" height="12" font="2">Samuel Gidding, MD, FAHA</text>
<text top="613" left="321" width="7" height="15" font="5"><a href="">{</a></text>
<text top="632" left="167" width="145" height="12" font="2">Kenneth A. Jamerson, MD</text>
<text top="632" left="312" width="7" height="12" font="5"><a href="">#</a></text>
<text top="650" left="167" width="155" height="12" font="2">Daniel W. Jones, MD, FAHA</text>
<text top="648" left="322" width="5" height="15" font="5"><a href="">y</a></text>
<text top="668" left="167" width="123" height="12" font="2">Eric J. MacLaughlin, P</text>
<text top="671" left="290" width="25" height="8" font="4">HARM</text>
<text top="668" left="315" width="8" height="12" font="2">D</text>
<text top="668" left="323" width="11" height="12" font="5"><a href="">**</a></text>
<text top="686" left="167" width="90" height="12" font="2">Paul Muntner, P</text>
<text top="689" left="257" width="6" height="8" font="4">H</text>
<text top="686" left="263" width="48" height="12" font="2">D, <a href="">FAHA</a></text>
<text top="684" left="311" width="5" height="15" font="5"><a href="">y</a></text>
<text top="704" left="167" width="140" height="12" font="2">Bruce Ovbiagele, MD, MS</text>
<text top="707" left="307" width="5" height="8" font="4">C</text>
<text top="704" left="312" width="106" height="12" font="2">, MAS, MBA, <a href="">FAHA</a></text>
<text top="702" left="418" width="5" height="15" font="5"><a href="">y</a></text>
<text top="722" left="167" width="101" height="12" font="2">Sidney C. Smith, J</text>
<text top="725" left="268" width="6" height="8" font="4">R</text>
<text top="722" left="273" width="108" height="12" font="2">, MD, MACC, FAHA</text>
<text top="720" left="381" width="10" height="15" font="5"><a href="">yy</a></text>
<text top="740" left="167" width="121" height="12" font="2">Crystal C. Spencer, <a href="">JD</a></text>
<text top="738" left="288" width="5" height="15" font="5"><a href="">z</a></text>
<text top="471" left="494" width="144" height="12" font="2">Randall S. Stafford, MD, P</text>
<text top="474" left="638" width="6" height="8" font="4">H</text>
<text top="471" left="644" width="8" height="12" font="2">D</text>
<text top="469" left="653" width="10" height="15" font="5"><a href="">zz</a></text>
<text top="489" left="494" width="148" height="12" font="2">Sandra J. Taler, MD, <a href="">FAHA</a></text>
<text top="487" left="642" width="10" height="15" font="5"><a href="">xx</a></text>
<text top="507" left="494" width="227" height="12" font="2">Randal J. Thomas, MD, MS, FACC, FAHA</text>
<text top="505" left="721" width="12" height="15" font="5"><a href="">kk</a></text>
<text top="525" left="494" width="103" height="12" font="2">Kim A. Williams, S</text>
<text top="528" left="597" width="6" height="8" font="4">R</text>
<text top="525" left="603" width="108" height="12" font="2">, MD, MACC, FAHA</text>
<text top="523" left="711" width="5" height="15" font="5"><a href="">y</a></text>
<text top="543" left="494" width="161" height="12" font="2">Jeff D. Williamson, MD, <a href="">MHS</a></text>
<text top="541" left="655" width="14" height="15" font="5"><a href="">{{</a></text>
<text top="561" left="494" width="112" height="12" font="2">Jackson T. Wright, J</text>
<text top="563" left="606" width="6" height="8" font="4">R</text>
<text top="561" left="611" width="41" height="12" font="2">, MD, P</text>
<text top="563" left="652" width="6" height="8" font="4">H</text>
<text top="561" left="658" width="48" height="12" font="2">D, FAHA</text>
<text top="561" left="707" width="13" height="12" font="5"><a href="">##</a></text>
<text top="611" left="494" width="260" height="9" font="4">*American Society for Preventive Cardiology Representative.</text>
<text top="610" left="757" width="45" height="12" font="4"><a href="">yACC/AHA</a></text>
<text top="626" left="494" width="67" height="9" font="4">Representative.</text>
<text top="624" left="563" width="220" height="12" font="4"><a href="">z</a>Lay Volunteer/Patient Representative. <a href="">x</a>Preventive</text>
<text top="640" left="494" width="214" height="9" font="4">Cardiovascular Nurses Association Representative.</text>
<text top="638" left="710" width="97" height="12" font="4"><a href="">k</a>American Academy of</text>
<text top="654" left="494" width="155" height="9" font="4">Physician Assistants Representative.</text>
<text top="653" left="652" width="155" height="12" font="4"><a href="">{</a>Task Force Liaison. #Association of</text>
<text top="668" left="494" width="307" height="9" font="4">Black Cardiologists Representative. **American Pharmacists Association</text>
<text top="682" left="494" width="67" height="9" font="4">Representative.</text>
<text top="681" left="563" width="199" height="12" font="4"><a href="">yy</a>ACC/AHA Prevention Subcommittee Liaison.</text>
<text top="695" left="494" width="305" height="12" font="4"><a href="">zzAmerican </a>College of Preventive Medicine Representative. <a href="">xxAmerican</a></text>
<text top="711" left="494" width="172" height="9" font="4">Society of Hypertension Representative.</text>
<text top="709" left="669" width="126" height="12" font="4"><a href="">kkTask </a>Force on Performance</text>
<text top="725" left="494" width="76" height="9" font="4">Measures Liaison.</text>
<text top="724" left="573" width="198" height="12" font="4"><a href="">{{</a>American Geriatrics Society Representative.</text>
<text top="739" left="494" width="203" height="9" font="4">##National Medical Association Representative.</text>
<text top="1120" left="63" width="108" height="9" font="6">ISSN 0735-1097/$36.00</text>
<text top="1120" left="626" width="180" height="9" font="7"><a href="https://doi.org/10.1016/j.jacc.2017.11.006">https://doi.org/10.1016/j.jacc.2017.11.006</a></text>
<text top="911" left="176" width="631" height="9" font="4">This document was approved by the American College of Cardiology Clinical Policy Approval Committee and the American Heart Association Science</text>
<text top="925" left="167" width="586" height="9" font="4">Advisory and Coordinating Committee in September 2017, and by the American Heart Association Executive Committee in October 2017.</text>
<text top="939" left="176" width="631" height="9" font="4">The American College of Cardiology requests that this document be cited as follows: Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ,</text>
<text top="953" left="167" width="640" height="9" font="4">Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford</text>
<text top="967" left="167" width="640" height="9" font="4">RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for</text>
<text top="982" left="167" width="640" height="9" font="4">the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart</text>
<text top="996" left="167" width="365" height="9" font="4">Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018;71:e127</text>
<text top="994" left="532" width="22" height="12" font="4">–248.</text>
<text top="1010" left="176" width="386" height="9" font="4">This article has been copublished in Hypertension, an American Heart Association journal.</text>
<text top="1024" left="176" width="450" height="9" font="4">Copies: This document is available on the World Wide Web sites of the American College of Cardiology (</text>
<text top="1024" left="626" width="55" height="9" font="8"><a href="http://www.acc.org">www.acc.org</a></text>
<text top="1024" left="681" width="126" height="9" font="4">) and the American Heart As-</text>
<text top="1038" left="167" width="45" height="9" font="4">sociation <a href="http://professional.heart.org">(</a></text>
<text top="1038" left="211" width="93" height="9" font="8"><a href="http://professional.heart.org">professional.heart.org</a></text>
<text top="1038" left="304" width="503" height="9" font="4">). For copies of this document, please contact the Elsevier Inc. Reprint Department via fax (212-633-3820) or e-mail</text>
<text top="1053" left="167" width="3" height="9" font="4">(</text>
<text top="1053" left="170" width="95" height="9" font="8"><a href="mailto:reprints@elsevier.com">reprints@elsevier.com</a></text>
<text top="1053" left="265" width="6" height="9" font="4">).</text>
<text top="1067" left="176" width="152" height="9" font="4">Permissions: Multiple copies, modi</text>
<text top="1065" left="327" width="480" height="12" font="4">ﬁcation, alteration, enhancement, and/or distribution of this document are not permitted without the express</text>
<text top="1081" left="167" width="499" height="9" font="4">permission of the American College of Cardiology. Requests may be completed online via the Elsevier site (</text>
<text top="1081" left="666" width="141" height="9" font="8"><a href="https://www.elsevier.com/about/ourbusiness/policies/copyright/permissions">https://www.elsevier.com/about/</a></text>
<text top="1095" left="167" width="185" height="9" font="8"><a href="https://www.elsevier.com/about/ourbusiness/policies/copyright/permissions">ourbusiness/policies/copyright/permissions</a></text>
<text top="1095" left="351" width="6" height="9" font="4">).</text>
<text top="54" left="167" width="256" height="7" font="9">J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y</text>
<text top="54" left="710" width="97" height="7" font="9">V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="66" left="167" width="331" height="10" font="9">ª 2 0 1 8 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N A N D</text>
<text top="81" left="167" width="195" height="7" font="9">T H E A M E R I C A N H E A R T A S S O C I A T I O N , I N C .</text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="10" size="11" family="Times" color="#e3202b"/>
	<fontspec id="11" size="8" family="Times" color="#e3202b"/>
	<fontspec id="12" size="9" family="Times" color="#0e2a52"/>
	<fontspec id="13" size="7" family="Times" color="#000000"/>
<text top="143" left="108" width="80" height="12" font="3">ACC/AHA Task</text>
<text top="161" left="108" width="84" height="12" font="3">Force Members</text>
<text top="143" left="211" width="231" height="12" font="2">Glenn N. Levine, MD, FACC, FAHA, Chair</text>
<text top="161" left="211" width="65" height="12" font="2">Patrick T. O</text>
<text top="159" left="277" width="204" height="15" font="2">’Gara, MD, MACC, FAHA, Chair-Elect</text>
<text top="179" left="211" width="285" height="12" font="2">Jonathan L. Halperin, MD, FACC, FAHA, Immediate</text>
<text top="197" left="211" width="56" height="12" font="2">Past Chair</text>
<text top="233" left="211" width="238" height="12" font="2">Sana M. Al-Khatib, MD, MHS, FACC, FAHA</text>
<text top="250" left="211" width="198" height="12" font="2">Joshua A. Beckman, MD, MS, FAHA</text>
<text top="268" left="211" width="125" height="12" font="2">Kim K. Birtcher, MS, P</text>
<text top="271" left="336" width="25" height="8" font="4">HARM</text>
<text top="268" left="361" width="47" height="12" font="2">D, AACC</text>
<text top="286" left="211" width="129" height="12" font="2">Biykem Bozkurt, MD, P</text>
<text top="289" left="341" width="6" height="8" font="4">H</text>
<text top="286" left="347" width="86" height="12" font="2">D, FACC, <a href="">FAHA</a></text>
<text top="286" left="433" width="16" height="12" font="5"><a href="">***</a></text>
<text top="304" left="211" width="192" height="12" font="2">Ralph G. Brindis, MD, MPH, MACC</text>
<text top="304" left="404" width="16" height="12" font="5"><a href="">***</a></text>
<text top="322" left="211" width="172" height="12" font="2">Joaquin E. Cigarroa, MD, FACC</text>
<text top="340" left="211" width="102" height="12" font="2">Lesley H. Curtis, P</text>
<text top="343" left="314" width="6" height="8" font="4">H</text>
<text top="340" left="320" width="48" height="12" font="2">D, <a href="">FAHA</a></text>
<text top="340" left="368" width="16" height="12" font="5"><a href="">***</a></text>
<text top="358" left="211" width="211" height="12" font="2">Anita Deswal, MD, MPH, FACC, FAHA</text>
<text top="376" left="211" width="187" height="12" font="2">Lee A. Fleisher, MD, FACC, FAHA</text>
<text top="143" left="513" width="155" height="12" font="2">Federico Gentile, MD, FACC</text>
<text top="161" left="513" width="154" height="12" font="2">Samuel Gidding, MD, <a href="">FAHA</a></text>
<text top="161" left="667" width="16" height="12" font="5"><a href="">***</a></text>
<text top="178" left="513" width="252" height="12" font="2">Zachary D. Goldberger, MD, MS, FACC, FAHA</text>
<text top="196" left="513" width="188" height="12" font="2">Mark A. Hlatky, MD, FACC, FAHA</text>
<text top="214" left="513" width="133" height="12" font="2">John Ikonomidis, MD, P</text>
<text top="217" left="646" width="6" height="8" font="4">H</text>
<text top="214" left="653" width="48" height="12" font="2">D, FAHA</text>
<text top="232" left="513" width="179" height="12" font="2">José A. Joglar, MD, FACC, FAHA</text>
<text top="250" left="513" width="118" height="12" font="2">Laura Mauri, MD, MS</text>
<text top="253" left="632" width="5" height="8" font="4">C</text>
<text top="250" left="637" width="40" height="12" font="2">, FAHA</text>
<text top="268" left="513" width="106" height="12" font="2">Susan J. Pressler, P</text>
<text top="271" left="620" width="6" height="8" font="4">H</text>
<text top="268" left="626" width="72" height="12" font="2">D, RN, <a href="">FAHA</a></text>
<text top="268" left="698" width="16" height="12" font="5"><a href="">***</a></text>
<text top="286" left="513" width="94" height="12" font="2">Barbara Riegel, P</text>
<text top="289" left="608" width="6" height="8" font="4">H</text>
<text top="286" left="614" width="72" height="12" font="2">D, RN, FAHA</text>
<text top="304" left="513" width="187" height="12" font="2">Duminda N. Wijeysundera, MD, P</text>
<text top="307" left="701" width="6" height="8" font="4">H</text>
<text top="304" left="707" width="8" height="12" font="2">D</text>
<text top="355" left="513" width="237" height="9" font="4">***Former Task Force member; current member during</text>
<text top="369" left="513" width="76" height="9" font="4">the writing effort.</text>
<text top="445" left="108" width="160" height="17" font="10">TABLE OF CONTENTS</text>
<text top="487" left="108" width="65" height="14" font="11">PREAMBLE</text>
<text top="487" left="176" width="235" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="488" left="417" width="24" height="11" font="2">e130</text>
<text top="525" left="117" width="106" height="14" font="11">1. INTRODUCTION</text>
<text top="525" left="229" width="182" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="526" left="418" width="23" height="11" font="2">e133</text>
<text top="550" left="130" width="218" height="12" font="12">1.1. Methodology and Evidence Review</text>
<text top="549" left="356" width="56" height="14" font="6">. . . . . . . . .</text>
<text top="550" left="418" width="23" height="11" font="2">e133</text>
<text top="575" left="129" width="240" height="12" font="12">1.2. Organization of the Writing Committee</text>
<text top="574" left="376" width="36" height="14" font="6">. . . . . .</text>
<text top="575" left="418" width="23" height="11" font="2">e133</text>
<text top="600" left="129" width="203" height="12" font="12">1.3. Document Review and Approval</text>
<text top="599" left="336" width="76" height="14" font="6">. . . . . . . . . . . .</text>
<text top="600" left="417" width="24" height="11" font="2">e134</text>
<text top="625" left="128" width="150" height="12" font="12">1.4. Scope of the Guideline</text>
<text top="624" left="283" width="129" height="14" font="6">. . . . . . . . . . . . . . . . . . . .</text>
<text top="625" left="417" width="24" height="11" font="2">e134</text>
<text top="650" left="129" width="183" height="12" font="12">1.5. Abbreviations and Acronyms</text>
<text top="649" left="316" width="95" height="14" font="6">. . . . . . . . . . . . . . .</text>
<text top="650" left="417" width="24" height="11" font="2">e134</text>
<text top="688" left="115" width="120" height="14" font="11">2. BP AND CVD RISK</text>
<text top="688" left="243" width="169" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="689" left="417" width="24" height="11" font="2">e134</text>
<text top="713" left="130" width="172" height="12" font="12">2.1. Observational Relationship</text>
<text top="713" left="309" width="102" height="14" font="6">. . . . . . . . . . . . . . . .</text>
<text top="714" left="417" width="24" height="11" font="2">e134</text>
<text top="738" left="129" width="112" height="12" font="12">2.2. BP Components</text>
<text top="737" left="250" width="162" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="739" left="418" width="23" height="11" font="2">e136</text>
<text top="763" left="129" width="111" height="12" font="12">2.3. Population Risk</text>
<text top="762" left="243" width="169" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="764" left="418" width="23" height="11" font="2">e136</text>
<text top="788" left="128" width="209" height="12" font="12">2.4. Coexistence of Hypertension and</text>
<text top="803" left="153" width="152" height="12" font="12">Related Chronic Conditions</text>
<text top="802" left="309" width="102" height="14" font="6">. . . . . . . . . . . . . . . .</text>
<text top="803" left="418" width="23" height="11" font="2">e136</text>
<text top="841" left="115" width="156" height="14" font="11">3. CLASSIFICATION OF BP</text>
<text top="841" left="276" width="135" height="14" font="6">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="842" left="419" width="22" height="11" font="2">e137</text>
<text top="867" left="130" width="38" height="12" font="12">3.1. De</text>
<text top="865" left="168" width="104" height="15" font="12">ﬁnition of High BP</text>
<text top="866" left="276" width="135" height="14" font="6">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="867" left="419" width="22" height="11" font="2">e137</text>
<text top="891" left="129" width="190" height="12" font="12">3.2. Lifetime Risk of Hypertension</text>
<text top="891" left="323" width="89" height="14" font="6">. . . . . . . . . . . . . .</text>
<text top="892" left="417" width="23" height="11" font="2">e138</text>
<text top="916" left="129" width="147" height="12" font="12">3.3. Prevalence of High BP</text>
<text top="916" left="283" width="129" height="14" font="6">. . . . . . . . . . . . . . . . . . . .</text>
<text top="917" left="417" width="23" height="11" font="2">e138</text>
<text top="941" left="128" width="222" height="12" font="12">3.4. Awareness, Treatment, and Control</text>
<text top="941" left="356" width="56" height="14" font="6">. . . . . . . . .</text>
<text top="942" left="418" width="23" height="11" font="2">e139</text>
<text top="980" left="114" width="146" height="14" font="11">4. MEASUREMENT OF BP</text>
<text top="980" left="269" width="142" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="981" left="416" width="25" height="11" font="2">e140</text>
<text top="1005" left="130" width="238" height="12" font="12">4.1. Accurate Measurement of BP in the Of</text>
<text top="1003" left="368" width="19" height="15" font="12">ﬁce</text>
<text top="1004" left="396" width="16" height="14" font="6">. . .</text>
<text top="1005" left="416" width="25" height="11" font="2">e140</text>
<text top="1030" left="129" width="78" height="12" font="12">4.2. Out-of-Of</text>
<text top="1028" left="207" width="167" height="15" font="12">ﬁce and Self-Monitoring of BP</text>
<text top="1029" left="382" width="29" height="14" font="6">. . . . .</text>
<text top="1030" left="418" width="23" height="11" font="2">e141</text>
<text top="484" left="489" width="174" height="12" font="12">4.3. Ambulatory BP Monitoring</text>
<text top="484" left="670" width="102" height="14" font="6">. . . . . . . . . . . . . . . .</text>
<text top="485" left="778" width="24" height="11" font="2">e142</text>
<text top="509" left="488" width="237" height="12" font="12">4.4. Masked and White Coat Hypertension</text>
<text top="509" left="729" width="42" height="14" font="6">. . . . . . .</text>
<text top="510" left="778" width="24" height="11" font="2">e143</text>
<text top="545" left="475" width="181" height="14" font="11">5. CAUSES OF HYPERTENSION</text>
<text top="545" left="663" width="109" height="14" font="6">. . . . . . . . . . . . . . . . .</text>
<text top="546" left="777" width="24" height="11" font="2">e146</text>
<text top="570" left="490" width="147" height="12" font="12">5.1. Genetic Predisposition</text>
<text top="569" left="643" width="129" height="14" font="6">. . . . . . . . . . . . . . . . . . . .</text>
<text top="570" left="777" width="24" height="11" font="2">e146</text>
<text top="595" left="489" width="177" height="12" font="12">5.2. Environmental Risk Factors</text>
<text top="594" left="670" width="102" height="14" font="6">. . . . . . . . . . . . . . . .</text>
<text top="595" left="777" width="24" height="11" font="2">e146</text>
<text top="615" left="516" width="165" height="12" font="2">5.2.1. Overweight and Obesity</text>
<text top="615" left="688" width="82" height="14" font="6">. . . . . . . . . . . . .</text>
<text top="616" left="777" width="24" height="11" font="2">e146</text>
<text top="636" left="515" width="113" height="12" font="2">5.2.2. Sodium Intake</text>
<text top="635" left="635" width="135" height="14" font="6">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="636" left="778" width="23" height="11" font="2">e147</text>
<text top="656" left="515" width="89" height="12" font="2">5.2.3. Potassium</text>
<text top="655" left="609" width="162" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="656" left="778" width="23" height="11" font="2">e147</text>
<text top="676" left="514" width="122" height="12" font="2">5.2.4. Physical Fitness</text>
<text top="675" left="642" width="129" height="14" font="6">. . . . . . . . . . . . . . . . . . . .</text>
<text top="677" left="778" width="23" height="11" font="2">e147</text>
<text top="697" left="515" width="74" height="12" font="2">5.2.5. Alcohol</text>
<text top="696" left="595" width="175" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="697" left="778" width="23" height="11" font="2">e147</text>
<text top="723" left="489" width="247" height="12" font="12">5.3. Childhood Risk Factors and BP Tracking</text>
<text top="722" left="743" width="29" height="14" font="6">. . . . .</text>
<text top="723" left="778" width="23" height="11" font="2">e147</text>
<text top="748" left="488" width="214" height="12" font="12">5.4. Secondary Forms of Hypertension</text>
<text top="747" left="709" width="62" height="14" font="6">. . . . . . . . . .</text>
<text top="748" left="777" width="25" height="11" font="2">e148</text>
<text top="768" left="516" width="219" height="12" font="2">5.4.1. Drugs and Other Substances With</text>
<text top="783" left="548" width="167" height="12" font="2">Potential to Impair BP Control</text>
<text top="782" left="722" width="56" height="14" font="6">. . . . . . . . .</text>
<text top="783" left="780" width="21" height="11" font="2">e151</text>
<text top="804" left="515" width="161" height="12" font="2">5.4.2. Primary Aldosteronism</text>
<text top="803" left="682" width="89" height="14" font="6">. . . . . . . . . . . . . .</text>
<text top="804" left="779" width="23" height="11" font="2">e152</text>
<text top="824" left="515" width="152" height="12" font="2">5.4.3. Renal Artery Stenosis</text>
<text top="823" left="675" width="95" height="14" font="6">. . . . . . . . . . . . . . .</text>
<text top="824" left="779" width="23" height="11" font="2">e153</text>
<text top="844" left="514" width="170" height="12" font="2">5.4.4. Obstructive Sleep Apnea</text>
<text top="843" left="688" width="82" height="14" font="6">. . . . . . . . . . . . .</text>
<text top="844" left="778" width="24" height="11" font="2">e154</text>
<text top="879" left="475" width="270" height="14" font="11">6. NONPHARMACOLOGICAL INTERVENTIONS</text>
<text top="879" left="749" width="22" height="14" font="6">. . . .</text>
<text top="880" left="778" width="24" height="11" font="2">e154</text>
<text top="905" left="489" width="77" height="12" font="12">6.1. Strategies</text>
<text top="904" left="570" width="202" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="905" left="778" width="24" height="11" font="2">e154</text>
<text top="930" left="488" width="216" height="12" font="12">6.2. Nonpharmacological Interventions</text>
<text top="929" left="709" width="62" height="14" font="6">. . . . . . . . . .</text>
<text top="930" left="779" width="23" height="11" font="2">e155</text>
<text top="965" left="475" width="149" height="14" font="11">7. PATIENT EVALUATION</text>
<text top="965" left="629" width="142" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="966" left="778" width="23" height="11" font="2">e158</text>
<text top="990" left="489" width="236" height="12" font="12">7.1. Laboratory Tests and Other Diagnostic</text>
<text top="1005" left="512" width="61" height="12" font="12">Procedures</text>
<text top="1004" left="576" width="195" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="1005" left="778" width="23" height="11" font="2">e159</text>
<text top="1030" left="488" width="229" height="12" font="12">7.2. Cardiovascular Target Organ Damage</text>
<text top="1029" left="723" width="49" height="14" font="6">. . . . . . . .</text>
<text top="1030" left="778" width="23" height="11" font="2">e159</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e128</text>
</page>
<page number="3" position="absolute" top="0" left="0" height="1160" width="864">
<text top="141" left="70" width="161" height="14" font="11">8. TREATMENT OF HIGH BP</text>
<text top="141" left="238" width="129" height="14" font="6">. . . . . . . . . . . . . . . . . . . .</text>
<text top="142" left="372" width="24" height="11" font="2">e160</text>
<text top="166" left="84" width="175" height="12" font="12">8.1. Pharmacological Treatment</text>
<text top="166" left="264" width="102" height="14" font="6">. . . . . . . . . . . . . . . .</text>
<text top="167" left="372" width="24" height="11" font="2">e160</text>
<text top="187" left="111" width="268" height="12" font="2">8.1.1. Initiation of Pharmacological BP Treatment</text>
<text top="202" left="142" width="193" height="12" font="2">in the Context of Overall CVD Risk</text>
<text top="201" left="343" width="22" height="14" font="6">. . . .</text>
<text top="202" left="372" width="24" height="11" font="2">e160</text>
<text top="222" left="109" width="253" height="12" font="2">8.1.2. BP Treatment Threshold and the Use of</text>
<text top="237" left="142" width="196" height="12" font="2">CVD Risk Estimation to Guide Drug</text>
<text top="252" left="142" width="151" height="12" font="2">Treatment of Hypertension</text>
<text top="251" left="296" width="69" height="14" font="6">. . . . . . . . . . .</text>
<text top="252" left="372" width="24" height="11" font="2">e160</text>
<text top="272" left="109" width="239" height="12" font="2">8.1.3. Follow-Up After Initial BP Evaluation</text>
<text top="272" left="356" width="9" height="14" font="6">. .</text>
<text top="273" left="373" width="23" height="11" font="2">e163</text>
<text top="293" left="108" width="228" height="12" font="2">8.1.4. General Principles of Drug Therapy</text>
<text top="292" left="343" width="22" height="14" font="6">. . . .</text>
<text top="293" left="372" width="24" height="11" font="2">e164</text>
<text top="313" left="109" width="248" height="12" font="2">8.1.5. BP Goal for Patients With Hypertension</text>
<text top="312" left="363" width="2" height="14" font="6">.</text>
<text top="313" left="373" width="23" height="11" font="2">e167</text>
<text top="333" left="109" width="187" height="12" font="2">8.1.6. Choice of Initial Medication</text>
<text top="333" left="303" width="62" height="14" font="6">. . . . . . . . . .</text>
<text top="334" left="372" width="24" height="11" font="2">e168</text>
<text top="360" left="83" width="266" height="12" font="12">8.2. Achieving BP Control in Individual Patients</text>
<text top="359" left="358" width="9" height="14" font="6">. .</text>
<text top="360" left="372" width="24" height="11" font="2">e169</text>
<text top="385" left="83" width="256" height="12" font="12">8.3. Follow-Up of BP During Antihypertensive</text>
<text top="400" left="108" width="76" height="12" font="12">Drug Therapy</text>
<text top="399" left="191" width="175" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="400" left="373" width="24" height="11" font="2">e170</text>
<text top="420" left="109" width="175" height="12" font="2">8.3.1. Follow-Up After Initiating</text>
<text top="435" left="142" width="175" height="12" font="2">Antihypertensive Drug Therapy</text>
<text top="434" left="323" width="42" height="14" font="6">. . . . . . .</text>
<text top="435" left="373" width="24" height="11" font="2">e170</text>
<text top="455" left="108" width="217" height="12" font="2">8.3.2. Monitoring Strategies to Improve</text>
<text top="470" left="142" width="155" height="12" font="2">Control of BP in Patients on</text>
<text top="485" left="142" width="144" height="12" font="2">Drug Therapy for High BP</text>
<text top="484" left="290" width="82" height="14" font="6">. . . . . . . . . . . . .</text>
<text top="485" left="375" width="21" height="11" font="2">e171</text>
<text top="516" left="70" width="225" height="14" font="11">9. HYPERTENSION IN PATIENTS WITH</text>
<text top="534" left="83" width="98" height="14" font="11">COMORBIDITIES</text>
<text top="534" left="185" width="182" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="535" left="375" width="21" height="11" font="2">e171</text>
<text top="559" left="90" width="189" height="12" font="12">9.1. Stable Ischemic Heart Disease</text>
<text top="558" left="284" width="82" height="14" font="6">. . . . . . . . . . . . .</text>
<text top="559" left="374" width="22" height="11" font="2">e172</text>
<text top="582" left="89" width="98" height="12" font="12">9.2. Heart Failure</text>
<text top="582" left="191" width="175" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="583" left="374" width="22" height="11" font="2">e173</text>
<text top="603" left="115" width="187" height="12" font="2">9.2.1. Heart Failure With Reduced</text>
<text top="618" left="147" width="94" height="12" font="2">Ejection Fraction</text>
<text top="617" left="249" width="115" height="14" font="6">. . . . . . . . . . . . . . . . . .</text>
<text top="618" left="373" width="23" height="11" font="2">e174</text>
<text top="638" left="114" width="195" height="12" font="2">9.2.2. Heart Failure With Preserved</text>
<text top="653" left="147" width="94" height="12" font="2">Ejection Fraction</text>
<text top="652" left="249" width="115" height="14" font="6">. . . . . . . . . . . . . . . . . .</text>
<text top="653" left="373" width="23" height="11" font="2">e174</text>
<text top="678" left="89" width="156" height="12" font="12">9.3. Chronic Kidney Disease</text>
<text top="677" left="251" width="115" height="14" font="6">. . . . . . . . . . . . . . . . . .</text>
<text top="678" left="374" width="22" height="11" font="2">e175</text>
<text top="698" left="114" width="173" height="12" font="2">9.3.1. Hypertension After Renal</text>
<text top="713" left="146" width="87" height="12" font="2">Transplantation</text>
<text top="713" left="242" width="129" height="14" font="6">. . . . . . . . . . . . . . . . . . . .</text>
<text top="714" left="374" width="22" height="11" font="2">e177</text>
<text top="738" left="88" width="159" height="12" font="12">9.4. Cerebrovascular Disease</text>
<text top="737" left="251" width="115" height="14" font="6">. . . . . . . . . . . . . . . . . .</text>
<text top="739" left="373" width="23" height="11" font="2">e178</text>
<text top="759" left="115" width="211" height="12" font="2">9.4.1. Acute Intracerebral Hemorrhage</text>
<text top="758" left="329" width="36" height="14" font="6">. . . . . .</text>
<text top="759" left="373" width="23" height="11" font="2">e178</text>
<text top="779" left="114" width="157" height="12" font="2">9.4.2. Acute Ischemic Stroke</text>
<text top="778" left="276" width="89" height="14" font="6">. . . . . . . . . . . . . .</text>
<text top="779" left="371" width="25" height="11" font="2">e180</text>
<text top="799" left="114" width="194" height="12" font="2">9.4.3. Secondary Stroke Prevention</text>
<text top="798" left="316" width="49" height="14" font="6">. . . . . . . .</text>
<text top="799" left="373" width="23" height="11" font="2">e182</text>
<text top="824" left="89" width="165" height="12" font="12">9.5. Peripheral Artery Disease</text>
<text top="823" left="258" width="109" height="14" font="6">. . . . . . . . . . . . . . . . .</text>
<text top="824" left="372" width="25" height="11" font="2">e184</text>
<text top="848" left="88" width="121" height="12" font="12">9.6. Diabetes Mellitus</text>
<text top="847" left="218" width="149" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="848" left="372" width="25" height="11" font="2">e184</text>
<text top="873" left="89" width="138" height="12" font="12">9.7. Metabolic Syndrome</text>
<text top="872" left="231" width="135" height="14" font="6">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="873" left="373" width="23" height="11" font="2">e185</text>
<text top="897" left="88" width="121" height="12" font="12">9.8. Atrial Fibrillation</text>
<text top="897" left="211" width="155" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="898" left="372" width="24" height="11" font="2">e186</text>
<text top="922" left="88" width="151" height="12" font="12">9.9. Valvular Heart Disease</text>
<text top="922" left="244" width="122" height="14" font="6">. . . . . . . . . . . . . . . . . . .</text>
<text top="923" left="373" width="23" height="11" font="2">e187</text>
<text top="947" left="83" width="109" height="12" font="12">9.10. Aortic Disease</text>
<text top="947" left="198" width="169" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="948" left="372" width="24" height="11" font="2">e188</text>
<text top="978" left="64" width="182" height="14" font="11">10. SPECIAL PATIENT GROUPS</text>
<text top="978" left="251" width="115" height="14" font="6">. . . . . . . . . . . . . . . . . .</text>
<text top="979" left="372" width="24" height="11" font="2">e188</text>
<text top="1003" left="84" width="134" height="12" font="12">10.1. Race and Ethnicity</text>
<text top="1003" left="225" width="142" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="1004" left="372" width="24" height="11" font="2">e188</text>
<text top="1024" left="114" width="210" height="12" font="2">10.1.1 Racial and Ethnic Differences in</text>
<text top="1039" left="146" width="58" height="12" font="2">Treatment</text>
<text top="1038" left="209" width="155" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="1039" left="372" width="24" height="11" font="2">e189</text>
<text top="143" left="443" width="133" height="12" font="12">10.2. Sex-Related Issues</text>
<text top="142" left="585" width="142" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="143" left="732" width="24" height="11" font="2">e189</text>
<text top="163" left="475" width="80" height="12" font="2">10.2.1. Women</text>
<text top="162" left="562" width="162" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="163" left="732" width="24" height="11" font="2">e190</text>
<text top="183" left="474" width="96" height="12" font="2">10.2.2. Pregnancy</text>
<text top="183" left="575" width="149" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="184" left="732" width="24" height="11" font="2">e190</text>
<text top="213" left="443" width="135" height="12" font="12">10.3. Age-Related Issues</text>
<text top="212" left="585" width="142" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="213" left="734" width="22" height="11" font="2">e191</text>
<text top="233" left="475" width="114" height="12" font="2">10.3.1. Older Persons</text>
<text top="232" left="595" width="135" height="14" font="6">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="233" left="734" width="22" height="11" font="2">e191</text>
<text top="253" left="474" width="180" height="12" font="2">10.3.2. Children and Adolescents</text>
<text top="253" left="662" width="69" height="14" font="6">. . . . . . . . . . .</text>
<text top="254" left="733" width="23" height="11" font="2">e192</text>
<text top="291" left="427" width="172" height="14" font="11">11. OTHER CONSIDERATIONS</text>
<text top="291" left="605" width="122" height="14" font="6">. . . . . . . . . . . . . . . . . . .</text>
<text top="292" left="733" width="23" height="11" font="2">e193</text>
<text top="317" left="446" width="156" height="12" font="12">11.1. Resistant Hypertension</text>
<text top="316" left="605" width="122" height="14" font="6">. . . . . . . . . . . . . . . . . . .</text>
<text top="317" left="733" width="23" height="11" font="2">e193</text>
<text top="345" left="444" width="138" height="12" font="12">11.2. Hypertensive Crises</text>
<text top="343" left="582" width="103" height="15" font="12">—Emergencies and</text>
<text top="360" left="472" width="54" height="12" font="12">Urgencies</text>
<text top="359" left="532" width="195" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="360" left="732" width="24" height="11" font="2">e194</text>
<text top="387" left="444" width="207" height="12" font="12">11.3. Cognitive Decline and Dementia</text>
<text top="386" left="658" width="69" height="14" font="6">. . . . . . . . . . .</text>
<text top="387" left="733" width="23" height="11" font="2">e197</text>
<text top="414" left="443" width="239" height="12" font="12">11.4. Sexual Dysfunction and Hypertension</text>
<text top="413" left="691" width="36" height="14" font="6">. . . . . .</text>
<text top="414" left="732" width="24" height="11" font="2">e198</text>
<text top="441" left="444" width="253" height="12" font="12">11.5. Patients Undergoing Surgical Procedures</text>
<text top="440" left="704" width="22" height="14" font="6">. . . .</text>
<text top="441" left="732" width="24" height="11" font="2">e199</text>
<text top="479" left="425" width="273" height="14" font="11">12. STRATEGIES TO IMPROVE HYPERTENSION</text>
<text top="497" left="443" width="168" height="14" font="11">TREATMENT AND CONTROL</text>
<text top="497" left="618" width="109" height="14" font="6">. . . . . . . . . . . . . . . . .</text>
<text top="498" left="730" width="26" height="11" font="2">e200</text>
<text top="524" left="446" width="240" height="12" font="12">12.1. Adherence Strategies for Treatment of</text>
<text top="539" left="473" width="75" height="12" font="12">Hypertension</text>
<text top="538" left="552" width="175" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="540" left="730" width="26" height="11" font="2">e200</text>
<text top="560" left="475" width="258" height="12" font="2">12.1.1. Antihypertensive Medication Adherence</text>
<text top="575" left="510" width="54" height="12" font="2">Strategies</text>
<text top="574" left="569" width="155" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="575" left="733" width="24" height="11" font="2">e201</text>
<text top="595" left="474" width="206" height="12" font="2">12.1.2. Strategies to Promote Lifestyle</text>
<text top="610" left="510" width="28" height="12" font="2">Modi</text>
<text top="608" left="538" width="41" height="15" font="2">ﬁcation</text>
<text top="609" left="582" width="142" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="610" left="732" width="25" height="11" font="2">e202</text>
<text top="631" left="474" width="200" height="12" font="2">12.1.3. Improving Quality of Care for</text>
<text top="646" left="510" width="190" height="12" font="2">Resource-Constrained Populations</text>
<text top="645" left="708" width="16" height="14" font="6">. . .</text>
<text top="646" left="732" width="25" height="11" font="2">e202</text>
<text top="674" left="444" width="288" height="12" font="12">12.2. Structured, Team-Based Care Interventions for</text>
<text top="689" left="473" width="119" height="12" font="12">Hypertension Control</text>
<text top="688" left="598" width="129" height="14" font="6">. . . . . . . . . . . . . . . . . . . .</text>
<text top="690" left="732" width="25" height="11" font="2">e203</text>
<text top="717" left="444" width="203" height="12" font="12">12.3. Health Information Technology</text>
<text top="715" left="648" width="38" height="15" font="12">–Based</text>
<text top="732" left="473" width="242" height="12" font="12">Strategies to Promote Hypertension Control</text>
<text top="731" left="724" width="2" height="14" font="6">.</text>
<text top="732" left="731" width="26" height="11" font="2">e204</text>
<text top="752" left="475" width="185" height="12" font="2">12.3.1. EHR and Patient Registries</text>
<text top="752" left="668" width="56" height="14" font="6">. . . . . . . . .</text>
<text top="753" left="731" width="26" height="11" font="2">e204</text>
<text top="774" left="474" width="239" height="12" font="2">12.3.2. Telehealth Interventions to Improve</text>
<text top="789" left="511" width="119" height="12" font="2">Hypertension Control</text>
<text top="788" left="635" width="89" height="14" font="6">. . . . . . . . . . . . . .</text>
<text top="790" left="731" width="26" height="11" font="2">e204</text>
<text top="818" left="443" width="242" height="12" font="12">12.4. Improving Quality of Care for Patients</text>
<text top="833" left="473" width="105" height="12" font="12">With Hypertension</text>
<text top="832" left="585" width="142" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="833" left="732" width="25" height="11" font="2">e205</text>
<text top="853" left="475" width="163" height="12" font="2">12.4.1. Performance Measures</text>
<text top="852" left="642" width="82" height="14" font="6">. . . . . . . . . . . . .</text>
<text top="853" left="732" width="25" height="11" font="2">e205</text>
<text top="875" left="474" width="215" height="12" font="2">12.4.2. Quality Improvement Strategies</text>
<text top="874" left="695" width="29" height="14" font="6">. . . . .</text>
<text top="875" left="732" width="25" height="11" font="2">e205</text>
<text top="904" left="444" width="140" height="12" font="12">12.5. Financial Incentives</text>
<text top="903" left="591" width="135" height="14" font="6">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="904" left="731" width="25" height="11" font="2">e206</text>
<text top="942" left="425" width="264" height="14" font="11">13. THE PLAN OF CARE FOR HYPERTENSION</text>
<text top="942" left="698" width="29" height="14" font="6">. . . . .</text>
<text top="943" left="732" width="25" height="11" font="2">e207</text>
<text top="969" left="444" width="113" height="12" font="12">13.1. Health Literacy</text>
<text top="969" left="565" width="162" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="970" left="732" width="25" height="11" font="2">e207</text>
<text top="997" left="443" width="269" height="12" font="12">13.2. Access to Health Insurance and Medication</text>
<text top="1012" left="472" width="90" height="12" font="12">Assistance Plans</text>
<text top="1011" left="572" width="155" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="1012" left="732" width="25" height="11" font="2">e207</text>
<text top="1039" left="443" width="203" height="12" font="12">13.3. Social and Community Services</text>
<text top="1038" left="651" width="75" height="14" font="6">. . . . . . . . . . . .</text>
<text top="1039" left="732" width="25" height="11" font="2">e207</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="19" height="9" font="4">e129</text>
</page>
<page number="4" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="14" size="9" family="Times" color="#e3202b"/>
<text top="141" left="109" width="310" height="14" font="11">14. SUMMARY OF BP THRESHOLDS AND GOALS FOR</text>
<text top="159" left="128" width="186" height="14" font="11">PHARMACOLOGICAL THERAPY</text>
<text top="159" left="322" width="89" height="14" font="6">. . . . . . . . . . . . . .</text>
<text top="160" left="415" width="26" height="11" font="2">e208</text>
<text top="195" left="110" width="279" height="14" font="11">15. EVIDENCE GAPS AND FUTURE DIRECTIONS</text>
<text top="195" left="395" width="16" height="14" font="6">. . .</text>
<text top="196" left="415" width="26" height="11" font="2">e208</text>
<text top="231" left="108" width="71" height="14" font="11">APPENDIX 1</text>
<text top="256" left="128" width="222" height="12" font="12">Author Relationships With Industry and</text>
<text top="271" left="128" width="137" height="12" font="12">Other Entities (Relevant)</text>
<text top="270" left="269" width="142" height="14" font="6">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="271" left="416" width="24" height="11" font="2">e238</text>
<text top="306" left="108" width="73" height="14" font="11">APPENDIX 2</text>
<text top="331" left="128" width="235" height="12" font="12">Reviewer Relationships With Industry and</text>
<text top="346" left="128" width="174" height="12" font="12">Other Entities (Comprehensive)</text>
<text top="346" left="309" width="102" height="14" font="6">. . . . . . . . . . . . . . . .</text>
<text top="347" left="415" width="26" height="11" font="2">e240</text>
<text top="390" left="108" width="73" height="16" font="14">PREAMBLE</text>
<text top="428" left="108" width="333" height="12" font="2">Since 1980, the American College of Cardiology (ACC) and</text>
<text top="446" left="108" width="333" height="12" font="2">American Heart Association (AHA) have translated sci-</text>
<text top="464" left="108" width="23" height="12" font="2">enti</text>
<text top="462" left="130" width="310" height="15" font="2">ﬁc evidence into clinical practice guidelines (guide-</text>
<text top="482" left="108" width="333" height="12" font="2">lines) with recommendations to improve cardiovascular</text>
<text top="499" left="108" width="333" height="12" font="2">health. In 2013, the National Heart, Lung, and Blood</text>
<text top="517" left="108" width="333" height="12" font="2">Institute (NHLBI) Advisory Council recommended that</text>
<text top="535" left="108" width="135" height="12" font="2">the NHLBI focus speci</text>
<text top="534" left="243" width="197" height="15" font="2">ﬁcally on reviewing the highest-</text>
<text top="553" left="108" width="333" height="12" font="2">quality evidence and partner with other organizations</text>
<text top="571" left="108" width="173" height="12" font="2">to develop recommendations</text>
<text top="571" left="286" width="48" height="12" font="5"><a href="e127.full.html#85">(P-1,P-2)</a></text>
<text top="571" left="335" width="106" height="12" font="2"><a href="e127.full.html#85">. </a>Accordingly, the</text>
<text top="589" left="108" width="333" height="12" font="2">ACC and AHA collaborated with the NHLBI and stake-</text>
<text top="607" left="108" width="333" height="12" font="2">holder and professional organizations to complete and</text>
<text top="625" left="108" width="333" height="12" font="2">publish 4 guidelines (on assessment of cardiovascular</text>
<text top="643" left="108" width="109" height="12" font="2">risk, lifestyle modi</text>
<text top="641" left="217" width="224" height="15" font="2">ﬁcations to reduce cardiovascular risk,</text>
<text top="661" left="108" width="333" height="12" font="2">management of blood cholesterol in adults, and man-</text>
<text top="679" left="108" width="333" height="12" font="2">agement of overweight and obesity in adults) to make</text>
<text top="697" left="108" width="333" height="12" font="2">them available to the widest possible constituency. In</text>
<text top="715" left="108" width="333" height="12" font="2">2014, the ACC and AHA, in partnership with several other</text>
<text top="733" left="108" width="333" height="12" font="2">professional societies, initiated a guideline on the pre-</text>
<text top="751" left="108" width="333" height="12" font="2">vention, detection, evaluation, and management of high</text>
<text top="768" left="108" width="333" height="12" font="2">blood pressure (BP) in adults. Under the management of</text>
<text top="786" left="108" width="333" height="12" font="2">the ACC/AHA Task Force, a Prevention Subcommittee</text>
<text top="804" left="108" width="333" height="12" font="2">was appointed to help guide development of the suite of</text>
<text top="822" left="108" width="333" height="12" font="2">guidelines on prevention of cardiovascular disease</text>
<text top="840" left="108" width="333" height="12" font="2">(CVD). These guidelines, which are based on systematic</text>
<text top="858" left="108" width="333" height="12" font="2">methods to evaluate and classify evidence, provide a</text>
<text top="876" left="108" width="333" height="12" font="2">cornerstone for quality cardiovascular care. The ACC and</text>
<text top="894" left="108" width="333" height="12" font="2">AHA sponsor the development and publication of</text>
<text top="912" left="108" width="334" height="12" font="2">guidelines without commercial support, and members of</text>
<text top="930" left="108" width="333" height="12" font="2">each organization volunteer their time to the writing and</text>
<text top="948" left="108" width="194" height="12" font="2">review efforts. Guidelines are of</text>
<text top="946" left="302" width="139" height="15" font="2">ﬁcial policy of the ACC</text>
<text top="966" left="108" width="56" height="12" font="2">and AHA.</text>
<text top="999" left="108" width="71" height="11" font="12">Intended Use</text>
<text top="1021" left="108" width="333" height="12" font="2">Practice guidelines provide recommendations applicable</text>
<text top="1039" left="108" width="333" height="12" font="2">to patients with or at risk of developing CVD. The focus is</text>
<text top="143" left="468" width="333" height="12" font="2">on medical practice in the United States, but guidelines</text>
<text top="161" left="468" width="333" height="12" font="2">developed in collaboration with other organizations can</text>
<text top="178" left="468" width="333" height="12" font="2">have a global impact. Although guidelines may be used</text>
<text top="196" left="468" width="333" height="12" font="2">to inform regulatory or payer decisions, they are inten-</text>
<text top="214" left="468" width="145" height="12" font="2">ded to improve patients</text>
<text top="213" left="613" width="188" height="15" font="2">’ quality of care and align with</text>
<text top="232" left="468" width="47" height="12" font="2">patients</text>
<text top="230" left="515" width="286" height="15" font="2">’ interests. Guidelines are intended to deﬁne</text>
<text top="250" left="468" width="333" height="12" font="2">practices meeting the needs of patients in most, but not</text>
<text top="268" left="468" width="145" height="12" font="2">all, circumstances and</text>
<text top="268" left="625" width="39" height="12" font="2">should</text>
<text top="268" left="676" width="19" height="12" font="2">not</text>
<text top="268" left="707" width="95" height="12" font="2">replace clinical</text>
<text top="286" left="468" width="60" height="12" font="2">judgment.</text>
<text top="326" left="468" width="126" height="11" font="12">Clinical Implementation</text>
<text top="347" left="468" width="333" height="12" font="2">Management in accordance with guideline recommen-</text>
<text top="365" left="468" width="333" height="12" font="2">dations is effective only when followed by both practi-</text>
<text top="383" left="468" width="333" height="12" font="2">tioners and patients. Adherence to recommendations</text>
<text top="401" left="468" width="333" height="12" font="2">can be enhanced by shared decision making between</text>
<text top="419" left="468" width="333" height="12" font="2">clinicians and patients, with patient engagement in</text>
<text top="437" left="468" width="51" height="12" font="2">selecting</text>
<text top="437" left="531" width="78" height="12" font="2">interventions</text>
<text top="437" left="621" width="14" height="12" font="2">on</text>
<text top="437" left="648" width="19" height="12" font="2">the</text>
<text top="437" left="678" width="28" height="12" font="2">basis</text>
<text top="437" left="719" width="11" height="12" font="2">of</text>
<text top="437" left="742" width="59" height="12" font="2">individual</text>
<text top="455" left="468" width="333" height="12" font="2">values, preferences, and associated conditions and</text>
<text top="473" left="468" width="83" height="12" font="2">comorbidities.</text>
<text top="514" left="468" width="174" height="11" font="12">Methodology and Modernization</text>
<text top="536" left="468" width="333" height="12" font="2">The ACC/AHA Task Force on Clinical Practice Guidelines</text>
<text top="554" left="468" width="313" height="12" font="2">(Task Force) continuously reviews, updates, and modi</text>
<text top="552" left="781" width="20" height="15" font="2">ﬁes</text>
<text top="572" left="468" width="333" height="12" font="2">guideline methodology on the basis of published stan-</text>
<text top="590" left="468" width="333" height="12" font="2">dards from organizations, including the Institute of</text>
<text top="608" left="468" width="53" height="12" font="2">Medicine</text>
<text top="608" left="526" width="50" height="12" font="5"><a href="e127.full.html#85">(P-3,P-4)</a></text>
<text top="608" left="576" width="225" height="12" font="2">, and on the basis of internal reevalu-</text>
<text top="626" left="468" width="334" height="12" font="2">ation. Similarly, the presentation and delivery of guide-</text>
<text top="644" left="468" width="201" height="12" font="2">lines are reevaluated and modi</text>
<text top="642" left="670" width="132" height="15" font="2">ﬁed on the basis of</text>
<text top="661" left="468" width="333" height="12" font="2">evolving technologies and other factors to facilitate</text>
<text top="679" left="468" width="333" height="12" font="2">optimal dissemination of information to healthcare pro-</text>
<text top="697" left="468" width="176" height="12" font="2">fessionals at the point of care.</text>
<text top="715" left="483" width="319" height="12" font="2">Toward this goal, this guideline continues the intro-</text>
<text top="733" left="468" width="333" height="12" font="2">duction of an evolved format of presenting guideline</text>
<text top="751" left="468" width="104" height="12" font="2">recommendations</text>
<text top="751" left="587" width="21" height="12" font="2">and</text>
<text top="751" left="622" width="60" height="12" font="2">associated</text>
<text top="751" left="697" width="23" height="12" font="2">text</text>
<text top="751" left="734" width="34" height="12" font="2">called</text>
<text top="751" left="783" width="19" height="12" font="2">the</text>
<text top="767" left="468" width="333" height="15" font="2">“modular knowledge chunk format.” Each modular</text>
<text top="785" left="468" width="333" height="15" font="2">“chunk” includes a table of related recommendations, a</text>
<text top="805" left="468" width="222" height="12" font="2">brief synopsis, recommendation-speci</text>
<text top="803" left="690" width="111" height="15" font="2">ﬁc supportive text,</text>
<text top="823" left="468" width="131" height="12" font="2">and when appropriate,</text>
<text top="821" left="602" width="199" height="15" font="2">ﬂow diagrams or additional tables.</text>
<text top="841" left="468" width="333" height="12" font="2">References are provided within the modular chunk itself</text>
<text top="859" left="468" width="333" height="12" font="2">to facilitate quick review. Additionally, this format will</text>
<text top="877" left="468" width="333" height="12" font="2">facilitate seamless updating of guidelines with focused</text>
<text top="895" left="468" width="333" height="12" font="2">updates as new evidence is published, as well as content</text>
<text top="913" left="468" width="333" height="12" font="2">tagging for rapid electronic retrieval of related recom-</text>
<text top="930" left="468" width="333" height="12" font="2">mendations on a topic of interest. This evolved approach</text>
<text top="948" left="468" width="333" height="12" font="2">format was instituted when this guideline was near</text>
<text top="966" left="468" width="333" height="12" font="2">completion; therefore, the present document represents a</text>
<text top="984" left="468" width="333" height="12" font="2">transitional format that best suits the text as written.</text>
<text top="1002" left="468" width="333" height="12" font="2">Future guidelines will fully implement this format,</text>
<text top="1020" left="468" width="333" height="12" font="2">including provisions for limiting the amount of text in a</text>
<text top="1038" left="468" width="58" height="12" font="2">guideline.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e130</text>
</page>
<page number="5" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="78" width="219" height="12" font="2">Recognizing the importance of cost</text>
<text top="141" left="298" width="99" height="15" font="2">–value consider-</text>
<text top="161" left="63" width="333" height="12" font="2">ations in certain guidelines, when appropriate and</text>
<text top="178" left="63" width="333" height="12" font="2">feasible, an analysis of the value of a drug, device, or</text>
<text top="196" left="63" width="333" height="12" font="2">intervention may be performed in accordance with the</text>
<text top="214" left="63" width="135" height="12" font="2">ACC/AHA methodology</text>
<text top="214" left="202" width="27" height="12" font="5"><a href="e127.full.html#85">(P-5)</a></text>
<text top="214" left="229" width="3" height="12" font="2">.</text>
<text top="232" left="78" width="318" height="12" font="2">To ensure that guideline recommendations remain</text>
<text top="250" left="63" width="333" height="12" font="2">current, new data are reviewed on an ongoing basis,</text>
<text top="268" left="63" width="333" height="12" font="2">with full guideline revisions commissioned in approxi-</text>
<text top="286" left="63" width="333" height="12" font="2">mately 6-year cycles. Publication of new, potentially</text>
<text top="304" left="63" width="333" height="12" font="2">practice-changing study results that are relevant to an</text>
<text top="322" left="63" width="333" height="12" font="2">existing or new drug, device, or management strategy</text>
<text top="340" left="63" width="333" height="12" font="2">will prompt evaluation by the Task Force, in con-</text>
<text top="358" left="63" width="333" height="12" font="2">sultation with the relevant guideline writing commit-</text>
<text top="376" left="63" width="333" height="12" font="2">tee, to determine whether a focused update should</text>
<text top="394" left="63" width="13" height="12" font="2">be</text>
<text top="394" left="89" width="87" height="12" font="2">commissioned.</text>
<text top="394" left="189" width="19" height="12" font="2">For</text>
<text top="394" left="221" width="59" height="12" font="2">additional</text>
<text top="394" left="293" width="69" height="12" font="2">information</text>
<text top="394" left="375" width="21" height="12" font="2">and</text>
<text top="412" left="63" width="44" height="12" font="2">policies</text>
<text top="412" left="128" width="55" height="12" font="2">regarding</text>
<text top="412" left="204" width="54" height="12" font="2">guideline</text>
<text top="412" left="279" width="80" height="12" font="2">development,</text>
<text top="412" left="380" width="16" height="12" font="2">we</text>
<text top="430" left="63" width="333" height="12" font="2">encourage readers to consult the ACC/AHA guideline</text>
<text top="447" left="63" width="131" height="12" font="2">methodology manual</text>
<text top="447" left="205" width="27" height="12" font="5"><a href="e127.full.html#85">(P-6)</a></text>
<text top="447" left="245" width="152" height="12" font="2">and other methodology</text>
<text top="465" left="63" width="42" height="12" font="2">articles</text>
<text top="465" left="111" width="22" height="12" font="5"><a href="e127.full.html#85">(P-7</a></text>
<text top="464" left="133" width="38" height="15" font="5"><a href="e127.full.html#85">—P-10)</a></text>
<text top="465" left="172" width="3" height="12" font="2"><a href="e127.full.html#85">.</a></text>
<text top="497" left="63" width="221" height="11" font="12">Selection of Writing Committee Members</text>
<text top="519" left="63" width="333" height="12" font="2">The Task Force strives to avoid bias by selecting experts</text>
<text top="537" left="63" width="333" height="12" font="2">from a broad array of backgrounds. Writing committee</text>
<text top="555" left="63" width="333" height="12" font="2">members represent different geographic regions, sexes,</text>
<text top="573" left="63" width="333" height="12" font="2">ethnicities, races, intellectual perspectives/biases, and</text>
<text top="590" left="63" width="333" height="12" font="2">scopes of clinical practice. The Task Force may also invite</text>
<text top="608" left="63" width="333" height="12" font="2">organizations and professional societies with related in-</text>
<text top="626" left="63" width="333" height="12" font="2">terests and expertise to participate as partners, collabo-</text>
<text top="644" left="63" width="118" height="12" font="2">rators, or endorsers.</text>
<text top="676" left="63" width="248" height="11" font="12">Relationships With Industry and Other Entities</text>
<text top="698" left="63" width="333" height="12" font="2">The ACC and AHA have rigorous policies and methods to</text>
<text top="715" left="63" width="333" height="12" font="2">ensure that guidelines are developed without bias or</text>
<text top="733" left="63" width="70" height="12" font="2">improper in</text>
<text top="732" left="133" width="263" height="15" font="2">ﬂuence. The complete relationships with in-</text>
<text top="751" left="63" width="333" height="12" font="2">dustry and other entities (RWI) policy can be found</text>
<text top="769" left="63" width="37" height="12" font="5"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">online</a></text>
<text top="769" left="100" width="3" height="12" font="2"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">.</a></text>
<text top="769" left="108" width="65" height="12" font="5"><a href="e127.full.html#112">Appendix 1</a></text>
<text top="769" left="177" width="219" height="12" font="2">of the present document lists writing</text>
<text top="787" left="63" width="120" height="12" font="2">committee members</text>
<text top="785" left="183" width="213" height="15" font="2">’ relevant RWI. For the purposes of</text>
<text top="805" left="63" width="276" height="12" font="2">full transparency, writing committee members</text>
<text top="803" left="340" width="57" height="15" font="2">’ compre-</text>
<text top="823" left="63" width="45" height="12" font="2">hensive</text>
<text top="823" left="120" width="59" height="12" font="2">disclosure</text>
<text top="823" left="192" width="69" height="12" font="2">information</text>
<text top="823" left="273" width="9" height="12" font="2">is</text>
<text top="823" left="295" width="52" height="12" font="2">available</text>
<text top="823" left="360" width="36" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017HBP_Authors_Comprehensive_RWI.pdf">online</a></text>
<text top="841" left="63" width="333" height="12" font="2">Comprehensive disclosure information for the Task</text>
<text top="859" left="63" width="101" height="12" font="2">Force is available</text>
<text top="859" left="168" width="36" height="12" font="5"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/guidelines-and-documents-task-forces">online</a></text>
<text top="859" left="205" width="3" height="12" font="2"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/guidelines-and-documents-task-forces">.</a></text>
<text top="891" left="63" width="272" height="11" font="12">Evidence Review and Evidence Review Committees</text>
<text top="912" left="63" width="12" height="12" font="2">In</text>
<text top="912" left="87" width="64" height="12" font="2">developing</text>
<text top="912" left="163" width="108" height="12" font="2">recommendations,</text>
<text top="912" left="283" width="19" height="12" font="2">the</text>
<text top="912" left="314" width="42" height="12" font="2">writing</text>
<text top="912" left="368" width="29" height="12" font="2">com-</text>
<text top="930" left="63" width="333" height="12" font="2">mittee uses evidence-based methodologies that are</text>
<text top="948" left="63" width="33" height="12" font="2">based</text>
<text top="948" left="109" width="14" height="12" font="2">on</text>
<text top="948" left="136" width="14" height="12" font="2">all</text>
<text top="948" left="163" width="52" height="12" font="2">available</text>
<text top="948" left="228" width="25" height="12" font="2">data</text>
<text top="948" left="266" width="23" height="12" font="5"><a href="e127.full.html#85">(P-6</a></text>
<text top="946" left="289" width="32" height="15" font="5"><a href="e127.full.html#85">—P-9)</a></text>
<text top="948" left="322" width="3" height="12" font="2">.</text>
<text top="948" left="339" width="58" height="12" font="2">Literature</text>
<text top="966" left="63" width="333" height="12" font="2">searches focus on randomized controlled trials (RCTs)</text>
<text top="143" left="423" width="333" height="12" font="2">but also include registries, nonrandomized comparative</text>
<text top="161" left="423" width="333" height="12" font="2">and descriptive studies, case series, cohort studies,</text>
<text top="178" left="423" width="333" height="12" font="2">systematic reviews, and expert opinion. Only key ref-</text>
<text top="196" left="423" width="105" height="12" font="2">erences are cited.</text>
<text top="214" left="438" width="318" height="12" font="2">An independent evidence review committee (ERC) is</text>
<text top="232" left="423" width="333" height="12" font="2">commissioned when there are 1 or more questions</text>
<text top="250" left="423" width="46" height="12" font="2">deemed</text>
<text top="250" left="481" width="11" height="12" font="2">of</text>
<text top="250" left="505" width="41" height="12" font="2">utmost</text>
<text top="250" left="558" width="41" height="12" font="2">clinical</text>
<text top="250" left="612" width="66" height="12" font="2">importance</text>
<text top="250" left="690" width="23" height="12" font="2">that</text>
<text top="250" left="725" width="31" height="12" font="2">merit</text>
<text top="268" left="423" width="333" height="12" font="2">formal systematic review. The systematic review will</text>
<text top="286" left="423" width="289" height="12" font="2">determine which patients are most likely to bene</text>
<text top="284" left="712" width="44" height="15" font="2">ﬁt from</text>
<text top="304" left="423" width="333" height="12" font="2">a drug, device, or treatment strategy and to what degree.</text>
<text top="322" left="423" width="333" height="12" font="2">Criteria for commissioning an ERC and formal systematic</text>
<text top="340" left="423" width="333" height="12" font="2">review include: a) the absence of a current authoritative</text>
<text top="358" left="423" width="272" height="12" font="2">systematic review, b) the feasibility of de</text>
<text top="356" left="695" width="61" height="15" font="2">ﬁning the</text>
<text top="376" left="423" width="28" height="12" font="2">bene</text>
<text top="374" left="451" width="305" height="15" font="2">ﬁt and risk in a time frame consistent with the</text>
<text top="394" left="423" width="333" height="12" font="2">writing of a guideline, c) the relevance to a substantial</text>
<text top="412" left="423" width="301" height="12" font="2">number of patients, and d) the likelihood that the</text>
<text top="410" left="729" width="27" height="15" font="2">ﬁnd-</text>
<text top="430" left="423" width="333" height="12" font="2">ings can be translated into actionable recommendations.</text>
<text top="447" left="423" width="333" height="12" font="2">ERC members may include methodologists, epidemiolo-</text>
<text top="465" left="423" width="333" height="12" font="2">gists, healthcare providers, and biostatisticians. The</text>
<text top="483" left="423" width="333" height="12" font="2">recommendations developed by the writing committee</text>
<text top="501" left="423" width="333" height="12" font="2">on the basis of the systematic review are marked with</text>
<text top="517" left="423" width="31" height="15" font="2">“SR”.</text>
<text top="559" left="423" width="242" height="11" font="12">Guideline-Directed Management and Therapy</text>
<text top="581" left="423" width="333" height="12" font="2">The term guideline-directed management and therapy</text>
<text top="598" left="423" width="333" height="12" font="2">(GDMT) encompasses clinical evaluation, diagnostic</text>
<text top="616" left="423" width="333" height="12" font="2">testing, and pharmacological and procedural treatments.</text>
<text top="634" left="423" width="333" height="12" font="2">For these and all recommended drug treatment regi-</text>
<text top="652" left="423" width="172" height="12" font="2">mens, the reader should con</text>
<text top="650" left="595" width="161" height="15" font="2">ﬁrm the dosage by review-</text>
<text top="670" left="423" width="333" height="12" font="2">ing product insert material and evaluate the treatment</text>
<text top="688" left="423" width="333" height="12" font="2">regimen for contraindications and interactions. The</text>
<text top="706" left="423" width="333" height="12" font="2">recommendations are limited to drugs, devices, and</text>
<text top="724" left="423" width="333" height="12" font="2">treatments approved for clinical use in the United</text>
<text top="742" left="423" width="38" height="12" font="2">States.</text>
<text top="783" left="423" width="258" height="11" font="12">Class of Recommendation and Level of Evidence</text>
<text top="805" left="423" width="333" height="12" font="2">The Class of Recommendation (COR) indicates the</text>
<text top="823" left="423" width="333" height="12" font="2">strength of the recommendation, encompassing the</text>
<text top="841" left="423" width="270" height="12" font="2">estimated magnitude and certainty of bene</text>
<text top="839" left="694" width="63" height="15" font="2">ﬁt in pro-</text>
<text top="859" left="423" width="333" height="12" font="2">portion to risk. The Level of Evidence (LOE) rates the</text>
<text top="876" left="423" width="105" height="12" font="2">quality of scienti</text>
<text top="875" left="529" width="228" height="15" font="2">ﬁc evidence that supports the inter-</text>
<text top="894" left="423" width="333" height="12" font="2">vention on the basis of the type, quantity, and consis-</text>
<text top="912" left="423" width="333" height="12" font="2">tency of data from clinical trials and other sources</text>
<text top="930" left="423" width="4" height="12" font="2"><a href="e127.full.html#6">(</a></text>
<text top="931" left="427" width="41" height="11" font="5"><a href="e127.full.html#6">Table 1</a></text>
<text top="930" left="468" width="4" height="12" font="2">)</text>
<text top="930" left="477" width="23" height="12" font="5"><a href="e127.full.html#85">(P-6</a></text>
<text top="929" left="501" width="33" height="15" font="5"><a href="e127.full.html#85">—P-8)</a></text>
<text top="930" left="534" width="3" height="12" font="2"><a href="e127.full.html#85">.</a></text>
<text top="948" left="558" width="199" height="12" font="2">Glenn N. Levine, MD, FACC, FAHA</text>
<text top="966" left="438" width="318" height="12" font="2">Chair, ACC/AHA Task Force on Clinical Practice Guidelines</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="791" width="17" height="9" font="4">e131</text>
</page>
<page number="6" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="15" size="8" family="Times" color="#ffffff"/>
	<fontspec id="16" size="8" family="Times" color="#0e2a52"/>
<text top="156" left="72" width="46" height="10" font="15">T A B L E 1</text>
<text top="149" left="135" width="645" height="10" font="16">Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic</text>
<text top="163" left="135" width="254" height="10" font="16">Testing in Patient Care* (Updated August 2015)</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="18" height="9" font="4">e132</text>
</page>
<page number="7" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="17" size="7" family="Times" color="#327eb1"/>
<text top="141" left="63" width="120" height="16" font="14">1. INTRODUCTION</text>
<text top="178" left="63" width="333" height="12" font="2">As early as the 1920s, and subsequently in the 1959</text>
<text top="196" left="63" width="202" height="12" font="2">Build and Blood Pressure Study</text>
<text top="196" left="274" width="41" height="12" font="5"><a href="e127.full.html#85">(S1.5-1)</a></text>
<text top="196" left="323" width="73" height="12" font="2">of almost 5</text>
<text top="214" left="63" width="333" height="12" font="2">million adults insured between 1934 and 1954, a strong</text>
<text top="232" left="63" width="333" height="12" font="2">direct relationship was noted between level of BP and</text>
<text top="250" left="63" width="333" height="12" font="2">risk of clinical complications and death. In the 1960s,</text>
<text top="268" left="63" width="31" height="12" font="2">these</text>
<text top="266" left="102" width="294" height="15" font="2">ﬁndings were conﬁrmed in a series of reports</text>
<text top="286" left="63" width="217" height="12" font="2">from the Framingham Heart Study</text>
<text top="286" left="288" width="42" height="12" font="5"><a href="e127.full.html#85">(S1.5-2)</a></text>
<text top="286" left="330" width="67" height="12" font="2"><a href="e127.full.html#85">. </a>The 1967</text>
<text top="304" left="63" width="333" height="12" font="2">and 1970 Veterans Administration Cooperative Study</text>
<text top="322" left="63" width="333" height="12" font="2">Group reports ushered in the era of effective treatment</text>
<text top="340" left="63" width="77" height="12" font="2">for high BP</text>
<text top="340" left="149" width="80" height="12" font="5"><a href="e127.full.html#85">(S1.5-3,S1.5-4)</a></text>
<text top="340" left="230" width="35" height="12" font="2"><a href="e127.full.html#85">. </a>The</text>
<text top="338" left="275" width="121" height="15" font="2">ﬁrst comprehensive</text>
<text top="358" left="63" width="333" height="12" font="2">guideline for detection, evaluation, and management of</text>
<text top="376" left="63" width="333" height="12" font="2">high BP was published in 1977, under the sponsorship</text>
<text top="394" left="63" width="81" height="12" font="2">of the NHLBI</text>
<text top="394" left="150" width="42" height="12" font="5"><a href="e127.full.html#85">(S1.5-5)</a></text>
<text top="394" left="192" width="205" height="12" font="2"><a href="e127.full.html#85">. </a>In subsequent years, a series of</text>
<text top="412" left="63" width="333" height="12" font="2">Joint National Committee (JNC) BP guidelines were</text>
<text top="430" left="63" width="333" height="12" font="2">published to assist the practice community and improve</text>
<text top="447" left="63" width="333" height="12" font="2">prevention, awareness, treatment, and control of high</text>
<text top="465" left="63" width="15" height="12" font="2">BP</text>
<text top="465" left="84" width="37" height="12" font="5"><a href="e127.full.html#85">(S1.5-5</a></text>
<text top="464" left="122" width="46" height="15" font="5"><a href="e127.full.html#85">—S1.5-7)</a></text>
<text top="465" left="168" width="228" height="12" font="2">. The present guideline updates prior</text>
<text top="483" left="63" width="73" height="12" font="2">JNC reports.</text>
<text top="521" left="63" width="208" height="11" font="12">1.1. Methodology and Evidence Review</text>
<text top="543" left="63" width="333" height="12" font="2">An extensive evidence review, which included literature</text>
<text top="560" left="63" width="333" height="12" font="2">derived from research involving human subjects, pub-</text>
<text top="578" left="63" width="333" height="12" font="2">lished in English, and indexed in MEDLINE (through</text>
<text top="596" left="63" width="333" height="12" font="2">PubMed), EMBASE, the Cochrane Library, the Agency for</text>
<text top="614" left="63" width="333" height="12" font="2">Healthcare Research and Quality, and other selected</text>
<text top="632" left="63" width="333" height="12" font="2">databases relevant to this guideline, was conducted</text>
<text top="650" left="63" width="333" height="12" font="2">between February and August 2015. Key search words</text>
<text top="668" left="63" width="333" height="12" font="2">included but were not limited to the following: adher-</text>
<text top="686" left="63" width="333" height="12" font="2">ence; aerobic; alcohol intake; ambulatory care; antihyper-</text>
<text top="704" left="63" width="333" height="12" font="2">tensive: agents, drug, medication, therapy; beta adrenergic</text>
<text top="722" left="63" width="333" height="12" font="2">blockers; blood pressure: arterial, control, determination,</text>
<text top="740" left="63" width="333" height="12" font="2">devices, goal, high, improve, measurement, monitoring,</text>
<text top="758" left="63" width="333" height="12" font="2">ambulatory; calcium channel blockers; diet; diuretic</text>
<text top="776" left="63" width="333" height="12" font="2">agent; drug therapy; heart failure: diastolic, systolic;</text>
<text top="794" left="63" width="333" height="12" font="2">hypertension: white coat, masked, ambulatory, isolated</text>
<text top="812" left="63" width="333" height="12" font="2">ambulatory, isolated clinic, diagnosis, reverse white coat,</text>
<text top="829" left="63" width="333" height="12" font="2">prevention, therapy, treatment, control; intervention;</text>
<text top="847" left="63" width="153" height="12" font="2">lifestyle: measures, modi</text>
<text top="846" left="216" width="180" height="15" font="2">ﬁcation; ofﬁce visits; patient</text>
<text top="865" left="63" width="333" height="12" font="2">outcome; performance measures; physical activity; potas-</text>
<text top="883" left="63" width="333" height="12" font="2">sium intake; protein intake; renin inhibitor; risk reduction:</text>
<text top="901" left="63" width="53" height="12" font="2">behavior,</text>
<text top="901" left="129" width="63" height="12" font="2">counseling;</text>
<text top="901" left="205" width="56" height="12" font="2">screening;</text>
<text top="901" left="274" width="122" height="12" font="2">sphygmomanometers;</text>
<text top="919" left="63" width="333" height="12" font="2">spironolactone; therapy; treatment: adherence, compli-</text>
<text top="937" left="63" width="46" height="12" font="2">ance, ef</text>
<text top="935" left="109" width="287" height="15" font="2">ﬁcacy, outcome, protocol, regimen; weight. Addi-</text>
<text top="955" left="63" width="333" height="12" font="2">tional relevant studies published through June 2016,</text>
<text top="973" left="63" width="333" height="12" font="2">during the guideline writing process, were also consid-</text>
<text top="991" left="63" width="333" height="12" font="2">ered by the writing committee and added to the evidence</text>
<text top="1009" left="63" width="190" height="12" font="2">tables when appropriate. The</text>
<text top="1007" left="264" width="133" height="15" font="2">ﬁnal evidence tables</text>
<text top="1027" left="63" width="91" height="12" font="2">included in the</text>
<text top="1027" left="159" width="145" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement</a></text>
<text top="1027" left="309" width="87" height="12" font="2">summarize the</text>
<text top="539" left="423" width="333" height="12" font="2">evidence used by the writing committee to formulate</text>
<text top="557" left="423" width="108" height="12" font="2">recommendations.</text>
<text top="575" left="438" width="318" height="12" font="2">As noted in the preamble, an independent ERC was</text>
<text top="593" left="423" width="333" height="12" font="2">commissioned to perform a formal systematic review of 4</text>
<text top="611" left="423" width="39" height="12" font="2">critical</text>
<text top="611" left="476" width="41" height="12" font="2">clinical</text>
<text top="611" left="531" width="56" height="12" font="2">questions</text>
<text top="611" left="601" width="40" height="12" font="2">related</text>
<text top="611" left="655" width="11" height="12" font="2">to</text>
<text top="611" left="680" width="77" height="12" font="2">hypertension</text>
<text top="629" left="423" width="4" height="12" font="2"><a href="e127.full.html#7">(</a></text>
<text top="629" left="427" width="43" height="11" font="5"><a href="e127.full.html#7">Table 2</a></text>
<text top="629" left="471" width="286" height="12" font="2"><a href="e127.full.html#7">), </a>the results of which were considered by the</text>
<text top="647" left="423" width="333" height="12" font="2">writing committee for incorporation into this guideline.</text>
<text top="665" left="423" width="65" height="12" font="2">Concurrent</text>
<text top="665" left="502" width="26" height="12" font="2">with</text>
<text top="665" left="542" width="22" height="12" font="2">this</text>
<text top="665" left="578" width="47" height="12" font="2">process,</text>
<text top="665" left="639" width="42" height="12" font="2">writing</text>
<text top="665" left="695" width="62" height="12" font="2">committee</text>
<text top="683" left="423" width="333" height="12" font="2">members evaluated other published data relevant to the</text>
<text top="701" left="423" width="89" height="12" font="2">guideline. The</text>
<text top="699" left="521" width="236" height="15" font="2">ﬁndings of the ERC and the writing</text>
<text top="719" left="423" width="62" height="12" font="2">committee</text>
<text top="719" left="497" width="53" height="12" font="2">members</text>
<text top="719" left="563" width="28" height="12" font="2">were</text>
<text top="719" left="604" width="49" height="12" font="2">formally</text>
<text top="719" left="665" width="58" height="12" font="2">presented</text>
<text top="719" left="735" width="21" height="12" font="2">and</text>
<text top="737" left="423" width="333" height="12" font="2">discussed, and then guideline recommendations were</text>
<text top="755" left="423" width="257" height="12" font="2">developed. The systematic review report,</text>
<text top="753" left="687" width="69" height="15" font="2">“Systematic</text>
<text top="773" left="423" width="333" height="12" font="2">Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/</text>
<text top="791" left="423" width="333" height="12" font="2">APhA/ASH/ASPC/NMA/PCNA Guideline for the Preven-</text>
<text top="808" left="423" width="333" height="12" font="2">tion, Detection, Evaluation, and Management of High</text>
<text top="826" left="423" width="155" height="12" font="2">Blood Pressure in Adults,</text>
<text top="825" left="578" width="178" height="15" font="2">” is published in conjunction</text>
<text top="844" left="423" width="112" height="12" font="2">with this guideline</text>
<text top="844" left="540" width="43" height="12" font="5"><a href="e127.full.html#85">(S1.5-8)</a></text>
<text top="844" left="583" width="174" height="12" font="2"><a href="e127.full.html#85">, </a>and its respective data sup-</text>
<text top="862" left="423" width="140" height="12" font="2">plements are available</text>
<text top="862" left="571" width="37" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">online</a></text>
<text top="862" left="608" width="148" height="12" font="2">. No writing committee</text>
<text top="880" left="423" width="333" height="12" font="2">member reported a RWI. Drs. Whelton, Wright, and</text>
<text top="898" left="423" width="333" height="12" font="2">Williamson had leadership roles in SPRINT (Systolic</text>
<text top="916" left="423" width="333" height="12" font="2">Blood Pressure Intervention Trial). Dr. Carey chaired</text>
<text top="934" left="423" width="333" height="12" font="2">committee discussions in which the SPRINT results were</text>
<text top="952" left="423" width="67" height="12" font="2">considered.</text>
<text top="987" left="423" width="231" height="11" font="12">1.2. Organization of the Writing Committee</text>
<text top="1009" left="423" width="333" height="12" font="2">The writing committee consisted of clinicians, cardiolo-</text>
<text top="1027" left="423" width="333" height="12" font="2">gists, epidemiologists, internists, an endocrinologist, a</text>
<text top="156" left="431" width="47" height="10" font="15">T A B L E 2</text>
<text top="149" left="495" width="217" height="10" font="16">Systematic Review Questions on High BP</text>
<text top="163" left="495" width="48" height="10" font="16">in Adults</text>
<text top="187" left="423" width="41" height="9" font="13">Question</text>
<text top="199" left="423" width="36" height="9" font="13">Number</text>
<text top="199" left="572" width="41" height="9" font="13">Question</text>
<text top="187" left="715" width="34" height="9" font="13">Section</text>
<text top="199" left="713" width="36" height="9" font="13">Number</text>
<text top="219" left="423" width="4" height="9" font="13">1</text>
<text top="219" left="482" width="221" height="9" font="13">Is there evidence that self-directed monitoring of BP</text>
<text top="231" left="497" width="206" height="9" font="13">and/or ambulatory BP monitoring are superior to</text>
<text top="242" left="497" width="9" height="9" font="13">of</text>
<text top="241" left="505" width="196" height="12" font="13">ﬁce-based measurement of BP by a healthcare</text>
<text top="254" left="497" width="196" height="9" font="13">worker for 1) preventing adverse outcomes for</text>
<text top="266" left="497" width="194" height="9" font="13">which high BP is a risk factor and 2) achieving</text>
<text top="278" left="497" width="77" height="9" font="13">better BP control?</text>
<text top="219" left="725" width="13" height="9" font="17"><a href="e127.full.html#15">4.2</a></text>
<text top="298" left="423" width="5" height="9" font="13">2</text>
<text top="298" left="482" width="210" height="9" font="13">What is the optimal target for BP lowering during</text>
<text top="310" left="497" width="147" height="9" font="13">antihypertensive therapy in adults?</text>
<text top="298" left="722" width="20" height="9" font="17"><a href="">8.1.5</a></text>
<text top="310" left="725" width="13" height="9" font="17"><a href="e127.full.html#49">9.3</a></text>
<text top="321" left="724" width="14" height="9" font="17"><a href="e127.full.html#58">9.6</a></text>
<text top="341" left="423" width="5" height="9" font="13">3</text>
<text top="341" left="482" width="164" height="9" font="13">In adults with hypertension, do various</text>
<text top="353" left="497" width="182" height="9" font="13">antihypertensive drug classes differ in their</text>
<text top="365" left="497" width="74" height="9" font="13">comparative bene</text>
<text top="363" left="571" width="64" height="12" font="13">ﬁts and harms?</text>
<text top="341" left="721" width="21" height="9" font="17"><a href="e127.full.html#42">8.1.6</a></text>
<text top="353" left="725" width="14" height="9" font="17"><a href="e127.full.html#43">8.2</a></text>
<text top="384" left="423" width="6" height="9" font="13">4</text>
<text top="384" left="482" width="221" height="9" font="13">In adults with hypertension, does initiating treatment</text>
<text top="396" left="497" width="162" height="9" font="13">with antihypertensive pharmacological</text>
<text top="408" left="497" width="191" height="9" font="13">monotherapy versus initiating treatment with</text>
<text top="420" left="497" width="76" height="9" font="13">2 drugs (including</text>
<text top="418" left="576" width="98" height="12" font="13">ﬁxed-dose combination</text>
<text top="432" left="497" width="206" height="9" font="13">therapy), either of which may be followed by the</text>
<text top="444" left="497" width="206" height="9" font="13">addition of sequential drugs, differ in comparative</text>
<text top="456" left="497" width="20" height="9" font="13">bene</text>
<text top="454" left="517" width="149" height="12" font="13">ﬁts and/or harms on speciﬁc health</text>
<text top="468" left="497" width="45" height="9" font="13">outcomes?</text>
<text top="384" left="718" width="27" height="9" font="17"><a href="e127.full.html#43">8.1.6.1</a></text>
<text top="491" left="423" width="109" height="8" font="4">BP indicates blood pressure.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="790" width="18" height="9" font="4">e133</text>
</page>
<page number="8" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="333" height="12" font="2">geriatrician, a nephrologist, a neurologist, a nurse, a</text>
<text top="161" left="108" width="333" height="12" font="2">pharmacist, a physician assistant, and 2 lay/patient rep-</text>
<text top="178" left="108" width="333" height="12" font="2">resentatives. It included representatives from the ACC,</text>
<text top="196" left="108" width="333" height="12" font="2">AHA, American Academy of Physician Assistants (AAPA),</text>
<text top="214" left="108" width="333" height="12" font="2">Association of Black Cardiologists (ABC), American Col-</text>
<text top="232" left="108" width="334" height="12" font="2">lege of Preventive Medicine (ACPM), American Geriatrics</text>
<text top="250" left="108" width="333" height="12" font="2">Society (AGS), American Pharmacists Association (APhA),</text>
<text top="268" left="108" width="333" height="12" font="2">American Society of Hypertension (ASH), American So-</text>
<text top="286" left="108" width="333" height="12" font="2">ciety for Preventive Cardiology (ASPC), National Medical</text>
<text top="304" left="108" width="66" height="12" font="2">Association</text>
<text top="304" left="188" width="41" height="12" font="2">(NMA),</text>
<text top="304" left="243" width="21" height="12" font="2">and</text>
<text top="304" left="279" width="62" height="12" font="2">Preventive</text>
<text top="304" left="355" width="86" height="12" font="2">Cardiovascular</text>
<text top="322" left="108" width="161" height="12" font="2">Nurses Association (PCNA).</text>
<text top="357" left="108" width="193" height="11" font="12">1.3. Document Review and Approval</text>
<text top="379" left="108" width="241" height="12" font="2">This document was reviewed by 2 of</text>
<text top="377" left="348" width="92" height="15" font="2">ﬁcial reviewers</text>
<text top="397" left="108" width="333" height="12" font="2">nominated by the ACC and AHA; 1 reviewer each from the</text>
<text top="415" left="108" width="333" height="12" font="2">AAPA, ABC, ACPM, AGS, APhA, ASH, ASPC, NMA, and</text>
<text top="433" left="108" width="330" height="12" font="2">PCNA; and 38 individual content reviewers. Reviewers</text>
<text top="431" left="437" width="3" height="15" font="2">’</text>
<text top="451" left="108" width="333" height="12" font="2">RWI information was distributed to the writing commit-</text>
<text top="469" left="108" width="229" height="12" font="2">tee and is published in this document (</text>
<text top="469" left="337" width="66" height="12" font="5"><a href="e127.full.html#114">Appendix 2</a></text>
<text top="469" left="404" width="8" height="12" font="2"><a href="e127.full.html#114">).</a></text>
<text top="486" left="123" width="319" height="12" font="2">This document was approved for publication by the</text>
<text top="504" left="108" width="333" height="12" font="2">governing bodies of the ACC, AHA, AAPA, ABC, ACPM,</text>
<text top="522" left="108" width="240" height="12" font="2">AGS, APhA, ASH, ASPC, NMA, and PCNA.</text>
<text top="558" left="108" width="144" height="11" font="12">1.4. Scope of the Guideline</text>
<text top="579" left="108" width="333" height="12" font="2">The present guideline is intended to be a resource for</text>
<text top="597" left="108" width="333" height="12" font="2">the clinical and public health practice communities. It is</text>
<text top="615" left="108" width="333" height="12" font="2">designed to be comprehensive but succinct and practical</text>
<text top="633" left="108" width="333" height="12" font="2">in providing guidance for prevention, detection, evalu-</text>
<text top="651" left="108" width="333" height="12" font="2">ation, and management of high BP. It is an update of the</text>
<text top="669" left="108" width="115" height="12" font="2">NHLBI publication,</text>
<text top="667" left="230" width="211" height="15" font="2">“The Seventh Report of the Joint</text>
<text top="687" left="108" width="334" height="12" font="2">National Committee on Prevention, Detection, Evalua-</text>
<text top="705" left="108" width="274" height="12" font="2">tion and Treatment of High Blood Pressure</text>
<text top="703" left="382" width="59" height="15" font="2">” (JNC 7)</text>
<text top="723" left="108" width="42" height="12" font="5"><a href="e127.full.html#85">(S1.5-7)</a></text>
<text top="723" left="149" width="292" height="12" font="2">. It incorporates new information from studies of</text>
<text top="741" left="108" width="11" height="12" font="2">of</text>
<text top="739" left="119" width="322" height="15" font="2">ﬁce-based BP-related risk of CVD, ambulatory blood</text>
<text top="759" left="108" width="333" height="12" font="2">pressure monitoring (ABPM), home blood pressure</text>
<text top="776" left="108" width="333" height="12" font="2">monitoring (HBPM), telemedicine, and various other</text>
<text top="794" left="108" width="333" height="12" font="2">areas. This guideline does not address the use of</text>
<text top="812" left="108" width="333" height="12" font="2">BP-lowering medications for the purposes of prevention</text>
<text top="830" left="108" width="333" height="12" font="2">of recurrent CVD events in patients with stable ischemic</text>
<text top="848" left="108" width="333" height="12" font="2">heart disease (SIHD) or chronic heart failure (HF) in the</text>
<text top="866" left="108" width="333" height="12" font="2">absence of hypertension; these topics are the focus of</text>
<text top="884" left="108" width="154" height="12" font="2">other ACC/AHA guidelines</text>
<text top="884" left="266" width="86" height="12" font="5"><a href="e127.full.html#85">(S1.5-9,S1.5-10)</a></text>
<text top="884" left="353" width="88" height="12" font="2"><a href="e127.full.html#85">. </a>In developing</text>
<text top="902" left="108" width="333" height="12" font="2">the present guideline, the writing committee reviewed</text>
<text top="920" left="108" width="28" height="12" font="2">prior</text>
<text top="920" left="148" width="57" height="12" font="2">published</text>
<text top="920" left="218" width="64" height="12" font="2">guidelines,</text>
<text top="920" left="294" width="52" height="12" font="2">evidence</text>
<text top="920" left="358" width="48" height="12" font="2">reviews,</text>
<text top="920" left="419" width="21" height="12" font="2">and</text>
<text top="938" left="108" width="115" height="12" font="2">related statements.</text>
<text top="938" left="230" width="44" height="11" font="5"><a href="e127.full.html#9">Table 3</a></text>
<text top="938" left="281" width="160" height="12" font="2">contains a list of publica-</text>
<text top="956" left="108" width="333" height="12" font="2">tions and statements deemed pertinent to this writing</text>
<text top="974" left="108" width="333" height="12" font="2">effort and is intended for use as a resource, thus</text>
<text top="992" left="108" width="54" height="12" font="2">obviating</text>
<text top="992" left="176" width="19" height="12" font="2">the</text>
<text top="992" left="209" width="28" height="12" font="2">need</text>
<text top="992" left="251" width="11" height="12" font="2">to</text>
<text top="992" left="276" width="36" height="12" font="2">repeat</text>
<text top="992" left="327" width="46" height="12" font="2">existing</text>
<text top="992" left="387" width="54" height="12" font="2">guideline</text>
<text top="1010" left="108" width="108" height="12" font="2">recommendations.</text>
<text top="143" left="468" width="175" height="11" font="12">1.5. Abbreviations and Acronyms</text>
<text top="897" left="468" width="136" height="16" font="14">2. BP AND CVD RISK</text>
<text top="935" left="468" width="165" height="11" font="12">2.1. Observational Relationship</text>
<text top="956" left="468" width="333" height="12" font="2">Observational studies have demonstrated graded asso-</text>
<text top="974" left="468" width="333" height="12" font="2">ciations between higher systolic blood pressure (SBP)</text>
<text top="992" left="468" width="333" height="12" font="2">and diastolic blood pressure (DBP) and increased CVD</text>
<text top="1010" left="468" width="21" height="12" font="2">risk</text>
<text top="1010" left="495" width="78" height="12" font="5"><a href="e127.full.html#86">(S2.1-1,S2.1-2)</a></text>
<text top="1010" left="573" width="228" height="12" font="2">. In a meta-analysis of 61 prospective</text>
<text top="189" left="468" width="105" height="9" font="13">Abbreviation/Acronym</text>
<text top="189" left="670" width="75" height="9" font="13">Meaning/Phrase</text>
<text top="208" left="468" width="25" height="9" font="13">ABPM</text>
<text top="208" left="614" width="161" height="9" font="13">ambulatory blood pressure monitoring</text>
<text top="228" left="468" width="17" height="9" font="13">ACE</text>
<text top="228" left="614" width="131" height="9" font="13">angiotensin-converting enzyme</text>
<text top="247" left="468" width="11" height="9" font="13">AF</text>
<text top="247" left="614" width="21" height="9" font="13">atrial</text>
<text top="245" left="638" width="43" height="12" font="13">ﬁbrillation</text>
<text top="266" left="468" width="17" height="9" font="13">ARB</text>
<text top="266" left="614" width="120" height="9" font="13">angiotensin receptor blocker</text>
<text top="285" left="468" width="11" height="9" font="13">BP</text>
<text top="285" left="614" width="62" height="9" font="13">blood pressure</text>
<text top="304" left="468" width="17" height="9" font="13">CCB</text>
<text top="304" left="614" width="101" height="9" font="13">calcium channel blocker</text>
<text top="324" left="468" width="18" height="9" font="13">CHD</text>
<text top="324" left="614" width="94" height="9" font="13">coronary heart disease</text>
<text top="343" left="468" width="18" height="9" font="13">CKD</text>
<text top="343" left="614" width="93" height="9" font="13">chronic kidney disease</text>
<text top="362" left="468" width="22" height="9" font="13">CPAP</text>
<text top="362" left="614" width="149" height="9" font="13">continuous positive airway pressure</text>
<text top="381" left="468" width="18" height="9" font="13">CVD</text>
<text top="381" left="614" width="92" height="9" font="13">cardiovascular disease</text>
<text top="400" left="468" width="18" height="9" font="13">DBP</text>
<text top="400" left="614" width="100" height="9" font="13">diastolic blood pressure</text>
<text top="420" left="468" width="14" height="9" font="13">DM</text>
<text top="420" left="614" width="71" height="9" font="13">diabetes mellitus</text>
<text top="439" left="468" width="17" height="9" font="13">ECG</text>
<text top="439" left="614" width="76" height="9" font="13">electrocardiogram</text>
<text top="458" left="468" width="22" height="9" font="13">ESRD</text>
<text top="458" left="614" width="99" height="9" font="13">end-stage renal disease</text>
<text top="477" left="468" width="26" height="9" font="13">GDMT</text>
<text top="477" left="614" width="186" height="9" font="13">guideline-directed management and therapy</text>
<text top="496" left="468" width="17" height="9" font="13">GFR</text>
<text top="496" left="614" width="45" height="9" font="13">glomerular</text>
<text top="495" left="662" width="56" height="12" font="13">ﬁltration rate</text>
<text top="516" left="468" width="26" height="9" font="13">HBPM</text>
<text top="516" left="614" width="137" height="9" font="13">home blood pressure monitoring</text>
<text top="535" left="468" width="18" height="9" font="13">EHR</text>
<text top="535" left="614" width="100" height="9" font="13">electronic health record</text>
<text top="554" left="468" width="12" height="9" font="13">HF</text>
<text top="554" left="614" width="51" height="9" font="13">heart failure</text>
<text top="573" left="468" width="27" height="9" font="13">HFpEF</text>
<text top="573" left="614" width="188" height="9" font="13">heart failure with preserved ejection fraction</text>
<text top="592" left="468" width="25" height="9" font="13">HFrEF</text>
<text top="592" left="614" width="180" height="9" font="13">heart failure with reduced ejection fraction</text>
<text top="612" left="468" width="15" height="9" font="13">ICH</text>
<text top="612" left="614" width="106" height="9" font="13">intracerebral hemorrhage</text>
<text top="631" left="468" width="16" height="9" font="13">JNC</text>
<text top="631" left="614" width="111" height="9" font="13">Joint National Commission</text>
<text top="650" left="468" width="11" height="9" font="13">LV</text>
<text top="650" left="614" width="62" height="9" font="13">left ventricular</text>
<text top="669" left="468" width="17" height="9" font="13">LVH</text>
<text top="669" left="614" width="116" height="9" font="13">left ventricular hypertrophy</text>
<text top="688" left="468" width="10" height="9" font="13">MI</text>
<text top="688" left="614" width="88" height="9" font="13">myocardial infarction</text>
<text top="708" left="468" width="16" height="9" font="13">MRI</text>
<text top="708" left="614" width="119" height="9" font="13">magnetic resonance imaging</text>
<text top="727" left="468" width="18" height="9" font="13">PAD</text>
<text top="727" left="614" width="103" height="9" font="13">peripheral artery disease</text>
<text top="746" left="468" width="17" height="9" font="13">RAS</text>
<text top="746" left="614" width="105" height="9" font="13">renin-angiotensin system</text>
<text top="765" left="468" width="17" height="9" font="13">RCT</text>
<text top="765" left="614" width="114" height="9" font="13">randomized controlled trial</text>
<text top="784" left="468" width="16" height="9" font="13">SBP</text>
<text top="784" left="614" width="96" height="9" font="13">systolic blood pressure</text>
<text top="804" left="468" width="20" height="9" font="13">SIHD</text>
<text top="804" left="614" width="122" height="9" font="13">stable ischemic heart disease</text>
<text top="823" left="468" width="14" height="9" font="13">TIA</text>
<text top="823" left="614" width="104" height="9" font="13">transient ischemic attack</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e134</text>
</page>
<page number="9" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="18" size="7" family="Times" color="#0e2a52"/>
<text top="149" left="71" width="47" height="10" font="15">T A B L E 3</text>
<text top="149" left="135" width="202" height="10" font="16">Associated Guidelines and Statements</text>
<text top="173" left="63" width="21" height="9" font="13">Title</text>
<text top="173" left="510" width="59" height="9" font="13">Organization</text>
<text top="173" left="669" width="76" height="9" font="13">Publication Year</text>
<text top="192" left="63" width="45" height="9" font="18">Guidelines</text>
<text top="212" left="63" width="175" height="9" font="13">Lower-extremity peripheral artery disease</text>
<text top="212" left="521" width="39" height="9" font="13">AHA/ACC</text>
<text top="212" left="678" width="21" height="9" font="13">2016</text>
<text top="212" left="702" width="35" height="9" font="17"><a href="e127.full.html#85">(S1.5-11)</a></text>
<text top="231" left="63" width="338" height="9" font="13">Management of primary aldosteronism: case detection, diagnosis, and treatment</text>
<text top="231" left="503" width="74" height="9" font="13">Endocrine Society</text>
<text top="231" left="677" width="21" height="9" font="13">2016</text>
<text top="231" left="702" width="36" height="9" font="17"><a href="e127.full.html#85">(S1.5-12)</a></text>
<text top="250" left="63" width="122" height="9" font="13">Stable ischemic heart disease</text>
<text top="250" left="474" width="133" height="9" font="13">ACC/AHA/AATS/PCNA/SCAI/STS</text>
<text top="250" left="664" width="21" height="9" font="13">2014</text>
<text top="250" left="688" width="40" height="9" font="17"><a href="e127.full.html#85">(S1.5-13)*</a></text>
<text top="250" left="731" width="20" height="9" font="13">2012</text>
<text top="262" left="699" width="33" height="9" font="17"><a href="e127.full.html#85">(S1.5-9)</a></text>
<text top="281" left="63" width="165" height="9" font="13">Pheochromocytoma and paraganglioma</text>
<text top="281" left="503" width="74" height="9" font="13">Endocrine Society</text>
<text top="281" left="677" width="21" height="9" font="13">2014</text>
<text top="281" left="701" width="37" height="9" font="17"><a href="e127.full.html#85">(S1.5-14)</a></text>
<text top="300" left="63" width="23" height="9" font="13">Atrial</text>
<text top="299" left="88" width="43" height="12" font="13">ﬁbrillation</text>
<text top="300" left="510" width="60" height="9" font="13">AHA/ACC/HRS</text>
<text top="300" left="678" width="21" height="9" font="13">2014</text>
<text top="300" left="701" width="36" height="9" font="17"><a href="e127.full.html#85">(S1.5-15)</a></text>
<text top="320" left="63" width="92" height="9" font="13">Valvular heart disease</text>
<text top="320" left="521" width="39" height="9" font="13">ACC/AHA</text>
<text top="320" left="678" width="20" height="9" font="13">2017</text>
<text top="320" left="701" width="37" height="9" font="17"><a href="e127.full.html#85">(S1.5-16)</a></text>
<text top="339" left="63" width="140" height="9" font="13">Assessment of cardiovascular risk</text>
<text top="339" left="521" width="39" height="9" font="13">ACC/AHA</text>
<text top="339" left="678" width="20" height="9" font="13">2013</text>
<text top="339" left="701" width="36" height="9" font="17"><a href="e127.full.html#85">(S1.5-17)</a></text>
<text top="358" left="63" width="112" height="9" font="13">Hypertension in pregnancy</text>
<text top="358" left="528" width="24" height="9" font="13">ACOG</text>
<text top="358" left="678" width="20" height="9" font="13">2013</text>
<text top="358" left="701" width="37" height="9" font="17"><a href="e127.full.html#85">(S1.5-18)</a></text>
<text top="377" left="63" width="53" height="9" font="13">Heart failure</text>
<text top="377" left="521" width="39" height="9" font="13">ACC/AHA</text>
<text top="377" left="678" width="20" height="9" font="13">2017</text>
<text top="377" left="701" width="37" height="9" font="17"><a href="e127.full.html#85">(S1.5-19)</a></text>
<text top="389" left="677" width="20" height="9" font="13">2013</text>
<text top="389" left="701" width="37" height="9" font="17"><a href="e127.full.html#85">(S1.5-10)</a></text>
<text top="408" left="63" width="215" height="9" font="13">Lifestyle management to reduce cardiovascular risk</text>
<text top="408" left="521" width="39" height="9" font="13">AHA/ACC</text>
<text top="408" left="677" width="20" height="9" font="13">2013</text>
<text top="408" left="700" width="38" height="9" font="17"><a href="e127.full.html#85">(S1.5-20)</a></text>
<text top="428" left="63" width="156" height="9" font="13">Management of arterial hypertension</text>
<text top="428" left="522" width="36" height="9" font="13">ESH/ESC</text>
<text top="428" left="678" width="20" height="9" font="13">2013</text>
<text top="428" left="701" width="36" height="9" font="17"><a href="e127.full.html#85">(S1.5-21)</a></text>
<text top="447" left="63" width="207" height="9" font="13">Management of overweight and obesity in adults</text>
<text top="447" left="510" width="59" height="9" font="13">AHA/ACC/TOS</text>
<text top="447" left="677" width="20" height="9" font="13">2013</text>
<text top="447" left="701" width="37" height="9" font="17"><a href="e127.full.html#86">(S1.5-22)</a></text>
<text top="466" left="63" width="143" height="9" font="13">ST-elevation myocardial infarction</text>
<text top="466" left="521" width="39" height="9" font="13">ACC/AHA</text>
<text top="466" left="677" width="20" height="9" font="13">2013</text>
<text top="466" left="701" width="37" height="9" font="17"><a href="e127.full.html#86">(S1.5-23)</a></text>
<text top="485" left="63" width="358" height="9" font="13">Treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults</text>
<text top="485" left="521" width="39" height="9" font="13">ACC/AHA</text>
<text top="485" left="677" width="20" height="9" font="13">2013</text>
<text top="485" left="700" width="38" height="9" font="17"><a href="e127.full.html#86">(S1.5-24)</a></text>
<text top="504" left="63" width="174" height="9" font="13">Cardiovascular diseases during pregnancy</text>
<text top="504" left="532" width="16" height="9" font="13">ESC</text>
<text top="504" left="678" width="19" height="9" font="13">2011</text>
<text top="504" left="700" width="37" height="9" font="17"><a href="e127.full.html#86">(S1.5-25)</a></text>
<text top="524" left="63" width="359" height="9" font="13">Effectiveness-based guidelines for the prevention of cardiovascular disease in women</text>
<text top="524" left="521" width="39" height="9" font="13">AHA/ACC</text>
<text top="524" left="677" width="19" height="9" font="13">2011</text>
<text top="524" left="700" width="38" height="9" font="17"><a href="e127.full.html#86">(S1.5-26)</a></text>
<text top="543" left="63" width="359" height="9" font="13">Secondary prevention and risk-reduction therapy for patients with coronary and other</text>
<text top="555" left="78" width="132" height="9" font="13">atherosclerotic vascular disease</text>
<text top="543" left="521" width="39" height="9" font="13">AHA/ACC</text>
<text top="543" left="678" width="19" height="9" font="13">2011</text>
<text top="543" left="700" width="37" height="9" font="17"><a href="e127.full.html#86">(S1.5-27)</a></text>
<text top="574" left="63" width="241" height="9" font="13">Assessment of cardiovascular risk in asymptomatic adults</text>
<text top="574" left="521" width="39" height="9" font="13">ACC/AHA</text>
<text top="574" left="676" width="22" height="9" font="13">2010</text>
<text top="574" left="701" width="38" height="9" font="17"><a href="e127.full.html#86">(S1.5-28)</a></text>
<text top="593" left="63" width="95" height="9" font="13">Thoracic aortic disease</text>
<text top="593" left="437" width="206" height="9" font="13">ACC/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM</text>
<text top="593" left="676" width="22" height="9" font="13">2010</text>
<text top="593" left="701" width="38" height="9" font="17"><a href="e127.full.html#86">(S1.5-29)</a></text>
<text top="612" left="63" width="317" height="9" font="13">Diagnosis, evaluation, and treatment of high blood pressure in children and</text>
<text top="624" left="78" width="49" height="9" font="13">adolescents</text>
<text top="612" left="527" width="26" height="9" font="13">NHLBI</text>
<text top="612" left="675" width="23" height="9" font="13">2004</text>
<text top="612" left="702" width="38" height="9" font="17"><a href="e127.full.html#86">(S1.5-30)</a></text>
<text top="644" left="63" width="49" height="9" font="18">Statements</text>
<text top="663" left="63" width="138" height="9" font="13">Salt sensitivity of blood pressure</text>
<text top="663" left="531" width="18" height="9" font="13">AHA</text>
<text top="663" left="678" width="21" height="9" font="13">2016</text>
<text top="663" left="702" width="36" height="9" font="17"><a href="e127.full.html#86">(S1.5-31)</a></text>
<text top="682" left="63" width="319" height="9" font="13">Cardiovascular team-based care and the role of advanced practice providers</text>
<text top="682" left="531" width="17" height="9" font="13">ACC</text>
<text top="682" left="677" width="20" height="9" font="13">2015</text>
<text top="682" left="701" width="37" height="9" font="17"><a href="e127.full.html#86">(S1.5-32)</a></text>
<text top="701" left="63" width="281" height="9" font="13">Treatment of hypertension in patients with coronary artery disease</text>
<text top="701" left="510" width="60" height="9" font="13">AHA/ACC/ASH</text>
<text top="701" left="677" width="20" height="9" font="13">2015</text>
<text top="701" left="701" width="37" height="9" font="17"><a href="e127.full.html#86">(S1.5-33)</a></text>
<text top="720" left="63" width="280" height="9" font="13">Ambulatory blood pressure monitoring in children and adolescents</text>
<text top="720" left="531" width="18" height="9" font="13">AHA</text>
<text top="720" left="677" width="21" height="9" font="13">2014</text>
<text top="720" left="701" width="38" height="9" font="17"><a href="e127.full.html#86">(S1.5-34)</a></text>
<text top="740" left="63" width="223" height="9" font="13">An effective approach to high blood pressure control</text>
<text top="740" left="510" width="60" height="9" font="13">AHA/ACC/CDC</text>
<text top="740" left="677" width="21" height="9" font="13">2014</text>
<text top="740" left="701" width="37" height="9" font="17"><a href="e127.full.html#86">(S1.5-35)</a></text>
<text top="759" left="63" width="163" height="9" font="13">Ambulatory blood pressure monitoring</text>
<text top="759" left="532" width="17" height="9" font="13">ESH</text>
<text top="759" left="677" width="20" height="9" font="13">2013</text>
<text top="759" left="700" width="38" height="9" font="17"><a href="e127.full.html#86">(S1.5-36)</a></text>
<text top="778" left="63" width="336" height="9" font="13">Performance measures for adults with coronary artery disease and hypertension</text>
<text top="778" left="497" width="85" height="9" font="13">ACC/AHA/AMA-PCPI</text>
<text top="778" left="678" width="19" height="9" font="13">2011</text>
<text top="778" left="700" width="37" height="9" font="17"><a href="e127.full.html#86">(S1.5-37)</a></text>
<text top="797" left="63" width="314" height="9" font="13">Interventions to promote physical activity and dietary lifestyle changes for</text>
<text top="809" left="78" width="186" height="9" font="13">cardiovascular risk factor reduction in adults</text>
<text top="797" left="531" width="18" height="9" font="13">AHA</text>
<text top="797" left="676" width="22" height="9" font="13">2010</text>
<text top="797" left="701" width="38" height="9" font="17"><a href="e127.full.html#86">(S1.5-38)</a></text>
<text top="828" left="63" width="254" height="9" font="13">Resistant hypertension: diagnosis, evaluation, and treatment</text>
<text top="828" left="531" width="18" height="9" font="13">AHA</text>
<text top="828" left="675" width="24" height="9" font="13">2008</text>
<text top="828" left="702" width="38" height="9" font="17"><a href="e127.full.html#86">(S1.5-39)</a></text>
<text top="853" left="63" width="163" height="8" font="4">*The full-text SIHD guideline is from 2012</text>
<text top="853" left="229" width="30" height="8" font="8"><a href="e127.full.html#85">(S1.5-9)</a></text>
<text top="853" left="259" width="162" height="8" font="4">. A focused update was published in 2014</text>
<text top="853" left="424" width="33" height="8" font="8"><a href="e127.full.html#85">(S1.5-13)</a></text>
<text top="853" left="457" width="2" height="8" font="4">.</text>
<text top="868" left="71" width="686" height="8" font="4">AATS indicates American Association for Thoracic Surgery; ACC, American College of Cardiology; ACOG, American College of Obstetricians and Gynecologists; ACR, American College</text>
<text top="880" left="63" width="694" height="8" font="4">of Radiology; AHA, American Heart Association; AMA, American Medical Association; ASA, American Stroke Association; ASH, American Society of Hypertension; CDC, Centers for</text>
<text top="892" left="63" width="694" height="8" font="4">Disease Control and Prevention; ESC, European Society of Cardiology; ESH, European Society of Hypertension; HRS, Heart Rhythm Society; NHLBI, National Heart, Lung, and Blood</text>
<text top="904" left="63" width="694" height="8" font="4">Institute; PCNA, Preventive Cardiovascular Nurses Association; PCPI, Physician Consortium for Performance Improvement; SCA, Society of Cardiovascular Anesthesiologists; SCAI,</text>
<text top="915" left="63" width="694" height="8" font="4">Society for Cardiovascular Angiography and Interventions; SIHD, stable ischemic heart disease; SIR, Society of Interventional Radiology; STS, Society of Thoracic Surgeons; SVM,</text>
<text top="927" left="63" width="235" height="8" font="4">Society for Vascular Medicine; and TOS, The Obesity Society.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="790" width="18" height="9" font="4">e135</text>
</page>
<page number="10" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="19" size="9" family="Times" color="#ffffff"/>
<text top="143" left="108" width="333" height="12" font="2">studies, the risk of CVD increased in a log-linear fashion</text>
<text top="161" left="108" width="94" height="12" font="2">from SBP levels</text>
<text top="159" left="207" width="234" height="15" font="2">&lt;115 mm Hg to &gt;180 mm Hg and from</text>
<text top="178" left="108" width="63" height="12" font="2">DBP levels</text>
<text top="177" left="176" width="169" height="15" font="2">&lt;75 mm Hg to &gt;105 mm Hg</text>
<text top="178" left="351" width="41" height="12" font="5"><a href="e127.full.html#86">(S2.1-1)</a></text>
<text top="178" left="392" width="49" height="12" font="2"><a href="e127.full.html#86">. </a>In that</text>
<text top="196" left="108" width="333" height="12" font="2">analysis, 20 mm Hg higher SBP and 10 mm Hg higher</text>
<text top="214" left="108" width="333" height="12" font="2">DBP were each associated with a doubling in the risk of</text>
<text top="232" left="108" width="333" height="12" font="2">death from stroke, heart disease, or other vascular dis-</text>
<text top="250" left="108" width="311" height="12" font="2">ease. In a separate observational study including</text>
<text top="248" left="427" width="14" height="15" font="2">&gt;1</text>
<text top="268" left="108" width="128" height="12" font="2">million adult patients</text>
<text top="266" left="241" width="200" height="15" font="2">$30 years of age, higher SBP and</text>
<text top="286" left="108" width="333" height="12" font="2">DBP were associated with increased risk of CVD inci-</text>
<text top="304" left="108" width="333" height="12" font="2">dence and angina, myocardial infarction (MI), HF,</text>
<text top="322" left="108" width="333" height="12" font="2">stroke, peripheral artery disease (PAD), and abdominal</text>
<text top="340" left="108" width="260" height="12" font="2">aortic aneurysm, each evaluated separately</text>
<text top="340" left="374" width="42" height="12" font="5"><a href="e127.full.html#86">(S2.1-2)</a></text>
<text top="340" left="416" width="25" height="12" font="2"><a href="e127.full.html#86">. </a>An</text>
<text top="358" left="108" width="333" height="12" font="2">increased risk of CVD associated with higher SBP and</text>
<text top="376" left="108" width="333" height="12" font="2">DBP has been reported across a broad age spectrum,</text>
<text top="394" left="108" width="97" height="12" font="2">from 30 years to</text>
<text top="392" left="209" width="232" height="15" font="2">&gt;80 years of age. Although the relative</text>
<text top="412" left="108" width="333" height="12" font="2">risk of incident CVD associated with higher SBP and DBP</text>
<text top="430" left="108" width="328" height="12" font="2">is smaller at older ages, the corresponding high BP</text>
<text top="428" left="436" width="5" height="15" font="2">–</text>
<text top="447" left="108" width="333" height="12" font="2">related increase in absolute risk is larger in older persons</text>
<text top="465" left="108" width="4" height="12" font="2">(</text>
<text top="464" left="112" width="329" height="15" font="2">$65 years) given the higher absolute risk of CVD at an</text>
<text top="483" left="108" width="54" height="12" font="2">older age</text>
<text top="483" left="167" width="41" height="12" font="5"><a href="e127.full.html#86">(S2.1-1)</a></text>
<text top="483" left="208" width="3" height="12" font="2"><a href="e127.full.html#86">.</a></text>
<text top="524" left="108" width="108" height="11" font="12">2.2. BP Components</text>
<text top="545" left="108" width="333" height="12" font="2">Epidemiological studies have evaluated associations of</text>
<text top="563" left="108" width="333" height="12" font="2">SBP and DBP, as well as derived components of BP</text>
<text top="581" left="108" width="333" height="12" font="2">measurements (including pulse pressure, mean BP, and</text>
<text top="599" left="108" width="190" height="12" font="2">mid-BP), with CVD outcomes (</text>
<text top="599" left="298" width="45" height="11" font="5"><a href="e127.full.html#10">Table 4</a></text>
<text top="599" left="343" width="98" height="12" font="2"><a href="e127.full.html#10">). </a>When consid-</text>
<text top="617" left="108" width="333" height="12" font="2">ered separately, higher levels of both SBP and DBP have</text>
<text top="635" left="108" width="244" height="12" font="2">been associated with increased CVD risk</text>
<text top="635" left="357" width="80" height="12" font="5"><a href="e127.full.html#86">(S2.2-1,S2.2-2)</a></text>
<text top="635" left="437" width="3" height="12" font="2">.</text>
<text top="653" left="108" width="333" height="12" font="2">Higher SBP has consistently been associated with</text>
<text top="671" left="108" width="333" height="12" font="2">increased CVD risk after adjustment for, or within strata</text>
<text top="689" left="108" width="45" height="12" font="2">of, DBP</text>
<text top="689" left="158" width="38" height="12" font="5"><a href="e127.full.html#86">(S2.2-3</a></text>
<text top="687" left="197" width="48" height="15" font="5"><a href="e127.full.html#86">—S2.2-5)</a></text>
<text top="689" left="245" width="196" height="12" font="2">. In contrast, after consideration</text>
<text top="707" left="108" width="11" height="12" font="2">of</text>
<text top="707" left="132" width="22" height="12" font="2">SBP</text>
<text top="707" left="166" width="46" height="12" font="2">through</text>
<text top="707" left="225" width="66" height="12" font="2">adjustment</text>
<text top="707" left="303" width="12" height="12" font="2">or</text>
<text top="707" left="327" width="30" height="12" font="2">strati</text>
<text top="705" left="358" width="83" height="15" font="2">ﬁcation, DBP</text>
<text top="725" left="108" width="333" height="12" font="2">has not been consistently associated with CVD risk</text>
<text top="742" left="108" width="82" height="12" font="5"><a href="e127.full.html#86">(S2.2-6,S2.2-7)</a></text>
<text top="742" left="190" width="251" height="12" font="2"><a href="e127.full.html#86">. </a>Although pulse pressure and mid-BP</text>
<text top="760" left="108" width="333" height="12" font="2">have been associated with increased CVD risk indepen-</text>
<text top="778" left="108" width="333" height="12" font="2">dent of SBP and DBP in some studies, SBP (especially)</text>
<text top="796" left="108" width="333" height="12" font="2">and DBP are prioritized in the present document</text>
<text top="814" left="108" width="333" height="12" font="2">because of the robust evidence base for these measures</text>
<text top="832" left="108" width="333" height="12" font="2">in both observational studies and clinical trials and</text>
<text top="850" left="108" width="333" height="12" font="2">because of their ease of measurement in practice</text>
<text top="868" left="108" width="45" height="12" font="2">settings</text>
<text top="868" left="158" width="39" height="12" font="5"><a href="e127.full.html#86">(S2.2-8</a></text>
<text top="866" left="198" width="52" height="15" font="5"><a href="e127.full.html#86">—S2.2-11)</a></text>
<text top="868" left="250" width="3" height="12" font="2">.</text>
<text top="364" left="468" width="107" height="11" font="12">2.3. Population Risk</text>
<text top="386" left="468" width="333" height="12" font="2">In 2010, high BP was the leading cause of death and</text>
<text top="404" left="468" width="230" height="12" font="2">disability-adjusted life years worldwide</text>
<text top="404" left="702" width="80" height="12" font="5"><a href="e127.full.html#86">(S2.3-1,S2.3-2)</a></text>
<text top="404" left="782" width="19" height="12" font="2">. In</text>
<text top="422" left="468" width="214" height="12" font="2">the United States, hypertension (see</text>
<text top="422" left="687" width="62" height="12" font="5"><a href="e127.full.html#11">Section 3.1</a></text>
<text top="422" left="754" width="35" height="12" font="2">for de</text>
<text top="420" left="789" width="12" height="15" font="2">ﬁ-</text>
<text top="439" left="468" width="333" height="12" font="2">nition) accounted for more CVD deaths than any other</text>
<text top="457" left="468" width="29" height="12" font="2">modi</text>
<text top="456" left="498" width="304" height="15" font="2">ﬁable CVD risk factor and was second only to ciga-</text>
<text top="475" left="468" width="333" height="12" font="2">rette smoking as a preventable cause of death for any</text>
<text top="493" left="468" width="38" height="12" font="2">reason</text>
<text top="493" left="515" width="43" height="12" font="5"><a href="e127.full.html#86">(S2.3-3)</a></text>
<text top="493" left="558" width="243" height="12" font="2">. In a follow-up study of 23,272 U.S.</text>
<text top="511" left="468" width="333" height="12" font="2">NHANES (National Health and Nutrition Examination</text>
<text top="529" left="468" width="121" height="12" font="2">Survey) participants,</text>
<text top="527" left="592" width="209" height="15" font="2">&gt;50% of deaths from coronary heart</text>
<text top="547" left="468" width="333" height="12" font="2">disease (CHD) and stroke occurred among individuals with</text>
<text top="565" left="468" width="77" height="12" font="2">hypertension</text>
<text top="565" left="549" width="44" height="12" font="5"><a href="e127.full.html#86">(S2.3-4)</a></text>
<text top="565" left="593" width="208" height="12" font="2">. Because of the high prevalence of</text>
<text top="583" left="468" width="333" height="12" font="2">hypertension and its associated increased risk of CHD,</text>
<text top="601" left="468" width="39" height="12" font="2">stroke,</text>
<text top="601" left="521" width="21" height="12" font="2">and</text>
<text top="601" left="556" width="57" height="12" font="2">end-stage</text>
<text top="601" left="626" width="29" height="12" font="2">renal</text>
<text top="601" left="669" width="42" height="12" font="2">disease</text>
<text top="601" left="725" width="44" height="12" font="2">(ESRD),</text>
<text top="601" left="783" width="19" height="12" font="2">the</text>
<text top="619" left="468" width="333" height="12" font="2">population-attributable risk of these outcomes associated</text>
<text top="637" left="468" width="26" height="12" font="2">with</text>
<text top="637" left="507" width="77" height="12" font="2">hypertension</text>
<text top="637" left="597" width="9" height="12" font="2">is</text>
<text top="637" left="620" width="25" height="12" font="2">high</text>
<text top="637" left="658" width="82" height="12" font="5"><a href="e127.full.html#86">(S2.3-4,S2.3-5)</a></text>
<text top="637" left="741" width="3" height="12" font="2"><a href="e127.full.html#86">.</a></text>
<text top="637" left="758" width="12" height="12" font="2">In</text>
<text top="637" left="783" width="19" height="12" font="2">the</text>
<text top="655" left="468" width="333" height="12" font="2">population-based ARIC (Atherosclerosis Risk in Commu-</text>
<text top="673" left="468" width="333" height="12" font="2">nities) study, 25% of the cardiovascular events (CHD,</text>
<text top="690" left="468" width="333" height="12" font="2">coronary revascularization, stroke, or HF) were attribut-</text>
<text top="708" left="468" width="333" height="12" font="2">able to hypertension. In the Northern Manhattan study,</text>
<text top="726" left="468" width="333" height="12" font="2">the percentage of events attributable to hypertension was</text>
<text top="744" left="468" width="333" height="12" font="2">higher in women (32%) than in men (19%) and higher in</text>
<text top="762" left="468" width="203" height="12" font="2">blacks (36%) than in whites (21%)</text>
<text top="762" left="677" width="43" height="12" font="5"><a href="e127.full.html#87">(S2.3-6)</a></text>
<text top="762" left="721" width="81" height="12" font="2"><a href="e127.full.html#87">. </a>In 2012, hy-</text>
<text top="780" left="468" width="333" height="12" font="2">pertension was the second leading assigned cause of</text>
<text top="798" left="468" width="333" height="12" font="2">ESRD, behind diabetes mellitus (DM), and accounted for</text>
<text top="816" left="468" width="284" height="12" font="2">34% of incident ESRD cases in the U.S. population</text>
<text top="816" left="755" width="43" height="12" font="5"><a href="e127.full.html#87">(S2.3-7)</a></text>
<text top="816" left="798" width="3" height="12" font="2"><a href="e127.full.html#87">.</a></text>
<text top="850" left="468" width="245" height="11" font="12">2.4. Coexistence of Hypertension and Related</text>
<text top="868" left="492" width="99" height="11" font="12">Chronic Conditions</text>
<text top="149" left="475" width="48" height="10" font="15">T A B L E 4</text>
<text top="149" left="540" width="107" height="10" font="16">BP Measurement De</text>
<text top="147" left="647" width="43" height="14" font="16">ﬁnitions</text>
<text top="173" left="468" width="79" height="9" font="13">BP Measurement</text>
<text top="173" left="705" width="12" height="9" font="13">De</text>
<text top="172" left="717" width="33" height="12" font="13">ﬁnition</text>
<text top="192" left="468" width="16" height="9" font="13">SBP</text>
<text top="192" left="654" width="90" height="9" font="13">First Korotkoff <a href="e127.full.html#10">sound</a></text>
<text top="192" left="743" width="4" height="9" font="17"><a href="e127.full.html#10">*</a></text>
<text top="212" left="468" width="18" height="9" font="13">DBP</text>
<text top="212" left="654" width="91" height="9" font="13">Fifth Korotkoff sound</text>
<text top="212" left="745" width="4" height="9" font="17"><a href="e127.full.html#10">*</a></text>
<text top="231" left="468" width="60" height="9" font="13">Pulse pressure</text>
<text top="231" left="654" width="64" height="9" font="13">SBP minus DBP</text>
<text top="250" left="468" width="93" height="9" font="13">Mean arterial pressure</text>
<text top="250" left="654" width="143" height="9" font="13">DBP plus one third pulse pressure</text>
<text top="248" left="797" width="5" height="12" font="17"><a href="e127.full.html#10">†</a></text>
<text top="269" left="468" width="31" height="9" font="13">Mid-BP</text>
<text top="269" left="654" width="145" height="9" font="13">Sum of SBP and DBP, divided by 2</text>
<text top="294" left="468" width="17" height="8" font="4">*See</text>
<text top="294" left="487" width="35" height="8" font="8"><a href="e127.full.html#14">Section 4</a></text>
<text top="294" left="525" width="142" height="8" font="4">for a description of Korotkoff sounds.</text>
<text top="293" left="669" width="132" height="11" font="4">†Calculation assumes normal heart</text>
<text top="306" left="468" width="18" height="8" font="4">rate.</text>
<text top="321" left="476" width="325" height="8" font="4">BP indicates blood pressure; DBP, diastolic blood pressure; and SBP, systolic blood</text>
<text top="333" left="468" width="35" height="8" font="4">pressure.</text>
<text top="922" left="63" width="460" height="11" font="19">Recommendation for Coexistence of Hypertension and Related Chronic Conditions</text>
<text top="936" left="63" width="362" height="11" font="19">References that support the recommendation are summarized in</text>
<text top="936" left="429" width="145" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 1</a></text>
<text top="936" left="574" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="977" left="89" width="19" height="10" font="13">COR</text>
<text top="977" left="161" width="18" height="10" font="13">LOE</text>
<text top="977" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="1014" left="97" width="3" height="9" font="4">I</text>
<text top="1014" left="160" width="21" height="9" font="4">B-NR</text>
<text top="1002" left="234" width="256" height="11" font="12">1. Screening for and management of other modi</text>
<text top="1000" left="490" width="294" height="15" font="12">ﬁable CVD risk factors are recommended in adults with</text>
<text top="1017" left="246" width="69" height="11" font="12">hypertension</text>
<text top="1017" left="319" width="80" height="11" font="5"><a href="e127.full.html#87">(S2.4-1,S2.4-2)</a></text>
<text top="1017" left="399" width="3" height="11" font="12">.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e136</text>
</page>
<page number="11" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="66" width="52" height="12" font="2">Synopsis</text>
<text top="161" left="78" width="318" height="12" font="2">Many adult patients with hypertension have other CVD</text>
<text top="178" left="63" width="183" height="12" font="2">risk factors; a list of such modi</text>
<text top="177" left="246" width="150" height="15" font="2">ﬁable and relatively ﬁxed</text>
<text top="196" left="63" width="146" height="12" font="2">risk factors is provided in</text>
<text top="197" left="213" width="40" height="11" font="5"><a href="e127.full.html#11">Table 5</a></text>
<text top="196" left="253" width="143" height="12" font="2">. Among U.S. adults with</text>
<text top="214" left="63" width="333" height="12" font="2">hypertension between 2009 and 2012, 15.5% were current</text>
<text top="232" left="63" width="333" height="12" font="2">smokers, 49.5% were obese, 63.2% had hypercholester-</text>
<text top="250" left="63" width="333" height="12" font="2">olemia, 27.2% had DM, and 15.8% had chronic kidney</text>
<text top="268" left="63" width="100" height="12" font="2">disease (CKD; de</text>
<text top="266" left="163" width="233" height="15" font="2">ﬁned as estimated glomerular ﬁltration</text>
<text top="286" left="63" width="22" height="12" font="2">rate</text>
<text top="286" left="100" width="40" height="12" font="2">[eGFR]</text>
<text top="284" left="155" width="23" height="15" font="2">&lt;60</text>
<text top="286" left="194" width="72" height="12" font="2">mL/min/1.73</text>
<text top="286" left="281" width="11" height="12" font="2">m</text>
<text top="284" left="293" width="5" height="8" font="9">2</text>
<text top="286" left="312" width="38" height="12" font="2">and/or</text>
<text top="286" left="366" width="30" height="12" font="2">urine</text>
<text top="304" left="63" width="110" height="12" font="2">albumin:creatinine</text>
<text top="302" left="177" width="68" height="15" font="2">$300 mg/g)</text>
<text top="304" left="250" width="44" height="12" font="5"><a href="e127.full.html#87">(S2.4-3)</a></text>
<text top="304" left="294" width="3" height="12" font="2"><a href="e127.full.html#87">.</a></text>
<text top="322" left="78" width="318" height="12" font="2">Not only are CVD risk factors common among adults</text>
<text top="340" left="63" width="333" height="12" font="2">with hypertension, a higher percentage of adults with</text>
<text top="358" left="63" width="333" height="12" font="2">CVD risk factors have hypertension. For example, 71% of</text>
<text top="376" left="63" width="333" height="12" font="2">U.S. adults with diagnosed DM have hypertension</text>
<text top="394" left="63" width="45" height="12" font="5"><a href="e127.full.html#87">(S2.4-4)</a></text>
<text top="394" left="108" width="157" height="12" font="2">. In the Chronic Renal Insuf</text>
<text top="392" left="265" width="131" height="15" font="2">ﬁciency Cohort (CRIC),</text>
<text top="412" left="63" width="247" height="12" font="2">86% of the participants had hypertension</text>
<text top="412" left="315" width="44" height="12" font="5"><a href="e127.full.html#87">(S2.4-5)</a></text>
<text top="412" left="359" width="37" height="12" font="2">. Also,</text>
<text top="430" left="63" width="333" height="12" font="2">28.1% of adults with hypertension and CKD in the</text>
<text top="447" left="63" width="333" height="12" font="2">population-based REGARDS (Reasons for Geographic and</text>
<text top="465" left="63" width="333" height="12" font="2">Racial Differences in Stroke) study had apparent resistant</text>
<text top="483" left="63" width="77" height="12" font="2">hypertension</text>
<text top="483" left="146" width="45" height="12" font="5"><a href="e127.full.html#87">(S2.4-6)</a></text>
<text top="483" left="191" width="111" height="12" font="2"><a href="e127.full.html#87">. </a>In NHANES 1999</text>
<text top="482" left="302" width="94" height="15" font="2">–2010, 35.7% of</text>
<text top="501" left="63" width="215" height="12" font="2">obese individuals had hypertension</text>
<text top="501" left="285" width="44" height="12" font="5"><a href="e127.full.html#87">(S2.4-7)</a></text>
<text top="501" left="329" width="67" height="12" font="2"><a href="e127.full.html#87">. </a>The pres-</text>
<text top="519" left="63" width="333" height="12" font="2">ence of multiple CVD risk factors in individuals with hy-</text>
<text top="537" left="63" width="333" height="12" font="2">pertension results in high absolute risks for CHD and</text>
<text top="555" left="63" width="333" height="12" font="2">stroke in this population. For example, among U.S. adults</text>
<text top="573" left="63" width="333" height="12" font="2">with hypertension between 2009 and 2012, 41.7% had a</text>
<text top="591" left="63" width="98" height="12" font="2">10-year CHD risk</text>
<text top="589" left="165" width="231" height="15" font="2">&gt;20%, 40.9% had a risk of 10% to 20%,</text>
<text top="609" left="63" width="151" height="12" font="2">and only 18.4% had a risk</text>
<text top="607" left="217" width="32" height="15" font="2">&lt;10%</text>
<text top="609" left="254" width="44" height="12" font="5"><a href="e127.full.html#87">(S2.4-3)</a></text>
<text top="609" left="298" width="3" height="12" font="2">.</text>
<text top="627" left="78" width="29" height="12" font="2">Modi</text>
<text top="625" left="107" width="289" height="15" font="2">ﬁable risk factors for CVD that are common among</text>
<text top="645" left="63" width="333" height="12" font="2">adults with hypertension include cigarette smoking/</text>
<text top="663" left="63" width="333" height="12" font="2">tobacco smoke exposure, DM, dyslipidemia (including</text>
<text top="681" left="63" width="333" height="12" font="2">high levels of low-density lipoprotein cholesterol or</text>
<text top="698" left="63" width="333" height="12" font="2">hypercholesterolemia, high levels of triglycerides, and</text>
<text top="716" left="63" width="333" height="12" font="2">low levels of high-density lipoprotein cholesterol), over-</text>
<text top="734" left="63" width="228" height="12" font="2">weight/obesity, physical inactivity/low</text>
<text top="733" left="296" width="101" height="15" font="2">ﬁtness level, and</text>
<text top="752" left="63" width="59" height="12" font="2">unhealthy</text>
<text top="752" left="134" width="22" height="12" font="2">diet</text>
<text top="752" left="169" width="45" height="12" font="5"><a href="e127.full.html#87">(S2.4-8)</a></text>
<text top="752" left="214" width="3" height="12" font="2">.</text>
<text top="752" left="231" width="22" height="12" font="2">The</text>
<text top="752" left="265" width="69" height="12" font="2">relationship</text>
<text top="752" left="347" width="49" height="12" font="2">between</text>
<text top="770" left="63" width="169" height="12" font="2">hypertension and other modi</text>
<text top="768" left="232" width="164" height="15" font="2">ﬁable risk factors is complex</text>
<text top="788" left="63" width="333" height="12" font="2">and interdependent, with several sharing mechanisms of</text>
<text top="806" left="63" width="333" height="12" font="2">action and pathophysiology. CVD risk factors affect BP</text>
<text top="413" left="423" width="46" height="12" font="2">through</text>
<text top="413" left="482" width="25" height="12" font="2">over</text>
<text top="413" left="521" width="58" height="12" font="2">activation</text>
<text top="413" left="592" width="11" height="12" font="2">of</text>
<text top="413" left="617" width="19" height="12" font="2">the</text>
<text top="413" left="648" width="108" height="12" font="2">renin-angiotensin-</text>
<text top="431" left="423" width="333" height="12" font="2">aldosterone system, activation of the sympathetic ner-</text>
<text top="449" left="423" width="333" height="12" font="2">vous system, inhibition of the cardiac natriuretic peptide</text>
<text top="467" left="423" width="333" height="12" font="2">system, endothelial dysfunction, and other mechanisms</text>
<text top="485" left="423" width="40" height="12" font="5"><a href="e127.full.html#87">(S2.4-9</a></text>
<text top="483" left="464" width="53" height="15" font="5"><a href="e127.full.html#87">—S2.4-11)</a></text>
<text top="485" left="517" width="208" height="12" font="2"><a href="e127.full.html#87">. </a>Treating some of the other modi</text>
<text top="483" left="725" width="32" height="15" font="2">ﬁable</text>
<text top="502" left="423" width="233" height="12" font="2">risk factors may reduce BP through modi</text>
<text top="501" left="657" width="100" height="15" font="2">ﬁcation of shared</text>
<text top="520" left="423" width="333" height="12" font="2">pathology, and CVD risk may be reduced by treating</text>
<text top="538" left="423" width="147" height="12" font="2">global risk factor burden.</text>
<text top="574" left="423" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="572" left="562" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="601" left="423" width="333" height="12" font="2">1. Observational studies have demonstrated that CVD risk</text>
<text top="619" left="437" width="272" height="12" font="2">factors frequently occur in combination, with</text>
<text top="617" left="714" width="42" height="15" font="2">$3 risk</text>
<text top="637" left="437" width="210" height="12" font="2">factors present in 17% of patients</text>
<text top="637" left="654" width="43" height="12" font="5"><a href="e127.full.html#87">(S2.4-1)</a></text>
<text top="637" left="697" width="59" height="12" font="2">. A meta-</text>
<text top="655" left="437" width="319" height="12" font="2">analysis from 18 cohort studies involving 257,384 pa-</text>
<text top="673" left="437" width="71" height="12" font="2">tients identi</text>
<text top="671" left="509" width="248" height="15" font="2">ﬁed a lifetime risk of CVD death, nonfatal</text>
<text top="691" left="437" width="319" height="12" font="2">MI, and fatal or nonfatal stroke that was substantially</text>
<text top="709" left="437" width="122" height="12" font="2">higher in adults with</text>
<text top="707" left="563" width="193" height="15" font="2">$2 CVD risk factors than in those</text>
<text top="727" left="437" width="127" height="12" font="2">with only 1 risk factor</text>
<text top="727" left="569" width="82" height="12" font="5"><a href="e127.full.html#87">(S2.4-1,S2.4-2)</a></text>
<text top="727" left="651" width="3" height="12" font="2">.</text>
<text top="762" left="423" width="176" height="16" font="14">3. CLASSIFICATION OF BP</text>
<text top="800" left="423" width="37" height="11" font="12">3.1. De</text>
<text top="798" left="460" width="99" height="15" font="12">ﬁnition of High BP</text>
<text top="156" left="431" width="47" height="10" font="15">T A B L E 5</text>
<text top="149" left="495" width="228" height="10" font="16">CVD Risk Factors Common in Patients With</text>
<text top="163" left="495" width="71" height="10" font="16">Hypertension</text>
<text top="187" left="423" width="22" height="9" font="13">Modi</text>
<text top="186" left="446" width="86" height="12" font="13">ﬁable Risk Factors</text>
<text top="187" left="532" width="4" height="9" font="17"><a href="e127.full.html#11">*</a></text>
<text top="187" left="617" width="135" height="9" font="13">Relatively Fixed Risk Factors</text>
<text top="186" left="752" width="5" height="12" font="17"><a href="e127.full.html#11">†</a></text>
<text top="210" left="427" width="6" height="10" font="9">n</text>
<text top="210" left="442" width="118" height="9" font="13">Current cigarette smoking,</text>
<text top="224" left="441" width="92" height="9" font="13">secondhand smoking</text>
<text top="236" left="427" width="6" height="10" font="9">n</text>
<text top="236" left="442" width="76" height="9" font="13">Diabetes mellitus</text>
<text top="248" left="427" width="6" height="10" font="9">n</text>
<text top="249" left="442" width="155" height="9" font="13">Dyslipidemia/hypercholesterolemia</text>
<text top="261" left="427" width="6" height="10" font="9">n</text>
<text top="262" left="442" width="87" height="9" font="13">Overweight/obesity</text>
<text top="274" left="427" width="6" height="10" font="9">n</text>
<text top="274" left="442" width="99" height="9" font="13">Physical inactivity/low</text>
<text top="273" left="544" width="29" height="12" font="13">ﬁtness</text>
<text top="286" left="427" width="6" height="10" font="9">n</text>
<text top="287" left="442" width="65" height="9" font="13">Unhealthy diet</text>
<text top="210" left="621" width="6" height="10" font="9">n</text>
<text top="210" left="635" width="18" height="9" font="13">CKD</text>
<text top="222" left="621" width="6" height="10" font="9">n</text>
<text top="223" left="635" width="62" height="9" font="13">Family history</text>
<text top="235" left="621" width="6" height="10" font="9">n</text>
<text top="236" left="635" width="60" height="9" font="13">Increased age</text>
<text top="248" left="621" width="6" height="10" font="9">n</text>
<text top="249" left="635" width="89" height="9" font="13">Low socioeconomic/</text>
<text top="262" left="635" width="81" height="9" font="13">educational status</text>
<text top="277" left="621" width="6" height="10" font="9">n</text>
<text top="277" left="635" width="39" height="9" font="13">Male sex</text>
<text top="289" left="621" width="6" height="10" font="9">n</text>
<text top="290" left="635" width="106" height="9" font="13">Obstructive sleep apnea</text>
<text top="302" left="621" width="6" height="10" font="9">n</text>
<text top="303" left="635" width="84" height="9" font="13">Psychosocial stress</text>
<text top="328" left="423" width="265" height="8" font="4">*Factors that can be changed and, if changed, may reduce CVD risk.</text>
<text top="326" left="691" width="66" height="11" font="4">†Factors that are</text>
<text top="340" left="423" width="10" height="8" font="4">dif</text>
<text top="338" left="433" width="323" height="11" font="4">ﬁcult to change (CKD, low socioeconomic/educational status, obstructive sleep</text>
<text top="352" left="423" width="333" height="8" font="4">apnea), cannot be changed (family history, increased age, male sex), or, if changed</text>
<text top="364" left="423" width="333" height="8" font="4">through the use of current intervention techniques, may not reduce CVD risk</text>
<text top="376" left="423" width="82" height="8" font="4">(psychosocial stress).</text>
<text top="390" left="431" width="273" height="8" font="4">CKD indicates chronic kidney disease; and CVD, cardiovascular disease.</text>
<text top="849" left="63" width="135" height="11" font="19">Recommendation for De</text>
<text top="847" left="198" width="103" height="15" font="19">ﬁnition of High BP</text>
<text top="863" left="63" width="362" height="11" font="19">References that support the recommendation are summarized in</text>
<text top="863" left="429" width="146" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 2</a></text>
<text top="863" left="575" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="904" left="89" width="19" height="10" font="13">COR</text>
<text top="904" left="161" width="18" height="10" font="13">LOE</text>
<text top="904" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="941" left="97" width="3" height="9" font="4">I</text>
<text top="941" left="160" width="21" height="9" font="4">B-NR</text>
<text top="929" left="234" width="566" height="11" font="12">1. BP should be categorized as normal, elevated, or stage 1 or 2 hypertension to prevent and treat high BP</text>
<text top="945" left="246" width="4" height="11" font="12">(</text>
<text top="945" left="251" width="40" height="11" font="5"><a href="e127.full.html#12">Table 6</a></text>
<text top="945" left="291" width="4" height="11" font="12"><a href="e127.full.html#12">)</a></text>
<text top="945" left="299" width="35" height="11" font="5"><a href="e127.full.html#87">(S3.1-1</a></text>
<text top="943" left="334" width="53" height="15" font="5"><a href="e127.full.html#87">—S3.1-20)</a></text>
<text top="945" left="388" width="3" height="11" font="12"><a href="e127.full.html#87">.</a></text>
<text top="996" left="60" width="52" height="12" font="2">Synopsis</text>
<text top="1014" left="78" width="321" height="12" font="2">Although a continuous association exists between</text>
<text top="1032" left="63" width="231" height="12" font="2">higher BP and increased CVD risk (see</text>
<text top="1032" left="299" width="63" height="12" font="5"><a href="e127.full.html#8">Section 2.1</a></text>
<text top="1032" left="363" width="36" height="12" font="2"><a href="e127.full.html#8">), </a>it is</text>
<text top="1050" left="63" width="336" height="12" font="2">useful to categorize BP levels for clinical and public health</text>
<text top="1067" left="63" width="336" height="12" font="2">decision making. In the present document, BP is catego-</text>
<text top="1085" left="63" width="336" height="12" font="2">rized into 4 levels on the basis of average BP measured in a</text>
<text top="996" left="420" width="131" height="12" font="2">healthcare setting (of</text>
<text top="994" left="552" width="205" height="15" font="2">ﬁce pressures): normal, elevated,</text>
<text top="1014" left="420" width="202" height="12" font="2">and stage 1 or 2 hypertension <a href="e127.full.html#12">(</a></text>
<text top="1014" left="622" width="46" height="11" font="5"><a href="e127.full.html#12">Table 6</a></text>
<text top="1014" left="668" width="8" height="12" font="2">).</text>
<text top="1014" left="684" width="72" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data</a></text>
<text top="1032" left="420" width="83" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Supplement C</a></text>
<text top="1032" left="508" width="248" height="12" font="2">illustrates schematically the SBP and DBP</text>
<text top="1050" left="420" width="79" height="12" font="2">categories de</text>
<text top="1048" left="499" width="257" height="15" font="2">ﬁning normal BP, elevated BP, and stages</text>
<text top="1067" left="420" width="336" height="12" font="2">1 and 2 hypertension. This categorization differs from that</text>
<text top="1085" left="420" width="336" height="12" font="2">previously recommended in the JNC 7 report, with stage</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="790" width="18" height="9" font="4">e137</text>
</page>
<page number="12" position="absolute" top="0" left="0" height="1160" width="864">
<text top="384" left="108" width="131" height="12" font="2">1 hypertension now de</text>
<text top="382" left="239" width="202" height="15" font="2">ﬁned as an SBP of 130–139 or a DBP</text>
<text top="402" left="108" width="32" height="12" font="2">of 80</text>
<text top="400" left="139" width="301" height="15" font="2">–89 mm Hg, and with stage 2 hypertension in the</text>
<text top="420" left="108" width="333" height="12" font="2">present document corresponding to stages 1 and 2 in the</text>
<text top="438" left="108" width="70" height="12" font="2">JNC 7 report</text>
<text top="438" left="181" width="47" height="12" font="5"><a href="e127.full.html#87">(S3.1-21)</a></text>
<text top="438" left="228" width="213" height="12" font="2">. The rationale for this categorization</text>
<text top="456" left="108" width="333" height="12" font="2">is based on observational data related to the association</text>
<text top="474" left="108" width="333" height="12" font="2">between SBP/DBP and CVD risk, RCTs of lifestyle modi-</text>
<text top="490" left="108" width="333" height="15" font="2">ﬁcation to lower BP, and RCTs of treatment with antihy-</text>
<text top="510" left="108" width="333" height="12" font="2">pertensive medication to prevent CVD. The increased risk</text>
<text top="528" left="108" width="333" height="12" font="2">of CVD among adults with stage 2 hypertension is well</text>
<text top="546" left="108" width="333" height="12" font="2">established. An increasing number of individual studies</text>
<text top="564" left="108" width="333" height="12" font="2">and meta-analyses of observational data have reported a</text>
<text top="582" left="108" width="333" height="12" font="2">gradient of progressively higher CVD risk going from</text>
<text top="600" left="108" width="298" height="12" font="2">normal BP to elevated BP and stage 1 hypertension</text>
<text top="600" left="410" width="31" height="12" font="5"><a href="e127.full.html#87">(S3.1-</a></text>
<text top="617" left="108" width="7" height="12" font="5"><a href="e127.full.html#87">4</a></text>
<text top="616" left="115" width="178" height="15" font="5"><a href="e127.full.html#87">–S3.1-10,S3.1-12,S3.1-13,S3.1-16)</a></text>
<text top="617" left="293" width="148" height="12" font="2">. In many of these meta-</text>
<text top="635" left="108" width="333" height="12" font="2">analyses, the hazard ratios for CHD and stroke were</text>
<text top="653" left="108" width="328" height="12" font="2">between 1.1 and 1.5 for the comparison of SBP/DBP of 120</text>
<text top="651" left="436" width="5" height="15" font="2">–</text>
<text top="671" left="108" width="38" height="12" font="2">129/80</text>
<text top="669" left="146" width="295" height="15" font="2">–84 mm Hg versus &lt;120/80 mm Hg and between 1.5</text>
<text top="689" left="108" width="270" height="12" font="2">and 2.0 for the comparison of SBP/DBP of 130</text>
<text top="687" left="378" width="63" height="15" font="2">–139/85–89</text>
<text top="707" left="108" width="87" height="12" font="2">mm Hg versus</text>
<text top="705" left="201" width="240" height="15" font="2">&lt;120/80 mm Hg. This risk gradient was</text>
<text top="725" left="108" width="191" height="12" font="2">consistent across subgroups de</text>
<text top="723" left="299" width="142" height="15" font="2">ﬁned by sex and race/</text>
<text top="743" left="108" width="333" height="12" font="2">ethnicity. The relative increase in CVD risk associated</text>
<text top="761" left="108" width="333" height="12" font="2">with higher BP was attenuated but still present among</text>
<text top="779" left="108" width="70" height="12" font="2">older adults</text>
<text top="779" left="182" width="41" height="12" font="5"><a href="e127.full.html#87">(S3.1-1)</a></text>
<text top="779" left="223" width="217" height="12" font="2">. The prevalence of severe hyperten-</text>
<text top="797" left="108" width="333" height="12" font="2">sion has been declining over time, but approximately</text>
<text top="815" left="108" width="333" height="12" font="2">12.3% of U.S. adults with hypertension have an average</text>
<text top="833" left="108" width="22" height="12" font="2">SBP</text>
<text top="831" left="134" width="251" height="15" font="2">$160 mm Hg or average DBP $100 mm Hg</text>
<text top="833" left="389" width="48" height="12" font="5"><a href="e127.full.html#87">(S3.1-22)</a></text>
<text top="833" left="437" width="3" height="12" font="2">.</text>
<text top="851" left="108" width="88" height="12" font="2">Lifestyle modi</text>
<text top="849" left="196" width="245" height="15" font="2">ﬁcation and pharmacological antihyper-</text>
<text top="868" left="108" width="333" height="12" font="2">tensive treatment recommendations for individuals with</text>
<text top="886" left="108" width="333" height="12" font="2">elevated BP and stages 1 and 2 hypertension are provided</text>
<text top="904" left="108" width="11" height="12" font="2">in</text>
<text top="904" left="123" width="96" height="12" font="5"><a href="e127.full.html#28">Sections 6 </a>and <a href="e127.full.html#34">8</a></text>
<text top="904" left="219" width="222" height="12" font="2"><a href="e127.full.html#34">, </a>respectively. The relationship of this</text>
<text top="922" left="108" width="31" height="12" font="2">classi</text>
<text top="921" left="139" width="302" height="15" font="2">ﬁcation schema with measurements obtained by</text>
<text top="940" left="108" width="333" height="12" font="2">ambulatory BP recording and home BP measurements is</text>
<text top="958" left="108" width="71" height="12" font="2">discussed in</text>
<text top="958" left="183" width="64" height="12" font="5"><a href="e127.full.html#15">Section 4.2</a></text>
<text top="958" left="247" width="3" height="12" font="2">.</text>
<text top="994" left="108" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="992" left="247" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="1021" left="108" width="234" height="12" font="2">1. As was the case in previous BP classi</text>
<text top="1019" left="343" width="98" height="15" font="2">ﬁcation systems,</text>
<text top="1039" left="122" width="319" height="12" font="2">the choice and the naming of the categories were based</text>
<text top="1057" left="122" width="319" height="12" font="2">on a pragmatic interpretation of BP-related CVD risk</text>
<text top="1075" left="122" width="56" height="12" font="2">and bene</text>
<text top="1073" left="178" width="263" height="15" font="2">ﬁt of BP reduction in clinical trials. Meta-</text>
<text top="1093" left="122" width="319" height="12" font="2">analyses of observational studies have demonstrated</text>
<text top="143" left="482" width="319" height="12" font="2">that elevated BP and hypertension are associated</text>
<text top="161" left="482" width="319" height="12" font="2">with increased risk of CVD, ESRD, subclinical athero-</text>
<text top="178" left="482" width="171" height="12" font="2">sclerosis, and all-cause death</text>
<text top="178" left="657" width="36" height="12" font="5"><a href="e127.full.html#87">(S3.1-1</a></text>
<text top="177" left="694" width="52" height="15" font="5"><a href="e127.full.html#87">—S3.1-17)</a></text>
<text top="178" left="746" width="56" height="12" font="2"><a href="e127.full.html#87">. </a>The rec-</text>
<text top="196" left="482" width="119" height="12" font="2">ommended BP classi</text>
<text top="195" left="601" width="200" height="15" font="2">ﬁcation system is most valuable in</text>
<text top="214" left="482" width="319" height="12" font="2">untreated adults as an aid in decisions about preven-</text>
<text top="232" left="482" width="319" height="12" font="2">tion or treatment of high BP. However, it is also useful</text>
<text top="250" left="482" width="319" height="12" font="2">in assessing the success of interventions to reduce BP.</text>
<text top="295" left="468" width="183" height="11" font="12">3.2. Lifetime Risk of Hypertension</text>
<text top="316" left="468" width="333" height="12" font="2">Observational studies have documented a relatively high</text>
<text top="334" left="468" width="333" height="12" font="2">incidence of hypertension over periods of 5 to 10 years of</text>
<text top="352" left="468" width="56" height="12" font="2">follow-up</text>
<text top="352" left="531" width="80" height="12" font="5"><a href="e127.full.html#87">(S3.2-1,S3.2-2)</a></text>
<text top="352" left="611" width="190" height="12" font="2"><a href="e127.full.html#87">. </a>Thus, there is a much higher</text>
<text top="370" left="468" width="333" height="12" font="2">long-term population burden of hypertension as BP pro-</text>
<text top="388" left="468" width="333" height="12" font="2">gressively increases with age. Several studies have esti-</text>
<text top="406" left="468" width="333" height="12" font="2">mated the long-term cumulative incidence of developing</text>
<text top="424" left="468" width="77" height="12" font="2">hypertension</text>
<text top="424" left="549" width="82" height="12" font="5"><a href="e127.full.html#87">(S3.2-3,S3.2-4)</a></text>
<text top="424" left="631" width="170" height="12" font="2"><a href="e127.full.html#87">. </a>In an analysis of 1132 white</text>
<text top="442" left="468" width="333" height="12" font="2">male medical students (mean age: approximately 23 years</text>
<text top="460" left="468" width="333" height="12" font="2">at baseline) in the Johns Hopkins Precursors study, 0.3%,</text>
<text top="477" left="468" width="333" height="12" font="2">6.5%, and 37% developed hypertension at age 25, 45, and</text>
<text top="495" left="468" width="133" height="12" font="2">65 years, respectively</text>
<text top="495" left="609" width="43" height="12" font="5"><a href="e127.full.html#87">(S3.2-5)</a></text>
<text top="495" left="652" width="150" height="12" font="2"><a href="e127.full.html#87">. </a>In MESA (Multi-Ethnic</text>
<text top="513" left="468" width="333" height="12" font="2">Study of Atherosclerosis), the percentage of the popula-</text>
<text top="531" left="468" width="333" height="12" font="2">tion developing hypertension over their lifetimes was</text>
<text top="549" left="468" width="333" height="12" font="2">higher for African Americans and Hispanics than for</text>
<text top="567" left="468" width="110" height="12" font="2">whites and Asians</text>
<text top="567" left="585" width="43" height="12" font="5"><a href="e127.full.html#87">(S3.2-3)</a></text>
<text top="567" left="628" width="173" height="12" font="2">. For adults 45 years of age</text>
<text top="585" left="468" width="333" height="12" font="2">without hypertension, the 40-year risk of developing</text>
<text top="603" left="468" width="333" height="12" font="2">hypertension was 93% for African-American, 92% for</text>
<text top="621" left="468" width="333" height="12" font="2">Hispanic, 86% for white, and 84% for Chinese adults</text>
<text top="639" left="468" width="43" height="12" font="5"><a href="e127.full.html#87">(S3.2-3)</a></text>
<text top="639" left="511" width="290" height="12" font="2">. In the Framingham Heart Study, approximately</text>
<text top="657" left="468" width="333" height="12" font="2">90% of adults free of hypertension at age 55 or 65 years</text>
<text top="675" left="468" width="279" height="12" font="2">developed hypertension during their lifetimes</text>
<text top="675" left="754" width="44" height="12" font="5"><a href="e127.full.html#87">(S3.2-4)</a></text>
<text top="675" left="798" width="3" height="12" font="2"><a href="e127.full.html#87">.</a></text>
<text top="693" left="468" width="328" height="12" font="2">All of these estimates were based on use of the 140/90</text>
<text top="691" left="796" width="5" height="15" font="2">–</text>
<text top="711" left="468" width="333" height="12" font="2">mm Hg cutpoint for recognition of hypertension and</text>
<text top="729" left="468" width="232" height="12" font="2">would have been higher had the 130/80</text>
<text top="727" left="700" width="101" height="15" font="2">–mm Hg cutpoint</text>
<text top="746" left="468" width="63" height="12" font="2">been used.</text>
<text top="782" left="468" width="143" height="11" font="12">3.3. Prevalence of High BP</text>
<text top="803" left="468" width="203" height="12" font="2">Prevalence estimates are greatly in</text>
<text top="802" left="671" width="130" height="15" font="2">ﬂuenced by the choice</text>
<text top="821" left="468" width="333" height="12" font="2">of cutpoints to categorize high BP, the methods used</text>
<text top="839" left="468" width="333" height="12" font="2">to establish the diagnosis, and the population studied</text>
<text top="857" left="468" width="80" height="12" font="5"><a href="e127.full.html#87">(S3.3-1,S3.3-2)</a></text>
<text top="857" left="548" width="253" height="12" font="2">. Most general population prevalence esti-</text>
<text top="875" left="468" width="236" height="12" font="2">mates are derived from national surveys.</text>
<text top="875" left="708" width="40" height="11" font="5"><a href="e127.full.html#13">Table 7</a></text>
<text top="875" left="751" width="50" height="12" font="2">provides</text>
<text top="893" left="468" width="333" height="12" font="2">estimates for prevalence of hypertension in the U.S. gen-</text>
<text top="911" left="468" width="130" height="12" font="2">eral adult population (</text>
<text top="909" left="598" width="203" height="15" font="2">$20 years of age) that are based on</text>
<text top="929" left="468" width="36" height="12" font="2">the de</text>
<text top="927" left="505" width="297" height="15" font="2">ﬁnitions of hypertension recommended in the pre-</text>
<text top="947" left="468" width="333" height="12" font="2">sent guideline and in the JNC 7 report. The prevalence of</text>
<text top="965" left="468" width="333" height="12" font="2">hypertension among U.S. adults is substantially higher</text>
<text top="983" left="468" width="70" height="12" font="2">when the de</text>
<text top="981" left="538" width="263" height="15" font="2">ﬁnition in the present guideline is used versus</text>
<text top="1001" left="468" width="85" height="12" font="2">the JNC 7 de</text>
<text top="999" left="553" width="248" height="15" font="2">ﬁnition (46% versus 32%). However, as</text>
<text top="1019" left="468" width="73" height="12" font="2">described in</text>
<text top="1019" left="546" width="64" height="12" font="5"><a href="">Section 8.1</a></text>
<text top="1019" left="611" width="190" height="12" font="2">, nonpharmacological treatment</text>
<text top="1037" left="468" width="333" height="12" font="2">(not antihypertensive medication) is recommended for</text>
<text top="1054" left="468" width="267" height="12" font="2">most U.S. adults who have hypertension as de</text>
<text top="1053" left="735" width="66" height="15" font="2">ﬁned in the</text>
<text top="1072" left="468" width="333" height="12" font="2">present guideline but who would not meet the JNC 7</text>
<text top="1090" left="468" width="14" height="12" font="2">de</text>
<text top="1089" left="482" width="319" height="15" font="2">ﬁnition for hypertension. As a consequence, the new</text>
<text top="149" left="115" width="48" height="10" font="15">T A B L E 6</text>
<text top="149" left="179" width="140" height="10" font="16">Categories of BP in Adults</text>
<text top="149" left="320" width="5" height="10" font="7"><a href="e127.full.html#12">*</a></text>
<text top="173" left="108" width="57" height="9" font="13">BP Category</text>
<text top="173" left="234" width="18" height="9" font="13">SBP</text>
<text top="173" left="401" width="19" height="9" font="13">DBP</text>
<text top="192" left="108" width="31" height="9" font="13">Normal</text>
<text top="191" left="209" width="56" height="12" font="13">&lt;120 mm Hg</text>
<text top="192" left="320" width="15" height="9" font="13">and</text>
<text top="191" left="379" width="53" height="12" font="13">&lt;80 mm Hg</text>
<text top="212" left="108" width="37" height="9" font="13">Elevated</text>
<text top="212" left="209" width="15" height="9" font="13">120</text>
<text top="210" left="224" width="53" height="12" font="13">–129 mm Hg</text>
<text top="212" left="320" width="15" height="9" font="13">and</text>
<text top="210" left="379" width="53" height="12" font="13">&lt;80 mm Hg</text>
<text top="231" left="108" width="58" height="9" font="18">Hypertension</text>
<text top="250" left="117" width="30" height="9" font="13">Stage 1</text>
<text top="250" left="209" width="15" height="9" font="13">130</text>
<text top="248" left="224" width="53" height="12" font="13">–139 mm Hg</text>
<text top="250" left="320" width="9" height="9" font="13">or</text>
<text top="250" left="379" width="12" height="9" font="13">80</text>
<text top="248" left="391" width="50" height="12" font="13">–89 mm Hg</text>
<text top="269" left="117" width="32" height="9" font="13">Stage 2</text>
<text top="268" left="209" width="57" height="12" font="13">$140 mm Hg</text>
<text top="269" left="320" width="9" height="9" font="13">or</text>
<text top="268" left="379" width="54" height="12" font="13">$90 mm Hg</text>
<text top="294" left="108" width="333" height="8" font="4">*Individuals with SBP and DBP in 2 categories should be designated to the higher BP</text>
<text top="306" left="108" width="36" height="8" font="4">category.</text>
<text top="321" left="116" width="208" height="8" font="4">BP indicates blood pressure (based on an average of</text>
<text top="319" left="327" width="114" height="11" font="4">$2 careful readings obtained</text>
<text top="333" left="108" width="10" height="8" font="4">on</text>
<text top="331" left="121" width="112" height="11" font="4">$2 occasions, as detailed in</text>
<text top="333" left="237" width="37" height="8" font="8"><a href="e127.full.html#14">Section 4</a></text>
<text top="333" left="274" width="167" height="8" font="4"><a href="e127.full.html#14">); </a>DBP, diastolic blood pressure; and SBP,</text>
<text top="345" left="108" width="91" height="8" font="4">systolic blood pressure.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e138</text>
</page>
<page number="13" position="absolute" top="0" left="0" height="1160" width="864">
<text top="537" left="63" width="14" height="12" font="2">de</text>
<text top="535" left="77" width="319" height="15" font="2">ﬁnition results in only a small increase in the percentage</text>
<text top="555" left="63" width="333" height="12" font="2">of U.S. adults for whom antihypertensive medication is</text>
<text top="573" left="63" width="283" height="12" font="2">recommended in conjunction with lifestyle modi</text>
<text top="571" left="346" width="47" height="15" font="2">ﬁcation.</text>
<text top="591" left="78" width="318" height="12" font="2">The prevalence of hypertension rises dramatically with</text>
<text top="609" left="63" width="333" height="12" font="2">increasing age and is higher in blacks than in whites,</text>
<text top="627" left="63" width="333" height="12" font="2">Asians, and Hispanic Americans. NHANES estimates of</text>
<text top="645" left="63" width="35" height="12" font="2">JNC 7</text>
<text top="643" left="98" width="298" height="15" font="2">–deﬁned hypertension prevalence have remained</text>
<text top="663" left="63" width="198" height="12" font="2">fairly stable since the early 2000s</text>
<text top="663" left="266" width="42" height="12" font="5"><a href="e127.full.html#87">(S3.3-1)</a></text>
<text top="663" left="308" width="89" height="12" font="2"><a href="e127.full.html#87">. </a>Most contem-</text>
<text top="681" left="63" width="333" height="12" font="2">porary population surveys, including NHANES, rely on an</text>
<text top="699" left="63" width="333" height="12" font="2">average of BP measurements obtained at a single visit</text>
<text top="716" left="63" width="43" height="12" font="5"><a href="e127.full.html#87">(S3.3-2)</a></text>
<text top="716" left="106" width="290" height="12" font="2"><a href="e127.full.html#87">, </a>which is likely to result in an overestimate of</text>
<text top="734" left="63" width="333" height="12" font="2">hypertension prevalence compared with what would be</text>
<text top="752" left="63" width="178" height="12" font="2">found by using an average of</text>
<text top="751" left="246" width="150" height="15" font="2">$2 readings taken on $2</text>
<text top="770" left="63" width="30" height="12" font="2">visits</text>
<text top="770" left="99" width="42" height="12" font="5"><a href="e127.full.html#87">(S3.3-1)</a></text>
<text top="770" left="141" width="255" height="12" font="2"><a href="e127.full.html#87">, </a>as recommended in current and previous</text>
<text top="788" left="63" width="85" height="12" font="2">BP guidelines</text>
<text top="788" left="159" width="38" height="12" font="5"><a href="e127.full.html#87">(S3.3-3</a></text>
<text top="786" left="197" width="48" height="15" font="5"><a href="e127.full.html#87">—S3.3-5)</a></text>
<text top="788" left="245" width="151" height="12" font="2">. The extent to which</text>
<text top="806" left="63" width="333" height="12" font="2">guideline recommendations for use of BP averages</text>
<text top="824" left="63" width="27" height="12" font="2">from</text>
<text top="822" left="98" width="298" height="15" font="2">$2 occasions is followed in practice is unclear.</text>
<text top="842" left="63" width="333" height="12" font="2">Adding self-report of previously diagnosed hypertension</text>
<text top="860" left="63" width="333" height="12" font="2">yields a 5% to 10% higher estimate of prevalence</text>
<text top="878" left="63" width="119" height="12" font="5"><a href="e127.full.html#87">(S3.3-1,S3.3-6,S3.3-7)</a></text>
<text top="878" left="182" width="214" height="12" font="2"><a href="e127.full.html#87">. </a>Most individuals who were added</text>
<text top="896" left="63" width="162" height="12" font="2">by use of this expanded de</text>
<text top="894" left="225" width="171" height="15" font="2">ﬁnition have been diagnosed</text>
<text top="914" left="63" width="313" height="12" font="2">as having hypertension by a health professional on</text>
<text top="912" left="382" width="14" height="15" font="2">&gt;1</text>
<text top="932" left="63" width="333" height="12" font="2">occasion, and many have been advised to change their</text>
<text top="950" left="63" width="46" height="12" font="2">lifestyle</text>
<text top="950" left="113" width="82" height="12" font="5"><a href="e127.full.html#87">(S3.3-2,S3.3-6)</a></text>
<text top="950" left="195" width="3" height="12" font="2">.</text>
<text top="982" left="63" width="213" height="11" font="12">3.4. Awareness, Treatment, and Control</text>
<text top="1003" left="63" width="333" height="12" font="2">Prevalence estimates for awareness, treatment, and con-</text>
<text top="1021" left="63" width="333" height="12" font="2">trol of hypertension are usually based on self-reports of the</text>
<text top="1039" left="63" width="333" height="12" font="2">hypertension diagnosis (awareness), use of BP-lowering</text>
<text top="1057" left="63" width="333" height="12" font="2">medications in those with hypertension (treatment), and</text>
<text top="1075" left="63" width="333" height="12" font="2">achievement of a satisfactory SBP/DBP during treatment of</text>
<text top="1093" left="63" width="333" height="12" font="2">hypertension (control). Before the present publication,</text>
<text top="537" left="423" width="333" height="12" font="2">awareness and treatment in adults were based on the SBP/</text>
<text top="555" left="423" width="333" height="12" font="2">DBP cutpoints of 140/90 mm Hg, and control was based on</text>
<text top="573" left="423" width="70" height="12" font="2">an SBP/DBP</text>
<text top="571" left="499" width="257" height="15" font="2">&lt;140/90 mm Hg. In the U.S. general adult</text>
<text top="591" left="423" width="333" height="12" font="2">population, hypertension awareness, treatment, and</text>
<text top="609" left="423" width="333" height="12" font="2">control have been steadily improving since the 1960s</text>
<text top="627" left="423" width="38" height="12" font="5"><a href="e127.full.html#88">(S3.4-1</a></text>
<text top="625" left="462" width="50" height="15" font="5"><a href="e127.full.html#88">—S3.4-4)</a></text>
<text top="627" left="512" width="244" height="12" font="2"><a href="e127.full.html#88">, </a>with NHANES 2009 to 2012 prevalence</text>
<text top="645" left="423" width="333" height="12" font="2">estimates for men and women, respectively, being 80.2%</text>
<text top="663" left="423" width="333" height="12" font="2">and 85.4% for awareness, 70.9% and 80.6% for treatment</text>
<text top="681" left="423" width="333" height="12" font="2">(88.4% and 94.4% in those who were aware), 69.5% and</text>
<text top="699" left="423" width="333" height="12" font="2">68.5% for control in those being treated, and 49.3% and</text>
<text top="716" left="423" width="333" height="12" font="2">55.2% for overall control in adults with hypertension</text>
<text top="734" left="423" width="44" height="12" font="5"><a href="e127.full.html#88">(S3.4-5)</a></text>
<text top="734" left="467" width="289" height="12" font="2">. The NHANES experience may underestimate</text>
<text top="752" left="423" width="333" height="12" font="2">awareness, treatment, and control of hypertension</text>
<text top="770" left="423" width="333" height="12" font="2">because it is based on BP estimates derived from an average</text>
<text top="788" left="423" width="333" height="12" font="2">of readings obtained at a single visit, whereas guidelines</text>
<text top="806" left="423" width="202" height="12" font="2">recommend use of BP averages of</text>
<text top="804" left="630" width="126" height="15" font="2">$2 readings obtained</text>
<text top="824" left="423" width="14" height="12" font="2">on</text>
<text top="822" left="444" width="313" height="15" font="2">$2 occasions. In addition, the current deﬁnition of</text>
<text top="842" left="423" width="333" height="12" font="2">control excludes the possibility of control resulting from</text>
<text top="860" left="423" width="333" height="12" font="2">lifestyle change or nonpharmacological interventions.</text>
<text top="878" left="423" width="333" height="12" font="2">NHANES hypertension control rates have been consis-</text>
<text top="896" left="423" width="333" height="12" font="2">tently higher in women than in men (55.3% versus 38.0% in</text>
<text top="914" left="423" width="28" height="12" font="2">2009</text>
<text top="912" left="452" width="305" height="15" font="2">–2012); in whites than in blacks and Hispanics (41.3%</text>
<text top="932" left="423" width="333" height="12" font="2">versus 31.1% and 23.6%, respectively, in men, and 57.2%</text>
<text top="950" left="423" width="328" height="12" font="2">versus 43.2% and 52.9%, respectively, in women, for 2009</text>
<text top="948" left="751" width="5" height="15" font="2">–</text>
<text top="968" left="423" width="333" height="12" font="2">2012); and in older than in younger adults (50.5% in</text>
<text top="985" left="423" width="36" height="12" font="2">adults</text>
<text top="984" left="463" width="294" height="15" font="2">$60 years of age versus 34.4% in patients 18 to 39</text>
<text top="1003" left="423" width="130" height="12" font="2">years of age for 2011</text>
<text top="1002" left="554" width="203" height="15" font="2">–2012) up to the seventh decade</text>
<text top="1021" left="423" width="84" height="12" font="5"><a href="e127.full.html#88">(S3.4-4,S3.4-5)</a></text>
<text top="1021" left="508" width="249" height="12" font="2"><a href="e127.full.html#88">, </a>although control rates are considerably</text>
<text top="1039" left="423" width="95" height="12" font="2">lower for those</text>
<text top="1037" left="526" width="230" height="15" font="2">$75 years (46%) and only 39.8% for</text>
<text top="1057" left="423" width="36" height="12" font="2">adults</text>
<text top="1055" left="464" width="60" height="15" font="2">$80 years</text>
<text top="1057" left="530" width="45" height="12" font="5"><a href="e127.full.html#88">(S3.4-6)</a></text>
<text top="1057" left="575" width="182" height="12" font="2"><a href="e127.full.html#88">. </a>In addition, control rates are</text>
<text top="1075" left="423" width="333" height="12" font="2">higher for persons of higher socioeconomic status (43.2%</text>
<text top="1093" left="423" width="175" height="12" font="2">for adults with an income</text>
<text top="1091" left="608" width="148" height="15" font="2">&gt;400% above the U.S.</text>
<text top="149" left="71" width="47" height="10" font="15">T A B L E 7</text>
<text top="149" left="135" width="322" height="10" font="16">Prevalence of Hypertension Based on 2 SBP/DBP Thresho<a href="e127.full.html#13">lds</a></text>
<text top="149" left="456" width="5" height="10" font="7"><a href="e127.full.html#13">*</a></text>
<text top="147" left="462" width="5" height="14" font="7"><a href="e127.full.html#13">†</a></text>
<text top="173" left="254" width="41" height="9" font="13">SBP/DBP</text>
<text top="172" left="298" width="158" height="12" font="13">$130/80 mm Hg or Self-Reported</text>
<text top="185" left="285" width="134" height="9" font="13">Antihypertensive Medication</text>
<text top="184" left="420" width="5" height="12" font="17"><a href="e127.full.html#13">†</a></text>
<text top="173" left="547" width="41" height="9" font="13">SBP/DBP</text>
<text top="172" left="592" width="159" height="12" font="13">$140/90 mm Hg or Self-Reported</text>
<text top="185" left="579" width="134" height="9" font="13">Antihypertensive Medication</text>
<text top="184" left="714" width="5" height="12" font="17"><a href="e127.full.html#13">‡</a></text>
<text top="204" left="63" width="59" height="9" font="13">Overall, crude</text>
<text top="204" left="345" width="20" height="9" font="13">46%</text>
<text top="204" left="639" width="19" height="9" font="13">32%</text>
<text top="224" left="248" width="30" height="9" font="13">Men (n</text>
<text top="222" left="277" width="30" height="12" font="13">¼4717)</text>
<text top="224" left="385" width="43" height="9" font="13">Women (n</text>
<text top="222" left="429" width="34" height="12" font="13">¼4906)</text>
<text top="224" left="541" width="30" height="9" font="13">Men (n</text>
<text top="222" left="571" width="30" height="12" font="13">¼4717)</text>
<text top="224" left="679" width="43" height="9" font="13">Women (n</text>
<text top="222" left="722" width="34" height="12" font="13">¼4906)</text>
<text top="243" left="63" width="106" height="9" font="13">Overall, age-sex adjusted</text>
<text top="243" left="267" width="20" height="9" font="13">48%</text>
<text top="243" left="414" width="19" height="9" font="13">43%</text>
<text top="243" left="562" width="18" height="9" font="13">31%</text>
<text top="243" left="708" width="19" height="9" font="13">32%</text>
<text top="262" left="63" width="56" height="9" font="18">Age group, y</text>
<text top="281" left="63" width="11" height="9" font="13">20</text>
<text top="280" left="74" width="15" height="12" font="13">–44</text>
<text top="281" left="267" width="20" height="9" font="13">30%</text>
<text top="281" left="415" width="19" height="9" font="13">19%</text>
<text top="281" left="563" width="17" height="9" font="13">11%</text>
<text top="281" left="708" width="19" height="9" font="13">10%</text>
<text top="300" left="63" width="11" height="9" font="13">45</text>
<text top="299" left="73" width="15" height="12" font="13">–54</text>
<text top="300" left="267" width="20" height="9" font="13">50%</text>
<text top="300" left="414" width="20" height="9" font="13">44%</text>
<text top="300" left="562" width="19" height="9" font="13">33%</text>
<text top="300" left="708" width="19" height="9" font="13">27%</text>
<text top="320" left="63" width="10" height="9" font="13">55</text>
<text top="318" left="73" width="16" height="12" font="13">–64</text>
<text top="320" left="267" width="20" height="9" font="13">70%</text>
<text top="320" left="414" width="20" height="9" font="13">63%</text>
<text top="320" left="562" width="19" height="9" font="13">53%</text>
<text top="320" left="708" width="19" height="9" font="13">52%</text>
<text top="339" left="63" width="11" height="9" font="13">65</text>
<text top="337" left="74" width="15" height="12" font="13">–74</text>
<text top="339" left="268" width="18" height="9" font="13">77%</text>
<text top="339" left="415" width="19" height="9" font="13">75%</text>
<text top="339" left="561" width="20" height="9" font="13">64%</text>
<text top="339" left="708" width="20" height="9" font="13">63%</text>
<text top="358" left="63" width="10" height="9" font="13">75</text>
<text top="356" left="73" width="7" height="12" font="13">þ</text>
<text top="358" left="267" width="19" height="9" font="13">79%</text>
<text top="358" left="414" width="20" height="9" font="13">85%</text>
<text top="358" left="562" width="17" height="9" font="13">71%</text>
<text top="358" left="708" width="19" height="9" font="13">78%</text>
<text top="377" left="63" width="67" height="9" font="18"><a href="e127.full.html#13">Race-ethnicity§</a></text>
<text top="396" left="63" width="82" height="9" font="13">Non-Hispanic white</text>
<text top="396" left="268" width="19" height="9" font="13">47%</text>
<text top="396" left="415" width="18" height="9" font="13">41%</text>
<text top="396" left="562" width="18" height="9" font="13">31%</text>
<text top="396" left="708" width="20" height="9" font="13">30%</text>
<text top="416" left="63" width="80" height="9" font="13">Non-Hispanic black</text>
<text top="416" left="267" width="20" height="9" font="13">59%</text>
<text top="416" left="414" width="20" height="9" font="13">56%</text>
<text top="416" left="561" width="20" height="9" font="13">42%</text>
<text top="416" left="708" width="20" height="9" font="13">46%</text>
<text top="435" left="63" width="81" height="9" font="13">Non-Hispanic Asian</text>
<text top="435" left="267" width="20" height="9" font="13">45%</text>
<text top="435" left="414" width="20" height="9" font="13">36%</text>
<text top="435" left="561" width="20" height="9" font="13">29%</text>
<text top="435" left="708" width="19" height="9" font="13">27%</text>
<text top="454" left="63" width="35" height="9" font="13">Hispanic</text>
<text top="454" left="267" width="20" height="9" font="13">44%</text>
<text top="454" left="414" width="20" height="9" font="13">42%</text>
<text top="454" left="562" width="19" height="9" font="13">27%</text>
<text top="454" left="708" width="19" height="9" font="13">32%</text>
<text top="478" left="63" width="482" height="8" font="4">The prevalence estimates have been rounded to the nearest full percentage. *130/80 and 140/90 mm Hg in 9623 participants (</text>
<text top="476" left="545" width="212" height="11" font="4">$20 years of age) in NHANES 2011–2014. †BP cutpoints</text>
<text top="490" left="63" width="23" height="8" font="4">for de</text>
<text top="488" left="86" width="671" height="11" font="4">ﬁnition of hypertension in the present guideline. ‡BP cutpoints for deﬁnition of hypertension in JNC 7. §Adjusted to the 2010 age-sex distribution of the U.S. adult population.</text>
<text top="504" left="71" width="595" height="8" font="4">BP indicates blood pressure; DBP, diastolic blood pressure; NHANES, National Health and Nutrition Examination Survey; and SBP, systolic blood pressure.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="19" height="9" font="4">e139</text>
</page>
<page number="14" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="333" height="12" font="2">government poverty line versus 30.2% for those below this</text>
<text top="161" left="108" width="135" height="12" font="2">line in 2003 to 2006)</text>
<text top="161" left="250" width="44" height="12" font="5"><a href="e127.full.html#88">(S3.4-5)</a></text>
<text top="161" left="294" width="147" height="12" font="2">. Research studies have</text>
<text top="178" left="108" width="333" height="12" font="2">repeatedly demonstrated that structured, goal-oriented BP</text>
<text top="196" left="108" width="333" height="12" font="2">treatment initiatives with feedback and provision of free</text>
<text top="214" left="108" width="333" height="12" font="2">medication result in a substantial improvement in BP</text>
<text top="232" left="108" width="41" height="12" font="2">control</text>
<text top="232" left="151" width="39" height="12" font="5"><a href="e127.full.html#88">(S3.4-7</a></text>
<text top="230" left="191" width="49" height="15" font="5"><a href="e127.full.html#88">—S3.4-9)</a></text>
<text top="232" left="241" width="200" height="12" font="2"><a href="e127.full.html#88">. </a>Control rates that are much higher</text>
<text top="250" left="108" width="333" height="12" font="2">than noted in the general population have been reported in</text>
<text top="143" left="468" width="333" height="12" font="2">care settings where a systems approach (detailed in</text>
<text top="161" left="468" width="125" height="12" font="5"><a href="e127.full.html#77">Sections 12.2 </a>and <a href="">12.3</a></text>
<text top="161" left="593" width="208" height="12" font="2"><a href="">) </a>has been implemented for insured</text>
<text top="178" left="468" width="36" height="12" font="2">adults</text>
<text top="178" left="507" width="46" height="12" font="5"><a href="e127.full.html#88">(S3.4-10</a></text>
<text top="177" left="553" width="54" height="15" font="5"><a href="e127.full.html#88">—S3.4-12)</a></text>
<text top="178" left="608" width="3" height="12" font="2"><a href="e127.full.html#88">.</a></text>
<text top="208" left="468" width="165" height="16" font="14">4. MEASUREMENT OF BP</text>
<text top="246" left="468" width="230" height="11" font="12">4.1. Accurate Measurement of BP in the Of</text>
<text top="244" left="698" width="18" height="15" font="12">ﬁce</text>
<text top="300" left="63" width="336" height="11" font="19">Recommendation for Accurate Measurement of BP in the Of</text>
<text top="298" left="400" width="19" height="15" font="19">ﬁce</text>
<text top="341" left="89" width="19" height="10" font="13">COR</text>
<text top="341" left="161" width="18" height="10" font="13">LOE</text>
<text top="341" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="378" left="97" width="3" height="9" font="4">I</text>
<text top="378" left="160" width="20" height="9" font="4">C-EO</text>
<text top="366" left="234" width="568" height="11" font="12">1. For diagnosis and management of high BP, proper methods are recommended for accurate measurement</text>
<text top="381" left="246" width="143" height="11" font="12">and documentation of BP (</text>
<text top="381" left="390" width="40" height="11" font="5"><a href="e127.full.html#14">Table 8</a></text>
<text top="381" left="430" width="7" height="11" font="12">).</text>
<text top="429" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="447" left="123" width="228" height="12" font="2">Although measurement of BP in of</text>
<text top="445" left="351" width="93" height="15" font="2">ﬁce settings is</text>
<text top="465" left="108" width="336" height="12" font="2">relatively easy, errors are common and can result in a</text>
<text top="483" left="108" width="227" height="12" font="2">misleading estimation of an individual</text>
<text top="481" left="335" width="109" height="15" font="2">’s true level of BP.</text>
<text top="501" left="108" width="336" height="12" font="2">There are various methods for measuring BP in the of-</text>
<text top="517" left="108" width="336" height="15" font="2">ﬁce. The clinical standard of auscultatory measures</text>
<text top="537" left="108" width="336" height="12" font="2">calibrated to a column of mercury has given way to</text>
<text top="555" left="108" width="336" height="12" font="2">oscillometric devices (in part because of toxicological</text>
<text top="573" left="108" width="336" height="12" font="2">issues with mercury). Oscillometric devices use a sensor</text>
<text top="591" left="108" width="336" height="12" font="2">that detects oscillations in pulsatile blood volume during</text>
<text top="609" left="108" width="41" height="12" font="2">cuff in</text>
<text top="607" left="149" width="295" height="15" font="2">ﬂation and deﬂation. BP is indirectly calculated</text>
<text top="627" left="108" width="28" height="12" font="2">from</text>
<text top="627" left="148" width="58" height="12" font="2">maximum</text>
<text top="627" left="219" width="59" height="12" font="2">amplitude</text>
<text top="627" left="291" width="62" height="12" font="2">algorithms</text>
<text top="627" left="365" width="23" height="12" font="2">that</text>
<text top="627" left="401" width="43" height="12" font="2">involve</text>
<text top="429" left="465" width="336" height="12" font="2">population-based data. For this reason, only devices with</text>
<text top="447" left="465" width="336" height="12" font="2">a validated measurement protocol can be recommended</text>
<text top="465" left="465" width="70" height="12" font="2">for use (see</text>
<text top="465" left="541" width="66" height="12" font="5"><a href="e127.full.html#15">Section 4.2</a></text>
<text top="465" left="613" width="188" height="12" font="2">for additional details). Many of</text>
<text top="483" left="465" width="311" height="12" font="2">the newer oscillometric devices automatically in</text>
<text top="481" left="776" width="25" height="15" font="2">ﬂate</text>
<text top="501" left="465" width="336" height="12" font="2">multiple times (in 1- to 2-minute intervals), allowing</text>
<text top="519" left="465" width="336" height="12" font="2">patients to be alone and undisturbed during measure-</text>
<text top="537" left="465" width="336" height="12" font="2">ment. Although much of the available BP-related risk</text>
<text top="555" left="465" width="336" height="12" font="2">information and antihypertensive treatment trial expe-</text>
<text top="573" left="465" width="220" height="12" font="2">rience have been generated by using</text>
<text top="571" left="690" width="111" height="15" font="2">“traditional” ofﬁce</text>
<text top="591" left="465" width="336" height="12" font="2">methods of BP measurement, there is a growing evidence</text>
<text top="609" left="465" width="257" height="12" font="2">base supporting the use of automated of</text>
<text top="607" left="722" width="79" height="15" font="2">ﬁce BP mea-</text>
<text top="627" left="465" width="60" height="12" font="2">surements</text>
<text top="627" left="531" width="42" height="12" font="5"><a href="e127.full.html#88">(S4.1-1)</a></text>
<text top="627" left="573" width="3" height="12" font="2"><a href="e127.full.html#88">.</a></text>
<text top="670" left="115" width="48" height="10" font="15">T A B L E 8</text>
<text top="670" left="179" width="225" height="10" font="16">Checklist for Accurate Measurement of BP</text>
<text top="670" left="409" width="78" height="10" font="7"><a href="e127.full.html#88">(S4.1-3,S4.1-4)</a></text>
<text top="695" left="108" width="185" height="9" font="13">Key Steps for Proper BP Measurements</text>
<text top="695" left="508" width="24" height="9" font="13">Speci</text>
<text top="693" left="533" width="69" height="12" font="13">ﬁc Instructions</text>
<text top="714" left="108" width="151" height="9" font="13">Step 1: Properly prepare the patient</text>
<text top="718" left="313" width="227" height="9" font="13">1. Have the patient relax, sitting in a chair (feet on</text>
<text top="716" left="543" width="152" height="12" font="13">ﬂoor, back supported) for &gt;5 min.</text>
<text top="730" left="312" width="448" height="9" font="13">2. The patient should avoid caffeine, exercise, and smoking for at least 30 min before measurement.</text>
<text top="743" left="312" width="207" height="9" font="13">3. Ensure patient has emptied his/her bladder.</text>
<text top="756" left="312" width="454" height="9" font="13">4. Neither the patient nor the observer should talk during the rest period or during the measurement.</text>
<text top="768" left="312" width="283" height="9" font="13">5. Remove all clothing covering the location of cuff placement.</text>
<text top="781" left="311" width="400" height="9" font="13">6. Measurements made while the patient is sitting or lying on an examining table do not ful</text>
<text top="779" left="712" width="74" height="12" font="13">ﬁll these criteria.</text>
<text top="800" left="108" width="138" height="9" font="13">Step 2: Use proper technique for</text>
<text top="812" left="123" width="75" height="9" font="13">BP measurements</text>
<text top="804" left="313" width="463" height="9" font="13">1. Use a BP measurement device that has been validated, and ensure that the device is calibrated periodically<a href="e127.full.html#14">.</a></text>
<text top="804" left="776" width="4" height="9" font="17"><a href="e127.full.html#14">*</a></text>
<text top="817" left="312" width="99" height="9" font="13">2. Support the patient</text>
<text top="815" left="412" width="138" height="12" font="13">’s arm (e.g., resting on a desk).</text>
<text top="829" left="312" width="215" height="9" font="13">3. Position the middle of the cuff on the patient</text>
<text top="828" left="528" width="258" height="12" font="13">’s upper arm at the level of the right atrium (the midpoint</text>
<text top="843" left="325" width="72" height="9" font="13">of the sternum).</text>
<text top="855" left="311" width="447" height="9" font="13">4. Use the correct cuff size, such that the bladder encircles 80% of the arm, and note if a larger- or</text>
<text top="867" left="325" width="171" height="9" font="13">smaller-than-normal cuff size is used <a href="e127.full.html#15">(</a></text>
<text top="867" left="496" width="34" height="9" font="17"><a href="e127.full.html#15">Table 9</a></text>
<text top="867" left="530" width="6" height="9" font="13">).</text>
<text top="881" left="312" width="368" height="9" font="13">5. Either the stethoscope diaphragm or bell may be used for auscultatory readings</text>
<text top="881" left="683" width="66" height="9" font="17"><a href="e127.full.html#88">(S4.1-5,S4.1-6)</a></text>
<text top="881" left="749" width="3" height="9" font="13">.</text>
<text top="900" left="108" width="197" height="9" font="13">Step 3: Take the proper measurements needed</text>
<text top="912" left="123" width="167" height="9" font="13">for diagnosis and treatment of elevated</text>
<text top="924" left="123" width="69" height="9" font="13">BP/hypertension</text>
<text top="904" left="313" width="38" height="9" font="13">1. At the</text>
<text top="902" left="354" width="436" height="12" font="13">ﬁrst visit, record BP in both arms. Use the arm that gives the higher reading for subsequent readings.</text>
<text top="917" left="312" width="181" height="9" font="13">2. Separate repeated measurements by 1</text>
<text top="915" left="493" width="32" height="12" font="13">–2 min.</text>
<text top="930" left="312" width="486" height="9" font="13">3. For auscultatory determinations, use a palpated estimate of radial pulse obliteration pressure to estimate SBP.</text>
<text top="943" left="325" width="8" height="9" font="13">In</text>
<text top="941" left="333" width="408" height="12" font="13">ﬂate the cuff 20–30 mm Hg above this level for an auscultatory determination of the BP level.</text>
<text top="959" left="311" width="138" height="9" font="13">4. For auscultatory readings, de</text>
<text top="957" left="449" width="330" height="12" font="13">ﬂate the cuff pressure 2 mm Hg per second, and listen for Korotkoff sounds.</text>
<text top="978" left="108" width="166" height="9" font="13">Step 4: Properly document accurate BP</text>
<text top="990" left="123" width="35" height="9" font="13">readings</text>
<text top="981" left="312" width="414" height="9" font="13">1. Record SBP and DBP. If using the auscultatory technique, record SBP and DBP as onset of the</text>
<text top="980" left="730" width="61" height="12" font="13">ﬁrst Korotkoff</text>
<text top="995" left="324" width="407" height="9" font="13">sound and disappearance of all Korotkoff sounds, respectively, using the nearest even number.</text>
<text top="1007" left="311" width="338" height="9" font="13">2. Note the time of most recent BP medication taken before measurements.</text>
<text top="1027" left="108" width="122" height="9" font="13">Step 5: Average the readings</text>
<text top="1027" left="309" width="76" height="9" font="13">Use an average of</text>
<text top="1025" left="388" width="331" height="12" font="13">$2 readings obtained on $2 occasions to estimate the individual’s level of BP.</text>
<text top="1046" left="108" width="162" height="9" font="13">Step 6: Provide BP readings to patient</text>
<text top="1046" left="309" width="286" height="9" font="13">Provide patients the SBP/DBP readings both verbally and in writing.</text>
<text top="1069" left="108" width="17" height="8" font="4">*See</text>
<text top="1069" left="127" width="43" height="8" font="8"><a href="e127.full.html#15">Section 4.2</a></text>
<text top="1069" left="172" width="258" height="8" font="4">for additional guidance. Adapted with permission from Mancia et al.</text>
<text top="1069" left="432" width="30" height="8" font="8"><a href="e127.full.html#88">(S4.1-3)</a></text>
<text top="1069" left="464" width="156" height="8" font="4">(Oxford University Press), Pickering et al.</text>
<text top="1069" left="622" width="30" height="8" font="8"><a href="e127.full.html#88">(S4.1-2)</a></text>
<text top="1069" left="654" width="147" height="8" font="4">(American Heart Association, Inc.), and</text>
<text top="1081" left="108" width="40" height="8" font="4">Weir et al.</text>
<text top="1081" left="150" width="31" height="8" font="8"><a href="e127.full.html#88">(S4.1-4)</a></text>
<text top="1081" left="184" width="147" height="8" font="4">(American College of Physicians, Inc.).</text>
<text top="1096" left="116" width="359" height="8" font="4">BP indicates blood pressure; DBP, diastolic blood pressure; and SBP, systolic blood pressure.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="20" height="9" font="4">e140</text>
</page>
<page number="15" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="20" size="3" family="Times" color="#000000"/>
<text top="354" left="63" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="352" left="202" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="381" left="63" width="333" height="12" font="2">1. Accurate measurement and recording of BP are essential</text>
<text top="399" left="77" width="319" height="12" font="2">to categorize level of BP, ascertain BP-related CVD risk,</text>
<text top="417" left="77" width="319" height="12" font="2">and guide management of high BP. Most systematic er-</text>
<text top="435" left="77" width="319" height="12" font="2">rors in BP measurement can be avoided by following the</text>
<text top="453" left="77" width="141" height="12" font="2">suggestions provided in</text>
<text top="453" left="222" width="43" height="11" font="5"><a href="e127.full.html#14">Table 8</a></text>
<text top="453" left="265" width="131" height="12" font="2">, including having the</text>
<text top="470" left="77" width="319" height="12" font="2">patient sit quietly for 5 minutes before a reading is taken,</text>
<text top="488" left="77" width="319" height="12" font="2">supporting the limb used to measure BP, ensuring the BP</text>
<text top="506" left="77" width="270" height="12" font="2">cuff is at heart level, using the correct cuff size <a href="e127.full.html#15">(</a></text>
<text top="507" left="347" width="40" height="11" font="5"><a href="e127.full.html#15">Table 9</a></text>
<text top="506" left="388" width="8" height="12" font="2">),</text>
<text top="524" left="77" width="194" height="12" font="2">and, for auscultatory readings, de</text>
<text top="522" left="271" width="125" height="15" font="2">ﬂating the cuff slowly</text>
<text top="143" left="437" width="43" height="12" font="5"><a href="e127.full.html#88">(S4.1-2)</a></text>
<text top="143" left="480" width="276" height="12" font="2">. In those who are already taking medication that</text>
<text top="161" left="437" width="319" height="12" font="2">affects BP, the timing of BP measurements in relation to</text>
<text top="178" left="437" width="141" height="12" font="2">ingestion of the patient</text>
<text top="177" left="579" width="178" height="15" font="2">’s medication should be stan-</text>
<text top="196" left="437" width="319" height="12" font="2">dardized. Because individual BP measurements tend to</text>
<text top="214" left="437" width="319" height="12" font="2">vary in an unpredictable or random fashion, a single</text>
<text top="232" left="437" width="319" height="12" font="2">reading is inadequate for clinical decision-making. An</text>
<text top="250" left="437" width="319" height="12" font="2">average of 2 to 3 BP measurements obtained on 2 to 3</text>
<text top="268" left="437" width="319" height="12" font="2">separate occasions will minimize random error and</text>
<text top="286" left="437" width="319" height="12" font="2">provide a more accurate basis for estimation of BP. In</text>
<text top="304" left="437" width="319" height="12" font="2">addition to clinicians, other caregivers and patients who</text>
<text top="322" left="437" width="319" height="12" font="2">perform BP self-monitoring should be trained to follow</text>
<text top="340" left="437" width="95" height="12" font="2">the checklist in</text>
<text top="340" left="540" width="45" height="11" font="5"><a href="e127.full.html#14">Table 8</a></text>
<text top="340" left="585" width="171" height="12" font="2">. Common errors in clinical</text>
<text top="358" left="437" width="319" height="12" font="2">practice that can lead to inaccurate estimation of BP</text>
<text top="376" left="437" width="319" height="12" font="2">include failure to allow for a rest period and/or talking</text>
<text top="394" left="437" width="319" height="12" font="2">with the patient during or immediately before the</text>
<text top="412" left="437" width="319" height="12" font="2">recording, improper patient positioning (e.g., sitting or</text>
<text top="430" left="437" width="258" height="12" font="2">lying on an examination table), rapid cuff de</text>
<text top="428" left="695" width="61" height="15" font="2">ﬂation (for</text>
<text top="447" left="437" width="319" height="12" font="2">auscultatory readings), and reliance on BPs measured at</text>
<text top="465" left="437" width="100" height="12" font="2">a single occasion.</text>
<text top="525" left="423" width="77" height="11" font="12">4.2. Out-of-Of</text>
<text top="523" left="500" width="162" height="15" font="12">ﬁce and Self-Monitoring of BP</text>
<text top="156" left="70" width="48" height="10" font="15">T A B L E 9</text>
<text top="149" left="135" width="198" height="10" font="16">Selection Criteria for BP Cuff Size for</text>
<text top="163" left="135" width="156" height="10" font="16">Measurement of BP in Adults</text>
<text top="187" left="63" width="89" height="9" font="13">Arm Circumference</text>
<text top="187" left="292" width="70" height="9" font="13">Usual Cuff Size</text>
<text top="207" left="63" width="10" height="9" font="13">22</text>
<text top="205" left="73" width="30" height="12" font="13">–26 cm</text>
<text top="207" left="258" width="48" height="9" font="13">Small adult</text>
<text top="226" left="63" width="10" height="9" font="13">27</text>
<text top="224" left="73" width="30" height="12" font="13">–34 cm</text>
<text top="226" left="258" width="23" height="9" font="13">Adult</text>
<text top="245" left="63" width="10" height="9" font="13">35</text>
<text top="243" left="73" width="31" height="12" font="13">–44 cm</text>
<text top="245" left="258" width="48" height="9" font="13">Large adult</text>
<text top="264" left="63" width="11" height="9" font="13">45</text>
<text top="263" left="73" width="30" height="12" font="13">–52 cm</text>
<text top="264" left="258" width="48" height="9" font="13">Adult thigh</text>
<text top="288" left="63" width="183" height="8" font="4">Adapted with permission from Pickering et al.</text>
<text top="288" left="249" width="30" height="8" font="8"><a href="e127.full.html#88">(S4.1-2)</a></text>
<text top="288" left="283" width="113" height="8" font="4">(American Heart Association,</text>
<text top="300" left="63" width="19" height="8" font="4">Inc.).</text>
<text top="314" left="71" width="109" height="8" font="4">BP indicates blood pressure.</text>
<text top="568" left="63" width="174" height="11" font="19">Recommendation for Out-of-Of</text>
<text top="566" left="238" width="169" height="15" font="19">ﬁce and Self-Monitoring of BP</text>
<text top="582" left="63" width="362" height="11" font="19">References that support the recommendation are summarized in</text>
<text top="582" left="429" width="146" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 3</a></text>
<text top="582" left="579" width="173" height="11" font="19">and Systematic Review Report.</text>
<text top="623" left="89" width="19" height="10" font="13">COR</text>
<text top="623" left="161" width="18" height="10" font="13">LOE</text>
<text top="623" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="660" left="97" width="3" height="9" font="4">I</text>
<text top="660" left="164" width="6" height="9" font="4">A</text>
<text top="658" left="169" width="8" height="6" font="20">SR</text>
<text top="648" left="234" width="64" height="11" font="12">1. Out-of-of</text>
<text top="646" left="298" width="444" height="15" font="12">ﬁce BP measurements are recommended to conﬁrm the diagnosis of hypertension (</text>
<text top="648" left="742" width="43" height="11" font="5"><a href="e127.full.html#16">Table 11</a></text>
<text top="648" left="785" width="4" height="11" font="12">)</text>
<text top="664" left="246" width="515" height="11" font="12">and for titration of BP-lowering medication, in conjunction with telehealth counseling or clinical</text>
<text top="679" left="246" width="70" height="11" font="12">interventions</text>
<text top="679" left="320" width="37" height="11" font="5"><a href="e127.full.html#88">(S4.2-1</a></text>
<text top="677" left="358" width="48" height="15" font="5"><a href="e127.full.html#88">—S4.2-4)</a></text>
<text top="679" left="406" width="3" height="11" font="12">.</text>
<text top="706" left="63" width="157" height="11" font="2">SR indicates systematic review.</text>
<text top="749" left="63" width="52" height="12" font="2">Synopsis</text>
<text top="767" left="78" width="54" height="12" font="2">Out-of-of</text>
<text top="765" left="132" width="267" height="15" font="2">ﬁce measurement of BP can be helpful for</text>
<text top="784" left="63" width="20" height="12" font="2">con</text>
<text top="783" left="84" width="315" height="15" font="2">ﬁrmation and management of hypertension. Self-</text>
<text top="802" left="63" width="336" height="12" font="2">monitoring of BP refers to the regular measurement of</text>
<text top="820" left="63" width="336" height="12" font="2">BP by an individual at home or elsewhere outside the</text>
<text top="838" left="63" width="336" height="12" font="2">clinic setting. Among individuals with hypertension, self-</text>
<text top="856" left="63" width="336" height="12" font="2">monitoring of BP, without other interventions, has shown</text>
<text top="874" left="63" width="336" height="12" font="2">limited evidence for treatment-related BP reduction and</text>
<text top="892" left="63" width="156" height="12" font="2">achievement of BP control</text>
<text top="892" left="223" width="122" height="12" font="5"><a href="e127.full.html#88">(S4.2-1,S4.2-5,S4.2-6)</a></text>
<text top="892" left="346" width="53" height="12" font="2"><a href="e127.full.html#88">. </a>Howev-</text>
<text top="910" left="63" width="336" height="12" font="2">er, with the increased recognition of inconsistencies be-</text>
<text top="928" left="63" width="52" height="12" font="2">tween of</text>
<text top="926" left="115" width="180" height="15" font="2">ﬁce and out-of-ofﬁce BPs (see</text>
<text top="928" left="301" width="66" height="12" font="5"><a href="e127.full.html#17">Section 4.4</a></text>
<text top="928" left="368" width="31" height="12" font="2"><a href="e127.full.html#17">) </a>and</text>
<text top="946" left="63" width="336" height="12" font="2">greater reduction in BP being recommended for hyper-</text>
<text top="964" left="63" width="336" height="12" font="2">tension control, increased attention is being paid to out-</text>
<text top="982" left="63" width="28" height="12" font="2">of-of</text>
<text top="980" left="91" width="308" height="15" font="2">ﬁce BP readings. Although ABPM is generally</text>
<text top="1000" left="63" width="178" height="12" font="2">accepted as the best out-of-of</text>
<text top="998" left="241" width="158" height="15" font="2">ﬁce measurement method,</text>
<text top="1018" left="63" width="336" height="12" font="2">HBPM is often a more practical approach in clinical prac-</text>
<text top="1036" left="63" width="336" height="12" font="2">tice. Recommended procedures for the collection of HBPM</text>
<text top="1053" left="63" width="117" height="12" font="2">data are provided in</text>
<text top="1054" left="183" width="47" height="11" font="5"><a href="e127.full.html#16">Table 10</a></text>
<text top="1053" left="230" width="168" height="12" font="2">. If self-monitoring is used, it</text>
<text top="1071" left="63" width="336" height="12" font="2">is important to ensure that the BP measurement device</text>
<text top="1089" left="63" width="336" height="12" font="2">used has been validated with an internationally accepted</text>
<text top="749" left="420" width="336" height="12" font="2">protocol and the results have been published in a peer-</text>
<text top="767" left="420" width="99" height="12" font="2">reviewed journal</text>
<text top="767" left="524" width="44" height="12" font="5"><a href="e127.full.html#88">(S4.2-7)</a></text>
<text top="767" left="568" width="189" height="12" font="2"><a href="e127.full.html#88">. </a>A guide to the relationship be-</text>
<text top="784" left="420" width="336" height="12" font="2">tween HBPM BP readings and corresponding readings</text>
<text top="802" left="420" width="117" height="12" font="2">obtained in the of</text>
<text top="801" left="538" width="219" height="15" font="2">ﬁce and by ABPM is presented in</text>
<text top="821" left="420" width="47" height="11" font="5"><a href="e127.full.html#16">Table 11</a></text>
<text top="820" left="467" width="232" height="12" font="2">. The precise relationships between of</text>
<text top="818" left="700" width="56" height="15" font="2">ﬁce read-</text>
<text top="838" left="420" width="336" height="12" font="2">ings, ABPM, and HBPM are unsettled, but there is general</text>
<text top="856" left="420" width="105" height="12" font="2">agreement that of</text>
<text top="854" left="526" width="231" height="15" font="2">ﬁce BPs are often higher than ABPM or</text>
<text top="874" left="420" width="210" height="12" font="2">HBPM BPs, especially at higher BPs.</text>
<text top="919" left="420" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="917" left="559" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="946" left="421" width="206" height="12" font="2">1. ABPM is used to obtain out-of-of</text>
<text top="944" left="627" width="129" height="15" font="2">ﬁce BP readings at set</text>
<text top="964" left="434" width="322" height="12" font="2">intervals, usually over a period of 24 hours. HBPM is</text>
<text top="982" left="434" width="224" height="12" font="2">used to obtain a record of out-of-of</text>
<text top="980" left="658" width="98" height="15" font="2">ﬁce BP readings</text>
<text top="999" left="434" width="322" height="12" font="2">taken by a patient. Both ABPM and HBPM typically</text>
<text top="1017" left="434" width="322" height="12" font="2">provide BP estimates that are based on multiple mea-</text>
<text top="1035" left="434" width="322" height="12" font="2">surements. A systematic review conducted by the U.S.</text>
<text top="1053" left="434" width="322" height="12" font="2">Preventive Services Task Force reported that ABPM</text>
<text top="1071" left="434" width="322" height="12" font="2">provided a better method to predict long-term CVD</text>
<text top="1089" left="434" width="138" height="12" font="2">outcomes than did of</text>
<text top="1087" left="572" width="184" height="15" font="2">ﬁce BPs. It incorporates new</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="790" width="18" height="9" font="4">e141</text>
</page>
<page number="16" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="21" size="5" family="Times" color="#999999"/>
<text top="762" left="122" width="319" height="12" font="2">information from studies of HBPM, ABPM, the rela-</text>
<text top="780" left="122" width="319" height="12" font="2">tionship of overall CVD risk to the effectiveness of</text>
<text top="798" left="122" width="319" height="12" font="2">blood pressure lowering, clinical outcomes related to</text>
<text top="816" left="122" width="319" height="12" font="2">different blood pressure goals, strategies to improve</text>
<text top="834" left="122" width="319" height="12" font="2">blood pressure control and various other areas. A small</text>
<text top="852" left="122" width="264" height="12" font="2">body of evidence suggested, but did not con</text>
<text top="850" left="386" width="55" height="15" font="2">ﬁrm, that</text>
<text top="870" left="122" width="319" height="12" font="2">HBPM could serve as a similar predictor of outcomes</text>
<text top="888" left="122" width="45" height="12" font="5"><a href="e127.full.html#88">(S4.2-4)</a></text>
<text top="888" left="167" width="3" height="12" font="2"><a href="e127.full.html#88">.</a></text>
<text top="888" left="183" width="83" height="12" font="2">Meta-analyses</text>
<text top="888" left="279" width="11" height="12" font="2">of</text>
<text top="888" left="303" width="29" height="12" font="2">RCTs</text>
<text top="888" left="345" width="27" height="12" font="2">have</text>
<text top="888" left="385" width="34" height="12" font="2">identi</text>
<text top="886" left="419" width="22" height="15" font="2">ﬁed</text>
<text top="906" left="122" width="319" height="12" font="2">clinically useful reductions in SBP and DBP and</text>
<text top="924" left="122" width="319" height="12" font="2">achievement of BP goals at 6 months and 1 year when</text>
<text top="941" left="122" width="319" height="12" font="2">self-monitoring of BP has been used in conjunction</text>
<text top="959" left="122" width="319" height="12" font="2">with other interventions, compared with usual care.</text>
<text top="977" left="122" width="206" height="12" font="2">Meta-analyses of RCTs have identi</text>
<text top="976" left="328" width="112" height="15" font="2">ﬁed only small net</text>
<text top="995" left="122" width="319" height="12" font="2">reductions in SBP and DBP at 6 months and 1 year for</text>
<text top="1013" left="122" width="319" height="12" font="2">use of self-monitoring of BP on its own, as compared</text>
<text top="1031" left="122" width="91" height="12" font="2">with usual care</text>
<text top="1031" left="218" width="122" height="12" font="5"><a href="e127.full.html#88">(S4.2-1,S4.2-5,S4.2-6)</a></text>
<text top="1031" left="341" width="28" height="12" font="2"><a href="e127.full.html#88">. </a>See</text>
<text top="1031" left="375" width="66" height="12" font="5"><a href="e127.full.html#17">Section 4.4</a></text>
<text top="1049" left="122" width="248" height="12" font="2">for additional details of diagnostic classi</text>
<text top="1047" left="370" width="71" height="15" font="2">ﬁcation and</text>
<text top="1067" left="122" width="58" height="12" font="5"><a href="e127.full.html#74">Section 12</a></text>
<text top="1067" left="185" width="256" height="12" font="2">for additional details of telehealth and out-</text>
<text top="1085" left="122" width="28" height="12" font="2">of-of</text>
<text top="1083" left="150" width="291" height="15" font="2">ﬁce BP measurement for management of high BP.</text>
<text top="762" left="468" width="167" height="11" font="12">4.3. Ambulatory BP Monitoring</text>
<text top="784" left="468" width="333" height="12" font="2">All of the major RCTs have been based on use of clinic BP</text>
<text top="802" left="468" width="333" height="12" font="2">readings. However, ABPM is often used to supplement BP</text>
<text top="820" left="468" width="133" height="12" font="2">readings obtained in of</text>
<text top="818" left="601" width="69" height="15" font="2">ﬁce settings</text>
<text top="820" left="674" width="43" height="12" font="5"><a href="e127.full.html#88">(S4.3-1)</a></text>
<text top="820" left="717" width="84" height="12" font="2">. The monitors</text>
<text top="838" left="468" width="333" height="12" font="2">are usually programmed to obtain readings every 15 to</text>
<text top="856" left="468" width="333" height="12" font="2">30 minutes throughout the day and every 15 minutes to</text>
<text top="874" left="468" width="333" height="12" font="2">1 hour during the night. ABPM is conducted while in-</text>
<text top="892" left="468" width="333" height="12" font="2">dividuals go about their normal daily activities. ABPM can</text>
<text top="909" left="468" width="333" height="12" font="2">a) provide estimates of mean BP over the entire moni-</text>
<text top="927" left="468" width="333" height="12" font="2">toring period and separately during nighttime and day-</text>
<text top="945" left="468" width="333" height="12" font="2">time, b) determine the daytime-to-nighttime BP ratio to</text>
<text top="963" left="468" width="183" height="12" font="2">identify the extent of nocturnal</text>
<text top="962" left="655" width="146" height="15" font="2">“dipping,” c) identify the</text>
<text top="981" left="468" width="333" height="12" font="2">early-morning BP surge pattern, d) estimate BP vari-</text>
<text top="999" left="468" width="333" height="12" font="2">ability, and e) allow for recognition of symptomatic hy-</text>
<text top="1017" left="468" width="333" height="12" font="2">potension. The U.S. Centers for Medicaid &amp; Medicare</text>
<text top="1035" left="468" width="333" height="12" font="2">Services and other agencies provide reimbursement for</text>
<text top="1053" left="468" width="333" height="12" font="2">ABPM in patients with suspected white coat hypertension</text>
<text top="1071" left="468" width="44" height="12" font="5"><a href="e127.full.html#88">(S4.3-2)</a></text>
<text top="1071" left="512" width="289" height="12" font="2">. Medicare claims for ABPM between 2007 and</text>
<text top="1089" left="468" width="333" height="12" font="2">2010 were reimbursed at a median of $52 and were</text>
<text top="149" left="112" width="54" height="10" font="15">T A B L E 1 0</text>
<text top="149" left="179" width="151" height="10" font="16">Procedures for Use of HBPM</text>
<text top="149" left="335" width="39" height="10" font="7"><a href="e127.full.html#88">(S4.2-8</a></text>
<text top="147" left="374" width="52" height="14" font="7"><a href="e127.full.html#88">—S4.2-10)</a></text>
<text top="171" left="108" width="286" height="9" font="13">Patient training should occur under medical supervision, including:</text>
<text top="186" left="112" width="6" height="10" font="9">n</text>
<text top="187" left="126" width="141" height="9" font="13">Information about hypertension</text>
<text top="199" left="112" width="6" height="10" font="9">n</text>
<text top="200" left="126" width="103" height="9" font="13">Selection of equipment</text>
<text top="211" left="112" width="6" height="10" font="9">n</text>
<text top="212" left="126" width="301" height="9" font="13">Acknowledgment that individual BP readings may vary substantially</text>
<text top="224" left="112" width="6" height="10" font="9">n</text>
<text top="225" left="126" width="107" height="9" font="13">Interpretation of results</text>
<text top="237" left="108" width="35" height="9" font="13">Devices:</text>
<text top="252" left="112" width="6" height="10" font="9">n</text>
<text top="253" left="126" width="675" height="9" font="13">Verify use of automated validated devices. Use of auscultatory devices (mercury, aneroid, or other) is not generally useful for HBPM because patients rarely</text>
<text top="266" left="126" width="358" height="9" font="13">master the technique required for measurement of BP with auscultatory devices.</text>
<text top="278" left="112" width="6" height="10" font="9">n</text>
<text top="279" left="126" width="324" height="9" font="13">Monitors with provision for storage of readings in memory are preferred.</text>
<text top="290" left="112" width="6" height="10" font="9">n</text>
<text top="291" left="126" width="163" height="9" font="13">Verify use of appropriate cuff size to</text>
<text top="290" left="293" width="53" height="12" font="13">ﬁt the arm <a href="e127.full.html#15">(</a></text>
<text top="291" left="346" width="34" height="9" font="17"><a href="e127.full.html#15">Table 9</a></text>
<text top="291" left="380" width="6" height="9" font="13">).</text>
<text top="303" left="112" width="6" height="10" font="9">n</text>
<text top="304" left="126" width="234" height="9" font="13">Verify that left/right inter-arm differences are insigni</text>
<text top="302" left="361" width="440" height="12" font="13">ﬁcant. If differences are signiﬁcant, instruct patient to measure BPs in the arm with higher readings.</text>
<text top="316" left="108" width="146" height="9" font="13">Instructions on HBPM procedures:</text>
<text top="331" left="112" width="6" height="10" font="9">n</text>
<text top="332" left="126" width="56" height="9" font="13">Remain still:</text>
<text top="346" left="127" width="6" height="10" font="21">n</text>
<text top="347" left="141" width="403" height="9" font="13">Avoid smoking, caffeinated beverages, or exercise within 30 min before BP measurements.</text>
<text top="359" left="127" width="6" height="10" font="21">n</text>
<text top="360" left="141" width="30" height="9" font="13">Ensure</text>
<text top="358" left="174" width="207" height="12" font="13">$5 min of quiet rest before BP measurements.</text>
<text top="372" left="112" width="6" height="10" font="9">n</text>
<text top="373" left="126" width="58" height="9" font="13">Sit correctly:</text>
<text top="388" left="127" width="6" height="10" font="21">n</text>
<text top="388" left="141" width="465" height="9" font="13">Sit with back straight and supported (on a straight-backed dining chair, for example, rather than a sofa).</text>
<text top="400" left="127" width="6" height="10" font="21">n</text>
<text top="401" left="141" width="55" height="9" font="13">Sit with feet</text>
<text top="399" left="199" width="161" height="12" font="13">ﬂat on the ﬂoor and legs uncrossed.</text>
<text top="413" left="127" width="6" height="10" font="21">n</text>
<text top="414" left="141" width="112" height="9" font="13">Keep arm supported on a</text>
<text top="412" left="256" width="283" height="12" font="13">ﬂat surface (such as a table), with the upper arm at heart level.</text>
<text top="426" left="112" width="6" height="10" font="9">n</text>
<text top="427" left="126" width="418" height="9" font="13">Bottom of the cuff should be placed directly above the antecubital fossa (bend of the elbow).</text>
<text top="438" left="112" width="6" height="10" font="9">n</text>
<text top="439" left="126" width="106" height="9" font="13">Take multiple readings:</text>
<text top="454" left="127" width="6" height="10" font="21">n</text>
<text top="455" left="141" width="660" height="9" font="13">Take at least 2 readings 1 min apart in morning before taking medications and in evening before supper. Optimally, measure and record BP daily. Ideally,</text>
<text top="468" left="159" width="568" height="9" font="13">obtain weekly BP readings beginning 2 weeks after a change in the treatment regimen and during the week before a clinic visit.</text>
<text top="480" left="112" width="6" height="10" font="9">n</text>
<text top="481" left="126" width="139" height="9" font="13">Record all readings accurately:</text>
<text top="496" left="127" width="6" height="10" font="21">n</text>
<text top="497" left="141" width="340" height="9" font="13">Monitors with built-in memory should be brought to all clinic appointments.</text>
<text top="508" left="127" width="6" height="10" font="21">n</text>
<text top="509" left="141" width="219" height="9" font="13">BP should be based on an average of readings on</text>
<text top="507" left="363" width="184" height="12" font="13">$2 occasions for clinical decision making.</text>
<text top="521" left="108" width="272" height="9" font="13">The information above may be reinforced with videos available</text>
<text top="521" left="382" width="26" height="9" font="17"><a href="http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/SymptomsDiagnosisMonitoringofHighBloodPressure/Home-Blood-Pressure-Monitoring_UCM_301874_Article.jsp#.WcQNfLKGMnM">online</a></text>
<text top="521" left="409" width="3" height="9" font="13"><a href="http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/SymptomsDiagnosisMonitoringofHighBloodPressure/Home-Blood-Pressure-Monitoring_UCM_301874_Article.jsp#.WcQNfLKGMnM">.</a></text>
<text top="545" left="108" width="13" height="8" font="4">See</text>
<text top="545" left="124" width="32" height="8" font="8"><a href="e127.full.html#16">Table 11</a></text>
<text top="545" left="158" width="70" height="8" font="4">for HBPM targets.</text>
<text top="559" left="116" width="286" height="8" font="4">BP indicates blood pressure; and HBPM, home blood pressure monitoring.</text>
<text top="606" left="113" width="51" height="10" font="15">T A B L E 1 1</text>
<text top="606" left="179" width="571" height="10" font="16">Corresponding Values of SBP/DBP for Clinic, HBPM, Daytime, Nighttime, and 24-Hour ABPM Measurements</text>
<text top="630" left="108" width="25" height="9" font="13">Clinic</text>
<text top="630" left="248" width="28" height="9" font="13">HBPM</text>
<text top="630" left="380" width="69" height="9" font="13">Daytime ABPM</text>
<text top="630" left="552" width="78" height="9" font="13">Nighttime ABPM</text>
<text top="630" left="732" width="69" height="9" font="13">24-Hour ABPM</text>
<text top="650" left="108" width="31" height="9" font="13">120/80</text>
<text top="650" left="246" width="31" height="9" font="13">120/80</text>
<text top="650" left="399" width="31" height="9" font="13">120/80</text>
<text top="650" left="575" width="31" height="9" font="13">100/65</text>
<text top="650" left="754" width="26" height="9" font="13">115/75</text>
<text top="669" left="108" width="31" height="9" font="13">130/80</text>
<text top="669" left="247" width="31" height="9" font="13">130/80</text>
<text top="669" left="399" width="31" height="9" font="13">130/80</text>
<text top="669" left="578" width="29" height="9" font="13">110/65</text>
<text top="669" left="752" width="27" height="9" font="13">125/75</text>
<text top="688" left="108" width="32" height="9" font="13">140/90</text>
<text top="688" left="248" width="28" height="9" font="13">135/85</text>
<text top="688" left="401" width="28" height="9" font="13">135/85</text>
<text top="688" left="576" width="30" height="9" font="13">120/70</text>
<text top="688" left="751" width="31" height="9" font="13">130/80</text>
<text top="707" left="108" width="36" height="9" font="13">160/100</text>
<text top="707" left="247" width="30" height="9" font="13">145/90</text>
<text top="707" left="400" width="30" height="9" font="13">145/90</text>
<text top="707" left="576" width="30" height="9" font="13">140/85</text>
<text top="707" left="752" width="30" height="9" font="13">145/90</text>
<text top="731" left="108" width="694" height="8" font="4">ABPM indicates ambulatory blood pressure monitoring; BP, blood pressure; DBP, diastolic blood pressure; HBPM, home blood pressure monitoring; and SBP, systolic blood pressure.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e142</text>
</page>
<page number="17" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="80" height="12" font="2">submitted for</text>
<text top="141" left="148" width="119" height="15" font="2">&lt;1% of beneﬁciaries</text>
<text top="143" left="272" width="84" height="12" font="5"><a href="e127.full.html#88">(S4.3-3,S4.3-4)</a></text>
<text top="143" left="357" width="39" height="12" font="2"><a href="e127.full.html#88">. </a>A list</text>
<text top="161" left="63" width="242" height="12" font="2">of devices validated for ABPM is available</text>
<text top="161" left="308" width="84" height="12" font="5"><a href="e127.full.html#88">(S4.3-5,S4.3-6)</a></text>
<text top="161" left="393" width="3" height="12" font="2"><a href="e127.full.html#88">.</a></text>
<text top="178" left="78" width="114" height="12" font="2">ABPM and HBPM de</text>
<text top="177" left="193" width="204" height="15" font="2">ﬁnitions of high BP use different BP</text>
<text top="196" left="63" width="333" height="12" font="2">thresholds than those used by the previously mentioned</text>
<text top="214" left="63" width="11" height="12" font="2">of</text>
<text top="213" left="74" width="322" height="15" font="2">ﬁce-based approach to categorize high BP identiﬁed</text>
<text top="232" left="63" width="11" height="12" font="2">in</text>
<text top="232" left="83" width="67" height="12" font="5"><a href="e127.full.html#11">Section 3.1</a></text>
<text top="232" left="151" width="3" height="12" font="2"><a href="e127.full.html#11">.</a></text>
<text top="233" left="163" width="50" height="11" font="5"><a href="e127.full.html#16">Table 11</a></text>
<text top="232" left="223" width="173" height="12" font="2">provides best estimates for</text>
<text top="250" left="63" width="333" height="12" font="2">corresponding home, daytime, nighttime, and 24-hour</text>
<text top="268" left="63" width="333" height="12" font="2">ambulatory levels of BP, including the values recom-</text>
<text top="286" left="63" width="113" height="12" font="2">mended for identi</text>
<text top="284" left="176" width="220" height="15" font="2">ﬁcation of hypertension with ofﬁce</text>
<text top="304" left="63" width="333" height="12" font="2">measurements. Typically, a clinic BP of 140/90 mm Hg</text>
<text top="322" left="63" width="333" height="12" font="2">corresponds to home BP values of 135/85 mm Hg and</text>
<text top="340" left="63" width="127" height="12" font="2">to ABPM values de</text>
<text top="338" left="190" width="206" height="15" font="2">ﬁned as a daytime SBP/DBP of</text>
<text top="358" left="63" width="333" height="12" font="2">135/85 mm Hg, a nighttime SBP/DBP of 120/70 mm Hg, and</text>
<text top="376" left="63" width="238" height="12" font="2">a 24-hour SBP/DBP of 130/80 mm Hg</text>
<text top="376" left="308" width="84" height="12" font="5"><a href="e127.full.html#88">(S4.3-7,S4.3-8)</a></text>
<text top="376" left="393" width="3" height="12" font="2"><a href="e127.full.html#88">.</a></text>
<text top="394" left="63" width="333" height="12" font="2">These thresholds are based on data from European,</text>
<text top="412" left="63" width="63" height="12" font="2">Australian,</text>
<text top="412" left="138" width="21" height="12" font="2">and</text>
<text top="412" left="172" width="32" height="12" font="2">Asian</text>
<text top="412" left="215" width="73" height="12" font="2">populations,</text>
<text top="412" left="300" width="26" height="12" font="2">with</text>
<text top="412" left="338" width="21" height="12" font="2">few</text>
<text top="412" left="371" width="25" height="12" font="2">data</text>
<text top="430" left="63" width="333" height="12" font="2">available for establishing appropriate thresholds for U.S.</text>
<text top="447" left="63" width="69" height="12" font="2">populations</text>
<text top="447" left="140" width="40" height="12" font="5"><a href="e127.full.html#88">(S4.3-9</a></text>
<text top="446" left="180" width="54" height="15" font="5"><a href="e127.full.html#88">—S4.3-13)</a></text>
<text top="447" left="235" width="161" height="12" font="2"><a href="e127.full.html#88">. </a>They are provided as a</text>
<text top="465" left="63" width="333" height="12" font="2">guide but should be interpreted with caution. Higher</text>
<text top="483" left="63" width="333" height="12" font="2">daytime SBP measurements from ABPM can be associated</text>
<text top="501" left="63" width="333" height="12" font="2">with an increased risk of CVD and all-cause death inde-</text>
<text top="519" left="63" width="179" height="12" font="2">pendent of clinic-measured BP</text>
<text top="519" left="246" width="50" height="12" font="5"><a href="e127.full.html#89">(S4.3-14)</a></text>
<text top="519" left="296" width="100" height="12" font="2">. A meta-analysis</text>
<text top="143" left="423" width="333" height="12" font="2">of observational studies that included 13,844 individuals</text>
<text top="161" left="423" width="333" height="12" font="2">suggested nighttime BP is a stronger risk factor for CHD</text>
<text top="178" left="423" width="251" height="12" font="2">and stroke than either clinic or daytime BP</text>
<text top="178" left="678" width="49" height="12" font="5"><a href="e127.full.html#89">(S4.3-15)</a></text>
<text top="178" left="728" width="3" height="12" font="2"><a href="e127.full.html#89">.</a></text>
<text top="196" left="438" width="318" height="12" font="2">Methodological issues complicate the interpretation</text>
<text top="214" left="423" width="208" height="12" font="2">of data from studies that report of</text>
<text top="213" left="631" width="125" height="15" font="2">ﬁce and out-of-ofﬁce</text>
<text top="232" left="423" width="101" height="12" font="2">BP readings. De</text>
<text top="230" left="525" width="232" height="15" font="2">ﬁnitions and diagnostic methods for</text>
<text top="250" left="423" width="333" height="12" font="2">identifying white coat hypertension and masked hyper-</text>
<text top="268" left="423" width="73" height="12" font="2">tension (see</text>
<text top="268" left="503" width="68" height="12" font="5"><a href="e127.full.html#17">Section 4.4</a></text>
<text top="268" left="571" width="185" height="12" font="2">) have not been standardized.</text>
<text top="286" left="423" width="333" height="12" font="2">The available studies have differed with regard to</text>
<text top="304" left="423" width="86" height="12" font="2">number of of</text>
<text top="302" left="509" width="247" height="15" font="2">ﬁce readings obtained, use of 24-hour</text>
<text top="322" left="423" width="333" height="12" font="2">ABPM, use of daytime-only ABPM, inclusion of daytime</text>
<text top="340" left="423" width="333" height="12" font="2">and nighttime BP readings as separate categories, HBPM</text>
<text top="358" left="423" width="144" height="12" font="2">for monitoring out-of-of</text>
<text top="356" left="567" width="189" height="15" font="2">ﬁce BP levels, and even the BP</text>
<text top="376" left="423" width="134" height="12" font="2">thresholds used to de</text>
<text top="374" left="558" width="199" height="15" font="2">ﬁne hypertension with ABPM or</text>
<text top="394" left="423" width="333" height="12" font="2">HBPM readings. In addition, there are few data that</text>
<text top="412" left="423" width="309" height="12" font="2">address reproducibility of these hypertension pro</text>
<text top="410" left="733" width="24" height="15" font="2">ﬁles</text>
<text top="430" left="423" width="333" height="12" font="2">over time, with several studies suggesting progression of</text>
<text top="447" left="423" width="333" height="12" font="2">white coat hypertension and especially of masked</text>
<text top="465" left="423" width="170" height="12" font="2">hypertension to sustained of</text>
<text top="464" left="593" width="163" height="15" font="2">ﬁce-measured hypertension</text>
<text top="483" left="423" width="45" height="12" font="5"><a href="e127.full.html#89">(S4.3-16</a></text>
<text top="482" left="469" width="55" height="15" font="5"><a href="e127.full.html#89">—S4.3-22)</a></text>
<text top="483" left="524" width="3" height="12" font="2">.</text>
<text top="519" left="423" width="226" height="11" font="12">4.4. Masked and White Coat Hypertension</text>
<text top="564" left="63" width="336" height="11" font="19">Recommendations for Masked and White Coat Hypertension</text>
<text top="578" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="578" left="412" width="205" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplements 4, 5, and 6</a></text>
<text top="578" left="618" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="619" left="89" width="19" height="10" font="13">COR</text>
<text top="619" left="161" width="18" height="10" font="13">LOE</text>
<text top="619" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="656" left="94" width="10" height="9" font="4">IIa</text>
<text top="656" left="160" width="21" height="9" font="4">B-NR</text>
<text top="644" left="234" width="566" height="11" font="12">1. In adults with an untreated SBP greater than 130 mm Hg but less than 160 mm Hg or DBP greater than</text>
<text top="659" left="246" width="542" height="11" font="12">80 mm Hg but less than 100 mm Hg, it is reasonable to screen for the presence of white coat hyper-</text>
<text top="675" left="246" width="433" height="11" font="12">tension by using either daytime ABPM or HBPM before diagnosis of hypertension</text>
<text top="675" left="683" width="38" height="11" font="5"><a href="e127.full.html#89">(S4.4-1</a></text>
<text top="673" left="721" width="49" height="15" font="5"><a href="e127.full.html#89">—S4.4-8)</a></text>
<text top="675" left="771" width="3" height="11" font="12"><a href="e127.full.html#89">.</a></text>
<text top="720" left="94" width="10" height="9" font="4">IIa</text>
<text top="720" left="160" width="20" height="9" font="4">C-LD</text>
<text top="707" left="234" width="566" height="11" font="12">2. In adults with white coat hypertension, periodic monitoring with either ABPM or HBPM is reasonable to</text>
<text top="723" left="248" width="230" height="11" font="12">detect transition to sustained hypertension</text>
<text top="723" left="482" width="121" height="11" font="5"><a href="e127.full.html#89">(S4.4-2,S4.4-5,S4.4-7)</a></text>
<text top="723" left="604" width="3" height="11" font="12"><a href="e127.full.html#89">.</a></text>
<text top="769" left="94" width="10" height="9" font="4">IIa</text>
<text top="769" left="159" width="23" height="9" font="4">C- LD</text>
<text top="757" left="234" width="270" height="11" font="12">3. In adults being treated for hypertension with of</text>
<text top="755" left="504" width="282" height="15" font="12">ﬁce BP readings not at goal and HBPM readings sug-</text>
<text top="773" left="248" width="91" height="11" font="12">gestive of a signi</text>
<text top="771" left="339" width="325" height="15" font="12">ﬁcant white coat effect, conﬁrmation by ABPM can be useful</text>
<text top="773" left="668" width="90" height="11" font="5"><a href="e127.full.html#89">(S4.4-9,S4.4-10)</a></text>
<text top="773" left="758" width="3" height="11" font="12">.</text>
<text top="818" left="94" width="10" height="9" font="4">IIa</text>
<text top="818" left="160" width="21" height="9" font="4">B-NR</text>
<text top="806" left="234" width="157" height="11" font="12">4. In adults with untreated of</text>
<text top="804" left="391" width="409" height="15" font="12">ﬁce BPs that are consistently between 120 mm Hg and 129 mm Hg for SBP or</text>
<text top="822" left="249" width="551" height="11" font="12">between 75 mm Hg and 79 mm Hg for DBP, screening for masked hypertension with HBPM (or ABPM) is</text>
<text top="838" left="249" width="57" height="11" font="12">reasonable</text>
<text top="838" left="310" width="205" height="11" font="5"><a href="e127.full.html#89">(S4.4-3,S4.4-4,S4.4-6,S4.4-8,S4.4-11)</a></text>
<text top="838" left="516" width="3" height="11" font="12"><a href="e127.full.html#89">.</a></text>
<text top="884" left="94" width="10" height="9" font="4">IIb</text>
<text top="884" left="160" width="20" height="9" font="4">C-LD</text>
<text top="872" left="234" width="332" height="11" font="12">5. In adults on multiple-drug therapies for hypertension and of</text>
<text top="870" left="566" width="233" height="15" font="12">ﬁce BPs within 10 mm Hg above goal, it may</text>
<text top="887" left="248" width="362" height="11" font="12">be reasonable to screen for white coat effect with HBPM (or ABPM)</text>
<text top="887" left="614" width="126" height="11" font="5"><a href="e127.full.html#89">(S4.4-3,S4.4-7,S4.4-12)</a></text>
<text top="887" left="741" width="3" height="11" font="12"><a href="e127.full.html#89">.</a></text>
<text top="933" left="94" width="10" height="9" font="4">IIb</text>
<text top="933" left="160" width="20" height="9" font="4">C-EO</text>
<text top="921" left="234" width="566" height="11" font="12">6. It may be reasonable to screen for masked uncontrolled hypertension with HBPM in adults being treated</text>
<text top="937" left="249" width="124" height="11" font="12">for hypertension and of</text>
<text top="935" left="373" width="427" height="15" font="12">ﬁce readings at goal, in the presence of target organ damage or increased overall</text>
<text top="952" left="249" width="48" height="11" font="12">CVD risk.</text>
<text top="998" left="94" width="10" height="9" font="4">IIb</text>
<text top="998" left="160" width="20" height="9" font="4">C-EO</text>
<text top="986" left="234" width="566" height="11" font="12">7. In adults being treated for hypertension with elevated HBPM readings suggestive of masked uncontrolled</text>
<text top="1002" left="247" width="95" height="11" font="12">hypertension, con</text>
<text top="1000" left="343" width="432" height="15" font="12">ﬁrmation of the diagnosis by ABPM might be reasonable before intensiﬁcation of</text>
<text top="1018" left="247" width="177" height="11" font="12">antihypertensive drug treatment.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="19" height="9" font="4">e143</text>
</page>
<page number="18" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="22" size="6" family="Times" color="#e3202b"/>
	<fontspec id="23" size="6" family="Times" color="#0e2a52"/>
<text top="323" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="341" left="123" width="318" height="12" font="2">The availability of noninvasive BP monitoring tech-</text>
<text top="359" left="108" width="333" height="12" font="2">niques has resulted in differentiation of hypertension into</text>
<text top="376" left="108" width="333" height="12" font="2">several clinically useful categories that are based on</text>
<text top="394" left="108" width="186" height="12" font="2">the place of BP measurement (</text>
<text top="395" left="294" width="48" height="11" font="5"><a href="e127.full.html#18">Table 12</a></text>
<text top="394" left="342" width="4" height="12" font="2">)</text>
<text top="394" left="352" width="89" height="12" font="5"><a href="e127.full.html#89">(S4.4-1,S4.4-13,</a></text>
<text top="412" left="108" width="47" height="12" font="5"><a href="e127.full.html#89">S4.4-14)</a></text>
<text top="412" left="155" width="286" height="12" font="2"><a href="e127.full.html#89">. </a>These include masked hypertension and white</text>
<text top="430" left="108" width="333" height="12" font="2">coat hypertension, in addition to sustained hypertension.</text>
<text top="448" left="108" width="333" height="12" font="2">White coat hypertension is characterized by elevated of-</text>
<text top="464" left="108" width="333" height="15" font="2">ﬁce BP but normal readings when measured outside the</text>
<text top="484" left="108" width="11" height="12" font="2">of</text>
<text top="482" left="119" width="322" height="15" font="2">ﬁce with either ABPM or HBPM. In contrast, masked</text>
<text top="502" left="108" width="207" height="12" font="2">hypertension is characterized by of</text>
<text top="500" left="314" width="126" height="15" font="2">ﬁce readings suggest-</text>
<text top="520" left="108" width="168" height="12" font="2">ing normal BP but out-of-of</text>
<text top="518" left="276" width="165" height="15" font="2">ﬁce (ABPM/HBPM) readings</text>
<text top="538" left="108" width="201" height="12" font="2">that are consistently above normal</text>
<text top="538" left="312" width="50" height="12" font="5"><a href="e127.full.html#89">(S4.4-15)</a></text>
<text top="538" left="363" width="78" height="12" font="2"><a href="e127.full.html#89">. </a>In sustained</text>
<text top="556" left="108" width="288" height="12" font="2">hypertension, BP readings are elevated in both of</text>
<text top="554" left="396" width="45" height="15" font="2">ﬁce and</text>
<text top="574" left="108" width="52" height="12" font="2">out-of-of</text>
<text top="572" left="160" width="73" height="15" font="2">ﬁce settings.</text>
<text top="592" left="123" width="246" height="12" font="2">In patients treated for hypertension, both</text>
<text top="590" left="373" width="68" height="15" font="2">“white coat</text>
<text top="610" left="108" width="33" height="12" font="2">effect</text>
<text top="608" left="141" width="300" height="15" font="2">” (higher ofﬁce BPs than out-of-ofﬁce BPs) and</text>
<text top="626" left="108" width="333" height="15" font="2">“masked uncontrolled hypertension” (controlled ofﬁce</text>
<text top="646" left="108" width="225" height="12" font="2">BPs but uncontrolled BPs in out-of-of</text>
<text top="644" left="332" width="109" height="15" font="2">ﬁce settings) cate-</text>
<text top="663" left="108" width="158" height="12" font="2">gories have been reported</text>
<text top="663" left="272" width="137" height="12" font="5"><a href="e127.full.html#89">(S4.4-5,S4.4-15,S4.4-16)</a></text>
<text top="663" left="410" width="31" height="12" font="2"><a href="e127.full.html#89">. </a>The</text>
<text top="681" left="108" width="301" height="12" font="2">white coat effect (usually considered clinically signi</text>
<text top="680" left="409" width="32" height="15" font="2">ﬁcant</text>
<text top="699" left="108" width="50" height="12" font="2">when of</text>
<text top="697" left="158" width="283" height="15" font="2">ﬁce SBP/DBPs are &gt;20/10 mm Hg higher than</text>
<text top="717" left="108" width="333" height="12" font="2">home or ABPM SBP/DBPs) has been implicated in</text>
<text top="733" left="108" width="224" height="15" font="2">“pseudo-resistant hypertension” (see</text>
<text top="735" left="339" width="69" height="12" font="5"><a href="e127.full.html#67">Section 11.1</a></text>
<text top="735" left="408" width="33" height="12" font="2">) and</text>
<text top="753" left="108" width="212" height="12" font="2">results in an underestimation of of</text>
<text top="751" left="319" width="122" height="15" font="2">ﬁce BP control rates</text>
<text top="143" left="468" width="97" height="12" font="5"><a href="e127.full.html#89">(S4.4-17,S4.4-18)</a></text>
<text top="143" left="565" width="236" height="12" font="2">. The prevalence of masked hypertension</text>
<text top="161" left="468" width="333" height="12" font="2">varies from 10% to 26% (mean 13%) in population-based</text>
<text top="178" left="468" width="333" height="12" font="2">surveys and from 14% to 30% in normotensive clinic</text>
<text top="196" left="468" width="69" height="12" font="2">populations</text>
<text top="196" left="541" width="134" height="12" font="5"><a href="e127.full.html#89">(S4.4-6,S4.4-16,S4.4-19</a></text>
<text top="195" left="675" width="55" height="15" font="5"><a href="e127.full.html#89">—S4.4-21)</a></text>
<text top="196" left="731" width="3" height="12" font="2"><a href="e127.full.html#89">.</a></text>
<text top="214" left="483" width="318" height="12" font="2">The risk of CVD and all-cause mortality in persons with</text>
<text top="232" left="468" width="333" height="12" font="2">masked hypertension is similar to that noted in those</text>
<text top="250" left="468" width="333" height="12" font="2">with sustained hypertension and about twice as high as</text>
<text top="268" left="468" width="333" height="12" font="2">the corresponding risk in their normotensive counterparts</text>
<text top="286" left="468" width="214" height="12" font="5"><a href="e127.full.html#89">(S4.4-3,S4.4-4,S4.4-6,S4.4-8,S4.4-11)</a></text>
<text top="286" left="682" width="119" height="12" font="2">. The prevalence of</text>
<text top="304" left="468" width="290" height="12" font="2">masked hypertension increases with higher of</text>
<text top="302" left="758" width="43" height="15" font="2">ﬁce BP</text>
<text top="322" left="468" width="49" height="12" font="2">readings</text>
<text top="322" left="521" width="146" height="12" font="5"><a href="e127.full.html#89">(S4.4-20,S4.4-22,S4.4-23)</a></text>
<text top="322" left="668" width="3" height="12" font="2"><a href="e127.full.html#89">.</a></text>
<text top="340" left="483" width="318" height="12" font="2">The prevalence of white coat hypertension is higher</text>
<text top="358" left="468" width="118" height="12" font="2">with increasing age</text>
<text top="358" left="592" width="52" height="12" font="5"><a href="e127.full.html#89">(S4.4-24)</a></text>
<text top="358" left="645" width="157" height="12" font="2"><a href="e127.full.html#89">, </a>female versus male sex,</text>
<text top="376" left="468" width="333" height="12" font="2">nonsmoking versus current smoking status, and routine</text>
<text top="394" left="468" width="11" height="12" font="2">of</text>
<text top="392" left="480" width="322" height="15" font="2">ﬁce measurement of BP by clinician observers versus</text>
<text top="412" left="468" width="333" height="12" font="2">unattended BP measurements. Many, but not all, studies</text>
<text top="430" left="468" width="223" height="12" font="5"><a href="e127.full.html#89">(S4.4-4,S4.4-6,S4.4-8,S4.4-25,S4.4-26)</a></text>
<text top="430" left="698" width="68" height="12" font="2">have identi</text>
<text top="428" left="766" width="35" height="15" font="2">ﬁed a</text>
<text top="447" left="468" width="333" height="12" font="2">minimal increase in risk of CVD complications or all-cause</text>
<text top="465" left="468" width="333" height="12" font="2">mortality in patients who have white coat hypertension.</text>
<text top="483" left="468" width="333" height="12" font="2">This has resulted in a recommendation by some panels to</text>
<text top="501" left="468" width="333" height="12" font="2">screen for white coat hypertension with ABPM (or HBPM)</text>
<text top="519" left="468" width="333" height="12" font="2">to avoid initiating antihypertensive drug treatment in</text>
<text top="537" left="468" width="97" height="12" font="2">such individuals</text>
<text top="537" left="570" width="132" height="12" font="5"><a href="e127.full.html#89">(S4.4-2,S4.4-5,S4.4-27)</a></text>
<text top="537" left="703" width="98" height="12" font="2"><a href="e127.full.html#89">. </a>The white coat</text>
<text top="555" left="468" width="333" height="12" font="2">effect and masked uncontrolled hypertension appear to</text>
<text top="573" left="468" width="111" height="12" font="2">follow the risk pro</text>
<text top="571" left="579" width="222" height="15" font="2">ﬁles of their white coat hypertension</text>
<text top="591" left="468" width="333" height="12" font="2">and masked hypertension counterparts, respectively</text>
<text top="609" left="468" width="91" height="12" font="5"><a href="e127.full.html#89">(S4.4-3,S4.4-12)</a></text>
<text top="609" left="559" width="3" height="12" font="2"><a href="e127.full.html#89">.</a></text>
<text top="627" left="483" width="235" height="12" font="2">There are no data on the risks and bene</text>
<text top="625" left="718" width="83" height="15" font="2">ﬁts of treating</text>
<text top="645" left="468" width="333" height="12" font="2">white coat and masked hypertension. Despite these</text>
<text top="663" left="468" width="333" height="12" font="2">methodological differences, the data are consistent in</text>
<text top="681" left="468" width="333" height="12" font="2">indicating that masked hypertension and masked un-</text>
<text top="698" left="468" width="333" height="12" font="2">controlled hypertension are associated with an increased</text>
<text top="716" left="468" width="333" height="12" font="2">prevalence of target organ damage and risk of CVD,</text>
<text top="734" left="468" width="333" height="12" font="2">stroke, and mortality compared with normotensive in-</text>
<text top="752" left="468" width="294" height="12" font="2">dividuals and those with white coat hypertension.</text>
<text top="156" left="113" width="52" height="10" font="15">T A B L E 1 2</text>
<text top="149" left="179" width="131" height="10" font="16">BP Patterns Based on Of</text>
<text top="147" left="310" width="114" height="14" font="16">ﬁce and Out-of-Ofﬁce</text>
<text top="163" left="179" width="77" height="10" font="16">Measurements</text>
<text top="187" left="254" width="11" height="9" font="13">Of</text>
<text top="186" left="265" width="49" height="12" font="13">ﬁce/Clinic/</text>
<text top="199" left="241" width="87" height="9" font="13">Healthcare Setting</text>
<text top="187" left="337" width="103" height="9" font="13">Home/Nonhealthcare/</text>
<text top="199" left="356" width="65" height="9" font="13">ABPM Setting</text>
<text top="219" left="108" width="58" height="9" font="13">Normotensive</text>
<text top="219" left="237" width="69" height="9" font="13">No hypertension</text>
<text top="219" left="335" width="69" height="9" font="13">No hypertension</text>
<text top="238" left="108" width="97" height="9" font="13">Sustained hypertension</text>
<text top="238" left="237" width="55" height="9" font="13">Hypertension</text>
<text top="238" left="335" width="55" height="9" font="13">Hypertension</text>
<text top="257" left="108" width="89" height="9" font="13">Masked hypertension</text>
<text top="257" left="237" width="69" height="9" font="13">No hypertension</text>
<text top="257" left="335" width="55" height="9" font="13">Hypertension</text>
<text top="276" left="108" width="102" height="9" font="13">White coat hypertension</text>
<text top="276" left="237" width="55" height="9" font="13">Hypertension</text>
<text top="276" left="335" width="69" height="9" font="13">No hypertension</text>
<text top="300" left="108" width="308" height="8" font="4">ABPM indicates ambulatory blood pressure monitoring; and BP, blood pressure.</text>
<text top="811" left="125" width="44" height="11" font="22">FIGURE 1</text>
<text top="812" left="177" width="427" height="9" font="23">Detection of White Coat Hypertension or Masked Hypertension in Patients Not on Drug Therapy</text>
<text top="1062" left="125" width="213" height="9" font="13">Colors correspond to Class of Recommendation in</text>
<text top="1062" left="342" width="31" height="9" font="17"><a href="e127.full.html#6">Table 1</a></text>
<text top="1062" left="373" width="405" height="9" font="13"><a href="e127.full.html#6">. </a>ABPM indicates ambulatory blood pressure monitoring; BP, blood pressure; and HBPM, home</text>
<text top="1077" left="125" width="115" height="9" font="13">blood pressure monitoring.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e144</text>
</page>
<page number="19" position="absolute" top="0" left="0" height="1160" width="864">
<text top="783" left="78" width="44" height="11" font="5"><a href="e127.full.html#18">Figure 1</a></text>
<text top="783" left="127" width="269" height="12" font="2">is an algorithm on the detection of white coat</text>
<text top="801" left="63" width="333" height="12" font="2">hypertension or masked hypertension in patients not on</text>
<text top="819" left="63" width="81" height="12" font="2">drug therapy.</text>
<text top="819" left="150" width="48" height="11" font="5"><a href="e127.full.html#19">Figure 2</a></text>
<text top="819" left="205" width="191" height="12" font="2">is an algorithm on detection of</text>
<text top="837" left="63" width="333" height="12" font="2">white coat effect or masked uncontrolled hypertension in</text>
<text top="855" left="63" width="154" height="12" font="2">patients on drug therapy.</text>
<text top="855" left="223" width="48" height="11" font="5"><a href="e127.full.html#18">Table 12</a></text>
<text top="855" left="277" width="119" height="12" font="2">is a summary of BP</text>
<text top="872" left="63" width="119" height="12" font="2">patterns based on of</text>
<text top="871" left="182" width="214" height="15" font="2">ﬁce and out-of-ofﬁce measurements.</text>
<text top="899" left="63" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="898" left="202" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="926" left="65" width="331" height="12" font="2">1. White coat hypertension prevalence averages approx-</text>
<text top="944" left="79" width="317" height="12" font="2">imately 13% and as high as 35% in some hypertensive</text>
<text top="962" left="79" width="69" height="12" font="2">populations</text>
<text top="962" left="153" width="84" height="12" font="5"><a href="e127.full.html#89">(S4.4-1,S4.4-2)</a></text>
<text top="962" left="237" width="159" height="12" font="2">, and ABPM and HBPM are</text>
<text top="980" left="79" width="317" height="12" font="2">better predictors of CVD risk due to elevated BP than</text>
<text top="998" left="79" width="37" height="12" font="2">are of</text>
<text top="996" left="116" width="280" height="15" font="2">ﬁce BP measurements, with ABPM being the</text>
<text top="1016" left="79" width="317" height="12" font="2">preferred measurement option. The major clinical</text>
<text top="1034" left="79" width="317" height="12" font="2">relevance of white coat hypertension is that it has</text>
<text top="1052" left="79" width="317" height="12" font="2">typically been associated with a minimal to only</text>
<text top="1070" left="79" width="317" height="12" font="2">slightly increased risk of CVD and all-cause mortality</text>
<text top="1088" left="79" width="21" height="12" font="2">risk</text>
<text top="1088" left="110" width="219" height="12" font="5"><a href="e127.full.html#89">(S4.4-3,S4.4-4,S4.4-7,S4.4-11,S4.4-24)</a></text>
<text top="1088" left="330" width="66" height="12" font="2"><a href="e127.full.html#89">. </a>If ABPM</text>
<text top="783" left="439" width="317" height="12" font="2">resources are not readily available, HBPM provides a</text>
<text top="801" left="439" width="317" height="12" font="2">reasonable but less desirable alternative to screen for</text>
<text top="819" left="439" width="317" height="12" font="2">white coat hypertension, although the overlap with</text>
<text top="837" left="439" width="317" height="12" font="2">ABPM is only 60% to 70% for detection of white coat</text>
<text top="855" left="439" width="77" height="12" font="2">hypertension</text>
<text top="855" left="520" width="129" height="12" font="5"><a href="e127.full.html#89">(S4.4-5,S4.4-9,S4.4-27</a></text>
<text top="853" left="649" width="57" height="15" font="5"><a href="e127.full.html#89">—S4.4-30)</a></text>
<text top="855" left="707" width="3" height="12" font="2"><a href="e127.full.html#89">.</a></text>
<text top="872" left="425" width="332" height="12" font="2">2. The incidence of white coat hypertension converting to</text>
<text top="890" left="439" width="317" height="12" font="2">sustained hypertension (justifying the addition of</text>
<text top="908" left="439" width="292" height="12" font="2">antihypertensive drug therapy to lifestyle modi</text>
<text top="906" left="732" width="25" height="15" font="2">ﬁca-</text>
<text top="926" left="439" width="317" height="12" font="2">tion) is 1% to 5% per year by ABPM or HBPM, with a</text>
<text top="944" left="439" width="317" height="12" font="2">higher incidence of conversion in those with elevated</text>
<text top="962" left="439" width="208" height="12" font="2">BP, older age, obesity, or black race</text>
<text top="962" left="651" width="85" height="12" font="5"><a href="e127.full.html#89">(S4.4-2,S4.4-7)</a></text>
<text top="962" left="737" width="3" height="12" font="2">.</text>
<text top="980" left="425" width="332" height="12" font="2">3. The overlap between HBPM and both daytime and 24-</text>
<text top="998" left="439" width="317" height="12" font="2">hour ABPM in diagnosing white coat hypertension is</text>
<text top="1016" left="439" width="317" height="12" font="2">only 60% to 70%, and the data for prediction of CVD</text>
<text top="1034" left="439" width="261" height="12" font="2">risk are stronger with ABPM than with of</text>
<text top="1032" left="700" width="56" height="15" font="2">ﬁce mea-</text>
<text top="1052" left="439" width="61" height="12" font="2">surements</text>
<text top="1052" left="504" width="128" height="12" font="5"><a href="e127.full.html#89">(S4.4-5,S4.4-9,S4.4-27</a></text>
<text top="1050" left="633" width="57" height="15" font="5"><a href="e127.full.html#89">—S4.4-30)</a></text>
<text top="1052" left="691" width="66" height="12" font="2"><a href="e127.full.html#89">. </a>Because a</text>
<text top="1070" left="439" width="317" height="12" font="2">diagnosis of white coat hypertension may result in a</text>
<text top="1088" left="439" width="317" height="12" font="2">decision not to treat or intensify treatment in patients</text>
<text top="153" left="80" width="45" height="11" font="22">FIGURE 2</text>
<text top="154" left="134" width="436" height="9" font="23">Detection of White Coat Effect or Masked Uncontrolled Hypertension in Patients on Drug Therapy</text>
<text top="702" left="80" width="213" height="9" font="13">Colors correspond to Class of Recommendation in</text>
<text top="702" left="297" width="31" height="9" font="17"><a href="e127.full.html#6">Table 1</a></text>
<text top="702" left="328" width="21" height="9" font="13"><a href="e127.full.html#6">. </a>See</text>
<text top="702" left="352" width="40" height="9" font="17"><a href="e127.full.html#34">Section 8</a></text>
<text top="702" left="395" width="334" height="9" font="13">for treatment options. ABPM indicates ambulatory blood pressure monitoring;</text>
<text top="717" left="80" width="403" height="9" font="13">BP, blood pressure; CVD, cardiovascular disease; and HBPM, home blood pressure monitoring.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="19" height="9" font="4">e145</text>
</page>
<page number="20" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="124" width="98" height="12" font="2">with elevated of</text>
<text top="141" left="222" width="218" height="15" font="2">ﬁce BP readings, conﬁrmation of BP</text>
<text top="161" left="124" width="317" height="12" font="2">control by ABPM in addition to HBPM provides added</text>
<text top="178" left="124" width="147" height="12" font="2">support for this decision.</text>
<text top="196" left="108" width="333" height="12" font="2">4. In contrast to white coat hypertension, masked hy-</text>
<text top="214" left="124" width="317" height="12" font="2">pertension is associated with a CVD and all-cause</text>
<text top="232" left="124" width="317" height="12" font="2">mortality risk twice as high as that seen in normoten-</text>
<text top="250" left="124" width="317" height="12" font="2">sive individuals, with a risk range similar to that of</text>
<text top="268" left="124" width="225" height="12" font="2">patients with sustained hypertension</text>
<text top="268" left="355" width="86" height="12" font="5"><a href="e127.full.html#89">(S4.4-3,S4.4-4,</a></text>
<text top="286" left="124" width="173" height="12" font="5"><a href="e127.full.html#89">S4.4-6,S4.4-8,S4.4-11,S4.4-31)</a></text>
<text top="286" left="297" width="3" height="12" font="2">.</text>
<text top="286" left="321" width="60" height="12" font="2">Therefore,</text>
<text top="286" left="401" width="40" height="12" font="2">out-of-</text>
<text top="304" left="124" width="11" height="12" font="2">of</text>
<text top="302" left="135" width="306" height="15" font="2">ﬁce readings are reasonable to conﬁrm BP control</text>
<text top="322" left="124" width="72" height="12" font="2">seen with of</text>
<text top="320" left="196" width="77" height="15" font="2">ﬁce readings.</text>
<text top="340" left="109" width="307" height="12" font="2">5. The white coat effect has been implicated in of</text>
<text top="338" left="416" width="25" height="15" font="2">ﬁce-</text>
<text top="358" left="124" width="317" height="12" font="2">measured uncontrolled hypertension and pseudo-</text>
<text top="376" left="124" width="317" height="12" font="2">resistant hypertension, which may result in BP</text>
<text top="394" left="124" width="317" height="12" font="2">control being underestimated when subsequently</text>
<text top="412" left="124" width="119" height="12" font="2">assessed by ABPM</text>
<text top="412" left="254" width="97" height="12" font="5"><a href="e127.full.html#89">(S4.4-17,S4.4-18)</a></text>
<text top="412" left="351" width="90" height="12" font="2">. The risk of</text>
<text top="430" left="124" width="48" height="12" font="2">vascular</text>
<text top="430" left="185" width="81" height="12" font="2">complications</text>
<text top="430" left="280" width="11" height="12" font="2">in</text>
<text top="430" left="304" width="47" height="12" font="2">patients</text>
<text top="430" left="365" width="26" height="12" font="2">with</text>
<text top="430" left="404" width="11" height="12" font="2">of</text>
<text top="428" left="416" width="25" height="15" font="2">ﬁce-</text>
<text top="447" left="124" width="317" height="12" font="2">measured uncontrolled hypertension with a white</text>
<text top="465" left="124" width="317" height="12" font="2">coat effect is similar to the risk in those with controlled</text>
<text top="483" left="124" width="77" height="12" font="2">hypertension</text>
<text top="483" left="220" width="217" height="12" font="5"><a href="e127.full.html#89">(S4.4-3,S4.4-4,S4.4-7,S4.4-11,S4.4-12)</a></text>
<text top="483" left="437" width="3" height="12" font="2">.</text>
<text top="501" left="124" width="317" height="12" font="2">White coat hypertension and white coat effect raise the</text>
<text top="519" left="124" width="317" height="12" font="2">concern that unnecessary antihypertensive drug ther-</text>
<text top="537" left="124" width="175" height="12" font="2">apy may be initiated or intensi</text>
<text top="535" left="299" width="142" height="15" font="2">ﬁed. Because a diagnosis</text>
<text top="555" left="124" width="317" height="12" font="2">of white coat hypertension or white coat effect would</text>
<text top="573" left="124" width="275" height="12" font="2">result in a decision to not treat elevated of</text>
<text top="571" left="399" width="42" height="15" font="2">ﬁce BP</text>
<text top="591" left="124" width="82" height="12" font="2">readings, con</text>
<text top="589" left="206" width="235" height="15" font="2">ﬁrmation of BP control by HBPM (or</text>
<text top="609" left="124" width="147" height="12" font="2">ABPM) provides more de</text>
<text top="607" left="271" width="169" height="15" font="2">ﬁnitive support for the deci-</text>
<text top="627" left="124" width="317" height="12" font="2">sion not to initiate antihypertensive drug therapy or</text>
<text top="645" left="124" width="123" height="12" font="2">accelerate treatment.</text>
<text top="663" left="108" width="333" height="12" font="2">6. Analogous to masked hypertension in untreated pa-</text>
<text top="681" left="124" width="273" height="12" font="2">tients, masked uncontrolled hypertension is de</text>
<text top="679" left="397" width="44" height="15" font="2">ﬁned in</text>
<text top="698" left="124" width="242" height="12" font="2">treated patients with hypertension by of</text>
<text top="697" left="366" width="75" height="15" font="2">ﬁce readings</text>
<text top="716" left="124" width="297" height="12" font="2">suggesting adequate BP control but out-of-of</text>
<text top="715" left="421" width="20" height="15" font="2">ﬁce</text>
<text top="734" left="124" width="317" height="12" font="2">readings (HBPM) that remain consistently above goal</text>
<text top="752" left="124" width="231" height="12" font="5"><a href="e127.full.html#89">(S4.4-3,S4.4-15,S4.4-16,S4.4-32,S4.4-33)</a></text>
<text top="752" left="355" width="86" height="12" font="2"><a href="e127.full.html#89">. </a>The CVD risk</text>
<text top="770" left="124" width="19" height="12" font="2">pro</text>
<text top="768" left="143" width="298" height="15" font="2">ﬁle for masked uncontrolled hypertension appears</text>
<text top="788" left="124" width="138" height="12" font="2">to follow the risk pro</text>
<text top="786" left="262" width="179" height="15" font="2">ﬁle for masked hypertension</text>
<text top="806" left="124" width="139" height="12" font="5"><a href="e127.full.html#89">(S4.4-3,S4.4-12,S4.4-34)</a></text>
<text top="806" left="263" width="178" height="12" font="2"><a href="e127.full.html#89">. </a>Although the evidence is</text>
<text top="824" left="124" width="317" height="12" font="2">consistent in identifying the increased risk of masked</text>
<text top="842" left="124" width="317" height="12" font="2">uncontrolled hypertension, evidence is lacking on</text>
<text top="860" left="124" width="317" height="12" font="2">whether the treatment of masked hypertension or</text>
<text top="878" left="124" width="317" height="12" font="2">masked uncontrolled hypertension reduces clinical</text>
<text top="896" left="124" width="317" height="12" font="2">outcomes. A suggestion for assessing CVD risk is pro-</text>
<text top="914" left="124" width="48" height="12" font="2">vided in</text>
<text top="914" left="176" width="54" height="12" font="5"><a href="e127.full.html#34">Section 8</a></text>
<text top="914" left="230" width="3" height="12" font="2"><a href="e127.full.html#34">.</a></text>
<text top="932" left="109" width="332" height="12" font="2">7. Although both ABPM and HBPM are better predictors of</text>
<text top="950" left="124" width="120" height="12" font="2">CVD risk than are of</text>
<text top="948" left="244" width="197" height="15" font="2">ﬁce BP readings, ABPM conﬁrma-</text>
<text top="967" left="124" width="317" height="12" font="2">tion of elevated BP by HBPM might be reasonable</text>
<text top="985" left="124" width="317" height="12" font="2">because of the more extensive documentation of CVD</text>
<text top="1003" left="124" width="317" height="12" font="2">risk with ABPM. However, unlike the documentation of</text>
<text top="1021" left="124" width="38" height="12" font="2">a signi</text>
<text top="1020" left="162" width="279" height="15" font="2">ﬁcant white coat effect to justify the decision to</text>
<text top="1039" left="124" width="317" height="12" font="2">not treat an elevated clinic BP, it is not mandatory to</text>
<text top="1057" left="124" width="21" height="12" font="2">con</text>
<text top="1055" left="145" width="296" height="15" font="2">ﬁrm masked uncontrolled hypertension deter-</text>
<text top="1075" left="124" width="98" height="12" font="2">mined by HBPM.</text>
<text top="141" left="468" width="205" height="16" font="14">5. CAUSES OF HYPERTENSION</text>
<text top="179" left="468" width="141" height="11" font="12">5.1. Genetic Predisposition</text>
<text top="200" left="468" width="333" height="12" font="2">Hypertension is a complex polygenic disorder in which</text>
<text top="218" left="468" width="32" height="12" font="2">many</text>
<text top="218" left="514" width="33" height="12" font="2">genes</text>
<text top="218" left="560" width="12" height="12" font="2">or</text>
<text top="218" left="586" width="27" height="12" font="2">gene</text>
<text top="218" left="627" width="78" height="12" font="2">combinations</text>
<text top="218" left="719" width="11" height="12" font="2">in</text>
<text top="216" left="730" width="71" height="15" font="2">ﬂuence BP</text>
<text top="236" left="468" width="78" height="12" font="5"><a href="e127.full.html#89">(S5.1-1,S5.1-2)</a></text>
<text top="236" left="546" width="255" height="12" font="2">. Although several monogenic forms of hy-</text>
<text top="254" left="468" width="167" height="12" font="2">pertension have been identi</text>
<text top="252" left="635" width="166" height="15" font="2">ﬁed, such as glucocorticoid-</text>
<text top="272" left="468" width="199" height="12" font="2">remediable aldosteronism, Liddle</text>
<text top="270" left="667" width="134" height="15" font="2">’s syndrome, Gordon’s</text>
<text top="290" left="468" width="333" height="12" font="2">syndrome, and others in which single-gene mutations</text>
<text top="308" left="468" width="333" height="12" font="2">fully explain the pathophysiology of hypertension, these</text>
<text top="326" left="468" width="111" height="12" font="2">disorders are rare</text>
<text top="326" left="587" width="42" height="12" font="5"><a href="e127.full.html#90">(S5.1-3)</a></text>
<text top="326" left="629" width="172" height="12" font="2">. The current tabulation of</text>
<text top="344" left="468" width="334" height="12" font="2">known genetic variants contributing to BP and hyper-</text>
<text top="362" left="468" width="333" height="12" font="2">tension includes more than 25 rare mutations and 120</text>
<text top="380" left="468" width="200" height="12" font="2">single-nucleotide polymorphisms</text>
<text top="380" left="677" width="80" height="12" font="5"><a href="e127.full.html#90">(S5.1-3,S5.1-4)</a></text>
<text top="380" left="757" width="44" height="12" font="2">. How-</text>
<text top="398" left="468" width="333" height="12" font="2">ever, even with the discovery of multiple single-</text>
<text top="415" left="468" width="182" height="12" font="2">nucleotide polymorphisms in</text>
<text top="414" left="650" width="151" height="15" font="2">ﬂuencing control of BP</text>
<text top="433" left="468" width="333" height="12" font="2">since completion of the Human Genome Project in 2003,</text>
<text top="451" left="468" width="333" height="12" font="2">the associated variants have only small effects. Indeed, at</text>
<text top="469" left="468" width="311" height="12" font="2">present, the collective effect of all BP loci identi</text>
<text top="468" left="780" width="22" height="15" font="2">ﬁed</text>
<text top="487" left="468" width="333" height="12" font="2">through genome-wide association studies accounts for</text>
<text top="505" left="468" width="188" height="12" font="2">only about 3.5% of BP variability</text>
<text top="505" left="660" width="43" height="12" font="5"><a href="e127.full.html#90">(S5.1-4)</a></text>
<text top="505" left="703" width="99" height="12" font="2"><a href="e127.full.html#90">. </a>The presence of</text>
<text top="523" left="468" width="333" height="12" font="2">a high number of small-effect alleles associated with</text>
<text top="541" left="468" width="333" height="12" font="2">higher BP results in a more rapid increase in BP with age</text>
<text top="559" left="468" width="42" height="12" font="5"><a href="e127.full.html#90">(S5.1-5)</a></text>
<text top="559" left="510" width="291" height="12" font="2"><a href="e127.full.html#90">. </a>Future studies will need to better elucidate</text>
<text top="577" left="468" width="333" height="12" font="2">genetic expression, epigenetic effects, transcriptomics,</text>
<text top="595" left="468" width="333" height="12" font="2">and proteomics that link genotypes with underlying</text>
<text top="613" left="468" width="189" height="12" font="2">pathophysiological mechanisms.</text>
<text top="648" left="468" width="169" height="11" font="12">5.2. Environmental Risk Factors</text>
<text top="670" left="468" width="333" height="12" font="2">Various environmental exposures, including components</text>
<text top="688" left="468" width="333" height="12" font="2">of diet, physical activity, and alcohol consumption, in-</text>
<text top="704" left="468" width="333" height="15" font="2">ﬂuence BP. Many dietary components have been associ-</text>
<text top="723" left="468" width="102" height="12" font="2">ated with high BP</text>
<text top="723" left="574" width="80" height="12" font="5"><a href="e127.full.html#90">(S5.2-1,S5.2-2)</a></text>
<text top="723" left="654" width="147" height="12" font="2">. Some of the diet-related</text>
<text top="741" left="468" width="333" height="12" font="2">factors associated with high BP include overweight and</text>
<text top="759" left="468" width="256" height="12" font="2">obesity, excess intake of sodium, and insuf</text>
<text top="758" left="724" width="77" height="15" font="2">ﬁcient intake</text>
<text top="777" left="468" width="333" height="12" font="2">of potassium, calcium, magnesium, protein (especially</text>
<text top="795" left="468" width="102" height="12" font="2">from vegetables),</text>
<text top="793" left="575" width="227" height="15" font="2">ﬁber, and ﬁsh fats. Poor diet, physical</text>
<text top="813" left="468" width="333" height="12" font="2">inactivity, and excess intake of alcohol, alone or in com-</text>
<text top="831" left="468" width="333" height="12" font="2">bination, are the underlying cause of a large proportion of</text>
<text top="849" left="468" width="333" height="12" font="2">hypertension. Gut microbiota have also been linked to</text>
<text top="867" left="468" width="283" height="12" font="2">hypertension, especially in experimental animals</text>
<text top="867" left="755" width="43" height="12" font="5"><a href="e127.full.html#90">(S5.2-3)</a></text>
<text top="867" left="798" width="3" height="12" font="2"><a href="e127.full.html#90">.</a></text>
<text top="885" left="468" width="333" height="12" font="2">Some of the best-proven environmental relationships</text>
<text top="903" left="468" width="143" height="12" font="2">with high BP are brie</text>
<text top="901" left="611" width="191" height="15" font="2">ﬂy reviewed below, and non-</text>
<text top="921" left="468" width="333" height="12" font="2">pharmacological interventions to lower BP are discussed</text>
<text top="939" left="468" width="11" height="12" font="2">in</text>
<text top="939" left="483" width="63" height="12" font="5"><a href="e127.full.html#29">Section 6.2</a></text>
<text top="939" left="547" width="3" height="12" font="2">.</text>
<text top="974" left="468" width="157" height="11" font="2">5.2.1. Overweight and Obesity</text>
<text top="996" left="468" width="297" height="12" font="2">Insurance industry actuarial reports have identi</text>
<text top="994" left="766" width="36" height="15" font="2">ﬁed a</text>
<text top="1014" left="468" width="333" height="12" font="2">striking relationship between body weight and high BP</text>
<text top="1032" left="468" width="51" height="12" font="5"><a href="e127.full.html#90">(S5.2.1-1)</a></text>
<text top="1032" left="524" width="277" height="12" font="2">and a direct relationship between overweight/</text>
<text top="1049" left="468" width="162" height="12" font="2">obesity and hypertension</text>
<text top="1049" left="641" width="52" height="12" font="5"><a href="e127.full.html#90">(S5.2.1-2)</a></text>
<text top="1049" left="693" width="108" height="12" font="2">. Epidemiological</text>
<text top="1067" left="468" width="277" height="12" font="2">studies, including the Framingham Heart Study</text>
<text top="1067" left="749" width="52" height="12" font="5"><a href="e127.full.html#90">(S5.2.1-3)</a></text>
<text top="1085" left="468" width="86" height="12" font="2">and the Nurses</text>
<text top="1084" left="554" width="82" height="15" font="2">’ Health Study</text>
<text top="1085" left="640" width="53" height="12" font="5"><a href="e127.full.html#90">(S5.2.1-4)</a></text>
<text top="1085" left="693" width="108" height="12" font="2">, have consistently</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e146</text>
</page>
<page number="21" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="34" height="12" font="2">identi</text>
<text top="141" left="97" width="299" height="15" font="2">ﬁed a direct relationship between body mass index</text>
<text top="161" left="63" width="333" height="12" font="2">and BP that is continuous and almost linear, with no ev-</text>
<text top="178" left="63" width="125" height="12" font="2">idence of a threshold</text>
<text top="178" left="192" width="100" height="12" font="5"><a href="e127.full.html#90">(S5.2.1-5,S5.2.1-6)</a></text>
<text top="178" left="292" width="104" height="12" font="2">. The relationship</text>
<text top="196" left="63" width="333" height="12" font="2">with BP is even stronger for waist-to-hip ratio and</text>
<text top="214" left="63" width="333" height="12" font="2">computed tomographic measures of central fat distribu-</text>
<text top="232" left="63" width="23" height="12" font="2">tion</text>
<text top="232" left="96" width="52" height="12" font="5"><a href="e127.full.html#90">(S5.2.1-7)</a></text>
<text top="232" left="148" width="248" height="12" font="2">. Attributable risk estimates from the</text>
<text top="250" left="63" width="39" height="12" font="2">Nurses</text>
<text top="248" left="103" width="294" height="15" font="2">’ Health Study suggest that obesity may be</text>
<text top="268" left="63" width="333" height="12" font="2">responsible for about 40% of hypertension, and in</text>
<text top="286" left="63" width="333" height="12" font="2">the Framingham Offspring Study, the corresponding es-</text>
<text top="304" left="63" width="333" height="12" font="2">timates were even higher (78% in men and 65% in</text>
<text top="322" left="63" width="47" height="12" font="2">women)</text>
<text top="322" left="120" width="101" height="12" font="5"><a href="e127.full.html#90">(S5.2.1-8,S5.2.1-9)</a></text>
<text top="322" left="221" width="175" height="12" font="2">. The relationship between</text>
<text top="340" left="63" width="333" height="12" font="2">obesity at a young age and change in obesity status over</text>
<text top="358" left="63" width="333" height="12" font="2">time is strongly related to future risk of hypertension. In</text>
<text top="376" left="63" width="333" height="12" font="2">combined data from 4 longitudinal studies begun in</text>
<text top="394" left="63" width="333" height="12" font="2">adolescence with repeat examination in young adulthood</text>
<text top="412" left="63" width="333" height="12" font="2">to early middle age, being obese continuously or</text>
<text top="430" left="63" width="333" height="12" font="2">acquiring obesity was associated with a relative risk of 2.7</text>
<text top="447" left="63" width="333" height="12" font="2">for developing hypertension. Becoming normal weight</text>
<text top="465" left="63" width="333" height="12" font="2">reduced the risk of developing hypertension to a level</text>
<text top="483" left="63" width="251" height="12" font="2">similar to those who had never been obese</text>
<text top="483" left="317" width="58" height="12" font="5"><a href="e127.full.html#90">(S5.2.1-10)</a></text>
<text top="483" left="376" width="3" height="12" font="2">.</text>
<text top="516" left="63" width="107" height="11" font="2">5.2.2. Sodium Intake</text>
<text top="537" left="63" width="333" height="12" font="2">Sodium intake is positively associated with BP in migrant</text>
<text top="555" left="63" width="57" height="12" font="5"><a href="e127.full.html#90">(S5.2.2-11)</a></text>
<text top="555" left="120" width="94" height="12" font="2">, cross-sectional</text>
<text top="555" left="219" width="54" height="12" font="5"><a href="e127.full.html#90">(S5.2.2-12</a></text>
<text top="553" left="273" width="64" height="15" font="5"><a href="e127.full.html#90">—S5.2.2-14)</a></text>
<text top="555" left="338" width="58" height="12" font="2"><a href="e127.full.html#90">, </a>and pro-</text>
<text top="573" left="63" width="134" height="12" font="2">spective cohort studies</text>
<text top="573" left="201" width="58" height="12" font="5"><a href="e127.full.html#90">(S5.2.2-15)</a></text>
<text top="573" left="263" width="133" height="12" font="2">and accounts for much</text>
<text top="591" left="63" width="195" height="12" font="2">of the age-related increase in BP</text>
<text top="591" left="264" width="112" height="12" font="5"><a href="e127.full.html#90">(S5.2.2-11,S5.2.2-16)</a></text>
<text top="591" left="376" width="21" height="12" font="2"><a href="e127.full.html#90">. </a>In</text>
<text top="609" left="63" width="333" height="12" font="2">addition to the well-accepted and important relationship</text>
<text top="627" left="63" width="333" height="12" font="2">of dietary sodium with BP, excessive consumption of so-</text>
<text top="645" left="63" width="333" height="12" font="2">dium is independently associated with an increased risk of</text>
<text top="663" left="63" width="36" height="12" font="2">stroke</text>
<text top="663" left="107" width="113" height="12" font="5"><a href="e127.full.html#90">(S5.2.2-17,S5.2.2-18)</a></text>
<text top="663" left="220" width="36" height="12" font="2"><a href="e127.full.html#90">, </a>CVD</text>
<text top="663" left="265" width="59" height="12" font="5"><a href="e127.full.html#90">(S5.2.2-19)</a></text>
<text top="663" left="324" width="72" height="12" font="2">, and other</text>
<text top="681" left="63" width="104" height="12" font="2">adverse outcomes</text>
<text top="681" left="170" width="61" height="12" font="5"><a href="e127.full.html#90">(S5.2.2-20)</a></text>
<text top="681" left="230" width="166" height="12" font="2">. Certain groups with various</text>
<text top="698" left="63" width="333" height="12" font="2">demographic, physiological, and genetic characteristics</text>
<text top="716" left="63" width="333" height="12" font="2">tend to be particularly sensitive to the effects of dietary</text>
<text top="734" left="63" width="84" height="12" font="2">sodium on BP</text>
<text top="734" left="153" width="54" height="12" font="5"><a href="e127.full.html#90">(S5.2.2-21</a></text>
<text top="733" left="207" width="64" height="15" font="5"><a href="e127.full.html#90">—S5.2.2-23)</a></text>
<text top="734" left="272" width="124" height="12" font="2"><a href="e127.full.html#90">. </a>Salt sensitivity is a</text>
<text top="752" left="63" width="333" height="12" font="2">quantitative trait in which an increase in sodium load</text>
<text top="770" left="63" width="185" height="12" font="2">disproportionately increases BP</text>
<text top="770" left="252" width="114" height="12" font="5"><a href="e127.full.html#90">(S5.2.2-21,S5.2.2-24)</a></text>
<text top="770" left="367" width="29" height="12" font="2"><a href="e127.full.html#90">. </a>Salt</text>
<text top="788" left="63" width="333" height="12" font="2">sensitivity is especially common in blacks, older adults,</text>
<text top="806" left="63" width="333" height="12" font="2">and those with a higher level of BP or comorbidities such as</text>
<text top="824" left="63" width="241" height="12" font="2">CKD, DM, or the metabolic syndrome</text>
<text top="824" left="312" width="59" height="12" font="5"><a href="e127.full.html#90">(S5.2.2-25)</a></text>
<text top="824" left="372" width="24" height="12" font="2">. In</text>
<text top="842" left="63" width="333" height="12" font="2">aggregate, these groups constitute more than half of all U.S.</text>
<text top="860" left="63" width="36" height="12" font="2">adults</text>
<text top="860" left="105" width="60" height="12" font="5"><a href="e127.full.html#90">(S5.2.2-26)</a></text>
<text top="860" left="165" width="231" height="12" font="2">. Salt sensitivity may be a marker for</text>
<text top="878" left="63" width="333" height="12" font="2">increased CVD and all-cause mortality risk independently</text>
<text top="896" left="63" width="30" height="12" font="2">of BP</text>
<text top="896" left="97" width="115" height="12" font="5"><a href="e127.full.html#90">(S5.2.2-27,S5.2.2-28)</a></text>
<text top="896" left="213" width="184" height="12" font="2"><a href="e127.full.html#90">, </a>and the trait has been demon-</text>
<text top="914" left="63" width="150" height="12" font="2">strated to be reproducible</text>
<text top="914" left="217" width="60" height="12" font="5"><a href="e127.full.html#90">(S5.2.2-29)</a></text>
<text top="914" left="277" width="119" height="12" font="2">. Current techniques</text>
<text top="932" left="63" width="333" height="12" font="2">for recognition of salt sensitivity are impractical in routine</text>
<text top="950" left="63" width="333" height="12" font="2">clinical practice, so salt sensitivity is best considered as a</text>
<text top="968" left="63" width="118" height="12" font="2">group characteristic.</text>
<text top="1000" left="63" width="86" height="11" font="2">5.2.3. Potassium</text>
<text top="1021" left="63" width="333" height="12" font="2">Potassium intake is inversely related to BP in migrant</text>
<text top="1039" left="63" width="61" height="12" font="5"><a href="e127.full.html#90">(S5.2.3-30)</a></text>
<text top="1039" left="124" width="98" height="12" font="2"><a href="e127.full.html#90">, </a>cross-sectional</text>
<text top="1039" left="230" width="166" height="12" font="5"><a href="e127.full.html#90">(S5.2.2-13,S5.2.2-16,S5.2.3-31,</a></text>
<text top="1057" left="63" width="55" height="12" font="5"><a href="e127.full.html#90">S5.2.3-32)</a></text>
<text top="1057" left="118" width="141" height="12" font="2">, and prospective cohort</text>
<text top="1057" left="262" width="59" height="12" font="5"><a href="e127.full.html#90">(S5.2.3-33)</a></text>
<text top="1057" left="326" width="71" height="12" font="2">studies. It is</text>
<text top="1075" left="63" width="199" height="12" font="2">also inversely related to stroke</text>
<text top="1075" left="271" width="56" height="12" font="5"><a href="e127.full.html#90">(S5.2.3-34</a></text>
<text top="1073" left="327" width="65" height="15" font="5"><a href="e127.full.html#90">—S5.2.3-36)</a></text>
<text top="1075" left="393" width="3" height="12" font="2"><a href="e127.full.html#90">.</a></text>
<text top="1093" left="63" width="333" height="12" font="2">A higher level of potassium seems to blunt the effect of</text>
<text top="143" left="423" width="79" height="12" font="2">sodium on BP</text>
<text top="143" left="506" width="59" height="12" font="5"><a href="e127.full.html#90">(S5.2.3-37)</a></text>
<text top="143" left="566" width="125" height="12" font="2"><a href="e127.full.html#90">, </a>with a lower sodium</text>
<text top="141" left="691" width="65" height="15" font="2">–potassium</text>
<text top="161" left="423" width="333" height="12" font="2">ratio being associated with a lower level of BP than that</text>
<text top="178" left="423" width="333" height="12" font="2">noted for corresponding levels of sodium or potassium on</text>
<text top="196" left="423" width="58" height="12" font="2">their own</text>
<text top="196" left="487" width="60" height="12" font="5"><a href="e127.full.html#90">(S5.2.3-38)</a></text>
<text top="196" left="547" width="209" height="12" font="2">. Likewise, epidemiological studies</text>
<text top="214" left="423" width="160" height="12" font="2">suggest that a lower sodium</text>
<text top="213" left="583" width="173" height="15" font="2">–potassium ratio may result in</text>
<text top="232" left="423" width="333" height="12" font="2">a reduced risk of CVD as compared with the pattern for</text>
<text top="250" left="423" width="267" height="12" font="2">corresponding levels of either cation on its own</text>
<text top="250" left="692" width="60" height="12" font="5"><a href="e127.full.html#90">(S5.2.3-39)</a></text>
<text top="250" left="753" width="3" height="12" font="2"><a href="e127.full.html#90">.</a></text>
<text top="283" left="423" width="116" height="11" font="2">5.2.4. Physical Fitness</text>
<text top="304" left="423" width="333" height="12" font="2">Epidemiological studies have demonstrated an inverse</text>
<text top="322" left="423" width="333" height="12" font="2">relationship between physical activity and physical</text>
<text top="338" left="423" width="231" height="15" font="2">ﬁtness and level of BP and hypertension</text>
<text top="340" left="658" width="63" height="12" font="5"><a href="e127.full.html#90">(S5.2.4-40)</a></text>
<text top="340" left="721" width="36" height="12" font="2"><a href="e127.full.html#90">. </a>Even</text>
<text top="358" left="423" width="333" height="12" font="2">modest levels of physical activity have been associated</text>
<text top="376" left="423" width="333" height="12" font="2">with a decrease in the risk of incident hypertension</text>
<text top="394" left="423" width="60" height="12" font="5"><a href="e127.full.html#90">(S5.2.4-41)</a></text>
<text top="394" left="484" width="273" height="12" font="2"><a href="e127.full.html#90">. </a>In several observational studies, the rela-</text>
<text top="412" left="423" width="333" height="12" font="2">tionship between physical activity and BP has been most</text>
<text top="430" left="423" width="139" height="12" font="2">apparent in white men</text>
<text top="430" left="568" width="63" height="12" font="5"><a href="e127.full.html#90">(S5.2.4-40)</a></text>
<text top="430" left="631" width="125" height="12" font="2"><a href="e127.full.html#90">. </a>With the advent of</text>
<text top="447" left="423" width="333" height="12" font="2">electronic activity trackers and ABPM, it has become</text>
<text top="465" left="423" width="333" height="12" font="2">increasingly feasible to conduct studies that relate phys-</text>
<text top="483" left="423" width="109" height="12" font="2">ical activity and BP</text>
<text top="483" left="536" width="62" height="12" font="5"><a href="e127.full.html#90">(S5.2.4-42)</a></text>
<text top="483" left="597" width="54" height="12" font="2">. Physical</text>
<text top="482" left="655" width="101" height="15" font="2">ﬁtness, measured</text>
<text top="501" left="423" width="333" height="12" font="2">objectively by graded exercise testing, attenuates the rise</text>
<text top="519" left="423" width="333" height="12" font="2">of BP with age and prevents the development of hyper-</text>
<text top="537" left="423" width="333" height="12" font="2">tension. In the CARDIA (Coronary Artery Risk Develop-</text>
<text top="555" left="423" width="170" height="12" font="2">ment in Young Adults) study</text>
<text top="555" left="597" width="62" height="12" font="5"><a href="e127.full.html#90">(S5.2.4-43)</a></text>
<text top="555" left="659" width="55" height="12" font="2"><a href="e127.full.html#90">, </a>physical</text>
<text top="553" left="719" width="38" height="15" font="2">ﬁtness</text>
<text top="573" left="423" width="333" height="12" font="2">measured at 18 to 30 years of age in the upper 2 deciles of</text>
<text top="591" left="423" width="333" height="12" font="2">an otherwise healthy population was associated with one</text>
<text top="609" left="423" width="333" height="12" font="2">third the risk of developing hypertension 15 years later,</text>
<text top="627" left="423" width="333" height="12" font="2">and one half the risk after adjustment for body mass in-</text>
<text top="645" left="423" width="333" height="12" font="2">dex, as compared with the lowest quintile. Change in</text>
<text top="661" left="423" width="287" height="15" font="2">ﬁtness assessed 7 years later further modiﬁed risk</text>
<text top="663" left="713" width="43" height="12" font="5"><a href="e127.full.html#90">(S5.2.4-</a></text>
<text top="681" left="423" width="18" height="12" font="5"><a href="e127.full.html#90">43)</a></text>
<text top="681" left="441" width="315" height="12" font="2">. In a cohort of men 20 to 90 years of age who were</text>
<text top="698" left="423" width="333" height="12" font="2">followed longitudinally for 3 to 28 years, higher physical</text>
<text top="715" left="423" width="333" height="15" font="2">ﬁtness decreased the rate of rise in SBP over time and</text>
<text top="734" left="423" width="246" height="12" font="2">delayed the time to onset of hypertension</text>
<text top="734" left="673" width="63" height="12" font="5"><a href="e127.full.html#90">(S5.2.4-44)</a></text>
<text top="734" left="736" width="3" height="12" font="2">.</text>
<text top="767" left="423" width="73" height="11" font="2">5.2.5. Alcohol</text>
<text top="788" left="423" width="333" height="12" font="2">The presence of a direct relationship between alcohol</text>
<text top="806" left="423" width="146" height="12" font="2">consumption and BP was</text>
<text top="804" left="573" width="119" height="15" font="2">ﬁrst reported in 1915</text>
<text top="806" left="696" width="60" height="12" font="5"><a href="e127.full.html#90">(S5.2.5-45)</a></text>
<text top="824" left="423" width="176" height="12" font="2">and has been repeatedly identi</text>
<text top="822" left="600" width="157" height="15" font="2">ﬁed in contemporary cross-</text>
<text top="842" left="423" width="240" height="12" font="2">sectional and prospective cohort studies</text>
<text top="842" left="668" width="61" height="12" font="5"><a href="e127.full.html#90">(S5.2.5-46)</a></text>
<text top="842" left="730" width="27" height="12" font="2"><a href="e127.full.html#90">. </a>Es-</text>
<text top="860" left="423" width="333" height="12" font="2">timates of the contribution of alcohol consumption to</text>
<text top="878" left="423" width="333" height="12" font="2">population incidence and prevalence of hypertension</text>
<text top="896" left="423" width="333" height="12" font="2">vary according to level of intake. In the United States, it</text>
<text top="914" left="423" width="333" height="12" font="2">seems likely that alcohol may account for close to 10% of</text>
<text top="932" left="423" width="333" height="12" font="2">the population burden of hypertension (higher in men</text>
<text top="950" left="423" width="333" height="12" font="2">than in women). In contrast to its detrimental effect on</text>
<text top="968" left="423" width="333" height="12" font="2">BP, alcohol intake is associated with a higher level of</text>
<text top="985" left="423" width="333" height="12" font="2">high-density lipoprotein cholesterol and, within modest</text>
<text top="1003" left="423" width="333" height="12" font="2">ranges of intake, a lower level of CHD than that associated</text>
<text top="1021" left="423" width="92" height="12" font="2">with abstinence</text>
<text top="1021" left="519" width="59" height="12" font="5"><a href="e127.full.html#90">(S5.2.3-35)</a></text>
<text top="1021" left="579" width="3" height="12" font="2">.</text>
<text top="1054" left="423" width="235" height="11" font="12">5.3. Childhood Risk Factors and BP Tracking</text>
<text top="1075" left="423" width="333" height="12" font="2">BP distribution in the general population increases with</text>
<text top="1093" left="423" width="333" height="12" font="2">age. Multiple longitudinal studies have investigated the</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="18" height="9" font="4">e147</text>
</page>
<page number="22" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="333" height="12" font="2">relationship of childhood BP to adult BP. A meta-</text>
<text top="161" left="108" width="333" height="12" font="2">analysis of 50 such studies showed correlation co-</text>
<text top="178" left="108" width="11" height="12" font="2">ef</text>
<text top="177" left="119" width="322" height="15" font="2">ﬁcients of about 0.38 for SBP and 0.28 for DBP, with</text>
<text top="196" left="108" width="333" height="12" font="2">BPs in the upper range of the pediatric distribution</text>
<text top="214" left="108" width="333" height="12" font="2">(particularly BPs obtained in adolescence) predicting</text>
<text top="232" left="108" width="169" height="12" font="2">hypertension in adulthood</text>
<text top="232" left="288" width="42" height="12" font="5"><a href="e127.full.html#90">(S5.3-1)</a></text>
<text top="232" left="330" width="111" height="12" font="2">. Several factors,</text>
<text top="250" left="108" width="333" height="12" font="2">including genetic factors and development of obesity,</text>
<text top="268" left="108" width="333" height="12" font="2">increase the likelihood that a high childhood BP will</text>
<text top="143" left="468" width="166" height="12" font="2">lead to future hypertension</text>
<text top="143" left="640" width="43" height="12" font="5"><a href="e127.full.html#91">(S5.3-2)</a></text>
<text top="143" left="683" width="118" height="12" font="2"><a href="e127.full.html#91">. </a>Premature birth is</text>
<text top="161" left="468" width="115" height="12" font="2">associated with a 4</text>
<text top="159" left="583" width="218" height="15" font="2">–mm Hg higher SBP and a 3–mm Hg</text>
<text top="178" left="468" width="333" height="12" font="2">higher DBP in adulthood, with somewhat larger effects</text>
<text top="196" left="468" width="139" height="12" font="2">in women than in men</text>
<text top="196" left="613" width="43" height="12" font="5"><a href="e127.full.html#91">(S5.3-3)</a></text>
<text top="196" left="656" width="145" height="12" font="2"><a href="e127.full.html#91">. </a>Low birth weight from</text>
<text top="214" left="468" width="333" height="12" font="2">other causes also contributes to higher BP in later life</text>
<text top="232" left="468" width="44" height="12" font="5"><a href="e127.full.html#91">(S5.3-4)</a></text>
<text top="232" left="512" width="3" height="12" font="2">.</text>
<text top="268" left="468" width="205" height="11" font="12">5.4. Secondary Forms of Hypertension</text>
<text top="317" left="63" width="315" height="11" font="19">Recommendations for Secondary Forms of Hypertension</text>
<text top="358" left="89" width="19" height="10" font="13">COR</text>
<text top="358" left="161" width="18" height="10" font="13">LOE</text>
<text top="358" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="395" left="97" width="3" height="9" font="4">I</text>
<text top="395" left="160" width="20" height="9" font="4">C-EO</text>
<text top="383" left="234" width="114" height="11" font="12">1. Screening for speci</text>
<text top="381" left="348" width="445" height="15" font="12">ﬁc form(s) of secondary hypertension is recommended when the clinical indications</text>
<text top="398" left="246" width="134" height="11" font="12">and physical examination</text>
<text top="396" left="384" width="88" height="15" font="12">ﬁndings listed in</text>
<text top="398" left="476" width="44" height="11" font="5"><a href="e127.full.html#23">Table 13</a></text>
<text top="398" left="524" width="277" height="11" font="12">are present or in adults with resistant hypertension.</text>
<text top="443" left="94" width="10" height="9" font="4">IIb</text>
<text top="443" left="160" width="20" height="9" font="4">C-EO</text>
<text top="431" left="234" width="568" height="11" font="12">2. If an adult with sustained hypertension screens positive for a form of secondary hypertension, referral to a</text>
<text top="446" left="248" width="483" height="11" font="12">physician with expertise in that form of hypertension may be reasonable for diagnostic con</text>
<text top="444" left="731" width="70" height="15" font="12">ﬁrmation and</text>
<text top="462" left="248" width="56" height="11" font="12">treatment.</text>
<text top="550" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="568" left="123" width="44" height="12" font="2">A speci</text>
<text top="566" left="167" width="277" height="15" font="2">ﬁc, remediable cause of hypertension can be</text>
<text top="586" left="108" width="34" height="12" font="2">identi</text>
<text top="584" left="142" width="302" height="15" font="2">ﬁed in approximately 10% of adult patients with</text>
<text top="604" left="108" width="77" height="12" font="2">hypertension</text>
<text top="604" left="191" width="43" height="12" font="5"><a href="e127.full.html#91">(S5.4-1)</a></text>
<text top="604" left="234" width="210" height="12" font="2"><a href="e127.full.html#91">. </a>If a cause can be correctly diag-</text>
<text top="622" left="108" width="336" height="12" font="2">nosed and treated, patients with secondary hypertension</text>
<text top="640" left="108" width="336" height="12" font="2">can achieve a cure or experience a marked improvement in</text>
<text top="658" left="108" width="336" height="12" font="2">BP control, with reduction in CVD risk. All new patients</text>
<text top="676" left="108" width="336" height="12" font="2">with hypertension should be screened with a history,</text>
<text top="693" left="108" width="336" height="12" font="2">physical examination, and laboratory investigations, as</text>
<text top="711" left="108" width="98" height="12" font="2">recommended in</text>
<text top="711" left="210" width="52" height="12" font="5"><a href="e127.full.html#32">Section 7</a></text>
<text top="711" left="262" width="182" height="12" font="2">, before initiation of treatment.</text>
<text top="729" left="123" width="321" height="12" font="2">Secondary hypertension can underlie severe elevation</text>
<text top="747" left="108" width="336" height="12" font="2">of BP, pharmacologically resistant hypertension, sudden</text>
<text top="765" left="108" width="336" height="12" font="2">onset of hypertension, increased BP in patients with hy-</text>
<text top="783" left="108" width="336" height="12" font="2">pertension previously controlled on drug therapy, onset of</text>
<text top="801" left="108" width="336" height="12" font="2">diastolic hypertension in older adults, and target organ</text>
<text top="819" left="108" width="336" height="12" font="2">damage disproportionate to the duration or severity of the</text>
<text top="837" left="108" width="336" height="12" font="2">hypertension. Although secondary hypertension should</text>
<text top="855" left="108" width="204" height="12" font="2">be suspected in younger patients (</text>
<text top="853" left="311" width="132" height="15" font="2">&lt;30 years of age) with</text>
<text top="873" left="108" width="336" height="12" font="2">elevated BP, it is not uncommon for primary hypertension</text>
<text top="891" left="108" width="285" height="12" font="2">to manifest at a younger age, especially in blacks</text>
<text top="891" left="396" width="44" height="12" font="5"><a href="e127.full.html#91">(S5.4-2)</a></text>
<text top="891" left="440" width="3" height="12" font="2">,</text>
<text top="909" left="108" width="336" height="12" font="2">and some forms of secondary hypertension, such as</text>
<text top="550" left="465" width="336" height="12" font="2">renovascular disease, are more common at older age.</text>
<text top="568" left="465" width="336" height="12" font="2">Many of the causes of secondary hypertension are strongly</text>
<text top="586" left="465" width="135" height="12" font="2">associated with clinical</text>
<text top="584" left="603" width="198" height="15" font="2">ﬁndings or groups of ﬁndings that</text>
<text top="604" left="465" width="87" height="12" font="2">suggest a speci</text>
<text top="602" left="553" width="69" height="15" font="2">ﬁc disorder.</text>
<text top="622" left="480" width="48" height="11" font="5"><a href="e127.full.html#23">Figure 3</a></text>
<text top="622" left="535" width="266" height="12" font="2">is an algorithm on screening for secondary</text>
<text top="640" left="465" width="80" height="12" font="2">hypertension.</text>
<text top="640" left="553" width="49" height="11" font="5"><a href="e127.full.html#23">Table 13</a></text>
<text top="640" left="609" width="192" height="12" font="2">is a detailed list of clinical in-</text>
<text top="658" left="465" width="336" height="12" font="2">dications and diagnostic screening tests for secondary</text>
<text top="676" left="465" width="109" height="12" font="2">hypertension, and</text>
<text top="676" left="581" width="50" height="11" font="5"><a href="e127.full.html#25">Table 14</a></text>
<text top="676" left="639" width="163" height="12" font="2">is a list of drugs that can</text>
<text top="693" left="465" width="187" height="12" font="2">induce secondary hypertension.</text>
<text top="738" left="465" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="736" left="604" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="765" left="467" width="335" height="12" font="2">1. The causes of secondary hypertension and recom-</text>
<text top="783" left="480" width="237" height="12" font="2">mended screening tests are provided in</text>
<text top="783" left="723" width="48" height="11" font="5"><a href="e127.full.html#23">Table 13</a></text>
<text top="783" left="771" width="30" height="12" font="2"><a href="e127.full.html#23">, </a>and</text>
<text top="801" left="480" width="321" height="12" font="2">drugs that can induce secondary hypertension are pro-</text>
<text top="819" left="480" width="48" height="12" font="2">vided in</text>
<text top="819" left="532" width="47" height="11" font="5"><a href="e127.full.html#25">Table 14</a></text>
<text top="819" left="580" width="3" height="12" font="2"><a href="e127.full.html#25">.</a></text>
<text top="837" left="466" width="336" height="12" font="2">2. Diagnosis of many of these disorders requires a com-</text>
<text top="855" left="480" width="321" height="12" font="2">plex set of measurements, specialized technical exper-</text>
<text top="873" left="480" width="321" height="12" font="2">tise, and/or experience in data interpretation. Similarly,</text>
<text top="891" left="480" width="29" height="12" font="2">speci</text>
<text top="889" left="510" width="292" height="15" font="2">ﬁc treatment often requires a level of technical</text>
<text top="909" left="480" width="143" height="12" font="2">training and experience.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e148</text>
</page>
<page number="23" position="absolute" top="0" left="0" height="1160" width="864">
<text top="153" left="80" width="45" height="11" font="22">FIGURE 3</text>
<text top="154" left="134" width="170" height="9" font="23">Screening for Secondary Hypertension</text>
<text top="767" left="80" width="211" height="9" font="13">Colors correspond to Class of Recommendation in</text>
<text top="767" left="294" width="31" height="9" font="17"><a href="e127.full.html#6">Table 1</a></text>
<text top="767" left="324" width="414" height="9" font="13">. TOD indicates target organ damage (e.g., cerebrovascular disease, hypertensive retinopathy, left</text>
<text top="782" left="80" width="658" height="9" font="13">ventricular hypertrophy, left ventricular dysfunction, heart failure, coronary artery disease, chronic kidney disease, albuminuria, peripheral artery disease).</text>
<text top="845" left="68" width="52" height="10" font="15">T A B L E 1 3</text>
<text top="845" left="135" width="484" height="10" font="16">Causes of Secondary Hypertension With Clinical Indications and Diagnostic Screening Tests</text>
<text top="881" left="163" width="51" height="9" font="13">Prevalence</text>
<text top="881" left="267" width="87" height="9" font="13">Clinical Indications</text>
<text top="869" left="440" width="38" height="9" font="13">Physical</text>
<text top="881" left="430" width="57" height="9" font="13">Examination</text>
<text top="881" left="537" width="73" height="9" font="13">Screening Tests</text>
<text top="869" left="669" width="52" height="9" font="13">Additional/</text>
<text top="881" left="651" width="17" height="9" font="13">Con</text>
<text top="879" left="668" width="71" height="12" font="13">ﬁrmatory Tests</text>
<text top="900" left="63" width="69" height="9" font="18">Common causes</text>
<text top="919" left="63" width="79" height="9" font="13">Renal parenchymal</text>
<text top="931" left="78" width="30" height="9" font="13">disease</text>
<text top="931" left="111" width="32" height="9" font="17"><a href="e127.full.html#91">(S5.4-1,</a></text>
<text top="943" left="78" width="30" height="9" font="17"><a href="e127.full.html#91">S5.4-3)</a></text>
<text top="919" left="161" width="13" height="9" font="13">1%</text>
<text top="918" left="174" width="18" height="12" font="13">–2%</text>
<text top="919" left="222" width="152" height="9" font="13">Urinary tract infections; obstruction,</text>
<text top="931" left="237" width="139" height="9" font="13">hematuria; urinary frequency and</text>
<text top="943" left="237" width="136" height="9" font="13">nocturia; analgesic abuse; family</text>
<text top="955" left="237" width="151" height="9" font="13">history of polycystic kidney disease;</text>
<text top="967" left="237" width="153" height="9" font="13">elevated serum creatinine; abnormal</text>
<text top="979" left="237" width="39" height="9" font="13">urinalysis</text>
<text top="919" left="405" width="68" height="9" font="13">Abdominal mass</text>
<text top="931" left="420" width="75" height="9" font="13">(polycystic kidney</text>
<text top="943" left="420" width="83" height="9" font="13">disease); skin pallor</text>
<text top="919" left="520" width="71" height="9" font="13">Renal ultrasound</text>
<text top="919" left="634" width="110" height="9" font="13">Tests to evaluate cause of</text>
<text top="931" left="649" width="54" height="9" font="13">renal disease</text>
<text top="997" left="63" width="55" height="9" font="13">Renovascular</text>
<text top="1009" left="78" width="30" height="9" font="13">disease</text>
<text top="1021" left="78" width="34" height="9" font="17"><a href="e127.full.html#91">(S5.4-4)</a></text>
<text top="997" left="161" width="14" height="9" font="13">5%</text>
<text top="995" left="175" width="24" height="12" font="13">–34%</text>
<text top="997" left="199" width="4" height="9" font="17"><a href="e127.full.html#25">*</a></text>
<text top="997" left="222" width="167" height="9" font="13">Resistant hypertension; hypertension of</text>
<text top="1009" left="237" width="123" height="9" font="13">abrupt onset or worsening or</text>
<text top="1021" left="237" width="63" height="9" font="13">increasingly dif</text>
<text top="1019" left="300" width="92" height="12" font="13">ﬁcult to control; ﬂash</text>
<text top="1033" left="237" width="149" height="9" font="13">pulmonary edema (atherosclerotic);</text>
<text top="1044" left="237" width="161" height="9" font="13">early-onset hypertension, especially in</text>
<text top="1056" left="237" width="37" height="9" font="13">women (</text>
<text top="1055" left="274" width="111" height="12" font="13">ﬁbromuscular hyperplasia)</text>
<text top="997" left="405" width="83" height="9" font="13">Abdominal systolic-</text>
<text top="1009" left="420" width="87" height="9" font="13">diastolic bruit; bruits</text>
<text top="1021" left="420" width="78" height="9" font="13">over other arteries</text>
<text top="1033" left="420" width="32" height="9" font="13">(carotid</text>
<text top="1031" left="455" width="4" height="12" font="13">–</text>
<text top="1044" left="420" width="74" height="9" font="13">atherosclerotic or</text>
<text top="1055" left="420" width="57" height="12" font="13">ﬁbromuscular</text>
<text top="1068" left="420" width="79" height="9" font="13">dysplasia), femoral</text>
<text top="997" left="520" width="92" height="9" font="13">Renal Duplex Doppler</text>
<text top="1009" left="535" width="73" height="9" font="13">ultrasound; MRA;</text>
<text top="1021" left="535" width="57" height="9" font="13">abdominal CT</text>
<text top="997" left="634" width="122" height="9" font="13">Bilateral selective renal intra-</text>
<text top="1009" left="649" width="84" height="9" font="13">arterial angiography</text>
<text top="1089" left="651" width="105" height="8" font="4">Continued on the next page</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="788" width="19" height="9" font="4">e149</text>
</page>
<page number="24" position="absolute" top="0" left="0" height="1160" width="864">
<text top="148" left="113" width="52" height="10" font="15">T A B L E 1 3</text>
<text top="148" left="179" width="53" height="10" font="16">Continued</text>
<text top="183" left="208" width="51" height="9" font="13">Prevalence</text>
<text top="183" left="311" width="87" height="9" font="13">Clinical Indications</text>
<text top="171" left="485" width="38" height="9" font="13">Physical</text>
<text top="183" left="475" width="57" height="9" font="13">Examination</text>
<text top="183" left="582" width="73" height="9" font="13">Screening Tests</text>
<text top="171" left="714" width="52" height="9" font="13">Additional/</text>
<text top="183" left="696" width="17" height="9" font="13">Con</text>
<text top="182" left="713" width="71" height="12" font="13">ﬁrmatory Tests</text>
<text top="203" left="108" width="32" height="9" font="13">Primary</text>
<text top="215" left="123" width="59" height="9" font="13">aldosteronism</text>
<text top="227" left="123" width="64" height="9" font="17"><a href="e127.full.html#91">(S5.4-5,S5.4-6)</a></text>
<text top="203" left="206" width="15" height="9" font="13">8%</text>
<text top="201" left="221" width="24" height="12" font="13">–<a href="e127.full.html#25">20%</a></text>
<text top="201" left="245" width="5" height="12" font="17"><a href="e127.full.html#25">†</a></text>
<text top="203" left="267" width="176" height="9" font="13">Resistant hypertension; hypertension with</text>
<text top="215" left="282" width="157" height="9" font="13">hypokalemia (spontaneous or diuretic</text>
<text top="227" left="282" width="146" height="9" font="13">induced); hypertension and muscle</text>
<text top="238" left="282" width="161" height="9" font="13">cramps or weakness; hypertension and</text>
<text top="250" left="282" width="156" height="9" font="13">incidentally discovered adrenal mass;</text>
<text top="262" left="282" width="147" height="9" font="13">hypertension and obstructive sleep</text>
<text top="274" left="282" width="161" height="9" font="13">apnea; hypertension and family history</text>
<text top="286" left="282" width="157" height="9" font="13">of early-onset hypertension or stroke</text>
<text top="203" left="450" width="75" height="9" font="13">Arrhythmias (with</text>
<text top="215" left="465" width="58" height="9" font="13">hypokalemia);</text>
<text top="227" left="465" width="65" height="9" font="13">especially atrial</text>
<text top="237" left="465" width="43" height="12" font="13">ﬁbrillation</text>
<text top="203" left="565" width="85" height="9" font="13">Plasma aldosterone/</text>
<text top="215" left="580" width="70" height="9" font="13">renin ratio under</text>
<text top="227" left="580" width="53" height="9" font="13">standardized</text>
<text top="238" left="580" width="91" height="9" font="13">conditions (correction</text>
<text top="250" left="580" width="82" height="9" font="13">of hypokalemia and</text>
<text top="262" left="580" width="58" height="9" font="13">withdrawal of</text>
<text top="274" left="580" width="49" height="9" font="13">aldosterone</text>
<text top="286" left="580" width="72" height="9" font="13">antagonists for 4</text>
<text top="285" left="651" width="10" height="12" font="13">–6</text>
<text top="298" left="580" width="15" height="9" font="13">wk)</text>
<text top="203" left="679" width="103" height="9" font="13">Oral sodium loading test</text>
<text top="215" left="694" width="68" height="9" font="13">(with 24-h urine</text>
<text top="227" left="694" width="103" height="9" font="13">aldosterone) or IV saline</text>
<text top="238" left="694" width="106" height="9" font="13">infusion test with plasma</text>
<text top="250" left="694" width="89" height="9" font="13">aldosterone at 4 h of</text>
<text top="262" left="694" width="106" height="9" font="13">infusion Adrenal CT scan,</text>
<text top="274" left="694" width="94" height="9" font="13">adrenal vein sampling.</text>
<text top="317" left="108" width="73" height="9" font="13">Obstructive sleep</text>
<text top="329" left="123" width="25" height="9" font="13">apnea</text>
<text top="329" left="150" width="34" height="9" font="17"><a href="e127.full.html#91">(S5.4-7)</a></text>
<text top="328" left="184" width="5" height="12" font="17"><a href="e127.full.html#91">‡</a></text>
<text top="317" left="206" width="19" height="9" font="13">25%</text>
<text top="316" left="225" width="24" height="12" font="13">–50%</text>
<text top="317" left="267" width="135" height="9" font="13">Resistant hypertension; snoring;</text>
<text top="316" left="405" width="20" height="12" font="13">ﬁtful</text>
<text top="329" left="282" width="129" height="9" font="13">sleep; breathing pauses during</text>
<text top="341" left="282" width="106" height="9" font="13">sleep; daytime sleepiness</text>
<text top="317" left="450" width="83" height="9" font="13">Obesity, Mallampati</text>
<text top="329" left="465" width="31" height="9" font="13">class III</text>
<text top="328" left="496" width="46" height="12" font="13">–IV; loss of</text>
<text top="341" left="465" width="72" height="9" font="13">normal nocturnal</text>
<text top="353" left="465" width="28" height="9" font="13">BP fall</text>
<text top="317" left="565" width="85" height="9" font="13">Berlin Questionnaire</text>
<text top="329" left="580" width="35" height="9" font="17"><a href="e127.full.html#91">(S5.4-8)</a></text>
<text top="329" left="614" width="41" height="9" font="13">; Epworth</text>
<text top="341" left="580" width="69" height="9" font="13">Sleepiness Score</text>
<text top="353" left="580" width="35" height="9" font="17"><a href="e127.full.html#91">(S5.4-9)</a></text>
<text top="353" left="614" width="46" height="9" font="13">; overnight</text>
<text top="365" left="580" width="37" height="9" font="13">oximetry</text>
<text top="317" left="679" width="75" height="9" font="13">Polysomnography</text>
<text top="384" left="108" width="65" height="9" font="13">Drug or alcohol</text>
<text top="396" left="123" width="33" height="9" font="13">induced</text>
<text top="408" left="123" width="44" height="9" font="17"><a href="e127.full.html#91">(S5.4-10)§</a></text>
<text top="384" left="206" width="14" height="9" font="13">2%</text>
<text top="383" left="220" width="19" height="12" font="13">–4%</text>
<text top="384" left="267" width="157" height="9" font="13">Sodium-containing antacids; caffeine;</text>
<text top="396" left="282" width="152" height="9" font="13">nicotine (smoking); alcohol; NSAIDs;</text>
<text top="408" left="282" width="149" height="9" font="13">oral contraceptives; cyclosporine or</text>
<text top="420" left="282" width="127" height="9" font="13">tacrolimus; sympathomimetics</text>
<text top="432" left="282" width="154" height="9" font="13">(decongestants, anorectics); cocaine,</text>
<text top="444" left="282" width="157" height="9" font="13">amphetamines and other illicit drugs;</text>
<text top="456" left="282" width="102" height="9" font="13">neuropsychiatric agents;</text>
<text top="468" left="282" width="143" height="9" font="13">erythropoiesis-stimulating agents;</text>
<text top="480" left="282" width="150" height="9" font="13">clonidine withdrawal; herbal agents</text>
<text top="492" left="282" width="89" height="9" font="13">(Ma Huang, ephedra)</text>
<text top="384" left="450" width="105" height="9" font="13">Fine tremor, tachycardia,</text>
<text top="396" left="465" width="77" height="9" font="13">sweating (cocaine,</text>
<text top="408" left="465" width="67" height="9" font="13">ephedrine, MAO</text>
<text top="420" left="465" width="71" height="9" font="13">inhibitors); acute</text>
<text top="432" left="465" width="64" height="9" font="13">abdominal pain</text>
<text top="444" left="465" width="38" height="9" font="13">(cocaine)</text>
<text top="384" left="565" width="82" height="9" font="13">Urinary drug screen</text>
<text top="396" left="580" width="53" height="9" font="13">(illicit drugs)</text>
<text top="384" left="679" width="112" height="9" font="13">Response to withdrawal of</text>
<text top="396" left="694" width="68" height="9" font="13">suspected agent</text>
<text top="511" left="108" width="80" height="9" font="18">Uncommon causes</text>
<text top="530" left="108" width="86" height="9" font="13">Pheochromocytoma/</text>
<text top="542" left="108" width="61" height="9" font="13">paraganglioma</text>
<text top="554" left="123" width="37" height="9" font="17"><a href="e127.full.html#91">(S5.4-11)</a></text>
<text top="530" left="206" width="22" height="9" font="13">0.1%</text>
<text top="529" left="228" width="188" height="12" font="13">–0.6% Resistant hypertension; paroxysmal</text>
<text top="542" left="282" width="161" height="9" font="13">hypertension or crisis superimposed on</text>
<text top="554" left="282" width="99" height="9" font="13">sustained hypertension;</text>
<text top="553" left="384" width="49" height="12" font="13">“spells,” BP</text>
<text top="566" left="282" width="119" height="9" font="13">lability, headache, sweating,</text>
<text top="578" left="282" width="146" height="9" font="13">palpitations, pallor; positive family</text>
<text top="590" left="282" width="129" height="9" font="13">history of pheochromocytoma/</text>
<text top="602" left="282" width="159" height="9" font="13">paraganglioma; adrenal incidentaloma</text>
<text top="530" left="450" width="68" height="9" font="13">Skin stigmata of</text>
<text top="542" left="465" width="24" height="9" font="13">neuro</text>
<text top="541" left="489" width="51" height="12" font="13">ﬁbromatosis</text>
<text top="554" left="465" width="79" height="9" font="13">(café-au-lait spots;</text>
<text top="566" left="465" width="24" height="9" font="13">neuro</text>
<text top="565" left="489" width="42" height="12" font="13">ﬁbromas);</text>
<text top="578" left="465" width="47" height="9" font="13">Orthostatic</text>
<text top="590" left="465" width="51" height="9" font="13">hypotension</text>
<text top="530" left="565" width="105" height="9" font="13">24-h urinary fractionated</text>
<text top="542" left="580" width="73" height="9" font="13">metanephrines or</text>
<text top="554" left="580" width="29" height="9" font="13">plasma</text>
<text top="566" left="580" width="89" height="9" font="13">metanephrines under</text>
<text top="578" left="580" width="82" height="9" font="13">standard conditions</text>
<text top="590" left="580" width="88" height="9" font="13">(supine position with</text>
<text top="602" left="580" width="93" height="9" font="13">indwelling IV cannula)</text>
<text top="530" left="679" width="75" height="9" font="13">CT or MRI scan of</text>
<text top="542" left="694" width="66" height="9" font="13">abdomen/pelvis</text>
<text top="621" left="108" width="33" height="9" font="13">Cushing</text>
<text top="620" left="140" width="50" height="12" font="13">’s syndrome</text>
<text top="633" left="123" width="38" height="9" font="17"><a href="e127.full.html#91">(S5.4-12)</a></text>
<text top="620" left="206" width="29" height="12" font="13">&lt;0.1%</text>
<text top="621" left="267" width="175" height="9" font="13">Rapid weight gain, especially with central</text>
<text top="633" left="282" width="122" height="9" font="13">distribution; proximal muscle</text>
<text top="645" left="282" width="156" height="9" font="13">weakness; depression; hyperglycemia</text>
<text top="621" left="450" width="66" height="9" font="13">Central obesity,</text>
<text top="620" left="519" width="32" height="12" font="13">“moon”</text>
<text top="633" left="465" width="67" height="9" font="13">face, dorsal and</text>
<text top="645" left="465" width="77" height="9" font="13">supraclavicular fat</text>
<text top="657" left="465" width="75" height="9" font="13">pads, wide (1-cm)</text>
<text top="669" left="465" width="72" height="9" font="13">violaceous striae,</text>
<text top="681" left="465" width="38" height="9" font="13">hirsutism</text>
<text top="621" left="565" width="65" height="9" font="13">Overnight 1-mg</text>
<text top="633" left="580" width="65" height="9" font="13">dexamethasone</text>
<text top="645" left="580" width="68" height="9" font="13">suppression test</text>
<text top="621" left="679" width="105" height="9" font="13">24-h urinary free cortisol</text>
<text top="633" left="694" width="88" height="9" font="13">excretion (preferably</text>
<text top="645" left="694" width="81" height="9" font="13">multiple); midnight</text>
<text top="657" left="694" width="65" height="9" font="13">salivary cortisol</text>
<text top="700" left="108" width="66" height="9" font="13">Hypothyroidism</text>
<text top="712" left="123" width="39" height="9" font="17"><a href="e127.full.html#91">(S5.4-10)</a></text>
<text top="699" left="206" width="20" height="12" font="13">&lt;1%</text>
<text top="700" left="267" width="166" height="9" font="13">Dry skin; cold intolerance; constipation;</text>
<text top="712" left="282" width="101" height="9" font="13">hoarseness; weight gain</text>
<text top="700" left="450" width="70" height="9" font="13">Delayed ankle re</text>
<text top="699" left="520" width="18" height="12" font="13">ﬂex;</text>
<text top="712" left="465" width="60" height="9" font="13">periorbital puf</text>
<text top="711" left="525" width="26" height="12" font="13">ﬁness;</text>
<text top="724" left="465" width="91" height="9" font="13">coarse skin; cold skin;</text>
<text top="736" left="465" width="69" height="9" font="13">slow movement;</text>
<text top="748" left="465" width="25" height="9" font="13">goiter</text>
<text top="700" left="565" width="82" height="9" font="13">Thyroid-stimulating</text>
<text top="712" left="580" width="59" height="9" font="13">hormone; free</text>
<text top="724" left="580" width="39" height="9" font="13">thyroxine</text>
<text top="700" left="679" width="22" height="9" font="13">None</text>
<text top="767" left="108" width="69" height="9" font="13">Hyperthyroidism</text>
<text top="779" left="123" width="39" height="9" font="17"><a href="e127.full.html#91">(S5.4-10)</a></text>
<text top="766" left="206" width="20" height="12" font="13">&lt;1%</text>
<text top="767" left="267" width="149" height="9" font="13">Warm, moist skin; heat intolerance;</text>
<text top="779" left="282" width="161" height="9" font="13">nervousness; tremulousness; insomnia;</text>
<text top="791" left="282" width="161" height="9" font="13">weight loss; diarrhea; proximal muscle</text>
<text top="803" left="282" width="40" height="9" font="13">weakness</text>
<text top="767" left="450" width="31" height="9" font="13">Lid lag;</text>
<text top="766" left="484" width="59" height="12" font="13">ﬁne tremor of</text>
<text top="779" left="465" width="70" height="9" font="13">the outstretched</text>
<text top="791" left="465" width="56" height="9" font="13">hands; warm,</text>
<text top="803" left="465" width="42" height="9" font="13">moist skin</text>
<text top="767" left="565" width="82" height="9" font="13">Thyroid-stimulating</text>
<text top="779" left="580" width="59" height="9" font="13">hormone; free</text>
<text top="791" left="580" width="39" height="9" font="13">thyroxine</text>
<text top="767" left="679" width="107" height="9" font="13">Radioactive iodine uptake</text>
<text top="779" left="694" width="37" height="9" font="13">and scan</text>
<text top="822" left="108" width="75" height="9" font="13">Aortic coarctation</text>
<text top="834" left="123" width="68" height="9" font="13">(undiagnosed or</text>
<text top="846" left="123" width="37" height="9" font="13">repaired)</text>
<text top="858" left="123" width="38" height="9" font="17"><a href="e127.full.html#91">(S5.4-13)</a></text>
<text top="822" left="206" width="22" height="9" font="13">0.1%</text>
<text top="822" left="267" width="138" height="9" font="13">Young patient with hypertension</text>
<text top="834" left="282" width="3" height="9" font="13">(</text>
<text top="833" left="285" width="59" height="12" font="13">&lt;30 y of age)</text>
<text top="822" left="450" width="78" height="9" font="13">BP higher in upper</text>
<text top="834" left="465" width="79" height="9" font="13">extremities than in</text>
<text top="846" left="465" width="76" height="9" font="13">lower extremities;</text>
<text top="858" left="465" width="63" height="9" font="13">absent femoral</text>
<text top="870" left="465" width="78" height="9" font="13">pulses; continuous</text>
<text top="882" left="465" width="86" height="9" font="13">murmur over patient</text>
<text top="881" left="551" width="6" height="12" font="13">’s</text>
<text top="894" left="465" width="61" height="9" font="13">back, chest, or</text>
<text top="906" left="465" width="87" height="9" font="13">abdominal bruit; left</text>
<text top="918" left="465" width="73" height="9" font="13">thoracotomy scar</text>
<text top="930" left="465" width="64" height="9" font="13">(postoperative)</text>
<text top="822" left="565" width="67" height="9" font="13">Echocardiogram</text>
<text top="822" left="679" width="113" height="9" font="13">Thoracic and abdominal CT</text>
<text top="834" left="694" width="78" height="9" font="13">angiogram or MRA</text>
<text top="949" left="108" width="80" height="9" font="13">Primary hyperpara-</text>
<text top="961" left="123" width="44" height="9" font="13">thyroidism</text>
<text top="973" left="123" width="38" height="9" font="17"><a href="e127.full.html#91">(S5.4-14)</a></text>
<text top="949" left="206" width="19" height="9" font="13">Rare</text>
<text top="949" left="267" width="61" height="9" font="13">Hypercalcemia</text>
<text top="949" left="450" width="54" height="9" font="13">Usually none</text>
<text top="949" left="565" width="61" height="9" font="13">Serum calcium</text>
<text top="949" left="679" width="117" height="9" font="13">Serum parathyroid hormone</text>
<text top="991" left="108" width="79" height="9" font="13">Congenital adrenal</text>
<text top="1003" left="123" width="47" height="9" font="13">hyperplasia</text>
<text top="1015" left="123" width="38" height="9" font="17"><a href="e127.full.html#91">(S5.4-15)</a></text>
<text top="991" left="206" width="19" height="9" font="13">Rare</text>
<text top="991" left="267" width="176" height="9" font="13">Hypertension and hypokalemia; virilization</text>
<text top="1003" left="282" width="100" height="9" font="13">(11-beta-hydroxylase de</text>
<text top="1001" left="382" width="50" height="12" font="13">ﬁciency [11-</text>
<text top="1015" left="282" width="161" height="9" font="13">beta-OH]); incomplete masculinization</text>
<text top="1027" left="282" width="151" height="9" font="13">in males and primary amenorrhea in</text>
<text top="1039" left="282" width="128" height="9" font="13">females (17-alpha-hydroxylase</text>
<text top="1051" left="282" width="10" height="9" font="13">de</text>
<text top="1049" left="292" width="97" height="12" font="13">ﬁciency [17-alpha-OH])</text>
<text top="991" left="450" width="80" height="9" font="13">Signs of virilization</text>
<text top="1003" left="465" width="65" height="9" font="13">(11-beta-OH) or</text>
<text top="1015" left="465" width="46" height="9" font="13">incomplete</text>
<text top="1027" left="465" width="64" height="9" font="13">masculinization</text>
<text top="1039" left="465" width="59" height="9" font="13">(17-alpha-OH)</text>
<text top="991" left="565" width="74" height="9" font="13">Hypertension and</text>
<text top="1003" left="580" width="74" height="9" font="13">hypokalemia with</text>
<text top="1015" left="580" width="59" height="9" font="13">low or normal</text>
<text top="1027" left="580" width="68" height="9" font="13">aldosterone and</text>
<text top="1039" left="580" width="21" height="9" font="13">renin</text>
<text top="991" left="679" width="89" height="9" font="13">11-beta-OH: elevated</text>
<text top="1003" left="694" width="85" height="9" font="13">deoxycorticosterone</text>
<text top="1015" left="694" width="101" height="9" font="13">(DOC), 11-deoxycortisol,</text>
<text top="1027" left="694" width="101" height="9" font="13">and androgens17-alpha-</text>
<text top="1039" left="694" width="107" height="9" font="13">OH; decreased androgens</text>
<text top="1051" left="694" width="96" height="9" font="13">and estrogen; elevated</text>
<text top="1063" left="694" width="103" height="9" font="13">deoxycorticosterone and</text>
<text top="1075" left="694" width="60" height="9" font="13">corticosterone</text>
<text top="1095" left="696" width="105" height="8" font="4">Continued on the next page</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e150</text>
</page>
<page number="25" position="absolute" top="0" left="0" height="1160" width="864">
<text top="445" left="63" width="273" height="11" font="2">5.4.1. Drugs and Other Substances With Potential to</text>
<text top="463" left="95" width="92" height="11" font="2">Impair BP Control</text>
<text top="484" left="63" width="333" height="12" font="2">Numerous substances, including prescription medica-</text>
<text top="502" left="63" width="333" height="12" font="2">tions, over-the-counter medications, herbals, and food</text>
<text top="520" left="63" width="165" height="12" font="2">substances, may affect BP (</text>
<text top="520" left="228" width="48" height="11" font="5"><a href="e127.full.html#25">Table 14</a></text>
<text top="520" left="276" width="4" height="12" font="2">)</text>
<text top="520" left="286" width="48" height="12" font="5"><a href="e127.full.html#91">(S5.4.1-1</a></text>
<text top="518" left="334" width="58" height="15" font="5"><a href="e127.full.html#91">—S5.4.1-6)</a></text>
<text top="520" left="393" width="3" height="12" font="2"><a href="e127.full.html#91">.</a></text>
<text top="538" left="63" width="333" height="12" font="2">Changes in BP that occur because of drugs and other agents</text>
<text top="556" left="63" width="333" height="12" font="2">have been associated with the development of hyperten-</text>
<text top="574" left="63" width="333" height="12" font="2">sion, worsening control in a patient who already has</text>
<text top="592" left="63" width="333" height="12" font="2">hypertension, or attenuation of the BP-lowering effects of</text>
<text top="444" left="423" width="333" height="12" font="2">antihypertensive therapy. A change in BP may also result</text>
<text top="462" left="423" width="65" height="12" font="2">from drug</text>
<text top="461" left="488" width="205" height="15" font="2">–drug or drug–food interactions</text>
<text top="462" left="704" width="52" height="12" font="5"><a href="e127.full.html#91">(S5.4.1-2,</a></text>
<text top="480" left="423" width="50" height="12" font="5"><a href="e127.full.html#91">S5.4.1-4)</a></text>
<text top="480" left="473" width="283" height="12" font="2">. In the clinical assessment of hypertension, a</text>
<text top="498" left="423" width="333" height="12" font="2">careful history should be taken with regard to substances that</text>
<text top="516" left="423" width="333" height="12" font="2">may impair BP control, with close attention paid to not only</text>
<text top="534" left="423" width="333" height="12" font="2">prescription medications, but also over-the-counter sub-</text>
<text top="552" left="423" width="333" height="12" font="2">stances, illicit drugs, and herbal products. When feasible,</text>
<text top="570" left="423" width="333" height="12" font="2">drugs associated with increased BP should be reduced or</text>
<text top="588" left="423" width="294" height="12" font="2">discontinued, and alternative agents should be used.</text>
<text top="148" left="68" width="52" height="10" font="15">T A B L E 1 3</text>
<text top="148" left="135" width="53" height="10" font="16">Continued</text>
<text top="183" left="163" width="51" height="9" font="13">Prevalence</text>
<text top="183" left="267" width="87" height="9" font="13">Clinical Indications</text>
<text top="171" left="440" width="38" height="9" font="13">Physical</text>
<text top="183" left="430" width="57" height="9" font="13">Examination</text>
<text top="183" left="537" width="73" height="9" font="13">Screening Tests</text>
<text top="171" left="669" width="52" height="9" font="13">Additional/</text>
<text top="183" left="651" width="17" height="9" font="13">Con</text>
<text top="182" left="668" width="71" height="12" font="13">ﬁrmatory Tests</text>
<text top="203" left="63" width="72" height="9" font="13">Mineralocorticoid</text>
<text top="215" left="78" width="75" height="9" font="13">excess syndromes</text>
<text top="227" left="78" width="44" height="9" font="13">other than</text>
<text top="238" left="78" width="32" height="9" font="13">primary</text>
<text top="250" left="78" width="59" height="9" font="13">aldosteronism</text>
<text top="262" left="78" width="38" height="9" font="17"><a href="e127.full.html#91">(S5.4-15)</a></text>
<text top="203" left="161" width="19" height="9" font="13">Rare</text>
<text top="203" left="222" width="146" height="9" font="13">Early-onset hypertension; resistant</text>
<text top="215" left="237" width="124" height="9" font="13">hypertension; hypokalemia or</text>
<text top="227" left="237" width="55" height="9" font="13">hyperkalemia</text>
<text top="203" left="405" width="75" height="9" font="13">Arrhythmias (with</text>
<text top="215" left="420" width="56" height="9" font="13">hypokalemia)</text>
<text top="203" left="520" width="70" height="9" font="13">Low aldosterone</text>
<text top="215" left="535" width="39" height="9" font="13">and renin</text>
<text top="203" left="634" width="119" height="9" font="13">Urinary cortisol metabolites;</text>
<text top="215" left="649" width="63" height="9" font="13">genetic testing</text>
<text top="282" left="63" width="49" height="9" font="13">Acromegaly</text>
<text top="294" left="78" width="38" height="9" font="17"><a href="e127.full.html#91">(S5.4-16)</a></text>
<text top="282" left="161" width="19" height="9" font="13">Rare</text>
<text top="282" left="222" width="157" height="9" font="13">Acral features, enlarging shoe, glove,</text>
<text top="294" left="237" width="118" height="9" font="13">or hat size; headache, visual</text>
<text top="305" left="237" width="129" height="9" font="13">disturbances; diabetes mellitus</text>
<text top="282" left="405" width="85" height="9" font="13">Acral features; large</text>
<text top="294" left="420" width="65" height="9" font="13">hands and feet;</text>
<text top="305" left="420" width="63" height="9" font="13">frontal bossing</text>
<text top="282" left="520" width="59" height="9" font="13">Serum growth</text>
<text top="294" left="535" width="37" height="9" font="13">hormone</text>
<text top="292" left="575" width="42" height="12" font="13">$1 ng/mL</text>
<text top="305" left="535" width="81" height="9" font="13">during oral glucose</text>
<text top="317" left="535" width="18" height="9" font="13">load</text>
<text top="282" left="634" width="97" height="9" font="13">Elevated age- and sex-</text>
<text top="294" left="649" width="106" height="9" font="13">matched IGF-1 level; MRI</text>
<text top="305" left="649" width="85" height="9" font="13">scan of the pituitary</text>
<text top="343" left="63" width="694" height="8" font="4">*Depending on the clinical situation (hypertension alone, 5%; hypertension starting dialysis, 22%; hypertension and peripheral vascular disease, 28%; hypertension in the elderly with</text>
<text top="355" left="63" width="118" height="8" font="4">congestive heart failure, 34%).</text>
<text top="353" left="183" width="574" height="11" font="4">†8% in general population with hypertension; up to 20% in patients with resistant hypertension. ‡Although obstructive sleep apnea is listed as a cause</text>
<text top="366" left="63" width="628" height="8" font="4">of secondary hypertension, RCTs on the effects of continuous positive airway pressure on lowering BP in patients with hypertension have produced mixed results (see</text>
<text top="366" left="693" width="50" height="8" font="8"><a href="e127.full.html#28">Section 5.4.4</a></text>
<text top="366" left="745" width="11" height="8" font="4">for</text>
<text top="378" left="63" width="384" height="8" font="4">details). §For a list of frequently used drugs causing hypertension and accompanying evidence, see</text>
<text top="378" left="449" width="33" height="8" font="8"><a href="e127.full.html#25">Table 14</a></text>
<text top="378" left="483" width="2" height="8" font="4"><a href="e127.full.html#25">.</a></text>
<text top="393" left="71" width="686" height="8" font="4">BP indicates blood pressure; CT, computed tomography; DOC, 11-deoxycorticosterone; IGF-1, insulin-like growth factor-1; IV, intravenous; MAO, monamine oxidase; MRI, magnetic</text>
<text top="405" left="63" width="345" height="8" font="4">resonance imaging; MRA, magnetic resonance arteriography; NSAIDs, nonsteroidal anti-in</text>
<text top="403" left="408" width="274" height="11" font="4">ﬂammatory drugs; OH, hydroxylase; and RCT, randomized clinical trial.</text>
<text top="655" left="67" width="53" height="10" font="15">T A B L E 1 4</text>
<text top="655" left="135" width="427" height="10" font="16">Frequently Used Medications and Other Substances That May Cause Elevated BP</text>
<text top="655" left="563" width="5" height="10" font="7"><a href="e127.full.html#26">*</a></text>
<text top="680" left="63" width="28" height="9" font="13">Agent</text>
<text top="680" left="479" width="145" height="9" font="13">Possible Management Strategy</text>
<text top="699" left="63" width="31" height="9" font="13">Alcohol</text>
<text top="698" left="352" width="6" height="10" font="9">n</text>
<text top="699" left="366" width="70" height="9" font="13">Limit alcohol to</text>
<text top="697" left="439" width="215" height="12" font="13">#1 drink daily for women and #2 drinks for men</text>
<text top="699" left="657" width="42" height="9" font="17"><a href="e127.full.html#91">(S5.4.1-7)</a></text>
<text top="718" left="63" width="222" height="9" font="13">Amphetamines (e.g., amphetamine, methylphenidate</text>
<text top="730" left="78" width="178" height="9" font="13">dexmethylphenidate, dextroamphetamine)</text>
<text top="717" left="352" width="6" height="10" font="9">n</text>
<text top="718" left="366" width="129" height="9" font="13">Discontinue or decrease dose</text>
<text top="718" left="498" width="44" height="9" font="17"><a href="e127.full.html#91">(S5.4.1-8)</a></text>
<text top="730" left="352" width="6" height="10" font="9">n</text>
<text top="731" left="366" width="176" height="9" font="13">Consider behavioral therapies for ADHD</text>
<text top="731" left="545" width="44" height="9" font="17"><a href="e127.full.html#91">(S5.4.1-9)</a></text>
<text top="750" left="63" width="180" height="9" font="13">Antidepressants (e.g., MAOIs, SNRIs, TCAs)</text>
<text top="749" left="352" width="6" height="10" font="9">n</text>
<text top="750" left="366" width="288" height="9" font="13">Consider alternative agents (e.g., SSRIs) depending on indication</text>
<text top="762" left="352" width="6" height="10" font="9">n</text>
<text top="762" left="366" width="199" height="9" font="13">Avoid tyramine-containing foods with MAOIs</text>
<text top="782" left="63" width="216" height="9" font="13">Atypical antipsychotics (e.g., clozapine, olanzapine)</text>
<text top="781" left="352" width="6" height="10" font="9">n</text>
<text top="781" left="366" width="171" height="9" font="13">Discontinue or limit use when possible</text>
<text top="793" left="352" width="6" height="10" font="9">n</text>
<text top="794" left="366" width="200" height="9" font="13">Consider behavior therapy where appropriate</text>
<text top="806" left="352" width="6" height="10" font="9">n</text>
<text top="807" left="366" width="117" height="9" font="13">Recommend lifestyle modi</text>
<text top="805" left="483" width="54" height="12" font="13">ﬁcation (see</text>
<text top="807" left="541" width="50" height="9" font="17"><a href="e127.full.html#29">Section 6.2</a></text>
<text top="807" left="590" width="3" height="9" font="13">)</text>
<text top="819" left="352" width="6" height="10" font="9">n</text>
<text top="819" left="366" width="391" height="9" font="13">Consider alternative agents associated with lower risk of weight gain, diabetes mellitus,</text>
<text top="833" left="366" width="215" height="9" font="13">and dyslipidemia (e.g., aripiprazole, ziprasidone)</text>
<text top="833" left="584" width="90" height="9" font="17"><a href="e127.full.html#91">(S5.4.1-10,S5.4.1-11)</a></text>
<text top="852" left="63" width="34" height="9" font="13">Caffeine</text>
<text top="851" left="352" width="6" height="10" font="9">n</text>
<text top="852" left="366" width="146" height="9" font="13">Generally limit caffeine intake to</text>
<text top="850" left="515" width="52" height="12" font="13">&lt;300 mg/d</text>
<text top="864" left="352" width="6" height="10" font="9">n</text>
<text top="864" left="366" width="235" height="9" font="13">Avoid use in patients with uncontrolled hypertension</text>
<text top="876" left="352" width="6" height="10" font="9">n</text>
<text top="877" left="366" width="361" height="9" font="13">Coffee use in patients with hypertension is associated with acute increases in BP;</text>
<text top="890" left="366" width="255" height="9" font="13">long-term use is not associated with increased BP or CVD</text>
<text top="890" left="624" width="47" height="9" font="17"><a href="e127.full.html#91">(S5.4.1-12)</a></text>
<text top="913" left="63" width="229" height="9" font="13">Decongestants (e.g., phenylephrine, pseudoephedrine)</text>
<text top="912" left="352" width="6" height="10" font="9">n</text>
<text top="912" left="366" width="375" height="9" font="13">Use for shortest duration possible, and avoid in severe or uncontrolled hypertension</text>
<text top="924" left="352" width="6" height="10" font="9">n</text>
<text top="925" left="366" width="334" height="9" font="13">Consider alternative therapies (e.g., nasal saline, intranasal corticosteroids,</text>
<text top="938" left="366" width="134" height="9" font="13">antihistamines) as appropriate</text>
<text top="958" left="63" width="237" height="9" font="13">Herbal supplements (e.g., Ma Huang [ephedra], St. John</text>
<text top="956" left="300" width="29" height="12" font="13">’s wort</text>
<text top="969" left="78" width="143" height="9" font="13">[with MAO inhibitors, yohimbine])</text>
<text top="957" left="352" width="6" height="10" font="9">n</text>
<text top="957" left="366" width="43" height="9" font="13">Avoid use</text>
<text top="989" left="63" width="171" height="9" font="13">Immunosuppressants (e.g., cyclosporine)</text>
<text top="988" left="352" width="6" height="10" font="9">n</text>
<text top="989" left="366" width="341" height="9" font="13">Consider converting to tacrolimus, which may be associated with fewer effects on BP</text>
<text top="989" left="709" width="41" height="9" font="17"><a href="e127.full.html#91">(S5.4.1-13</a></text>
<text top="987" left="750" width="7" height="12" font="17"><a href="e127.full.html#91">—</a></text>
<text top="1005" left="362" width="41" height="9" font="17"><a href="e127.full.html#91">S5.4.1-15)</a></text>
<text top="1022" left="63" width="81" height="9" font="13">Oral contraceptives</text>
<text top="1022" left="352" width="6" height="10" font="9">n</text>
<text top="1022" left="366" width="101" height="9" font="13">Use low-dose (e.g., 20</text>
<text top="1021" left="467" width="149" height="12" font="13">–30 mcg ethinyl estradiol) agents</text>
<text top="1022" left="619" width="48" height="9" font="17"><a href="e127.full.html#91">(S5.4.1-16)</a></text>
<text top="1022" left="671" width="85" height="9" font="13">or a progestin-only</text>
<text top="1034" left="366" width="387" height="9" font="13">form of contraception, or consider alternative forms of birth control where appropriate</text>
<text top="1043" left="366" width="134" height="9" font="13">(e.g., barrier, abstinence, IUD)</text>
<text top="1055" left="352" width="6" height="10" font="9">n</text>
<text top="1056" left="366" width="231" height="9" font="13">Avoid use in women with uncontrolled hypertension</text>
<text top="1056" left="600" width="48" height="9" font="17"><a href="e127.full.html#91">(S5.4.1-16)</a></text>
<text top="1076" left="651" width="105" height="8" font="4">Continued on the next page</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="791" width="17" height="9" font="4">e151</text>
</page>
<page number="26" position="absolute" top="0" left="0" height="1160" width="864">
<text top="412" left="108" width="152" height="11" font="2">5.4.2. Primary Aldosteronism</text>
<text top="727" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="745" left="123" width="166" height="12" font="2">Primary aldosteronism is de</text>
<text top="744" left="289" width="152" height="15" font="2">ﬁned as a group of disor-</text>
<text top="763" left="108" width="333" height="12" font="2">ders in which aldosterone production is inappropriately</text>
<text top="781" left="108" width="333" height="12" font="2">high for sodium status, is relatively autonomous of the</text>
<text top="799" left="108" width="333" height="12" font="2">major regulators of secretion (angiotensin II and potas-</text>
<text top="817" left="108" width="333" height="12" font="2">sium), and cannot be suppressed with sodium loading</text>
<text top="835" left="108" width="104" height="12" font="5"><a href="e127.full.html#91">(S5.4.2-2,S5.4.2-3)</a></text>
<text top="835" left="212" width="229" height="12" font="2"><a href="e127.full.html#91">. </a>The increased production of aldoste-</text>
<text top="853" left="108" width="333" height="12" font="2">rone induces hypertension; cardiovascular and kidney</text>
<text top="871" left="108" width="333" height="12" font="2">damage; sodium retention; suppressed plasma renin ac-</text>
<text top="889" left="108" width="333" height="12" font="2">tivity; and increased potassium excretion, which, if pro-</text>
<text top="907" left="108" width="333" height="12" font="2">longed and severe, may cause hypokalemia. However,</text>
<text top="925" left="108" width="333" height="12" font="2">hypokalemia is absent in the majority of cases and has a</text>
<text top="943" left="108" width="333" height="12" font="2">low negative predictive value for the diagnosis of primary</text>
<text top="960" left="108" width="82" height="12" font="2">aldosteronism</text>
<text top="960" left="196" width="55" height="12" font="5"><a href="e127.full.html#91">(S5.4.2-4)</a></text>
<text top="960" left="251" width="190" height="12" font="2">. In about 50% of the patients,</text>
<text top="978" left="108" width="333" height="12" font="2">primary aldosteronism is due to increased unilateral</text>
<text top="996" left="108" width="333" height="12" font="2">aldosterone production (usually aldosterone-producing</text>
<text top="1014" left="108" width="333" height="12" font="2">adenoma or, rarely, unilateral adrenal hyperplasia); in</text>
<text top="1032" left="108" width="333" height="12" font="2">the remaining 50%, primary aldosteronism is due to</text>
<text top="1050" left="108" width="48" height="12" font="2">bilateral</text>
<text top="1050" left="174" width="43" height="12" font="2">adrenal</text>
<text top="1050" left="236" width="67" height="12" font="2">hyperplasia</text>
<text top="1050" left="322" width="62" height="12" font="2">(idiopathic</text>
<text top="1050" left="403" width="38" height="12" font="2">hyper-</text>
<text top="1068" left="108" width="87" height="12" font="2">aldosteronism)</text>
<text top="1068" left="198" width="104" height="12" font="5"><a href="e127.full.html#91">(S5.4.2-2,S5.4.2-3)</a></text>
<text top="1068" left="302" width="3" height="12" font="2">.</text>
<text top="727" left="453" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="726" left="592" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="754" left="469" width="332" height="12" font="2">1. Primary aldosteronism is one of the most frequent</text>
<text top="772" left="483" width="318" height="12" font="2">disorders (occurring in 5% to 10% of patients with</text>
<text top="790" left="483" width="318" height="12" font="2">hypertension and 20% of patients with resistant</text>
<text top="808" left="483" width="318" height="12" font="2">hypertension) that causes secondary hypertension</text>
<text top="826" left="483" width="104" height="12" font="5"><a href="e127.full.html#91">(S5.4.2-5,S5.4.2-6)</a></text>
<text top="826" left="588" width="214" height="12" font="2"><a href="e127.full.html#91">. </a>The toxic tissue effects of aldoste-</text>
<text top="844" left="483" width="318" height="12" font="2">rone induce greater target organ damage in primary</text>
<text top="862" left="483" width="318" height="12" font="2">aldosteronism than in primary hypertension. Patients</text>
<text top="880" left="483" width="318" height="12" font="2">with primary aldosteronism have a 3.7-fold increase in</text>
<text top="898" left="483" width="318" height="12" font="2">HF, a 4.2-fold increase in stroke, a 6.5-fold increase in</text>
<text top="916" left="483" width="210" height="12" font="2">MI, a 12.1-fold increase in atrial</text>
<text top="914" left="703" width="99" height="15" font="2">ﬁbrillation (AF),</text>
<text top="934" left="483" width="318" height="12" font="2">increased left ventricular hypertrophy (LVH) and dia-</text>
<text top="952" left="483" width="318" height="12" font="2">stolic dysfunction, increased stiffness of large arteries,</text>
<text top="970" left="483" width="108" height="12" font="2">widespread tissue</text>
<text top="968" left="599" width="202" height="15" font="2">ﬁbrosis, increased remodeling of</text>
<text top="987" left="483" width="318" height="12" font="2">resistance vessels, and increased kidney damage as</text>
<text top="1005" left="483" width="318" height="12" font="2">compared with patients with primary hypertension</text>
<text top="1023" left="483" width="124" height="12" font="2">matched for BP level</text>
<text top="1023" left="612" width="50" height="12" font="5"><a href="e127.full.html#91">(S5.4.2-6</a></text>
<text top="1021" left="662" width="60" height="15" font="5"><a href="e127.full.html#91">—S5.4.2-8)</a></text>
<text top="1023" left="723" width="79" height="12" font="2"><a href="e127.full.html#91">. </a>Because the</text>
<text top="1041" left="483" width="318" height="12" font="2">deleterious effects of aldosterone overproduction</text>
<text top="1059" left="483" width="18" height="12" font="2">are</text>
<text top="1059" left="513" width="30" height="12" font="2">often</text>
<text top="1059" left="555" width="57" height="12" font="2">reversible</text>
<text top="1059" left="624" width="26" height="12" font="2">with</text>
<text top="1059" left="661" width="56" height="12" font="2">unilateral</text>
<text top="1059" left="729" width="72" height="12" font="2">laparoscopic</text>
<text top="1077" left="483" width="318" height="12" font="2">adrenalectomy or treatment with mineralocorticoid</text>
<text top="148" left="112" width="53" height="10" font="15">T A B L E 1 4</text>
<text top="148" left="179" width="53" height="10" font="16">Continued</text>
<text top="171" left="108" width="26" height="9" font="13">Agent</text>
<text top="171" left="524" width="145" height="9" font="13">Possible Management Strategy</text>
<text top="191" left="108" width="30" height="9" font="13">NSAIDs</text>
<text top="189" left="397" width="6" height="10" font="9">n</text>
<text top="190" left="411" width="167" height="9" font="13">Avoid systemic NSAIDs when possible</text>
<text top="202" left="397" width="6" height="10" font="9">n</text>
<text top="203" left="411" width="356" height="9" font="13">Consider alternative analgesics (e.g., acetaminophen, tramadol, topical NSAIDs),</text>
<text top="216" left="411" width="144" height="9" font="13">depending on indication and risk</text>
<text top="238" left="108" width="102" height="9" font="13">Recreational drugs (e.g.,</text>
<text top="236" left="213" width="124" height="12" font="13">“bath salts” [MDPV], cocaine,</text>
<text top="250" left="123" width="102" height="9" font="13">methamphetamine, etc.)</text>
<text top="236" left="397" width="6" height="10" font="9">n</text>
<text top="237" left="411" width="108" height="9" font="13">Discontinue or avoid use</text>
<text top="269" left="108" width="196" height="9" font="13">Systemic corticosteroids (e.g., dexamethasone,</text>
<text top="267" left="307" width="66" height="12" font="13">ﬂudrocortisone,</text>
<text top="281" left="123" width="197" height="9" font="13">methylprednisolone, prednisone, prednisolone)</text>
<text top="268" left="397" width="6" height="10" font="9">n</text>
<text top="268" left="411" width="144" height="9" font="13">Avoid or limit use when possible</text>
<text top="280" left="397" width="6" height="10" font="9">n</text>
<text top="281" left="411" width="365" height="9" font="13">Consider alternative modes of administration (e.g., inhaled, topical) when feasible</text>
<text top="300" left="108" width="261" height="9" font="13">Angiogenesis inhibitor (e.g., bevacizumab) and tyrosine kinase</text>
<text top="312" left="123" width="149" height="9" font="13">inhibitors (e.g., sunitinib, sorafenib)</text>
<text top="299" left="397" width="6" height="10" font="9">n</text>
<text top="300" left="411" width="198" height="9" font="13">Initiate or intensify antihypertensive therapy</text>
<text top="337" left="108" width="92" height="8" font="4">*List is not all inclusive.</text>
<text top="352" left="116" width="111" height="8" font="4">ADHD indicates attention-de</text>
<text top="350" left="227" width="574" height="11" font="4">ﬁcit/hyperactivity disorder; BP, blood pressure; CVD, cardiovascular disease; IUD, intra-uterine device; MAOI, monoamine-oxidase inhibitors; MDPV,</text>
<text top="364" left="108" width="224" height="8" font="4">methylenedioxypyrovalerone; NSAIDs, nonsteroidal anti-in</text>
<text top="362" left="331" width="470" height="11" font="4">ﬂammatory drugs; SNRI, serotonin norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; and TCA,</text>
<text top="375" left="108" width="91" height="8" font="4">tricyclic antidepressant.</text>
<text top="459" left="63" width="255" height="11" font="19">Recommendations for Primary Aldosteronism</text>
<text top="500" left="89" width="19" height="10" font="13">COR</text>
<text top="500" left="161" width="18" height="10" font="13">LOE</text>
<text top="500" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="537" left="97" width="3" height="9" font="4">I</text>
<text top="537" left="160" width="20" height="9" font="4">C-EO</text>
<text top="525" left="234" width="568" height="11" font="12">1. In adults with hypertension, screening for primary aldosteronism is recommended in the presence of any</text>
<text top="541" left="246" width="555" height="11" font="12">of the following concurrent conditions: resistant hypertension, hypokalemia (spontaneous or substantial,</text>
<text top="556" left="246" width="554" height="11" font="12">if diuretic induced), incidentally discovered adrenal mass, family history of early-onset hypertension, or</text>
<text top="572" left="246" width="124" height="11" font="12">stroke at a young age (</text>
<text top="570" left="370" width="60" height="15" font="12">&lt;40 years).</text>
<text top="616" left="97" width="3" height="9" font="4">I</text>
<text top="616" left="160" width="20" height="9" font="4">C-LD</text>
<text top="604" left="234" width="568" height="11" font="12">2. Use of the plasma aldosterone: renin activity ratio is recommended when adults are screened for primary</text>
<text top="620" left="248" width="74" height="11" font="12">aldosteronism</text>
<text top="620" left="326" width="52" height="11" font="5"><a href="e127.full.html#91">(S5.4.2-1)</a></text>
<text top="620" left="378" width="3" height="11" font="12">.</text>
<text top="666" left="97" width="3" height="9" font="4">I</text>
<text top="666" left="160" width="20" height="9" font="4">C-EO</text>
<text top="654" left="234" width="531" height="11" font="12">3. In adults with hypertension and a positive screening test for primary aldosteronism, referral to a</text>
<text top="669" left="248" width="516" height="11" font="12">hypertension specialist or endocrinologist is recommended for further evaluation and treatment.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="18" height="9" font="4">e152</text>
</page>
<page number="27" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="78" width="318" height="12" font="2">receptor antagonists (i.e., spironolactone or epler-</text>
<text top="161" left="78" width="318" height="12" font="2">enone), screening of patients with hypertension at</text>
<text top="178" left="78" width="290" height="12" font="2">increased risk of primary aldosteronism is bene</text>
<text top="177" left="368" width="28" height="15" font="2">ﬁcial</text>
<text top="196" left="78" width="104" height="12" font="5"><a href="e127.full.html#91">(S5.4.2-2,S5.4.2-3)</a></text>
<text top="196" left="182" width="3" height="12" font="2"><a href="e127.full.html#91">.</a></text>
<text top="196" left="205" width="34" height="12" font="2">These</text>
<text top="196" left="258" width="43" height="12" font="2">include</text>
<text top="196" left="321" width="75" height="12" font="2">hypertensive</text>
<text top="214" left="78" width="124" height="12" font="2">patients with adrenal</text>
<text top="213" left="206" width="190" height="15" font="2">“incidentaloma,” an incidentally</text>
<text top="232" left="78" width="318" height="12" font="2">discovered adrenal lesion on a computed tomography</text>
<text top="250" left="78" width="318" height="12" font="2">or magnetic resonance imaging (MRI) scan performed</text>
<text top="268" left="78" width="318" height="12" font="2">for other purposes. Patients with hypertension and a</text>
<text top="286" left="78" width="318" height="12" font="2">history of early onset hypertension and/or cerebro-</text>
<text top="304" left="78" width="318" height="12" font="2">vascular accident at a young age may have primary</text>
<text top="322" left="78" width="318" height="12" font="2">aldosteronism due to glucocorticoid-remediable aldo-</text>
<text top="340" left="78" width="318" height="12" font="2">steronism (familial hyperaldosteronism type-1) and</text>
<text top="358" left="78" width="162" height="12" font="2">therefore warrant screening</text>
<text top="358" left="244" width="104" height="12" font="5"><a href="e127.full.html#91">(S5.4.2-2,S5.4.2-3)</a></text>
<text top="358" left="348" width="3" height="12" font="2">.</text>
<text top="376" left="63" width="333" height="12" font="2">2. The aldosterone:renin activity ratio is currently the</text>
<text top="394" left="78" width="318" height="12" font="2">most accurate and reliable means of screening for</text>
<text top="412" left="78" width="132" height="12" font="2">primary aldosteronism</text>
<text top="412" left="215" width="53" height="12" font="5"><a href="e127.full.html#91">(S5.4.2-1)</a></text>
<text top="412" left="268" width="128" height="12" font="2">. The most commonly</text>
<text top="430" left="78" width="318" height="12" font="2">used cutoff value is 30 when plasma aldosterone</text>
<text top="447" left="78" width="318" height="12" font="2">concentration is reported in nanograms per deciliter</text>
<text top="465" left="78" width="318" height="12" font="2">(ng/dL) and plasma renin activity in nanograms per</text>
<text top="483" left="78" width="175" height="12" font="2">milliliter per hour (ng/mL/h)</text>
<text top="483" left="259" width="54" height="12" font="5"><a href="e127.full.html#91">(S5.4.2-3)</a></text>
<text top="483" left="314" width="82" height="12" font="2"><a href="e127.full.html#91">. </a>Because the</text>
<text top="501" left="78" width="248" height="12" font="2">aldosterone:renin activity ratio can be in</text>
<text top="499" left="327" width="70" height="15" font="2">ﬂuenced by</text>
<text top="519" left="78" width="318" height="12" font="2">the presence of very low renin levels, the plasma</text>
<text top="537" left="78" width="318" height="12" font="2">aldosterone concentration should be at least 10 ng/dL to</text>
<text top="555" left="78" width="164" height="12" font="2">interpret the test as positive</text>
<text top="555" left="245" width="54" height="12" font="5"><a href="e127.full.html#91">(S5.4.2-3)</a></text>
<text top="555" left="299" width="97" height="12" font="2">. Patients should</text>
<text top="573" left="78" width="318" height="12" font="2">have unrestricted salt intake, serum potassium in the</text>
<text top="591" left="78" width="318" height="12" font="2">normal range, and mineralocorticoid receptor antago-</text>
<text top="609" left="78" width="318" height="12" font="2">nists (e.g., spironolactone or eplerenone) withdrawn for</text>
<text top="627" left="78" width="176" height="12" font="2">at least 4 weeks before testing</text>
<text top="627" left="258" width="104" height="12" font="5"><a href="e127.full.html#91">(S5.4.2-2,S5.4.2-3)</a></text>
<text top="627" left="362" width="3" height="12" font="2"><a href="e127.full.html#91">.</a></text>
<text top="143" left="423" width="333" height="12" font="2">3. The diagnosis of primary aldosteronism generally re-</text>
<text top="161" left="438" width="70" height="12" font="2">quires a con</text>
<text top="159" left="508" width="248" height="15" font="2">ﬁrmatory test (intravenous saline suppres-</text>
<text top="178" left="438" width="194" height="12" font="2">sion test or oral salt-loading test)</text>
<text top="178" left="636" width="104" height="12" font="5"><a href="e127.full.html#91">(S5.4.2-2,S5.4.2-3)</a></text>
<text top="178" left="740" width="16" height="12" font="2">. If</text>
<text top="196" left="438" width="280" height="12" font="2">the diagnosis of primary aldosteronism is con</text>
<text top="195" left="719" width="38" height="15" font="2">ﬁrmed</text>
<text top="214" left="438" width="318" height="12" font="2">(and the patient agrees that surgery would be desirable),</text>
<text top="232" left="438" width="318" height="12" font="2">the patient is referred for an adrenal venous sampling</text>
<text top="250" left="438" width="318" height="12" font="2">procedure to determine whether the increased aldo-</text>
<text top="268" left="438" width="318" height="12" font="2">sterone production is unilateral or bilateral in origin. If</text>
<text top="286" left="438" width="318" height="12" font="2">unilateral aldosterone production is documented on</text>
<text top="304" left="438" width="318" height="12" font="2">adrenal venous sampling, the patient is referred for</text>
<text top="322" left="438" width="318" height="12" font="2">unilateral laparoscopic adrenalectomy, which improves</text>
<text top="340" left="438" width="318" height="12" font="2">BP in virtually 100% of patients and results in a</text>
<text top="358" left="438" width="260" height="12" font="2">complete cure of hypertension in about 50%</text>
<text top="358" left="703" width="54" height="12" font="5"><a href="e127.full.html#91">(S5.4.2-2,</a></text>
<text top="376" left="438" width="50" height="12" font="5"><a href="e127.full.html#91">S5.4.2-3)</a></text>
<text top="376" left="488" width="268" height="12" font="2">. If the patient has bilaterally increased aldo-</text>
<text top="394" left="438" width="318" height="12" font="2">sterone secretion on adrenal venous sampling or has a</text>
<text top="412" left="438" width="318" height="12" font="2">unilateral source of excess aldosterone production</text>
<text top="430" left="438" width="318" height="12" font="2">but cannot undergo surgery, the patient is treated</text>
<text top="447" left="438" width="318" height="12" font="2">with spironolactone or eplerenone as agent of choice</text>
<text top="465" left="438" width="104" height="12" font="5"><a href="e127.full.html#91">(S5.4.2-2,S5.4.2-3)</a></text>
<text top="465" left="542" width="214" height="12" font="2">. Both adrenalectomy and medical</text>
<text top="483" left="438" width="318" height="12" font="2">ktherapy are effective in lowering BP and reversing</text>
<text top="501" left="438" width="318" height="12" font="2">LVH. Treating primary aldosteronism, either by miner-</text>
<text top="519" left="438" width="318" height="12" font="2">alocorticoid receptor antagonists or unilateral adrenal-</text>
<text top="537" left="438" width="318" height="12" font="2">ectomy (if indicated), resolves hypokalemia, lowers BP,</text>
<text top="555" left="438" width="318" height="12" font="2">reduces the number of antihypertensive medications</text>
<text top="573" left="438" width="318" height="12" font="2">required, and improves parameters of impaired cardiac</text>
<text top="591" left="438" width="117" height="12" font="2">and kidney function</text>
<text top="591" left="558" width="111" height="12" font="5"><a href="e127.full.html#92">(S5.4.2-9,S5.4.2-10)</a></text>
<text top="591" left="670" width="3" height="12" font="2"><a href="e127.full.html#92">.</a></text>
<text top="627" left="423" width="145" height="11" font="2">5.4.3. Renal Artery Stenosis</text>
<text top="672" left="63" width="247" height="11" font="19">Recommendations for Renal Artery Stenosis</text>
<text top="686" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="686" left="412" width="193" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplements 7 and 24</a></text>
<text top="686" left="606" width="3" height="11" font="19">.</text>
<text top="727" left="89" width="19" height="10" font="13">COR</text>
<text top="727" left="161" width="18" height="10" font="13">LOE</text>
<text top="727" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="764" left="97" width="3" height="9" font="4">I</text>
<text top="764" left="168" width="6" height="9" font="4">A</text>
<text top="752" left="234" width="462" height="11" font="12">1. Medical therapy is recommended for adults with atherosclerotic renal artery stenosis</text>
<text top="752" left="699" width="99" height="11" font="5"><a href="e127.full.html#92">(S5.4.3-1,S5.4.3-2)</a></text>
<text top="752" left="798" width="3" height="11" font="12">.</text>
<text top="812" left="94" width="10" height="9" font="4">IIb</text>
<text top="812" left="160" width="20" height="9" font="4">C-EO</text>
<text top="800" left="234" width="564" height="11" font="12">2. In adults with renal artery stenosis for whom medical management has failed (refractory hypertension,</text>
<text top="815" left="248" width="543" height="11" font="12">worsening renal function, and/or intractable HF) and those with nonatherosclerotic disease, including</text>
<text top="829" left="248" width="552" height="15" font="12">ﬁbromuscular dysplasia, it may be reasonable to refer the patient for consideration of revascularization</text>
<text top="847" left="248" width="343" height="11" font="12">(percutaneous renal artery angioplasty and/or stent placement).</text>
<text top="910" left="63" width="52" height="12" font="2">Synopsis</text>
<text top="928" left="78" width="321" height="12" font="2">Renal artery stenosis refers to a narrowing of the renal</text>
<text top="946" left="63" width="299" height="12" font="2">artery that can result in a restriction of blood</text>
<text top="944" left="371" width="28" height="15" font="2">ﬂow.</text>
<text top="964" left="63" width="336" height="12" font="2">Atherosclerotic disease (90%) is by far the most common</text>
<text top="982" left="63" width="336" height="12" font="2">cause of renal artery stenosis, whereas nonatherosclerotic</text>
<text top="1000" left="63" width="108" height="12" font="2">disease (of which</text>
<text top="998" left="178" width="221" height="15" font="2">ﬁbromuscular dysplasia is the most</text>
<text top="1018" left="63" width="336" height="12" font="2">common) is much less prevalent and tends to occur in</text>
<text top="1036" left="63" width="163" height="12" font="2">younger, healthier patients</text>
<text top="1036" left="233" width="54" height="12" font="5"><a href="e127.full.html#92">(S5.4.3-3)</a></text>
<text top="1036" left="287" width="112" height="12" font="2">. Renal artery ste-</text>
<text top="1054" left="63" width="336" height="12" font="2">nosis is a common form of secondary hypertension.</text>
<text top="1072" left="63" width="336" height="12" font="2">Relieving ischemia and the ensuing postischemic release</text>
<text top="1090" left="63" width="336" height="12" font="2">of renin by surgical renal artery reconstruction is an</text>
<text top="910" left="420" width="336" height="12" font="2">invasive strategy with a postoperative mortality as high as</text>
<text top="928" left="420" width="22" height="12" font="2">13%</text>
<text top="928" left="447" width="55" height="12" font="5"><a href="e127.full.html#92">(S5.4.3-4)</a></text>
<text top="928" left="503" width="253" height="12" font="2">. With the advent of endovascular proced-</text>
<text top="946" left="420" width="121" height="12" font="2">ures to restore blood</text>
<text top="944" left="546" width="211" height="15" font="2">ﬂow, several trials were designed to</text>
<text top="964" left="420" width="68" height="12" font="2">test the ef</text>
<text top="962" left="488" width="268" height="15" font="2">ﬁcacy of these procedures against medical</text>
<text top="982" left="420" width="236" height="12" font="2">therapy, but they suggested no bene</text>
<text top="980" left="656" width="100" height="15" font="2">ﬁt over medical</text>
<text top="1000" left="420" width="80" height="12" font="2">therapy alone</text>
<text top="1000" left="504" width="103" height="12" font="5"><a href="e127.full.html#92">(S5.4.3-1,S5.4.3-2)</a></text>
<text top="1000" left="607" width="3" height="12" font="2">.</text>
<text top="1027" left="420" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="1025" left="559" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="1054" left="422" width="335" height="12" font="2">1. Atherosclerotic disease in the renal arteries represents</text>
<text top="1072" left="435" width="321" height="12" font="2">systemic disease and higher risk of both renal failure</text>
<text top="1090" left="435" width="321" height="12" font="2">and cardiovascular morbidity and mortality. No RCT to</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="790" width="18" height="9" font="4">e153</text>
</page>
<page number="28" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="123" width="318" height="12" font="2">date has demonstrated a clinical advantage of renal</text>
<text top="161" left="123" width="318" height="12" font="2">artery revascularization (with either angioplasty or</text>
<text top="178" left="123" width="180" height="12" font="2">stenting) over medical therapy</text>
<text top="178" left="307" width="54" height="12" font="5"><a href="e127.full.html#92">(S5.4.3-2)</a></text>
<text top="178" left="361" width="80" height="12" font="2">. On the basis</text>
<text top="196" left="123" width="318" height="12" font="2">of the CORAL (Cardiovascular Outcomes in Renal</text>
<text top="214" left="123" width="318" height="12" font="2">Atherosclerotic Lesions) trial, the recommended med-</text>
<text top="232" left="123" width="318" height="12" font="2">ical approach encompasses optimal management of</text>
<text top="250" left="123" width="318" height="12" font="2">hypertension with an antihypertensive regimen that</text>
<text top="268" left="123" width="318" height="12" font="2">includes a renin-angiotensin system (RAS) blocker, in</text>
<text top="286" left="123" width="318" height="12" font="2">addition to low-density lipoprotein cholesterol reduc-</text>
<text top="304" left="123" width="318" height="12" font="2">tion with a high-intensity statin, smoking cessation,</text>
<text top="322" left="123" width="318" height="12" font="2">hemoglobin A1c reduction in patients with DM, and</text>
<text top="340" left="123" width="115" height="12" font="2">antiplatelet therapy</text>
<text top="340" left="242" width="53" height="12" font="5"><a href="e127.full.html#92">(S5.4.3-1)</a></text>
<text top="340" left="296" width="3" height="12" font="2"><a href="e127.full.html#92">.</a></text>
<text top="143" left="468" width="333" height="12" font="2">2. Revascularization may be considered for those who do</text>
<text top="161" left="483" width="318" height="12" font="2">not respond to medical therapy and for those who have</text>
<text top="178" left="483" width="318" height="12" font="2">nonatherosclerotic disease (e.g., Takayasu arteritis in</text>
<text top="196" left="483" width="112" height="12" font="2">Asian populations,</text>
<text top="195" left="603" width="199" height="15" font="2">ﬁbromuscular dysplasia in other</text>
<text top="214" left="483" width="318" height="12" font="2">populations). Fibromuscular dysplasia occurs over the</text>
<text top="232" left="483" width="318" height="12" font="2">lifespan of women (mean: 53 years of age) with almost</text>
<text top="250" left="483" width="318" height="12" font="2">equal frequency in the renal and carotid circulations</text>
<text top="268" left="483" width="54" height="12" font="5"><a href="e127.full.html#92">(S5.4.3-3)</a></text>
<text top="268" left="537" width="264" height="12" font="2">. Percutaneous transluminal angioplasty alone</text>
<text top="286" left="483" width="318" height="12" font="2">(without stenting) can improve BP control and even</text>
<text top="304" left="483" width="318" height="12" font="2">normalize BP, especially in patients with recent onset of</text>
<text top="322" left="483" width="225" height="12" font="2">hypertension or resistant hypertension</text>
<text top="322" left="711" width="54" height="12" font="5"><a href="e127.full.html#92">(S5.4.3-5)</a></text>
<text top="322" left="766" width="3" height="12" font="2"><a href="e127.full.html#92">.</a></text>
<text top="428" left="63" width="258" height="11" font="19">Recommendation for Obstructive Sleep Apnea</text>
<text top="442" left="63" width="362" height="11" font="19">References that support the recommendation are summarized in</text>
<text top="442" left="429" width="147" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 8</a></text>
<text top="442" left="576" width="3" height="11" font="19">.</text>
<text top="483" left="89" width="19" height="10" font="13">COR</text>
<text top="483" left="161" width="18" height="10" font="13">LOE</text>
<text top="483" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="520" left="94" width="10" height="9" font="4">IIb</text>
<text top="520" left="163" width="15" height="9" font="4">B-R</text>
<text top="507" left="234" width="568" height="11" font="12">1. In adults with hypertension and obstructive sleep apnea, the effectiveness of continuous positive airway</text>
<text top="523" left="246" width="281" height="11" font="12">pressure (CPAP) to reduce BP is not well established</text>
<text top="523" left="531" width="48" height="11" font="5"><a href="e127.full.html#92">(S5.4.4-1</a></text>
<text top="521" left="580" width="58" height="15" font="5"><a href="e127.full.html#92">—S5.4.4-5)</a></text>
<text top="523" left="638" width="3" height="11" font="12"><a href="e127.full.html#92">.</a></text>
<text top="375" left="108" width="163" height="11" font="2">5.4.4. Obstructive Sleep Apnea</text>
<text top="578" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="596" left="123" width="321" height="12" font="2">Obstructive sleep apnea is a common chronic condition</text>
<text top="614" left="108" width="336" height="12" font="2">characterized by recurrent collapse of upper airways dur-</text>
<text top="632" left="108" width="336" height="12" font="2">ing sleep, inducing intermittent episodes of apnea/hypo-</text>
<text top="650" left="108" width="32" height="12" font="2">pnea,</text>
<text top="650" left="152" width="68" height="12" font="2">hypoxemia,</text>
<text top="650" left="234" width="21" height="12" font="2">and</text>
<text top="650" left="268" width="30" height="12" font="2">sleep</text>
<text top="650" left="311" width="60" height="12" font="2">disruption</text>
<text top="650" left="384" width="56" height="12" font="5"><a href="e127.full.html#92">(S5.4.4-6)</a></text>
<text top="650" left="440" width="3" height="12" font="2">.</text>
<text top="668" left="108" width="336" height="12" font="2">Obstructive sleep apnea is a risk factor for several CVDs,</text>
<text top="686" left="108" width="336" height="12" font="2">including hypertension, coronary and cerebrovascular</text>
<text top="704" left="108" width="127" height="12" font="2">diseases, HF, and AF</text>
<text top="704" left="241" width="51" height="12" font="5"><a href="e127.full.html#92">(S5.4.4-6</a></text>
<text top="702" left="293" width="61" height="15" font="5"><a href="e127.full.html#92">—S5.4.4-9)</a></text>
<text top="704" left="354" width="90" height="12" font="2">. Observational</text>
<text top="722" left="108" width="336" height="12" font="2">studies have shown that the presence of obstructive sleep</text>
<text top="740" left="108" width="336" height="12" font="2">apnea is associated with increased risk of incident hy-</text>
<text top="758" left="108" width="62" height="12" font="2">pertension</text>
<text top="758" left="175" width="117" height="12" font="5"><a href="e127.full.html#92">(S5.4.4-10,S5.4.4-11)</a></text>
<text top="758" left="292" width="152" height="12" font="2">. Obstructive sleep apnea</text>
<text top="776" left="108" width="336" height="12" font="2">is highly prevalent in adults with resistant hypertension</text>
<text top="794" left="108" width="4" height="12" font="2">(</text>
<text top="792" left="112" width="39" height="15" font="2">$80%)</text>
<text top="794" left="158" width="116" height="12" font="5"><a href="e127.full.html#92">(S5.4.4-12,S5.4.4-13)</a></text>
<text top="794" left="275" width="169" height="12" font="2">, and it has been hypothe-</text>
<text top="812" left="108" width="336" height="12" font="2">sized that treatment with CPAP may have more pro-</text>
<text top="829" left="108" width="336" height="12" font="2">nounced effects on BP reduction in resistant hypertension</text>
<text top="847" left="108" width="56" height="12" font="5"><a href="e127.full.html#92">(S5.4.4-6)</a></text>
<text top="847" left="164" width="3" height="12" font="2"><a href="e127.full.html#92">.</a></text>
<text top="869" left="108" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="867" left="247" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="896" left="108" width="44" height="12" font="2">1. CPAP</text>
<text top="896" left="165" width="9" height="12" font="2">is</text>
<text top="896" left="186" width="14" height="12" font="2">an</text>
<text top="896" left="212" width="11" height="12" font="2">ef</text>
<text top="894" left="223" width="220" height="15" font="2">ﬁcacious treatment for improving</text>
<text top="914" left="122" width="322" height="12" font="2">obstructive sleep apnea. However, studies of the effects</text>
<text top="931" left="122" width="322" height="12" font="2">of CPAP on BP have demonstrated only small effects on</text>
<text top="949" left="122" width="67" height="12" font="2">BP (e.g., 2</text>
<text top="948" left="189" width="254" height="15" font="2">– to 3–mm Hg reductions), with results</text>
<text top="967" left="122" width="322" height="12" font="2">dependent on patient compliance with CPAP use,</text>
<text top="985" left="122" width="322" height="12" font="2">severity of obstructive sleep apnea, and presence of</text>
<text top="1003" left="122" width="254" height="12" font="2">daytime sleepiness in study participants</text>
<text top="1003" left="385" width="50" height="12" font="5"><a href="e127.full.html#92">(S5.4.4-1</a></text>
<text top="1001" left="435" width="9" height="15" font="5"><a href="e127.full.html#92">—</a></text>
<text top="1021" left="122" width="51" height="12" font="5"><a href="e127.full.html#92">S5.4.4-5)</a></text>
<text top="1021" left="173" width="271" height="12" font="2"><a href="e127.full.html#92">. </a>Although many RCTs have been reported</text>
<text top="1039" left="122" width="322" height="12" font="2">that address the effects of CPAP on BP in obstructive</text>
<text top="1057" left="122" width="322" height="12" font="2">sleep apnea, most of the patients studied did not have</text>
<text top="1075" left="122" width="322" height="12" font="2">documented hypertension, and the studies were too</text>
<text top="1093" left="122" width="322" height="12" font="2">small and the follow-up period too short to allow for</text>
<text top="578" left="479" width="322" height="12" font="2">adequate evaluation. In addition, a well-designed RCT</text>
<text top="596" left="479" width="322" height="12" font="2">demonstrated that CPAP plus usual care, compared with</text>
<text top="614" left="479" width="322" height="12" font="2">usual care alone, did not prevent cardiovascular events</text>
<text top="632" left="479" width="152" height="12" font="2">in patients with moderate</text>
<text top="630" left="632" width="170" height="15" font="2">–severe obstructive sleep ap-</text>
<text top="650" left="479" width="145" height="12" font="2">nea and established CVD</text>
<text top="650" left="628" width="62" height="12" font="5"><a href="e127.full.html#92">(S5.4.4-14)</a></text>
<text top="650" left="690" width="3" height="12" font="2"><a href="e127.full.html#92">.</a></text>
<text top="684" left="465" width="304" height="16" font="14">6. NONPHARMACOLOGICAL INTERVENTIONS</text>
<text top="722" left="465" width="336" height="12" font="2">Correcting the dietary aberrations, physical inactivity, and</text>
<text top="740" left="465" width="336" height="12" font="2">excessive consumption of alcohol that cause high BP is a</text>
<text top="758" left="465" width="336" height="12" font="2">fundamentally important approach to prevention and</text>
<text top="775" left="465" width="336" height="12" font="2">management of high BP, either on their own or in combi-</text>
<text top="793" left="465" width="336" height="12" font="2">nation with pharmacological therapy. Prevention of hy-</text>
<text top="811" left="465" width="336" height="12" font="2">pertension and treatment of established hypertension are</text>
<text top="829" left="465" width="336" height="12" font="2">complementary approaches to reducing CVD risk in the</text>
<text top="847" left="465" width="336" height="12" font="2">population, but prevention of hypertension provides</text>
<text top="865" left="465" width="336" height="12" font="2">the optimal means of reducing risk and avoiding the</text>
<text top="883" left="465" width="228" height="12" font="2">harmful consequences of hypertension</text>
<text top="883" left="698" width="28" height="12" font="5"><a href="e127.full.html#92">(S6-1</a></text>
<text top="881" left="726" width="38" height="15" font="5"><a href="e127.full.html#92">—S6-3)</a></text>
<text top="883" left="765" width="36" height="12" font="2"><a href="e127.full.html#92">. </a>Non-</text>
<text top="901" left="465" width="336" height="12" font="2">pharmacological therapy alone is especially useful for</text>
<text top="919" left="465" width="336" height="12" font="2">prevention of hypertension, including in adults with</text>
<text top="937" left="465" width="336" height="12" font="2">elevated BP, and for management of high BP in adults with</text>
<text top="955" left="465" width="171" height="12" font="2">milder forms of hypertension</text>
<text top="955" left="641" width="63" height="12" font="5"><a href="e127.full.html#92">(S6-4,S6-5)</a></text>
<text top="955" left="704" width="3" height="12" font="2">.</text>
<text top="981" left="465" width="76" height="11" font="12">6.1. Strategies</text>
<text top="1003" left="465" width="336" height="12" font="2">Nonpharmacological interventions can be accomplished</text>
<text top="1021" left="465" width="336" height="12" font="2">by means of behavioral strategies aimed at lifestyle</text>
<text top="1039" left="465" width="336" height="12" font="2">change, prescription of dietary supplements, or imple-</text>
<text top="1057" left="465" width="336" height="12" font="2">mentation of kitchen-based interventions that directly</text>
<text top="1074" left="465" width="336" height="12" font="2">modify elements of the diet. At a societal level, policy</text>
<text top="1092" left="465" width="336" height="12" font="2">changes can enhance the availability of healthy foods and</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e154</text>
</page>
<page number="29" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="24" size="5" family="Times" color="#327eb1"/>
<text top="143" left="63" width="333" height="12" font="2">facilitate physical activity. The goal can be to modestly</text>
<text top="161" left="63" width="333" height="12" font="2">reduce BP in the general population or to undertake</text>
<text top="178" left="63" width="333" height="12" font="2">more intensive targeted lowering of BP in adults with</text>
<text top="196" left="63" width="333" height="12" font="2">hypertension or at high risk of developing hypertension</text>
<text top="214" left="63" width="41" height="12" font="5"><a href="e127.full.html#92">(S6.1-1)</a></text>
<text top="214" left="104" width="292" height="12" font="2">. The intent of the general population approach is</text>
<text top="232" left="63" width="333" height="12" font="2">to achieve a small downward shift in the general</text>
<text top="250" left="63" width="333" height="12" font="2">population distribution of BP, which would be expected</text>
<text top="268" left="63" width="229" height="12" font="2">to result in substantial health bene</text>
<text top="266" left="292" width="18" height="15" font="2">ﬁts</text>
<text top="268" left="319" width="42" height="12" font="5"><a href="e127.full.html#92">(S6.1-2)</a></text>
<text top="268" left="362" width="34" height="12" font="2"><a href="e127.full.html#92">. </a>The</text>
<text top="286" left="63" width="333" height="12" font="2">targeted approach focuses on BP reduction in adults at</text>
<text top="304" left="63" width="333" height="12" font="2">greatest risk of developing BP-related CVD, including</text>
<text top="322" left="63" width="333" height="12" font="2">individuals with hypertension, as well as those at</text>
<text top="340" left="63" width="333" height="12" font="2">increased risk of developing hypertension, especially</text>
<text top="358" left="63" width="333" height="12" font="2">blacks and adults who are overweight, consume excessive</text>
<text top="143" left="423" width="333" height="12" font="2">amounts of dietary sodium, have a high intake of alcohol,</text>
<text top="161" left="423" width="333" height="12" font="2">or are physically inactive. The targeted approach tends to</text>
<text top="178" left="423" width="333" height="12" font="2">be intensive, with a more ambitious goal for BP reduction.</text>
<text top="196" left="423" width="333" height="12" font="2">Both approaches are complementary and mutually</text>
<text top="214" left="423" width="333" height="12" font="2">reinforcing, and modeling studies suggest they are likely</text>
<text top="232" left="423" width="229" height="12" font="2">to provide similar public health bene</text>
<text top="230" left="652" width="12" height="15" font="2">ﬁt</text>
<text top="232" left="671" width="81" height="12" font="5"><a href="e127.full.html#92">(S6.1-3,S6.1-4)</a></text>
<text top="232" left="753" width="3" height="12" font="2"><a href="e127.full.html#92">.</a></text>
<text top="250" left="423" width="333" height="12" font="2">However, as the precision of risk prediction tools</text>
<text top="268" left="423" width="333" height="12" font="2">increases, targeted prevention strategies that focus on</text>
<text top="286" left="423" width="266" height="12" font="2">high-risk individuals seem to become more ef</text>
<text top="284" left="690" width="67" height="15" font="2">ﬁcient than</text>
<text top="304" left="423" width="161" height="12" font="2">population-based strategies</text>
<text top="304" left="588" width="42" height="12" font="5"><a href="e127.full.html#92">(S6.1-5)</a></text>
<text top="304" left="631" width="3" height="12" font="2">.</text>
<text top="358" left="423" width="207" height="11" font="12">6.2. Nonpharmacological Interventions</text>
<text top="398" left="63" width="318" height="11" font="19">Recommendations for Nonpharmacological Interventions</text>
<text top="412" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="412" left="412" width="169" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplements 9-21</a></text>
<text top="412" left="582" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="453" left="89" width="19" height="10" font="13">COR</text>
<text top="453" left="161" width="18" height="10" font="13">LOE</text>
<text top="453" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="490" left="97" width="3" height="9" font="4">I</text>
<text top="490" left="168" width="6" height="9" font="4">A</text>
<text top="478" left="234" width="568" height="11" font="12">1. Weight loss is recommended to reduce BP in adults with elevated BP or hypertension who are overweight</text>
<text top="493" left="246" width="45" height="11" font="12">or obese</text>
<text top="493" left="296" width="38" height="11" font="5"><a href="e127.full.html#92">(S6.2-1</a></text>
<text top="491" left="334" width="48" height="15" font="5"><a href="e127.full.html#92">—S6.2-4)</a></text>
<text top="493" left="382" width="3" height="11" font="12">.</text>
<text top="538" left="97" width="3" height="9" font="4">I</text>
<text top="538" left="168" width="6" height="9" font="4">A</text>
<text top="526" left="234" width="510" height="11" font="12">2. A heart-healthy diet, such as the DASH (Dietary Approaches to Stop Hypertension) diet, that</text>
<text top="541" left="248" width="535" height="11" font="12">facilitates achieving a desirable weight is recommended for adults with elevated BP or hypertension</text>
<text top="557" left="248" width="39" height="11" font="5"><a href="e127.full.html#92">(S6.2-5</a></text>
<text top="555" left="287" width="47" height="15" font="5"><a href="e127.full.html#92">—S6.2-7)</a></text>
<text top="557" left="335" width="3" height="11" font="12"><a href="e127.full.html#92">.</a></text>
<text top="603" left="97" width="3" height="9" font="4">I</text>
<text top="603" left="168" width="6" height="9" font="4">A</text>
<text top="591" left="234" width="435" height="11" font="12">3. Sodium reduction is recommended for adults with elevated BP or hypertension</text>
<text top="591" left="673" width="40" height="11" font="5"><a href="e127.full.html#92">(S6.2-8</a></text>
<text top="589" left="713" width="53" height="15" font="5"><a href="e127.full.html#92">—S6.2-12)</a></text>
<text top="591" left="766" width="3" height="11" font="12"><a href="e127.full.html#92">.</a></text>
<text top="652" left="97" width="3" height="9" font="4">I</text>
<text top="652" left="168" width="6" height="9" font="4">A</text>
<text top="640" left="234" width="305" height="11" font="12">4. Potassium supplementation, preferably in dietary modi</text>
<text top="638" left="539" width="262" height="15" font="12">ﬁcation, is recommended for adults with elevated</text>
<text top="656" left="249" width="553" height="11" font="12">BP or hypertension, unless contraindicated by the presence of CKD or use of drugs that reduce potassium</text>
<text top="672" left="249" width="49" height="11" font="12">excretion</text>
<text top="672" left="302" width="44" height="11" font="5"><a href="e127.full.html#92">(S6.2-13</a></text>
<text top="670" left="346" width="52" height="15" font="5"><a href="e127.full.html#92">—S6.2-17)</a></text>
<text top="672" left="398" width="3" height="11" font="12">.</text>
<text top="718" left="97" width="3" height="9" font="4">I</text>
<text top="718" left="168" width="6" height="9" font="4">A</text>
<text top="705" left="234" width="567" height="11" font="12">5. Increased physical activity with a structured exercise program is recommended for adults with elevated</text>
<text top="721" left="248" width="101" height="11" font="12">BP or hypertension</text>
<text top="721" left="353" width="166" height="11" font="5"><a href="e127.full.html#92">(S6.2-3,S6.2-4,S6.2-12,S6.2-18</a></text>
<text top="719" left="520" width="54" height="15" font="5"><a href="e127.full.html#92">—S6.2-22)</a></text>
<text top="721" left="574" width="3" height="11" font="12"><a href="e127.full.html#92">.</a></text>
<text top="767" left="97" width="3" height="9" font="4">I</text>
<text top="767" left="168" width="6" height="9" font="4">A</text>
<text top="755" left="234" width="543" height="11" font="12">6. Adult men and women with elevated BP or hypertension who currently consume alcohol should be</text>
<text top="771" left="249" width="288" height="11" font="12">advised to drink no more than 2 and 1 standard drink<a href="e127.full.html#29">s</a></text>
<text top="768" left="537" width="4" height="7" font="24"><a href="e127.full.html#29">*</a></text>
<text top="771" left="545" width="111" height="11" font="12">per day, respectively</text>
<text top="771" left="660" width="45" height="11" font="5"><a href="e127.full.html#93">(S6.2-23</a></text>
<text top="769" left="706" width="55" height="15" font="5"><a href="e127.full.html#93">—S6.2-28)</a></text>
<text top="771" left="761" width="3" height="11" font="12"><a href="e127.full.html#93">.</a></text>
<text top="811" left="63" width="87" height="8" font="4">*In the United States, 1</text>
<text top="810" left="152" width="649" height="11" font="4">“standard” drink contains roughly 14 g of pure alcohol, which is typically found in 12 oz of regular beer (usually about 5% alcohol), 5 oz of wine (usually about 12% alcohol),</text>
<text top="823" left="63" width="222" height="8" font="4">and 1.5 oz of distilled spirits (usually about 40% alcohol)</text>
<text top="823" left="288" width="37" height="8" font="8"><a href="e127.full.html#93">(S6.2-29)</a></text>
<text top="823" left="325" width="2" height="8" font="4"><a href="e127.full.html#93">.</a></text>
<text top="864" left="63" width="52" height="12" font="2">Synopsis</text>
<text top="882" left="78" width="321" height="12" font="2">Nonpharmacological interventions are effective in</text>
<text top="900" left="63" width="336" height="12" font="2">lowering BP, with the most important interventions being</text>
<text top="918" left="63" width="64" height="12" font="2">weight loss</text>
<text top="918" left="131" width="42" height="12" font="5"><a href="e127.full.html#92">(S6.2-1)</a></text>
<text top="918" left="173" width="226" height="12" font="2">, the DASH (Dietary Approaches to Stop</text>
<text top="935" left="63" width="83" height="12" font="2">Hypertension)</text>
<text top="935" left="162" width="22" height="12" font="2">diet</text>
<text top="935" left="201" width="39" height="12" font="5"><a href="e127.full.html#92">(S6.2-5</a></text>
<text top="934" left="241" width="95" height="15" font="5"><a href="e127.full.html#92">—S6.2-7,S6.2-30)</a></text>
<text top="935" left="336" width="3" height="12" font="2"><a href="e127.full.html#92">,</a></text>
<text top="935" left="356" width="43" height="12" font="2">sodium</text>
<text top="953" left="63" width="56" height="12" font="2">reduction</text>
<text top="953" left="127" width="40" height="12" font="5"><a href="e127.full.html#92">(S6.2-8</a></text>
<text top="952" left="167" width="54" height="15" font="5"><a href="e127.full.html#92">—S6.2-12)</a></text>
<text top="953" left="221" width="178" height="12" font="2">, potassium supplementation</text>
<text top="971" left="63" width="93" height="12" font="5"><a href="e127.full.html#92">(S6.2-13,S6.2-17)</a></text>
<text top="971" left="156" width="179" height="12" font="2">, increased physical activity</text>
<text top="971" left="344" width="45" height="12" font="5"><a href="e127.full.html#93">(S6.2-18</a></text>
<text top="970" left="390" width="9" height="15" font="5"><a href="e127.full.html#93">—</a></text>
<text top="989" left="63" width="90" height="12" font="5"><a href="e127.full.html#93">S6.2-22,S6.2-31)</a></text>
<text top="989" left="153" width="246" height="12" font="2"><a href="e127.full.html#93">, </a>and a reduction in alcohol consumption</text>
<text top="1007" left="63" width="96" height="12" font="5"><a href="e127.full.html#93">(S6.2-23,S6.2-24)</a></text>
<text top="1007" left="159" width="239" height="12" font="2">. Various other nonpharmacological in-</text>
<text top="1025" left="63" width="336" height="12" font="2">terventions have been reported to lower BP, but the extent</text>
<text top="1043" left="63" width="336" height="12" font="2">and/or quality of the supporting clinical trial experience is</text>
<text top="1061" left="63" width="336" height="12" font="2">less persuasive. Such interventions include consumption</text>
<text top="1079" left="63" width="73" height="12" font="2">of probiotics</text>
<text top="1079" left="139" width="142" height="12" font="5"><a href="e127.full.html#93">(S6.2-32,S6.2-33,S6.2-34)</a></text>
<text top="1079" left="281" width="118" height="12" font="2">; increased intake of</text>
<text top="864" left="420" width="42" height="12" font="2">protein</text>
<text top="864" left="466" width="46" height="12" font="5"><a href="e127.full.html#93">(S6.2-35</a></text>
<text top="862" left="512" width="55" height="15" font="5"><a href="e127.full.html#93">—S6.2-37)</a></text>
<text top="864" left="567" width="3" height="12" font="2"><a href="e127.full.html#93">,</a></text>
<text top="862" left="574" width="26" height="15" font="2">ﬁber</text>
<text top="864" left="604" width="97" height="12" font="5"><a href="e127.full.html#93">(S6.2-38,S6.2-39)</a></text>
<text top="864" left="702" width="3" height="12" font="2"><a href="e127.full.html#93">,</a></text>
<text top="862" left="709" width="48" height="15" font="2">ﬂaxseed</text>
<text top="882" left="420" width="52" height="12" font="5"><a href="e127.full.html#93">(S6.2-40)</a></text>
<text top="882" left="473" width="20" height="12" font="2"><a href="e127.full.html#93">, </a>or</text>
<text top="880" left="498" width="40" height="15" font="2">ﬁsh oil</text>
<text top="882" left="543" width="50" height="12" font="5"><a href="e127.full.html#93">(S6.2-41)</a></text>
<text top="882" left="593" width="164" height="12" font="2"><a href="e127.full.html#93">; </a>supplementation with cal-</text>
<text top="900" left="420" width="28" height="12" font="2">cium</text>
<text top="900" left="456" width="97" height="12" font="5"><a href="e127.full.html#93">(S6.2-42,S6.2-43)</a></text>
<text top="900" left="561" width="86" height="12" font="2">or magnesium</text>
<text top="900" left="654" width="98" height="12" font="5"><a href="e127.full.html#93">(S6.2-44,S6.2-45)</a></text>
<text top="900" left="753" width="4" height="12" font="2"><a href="e127.full.html#93">;</a></text>
<text top="918" left="420" width="336" height="12" font="2">and use of dietary patterns other than the DASH diet,</text>
<text top="935" left="420" width="336" height="12" font="2">including low-carbohydrate, vegetarian, and Mediterra-</text>
<text top="953" left="420" width="63" height="12" font="2">nean diets</text>
<text top="953" left="490" width="47" height="12" font="5"><a href="e127.full.html#93">(S6.2-46</a></text>
<text top="952" left="538" width="57" height="15" font="5"><a href="e127.full.html#93">—S6.2-49)</a></text>
<text top="953" left="595" width="162" height="12" font="2"><a href="e127.full.html#93">. </a>Stress reduction is intui-</text>
<text top="971" left="420" width="149" height="12" font="2">tively attractive but insuf</text>
<text top="970" left="570" width="92" height="15" font="2">ﬁciently proved</text>
<text top="971" left="666" width="49" height="12" font="5"><a href="e127.full.html#93">(S6.2-51)</a></text>
<text top="971" left="715" width="41" height="12" font="2"><a href="e127.full.html#93">, </a>as are</text>
<text top="989" left="420" width="336" height="12" font="2">several other interventions, including consumption of</text>
<text top="1007" left="420" width="32" height="12" font="2">garlic</text>
<text top="1007" left="455" width="50" height="12" font="5"><a href="e127.full.html#93">(S6.2-52)</a></text>
<text top="1007" left="505" width="91" height="12" font="2">, dark chocolate</text>
<text top="1007" left="599" width="96" height="12" font="5"><a href="e127.full.html#93">(S6.2-53,S6.2-54)</a></text>
<text top="1007" left="696" width="24" height="12" font="2">, tea</text>
<text top="1007" left="724" width="33" height="12" font="5"><a href="e127.full.html#93">(S6.2-</a></text>
<text top="1025" left="420" width="17" height="12" font="5"><a href="e127.full.html#93">55)</a></text>
<text top="1025" left="437" width="64" height="12" font="2">, or coffee</text>
<text top="1025" left="508" width="51" height="12" font="5"><a href="e127.full.html#93">(S6.2-56)</a></text>
<text top="1025" left="559" width="198" height="12" font="2"><a href="e127.full.html#93">. </a>Behavioral therapies, including</text>
<text top="1043" left="420" width="336" height="12" font="2">guided breathing, yoga, transcendental meditation, and</text>
<text top="1061" left="420" width="336" height="12" font="2">biofeedback, lack strong evidence for their long-term BP-</text>
<text top="1079" left="420" width="87" height="12" font="2">lowering effect</text>
<text top="1079" left="511" width="90" height="12" font="5"><a href="e127.full.html#93">(S6.2-51,S6.2-57</a></text>
<text top="1077" left="601" width="54" height="15" font="5"><a href="e127.full.html#93">—S6.2-61)</a></text>
<text top="1079" left="656" width="101" height="12" font="2"><a href="e127.full.html#93">. </a>The best proven</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="18" height="9" font="4">e155</text>
</page>
<page number="30" position="absolute" top="0" left="0" height="1160" width="864">
<text top="672" left="108" width="333" height="12" font="2">nonpharmacological measures to prevent and treat hy-</text>
<text top="690" left="108" width="175" height="12" font="2">pertension are summarized in</text>
<text top="690" left="286" width="46" height="11" font="5"><a href="e127.full.html#30">Table 15</a></text>
<text top="690" left="337" width="51" height="12" font="5"><a href="e127.full.html#93">(S6.2-62)</a></text>
<text top="690" left="388" width="3" height="12" font="2"><a href="e127.full.html#93">.</a></text>
<text top="708" left="123" width="318" height="12" font="2">The nonpharmacological interventions presented in</text>
<text top="726" left="108" width="48" height="11" font="5"><a href="e127.full.html#30">Table 15</a></text>
<text top="726" left="161" width="67" height="12" font="2">may be suf</text>
<text top="724" left="228" width="213" height="15" font="2">ﬁcient to prevent hypertension and</text>
<text top="744" left="108" width="333" height="12" font="2">meet goal BP in managing patients with stage 1 hyper-</text>
<text top="762" left="108" width="333" height="12" font="2">tension, and they are an integral part of the management</text>
<text top="780" left="108" width="333" height="12" font="2">of persons with stage 2 hypertension. To a lesser extent,</text>
<text top="798" left="108" width="148" height="12" font="2">the Mediterranean diet</text>
<text top="798" left="266" width="98" height="12" font="5"><a href="e127.full.html#93">(S6.2-49,S6.2-63)</a></text>
<text top="798" left="375" width="66" height="12" font="2">(which in-</text>
<text top="816" left="108" width="333" height="12" font="2">corporates the basics of healthy eating but emphasizes</text>
<text top="833" left="108" width="333" height="12" font="2">consumption of legumes and monounsaturated fat,</text>
<text top="851" left="108" width="333" height="12" font="2">avoidance of red meats, and moderate intake of wine) has</text>
<text top="869" left="108" width="333" height="12" font="2">been effective in reducing BP, as well as improving lipid</text>
<text top="887" left="108" width="19" height="12" font="2">pro</text>
<text top="885" left="127" width="22" height="15" font="2">ﬁle.</text>
<text top="914" left="108" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="912" left="247" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="941" left="110" width="331" height="12" font="2">1. Weight loss is a core recommendation and should be</text>
<text top="959" left="124" width="317" height="12" font="2">achieved through a combination of reduced calorie</text>
<text top="977" left="124" width="234" height="12" font="2">intake and increased physical activity</text>
<text top="977" left="365" width="42" height="12" font="5"><a href="e127.full.html#92">(S6.2-1)</a></text>
<text top="977" left="408" width="33" height="12" font="2">. The</text>
<text top="995" left="124" width="317" height="12" font="2">BP-lowering effect of weight loss in patients with</text>
<text top="1013" left="124" width="317" height="12" font="2">elevated BP is consistent with the corresponding effect</text>
<text top="1031" left="124" width="317" height="12" font="2">in patients with established hypertension, with an</text>
<text top="1049" left="124" width="82" height="12" font="2">apparent dose</text>
<text top="1047" left="206" width="235" height="15" font="2">–response relationship of about 1 mm Hg</text>
<text top="1067" left="124" width="19" height="12" font="2">per</text>
<text top="1067" left="155" width="51" height="12" font="2">kilogram</text>
<text top="1067" left="218" width="11" height="12" font="2">of</text>
<text top="1067" left="241" width="39" height="12" font="2">weight</text>
<text top="1067" left="293" width="26" height="12" font="2">loss.</text>
<text top="1067" left="331" width="76" height="12" font="2">Achievement</text>
<text top="1067" left="420" width="21" height="12" font="2">and</text>
<text top="672" left="484" width="317" height="12" font="2">maintenance of weight loss through behavior change</text>
<text top="690" left="484" width="92" height="12" font="2">are challenging</text>
<text top="690" left="584" width="47" height="12" font="5"><a href="e127.full.html#94">(S6.2-64</a></text>
<text top="688" left="632" width="56" height="15" font="5"><a href="e127.full.html#94">—S6.2-66)</a></text>
<text top="690" left="696" width="105" height="12" font="2">but feasible over</text>
<text top="708" left="484" width="190" height="12" font="2">prolonged periods of follow-up</text>
<text top="708" left="681" width="52" height="12" font="5"><a href="e127.full.html#94">(S6.2-64)</a></text>
<text top="708" left="733" width="68" height="12" font="2">. For those</text>
<text top="726" left="484" width="317" height="12" font="2">who do not meet their weight loss goals with non-</text>
<text top="744" left="484" width="317" height="12" font="2">pharmacological interventions, pharmacotherapy or</text>
<text top="762" left="484" width="317" height="12" font="2">minimally invasive and bariatric surgical procedures</text>
<text top="780" left="484" width="108" height="12" font="2">can be considered</text>
<text top="780" left="598" width="98" height="12" font="5"><a href="e127.full.html#94">(S6.2-67,S6.2-68)</a></text>
<text top="780" left="696" width="105" height="12" font="2"><a href="e127.full.html#94">. </a>Surgical proced-</text>
<text top="798" left="484" width="317" height="12" font="2">ures tend to be more effective but are usually reserved</text>
<text top="816" left="484" width="317" height="12" font="2">for those with more severe and intractable obesity</text>
<text top="833" left="484" width="247" height="12" font="2">because of the frequency of complications</text>
<text top="833" left="735" width="51" height="12" font="5"><a href="e127.full.html#94">(S6.2-69)</a></text>
<text top="833" left="787" width="3" height="12" font="2"><a href="e127.full.html#94">.</a></text>
<text top="851" left="469" width="332" height="12" font="2">2. The DASH eating plan is the diet best demonstrated to</text>
<text top="869" left="484" width="317" height="12" font="2">be effective for lowering BP. Because the DASH diet is</text>
<text top="887" left="484" width="317" height="12" font="2">high in fruits, vegetables, and low-fat dairy products, it</text>
<text top="905" left="484" width="317" height="12" font="2">provides a means to enhance intake of potassium,</text>
<text top="923" left="484" width="153" height="12" font="2">calcium, magnesium, and</text>
<text top="921" left="644" width="158" height="15" font="2">ﬁber. In hypertensive and</text>
<text top="941" left="484" width="317" height="12" font="2">nonhypertensive adults, the DASH diet has produced</text>
<text top="959" left="484" width="317" height="12" font="2">overall reductions in SBP of approximately 11 mm Hg</text>
<text top="977" left="484" width="160" height="12" font="2">and 3 mm Hg, respectively</text>
<text top="977" left="649" width="43" height="12" font="5"><a href="e127.full.html#92">(S6.2-7)</a></text>
<text top="977" left="693" width="108" height="12" font="2"><a href="e127.full.html#92">, </a>and the diet was</text>
<text top="995" left="484" width="177" height="12" font="2">especially effective in blacks</text>
<text top="995" left="669" width="51" height="12" font="5"><a href="e127.full.html#94">(S6.2-70)</a></text>
<text top="995" left="720" width="81" height="12" font="2">. When com-</text>
<text top="1013" left="484" width="137" height="12" font="2">bined with weight loss</text>
<text top="1013" left="626" width="44" height="12" font="5"><a href="e127.full.html#92">(S6.2-6)</a></text>
<text top="1013" left="676" width="125" height="12" font="2">or a reduction in so-</text>
<text top="1031" left="484" width="76" height="12" font="2">dium intake</text>
<text top="1031" left="571" width="90" height="12" font="5"><a href="e127.full.html#92">(S6.2-5,S6.2-30)</a></text>
<text top="1031" left="661" width="140" height="12" font="2">, the effect size was</text>
<text top="1049" left="484" width="317" height="12" font="2">substantially increased. Most of the clinical trial</text>
<text top="1067" left="484" width="317" height="12" font="2">experience comes from short-term feeding studies</text>
<text top="153" left="113" width="52" height="10" font="15">T A B L E 1 5</text>
<text top="154" left="179" width="503" height="10" font="16">Best Proven Nonpharmacological Interventions for Prevention and Treatment of Hypertension</text>
<text top="154" left="683" width="5" height="10" font="7"><a href="e127.full.html#30">*</a></text>
<text top="184" left="226" width="94" height="9" font="13">Nonpharmacological</text>
<text top="196" left="245" width="58" height="9" font="13">Intervention</text>
<text top="196" left="437" width="22" height="9" font="13">Dose</text>
<text top="178" left="620" width="131" height="9" font="13">Approximate Impact on SBP</text>
<text top="196" left="573" width="62" height="9" font="13">Hypertension</text>
<text top="196" left="648" width="65" height="9" font="13">Normotension</text>
<text top="196" left="738" width="46" height="9" font="13">Reference</text>
<text top="213" left="108" width="49" height="9" font="13">Weight loss</text>
<text top="213" left="220" width="69" height="9" font="13">Weight/body fat</text>
<text top="213" left="331" width="233" height="9" font="13">Best goal is ideal body weight, but aim for at least a 1-kg</text>
<text top="225" left="346" width="210" height="9" font="13">reduction in body weight for most adults who are</text>
<text top="236" left="346" width="210" height="9" font="13">overweight. Expect about 1 mm Hg for every 1-kg</text>
<text top="248" left="346" width="108" height="9" font="13">reduction in body weight.</text>
<text top="211" left="581" width="46" height="12" font="13">5 mm Hg</text>
<text top="211" left="653" width="54" height="12" font="13">2/3 mm Hg</text>
<text top="213" left="744" width="33" height="9" font="17"><a href="e127.full.html#92">(S6.2-1)</a></text>
<text top="268" left="108" width="51" height="9" font="13">Healthy diet</text>
<text top="268" left="220" width="89" height="9" font="13">DASH dietary pattern</text>
<text top="268" left="331" width="231" height="9" font="13">Consume a diet rich in fruits, vegetables, whole grains,</text>
<text top="280" left="346" width="218" height="9" font="13">and low-fat dairy products, with reduced content of</text>
<text top="292" left="346" width="98" height="9" font="13">saturated and total fat.</text>
<text top="266" left="580" width="49" height="12" font="13">11 mm Hg</text>
<text top="266" left="657" width="46" height="12" font="13">3 mm Hg</text>
<text top="268" left="729" width="65" height="9" font="17"><a href="e127.full.html#92">(S6.2-6,S6.2-7)</a></text>
<text top="311" left="108" width="76" height="9" font="13">Reduced intake of</text>
<text top="323" left="123" width="62" height="9" font="13">dietary sodium</text>
<text top="311" left="220" width="63" height="9" font="13">Dietary sodium</text>
<text top="311" left="331" width="63" height="9" font="13">Optimal goal is</text>
<text top="309" left="398" width="149" height="12" font="13">&lt;1500 mg/d, but aim for at least a</text>
<text top="323" left="346" width="157" height="9" font="13">1000-mg/d reduction in most adults.</text>
<text top="309" left="577" width="55" height="12" font="13">5/6 mm Hg</text>
<text top="309" left="653" width="54" height="12" font="13">2/3 mm Hg</text>
<text top="311" left="726" width="70" height="9" font="17"><a href="e127.full.html#92">(S6.2-9,S6.2-10)</a></text>
<text top="342" left="108" width="80" height="9" font="13">Enhanced intake of</text>
<text top="354" left="123" width="74" height="9" font="13">dietary potassium</text>
<text top="342" left="220" width="75" height="9" font="13">Dietary potassium</text>
<text top="342" left="331" width="57" height="9" font="13">Aim for 3500</text>
<text top="340" left="388" width="172" height="12" font="13">–5000 mg/d, preferably by consumption</text>
<text top="354" left="346" width="112" height="9" font="13">of a diet rich in potassium.</text>
<text top="340" left="577" width="55" height="12" font="13">4/5 mm Hg</text>
<text top="340" left="657" width="46" height="12" font="13">2 mm Hg</text>
<text top="342" left="742" width="38" height="9" font="17"><a href="e127.full.html#92">(S6.2-13)</a></text>
<text top="373" left="108" width="67" height="9" font="13">Physical activity</text>
<text top="373" left="220" width="31" height="9" font="13">Aerobic</text>
<text top="373" left="336" width="6" height="10" font="9">n</text>
<text top="374" left="350" width="12" height="9" font="13">90</text>
<text top="372" left="363" width="56" height="12" font="13">–150 min/wk</text>
<text top="386" left="336" width="6" height="10" font="9">n</text>
<text top="386" left="350" width="20" height="9" font="13">65%</text>
<text top="385" left="370" width="106" height="12" font="13">–75% heart rate reserve</text>
<text top="371" left="577" width="55" height="12" font="13">5/8 mm Hg</text>
<text top="371" left="653" width="55" height="12" font="13">2/4 mm Hg</text>
<text top="373" left="724" width="74" height="9" font="17"><a href="e127.full.html#93">(S6.2-18,S6.2-22)</a></text>
<text top="402" left="220" width="80" height="9" font="13">Dynamic resistance</text>
<text top="404" left="336" width="6" height="10" font="9">n</text>
<text top="405" left="350" width="12" height="9" font="13">90</text>
<text top="403" left="363" width="56" height="12" font="13">–150 min/wk</text>
<text top="417" left="336" width="6" height="10" font="9">n</text>
<text top="418" left="350" width="21" height="9" font="13">50%</text>
<text top="416" left="371" width="96" height="12" font="13">–80% 1 rep maximum</text>
<text top="429" left="336" width="6" height="10" font="9">n</text>
<text top="430" left="350" width="205" height="9" font="13">6 exercises, 3 sets/exercise, 10 repetitions/set</text>
<text top="400" left="581" width="47" height="12" font="13">4 mm Hg</text>
<text top="400" left="657" width="46" height="12" font="13">2 mm Hg</text>
<text top="402" left="742" width="39" height="9" font="17"><a href="e127.full.html#93">(S6.2-18)</a></text>
<text top="446" left="220" width="83" height="9" font="13">Isometric resistance</text>
<text top="448" left="336" width="6" height="10" font="9">n</text>
<text top="449" left="350" width="6" height="9" font="13">4</text>
<text top="447" left="358" width="198" height="12" font="13"> 2 min (hand grip), 1 min rest between exer-</text>
<text top="461" left="349" width="46" height="9" font="13">cises, 30%</text>
<text top="459" left="396" width="168" height="12" font="13">–40% maximum voluntary contraction,</text>
<text top="473" left="350" width="60" height="9" font="13">3 sessions/wk</text>
<text top="483" left="336" width="6" height="10" font="9">n</text>
<text top="484" left="350" width="6" height="9" font="13">8</text>
<text top="483" left="356" width="30" height="12" font="13">–10 wk</text>
<text top="444" left="581" width="46" height="12" font="13">5 mm Hg</text>
<text top="444" left="657" width="47" height="12" font="13">4 mm Hg</text>
<text top="446" left="725" width="73" height="9" font="17"><a href="e127.full.html#93">(S6.2-19,S6.2-31)</a></text>
<text top="500" left="108" width="92" height="9" font="13">Moderation in alcohol</text>
<text top="512" left="123" width="25" height="9" font="13">intake</text>
<text top="500" left="220" width="88" height="9" font="13">Alcohol consumption</text>
<text top="500" left="331" width="200" height="9" font="13">In individuals who drink alcohol, reduce <a href="e127.full.html#30">alcohol</a></text>
<text top="498" left="531" width="5" height="12" font="17"><a href="e127.full.html#30">†</a></text>
<text top="500" left="539" width="12" height="9" font="13">to:</text>
<text top="514" left="336" width="6" height="10" font="9">n</text>
<text top="515" left="350" width="22" height="9" font="13">Men:</text>
<text top="513" left="375" width="67" height="12" font="13">#2 drinks daily</text>
<text top="527" left="336" width="6" height="10" font="9">n</text>
<text top="527" left="350" width="36" height="9" font="13">Women:</text>
<text top="526" left="389" width="61" height="12" font="13">#1 drink daily</text>
<text top="498" left="581" width="47" height="12" font="13">4 mm Hg</text>
<text top="498" left="657" width="46" height="12" font="13">3 mm Hg</text>
<text top="500" left="721" width="36" height="9" font="17"><a href="e127.full.html#93">(S6.2-22</a></text>
<text top="498" left="757" width="43" height="12" font="17"><a href="e127.full.html#93">—S6.2-24)</a></text>
<text top="549" left="108" width="264" height="8" font="4">Resources: Your Guide to Lowering Your Blood Pressure With DASH</text>
<text top="547" left="371" width="162" height="11" font="4">—How Do I Make the DASH? Available at:</text>
<text top="549" left="536" width="263" height="8" font="8"><a href="https://www.nhlbi.nih.gov/health/resources/heart/hbp-dash-how-to">https://www.nhlbi.nih.gov/health/resources/heart/hbp-dash-how-to</a></text>
<text top="549" left="799" width="2" height="8" font="4"><a href="https://www.nhlbi.nih.gov/health/resources/heart/hbp-dash-how-to">.</a></text>
<text top="561" left="108" width="114" height="8" font="4">Accessed September 15, 2017.</text>
<text top="561" left="224" width="36" height="8" font="8"><a href="e127.full.html#94">(S6.2-72)</a></text>
<text top="561" left="262" width="134" height="8" font="4">Top 10 Dash Diet Tips. Available at:</text>
<text top="561" left="398" width="144" height="8" font="8"><a href="http://dashdiet.org/dash_diet_tips.asp">http://dashdiet.org/dash_diet_tips.asp</a></text>
<text top="561" left="542" width="119" height="8" font="4">. Accessed September 15, 2017.</text>
<text top="561" left="663" width="36" height="8" font="8"><a href="e127.full.html#94">(S6.2-73)</a></text>
<text top="561" left="701" width="101" height="8" font="4">*Type, dose, and expected</text>
<text top="573" left="108" width="244" height="8" font="4">impact on BP in adults with a normal BP and with hypertension.</text>
<text top="571" left="355" width="447" height="11" font="4">†In the United States, one “standard” drink contains roughly 14 g of pure alcohol, which is typically found in 12 oz of</text>
<text top="585" left="108" width="545" height="8" font="4">regular beer (usually about 5% alcohol), 5 oz of wine (usually about 12% alcohol), and 1.5 oz of distilled spirits (usually about 40% alcohol)</text>
<text top="585" left="656" width="37" height="8" font="8"><a href="e127.full.html#93">(S6.2-29)</a></text>
<text top="585" left="692" width="2" height="8" font="4">.</text>
<text top="599" left="116" width="355" height="8" font="4">DASH indicates Dietary Approaches to Stop Hypertension; and SBP, systolic blood pressure.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e156</text>
</page>
<page number="31" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="79" width="43" height="12" font="5"><a href="e127.full.html#92">(S6.2-7)</a></text>
<text top="143" left="123" width="274" height="12" font="2"><a href="e127.full.html#92">, </a>but lifestyle change with the DASH diet has</text>
<text top="161" left="79" width="317" height="12" font="2">been successful in at least 2 trials that used a behav-</text>
<text top="178" left="79" width="194" height="12" font="2">ioral intervention over a 4-month</text>
<text top="178" left="277" width="51" height="12" font="5"><a href="e127.full.html#93">(S6.2-30)</a></text>
<text top="178" left="331" width="65" height="12" font="2">or 6-month</text>
<text top="196" left="79" width="44" height="12" font="5"><a href="e127.full.html#92">(S6.2-6)</a></text>
<text top="196" left="128" width="268" height="12" font="2">period of follow-up. Websites and books pro-</text>
<text top="214" left="79" width="281" height="12" font="2">vide advice on implementation of the DASH diet</text>
<text top="214" left="363" width="33" height="12" font="5"><a href="e127.full.html#92">(S6.2-</a></text>
<text top="232" left="79" width="56" height="12" font="5"><a href="e127.full.html#92">13,S6.2-71</a></text>
<text top="230" left="135" width="56" height="15" font="5"><a href="e127.full.html#92">—S6.2-74)</a></text>
<text top="232" left="191" width="205" height="12" font="2"><a href="e127.full.html#92">. </a>Counseling by a knowledgeable</text>
<text top="250" left="79" width="317" height="12" font="2">nutritionist can be helpful. Several other diets,</text>
<text top="268" left="79" width="317" height="12" font="2">including diets that are low in calories from carbohy-</text>
<text top="286" left="79" width="36" height="12" font="2">drates</text>
<text top="286" left="123" width="52" height="12" font="5"><a href="e127.full.html#93">(S6.2-46)</a></text>
<text top="286" left="175" width="120" height="12" font="2"><a href="e127.full.html#93">, </a>high-protein diets</text>
<text top="286" left="303" width="50" height="12" font="5"><a href="e127.full.html#94">(S6.2-75)</a></text>
<text top="286" left="353" width="43" height="12" font="2">, vege-</text>
<text top="304" left="79" width="70" height="12" font="2">tarian diets</text>
<text top="304" left="156" width="52" height="12" font="5"><a href="e127.full.html#93">(S6.2-48)</a></text>
<text top="304" left="208" width="188" height="12" font="2">, and a Mediterranean dietary</text>
<text top="322" left="79" width="42" height="12" font="2">pattern</text>
<text top="322" left="127" width="98" height="12" font="5"><a href="e127.full.html#93">(S6.2-49,S6.2-63)</a></text>
<text top="322" left="225" width="171" height="12" font="2">, have been shown to lower</text>
<text top="340" left="79" width="19" height="12" font="2">BP.</text>
<text top="358" left="64" width="332" height="12" font="2">3. Sodium reduction interventions prevent hypertension</text>
<text top="376" left="79" width="317" height="12" font="2">and lower BP in adults with hypertension, especially in</text>
<text top="394" left="79" width="317" height="12" font="2">those with higher levels of BP, blacks, older persons,</text>
<text top="412" left="79" width="317" height="12" font="2">and others who are particularly susceptible to the ef-</text>
<text top="430" left="79" width="155" height="12" font="2">fects of sodium on BP</text>
<text top="430" left="244" width="40" height="12" font="5"><a href="e127.full.html#92">(S6.2-8</a></text>
<text top="428" left="285" width="52" height="15" font="5"><a href="e127.full.html#92">—S6.2-11)</a></text>
<text top="430" left="338" width="58" height="12" font="2"><a href="e127.full.html#92">. </a>Sodium</text>
<text top="447" left="79" width="273" height="12" font="2">reduction interventions may prevent CVD</text>
<text top="447" left="363" width="33" height="12" font="5"><a href="e127.full.html#94">(S6.2-</a></text>
<text top="465" left="79" width="63" height="12" font="5"><a href="e127.full.html#94">76,S6.2-77)</a></text>
<text top="465" left="142" width="3" height="12" font="2"><a href="e127.full.html#94">.</a></text>
<text top="465" left="164" width="50" height="12" font="2">Lifestyle</text>
<text top="465" left="232" width="41" height="12" font="2">change</text>
<text top="465" left="292" width="70" height="12" font="2">(behavioral)</text>
<text top="465" left="380" width="16" height="12" font="2">in-</text>
<text top="483" left="79" width="317" height="12" font="2">terventions usually reduce sodium intake by about 25%</text>
<text top="501" left="79" width="317" height="12" font="2">(approximately 1,000 mg per day) and result in an</text>
<text top="519" left="79" width="118" height="12" font="2">average of about a 2</text>
<text top="517" left="198" width="198" height="15" font="2">–mm Hg to 3–mm Hg reduction in</text>
<text top="537" left="79" width="317" height="12" font="2">SBP in nonhypertensive individuals, though the</text>
<text top="555" left="79" width="317" height="12" font="2">reduction can be more than double this in more sus-</text>
<text top="573" left="79" width="317" height="12" font="2">ceptible individuals, those with hypertension, and</text>
<text top="591" left="79" width="243" height="12" font="2">those concurrently on the DASH diet</text>
<text top="591" left="331" width="43" height="12" font="5"><a href="e127.full.html#92">(S6.2-5)</a></text>
<text top="591" left="384" width="12" height="12" font="2">or</text>
<text top="609" left="79" width="211" height="12" font="2">receiving a weight loss intervention</text>
<text top="609" left="295" width="49" height="12" font="5"><a href="e127.full.html#92">(S6.2-12)</a></text>
<text top="609" left="344" width="52" height="12" font="2">. Sodium</text>
<text top="627" left="79" width="317" height="12" font="2">reduction in adults with hypertension who are already</text>
<text top="645" left="79" width="317" height="12" font="2">being treated with BP-lowering medications further</text>
<text top="663" left="79" width="317" height="12" font="2">reduces SBP by about 3 mm Hg and can facilitate</text>
<text top="681" left="79" width="317" height="12" font="2">discontinuation of medication, although this requires</text>
<text top="698" left="79" width="317" height="12" font="2">maintenance of the lifestyle change and warrants</text>
<text top="716" left="79" width="113" height="12" font="2">careful monitoring</text>
<text top="716" left="201" width="49" height="12" font="5"><a href="e127.full.html#92">(S6.2-12)</a></text>
<text top="716" left="250" width="146" height="12" font="2">. When combined with</text>
<text top="734" left="79" width="317" height="12" font="2">weight loss, the reduction in BP is almost doubled. A</text>
<text top="752" left="79" width="317" height="12" font="2">reduction in sodium intake may also lower SBP</text>
<text top="770" left="79" width="27" height="12" font="2">signi</text>
<text top="768" left="107" width="289" height="15" font="2">ﬁcantly in individuals with resistant hypertension</text>
<text top="788" left="79" width="317" height="12" font="2">who are taking multiple antihypertensive medications</text>
<text top="806" left="79" width="51" height="12" font="5"><a href="e127.full.html#94">(S6.2-78)</a></text>
<text top="806" left="136" width="23" height="12" font="2">(see</text>
<text top="806" left="166" width="68" height="12" font="5"><a href="e127.full.html#67">Section 11.1</a></text>
<text top="806" left="235" width="161" height="12" font="2"><a href="e127.full.html#67">). </a>Reduced dietary sodium</text>
<text top="824" left="79" width="317" height="12" font="2">has been reported to augment the BP-lowering effects</text>
<text top="842" left="79" width="137" height="12" font="2">of RAS blocker therapy</text>
<text top="842" left="221" width="50" height="12" font="5"><a href="e127.full.html#94">(S6.2-79)</a></text>
<text top="842" left="272" width="124" height="12" font="2">. Maintenance of the</text>
<text top="860" left="79" width="317" height="12" font="2">lifestyle changes necessary to reduce sodium intake is</text>
<text top="878" left="79" width="67" height="12" font="2">challenging</text>
<text top="878" left="152" width="39" height="12" font="5"><a href="e127.full.html#92">(S6.2-2</a></text>
<text top="876" left="191" width="94" height="15" font="5"><a href="e127.full.html#92">—S6.2-4,S6.2-12)</a></text>
<text top="878" left="285" width="111" height="12" font="2">, but even a small</text>
<text top="896" left="79" width="317" height="12" font="2">decrement in sodium consumption is likely to be safe</text>
<text top="914" left="79" width="215" height="12" font="5"><a href="e127.full.html#92">(S6.2-2,S6.2-4,S6.2-9,S6.2-12,S6.2-80)</a></text>
<text top="914" left="306" width="21" height="12" font="2">and</text>
<text top="914" left="340" width="28" height="12" font="2">bene</text>
<text top="912" left="368" width="28" height="15" font="2">ﬁcial</text>
<text top="932" left="79" width="90" height="12" font="5"><a href="e127.full.html#92">(S6.2-8,S6.2-81)</a></text>
<text top="932" left="169" width="227" height="12" font="2"><a href="e127.full.html#92">, </a>especially in those whose BP is salt</text>
<text top="950" left="79" width="51" height="12" font="2">sensitive</text>
<text top="950" left="135" width="51" height="12" font="5"><a href="e127.full.html#94">(S6.2-82)</a></text>
<text top="950" left="186" width="210" height="12" font="2">. In the United States, most dietary</text>
<text top="967" left="79" width="317" height="12" font="2">sodium comes from additions during food processing</text>
<text top="985" left="79" width="317" height="12" font="2">or during commercial food preparation at sit-down and</text>
<text top="1003" left="79" width="121" height="12" font="2">fast-food restaurants</text>
<text top="1003" left="203" width="98" height="12" font="5"><a href="e127.full.html#94">(S6.2-83,S6.2-84)</a></text>
<text top="1003" left="302" width="80" height="12" font="2"><a href="e127.full.html#94">. </a>Person-speci</text>
<text top="1002" left="383" width="14" height="15" font="2">ﬁc</text>
<text top="1021" left="79" width="317" height="12" font="2">and policy approaches can be used to reduce dietary</text>
<text top="1039" left="79" width="84" height="12" font="2">sodium intake</text>
<text top="1039" left="168" width="98" height="12" font="5"><a href="e127.full.html#94">(S6.2-85,S6.2-86)</a></text>
<text top="1039" left="267" width="129" height="12" font="2"><a href="e127.full.html#94">. </a>Individuals can take</text>
<text top="1057" left="79" width="317" height="12" font="2">action to reduce their dietary intake of sodium by</text>
<text top="1075" left="79" width="317" height="12" font="2">choice of fresh foods, use of food labels to choose foods</text>
<text top="1093" left="79" width="317" height="12" font="2">that are lower in sodium content, choice of foods with</text>
<text top="143" left="439" width="6" height="12" font="2">a</text>
<text top="141" left="452" width="304" height="15" font="2">“no added sodium” label, judicious use of condi-</text>
<text top="161" left="439" width="317" height="12" font="2">ments and sodium-infused foods, use of spices and</text>
<text top="178" left="439" width="69" height="12" font="2">low-sodium</text>
<text top="177" left="514" width="242" height="15" font="2">ﬂavorings, careful ordering when eating</text>
<text top="196" left="439" width="317" height="12" font="2">out, control of food portion size, and avoiding or</text>
<text top="214" left="439" width="317" height="12" font="2">minimizing use of salt at the table. Dietary counseling</text>
<text top="232" left="439" width="292" height="12" font="2">by a nutritionist with expertise in behavior modi</text>
<text top="230" left="732" width="25" height="15" font="2">ﬁca-</text>
<text top="250" left="439" width="317" height="12" font="2">tion can be helpful. A reduction in the amount of so-</text>
<text top="268" left="439" width="317" height="12" font="2">dium added during food processing, as well as fast food</text>
<text top="286" left="439" width="317" height="12" font="2">and restaurant food preparation, has the potential to</text>
<text top="304" left="439" width="317" height="12" font="2">substantially reduce sodium intake without the need</text>
<text top="322" left="439" width="229" height="12" font="2">for a conscious change in lifestyle</text>
<text top="322" left="678" width="78" height="12" font="5"><a href="e127.full.html#94">(S6.2-81,S6.2-</a></text>
<text top="340" left="439" width="64" height="12" font="5"><a href="e127.full.html#94">85,S6.2-87)</a></text>
<text top="340" left="504" width="3" height="12" font="2"><a href="e127.full.html#94">.</a></text>
<text top="358" left="423" width="333" height="12" font="2">4. Dietary potassium is inversely related to BP and hy-</text>
<text top="376" left="439" width="170" height="12" font="2">pertension in migrant studies</text>
<text top="376" left="612" width="52" height="12" font="5"><a href="e127.full.html#94">(S6.2-88)</a></text>
<text top="376" left="664" width="92" height="12" font="2"><a href="e127.full.html#94">, </a>cross-sectional</text>
<text top="394" left="439" width="41" height="12" font="2">reports</text>
<text top="394" left="491" width="47" height="12" font="5"><a href="e127.full.html#94">(S6.2-89</a></text>
<text top="392" left="539" width="54" height="15" font="5"><a href="e127.full.html#94">—S6.2-91)</a></text>
<text top="394" left="594" width="163" height="12" font="2"><a href="e127.full.html#94">, </a>and prospective cohort</text>
<text top="412" left="439" width="41" height="12" font="2">studies</text>
<text top="412" left="487" width="51" height="12" font="5"><a href="e127.full.html#94">(S6.2-92)</a></text>
<text top="412" left="538" width="179" height="12" font="2">. Likewise, dietary potassium</text>
<text top="412" left="724" width="33" height="12" font="5"><a href="e127.full.html#94">(S6.2-</a></text>
<text top="430" left="439" width="13" height="12" font="5"><a href="e127.full.html#94">93</a></text>
<text top="428" left="453" width="56" height="15" font="5"><a href="e127.full.html#94">—S6.2-96)</a></text>
<text top="430" left="513" width="243" height="12" font="2">and a high intake of fruits and vegetables</text>
<text top="447" left="439" width="279" height="12" font="2">are associated with a lower incidence of stroke</text>
<text top="447" left="724" width="33" height="12" font="5"><a href="e127.full.html#94">(S6.2-</a></text>
<text top="465" left="439" width="17" height="12" font="5"><a href="e127.full.html#94">97)</a></text>
<text top="465" left="457" width="299" height="12" font="2"><a href="e127.full.html#94">. </a>Potassium interventions have been effective in</text>
<text top="483" left="439" width="77" height="12" font="2">lowering BP</text>
<text top="483" left="526" width="184" height="12" font="5"><a href="e127.full.html#92">(S6.2-13,S6.2-14,S6.2-16,S6.2-81)</a></text>
<text top="483" left="711" width="45" height="12" font="2">, espe-</text>
<text top="501" left="439" width="317" height="12" font="2">cially in adult patients consuming an excess of sodium</text>
<text top="519" left="439" width="142" height="12" font="5"><a href="e127.full.html#92">(S6.2-13,S6.2-74,S6.2-98)</a></text>
<text top="519" left="588" width="81" height="12" font="2">and in blacks</text>
<text top="519" left="676" width="49" height="12" font="5"><a href="e127.full.html#92">(S6.2-13)</a></text>
<text top="519" left="725" width="32" height="12" font="2"><a href="e127.full.html#92">. </a>The</text>
<text top="537" left="439" width="317" height="12" font="2">typical BP-lowering effect of a 60-mmol (1380-mg)</text>
<text top="555" left="439" width="317" height="12" font="2">administration of potassium chloride has been about</text>
<text top="573" left="439" width="317" height="12" font="2">2 mm Hg and 4 to 5 mm Hg in adults with normo-</text>
<text top="591" left="439" width="317" height="12" font="2">tension and hypertension, respectively, although the</text>
<text top="609" left="439" width="317" height="12" font="2">response is up to twice as much in persons consuming</text>
<text top="627" left="439" width="317" height="12" font="2">a high-sodium diet. A reduction in the sodium/potas-</text>
<text top="645" left="439" width="317" height="12" font="2">sium index may be more important than the corre-</text>
<text top="663" left="439" width="258" height="12" font="2">sponding changes in either electrolyte alone</text>
<text top="663" left="701" width="51" height="12" font="5"><a href="e127.full.html#94">(S6.2-99)</a></text>
<text top="663" left="753" width="3" height="12" font="2"><a href="e127.full.html#94">.</a></text>
<text top="681" left="439" width="317" height="12" font="2">Some but not all studies suggest that the intervention</text>
<text top="698" left="439" width="317" height="12" font="2">effect may be restricted to adult patients with a</text>
<text top="716" left="439" width="317" height="12" font="2">low (1500-mg to 2000-mg) daily intake of potassium</text>
<text top="734" left="439" width="104" height="12" font="5"><a href="e127.full.html#94">(S6.2-92,S6.2-100)</a></text>
<text top="734" left="543" width="213" height="12" font="2">. Most of the intervention experience</text>
<text top="752" left="439" width="317" height="12" font="2">comes from trials of relatively short duration (median</text>
<text top="770" left="439" width="93" height="12" font="2">of 5 to 6 weeks)</text>
<text top="770" left="537" width="94" height="12" font="5"><a href="e127.full.html#92">(S6.2-13,S6.2-14)</a></text>
<text top="770" left="631" width="125" height="12" font="2">, but the BP-lowering</text>
<text top="788" left="439" width="317" height="12" font="2">effect of potassium in adult patients consuming a</text>
<text top="806" left="439" width="317" height="12" font="2">high-sodium diet has been reproduced after an interval</text>
<text top="824" left="439" width="71" height="12" font="2">of 4.4 years</text>
<text top="824" left="516" width="52" height="12" font="5"><a href="e127.full.html#94">(S6.2-98)</a></text>
<text top="824" left="568" width="189" height="12" font="2"><a href="e127.full.html#94">. </a>In most trials, potassium sup-</text>
<text top="842" left="439" width="317" height="12" font="2">plementation was achieved by administration of po-</text>
<text top="860" left="439" width="317" height="12" font="2">tassium chloride pills, but the BP response pattern was</text>
<text top="878" left="439" width="157" height="12" font="2">similar when dietary modi</text>
<text top="876" left="596" width="103" height="15" font="2">ﬁcation was used</text>
<text top="878" left="704" width="49" height="12" font="5"><a href="e127.full.html#92">(S6.2-13)</a></text>
<text top="878" left="753" width="3" height="12" font="2"><a href="e127.full.html#92">.</a></text>
<text top="896" left="439" width="317" height="12" font="2">Because potassium-rich diets tend to be heart healthy,</text>
<text top="914" left="439" width="317" height="12" font="2">they are preferred over use of pills for potassium sup-</text>
<text top="932" left="439" width="317" height="12" font="2">plementation. The 2015 Dietary Guidelines for Ameri-</text>
<text top="950" left="439" width="26" height="12" font="2">cans</text>
<text top="950" left="469" width="55" height="12" font="5"><a href="e127.full.html#94">(S6.2-101)</a></text>
<text top="950" left="529" width="228" height="12" font="2">encourage a diet rich in potassium and</text>
<text top="967" left="439" width="317" height="12" font="2">identify the adequate intake level for adult patients as</text>
<text top="985" left="439" width="78" height="12" font="2">4700 mg/day</text>
<text top="985" left="523" width="56" height="12" font="5"><a href="e127.full.html#94">(S6.2-102)</a></text>
<text top="985" left="579" width="177" height="12" font="2">. The World Health Organiza-</text>
<text top="1003" left="439" width="317" height="12" font="2">tion recommends a potassium intake of at least 90</text>
<text top="1021" left="439" width="317" height="12" font="2">mmol (3510 mg) per day from food for adult patients</text>
<text top="1039" left="439" width="49" height="12" font="5"><a href="e127.full.html#93">(S6.2-15)</a></text>
<text top="1039" left="488" width="268" height="12" font="2">. Good sources of dietary potassium include</text>
<text top="1057" left="439" width="317" height="12" font="2">fruits and vegetables, as well as low-fat dairy products,</text>
<text top="1075" left="439" width="47" height="12" font="2">selected</text>
<text top="1073" left="491" width="265" height="15" font="2">ﬁsh and meats, nuts, and soy products. Four</text>
<text top="1093" left="439" width="12" height="12" font="2">to</text>
<text top="1091" left="457" width="300" height="15" font="2">ﬁve servings of fruits and vegetables will usually</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="790" width="18" height="9" font="4">e157</text>
</page>
<page number="32" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="124" width="93" height="12" font="2">provide 1500 to</text>
<text top="141" left="222" width="219" height="15" font="2">&gt;3000 mg of potassium. This can be</text>
<text top="161" left="124" width="317" height="12" font="2">achieved by a diet, such as the DASH diet, that is high</text>
<text top="178" left="124" width="123" height="12" font="2">in potassium content</text>
<text top="178" left="251" width="43" height="12" font="5"><a href="e127.full.html#92">(S6.2-7)</a></text>
<text top="178" left="295" width="3" height="12" font="2"><a href="e127.full.html#92">.</a></text>
<text top="196" left="109" width="332" height="12" font="2">5. A BP-lowering effect of increased physical activity has</text>
<text top="214" left="124" width="317" height="12" font="2">been repeatedly demonstrated in clinical trials, espe-</text>
<text top="232" left="124" width="233" height="12" font="2">cially during dynamic aerobic exercise</text>
<text top="232" left="363" width="78" height="12" font="5"><a href="e127.full.html#93">(S6.2-18,S6.2-</a></text>
<text top="250" left="124" width="63" height="12" font="5"><a href="e127.full.html#93">20,S6.2-22)</a></text>
<text top="250" left="187" width="3" height="12" font="2">,</text>
<text top="250" left="203" width="19" height="12" font="2">but</text>
<text top="250" left="235" width="23" height="12" font="2">also</text>
<text top="250" left="270" width="38" height="12" font="2">during</text>
<text top="250" left="321" width="50" height="12" font="2">dynamic</text>
<text top="250" left="383" width="58" height="12" font="2">resistance</text>
<text top="268" left="124" width="46" height="12" font="2">training</text>
<text top="268" left="174" width="94" height="12" font="5"><a href="e127.full.html#93">(S6.2-18,S6.2-21)</a></text>
<text top="268" left="273" width="168" height="12" font="2">and static isometric exercise</text>
<text top="286" left="124" width="139" height="12" font="5"><a href="e127.full.html#93">(S6.2-18,S6.2-19,S6.2-31)</a></text>
<text top="286" left="263" width="178" height="12" font="2">. The average reductions in</text>
<text top="304" left="124" width="317" height="12" font="2">SBP with aerobic exercise are approximately 2 to</text>
<text top="322" left="124" width="317" height="12" font="2">4 mm Hg and 5 to 8 mm Hg in adult patients with</text>
<text top="340" left="124" width="277" height="12" font="2">normotension and hypertension, respectively</text>
<text top="340" left="408" width="33" height="12" font="5"><a href="e127.full.html#93">(S6.2-</a></text>
<text top="358" left="124" width="17" height="12" font="5"><a href="e127.full.html#93">18)</a></text>
<text top="358" left="141" width="300" height="12" font="2"><a href="e127.full.html#93">. </a>Most trials have been of relatively short duration,</text>
<text top="376" left="124" width="317" height="12" font="2">but increased physical activity has been an intrinsic</text>
<text top="394" left="124" width="65" height="12" font="2">component</text>
<text top="394" left="201" width="11" height="12" font="2">of</text>
<text top="394" left="225" width="69" height="12" font="2">longer-term</text>
<text top="394" left="306" width="39" height="12" font="2">weight</text>
<text top="394" left="357" width="56" height="12" font="2">reduction</text>
<text top="394" left="425" width="16" height="12" font="2">in-</text>
<text top="412" left="124" width="317" height="12" font="2">terventions used to reduce BP and prevent hyperten-</text>
<text top="430" left="124" width="24" height="12" font="2">sion</text>
<text top="430" left="154" width="128" height="12" font="5"><a href="e127.full.html#92">(S6.2-3,S6.2-4,S6.2-12)</a></text>
<text top="430" left="282" width="159" height="12" font="2">. BP-lowering effects have</text>
<text top="447" left="124" width="317" height="12" font="2">been reported with lower- and higher-intensity exer-</text>
<text top="465" left="124" width="317" height="12" font="2">cise and with continuous and interval exercise training</text>
<text top="483" left="124" width="102" height="12" font="5"><a href="e127.full.html#93">(S6.2-18,S6.2-103)</a></text>
<text top="483" left="226" width="215" height="12" font="2"><a href="e127.full.html#93">. </a>Meta-analyses suggest isometric</text>
<text top="501" left="124" width="47" height="12" font="2">exercise</text>
<text top="501" left="184" width="39" height="12" font="2">results</text>
<text top="501" left="236" width="11" height="12" font="2">in</text>
<text top="501" left="261" width="64" height="12" font="2">substantial</text>
<text top="501" left="338" width="51" height="12" font="2">lowering</text>
<text top="501" left="401" width="11" height="12" font="2">of</text>
<text top="501" left="426" width="15" height="12" font="2">BP</text>
<text top="519" left="124" width="139" height="12" font="5"><a href="e127.full.html#93">(S6.2-18,S6.2-19,S6.2-31)</a></text>
<text top="519" left="263" width="3" height="12" font="2">.</text>
<text top="537" left="108" width="332" height="12" font="2">6. In observational studies, there is a strong, predictable</text>
<text top="555" left="124" width="317" height="12" font="2">direct relationship between alcohol consumption and</text>
<text top="573" left="124" width="317" height="12" font="2">BP, especially above an intake of 3 standard drinks per</text>
<text top="591" left="124" width="317" height="12" font="2">day (approximately 36 ounces of regular beer, 15 oun-</text>
<text top="609" left="124" width="278" height="12" font="2">ces of wine, or 4.5 ounces of distilled spirits)</text>
<text top="609" left="408" width="33" height="12" font="5"><a href="e127.full.html#93">(S6.2-</a></text>
<text top="627" left="124" width="122" height="12" font="5"><a href="e127.full.html#93">29,S6.2-104,S6.2-105)</a></text>
<text top="627" left="246" width="194" height="12" font="2">. Meta-analyses of RCTs that</text>
<text top="645" left="124" width="317" height="12" font="2">have studied the effect of reduced alcohol consump-</text>
<text top="663" left="124" width="212" height="12" font="2">tion on BP in adults have identi</text>
<text top="661" left="336" width="105" height="15" font="2">ﬁed a signiﬁcant</text>
<text top="681" left="124" width="146" height="12" font="2">reduction in SBP and DBP</text>
<text top="681" left="273" width="96" height="12" font="5"><a href="e127.full.html#93">(S6.2-23,S6.2-24)</a></text>
<text top="681" left="369" width="59" height="12" font="2">. The bene</text>
<text top="679" left="429" width="12" height="15" font="2">ﬁt</text>
<text top="698" left="124" width="287" height="12" font="2">has seemed to be consistent across trials, but con</text>
<text top="697" left="412" width="29" height="15" font="2">ﬁned</text>
<text top="716" left="124" width="120" height="12" font="2">to those consuming</text>
<text top="715" left="251" width="190" height="15" font="2">$3 drinks/day, as well as dose</text>
<text top="734" left="124" width="207" height="12" font="2">dependent, with those consuming</text>
<text top="733" left="338" width="103" height="15" font="2">$6 drinks/day at</text>
<text top="752" left="124" width="317" height="12" font="2">baseline who reduce their alcohol intake by about 50%,</text>
<text top="770" left="124" width="317" height="12" font="2">experiencing an average reduction in SBP/DBP of</text>
<text top="788" left="124" width="179" height="12" font="2">approximately 5.5/4.0 mm Hg</text>
<text top="788" left="308" width="96" height="12" font="5"><a href="e127.full.html#93">(S6.2-23,S6.2-24)</a></text>
<text top="788" left="405" width="36" height="12" font="2"><a href="e127.full.html#93">. </a>Only</text>
<text top="806" left="124" width="317" height="12" font="2">limited information is available on the effect of alcohol</text>
<text top="824" left="124" width="177" height="12" font="2">reduction on BP in blacks</text>
<text top="824" left="312" width="103" height="12" font="5"><a href="e127.full.html#93">(S6.2-23,S6.2-106)</a></text>
<text top="824" left="415" width="26" height="12" font="2"><a href="e127.full.html#93">. </a>In</text>
<text top="842" left="124" width="317" height="12" font="2">contrast to its effect on BP, alcohol seems to have a</text>
<text top="143" left="484" width="28" height="12" font="2">bene</text>
<text top="141" left="512" width="289" height="15" font="2">ﬁcial effect on several biomarkers for CVD risk,</text>
<text top="161" left="484" width="277" height="12" font="2">including high-density lipoprotein cholesterol</text>
<text top="161" left="768" width="33" height="12" font="5"><a href="e127.full.html#94">(S6.2-</a></text>
<text top="178" left="484" width="76" height="12" font="5"><a href="e127.full.html#94">107,S6.2-108)</a></text>
<text top="178" left="560" width="241" height="12" font="2">. Observational studies have shown a</text>
<text top="196" left="484" width="118" height="12" font="2">relatively consistent</text>
<text top="195" left="606" width="195" height="15" font="2">ﬁnding of an inverse relationship</text>
<text top="214" left="484" width="199" height="12" font="2">between alcohol intake and CHD</text>
<text top="214" left="689" width="108" height="12" font="5"><a href="e127.full.html#94">(S6.2-109,S6.2-110)</a></text>
<text top="214" left="798" width="3" height="12" font="2"><a href="e127.full.html#94">,</a></text>
<text top="232" left="484" width="252" height="12" font="2">within a moderate range (approximately 12</text>
<text top="230" left="737" width="65" height="15" font="2">–14 and #9</text>
<text top="250" left="484" width="317" height="12" font="2">standard drinks/week for men and women, respec-</text>
<text top="268" left="484" width="317" height="12" font="2">tively). On balance, it seems reasonable for those who</text>
<text top="286" left="484" width="301" height="12" font="2">are consuming moderate quantities of alcohol (</text>
<text top="284" left="786" width="16" height="15" font="2">#2</text>
<text top="304" left="484" width="317" height="12" font="2">drinks/day) to continue their moderate consumption of</text>
<text top="322" left="484" width="46" height="12" font="2">alcohol.</text>
<text top="364" left="468" width="169" height="16" font="14">7. PATIENT EVALUATION</text>
<text top="402" left="468" width="333" height="12" font="2">The patient evaluation is designed to identify target or-</text>
<text top="420" left="468" width="333" height="12" font="2">gan damage and possible secondary causes of hyper-</text>
<text top="438" left="468" width="333" height="12" font="2">tension and to assist in planning an effective treatment</text>
<text top="456" left="468" width="333" height="12" font="2">regimen. Historical features are relevant to the evalua-</text>
<text top="474" left="468" width="124" height="12" font="2">tion of the patient (</text>
<text top="474" left="592" width="49" height="11" font="5"><a href="e127.full.html#32">Table 16</a></text>
<text top="474" left="642" width="159" height="12" font="2">). The pattern of BP mea-</text>
<text top="492" left="468" width="333" height="12" font="2">surements and changes over time may differentiate</text>
<text top="509" left="468" width="333" height="12" font="2">primary from secondary causes of hypertension. A rise in</text>
<text top="527" left="468" width="333" height="12" font="2">BP associated with weight gain, lifestyle factors (such as</text>
<text top="545" left="468" width="333" height="12" font="2">a job change requiring travel and meals away from</text>
<text top="563" left="468" width="333" height="12" font="2">home), reduced frequency or intensity of physical ac-</text>
<text top="581" left="468" width="333" height="12" font="2">tivity, or advancing age in a patient with a strong family</text>
<text top="599" left="468" width="333" height="12" font="2">history of hypertension would suggest the diagnosis of</text>
<text top="617" left="468" width="324" height="12" font="2">primary hypertension. An evaluation of the patient</text>
<text top="615" left="792" width="9" height="15" font="2">’s</text>
<text top="635" left="468" width="333" height="12" font="2">dietary habits, physical activity, alcohol consumption,</text>
<text top="653" left="468" width="333" height="12" font="2">and tobacco use should be performed, with recommen-</text>
<text top="671" left="468" width="333" height="12" font="2">dation of the nonpharmacological interventions detailed</text>
<text top="689" left="468" width="11" height="12" font="2">in</text>
<text top="689" left="483" width="63" height="12" font="5"><a href="e127.full.html#29">Section 6.2</a></text>
<text top="689" left="550" width="251" height="12" font="2">where appropriate. The history should also</text>
<text top="707" left="468" width="333" height="12" font="2">include inquiry into possible occurrence of symptoms to</text>
<text top="725" left="468" width="173" height="12" font="2">indicate a secondary cause (</text>
<text top="725" left="641" width="99" height="11" font="5"><a href="e127.full.html#23">Tables 13 </a>and <a href="e127.full.html#32">16</a></text>
<text top="725" left="741" width="61" height="12" font="2"><a href="e127.full.html#32">). </a>The pa-</text>
<text top="743" left="468" width="27" height="12" font="2">tient</text>
<text top="741" left="495" width="306" height="15" font="2">’s treatment goals and risk tolerance should also be</text>
<text top="760" left="468" width="333" height="12" font="2">elicited. This is especially true for older persons, for</text>
<text top="778" left="468" width="333" height="12" font="2">whom an assessment of multiple chronic conditions,</text>
<text top="796" left="468" width="333" height="12" font="2">frailty, and prognosis should be performed, including</text>
<text top="814" left="468" width="287" height="12" font="2">consideration of the time required to see bene</text>
<text top="813" left="755" width="46" height="15" font="2">ﬁt from</text>
<text top="832" left="468" width="333" height="12" font="2">intervention, which may not be realized for some</text>
<text top="850" left="468" width="69" height="12" font="2">individuals.</text>
<text top="895" left="112" width="53" height="10" font="15">T A B L E 1 6</text>
<text top="896" left="179" width="259" height="10" font="16">Historical Features Favoring Hypertension Cause</text>
<text top="919" left="108" width="102" height="9" font="13">Primary Hypertension</text>
<text top="919" left="555" width="113" height="9" font="13">Secondary Hypertension</text>
<text top="937" left="112" width="6" height="10" font="9">n</text>
<text top="938" left="126" width="225" height="9" font="13">Gradual increase in BP, with slow rate of rise in BP</text>
<text top="950" left="112" width="6" height="10" font="9">n</text>
<text top="951" left="126" width="249" height="9" font="13">Lifestyle factors that favor higher BP (e.g., weight gain,</text>
<text top="963" left="127" width="250" height="9" font="13">high-sodium diet, decreased physical activity, job change</text>
<text top="975" left="127" width="231" height="9" font="13">entailing increased travel, excessive consumption of</text>
<text top="987" left="127" width="36" height="9" font="13">alcohol)</text>
<text top="998" left="112" width="6" height="10" font="9">n</text>
<text top="998" left="126" width="135" height="9" font="13">Family history of hypertension</text>
<text top="937" left="426" width="6" height="10" font="9">n</text>
<text top="938" left="441" width="275" height="9" font="13">BP lability, episodic pallor and dizziness (pheochromocytoma)</text>
<text top="950" left="426" width="6" height="10" font="9">n</text>
<text top="951" left="441" width="232" height="9" font="13">Snoring, hypersomnolence (obstructive sleep apnea)</text>
<text top="963" left="426" width="6" height="10" font="9">n</text>
<text top="964" left="441" width="348" height="9" font="13">Prostatism (chronic kidney disease due to post-renal urinary tract obstruction)</text>
<text top="975" left="426" width="6" height="10" font="9">n</text>
<text top="976" left="441" width="361" height="9" font="13">Muscle cramps, weakness (hypokalemia from primary aldosteronism or secondary</text>
<text top="988" left="441" width="191" height="9" font="13">aldosteronism due to renovascular disease)</text>
<text top="999" left="426" width="6" height="10" font="9">n</text>
<text top="1000" left="441" width="270" height="9" font="13">Weight loss, palpitations, heat intolerance (hyperthyroidism)</text>
<text top="1012" left="426" width="6" height="10" font="9">n</text>
<text top="1013" left="441" width="271" height="9" font="13">Edema, fatigue, frequent urination (kidney disease or failure)</text>
<text top="1025" left="426" width="6" height="10" font="9">n</text>
<text top="1025" left="441" width="355" height="9" font="13">History of coarctation repair (residual hypertension associated with coarctation)</text>
<text top="1037" left="426" width="6" height="10" font="9">n</text>
<text top="1038" left="441" width="258" height="9" font="13">Central obesity, facial rounding, easy bruisability (Cushing</text>
<text top="1036" left="699" width="56" height="12" font="13">’s syndrome)</text>
<text top="1050" left="426" width="6" height="10" font="9">n</text>
<text top="1051" left="441" width="338" height="9" font="13">Medication or substance use (e.g., alcohol, NSAIDS, cocaine, amphetamines)</text>
<text top="1063" left="426" width="6" height="10" font="9">n</text>
<text top="1064" left="441" width="185" height="9" font="13">Absence of family history of hypertension</text>
<text top="1088" left="108" width="238" height="8" font="4">BP indicates blood pressure; and NSAIDs, nonsteroidal anti-in</text>
<text top="1087" left="345" width="71" height="11" font="4">ﬂammatory drugs.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e158</text>
</page>
<page number="33" position="absolute" top="0" left="0" height="1160" width="864">
<text top="438" left="78" width="318" height="12" font="2">The physical examination should include accurate</text>
<text top="456" left="63" width="129" height="12" font="2">measurement of BP (</text>
<text top="456" left="192" width="44" height="11" font="5"><a href="e127.full.html#14">Table 8</a></text>
<text top="456" left="237" width="159" height="12" font="2"><a href="e127.full.html#14">). </a>Automated oscillometric</text>
<text top="474" left="63" width="333" height="12" font="2">devices provide an opportunity to obtain repeated mea-</text>
<text top="492" left="63" width="333" height="12" font="2">surements without a provider present, thereby mini-</text>
<text top="510" left="63" width="333" height="12" font="2">mizing the potential for a white coat effect. Change in BP</text>
<text top="528" left="63" width="333" height="12" font="2">from seated to standing position should be measured to</text>
<text top="546" left="63" width="242" height="12" font="2">detect orthostatic hypotension (a decline</text>
<text top="544" left="310" width="86" height="15" font="2">&gt;20 mm Hg in</text>
<text top="564" left="63" width="37" height="12" font="2">SBP or</text>
<text top="562" left="103" width="293" height="15" font="2">&gt;10 mm Hg in DBP after 1 minute is abnormal). For</text>
<text top="581" left="63" width="36" height="12" font="2">adults</text>
<text top="580" left="102" width="294" height="15" font="2">#30 years of age with elevated brachial BP, a thigh</text>
<text top="599" left="63" width="333" height="12" font="2">BP measurement is indicated; if the thigh measurement is</text>
<text top="617" left="63" width="333" height="12" font="2">lower than arm pressures, a diagnosis of coarctation of the</text>
<text top="635" left="63" width="333" height="12" font="2">aorta should be considered. The physical examination</text>
<text top="653" left="63" width="333" height="12" font="2">should include assessment of hypertension-related target</text>
<text top="671" left="63" width="333" height="12" font="2">organ damage. Attention should be paid to physical fea-</text>
<text top="689" left="63" width="256" height="12" font="2">tures that suggest secondary hypertension (</text>
<text top="689" left="319" width="46" height="11" font="5"><a href="e127.full.html#23">Table 13</a></text>
<text top="689" left="366" width="8" height="12" font="2"><a href="e127.full.html#23">).</a></text>
<text top="717" left="63" width="291" height="11" font="12">7.1. Laboratory Tests and Other Diagnostic Procedures</text>
<text top="739" left="63" width="333" height="12" font="2">Laboratory measurements should be obtained for all pa-</text>
<text top="757" left="63" width="333" height="12" font="2">tients with a new diagnosis of hypertension to facilitate</text>
<text top="775" left="63" width="111" height="12" font="2">CVD risk factor pro</text>
<text top="773" left="174" width="222" height="15" font="2">ﬁling, establish a baseline for medica-</text>
<text top="792" left="63" width="333" height="12" font="2">tion use, and screen for secondary causes of hypertension</text>
<text top="810" left="63" width="4" height="12" font="2">(</text>
<text top="811" left="67" width="49" height="11" font="5"><a href="e127.full.html#33">Table 17</a></text>
<text top="810" left="117" width="280" height="12" font="2"><a href="e127.full.html#33">)</a>. Optional tests may provide information on</text>
<text top="828" left="63" width="333" height="12" font="2">target organ damage. Monitoring of serum sodium and</text>
<text top="846" left="63" width="333" height="12" font="2">potassium levels is helpful during diuretic or RAS blocker</text>
<text top="864" left="63" width="333" height="12" font="2">titration, as are serum creatinine and urinary albumin as</text>
<text top="882" left="63" width="174" height="12" font="2">markers of CKD progression</text>
<text top="882" left="245" width="40" height="12" font="5"><a href="e127.full.html#95">(S7.1-1)</a></text>
<text top="882" left="286" width="110" height="12" font="2">. Measurement of</text>
<text top="900" left="63" width="333" height="12" font="2">thyroid-stimulating hormone is a simple test to easily</text>
<text top="918" left="63" width="333" height="12" font="2">detect hypothyroidism and hyperthyroidism, 2 remedi-</text>
<text top="936" left="63" width="333" height="12" font="2">able causes of hypertension. A decision to conduct addi-</text>
<text top="954" left="63" width="333" height="12" font="2">tional laboratory testing would be appropriate in the</text>
<text top="972" left="63" width="333" height="12" font="2">context of increased hypertension severity, poor response</text>
<text top="990" left="63" width="333" height="12" font="2">to standard treatment approaches, a disproportionate</text>
<text top="1008" left="63" width="333" height="12" font="2">severity of target organ damage for the level of BP, or</text>
<text top="1026" left="63" width="333" height="12" font="2">historical or clinical clues that support a secondary cause.</text>
<text top="1054" left="63" width="221" height="11" font="12">7.2. Cardiovascular Target Organ Damage</text>
<text top="1075" left="63" width="333" height="12" font="2">Pulse-wave velocity, carotid intima-media thickness, and</text>
<text top="1093" left="63" width="333" height="12" font="2">coronary artery calcium score provide noninvasive</text>
<text top="143" left="423" width="333" height="12" font="2">estimates of vascular target organ injury and atheroscle-</text>
<text top="161" left="423" width="27" height="12" font="2">rosis</text>
<text top="161" left="454" width="42" height="12" font="5"><a href="e127.full.html#95">(S7.2-1)</a></text>
<text top="161" left="496" width="261" height="12" font="2"><a href="e127.full.html#95">. </a>High BP readings, especially when obtained</text>
<text top="178" left="423" width="333" height="12" font="2">several years before a noninvasive measurement, are</text>
<text top="196" left="423" width="333" height="12" font="2">associated with an increase in subclinical CVD risk</text>
<text top="214" left="423" width="38" height="12" font="5"><a href="e127.full.html#95">(S7.2-2</a></text>
<text top="213" left="462" width="49" height="15" font="5"><a href="e127.full.html#95">—S7.2-4)</a></text>
<text top="214" left="511" width="246" height="12" font="2"><a href="e127.full.html#95">. </a>Although carotid intima-media thickness</text>
<text top="232" left="423" width="333" height="12" font="2">values and coronary artery calcium scores are associated</text>
<text top="250" left="423" width="333" height="12" font="2">with cardiovascular events, inadequate or absent infor-</text>
<text top="268" left="423" width="333" height="12" font="2">mation on the effect of improvement in these markers on</text>
<text top="286" left="423" width="333" height="12" font="2">cardiovascular events prevents their routine use as</text>
<text top="304" left="423" width="305" height="12" font="2">surrogate markers in the treatment of hypertension.</text>
<text top="322" left="438" width="319" height="12" font="2">LVH is a secondary manifestation of hypertension and</text>
<text top="340" left="423" width="333" height="12" font="2">independently predicts future CVD events. LVH is</text>
<text top="358" left="423" width="333" height="12" font="2">commonly measured by electrocardiography, echocardi-</text>
<text top="376" left="423" width="92" height="12" font="2">ography, or MRI</text>
<text top="376" left="519" width="82" height="12" font="5"><a href="e127.full.html#95">(S7.2-5,S7.2-6)</a></text>
<text top="376" left="601" width="156" height="12" font="2"><a href="e127.full.html#95">. </a>Left ventricular (LV) mass</text>
<text top="394" left="423" width="333" height="12" font="2">is associated with body size (particularly lean body mass),</text>
<text top="412" left="423" width="333" height="12" font="2">tobacco use, heart rate (inverse), and long-standing DM</text>
<text top="430" left="423" width="38" height="12" font="5"><a href="e127.full.html#95">(S7.2-7</a></text>
<text top="428" left="462" width="48" height="15" font="5"><a href="e127.full.html#95">—S7.2-9)</a></text>
<text top="430" left="510" width="246" height="12" font="2">. BP lowering leads to a reduction in LV</text>
<text top="447" left="423" width="333" height="12" font="2">mass. In TOMHS (Treatment of Mild Hypertension Study),</text>
<text top="465" left="423" width="333" height="12" font="2">the long-acting diuretic chlorthalidone was slightly more</text>
<text top="483" left="423" width="333" height="12" font="2">effective in reducing LVH than were a calcium channel</text>
<text top="501" left="423" width="333" height="12" font="2">blocker (CCB) (amlodipine), ACE inhibitor (enalapril),</text>
<text top="519" left="423" width="333" height="12" font="2">alpha-receptor blocker (doxazosin), or beta-receptor</text>
<text top="537" left="423" width="117" height="12" font="2">blocker (acebutolol)</text>
<text top="537" left="546" width="49" height="12" font="5"><a href="e127.full.html#95">(S7.2-10)</a></text>
<text top="537" left="595" width="161" height="12" font="2">. Beta blockers are inferior</text>
<text top="555" left="423" width="333" height="12" font="2">to angiotensin receptor blockers (ARBs), angiotensin-</text>
<text top="573" left="423" width="62" height="12" font="2">converting</text>
<text top="573" left="497" width="45" height="12" font="2">enzyme</text>
<text top="573" left="554" width="32" height="12" font="2">(ACE)</text>
<text top="573" left="599" width="60" height="12" font="2">inhibitors,</text>
<text top="573" left="671" width="21" height="12" font="2">and</text>
<text top="573" left="704" width="29" height="12" font="2">CCBs</text>
<text top="573" left="745" width="11" height="12" font="2">in</text>
<text top="591" left="423" width="80" height="12" font="2">reducing LVH</text>
<text top="591" left="507" width="47" height="12" font="5"><a href="e127.full.html#95">(S7.2-11)</a></text>
<text top="591" left="554" width="3" height="12" font="2">.</text>
<text top="609" left="438" width="318" height="12" font="2">Hypertension adversely impacts other echocardio-</text>
<text top="627" left="423" width="333" height="12" font="2">graphic markers of cardiac structure and function,</text>
<text top="645" left="423" width="333" height="12" font="2">including left atrial size (both diameter and area; left</text>
<text top="663" left="423" width="333" height="12" font="2">atrial size is also a precursor of AF); diastolic function</text>
<text top="681" left="423" width="333" height="12" font="2">(many parameters; a precursor of HF with preserved</text>
<text top="698" left="423" width="333" height="12" font="2">ejection fraction [HFpEF]); cardiac structure; and sub-</text>
<text top="716" left="423" width="333" height="12" font="2">clinical markers of LV systolic function, such as myocar-</text>
<text top="734" left="423" width="323" height="12" font="2">dial strain assessment with echocardiography and MRI.</text>
<text top="752" left="438" width="318" height="12" font="2">Assessment of LVH by means of echocardiography or</text>
<text top="770" left="423" width="333" height="12" font="2">MRI is not universally recommended during evaluation</text>
<text top="788" left="423" width="333" height="12" font="2">and management of hypertension in adults because</text>
<text top="806" left="423" width="333" height="12" font="2">there are limited data on the cost and value of these</text>
<text top="824" left="423" width="189" height="12" font="2">measures for CVD risk reclassi</text>
<text top="822" left="612" width="144" height="15" font="2">ﬁcation and changes in</text>
<text top="842" left="423" width="333" height="12" font="2">type or intensity of treatment. Assessment of LVH is</text>
<text top="860" left="423" width="230" height="12" font="2">most useful in adults who are young (</text>
<text top="858" left="653" width="103" height="15" font="2">#18 years of age)</text>
<text top="878" left="423" width="333" height="12" font="2">or have evidence of secondary hypertension, chronic</text>
<text top="896" left="423" width="333" height="12" font="2">uncontrolled hypertension, or history of symptoms of</text>
<text top="914" left="423" width="20" height="12" font="2">HF.</text>
<text top="914" left="456" width="120" height="12" font="2">Electrocardiographic</text>
<text top="914" left="587" width="41" height="12" font="2">criteria</text>
<text top="914" left="640" width="16" height="12" font="2">for</text>
<text top="914" left="669" width="25" height="12" font="2">LVH</text>
<text top="914" left="706" width="51" height="12" font="2">correlate</text>
<text top="932" left="423" width="265" height="12" font="2">weakly with echocardiographic or MRI de</text>
<text top="930" left="688" width="68" height="15" font="2">ﬁnitions of</text>
<text top="950" left="423" width="333" height="12" font="2">LVH and are less strongly related to CVD outcomes</text>
<text top="967" left="423" width="44" height="12" font="5"><a href="e127.full.html#95">(S7.2-12</a></text>
<text top="966" left="467" width="53" height="15" font="5"><a href="e127.full.html#95">—S7.2-15)</a></text>
<text top="967" left="520" width="236" height="12" font="2">. Imprecision in lead placement ac-</text>
<text top="985" left="423" width="333" height="12" font="2">counts, in part, for the poor correlation of electrocar-</text>
<text top="1003" left="423" width="333" height="12" font="2">diographic measurements with direct imaging results.</text>
<text top="1021" left="423" width="333" height="12" font="2">However, electrocardiographic LVH has been valuable in</text>
<text top="1039" left="423" width="229" height="12" font="2">predicting CVD risk in some reports</text>
<text top="1039" left="661" width="92" height="12" font="5"><a href="e127.full.html#95">(S7.2-16,S7.2-17)</a></text>
<text top="1039" left="753" width="3" height="12" font="2"><a href="e127.full.html#95">.</a></text>
<text top="1057" left="423" width="333" height="12" font="2">Electrocardiography may also be useful in the assess-</text>
<text top="1075" left="423" width="333" height="12" font="2">ment of comorbidities, such as rhythm disturbances and</text>
<text top="1093" left="423" width="52" height="12" font="2">prior MI.</text>
<text top="160" left="68" width="52" height="10" font="15">T A B L E 1 7</text>
<text top="152" left="135" width="253" height="10" font="16">Basic and Optional Laboratory Tests for Primary</text>
<text top="167" left="135" width="71" height="10" font="16">Hypertension</text>
<text top="187" left="63" width="54" height="9" font="13">Basic testing</text>
<text top="187" left="248" width="92" height="9" font="13">Fasting blood glucose</text>
<text top="187" left="340" width="4" height="9" font="17"><a href="e127.full.html#33">*</a></text>
<text top="206" left="248" width="94" height="9" font="13">Complete blood count</text>
<text top="225" left="248" width="37" height="9" font="13">Lipid pro</text>
<text top="224" left="285" width="13" height="12" font="13">ﬁle</text>
<text top="244" left="248" width="116" height="9" font="13">Serum creatinine with eGFR</text>
<text top="244" left="364" width="4" height="9" font="17"><a href="e127.full.html#33">*</a></text>
<text top="264" left="248" width="144" height="9" font="13">Serum sodium, potassium, calcium</text>
<text top="264" left="392" width="4" height="9" font="17"><a href="e127.full.html#33">*</a></text>
<text top="283" left="248" width="122" height="9" font="13">Thyroid-stimulating hormone</text>
<text top="302" left="248" width="40" height="9" font="13">Urinalysis</text>
<text top="321" left="248" width="76" height="9" font="13">Electrocardiogram</text>
<text top="340" left="63" width="69" height="9" font="13">Optional testing</text>
<text top="340" left="248" width="67" height="9" font="13">Echocardiogram</text>
<text top="360" left="248" width="36" height="9" font="13">Uric acid</text>
<text top="379" left="248" width="144" height="9" font="13">Urinary albumin to creatinine ratio</text>
<text top="401" left="63" width="211" height="8" font="4">*May be included in a comprehensive metabolic panel.</text>
<text top="415" left="71" width="142" height="8" font="4">eGFR indicates estimated glomerular</text>
<text top="414" left="215" width="54" height="11" font="4">ﬁltration rate.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="19" height="9" font="4">e159</text>
</page>
<page number="34" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="123" width="318" height="12" font="2">LVH, as assessed by electrocardiography, echocardi-</text>
<text top="161" left="108" width="333" height="12" font="2">ography, or MRI, is an independent predictor of CVD</text>
<text top="178" left="108" width="81" height="12" font="2">complications</text>
<text top="178" left="196" width="93" height="12" font="5"><a href="e127.full.html#95">(S7.2-18,S7.2-19)</a></text>
<text top="178" left="290" width="151" height="12" font="2"><a href="e127.full.html#95">. </a>Reduction in LVH can</text>
<text top="196" left="108" width="333" height="12" font="2">predict a reduction in CVD risk, independent of change in</text>
<text top="214" left="108" width="15" height="12" font="2">BP</text>
<text top="214" left="129" width="50" height="12" font="5"><a href="e127.full.html#95">(S7.2-20)</a></text>
<text top="214" left="179" width="262" height="12" font="2">. When used in CVD risk predictor models,</text>
<text top="232" left="108" width="265" height="12" font="2">echocardiographic LVH has a small but signi</text>
<text top="230" left="373" width="68" height="15" font="2">ﬁcant inde-</text>
<text top="250" left="108" width="333" height="12" font="2">pendent effect on CVD risk in younger patients. At older</text>
<text top="268" left="108" width="333" height="12" font="2">ages, LVH measured by electrocardiography or MRI pro-</text>
<text top="286" left="108" width="333" height="12" font="2">vides no independent contribution to prediction of CVD</text>
<text top="304" left="108" width="21" height="12" font="2">risk</text>
<text top="304" left="135" width="44" height="12" font="5"><a href="e127.full.html#95">(S7.2-21</a></text>
<text top="302" left="179" width="54" height="15" font="5"><a href="e127.full.html#95">—S7.2-23)</a></text>
<text top="304" left="234" width="142" height="12" font="2"><a href="e127.full.html#95">. </a>Patients can be classi</text>
<text top="302" left="376" width="65" height="15" font="2">ﬁed into 4</text>
<text top="322" left="108" width="333" height="12" font="2">groups on the basis of the presence or absence of LVH and</text>
<text top="340" left="108" width="333" height="12" font="2">a determination of whether the LVH has an eccentric</text>
<text top="358" left="108" width="333" height="12" font="2">(normal relative wall thickness) or concentric geometry</text>
<text top="376" left="108" width="88" height="12" font="5"><a href="e127.full.html#95">(S7.2-6,S7.2-22)</a></text>
<text top="376" left="196" width="3" height="12" font="2"><a href="e127.full.html#95">.</a></text>
<text top="418" left="108" width="182" height="16" font="14">8. TREATMENT OF HIGH BP</text>
<text top="456" left="108" width="333" height="12" font="2">Clinicians managing adults with high BP should focus on</text>
<text top="474" left="108" width="333" height="12" font="2">overall patient health, with a particular emphasis on</text>
<text top="492" left="108" width="333" height="12" font="2">reducing the risk of future adverse CVD outcomes. All</text>
<text top="510" left="108" width="333" height="12" font="2">patient risk factors need to be managed in an integrated</text>
<text top="528" left="108" width="333" height="12" font="2">fashion with a comprehensive set of nonpharmacological</text>
<text top="546" left="108" width="23" height="12" font="2">(see</text>
<text top="546" left="134" width="53" height="12" font="5"><a href="e127.full.html#28">Section 6</a></text>
<text top="546" left="188" width="253" height="12" font="2"><a href="e127.full.html#28">) </a>and pharmacological strategies. As patient</text>
<text top="564" left="108" width="333" height="12" font="2">BP and risk of future CVD events increase, BP manage-</text>
<text top="582" left="108" width="135" height="12" font="2">ment should be intensi</text>
<text top="580" left="243" width="26" height="15" font="2">ﬁed.</text>
<text top="143" left="468" width="169" height="11" font="12">8.1. Pharmacological Treatment</text>
<text top="165" left="468" width="333" height="11" font="2">8.1.1. Initiation of Pharmacological BP Treatment in the Context</text>
<text top="183" left="499" width="102" height="11" font="2">of Overall CVD Risk</text>
<text top="204" left="468" width="78" height="12" font="2">For any speci</text>
<text top="202" left="546" width="255" height="15" font="2">ﬁc difference in BP, the relative risk of CVD</text>
<text top="222" left="468" width="333" height="12" font="2">is constant across groups that differ in absolute risk of</text>
<text top="240" left="468" width="116" height="12" font="2">atherosclerotic CVD</text>
<text top="240" left="589" width="46" height="12" font="5"><a href="e127.full.html#95">(S8.1.1-1</a></text>
<text top="238" left="636" width="58" height="15" font="5"><a href="e127.full.html#95">—S8.1.1-4)</a></text>
<text top="240" left="694" width="108" height="12" font="2"><a href="e127.full.html#95">, </a>albeit with some</text>
<text top="258" left="468" width="333" height="12" font="2">evidence of lesser relative risk but greater excess risk in</text>
<text top="276" left="468" width="178" height="12" font="2">older than in younger adults</text>
<text top="276" left="653" width="47" height="12" font="5"><a href="e127.full.html#95">(S8.1.1-5</a></text>
<text top="274" left="701" width="58" height="15" font="5"><a href="e127.full.html#95">—S8.1.1-8)</a></text>
<text top="276" left="758" width="43" height="12" font="2">. Thus,</text>
<text top="294" left="468" width="333" height="12" font="2">there are more potentially preventable CVD events</text>
<text top="312" left="468" width="333" height="12" font="2">attributable to elevated BP in individuals with higher than</text>
<text top="330" left="468" width="333" height="12" font="2">with lower risk of CVD and in older than in younger</text>
<text top="348" left="468" width="333" height="12" font="2">adults. The relative risk reduction for CVD prevention</text>
<text top="366" left="468" width="333" height="12" font="2">with use of BP-lowering medications is fairly constant for</text>
<text top="384" left="468" width="333" height="12" font="2">groups that differ in CVD risk across a wide range of</text>
<text top="401" left="468" width="144" height="12" font="2">estimated absolute risk</text>
<text top="401" left="621" width="106" height="12" font="5"><a href="e127.full.html#95">(S8.1.1-9,S8.1.1-10)</a></text>
<text top="401" left="736" width="66" height="12" font="2">and across</text>
<text top="419" left="468" width="59" height="12" font="2">groups de</text>
<text top="418" left="528" width="274" height="15" font="2">ﬁned by sex, age, body mass index, and the</text>
<text top="437" left="468" width="241" height="12" font="2">presence or absence of DM, AF, and CKD</text>
<text top="437" left="713" width="88" height="12" font="5"><a href="e127.full.html#95">(S8.1.1-5,S8.1.1-</a></text>
<text top="455" left="468" width="10" height="12" font="5"><a href="e127.full.html#95">11</a></text>
<text top="453" left="478" width="62" height="15" font="5"><a href="e127.full.html#95">—S8.1.1-21)</a></text>
<text top="455" left="541" width="261" height="12" font="2"><a href="e127.full.html#95">. </a>As a consequence, the absolute CVD risk</text>
<text top="473" left="468" width="333" height="12" font="2">reduction attributable to BP lowering is greater at greater</text>
<text top="491" left="468" width="180" height="12" font="2">absolute levels of CVD risk</text>
<text top="491" left="658" width="143" height="12" font="5"><a href="e127.full.html#95">(S8.1.1-9,S8.1.1-10,S8.1.1-</a></text>
<text top="509" left="468" width="64" height="12" font="5"><a href="e127.full.html#95">12,S8.1.1-15</a></text>
<text top="507" left="532" width="170" height="15" font="5"><a href="e127.full.html#95">—S8.1.1-19,S8.1.1-22,S8.1.1-23)</a></text>
<text top="509" left="703" width="3" height="12" font="2"><a href="e127.full.html#95">.</a></text>
<text top="509" left="722" width="19" height="12" font="2">Put</text>
<text top="509" left="756" width="45" height="12" font="2">another</text>
<text top="527" left="468" width="333" height="12" font="2">way, for a given magnitude of BP reduction due to anti-</text>
<text top="545" left="468" width="333" height="12" font="2">hypertensive medications, fewer individuals at high CVD</text>
<text top="563" left="468" width="333" height="12" font="2">risk would need to be treated to prevent a CVD event (i.e.,</text>
<text top="581" left="468" width="333" height="12" font="2">lower number needed to treat) than those at low CVD risk.</text>
<text top="692" left="63" width="417" height="11" font="19">Recommendations for BP Treatment Threshold and Use of Risk Estimation</text>
<text top="692" left="480" width="5" height="11" font="5"><a href="e127.full.html#34">*</a></text>
<text top="692" left="490" width="234" height="11" font="19">to Guide Drug Treatment of Hypertension</text>
<text top="706" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="706" left="412" width="152" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 23</a></text>
<text top="706" left="565" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="747" left="89" width="19" height="10" font="13">COR</text>
<text top="747" left="161" width="18" height="10" font="13">LOE</text>
<text top="747" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="784" left="97" width="3" height="9" font="4">I</text>
<text top="777" left="157" width="27" height="9" font="4">SBP: A</text>
<text top="772" left="234" width="557" height="11" font="12">1. Use of BP-lowering medications is recommended for secondary prevention of recurrent CVD events in</text>
<text top="787" left="246" width="555" height="11" font="12">patients with clinical CVD and an average SBP of 130 mm Hg or higher or an average DBP of 80 mm Hg or</text>
<text top="803" left="246" width="541" height="11" font="12">higher, and for primary prevention in adults with an estimated 10-year atherosclerotic cardiovascular</text>
<text top="819" left="246" width="531" height="11" font="12">disease (ASCVD) risk of 10% or higher and an average SBP 130 mm Hg or higher or an average DBP</text>
<text top="834" left="246" width="109" height="11" font="12">80 mm Hg or higher</text>
<text top="834" left="360" width="46" height="11" font="5"><a href="e127.full.html#96">(S8.1.2-1</a></text>
<text top="832" left="406" width="57" height="15" font="5"><a href="e127.full.html#96">—S8.1.2-9)</a></text>
<text top="834" left="463" width="3" height="11" font="12">.</text>
<text top="792" left="149" width="43" height="9" font="4">DBP: C-EO</text>
<text top="888" left="97" width="3" height="9" font="4">I</text>
<text top="888" left="160" width="20" height="9" font="4">C-LD</text>
<text top="876" left="234" width="568" height="11" font="12">2. Use of BP-lowering medication is recommended for primary prevention of CVD in adults with no history of</text>
<text top="892" left="248" width="251" height="11" font="12">CVD and with an estimated 10-year ASCVD risk</text>
<text top="890" left="503" width="291" height="15" font="12">&lt;10% and an SBP of 140 mm Hg or higher or a DBP of</text>
<text top="908" left="248" width="109" height="11" font="12">90 mm Hg or higher</text>
<text top="908" left="361" width="101" height="11" font="5"><a href="e127.full.html#96">(S8.1.2-3,S8.1.2-10</a></text>
<text top="906" left="462" width="61" height="15" font="5"><a href="e127.full.html#96">—S8.1.2-13)</a></text>
<text top="908" left="523" width="3" height="11" font="12">.</text>
<text top="933" left="63" width="142" height="8" font="4">*ACC/AHA Pooled Cohort Equations <a href="http://tools.acc.org/ASCVD-Risk-Estimator/">(</a></text>
<text top="933" left="205" width="167" height="8" font="8"><a href="http://tools.acc.org/ASCVD-Risk-Estimator/">http://tools.acc.org/ASCVD-Risk-Estimator/</a></text>
<text top="933" left="372" width="3" height="8" font="4">)</text>
<text top="933" left="378" width="45" height="8" font="8"><a href="e127.full.html#96">(S8.1.2-13a)</a></text>
<text top="933" left="425" width="239" height="8" font="4">to estimate 10-year risk of atherosclerotic CVD. ASCVD was de</text>
<text top="931" left="664" width="138" height="11" font="4">ﬁned as a ﬁrst CHD death, non-fatal</text>
<text top="945" left="63" width="119" height="8" font="4">MI or fatal or non-fatal stroke.</text>
<text top="621" left="108" width="291" height="11" font="2">8.1.2. BP Treatment Threshold and the Use of CVD Risk</text>
<text top="639" left="140" width="277" height="11" font="2">Estimation to Guide Drug Treatment of Hypertension</text>
<text top="987" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="1005" left="123" width="321" height="12" font="2">Whereas treatment of high BP with BP-lowering medi-</text>
<text top="1023" left="108" width="336" height="12" font="2">cations on the basis of BP level alone is considered cost</text>
<text top="1041" left="108" width="50" height="12" font="2">effective</text>
<text top="1041" left="161" width="59" height="12" font="5"><a href="e127.full.html#96">(S8.1.2-14)</a></text>
<text top="1041" left="221" width="223" height="12" font="2">, use of a combination of absolute CVD</text>
<text top="1059" left="108" width="299" height="12" font="2">risk and BP level to guide such treatment is more ef</text>
<text top="1057" left="407" width="36" height="15" font="2">ﬁcient</text>
<text top="1077" left="108" width="336" height="12" font="2">and cost effective at reducing risk of CVD than is use of BP</text>
<text top="987" left="465" width="69" height="12" font="2">level alone</text>
<text top="987" left="544" width="54" height="12" font="5"><a href="e127.full.html#96">(S8.1.2-15</a></text>
<text top="985" left="598" width="65" height="15" font="5"><a href="e127.full.html#96">—S8.1.2-24)</a></text>
<text top="987" left="663" width="138" height="12" font="2">. Practical approaches</text>
<text top="1005" left="465" width="336" height="12" font="2">have been developed to translate evidence from RCTs into</text>
<text top="1023" left="465" width="336" height="12" font="2">individual patient treatment recommendations that are</text>
<text top="1041" left="465" width="158" height="12" font="2">based on absolute net bene</text>
<text top="1039" left="624" width="86" height="15" font="2">ﬁt for CVD risk</text>
<text top="1041" left="713" width="59" height="12" font="5"><a href="e127.full.html#96">(S8.1.2-25)</a></text>
<text top="1041" left="772" width="29" height="12" font="2">, and</text>
<text top="1059" left="465" width="336" height="12" font="2">several national and international guidelines recommend</text>
<text top="1077" left="465" width="336" height="12" font="2">basing use of BP-lowering medications on a combination</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="20" height="9" font="4">e160</text>
</page>
<page number="35" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="333" height="12" font="2">of absolute risk of CVD and level of BP instead of relying</text>
<text top="161" left="63" width="119" height="12" font="2">solely on level of BP</text>
<text top="161" left="186" width="56" height="12" font="5"><a href="e127.full.html#96">(S8.1.2-26</a></text>
<text top="159" left="242" width="63" height="15" font="5"><a href="e127.full.html#96">—S8.1.2-31)</a></text>
<text top="161" left="305" width="3" height="12" font="2">.</text>
<text top="178" left="78" width="318" height="12" font="2">Attempts to use absolute risk to guide implementation</text>
<text top="196" left="63" width="333" height="12" font="2">of pharmacological treatment to prevent CVD have had</text>
<text top="214" left="63" width="333" height="12" font="2">mixed results, with many reports of improvements in</text>
<text top="232" left="63" width="333" height="12" font="2">provider prescribing behaviors, patient adherence, and</text>
<text top="250" left="63" width="105" height="12" font="2">reductions in risk</text>
<text top="250" left="174" width="55" height="12" font="5"><a href="e127.full.html#96">(S8.1.2-32</a></text>
<text top="248" left="229" width="65" height="15" font="5"><a href="e127.full.html#96">—S8.1.2-38)</a></text>
<text top="250" left="294" width="102" height="12" font="2">, but with others</text>
<text top="268" left="63" width="280" height="12" font="2">showing no impact on provider behaviors</text>
<text top="268" left="354" width="42" height="12" font="5"><a href="e127.full.html#97">(S8.1.2-</a></text>
<text top="286" left="63" width="75" height="12" font="5"><a href="e127.full.html#97">39,S8.1.2-40)</a></text>
<text top="286" left="138" width="258" height="12" font="2"><a href="e127.full.html#97">. </a>Use of global CVD risk assessment is infre-</text>
<text top="304" left="63" width="201" height="12" font="2">quent in routine clinical practice</text>
<text top="304" left="271" width="55" height="12" font="5"><a href="e127.full.html#97">(S8.1.2-41</a></text>
<text top="302" left="326" width="66" height="15" font="5"><a href="e127.full.html#97">—S8.1.2-46)</a></text>
<text top="304" left="393" width="3" height="12" font="2"><a href="e127.full.html#97">,</a></text>
<text top="322" left="63" width="333" height="12" font="2">which suggests that intensive efforts would be required to</text>
<text top="340" left="63" width="319" height="12" font="2">achieve universal implementation. The choice of speci</text>
<text top="338" left="383" width="14" height="15" font="2">ﬁc</text>
<text top="358" left="63" width="333" height="12" font="2">risk calculators for estimation of risk and risk threshold</text>
<text top="376" left="63" width="333" height="12" font="2">has been an important source of variability, ambiguity,</text>
<text top="394" left="63" width="21" height="12" font="2">and</text>
<text top="394" left="98" width="69" height="12" font="2">controversy</text>
<text top="394" left="180" width="56" height="12" font="5"><a href="e127.full.html#97">(S8.1.2-47</a></text>
<text top="392" left="236" width="65" height="15" font="5"><a href="e127.full.html#97">—S8.1.2-54)</a></text>
<text top="394" left="302" width="3" height="12" font="2"><a href="e127.full.html#97">.</a></text>
<text top="394" left="319" width="12" height="12" font="2">In</text>
<text top="394" left="344" width="52" height="12" font="2">addition,</text>
<text top="412" left="63" width="333" height="12" font="2">implementation of a standard (worldwide) absolute CVD</text>
<text top="430" left="63" width="333" height="12" font="2">risk threshold for initiating use of BP-lowering medica-</text>
<text top="447" left="63" width="333" height="12" font="2">tions would result in large variations in medication use at</text>
<text top="465" left="63" width="227" height="12" font="2">a given level of BP across countries</text>
<text top="465" left="297" width="99" height="12" font="5"><a href="e127.full.html#97">(S8.1.2-48,S8.1.2-</a></text>
<text top="483" left="63" width="73" height="12" font="5"><a href="e127.full.html#97">54,S8.1.2-55)</a></text>
<text top="483" left="136" width="260" height="12" font="2"><a href="e127.full.html#97">. </a>Future research in this area should focus</text>
<text top="501" left="63" width="334" height="12" font="2">on issues related to implementation of a risk-based</text>
<text top="519" left="63" width="333" height="12" font="2">approach to CVD prevention, including the use of</text>
<text top="537" left="63" width="333" height="12" font="2">BP-lowering medications. Although several CVD risk</text>
<text top="555" left="63" width="333" height="12" font="2">assessment tools are available, on the basis of current</text>
<text top="573" left="63" width="333" height="12" font="2">knowledge, we recommend use of the ACC/AHA Pooled</text>
<text top="591" left="63" width="39" height="12" font="2">Cohort</text>
<text top="591" left="123" width="58" height="12" font="2">Equations</text>
<text top="591" left="202" width="4" height="12" font="2">(</text>
<text top="591" left="206" width="190" height="12" font="5"><a href="http://tools.acc.org/ASCVD-Risk-Estimator/">http://tools.acc.org/ASCVD-Risk-</a></text>
<text top="609" left="63" width="61" height="12" font="5"><a href="http://tools.acc.org/ASCVD-Risk-Estimator/">Estimator/</a></text>
<text top="609" left="124" width="272" height="12" font="2"><a href="http://tools.acc.org/ASCVD-Risk-Estimator/">) </a>to estimate 10-year risk of atherosclerotic</text>
<text top="627" left="63" width="333" height="12" font="2">CVD (ASCVD) to establish the BP threshold for treatment</text>
<text top="645" left="63" width="115" height="12" font="5"><a href="e127.full.html#97">(S8.1.2-56,S8.1.2-57)</a></text>
<text top="645" left="178" width="218" height="12" font="2"><a href="e127.full.html#97">. </a>It should be kept in mind that the</text>
<text top="663" left="63" width="333" height="12" font="2">ACC/AHA Pooled Cohort Equations are validated for U.S.</text>
<text top="681" left="63" width="333" height="12" font="2">adults ages 40 to 79 years in the absence of concurrent</text>
<text top="698" left="63" width="83" height="12" font="2">statin therapy</text>
<text top="698" left="152" width="60" height="12" font="5"><a href="e127.full.html#97">(S8.1.2-56)</a></text>
<text top="698" left="213" width="66" height="12" font="2"><a href="e127.full.html#97">. </a>For those</text>
<text top="697" left="285" width="111" height="15" font="2">&gt;79 years old, the</text>
<text top="716" left="63" width="186" height="12" font="2">10-year ASCVD risk is generally</text>
<text top="715" left="253" width="143" height="15" font="2">&gt;10%, and thus the SBP</text>
<text top="734" left="63" width="55" height="12" font="2">threshold</text>
<text top="734" left="131" width="16" height="12" font="2">for</text>
<text top="734" left="160" width="98" height="12" font="2">antihypertensive</text>
<text top="734" left="271" width="27" height="12" font="2">drug</text>
<text top="734" left="310" width="57" height="12" font="2">treatment</text>
<text top="734" left="380" width="16" height="12" font="2">for</text>
<text top="752" left="63" width="47" height="12" font="2">patients</text>
<text top="751" left="114" width="282" height="15" font="2">&gt;79 years old is 130 mm Hg. Two recent reviews</text>
<text top="770" left="63" width="333" height="12" font="2">have highlighted the importance of using predicted CVD</text>
<text top="788" left="63" width="333" height="12" font="2">risk together with BP to guide antihypertensive drug</text>
<text top="806" left="63" width="44" height="12" font="2">therapy</text>
<text top="806" left="111" width="114" height="12" font="5"><a href="e127.full.html#96">(S8.1.2-22,S8.1.2-23)</a></text>
<text top="806" left="226" width="3" height="12" font="2"><a href="e127.full.html#96">.</a></text>
<text top="824" left="78" width="47" height="11" font="5"><a href="e127.full.html#36">Figure 4</a></text>
<text top="824" left="130" width="266" height="12" font="2">is an algorithm on BP thresholds and recom-</text>
<text top="842" left="63" width="240" height="12" font="2">mendations for treatment and follow-up.</text>
<text top="868" left="63" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="866" left="202" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="895" left="64" width="332" height="12" font="2">1. For the purposes of secondary prevention, clinical CVD</text>
<text top="913" left="78" width="28" height="12" font="2">is de</text>
<text top="911" left="106" width="290" height="15" font="2">ﬁned as CHD, congestive HF, and stroke. Several</text>
<text top="931" left="78" width="318" height="12" font="2">meta-analyses of RCTs support the value of using</text>
<text top="949" left="78" width="71" height="12" font="2">BP-lowering</text>
<text top="949" left="163" width="74" height="12" font="2">medications,</text>
<text top="949" left="253" width="11" height="12" font="2">in</text>
<text top="949" left="279" width="49" height="12" font="2">addition</text>
<text top="949" left="343" width="11" height="12" font="2">to</text>
<text top="949" left="369" width="27" height="12" font="2">non-</text>
<text top="967" left="78" width="318" height="12" font="2">pharmacological treatment, in patients with estab-</text>
<text top="985" left="78" width="289" height="12" font="2">lished CVD in the absence of hypertension, de</text>
<text top="983" left="367" width="29" height="15" font="2">ﬁned</text>
<text top="1003" left="78" width="120" height="12" font="2">previously by an SBP</text>
<text top="1001" left="201" width="196" height="15" font="2">$140 mm Hg or a DBP $90 mm Hg</text>
<text top="1021" left="78" width="198" height="12" font="5"><a href="e127.full.html#96">(S8.1.2-1,S8.1.2-6,S8.1.2-7,S8.1.2-9)</a></text>
<text top="1021" left="276" width="120" height="12" font="2">. Many RCTs of BP</text>
<text top="1038" left="78" width="318" height="12" font="2">lowering in adults without CVD have used inclusion</text>
<text top="1056" left="78" width="318" height="12" font="2">criteria designed to increase the level of CVD risk in</text>
<text top="1074" left="78" width="253" height="12" font="2">the study populations to increase trial ef</text>
<text top="1073" left="331" width="65" height="15" font="2">ﬁciency by</text>
<text top="1092" left="78" width="318" height="12" font="2">facilitating shorter duration and a smaller sample size.</text>
<text top="143" left="438" width="318" height="12" font="2">As a consequence, few relatively low-risk adults with</text>
<text top="161" left="438" width="318" height="12" font="2">hypertension have been included in the trials. Trial</text>
<text top="178" left="438" width="318" height="12" font="2">results provide evidence of CVD prevention from use of</text>
<text top="196" left="438" width="318" height="12" font="2">BP-lowering medications in adults with an average</text>
<text top="214" left="438" width="22" height="12" font="2">SBP</text>
<text top="213" left="465" width="292" height="15" font="2">$130 mm Hg or an average DBP $80 mm Hg and</text>
<text top="232" left="438" width="223" height="12" font="2">clinical CVD; 5-year risk of CVD (de</text>
<text top="230" left="662" width="95" height="15" font="2">ﬁned as stroke,</text>
<text top="250" left="438" width="318" height="12" font="2">CHD, HF, or other CVD death) of approximately 6% to</text>
<text top="268" left="438" width="17" height="12" font="2">7%</text>
<text top="268" left="459" width="101" height="12" font="5"><a href="e127.full.html#96">(S8.1.2-3,S8.1.2-5)</a></text>
<text top="268" left="561" width="196" height="12" font="2"><a href="e127.full.html#96">; </a>an estimated 10-year CVD death</text>
<text top="286" left="438" width="156" height="12" font="2">rate of approximately 4.5%</text>
<text top="286" left="597" width="54" height="12" font="5"><a href="e127.full.html#96">(S8.1.2-4)</a></text>
<text top="286" left="652" width="105" height="12" font="2"><a href="e127.full.html#96">; </a>or an annual rate</text>
<text top="304" left="438" width="318" height="12" font="2">of major CVD events of approximately 0.9% per year</text>
<text top="322" left="438" width="53" height="12" font="5"><a href="e127.full.html#96">(S8.1.2-7)</a></text>
<text top="322" left="491" width="265" height="12" font="2">. In the absence of clinical CVD, these risk</text>
<text top="340" left="438" width="318" height="12" font="2">estimates are roughly equivalent to a 10-year risk of</text>
<text top="358" left="438" width="318" height="12" font="2">ASCVD exceeding 10% as per the ACC/AHA Pooled</text>
<text top="376" left="438" width="103" height="12" font="2">Cohort Equations</text>
<text top="376" left="548" width="60" height="12" font="5"><a href="e127.full.html#97">(S8.1.2-56)</a></text>
<text top="376" left="608" width="148" height="12" font="2">. SPRINT (Systolic Blood</text>
<text top="394" left="438" width="318" height="12" font="2">Pressure Intervention Trial) provides additional sup-</text>
<text top="412" left="438" width="318" height="12" font="2">port for the use of BP-lowering medications in patients</text>
<text top="430" left="438" width="152" height="12" font="2">without CVD at SBP levels</text>
<text top="428" left="595" width="162" height="15" font="2">$130 mm Hg; however, it is</text>
<text top="447" left="438" width="318" height="12" font="2">important to note that few SPRINT participants had</text>
<text top="465" left="438" width="318" height="12" font="2">untreated SBP between 130 mm Hg and 139 mm Hg at</text>
<text top="483" left="438" width="318" height="12" font="2">baseline. Furthermore, SPRINT used a Framingham</text>
<text top="501" left="438" width="318" height="12" font="2">10-year risk of general CVD exceeding 15% to identify</text>
<text top="519" left="438" width="107" height="12" font="2">increased CVD risk</text>
<text top="519" left="548" width="54" height="12" font="5"><a href="e127.full.html#96">(S8.1.2-8)</a></text>
<text top="519" left="603" width="154" height="12" font="2"><a href="e127.full.html#96">. </a>Although this level of risk</text>
<text top="537" left="438" width="318" height="12" font="2">is lower than the levels described previously, being</text>
<text top="555" left="438" width="318" height="12" font="2">roughly equivalent to a 6% to 7% 10-year ASCVD risk</text>
<text top="573" left="438" width="318" height="12" font="2">per the ACC/AHA Pooled Cohort Equations, most of the</text>
<text top="591" left="438" width="318" height="12" font="2">participants in SPRINT had a much higher level of CVD</text>
<text top="609" left="438" width="318" height="12" font="2">risk. This recommendation differs from JNC 7 in its use</text>
<text top="627" left="438" width="318" height="12" font="2">of CVD risk, rather than diabetes or CKD, to recognize</text>
<text top="645" left="438" width="281" height="12" font="2">patients, including older adults, with a SBP/DBP</text>
<text top="643" left="723" width="34" height="15" font="2">&lt;140/</text>
<text top="663" left="438" width="199" height="12" font="2">90 mm Hg who are likely to bene</text>
<text top="661" left="637" width="119" height="15" font="2">ﬁt from BP lowering</text>
<text top="681" left="438" width="318" height="12" font="2">drug therapy in addition to nonpharmacological anti-</text>
<text top="698" left="438" width="318" height="12" font="2">hypertensive treatment. In JNC 7, the BP threshold for</text>
<text top="716" left="438" width="276" height="12" font="2">initiation of antihypertensive drug therapy was</text>
<text top="715" left="718" width="38" height="15" font="2">$ 140/</text>
<text top="734" left="438" width="277" height="12" font="2">90 mm Hg for the general adult population and</text>
<text top="733" left="720" width="37" height="15" font="2">$ 130/</text>
<text top="752" left="438" width="318" height="12" font="2">80 mm Hg for adults with diabetes or CKD. Since the</text>
<text top="770" left="438" width="318" height="12" font="2">publication of JNC 7 in 2003, we have gained additional</text>
<text top="788" left="438" width="318" height="12" font="2">experience with risk assessment and new data from</text>
<text top="806" left="438" width="318" height="12" font="2">randomized trials, observational studies and simula-</text>
<text top="824" left="438" width="318" height="12" font="2">tion analyses have demonstrated that antihypertensive</text>
<text top="842" left="438" width="318" height="12" font="2">drug treatment based on overall ASCVD risk assess-</text>
<text top="860" left="438" width="318" height="12" font="2">ment combined with BP levels may prevent more CVD</text>
<text top="878" left="438" width="273" height="12" font="2">events than treatment based on BP levels alone</text>
<text top="878" left="714" width="42" height="12" font="5"><a href="e127.full.html#96">(S8.1.2-</a></text>
<text top="896" left="438" width="11" height="12" font="5"><a href="e127.full.html#96">15</a></text>
<text top="894" left="450" width="65" height="15" font="5"><a href="e127.full.html#96">—S8.1.2-24)</a></text>
<text top="896" left="515" width="241" height="12" font="2">. According to an analysis of NHANES</text>
<text top="914" left="438" width="134" height="12" font="2">2011-2014, the new de</text>
<text top="912" left="572" width="184" height="15" font="2">ﬁnition results in only a small</text>
<text top="932" left="438" width="318" height="12" font="2">increase in the percentage of U.S. adults for whom</text>
<text top="950" left="438" width="98" height="12" font="2">antihypertensive</text>
<text top="950" left="549" width="65" height="12" font="2">medication</text>
<text top="950" left="627" width="9" height="12" font="2">is</text>
<text top="950" left="649" width="83" height="12" font="2">recommended</text>
<text top="950" left="745" width="11" height="12" font="2">in</text>
<text top="967" left="438" width="181" height="12" font="2">conjunction with lifestyle modi</text>
<text top="966" left="620" width="137" height="15" font="2">ﬁcation. The previously</text>
<text top="985" left="438" width="318" height="12" font="2">cited meta-analyses are consistent with the conclusion</text>
<text top="1003" left="438" width="218" height="12" font="2">that lowering of BP results in bene</text>
<text top="1002" left="657" width="100" height="15" font="2">ﬁt in higher-risk</text>
<text top="1021" left="438" width="318" height="12" font="2">individuals, regardless of their baseline treated or</text>
<text top="1039" left="438" width="77" height="12" font="2">untreated BP</text>
<text top="1037" left="520" width="236" height="15" font="2">$130/80 mm Hg and irrespective of the</text>
<text top="1057" left="438" width="29" height="12" font="2">speci</text>
<text top="1055" left="468" width="289" height="15" font="2">ﬁc cause of their elevated risk. These analyses</text>
<text top="1075" left="438" width="134" height="12" font="2">indicate that the bene</text>
<text top="1073" left="573" width="184" height="15" font="2">ﬁt of treatment outweighs the</text>
<text top="1093" left="438" width="180" height="12" font="2">potential harm at threshold BP</text>
<text top="1091" left="622" width="98" height="15" font="2">$130/80 mm Hg.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="790" width="18" height="9" font="4">e161</text>
</page>
<page number="36" position="absolute" top="0" left="0" height="1160" width="864">
<text top="824" left="108" width="333" height="12" font="2">2. This recommendation is consistent with prior guide-</text>
<text top="842" left="123" width="318" height="12" font="2">lines, such as JNC 7. In addition, for those for whom</text>
<text top="860" left="123" width="318" height="12" font="2">nonpharmacological therapy has been ineffective,</text>
<text top="878" left="123" width="318" height="12" font="2">antihypertensive drug treatment should be added in</text>
<text top="896" left="123" width="131" height="12" font="2">patients with an SBP</text>
<text top="894" left="262" width="179" height="15" font="2">$140 mm Hg or a DBP $90</text>
<text top="914" left="123" width="318" height="12" font="2">mm Hg, even in adults who are at lower risk than those</text>
<text top="932" left="123" width="318" height="12" font="2">included in RCTs. The rationale for drug treatment in</text>
<text top="950" left="123" width="118" height="12" font="2">patients with an SBP</text>
<text top="948" left="244" width="197" height="15" font="2">$140 mm Hg or a DBP $90 mm Hg</text>
<text top="968" left="123" width="214" height="12" font="2">and an estimated 10-year risk of CVD</text>
<text top="966" left="341" width="100" height="15" font="2">&lt;10% is based on</text>
<text top="985" left="123" width="318" height="12" font="2">several lines of evidence. First, the relationship of SBP</text>
<text top="1003" left="123" width="318" height="12" font="2">with risk of CVD is known to be continuous across</text>
<text top="1021" left="123" width="318" height="12" font="2">levels of SBP and similar across groups that differ in</text>
<text top="1039" left="123" width="126" height="12" font="2">level of absolute risk</text>
<text top="1039" left="254" width="59" height="12" font="5"><a href="e127.full.html#96">(S8.1.2-10)</a></text>
<text top="1039" left="313" width="128" height="12" font="2">. Second, the relative</text>
<text top="1057" left="123" width="318" height="12" font="2">risk reduction attributable to BP-lowering medication</text>
<text top="1075" left="123" width="318" height="12" font="2">therapy is consistent across the range of absolute risk</text>
<text top="1093" left="123" width="52" height="12" font="2">observed</text>
<text top="1093" left="195" width="11" height="12" font="2">in</text>
<text top="1093" left="227" width="29" height="12" font="2">trials</text>
<text top="1093" left="276" width="161" height="12" font="5"><a href="e127.full.html#96">(S8.1.2-3,S8.1.2-11,S8.1.2-58)</a></text>
<text top="1093" left="437" width="3" height="12" font="2">,</text>
<text top="824" left="483" width="318" height="12" font="2">supporting the contention that the relative risk</text>
<text top="842" left="483" width="318" height="12" font="2">reduction may be similar at lower levels of absolute</text>
<text top="860" left="483" width="318" height="12" font="2">risk. This is the case even in a meta-analysis of trials in</text>
<text top="878" left="483" width="318" height="12" font="2">adults without clinical CVD and an average SBP/DBP of</text>
<text top="896" left="483" width="92" height="12" font="2">146/84 mm Hg</text>
<text top="896" left="582" width="53" height="12" font="5"><a href="e127.full.html#96">(S8.1.2-5)</a></text>
<text top="896" left="636" width="166" height="12" font="2"><a href="e127.full.html#96">. </a>Finally, modeling studies</text>
<text top="914" left="483" width="318" height="12" font="2">support the effectiveness and cost-effectiveness of</text>
<text top="932" left="483" width="318" height="12" font="2">treatment of younger, lower-risk patients over the</text>
<text top="950" left="483" width="142" height="12" font="2">course of their life spans</text>
<text top="950" left="629" width="112" height="12" font="5"><a href="e127.full.html#96">(S8.1.2-12,S8.1.2-13)</a></text>
<text top="950" left="741" width="60" height="12" font="2"><a href="e127.full.html#96">. </a>Although</text>
<text top="968" left="483" width="318" height="12" font="2">the numbers needed to treat with BP-lowering medi-</text>
<text top="985" left="483" width="318" height="12" font="2">cations to prevent a CVD event in the short term</text>
<text top="1003" left="483" width="318" height="12" font="2">are greater in younger, lower-risk individuals with</text>
<text top="1021" left="483" width="318" height="12" font="2">hypertension than in older, higher-risk adults with</text>
<text top="1039" left="483" width="318" height="12" font="2">hypertension, the estimated gains in life expectancy</text>
<text top="1057" left="483" width="318" height="12" font="2">attributable to long-term use of BP-lowering medica-</text>
<text top="1075" left="483" width="318" height="12" font="2">tions are correspondingly greater in younger, lower-</text>
<text top="1093" left="483" width="318" height="12" font="2">risk individuals than in older adults with a higher</text>
<text top="153" left="125" width="46" height="11" font="22">FIGURE 4</text>
<text top="154" left="179" width="376" height="9" font="23">Blood Pressure (BP) Thresholds and Recommendations for Treatment and Follow-Up</text>
<text top="652" left="125" width="211" height="9" font="13">Colors correspond to Class of Recommendation in</text>
<text top="652" left="339" width="31" height="9" font="17"><a href="e127.full.html#6">Table 1</a></text>
<text top="652" left="369" width="200" height="9" font="13">. *Using the ACC/AHA Pooled Cohort Equations</text>
<text top="652" left="572" width="89" height="9" font="17"><a href="e127.full.html#97">(S8.1.2-56,S8.1.2-57)</a></text>
<text top="652" left="662" width="121" height="9" font="13"><a href="e127.full.html#97">. </a>Note that patients with DM</text>
<text top="667" left="125" width="653" height="9" font="13">or CKD are automatically placed in the high-risk category. For initiation of RAS inhibitor or diuretic therapy, assess blood tests for electrolytes and renal</text>
<text top="682" left="125" width="196" height="9" font="13">function 2 to 4 weeks after initiating therapy.</text>
<text top="680" left="324" width="456" height="12" font="13">†Consider initiation of pharmacological therapy for stage 2 hypertension with 2 antihypertensive agents of</text>
<text top="697" left="125" width="257" height="9" font="13">different classes. Patients with stage 2 hypertension and BP</text>
<text top="695" left="385" width="391" height="12" font="13">$160/100 mm Hg should be promptly treated, carefully monitored, and subject to upward</text>
<text top="712" left="125" width="658" height="9" font="13">medication dose adjustment as necessary to control BP. Reassessment includes BP measurement, detection of orthostatic hypotension in selected patients</text>
<text top="727" left="125" width="198" height="9" font="13">(e.g., older or with postural symptoms), identi</text>
<text top="725" left="323" width="455" height="12" font="13">ﬁcation of white coat hypertension or a white coat effect, documentation of adherence, monitoring of the</text>
<text top="742" left="125" width="658" height="9" font="13">response to therapy, reinforcement of the importance of adherence, reinforcement of the importance of treatment, and assistance with treatment to achieve</text>
<text top="757" left="125" width="637" height="9" font="13">BP target. ACC indicates American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; BP, blood</text>
<text top="772" left="125" width="416" height="9" font="13">pressure; CKD, chronic kidney disease; DM, diabetes mellitus; and RAS, renin-angiotensin system.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e162</text>
</page>
<page number="37" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="78" width="64" height="12" font="2">risk of CVD</text>
<text top="143" left="145" width="112" height="12" font="5"><a href="e127.full.html#96">(S8.1.2-12,S8.1.2-13)</a></text>
<text top="143" left="257" width="139" height="12" font="2">. Indirect support is also</text>
<text top="161" left="78" width="318" height="12" font="2">provided by evidence from trials using BP-lowering</text>
<text top="178" left="78" width="318" height="12" font="2">medications to reduce the risk of developing higher</text>
<text top="196" left="78" width="70" height="12" font="2">levels of BP</text>
<text top="196" left="153" width="56" height="12" font="5"><a href="e127.full.html#97">(S8.1.2-59</a></text>
<text top="195" left="209" width="64" height="15" font="5"><a href="e127.full.html#97">—S8.1.2-61)</a></text>
<text top="196" left="278" width="118" height="12" font="2">and, in one case, to</text>
<text top="214" left="78" width="201" height="12" font="2">achieve a reduction in LV mass</text>
<text top="214" left="286" width="60" height="12" font="5"><a href="e127.full.html#97">(S8.1.2-62)</a></text>
<text top="214" left="347" width="49" height="12" font="2"><a href="e127.full.html#97">. </a>In the</text>
<text top="232" left="78" width="318" height="12" font="2">HOPE-3 (Heart Outcomes Prevention Evaluation-3) BP</text>
<text top="250" left="78" width="306" height="12" font="2">Trial, there was no evidence of short-term bene</text>
<text top="248" left="384" width="12" height="15" font="2">ﬁt</text>
<text top="268" left="78" width="318" height="12" font="2">during treatment of adults (average age 66 years) with</text>
<text top="286" left="78" width="318" height="12" font="2">a relatively low risk of CVD (3.8% CVD event rate</text>
<text top="304" left="78" width="318" height="12" font="2">during 5.6 years of follow-up). However, subgroup</text>
<text top="143" left="438" width="145" height="12" font="2">analysis suggested bene</text>
<text top="141" left="584" width="173" height="15" font="2">ﬁt in those with an average</text>
<text top="161" left="438" width="112" height="12" font="2">SBP approximately</text>
<text top="159" left="556" width="200" height="15" font="2">&gt;140 mm Hg (and a CVD risk of</text>
<text top="178" left="438" width="228" height="12" font="2">6.5% during the 5.6 years of follow-up)</text>
<text top="178" left="670" width="60" height="12" font="5"><a href="e127.full.html#97">(S8.1.2-63)</a></text>
<text top="178" left="731" width="26" height="12" font="2"><a href="e127.full.html#97">. </a>We</text>
<text top="196" left="438" width="318" height="12" font="2">acknowledge the importance of excluding white coat</text>
<text top="214" left="438" width="318" height="12" font="2">hypertension before initiating pharmacological ther-</text>
<text top="232" left="438" width="318" height="12" font="2">apy in hypertensive patients with low ASCVD risk. This</text>
<text top="250" left="438" width="232" height="12" font="2">may be accomplished (as described in</text>
<text top="250" left="676" width="56" height="12" font="5"><a href="e127.full.html#14">Section 4</a></text>
<text top="250" left="732" width="24" height="12" font="2">) by</text>
<text top="268" left="438" width="182" height="12" font="2">HBPM or ABPM as appropriate.</text>
<text top="305" left="423" width="226" height="11" font="2">8.1.3. Follow-Up After Initial BP Evaluation</text>
<text top="359" left="63" width="334" height="11" font="19">Recommendations for Follow-Up After Initial BP Evaluation</text>
<text top="374" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="374" left="412" width="153" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 24</a></text>
<text top="374" left="566" width="3" height="11" font="19">.</text>
<text top="415" left="89" width="19" height="10" font="13">COR</text>
<text top="415" left="161" width="18" height="10" font="13">LOE</text>
<text top="415" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="451" left="97" width="3" height="9" font="4">I</text>
<text top="451" left="163" width="15" height="9" font="4">B-R</text>
<text top="439" left="234" width="568" height="11" font="12">1. Adults with an elevated BP or stage 1 hypertension who have an estimated 10-year ASCVD risk less than</text>
<text top="455" left="246" width="551" height="11" font="12">10% should be managed with nonpharmacological therapy and have a repeat BP evaluation within 3 to</text>
<text top="471" left="246" width="50" height="11" font="12">6 months</text>
<text top="471" left="301" width="97" height="11" font="5"><a href="e127.full.html#97">(S8.1.3-1,S8.1.3-2)</a></text>
<text top="471" left="398" width="3" height="11" font="12">.</text>
<text top="515" left="97" width="3" height="9" font="4">I</text>
<text top="515" left="163" width="15" height="9" font="4">B-R</text>
<text top="503" left="234" width="568" height="11" font="12">2. Adults with stage 1 hypertension who have an estimated 10-year ASCVD risk of 10% or higher should be</text>
<text top="519" left="248" width="554" height="11" font="12">managed initially with a combination of nonpharmacological and antihypertensive drug therapy and have</text>
<text top="534" left="248" width="180" height="11" font="12">a repeat BP evaluation in 1 month</text>
<text top="534" left="432" width="97" height="11" font="5"><a href="e127.full.html#97">(S8.1.3-1,S8.1.3-2)</a></text>
<text top="534" left="530" width="3" height="11" font="12"><a href="e127.full.html#97">.</a></text>
<text top="580" left="97" width="3" height="9" font="4">I</text>
<text top="580" left="163" width="15" height="9" font="4">B-R</text>
<text top="568" left="234" width="559" height="11" font="12">3. Adults with stage 2 hypertension should be evaluated by or referred to a primary care provider within</text>
<text top="584" left="248" width="517" height="11" font="12">1 month of the initial diagnosis, have a combination of nonpharmacological and antihypertensive</text>
<text top="599" left="248" width="547" height="11" font="12">drug therapy (with 2 agents of different classes) initiated, and have a repeat BP evaluation in 1 month</text>
<text top="615" left="248" width="97" height="11" font="5"><a href="e127.full.html#97">(S8.1.3-1,S8.1.3-2)</a></text>
<text top="615" left="345" width="3" height="11" font="12">.</text>
<text top="661" left="97" width="3" height="9" font="4">I</text>
<text top="661" left="163" width="15" height="9" font="4">B-R</text>
<text top="649" left="234" width="272" height="11" font="12">4. For adults with a very high average BP (e.g., SBP</text>
<text top="647" left="509" width="292" height="15" font="12">‡180 mm Hg or DBP ‡110 mm Hg), evaluation followed</text>
<text top="665" left="249" width="323" height="11" font="12">by prompt antihypertensive drug treatment is recommended</text>
<text top="665" left="576" width="97" height="11" font="5"><a href="e127.full.html#97">(S8.1.3-1,S8.1.3-2)</a></text>
<text top="665" left="673" width="3" height="11" font="12">.</text>
<text top="711" left="94" width="10" height="9" font="4">IIa</text>
<text top="711" left="160" width="20" height="9" font="4">C-EO</text>
<text top="698" left="234" width="399" height="11" font="12">5. For adults with a normal BP, repeat evaluation every year is reasonable.</text>
<text top="787" left="63" width="52" height="12" font="2">Synopsis</text>
<text top="805" left="78" width="321" height="12" font="2">An important component of BP management in hyper-</text>
<text top="823" left="63" width="336" height="12" font="2">tensive patients is follow-up. Different periods of time for</text>
<text top="841" left="63" width="336" height="12" font="2">follow-up are recommended depending on the stage of</text>
<text top="859" left="63" width="336" height="12" font="2">hypertension, the presence or absence of target organ</text>
<text top="877" left="63" width="336" height="12" font="2">damage, treatment with antihypertensive medications,</text>
<text top="895" left="63" width="336" height="12" font="2">and the level of BP control. Recommendations for follow-</text>
<text top="913" left="63" width="128" height="12" font="2">up are summarized in</text>
<text top="913" left="194" width="47" height="11" font="5"><a href="e127.full.html#36">Figure 4</a></text>
<text top="913" left="241" width="3" height="12" font="2">.</text>
<text top="956" left="63" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="954" left="202" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="983" left="65" width="214" height="12" font="2">1. Nonpharmacological therapy (see</text>
<text top="983" left="286" width="66" height="12" font="5"><a href="e127.full.html#29">Section 6.2</a></text>
<text top="983" left="353" width="46" height="12" font="2">) is the</text>
<text top="1001" left="79" width="320" height="12" font="2">preferred therapy for adults with elevated BP and an</text>
<text top="1019" left="79" width="67" height="12" font="2">appropriate</text>
<text top="1017" left="153" width="246" height="15" font="2">ﬁrst-line therapy for adults with stage 1</text>
<text top="1037" left="79" width="320" height="12" font="2">hypertension who have an estimated 10-year ASCVD</text>
<text top="1055" left="79" width="42" height="12" font="2">risk of</text>
<text top="1053" left="131" width="268" height="15" font="2">&lt;10%. Adherence to and impact of non-</text>
<text top="1072" left="79" width="320" height="12" font="2">pharmacological therapy should be assessed within 3 to</text>
<text top="1090" left="79" width="58" height="12" font="2">6 months.</text>
<text top="787" left="422" width="335" height="12" font="2">2. Nonpharmacological therapy can help reduce BP in</text>
<text top="805" left="436" width="320" height="12" font="2">patients with stage 1 hypertension with an estimated</text>
<text top="823" left="436" width="135" height="12" font="2">10-year ASCVD risk of</text>
<text top="821" left="578" width="179" height="15" font="2">$10% and should be used in</text>
<text top="841" left="436" width="232" height="12" font="2">addition to pharmacological therapy as</text>
<text top="839" left="674" width="83" height="15" font="2">ﬁrst-line ther-</text>
<text top="859" left="436" width="145" height="12" font="2">apy in such patients (see</text>
<text top="859" left="585" width="64" height="12" font="5"><a href="e127.full.html#29">Section 6.2</a></text>
<text top="859" left="649" width="8" height="12" font="2">).</text>
<text top="877" left="422" width="335" height="12" font="2">3. Prompt evaluation and treatment of patients with stage</text>
<text top="895" left="436" width="320" height="12" font="2">2 hypertension with a combination of drug and non-</text>
<text top="913" left="436" width="320" height="12" font="2">pharmacological therapy are important because of the</text>
<text top="931" left="436" width="320" height="12" font="2">elevated risk of CVD events in this subgroup, especially</text>
<text top="949" left="436" width="320" height="12" font="2">those with multiple ASCVD risk factors or target organ</text>
<text top="966" left="436" width="45" height="12" font="2">damage</text>
<text top="966" left="485" width="100" height="12" font="5"><a href="e127.full.html#97">(S8.1.3-1,S8.1.3-2)</a></text>
<text top="966" left="586" width="3" height="12" font="2"><a href="e127.full.html#97">.</a></text>
<text top="984" left="421" width="336" height="12" font="2">4. Prompt management of very high BP is important to</text>
<text top="1002" left="436" width="271" height="12" font="2">reduce the risk of target organ damage (see</text>
<text top="1002" left="714" width="42" height="12" font="5"><a href="e127.full.html#68">Section</a></text>
<text top="1020" left="436" width="20" height="12" font="5"><a href="e127.full.html#68">11.2</a></text>
<text top="1020" left="457" width="299" height="12" font="2">). The rapidity of the treatment needed is depen-</text>
<text top="1038" left="436" width="113" height="12" font="2">dent on the patient</text>
<text top="1036" left="549" width="207" height="15" font="2">’s clinical presentation (presence of</text>
<text top="1056" left="436" width="320" height="12" font="2">new or worsening target organ damage) and presence</text>
<text top="1074" left="436" width="320" height="12" font="2">or absence of CVD complications, but treatment should</text>
<text top="1092" left="436" width="202" height="12" font="2">be initiated within at least 1 week.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="19" height="9" font="4">e163</text>
</page>
<page number="38" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="109" width="332" height="12" font="2">5. Given that the lifetime risk of hypertension exceeds</text>
<text top="161" left="124" width="104" height="12" font="2">80% in U.S. adults</text>
<text top="161" left="231" width="53" height="12" font="5"><a href="e127.full.html#97">(S8.1.3-3)</a></text>
<text top="161" left="285" width="156" height="12" font="2"><a href="e127.full.html#97">, </a>it is likely that individuals</text>
<text top="178" left="124" width="317" height="12" font="2">with a normal BP will develop elevated BP in the</text>
<text top="196" left="124" width="317" height="12" font="2">future. BP may change over time because of changes in</text>
<text top="214" left="124" width="317" height="12" font="2">BP-related lifestyle factors, such as degree of sedentary</text>
<text top="232" left="124" width="317" height="12" font="2">lifestyle, dietary sodium intake, body weight, and</text>
<text top="250" left="124" width="317" height="12" font="2">alcohol intake. Less commonly, secondary causes of</text>
<text top="143" left="484" width="317" height="12" font="2">hypertension can occur over time and lead to an in-</text>
<text top="161" left="484" width="317" height="12" font="2">crease in BP. Periodic BP screening can identify in-</text>
<text top="178" left="484" width="317" height="12" font="2">dividuals who develop elevated BP over time. More</text>
<text top="196" left="484" width="317" height="12" font="2">frequent BP screening may be particularly important</text>
<text top="214" left="484" width="242" height="12" font="2">for individuals with elevated ASCVD risk.</text>
<text top="250" left="468" width="216" height="11" font="2">8.1.4. General Principles of Drug Therapy</text>
<text top="296" left="63" width="312" height="11" font="19">Recommendation for General Principle of Drug Therapy</text>
<text top="310" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="310" left="412" width="152" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 25</a></text>
<text top="310" left="565" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="351" left="89" width="19" height="10" font="13">COR</text>
<text top="351" left="161" width="18" height="10" font="13">LOE</text>
<text top="351" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="388" left="81" width="35" height="9" font="4">III: Harm</text>
<text top="388" left="168" width="6" height="9" font="4">A</text>
<text top="376" left="234" width="536" height="11" font="12">1. Simultaneous use of an ACE inhibitor, ARB, and/or renin inhibitor is potentially harmful and is not</text>
<text top="392" left="246" width="256" height="11" font="12">recommended to treat adults with hypertension</text>
<text top="392" left="506" width="47" height="11" font="5"><a href="e127.full.html#97">(S8.1.4-1</a></text>
<text top="390" left="553" width="57" height="15" font="5"><a href="e127.full.html#97">—S8.1.4-3)</a></text>
<text top="392" left="610" width="3" height="11" font="12"><a href="e127.full.html#97">.</a></text>
<text top="446" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="464" left="123" width="309" height="12" font="2">Pharmacological agents, in addition to lifestyle modi</text>
<text top="462" left="432" width="12" height="15" font="2">ﬁ-</text>
<text top="482" left="108" width="66" height="12" font="2">cation (see</text>
<text top="482" left="180" width="66" height="12" font="5"><a href="e127.full.html#29">Section 6.2</a></text>
<text top="482" left="247" width="197" height="12" font="2">), provide the primary basis for</text>
<text top="500" left="108" width="336" height="12" font="2">treatment of high BP. A large number of clinical trials have</text>
<text top="518" left="108" width="336" height="12" font="2">demonstrated that antihypertensive pharmacotherapy not</text>
<text top="536" left="108" width="336" height="12" font="2">only lowers BP but reduces the risk of CVD, cerebrovas-</text>
<text top="554" left="108" width="137" height="12" font="2">cular events, and death</text>
<text top="554" left="249" width="51" height="12" font="5"><a href="e127.full.html#97">(S8.1.4-4</a></text>
<text top="552" left="300" width="59" height="15" font="5"><a href="e127.full.html#97">—S8.1.4-7)</a></text>
<text top="554" left="359" width="3" height="12" font="2">.</text>
<text top="572" left="123" width="321" height="12" font="2">Numerous classes of antihypertensive agents are</text>
<text top="590" left="108" width="151" height="12" font="2">available to treat high BP (</text>
<text top="590" left="259" width="46" height="11" font="5"><a href="e127.full.html#39">Table 18</a></text>
<text top="590" left="305" width="139" height="12" font="2">). Agents that have been</text>
<text top="608" left="108" width="336" height="12" font="2">shown to reduce clinical events should be used preferen-</text>
<text top="626" left="108" width="336" height="12" font="2">tially. Therefore, the primary agents used in the treatment</text>
<text top="644" left="108" width="336" height="12" font="2">of hypertension include thiazide diuretics, ACE inhibitors,</text>
<text top="661" left="108" width="97" height="12" font="2">ARBs, and CCBs</text>
<text top="661" left="211" width="51" height="12" font="5"><a href="e127.full.html#97">(S8.1.4-8</a></text>
<text top="660" left="262" width="63" height="15" font="5"><a href="e127.full.html#97">—S8.1.4-11)</a></text>
<text top="661" left="331" width="23" height="12" font="2">(see</text>
<text top="661" left="360" width="76" height="12" font="5"><a href="e127.full.html#42">Section 8.1.6</a></text>
<text top="661" left="436" width="8" height="12" font="2"><a href="e127.full.html#42">).</a></text>
<text top="679" left="108" width="336" height="12" font="2">Although many other drugs and drug classes are available,</text>
<text top="697" left="108" width="62" height="12" font="2">either con</text>
<text top="696" left="170" width="274" height="15" font="2">ﬁrmation that these agents decrease clinical</text>
<text top="715" left="108" width="336" height="12" font="2">outcomes to an extent similar to that of the primary agents</text>
<text top="733" left="108" width="336" height="12" font="2">is lacking, or safety and tolerability may relegate their role</text>
<text top="751" left="108" width="336" height="12" font="2">to use as secondary agents. In particular, there is inade-</text>
<text top="769" left="108" width="336" height="12" font="2">quate evidence to support the initial use of beta blockers</text>
<text top="787" left="108" width="234" height="12" font="2">for hypertension in the absence of speci</text>
<text top="785" left="342" width="102" height="15" font="2">ﬁc cardiovascular</text>
<text top="805" left="108" width="106" height="12" font="2">comorbidities (see</text>
<text top="805" left="218" width="53" height="12" font="5"><a href="e127.full.html#45">Section 9</a></text>
<text top="805" left="272" width="8" height="12" font="2"><a href="e127.full.html#45">).</a></text>
<text top="823" left="123" width="321" height="12" font="2">When the initial drug treatment of high BP is being</text>
<text top="841" left="108" width="336" height="12" font="2">considered, several different strategies may be contem-</text>
<text top="859" left="108" width="336" height="12" font="2">plated. Many patients can be started on a single agent, but</text>
<text top="877" left="108" width="336" height="12" font="2">consideration should be given to starting with 2 drugs of</text>
<text top="895" left="108" width="336" height="12" font="2">different classes for those with stage 2 hypertension (see</text>
<text top="913" left="108" width="82" height="12" font="5"><a href="e127.full.html#43">Section 8.1.6.1</a></text>
<text top="913" left="190" width="193" height="12" font="2">). In addition, other patient-speci</text>
<text top="911" left="384" width="60" height="15" font="2">ﬁc factors,</text>
<text top="931" left="108" width="336" height="12" font="2">such as age, concurrent medications, drug adherence,</text>
<text top="948" left="108" width="336" height="12" font="2">drug interactions, the overall treatment regimen, out-of-</text>
<text top="966" left="108" width="336" height="12" font="2">pocket costs, and comorbidities, should be considered.</text>
<text top="984" left="108" width="336" height="12" font="2">From a societal perspective, total costs must be taken into</text>
<text top="1002" left="108" width="316" height="12" font="2">account. Shared decision making, with the patient in</text>
<text top="1000" left="424" width="20" height="15" font="2">ﬂu-</text>
<text top="1020" left="108" width="336" height="12" font="2">enced by clinician judgment, should drive the ultimate</text>
<text top="1038" left="108" width="209" height="12" font="2">choice of antihypertensive agent(s).</text>
<text top="1056" left="123" width="321" height="12" font="2">Many patients started on a single agent will subsequently</text>
<text top="1074" left="108" width="42" height="12" font="2">require</text>
<text top="1072" left="152" width="291" height="15" font="2">$2 drugs from different pharmacological classes to</text>
<text top="446" left="465" width="31" height="12" font="2">reach</text>
<text top="446" left="511" width="27" height="12" font="2">their</text>
<text top="446" left="553" width="15" height="12" font="2">BP</text>
<text top="446" left="583" width="30" height="12" font="2">goals</text>
<text top="446" left="628" width="170" height="12" font="5"><a href="e127.full.html#97">(S8.1.4-12,S8.1.4-13,S8.1.4-14)</a></text>
<text top="446" left="798" width="3" height="12" font="2"><a href="e127.full.html#97">.</a></text>
<text top="464" left="465" width="336" height="12" font="2">Knowledge of the pharmacological mechanisms of action of</text>
<text top="482" left="465" width="336" height="12" font="2">each agent is important. Drug regimens with complemen-</text>
<text top="500" left="465" width="336" height="12" font="2">tary activity, where a second antihypertensive agent is used</text>
<text top="518" left="465" width="336" height="12" font="2">to block compensatory responses to the initial agent or</text>
<text top="536" left="465" width="336" height="12" font="2">affect a different pressor mechanism, can result in additive</text>
<text top="554" left="465" width="336" height="12" font="2">lowering of BP. For example, thiazide diuretics may</text>
<text top="572" left="465" width="336" height="12" font="2">stimulate the renin-angiotensin-aldosterone system. By</text>
<text top="590" left="465" width="336" height="12" font="2">adding an ACE inhibitor or ARB to the thiazide, an additive</text>
<text top="608" left="465" width="220" height="12" font="2">BP-lowering effect may be obtained</text>
<text top="608" left="692" width="59" height="12" font="5"><a href="e127.full.html#98">(S8.1.4-13)</a></text>
<text top="608" left="752" width="50" height="12" font="2"><a href="e127.full.html#98">. </a>Use of</text>
<text top="626" left="465" width="336" height="12" font="2">combination therapy may also improve adherence. Several</text>
<text top="644" left="465" width="49" height="12" font="2">2- and 3-</text>
<text top="642" left="514" width="287" height="15" font="2">ﬁxed-dose drug combinations of antihypertensive</text>
<text top="661" left="465" width="336" height="12" font="2">drug therapy are available, with complementary mecha-</text>
<text top="679" left="465" width="263" height="12" font="2">nisms of action among the components (</text>
<text top="679" left="729" width="73" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data</a></text>
<text top="697" left="465" width="84" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Supplement D</a></text>
<text top="697" left="549" width="252" height="12" font="2">). However, it should be noted that many</text>
<text top="715" left="465" width="336" height="12" font="2">triple-dose combinations may contain a lower-than-</text>
<text top="733" left="465" width="191" height="12" font="2">optimal dose of thiazide diuretic.</text>
<text top="752" left="480" width="47" height="11" font="5"><a href="e127.full.html#39">Table 18</a></text>
<text top="751" left="531" width="262" height="12" font="2">is a summary of oral antihypertensive drugs.</text>
<text top="778" left="465" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="776" left="604" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="805" left="466" width="336" height="12" font="2">1. Drug combinations that have similar mechanisms of</text>
<text top="823" left="479" width="322" height="12" font="2">action or clinical effects should be avoided. For</text>
<text top="841" left="479" width="322" height="12" font="2">example, 2 drugs from the same class should not be</text>
<text top="859" left="479" width="322" height="12" font="2">administered together (e.g., 2 different beta blockers,</text>
<text top="877" left="479" width="322" height="12" font="2">ACE inhibitors, or nondihydropyridine CCBs). Likewise,</text>
<text top="895" left="479" width="322" height="12" font="2">2 drugs from classes that target the same BP control</text>
<text top="913" left="479" width="322" height="12" font="2">system are less effective and potentially harmful when</text>
<text top="931" left="479" width="322" height="12" font="2">used together (e.g., ACE inhibitors, ARBs). Exceptions</text>
<text top="948" left="479" width="322" height="12" font="2">to this rule include concomitant use of a thiazide</text>
<text top="966" left="479" width="322" height="12" font="2">diuretic, K-sparing diuretic, and/or loop diuretic in</text>
<text top="984" left="479" width="322" height="12" font="2">various combinations. Also, dihydropyridine and non-</text>
<text top="1002" left="479" width="322" height="12" font="2">dihydropyridine CCBs can be combined. High-quality</text>
<text top="1020" left="479" width="322" height="12" font="2">RCT data demonstrate that simultaneous administra-</text>
<text top="1038" left="479" width="322" height="12" font="2">tion of RAS blockers (i.e., ACE inhibitor with ARB; ACE</text>
<text top="1056" left="479" width="322" height="12" font="2">inhibitor or ARB with renin inhibitor aliskiren) increases</text>
<text top="1074" left="479" width="166" height="12" font="2">cardiovascular and renal risk</text>
<text top="1074" left="649" width="49" height="12" font="5"><a href="e127.full.html#97">(S8.1.4-1</a></text>
<text top="1072" left="698" width="59" height="15" font="5"><a href="e127.full.html#97">—S8.1.4-3)</a></text>
<text top="1074" left="757" width="3" height="12" font="2"><a href="e127.full.html#97">.</a></text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e164</text>
</page>
<page number="39" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="25" size="4" family="Times" color="#000000"/>
<text top="149" left="67" width="53" height="10" font="15">T A B L E 1 8</text>
<text top="149" left="135" width="152" height="10" font="16">Oral Antihypertensive Drugs</text>
<text top="185" left="63" width="23" height="9" font="13">Class</text>
<text top="185" left="226" width="22" height="9" font="13">Drug</text>
<text top="173" left="296" width="54" height="9" font="13">Usual Dose,</text>
<text top="185" left="288" width="64" height="9" font="13">Range (mg/d)</text>
<text top="185" left="353" width="4" height="9" font="17"><a href="e127.full.html#40">*</a></text>
<text top="173" left="386" width="23" height="9" font="13">Daily</text>
<text top="185" left="374" width="48" height="9" font="13">Frequency</text>
<text top="185" left="571" width="48" height="9" font="13">Comments</text>
<text top="204" left="63" width="66" height="9" font="18">Primary agents</text>
<text top="224" left="63" width="104" height="9" font="13">Thiazide or thiazide-type</text>
<text top="236" left="75" width="35" height="9" font="13">diuretics</text>
<text top="224" left="195" width="61" height="9" font="13">Chlorthalidone</text>
<text top="224" left="308" width="17" height="9" font="13">12.5</text>
<text top="222" left="324" width="14" height="12" font="13">–25</text>
<text top="224" left="396" width="4" height="9" font="13">1</text>
<text top="223" left="438" width="6" height="10" font="9">n</text>
<text top="223" left="452" width="294" height="9" font="13">Chlorthalidone is preferred on the basis of prolonged half-life and</text>
<text top="235" left="453" width="133" height="9" font="13">proven trial reduction of CVD.</text>
<text top="247" left="438" width="6" height="10" font="9">n</text>
<text top="248" left="452" width="290" height="9" font="13">Monitor for hyponatremia and hypokalemia, uric acid and calcium</text>
<text top="260" left="453" width="28" height="9" font="13">levels.</text>
<text top="272" left="438" width="6" height="10" font="9">n</text>
<text top="273" left="452" width="304" height="9" font="13">Use with caution in patients with history of acute gout unless patient</text>
<text top="285" left="453" width="61" height="9" font="13">is on uric acid</text>
<text top="283" left="514" width="82" height="12" font="13">–lowering therapy.</text>
<text top="243" left="195" width="84" height="9" font="13">Hydrochlorothiazide</text>
<text top="243" left="310" width="10" height="9" font="13">25</text>
<text top="241" left="320" width="16" height="12" font="13">–50</text>
<text top="243" left="396" width="4" height="9" font="13">1</text>
<text top="262" left="195" width="48" height="9" font="13">Indapamide</text>
<text top="262" left="306" width="17" height="9" font="13">1.25</text>
<text top="260" left="323" width="17" height="12" font="13">–2.5</text>
<text top="262" left="396" width="4" height="9" font="13">1</text>
<text top="281" left="195" width="49" height="9" font="13">Metolazone</text>
<text top="281" left="312" width="13" height="9" font="13">2.5</text>
<text top="280" left="325" width="9" height="12" font="13">–5</text>
<text top="281" left="396" width="4" height="9" font="13">1</text>
<text top="304" left="63" width="59" height="9" font="13">ACE inhibitors</text>
<text top="304" left="195" width="43" height="9" font="13">Benazepril</text>
<text top="304" left="310" width="10" height="9" font="13">10</text>
<text top="302" left="320" width="16" height="12" font="13">–40</text>
<text top="304" left="386" width="24" height="9" font="13">1 or 2</text>
<text top="303" left="438" width="6" height="10" font="9">n</text>
<text top="304" left="452" width="274" height="9" font="13">Do not use in combination with ARBs or direct renin inhibitor.</text>
<text top="316" left="438" width="6" height="10" font="9">n</text>
<text top="316" left="452" width="304" height="9" font="13">There is an increased risk of hyperkalemia, especially in patients with</text>
<text top="328" left="453" width="92" height="9" font="13">CKD or in those on K</text>
<text top="326" left="545" width="5" height="8" font="25">þ</text>
<text top="328" left="554" width="77" height="9" font="13">supplements or K</text>
<text top="326" left="631" width="5" height="8" font="25">þ</text>
<text top="328" left="637" width="67" height="9" font="13">-sparing drugs.</text>
<text top="340" left="438" width="6" height="10" font="9">n</text>
<text top="341" left="452" width="301" height="9" font="13">There is a risk of acute renal failure in patients with severe bilateral</text>
<text top="353" left="453" width="93" height="9" font="13">renal artery stenosis.</text>
<text top="365" left="438" width="6" height="10" font="9">n</text>
<text top="366" left="452" width="302" height="9" font="13">Do not use if patient has history of angioedema with ACE inhibitors.</text>
<text top="378" left="438" width="6" height="10" font="9">n</text>
<text top="379" left="452" width="88" height="9" font="13">Avoid in pregnancy.</text>
<text top="323" left="195" width="38" height="9" font="13">Captopril</text>
<text top="323" left="305" width="17" height="9" font="13">12.5</text>
<text top="322" left="322" width="20" height="12" font="13">–150</text>
<text top="323" left="386" width="25" height="9" font="13">2 or 3</text>
<text top="342" left="195" width="36" height="9" font="13">Enalapril</text>
<text top="342" left="312" width="5" height="9" font="13">5</text>
<text top="341" left="317" width="16" height="12" font="13">–40</text>
<text top="342" left="386" width="24" height="9" font="13">1 or 2</text>
<text top="362" left="195" width="41" height="9" font="13">Fosinopril</text>
<text top="362" left="310" width="10" height="9" font="13">10</text>
<text top="360" left="320" width="16" height="12" font="13">–40</text>
<text top="362" left="396" width="4" height="9" font="13">1</text>
<text top="381" left="195" width="38" height="9" font="13">Lisinopril</text>
<text top="381" left="310" width="10" height="9" font="13">10</text>
<text top="379" left="320" width="16" height="12" font="13">–40</text>
<text top="381" left="396" width="4" height="9" font="13">1</text>
<text top="400" left="195" width="39" height="9" font="13">Moexipril</text>
<text top="400" left="309" width="12" height="9" font="13">7.5</text>
<text top="398" left="321" width="15" height="12" font="13">–30</text>
<text top="400" left="386" width="24" height="9" font="13">1 or 2</text>
<text top="419" left="195" width="45" height="9" font="13">Perindopril</text>
<text top="419" left="313" width="6" height="9" font="13">4</text>
<text top="418" left="319" width="14" height="12" font="13">–16</text>
<text top="419" left="396" width="4" height="9" font="13">1</text>
<text top="438" left="195" width="38" height="9" font="13">Quinapril</text>
<text top="438" left="310" width="10" height="9" font="13">10</text>
<text top="437" left="320" width="16" height="12" font="13">–80</text>
<text top="438" left="386" width="24" height="9" font="13">1 or 2</text>
<text top="458" left="195" width="34" height="9" font="13">Ramipril</text>
<text top="458" left="309" width="13" height="9" font="13">2.5</text>
<text top="456" left="322" width="16" height="12" font="13">–20</text>
<text top="458" left="386" width="24" height="9" font="13">1 or 2</text>
<text top="477" left="195" width="50" height="9" font="13">Trandolapril</text>
<text top="477" left="316" width="4" height="9" font="13">1</text>
<text top="475" left="320" width="10" height="12" font="13">–4</text>
<text top="477" left="396" width="4" height="9" font="13">1</text>
<text top="496" left="63" width="21" height="9" font="13">ARBs</text>
<text top="496" left="195" width="41" height="9" font="13">Azilsartan</text>
<text top="496" left="309" width="12" height="9" font="13">40</text>
<text top="494" left="321" width="16" height="12" font="13">–80</text>
<text top="496" left="396" width="4" height="9" font="13">1</text>
<text top="495" left="438" width="6" height="10" font="9">n</text>
<text top="496" left="452" width="304" height="9" font="13">Do not use in combination with ACE inhibitors or direct renin inhibitor.</text>
<text top="508" left="438" width="6" height="10" font="9">n</text>
<text top="508" left="452" width="292" height="9" font="13">There is an increased risk of hyperkalemia in CKD or in those on K</text>
<text top="506" left="745" width="5" height="8" font="25">þ</text>
<text top="520" left="453" width="77" height="9" font="13">supplements or K</text>
<text top="518" left="530" width="5" height="8" font="25">þ</text>
<text top="520" left="536" width="67" height="9" font="13">-sparing drugs.</text>
<text top="532" left="438" width="6" height="10" font="9">n</text>
<text top="533" left="452" width="301" height="9" font="13">There is a risk of acute renal failure in patients with severe bilateral</text>
<text top="545" left="453" width="93" height="9" font="13">renal artery stenosis.</text>
<text top="557" left="438" width="6" height="10" font="9">n</text>
<text top="558" left="452" width="212" height="9" font="13">Do not use if patient has history of angioedema</text>
<text top="571" left="453" width="291" height="9" font="13">with ARBs. Patients with a history of angioedema with an ACE in-</text>
<text top="582" left="453" width="298" height="9" font="13">hibitor can receive an ARB beginning 6 weeks after ACE inhibitor is</text>
<text top="594" left="453" width="59" height="9" font="13">discontinued.</text>
<text top="608" left="438" width="6" height="10" font="9">n</text>
<text top="609" left="452" width="88" height="9" font="13">Avoid in pregnancy.</text>
<text top="515" left="195" width="51" height="9" font="13">Candesartan</text>
<text top="515" left="313" width="6" height="9" font="13">8</text>
<text top="514" left="319" width="14" height="12" font="13">–32</text>
<text top="515" left="396" width="4" height="9" font="13">1</text>
<text top="534" left="195" width="45" height="9" font="13">Eprosartan</text>
<text top="534" left="302" width="18" height="9" font="13">600</text>
<text top="533" left="321" width="23" height="12" font="13">–800</text>
<text top="534" left="386" width="24" height="9" font="13">1 or 2</text>
<text top="554" left="195" width="42" height="9" font="13">Irbesartan</text>
<text top="554" left="304" width="15" height="9" font="13">150</text>
<text top="552" left="320" width="22" height="12" font="13">–300</text>
<text top="554" left="396" width="4" height="9" font="13">1</text>
<text top="573" left="195" width="36" height="9" font="13">Losartan</text>
<text top="573" left="307" width="11" height="9" font="13">50</text>
<text top="571" left="318" width="21" height="12" font="13">–100</text>
<text top="573" left="386" width="24" height="9" font="13">1 or 2</text>
<text top="592" left="195" width="48" height="9" font="13">Olmesartan</text>
<text top="592" left="309" width="11" height="9" font="13">20</text>
<text top="590" left="321" width="16" height="12" font="13">–40</text>
<text top="592" left="396" width="4" height="9" font="13">1</text>
<text top="611" left="195" width="49" height="9" font="13">Telmisartan</text>
<text top="611" left="309" width="11" height="9" font="13">20</text>
<text top="610" left="321" width="16" height="12" font="13">–80</text>
<text top="611" left="396" width="4" height="9" font="13">1</text>
<text top="630" left="195" width="39" height="9" font="13">Valsartan</text>
<text top="630" left="307" width="12" height="9" font="13">80</text>
<text top="629" left="319" width="21" height="12" font="13">–320</text>
<text top="630" left="396" width="4" height="9" font="13">1</text>
<text top="650" left="63" width="17" height="9" font="13">CCB</text>
<text top="648" left="80" width="76" height="12" font="13">—dihydropyridines</text>
<text top="650" left="195" width="47" height="9" font="13">Amlodipine</text>
<text top="650" left="309" width="13" height="9" font="13">2.5</text>
<text top="648" left="322" width="14" height="12" font="13">–10</text>
<text top="650" left="396" width="4" height="9" font="13">1</text>
<text top="649" left="438" width="6" height="10" font="9">n</text>
<text top="649" left="452" width="294" height="9" font="13">Avoid use in patients with HFrEF; amlodipine or felodipine may be</text>
<text top="661" left="453" width="72" height="9" font="13">used if required.</text>
<text top="673" left="438" width="6" height="10" font="9">n</text>
<text top="674" left="452" width="295" height="9" font="13">They are associated with dose-related pedal edema, which is more</text>
<text top="686" left="453" width="131" height="9" font="13">common in women than men.</text>
<text top="669" left="195" width="43" height="9" font="13">Felodipine</text>
<text top="669" left="309" width="13" height="9" font="13">2.5</text>
<text top="667" left="322" width="14" height="12" font="13">–10</text>
<text top="669" left="396" width="4" height="9" font="13">1</text>
<text top="688" left="195" width="40" height="9" font="13">Isradipine</text>
<text top="688" left="313" width="5" height="9" font="13">5</text>
<text top="686" left="318" width="14" height="12" font="13">–10</text>
<text top="688" left="395" width="5" height="9" font="13">2</text>
<text top="707" left="195" width="60" height="9" font="13">Nicardipine SR</text>
<text top="707" left="307" width="12" height="9" font="13">60</text>
<text top="706" left="319" width="19" height="12" font="13">–120</text>
<text top="707" left="395" width="5" height="9" font="13">2</text>
<text top="726" left="195" width="56" height="9" font="13">Nifedipine LA</text>
<text top="726" left="309" width="11" height="9" font="13">30</text>
<text top="725" left="320" width="16" height="12" font="13">–90</text>
<text top="726" left="396" width="4" height="9" font="13">1</text>
<text top="746" left="195" width="46" height="9" font="13">Nisoldipine</text>
<text top="746" left="311" width="9" height="9" font="13">17</text>
<text top="744" left="320" width="15" height="12" font="13">–34</text>
<text top="746" left="396" width="4" height="9" font="13">1</text>
<text top="765" left="63" width="17" height="9" font="13">CCB</text>
<text top="763" left="80" width="92" height="12" font="13">—nondihydropyridines</text>
<text top="765" left="195" width="53" height="9" font="13">Diltiazem ER</text>
<text top="765" left="305" width="15" height="9" font="13">120</text>
<text top="763" left="320" width="21" height="12" font="13">–360</text>
<text top="765" left="396" width="4" height="9" font="13">1</text>
<text top="764" left="438" width="6" height="10" font="9">n</text>
<text top="765" left="452" width="289" height="9" font="13">Avoid routine use with beta blockers because of increased risk of</text>
<text top="777" left="453" width="126" height="9" font="13">bradycardia and heart block.</text>
<text top="789" left="438" width="6" height="10" font="9">n</text>
<text top="789" left="452" width="153" height="9" font="13">Do not use in patients with HFrEF.</text>
<text top="801" left="438" width="6" height="10" font="9">n</text>
<text top="802" left="452" width="292" height="9" font="13">There are drug interactions with diltiazem and verapamil (CYP3A4</text>
<text top="814" left="453" width="180" height="9" font="13">major substrate and moderate inhibitor).</text>
<text top="784" left="195" width="53" height="9" font="13">Verapamil IR</text>
<text top="784" left="305" width="15" height="9" font="13">120</text>
<text top="782" left="320" width="21" height="12" font="13">–360</text>
<text top="784" left="396" width="5" height="9" font="13">3</text>
<text top="803" left="195" width="55" height="9" font="13">Verapamil SR</text>
<text top="803" left="305" width="15" height="9" font="13">120</text>
<text top="802" left="320" width="21" height="12" font="13">–360</text>
<text top="803" left="386" width="24" height="9" font="13">1 or 2</text>
<text top="822" left="195" width="78" height="9" font="13">Verapamil-delayed</text>
<text top="834" left="210" width="37" height="9" font="13">onset ER</text>
<text top="822" left="304" width="17" height="9" font="13">100</text>
<text top="821" left="320" width="22" height="12" font="13">–300</text>
<text top="822" left="381" width="35" height="9" font="13">1 (in the</text>
<text top="834" left="388" width="36" height="9" font="13">evening)</text>
<text top="854" left="63" width="76" height="9" font="18">Secondary agents</text>
<text top="873" left="63" width="36" height="9" font="13">Diuretics</text>
<text top="871" left="99" width="25" height="12" font="13">—loop</text>
<text top="873" left="195" width="50" height="9" font="13">Bumetanide</text>
<text top="873" left="311" width="14" height="9" font="13">0.5</text>
<text top="871" left="325" width="9" height="12" font="13">–2</text>
<text top="873" left="395" width="5" height="9" font="13">2</text>
<text top="872" left="438" width="6" height="10" font="9">n</text>
<text top="873" left="452" width="302" height="9" font="13">These are preferred diuretics in patients with symptomatic HF. They</text>
<text top="885" left="453" width="304" height="9" font="13">are preferred over thiazides in patients with moderate-to-severe CKD</text>
<text top="897" left="453" width="44" height="9" font="13">(e.g., GFR</text>
<text top="895" left="500" width="62" height="12" font="13">&lt;30 mL/min).</text>
<text top="892" left="195" width="48" height="9" font="13">Furosemide</text>
<text top="892" left="309" width="11" height="9" font="13">20</text>
<text top="890" left="321" width="16" height="12" font="13">–80</text>
<text top="892" left="395" width="5" height="9" font="13">2</text>
<text top="911" left="195" width="43" height="9" font="13">Torsemide</text>
<text top="911" left="313" width="5" height="9" font="13">5</text>
<text top="910" left="318" width="14" height="12" font="13">–10</text>
<text top="911" left="396" width="4" height="9" font="13">1</text>
<text top="929" left="63" width="36" height="9" font="13">Diuretics</text>
<text top="927" left="99" width="82" height="12" font="13">—potassium sparing</text>
<text top="929" left="195" width="40" height="9" font="13">Amiloride</text>
<text top="929" left="313" width="5" height="9" font="13">5</text>
<text top="927" left="318" width="14" height="12" font="13">–10</text>
<text top="929" left="386" width="24" height="9" font="13">1 or 2</text>
<text top="928" left="438" width="6" height="10" font="9">n</text>
<text top="929" left="452" width="293" height="9" font="13">These are monotherapy agents and minimally effective antihyper-</text>
<text top="941" left="453" width="67" height="9" font="13">tensive agents.</text>
<text top="953" left="438" width="6" height="10" font="9">n</text>
<text top="953" left="452" width="294" height="9" font="13">Combination therapy of potassium-sparing diuretic with a thiazide</text>
<text top="965" left="453" width="262" height="9" font="13">can be considered in patients with hypokalemia on thiazide</text>
<text top="977" left="453" width="61" height="9" font="13">monotherapy.</text>
<text top="989" left="438" width="6" height="10" font="9">n</text>
<text top="990" left="452" width="121" height="9" font="13">Avoid in patients with signi</text>
<text top="988" left="573" width="157" height="12" font="13">ﬁcant CKD (e.g., GFR &lt;45 mL/min).</text>
<text top="944" left="195" width="50" height="9" font="13">Triamterene</text>
<text top="944" left="307" width="11" height="9" font="13">50</text>
<text top="942" left="318" width="21" height="12" font="13">–100</text>
<text top="944" left="386" width="24" height="9" font="13">1 or 2</text>
<text top="1010" left="651" width="105" height="8" font="4">Continued on the next page</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="19" height="9" font="4">e165</text>
</page>
<page number="40" position="absolute" top="0" left="0" height="1160" width="864">
<text top="149" left="112" width="53" height="10" font="15">T A B L E 1 8</text>
<text top="149" left="179" width="53" height="10" font="16">Continued</text>
<text top="184" left="107" width="22" height="9" font="13">Class</text>
<text top="184" left="271" width="22" height="9" font="13">Drug</text>
<text top="173" left="340" width="54" height="9" font="13">Usual Dose,</text>
<text top="184" left="333" width="64" height="9" font="13">Range (mg/d)</text>
<text top="184" left="398" width="4" height="9" font="17"><a href="e127.full.html#40">*</a></text>
<text top="173" left="431" width="23" height="9" font="13">Daily</text>
<text top="184" left="418" width="48" height="9" font="13">Frequency</text>
<text top="184" left="615" width="48" height="9" font="13">Comments</text>
<text top="204" left="107" width="36" height="9" font="13">Diuretics</text>
<text top="202" left="143" width="56" height="12" font="13">—aldosterone</text>
<text top="216" left="120" width="48" height="9" font="13">antagonists</text>
<text top="204" left="240" width="47" height="9" font="13">Eplerenone</text>
<text top="204" left="351" width="11" height="9" font="13">50</text>
<text top="202" left="363" width="21" height="12" font="13">–100</text>
<text top="204" left="430" width="24" height="9" font="13">1 or 2</text>
<text top="202" left="483" width="6" height="10" font="9">n</text>
<text top="203" left="497" width="293" height="9" font="13">These are preferred agents in primary aldosteronism and resistant</text>
<text top="215" left="497" width="60" height="9" font="13">hypertension.</text>
<text top="227" left="483" width="6" height="10" font="9">n</text>
<text top="227" left="497" width="296" height="9" font="13">Spironolactone is associated with greater risk of gynecomastia and</text>
<text top="239" left="497" width="183" height="9" font="13">impotence as compared with eplerenone.</text>
<text top="251" left="483" width="6" height="10" font="9">n</text>
<text top="252" left="497" width="255" height="9" font="13">This is common add-on therapy in resistant hypertension.</text>
<text top="264" left="483" width="6" height="10" font="9">n</text>
<text top="265" left="497" width="74" height="9" font="13">Avoid use with K</text>
<text top="262" left="571" width="5" height="8" font="25">þ</text>
<text top="265" left="580" width="95" height="9" font="13">supplements, other K</text>
<text top="262" left="675" width="5" height="8" font="25">þ</text>
<text top="265" left="680" width="112" height="9" font="13">-sparing diuretics, or sig-</text>
<text top="277" left="497" width="8" height="9" font="13">ni</text>
<text top="275" left="505" width="107" height="12" font="13">ﬁcant renal dysfunction.</text>
<text top="288" left="483" width="6" height="10" font="9">n</text>
<text top="289" left="497" width="274" height="9" font="13">Eplerenone often requires twice-daily dosing for adequate BP</text>
<text top="301" left="497" width="41" height="9" font="13">lowering.</text>
<text top="227" left="240" width="62" height="9" font="13">Spironolactone</text>
<text top="227" left="352" width="10" height="9" font="13">25</text>
<text top="225" left="362" width="21" height="12" font="13">–100</text>
<text top="227" left="440" width="4" height="9" font="13">1</text>
<text top="320" left="107" width="57" height="9" font="13">Beta blockers</text>
<text top="319" left="164" width="7" height="12" font="13">—</text>
<text top="332" left="120" width="62" height="9" font="13">cardioselective</text>
<text top="319" left="240" width="36" height="9" font="13">Atenolol</text>
<text top="319" left="352" width="10" height="9" font="13">25</text>
<text top="317" left="362" width="21" height="12" font="13">–100</text>
<text top="319" left="440" width="5" height="9" font="13">2</text>
<text top="320" left="483" width="6" height="10" font="9">n</text>
<text top="320" left="497" width="172" height="9" font="13">Beta blockers are not recommended as</text>
<text top="319" left="672" width="119" height="12" font="13">ﬁrst-line agents unless the</text>
<text top="332" left="497" width="99" height="9" font="13">patient has IHD or HF.</text>
<text top="344" left="483" width="6" height="10" font="9">n</text>
<text top="345" left="497" width="295" height="9" font="13">These are preferred in patients with bronchospastic airway disease</text>
<text top="357" left="497" width="109" height="9" font="13">requiring a beta blocker.</text>
<text top="369" left="483" width="6" height="10" font="9">n</text>
<text top="370" left="497" width="294" height="9" font="13">Bisoprolol and metoprolol succinate are preferred in patients with</text>
<text top="382" left="497" width="29" height="9" font="13">HFrEF.</text>
<text top="393" left="483" width="6" height="10" font="9">n</text>
<text top="394" left="497" width="104" height="9" font="13">Avoid abrupt cessation.</text>
<text top="335" left="240" width="39" height="9" font="13">Betaxolol</text>
<text top="335" left="357" width="5" height="9" font="13">5</text>
<text top="334" left="362" width="16" height="12" font="13">–20</text>
<text top="335" left="440" width="4" height="9" font="13">1</text>
<text top="355" left="240" width="42" height="9" font="13">Bisoprolol</text>
<text top="355" left="354" width="13" height="9" font="13">2.5</text>
<text top="353" left="367" width="14" height="12" font="13">–10</text>
<text top="355" left="440" width="4" height="9" font="13">1</text>
<text top="374" left="240" width="81" height="9" font="13">Metoprolol tartrate</text>
<text top="374" left="348" width="17" height="9" font="13">100</text>
<text top="372" left="365" width="22" height="12" font="13">–200</text>
<text top="374" left="440" width="5" height="9" font="13">2</text>
<text top="393" left="240" width="46" height="9" font="13">Metoprolol</text>
<text top="405" left="255" width="39" height="9" font="13">succinate</text>
<text top="393" left="351" width="11" height="9" font="13">50</text>
<text top="391" left="362" width="22" height="12" font="13">–200</text>
<text top="393" left="440" width="4" height="9" font="13">1</text>
<text top="424" left="107" width="57" height="9" font="13">Beta blockers</text>
<text top="422" left="164" width="7" height="12" font="13">—</text>
<text top="436" left="122" width="80" height="9" font="13">cardioselective and</text>
<text top="448" left="122" width="51" height="9" font="13">vasodilatory</text>
<text top="424" left="240" width="40" height="9" font="13">Nebivolol</text>
<text top="424" left="357" width="5" height="9" font="13">5</text>
<text top="422" left="362" width="16" height="12" font="13">–40</text>
<text top="424" left="440" width="4" height="9" font="13">1</text>
<text top="427" left="483" width="6" height="10" font="9">n</text>
<text top="428" left="497" width="131" height="9" font="13">Nebivolol induces nitric oxide</text>
<text top="426" left="628" width="98" height="12" font="13">–induced vasodilation.</text>
<text top="440" left="483" width="6" height="10" font="9">n</text>
<text top="441" left="497" width="104" height="9" font="13">Avoid abrupt cessation.</text>
<text top="467" left="107" width="57" height="9" font="13">Beta blockers</text>
<text top="466" left="164" width="7" height="12" font="13">—</text>
<text top="479" left="120" width="77" height="9" font="13">noncardioselective</text>
<text top="466" left="240" width="32" height="9" font="13">Nadolol</text>
<text top="466" left="352" width="12" height="9" font="13">40</text>
<text top="464" left="364" width="19" height="12" font="13">–120</text>
<text top="466" left="440" width="4" height="9" font="13">1</text>
<text top="466" left="483" width="6" height="10" font="9">n</text>
<text top="467" left="497" width="209" height="9" font="13">Avoid in patients with reactive airways disease.</text>
<text top="479" left="483" width="6" height="10" font="9">n</text>
<text top="480" left="497" width="104" height="9" font="13">Avoid abrupt cessation.</text>
<text top="482" left="240" width="60" height="9" font="13">Propranolol IR</text>
<text top="482" left="351" width="12" height="9" font="13">80</text>
<text top="481" left="363" width="20" height="12" font="13">–160</text>
<text top="482" left="440" width="5" height="9" font="13">2</text>
<text top="501" left="240" width="63" height="9" font="13">Propranolol LA</text>
<text top="501" left="351" width="12" height="9" font="13">80</text>
<text top="500" left="363" width="20" height="12" font="13">–160</text>
<text top="501" left="440" width="4" height="9" font="13">1</text>
<text top="521" left="107" width="57" height="9" font="13">Beta blockers</text>
<text top="519" left="164" width="39" height="12" font="13">—intrinsic</text>
<text top="533" left="120" width="107" height="9" font="13">sympathomimetic activity</text>
<text top="519" left="240" width="45" height="9" font="13">Acebutolol</text>
<text top="519" left="347" width="18" height="9" font="13">200</text>
<text top="517" left="365" width="23" height="12" font="13">–800</text>
<text top="519" left="440" width="5" height="9" font="13">2</text>
<text top="520" left="483" width="6" height="10" font="9">n</text>
<text top="520" left="497" width="240" height="9" font="13">Generally avoid, especially in patients with IHD or HF.</text>
<text top="532" left="483" width="6" height="10" font="9">n</text>
<text top="533" left="497" width="104" height="9" font="13">Avoid abrupt cessation.</text>
<text top="533" left="240" width="46" height="9" font="13">Penbutolol</text>
<text top="533" left="354" width="10" height="9" font="13">10</text>
<text top="532" left="364" width="16" height="12" font="13">–40</text>
<text top="533" left="440" width="4" height="9" font="13">1</text>
<text top="551" left="240" width="34" height="9" font="13">Pindolol</text>
<text top="551" left="354" width="10" height="9" font="13">10</text>
<text top="549" left="364" width="16" height="12" font="13">–60</text>
<text top="551" left="440" width="5" height="9" font="13">2</text>
<text top="570" left="107" width="57" height="9" font="13">Beta blockers</text>
<text top="569" left="164" width="47" height="12" font="13">—combined</text>
<text top="582" left="120" width="105" height="9" font="13">alpha- and beta-receptor</text>
<text top="569" left="240" width="42" height="9" font="13">Carvedilol</text>
<text top="569" left="351" width="17" height="9" font="13">12.5</text>
<text top="567" left="368" width="16" height="12" font="13">–50</text>
<text top="569" left="440" width="5" height="9" font="13">2</text>
<text top="569" left="483" width="6" height="10" font="9">n</text>
<text top="570" left="497" width="204" height="9" font="13">Carvedilol is preferred in patients with HFrEF.</text>
<text top="582" left="483" width="6" height="10" font="9">n</text>
<text top="583" left="497" width="104" height="9" font="13">Avoid abrupt cessation.</text>
<text top="585" left="240" width="42" height="9" font="13">Carvedilol</text>
<text top="597" left="255" width="44" height="9" font="13">phosphate</text>
<text top="585" left="354" width="11" height="9" font="13">20</text>
<text top="584" left="365" width="16" height="12" font="13">–80</text>
<text top="585" left="440" width="4" height="9" font="13">1</text>
<text top="616" left="240" width="39" height="9" font="13">Labetalol</text>
<text top="616" left="347" width="18" height="9" font="13">200</text>
<text top="615" left="365" width="23" height="12" font="13">–800</text>
<text top="616" left="440" width="5" height="9" font="13">2</text>
<text top="636" left="107" width="87" height="9" font="13">Direct renin inhibitor</text>
<text top="636" left="240" width="35" height="9" font="13">Aliskiren</text>
<text top="636" left="349" width="15" height="9" font="13">150</text>
<text top="634" left="364" width="22" height="12" font="13">–300</text>
<text top="636" left="440" width="4" height="9" font="13">1</text>
<text top="635" left="483" width="6" height="10" font="9">n</text>
<text top="636" left="497" width="245" height="9" font="13">Do not use in combination with ACE inhibitors or ARBs.</text>
<text top="647" left="483" width="6" height="10" font="9">n</text>
<text top="648" left="497" width="125" height="9" font="13">Aliskiren is very long acting.</text>
<text top="660" left="483" width="6" height="10" font="9">n</text>
<text top="661" left="497" width="292" height="9" font="13">There is an increased risk of hyperkalemia in CKD or in those on K</text>
<text top="658" left="789" width="5" height="8" font="25">þ</text>
<text top="673" left="497" width="77" height="9" font="13">supplements or K</text>
<text top="670" left="575" width="5" height="8" font="25">þ</text>
<text top="673" left="580" width="67" height="9" font="13">-sparing drugs.</text>
<text top="685" left="483" width="6" height="10" font="9">n</text>
<text top="686" left="497" width="302" height="9" font="13">Aliskiren may cause acute renal failure in patients with severe bilat-</text>
<text top="698" left="497" width="113" height="9" font="13">eral renal artery stenosis.</text>
<text top="709" left="483" width="6" height="10" font="9">n</text>
<text top="710" left="497" width="87" height="9" font="13">Avoid in pregnancy.</text>
<text top="730" left="107" width="69" height="9" font="13">Alpha-1 blockers</text>
<text top="728" left="240" width="42" height="9" font="13">Doxazosin</text>
<text top="728" left="358" width="4" height="9" font="13">1</text>
<text top="726" left="362" width="14" height="12" font="13">–16</text>
<text top="728" left="440" width="4" height="9" font="13">1</text>
<text top="728" left="483" width="6" height="10" font="9">n</text>
<text top="729" left="497" width="304" height="9" font="13">These are associated with orthostatic hypotension, especially in older</text>
<text top="741" left="497" width="30" height="9" font="13">adults.</text>
<text top="753" left="483" width="6" height="10" font="9">n</text>
<text top="754" left="497" width="274" height="9" font="13">They may be considered as second-line agent in patients with</text>
<text top="766" left="497" width="79" height="9" font="13">concomitant BPH.</text>
<text top="742" left="240" width="35" height="9" font="13">Prazosin</text>
<text top="742" left="357" width="5" height="9" font="13">2</text>
<text top="741" left="362" width="16" height="12" font="13">–20</text>
<text top="742" left="430" width="25" height="9" font="13">2 or 3</text>
<text top="760" left="240" width="39" height="9" font="13">Terazosin</text>
<text top="760" left="358" width="4" height="9" font="13">1</text>
<text top="758" left="362" width="16" height="12" font="13">–20</text>
<text top="760" left="430" width="24" height="9" font="13">1 or 2</text>
<text top="785" left="107" width="56" height="9" font="13">Central alpha</text>
<text top="789" left="163" width="4" height="6" font="25">2</text>
<text top="785" left="167" width="53" height="9" font="13">-agonist and</text>
<text top="797" left="120" width="90" height="9" font="13">other centrally acting</text>
<text top="809" left="120" width="23" height="9" font="13">drugs</text>
<text top="785" left="240" width="58" height="9" font="13">Clonidine oral</text>
<text top="785" left="351" width="13" height="9" font="13">0.1</text>
<text top="783" left="364" width="19" height="12" font="13">–0.8</text>
<text top="785" left="440" width="5" height="9" font="13">2</text>
<text top="784" left="483" width="6" height="10" font="9">n</text>
<text top="785" left="497" width="254" height="9" font="13">These are generally reserved as last-line because of signi</text>
<text top="783" left="751" width="45" height="12" font="13">ﬁcant CNS</text>
<text top="797" left="497" width="187" height="9" font="13">adverse effects, especially in older adults.</text>
<text top="809" left="483" width="6" height="10" font="9">n</text>
<text top="810" left="497" width="300" height="9" font="13">Avoid abrupt discontinuation of clonidine, which may induce hyper-</text>
<text top="822" left="497" width="257" height="9" font="13">tensive crisis; clonidine must be tapered to avoid rebound</text>
<text top="834" left="497" width="60" height="9" font="13">hypertension.</text>
<text top="808" left="240" width="65" height="9" font="13">Clonidine patch</text>
<text top="808" left="352" width="13" height="9" font="13">0.1</text>
<text top="806" left="365" width="18" height="12" font="13">–0.3</text>
<text top="808" left="424" width="36" height="9" font="13">1 weekly</text>
<text top="827" left="240" width="50" height="9" font="13">Methyldopa</text>
<text top="827" left="346" width="16" height="9" font="13">250</text>
<text top="825" left="362" width="27" height="12" font="13">–1000</text>
<text top="827" left="440" width="5" height="9" font="13">2</text>
<text top="846" left="240" width="46" height="9" font="13">Guanfacine</text>
<text top="846" left="356" width="14" height="9" font="13">0.5</text>
<text top="845" left="370" width="9" height="12" font="13">–2</text>
<text top="846" left="440" width="4" height="9" font="13">1</text>
<text top="866" left="107" width="78" height="9" font="13">Direct vasodilators</text>
<text top="864" left="240" width="49" height="9" font="13">Hydralazine</text>
<text top="864" left="348" width="17" height="9" font="13">100</text>
<text top="862" left="365" width="22" height="12" font="13">–200</text>
<text top="864" left="430" width="25" height="9" font="13">2 or 3</text>
<text top="865" left="483" width="6" height="10" font="9">n</text>
<text top="865" left="497" width="271" height="9" font="13">These are associated with sodium and water retention and re</text>
<text top="864" left="768" width="16" height="12" font="13">ﬂex</text>
<text top="877" left="497" width="218" height="9" font="13">tachycardia; use with a diuretic and beta blocker.</text>
<text top="889" left="483" width="6" height="10" font="9">n</text>
<text top="890" left="497" width="300" height="9" font="13">Hydralazine is associated with drug-induced lupus-like syndrome at</text>
<text top="902" left="497" width="59" height="9" font="13">higher doses.</text>
<text top="914" left="483" width="6" height="10" font="9">n</text>
<text top="915" left="497" width="293" height="9" font="13">Minoxidil is associated with hirsutism and requires a loop diuretic.</text>
<text top="927" left="497" width="181" height="9" font="13">Minoxidil can induce pericardial effusion.</text>
<text top="880" left="240" width="38" height="9" font="13">Minoxidil</text>
<text top="880" left="355" width="5" height="9" font="13">5</text>
<text top="879" left="360" width="21" height="12" font="13">–100</text>
<text top="880" left="434" width="16" height="9" font="13">1 -3</text>
<text top="950" left="107" width="309" height="8" font="4">*Dosages may vary from those listed in the FDA-approved labeling (available at</text>
<text top="950" left="419" width="153" height="8" font="8"><a href="https://dailymed.nlm.nih.gov/dailymed/">https://dailymed.nlm.nih.gov/dailymed/</a></text>
<text top="950" left="572" width="119" height="8" font="4">). From Chobanian et al. JNC 7</text>
<text top="950" left="694" width="41" height="8" font="8"><a href="e127.full.html#98">(S8.1.4-15)</a></text>
<text top="950" left="735" width="2" height="8" font="4">.</text>
<text top="965" left="115" width="686" height="8" font="4">ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; BPH, benign prostatic hyperplasia; CCB, calcium channel blocker; CKD, chronic</text>
<text top="976" left="107" width="437" height="8" font="4">kidney disease; CNS, central nervous system; CVD, cardiovascular disease; ER, extended release; GFR, glomerular</text>
<text top="975" left="547" width="254" height="11" font="4">ﬁltration rate; HF, heart failure; HFrEF, heart failure with reduced</text>
<text top="988" left="107" width="432" height="8" font="4">ejection fraction; IHD, ischemic heart disease; IR, immediate release; LA, long-acting; and SR, sustained release.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="20" height="9" font="4">e166</text>
</page>
<page number="41" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="239" height="11" font="2">8.1.5. BP Goal for Patients With Hypertension</text>
<text top="417" left="63" width="52" height="12" font="2">Synopsis</text>
<text top="434" left="78" width="67" height="12" font="2">Refer to the</text>
<text top="433" left="148" width="248" height="15" font="2">“Systematic Review for the 2017 ACC/AHA/</text>
<text top="452" left="63" width="333" height="12" font="2">AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guide-</text>
<text top="470" left="63" width="21" height="12" font="2">line</text>
<text top="470" left="96" width="16" height="12" font="2">for</text>
<text top="470" left="124" width="18" height="12" font="2">the</text>
<text top="470" left="155" width="64" height="12" font="2">Prevention,</text>
<text top="470" left="231" width="56" height="12" font="2">Detection,</text>
<text top="470" left="300" width="63" height="12" font="2">Evaluation,</text>
<text top="470" left="375" width="21" height="12" font="2">and</text>
<text top="488" left="63" width="279" height="12" font="2">Management of High Blood Pressure in Adults</text>
<text top="486" left="342" width="54" height="15" font="2">” for the</text>
<text top="506" left="63" width="333" height="12" font="2">complete systematic evidence review for additional data</text>
<text top="524" left="63" width="72" height="12" font="2">and analyses</text>
<text top="524" left="139" width="57" height="12" font="5"><a href="e127.full.html#98">(S8.1.5-10)</a></text>
<text top="524" left="196" width="200" height="12" font="2">. Several trials have tested whether</text>
<text top="542" left="63" width="333" height="12" font="2">more intensive BP control improves major CVD outcomes.</text>
<text top="560" left="63" width="333" height="12" font="2">Meta-analyses and systematic reviews of these trials pro-</text>
<text top="578" left="63" width="333" height="12" font="2">vide strong support for the more intensive approach, but</text>
<text top="596" left="63" width="174" height="12" font="2">the data are less clear in identi</text>
<text top="594" left="237" width="159" height="15" font="2">ﬁcation of a speciﬁc optimal</text>
<text top="614" left="63" width="15" height="12" font="2">BP</text>
<text top="614" left="91" width="33" height="12" font="2">target</text>
<text top="614" left="138" width="46" height="12" font="5"><a href="e127.full.html#98">(S8.1.5-1</a></text>
<text top="612" left="184" width="209" height="15" font="5"><a href="e127.full.html#98">—S8.1.5-5,S8.1.5-7,S8.1.5-11—S8.1.5-13)</a></text>
<text top="614" left="393" width="3" height="12" font="2"><a href="e127.full.html#98">.</a></text>
<text top="632" left="63" width="333" height="12" font="2">Recent trials that address optimal BP targets include</text>
<text top="650" left="63" width="333" height="12" font="2">SPRINT and ACCORD (Action to Control Cardiovascular Risk</text>
<text top="668" left="63" width="299" height="12" font="2">in Diabetes), with targets for more intensive (SBP</text>
<text top="666" left="369" width="27" height="15" font="2">&lt;120</text>
<text top="685" left="63" width="151" height="12" font="2">mm Hg) and standard (SBP</text>
<text top="684" left="217" width="136" height="15" font="2">&lt;140 mm Hg) treatment</text>
<text top="685" left="356" width="41" height="12" font="5"><a href="e127.full.html#98">(S8.1.5-</a></text>
<text top="703" left="63" width="68" height="12" font="5"><a href="e127.full.html#98">14,S8.1.5-15)</a></text>
<text top="703" left="131" width="266" height="12" font="2"><a href="e127.full.html#98">, </a>and SPS-3, with a more intensive target</text>
<text top="721" left="63" width="11" height="12" font="2">of</text>
<text top="720" left="79" width="94" height="15" font="2">&lt;130/80 mm Hg</text>
<text top="721" left="178" width="57" height="12" font="5"><a href="e127.full.html#98">(S8.1.5-16)</a></text>
<text top="721" left="235" width="161" height="12" font="2"><a href="e127.full.html#98">. </a>These trials yielded mixed</text>
<text top="739" left="63" width="333" height="12" font="2">results in achieving their primary endpoints. SPRINT was</text>
<text top="757" left="63" width="333" height="12" font="2">stopped early, after a median follow-up of 3.26 years, when</text>
<text top="775" left="63" width="245" height="12" font="2">more intensive treatment resulted in a signi</text>
<text top="773" left="307" width="89" height="15" font="2">ﬁcant reduction</text>
<text top="793" left="63" width="333" height="12" font="2">in the primary outcome (a CVD composite) and in all-cause</text>
<text top="811" left="63" width="333" height="12" font="2">mortality rate. In ACCORD, more intensive BP treatment</text>
<text top="829" left="63" width="160" height="12" font="2">failed to demonstrate a signi</text>
<text top="827" left="223" width="173" height="15" font="2">ﬁcant reduction in the primary</text>
<text top="847" left="63" width="333" height="12" font="2">outcome (a CVD composite). However, the incidence of</text>
<text top="865" left="63" width="321" height="12" font="2">stroke, a component of the primary outcome, was signi</text>
<text top="863" left="384" width="12" height="15" font="2">ﬁ-</text>
<text top="883" left="63" width="333" height="12" font="2">cantly reduced. The standard glycemia subgroup did show</text>
<text top="901" left="63" width="27" height="12" font="2">signi</text>
<text top="899" left="89" width="307" height="15" font="2">ﬁcant beneﬁt in ACCORD, and a meta-analysis of the</text>
<text top="919" left="63" width="333" height="12" font="2">only 2 trials (ACCORD and SPRINT) testing an SBP goal</text>
<text top="937" left="63" width="11" height="12" font="2">of</text>
<text top="935" left="77" width="319" height="15" font="2">&lt;120 mm Hg showed signiﬁcant reduction in CVD events</text>
<text top="954" left="63" width="56" height="12" font="5"><a href="e127.full.html#98">(S8.1.5-17)</a></text>
<text top="954" left="119" width="215" height="12" font="2"><a href="e127.full.html#98">. </a>SPS-3 failed to demonstrate bene</text>
<text top="953" left="334" width="62" height="15" font="2">ﬁt for the</text>
<text top="972" left="63" width="223" height="12" font="2">primary endpoint of recurrent stoke (p</text>
<text top="971" left="285" width="111" height="15" font="2">¼0.08) but found a</text>
<text top="990" left="63" width="27" height="12" font="2">signi</text>
<text top="989" left="89" width="307" height="15" font="2">ﬁcant reduction in a subgroup with hemorrhagic</text>
<text top="1008" left="63" width="333" height="12" font="2">stroke. Pooling of the experience from 19 trials (excluding</text>
<text top="1026" left="63" width="333" height="12" font="2">SPRINT) that randomly assigned participants to different BP</text>
<text top="1044" left="63" width="136" height="12" font="2">treatment targets identi</text>
<text top="1042" left="198" width="198" height="15" font="2">ﬁed a signiﬁcant reduction in CVD</text>
<text top="1062" left="63" width="333" height="12" font="2">events, MI, and stroke in those assigned to a lower (average</text>
<text top="1080" left="63" width="333" height="12" font="2">achieved SBP/DBP was 133/76 mm Hg) versus a higher BP</text>
<text top="417" left="423" width="92" height="12" font="2">treatment target</text>
<text top="417" left="519" width="51" height="12" font="5"><a href="e127.full.html#98">(S8.1.5-2)</a></text>
<text top="417" left="570" width="143" height="12" font="2">. Similar patterns of bene</text>
<text top="415" left="713" width="43" height="15" font="2">ﬁt were</text>
<text top="434" left="423" width="333" height="12" font="2">reported in 3 other meta-analyses of trials in which partic-</text>
<text top="452" left="423" width="333" height="12" font="2">ipants were randomly assigned to different BP targets</text>
<text top="470" left="423" width="47" height="12" font="5"><a href="e127.full.html#98">(S8.1.5-3</a></text>
<text top="468" left="470" width="56" height="15" font="5"><a href="e127.full.html#98">—S8.1.5-5)</a></text>
<text top="470" left="531" width="225" height="12" font="2">and in larger meta-analyses that addi-</text>
<text top="488" left="423" width="333" height="12" font="2">tionally included trials that compared different intensities</text>
<text top="506" left="423" width="72" height="12" font="2">of treatment</text>
<text top="506" left="500" width="56" height="12" font="5"><a href="e127.full.html#98">(S8.1.5-12)</a></text>
<text top="506" left="556" width="200" height="12" font="2">. Data from the most recent meta-</text>
<text top="524" left="423" width="229" height="12" font="2">analysis (42 trials and 144,220 patients)</text>
<text top="524" left="657" width="51" height="12" font="5"><a href="e127.full.html#98">(S8.1.5-5)</a></text>
<text top="524" left="713" width="43" height="12" font="2">demon-</text>
<text top="542" left="423" width="333" height="12" font="2">strate a linear association between mean achieved SBP and</text>
<text top="560" left="423" width="333" height="12" font="2">risk of CVD mortality with the lowest risk at 120 to</text>
<text top="578" left="423" width="333" height="12" font="2">124 mm Hg. The totality of the available information pro-</text>
<text top="596" left="423" width="333" height="12" font="2">vides evidence that a lower BP target is generally better</text>
<text top="614" left="423" width="321" height="12" font="2">than a higher BP target and that some patients will bene</text>
<text top="612" left="744" width="12" height="15" font="2">ﬁt</text>
<text top="632" left="423" width="152" height="12" font="2">from an SBP treatment goal</text>
<text top="630" left="578" width="179" height="15" font="2">&lt;120 mm Hg, especially those at</text>
<text top="650" left="423" width="102" height="12" font="2">high risk of CVD</text>
<text top="650" left="533" width="56" height="12" font="5"><a href="e127.full.html#98">(S8.1.5-15)</a></text>
<text top="650" left="589" width="68" height="12" font="2"><a href="e127.full.html#98">. </a>The speci</text>
<text top="648" left="656" width="100" height="15" font="2">ﬁc inclusion and</text>
<text top="668" left="423" width="333" height="12" font="2">exclusion criteria of any RCT may limit extrapolation to a</text>
<text top="685" left="423" width="333" height="12" font="2">more general population with hypertension. In addition, all</text>
<text top="703" left="423" width="188" height="12" font="2">of the relevant trials have been ef</text>
<text top="702" left="611" width="145" height="15" font="2">ﬁcacy studies in which BP</text>
<text top="721" left="423" width="82" height="12" font="2">measurements</text>
<text top="721" left="517" width="27" height="12" font="2">were</text>
<text top="721" left="557" width="29" height="12" font="2">more</text>
<text top="721" left="597" width="57" height="12" font="2">consistent</text>
<text top="721" left="667" width="25" height="12" font="2">with</text>
<text top="721" left="704" width="52" height="12" font="2">guideline</text>
<text top="739" left="423" width="333" height="12" font="2">recommendations than is common in clinical practice,</text>
<text top="757" left="423" width="333" height="12" font="2">resulting in lower absolute values for SBP. For both of these</text>
<text top="775" left="423" width="333" height="12" font="2">reasons, the SBP target recommended during BP lowering</text>
<text top="793" left="423" width="4" height="12" font="2">(</text>
<text top="791" left="427" width="329" height="15" font="2">&lt;130 mm Hg) is higher than that which was used in</text>
<text top="811" left="423" width="46" height="12" font="2">SPRINT.</text>
<text top="837" left="423" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="835" left="562" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="864" left="425" width="332" height="12" font="2">1. Meta-analysis and systematic review of trials that</text>
<text top="882" left="438" width="318" height="12" font="2">compare more intensive BP reduction to standard BP</text>
<text top="900" left="438" width="306" height="12" font="2">reduction report that more intense BP lowering signi</text>
<text top="898" left="744" width="12" height="15" font="2">ﬁ-</text>
<text top="918" left="438" width="318" height="12" font="2">cantly reduces the risk of stroke, coronary events, major</text>
<text top="935" left="438" width="318" height="12" font="2">cardiovascular events, and cardiovascular mortality</text>
<text top="953" left="438" width="52" height="12" font="5"><a href="e127.full.html#98">(S8.1.5-1)</a></text>
<text top="953" left="490" width="59" height="12" font="2">. In a strati</text>
<text top="952" left="549" width="207" height="15" font="2">ﬁed analysis of these data, achieving</text>
<text top="971" left="438" width="92" height="12" font="2">an additional 10</text>
<text top="970" left="531" width="226" height="15" font="2">–mm Hg reduction in SBP reduced CVD</text>
<text top="989" left="438" width="318" height="12" font="2">risk when compared with an average SBP of 158/82 to</text>
<text top="1007" left="438" width="318" height="12" font="2">143/76 mm Hg, 144/85 to 137/81 mm Hg, and 134/79 to</text>
<text top="1025" left="438" width="318" height="12" font="2">125/76 mm Hg. Patients with DM and CKD were included</text>
<text top="1043" left="438" width="11" height="12" font="2">in</text>
<text top="1043" left="465" width="19" height="12" font="2">the</text>
<text top="1043" left="499" width="46" height="12" font="2">analysis</text>
<text top="1043" left="561" width="148" height="12" font="5"><a href="e127.full.html#98">(S8.1.5-1,S8.1.5-2,S8.1.5-11</a></text>
<text top="1041" left="709" width="47" height="15" font="5"><a href="e127.full.html#98">—S8.1.5-</a></text>
<text top="1061" left="438" width="70" height="12" font="5"><a href="e127.full.html#98">13,S8.1.5-18)</a></text>
<text top="1061" left="509" width="49" height="12" font="2"><a href="e127.full.html#98">. </a>(Speci</text>
<text top="1059" left="558" width="198" height="15" font="2">ﬁc management details are in</text>
<text top="1079" left="438" width="63" height="12" font="5"><a href="e127.full.html#49">Section 9.3</a></text>
<text top="1079" left="504" width="69" height="12" font="2">for CKD and</text>
<text top="1079" left="577" width="64" height="12" font="5"><a href="e127.full.html#58">Section 9.6</a></text>
<text top="1079" left="645" width="47" height="12" font="2">for DM.)</text>
<text top="185" left="63" width="349" height="11" font="19">Recommendations for BP Goal for Patients With Hypertension</text>
<text top="199" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="199" left="412" width="153" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 26</a></text>
<text top="199" left="570" width="173" height="11" font="19">and Systematic Review Report.</text>
<text top="240" left="89" width="19" height="10" font="13">COR</text>
<text top="240" left="161" width="18" height="10" font="13">LOE</text>
<text top="240" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="277" left="97" width="3" height="9" font="4">I</text>
<text top="272" left="149" width="36" height="9" font="4">SBP: B-R</text>
<text top="269" left="185" width="8" height="6" font="20">SR</text>
<text top="265" left="234" width="116" height="11" font="12">1. For adults with con</text>
<text top="263" left="350" width="443" height="15" font="12">ﬁrmed hypertension and known CVD or 10-year ASCVD event risk of 10% or higher</text>
<text top="280" left="246" width="22" height="11" font="12">(see</text>
<text top="280" left="272" width="68" height="11" font="5"><a href="e127.full.html#34">Section 8.1.2</a></text>
<text top="280" left="341" width="313" height="11" font="12"><a href="e127.full.html#34">), </a>a BP target of less than 130/80 mm Hg is recommended</text>
<text top="280" left="658" width="46" height="11" font="5"><a href="e127.full.html#98">(S8.1.5-1</a></text>
<text top="278" left="704" width="56" height="15" font="5"><a href="e127.full.html#98">—S8.1.5-5)</a></text>
<text top="280" left="760" width="3" height="11" font="12">.</text>
<text top="285" left="149" width="43" height="9" font="4">DBP: C-EO</text>
<text top="337" left="94" width="10" height="9" font="4">IIb</text>
<text top="329" left="149" width="42" height="9" font="4">SBP: B-NR</text>
<text top="322" left="234" width="116" height="11" font="12">2. For adults with con</text>
<text top="320" left="350" width="451" height="15" font="12">ﬁrmed hypertension, without additional markers of increased CVD risk, a BP target of</text>
<text top="338" left="248" width="236" height="11" font="12">less than 130/80 mm Hg may be reasonable</text>
<text top="338" left="488" width="48" height="11" font="5"><a href="e127.full.html#98">(S8.1.5-6</a></text>
<text top="336" left="536" width="57" height="15" font="5"><a href="e127.full.html#98">—S8.1.5-9)</a></text>
<text top="338" left="594" width="3" height="11" font="12"><a href="e127.full.html#98">.</a></text>
<text top="344" left="149" width="43" height="9" font="4">DBP: C-EO</text>
<text top="372" left="63" width="157" height="11" font="2">SR indicates systematic review.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="19" height="9" font="4">e167</text>
</page>
<page number="42" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="333" height="12" font="2">2. The treatment of patients with hypertension without</text>
<text top="161" left="123" width="318" height="12" font="2">elevated risk has been systematically understudied</text>
<text top="178" left="123" width="318" height="12" font="2">because lower-risk groups would require prolonged</text>
<text top="196" left="123" width="132" height="12" font="2">follow-up to have a suf</text>
<text top="195" left="255" width="186" height="15" font="2">ﬁcient number of clinical events</text>
<text top="214" left="123" width="318" height="12" font="2">to provide useful information. Although there is clin-</text>
<text top="232" left="123" width="318" height="12" font="2">ical trial evidence that both drug and nondrug therapy</text>
<text top="250" left="123" width="318" height="12" font="2">will interrupt the progressive course of hypertension</text>
<text top="268" left="123" width="54" height="12" font="5"><a href="e127.full.html#98">(S8.1.5-6)</a></text>
<text top="268" left="177" width="264" height="12" font="2"><a href="e127.full.html#98">, </a>there is no trial evidence that this treatment</text>
<text top="143" left="483" width="318" height="12" font="2">decreases CVD morbidity and mortality. The clinical</text>
<text top="161" left="483" width="318" height="12" font="2">trial evidence is strongest for a target BP of 140/90</text>
<text top="178" left="483" width="318" height="12" font="2">mm Hg in this population. However, observational</text>
<text top="196" left="483" width="318" height="12" font="2">studies suggest that these individuals often have a high</text>
<text top="214" left="483" width="168" height="12" font="2">lifetime risk and would bene</text>
<text top="213" left="652" width="150" height="15" font="2">ﬁt from BP control earlier</text>
<text top="232" left="483" width="34" height="12" font="2">in life</text>
<text top="232" left="521" width="115" height="12" font="5"><a href="e127.full.html#98">(S8.1.5-19,S8.1.5-20)</a></text>
<text top="232" left="636" width="3" height="12" font="2">.</text>
<text top="268" left="468" width="176" height="11" font="2">8.1.6. Choice of Initial Medication</text>
<text top="321" left="63" width="273" height="11" font="19">Recommendation for Choice of Initial Medication</text>
<text top="335" left="63" width="362" height="11" font="19">References that support the recommendation are summarized in</text>
<text top="335" left="429" width="152" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 27</a></text>
<text top="335" left="585" width="173" height="11" font="19">and Systematic Review Report.</text>
<text top="376" left="89" width="19" height="10" font="13">COR</text>
<text top="376" left="161" width="18" height="10" font="13">LOE</text>
<text top="376" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="413" left="97" width="3" height="9" font="4">I</text>
<text top="413" left="164" width="6" height="9" font="4">A</text>
<text top="411" left="169" width="8" height="6" font="20">SR</text>
<text top="401" left="234" width="261" height="11" font="12">1. For initiation of antihypertensive drug therapy,</text>
<text top="399" left="499" width="303" height="15" font="12">ﬁrst-line agents include thiazide diuretics, CCBs, and ACE</text>
<text top="417" left="246" width="99" height="11" font="12">inhibitors or ARBs.</text>
<text top="417" left="349" width="99" height="11" font="5"><a href="e127.full.html#98">(S8.1.6-1,S8.1.6-2)</a></text>
<text top="459" left="63" width="157" height="11" font="2">SR indicates systematic review.</text>
<text top="497" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="515" left="123" width="309" height="12" font="2">The overwhelming majority of persons with BP suf</text>
<text top="514" left="432" width="12" height="15" font="2">ﬁ-</text>
<text top="533" left="108" width="336" height="12" font="2">ciently elevated to warrant pharmacological therapy may</text>
<text top="551" left="108" width="242" height="12" font="2">be best treated initially with 2 agents (see</text>
<text top="551" left="353" width="82" height="12" font="5"><a href="e127.full.html#43">Section 8.1.6.1</a></text>
<text top="551" left="436" width="8" height="12" font="2"><a href="e127.full.html#43">).</a></text>
<text top="569" left="108" width="336" height="12" font="2">When initiation of pharmacological therapy with a single</text>
<text top="587" left="108" width="336" height="12" font="2">medication is appropriate, primary consideration should</text>
<text top="605" left="108" width="336" height="12" font="2">be given to comorbid conditions (e.g., HF, CKD) for which</text>
<text top="623" left="108" width="29" height="12" font="2">speci</text>
<text top="621" left="137" width="306" height="15" font="2">ﬁc classes of BP-lowering medication are indicated</text>
<text top="641" left="108" width="23" height="12" font="2">(see</text>
<text top="641" left="139" width="57" height="12" font="5"><a href="e127.full.html#45">Section 9</a></text>
<text top="641" left="196" width="4" height="12" font="2">)</text>
<text top="641" left="208" width="53" height="12" font="5"><a href="e127.full.html#98">(S8.1.6-1)</a></text>
<text top="641" left="261" width="182" height="12" font="2">. In the largest head-to-head</text>
<text top="659" left="108" width="86" height="12" font="2">comparison of</text>
<text top="657" left="200" width="244" height="15" font="2">ﬁrst-step drug therapy for hypertension</text>
<text top="677" left="108" width="54" height="12" font="5"><a href="e127.full.html#98">(S8.1.6-3)</a></text>
<text top="677" left="162" width="282" height="12" font="2"><a href="e127.full.html#98">, </a>the thiazide-type diuretic chlorthalidone was</text>
<text top="695" left="108" width="336" height="12" font="2">superior to the CCB amlodipine and the ACE inhibitor</text>
<text top="713" left="108" width="336" height="12" font="2">lisinopril in preventing HF, a BP-related outcome of</text>
<text top="731" left="108" width="336" height="12" font="2">increasing importance in the growing population of older</text>
<text top="748" left="108" width="158" height="12" font="2">persons with hypertension</text>
<text top="748" left="271" width="50" height="12" font="5"><a href="e127.full.html#98">(S8.1.6-4</a></text>
<text top="747" left="321" width="58" height="15" font="5"><a href="e127.full.html#98">—S8.1.6-7)</a></text>
<text top="748" left="380" width="64" height="12" font="2"><a href="e127.full.html#98">. </a>Addition-</text>
<text top="766" left="108" width="336" height="12" font="2">ally, ACE inhibitors were less effective than thiazide di-</text>
<text top="784" left="108" width="336" height="12" font="2">uretics and CCBs in lowering BP and in prevention of</text>
<text top="802" left="108" width="336" height="12" font="2">stroke. For black patients, ACE inhibitors were also</text>
<text top="820" left="108" width="289" height="12" font="2">notably less effective than CCBs in preventing HF</text>
<text top="820" left="401" width="43" height="12" font="5"><a href="e127.full.html#98">(S8.1.6-</a></text>
<text top="838" left="108" width="11" height="12" font="5"><a href="e127.full.html#98">8)</a></text>
<text top="838" left="124" width="186" height="12" font="2">and in the prevention of stroke</text>
<text top="838" left="314" width="54" height="12" font="5"><a href="e127.full.html#98">(S8.1.6-9)</a></text>
<text top="838" left="374" width="23" height="12" font="2">(see</text>
<text top="838" left="401" width="42" height="12" font="5"><a href="e127.full.html#62">Section</a></text>
<text top="856" left="108" width="22" height="12" font="5"><a href="e127.full.html#62">10.1</a></text>
<text top="856" left="130" width="314" height="12" font="2"><a href="e127.full.html#62">). </a>ARBs may be better tolerated than ACE inhibitors</text>
<text top="874" left="108" width="336" height="12" font="2">in black patients, with less cough and angioedema, but</text>
<text top="892" left="108" width="336" height="12" font="2">according to the limited available experience they offer no</text>
<text top="910" left="108" width="336" height="12" font="2">proven advantage over ACE inhibitors in preventing</text>
<text top="928" left="108" width="336" height="12" font="2">stroke or CVD in this population, making thiazide diuretics</text>
<text top="946" left="108" width="336" height="12" font="2">(especially chlorthalidone) or CCBs the best initial choice</text>
<text top="964" left="108" width="336" height="12" font="2">for single-drug therapy. For stroke, in the general popu-</text>
<text top="982" left="108" width="336" height="12" font="2">lation, beta blockers were less effective than CCBs (36%</text>
<text top="1000" left="108" width="336" height="12" font="2">lower risk) and thiazide diuretics (30% lower risk). CCBs</text>
<text top="1017" left="108" width="336" height="12" font="2">have been shown to be as effective as diuretics for</text>
<text top="1035" left="108" width="336" height="12" font="2">reducing all CVD events other than HF, and CCBs are a</text>
<text top="1053" left="108" width="336" height="12" font="2">good alternative choice for initial therapy when thiazide</text>
<text top="1071" left="108" width="336" height="12" font="2">diuretics are not tolerated. Alpha blockers are not used as</text>
<text top="1087" left="108" width="336" height="15" font="2">ﬁrst-line therapy for hypertension because they are less</text>
<text top="497" left="465" width="275" height="12" font="2">effective for prevention of CVD than other</text>
<text top="496" left="749" width="52" height="15" font="2">ﬁrst-step</text>
<text top="515" left="465" width="194" height="12" font="2">agents, such as thiazide diuretics</text>
<text top="515" left="663" width="109" height="12" font="5"><a href="e127.full.html#98">(S8.1.6-3,S8.1.6-10)</a></text>
<text top="515" left="773" width="3" height="12" font="2"><a href="e127.full.html#98">.</a></text>
<text top="542" left="465" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="540" left="604" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="569" left="465" width="336" height="12" font="2">1. The overall goal of treatment should be reduction in BP,</text>
<text top="587" left="479" width="322" height="12" font="2">in the context of underlying CVD risk. Five drug classes</text>
<text top="605" left="479" width="322" height="12" font="2">have been shown, in high-quality RCTs, to prevent CVD</text>
<text top="623" left="479" width="322" height="12" font="2">as compared with placebo (diuretics, ACE inhibitors,</text>
<text top="641" left="479" width="185" height="12" font="2">ARBs, CCBs, and beta blockers)</text>
<text top="641" left="669" width="112" height="12" font="5"><a href="e127.full.html#98">(S8.1.6-11,S8.1.6-12)</a></text>
<text top="641" left="781" width="20" height="12" font="2">. In</text>
<text top="659" left="479" width="77" height="12" font="2">head-to-head</text>
<text top="659" left="572" width="73" height="12" font="2">comparisons</text>
<text top="659" left="660" width="11" height="12" font="2">of</text>
<text top="657" left="686" width="52" height="15" font="2">ﬁrst-step</text>
<text top="659" left="753" width="48" height="12" font="2">therapy,</text>
<text top="677" left="479" width="322" height="12" font="2">different drug classes have been reported to provide</text>
<text top="695" left="479" width="278" height="12" font="2">somewhat divergent capacity to prevent speci</text>
<text top="693" left="757" width="44" height="15" font="2">ﬁc CVD</text>
<text top="713" left="479" width="322" height="12" font="2">events. Interpretation of meta-analyses comparing</text>
<text top="731" left="479" width="322" height="12" font="2">agents from different drug classes is challenging</text>
<text top="748" left="479" width="322" height="12" font="2">because the relevant RCTs were conducted in different</text>
<text top="766" left="479" width="322" height="12" font="2">time periods, during which concurrent antihyperten-</text>
<text top="784" left="479" width="289" height="12" font="2">sive therapy was less or more common, and the ef</text>
<text top="783" left="768" width="33" height="15" font="2">ﬁcacy</text>
<text top="802" left="479" width="322" height="12" font="2">of agents from certain drug classes may have changed.</text>
<text top="820" left="479" width="157" height="12" font="2">In recognition of this, some</text>
<text top="820" left="640" width="54" height="12" font="5"><a href="e127.full.html#98">(S8.1.6-2)</a></text>
<text top="820" left="697" width="59" height="12" font="2">but not all</text>
<text top="820" left="758" width="43" height="12" font="5"><a href="e127.full.html#98">(S8.1.6-</a></text>
<text top="838" left="479" width="69" height="12" font="5"><a href="e127.full.html#98">11,S8.1.6-12)</a></text>
<text top="838" left="553" width="248" height="12" font="2">meta-analyses, as well as the largest indi-</text>
<text top="856" left="479" width="158" height="12" font="2">vidual RCT that compared</text>
<text top="854" left="643" width="95" height="15" font="2">ﬁrst-step agents</text>
<text top="856" left="744" width="54" height="12" font="5"><a href="e127.full.html#98">(S8.1.6-3)</a></text>
<text top="856" left="798" width="3" height="12" font="2"><a href="e127.full.html#98">,</a></text>
<text top="874" left="479" width="322" height="12" font="2">have suggested that diuretics, especially the long-acting</text>
<text top="892" left="479" width="322" height="12" font="2">thiazide-type agent chlorthalidone, may provide an</text>
<text top="910" left="479" width="107" height="12" font="2">optimal choice for</text>
<text top="908" left="591" width="211" height="15" font="2">ﬁrst-step drug therapy of hyperten-</text>
<text top="928" left="479" width="322" height="12" font="2">sion. In contrast, some meta-analyses have suggested</text>
<text top="946" left="479" width="322" height="12" font="2">that beta blockers may be less effective, especially for</text>
<text top="964" left="479" width="322" height="12" font="2">stroke prevention in older adults, but interpretation is</text>
<text top="982" left="479" width="322" height="12" font="2">hampered by inclusion of RCTs that used beta blockers</text>
<text top="1000" left="479" width="322" height="12" font="2">that are now considered to be inferior for prevention of</text>
<text top="1017" left="479" width="25" height="12" font="2">CVD</text>
<text top="1017" left="516" width="114" height="12" font="5"><a href="e127.full.html#98">(S8.1.6-13,S8.1.6-14)</a></text>
<text top="1017" left="631" width="3" height="12" font="2"><a href="e127.full.html#98">.</a></text>
<text top="1017" left="646" width="12" height="12" font="2">In</text>
<text top="1017" left="670" width="6" height="12" font="2">a</text>
<text top="1017" left="689" width="62" height="12" font="2">systematic</text>
<text top="1017" left="762" width="39" height="12" font="2">review</text>
<text top="1035" left="479" width="21" height="12" font="2">and</text>
<text top="1035" left="516" width="48" height="12" font="2">network</text>
<text top="1035" left="579" width="80" height="12" font="2">meta-analysis</text>
<text top="1035" left="675" width="61" height="12" font="2">conducted</text>
<text top="1035" left="751" width="16" height="12" font="2">for</text>
<text top="1035" left="783" width="19" height="12" font="2">the</text>
<text top="1053" left="479" width="279" height="12" font="2">present guideline, beta blockers were signi</text>
<text top="1052" left="758" width="43" height="15" font="2">ﬁcantly</text>
<text top="1071" left="479" width="322" height="12" font="2">less effective than diuretics for prevention of stroke</text>
<text top="1089" left="479" width="150" height="12" font="2">and cardiovascular events</text>
<text top="1089" left="633" width="52" height="12" font="5"><a href="e127.full.html#98">(S8.1.6-1)</a></text>
<text top="1089" left="685" width="116" height="12" font="2">. Diuretics were also</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="20" height="9" font="4">e168</text>
</page>
<page number="43" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="77" width="27" height="12" font="2">signi</text>
<text top="141" left="105" width="292" height="15" font="2">ﬁcantly better than CCBs for prevention of HF.</text>
<text top="161" left="77" width="212" height="12" font="2">There were some other nonsigni</text>
<text top="159" left="289" width="107" height="15" font="2">ﬁcant differences</text>
<text top="178" left="77" width="320" height="12" font="2">between diuretics, ACE inhibitors, ARBs, and CCBs, but</text>
<text top="196" left="77" width="319" height="12" font="2">the general pattern was for similarity in effect.</text>
<text top="214" left="77" width="99" height="12" font="2">As indicated in</text>
<text top="214" left="185" width="88" height="12" font="5"><a href="e127.full.html#43">Section 8.1.6.1</a></text>
<text top="214" left="274" width="122" height="12" font="2"><a href="e127.full.html#43">, </a>most adults with</text>
<text top="232" left="77" width="127" height="12" font="2">hypertension require</text>
<text top="230" left="213" width="184" height="15" font="2">&gt;1 drug to control their BP.</text>
<text top="250" left="77" width="117" height="12" font="2">As recommended in</text>
<text top="250" left="198" width="69" height="12" font="5"><a href="e127.full.html#62">Section 10.1</a></text>
<text top="250" left="267" width="129" height="12" font="2"><a href="e127.full.html#62">, </a>for black adults with</text>
<text top="143" left="437" width="319" height="12" font="2">hypertension (without HF or CKD), initial antihyper-</text>
<text top="161" left="437" width="319" height="12" font="2">tensive treatment should include a thiazide diuretic</text>
<text top="178" left="437" width="43" height="12" font="2">or CCB.</text>
<text top="232" left="423" width="281" height="12" font="3">8.1.6.1. Choice of Initial Monotherapy Versus Initial</text>
<text top="250" left="466" width="147" height="12" font="3">Combination Drug Therapy</text>
<text top="304" left="63" width="524" height="11" font="19">Recommendations for Choice of Initial Monotherapy Versus Initial Combination Drug Therapy</text>
<text top="304" left="587" width="5" height="11" font="5"><a href="e127.full.html#43">*</a></text>
<text top="345" left="89" width="19" height="10" font="13">COR</text>
<text top="345" left="161" width="18" height="10" font="13">LOE</text>
<text top="345" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="382" left="97" width="3" height="9" font="4">I</text>
<text top="382" left="160" width="20" height="9" font="4">C-EO</text>
<text top="370" left="234" width="274" height="11" font="12">1. Initiation of antihypertensive drug therapy with 2</text>
<text top="368" left="512" width="290" height="15" font="12">ﬁrst-line agents of different classes, either as separate</text>
<text top="385" left="246" width="70" height="11" font="12">agents or in a</text>
<text top="383" left="319" width="483" height="15" font="12">ﬁxed-dose combination, is recommended in adults with stage 2 hypertension and an average</text>
<text top="401" left="246" width="271" height="11" font="12">BP more than 20/10 mm Hg above their BP target.</text>
<text top="446" left="94" width="10" height="9" font="4">IIa</text>
<text top="446" left="160" width="20" height="9" font="4">C-EO</text>
<text top="433" left="234" width="568" height="11" font="12">2. Initiation of antihypertensive drug therapy with a single antihypertensive drug is reasonable in adults with</text>
<text top="449" left="248" width="175" height="11" font="12">stage 1 hypertension and BP goal</text>
<text top="447" left="427" width="375" height="15" font="12">&lt;130/80 mm Hg with dosage titration and sequential addition of other</text>
<text top="465" left="248" width="172" height="11" font="12">agents to achieve the BP target.</text>
<text top="490" left="63" width="259" height="8" font="4">*Fixed-dose combination antihypertensive medications are listed in</text>
<text top="490" left="325" width="103" height="8" font="8"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement D</a></text>
<text top="490" left="427" width="2" height="8" font="4">.</text>
<text top="536" left="63" width="52" height="12" font="2">Synopsis</text>
<text top="554" left="78" width="321" height="12" font="2">Systematic review of the evidence comparing the initi-</text>
<text top="571" left="63" width="336" height="12" font="2">ation of antihypertensive treatment with monotherapy</text>
<text top="589" left="63" width="336" height="12" font="2">and sequential (stepped-care) titration of additional</text>
<text top="607" left="63" width="336" height="12" font="2">agents versus initiation of treatment with combination</text>
<text top="625" left="63" width="114" height="12" font="2">therapy (including</text>
<text top="623" left="187" width="212" height="15" font="2">ﬁxed-dose combinations) did not</text>
<text top="643" left="63" width="336" height="12" font="2">identify any RCTs meeting the systematic review ques-</text>
<text top="661" left="63" width="29" height="12" font="2">tions</text>
<text top="661" left="104" width="34" height="12" font="2">posed</text>
<text top="661" left="150" width="11" height="12" font="2">in</text>
<text top="661" left="174" width="19" height="12" font="2">the</text>
<text top="661" left="205" width="43" height="12" font="2">PICOTS</text>
<text top="661" left="260" width="39" height="12" font="2">format</text>
<text top="661" left="311" width="11" height="12" font="2">(P</text>
<text top="659" left="323" width="76" height="15" font="2">¼population,</text>
<text top="679" left="63" width="4" height="12" font="2">I</text>
<text top="677" left="67" width="332" height="15" font="2">¼intervention, C¼comparator, O¼outcome, T¼timing,</text>
<text top="697" left="63" width="6" height="12" font="2">S</text>
<text top="695" left="69" width="329" height="15" font="2">¼setting). However, in both ACCORD and SPRINT, 2-drug</text>
<text top="715" left="63" width="336" height="12" font="2">therapy was recommended for most participants in the</text>
<text top="733" left="63" width="257" height="12" font="2">intensive- but not standard-therapy groups.</text>
<text top="769" left="63" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="767" left="202" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="796" left="64" width="335" height="12" font="2">1. Because most patients with hypertension require mul-</text>
<text top="814" left="78" width="321" height="12" font="2">tiple agents for control of their BP and those with higher</text>
<text top="831" left="78" width="321" height="12" font="2">BPs are at greater risk, more rapid titration of antihy-</text>
<text top="849" left="78" width="321" height="12" font="2">pertensive medications began to be recommended in</text>
<text top="867" left="78" width="102" height="12" font="2">patients with BP</text>
<text top="866" left="187" width="212" height="15" font="2">&gt;20/10 mm Hg above their target,</text>
<text top="885" left="78" width="195" height="12" font="2">beginning with the JNC 7 report</text>
<text top="885" left="279" width="62" height="12" font="5"><a href="e127.full.html#98">(S8.1.6.1-1)</a></text>
<text top="885" left="341" width="58" height="12" font="2">. In these</text>
<text top="903" left="78" width="321" height="12" font="2">patients, initiation of antihypertensive therapy with 2</text>
<text top="921" left="78" width="38" height="12" font="2">agents</text>
<text top="921" left="128" width="9" height="12" font="2">is</text>
<text top="921" left="151" width="87" height="12" font="2">recommended.</text>
<text top="921" left="250" width="53" height="12" font="2">Evidence</text>
<text top="921" left="316" width="48" height="12" font="2">favoring</text>
<text top="921" left="378" width="21" height="12" font="2">this</text>
<text top="939" left="78" width="255" height="12" font="2">approach comes mostly from studies using</text>
<text top="937" left="338" width="60" height="15" font="2">ﬁxed-dose</text>
<text top="957" left="78" width="321" height="12" font="2">combination products showing greater BP lowering</text>
<text top="975" left="78" width="26" height="12" font="2">with</text>
<text top="973" left="110" width="289" height="15" font="2">ﬁxed-dose combination agents than with single</text>
<text top="993" left="78" width="265" height="12" font="2">agents, as well as better adherence to therapy</text>
<text top="993" left="347" width="52" height="12" font="5"><a href="e127.full.html#98">(S8.1.6.1-</a></text>
<text top="1011" left="78" width="69" height="12" font="5"><a href="e127.full.html#98">2,S8.1.6.1-3)</a></text>
<text top="1011" left="147" width="119" height="12" font="2"><a href="e127.full.html#98">. </a>The safety and ef</text>
<text top="1009" left="266" width="132" height="15" font="2">ﬁcacy of this strategy</text>
<text top="1029" left="78" width="321" height="12" font="2">have been demonstrated in adults to reduce BPs</text>
<text top="1047" left="78" width="11" height="12" font="2">to</text>
<text top="1045" left="96" width="303" height="15" font="2">&lt;140/90 mm Hg though not compared with other</text>
<text top="1065" left="78" width="56" height="12" font="2">strategies</text>
<text top="1065" left="147" width="59" height="12" font="5"><a href="e127.full.html#98">(S8.1.6.1-4</a></text>
<text top="1063" left="207" width="68" height="15" font="5"><a href="e127.full.html#98">—S8.1.6.1-6)</a></text>
<text top="1065" left="275" width="3" height="12" font="2">.</text>
<text top="1065" left="292" width="12" height="12" font="2">In</text>
<text top="1065" left="318" width="47" height="12" font="2">general,</text>
<text top="1065" left="377" width="21" height="12" font="2">this</text>
<text top="1083" left="78" width="321" height="12" font="2">approach is reasonable in older adults, those at high</text>
<text top="536" left="435" width="321" height="12" font="2">CVD risk, or those who have a history of hypotension or</text>
<text top="554" left="435" width="321" height="12" font="2">drug-associated side effects. However, caution is</text>
<text top="571" left="435" width="321" height="12" font="2">advised in initiating antihypertensive pharmacotherapy</text>
<text top="589" left="435" width="321" height="12" font="2">with 2 drugs in older patients because hypotension or</text>
<text top="607" left="435" width="321" height="12" font="2">orthostatic hypotension may develop in some patients;</text>
<text top="625" left="435" width="199" height="12" font="2">BP should be carefully monitored.</text>
<text top="643" left="421" width="191" height="12" font="2">2. The stepped-care approach de</text>
<text top="641" left="612" width="144" height="15" font="2">ﬁned by the initiation of</text>
<text top="661" left="435" width="321" height="12" font="2">antihypertensive drug therapy with a single agent</text>
<text top="679" left="435" width="321" height="12" font="2">followed by the sequential titration of the dose and</text>
<text top="697" left="435" width="321" height="12" font="2">addition of other agents has been the recommended</text>
<text top="715" left="435" width="164" height="12" font="2">treatment strategy since the</text>
<text top="713" left="603" width="153" height="15" font="2">ﬁrst report of the National</text>
<text top="733" left="435" width="247" height="12" font="2">High Blood Pressure Education Program</text>
<text top="733" left="690" width="63" height="12" font="5"><a href="e127.full.html#99">(S8.1.6.1-7)</a></text>
<text top="733" left="753" width="3" height="12" font="2"><a href="e127.full.html#99">.</a></text>
<text top="751" left="435" width="321" height="12" font="2">This approach is also reasonable in older adults or those</text>
<text top="769" left="435" width="321" height="12" font="2">at risk or who have a history of hypotension or drug-</text>
<text top="787" left="435" width="321" height="12" font="2">associated side effects. This strategy has been used</text>
<text top="805" left="435" width="321" height="12" font="2">successfully in nearly all hypertension treatment trials</text>
<text top="823" left="435" width="321" height="12" font="2">but has not been formally tested against other antihy-</text>
<text top="841" left="435" width="321" height="12" font="2">pertensive drug treatment strategies for effectiveness in</text>
<text top="858" left="435" width="321" height="12" font="2">achieving BP control or in preventing adverse outcomes.</text>
<text top="898" left="420" width="254" height="11" font="12">8.2. Achieving BP Control in Individual Patients</text>
<text top="920" left="420" width="223" height="12" font="2">Recommendations for lifestyle modi</text>
<text top="918" left="644" width="113" height="15" font="2">ﬁcations and drug</text>
<text top="938" left="420" width="112" height="12" font="2">selection are speci</text>
<text top="936" left="533" width="40" height="15" font="2">ﬁed in</text>
<text top="938" left="579" width="173" height="12" font="5"><a href="e127.full.html#29">Sections 6.2</a>, <a href="e127.full.html#38">8.1.4, </a>and <a href="e127.full.html#42">8.1.6</a></text>
<text top="938" left="753" width="3" height="12" font="2"><a href="e127.full.html#42">.</a></text>
<text top="956" left="420" width="336" height="12" font="2">Initial drug selections should be based on trial evidence of</text>
<text top="974" left="420" width="57" height="12" font="2">treatment</text>
<text top="974" left="492" width="11" height="12" font="2">ef</text>
<text top="972" left="503" width="253" height="15" font="2">ﬁcacy, combined with recognition of</text>
<text top="992" left="420" width="322" height="12" font="2">compelling indications for use of an agent from a speci</text>
<text top="990" left="743" width="13" height="15" font="2">ﬁc</text>
<text top="1009" left="420" width="273" height="12" font="2">drug class, as well as the individual patient</text>
<text top="1008" left="694" width="62" height="15" font="2">’s lifestyle</text>
<text top="1027" left="420" width="336" height="12" font="2">preferences and traits. For a subset of patients (25% to</text>
<text top="1045" left="420" width="29" height="12" font="2">50%)</text>
<text top="1045" left="459" width="43" height="12" font="5"><a href="e127.full.html#99">(S8.2-1)</a></text>
<text top="1045" left="502" width="255" height="12" font="2"><a href="e127.full.html#99">, </a>the initial drug therapy will be well</text>
<text top="1063" left="420" width="336" height="12" font="2">tolerated and effective in achieving the desired level of</text>
<text top="1081" left="420" width="336" height="12" font="2">BP, with only the need for subsequent monitoring</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="788" width="20" height="9" font="4">e169</text>
</page>
<page number="44" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="23" height="12" font="2">(see</text>
<text top="143" left="136" width="65" height="12" font="5"><a href="e127.full.html#44">Section 8.3</a></text>
<text top="143" left="206" width="235" height="12" font="2">for an appropriate follow-up schedule).</text>
<text top="161" left="108" width="333" height="12" font="2">For others, the initial drug will not be tolerated or will not</text>
<text top="178" left="108" width="333" height="12" font="2">be effective, requiring either a change in medication</text>
<text top="196" left="108" width="333" height="12" font="2">or addition of another medication, followed by BP</text>
<text top="214" left="108" width="65" height="12" font="2">monitoring</text>
<text top="214" left="178" width="44" height="12" font="5"><a href="e127.full.html#99">(S8.2-2)</a></text>
<text top="214" left="222" width="219" height="12" font="2"><a href="e127.full.html#99">. </a>Approximately 25% of patients will</text>
<text top="232" left="108" width="333" height="12" font="2">require additional treatment adjustments. In a minority</text>
<text top="250" left="108" width="333" height="12" font="2">of this group, achievement of goal BP can be challenging.</text>
<text top="268" left="123" width="318" height="12" font="2">In patients who do not respond to or do not tolerate</text>
<text top="286" left="108" width="333" height="12" font="2">treatment with 2 to 3 medications or medication combi-</text>
<text top="304" left="108" width="333" height="12" font="2">nations, additional trials of treatment tend to be ineffec-</text>
<text top="322" left="108" width="333" height="12" font="2">tive or poorly tolerated. Some patients may become</text>
<text top="340" left="108" width="333" height="12" font="2">disillusioned and lost to follow-up, whereas others will</text>
<text top="358" left="108" width="333" height="12" font="2">identify an alternative healthcare provider, including</text>
<text top="376" left="108" width="333" height="12" font="2">nontraditional healers, or will try popular home remedies.</text>
<text top="394" left="108" width="333" height="12" font="2">Working with this more demanding subset requires pro-</text>
<text top="412" left="108" width="333" height="12" font="2">vider expertise, patience, and a mechanism to respond</text>
<text top="430" left="108" width="11" height="12" font="2">ef</text>
<text top="428" left="119" width="322" height="15" font="2">ﬁciently and sensitively to concerns as they arise. In</text>
<text top="447" left="108" width="208" height="12" font="2">this setting, team-based care (see</text>
<text top="447" left="323" width="61" height="12" font="5"><a href="e127.full.html#74">Section 12</a></text>
<text top="447" left="384" width="57" height="12" font="2">) may be</text>
<text top="465" left="108" width="333" height="12" font="2">effective, encouraging coupling of nonpharmacological</text>
<text top="483" left="108" width="333" height="12" font="2">and pharmacological treatments, while improving access</text>
<text top="501" left="108" width="253" height="12" font="2">to and communication with care providers.</text>
<text top="519" left="123" width="318" height="12" font="2">In the setting of medication intolerance, consider</text>
<text top="537" left="108" width="76" height="12" font="2">allowing a de</text>
<text top="535" left="184" width="257" height="15" font="2">ﬁned period of time to evaluate the effects of</text>
<text top="555" left="108" width="83" height="12" font="2">lifestyle modi</text>
<text top="553" left="191" width="250" height="15" font="2">ﬁcation in patients with a relatively low</text>
<text top="573" left="108" width="202" height="12" font="2">CVD risk (10-year risk of ASCVD</text>
<text top="571" left="317" width="124" height="15" font="2">&lt;10%, based on the</text>
<text top="591" left="108" width="143" height="12" font="2">ASCVD Risk Estimator [</text>
<text top="591" left="251" width="190" height="12" font="5"><a href="http://tools.acc.org/ASCVD-Risk-Estimator">http://tools.acc.org/ASCVD-Risk-</a></text>
<text top="609" left="108" width="56" height="12" font="5"><a href="http://tools.acc.org/ASCVD-Risk-Estimator">Estimator</a></text>
<text top="609" left="164" width="277" height="12" font="2"><a href="http://tools.acc.org/ASCVD-Risk-Estimator">]), </a>with scheduled follow-up visits for assess-</text>
<text top="627" left="108" width="333" height="12" font="2">ment of BP levels, including a review of HBPM data, and</text>
<text top="645" left="108" width="333" height="12" font="2">an appraisal of lifestyle change goal achievements. For</text>
<text top="663" left="108" width="301" height="12" font="2">patients with a higher level of CVD risk or with signi</text>
<text top="661" left="409" width="32" height="15" font="2">ﬁcant</text>
<text top="681" left="108" width="193" height="12" font="2">elevations in BP (SBP or DBP</text>
<text top="679" left="310" width="131" height="15" font="2">&gt;20 or &gt;10 mm Hg</text>
<text top="698" left="108" width="333" height="12" font="2">above target, respectively), medication is usually started</text>
<text top="716" left="108" width="333" height="12" font="2">even while the patient is pursuing lifestyle change</text>
<text top="734" left="108" width="23" height="12" font="2">(see</text>
<text top="734" left="135" width="73" height="12" font="5"><a href="e127.full.html#34">Section 8.1.2</a></text>
<text top="734" left="208" width="8" height="12" font="2">).</text>
<text top="752" left="123" width="318" height="12" font="2">Consideration of patient comorbidities, lifestyle, and</text>
<text top="770" left="108" width="333" height="12" font="2">preferences may suggest better tolerance or greater effect</text>
<text top="788" left="108" width="333" height="12" font="2">from one class of medication versus other classes. For</text>
<text top="806" left="108" width="333" height="12" font="2">example, if hyponatremia is present, it would be impor-</text>
<text top="824" left="108" width="333" height="12" font="2">tant to avoid or stop thiazide diuretic therapy. In this</text>
<text top="143" left="468" width="333" height="12" font="2">case, a loop diuretic should be used if a diuretic is</text>
<text top="161" left="468" width="333" height="12" font="2">required. If hypokalemia is present, primary or secondary</text>
<text top="178" left="468" width="333" height="12" font="2">aldosteronism should be excluded, after which one</text>
<text top="196" left="468" width="333" height="12" font="2">should consider a potassium-sparing agent, such as spi-</text>
<text top="214" left="468" width="333" height="12" font="2">ronolactone, eplerenone, triamterene, or amiloride. In</text>
<text top="232" left="468" width="333" height="12" font="2">addition, reducing dietary sodium intake will diminish</text>
<text top="250" left="468" width="333" height="12" font="2">urinary potassium losses. If the patient has chronic cough</text>
<text top="268" left="468" width="162" height="12" font="2">or a history of ACE inhibitor</text>
<text top="266" left="630" width="171" height="15" font="2">–induced cough or develops a</text>
<text top="286" left="468" width="333" height="12" font="2">cough or bronchial responsiveness while on an ACE in-</text>
<text top="304" left="468" width="333" height="12" font="2">hibitor, one should use an ARB in place of an ACE inhib-</text>
<text top="322" left="468" width="333" height="12" font="2">itor. For patients with bronchospastic lung disease, a</text>
<text top="340" left="468" width="333" height="12" font="2">beta-1-selective blocker (e.g., bisoprolol, metoprolol)</text>
<text top="358" left="468" width="333" height="12" font="2">should be considered if beta-blocker therapy is required.</text>
<text top="376" left="468" width="333" height="12" font="2">A patient who is already adherent to lifestyle change</text>
<text top="394" left="468" width="333" height="12" font="2">recommendations, including diligent reduction in sodium</text>
<text top="412" left="468" width="333" height="12" font="2">intake, may show a greater response to a RAS blocker.</text>
<text top="430" left="468" width="333" height="12" font="2">Prior patient experience should be considered, as in the</text>
<text top="447" left="468" width="333" height="12" font="2">case of cough associated with prior use of an ACE inhibi-</text>
<text top="465" left="468" width="333" height="12" font="2">tor, which is likely to reoccur if an agent from the same</text>
<text top="483" left="468" width="109" height="12" font="2">class is prescribed.</text>
<text top="519" left="468" width="323" height="11" font="12">8.3. Follow-Up of BP During Antihypertensive Drug Therapy</text>
<text top="540" left="468" width="333" height="12" font="2">Appropriate follow-up and monitoring enable assessment</text>
<text top="558" left="468" width="104" height="12" font="2">of adherence (see</text>
<text top="558" left="577" width="68" height="12" font="5"><a href="e127.full.html#74">Section 12.1</a></text>
<text top="558" left="645" width="156" height="12" font="2"><a href="e127.full.html#74">) </a>and response to therapy,</text>
<text top="576" left="468" width="333" height="12" font="2">help identify adverse responses to therapy and target</text>
<text top="594" left="468" width="333" height="12" font="2">organ damage, and allow assessment of progress toward</text>
<text top="612" left="468" width="333" height="12" font="2">treatment goals. High-quality RCTs have successfully and</text>
<text top="630" left="468" width="333" height="12" font="2">safely developed strategies for follow-up, monitoring,</text>
<text top="648" left="468" width="333" height="12" font="2">and reassessment from which recommendations can be</text>
<text top="666" left="468" width="40" height="12" font="2">made (</text>
<text top="666" left="508" width="47" height="11" font="5"><a href="e127.full.html#36">Figure 4</a></text>
<text top="666" left="555" width="4" height="12" font="2">)</text>
<text top="666" left="564" width="82" height="12" font="5"><a href="e127.full.html#99">(S8.2-1,S8.2-2)</a></text>
<text top="666" left="646" width="155" height="12" font="2"><a href="e127.full.html#99">. </a>A systematic approach to</text>
<text top="684" left="468" width="52" height="12" font="2">out-of-of</text>
<text top="682" left="520" width="281" height="15" font="2">ﬁce BP assessment is an essential part of follow-</text>
<text top="701" left="468" width="333" height="12" font="2">up and monitoring of BP, to assess response to therapy;</text>
<text top="719" left="468" width="333" height="12" font="2">check for evidence of white coat hypertension, white coat</text>
<text top="737" left="468" width="333" height="12" font="2">effect, masked hypertension, or masked uncontrolled</text>
<text top="755" left="468" width="271" height="12" font="2">hypertension; and help achieve BP targets (see</text>
<text top="755" left="742" width="59" height="12" font="5"><a href="e127.full.html#14">Sections 4</a></text>
<text top="773" left="468" width="37" height="12" font="5">and <a href="e127.full.html#74">12</a></text>
<text top="773" left="505" width="8" height="12" font="2">).</text>
<text top="824" left="468" width="333" height="11" font="2">8.3.1. Follow-Up After Initiating Antihypertensive Drug Therapy</text>
<text top="871" left="63" width="446" height="11" font="19">Recommendation for Follow-Up After Initiating Antihypertensive Drug Therapy</text>
<text top="885" left="63" width="362" height="11" font="19">References that support the recommendation are summarized in</text>
<text top="885" left="429" width="153" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 28</a></text>
<text top="885" left="583" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="926" left="89" width="19" height="10" font="13">COR</text>
<text top="926" left="161" width="18" height="10" font="13">LOE</text>
<text top="926" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="963" left="97" width="3" height="9" font="4">I</text>
<text top="963" left="163" width="15" height="9" font="4">B-R</text>
<text top="950" left="234" width="497" height="11" font="12">1. Adults initiating a new or adjusted drug regimen for hypertension should have a follow-up</text>
<text top="966" left="246" width="518" height="11" font="12">evaluation of adherence and response to treatment at monthly intervals until control is achieved</text>
<text top="982" left="246" width="46" height="11" font="5"><a href="e127.full.html#99">(S8.3.1-1</a></text>
<text top="980" left="293" width="56" height="15" font="5"><a href="e127.full.html#99">—S8.3.1-3)</a></text>
<text top="982" left="349" width="3" height="11" font="12"><a href="e127.full.html#99">.</a></text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e170</text>
</page>
<page number="45" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="141" left="202" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="169" left="63" width="86" height="12" font="2">1. Components</text>
<text top="169" left="162" width="11" height="12" font="2">of</text>
<text top="169" left="185" width="19" height="12" font="2">the</text>
<text top="169" left="215" width="56" height="12" font="2">follow-up</text>
<text top="169" left="284" width="61" height="12" font="2">evaluation</text>
<text top="169" left="357" width="39" height="12" font="2">should</text>
<text top="187" left="77" width="319" height="12" font="2">include assessment of BP control, as well as evaluation</text>
<text top="205" left="77" width="319" height="12" font="2">for orthostatic hypotension, adverse effects from</text>
<text top="223" left="77" width="319" height="12" font="2">medication therapy, adherence to medication and life-</text>
<text top="241" left="77" width="319" height="12" font="2">style therapy, need for adjustment of medication</text>
<text top="143" left="437" width="319" height="12" font="2">dosage, laboratory testing (including electrolyte and</text>
<text top="161" left="437" width="319" height="12" font="2">renal function status), and other assessments of target</text>
<text top="178" left="437" width="82" height="12" font="2">organ damage</text>
<text top="178" left="523" width="47" height="12" font="5"><a href="e127.full.html#99">(S8.3.1-1</a></text>
<text top="177" left="571" width="58" height="15" font="5"><a href="e127.full.html#99">—S8.3.1-3)</a></text>
<text top="178" left="629" width="3" height="12" font="2"><a href="e127.full.html#99">.</a></text>
<text top="224" left="423" width="333" height="11" font="2">8.3.2. Monitoring Strategies to Improve Control of BP in Patients</text>
<text top="242" left="457" width="152" height="11" font="2">on Drug Therapy for High BP</text>
<text top="295" left="63" width="618" height="11" font="19">Recommendation for Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP</text>
<text top="310" left="63" width="362" height="11" font="19">References that support the recommendation are summarized in</text>
<text top="310" left="429" width="153" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 29</a></text>
<text top="310" left="583" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="351" left="89" width="19" height="10" font="13">COR</text>
<text top="351" left="161" width="18" height="10" font="13">LOE</text>
<text top="351" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="388" left="97" width="3" height="9" font="4">I</text>
<text top="388" left="168" width="6" height="9" font="4">A</text>
<text top="375" left="234" width="534" height="11" font="12">1. Follow-up and monitoring after initiation of drug therapy for hypertension control should include</text>
<text top="391" left="246" width="527" height="11" font="12">systematic strategies to help improve BP, including use of HBPM, team-based care, and telehealth</text>
<text top="407" left="246" width="52" height="11" font="12">strategies</text>
<text top="407" left="302" width="47" height="11" font="5"><a href="e127.full.html#99">(S8.3.2-1</a></text>
<text top="405" left="350" width="58" height="15" font="5"><a href="e127.full.html#99">—S8.3.2-6)</a></text>
<text top="407" left="409" width="3" height="11" font="12"><a href="e127.full.html#99">.</a></text>
<text top="516" left="63" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="514" left="202" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="543" left="63" width="336" height="12" font="2">1. Systematic approaches to follow-up have been shown to</text>
<text top="561" left="77" width="322" height="12" font="2">improve hypertension control and can be adapted and</text>
<text top="579" left="77" width="322" height="12" font="2">incorporated into clinical practices according to local</text>
<text top="597" left="77" width="218" height="12" font="2">needs and resource availability (see</text>
<text top="597" left="301" width="75" height="12" font="5"><a href="e127.full.html#44">Section 8.3.1</a></text>
<text top="597" left="383" width="16" height="12" font="2">for</text>
<text top="615" left="77" width="322" height="12" font="2">time intervals for treatment follow-up and monitoring</text>
<text top="633" left="77" width="22" height="12" font="2">and</text>
<text top="633" left="103" width="135" height="12" font="5"><a href="e127.full.html#77">Sections 12.2 </a>and <a href="e127.full.html#78">12.3.2</a></text>
<text top="633" left="242" width="157" height="12" font="2">on systematic strategies to</text>
<text top="651" left="77" width="121" height="12" font="2">improve BP control).</text>
<text top="693" left="63" width="254" height="16" font="14">9. HYPERTENSION IN PATIENTS WITH</text>
<text top="711" left="62" width="110" height="16" font="14">COMORBIDITIES</text>
<text top="749" left="63" width="336" height="12" font="2">Certain comorbidities may affect clinical decision-making</text>
<text top="767" left="63" width="336" height="12" font="2">in hypertension. These include ischemic heart disease,</text>
<text top="785" left="63" width="336" height="12" font="2">HF with reduced ejection fraction (HFrEF), HFpEF, CKD</text>
<text top="803" left="63" width="336" height="12" font="2">(including renal transplantation), cerebrovascular disease,</text>
<text top="821" left="63" width="226" height="12" font="2">AF, PAD, DM, and metabolic syndrome</text>
<text top="821" left="293" width="32" height="12" font="5"><a href="e127.full.html#99">(S9-1)</a></text>
<text top="821" left="325" width="74" height="12" font="2">. As noted in</text>
<text top="839" left="63" width="73" height="12" font="5"><a href="e127.full.html#34">Section 8.1.2</a></text>
<text top="839" left="136" width="263" height="12" font="2">, this guideline generally recommends use of</text>
<text top="857" left="63" width="336" height="12" font="2">BP-lowering medications for secondary prevention of CVD</text>
<text top="516" left="420" width="336" height="12" font="2">in patients with clinical CVD (CHD, HF, and stroke) and an</text>
<text top="534" left="420" width="63" height="12" font="2">average BP</text>
<text top="532" left="487" width="269" height="15" font="2">$130/80 mm Hg and for primary prevention of</text>
<text top="552" left="420" width="336" height="12" font="2">CVD in adults with an estimated 10-year ASCVD risk</text>
<text top="570" left="420" width="11" height="12" font="2">of</text>
<text top="568" left="436" width="320" height="15" font="2">$10% and an average SBP $130 mm Hg or an average</text>
<text top="588" left="420" width="24" height="12" font="2">DBP</text>
<text top="586" left="450" width="306" height="15" font="2">$80 mm Hg. Although we recommend use of the</text>
<text top="606" left="420" width="220" height="12" font="2">ACC/AHA Pooled Cohort Equations (</text>
<text top="606" left="641" width="116" height="12" font="5"><a href="http://tools.acc.org/ASCVD-Risk-Estimator/">http://tools.acc.org/</a></text>
<text top="624" left="420" width="135" height="12" font="5"><a href="http://tools.acc.org/ASCVD-Risk-Estimator/">ASCVD-Risk-Estimator/</a></text>
<text top="624" left="556" width="4" height="12" font="2"><a href="http://tools.acc.org/ASCVD-Risk-Estimator/">)</a></text>
<text top="624" left="572" width="11" height="12" font="2">to</text>
<text top="624" left="596" width="50" height="12" font="2">estimate</text>
<text top="624" left="657" width="42" height="12" font="2">10-year</text>
<text top="624" left="712" width="21" height="12" font="2">risk</text>
<text top="624" left="745" width="11" height="12" font="2">of</text>
<text top="642" left="420" width="336" height="12" font="2">ASCVD to establish the BP threshold for treatment, the</text>
<text top="660" left="420" width="336" height="12" font="2">vast majority of adults with a co-morbidity are likely to</text>
<text top="677" left="420" width="336" height="12" font="2">have a 10-year risk of ASCVD that exceeds 10%. In some</text>
<text top="695" left="420" width="161" height="12" font="2">instances, clinical trial con</text>
<text top="694" left="581" width="175" height="15" font="2">ﬁrmation of treatment in pa-</text>
<text top="713" left="420" width="336" height="12" font="2">tients with comorbidities is limited to a target BP of 140/90</text>
<text top="731" left="420" width="336" height="12" font="2">mm Hg. In addition, the selection of medications for use in</text>
<text top="749" left="420" width="336" height="12" font="2">treating high BP in patients with CVD is guided by their</text>
<text top="767" left="420" width="336" height="12" font="2">use for other compelling indications (e.g., beta blockers</text>
<text top="785" left="420" width="336" height="12" font="2">after MI, ACE inhibitors for HFrEF), as discussed in spe-</text>
<text top="803" left="420" width="10" height="12" font="2">ci</text>
<text top="801" left="430" width="224" height="15" font="2">ﬁc guidelines for the clinical condition</text>
<text top="803" left="658" width="29" height="12" font="5"><a href="e127.full.html#99">(S9-2</a></text>
<text top="801" left="688" width="39" height="15" font="5"><a href="e127.full.html#99">—S9-4)</a></text>
<text top="803" left="727" width="29" height="12" font="2">. The</text>
<text top="821" left="420" width="336" height="12" font="2">present guideline does not address the recommendations</text>
<text top="839" left="420" width="336" height="12" font="2">for treatment of hypertension occurring with acute coro-</text>
<text top="857" left="420" width="97" height="12" font="2">nary syndromes.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="791" width="17" height="9" font="4">e171</text>
</page>
<page number="46" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="182" height="11" font="12">9.1. Stable Ischemic Heart Disease</text>
<text top="597" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="614" left="123" width="318" height="12" font="2">Hypertension is a major risk factor for ischemic heart</text>
<text top="632" left="108" width="315" height="12" font="2">disease. Numerous RCTs have demonstrated the bene</text>
<text top="631" left="423" width="18" height="15" font="2">ﬁts</text>
<text top="650" left="108" width="333" height="12" font="2">of antihypertensive drug therapy in reducing the risk of</text>
<text top="668" left="108" width="333" height="12" font="2">ischemic heart disease. The following recommendations</text>
<text top="686" left="108" width="333" height="12" font="2">apply only to management of hypertension in patients</text>
<text top="704" left="108" width="159" height="12" font="2">with SIHD without HF. See</text>
<text top="704" left="271" width="64" height="12" font="5"><a href="e127.full.html#47">Section 9.2</a></text>
<text top="704" left="340" width="101" height="12" font="2">for recommenda-</text>
<text top="722" left="108" width="313" height="12" font="2">tions for the treatment of patients with SIHD and HF.</text>
<text top="740" left="123" width="46" height="11" font="5"><a href="e127.full.html#46">Figure 5</a></text>
<text top="740" left="174" width="267" height="12" font="2">is an algorithm on management of hyperten-</text>
<text top="758" left="108" width="157" height="12" font="2">sion in patients with SIHD.</text>
<text top="776" left="108" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="774" left="247" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="803" left="110" width="331" height="12" font="2">1. In patients with increased cardiovascular risk, reduc-</text>
<text top="821" left="124" width="88" height="12" font="2">tion of SBP to</text>
<text top="819" left="218" width="223" height="15" font="2">&lt;130/80 mm Hg has been shown to</text>
<text top="839" left="124" width="317" height="12" font="2">reduce CVD complications by 25% and all-cause mor-</text>
<text top="856" left="124" width="75" height="12" font="2">tality by 27%</text>
<text top="856" left="203" width="41" height="12" font="5"><a href="e127.full.html#99">(S9.1-1)</a></text>
<text top="856" left="245" width="3" height="12" font="2"><a href="e127.full.html#99">.</a></text>
<text top="874" left="109" width="332" height="12" font="2">2. After 5 years of randomized therapy in high-CVD-risk</text>
<text top="892" left="124" width="317" height="12" font="2">patients, ramipril produced a 22% reduction in MI,</text>
<text top="910" left="124" width="236" height="12" font="2">stroke, or CVD compared with placebo</text>
<text top="910" left="366" width="49" height="12" font="5"><a href="e127.full.html#99">(S9.1-10)</a></text>
<text top="910" left="415" width="26" height="12" font="2">. No</text>
<text top="928" left="124" width="73" height="12" font="2">added bene</text>
<text top="926" left="197" width="244" height="15" font="2">ﬁt on CVD outcomes was seen when</text>
<text top="946" left="124" width="214" height="12" font="2">compared with CCBs and diuretics</text>
<text top="946" left="346" width="92" height="12" font="5"><a href="e127.full.html#99">(S9.1-15,S9.1-16)</a></text>
<text top="946" left="437" width="3" height="12" font="2">.</text>
<text top="964" left="124" width="317" height="12" font="2">After 4.2 years of randomized therapy in patients with</text>
<text top="982" left="124" width="317" height="12" font="2">SIHD, perindopril reduced CVD death, MI, or cardiac</text>
<text top="1000" left="124" width="232" height="12" font="2">arrest by 20% compared with placebo</text>
<text top="1000" left="363" width="42" height="12" font="5"><a href="e127.full.html#99">(S9.1-7)</a></text>
<text top="1000" left="405" width="36" height="12" font="2">. Beta</text>
<text top="1018" left="124" width="317" height="12" font="2">blockers are effective drugs for preventing angina</text>
<text top="1036" left="124" width="317" height="12" font="2">pectoris, improving exercise time until the onset of</text>
<text top="1054" left="124" width="317" height="12" font="2">angina pectoris, reducing exercise-induced ischemic</text>
<text top="1072" left="124" width="317" height="12" font="2">ST-segment depression, and preventing coronary</text>
<text top="1090" left="124" width="38" height="12" font="2">events</text>
<text top="1090" left="175" width="82" height="12" font="5"><a href="e127.full.html#99">(S9.1-8,S9.1-17</a></text>
<text top="1088" left="258" width="54" height="15" font="5"><a href="e127.full.html#99">—S9.1-22)</a></text>
<text top="1090" left="312" width="3" height="12" font="2"><a href="e127.full.html#99">.</a></text>
<text top="1090" left="329" width="47" height="12" font="2">Because</text>
<text top="1090" left="389" width="11" height="12" font="2">of</text>
<text top="1090" left="414" width="27" height="12" font="2">their</text>
<text top="181" left="63" width="584" height="11" font="19">Recommendations for Treatment of Hypertension in Patients With Stable Ischemic Heart Disease (SIHD)</text>
<text top="195" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="195" left="412" width="177" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplements 30-32</a></text>
<text top="195" left="590" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="236" left="89" width="19" height="10" font="13">COR</text>
<text top="236" left="161" width="18" height="10" font="13">LOE</text>
<text top="236" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="273" left="97" width="3" height="9" font="4">I</text>
<text top="266" left="152" width="36" height="9" font="4">SBP: B-R</text>
<text top="260" left="234" width="521" height="11" font="12">1. In adults with SIHD and hypertension, a BP target of less than 130/80 mm Hg is recommended</text>
<text top="276" left="246" width="36" height="11" font="5"><a href="e127.full.html#99">(S9.1-1</a></text>
<text top="274" left="283" width="46" height="15" font="5"><a href="e127.full.html#99">—S9.1-5)</a></text>
<text top="276" left="329" width="3" height="11" font="12">.</text>
<text top="281" left="149" width="43" height="9" font="4">DBP: C-EO</text>
<text top="330" left="97" width="3" height="9" font="4">I</text>
<text top="323" left="152" width="36" height="9" font="4">SBP: B-R</text>
<text top="318" left="234" width="219" height="11" font="12">2. Adults with SIHD and hypertension (BP</text>
<text top="316" left="456" width="345" height="15" font="12">‡130/80 mm Hg) should be treated with medications (e.g., GDMT</text>
<text top="334" left="248" width="43" height="11" font="5"><a href="e127.full.html#99">(S9.1-6)</a></text>
<text top="334" left="295" width="486" height="11" font="12">beta blockers, ACE inhibitors, or ARBs) for compelling indications (e.g., previous MI, stable</text>
<text top="349" left="248" width="54" height="11" font="12">angina) as</text>
<text top="347" left="306" width="467" height="15" font="12">ﬁrst-line therapy, with the addition of other drugs (e.g., dihydropyridine CCBs, thiazide</text>
<text top="365" left="248" width="530" height="11" font="12">diuretics, and/or mineralocorticoid receptor antagonists) as needed to further control hypertension</text>
<text top="381" left="248" width="37" height="11" font="5"><a href="e127.full.html#99">(S9.1-7</a></text>
<text top="379" left="285" width="53" height="15" font="5"><a href="e127.full.html#99">—S9.1-10)</a></text>
<text top="381" left="338" width="3" height="11" font="12">.</text>
<text top="341" left="149" width="43" height="9" font="4">DBP: C-EO</text>
<text top="422" left="97" width="3" height="9" font="4">I</text>
<text top="422" left="160" width="21" height="9" font="4">B-NR</text>
<text top="410" left="234" width="568" height="11" font="12">3. In adults with SIHD with angina and persistent uncontrolled hypertension, the addition of dihydropyridine</text>
<text top="426" left="248" width="77" height="11" font="12">CCBs to GDMT</text>
<text top="426" left="329" width="43" height="11" font="5"><a href="e127.full.html#99">(S9.1-6)</a></text>
<text top="426" left="376" width="162" height="11" font="12">beta blockers is recommended</text>
<text top="426" left="542" width="126" height="11" font="5"><a href="e127.full.html#99">(S9.1-8,S9.1-11,S9.1-12)</a></text>
<text top="426" left="667" width="3" height="11" font="12">.</text>
<text top="472" left="94" width="10" height="9" font="4">IIa</text>
<text top="472" left="160" width="21" height="9" font="4">B-NR</text>
<text top="460" left="234" width="495" height="11" font="12">4. In adults who have had a MI or acute coronary syndrome, it is reasonable to continue GDMT</text>
<text top="460" left="732" width="43" height="11" font="5"><a href="e127.full.html#99">(S9.1-6)</a></text>
<text top="460" left="778" width="23" height="11" font="12">beta</text>
<text top="475" left="249" width="337" height="11" font="12">blockers beyond 3 years as long-term therapy for hypertension</text>
<text top="475" left="590" width="90" height="11" font="5"><a href="e127.full.html#99">(S9.1-13,S9.1-14)</a></text>
<text top="475" left="680" width="3" height="11" font="12"><a href="e127.full.html#99">.</a></text>
<text top="521" left="94" width="10" height="9" font="4">IIb</text>
<text top="521" left="160" width="20" height="9" font="4">C-EO</text>
<text top="509" left="234" width="560" height="11" font="12">5. Beta blockers and/or CCBs might be considered to control hypertension in patients with CAD (without</text>
<text top="525" left="248" width="14" height="11" font="12">HF</text>
<text top="523" left="262" width="321" height="15" font="12">rEF) who had an MI more than 3 years ago and have angina.</text>
<text top="598" left="486" width="45" height="11" font="22">FIGURE 5</text>
<text top="598" left="539" width="230" height="9" font="23">Management of Hypertension in Patients With SIHD</text>
<text top="959" left="486" width="208" height="9" font="13">Colors correspond to Class of Recommendation in</text>
<text top="959" left="696" width="30" height="9" font="17"><a href="e127.full.html#6">Table 1</a></text>
<text top="959" left="726" width="57" height="9" font="13">. *GDMT beta</text>
<text top="974" left="486" width="288" height="9" font="13">blockers for BP control or relief of angina include carvedilol, meto-</text>
<text top="989" left="486" width="297" height="9" font="13">prolol tartrate, metoprolol succinate, nadolol, bisoprolol, propranolol,</text>
<text top="1004" left="486" width="291" height="9" font="13">and timolol. Avoid beta blockers with intrinsic sympathomimetic ac-</text>
<text top="1019" left="486" width="297" height="9" font="13">tivity. The beta blocker atenolol should not be used because it is less</text>
<text top="1034" left="486" width="243" height="9" font="13">effective than placebo in reducing cardiovascular events.</text>
<text top="1032" left="732" width="45" height="12" font="13">†If needed</text>
<text top="1049" left="486" width="286" height="9" font="13">for BP control. ACE indicates angiotensin-converting enzyme; ARB,</text>
<text top="1064" left="486" width="297" height="9" font="13">angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel</text>
<text top="1079" left="486" width="280" height="9" font="13">blocker; GDMT, guideline-directed management and therapy; and</text>
<text top="1094" left="486" width="153" height="9" font="13">SIHD, stable ischemic heart disease.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="18" height="9" font="4">e172</text>
</page>
<page number="47" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="79" width="317" height="12" font="2">compelling indications for treatment of SIHD, these</text>
<text top="161" left="79" width="172" height="12" font="2">drugs are recommended as a</text>
<text top="159" left="256" width="140" height="15" font="2">ﬁrst-line therapy in the</text>
<text top="178" left="79" width="317" height="12" font="2">treatment of hypertension when it occurs in patients</text>
<text top="196" left="79" width="317" height="12" font="2">with SIHD. GDMT beta blockers for SIHD that are also</text>
<text top="214" left="79" width="317" height="12" font="2">effective in lowering BP include carvedilol, metoprolol</text>
<text top="232" left="79" width="317" height="12" font="2">tartrate, metoprolol succinate, nadolol, bisoprolol,</text>
<text top="250" left="79" width="317" height="12" font="2">propranolol, and timolol. Atenolol is not as effective as</text>
<text top="268" left="79" width="317" height="12" font="2">other antihypertensive drugs in the treatment of hy-</text>
<text top="286" left="79" width="62" height="12" font="2">pertension</text>
<text top="286" left="145" width="49" height="12" font="5"><a href="e127.full.html#100">(S9.1-23)</a></text>
<text top="286" left="194" width="3" height="12" font="2">.</text>
<text top="304" left="64" width="332" height="12" font="2">3. Dihydropyridine CCBs are effective antianginal drugs</text>
<text top="322" left="79" width="317" height="12" font="2">that can lower BP and relieve angina pectoris when</text>
<text top="340" left="79" width="317" height="12" font="2">added to beta blockers in patients in whom hyperten-</text>
<text top="358" left="79" width="317" height="12" font="2">sion is present and angina pectoris persists despite</text>
<text top="376" left="79" width="72" height="12" font="2">beta-blocker</text>
<text top="376" left="170" width="44" height="12" font="2">therapy</text>
<text top="376" left="233" width="126" height="12" font="5"><a href="e127.full.html#99">(S9.1-8,S9.1-17,S9.1-19</a></text>
<text top="374" left="360" width="36" height="15" font="5"><a href="e127.full.html#99">—S9.1-</a></text>
<text top="394" left="79" width="106" height="12" font="5"><a href="e127.full.html#99">22,S9.1-24,S9.1-25)</a></text>
<text top="394" left="186" width="210" height="12" font="2"><a href="e127.full.html#99">. </a>GDMT beta blockers for SIHD that</text>
<text top="412" left="79" width="317" height="12" font="2">are also effective in lowering BP include carvedilol,</text>
<text top="143" left="439" width="317" height="12" font="2">metoprolol tartrate, metoprolol succinate, nadolol,</text>
<text top="161" left="439" width="212" height="12" font="2">bisoprolol, propranolol, and timolol.</text>
<text top="178" left="423" width="333" height="12" font="2">4. In randomized long-term trials, use of beta blockers</text>
<text top="196" left="439" width="261" height="12" font="2">after MI reduced all-cause mortality by 23%</text>
<text top="196" left="705" width="48" height="12" font="5"><a href="e127.full.html#99">(S9.1-13)</a></text>
<text top="196" left="753" width="3" height="12" font="2"><a href="e127.full.html#99">.</a></text>
<text top="214" left="439" width="152" height="12" font="2">Given the established ef</text>
<text top="213" left="592" width="165" height="15" font="2">ﬁcacy of beta blockers for</text>
<text top="232" left="439" width="317" height="12" font="2">treating hypertension and SIHD, their use for treat-</text>
<text top="250" left="439" width="317" height="12" font="2">ment continuing beyond 3 years after MI is reasonable</text>
<text top="268" left="439" width="87" height="12" font="5"><a href="e127.full.html#99">(S9.1-6,S9.1-25)</a></text>
<text top="268" left="527" width="3" height="12" font="2"><a href="e127.full.html#99">.</a></text>
<text top="286" left="425" width="332" height="12" font="2">5. GDMT beta blockers and CCBs are effective antihy-</text>
<text top="304" left="439" width="317" height="12" font="2">pertensive and antianginal agents. CCBs include dihy-</text>
<text top="322" left="439" width="317" height="12" font="2">dropyridine and nondihydropyridine agents. CCBs can</text>
<text top="340" left="439" width="317" height="12" font="2">be used separately or together with beta blockers</text>
<text top="358" left="439" width="317" height="12" font="2">beginning 3 years after MI in patients with CAD who</text>
<text top="376" left="439" width="211" height="12" font="2">have both hypertension and angina.</text>
<text top="412" left="423" width="94" height="11" font="12">9.2. Heart Failure</text>
<text top="479" left="63" width="379" height="11" font="19">Recommendation for Prevention of HF in Adults With Hypertension</text>
<text top="493" left="63" width="362" height="11" font="19">References that support the recommendation are summarized in</text>
<text top="493" left="429" width="152" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 33</a></text>
<text top="493" left="581" width="3" height="11" font="19">.</text>
<text top="534" left="89" width="19" height="10" font="13">COR</text>
<text top="534" left="161" width="18" height="10" font="13">LOE</text>
<text top="534" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="571" left="97" width="3" height="9" font="4">I</text>
<text top="564" left="152" width="36" height="9" font="4">SBP: B-R</text>
<text top="559" left="234" width="523" height="11" font="12">1. In adults at increased risk of HF, the optimal BP in those with hypertension should be less than</text>
<text top="574" left="246" width="81" height="11" font="12">130/80 mm Hg</text>
<text top="574" left="331" width="38" height="11" font="5"><a href="e127.full.html#100">(S9.2-1</a></text>
<text top="572" left="369" width="47" height="15" font="5"><a href="e127.full.html#100">—S9.2-3)</a></text>
<text top="574" left="417" width="3" height="11" font="12"><a href="e127.full.html#100">.</a></text>
<text top="579" left="149" width="43" height="9" font="4">DBP: C-EO</text>
<text top="651" left="63" width="52" height="12" font="2">Synopsis</text>
<text top="669" left="78" width="321" height="12" font="2">Antecedent hypertension is present in 75% of patients</text>
<text top="687" left="63" width="99" height="12" font="2">with chronic HF</text>
<text top="687" left="169" width="45" height="12" font="5"><a href="e127.full.html#100">(S9.2-4)</a></text>
<text top="687" left="214" width="185" height="12" font="2"><a href="e127.full.html#100">. </a>In the Cardiovascular Health</text>
<text top="704" left="63" width="33" height="12" font="2">Study</text>
<text top="704" left="101" width="44" height="12" font="5"><a href="e127.full.html#100">(S9.2-5)</a></text>
<text top="704" left="149" width="250" height="12" font="2">and the Health, Aging and Body Composi-</text>
<text top="722" left="63" width="60" height="12" font="2">tion Study</text>
<text top="722" left="127" width="44" height="12" font="5"><a href="e127.full.html#100">(S9.2-6)</a></text>
<text top="722" left="172" width="227" height="12" font="2"><a href="e127.full.html#100">, </a>11.2% of 4408 persons (53.1% women,</text>
<text top="740" left="63" width="336" height="12" font="2">with a mean age of 72.8 years, living in the community,</text>
<text top="758" left="63" width="336" height="12" font="2">and not receiving antihypertensive drugs at baseline)</text>
<text top="776" left="63" width="159" height="12" font="2">developed HF over 10 years</text>
<text top="776" left="225" width="43" height="12" font="5"><a href="e127.full.html#100">(S9.2-7)</a></text>
<text top="776" left="269" width="130" height="12" font="2"><a href="e127.full.html#100">. </a>Compared with those</text>
<text top="794" left="63" width="118" height="12" font="2">with an average SBP</text>
<text top="792" left="185" width="214" height="15" font="2">&lt;120 mm Hg, the adjusted incidence</text>
<text top="812" left="63" width="336" height="12" font="2">of HF was increased 1.6, 2.2, and 2.6 times in those with</text>
<text top="830" left="63" width="336" height="12" font="2">average SBPs between 120 and 139 mm Hg, between 140</text>
<text top="848" left="63" width="120" height="12" font="2">and 159 mm Hg, and</text>
<text top="846" left="187" width="154" height="15" font="2">$160 mm Hg, respectively</text>
<text top="848" left="344" width="43" height="12" font="5"><a href="e127.full.html#100">(S9.2-7)</a></text>
<text top="848" left="388" width="3" height="12" font="2">.</text>
<text top="866" left="78" width="321" height="12" font="2">No RCTs are available that compare one BP-lowering</text>
<text top="884" left="63" width="336" height="12" font="2">agent to another for the management of patients with</text>
<text top="902" left="63" width="336" height="12" font="2">HF. The following recommendations for treatment of hy-</text>
<text top="920" left="63" width="336" height="12" font="2">pertension in HF are based on use of drugs that lower BP</text>
<text top="938" left="63" width="336" height="12" font="2">and also have compelling indications for management of</text>
<text top="955" left="63" width="336" height="12" font="2">HF (with HFrEF or HFpEF) as recommended in current</text>
<text top="973" left="63" width="119" height="12" font="2">ACC/AHA guidelines</text>
<text top="973" left="186" width="85" height="12" font="5"><a href="e127.full.html#100">(S9.2-4,S9.2-8)</a></text>
<text top="973" left="271" width="3" height="12" font="2"><a href="e127.full.html#100">.</a></text>
<text top="1000" left="63" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="999" left="202" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="1027" left="63" width="223" height="12" font="2">1. In adults with hypertension (SBP</text>
<text top="1025" left="295" width="104" height="15" font="2">$130 mm Hg or</text>
<text top="1045" left="77" width="24" height="12" font="2">DBP</text>
<text top="1043" left="107" width="292" height="15" font="2">$80 mm Hg) and a high risk of CVD, a strong</text>
<text top="651" left="434" width="322" height="12" font="2">body of evidence supports treatment with antihyper-</text>
<text top="669" left="434" width="155" height="12" font="2">tensive medications (see</text>
<text top="669" left="599" width="78" height="12" font="5"><a href="e127.full.html#34">Section 8.1.2</a></text>
<text top="669" left="677" width="79" height="12" font="2">) and more-</text>
<text top="687" left="434" width="53" height="12" font="2">intensive</text>
<text top="687" left="501" width="35" height="12" font="2">rather</text>
<text top="687" left="550" width="26" height="12" font="2">than</text>
<text top="687" left="590" width="80" height="12" font="2">less-intensive</text>
<text top="687" left="684" width="72" height="12" font="2">intervention</text>
<text top="704" left="434" width="23" height="12" font="2">(see</text>
<text top="704" left="468" width="79" height="12" font="5"><a href="">Section 8.1.5</a></text>
<text top="704" left="547" width="209" height="12" font="2">). In SPRINT, a more intensive</text>
<text top="722" left="434" width="223" height="12" font="2">intervention that targeted an SBP</text>
<text top="721" left="669" width="88" height="15" font="2">&lt;120 mm Hg</text>
<text top="740" left="434" width="27" height="12" font="2">signi</text>
<text top="738" left="462" width="294" height="15" font="2">ﬁcantly reduced the primary outcome (CVD</text>
<text top="758" left="434" width="156" height="12" font="2">composite) by about 25%</text>
<text top="758" left="597" width="44" height="12" font="5"><a href="e127.full.html#100">(S9.2-9)</a></text>
<text top="758" left="642" width="115" height="12" font="2"><a href="e127.full.html#100">. </a>The incidence of</text>
<text top="776" left="434" width="322" height="12" font="2">HF, a component of the primary outcome, was also</text>
<text top="794" left="434" width="75" height="12" font="2">substantially</text>
<text top="794" left="521" width="58" height="12" font="2">decreased</text>
<text top="794" left="592" width="43" height="12" font="2">(hazard</text>
<text top="794" left="648" width="31" height="12" font="2">ratio:</text>
<text top="794" left="691" width="29" height="12" font="2">0.62;</text>
<text top="794" left="733" width="24" height="12" font="2">95%</text>
<text top="812" left="434" width="20" height="12" font="2">con</text>
<text top="810" left="455" width="301" height="15" font="2">ﬁdence interval: 0.45–0.84). Meta-analyses of</text>
<text top="830" left="434" width="146" height="12" font="2">clinical trials have identi</text>
<text top="828" left="581" width="175" height="15" font="2">ﬁed a similar beneﬁcial effect</text>
<text top="848" left="434" width="322" height="12" font="2">of more-intensive BP reduction on the incidence of</text>
<text top="866" left="434" width="17" height="12" font="2">HF</text>
<text top="866" left="456" width="89" height="12" font="5"><a href="e127.full.html#100">(S9.2-2,S9.2-10)</a></text>
<text top="866" left="546" width="211" height="12" font="2"><a href="e127.full.html#100">, </a>but the body of information from</text>
<text top="884" left="434" width="72" height="12" font="2">studies con</text>
<text top="882" left="507" width="250" height="15" font="2">ﬁned to trials that randomly assigned</text>
<text top="902" left="434" width="322" height="12" font="2">participants to different BP targets is more limited</text>
<text top="920" left="434" width="117" height="12" font="2">and less compelling</text>
<text top="920" left="556" width="43" height="12" font="5"><a href="e127.full.html#100">(S9.2-3)</a></text>
<text top="920" left="599" width="157" height="12" font="2">. In addition, the available</text>
<text top="938" left="434" width="78" height="12" font="2">trials were ef</text>
<text top="936" left="512" width="244" height="15" font="2">ﬁcacy studies in which BP measurements</text>
<text top="955" left="434" width="322" height="12" font="2">were more consistent with guideline recommenda-</text>
<text top="973" left="434" width="322" height="12" font="2">tions than is common in clinical practice, resulting in</text>
<text top="991" left="434" width="322" height="12" font="2">lower absolute values for SBP. For both of these</text>
<text top="1009" left="434" width="322" height="12" font="2">reasons, the SBP target recommended during BP</text>
<text top="1027" left="434" width="62" height="12" font="2">lowering (</text>
<text top="1025" left="496" width="260" height="15" font="2">&lt;130 mm Hg) is higher than that used in</text>
<text top="1045" left="434" width="47" height="12" font="2">SPRINT.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="790" width="18" height="9" font="4">e173</text>
</page>
<page number="48" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="267" height="11" font="2">9.2.1. Heart Failure With Reduced Ejection Fraction</text>
<text top="396" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="414" left="123" width="318" height="12" font="2">Approximately 50% of patients with HF have HFrEF</text>
<text top="432" left="108" width="48" height="12" font="5"><a href="e127.full.html#100">(S9.2.1-2</a></text>
<text top="430" left="156" width="58" height="15" font="5"><a href="e127.full.html#100">—S9.2.1-6)</a></text>
<text top="432" left="215" width="226" height="12" font="2"><a href="e127.full.html#100">. </a>Numerous RCTs have shown that</text>
<text top="450" left="108" width="333" height="12" font="2">treatment of HFrEF with GDMT reduces mortality and HF</text>
<text top="468" left="108" width="92" height="12" font="2">hospitalizations</text>
<text top="468" left="205" width="53" height="12" font="5"><a href="e127.full.html#100">(S9.2.1-7)</a></text>
<text top="468" left="257" width="183" height="12" font="2">. Large-scale RCTs have shown</text>
<text top="486" left="108" width="333" height="12" font="2">that antihypertensive drug therapy reduces the incidence</text>
<text top="503" left="108" width="213" height="12" font="2">of HF in patients with hypertension</text>
<text top="503" left="326" width="49" height="12" font="5"><a href="e127.full.html#100">(S9.2.1-8</a></text>
<text top="502" left="375" width="62" height="15" font="5"><a href="e127.full.html#100">—S9.2.1-11)</a></text>
<text top="503" left="437" width="3" height="12" font="2">.</text>
<text top="521" left="108" width="333" height="12" font="2">In ALLHAT (Antihypertensive and Lipid-Lowering Treat-</text>
<text top="539" left="108" width="333" height="12" font="2">ment to Prevent Heart Attack Trial), chlorthalidone</text>
<text top="557" left="108" width="333" height="12" font="2">reduced the risk of HFrEF more than amlodipine and</text>
<text top="575" left="108" width="208" height="12" font="2">doxazosin but similarly to lisinopril</text>
<text top="575" left="320" width="111" height="12" font="5"><a href="e127.full.html#100">(S9.2.1-12,S9.2.1-13)</a></text>
<text top="575" left="431" width="3" height="12" font="2">.</text>
<text top="611" left="108" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="609" left="247" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="638" left="108" width="333" height="12" font="2">1. This recommendation is based on guidance in the 2017</text>
<text top="656" left="122" width="319" height="12" font="2">ACC/AHA/HFSA guideline focused update on heart</text>
<text top="674" left="122" width="38" height="12" font="2">failure</text>
<text top="674" left="164" width="59" height="12" font="5"><a href="e127.full.html#100">(S9.2.1-14)</a></text>
<text top="674" left="228" width="23" height="12" font="2">(see</text>
<text top="672" left="256" width="185" height="15" font="2">ﬁgure from the HF focused up-</text>
<text top="692" left="122" width="152" height="12" font="2">date that is reproduced in</text>
<text top="692" left="278" width="155" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement A</a></text>
<text top="692" left="433" width="8" height="12" font="2">).</text>
<text top="710" left="122" width="83" height="12" font="2">Lifestyle modi</text>
<text top="708" left="205" width="236" height="15" font="2">ﬁcation, such as weight loss and sodium</text>
<text top="728" left="122" width="319" height="12" font="2">reduction, may serve as adjunctive measures to help</text>
<text top="746" left="122" width="319" height="12" font="2">these agents work better. No RCT evidence is available</text>
<text top="764" left="122" width="319" height="12" font="2">to support the superiority of one BP-lowering medica-</text>
<text top="781" left="122" width="319" height="12" font="2">tion with compelling indications for treatment of</text>
<text top="799" left="122" width="319" height="12" font="2">HFrEF over another. Medications with compelling in-</text>
<text top="817" left="122" width="217" height="12" font="2">dications for HF that may be used as</text>
<text top="815" left="343" width="98" height="15" font="2">ﬁrst-line therapy</text>
<text top="396" left="482" width="319" height="12" font="2">to treat high BP include ACE inhibitors or ARBs,</text>
<text top="414" left="482" width="124" height="12" font="2">angiotensin receptor</text>
<text top="412" left="606" width="195" height="15" font="2">–neprilysin inhibitors, mineralo-</text>
<text top="432" left="482" width="319" height="12" font="2">corticoid receptor antagonists, diuretics, and GDMT</text>
<text top="450" left="482" width="319" height="12" font="2">beta blockers (carvedilol, metoprolol succinate, or</text>
<text top="468" left="482" width="66" height="12" font="2">bisoprolol).</text>
<text top="495" left="483" width="319" height="12" font="2">Clinical trials evaluating goal BP reduction and optimal</text>
<text top="512" left="468" width="333" height="12" font="2">BP-lowering agents in the setting of HFrEF and concom-</text>
<text top="530" left="468" width="333" height="12" font="2">itant hypertension have not been performed. However, in</text>
<text top="548" left="468" width="333" height="12" font="2">patients at higher CVD risk, BP lowering is associated with</text>
<text top="566" left="468" width="212" height="12" font="2">fewer adverse cardiovascular events</text>
<text top="566" left="684" width="53" height="12" font="5"><a href="e127.full.html#100">(S9.2.1-7)</a></text>
<text top="566" left="737" width="64" height="12" font="2">. GDMT for</text>
<text top="584" left="468" width="333" height="12" font="2">HFrEF with agents known to lower BP should consider a</text>
<text top="602" left="468" width="333" height="12" font="2">goal BP reduction consistent with a threshold now asso-</text>
<text top="620" left="468" width="333" height="12" font="2">ciated with improved clinical outcomes but not yet</text>
<text top="638" left="468" width="217" height="12" font="2">proven by RCTs in an HF population.</text>
<text top="665" left="468" width="333" height="12" font="2">2. Nondihydropyridine CCBs (verapamil, diltiazem) have</text>
<text top="683" left="483" width="318" height="12" font="2">myocardial depressant activity. Several clinical trials</text>
<text top="701" left="483" width="255" height="12" font="2">have demonstrated either no clinical bene</text>
<text top="699" left="738" width="63" height="15" font="2">ﬁt or even</text>
<text top="719" left="483" width="318" height="12" font="2">worse outcomes in patients with HF treated with these</text>
<text top="737" left="483" width="32" height="12" font="2">drugs</text>
<text top="737" left="521" width="51" height="12" font="5"><a href="e127.full.html#100">(S9.2.1-1)</a></text>
<text top="737" left="573" width="228" height="12" font="2">. Therefore, nondihydropyridine CCBs</text>
<text top="755" left="483" width="318" height="12" font="2">are not recommended in patients with hypertension</text>
<text top="772" left="483" width="67" height="12" font="2">and HFrEF.</text>
<text top="818" left="468" width="275" height="11" font="2">9.2.2. Heart Failure With Preserved Ejection Fraction</text>
<text top="179" left="63" width="391" height="11" font="19">Recommendations for Treatment of Hypertension in Patients With HF</text>
<text top="177" left="455" width="18" height="15" font="19">rEF</text>
<text top="194" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="194" left="412" width="153" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 34</a></text>
<text top="194" left="566" width="3" height="11" font="19">.</text>
<text top="235" left="89" width="19" height="10" font="13">COR</text>
<text top="235" left="161" width="18" height="10" font="13">LOE</text>
<text top="235" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="272" left="97" width="3" height="9" font="4">I</text>
<text top="272" left="160" width="20" height="9" font="4">C-EO</text>
<text top="259" left="234" width="92" height="11" font="12">1. Adults with HF</text>
<text top="257" left="326" width="264" height="15" font="12">rEF and hypertension should be prescribed GDMT</text>
<text top="259" left="594" width="52" height="11" font="5"><a href="e127.full.html#100">(S9.2.1-2)</a></text>
<text top="259" left="650" width="132" height="11" font="12">titrated to attain a BP of</text>
<text top="275" left="246" width="136" height="11" font="12">less than 130/80 mm Hg.</text>
<text top="319" left="71" width="47" height="9" font="4">III: No Bene</text>
<text top="318" left="118" width="9" height="12" font="4">ﬁt</text>
<text top="319" left="163" width="15" height="9" font="4">B-R</text>
<text top="307" left="234" width="525" height="11" font="12">2. Nondihydropyridine CCBs are not recommended in the treatment of hypertension in adults with</text>
<text top="323" left="248" width="14" height="11" font="12">HF</text>
<text top="321" left="262" width="17" height="15" font="12">rEF</text>
<text top="323" left="284" width="50" height="11" font="5"><a href="e127.full.html#100">(S9.2.1-1)</a></text>
<text top="323" left="334" width="3" height="11" font="12">.</text>
<text top="871" left="63" width="391" height="11" font="19">Recommendations for Treatment of Hypertension in Patients With HF</text>
<text top="868" left="455" width="20" height="15" font="19">pEF</text>
<text top="885" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="885" left="412" width="200" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplements 35 and 36</a></text>
<text top="885" left="612" width="3" height="11" font="19">.</text>
<text top="926" left="89" width="19" height="10" font="13">COR</text>
<text top="926" left="161" width="18" height="10" font="13">LOE</text>
<text top="926" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="963" left="97" width="3" height="9" font="4">I</text>
<text top="963" left="160" width="20" height="9" font="4">C-EO</text>
<text top="950" left="234" width="104" height="11" font="12">1. In adults with HF</text>
<text top="948" left="338" width="463" height="15" font="12">pEF who present with symptoms of volume overload, diuretics should be prescribed to</text>
<text top="966" left="246" width="114" height="11" font="12">control hypertension.</text>
<text top="1011" left="97" width="3" height="9" font="4">I</text>
<text top="1011" left="160" width="20" height="9" font="4">C-LD</text>
<text top="998" left="234" width="94" height="11" font="12">2. Adults with HF</text>
<text top="996" left="327" width="437" height="15" font="12">pEF and persistent hypertension after management of volume overload should be</text>
<text top="1014" left="248" width="527" height="11" font="12">prescribed ACE inhibitors or ARBs and beta blockers titrated to attain SBP of less than 130 mm Hg</text>
<text top="1030" left="248" width="47" height="11" font="5"><a href="e127.full.html#100">(S9.2.2-1</a></text>
<text top="1028" left="296" width="58" height="15" font="5"><a href="e127.full.html#100">—S9.2.2-6)</a></text>
<text top="1030" left="354" width="3" height="11" font="12">.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="18" height="9" font="4">e174</text>
</page>
<page number="49" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="52" height="12" font="2">Synopsis</text>
<text top="161" left="78" width="318" height="12" font="2">Approximately 50% of patients with HF have HFpEF</text>
<text top="178" left="63" width="99" height="12" font="5"><a href="e127.full.html#100">(S9.2.2-2,S9.2.2-7</a></text>
<text top="177" left="162" width="63" height="15" font="5"><a href="e127.full.html#100">—S9.2.2-11)</a></text>
<text top="178" left="225" width="171" height="12" font="2"><a href="e127.full.html#100">. </a>The ejection fraction in</text>
<text top="196" left="63" width="176" height="12" font="2">these studies has varied from</text>
<text top="195" left="244" width="89" height="15" font="2">&gt;40% to $55%</text>
<text top="196" left="339" width="54" height="12" font="5"><a href="e127.full.html#100">(S9.2.2-2)</a></text>
<text top="196" left="393" width="3" height="12" font="2"><a href="e127.full.html#100">.</a></text>
<text top="214" left="63" width="333" height="12" font="2">Patients with HFpEF are usually older women with a</text>
<text top="232" left="63" width="333" height="12" font="2">history of hypertension. Obesity, CHD, DM, AF, and</text>
<text top="250" left="63" width="333" height="12" font="2">hyperlipidemia are also highly prevalent in patients with</text>
<text top="268" left="63" width="39" height="12" font="2">HFpEF</text>
<text top="268" left="107" width="162" height="12" font="5"><a href="e127.full.html#100">(S9.2.2-2,S9.2.2-11,S9.2.2-12)</a></text>
<text top="268" left="269" width="127" height="12" font="2">. Hypertension is the</text>
<text top="286" left="63" width="333" height="12" font="2">most important cause of HFpEF, with a prevalence of 60%</text>
<text top="304" left="63" width="333" height="12" font="2">to 89% in large RCTs, epidemiological studies, and HF</text>
<text top="322" left="63" width="53" height="12" font="2">registries</text>
<text top="322" left="123" width="108" height="12" font="5"><a href="e127.full.html#100">(S9.2.2-2,S9.2.2-13)</a></text>
<text top="322" left="231" width="165" height="12" font="2">. Patients with HFpEF also</text>
<text top="340" left="63" width="333" height="12" font="2">have an exaggerated hypertensive response to exercise</text>
<text top="358" left="63" width="60" height="12" font="5"><a href="e127.full.html#101">(S9.2.2-14)</a></text>
<text top="358" left="123" width="273" height="12" font="2">. Hypertensive acute pulmonary edema is an</text>
<text top="376" left="63" width="121" height="12" font="2">expression of HFpEF</text>
<text top="376" left="188" width="59" height="12" font="5"><a href="e127.full.html#101">(S9.2.2-15)</a></text>
<text top="376" left="247" width="3" height="12" font="2">.</text>
<text top="394" left="78" width="318" height="12" font="2">BP control is important for prevention of HFpEF in</text>
<text top="412" left="63" width="156" height="12" font="2">patients with hypertension</text>
<text top="412" left="223" width="105" height="12" font="5"><a href="e127.full.html#100">(S9.2.2-2,S9.2.2-16</a></text>
<text top="410" left="328" width="65" height="15" font="5"><a href="e127.full.html#100">—S9.2.2-19)</a></text>
<text top="412" left="393" width="3" height="12" font="2"><a href="e127.full.html#100">.</a></text>
<text top="430" left="63" width="333" height="12" font="2">ALLHAT showed that treatment of hypertension with</text>
<text top="447" left="63" width="333" height="12" font="2">chlorthalidone reduced the risk of HF compared with</text>
<text top="465" left="63" width="228" height="12" font="2">amlodipine, doxazosin, and lisinopril</text>
<text top="465" left="298" width="98" height="12" font="5"><a href="e127.full.html#101">(S9.2.2-19,S9.2.2-</a></text>
<text top="483" left="63" width="18" height="12" font="5"><a href="e127.full.html#101">20)</a></text>
<text top="483" left="81" width="315" height="12" font="2">. Improved BP control also reduces hospitalization,</text>
<text top="501" left="63" width="154" height="12" font="2">CVD events, and mortality</text>
<text top="501" left="221" width="105" height="12" font="5"><a href="e127.full.html#100">(S9.2.2-2,S9.2.2-16</a></text>
<text top="499" left="326" width="64" height="15" font="5"><a href="e127.full.html#100">—S9.2.2-19)</a></text>
<text top="501" left="391" width="3" height="12" font="2"><a href="e127.full.html#100">.</a></text>
<text top="537" left="63" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="535" left="202" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="564" left="64" width="332" height="12" font="2">1. Diuretics are the only drugs used for the treatment of</text>
<text top="582" left="78" width="318" height="12" font="2">hypertension and HF that can adequately control the</text>
<text top="598" left="78" width="318" height="15" font="2">ﬂuid retention of HF. Appropriate use of diuretics is</text>
<text top="618" left="78" width="318" height="12" font="2">also crucial to the success of other drugs used for the</text>
<text top="636" left="78" width="318" height="12" font="2">treatment of hypertension in the presence of HF. The</text>
<text top="654" left="78" width="318" height="12" font="2">use of inappropriately low doses of diuretics can result</text>
<text top="672" left="78" width="11" height="12" font="2">in</text>
<text top="670" left="95" width="301" height="15" font="2">ﬂuid retention. Conversely, the use of inappropri-</text>
<text top="690" left="78" width="318" height="12" font="2">ately high doses of diuretics can lead to volume</text>
<text top="143" left="438" width="318" height="12" font="2">contraction, which can increase the risk of hypotension</text>
<text top="161" left="438" width="88" height="12" font="2">and renal insuf</text>
<text top="159" left="527" width="230" height="15" font="2">ﬁciency. Diuretics should be prescribed</text>
<text top="178" left="438" width="318" height="12" font="2">to all patients with hypertension and HFpEF who have</text>
<text top="196" left="438" width="318" height="12" font="2">evidence of, and to most patients with a prior history</text>
<text top="214" left="438" width="15" height="12" font="2">of,</text>
<text top="213" left="457" width="88" height="15" font="2">ﬂuid retention.</text>
<text top="232" left="423" width="333" height="12" font="2">2. In a trial of patients with HFpEF and MI, patients</text>
<text top="250" left="438" width="318" height="12" font="2">randomized to propranolol had at 32-month follow-up a</text>
<text top="268" left="438" width="210" height="12" font="2">35% reduction in mortality rate</text>
<text top="268" left="659" width="54" height="12" font="5"><a href="e127.full.html#101">(S9.2.2-3)</a></text>
<text top="268" left="713" width="43" height="12" font="2">. After</text>
<text top="286" left="438" width="318" height="12" font="2">21 months of treatment in patients with HFrEF and</text>
<text top="304" left="438" width="318" height="12" font="2">HFpEF, compared with placebo, those randomized to</text>
<text top="322" left="438" width="318" height="12" font="2">nebivolol had a 14% reduction in mortality or CVD</text>
<text top="340" left="438" width="318" height="12" font="2">hospitalization if they had HFrEF and a 19% reduction if</text>
<text top="358" left="438" width="93" height="12" font="2">they had HFpEF</text>
<text top="358" left="534" width="55" height="12" font="5"><a href="e127.full.html#101">(S9.2.2-4)</a></text>
<text top="358" left="590" width="167" height="12" font="2"><a href="e127.full.html#101">. </a>In patients with HFpEF, the</text>
<text top="376" left="438" width="318" height="12" font="2">primary outcome (a composite of CVD death or HF</text>
<text top="394" left="438" width="318" height="12" font="2">hospitalization) was observed in 22% for candesartan</text>
<text top="412" left="438" width="318" height="12" font="2">and 24% for placebo (11% reduction), but fewer</text>
<text top="430" left="438" width="318" height="12" font="2">patients receiving candesartan were hospitalized for HF</text>
<text top="447" left="438" width="54" height="12" font="5"><a href="e127.full.html#101">(S9.2.2-5)</a></text>
<text top="447" left="492" width="264" height="12" font="2">. The use of nitrates in the setting of HFpEF is</text>
<text top="465" left="438" width="318" height="12" font="2">associated with a signal of harm and in most situations</text>
<text top="483" left="438" width="318" height="12" font="2">should be avoided. For many other common antihyper-</text>
<text top="501" left="438" width="318" height="12" font="2">tensive agents, including alpha blockers, beta blockers,</text>
<text top="519" left="438" width="318" height="12" font="2">and calcium channel blockers, limited data exist to guide</text>
<text top="537" left="438" width="318" height="12" font="2">the choice of antihypertensive therapy in the setting</text>
<text top="555" left="438" width="59" height="12" font="2">of HFpEF</text>
<text top="555" left="505" width="59" height="12" font="5"><a href="e127.full.html#101">(S9.2.2-21)</a></text>
<text top="555" left="565" width="192" height="12" font="2"><a href="e127.full.html#101">. </a>Renin-angiotensin-aldosterone</text>
<text top="573" left="438" width="318" height="12" font="2">system inhibition, however, with ACE inhibitor or ARB</text>
<text top="591" left="438" width="318" height="12" font="2">and especially MRA would represent the preferred</text>
<text top="609" left="438" width="318" height="12" font="2">choice. A shared decision-making discussion, with the</text>
<text top="627" left="438" width="56" height="12" font="2">patient in</text>
<text top="625" left="495" width="261" height="15" font="2">ﬂuenced by clinician judgment, should drive</text>
<text top="645" left="438" width="271" height="12" font="2">the ultimate choice of antihypertensive agents.</text>
<text top="689" left="423" width="148" height="11" font="12">9.3. Chronic Kidney Disease</text>
<text top="751" left="63" width="399" height="11" font="19">Recommendations for Treatment of Hypertension in Patients With CKD</text>
<text top="765" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="765" left="412" width="200" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplements 37 and 38</a></text>
<text top="765" left="616" width="173" height="11" font="19">and Systematic Review Report.</text>
<text top="806" left="89" width="19" height="10" font="13">COR</text>
<text top="806" left="161" width="18" height="10" font="13">LOE</text>
<text top="806" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="843" left="97" width="3" height="9" font="4">I</text>
<text top="837" left="149" width="36" height="9" font="4">SBP: B-R</text>
<text top="834" left="184" width="8" height="6" font="20">SR</text>
<text top="831" left="234" width="474" height="11" font="12">1. Adults with hypertension and CKD should be treated to a BP goal of less than 130/80 mm Hg</text>
<text top="831" left="711" width="37" height="11" font="5"><a href="e127.full.html#101">(S9.3-1</a></text>
<text top="829" left="749" width="48" height="15" font="5"><a href="e127.full.html#101">—S9.3-6)</a></text>
<text top="831" left="797" width="3" height="11" font="12">.</text>
<text top="852" left="149" width="43" height="9" font="4">DBP: C-EO</text>
<text top="897" left="94" width="10" height="9" font="4">IIa</text>
<text top="897" left="163" width="15" height="9" font="4">B-R</text>
<text top="885" left="234" width="490" height="11" font="12">2. In adults with hypertension and CKD (stage 3 or higher or stage 1 or 2 with albuminuria [</text>
<text top="883" left="724" width="64" height="15" font="12">‡300 mg/d,</text>
<text top="900" left="248" width="11" height="11" font="12">or</text>
<text top="898" left="262" width="540" height="15" font="12">‡300 mg/g albumin-to-creatinine ratio or the equivalent in the ﬁrst morning void]), treatment with an</text>
<text top="916" left="248" width="332" height="11" font="12">ACE inhibitor is reasonable to slow kidney disease progression</text>
<text top="916" left="584" width="77" height="11" font="5"><a href="e127.full.html#101">(S9.3-3,S9.3-7</a></text>
<text top="914" left="661" width="52" height="15" font="5"><a href="e127.full.html#101">—S9.3-12)</a></text>
<text top="916" left="714" width="3" height="11" font="12"><a href="e127.full.html#101">.</a></text>
<text top="962" left="94" width="10" height="9" font="4">IIb</text>
<text top="962" left="160" width="20" height="9" font="4">C-EO</text>
<text top="950" left="234" width="490" height="11" font="12">3. In adults with hypertension and CKD (stage 3 or higher or stage 1 or 2 with albuminuria [</text>
<text top="948" left="724" width="64" height="15" font="12">‡300 mg/d,</text>
<text top="966" left="248" width="11" height="11" font="12">or</text>
<text top="964" left="262" width="350" height="15" font="12">‡300 mg/g albumin-to-creatinine ratio in the ﬁrst morning void])</text>
<text top="966" left="616" width="82" height="11" font="5"><a href="e127.full.html#101">(S9.3-7,S9.3-8)</a></text>
<text top="966" left="699" width="103" height="11" font="12"><a href="e127.full.html#101">, </a>treatment with an</text>
<text top="981" left="248" width="316" height="11" font="12">ARB may be reasonable if an ACE inhibitor is not tolerated.</text>
<text top="1008" left="63" width="157" height="11" font="2">SR indicates systematic review.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="790" width="18" height="9" font="4">e175</text>
</page>
<page number="50" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="161" left="123" width="67" height="12" font="2">Refer to the</text>
<text top="159" left="193" width="248" height="15" font="2">“Systematic Review for the 2017 ACC/AHA/</text>
<text top="178" left="108" width="333" height="12" font="2">AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guide-</text>
<text top="196" left="108" width="21" height="12" font="2">line</text>
<text top="196" left="141" width="16" height="12" font="2">for</text>
<text top="196" left="169" width="18" height="12" font="2">the</text>
<text top="196" left="199" width="64" height="12" font="2">Prevention,</text>
<text top="196" left="276" width="57" height="12" font="2">Detection,</text>
<text top="196" left="345" width="63" height="12" font="2">Evaluation,</text>
<text top="196" left="420" width="21" height="12" font="2">and</text>
<text top="214" left="108" width="279" height="12" font="2">Management of High Blood Pressure in Adults</text>
<text top="213" left="387" width="54" height="15" font="2">” for the</text>
<text top="232" left="108" width="333" height="12" font="2">complete systematic evidence review for additional data</text>
<text top="250" left="108" width="73" height="12" font="2">and analyses</text>
<text top="250" left="186" width="46" height="12" font="5"><a href="e127.full.html#101">(S9.3-13)</a></text>
<text top="250" left="233" width="208" height="12" font="2"><a href="e127.full.html#101">. </a>Hypertension is the most common</text>
<text top="268" left="108" width="333" height="12" font="2">comorbidity affecting patients with CKD. Hypertension has</text>
<text top="286" left="108" width="333" height="12" font="2">been reported in 67% to 92% of patients with CKD, with</text>
<text top="304" left="108" width="278" height="12" font="2">increasing prevalence as kidney function declines</text>
<text top="304" left="390" width="48" height="12" font="5"><a href="e127.full.html#101">(S9.3-14)</a></text>
<text top="304" left="437" width="3" height="12" font="2">.</text>
<text top="322" left="108" width="333" height="12" font="2">Hypertension may occur as a result of kidney disease, yet</text>
<text top="340" left="108" width="333" height="12" font="2">the presence of hypertension may also accelerate further</text>
<text top="358" left="108" width="333" height="12" font="2">kidney injury; therefore, treatment is an important means to</text>
<text top="376" left="108" width="333" height="12" font="2">prevent further kidney functional decline. This tight inter-</text>
<text top="394" left="108" width="333" height="12" font="2">action has led to extensive debate about the optimal BP</text>
<text top="412" left="108" width="160" height="12" font="2">target for patients with CKD</text>
<text top="412" left="273" width="42" height="12" font="5"><a href="e127.full.html#101">(S9.3-15</a></text>
<text top="410" left="315" width="52" height="15" font="5"><a href="e127.full.html#101">—S9.3-18)</a></text>
<text top="412" left="367" width="73" height="12" font="2">. Masked hy-</text>
<text top="430" left="108" width="333" height="12" font="2">pertension may occur in up to 30% of patients with CKD and</text>
<text top="447" left="108" width="229" height="12" font="2">portends higher risk of CKD progression</text>
<text top="447" left="342" width="43" height="12" font="5"><a href="e127.full.html#101">(S9.3-19</a></text>
<text top="446" left="385" width="52" height="15" font="5"><a href="e127.full.html#101">—S9.3-23)</a></text>
<text top="447" left="437" width="3" height="12" font="2">.</text>
<text top="465" left="108" width="228" height="12" font="2">CKD is an important risk factor for CVD</text>
<text top="465" left="340" width="49" height="12" font="5"><a href="e127.full.html#102">(S9.3-24)</a></text>
<text top="465" left="389" width="52" height="12" font="2"><a href="e127.full.html#102">, </a>and the</text>
<text top="483" left="108" width="333" height="12" font="2">coexistence of hypertension and CKD further increases the</text>
<text top="501" left="108" width="333" height="12" font="2">risk of adverse CVD and cerebrovascular events, particularly</text>
<text top="519" left="108" width="160" height="12" font="2">when proteinuria is present</text>
<text top="519" left="273" width="48" height="12" font="5"><a href="e127.full.html#102">(S9.3-25)</a></text>
<text top="519" left="321" width="120" height="12" font="2"><a href="e127.full.html#102">. </a>Even as the impor-</text>
<text top="537" left="108" width="333" height="12" font="2">tance of hypertension treatment is widely accepted, data</text>
<text top="555" left="108" width="333" height="12" font="2">supporting BP targets in CKD are limited, as patients with</text>
<text top="573" left="108" width="24" height="12" font="2">CKD</text>
<text top="573" left="144" width="27" height="12" font="2">were</text>
<text top="573" left="183" width="61" height="12" font="2">historically</text>
<text top="573" left="257" width="51" height="12" font="2">excluded</text>
<text top="573" left="320" width="27" height="12" font="2">from</text>
<text top="573" left="358" width="39" height="12" font="2">clinical</text>
<text top="573" left="410" width="31" height="12" font="2">trials.</text>
<text top="591" left="108" width="333" height="12" font="2">Furthermore, CKD is not included in the CVD risk calcula-</text>
<text top="609" left="108" width="333" height="12" font="2">tions used to determine suitability for most clinical trials</text>
<text top="627" left="108" width="44" height="12" font="5"><a href="e127.full.html#102">(S9.3-26</a></text>
<text top="625" left="152" width="53" height="15" font="5"><a href="e127.full.html#102">—S9.3-28)</a></text>
<text top="627" left="205" width="3" height="12" font="2">.</text>
<text top="645" left="123" width="318" height="12" font="2">Until publication of the SPRINT results, most guide-</text>
<text top="663" left="108" width="333" height="12" font="2">lines for BP targets in patients with CKD favored treat-</text>
<text top="681" left="108" width="72" height="12" font="2">ment to a BP</text>
<text top="679" left="182" width="92" height="15" font="2">&lt;140/90 mm Hg</text>
<text top="681" left="277" width="49" height="12" font="5"><a href="e127.full.html#101">(S9.3-15)</a></text>
<text top="681" left="326" width="115" height="12" font="2">, with consideration</text>
<text top="698" left="108" width="134" height="12" font="2">of the lower target of</text>
<text top="697" left="248" width="192" height="15" font="2">&lt;130/80 mm Hg for those with</text>
<text top="716" left="108" width="169" height="12" font="2">more severe proteinuria (</text>
<text top="715" left="277" width="164" height="15" font="2">$300 mg albuminuria in</text>
<text top="734" left="108" width="226" height="12" font="2">24 hours or the equivalent), if tolerated</text>
<text top="734" left="337" width="45" height="12" font="5"><a href="e127.full.html#101">(S9.3-16</a></text>
<text top="733" left="383" width="55" height="15" font="5"><a href="e127.full.html#101">—S9.3-18)</a></text>
<text top="734" left="437" width="3" height="12" font="2">.</text>
<text top="752" left="108" width="277" height="12" font="2">Patients with stage 3 to 4 CKD (eGFR of 20 to</text>
<text top="751" left="389" width="51" height="15" font="2">&lt;60 mL/</text>
<text top="770" left="108" width="87" height="12" font="2">minute/1.73 m</text>
<text top="768" left="195" width="5" height="8" font="9">2</text>
<text top="770" left="200" width="241" height="12" font="2">) comprised 28% of the SPRINT study</text>
<text top="788" left="108" width="333" height="12" font="2">population, and in this group intensive BP management</text>
<text top="806" left="108" width="197" height="12" font="2">seemed to provide the same bene</text>
<text top="804" left="305" width="136" height="15" font="2">ﬁts for reduction in the</text>
<text top="824" left="108" width="333" height="12" font="2">CVD composite primary outcome and all-cause mortality</text>
<text top="842" left="108" width="333" height="12" font="2">as were seen in the full study cohort. Given that most</text>
<text top="860" left="108" width="333" height="12" font="2">patients with CKD die from CVD complications, this RCT</text>
<text top="878" left="108" width="202" height="12" font="2">evidence supports a lower target of</text>
<text top="876" left="313" width="128" height="15" font="2">&lt;130/80 mm Hg for all</text>
<text top="896" left="108" width="133" height="12" font="2">patients with CKD (</text>
<text top="896" left="241" width="53" height="11" font="5"><a href="e127.full.html#50">Figure 6</a></text>
<text top="896" left="294" width="146" height="12" font="2">). It is appropriate to</text>
<text top="914" left="108" width="333" height="12" font="2">acknowledge that many patients with CKD have addi-</text>
<text top="932" left="108" width="333" height="12" font="2">tional comorbidities and evidence of frailty that caused</text>
<text top="950" left="108" width="333" height="12" font="2">them to be excluded from past clinical trials. Observa-</text>
<text top="967" left="108" width="333" height="12" font="2">tional studies of CKD cohorts indicate a higher risk of</text>
<text top="985" left="108" width="255" height="12" font="2">mortality at lower systolic pressures and a</text>
<text top="984" left="367" width="73" height="15" font="2">ﬂat relation-</text>
<text top="1003" left="108" width="333" height="12" font="2">ship of SBP to event risk in elderly patients with CKD</text>
<text top="1021" left="108" width="97" height="12" font="5"><a href="e127.full.html#102">(S9.3-29,S9.3-30)</a></text>
<text top="1021" left="205" width="236" height="12" font="2">, which supports concerns that these</text>
<text top="1039" left="108" width="333" height="12" font="2">complex patients may be at greater risk of complications</text>
<text top="1057" left="108" width="333" height="12" font="2">from intensive BP treatment and may fail to achieve</text>
<text top="1075" left="108" width="28" height="12" font="2">bene</text>
<text top="1073" left="136" width="305" height="15" font="2">ﬁts from lower BP targets. In contrast, in the pre-</text>
<text top="1093" left="108" width="29" height="12" font="2">speci</text>
<text top="1091" left="137" width="304" height="15" font="2">ﬁed subgroup analysis of the elderly cohort in</text>
<text top="734" left="468" width="267" height="12" font="2">SPRINT, frail elderly patients did sustain bene</text>
<text top="733" left="736" width="66" height="15" font="2">ﬁt from the</text>
<text top="752" left="468" width="333" height="12" font="2">lower BP target, which supports a lower goal for all</text>
<text top="770" left="468" width="222" height="12" font="2">patients, including those with CKD</text>
<text top="770" left="698" width="49" height="12" font="5"><a href="e127.full.html#102">(S9.3-31)</a></text>
<text top="770" left="747" width="54" height="12" font="2">. In this</text>
<text top="788" left="468" width="333" height="12" font="2">setting, incremental BP reduction may be appropriate,</text>
<text top="806" left="468" width="332" height="12" font="2">with careful monitoring of physical and kidney function.</text>
<text top="824" left="483" width="318" height="12" font="2">An ACE inhibitor (or an ARB, in case of ACE inhibitor</text>
<text top="842" left="468" width="333" height="12" font="2">intolerance) is a preferred drug for treatment of hyper-</text>
<text top="860" left="468" width="152" height="12" font="2">tension if albuminuria (</text>
<text top="858" left="620" width="181" height="15" font="2">$300 mg/day or $300 mg/g</text>
<text top="878" left="468" width="76" height="12" font="2">creatinine by</text>
<text top="876" left="548" width="253" height="15" font="2">ﬁrst morning void) is present, although the</text>
<text top="896" left="468" width="114" height="12" font="2">evidence is mixed</text>
<text top="896" left="590" width="93" height="12" font="5"><a href="e127.full.html#101">(S9.3-10,S9.3-11)</a></text>
<text top="896" left="691" width="4" height="12" font="2">(</text>
<text top="896" left="696" width="51" height="11" font="5"><a href="e127.full.html#50">Figure 6</a></text>
<text top="896" left="747" width="55" height="12" font="2"><a href="e127.full.html#50">). </a>In the</text>
<text top="914" left="468" width="333" height="12" font="2">course of reducing intraglomerular pressure and thereby</text>
<text top="932" left="468" width="333" height="12" font="2">reducing albuminuria, serum creatinine may increase up</text>
<text top="950" left="468" width="276" height="12" font="2">to 30% because of concurrent reduction in GFR</text>
<text top="950" left="747" width="50" height="12" font="5"><a href="e127.full.html#102">(S9.3-32)</a></text>
<text top="950" left="798" width="3" height="12" font="2"><a href="e127.full.html#102">.</a></text>
<text top="968" left="468" width="333" height="12" font="2">Further GFR decline should be investigated and may be</text>
<text top="985" left="468" width="333" height="12" font="2">related to other factors, including volume contraction,</text>
<text top="1003" left="468" width="296" height="12" font="2">use of nephrotoxic agents, or renovascular disease</text>
<text top="1003" left="768" width="33" height="12" font="5"><a href="e127.full.html#102">(S9.3-</a></text>
<text top="1021" left="468" width="17" height="12" font="5"><a href="e127.full.html#102">33)</a></text>
<text top="1021" left="485" width="316" height="12" font="2"><a href="e127.full.html#102">. </a>The combination of an ACE inhibitor and an ARB</text>
<text top="1039" left="468" width="333" height="12" font="2">should be avoided because of reported harms demon-</text>
<text top="1057" left="468" width="232" height="12" font="2">strated in several large cardiology trials</text>
<text top="1057" left="705" width="96" height="12" font="5"><a href="e127.full.html#102">(S9.3-34,S9.3-35)</a></text>
<text top="1075" left="468" width="206" height="12" font="2">and in 1 diabetic nephropathy trial</text>
<text top="1075" left="679" width="51" height="12" font="5"><a href="e127.full.html#102">(S9.3-36)</a></text>
<text top="1075" left="730" width="71" height="12" font="2"><a href="e127.full.html#102">. </a>Because of</text>
<text top="1093" left="468" width="333" height="12" font="2">the greater risk of hyperkalemia and hypotension and lack</text>
<text top="154" left="486" width="46" height="11" font="22">FIGURE 6</text>
<text top="155" left="539" width="227" height="9" font="23">Management of Hypertension in Patients With CKD</text>
<text top="613" left="486" width="211" height="9" font="13">Colors correspond to Class of Recommendation in</text>
<text top="613" left="699" width="31" height="9" font="17"><a href="e127.full.html#6">Table 1</a></text>
<text top="613" left="730" width="53" height="9" font="13"><a href="e127.full.html#6">. </a>*CKD stage</text>
<text top="628" left="486" width="180" height="9" font="13">3 or higher or stage 1 or 2 with albuminuria</text>
<text top="626" left="668" width="115" height="12" font="13">$300 mg/d or $300 mg/g</text>
<text top="643" left="486" width="268" height="9" font="13">creatinine. ACE indicates angiotensin-converting enzyme; ARB,</text>
<text top="658" left="486" width="284" height="9" font="13">angiotensin receptor blocker; BP blood pressure; and CKD, chronic</text>
<text top="673" left="486" width="64" height="9" font="13">kidney disease.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e176</text>
</page>
<page number="51" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="136" height="12" font="2">of demonstrated bene</text>
<text top="141" left="199" width="197" height="15" font="2">ﬁt, the combination of an ARB</text>
<text top="161" left="63" width="333" height="12" font="2">(or ACE inhibitor) and a direct renin inhibitor is also</text>
<text top="178" left="63" width="333" height="12" font="2">contraindicated during management of patients with</text>
<text top="196" left="63" width="25" height="12" font="2">CKD</text>
<text top="196" left="92" width="50" height="12" font="5"><a href="e127.full.html#102">(S9.3-37)</a></text>
<text top="196" left="142" width="3" height="12" font="2"><a href="e127.full.html#102">.</a></text>
<text top="215" left="78" width="47" height="11" font="5"><a href="e127.full.html#50">Figure 6</a></text>
<text top="214" left="130" width="266" height="12" font="2">is an algorithm on management of hyperten-</text>
<text top="232" left="63" width="153" height="12" font="2">sion in patients with CKD.</text>
<text top="268" left="63" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="266" left="202" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="295" left="64" width="332" height="12" font="2">1. We recommend ASCVD risk assessment in all adults</text>
<text top="313" left="78" width="318" height="12" font="2">with hypertension, including those with CKD. As a</text>
<text top="331" left="78" width="318" height="12" font="2">matter of convenience, however, it can be assumed</text>
<text top="349" left="78" width="318" height="12" font="2">that the vast majority of patients with CKD have a</text>
<text top="367" left="78" width="110" height="12" font="2">10-year ASCVD risk</text>
<text top="365" left="191" width="205" height="15" font="2">$10%, placing them in the high risk</text>
<text top="385" left="78" width="318" height="12" font="2">category that requires initiation of antihypertensive</text>
<text top="403" left="78" width="110" height="12" font="2">drug therapy at BP</text>
<text top="401" left="193" width="122" height="15" font="2">$130/80 mm Hg (see</text>
<text top="403" left="319" width="77" height="12" font="5"><a href="e127.full.html#34">Section 8.1.2,</a></text>
<text top="421" left="78" width="128" height="11" font="5"><a href="e127.full.html#36">Figure 4 </a>and <a href="e127.full.html#83">Table 23</a></text>
<text top="421" left="212" width="184" height="12" font="2">for BP thresholds for initiating</text>
<text top="439" left="78" width="318" height="12" font="2">antihypertensive drug treatment). In SPRINT, the par-</text>
<text top="456" left="78" width="318" height="12" font="2">ticipants with CKD who were randomized to intensive</text>
<text top="474" left="78" width="225" height="12" font="2">antihypertensive therapy (SBP target</text>
<text top="473" left="311" width="85" height="15" font="2">&lt;120 mm Hg)</text>
<text top="492" left="78" width="210" height="12" font="2">appeared to derive the same bene</text>
<text top="490" left="288" width="108" height="15" font="2">ﬁcial reduction in</text>
<text top="510" left="78" width="318" height="12" font="2">CVD events and all-cause mortality that was seen in</text>
<text top="528" left="78" width="318" height="12" font="2">their counterparts without CKD at baseline. Likewise,</text>
<text top="546" left="78" width="169" height="12" font="2">intensive therapy was bene</text>
<text top="544" left="247" width="149" height="15" font="2">ﬁcial even in those $75</text>
<text top="564" left="78" width="318" height="12" font="2">years of age with frailty or the slowest gait speed. There</text>
<text top="582" left="78" width="318" height="12" font="2">was no difference in the principal kidney outcome</text>
<text top="600" left="78" width="4" height="12" font="2">(</text>
<text top="598" left="82" width="314" height="15" font="2">$50% decline in eGFR or ESRD) between the</text>
<text top="618" left="78" width="80" height="12" font="2">intensive-and</text>
<text top="618" left="170" width="100" height="12" font="2">standard-therapy</text>
<text top="618" left="283" width="26" height="12" font="2">(SBP</text>
<text top="618" left="321" width="34" height="12" font="2">target</text>
<text top="616" left="367" width="29" height="15" font="2">&lt;140</text>
<text top="636" left="78" width="93" height="12" font="2">mm Hg) groups</text>
<text top="636" left="177" width="51" height="12" font="5"><a href="e127.full.html#102">(S9.3-26)</a></text>
<text top="636" left="228" width="115" height="12" font="2">. Three other RCTs</text>
<text top="636" left="349" width="38" height="12" font="5"><a href="e127.full.html#101">(S9.3-1</a></text>
<text top="634" left="387" width="9" height="15" font="5"><a href="e127.full.html#101">—</a></text>
<text top="654" left="78" width="39" height="12" font="5"><a href="e127.full.html#101">S9.3-3)</a></text>
<text top="654" left="122" width="275" height="12" font="2">have evaluated the effect of differing BP goals</text>
<text top="672" left="78" width="11" height="12" font="2">of</text>
<text top="670" left="95" width="301" height="15" font="2">&lt;140/90 mm Hg versus 125–130/75–80 mm Hg on</text>
<text top="690" left="78" width="318" height="12" font="2">CKD progression in patients with CKD. None of these</text>
<text top="708" left="78" width="164" height="12" font="2">trials demonstrated a bene</text>
<text top="706" left="242" width="154" height="15" font="2">ﬁt for more intensive BP</text>
<text top="143" left="438" width="318" height="12" font="2">reduction, although post hoc follow-up analyses</text>
<text top="161" left="438" width="318" height="12" font="2">favored the lower targets in patients with more severe</text>
<text top="178" left="438" width="65" height="12" font="2">proteinuria</text>
<text top="178" left="512" width="97" height="12" font="5"><a href="e127.full.html#102">(S9.3-38,S9.3-39)</a></text>
<text top="178" left="609" width="147" height="12" font="2">, and these trials were</text>
<text top="196" left="438" width="318" height="12" font="2">underpowered to detect differences in CVD event rates.</text>
<text top="214" left="438" width="318" height="12" font="2">Recent meta-analyses and systematic reviews that</text>
<text top="232" left="438" width="318" height="12" font="2">included patients with CKD from SPRINT support more</text>
<text top="250" left="438" width="141" height="12" font="2">intensive BP treatment</text>
<text top="250" left="587" width="48" height="12" font="5"><a href="e127.full.html#102">(S9.3-40</a></text>
<text top="248" left="635" width="56" height="15" font="5"><a href="e127.full.html#102">—S9.3-42)</a></text>
<text top="250" left="698" width="58" height="12" font="2">to reduce</text>
<text top="268" left="438" width="318" height="12" font="2">cardiovascular events but do not demonstrate a</text>
<text top="286" left="438" width="318" height="12" font="2">reduction in the rate of progression of kidney disease</text>
<text top="304" left="438" width="318" height="12" font="2">(doubling of serum creatinine or reaching ESRD). More</text>
<text top="322" left="438" width="318" height="12" font="2">intensive BP treatment may result in a modest reduc-</text>
<text top="340" left="438" width="318" height="12" font="2">tion in GFR, which is thought to be primarily due to a</text>
<text top="358" left="438" width="318" height="12" font="2">hemodynamic effect and may be reversible. Electrolyte</text>
<text top="376" left="438" width="318" height="12" font="2">abnormalities are also more likely during intensive BP</text>
<text top="394" left="438" width="318" height="12" font="2">treatment. More intensive BP lowering in patients with</text>
<text top="412" left="438" width="318" height="12" font="2">CKD is also supported by a BP Lowering Treatment</text>
<text top="430" left="438" width="46" height="12" font="2">Trialists</text>
<text top="428" left="485" width="272" height="15" font="2">’ Collaboration meta-analysis of RCTs in pa-</text>
<text top="447" left="438" width="92" height="12" font="2">tients with CKD</text>
<text top="447" left="534" width="51" height="12" font="5"><a href="e127.full.html#102">(S9.3-43)</a></text>
<text top="447" left="585" width="3" height="12" font="2">.</text>
<text top="465" left="423" width="333" height="12" font="2">2. Evidence comes from AASK (The African American</text>
<text top="483" left="438" width="318" height="12" font="2">Study of Kidney Disease and Hypertension), 2 small</text>
<text top="501" left="438" width="318" height="12" font="2">trials (1 positive, 1 negative), and a meta-analysis</text>
<text top="519" left="438" width="172" height="12" font="5"><a href="e127.full.html#101">(S9.3-3,S9.3-6,S9.3-10,S9.3-11)</a></text>
<text top="519" left="610" width="146" height="12" font="2">. Albuminuria is quanti-</text>
<text top="535" left="438" width="318" height="15" font="2">ﬁed by 24-hour urine collection. A 10% to 25% increase</text>
<text top="555" left="438" width="318" height="12" font="2">in serum creatinine may occur in some patients with</text>
<text top="573" left="438" width="239" height="12" font="2">CKD as a result of ACE inhibitor therapy.</text>
<text top="591" left="423" width="333" height="12" font="2">3. ARBs were shown to be noninferior to ACE inhibitors in</text>
<text top="609" left="438" width="245" height="12" font="2">clinical trials in the non-CKD population</text>
<text top="609" left="689" width="50" height="12" font="5"><a href="e127.full.html#102">(S9.3-35)</a></text>
<text top="609" left="739" width="18" height="12" font="2"><a href="e127.full.html#102">. </a>A</text>
<text top="627" left="438" width="318" height="12" font="2">10% to 25% increase in serum creatinine may occur in</text>
<text top="645" left="438" width="300" height="12" font="2">some patients with CKD as a result of ARB therapy.</text>
<text top="707" left="423" width="249" height="11" font="2">9.3.1. Hypertension After Renal Transplantation</text>
<text top="760" left="63" width="439" height="11" font="19">Recommendations for Treatment of Hypertension After Renal Transplantation</text>
<text top="774" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="774" left="412" width="202" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplements 39 and 40</a></text>
<text top="774" left="615" width="3" height="11" font="19">.</text>
<text top="815" left="89" width="19" height="10" font="13">COR</text>
<text top="815" left="161" width="18" height="10" font="13">LOE</text>
<text top="815" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="852" left="94" width="10" height="9" font="4">IIa</text>
<text top="845" left="149" width="42" height="9" font="4">SBP: B-NR</text>
<text top="840" left="234" width="568" height="11" font="12">1. After kidney transplantation, it is reasonable to treat patients with hypertension to a BP goal of less than</text>
<text top="855" left="246" width="81" height="11" font="12">130/80 mm Hg</text>
<text top="855" left="331" width="50" height="11" font="5"><a href="e127.full.html#102">(S9.3.1-1)</a></text>
<text top="855" left="382" width="3" height="11" font="12"><a href="e127.full.html#102">.</a></text>
<text top="860" left="149" width="43" height="9" font="4">DBP: C-EO</text>
<text top="909" left="94" width="10" height="9" font="4">IIa</text>
<text top="909" left="163" width="15" height="9" font="4">B-R</text>
<text top="897" left="234" width="524" height="11" font="12">2. After kidney transplantation, it is reasonable to treat patients with hypertension with a calcium</text>
<text top="913" left="248" width="323" height="11" font="12">antagonist on the basis of improved GFR and kidney survival</text>
<text top="913" left="575" width="52" height="11" font="5"><a href="e127.full.html#102">(S9.3.1-2)</a></text>
<text top="913" left="627" width="3" height="11" font="12">.</text>
<text top="1000" left="63" width="52" height="12" font="2">Synopsis</text>
<text top="1018" left="78" width="321" height="12" font="2">After kidney transplantation, hypertension is common</text>
<text top="1036" left="63" width="336" height="12" font="2">because of preexisting kidney disease, the effects of</text>
<text top="1054" left="63" width="336" height="12" font="2">immunosuppressive medications, and the presence of</text>
<text top="1072" left="63" width="48" height="12" font="2">allograft</text>
<text top="1072" left="125" width="58" height="12" font="2">pathology</text>
<text top="1072" left="196" width="53" height="12" font="5"><a href="e127.full.html#102">(S9.3.1-3)</a></text>
<text top="1072" left="249" width="3" height="12" font="2"><a href="e127.full.html#102">.</a></text>
<text top="1072" left="266" width="63" height="12" font="2">Transplant</text>
<text top="1072" left="342" width="57" height="12" font="2">recipients</text>
<text top="1090" left="63" width="336" height="12" font="2">frequently harbor multiple CVD risk factors and are at high</text>
<text top="1000" left="420" width="336" height="12" font="2">risk of CVD events. Hypertension may accelerate target</text>
<text top="1018" left="420" width="336" height="12" font="2">organ damage and kidney function decline, particularly</text>
<text top="1036" left="420" width="162" height="12" font="2">when proteinuria is present</text>
<text top="1036" left="586" width="49" height="12" font="5"><a href="e127.full.html#102">(S9.3.1-4</a></text>
<text top="1034" left="636" width="58" height="15" font="5"><a href="e127.full.html#102">—S9.3.1-6)</a></text>
<text top="1036" left="694" width="3" height="12" font="2">.</text>
<text top="1054" left="435" width="159" height="12" font="2">Use of calcineurin inhibitor</text>
<text top="1052" left="595" width="161" height="15" font="2">–based immunosuppression</text>
<text top="1072" left="420" width="336" height="12" font="2">regimens after transplantation is associated with a high</text>
<text top="1090" left="420" width="270" height="12" font="2">(70% to 90%) prevalence of hypertension</text>
<text top="1090" left="700" width="53" height="12" font="5"><a href="e127.full.html#102">(S9.3.1-7)</a></text>
<text top="1090" left="753" width="3" height="12" font="2"><a href="e127.full.html#102">.</a></text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="790" width="18" height="9" font="4">e177</text>
</page>
<page number="52" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="333" height="12" font="2">Hypertension is less common when calcineurin inhibitors</text>
<text top="161" left="108" width="333" height="12" font="2">have been used without corticosteroids in liver trans-</text>
<text top="178" left="108" width="112" height="12" font="2">plantation patients</text>
<text top="178" left="225" width="54" height="12" font="5"><a href="e127.full.html#102">(S9.3.1-8)</a></text>
<text top="178" left="279" width="162" height="12" font="2"><a href="e127.full.html#102">, </a>although prevalence rates</text>
<text top="196" left="108" width="333" height="12" font="2">have not differed in steroid minimization trials after</text>
<text top="214" left="108" width="134" height="12" font="2">kidney transplantation</text>
<text top="214" left="247" width="108" height="12" font="5"><a href="e127.full.html#102">(S9.3.1-9,S9.3.1-10)</a></text>
<text top="214" left="355" width="86" height="12" font="2">. Reports from</text>
<text top="232" left="108" width="334" height="12" font="2">long-term belatacept-based immunosuppression studies</text>
<text top="250" left="108" width="333" height="12" font="2">indicate higher GFR and preservation of kidney function.</text>
<text top="268" left="108" width="333" height="12" font="2">However, hypertension was still present in the majority of</text>
<text top="286" left="108" width="333" height="12" font="2">patients, although fewer agents were needed to achieve</text>
<text top="304" left="108" width="52" height="12" font="2">BP goals</text>
<text top="304" left="168" width="57" height="12" font="5"><a href="e127.full.html#102">(S9.3.1-11)</a></text>
<text top="304" left="225" width="216" height="12" font="2">. Severity of hypertension and in-</text>
<text top="322" left="108" width="333" height="12" font="2">tensity of treatment may differ somewhat depending on</text>
<text top="340" left="108" width="333" height="12" font="2">the type of organ transplanted; however, most concepts</text>
<text top="358" left="108" width="333" height="12" font="2">relevant to kidney transplant recipients will apply to the</text>
<text top="376" left="108" width="209" height="12" font="2">other solid organ recipients as well.</text>
<text top="394" left="123" width="318" height="12" font="2">BP targets change over time after transplantation.</text>
<text top="412" left="108" width="333" height="12" font="2">Initially, it is important to maintain ample organ perfu-</text>
<text top="430" left="108" width="215" height="12" font="2">sion with less stringent BP targets (</text>
<text top="428" left="323" width="118" height="15" font="2">&lt;160/90 mm Hg) to</text>
<text top="447" left="108" width="333" height="12" font="2">avoid hypotension and risk of graft thrombosis. Beyond</text>
<text top="465" left="108" width="19" height="12" font="2">the</text>
<text top="464" left="130" width="311" height="15" font="2">ﬁrst month, BP should be controlled to prevent target</text>
<text top="483" left="108" width="288" height="12" font="2">organ damage as in the nontransplantation setting</text>
<text top="483" left="399" width="42" height="12" font="5"><a href="e127.full.html#102">(S9.3.1-</a></text>
<text top="501" left="108" width="69" height="12" font="5"><a href="e127.full.html#102">12,S9.3.1-13)</a></text>
<text top="501" left="177" width="264" height="12" font="2">. Hypertension after transplantation is often</text>
<text top="519" left="108" width="333" height="12" font="2">associated with altered circadian BP rhythm with loss of</text>
<text top="537" left="108" width="169" height="12" font="2">the normal nocturnal BP fall</text>
<text top="537" left="282" width="112" height="12" font="5"><a href="e127.full.html#102">(S9.3.1-14,S9.3.1-15)</a></text>
<text top="537" left="399" width="42" height="12" font="2">and, in</text>
<text top="555" left="108" width="333" height="12" font="2">some, a nocturnal BP rise. These changes may return to</text>
<text top="573" left="108" width="240" height="12" font="2">normal after a longer period of follow-up</text>
<text top="573" left="351" width="59" height="12" font="5"><a href="e127.full.html#102">(S9.3.1-16)</a></text>
<text top="573" left="410" width="3" height="12" font="2">.</text>
<text top="609" left="108" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="607" left="247" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="636" left="109" width="332" height="12" font="2">1. Although treatment targets for hypertension after</text>
<text top="654" left="123" width="318" height="12" font="2">transplantation should probably be similar to those for</text>
<text top="672" left="123" width="318" height="12" font="2">other patients with CKD, there are no trials in post-</text>
<text top="690" left="123" width="318" height="12" font="2">transplantation patients comparing different BP tar-</text>
<text top="708" left="123" width="318" height="12" font="2">gets. As kidney transplant recipients generally have a</text>
<text top="143" left="483" width="318" height="12" font="2">single functioning kidney and CKD, BP targets should</text>
<text top="161" left="483" width="298" height="12" font="2">be similar to those for the general CKD population.</text>
<text top="178" left="468" width="333" height="12" font="2">2. Limited studies have compared drug choice for initial</text>
<text top="196" left="483" width="318" height="12" font="2">antihypertensive therapy in patients after kidney</text>
<text top="214" left="483" width="318" height="12" font="2">transplantation. On the basis of a Cochrane analysis</text>
<text top="232" left="483" width="53" height="12" font="5"><a href="e127.full.html#102">(S9.3.1-2)</a></text>
<text top="232" left="536" width="265" height="12" font="2"><a href="e127.full.html#102">, </a>most studies favor CCBs to reduce graft loss</text>
<text top="250" left="483" width="318" height="12" font="2">and maintain higher GFR, with some evidence sug-</text>
<text top="268" left="483" width="318" height="12" font="2">gesting potential harm from ACE inhibitors because of</text>
<text top="286" left="483" width="318" height="12" font="2">anemia, hyperkalemia, and lower GFR. In recognition</text>
<text top="304" left="483" width="318" height="12" font="2">of this concern, RAS inhibitors may be reserved for the</text>
<text top="322" left="483" width="318" height="12" font="2">subset of patients with hypertension and additional</text>
<text top="340" left="483" width="318" height="12" font="2">comorbidities that support the need for ACE inhibitor</text>
<text top="358" left="483" width="318" height="12" font="2">therapy (i.e., proteinuria or HF after transplantation).</text>
<text top="376" left="483" width="318" height="12" font="2">With appropriate potassium and creatinine monitoring,</text>
<text top="394" left="483" width="222" height="12" font="2">this has been demonstrated to be safe</text>
<text top="394" left="709" width="58" height="12" font="5"><a href="e127.full.html#102">(S9.3.1-17)</a></text>
<text top="394" left="767" width="3" height="12" font="2">.</text>
<text top="438" left="468" width="154" height="11" font="12">9.4. Cerebrovascular Disease</text>
<text top="460" left="468" width="333" height="12" font="2">Stroke is a leading cause of death, disability, and de-</text>
<text top="477" left="468" width="40" height="12" font="2">mentia</text>
<text top="477" left="512" width="43" height="12" font="5"><a href="e127.full.html#102">(S9.4-1)</a></text>
<text top="477" left="556" width="245" height="12" font="2">. Because of its heterogeneous causes and</text>
<text top="495" left="468" width="333" height="12" font="2">hemodynamic consequences, the management of BP in</text>
<text top="513" left="468" width="264" height="12" font="2">adults with stroke is complex and challenging</text>
<text top="513" left="735" width="45" height="12" font="5"><a href="e127.full.html#102">(S9.4-2)</a></text>
<text top="513" left="780" width="21" height="12" font="2"><a href="e127.full.html#102">. </a>To</text>
<text top="531" left="468" width="333" height="12" font="2">accommodate the variety of important issues pertaining</text>
<text top="549" left="468" width="333" height="12" font="2">to BP management in the stroke patient, treatment rec-</text>
<text top="567" left="468" width="333" height="12" font="2">ommendations require recognition of stroke acuity,</text>
<text top="585" left="468" width="333" height="12" font="2">stroke type, and therapeutic objectives. Future studies</text>
<text top="603" left="468" width="189" height="12" font="2">should target more narrowly de</text>
<text top="601" left="658" width="143" height="15" font="2">ﬁned questions, such as</text>
<text top="621" left="468" width="333" height="12" font="2">optimal BP-reduction timing and target, as well as ideal</text>
<text top="639" left="468" width="333" height="12" font="2">antihypertensive agent therapeutic class by patient type</text>
<text top="657" left="468" width="91" height="12" font="2">and event type.</text>
<text top="708" left="468" width="201" height="11" font="2">9.4.1. Acute Intracerebral Hemorrhage</text>
<text top="755" left="63" width="604" height="11" font="19">Recommendations for Management of Hypertension in Patients With Acute Intracerebral Hemorrhage (ICH)</text>
<text top="770" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="770" left="412" width="152" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 41</a></text>
<text top="770" left="565" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="811" left="89" width="19" height="10" font="13">COR</text>
<text top="811" left="161" width="18" height="10" font="13">LOE</text>
<text top="811" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="848" left="94" width="10" height="9" font="4">IIa</text>
<text top="848" left="160" width="20" height="9" font="4">C-EO</text>
<text top="835" left="234" width="552" height="11" font="12">1. In adults with ICH who present with SBP greater than 220 mm Hg, it is reasonable to use continuous</text>
<text top="851" left="246" width="144" height="11" font="12">intravenous drug infusion (</text>
<text top="851" left="391" width="45" height="11" font="5"><a href="e127.full.html#70">Table 19</a></text>
<text top="851" left="436" width="214" height="11" font="12"><a href="e127.full.html#70">) </a>and close BP monitoring to lower SBP.</text>
<text top="896" left="81" width="35" height="9" font="4">III: Harm</text>
<text top="896" left="168" width="6" height="9" font="4">A</text>
<text top="883" left="234" width="167" height="11" font="12">2. Immediate lowering of SBP (</text>
<text top="883" left="401" width="45" height="11" font="5"><a href="e127.full.html#70">Table 19</a></text>
<text top="883" left="446" width="332" height="11" font="12"><a href="e127.full.html#70">) </a>to less than 140 mm Hg in adults with spontaneous ICH who</text>
<text top="899" left="248" width="554" height="11" font="12">present within 6 hours of the acute event and have an SBP between 150 mm Hg and 220 mm Hg is not of</text>
<text top="915" left="248" width="25" height="11" font="12">bene</text>
<text top="913" left="274" width="372" height="15" font="12">ﬁt to reduce death or severe disability and can be potentially harmful</text>
<text top="915" left="650" width="99" height="11" font="5"><a href="e127.full.html#102">(S9.4.1-1,S9.4.1-2)</a></text>
<text top="915" left="749" width="3" height="11" font="12">.</text>
<text top="966" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="984" left="123" width="248" height="12" font="2">Spontaneous, nontraumatic ICH is a signi</text>
<text top="982" left="371" width="73" height="15" font="2">ﬁcant global</text>
<text top="1002" left="108" width="190" height="12" font="2">cause of morbidity and mortality</text>
<text top="1002" left="301" width="54" height="12" font="5"><a href="e127.full.html#102">(S9.4.1-3)</a></text>
<text top="1002" left="355" width="89" height="12" font="2">. Elevated BP is</text>
<text top="1020" left="108" width="336" height="12" font="2">highly prevalent in the setting of acute ICH and is linked</text>
<text top="1038" left="108" width="336" height="12" font="2">to greater hematoma expansion, neurological worsening,</text>
<text top="1056" left="108" width="219" height="12" font="2">and death and dependency after ICH.</text>
<text top="1074" left="123" width="47" height="11" font="5"><a href="e127.full.html#53">Figure 7</a></text>
<text top="1074" left="175" width="269" height="12" font="2">is an algorithm on management of hyperten-</text>
<text top="1091" left="108" width="185" height="12" font="2">sion in patients with acute ICH.</text>
<text top="966" left="465" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="964" left="604" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="993" left="467" width="335" height="12" font="2">1. Information about the safety and effectiveness of early</text>
<text top="1011" left="480" width="321" height="12" font="2">intensive BP-lowering treatment is least well estab-</text>
<text top="1029" left="480" width="321" height="12" font="2">lished for patients with markedly elevated BP (sus-</text>
<text top="1047" left="480" width="62" height="12" font="2">tained SBP</text>
<text top="1045" left="545" width="256" height="15" font="2">&gt;220 mm Hg) on presentation, patients with</text>
<text top="1065" left="480" width="321" height="12" font="2">large and severe ICH, or patients requiring surgical</text>
<text top="1083" left="480" width="321" height="12" font="2">decompression. However, given the consistent nature</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e178</text>
</page>
<page number="53" position="absolute" top="0" left="0" height="1160" width="864">
<text top="589" left="78" width="318" height="12" font="2">of the data linking high BP with poor clinical outcomes</text>
<text top="607" left="78" width="50" height="12" font="5"><a href="e127.full.html#102">(S9.4.1-4</a></text>
<text top="605" left="129" width="59" height="15" font="5"><a href="e127.full.html#102">—S9.4.1-6)</a></text>
<text top="607" left="199" width="197" height="12" font="2">and some suggestive data for</text>
<text top="625" left="78" width="318" height="12" font="2">treatment in patients with modestly high initial SBP</text>
<text top="643" left="78" width="33" height="12" font="2">levels</text>
<text top="643" left="116" width="102" height="12" font="5"><a href="e127.full.html#102">(S9.4.1-1,S9.4.1-7)</a></text>
<text top="643" left="218" width="178" height="12" font="2">, early lowering of SBP in ICH</text>
<text top="661" left="78" width="238" height="12" font="2">patients with markedly high SBP levels (</text>
<text top="659" left="316" width="80" height="15" font="2">&gt;220 mm Hg)</text>
<text top="679" left="78" width="318" height="12" font="2">might be sensible. A secondary endpoint in 1 RCT and</text>
<text top="697" left="78" width="318" height="12" font="2">an overview of data from 4 RCTs indicate that intensive</text>
<text top="715" left="78" width="318" height="12" font="2">BP reduction, versus BP-lowering guideline treatment,</text>
<text top="733" left="78" width="318" height="12" font="2">is associated with greater functional recovery at 3</text>
<text top="751" left="78" width="44" height="12" font="2">months</text>
<text top="751" left="126" width="102" height="12" font="5"><a href="e127.full.html#102">(S9.4.1-1,S9.4.1-7)</a></text>
<text top="751" left="228" width="3" height="12" font="2"><a href="e127.full.html#102">.</a></text>
<text top="769" left="63" width="333" height="12" font="2">2. RCT data have suggested that immediate BP lowering</text>
<text top="787" left="78" width="16" height="12" font="2">(to</text>
<text top="785" left="97" width="299" height="15" font="2">&lt;140/90 mm Hg) within 6 hours of an acute ICH was</text>
<text top="804" left="78" width="103" height="12" font="2">feasible and safe</text>
<text top="804" left="188" width="153" height="12" font="5"><a href="e127.full.html#102">(S9.4.1-1,S9.4.1-8,S9.4.1-9)</a></text>
<text top="804" left="341" width="55" height="12" font="2"><a href="e127.full.html#102">, </a>may be</text>
<text top="822" left="78" width="318" height="12" font="2">linked to greater attenuation of absolute hematoma</text>
<text top="840" left="78" width="111" height="12" font="2">growth at 24 hours</text>
<text top="840" left="193" width="54" height="12" font="5"><a href="e127.full.html#103">(S9.4.1-7)</a></text>
<text top="840" left="247" width="149" height="12" font="2"><a href="e127.full.html#103">, </a>and might be associated</text>
<text top="589" left="438" width="318" height="12" font="2">with modestly better functional recovery in survivors</text>
<text top="607" left="438" width="102" height="12" font="5"><a href="e127.full.html#102">(S9.4.1-1,S9.4.1-7)</a></text>
<text top="607" left="540" width="155" height="12" font="2">. However, a recent RCT</text>
<text top="607" left="703" width="54" height="12" font="5"><a href="e127.full.html#102">(S9.4.1-2)</a></text>
<text top="625" left="438" width="318" height="12" font="2">that examined immediate BP lowering within 4.5</text>
<text top="643" left="438" width="318" height="12" font="2">hours of an acute ICH found that treatment to achieve a</text>
<text top="661" left="438" width="318" height="12" font="2">target SBP of 110 to 139 mm Hg did not lead to a lower</text>
<text top="679" left="438" width="318" height="12" font="2">rate of death or disability than standard reduction to a</text>
<text top="697" left="438" width="318" height="12" font="2">target of 140 to 179 mm Hg. Moreover, there were</text>
<text top="715" left="438" width="27" height="12" font="2">signi</text>
<text top="713" left="466" width="290" height="15" font="2">ﬁcantly more renal adverse events within 7 days</text>
<text top="733" left="438" width="318" height="12" font="2">after randomization in the intensive-treatment group</text>
<text top="751" left="438" width="229" height="12" font="2">than in the standard-treatment group</text>
<text top="751" left="673" width="54" height="12" font="5"><a href="e127.full.html#102">(S9.4.1-2)</a></text>
<text top="751" left="727" width="29" height="12" font="2">. Put</text>
<text top="769" left="438" width="211" height="12" font="2">together, neither of the 2 key trials</text>
<text top="769" left="655" width="102" height="12" font="5"><a href="e127.full.html#102">(S9.4.1-1,S9.4.1-2)</a></text>
<text top="787" left="438" width="318" height="12" font="2">evaluating the effect of lowering SBP in the acute</text>
<text top="804" left="438" width="318" height="12" font="2">period after spontaneous ICH met their primary out-</text>
<text top="822" left="438" width="318" height="12" font="2">comes of reducing death and severe disability at 3</text>
<text top="840" left="438" width="47" height="12" font="2">months.</text>
<text top="154" left="80" width="45" height="11" font="22">FIGURE 7</text>
<text top="155" left="134" width="253" height="9" font="23">Management of Hypertension in Patients With Acute ICH</text>
<text top="486" left="80" width="213" height="9" font="13">Colors correspond to Class of Recommendation in</text>
<text top="486" left="297" width="31" height="9" font="17"><a href="e127.full.html#6">Table 1</a></text>
<text top="486" left="328" width="406" height="9" font="13"><a href="e127.full.html#6">. </a>BP indicates blood pressure; ICH, intracerebral hemorrhage; IV, intravenous; and SBP, systolic</text>
<text top="501" left="80" width="66" height="9" font="13">blood pressure.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="19" height="9" font="4">e179</text>
</page>
<page number="54" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="150" height="11" font="2">9.4.2. Acute Ischemic Stroke</text>
<text top="668" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="686" left="123" width="319" height="12" font="2">Elevated BP is common during acute ischemic stroke</text>
<text top="704" left="108" width="333" height="12" font="2">(occurring in up to 80% of patients), especially among</text>
<text top="722" left="108" width="258" height="12" font="2">patients with a history of hypertension</text>
<text top="722" left="376" width="61" height="12" font="5"><a href="e127.full.html#103">(S9.4.2-10)</a></text>
<text top="722" left="437" width="3" height="12" font="2">.</text>
<text top="739" left="108" width="333" height="12" font="2">However, BP often decreases spontaneously during the</text>
<text top="757" left="108" width="333" height="12" font="2">acute phase of ischemic stroke, as soon as 90 minutes</text>
<text top="775" left="108" width="333" height="12" font="2">after the onset of symptoms. Countervailing theoretical</text>
<text top="793" left="108" width="51" height="12" font="2">concerns</text>
<text top="793" left="171" width="33" height="12" font="2">about</text>
<text top="793" left="216" width="42" height="12" font="2">arterial</text>
<text top="793" left="270" width="77" height="12" font="2">hypertension</text>
<text top="793" left="359" width="38" height="12" font="2">during</text>
<text top="793" left="410" width="31" height="12" font="2">acute</text>
<text top="811" left="108" width="333" height="12" font="2">ischemic stroke include aiming to enhance cerebral</text>
<text top="829" left="108" width="333" height="12" font="2">perfusion of the ischemic tissue while minimizing the</text>
<text top="847" left="108" width="333" height="12" font="2">exacerbation of brain edema and hemorrhagic trans-</text>
<text top="865" left="108" width="206" height="12" font="2">formation of the ischemic tissue</text>
<text top="865" left="322" width="115" height="12" font="5"><a href="e127.full.html#103">(S9.4.2-11,S9.4.2-12)</a></text>
<text top="865" left="437" width="3" height="12" font="2">.</text>
<text top="883" left="108" width="333" height="12" font="2">Some studies have shown a U-shaped relationship</text>
<text top="901" left="108" width="333" height="12" font="2">between the admission BP and favorable clinical out-</text>
<text top="919" left="108" width="333" height="12" font="2">comes, with an optimal SBP and DBP ranging from 121</text>
<text top="937" left="108" width="333" height="12" font="2">to 200 mm Hg and 81 to 110 mm Hg, respectively</text>
<text top="955" left="108" width="60" height="12" font="5"><a href="e127.full.html#103">(S9.4.2-13)</a></text>
<text top="955" left="168" width="273" height="12" font="2">. It is conceivable that an optimal arterial BP</text>
<text top="973" left="108" width="333" height="12" font="2">range exists during acute ischemic stroke on an indi-</text>
<text top="991" left="108" width="333" height="12" font="2">vidual basis, contingent on the ischemic stroke subtype</text>
<text top="668" left="468" width="138" height="12" font="2">and other patient-speci</text>
<text top="666" left="606" width="195" height="15" font="2">ﬁc comorbidities. Early initiation</text>
<text top="686" left="468" width="333" height="12" font="2">or resumption of antihypertensive treatment after acute</text>
<text top="704" left="468" width="252" height="12" font="2">ischemic stroke is indicated only in speci</text>
<text top="702" left="720" width="81" height="15" font="2">ﬁc situations:</text>
<text top="722" left="468" width="333" height="12" font="2">1) patients treated with tissue-type plasminogen acti-</text>
<text top="739" left="468" width="30" height="12" font="2">vator</text>
<text top="739" left="504" width="104" height="12" font="5"><a href="e127.full.html#103">(S9.4.2-1,S9.4.2-2)</a></text>
<text top="739" left="608" width="159" height="12" font="2">, and 2) patients with SBP</text>
<text top="738" left="772" width="29" height="15" font="2">&gt;220</text>
<text top="757" left="468" width="94" height="12" font="2">mm Hg or DBP</text>
<text top="756" left="569" width="233" height="15" font="2">&gt;120 mm Hg. For the latter group, it</text>
<text top="775" left="468" width="333" height="12" font="2">should be kept in mind that cerebral autoregulation in</text>
<text top="793" left="468" width="333" height="12" font="2">the ischemic penumbra of the stroke is grossly abnormal</text>
<text top="811" left="468" width="333" height="12" font="2">and that systemic perfusion pressure is needed for</text>
<text top="829" left="468" width="32" height="12" font="2">blood</text>
<text top="827" left="506" width="296" height="15" font="2">ﬂow and oxygen delivery. Rapid reduction of BP,</text>
<text top="847" left="468" width="333" height="12" font="2">even to lower levels within the hypertensive range, can</text>
<text top="865" left="468" width="333" height="12" font="2">be detrimental. For all other acute ischemic stroke</text>
<text top="883" left="468" width="333" height="12" font="2">patients, the advantage of lowering BP early to reduce</text>
<text top="901" left="468" width="212" height="12" font="2">death and dependency is uncertain</text>
<text top="901" left="685" width="52" height="12" font="5"><a href="e127.full.html#103">(S9.4.2-4</a></text>
<text top="899" left="737" width="60" height="15" font="5"><a href="e127.full.html#103">—S9.4.2-9)</a></text>
<text top="901" left="798" width="3" height="12" font="2"><a href="e127.full.html#103">,</a></text>
<text top="919" left="468" width="334" height="12" font="2">but restarting antihypertensive therapy to improve</text>
<text top="937" left="468" width="280" height="12" font="2">long-term BP control is reasonable after the</text>
<text top="935" left="757" width="45" height="15" font="2">ﬁrst 24</text>
<text top="955" left="468" width="33" height="12" font="2">hours</text>
<text top="955" left="525" width="16" height="12" font="2">for</text>
<text top="955" left="565" width="47" height="12" font="2">patients</text>
<text top="955" left="636" width="24" height="12" font="2">who</text>
<text top="955" left="685" width="28" height="12" font="2">have</text>
<text top="955" left="736" width="65" height="12" font="2">preexisting</text>
<text top="973" left="468" width="278" height="12" font="2">hypertension and are neurologically stable</text>
<text top="973" left="757" width="44" height="12" font="5"><a href="e127.full.html#103">(S9.4.2-</a></text>
<text top="991" left="468" width="118" height="12" font="5"><a href="e127.full.html#103">4,S9.4.2-5,S9.4.2-14)</a></text>
<text top="991" left="587" width="3" height="12" font="2"><a href="e127.full.html#103">.</a></text>
<text top="179" left="63" width="514" height="11" font="19">Recommendations for Management of Hypertension in Patients With Acute Ischemic Stroke</text>
<text top="194" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="194" left="412" width="153" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 42</a></text>
<text top="194" left="566" width="3" height="11" font="19">.</text>
<text top="235" left="89" width="19" height="10" font="13">COR</text>
<text top="235" left="161" width="18" height="10" font="13">LOE</text>
<text top="235" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="272" left="97" width="3" height="9" font="4">I</text>
<text top="272" left="160" width="21" height="9" font="4">B-NR</text>
<text top="259" left="234" width="568" height="11" font="12">1. Adults with acute ischemic stroke and elevated BP who are eligible for treatment with intravenous tissue</text>
<text top="275" left="246" width="549" height="11" font="12">plasminogen activator should have their BP slowly lowered to less than 185/110 mm Hg before throm-</text>
<text top="291" left="246" width="140" height="11" font="12">bolytic therapy is initiated</text>
<text top="291" left="390" width="102" height="11" font="5"><a href="e127.full.html#103">(S9.4.2-1,S9.4.2-2)</a></text>
<text top="291" left="492" width="3" height="11" font="12">.</text>
<text top="335" left="97" width="3" height="9" font="4">I</text>
<text top="335" left="160" width="21" height="9" font="4">B-NR</text>
<text top="323" left="234" width="568" height="11" font="12">2. In adults with an acute ischemic stroke, BP should be less than 185/110 mm Hg before administration of</text>
<text top="339" left="248" width="554" height="11" font="12">intravenous tissue plasminogen activator and should be maintained below 180/105 mm Hg for at least the</text>
<text top="352" left="248" width="224" height="15" font="12">ﬁrst 24 hours after initiating drug therapy</text>
<text top="354" left="476" width="54" height="11" font="5"><a href="e127.full.html#103">(S9.4.2-3)</a></text>
<text top="354" left="530" width="3" height="11" font="12">.</text>
<text top="400" left="94" width="10" height="9" font="4">IIa</text>
<text top="400" left="160" width="21" height="9" font="4">B-NR</text>
<text top="388" left="234" width="558" height="11" font="12">3. Starting or restarting antihypertensive therapy during hospitalization in patients with BP greater than</text>
<text top="404" left="248" width="547" height="11" font="12">140/90 mm Hg who are neurologically stable is safe and reasonable to improve long-term BP control,</text>
<text top="420" left="248" width="119" height="11" font="12">unless contraindicated</text>
<text top="420" left="371" width="104" height="11" font="5"><a href="e127.full.html#103">(S9.4.2-4,S9.4.2-5)</a></text>
<text top="420" left="475" width="3" height="11" font="12">.</text>
<text top="465" left="94" width="10" height="9" font="4">IIb</text>
<text top="465" left="160" width="20" height="9" font="4">C-EO</text>
<text top="453" left="234" width="516" height="11" font="12">4. In patients with BP of 220/120 mm Hg or higher who did not receive intravenous alteplase or</text>
<text top="469" left="249" width="553" height="11" font="12">endovascular treatment and have no comorbid conditions requiring acute antihypertensive treatment, the</text>
<text top="485" left="249" width="25" height="11" font="12">bene</text>
<text top="483" left="274" width="527" height="15" font="12">ﬁt of initiating or reinitiating treatment of hypertension within the ﬁrst 48 to 72 hours is uncertain.</text>
<text top="501" left="249" width="288" height="11" font="12">It might be reasonable to lower BP by 15% during the</text>
<text top="498" left="541" width="189" height="15" font="12">ﬁrst 24 hours after onset of stroke.</text>
<text top="546" left="71" width="47" height="9" font="4">III: No Bene</text>
<text top="545" left="118" width="9" height="12" font="4">ﬁt</text>
<text top="546" left="168" width="6" height="9" font="4">A</text>
<text top="534" left="234" width="520" height="11" font="12">5. In patients with BP less than 220/120 mm Hg who did not receive intravenous thrombolysis or</text>
<text top="550" left="248" width="509" height="11" font="12">endovascular treatment and do not have a comorbid condition requiring acute antihypertensive</text>
<text top="566" left="248" width="386" height="11" font="12">treatment, initiating or reinitiating treatment of hypertension within the</text>
<text top="564" left="638" width="133" height="15" font="12">ﬁrst 48 to 72 hours after</text>
<text top="581" left="248" width="391" height="11" font="12">an acute ischemic stroke is not effective to prevent death or dependency</text>
<text top="581" left="642" width="50" height="11" font="5"><a href="e127.full.html#103">(S9.4.2-4</a></text>
<text top="579" left="693" width="59" height="15" font="5"><a href="e127.full.html#103">—S9.4.2-9)</a></text>
<text top="581" left="752" width="3" height="11" font="12">.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="20" height="9" font="4">e180</text>
</page>
<page number="55" position="absolute" top="0" left="0" height="1160" width="864">
<text top="747" left="63" width="47" height="11" font="5"><a href="e127.full.html#55">Figure 8</a></text>
<text top="747" left="114" width="282" height="12" font="2">is an algorithm on management of hypertension</text>
<text top="764" left="63" width="226" height="12" font="2">in patients with acute ischemic stroke.</text>
<text top="788" left="63" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="787" left="202" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="815" left="65" width="331" height="12" font="2">1. These BP cutoffs correspond to study inclusion criteria</text>
<text top="833" left="79" width="317" height="12" font="2">in pivotal clinical trials of intravenous thrombolysis for</text>
<text top="851" left="79" width="126" height="12" font="2">acute ischemic stroke</text>
<text top="851" left="209" width="54" height="12" font="5"><a href="e127.full.html#103">(S9.4.2-1)</a></text>
<text top="851" left="263" width="3" height="12" font="2"><a href="e127.full.html#103">.</a></text>
<text top="869" left="64" width="332" height="12" font="2">2. In a large observational study of patients with acute</text>
<text top="887" left="79" width="317" height="12" font="2">ischemic stroke who received intravenous tissue-type</text>
<text top="905" left="79" width="317" height="12" font="2">plasminogen activator, high BP during the initial 24</text>
<text top="923" left="79" width="317" height="12" font="2">hours was linked to greater risk of symptomatic ICH</text>
<text top="941" left="79" width="55" height="12" font="5"><a href="e127.full.html#103">(S9.4.2-3)</a></text>
<text top="941" left="134" width="3" height="12" font="2">.</text>
<text top="959" left="64" width="258" height="12" font="2">3. For the goal of antihypertensive therapy, see</text>
<text top="959" left="325" width="68" height="12" font="5"><a href="">Section 8.1.5</a></text>
<text top="959" left="393" width="3" height="12" font="2"><a href="">.</a></text>
<text top="977" left="63" width="333" height="12" font="2">4. Extreme arterial hypertension is detrimental because it</text>
<text top="995" left="79" width="317" height="12" font="2">can lead to encephalopathy, cardiac compromise, and</text>
<text top="747" left="439" width="317" height="12" font="2">renal damage. However, hypotension, especially when</text>
<text top="764" left="439" width="317" height="12" font="2">too rapidly achieved, is potentially harmful because it</text>
<text top="782" left="439" width="49" height="12" font="2">abruptly</text>
<text top="782" left="501" width="45" height="12" font="2">reduces</text>
<text top="782" left="559" width="55" height="12" font="2">perfusion</text>
<text top="782" left="628" width="11" height="12" font="2">to</text>
<text top="782" left="652" width="49" height="12" font="2">multiple</text>
<text top="782" left="714" width="42" height="12" font="2">organs,</text>
<text top="800" left="439" width="115" height="12" font="2">including the brain.</text>
<text top="818" left="425" width="122" height="12" font="2">5. Data from 2 RCTs</text>
<text top="818" left="552" width="106" height="12" font="5"><a href="e127.full.html#103">(S9.4.2-5,S9.4.2-9)</a></text>
<text top="818" left="658" width="98" height="12" font="2">, as well as sys-</text>
<text top="836" left="439" width="211" height="12" font="2">tematic reviews and meta-analyses</text>
<text top="836" left="656" width="51" height="12" font="5"><a href="e127.full.html#103">(S9.4.2-6</a></text>
<text top="834" left="708" width="49" height="15" font="5"><a href="e127.full.html#103">—S9.4.2-</a></text>
<text top="854" left="439" width="11" height="12" font="5"><a href="e127.full.html#103">8)</a></text>
<text top="854" left="451" width="306" height="12" font="2"><a href="e127.full.html#103">, </a>indicate that antihypertensive agents reduce BP</text>
<text top="872" left="439" width="317" height="12" font="2">during the acute phase of an ischemic stroke but do not</text>
<text top="890" left="439" width="69" height="12" font="2">confer bene</text>
<text top="888" left="508" width="248" height="15" font="2">ﬁt with regard to short- and long-term de-</text>
<text top="908" left="439" width="317" height="12" font="2">pendency and mortality rate. One RCT did not</text>
<text top="926" left="439" width="116" height="12" font="2">demonstrate a bene</text>
<text top="924" left="556" width="201" height="15" font="2">ﬁt of continuing prestroke antihy-</text>
<text top="944" left="439" width="171" height="12" font="2">pertensive drugs during the</text>
<text top="942" left="617" width="139" height="15" font="2">ﬁrst few days after an</text>
<text top="962" left="439" width="317" height="12" font="2">acute stroke, but it was substantially underpowered to</text>
<text top="980" left="439" width="118" height="12" font="2">answer the question</text>
<text top="980" left="562" width="56" height="12" font="5"><a href="e127.full.html#103">(S9.4.2-4)</a></text>
<text top="980" left="618" width="3" height="12" font="2"><a href="e127.full.html#103">.</a></text>
<text top="153" left="80" width="46" height="11" font="22">FIGURE 8</text>
<text top="154" left="134" width="307" height="9" font="23">Management of Hypertension in Patients With Acute Ischemic Stroke</text>
<text top="660" left="80" width="208" height="9" font="13">Colors correspond to Class of Recommendation in</text>
<text top="660" left="290" width="30" height="9" font="17"><a href="e127.full.html#6">Table 1</a></text>
<text top="660" left="321" width="418" height="9" font="13"><a href="e127.full.html#6">. </a>BP indicates blood pressure; DBP, diastolic blood pressure; IV, intravenous; and SBP, systolic blood</text>
<text top="675" left="80" width="38" height="9" font="13">pressure.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="790" width="18" height="9" font="4">e181</text>
</page>
<page number="56" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="185" height="11" font="2">9.4.3. Secondary Stroke Prevention</text>
<text top="698" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="715" left="123" width="212" height="12" font="2">Each year in the United States,</text>
<text top="714" left="345" width="96" height="15" font="2">&gt;750,000 adult</text>
<text top="733" left="108" width="333" height="12" font="2">patients experience a stroke, of which up to 25% are</text>
<text top="751" left="108" width="105" height="12" font="2">recurrent strokes</text>
<text top="751" left="221" width="61" height="12" font="5"><a href="e127.full.html#103">(S9.4.3-10)</a></text>
<text top="751" left="283" width="158" height="12" font="2">. For an individual who</text>
<text top="769" left="108" width="333" height="12" font="2">experiences an initial stroke or TIA, the annual risk of a</text>
<text top="787" left="108" width="84" height="12" font="2">subsequent or</text>
<text top="785" left="198" width="243" height="15" font="2">“secondary” stroke is approximately 4%</text>
<text top="805" left="108" width="59" height="12" font="5"><a href="e127.full.html#103">(S9.4.3-11)</a></text>
<text top="805" left="167" width="274" height="12" font="2"><a href="e127.full.html#103">, </a>and the case mortality rate is 41% after a</text>
<text top="823" left="108" width="333" height="12" font="2">recurrent stroke versus 22% after an initial stroke</text>
<text top="841" left="108" width="60" height="12" font="5"><a href="e127.full.html#103">(S9.4.3-12)</a></text>
<text top="841" left="168" width="273" height="12" font="2">. Among patients with a recent stroke or TIA,</text>
<text top="859" left="108" width="333" height="12" font="2">the prevalence of premorbid hypertension is approxi-</text>
<text top="877" left="108" width="74" height="12" font="2">mately 70%</text>
<text top="877" left="192" width="60" height="12" font="5"><a href="e127.full.html#103">(S9.4.3-13)</a></text>
<text top="877" left="252" width="189" height="12" font="2">. Risk of recurrent stroke is</text>
<text top="895" left="108" width="333" height="12" font="2">heightened by presence of elevated BP, and guideline-</text>
<text top="913" left="108" width="333" height="12" font="2">recommended antihypertensive drug treatment to lower</text>
<text top="931" left="108" width="333" height="12" font="2">BP has been linked to a reduction in 1-year recurrent</text>
<text top="949" left="108" width="67" height="12" font="2">stroke risk</text>
<text top="949" left="185" width="61" height="12" font="5"><a href="e127.full.html#103">(S9.4.3-14)</a></text>
<text top="949" left="246" width="195" height="12" font="2">. RCT meta-analyses show an</text>
<text top="967" left="108" width="333" height="12" font="2">approximately 30% decrease in recurrent stroke risk with</text>
<text top="984" left="108" width="71" height="12" font="2">BP-lowering</text>
<text top="984" left="191" width="54" height="12" font="2">therapies</text>
<text top="984" left="257" width="49" height="12" font="5"><a href="e127.full.html#103">(S9.4.3-1</a></text>
<text top="983" left="307" width="60" height="15" font="5"><a href="e127.full.html#103">—S9.4.3-3)</a></text>
<text top="984" left="367" width="3" height="12" font="2">.</text>
<text top="984" left="383" width="16" height="12" font="2">An</text>
<text top="984" left="412" width="29" height="12" font="2">issue</text>
<text top="1002" left="108" width="334" height="12" font="2">frequently raised by clinicians is whether the presence of</text>
<text top="1020" left="108" width="333" height="12" font="2">clinically asymptomatic cerebral infarction incidentally</text>
<text top="1038" left="108" width="333" height="12" font="2">noted on brain imaging (computed tomography or MRI</text>
<text top="1056" left="108" width="333" height="12" font="2">scan) in patients without a history of or symptoms of a</text>
<text top="1074" left="108" width="333" height="12" font="2">stroke or TIA warrants implementation of secondary</text>
<text top="1092" left="108" width="333" height="12" font="2">stroke prevention measures. Clinically asymptomatic</text>
<text top="698" left="468" width="333" height="12" font="2">vascular brain injury is increasingly being considered as</text>
<text top="715" left="468" width="333" height="12" font="2">an entry point for secondary stroke prevention therapies,</text>
<text top="733" left="468" width="152" height="12" font="2">because these apparently</text>
<text top="732" left="627" width="174" height="15" font="2">“silent” brain infarctions are</text>
<text top="751" left="468" width="333" height="12" font="2">associated with typical stroke risk factors, accumulatively</text>
<text top="769" left="468" width="333" height="12" font="2">lead to subtle neurological impairments, and bolster</text>
<text top="787" left="468" width="261" height="12" font="2">risk of future symptomatic stroke events</text>
<text top="787" left="737" width="60" height="12" font="5"><a href="e127.full.html#103">(S9.4.3-15)</a></text>
<text top="787" left="798" width="3" height="12" font="2"><a href="e127.full.html#103">.</a></text>
<text top="805" left="468" width="333" height="12" font="2">Although the evidence for using antihypertensive treat-</text>
<text top="823" left="468" width="333" height="12" font="2">ment to prevent recurrent stroke in stroke patients with</text>
<text top="841" left="468" width="153" height="12" font="2">elevated BP is compelling</text>
<text top="841" left="627" width="49" height="12" font="5"><a href="e127.full.html#103">(S9.4.3-1</a></text>
<text top="839" left="676" width="60" height="15" font="5"><a href="e127.full.html#103">—S9.4.3-3)</a></text>
<text top="841" left="736" width="65" height="12" font="2">, questions</text>
<text top="859" left="468" width="333" height="12" font="2">remain about when precisely after an index stroke to</text>
<text top="877" left="468" width="129" height="12" font="2">initiate it, what speci</text>
<text top="875" left="598" width="203" height="15" font="2">ﬁc agent(s) to use (if any), which</text>
<text top="895" left="468" width="333" height="12" font="2">therapeutic targets to aim for, and whether the treatment</text>
<text top="913" left="468" width="333" height="12" font="2">approach should vary by index stroke mechanism and</text>
<text top="931" left="468" width="115" height="12" font="2">baseline level of BP</text>
<text top="931" left="588" width="61" height="12" font="5"><a href="e127.full.html#103">(S9.4.3-16)</a></text>
<text top="931" left="649" width="3" height="12" font="2"><a href="e127.full.html#103">.</a></text>
<text top="949" left="483" width="47" height="11" font="5"><a href="e127.full.html#57">Figure 9</a></text>
<text top="949" left="535" width="266" height="12" font="2">is an algorithm on management of hyperten-</text>
<text top="967" left="468" width="333" height="12" font="2">sion in patients with a previous history of stroke (sec-</text>
<text top="984" left="468" width="156" height="12" font="2">ondary stroke prevention).</text>
<text top="1011" left="468" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="1010" left="607" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="1038" left="471" width="331" height="12" font="2">1. Two overviews of RCTs published through 2009</text>
<text top="1056" left="484" width="317" height="12" font="2">showed that antihypertensive medications lowered the</text>
<text top="1074" left="484" width="317" height="12" font="2">risk of recurrent vascular events in patients with stroke</text>
<text top="1092" left="484" width="36" height="12" font="2">or TIA</text>
<text top="1092" left="524" width="49" height="12" font="5"><a href="e127.full.html#103">(S9.4.3-1</a></text>
<text top="1090" left="574" width="60" height="15" font="5"><a href="e127.full.html#103">—S9.4.3-3)</a></text>
<text top="1092" left="634" width="3" height="12" font="2"><a href="e127.full.html#103">.</a></text>
<text top="179" left="63" width="465" height="11" font="19">Recommendations for Treatment of Hypertension for Secondary Stroke Prevention</text>
<text top="194" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="194" left="412" width="202" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplements 43 and 44</a></text>
<text top="194" left="615" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="235" left="89" width="19" height="10" font="13">COR</text>
<text top="235" left="161" width="18" height="10" font="13">LOE</text>
<text top="235" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="272" left="97" width="3" height="9" font="4">I</text>
<text top="272" left="168" width="6" height="9" font="4">A</text>
<text top="259" left="234" width="562" height="11" font="12">1. Adults with previously treated hypertension who experience a stroke or transient ischemic attack (TIA)</text>
<text top="275" left="246" width="313" height="11" font="12">should be restarted on antihypertensive treatment after the</text>
<text top="273" left="562" width="239" height="15" font="12">ﬁrst few days of the index event to reduce the</text>
<text top="291" left="246" width="264" height="11" font="12">risk of recurrent stroke and other vascular events</text>
<text top="291" left="514" width="48" height="11" font="5"><a href="e127.full.html#103">(S9.4.3-1</a></text>
<text top="289" left="563" width="58" height="15" font="5"><a href="e127.full.html#103">—S9.4.3-3)</a></text>
<text top="291" left="621" width="3" height="11" font="12"><a href="e127.full.html#103">.</a></text>
<text top="335" left="97" width="3" height="9" font="4">I</text>
<text top="335" left="168" width="6" height="9" font="4">A</text>
<text top="323" left="234" width="548" height="11" font="12">2. For adults who experience a stroke or TIA, treatment with a thiazide diuretic, ACE inhibitor, or ARB,</text>
<text top="339" left="248" width="459" height="11" font="12">or combination treatment consisting of a thiazide diuretic plus ACE inhibitor, is useful</text>
<text top="354" left="248" width="97" height="11" font="5"><a href="e127.full.html#103">(S9.4.3-1,S9.4.3-3</a></text>
<text top="352" left="345" width="58" height="15" font="5"><a href="e127.full.html#103">—S9.4.3-5)</a></text>
<text top="354" left="403" width="3" height="11" font="12">.</text>
<text top="400" left="97" width="3" height="9" font="4">I</text>
<text top="400" left="163" width="15" height="9" font="4">B-R</text>
<text top="388" left="234" width="568" height="11" font="12">3. Adults not previously treated for hypertension who experience a stroke or TIA and have an established BP</text>
<text top="404" left="248" width="554" height="11" font="12">of 140/90 mm Hg or higher should be prescribed antihypertensive treatment a few days after the index</text>
<text top="420" left="248" width="373" height="11" font="12">event to reduce the risk of recurrent stroke and other vascular events</text>
<text top="420" left="625" width="48" height="11" font="5"><a href="e127.full.html#103">(S9.4.3-1</a></text>
<text top="418" left="673" width="58" height="15" font="5"><a href="e127.full.html#103">—S9.4.3-3)</a></text>
<text top="420" left="731" width="3" height="11" font="12">.</text>
<text top="465" left="97" width="3" height="9" font="4">I</text>
<text top="465" left="160" width="21" height="9" font="4">B-NR</text>
<text top="453" left="234" width="328" height="11" font="12">4. For adults who experience a stroke or TIA, selection of speci</text>
<text top="451" left="562" width="239" height="15" font="12">ﬁc drugs should be individualized on the basis</text>
<text top="469" left="249" width="305" height="11" font="12">of patient comorbidities and agent pharmacological class</text>
<text top="469" left="557" width="55" height="11" font="5"><a href="e127.full.html#103">(S9.4.3-6)</a></text>
<text top="469" left="612" width="3" height="11" font="12">.</text>
<text top="515" left="94" width="10" height="9" font="4">IIb</text>
<text top="515" left="163" width="15" height="9" font="4">B-R</text>
<text top="503" left="234" width="549" height="11" font="12">5. For adults who experience a stroke or TIA, a BP goal of less than 130/80 mm Hg may be reasonable</text>
<text top="519" left="248" width="103" height="11" font="5"><a href="e127.full.html#103">(S9.4.3-6,S9.4.3-7)</a></text>
<text top="519" left="351" width="3" height="11" font="12">.</text>
<text top="564" left="94" width="10" height="9" font="4">IIb</text>
<text top="564" left="163" width="15" height="9" font="4">B-R</text>
<text top="552" left="234" width="507" height="11" font="12">6. For adults with a lacunar stroke, a target SBP goal of less than 130 mm Hg may be reasonable</text>
<text top="552" left="743" width="55" height="11" font="5"><a href="e127.full.html#103">(S9.4.3-8)</a></text>
<text top="552" left="798" width="3" height="11" font="12">.</text>
<text top="614" left="94" width="10" height="9" font="4">IIb</text>
<text top="614" left="160" width="20" height="9" font="4">C-LD</text>
<text top="602" left="234" width="568" height="11" font="12">7. In adults previously untreated for hypertension who experience an ischemic stroke or TIA and have a SBP</text>
<text top="618" left="247" width="526" height="11" font="12">less than 140 mm Hg and a DBP less than 90 mm Hg, the usefulness of initiating antihypertensive</text>
<text top="633" left="247" width="177" height="11" font="12">treatment is not well established</text>
<text top="633" left="428" width="55" height="11" font="5"><a href="e127.full.html#103">(S9.4.3-9)</a></text>
<text top="633" left="483" width="3" height="11" font="12">.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e182</text>
</page>
<page number="57" position="absolute" top="0" left="0" height="1160" width="864">
<text top="789" left="64" width="45" height="12" font="2">2. Speci</text>
<text top="787" left="110" width="286" height="15" font="2">ﬁc agents that have shown beneﬁt in either</text>
<text top="807" left="79" width="317" height="12" font="2">dedicated RCTs or systematic reviews of RCT data</text>
<text top="825" left="79" width="257" height="12" font="2">include diuretics, ACE inhibitors, and ARBs.</text>
<text top="843" left="64" width="332" height="12" font="2">3. Support for this recommendation is based on data from</text>
<text top="861" left="79" width="317" height="12" font="2">2 dedicated RCTs, as well as a systematic review and</text>
<text top="879" left="79" width="317" height="12" font="2">meta-analysis, among patients with a history of stroke</text>
<text top="897" left="79" width="36" height="12" font="2">or TIA</text>
<text top="897" left="119" width="49" height="12" font="5"><a href="e127.full.html#103">(S9.4.3-1</a></text>
<text top="895" left="169" width="60" height="15" font="5"><a href="e127.full.html#103">—S9.4.3-3)</a></text>
<text top="897" left="229" width="3" height="12" font="2"><a href="e127.full.html#103">.</a></text>
<text top="915" left="63" width="333" height="12" font="2">4. Reduction in BP appears to be more important than the</text>
<text top="933" left="79" width="92" height="12" font="2">choice of speci</text>
<text top="931" left="171" width="225" height="15" font="2">ﬁc agents used to achieve this goal.</text>
<text top="951" left="79" width="317" height="12" font="2">Thus, if diuretic and ACE inhibitor or ARB treatment do</text>
<text top="969" left="79" width="317" height="12" font="2">not achieve BP target, other agents, such as CCB and/or</text>
<text top="987" left="79" width="313" height="12" font="2">mineralocorticoid receptor antagonist, may be added.</text>
<text top="1004" left="64" width="332" height="12" font="2">5. An overview of RCTs showed that larger reductions in</text>
<text top="1022" left="79" width="317" height="12" font="2">SBP tended to be associated with greater reduction in</text>
<text top="789" left="439" width="317" height="12" font="2">risk of recurrent stroke. However, a separate overview</text>
<text top="807" left="439" width="317" height="12" font="2">of RCTs in patients who experienced a stroke noted</text>
<text top="825" left="439" width="172" height="12" font="2">that achieving an SBP level</text>
<text top="823" left="619" width="137" height="15" font="2">&lt;130 mm Hg was not</text>
<text top="843" left="439" width="317" height="12" font="2">associated with a lower stroke risk, and several obser-</text>
<text top="861" left="439" width="215" height="12" font="2">vational studies did not show bene</text>
<text top="859" left="654" width="102" height="15" font="2">ﬁt with achieved</text>
<text top="879" left="439" width="59" height="12" font="2">SBP levels</text>
<text top="877" left="503" width="74" height="15" font="2">&lt;120 mm Hg</text>
<text top="879" left="581" width="55" height="12" font="5"><a href="e127.full.html#103">(S9.4.3-5)</a></text>
<text top="879" left="636" width="3" height="12" font="2">.</text>
<text top="897" left="424" width="333" height="12" font="2">6. Patients with a lacunar stroke treated to an SBP target</text>
<text top="915" left="439" width="11" height="12" font="2">of</text>
<text top="913" left="455" width="301" height="15" font="2">&lt;130 mm Hg versus 130 to 140 mm Hg may be less</text>
<text top="933" left="439" width="195" height="12" font="2">likely to experience a future ICH.</text>
<text top="951" left="425" width="202" height="12" font="2">7. No published RCTs have speci</text>
<text top="949" left="627" width="129" height="15" font="2">ﬁcally addressed this</text>
<text top="969" left="439" width="317" height="12" font="2">question, but a post hoc analysis of an RCT suggests</text>
<text top="987" left="439" width="317" height="12" font="2">that the effectiveness of antihypertensive treatment</text>
<text top="1004" left="439" width="317" height="12" font="2">for secondary stroke prevention diminishes as initial</text>
<text top="1022" left="439" width="118" height="12" font="2">baseline BP declines</text>
<text top="1022" left="562" width="56" height="12" font="5"><a href="e127.full.html#103">(S9.4.3-9)</a></text>
<text top="1022" left="618" width="3" height="12" font="2"><a href="e127.full.html#103">.</a></text>
<text top="153" left="80" width="46" height="11" font="22">FIGURE 9</text>
<text top="154" left="134" width="474" height="9" font="23">Management of Hypertension in Patients With a Previous History of Stroke (Secondary Stroke Prevention)</text>
<text top="711" left="80" width="213" height="9" font="13">Colors correspond to Class of Recommendation in</text>
<text top="711" left="297" width="31" height="9" font="17"><a href="e127.full.html#6">Table 1</a></text>
<text top="711" left="328" width="376" height="9" font="13"><a href="e127.full.html#6">. </a>DBP indicates diastolic blood pressure; SBP, systolic blood pressure; and TIA, transient</text>
<text top="726" left="80" width="68" height="9" font="13">ischemic attack.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="19" height="9" font="4">e183</text>
</page>
<page number="58" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="160" height="11" font="12">9.5. Peripheral Artery Disease</text>
<text top="349" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="367" left="123" width="318" height="12" font="2">Patients with PAD are at increased risk of CVD and</text>
<text top="385" left="108" width="333" height="12" font="2">stroke. Hypertension is a major risk factor for PAD, so</text>
<text top="403" left="108" width="333" height="12" font="2">these patients are commonly enrolled in trials of antihy-</text>
<text top="421" left="108" width="333" height="12" font="2">pertensive drug therapy. However, patients with PAD</text>
<text top="439" left="108" width="333" height="12" font="2">typically comprise a small fraction of participants, so in</text>
<text top="457" left="108" width="333" height="12" font="2">the few trials that report results in patients with PAD,</text>
<text top="475" left="108" width="280" height="12" font="2">subgroup analyses are generally underpowered.</text>
<text top="511" left="108" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="509" left="247" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="538" left="108" width="333" height="12" font="2">1. There is no major difference in the relative risk</text>
<text top="556" left="122" width="319" height="12" font="2">reduction in CVD from BP-lowering therapy between</text>
<text top="574" left="122" width="319" height="12" font="2">patients with hypertension and PAD and patients</text>
<text top="592" left="122" width="76" height="12" font="2">without PAD</text>
<text top="592" left="203" width="42" height="12" font="5"><a href="e127.full.html#103">(S9.5-1)</a></text>
<text top="592" left="246" width="195" height="12" font="2">. There is also no evidence that</text>
<text top="609" left="122" width="319" height="12" font="2">any one class of antihypertensive medication or</text>
<text top="349" left="482" width="120" height="12" font="2">strategy is superior</text>
<text top="349" left="610" width="39" height="12" font="5"><a href="e127.full.html#103">(S9.5-2</a></text>
<text top="348" left="649" width="49" height="15" font="5"><a href="e127.full.html#103">—S9.5-4)</a></text>
<text top="349" left="699" width="102" height="12" font="2">. In the INVEST</text>
<text top="367" left="482" width="319" height="12" font="2">(International Verapamil-Trandolapril) study, the beta</text>
<text top="385" left="482" width="319" height="12" font="2">blocker atenolol (with or without hydrochlorothia-</text>
<text top="403" left="482" width="319" height="12" font="2">zide) was compared with the CCB verapamil (with or</text>
<text top="421" left="482" width="286" height="12" font="2">without perindopril). The study showed no signi</text>
<text top="419" left="769" width="32" height="15" font="2">ﬁcant</text>
<text top="439" left="482" width="319" height="12" font="2">difference in CVD outcomes between the 2 drug</text>
<text top="457" left="482" width="266" height="12" font="2">regimens in patients with and without PAD</text>
<text top="457" left="754" width="43" height="12" font="5"><a href="e127.full.html#103">(S9.5-3)</a></text>
<text top="457" left="798" width="3" height="12" font="2"><a href="e127.full.html#103">.</a></text>
<text top="475" left="482" width="319" height="12" font="2">No trials have reported the effects of a higher versus</text>
<text top="493" left="482" width="319" height="12" font="2">a lower BP goal in patients with PAD. In the 1 trial</text>
<text top="511" left="482" width="319" height="12" font="2">(ALLHAT) that reported the effects of different clas-</text>
<text top="529" left="482" width="319" height="12" font="2">ses of BP medications on PAD as an outcome, there</text>
<text top="547" left="482" width="83" height="12" font="2">was no signi</text>
<text top="545" left="565" width="236" height="15" font="2">ﬁcant difference by medication class</text>
<text top="565" left="482" width="43" height="12" font="5"><a href="e127.full.html#103">(S9.5-5)</a></text>
<text top="565" left="526" width="3" height="12" font="2"><a href="e127.full.html#103">.</a></text>
<text top="610" left="468" width="118" height="11" font="12">9.6. Diabetes Mellitus</text>
<text top="189" left="63" width="395" height="11" font="19">Recommendation for Treatment of Hypertension in Patients With PAD</text>
<text top="203" left="63" width="362" height="11" font="19">References that support the recommendation are summarized in</text>
<text top="203" left="429" width="154" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 45</a></text>
<text top="203" left="583" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="244" left="89" width="19" height="10" font="13">COR</text>
<text top="244" left="161" width="18" height="10" font="13">LOE</text>
<text top="244" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="281" left="97" width="3" height="9" font="4">I</text>
<text top="281" left="160" width="21" height="9" font="4">B-NR</text>
<text top="269" left="234" width="568" height="11" font="12">1. Adults with hypertension and PAD should be treated similarly to patients with hypertension without PAD</text>
<text top="285" left="246" width="38" height="11" font="5"><a href="e127.full.html#103">(S9.5-1</a></text>
<text top="283" left="284" width="48" height="15" font="5"><a href="e127.full.html#103">—S9.5-4)</a></text>
<text top="285" left="333" width="3" height="11" font="12"><a href="e127.full.html#103">.</a></text>
<text top="662" left="63" width="395" height="11" font="19">Recommendations for Treatment of Hypertension in Patients With DM</text>
<text top="676" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="676" left="412" width="202" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplements 46 and 47</a></text>
<text top="676" left="618" width="173" height="11" font="19">and Systematic Review Report.</text>
<text top="717" left="89" width="19" height="10" font="13">COR</text>
<text top="717" left="161" width="18" height="10" font="13">LOE</text>
<text top="717" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="754" left="97" width="3" height="9" font="4">I</text>
<text top="749" left="149" width="36" height="9" font="4">SBP: B-R</text>
<text top="746" left="184" width="8" height="6" font="20">SR</text>
<text top="742" left="234" width="544" height="11" font="12">1. In adults with DM and hypertension, antihypertensive drug treatment should be initiated at a BP of</text>
<text top="757" left="246" width="404" height="11" font="12">130/80 mm Hg or higher with a treatment goal of less than 130/80 mm Hg</text>
<text top="757" left="655" width="38" height="11" font="5"><a href="e127.full.html#103">(S9.6-1</a></text>
<text top="755" left="694" width="49" height="15" font="5"><a href="e127.full.html#103">—S9.6-8)</a></text>
<text top="757" left="743" width="3" height="11" font="12">.</text>
<text top="762" left="149" width="43" height="9" font="4">DBP: C-EO</text>
<text top="812" left="97" width="3" height="9" font="4">I</text>
<text top="812" left="164" width="6" height="9" font="4">A</text>
<text top="810" left="169" width="8" height="6" font="20">SR</text>
<text top="799" left="234" width="225" height="11" font="12">2. In adults with DM and hypertension, all</text>
<text top="797" left="463" width="313" height="15" font="12">ﬁrst-line classes of antihypertensive agents (i.e., diuretics,</text>
<text top="815" left="248" width="300" height="11" font="12">ACE inhibitors, ARBs, and CCBs) are useful and effective</text>
<text top="815" left="552" width="129" height="11" font="5"><a href="e127.full.html#103">(S9.6-1,S9.6-9,S9.6-10)</a></text>
<text top="815" left="681" width="3" height="11" font="12">.</text>
<text top="861" left="94" width="10" height="9" font="4">IIb</text>
<text top="861" left="160" width="21" height="9" font="4">B-NR</text>
<text top="849" left="234" width="536" height="11" font="12">3. In adults with DM and hypertension, ACE inhibitors or ARBs may be considered in the presence of</text>
<text top="865" left="248" width="62" height="11" font="12">albuminuria</text>
<text top="865" left="314" width="92" height="11" font="5"><a href="e127.full.html#104">(S9.6-11,S9.6-12)</a></text>
<text top="865" left="406" width="3" height="11" font="12">.</text>
<text top="907" left="63" width="157" height="11" font="2">SR indicates systematic review.</text>
<text top="957" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="975" left="123" width="76" height="12" font="2">Refer to the</text>
<text top="974" left="206" width="238" height="15" font="2">“Systematic Review for the 2017 ACC/</text>
<text top="993" left="108" width="332" height="12" font="2">AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA</text>
<text top="1011" left="108" width="336" height="12" font="2">Guideline for the Prevention, Detection, Evaluation, and</text>
<text top="1029" left="108" width="282" height="12" font="2">Management of High Blood Pressure in Adults</text>
<text top="1027" left="390" width="53" height="15" font="2">” for the</text>
<text top="1047" left="108" width="336" height="12" font="2">complete systematic evidence review for additional data</text>
<text top="1065" left="108" width="77" height="12" font="2">and analyses</text>
<text top="1065" left="191" width="49" height="12" font="5"><a href="e127.full.html#104">(S9.6-13)</a></text>
<text top="1065" left="241" width="203" height="12" font="2">. The prevalence of hypertension</text>
<text top="1083" left="108" width="336" height="12" font="2">among adults with DM is approximately 80%, and</text>
<text top="957" left="465" width="336" height="12" font="2">hypertension is at least twice as common in persons with</text>
<text top="975" left="465" width="336" height="12" font="2">type 2 DM than in age-matched individuals without DM</text>
<text top="993" left="465" width="46" height="12" font="5"><a href="e127.full.html#104">(S9.6-14</a></text>
<text top="992" left="512" width="55" height="15" font="5"><a href="e127.full.html#104">—S9.6-16)</a></text>
<text top="993" left="567" width="234" height="12" font="2">. The coexistence of hypertension and</text>
<text top="1011" left="465" width="336" height="12" font="2">DM markedly increases the risk of developing CVD dam-</text>
<text top="1029" left="465" width="336" height="12" font="2">age, resulting in a higher incidence of CHD, HF, PAD,</text>
<text top="1047" left="465" width="150" height="12" font="2">stroke, and CVD mortality</text>
<text top="1047" left="619" width="49" height="12" font="5"><a href="e127.full.html#104">(S9.6-17)</a></text>
<text top="1047" left="669" width="133" height="12" font="2"><a href="e127.full.html#104">, </a>and may increase risk</text>
<text top="1065" left="465" width="336" height="12" font="2">of microvascular disease, such as nephropathy or reti-</text>
<text top="1083" left="465" width="48" height="12" font="2">nopathy</text>
<text top="1083" left="517" width="96" height="12" font="5"><a href="e127.full.html#104">(S9.6-16,S9.6-18)</a></text>
<text top="1083" left="613" width="3" height="12" font="2">.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e184</text>
</page>
<page number="59" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="78" width="318" height="12" font="2">There is limited quality evidence to determine a precise</text>
<text top="161" left="63" width="333" height="12" font="2">BP target in adults with DM. No RCTs have explicitly 1)</text>
<text top="178" left="63" width="297" height="12" font="2">documented whether treatment to an SBP goal</text>
<text top="177" left="367" width="29" height="15" font="2">&lt;140</text>
<text top="196" left="63" width="333" height="12" font="2">mm Hg versus a higher goal improves clinical outcomes in</text>
<text top="214" left="63" width="333" height="12" font="2">adults with hypertension and DM or 2) directly evaluated</text>
<text top="232" left="63" width="241" height="12" font="2">clinical outcomes associated with SBP</text>
<text top="230" left="312" width="84" height="15" font="2">&lt;130 mm Hg</text>
<text top="250" left="63" width="44" height="12" font="5"><a href="e127.full.html#103">(S9.6-2)</a></text>
<text top="250" left="107" width="289" height="12" font="2">. However, 2 high-quality systematic reviews of</text>
<text top="268" left="63" width="168" height="12" font="2">RCTs support an SBP target of</text>
<text top="266" left="233" width="72" height="15" font="2">&lt;140 mm Hg</text>
<text top="268" left="307" width="85" height="12" font="5"><a href="e127.full.html#103">(S9.6-4,S9.6-7)</a></text>
<text top="268" left="393" width="3" height="12" font="2"><a href="e127.full.html#103">.</a></text>
<text top="286" left="78" width="318" height="12" font="2">There is little or no available RCT evidence supporting</text>
<text top="304" left="63" width="40" height="12" font="2">a speci</text>
<text top="302" left="103" width="293" height="15" font="2">ﬁc DBP threshold for initiation of pharmacological</text>
<text top="322" left="63" width="333" height="12" font="2">therapy. Several RCTs, including the HOT (Hypertension</text>
<text top="340" left="63" width="333" height="12" font="2">Optimal Treatment) trial, UKPDS (United Kingdom Pro-</text>
<text top="358" left="63" width="333" height="12" font="2">spective Diabetes Study), and ABCD (Appropriate Blood</text>
<text top="376" left="63" width="200" height="12" font="2">Pressure Control in Diabetes) trial</text>
<text top="376" left="268" width="46" height="12" font="5"><a href="e127.full.html#104">(S9.6-19</a></text>
<text top="374" left="314" width="55" height="15" font="5"><a href="e127.full.html#104">—S9.6-22)</a></text>
<text top="376" left="370" width="26" height="12" font="2">, are</text>
<text top="394" left="63" width="272" height="12" font="2">often cited to support a lower DBP target (e.g.,</text>
<text top="392" left="339" width="57" height="15" font="2">#85 or 80</text>
<text top="412" left="63" width="333" height="12" font="2">mm Hg) for adults with hypertension and DM. However,</text>
<text top="430" left="63" width="333" height="12" font="2">these trials were conducted when the diagnostic criteria</text>
<text top="447" left="63" width="333" height="12" font="2">for DM were more conservative than they are currently</text>
<text top="465" left="63" width="143" height="12" font="2">(2 fasting glucose levels</text>
<text top="464" left="212" width="185" height="15" font="2">&gt;140 mg/dL as opposed to 126</text>
<text top="483" left="63" width="87" height="12" font="2">mm/dL today).</text>
<text top="519" left="63" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="517" left="202" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="546" left="64" width="332" height="12" font="2">1. We recommend ASCVD risk assessment in all adults</text>
<text top="564" left="78" width="318" height="12" font="2">with hypertension, including adults with DM. As a</text>
<text top="582" left="78" width="318" height="12" font="2">matter of convenience, however, it can be assumed</text>
<text top="600" left="78" width="318" height="12" font="2">that the vast majority of adults with DM have a 10-year</text>
<text top="618" left="78" width="65" height="12" font="2">ASCVD risk</text>
<text top="616" left="148" width="248" height="15" font="2">$ 10%, placing them in the high risk cate-</text>
<text top="636" left="78" width="318" height="12" font="2">gory that requires initiation of antihypertensive drug</text>
<text top="654" left="78" width="85" height="12" font="2">therapy at BP</text>
<text top="652" left="171" width="138" height="15" font="2">$ 130/80 mm Hg (see</text>
<text top="654" left="316" width="80" height="12" font="5"><a href="e127.full.html#34">Section 8.1.2,</a></text>
<text top="672" left="78" width="128" height="11" font="5"><a href="e127.full.html#36">Figure 4 </a>and <a href="e127.full.html#83">Table 23</a></text>
<text top="672" left="212" width="184" height="12" font="2">for BP thresholds for initiating</text>
<text top="690" left="78" width="318" height="12" font="2">antihypertensive drug treatment). The ACCORD trial</text>
<text top="708" left="78" width="44" height="12" font="5"><a href="e127.full.html#104">(S9.6-5)</a></text>
<text top="708" left="122" width="274" height="12" font="2">, which compared CVD outcomes in adults with</text>
<text top="725" left="78" width="318" height="12" font="2">DM and hypertension who were randomized to an SBP</text>
<text top="743" left="78" width="53" height="12" font="2">target of</text>
<text top="742" left="139" width="257" height="15" font="2">&lt;140 mm Hg (standard therapy) or &lt;120</text>
<text top="761" left="78" width="318" height="12" font="2">mm Hg (intensive therapy), did not document a</text>
<text top="779" left="78" width="27" height="12" font="2">signi</text>
<text top="777" left="106" width="290" height="15" font="2">ﬁcant reduction in the primary outcome (CVD</text>
<text top="797" left="78" width="318" height="12" font="2">composite) with the lower BP goal, but the trial was</text>
<text top="815" left="78" width="260" height="12" font="2">underpowered to detect a statistically signi</text>
<text top="813" left="338" width="58" height="15" font="2">ﬁcant dif-</text>
<text top="833" left="78" width="318" height="12" font="2">ference between the 2 treatment arms. The ACCORD</text>
<text top="851" left="78" width="318" height="12" font="2">trial demonstrated a small reduction in absolute risk</text>
<text top="869" left="78" width="318" height="12" font="2">(1.1%) for stroke, but there were few such events. More</text>
<text top="887" left="78" width="318" height="12" font="2">adverse events (2% increase in absolute risk) were</text>
<text top="905" left="78" width="34" height="12" font="2">identi</text>
<text top="903" left="112" width="284" height="15" font="2">ﬁed in the lower BP group, especially self-</text>
<text top="923" left="78" width="318" height="12" font="2">reported hypotension and a reduction in estimated</text>
<text top="941" left="78" width="318" height="12" font="2">GFR, but these did not result in an excess of stroke or</text>
<text top="959" left="78" width="318" height="12" font="2">ESRD. The ACCORD trial was a factorial study; sec-</text>
<text top="976" left="78" width="229" height="12" font="2">ondary analysis demonstrated a signi</text>
<text top="975" left="307" width="89" height="15" font="2">ﬁcant outcome</text>
<text top="994" left="78" width="28" height="12" font="2">bene</text>
<text top="993" left="106" width="290" height="15" font="2">ﬁt in the intensive BP/standard glycemic group</text>
<text top="1012" left="78" width="44" height="12" font="5"><a href="e127.full.html#103">(S9.6-3)</a></text>
<text top="1012" left="122" width="60" height="12" font="2">, but bene</text>
<text top="1011" left="182" width="214" height="15" font="2">ﬁt in the intensive BP/intensive gly-</text>
<text top="1030" left="78" width="318" height="12" font="2">cemic control group was no better than in the intensive</text>
<text top="1048" left="78" width="318" height="12" font="2">BP/standard glycemic control group, which suggests a</text>
<text top="1064" left="78" width="318" height="15" font="2">ﬂoor beneﬁt beyond which the combined intensive</text>
<text top="1084" left="78" width="182" height="12" font="2">interventions were ineffective</text>
<text top="1084" left="268" width="44" height="12" font="5"><a href="e127.full.html#104">(S9.6-5)</a></text>
<text top="1084" left="312" width="84" height="12" font="2">. An ACCORD</text>
<text top="143" left="438" width="241" height="12" font="2">secondary analysis suggested that an SBP</text>
<text top="141" left="683" width="73" height="15" font="2">&lt;120 mm Hg</text>
<text top="161" left="438" width="318" height="12" font="2">is superior to standard BP control in reducing LVH</text>
<text top="178" left="438" width="45" height="12" font="5"><a href="e127.full.html#104">(S9.6-6)</a></text>
<text top="178" left="483" width="3" height="12" font="2">.</text>
<text top="196" left="450" width="306" height="12" font="2">A meta-analysis of 73,913 patients with DM reported</text>
<text top="214" left="438" width="66" height="12" font="2">that an SBP</text>
<text top="213" left="509" width="247" height="15" font="2">&lt;130 mm Hg reduced stroke by 39%. How-</text>
<text top="232" left="438" width="133" height="12" font="2">ever, there was no signi</text>
<text top="230" left="571" width="150" height="15" font="2">ﬁcant risk reduction for MI</text>
<text top="232" left="725" width="32" height="12" font="5"><a href="e127.full.html#104">(S9.6-</a></text>
<text top="250" left="438" width="16" height="12" font="5"><a href="e127.full.html#104">23)</a></text>
<text top="250" left="454" width="302" height="12" font="2">. Two meta-analyses addressing target BP in adults</text>
<text top="268" left="438" width="318" height="12" font="2">with DM restricted the analysis to RCTs that randomized</text>
<text top="286" left="438" width="162" height="12" font="2">patients to different BP levels</text>
<text top="286" left="603" width="80" height="12" font="5"><a href="e127.full.html#103">(S9.6-4,S9.6-7)</a></text>
<text top="286" left="683" width="73" height="12" font="2"><a href="e127.full.html#103">. </a>Target BP of</text>
<text top="304" left="438" width="160" height="12" font="2">133/76 mm Hg provided signi</text>
<text top="302" left="598" width="159" height="15" font="2">ﬁcant beneﬁt compared with</text>
<text top="322" left="438" width="318" height="12" font="2">that of 140/81 mm Hg for major cardiovascular events, MI,</text>
<text top="340" left="438" width="269" height="12" font="2">stroke, albuminuria, and retinopathy progression</text>
<text top="340" left="710" width="43" height="12" font="5"><a href="e127.full.html#103">(S9.6-4)</a></text>
<text top="340" left="753" width="3" height="12" font="2"><a href="e127.full.html#103">.</a></text>
<text top="358" left="438" width="318" height="12" font="2">Several meta-analyses of RCTs included all trials with a</text>
<text top="376" left="438" width="92" height="12" font="2">difference in BP</text>
<text top="376" left="536" width="92" height="12" font="5"><a href="e127.full.html#104">(S9.6-24,S9.6-25)</a></text>
<text top="376" left="628" width="128" height="12" font="2">, but 2 restricted their</text>
<text top="394" left="438" width="318" height="12" font="2">analyses to trials in which participants were randomized</text>
<text top="412" left="438" width="153" height="12" font="2">to different BP target levels</text>
<text top="412" left="595" width="80" height="12" font="5"><a href="e127.full.html#103">(S9.6-4,S9.6-7)</a></text>
<text top="412" left="675" width="3" height="12" font="2"><a href="e127.full.html#103">.</a></text>
<text top="430" left="450" width="257" height="12" font="2">SPRINT demonstrated cardiovascular bene</text>
<text top="428" left="707" width="49" height="15" font="2">ﬁt from</text>
<text top="447" left="438" width="221" height="12" font="2">intensive treatment of BP to a goal of</text>
<text top="446" left="664" width="92" height="15" font="2">&lt;120 mm Hg as</text>
<text top="465" left="438" width="83" height="12" font="2">compared with</text>
<text top="464" left="525" width="231" height="15" font="2">&lt;140 mm Hg but did not include patients</text>
<text top="483" left="438" width="318" height="12" font="2">with DM. However, the results of ACCORD and SPRINT</text>
<text top="501" left="438" width="141" height="12" font="2">were generally consistent</text>
<text top="501" left="582" width="48" height="12" font="5"><a href="e127.full.html#104">(S9.6-26)</a></text>
<text top="501" left="631" width="126" height="12" font="2"><a href="e127.full.html#104">. </a>In addition, a SPRINT</text>
<text top="519" left="438" width="318" height="12" font="2">substudy demonstrated that patients with prediabetes</text>
<text top="537" left="438" width="84" height="12" font="2">derived a bene</text>
<text top="535" left="522" width="235" height="15" font="2">ﬁt similar to that of patients with normo-</text>
<text top="555" left="438" width="49" height="12" font="2">glycemia</text>
<text top="555" left="495" width="43" height="12" font="5"><a href="e127.full.html#104">(S9.6-8)</a></text>
<text top="555" left="538" width="219" height="12" font="2"><a href="e127.full.html#104">. </a>Previous trials have shown similar</text>
<text top="573" left="438" width="99" height="12" font="2">quantitative bene</text>
<text top="571" left="537" width="219" height="15" font="2">ﬁts from lowering BP in persons with</text>
<text top="591" left="438" width="91" height="12" font="2">and without DM</text>
<text top="591" left="533" width="42" height="12" font="5"><a href="e127.full.html#104">(S9.6-9)</a></text>
<text top="591" left="575" width="3" height="12" font="2">.</text>
<text top="609" left="423" width="142" height="12" font="2">2. BP control is more dif</text>
<text top="607" left="566" width="190" height="15" font="2">ﬁcult to achieve in patients with</text>
<text top="627" left="438" width="318" height="12" font="2">DM than in those without DM, necessitating use of</text>
<text top="645" left="438" width="280" height="12" font="2">combination therapy in the majority of patients</text>
<text top="645" left="723" width="33" height="12" font="5"><a href="e127.full.html#104">(S9.6-</a></text>
<text top="663" left="438" width="17" height="12" font="5"><a href="e127.full.html#104">27)</a></text>
<text top="663" left="455" width="301" height="12" font="2">. All major antihypertensive drug classes (i.e., ACE</text>
<text top="681" left="438" width="318" height="12" font="2">inhibitors, ARBs, CCBs, and diuretics) are useful in the</text>
<text top="698" left="438" width="220" height="12" font="2">treatment of hypertension in DM</text>
<text top="698" left="669" width="84" height="12" font="5"><a href="e127.full.html#103">(S9.6-1,S9.6-9)</a></text>
<text top="698" left="753" width="3" height="12" font="2"><a href="e127.full.html#103">.</a></text>
<text top="716" left="438" width="318" height="12" font="2">However, in ALLHAT, doxazosin was clearly inferior to</text>
<text top="734" left="438" width="318" height="12" font="2">chlorthalidone, which also reduced some events more</text>
<text top="752" left="438" width="168" height="12" font="2">than amlodipine or lisinopril</text>
<text top="752" left="610" width="52" height="12" font="5"><a href="e127.full.html#104">(S9.6-28)</a></text>
<text top="752" left="662" width="3" height="12" font="2"><a href="e127.full.html#104">.</a></text>
<text top="770" left="423" width="256" height="12" font="2">3. ACE inhibitors and ARBs have the best ef</text>
<text top="768" left="680" width="76" height="15" font="2">ﬁcacy among</text>
<text top="788" left="438" width="265" height="12" font="2">the drug classes on urinary albumin excretion</text>
<text top="788" left="707" width="49" height="12" font="5"><a href="e127.full.html#104">(S9.6-12)</a></text>
<text top="806" left="438" width="23" height="12" font="2">(see</text>
<text top="806" left="466" width="65" height="12" font="5"><a href="e127.full.html#49">Section 9.3</a></text>
<text top="806" left="532" width="225" height="12" font="2"><a href="e127.full.html#49">)</a>. Therefore, an ACE inhibitor or ARB</text>
<text top="824" left="438" width="318" height="12" font="2">may be considered as part of the combination. A meta-</text>
<text top="842" left="438" width="318" height="12" font="2">analysis of RCTs of primary prevention of albuminuria</text>
<text top="860" left="438" width="244" height="12" font="2">in patients with DM demonstrated a signi</text>
<text top="858" left="682" width="74" height="15" font="2">ﬁcant reduc-</text>
<text top="878" left="438" width="318" height="12" font="2">tion in progression of moderately to severely increased</text>
<text top="896" left="438" width="318" height="12" font="2">albuminuria with the use of ACE inhibitors or ARBs</text>
<text top="914" left="438" width="48" height="12" font="5"><a href="e127.full.html#104">(S9.6-11)</a></text>
<text top="914" left="487" width="3" height="12" font="2"><a href="e127.full.html#104">.</a></text>
<text top="955" left="423" width="133" height="11" font="12">9.7. Metabolic Syndrome</text>
<text top="976" left="423" width="333" height="12" font="2">Metabolic syndrome is a state of metabolic dysregulation</text>
<text top="994" left="423" width="333" height="12" font="2">characterized by visceral fat accumulation, insulin resis-</text>
<text top="1012" left="423" width="333" height="12" font="2">tance, hyperinsulinemia, and hyperlipidemia, as well as</text>
<text top="1030" left="423" width="333" height="12" font="2">predisposition to type 2 DM, hypertension, and athero-</text>
<text top="1048" left="423" width="77" height="12" font="2">sclerotic CVD</text>
<text top="1048" left="505" width="38" height="12" font="5"><a href="e127.full.html#104">(S9.7-1</a></text>
<text top="1046" left="543" width="48" height="15" font="5"><a href="e127.full.html#104">—S9.7-3)</a></text>
<text top="1048" left="591" width="165" height="12" font="2">. According to data from the</text>
<text top="1066" left="423" width="183" height="12" font="2">NHANES III and NHANES 1999</text>
<text top="1064" left="607" width="34" height="15" font="2">–2006</text>
<text top="1066" left="646" width="82" height="12" font="5"><a href="e127.full.html#104">(S9.7-1,S9.7-4)</a></text>
<text top="1066" left="729" width="28" height="12" font="2"><a href="e127.full.html#104">, </a>the</text>
<text top="1084" left="423" width="333" height="12" font="2">prevalence of metabolic syndrome in the United States</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="19" height="9" font="4">e185</text>
</page>
<page number="60" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="333" height="12" font="2">was 34.2% in 2006 and has likely increased substantially</text>
<text top="161" left="108" width="333" height="12" font="2">since that time. The metabolic syndrome is linked to</text>
<text top="178" left="108" width="333" height="12" font="2">several other disorders, including nonalcoholic steatohe-</text>
<text top="196" left="108" width="333" height="12" font="2">patitis, polycystic ovary syndrome, certain cancers, CKD,</text>
<text top="214" left="108" width="59" height="12" font="2">Alzheimer</text>
<text top="213" left="167" width="274" height="15" font="2">’s disease, Cushing’s syndrome, lipodystrophy,</text>
<text top="232" left="108" width="133" height="12" font="2">and hyperalimentation</text>
<text top="232" left="245" width="83" height="12" font="5"><a href="e127.full.html#104">(S9.7-5,S9.7-6)</a></text>
<text top="232" left="328" width="3" height="12" font="2">.</text>
<text top="250" left="123" width="83" height="12" font="2">Lifestyle modi</text>
<text top="248" left="206" width="235" height="15" font="2">ﬁcation, with an emphasis on improving</text>
<text top="268" left="108" width="286" height="12" font="2">insulin sensitivity by means of dietary modi</text>
<text top="266" left="394" width="47" height="15" font="2">ﬁcation,</text>
<text top="286" left="108" width="333" height="12" font="2">weight reduction, and exercise, is the foundation of</text>
<text top="304" left="108" width="333" height="12" font="2">treatment of the metabolic syndrome. The optimal anti-</text>
<text top="322" left="108" width="333" height="12" font="2">hypertensive drug therapy for patients with hypertension</text>
<text top="340" left="108" width="333" height="12" font="2">in the setting of the metabolic syndrome has not been</text>
<text top="358" left="108" width="57" height="12" font="2">clearly de</text>
<text top="356" left="165" width="29" height="15" font="2">ﬁned</text>
<text top="358" left="199" width="42" height="12" font="5"><a href="e127.full.html#104">(S9.7-1)</a></text>
<text top="358" left="242" width="199" height="12" font="2"><a href="e127.full.html#104">. </a>Although caution exists with re-</text>
<text top="376" left="108" width="333" height="12" font="2">gard to the use of thiazide diuretics in this population</text>
<text top="394" left="108" width="333" height="12" font="2">because of their ability to increase insulin resistance,</text>
<text top="412" left="108" width="333" height="12" font="2">dyslipidemia, and hyperuricemia and to accelerate con-</text>
<text top="430" left="108" width="333" height="12" font="2">version to overt DM, no data are currently available</text>
<text top="447" left="108" width="333" height="12" font="2">demonstrating deterioration in cardiovascular or renal</text>
<text top="465" left="108" width="282" height="12" font="2">outcomes in patients treated with these agents</text>
<text top="465" left="395" width="42" height="12" font="5"><a href="e127.full.html#104">(S9.7-1)</a></text>
<text top="465" left="437" width="3" height="12" font="2">.</text>
<text top="483" left="108" width="333" height="12" font="2">Indeed, as shown in follow-up of ALLHAT, chlorthalidone</text>
<text top="501" left="108" width="333" height="12" font="2">use was associated with only a small increase in fasting</text>
<text top="519" left="108" width="106" height="12" font="2">glucose levels (1.5</text>
<text top="517" left="214" width="227" height="15" font="2">–4.0 mg/dL), and this increase did not</text>
<text top="143" left="468" width="281" height="12" font="2">translate into increased CVD risk at a later date</text>
<text top="143" left="753" width="39" height="12" font="5"><a href="e127.full.html#104">(S9.7-7</a></text>
<text top="141" left="792" width="9" height="15" font="5"><a href="e127.full.html#104">—</a></text>
<text top="161" left="468" width="45" height="12" font="5"><a href="e127.full.html#104">S9.7-10)</a></text>
<text top="161" left="514" width="287" height="12" font="2"><a href="e127.full.html#104">. </a>In addition, in post hoc analysis of the nearly</text>
<text top="178" left="468" width="333" height="12" font="2">two thirds of participants in ALLHAT that met criteria for</text>
<text top="196" left="468" width="333" height="12" font="2">the metabolic syndrome, chlorthalidone was unsurpassed</text>
<text top="214" left="468" width="333" height="12" font="2">in reducing CVD and renal outcomes compared with lisi-</text>
<text top="232" left="468" width="198" height="12" font="2">nopril, amlodipine, or doxazosin</text>
<text top="232" left="673" width="87" height="12" font="5"><a href="e127.full.html#104">(S9.7-9,S9.7-11)</a></text>
<text top="232" left="761" width="40" height="12" font="2"><a href="e127.full.html#104">. </a>Simi-</text>
<text top="250" left="468" width="333" height="12" font="2">larly, high-dose ARB therapy reduces arterial stiffness in</text>
<text top="268" left="468" width="333" height="12" font="2">patients with hypertension with the metabolic syndrome,</text>
<text top="286" left="468" width="333" height="12" font="2">but no outcomes data are available from patients in which</text>
<text top="304" left="468" width="195" height="12" font="2">this form of treatment was used</text>
<text top="304" left="668" width="49" height="12" font="5"><a href="e127.full.html#104">(S9.7-12)</a></text>
<text top="304" left="717" width="84" height="12" font="2">. Use of tradi-</text>
<text top="322" left="468" width="333" height="12" font="2">tional beta blockers may lead to dyslipidemia or deterio-</text>
<text top="340" left="468" width="333" height="12" font="2">ration of glucose tolerance, and ability to lose weight</text>
<text top="358" left="468" width="43" height="12" font="5"><a href="e127.full.html#104">(S9.7-2)</a></text>
<text top="358" left="512" width="290" height="12" font="2"><a href="e127.full.html#104">. </a>In several large clinical trials, the risk of devel-</text>
<text top="376" left="468" width="333" height="12" font="2">oping DM as a result of traditional beta-blocker therapy</text>
<text top="394" left="468" width="89" height="12" font="2">was 15% to 29%</text>
<text top="394" left="560" width="43" height="12" font="5"><a href="e127.full.html#104">(S9.7-2)</a></text>
<text top="394" left="604" width="197" height="12" font="2">. However, the newer vasodilating</text>
<text top="412" left="468" width="333" height="12" font="2">beta blockers (e.g., labetalol, carvedilol, nebivolol) have</text>
<text top="430" left="468" width="309" height="12" font="2">shown neutral or favorable effects on metabolic pro</text>
<text top="428" left="778" width="24" height="15" font="2">ﬁles</text>
<text top="447" left="468" width="273" height="12" font="2">compared with the traditional beta blockers</text>
<text top="447" left="749" width="49" height="12" font="5"><a href="e127.full.html#104">(S9.7-13)</a></text>
<text top="447" left="798" width="3" height="12" font="2"><a href="e127.full.html#104">.</a></text>
<text top="465" left="468" width="333" height="12" font="2">Trials using vasodilator beta blockers have not been</text>
<text top="483" left="468" width="307" height="12" font="2">performed to demonstrate effects on CVD outcomes.</text>
<text top="520" left="468" width="116" height="11" font="12">9.8. Atrial Fibrillation</text>
<text top="569" left="63" width="386" height="11" font="19">Recommendation for Treatment of Hypertension in Patients With AF</text>
<text top="583" left="63" width="362" height="11" font="19">References that support the recommendation are summarized in</text>
<text top="583" left="429" width="155" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 48</a></text>
<text top="583" left="584" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="624" left="89" width="19" height="10" font="13">COR</text>
<text top="624" left="161" width="18" height="10" font="13">LOE</text>
<text top="624" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="661" left="94" width="10" height="9" font="4">IIa</text>
<text top="661" left="163" width="15" height="9" font="4">B-R</text>
<text top="649" left="234" width="479" height="11" font="12">1. Treatment of hypertension with an ARB can be useful for prevention of recurrence of AF</text>
<text top="649" left="716" width="82" height="11" font="5"><a href="e127.full.html#104">(S9.8-1,S9.8-2)</a></text>
<text top="649" left="798" width="3" height="11" font="12">.</text>
<text top="740" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="758" left="123" width="321" height="12" font="2">AF and hypertension are common and often coexistent</text>
<text top="776" left="108" width="336" height="12" font="2">conditions, both of which increase in frequency with age.</text>
<text top="794" left="108" width="236" height="12" font="2">AF occurs in 3% to 4% of the population</text>
<text top="792" left="348" width="96" height="15" font="2">&gt;65 years of age</text>
<text top="812" left="108" width="44" height="12" font="5"><a href="e127.full.html#104">(S9.8-3)</a></text>
<text top="812" left="152" width="159" height="12" font="2">. Hypertension is present in</text>
<text top="810" left="315" width="129" height="15" font="2">&gt;80% of patients with</text>
<text top="830" left="108" width="336" height="12" font="2">AF and is by far the most common comorbid condition,</text>
<text top="848" left="108" width="99" height="12" font="2">regardless of age</text>
<text top="848" left="211" width="46" height="12" font="5"><a href="e127.full.html#104">(S9.8-4)</a></text>
<text top="848" left="257" width="187" height="12" font="2"><a href="e127.full.html#104">. </a>AF is associated with systemic</text>
<text top="866" left="108" width="336" height="12" font="2">thromboembolism, as recognized in the CHADS2 and</text>
<text top="884" left="108" width="271" height="12" font="2">CHA2DS2-VASc scoring systems for stroke risk</text>
<text top="884" left="383" width="44" height="12" font="5"><a href="e127.full.html#104">(S9.8-5)</a></text>
<text top="884" left="427" width="17" height="12" font="2">. It</text>
<text top="902" left="108" width="336" height="12" font="2">is also associated with gradual worsening of ventricular</text>
<text top="920" left="108" width="336" height="12" font="2">function, the subsequent development of HF, and</text>
<text top="937" left="108" width="117" height="12" font="2">increased mortality.</text>
<text top="955" left="123" width="321" height="12" font="2">Hypertension has long been recognized as a risk factor</text>
<text top="973" left="108" width="336" height="12" font="2">for AF because it is associated with LVH, decreased dia-</text>
<text top="991" left="108" width="195" height="12" font="2">stolic function with impaired LV</text>
<text top="989" left="308" width="136" height="15" font="2">ﬁlling, rising left atrial</text>
<text top="1009" left="108" width="336" height="12" font="2">pressures with left atrial hypertrophy and enlargement,</text>
<text top="1027" left="108" width="92" height="12" font="2">increased atrial</text>
<text top="1025" left="205" width="238" height="15" font="2">ﬁbrosis, and slowing of intra-atrial and</text>
<text top="1045" left="108" width="336" height="12" font="2">interatrial electrical conduction velocities. Such a distor-</text>
<text top="1063" left="108" width="336" height="12" font="2">tion of atrial anatomy and physiology increases the inci-</text>
<text top="1081" left="108" width="73" height="12" font="2">dence of AF</text>
<text top="1081" left="187" width="45" height="12" font="5"><a href="e127.full.html#104">(S9.8-6)</a></text>
<text top="1081" left="232" width="212" height="12" font="2">. Left atrial pressure also increases</text>
<text top="740" left="465" width="336" height="12" font="2">with ischemic or valvular heart disease and myopathies</text>
<text top="758" left="465" width="336" height="12" font="2">that are often associated with systemic hypertension,</text>
<text top="776" left="465" width="149" height="12" font="2">potentially leading to AF.</text>
<text top="794" left="480" width="321" height="12" font="2">Although management of AF will continue to revolve</text>
<text top="812" left="465" width="336" height="12" font="2">around restoration of sinus rhythm when appropriate, rate</text>
<text top="830" left="465" width="336" height="12" font="2">control when it is not, and anticoagulation, control</text>
<text top="848" left="465" width="295" height="12" font="2">of hypertension is a key component of therapy</text>
<text top="848" left="767" width="34" height="12" font="5"><a href="e127.full.html#104">(S9.8-</a></text>
<text top="866" left="465" width="49" height="12" font="5"><a href="e127.full.html#104">1,S9.8-2)</a></text>
<text top="866" left="515" width="3" height="12" font="2"><a href="e127.full.html#104">.</a></text>
<text top="884" left="480" width="321" height="12" font="2">Treatment of hypertension may prevent new-onset AF,</text>
<text top="902" left="465" width="286" height="12" font="2">especially in patients with LVH or LV dysfunction</text>
<text top="902" left="754" width="43" height="12" font="5"><a href="e127.full.html#104">(S9.8-1)</a></text>
<text top="902" left="798" width="3" height="12" font="2"><a href="e127.full.html#104">.</a></text>
<text top="920" left="465" width="336" height="12" font="2">Five RCTs have compared the value of antihypertensive</text>
<text top="937" left="465" width="232" height="12" font="2">agents for reduction of new-onset AF</text>
<text top="937" left="704" width="40" height="12" font="5"><a href="e127.full.html#105">(S9.8-7</a></text>
<text top="936" left="744" width="53" height="15" font="5"><a href="e127.full.html#105">—S9.8-11)</a></text>
<text top="937" left="798" width="3" height="12" font="2"><a href="e127.full.html#105">.</a></text>
<text top="955" left="465" width="336" height="12" font="2">One study suggested superiority of RAS blockade over a</text>
<text top="973" left="465" width="24" height="12" font="2">CCB</text>
<text top="973" left="496" width="45" height="12" font="5"><a href="e127.full.html#105">(S9.8-8)</a></text>
<text top="973" left="541" width="260" height="12" font="2">, and another reported superiority of RAS</text>
<text top="991" left="465" width="336" height="12" font="2">blockade over a beta blocker that is no longer recom-</text>
<text top="1009" left="465" width="236" height="12" font="2">mended for treatment of hypertension</text>
<text top="1009" left="708" width="45" height="12" font="5"><a href="e127.full.html#105">(S9.8-9)</a></text>
<text top="1009" left="754" width="48" height="12" font="2"><a href="e127.full.html#105">. </a>In the</text>
<text top="1027" left="465" width="336" height="12" font="2">largest trial, there was no difference in incident AF among</text>
<text top="1045" left="465" width="226" height="12" font="2">adults with hypertension assigned to</text>
<text top="1043" left="698" width="103" height="15" font="2">ﬁrst-step therapy</text>
<text top="1063" left="465" width="226" height="12" font="2">with a diuretic, ACE inhibitor, or CCB</text>
<text top="1063" left="697" width="51" height="12" font="5"><a href="e127.full.html#105">(S9.8-10)</a></text>
<text top="1063" left="748" width="53" height="12" font="2"><a href="e127.full.html#105">. </a>In ALL-</text>
<text top="1081" left="465" width="281" height="12" font="2">HAT, the incidence of AF was 23% higher during</text>
<text top="1079" left="749" width="52" height="15" font="2">ﬁrst-step</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="20" height="9" font="4">e186</text>
</page>
<page number="61" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="333" height="12" font="2">antihypertensive therapy with the alpha-receptor blocker</text>
<text top="161" left="63" width="333" height="12" font="2">doxazosin than with chlorthalidone. Furthermore, the</text>
<text top="178" left="63" width="149" height="12" font="2">occurrence of AF or atrial</text>
<text top="177" left="216" width="180" height="15" font="2">ﬂutter during the study, either</text>
<text top="196" left="63" width="333" height="12" font="2">new onset or recurrent, was associated with an increase in</text>
<text top="214" left="63" width="158" height="12" font="2">mortality of nearly 2.5-fold</text>
<text top="214" left="225" width="51" height="12" font="5"><a href="e127.full.html#105">(S9.8-10)</a></text>
<text top="214" left="276" width="3" height="12" font="2"><a href="e127.full.html#105">.</a></text>
<text top="250" left="63" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="248" left="202" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="277" left="63" width="333" height="12" font="2">1. Although RAS blockade in theory is the treatment of</text>
<text top="295" left="77" width="320" height="12" font="2">choice for hypertension in patients with prior AF,</text>
<text top="143" left="437" width="319" height="12" font="2">relative to other classes of agents, all of the trials that</text>
<text top="161" left="437" width="319" height="12" font="2">have shown clinical superiority of ARBs over other</text>
<text top="178" left="437" width="319" height="12" font="2">agents were comparisons with CCBs or beta blockers</text>
<text top="196" left="437" width="205" height="12" font="2">that are no longer recommended as</text>
<text top="195" left="646" width="111" height="15" font="2">ﬁrst-line agents for</text>
<text top="214" left="437" width="165" height="12" font="2">treatment of hypertension</text>
<text top="214" left="612" width="44" height="12" font="5"><a href="e127.full.html#104">(S9.8-2)</a></text>
<text top="214" left="657" width="99" height="12" font="2">. There are no</text>
<text top="232" left="437" width="319" height="12" font="2">available trials comparing ACE inhibitors with other</text>
<text top="250" left="437" width="285" height="12" font="2">drugs or any RAS-blocking agents with diuretics.</text>
<text top="295" left="423" width="146" height="11" font="12">9.9. Valvular Heart Disease</text>
<text top="351" left="63" width="504" height="11" font="19">Recommendations for Treatment of Hypertension in Patients With Valvular Heart Disease</text>
<text top="365" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="365" left="412" width="202" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplements 49 and 50</a></text>
<text top="365" left="615" width="3" height="11" font="19">.</text>
<text top="406" left="89" width="19" height="10" font="13">COR</text>
<text top="406" left="161" width="18" height="10" font="13">LOE</text>
<text top="406" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="443" left="97" width="3" height="9" font="4">I</text>
<text top="443" left="160" width="21" height="9" font="4">B-NR</text>
<text top="431" left="234" width="546" height="11" font="12">1. In adults with asymptomatic aortic stenosis, hypertension should be treated with pharmacotherapy,</text>
<text top="447" left="246" width="341" height="11" font="12">starting at a low dose and gradually titrating upward as needed</text>
<text top="447" left="591" width="38" height="11" font="5"><a href="e127.full.html#105">(S9.9-1</a></text>
<text top="444" left="630" width="49" height="15" font="5"><a href="e127.full.html#105">—S9.9-4)</a></text>
<text top="447" left="680" width="3" height="11" font="12"><a href="e127.full.html#105">.</a></text>
<text top="491" left="94" width="10" height="9" font="4">IIa</text>
<text top="491" left="160" width="20" height="9" font="4">C-LD</text>
<text top="479" left="234" width="204" height="11" font="12">2. In patients with chronic aortic insuf</text>
<text top="477" left="438" width="362" height="15" font="12">ﬁciency, treatment of systolic hypertension with agents that do not</text>
<text top="494" left="248" width="315" height="11" font="12">slow the heart rate (i.e., avoid beta blockers) is reasonable</text>
<text top="494" left="567" width="84" height="11" font="5"><a href="e127.full.html#105">(S9.9-5,S9.9-6)</a></text>
<text top="494" left="651" width="3" height="11" font="12">.</text>
<text top="608" left="63" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="606" left="202" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="635" left="64" width="335" height="12" font="2">1. Hypertension is a risk factor for the development of</text>
<text top="653" left="78" width="321" height="12" font="2">aortic stenosis (stage A [e.g., aortic sclerosis or</text>
<text top="671" left="78" width="49" height="12" font="2">bicuspid</text>
<text top="671" left="140" width="33" height="12" font="2">aortic</text>
<text top="671" left="185" width="40" height="12" font="2">valve])</text>
<text top="671" left="238" width="21" height="12" font="2">and</text>
<text top="671" left="272" width="82" height="12" font="2">asymptomatic</text>
<text top="671" left="366" width="33" height="12" font="2">aortic</text>
<text top="689" left="78" width="321" height="12" font="2">stenosis (stage B [progressive asymptomatic aortic</text>
<text top="707" left="78" width="321" height="12" font="2">stenosis]). The combination of hypertension and aortic</text>
<text top="725" left="78" width="50" height="12" font="2">stenosis,</text>
<text top="723" left="134" width="264" height="15" font="2">“2 resistors in series,” increases the rate of</text>
<text top="743" left="78" width="321" height="12" font="2">complications. In patients with asymptomatic mild-to-</text>
<text top="761" left="78" width="55" height="12" font="2">moderate</text>
<text top="761" left="145" width="33" height="12" font="2">aortic</text>
<text top="761" left="189" width="50" height="12" font="2">stenosis,</text>
<text top="761" left="252" width="77" height="12" font="2">hypertension</text>
<text top="761" left="340" width="59" height="12" font="2">has been</text>
<text top="779" left="78" width="321" height="12" font="2">associated with more abnormal LV structure and</text>
<text top="796" left="78" width="55" height="12" font="2">increased</text>
<text top="796" left="146" width="84" height="12" font="2">cardiovascular</text>
<text top="796" left="242" width="57" height="12" font="2">morbidity</text>
<text top="796" left="312" width="21" height="12" font="2">and</text>
<text top="796" left="345" width="54" height="12" font="2">mortality</text>
<text top="814" left="78" width="43" height="12" font="5"><a href="e127.full.html#105">(S9.9-1)</a></text>
<text top="814" left="121" width="278" height="12" font="2">. There is no evidence that antihypertensive</text>
<text top="832" left="78" width="321" height="12" font="2">medications will produce an inordinate degree of hy-</text>
<text top="850" left="78" width="321" height="12" font="2">potension in patients with aortic stenosis. Nitroprus-</text>
<text top="868" left="78" width="321" height="12" font="2">side infusion in hypertensive patients with severe</text>
<text top="886" left="78" width="321" height="12" font="2">aortic stenosis lowers pulmonary and systemic resis-</text>
<text top="904" left="78" width="321" height="12" font="2">tance, with improvements in stroke volume and LV</text>
<text top="922" left="78" width="132" height="12" font="2">end-diastolic pressure</text>
<text top="922" left="218" width="44" height="12" font="5"><a href="e127.full.html#105">(S9.9-2)</a></text>
<text top="922" left="262" width="137" height="12" font="2">. Thus, careful use of</text>
<text top="940" left="78" width="321" height="12" font="2">antihypertensive agents to achieve BP control in</text>
<text top="958" left="78" width="321" height="12" font="2">patients with hypertension and aortic stenosis is</text>
<text top="976" left="78" width="28" height="12" font="2">bene</text>
<text top="974" left="106" width="293" height="15" font="2">ﬁcial. Although there are no speciﬁc trials</text>
<text top="994" left="78" width="321" height="12" font="2">comparing various classes of antihypertensive agents,</text>
<text top="1012" left="78" width="321" height="12" font="2">RAS blockade may be advantageous because of the</text>
<text top="608" left="435" width="98" height="12" font="2">potentially bene</text>
<text top="606" left="534" width="167" height="15" font="2">ﬁcial effects on LV ﬁbrosis</text>
<text top="608" left="708" width="44" height="12" font="5"><a href="e127.full.html#105">(S9.9-3)</a></text>
<text top="608" left="753" width="3" height="12" font="2"><a href="e127.full.html#105">,</a></text>
<text top="626" left="435" width="321" height="12" font="2">control of hypertension, reduction of dyspnea, and</text>
<text top="644" left="435" width="150" height="12" font="2">improved effort tolerance</text>
<text top="644" left="590" width="45" height="12" font="5"><a href="e127.full.html#105">(S9.9-4)</a></text>
<text top="644" left="635" width="121" height="12" font="2">. Diuretics should be</text>
<text top="662" left="435" width="321" height="12" font="2">used sparingly in patients with small LV chamber</text>
<text top="680" left="435" width="321" height="12" font="2">dimensions. Beta blockers may be appropriate for</text>
<text top="698" left="435" width="321" height="12" font="2">patients with aortic stenosis who have reduced ejec-</text>
<text top="716" left="435" width="321" height="12" font="2">tion fraction, prior MI, arrhythmias, or angina pectoris.</text>
<text top="734" left="435" width="321" height="12" font="2">In patients with moderate or severe aortic stenosis,</text>
<text top="752" left="435" width="321" height="12" font="2">consultation or co-management with a cardiologist is</text>
<text top="770" left="435" width="241" height="12" font="2">preferred for hypertension management.</text>
<text top="788" left="421" width="336" height="12" font="2">2. Vasodilator therapy can reduce the LV volume and mass</text>
<text top="805" left="435" width="321" height="12" font="2">and improve LV performance in patients with aortic</text>
<text top="823" left="435" width="76" height="12" font="2">regurgitation</text>
<text top="823" left="517" width="44" height="12" font="5"><a href="e127.full.html#105">(S9.9-5)</a></text>
<text top="823" left="562" width="195" height="12" font="2"><a href="e127.full.html#105">, </a>but improvement of long-term</text>
<text top="841" left="435" width="321" height="12" font="2">clinical outcomes, such as time to valve replacement,</text>
<text top="859" left="435" width="113" height="12" font="2">have been variable</text>
<text top="859" left="553" width="85" height="12" font="5"><a href="e127.full.html#105">(S9.9-5,S9.9-6)</a></text>
<text top="859" left="638" width="118" height="12" font="2">. Beta blockers may</text>
<text top="877" left="435" width="168" height="12" font="2">result in increased diastolic</text>
<text top="875" left="609" width="147" height="15" font="2">ﬁlling period because of</text>
<text top="895" left="435" width="72" height="12" font="2">bradycardia,</text>
<text top="895" left="521" width="63" height="12" font="2">potentially</text>
<text top="895" left="597" width="44" height="12" font="2">causing</text>
<text top="895" left="655" width="55" height="12" font="2">increased</text>
<text top="895" left="724" width="33" height="12" font="2">aortic</text>
<text top="913" left="435" width="29" height="12" font="2">insuf</text>
<text top="911" left="465" width="292" height="15" font="2">ﬁciency. Marked reduction in DBP may lower</text>
<text top="931" left="435" width="321" height="12" font="2">coronary perfusion pressure in patients with chronic</text>
<text top="949" left="435" width="37" height="12" font="2">severe</text>
<text top="949" left="485" width="33" height="12" font="2">aortic</text>
<text top="949" left="530" width="76" height="12" font="2">regurgitation</text>
<text top="949" left="619" width="34" height="12" font="2">(stage</text>
<text top="949" left="665" width="8" height="12" font="2">B</text>
<text top="949" left="685" width="71" height="12" font="2">[progressive</text>
<text top="967" left="435" width="82" height="12" font="2">asymptomatic</text>
<text top="967" left="530" width="33" height="12" font="2">aortic</text>
<text top="967" left="577" width="80" height="12" font="2">regurgitation]</text>
<text top="967" left="670" width="21" height="12" font="2">and</text>
<text top="967" left="705" width="30" height="12" font="2">stage</text>
<text top="967" left="749" width="8" height="12" font="2">C</text>
<text top="985" left="435" width="321" height="12" font="2">[asymptomatic severe AR]). However, there are no</text>
<text top="1003" left="435" width="310" height="12" font="2">outcomes data to support these theoretical concerns.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="19" height="9" font="4">e187</text>
</page>
<page number="62" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="106" height="11" font="12">9.10. Aortic Disease</text>
<text top="336" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="353" left="123" width="319" height="12" font="2">Thoracic aortic aneurysms are generally asymptomatic</text>
<text top="371" left="108" width="333" height="12" font="2">until a person presents with a sudden catastrophic event,</text>
<text top="389" left="108" width="333" height="12" font="2">such as an aortic dissection or rupture, which is rapidly</text>
<text top="407" left="108" width="197" height="12" font="2">fatal in the majority of patients</text>
<text top="407" left="312" width="97" height="12" font="5"><a href="e127.full.html#105">(S9.10-3,S9.10-4)</a></text>
<text top="407" left="409" width="32" height="12" font="2"><a href="e127.full.html#105">. </a>The</text>
<text top="425" left="108" width="333" height="12" font="2">rationale for antihypertensive therapy is based largely on</text>
<text top="443" left="108" width="333" height="12" font="2">animal and observational studies associating hypertension</text>
<text top="461" left="108" width="126" height="12" font="2">with aortic dissection</text>
<text top="461" left="238" width="96" height="12" font="5"><a href="e127.full.html#105">(S9.10-5,S9.10-6)</a></text>
<text top="461" left="335" width="71" height="12" font="2"><a href="e127.full.html#105">. </a>RCTs speci</text>
<text top="459" left="406" width="35" height="15" font="2">ﬁcally</text>
<text top="479" left="108" width="333" height="12" font="2">addressing hypertension and aortic disease are not avail-</text>
<text top="497" left="108" width="333" height="12" font="2">able, and trials in patients with primary hypertension do</text>
<text top="515" left="108" width="333" height="12" font="2">not provide insight on either the optimal BP target or</text>
<text top="533" left="108" width="333" height="12" font="2">choice of antihypertensive drug therapy in patients with</text>
<text top="551" left="108" width="333" height="12" font="2">thoracic aortic aneurysm, aortic dissection, or aortic dis-</text>
<text top="569" left="108" width="25" height="12" font="2">ease</text>
<text top="569" left="137" width="96" height="12" font="5"><a href="e127.full.html#105">(S9.10-7,S9.10-8)</a></text>
<text top="569" left="234" width="207" height="12" font="2"><a href="e127.full.html#105">. </a>A study in 20 humans with hyper-</text>
<text top="587" left="108" width="333" height="12" font="2">tension suggested that hypertension is associated with</text>
<text top="605" left="108" width="27" height="12" font="2">signi</text>
<text top="603" left="135" width="306" height="15" font="2">ﬁcant changes in the mechanical properties of the</text>
<text top="622" left="108" width="333" height="12" font="2">aortic wall, with more strain-induced stiffening in hyper-</text>
<text top="640" left="108" width="43" height="12" font="2">tension</text>
<text top="640" left="163" width="26" height="12" font="2">than</text>
<text top="640" left="201" width="11" height="12" font="2">in</text>
<text top="640" left="224" width="85" height="12" font="2">normotension,</text>
<text top="640" left="321" width="35" height="12" font="2">which</text>
<text top="640" left="368" width="24" height="12" font="2">may</text>
<text top="640" left="405" width="11" height="12" font="2">re</text>
<text top="639" left="416" width="25" height="15" font="2">ﬂect</text>
<text top="658" left="108" width="333" height="12" font="2">destruction of elastin and predisposition to aortic dissec-</text>
<text top="676" left="108" width="212" height="12" font="2">tion in the presence of hypertension</text>
<text top="676" left="324" width="51" height="12" font="5"><a href="e127.full.html#105">(S9.10-9)</a></text>
<text top="676" left="375" width="66" height="12" font="2"><a href="e127.full.html#105">. </a>In a retro-</text>
<text top="694" left="108" width="333" height="12" font="2">spective observational study, high BP variability was an</text>
<text top="712" left="108" width="333" height="12" font="2">independent risk factor for the prognosis of aortic dissec-</text>
<text top="730" left="108" width="23" height="12" font="2">tion</text>
<text top="730" left="135" width="57" height="12" font="5"><a href="e127.full.html#105">(S9.10-10)</a></text>
<text top="730" left="192" width="249" height="12" font="2"><a href="e127.full.html#105">. </a>Recommendations for treatment of acute</text>
<text top="748" left="108" width="186" height="12" font="2">aortic dissection are provided in</text>
<text top="748" left="298" width="66" height="12" font="5"><a href="e127.full.html#68">Section 11.2</a></text>
<text top="748" left="364" width="3" height="12" font="2">.</text>
<text top="775" left="108" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="773" left="247" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="802" left="108" width="333" height="12" font="2">1. In patients with chronic aortic dissection, observational</text>
<text top="820" left="122" width="319" height="12" font="2">studies suggest lower risk for operative repair with</text>
<text top="838" left="122" width="122" height="12" font="2">beta-blocker therapy</text>
<text top="838" left="250" width="49" height="12" font="5"><a href="e127.full.html#105">(S9.10-1)</a></text>
<text top="838" left="299" width="142" height="12" font="2"><a href="e127.full.html#105">. </a>In a series of patients</text>
<text top="856" left="122" width="319" height="12" font="2">with type A and type B aortic dissections, beta blockers</text>
<text top="874" left="122" width="319" height="12" font="2">were associated with improved survival in both groups,</text>
<text top="891" left="122" width="319" height="12" font="2">whereas ACE inhibitors did not improve survival</text>
<text top="909" left="122" width="50" height="12" font="5"><a href="e127.full.html#105">(S9.10-2)</a></text>
<text top="909" left="172" width="3" height="12" font="2"><a href="e127.full.html#105">.</a></text>
<text top="948" left="108" width="205" height="16" font="14">10. SPECIAL PATIENT GROUPS</text>
<text top="986" left="108" width="208" height="12" font="2">Special attention is needed for speci</text>
<text top="984" left="316" width="125" height="15" font="2">ﬁc patient subgroups.</text>
<text top="1018" left="108" width="127" height="11" font="12">10.1. Race and Ethnicity</text>
<text top="1039" left="108" width="333" height="12" font="2">In the United States, at any decade of life, blacks have a</text>
<text top="1057" left="108" width="333" height="12" font="2">higher prevalence of hypertension than that of Hispanic</text>
<text top="1075" left="108" width="333" height="12" font="2">Americans, whites, Native Americans, and other sub-</text>
<text top="1093" left="108" width="59" height="12" font="2">groups de</text>
<text top="1091" left="167" width="194" height="15" font="2">ﬁned by race and ethnicity (see</text>
<text top="1093" left="368" width="65" height="12" font="5"><a href="e127.full.html#12">Section 3.3</a></text>
<text top="1093" left="433" width="8" height="12" font="2">).</text>
<text top="336" left="468" width="333" height="12" font="2">Hypertension control rates are lower for blacks, Hispanic</text>
<text top="353" left="468" width="279" height="12" font="2">Americans, and Asian Americans than for whites</text>
<text top="353" left="750" width="47" height="12" font="5"><a href="e127.full.html#105">(S10.1-1)</a></text>
<text top="353" left="798" width="3" height="12" font="2"><a href="e127.full.html#105">.</a></text>
<text top="371" left="468" width="333" height="12" font="2">Among men with hypertension, non-Hispanic white</text>
<text top="389" left="468" width="333" height="12" font="2">(53.8%) adults had a higher prevalence of controlled high</text>
<text top="407" left="468" width="333" height="12" font="2">blood pressure than did non-Hispanic black (43.8%), non-</text>
<text top="425" left="468" width="333" height="12" font="2">Hispanic Asian (39.9%), and Hispanic (43.5%) adults. For</text>
<text top="443" left="468" width="333" height="12" font="2">women with hypertension, the percentage of non-</text>
<text top="461" left="468" width="333" height="12" font="2">Hispanic white (59.1%) adults with controlled high blood</text>
<text top="479" left="468" width="333" height="12" font="2">pressure was higher than among non-Hispanic black</text>
<text top="497" left="468" width="278" height="12" font="2">(52.3%) and non-Hispanic Asian (46.8%) adults</text>
<text top="497" left="750" width="47" height="12" font="5"><a href="e127.full.html#105">(S10.1-1)</a></text>
<text top="497" left="798" width="3" height="12" font="2"><a href="e127.full.html#105">.</a></text>
<text top="515" left="468" width="333" height="12" font="2">In Hispanic Americans, the lower control rates result</text>
<text top="533" left="468" width="290" height="12" font="2">primarily from lack of awareness and treatment</text>
<text top="533" left="764" width="38" height="12" font="5"><a href="e127.full.html#105">(S10.1-</a></text>
<text top="551" left="468" width="54" height="12" font="5"><a href="e127.full.html#105">2,S10.1-3)</a></text>
<text top="551" left="522" width="279" height="12" font="2">, whereas in blacks, awareness and treatment</text>
<text top="569" left="468" width="333" height="12" font="2">are at least as high as in whites, but hypertension is more</text>
<text top="587" left="468" width="333" height="12" font="2">severe and some agents are less effective at BP control</text>
<text top="605" left="468" width="49" height="12" font="5"><a href="e127.full.html#105">(S10.1-4)</a></text>
<text top="605" left="517" width="284" height="12" font="2">. Morbidity and mortality attributed to hyper-</text>
<text top="622" left="468" width="333" height="12" font="2">tension are also more common in blacks and Hispanic</text>
<text top="640" left="468" width="333" height="12" font="2">Americans than in whites. Blacks have a 1.3-times greater</text>
<text top="658" left="468" width="333" height="12" font="2">risk of nonfatal stroke, 1.8-times greater risk of fatal</text>
<text top="676" left="468" width="333" height="12" font="2">strokes, 1.5-times greater risk of HF, and 4.2-times greater</text>
<text top="694" left="468" width="77" height="12" font="2">risk of ESRD</text>
<text top="694" left="551" width="49" height="12" font="5"><a href="e127.full.html#105">(S10.1-4)</a></text>
<text top="694" left="601" width="200" height="12" font="2"><a href="e127.full.html#105">. </a>Hispanic Americans have lower</text>
<text top="712" left="468" width="333" height="12" font="2">rates of hypertension awareness and treatment than</text>
<text top="730" left="468" width="333" height="12" font="2">those of whites and blacks, as well as a high prevalence of</text>
<text top="748" left="468" width="333" height="12" font="2">comorbid CVD risk factors (e.g., obesity, DM). In 2014,</text>
<text top="766" left="468" width="333" height="12" font="2">age-adjusted hypertension-attributable mortality rates</text>
<text top="784" left="468" width="333" height="12" font="2">per 1,000 persons for non-Hispanic white, non-Hispanic</text>
<text top="802" left="468" width="333" height="12" font="2">black, and Hispanic-American men and women were</text>
<text top="820" left="468" width="333" height="12" font="2">19.3 and 15.8, 50.1 and 35.6, and 19.1 and 14.6, respectively</text>
<text top="838" left="468" width="48" height="12" font="5"><a href="e127.full.html#105">(S10.1-5)</a></text>
<text top="838" left="516" width="285" height="12" font="2">. However, Hispanics in the United States are a</text>
<text top="856" left="468" width="333" height="12" font="2">heterogeneous subgroup, and rates of both hypertension</text>
<text top="874" left="468" width="333" height="12" font="2">and its consequences vary according to whether their</text>
<text top="891" left="468" width="333" height="12" font="2">ancestry is from the Caribbean, Mexico, Central or South</text>
<text top="909" left="468" width="121" height="12" font="2">America, or Europe</text>
<text top="909" left="598" width="44" height="12" font="5"><a href="e127.full.html#105">(S10.1-6</a></text>
<text top="908" left="643" width="54" height="15" font="5"><a href="e127.full.html#105">—S10.1-8)</a></text>
<text top="909" left="697" width="104" height="12" font="2">. Hispanics from</text>
<text top="927" left="468" width="333" height="12" font="2">Mexico and Central America have lower CVD rates than</text>
<text top="945" left="468" width="333" height="12" font="2">U.S. whites, whereas those of Caribbean origin have</text>
<text top="963" left="468" width="333" height="12" font="2">higher rates. Thus, pooling of data for Hispanics may not</text>
<text top="981" left="468" width="78" height="12" font="2">accurately re</text>
<text top="979" left="546" width="255" height="15" font="2">ﬂect risk in a given patient. Finally, the</text>
<text top="999" left="468" width="333" height="12" font="2">excess risk of CKD outcomes in at least some blacks with</text>
<text top="1017" left="468" width="333" height="12" font="2">hypertension may be due to the presence of high-risk</text>
<text top="1035" left="468" width="270" height="12" font="2">APOL1 (apolipoprotein L1) genetic variants</text>
<text top="1035" left="747" width="45" height="12" font="5"><a href="e127.full.html#105">(S10.1-9</a></text>
<text top="1033" left="792" width="9" height="15" font="5"><a href="e127.full.html#105">—</a></text>
<text top="1053" left="468" width="48" height="12" font="5"><a href="e127.full.html#105">S10.1-11)</a></text>
<text top="1053" left="516" width="285" height="12" font="2">. The rate of renal decline associated with this</text>
<text top="1071" left="468" width="333" height="12" font="2">genotype appears to be largely unresponsive to either BP</text>
<text top="1089" left="468" width="155" height="12" font="2">lowering or RAS inhibition</text>
<text top="1089" left="627" width="45" height="12" font="5"><a href="e127.full.html#105">(S10.1-9</a></text>
<text top="1087" left="672" width="58" height="15" font="5"><a href="e127.full.html#105">—S10.1-12)</a></text>
<text top="1089" left="730" width="3" height="12" font="2">.</text>
<text top="179" left="63" width="465" height="11" font="19">Recommendation for Management of Hypertension in Patients With Aortic Disease</text>
<text top="220" left="89" width="19" height="10" font="13">COR</text>
<text top="220" left="161" width="18" height="10" font="13">LOE</text>
<text top="220" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="257" left="97" width="3" height="9" font="4">I</text>
<text top="257" left="160" width="20" height="9" font="4">C-EO</text>
<text top="245" left="234" width="564" height="11" font="12">1. Beta blockers are recommended as the preferred antihypertensive agents in patients with hypertension</text>
<text top="261" left="246" width="142" height="11" font="12">and thoracic aortic disease</text>
<text top="261" left="392" width="93" height="11" font="5"><a href="e127.full.html#105">(S9.10-1,S9.10-2)</a></text>
<text top="261" left="486" width="3" height="11" font="12"><a href="e127.full.html#105">.</a></text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="20" height="9" font="4">e188</text>
</page>
<page number="63" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="259" height="11" font="2">10.1.1. Racial and Ethnic Differences in Treatment</text>
<text top="408" left="63" width="52" height="12" font="2">Synopsis</text>
<text top="426" left="78" width="85" height="12" font="2">Lifestyle modi</text>
<text top="424" left="163" width="233" height="15" font="2">ﬁcation (i.e., weight reduction, dietary</text>
<text top="444" left="63" width="29" height="12" font="2">modi</text>
<text top="442" left="93" width="304" height="15" font="2">ﬁcation, and increased physical activity) is particu-</text>
<text top="462" left="63" width="333" height="12" font="2">larly important in blacks and Hispanic Americans for</text>
<text top="480" left="63" width="90" height="12" font="2">prevention and</text>
<text top="478" left="157" width="239" height="15" font="2">ﬁrst-line or adjunctive therapy of hyper-</text>
<text top="498" left="63" width="74" height="12" font="2">tension (see</text>
<text top="498" left="145" width="153" height="12" font="5"><a href="">Sections 12.1.2 </a>and <a href="e127.full.html#76">12.1.3</a></text>
<text top="498" left="298" width="98" height="12" font="2">). However, the</text>
<text top="516" left="63" width="333" height="12" font="2">adoption of lifestyle recommendations is often chal-</text>
<text top="534" left="63" width="333" height="12" font="2">lenging in ethnic minority patients because of poor social</text>
<text top="551" left="63" width="333" height="12" font="2">support, limited access to exercise opportunities and</text>
<text top="569" left="63" width="111" height="12" font="2">healthy foods, and</text>
<text top="568" left="179" width="217" height="15" font="2">ﬁnancial considerations. The greater</text>
<text top="587" left="63" width="333" height="12" font="2">prevalence of lower socioeconomic status may impede</text>
<text top="605" left="63" width="202" height="12" font="2">access to basic living necessities</text>
<text top="605" left="272" width="58" height="12" font="5"><a href="e127.full.html#106">(S10.1.1-8)</a></text>
<text top="605" left="330" width="66" height="12" font="2">, including</text>
<text top="623" left="63" width="333" height="12" font="2">medical care and medications. Consideration must also be</text>
<text top="641" left="63" width="333" height="12" font="2">given to learning styles and preference, personal beliefs,</text>
<text top="659" left="63" width="112" height="12" font="2">values, and culture</text>
<text top="659" left="179" width="117" height="12" font="5"><a href="e127.full.html#106">(S10.1.1-9,S10.1.1-10)</a></text>
<text top="659" left="297" width="3" height="12" font="2"><a href="e127.full.html#106">.</a></text>
<text top="677" left="78" width="318" height="12" font="2">The principles of antihypertensive drug selection dis-</text>
<text top="695" left="63" width="57" height="12" font="2">cussed in</text>
<text top="695" left="127" width="169" height="12" font="5"><a href="e127.full.html#38">Sections 8.1.4 through 8.1.6</a></text>
<text top="695" left="303" width="93" height="12" font="2">apply to ethnic</text>
<text top="713" left="63" width="333" height="12" font="2">minorities with a few caveats. In blacks, thiazide-type</text>
<text top="731" left="63" width="333" height="12" font="2">diuretics and CCBs are more effective in lowering BP</text>
<text top="749" left="63" width="333" height="12" font="2">when given as monotherapy or as initial agents in multi-</text>
<text top="767" left="63" width="27" height="12" font="2">drug</text>
<text top="767" left="105" width="53" height="12" font="2">regimens</text>
<text top="767" left="173" width="57" height="12" font="5"><a href="e127.full.html#106">(S10.1.1-11</a></text>
<text top="765" left="230" width="67" height="15" font="5"><a href="e127.full.html#106">—S10.1.1-13)</a></text>
<text top="767" left="298" width="3" height="12" font="2">.</text>
<text top="767" left="317" width="12" height="12" font="2">In</text>
<text top="767" left="344" width="52" height="12" font="2">addition,</text>
<text top="785" left="63" width="333" height="12" font="2">thiazide-type agents are superior to drugs that inhibit the</text>
<text top="802" left="63" width="333" height="12" font="2">RAS (i.e., ACE inhibitors, ARBs, renin inhibitors, and beta</text>
<text top="820" left="63" width="333" height="12" font="2">blockers) for prevention of selected clinical outcomes in</text>
<text top="838" left="63" width="36" height="12" font="2">blacks</text>
<text top="838" left="112" width="112" height="12" font="5"><a href="e127.full.html#105">(S10.1.1-2,S10.1.1-14</a></text>
<text top="837" left="225" width="68" height="15" font="5"><a href="e127.full.html#105">—S10.1.1-16)</a></text>
<text top="838" left="293" width="3" height="12" font="2">.</text>
<text top="838" left="310" width="19" height="12" font="2">For</text>
<text top="838" left="343" width="53" height="12" font="2">optimum</text>
<text top="856" left="63" width="333" height="12" font="2">endpoint protection, the thiazide chlorthalidone should</text>
<text top="874" left="63" width="314" height="12" font="2">be administered at a dose of 12.5 to 25 mg/day (or 25</text>
<text top="872" left="377" width="19" height="15" font="2">–50</text>
<text top="892" left="63" width="333" height="12" font="2">mg/d for hydrochlorothiazide) because lower doses are</text>
<text top="910" left="63" width="333" height="12" font="2">either unproven or less effective in clinical outcome trials</text>
<text top="928" left="63" width="116" height="12" font="5"><a href="e127.full.html#105">(S10.1.1-2,S10.1.1-16)</a></text>
<text top="928" left="179" width="217" height="12" font="2">. The CCB amlodipine is as effective</text>
<text top="946" left="63" width="333" height="12" font="2">as chlorthalidone and more effective than the ACE in-</text>
<text top="964" left="63" width="333" height="12" font="2">hibitor lisinopril in reducing BP, CVD, and stroke events</text>
<text top="982" left="63" width="333" height="12" font="2">but less effective in preventing HF. Blacks have a greater</text>
<text top="1000" left="63" width="230" height="12" font="2">risk of angioedema with ACE inhibitors</text>
<text top="1000" left="297" width="100" height="12" font="5"><a href="e127.full.html#105">(S10.1.1-2,S10.1.1-</a></text>
<text top="1018" left="63" width="10" height="12" font="5"><a href="e127.full.html#105">3)</a></text>
<text top="1018" left="73" width="323" height="12" font="2">, and Asian Americans have a higher incidence of ACE</text>
<text top="1036" left="63" width="50" height="12" font="2">inhibitor</text>
<text top="1034" left="113" width="93" height="15" font="2">–induced cough</text>
<text top="1036" left="212" width="63" height="12" font="5"><a href="e127.full.html#106">(S10.1.1-17)</a></text>
<text top="1036" left="275" width="121" height="12" font="2"><a href="e127.full.html#106">. </a>ACE inhibitors and</text>
<text top="1054" left="63" width="333" height="12" font="2">ARBs are recommended more generally as components of</text>
<text top="1071" left="63" width="333" height="12" font="2">multidrug antihypertensive regimens in blacks with CKD</text>
<text top="1089" left="63" width="23" height="12" font="2">(see</text>
<text top="1089" left="92" width="65" height="12" font="5"><a href="e127.full.html#49">Section 9.3</a></text>
<text top="1089" left="158" width="239" height="12" font="2"><a href="e127.full.html#49">), </a>with the addition of beta blockers in</text>
<text top="408" left="423" width="115" height="12" font="2">those with HF (see</text>
<text top="408" left="545" width="66" height="12" font="5"><a href="e127.full.html#47">Section 9.2</a></text>
<text top="408" left="611" width="146" height="12" font="2"><a href="e127.full.html#47">). </a>Beta blockers are rec-</text>
<text top="426" left="423" width="333" height="12" font="2">ommended for treatment of patients with CHD who have</text>
<text top="444" left="423" width="333" height="12" font="2">had a MI. Most patients with hypertension, especially</text>
<text top="462" left="423" width="86" height="12" font="2">blacks, require</text>
<text top="460" left="515" width="242" height="15" font="2">$2 antihypertensive medications to ach-</text>
<text top="480" left="423" width="333" height="12" font="2">ieve adequate BP control. A single-tablet combination</text>
<text top="498" left="423" width="333" height="12" font="2">that includes either a diuretic or a CCB may be particularly</text>
<text top="516" left="423" width="333" height="12" font="2">effective in achieving BP control in blacks. Racial and</text>
<text top="534" left="423" width="333" height="12" font="2">ethnic differences should not be the basis for excluding</text>
<text top="551" left="423" width="333" height="12" font="2">any class of antihypertensive agent in combination</text>
<text top="569" left="423" width="48" height="12" font="2">therapy.</text>
<text top="599" left="423" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="597" left="562" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="626" left="425" width="332" height="12" font="2">1. In blacks, thiazide diuretics or CCBs are more effective</text>
<text top="644" left="438" width="318" height="12" font="2">in lowering BP than are RAS inhibitors or beta blockers</text>
<text top="662" left="438" width="318" height="12" font="2">and more effective in reducing CVD events than are</text>
<text top="680" left="438" width="318" height="12" font="2">RAS inhibitors or alpha blockers. RAS inhibitors are</text>
<text top="698" left="438" width="318" height="12" font="2">recommended in black patients with hypertension,</text>
<text top="716" left="438" width="318" height="12" font="2">DM, and nephropathy, but they offer no advantage</text>
<text top="734" left="438" width="318" height="12" font="2">over diuretics or CCBs in hypertensive patients with</text>
<text top="752" left="438" width="188" height="12" font="2">DM without nephropathy or HF.</text>
<text top="770" left="423" width="333" height="12" font="2">2. Four drug classes (thiazide diuretic, CCB, ACE inhibi-</text>
<text top="788" left="438" width="318" height="12" font="2">tor, or ARB) lower BP and reduce cardiovascular or</text>
<text top="805" left="438" width="88" height="12" font="2">renal outcomes</text>
<text top="805" left="529" width="59" height="12" font="5"><a href="e127.full.html#106">(S10.1.1-18</a></text>
<text top="804" left="589" width="67" height="15" font="5"><a href="e127.full.html#106">—S10.1.1-21)</a></text>
<text top="805" left="657" width="100" height="12" font="2"><a href="e127.full.html#106">. </a>Thus, except for</text>
<text top="823" left="438" width="318" height="12" font="2">the combination of ACE inhibitors and ARBs, regimens</text>
<text top="841" left="438" width="318" height="12" font="2">containing a combination of these classes are reason-</text>
<text top="859" left="438" width="185" height="12" font="2">able to achieve the BP target</text>
<text top="859" left="631" width="122" height="12" font="5"><a href="e127.full.html#106">(S10.1.1-16,S10.1.1-21)</a></text>
<text top="859" left="753" width="3" height="12" font="2"><a href="e127.full.html#106">.</a></text>
<text top="877" left="438" width="318" height="12" font="2">Furthermore, the combination of an ACE inhibitor or</text>
<text top="895" left="438" width="318" height="12" font="2">ARB with a CCB or thiazide diuretic produces similar BP</text>
<text top="913" left="438" width="318" height="12" font="2">lowering in blacks as in other racial or ethnic groups.</text>
<text top="931" left="438" width="318" height="12" font="2">For blacks who do not achieve control with 3 drugs, see</text>
<text top="949" left="438" width="158" height="12" font="2">resistant hypertension (see</text>
<text top="949" left="600" width="66" height="12" font="5"><a href="e127.full.html#67">Section 11.1</a></text>
<text top="949" left="666" width="8" height="12" font="2">).</text>
<text top="978" left="423" width="129" height="11" font="12">10.2. Sex-Related Issues</text>
<text top="1000" left="423" width="333" height="12" font="2">The prevalence of hypertension is lower in women than in</text>
<text top="1018" left="423" width="116" height="12" font="2">men until about the</text>
<text top="1016" left="543" width="214" height="15" font="2">ﬁfth decade but is higher later in life</text>
<text top="1036" left="423" width="48" height="12" font="5"><a href="e127.full.html#106">(S10.2-1)</a></text>
<text top="1036" left="472" width="285" height="12" font="2"><a href="e127.full.html#106">. </a>Other than special recommendations for man-</text>
<text top="1054" left="423" width="333" height="12" font="2">agement of hypertension during pregnancy, there is no</text>
<text top="1072" left="423" width="333" height="12" font="2">evidence that the BP threshold for initiating drug treat-</text>
<text top="1090" left="423" width="34" height="12" font="2">ment,</text>
<text top="1090" left="469" width="19" height="12" font="2">the</text>
<text top="1090" left="500" width="57" height="12" font="2">treatment</text>
<text top="1090" left="569" width="38" height="12" font="2">target,</text>
<text top="1090" left="619" width="19" height="12" font="2">the</text>
<text top="1090" left="650" width="37" height="12" font="2">choice</text>
<text top="1090" left="699" width="11" height="12" font="2">of</text>
<text top="1090" left="722" width="34" height="12" font="2">initial</text>
<text top="185" left="63" width="229" height="11" font="19">Recommendations for Race and Ethnicity</text>
<text top="199" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="199" left="412" width="151" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 51</a></text>
<text top="199" left="564" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="240" left="89" width="19" height="10" font="13">COR</text>
<text top="240" left="161" width="18" height="10" font="13">LOE</text>
<text top="240" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="277" left="97" width="3" height="9" font="4">I</text>
<text top="277" left="163" width="15" height="9" font="4">B-R</text>
<text top="265" left="234" width="568" height="11" font="12">1. In black adults with hypertension but without HF or CKD, including those with DM, initial antihypertensive</text>
<text top="280" left="246" width="301" height="11" font="12">treatment should include a thiazide-type diuretic or CCB</text>
<text top="280" left="552" width="50" height="11" font="5"><a href="e127.full.html#105">(S10.1.1-1</a></text>
<text top="278" left="603" width="61" height="15" font="5"><a href="e127.full.html#105">—S10.1.1-4)</a></text>
<text top="280" left="664" width="3" height="11" font="12"><a href="e127.full.html#105">.</a></text>
<text top="325" left="97" width="3" height="9" font="4">I</text>
<text top="325" left="160" width="20" height="9" font="4">C-LD</text>
<text top="313" left="234" width="529" height="11" font="12">2. Two or more antihypertensive medications are recommended to achieve a BP target of less than</text>
<text top="328" left="248" width="501" height="11" font="12">130/80 mm Hg in most adults with hypertension, especially in black adults with hypertension</text>
<text top="344" left="248" width="52" height="11" font="5"><a href="e127.full.html#105">(S10.1.1-5</a></text>
<text top="342" left="300" width="60" height="15" font="5"><a href="e127.full.html#105">—S10.1.1-7)</a></text>
<text top="344" left="360" width="3" height="11" font="12"><a href="e127.full.html#105">.</a></text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="788" width="20" height="9" font="4">e189</text>
</page>
<page number="64" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="333" height="12" font="2">antihypertensive medication, or the combination of</text>
<text top="161" left="108" width="333" height="12" font="2">medications for lowering BP differs for women versus</text>
<text top="178" left="108" width="25" height="12" font="2">men</text>
<text top="178" left="137" width="94" height="12" font="5"><a href="e127.full.html#106">(S10.2-2,S10.2-3)</a></text>
<text top="178" left="231" width="3" height="12" font="2">.</text>
<text top="214" left="108" width="77" height="11" font="2">10.2.1. Women</text>
<text top="235" left="108" width="333" height="12" font="2">A potential limitation of RCTs, including SPRINT, is that</text>
<text top="253" left="108" width="100" height="12" font="2">they are not speci</text>
<text top="252" left="208" width="233" height="15" font="2">ﬁcally powered to determine the value of</text>
<text top="271" left="108" width="333" height="12" font="2">intensive SBP reduction in subgroups, including women in</text>
<text top="289" left="108" width="252" height="12" font="2">the case of SPRINT. However, in prespeci</text>
<text top="287" left="360" width="81" height="15" font="2">ﬁed analyses,</text>
<text top="307" left="108" width="333" height="12" font="2">there was no evidence of an interaction between sex and</text>
<text top="325" left="108" width="232" height="12" font="2">treatment effect. Furthermore, no signi</text>
<text top="323" left="340" width="101" height="15" font="2">ﬁcant differences</text>
<text top="343" left="108" width="333" height="12" font="2">in CVD outcomes were observed between men and women</text>
<text top="361" left="108" width="333" height="12" font="2">in a large meta-analysis that included 31 RCTs with about</text>
<text top="379" left="108" width="333" height="12" font="2">100,000 men and 90,000 women with hypertension</text>
<text top="397" left="108" width="57" height="12" font="5"><a href="e127.full.html#106">(S10.2.1-1)</a></text>
<text top="397" left="165" width="276" height="12" font="2">. Some have called for a SPRINT-like trial with</text>
<text top="415" left="108" width="18" height="12" font="2">suf</text>
<text top="413" left="126" width="315" height="15" font="2">ﬁcient power to assess the effects of intensive SBP</text>
<text top="433" left="108" width="121" height="12" font="2">reduction in women</text>
<text top="433" left="234" width="58" height="12" font="5"><a href="e127.full.html#106">(S10.2.1-2)</a></text>
<text top="433" left="292" width="149" height="12" font="2">. In meta-analyses, there</text>
<text top="451" left="108" width="333" height="12" font="2">was no convincing evidence that different antihyperten-</text>
<text top="469" left="108" width="333" height="12" font="2">sive drug classes exerted sex-related differences in BP</text>
<text top="486" left="108" width="267" height="12" font="2">lowering or provided distinct CVD protection</text>
<text top="486" left="380" width="57" height="12" font="5"><a href="e127.full.html#106">(S10.2.1-1)</a></text>
<text top="486" left="437" width="3" height="12" font="2">.</text>
<text top="504" left="108" width="293" height="12" font="2">Calcium antagonists offered slightly greater bene</text>
<text top="503" left="401" width="40" height="15" font="2">ﬁts for</text>
<text top="522" left="108" width="333" height="12" font="2">stroke prevention than did ACE inhibitors for women than</text>
<text top="540" left="108" width="333" height="12" font="2">for men, whereas calcium antagonists reduced all-cause</text>
<text top="143" left="468" width="333" height="12" font="2">deaths compared with placebo in men but not in women.</text>
<text top="161" left="468" width="333" height="12" font="2">However, these sex-related differences might have been</text>
<text top="178" left="468" width="333" height="12" font="2">due to chance because of the large number of statistical</text>
<text top="196" left="468" width="333" height="12" font="2">comparisons that were performed. The Heart Attack Trial</text>
<text top="214" left="468" width="333" height="12" font="2">and Hypertension Care Computing Project reported that</text>
<text top="232" left="468" width="333" height="12" font="2">beta blockers were associated with reduced mortality in</text>
<text top="250" left="468" width="186" height="12" font="2">men but not in women, but this</text>
<text top="248" left="657" width="144" height="15" font="2">ﬁnding was likely due to</text>
<text top="268" left="468" width="172" height="12" font="2">the low event rates in women</text>
<text top="268" left="643" width="58" height="12" font="5"><a href="e127.full.html#106">(S10.2.1-3)</a></text>
<text top="268" left="702" width="99" height="12" font="2"><a href="e127.full.html#106">. </a>Similarly, in the</text>
<text top="286" left="468" width="333" height="12" font="2">open-label Second Australian National BP study, a signif-</text>
<text top="304" left="468" width="333" height="12" font="2">icant reduction in CVD events was demonstrated in men</text>
<text top="322" left="468" width="333" height="12" font="2">but not in women with ACE inhibitors versus diuretics</text>
<text top="340" left="468" width="59" height="12" font="5"><a href="e127.full.html#106">(S10.2.1-4)</a></text>
<text top="340" left="528" width="3" height="12" font="2"><a href="e127.full.html#106">.</a></text>
<text top="358" left="483" width="318" height="12" font="2">Adverse effects of antihypertensive therapy were</text>
<text top="376" left="468" width="333" height="12" font="2">noted twice as often in women as in men in the TOMHS</text>
<text top="394" left="468" width="32" height="12" font="2">study</text>
<text top="394" left="507" width="58" height="12" font="5"><a href="e127.full.html#106">(S10.2.1-5)</a></text>
<text top="394" left="566" width="230" height="12" font="2"><a href="e127.full.html#106">. </a>A higher incidence of ACE inhibitor</text>
<text top="392" left="796" width="5" height="15" font="2">–</text>
<text top="412" left="468" width="333" height="12" font="2">induced cough and of edema with calcium antagonists</text>
<text top="430" left="468" width="217" height="12" font="2">was observed in women than in men</text>
<text top="430" left="690" width="59" height="12" font="5"><a href="e127.full.html#106">(S10.2.1-6)</a></text>
<text top="430" left="749" width="52" height="12" font="2">. Women</text>
<text top="447" left="468" width="333" height="12" font="2">were more likely to experience hypokalemia and hypo-</text>
<text top="465" left="468" width="333" height="12" font="2">natremia and less likely to experience gout with diuretics</text>
<text top="483" left="468" width="58" height="12" font="5"><a href="e127.full.html#106">(S10.2.1-7)</a></text>
<text top="483" left="526" width="275" height="12" font="2">. Hypertension in pregnancy has special re-</text>
<text top="501" left="468" width="93" height="12" font="2">quirements (see</text>
<text top="501" left="565" width="80" height="12" font="5"><a href="e127.full.html#64">Section 10.2.2</a></text>
<text top="501" left="645" width="8" height="12" font="2"><a href="e127.full.html#64">).</a></text>
<text top="541" left="468" width="94" height="11" font="2">10.2.2. Pregnancy</text>
<text top="589" left="63" width="355" height="11" font="19">Recommendations for Treatment of Hypertension in Pregnancy</text>
<text top="604" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="604" left="412" width="152" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 53</a></text>
<text top="604" left="565" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="645" left="89" width="19" height="10" font="13">COR</text>
<text top="645" left="161" width="18" height="10" font="13">LOE</text>
<text top="645" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="681" left="97" width="3" height="9" font="4">I</text>
<text top="681" left="160" width="20" height="9" font="4">C-LD</text>
<text top="669" left="234" width="534" height="11" font="12">1. Women with hypertension who become pregnant, or are planning to become pregnant, should be</text>
<text top="685" left="246" width="298" height="11" font="12">transitioned to methyldopa, nifedipine, and/or labetalol</text>
<text top="685" left="549" width="57" height="11" font="5"><a href="e127.full.html#106">(S10.2.2-1)</a></text>
<text top="685" left="610" width="93" height="11" font="12">during pregnancy</text>
<text top="701" left="246" width="54" height="11" font="5"><a href="e127.full.html#106">(S10.2.2-2</a></text>
<text top="699" left="301" width="64" height="15" font="5"><a href="e127.full.html#106">—S10.2.2-6)</a></text>
<text top="701" left="365" width="3" height="11" font="12">.</text>
<text top="745" left="81" width="35" height="9" font="4">III: Harm</text>
<text top="745" left="160" width="20" height="9" font="4">C-LD</text>
<text top="733" left="234" width="554" height="11" font="12">2. Women with hypertension who become pregnant should not be treated with ACE inhibitors, ARBs, or</text>
<text top="749" left="248" width="115" height="11" font="12">direct renin inhibitors</text>
<text top="749" left="367" width="55" height="11" font="5"><a href="e127.full.html#106">(S10.2.2-4</a></text>
<text top="747" left="422" width="64" height="15" font="5"><a href="e127.full.html#106">—S10.2.2-6)</a></text>
<text top="749" left="486" width="3" height="11" font="12">.</text>
<text top="817" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="835" left="123" width="183" height="12" font="2">BP usually declines during the</text>
<text top="833" left="311" width="133" height="15" font="2">ﬁrst trimester of preg-</text>
<text top="853" left="108" width="336" height="12" font="2">nancy and then slowly rises. Hypertension management</text>
<text top="871" left="108" width="336" height="12" font="2">during pregnancy includes 4 general areas: 1) the newly</text>
<text top="889" left="108" width="336" height="12" font="2">pregnant mother with existing hypertension; 2) incident</text>
<text top="907" left="108" width="336" height="12" font="2">hypertension; 3) preeclampsia (a dangerous form of hy-</text>
<text top="925" left="108" width="336" height="12" font="2">pertension with proteinuria that has the potential to result</text>
<text top="942" left="108" width="336" height="12" font="2">in serious adverse consequences for the mother [stroke,</text>
<text top="960" left="108" width="336" height="12" font="2">HF] and fetus [small for gestational age, premature birth]);</text>
<text top="978" left="108" width="336" height="12" font="2">and 4) severe hypertension, often in the setting of pre-</text>
<text top="996" left="108" width="336" height="12" font="2">eclampsia, requiring urgent treatment to prevent HF,</text>
<text top="1014" left="108" width="336" height="12" font="2">stroke, and adverse fetal outcomes. Hypertension during</text>
<text top="1032" left="108" width="336" height="12" font="2">pregnancy and preeclampsia are recognized as risk factors</text>
<text top="1050" left="108" width="190" height="12" font="2">for future hypertension and CVD</text>
<text top="1050" left="301" width="55" height="12" font="5"><a href="e127.full.html#106">(S10.2.2-7</a></text>
<text top="1048" left="356" width="65" height="15" font="5"><a href="e127.full.html#106">—S10.2.2-9)</a></text>
<text top="1050" left="422" width="22" height="12" font="2"><a href="e127.full.html#106">. </a>BP</text>
<text top="1068" left="108" width="336" height="12" font="2">management during pregnancy is complicated by the fact</text>
<text top="1086" left="108" width="336" height="12" font="2">that many commonly used antihypertensive agents,</text>
<text top="817" left="465" width="336" height="12" font="2">including ACE inhibitors and ARBs, are contraindicated</text>
<text top="835" left="465" width="336" height="12" font="2">during pregnancy because of potential harm to the fetus</text>
<text top="853" left="465" width="114" height="12" font="5"><a href="e127.full.html#106">(S10.2.2-2,S10.2.2-3)</a></text>
<text top="853" left="580" width="221" height="12" font="2"><a href="e127.full.html#106">. </a>The goal of antihypertensive treat-</text>
<text top="871" left="465" width="336" height="12" font="2">ment during pregnancy includes prevention of severe</text>
<text top="889" left="465" width="336" height="12" font="2">hypertension and the possibility of prolonging gestation</text>
<text top="907" left="465" width="324" height="12" font="2">to allow the fetus more time to mature before delivery.</text>
<text top="925" left="480" width="321" height="12" font="2">There are 3 Cochrane database reviews of treatment for</text>
<text top="942" left="465" width="103" height="12" font="2">mild-to-moderate</text>
<text top="942" left="587" width="77" height="12" font="2">hypertension</text>
<text top="942" left="683" width="38" height="12" font="2">during</text>
<text top="942" left="741" width="60" height="12" font="2">pregnancy</text>
<text top="960" left="465" width="62" height="12" font="5"><a href="e127.full.html#106">(S10.2.2-10</a></text>
<text top="959" left="527" width="70" height="15" font="5"><a href="e127.full.html#106">—S10.2.2-12)</a></text>
<text top="960" left="597" width="204" height="12" font="2">. With regard to the treatment of</text>
<text top="978" left="465" width="252" height="12" font="2">mild-to-moderate hypertension (SBP of 140</text>
<text top="976" left="718" width="83" height="15" font="2">–169 or DBP of</text>
<text top="996" left="465" width="14" height="12" font="2">90</text>
<text top="994" left="480" width="322" height="15" font="2">–109 mm Hg), antihypertensive treatment reduces the</text>
<text top="1014" left="465" width="336" height="12" font="2">risk of progression to severe hypertension by 50%</text>
<text top="1032" left="465" width="336" height="12" font="2">compared with placebo but has not been shown to</text>
<text top="1050" left="465" width="336" height="12" font="2">prevent preeclampsia, preterm birth, small for gestational</text>
<text top="1068" left="465" width="23" height="12" font="2">age,</text>
<text top="1068" left="501" width="12" height="12" font="2">or</text>
<text top="1068" left="524" width="35" height="12" font="2">infant</text>
<text top="1068" left="571" width="57" height="12" font="2">mortality.</text>
<text top="1068" left="641" width="25" height="12" font="2">Beta</text>
<text top="1068" left="678" width="48" height="12" font="2">blockers</text>
<text top="1068" left="739" width="21" height="12" font="2">and</text>
<text top="1068" left="772" width="29" height="12" font="2">CCBs</text>
<text top="1086" left="465" width="336" height="12" font="2">appear superior to alpha-methyldopa in preventing</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="20" height="9" font="4">e190</text>
</page>
<page number="65" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="76" height="12" font="2">preeclampsia</text>
<text top="143" left="146" width="66" height="12" font="5"><a href="e127.full.html#106">(S10.2.2-10)</a></text>
<text top="143" left="212" width="184" height="12" font="2">. An earlier review of 2 small</text>
<text top="161" left="63" width="333" height="12" font="2">trials did not show improved outcomes with more</text>
<text top="178" left="63" width="280" height="12" font="2">comprehensive treatment of BP to a target of</text>
<text top="177" left="349" width="47" height="15" font="2">&lt;130/80</text>
<text top="196" left="63" width="45" height="12" font="2">mm Hg</text>
<text top="196" left="114" width="64" height="12" font="5"><a href="e127.full.html#106">(S10.2.2-11)</a></text>
<text top="196" left="178" width="218" height="12" font="2">. Consistent with the results of the</text>
<text top="214" left="63" width="333" height="12" font="2">Cochrane reviews, a large multinational RCT of treatment</text>
<text top="232" left="63" width="333" height="12" font="2">in pregnant women with mild-to-moderate hypertension</text>
<text top="250" left="63" width="333" height="12" font="2">also reported that treatment prevented progression to</text>
<text top="268" left="63" width="333" height="12" font="2">severe hypertension, but other maternal and infant out-</text>
<text top="286" left="63" width="333" height="12" font="2">comes were unaffected by the intensity of treatment</text>
<text top="304" left="63" width="65" height="12" font="5"><a href="e127.full.html#106">(S10.2.2-13)</a></text>
<text top="304" left="128" width="138" height="12" font="2"><a href="e127.full.html#106">. </a>An earlier review con</text>
<text top="302" left="266" width="130" height="15" font="2">ﬁned to assessing the</text>
<text top="322" left="63" width="333" height="12" font="2">effect of beta blockers found them generally safe and</text>
<text top="340" left="63" width="142" height="12" font="2">effective but of no bene</text>
<text top="338" left="205" width="192" height="15" font="2">ﬁt for newborn outcomes, either</text>
<text top="358" left="63" width="333" height="12" font="2">in placebo-controlled studies or when compared with</text>
<text top="376" left="63" width="333" height="12" font="2">other antihypertensive agents. There was a suggestion</text>
<text top="394" left="63" width="333" height="12" font="2">that beta-blocker therapy might be associated with small</text>
<text top="412" left="63" width="261" height="12" font="2">for gestational age and neonatal bradycardia</text>
<text top="412" left="327" width="65" height="12" font="5"><a href="e127.full.html#106">(S10.2.2-12)</a></text>
<text top="412" left="393" width="3" height="12" font="2"><a href="e127.full.html#106">.</a></text>
<text top="430" left="63" width="333" height="12" font="2">The largest experience for beta blockers is with labetalol;</text>
<text top="447" left="63" width="333" height="12" font="2">the largest experience for CCBs is with nifedipine. Meth-</text>
<text top="465" left="63" width="333" height="12" font="2">yldopa and hydralazine may also be used. A review of</text>
<text top="483" left="63" width="333" height="12" font="2">treatment for pregnancy-associated severe hypertension</text>
<text top="501" left="63" width="75" height="12" font="2">found insuf</text>
<text top="499" left="138" width="258" height="15" font="2">ﬁcient evidence to recommend speciﬁc</text>
<text top="519" left="63" width="333" height="12" font="2">agents; rather, clinician experience was recommended in</text>
<text top="537" left="63" width="65" height="12" font="2">this setting</text>
<text top="537" left="132" width="66" height="12" font="5"><a href="e127.full.html#106">(S10.2.2-14)</a></text>
<text top="537" left="198" width="3" height="12" font="2">.</text>
<text top="555" left="78" width="318" height="12" font="2">Preeclampsia is a potentially dangerous condition for</text>
<text top="573" left="63" width="333" height="12" font="2">the pregnant woman and fetus, occurring in 3.8% of</text>
<text top="591" left="63" width="333" height="12" font="2">pregnancies, and preeclampsia and eclampsia account for</text>
<text top="609" left="63" width="259" height="12" font="2">9% of maternal deaths in the United States</text>
<text top="609" left="327" width="65" height="12" font="5"><a href="e127.full.html#106">(S10.2.2-15)</a></text>
<text top="609" left="393" width="3" height="12" font="2"><a href="e127.full.html#106">.</a></text>
<text top="627" left="63" width="333" height="12" font="2">Preeclampsia is associated with an increased risk of pre-</text>
<text top="645" left="63" width="333" height="12" font="2">term delivery, intrauterine growth restriction, placental</text>
<text top="663" left="63" width="333" height="12" font="2">abruption, and perinatal mortality and is twice as likely to</text>
<text top="681" left="63" width="69" height="12" font="2">occur in the</text>
<text top="679" left="136" width="261" height="15" font="2">ﬁrst pregnancy. The U.S. Preventive Services</text>
<text top="698" left="63" width="333" height="12" font="2">Task Force has recommended screening all pregnant</text>
<text top="716" left="63" width="333" height="12" font="2">women for preeclampsia by measuring BP at every pre-</text>
<text top="734" left="63" width="58" height="12" font="2">natal visit</text>
<text top="734" left="125" width="65" height="12" font="5"><a href="e127.full.html#106">(S10.2.2-16)</a></text>
<text top="734" left="191" width="3" height="12" font="2"><a href="e127.full.html#106">.</a></text>
<text top="143" left="438" width="318" height="12" font="2">It is beyond the scope of the present guideline to</text>
<text top="161" left="423" width="333" height="12" font="2">address the management of hypertension during preg-</text>
<text top="178" left="423" width="333" height="12" font="2">nancy in detail. Several international guidelines provide</text>
<text top="196" left="423" width="333" height="12" font="2">guidance on management of hypertension during preg-</text>
<text top="214" left="423" width="35" height="12" font="2">nancy</text>
<text top="214" left="463" width="175" height="12" font="5"><a href="e127.full.html#106">(S10.2.2-2,S10.2.2-3,S10.2.2-17)</a></text>
<text top="214" left="638" width="119" height="12" font="2"><a href="e127.full.html#106">. </a>The American Col-</text>
<text top="232" left="423" width="333" height="12" font="2">lege of Obstetricians and Gynecologists has issued a task</text>
<text top="250" left="423" width="333" height="12" font="2">force report that includes recommendations for preven-</text>
<text top="268" left="423" width="333" height="12" font="2">tion (aspirin in selected cases) and treatment (magnesium</text>
<text top="286" left="423" width="333" height="12" font="2">for severe hypertension) of hypertension in pregnancy</text>
<text top="304" left="423" width="59" height="12" font="5"><a href="e127.full.html#106">(S10.2.2-2)</a></text>
<text top="304" left="483" width="274" height="12" font="2"><a href="e127.full.html#106">. </a>A report detailing treatment of hypertensive</text>
<text top="322" left="423" width="333" height="12" font="2">emergencies during pregnancy and postpartum has also</text>
<text top="340" left="423" width="80" height="12" font="2">been released</text>
<text top="340" left="507" width="181" height="12" font="5"><a href="e127.full.html#106">(S10.2.2-2,S10.2.2-17,S10.2.2-18)</a></text>
<text top="340" left="688" width="3" height="12" font="2">.</text>
<text top="376" left="423" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="374" left="562" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="403" left="425" width="332" height="12" font="2">1. ACE inhibitors and ARBs are not approved for use</text>
<text top="421" left="438" width="318" height="12" font="2">during pregnancy; they are fetotoxic. Among the</text>
<text top="439" left="438" width="183" height="12" font="2">agents recommended, no speci</text>
<text top="437" left="622" width="135" height="15" font="2">ﬁc agent is ﬁrst choice</text>
<text top="456" left="438" width="318" height="12" font="2">because there are no data supporting one over</text>
<text top="474" left="438" width="318" height="12" font="2">another. Therapeutic classes are not recommended</text>
<text top="492" left="438" width="318" height="12" font="2">because potential toxicity differs among agents within</text>
<text top="510" left="438" width="43" height="12" font="2">classes.</text>
<text top="528" left="423" width="333" height="12" font="2">2. ACE inhibitors and ARBs are fetotoxic in the second</text>
<text top="546" left="438" width="318" height="12" font="2">and third trimesters of pregnancy. Adverse effects in</text>
<text top="564" left="438" width="19" height="12" font="2">the</text>
<text top="562" left="462" width="294" height="15" font="2">ﬁrst trimester of pregnancy may be secondary to</text>
<text top="582" left="438" width="192" height="12" font="2">hypertension or the medication</text>
<text top="582" left="637" width="116" height="12" font="5"><a href="e127.full.html#106">(S10.2.2-4,S10.2.2-5)</a></text>
<text top="582" left="753" width="3" height="12" font="2"><a href="e127.full.html#106">.</a></text>
<text top="600" left="438" width="318" height="12" font="2">Adverse events in the later trimesters have been sug-</text>
<text top="618" left="438" width="38" height="12" font="2">gested</text>
<text top="618" left="488" width="14" height="12" font="2">by</text>
<text top="618" left="513" width="78" height="12" font="2">observational</text>
<text top="618" left="603" width="58" height="12" font="2">data and</text>
<text top="618" left="674" width="83" height="12" font="2">meta-analyses</text>
<text top="636" left="438" width="60" height="12" font="5"><a href="e127.full.html#106">(S10.2.2-6)</a></text>
<text top="636" left="499" width="258" height="12" font="2"><a href="e127.full.html#106">. </a>For ARBs, case reports with effects similar</text>
<text top="654" left="438" width="224" height="12" font="2">to ACE inhibitors have been published</text>
<text top="654" left="667" width="66" height="12" font="5"><a href="e127.full.html#107">(S10.2.2-19)</a></text>
<text top="654" left="733" width="3" height="12" font="2"><a href="e127.full.html#107">.</a></text>
<text top="713" left="423" width="132" height="11" font="12">10.3. Age-Related Issues</text>
<text top="735" left="423" width="111" height="11" font="2">10.3.1. Older Persons</text>
<text top="773" left="63" width="375" height="11" font="19">Recommendations for Treatment of Hypertension in Older Persons</text>
<text top="787" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="787" left="412" width="153" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 54</a></text>
<text top="787" left="566" width="3" height="11" font="19">.</text>
<text top="828" left="89" width="19" height="10" font="13">COR</text>
<text top="828" left="161" width="18" height="10" font="13">LOE</text>
<text top="828" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="865" left="97" width="3" height="9" font="4">I</text>
<text top="865" left="168" width="6" height="9" font="4">A</text>
<text top="852" left="234" width="541" height="11" font="12">1. Treatment of hypertension with a SBP treatment goal of less than 130 mm Hg is recommended for</text>
<text top="868" left="246" width="327" height="11" font="12">noninstitutionalized ambulatory community-dwelling adults (</text>
<text top="866" left="574" width="221" height="15" font="12">‡65 years of age) with an average SBP of</text>
<text top="884" left="246" width="113" height="11" font="12">130 mm Hg or higher</text>
<text top="884" left="363" width="56" height="11" font="5"><a href="e127.full.html#107">(S10.3.1-1)</a></text>
<text top="884" left="420" width="3" height="11" font="12"><a href="e127.full.html#107">.</a></text>
<text top="928" left="94" width="10" height="9" font="4">IIa</text>
<text top="928" left="160" width="20" height="9" font="4">C-EO</text>
<text top="916" left="234" width="107" height="11" font="12">2. For older adults (</text>
<text top="914" left="341" width="460" height="15" font="12">‡65 years of age) with hypertension and a high burden of comorbidity and limited life</text>
<text top="932" left="248" width="523" height="11" font="12">expectancy, clinical judgment, patient preference, and a team-based approach to assess risk/bene</text>
<text top="930" left="771" width="23" height="15" font="12">ﬁt is</text>
<text top="948" left="248" width="520" height="11" font="12">reasonable for decisions regarding intensity of BP lowering and choice of antihypertensive drugs.</text>
<text top="987" left="63" width="52" height="12" font="2">Synopsis</text>
<text top="1005" left="78" width="321" height="12" font="2">Because of its extremely high prevalence in older</text>
<text top="1023" left="63" width="336" height="12" font="2">adults, hypertension is not only a leading cause of pre-</text>
<text top="1041" left="63" width="336" height="12" font="2">ventable morbidity and mortality but, perhaps more</text>
<text top="1059" left="63" width="336" height="12" font="2">importantly, is under-recognized as a major contributor</text>
<text top="1077" left="63" width="11" height="12" font="2">to</text>
<text top="1077" left="94" width="60" height="12" font="2">premature</text>
<text top="1077" left="173" width="54" height="12" font="2">disability</text>
<text top="1077" left="246" width="21" height="12" font="2">and</text>
<text top="1077" left="287" width="112" height="12" font="2">institutionalization</text>
<text top="987" left="420" width="54" height="12" font="5"><a href="e127.full.html#107">(S10.3.1-2</a></text>
<text top="985" left="475" width="63" height="15" font="5"><a href="e127.full.html#107">—S10.3.1-5)</a></text>
<text top="987" left="538" width="218" height="12" font="2">. Both SBP and DBP increase linearly</text>
<text top="1005" left="420" width="63" height="12" font="2">up to the</text>
<text top="1003" left="492" width="264" height="15" font="2">ﬁfth or sixth decade of life, after which</text>
<text top="1023" left="420" width="336" height="12" font="2">DBP gradually decreases while SBP continues to rise</text>
<text top="1041" left="420" width="59" height="12" font="5"><a href="e127.full.html#107">(S10.3.1-6)</a></text>
<text top="1041" left="480" width="277" height="12" font="2"><a href="e127.full.html#107">. </a>Thus, isolated systolic hypertension is the</text>
<text top="1059" left="420" width="336" height="12" font="2">predominant form of hypertension in older persons</text>
<text top="1077" left="420" width="113" height="12" font="5"><a href="e127.full.html#107">(S10.3.1-7,S10.3.1-8)</a></text>
<text top="1077" left="534" width="223" height="12" font="2"><a href="e127.full.html#107">. </a>RCTs have clearly demonstrated that</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="790" width="18" height="9" font="4">e191</text>
</page>
<page number="66" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="287" height="12" font="2">BP lowering in isolated systolic hypertension (de</text>
<text top="141" left="395" width="46" height="15" font="2">ﬁned as</text>
<text top="161" left="108" width="22" height="12" font="2">SBP</text>
<text top="159" left="135" width="306" height="15" font="2">$160 mm Hg with variable DBP #90, #95, or #110</text>
<text top="178" left="108" width="333" height="12" font="2">mm Hg) is effective in reducing the risk of fatal and</text>
<text top="196" left="108" width="333" height="12" font="2">nonfatal stroke (primary outcome), cardiovascular events,</text>
<text top="214" left="108" width="58" height="12" font="2">and death</text>
<text top="214" left="170" width="55" height="12" font="5"><a href="e127.full.html#107">(S10.3.1-9</a></text>
<text top="213" left="225" width="69" height="15" font="5"><a href="e127.full.html#107">—S10.3.1-12)</a></text>
<text top="214" left="294" width="3" height="12" font="2">.</text>
<text top="232" left="123" width="318" height="12" font="2">Cross-sectional and longitudinal epidemiologic studies</text>
<text top="250" left="108" width="301" height="12" font="2">in older adults have raised questions about the bene</text>
<text top="248" left="408" width="33" height="15" font="2">ﬁts of</text>
<text top="268" left="108" width="333" height="12" font="2">more intensive antihypertensive treatment and the rela-</text>
<text top="286" left="108" width="263" height="12" font="2">tionship between BP lowering and risk of falls</text>
<text top="286" left="373" width="64" height="12" font="5"><a href="e127.full.html#107">(S10.3.1-13)</a></text>
<text top="286" left="437" width="3" height="12" font="2">.</text>
<text top="304" left="108" width="333" height="12" font="2">Treatment of elevated BP in older persons is challenging</text>
<text top="322" left="108" width="333" height="12" font="2">because of a high degree of heterogeneity in comorbidity,</text>
<text top="340" left="108" width="333" height="12" font="2">as well as poly-pharmacy, frailty, cognitive impairment,</text>
<text top="358" left="108" width="333" height="12" font="2">and variable life expectancy. However, over the past 3</text>
<text top="376" left="108" width="333" height="12" font="2">decades, RCTs of antihypertensive therapy have included</text>
<text top="394" left="108" width="333" height="12" font="2">large numbers of older persons, and in every instance,</text>
<text top="412" left="108" width="252" height="12" font="2">including when the SBP treatment goal was</text>
<text top="410" left="364" width="77" height="15" font="2">&lt;120 mm Hg,</text>
<text top="430" left="108" width="333" height="12" font="2">more intensive treatment has safely reduced the risk of</text>
<text top="447" left="108" width="333" height="12" font="2">CVD for persons over the ages of 65, 75, and 80 years</text>
<text top="465" left="108" width="118" height="12" font="5"><a href="e127.full.html#107">(S10.3.1-1,S10.3.1-14)</a></text>
<text top="465" left="226" width="215" height="12" font="2"><a href="e127.full.html#107">. </a>Both HYVET (Hypertension in the</text>
<text top="483" left="108" width="333" height="12" font="2">Very Elderly Trial) and SPRINT included those who were</text>
<text top="501" left="108" width="333" height="12" font="2">frail but still living independently in the community</text>
<text top="519" left="108" width="118" height="12" font="5"><a href="e127.full.html#107">(S10.3.1-1,S10.3.1-14)</a></text>
<text top="519" left="226" width="215" height="12" font="2"><a href="e127.full.html#107">, </a>and both were stopped early for</text>
<text top="537" left="108" width="28" height="12" font="2">bene</text>
<text top="535" left="136" width="305" height="15" font="2">ﬁt (HYVET after 1.8 years and SPRINT after 3.26</text>
<text top="555" left="108" width="333" height="12" font="2">years). In fact, BP-lowering therapy is one of the few in-</text>
<text top="573" left="108" width="333" height="12" font="2">terventions shown to reduce mortality risk in frail older</text>
<text top="591" left="108" width="333" height="12" font="2">individuals. RCTs in noninstitutionalized community-</text>
<text top="609" left="108" width="333" height="12" font="2">dwelling older persons have also demonstrated that</text>
<text top="627" left="108" width="333" height="12" font="2">improved BP control does not exacerbate orthostatic hy-</text>
<text top="645" left="108" width="333" height="12" font="2">potension and has no adverse impact on risk of injurious</text>
<text top="663" left="108" width="24" height="12" font="2">falls</text>
<text top="663" left="138" width="177" height="12" font="5"><a href="e127.full.html#107">(S10.3.1-1,S10.3.1-15,S10.3.1-16)</a></text>
<text top="663" left="315" width="126" height="12" font="2"><a href="e127.full.html#107">. </a>It should be noted,</text>
<text top="681" left="108" width="306" height="12" font="2">however, that SPRINT excluded those with low (</text>
<text top="679" left="414" width="27" height="15" font="2">&lt;110</text>
<text top="698" left="108" width="333" height="12" font="2">mm Hg) standing BP on study entry. Older persons need</text>
<text top="716" left="108" width="333" height="12" font="2">to be carefully monitored for orthostatic hypotension</text>
<text top="734" left="108" width="333" height="12" font="2">during treatment. Intensive BP control increases the risk</text>
<text top="752" left="108" width="333" height="12" font="2">of acute kidney injury, but this is no different from the</text>
<text top="770" left="108" width="177" height="12" font="2">risk seen in younger adults</text>
<text top="770" left="293" width="57" height="12" font="5"><a href="e127.full.html#107">(S10.3.1-1)</a></text>
<text top="770" left="351" width="90" height="12" font="2"><a href="e127.full.html#107">. </a>In summary,</text>
<text top="788" left="108" width="333" height="12" font="2">despite the complexity of management in caring for older</text>
<text top="806" left="108" width="333" height="12" font="2">persons with hypertension, RCTs have demonstrated that</text>
<text top="824" left="108" width="333" height="12" font="2">in many community-dwelling older adults, even adults</text>
<text top="840" left="108" width="333" height="15" font="2">&gt;80 years of age, BP-lowering goals during antihyper-</text>
<text top="860" left="108" width="333" height="12" font="2">tensive treatment need not differ from those selected for</text>
<text top="878" left="108" width="45" height="12" font="2">persons</text>
<text top="876" left="160" width="105" height="15" font="2">&lt;65 years of age</text>
<text top="878" left="272" width="64" height="12" font="5"><a href="e127.full.html#107">(S10.3.1-17)</a></text>
<text top="878" left="336" width="105" height="12" font="2"><a href="e127.full.html#107">. </a>Importantly, no</text>
<text top="896" left="108" width="255" height="12" font="2">randomized trial of BP lowering in persons</text>
<text top="894" left="367" width="74" height="15" font="2">&gt;65 years of</text>
<text top="914" left="108" width="224" height="12" font="2">age has ever shown harm or less bene</text>
<text top="912" left="332" width="109" height="15" font="2">ﬁt for older versus</text>
<text top="932" left="108" width="333" height="12" font="2">younger adults. However, clinicians should implement</text>
<text top="950" left="108" width="333" height="12" font="2">careful titration of BP lowering and monitoring in persons</text>
<text top="967" left="108" width="333" height="12" font="2">with high comorbidity burden; large RCTs have excluded</text>
<text top="985" left="108" width="334" height="12" font="2">older persons at any age who live in nursing homes, as</text>
<text top="1003" left="108" width="333" height="12" font="2">well as those with prevalent dementia and advanced HF.</text>
<text top="1039" left="108" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="1037" left="247" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="1066" left="109" width="332" height="12" font="2">1. We recommend ASCVD risk assessment in all adults</text>
<text top="1084" left="123" width="318" height="12" font="2">with hypertension, including older persons. As a</text>
<text top="143" left="483" width="318" height="12" font="2">matter of convenience, however, it can be assumed</text>
<text top="161" left="483" width="318" height="12" font="2">that the vast majority of older adults have a 10-year</text>
<text top="178" left="483" width="65" height="12" font="2">ASCVD risk</text>
<text top="177" left="553" width="248" height="15" font="2">$ 10%, placing them in the high risk cate-</text>
<text top="196" left="483" width="318" height="12" font="2">gory that requires initiation of antihypertensive drug</text>
<text top="214" left="483" width="85" height="12" font="2">therapy at BP</text>
<text top="213" left="576" width="138" height="15" font="2">$ 130/80 mm Hg (see</text>
<text top="214" left="721" width="80" height="12" font="5"><a href="e127.full.html#34">Section 8.1.2</a>,</text>
<text top="233" left="483" width="128" height="11" font="5"><a href="e127.full.html#36">Figure 4 </a>and <a href="e127.full.html#83">Table 23</a></text>
<text top="232" left="617" width="184" height="12" font="2">for BP thresholds for initiating</text>
<text top="250" left="483" width="318" height="12" font="2">antihypertensive drug treatment). Large RCTs using</text>
<text top="268" left="483" width="318" height="12" font="2">medications to reduce hypertension-related CVD risk</text>
<text top="286" left="483" width="144" height="12" font="2">with a mean follow-up of</text>
<text top="284" left="630" width="171" height="15" font="2">$2 years have now included a</text>
<text top="304" left="483" width="136" height="12" font="2">large number of adults</text>
<text top="302" left="624" width="177" height="15" font="2">$65 years of age. These trials</text>
<text top="322" left="483" width="242" height="12" font="2">have enrolled a broad range of ages</text>
<text top="320" left="735" width="67" height="15" font="2">$65 years,</text>
<text top="340" left="483" width="318" height="12" font="2">including persons in their 90s and even 100s, as well as</text>
<text top="358" left="483" width="318" height="12" font="2">those with mild-to-moderate frailty but who were</text>
<text top="376" left="483" width="318" height="12" font="2">ambulatory and able to travel to a treatment clinic. In</text>
<text top="394" left="483" width="318" height="12" font="2">these patients, RCTs have shown that BP lowering</text>
<text top="412" left="483" width="318" height="12" font="2">decreased CVD morbidity and mortality but did not</text>
<text top="430" left="483" width="318" height="12" font="2">increase the risk of orthostatic hypotension or falls</text>
<text top="447" left="483" width="176" height="12" font="5"><a href="e127.full.html#107">(S10.3.1-1,S10.3.1-15,S10.3.1-16)</a></text>
<text top="447" left="660" width="3" height="12" font="2"><a href="e127.full.html#107">.</a></text>
<text top="447" left="683" width="48" height="12" font="2">Analysis</text>
<text top="447" left="751" width="11" height="12" font="2">of</text>
<text top="447" left="783" width="19" height="12" font="2">the</text>
<text top="465" left="483" width="82" height="12" font="2">NHANES (2011</text>
<text top="464" left="565" width="236" height="15" font="2">–2014) data set indicates that 88% of U.S.</text>
<text top="483" left="483" width="204" height="12" font="2">adults (98% men and 80% women)</text>
<text top="482" left="691" width="111" height="15" font="2">$65 years old have</text>
<text top="501" left="483" width="180" height="12" font="2">a 10-year predicted ASCVD risk</text>
<text top="499" left="667" width="134" height="15" font="2">$10% or have a history</text>
<text top="519" left="483" width="241" height="12" font="2">of CVD (CHD, stroke, or HF). For persons</text>
<text top="517" left="729" width="72" height="15" font="2">$75 years of</text>
<text top="537" left="483" width="211" height="12" font="2">age, 100% have an ASCVD risk score</text>
<text top="535" left="698" width="103" height="15" font="2">$10% or a history</text>
<text top="555" left="483" width="214" height="12" font="2">of CVD. Therefore, the BP target of</text>
<text top="553" left="703" width="98" height="15" font="2">#130/80 mm Hg</text>
<text top="573" left="483" width="155" height="12" font="2">would be appropriate (see</text>
<text top="573" left="643" width="74" height="12" font="5"><a href="e127.full.html#34">Section 8.1.2</a></text>
<text top="573" left="718" width="84" height="12" font="2"><a href="e127.full.html#34">). </a>Initiation of</text>
<text top="591" left="483" width="318" height="12" font="2">antihypertensive therapy with 2 agents should be un-</text>
<text top="609" left="483" width="318" height="12" font="2">dertaken cautiously in older persons, and they need to</text>
<text top="627" left="483" width="318" height="12" font="2">be monitored carefully for orthostatic hypotension and</text>
<text top="645" left="483" width="213" height="12" font="2">history of falls. In SPRINT, the bene</text>
<text top="643" left="696" width="105" height="15" font="2">ﬁt was for an SBP</text>
<text top="663" left="483" width="40" height="12" font="2">goal of</text>
<text top="661" left="528" width="274" height="15" font="2">&lt;120 mm Hg. Older persons may present with</text>
<text top="681" left="483" width="318" height="12" font="2">neurogenic orthostatic hypotension associated with</text>
<text top="698" left="483" width="318" height="12" font="2">supine hypertension. This is particularly common in</text>
<text top="716" left="483" width="57" height="12" font="2">Parkinson</text>
<text top="715" left="541" width="261" height="15" font="2">’s disease and other neurodegenerative dis-</text>
<text top="734" left="483" width="318" height="12" font="2">orders. For management of this problem, the reader is</text>
<text top="752" left="483" width="318" height="12" font="2">referred to the recommendations of a 2017 consensus</text>
<text top="770" left="483" width="32" height="12" font="2">panel</text>
<text top="770" left="519" width="65" height="12" font="5"><a href="e127.full.html#107">(S10.3.1-18)</a></text>
<text top="770" left="584" width="3" height="12" font="2"><a href="e127.full.html#107">.</a></text>
<text top="788" left="468" width="333" height="12" font="2">2. Patients with prevalent and frequent falls, advanced</text>
<text top="806" left="483" width="318" height="12" font="2">cognitive impairment, and multiple comorbidities may</text>
<text top="824" left="483" width="318" height="12" font="2">be at risk of adverse outcomes with intensive BP</text>
<text top="842" left="483" width="318" height="12" font="2">lowering, especially when they require multiple BP-</text>
<text top="860" left="483" width="318" height="12" font="2">lowering medications. Older persons in this category</text>
<text top="878" left="483" width="318" height="12" font="2">typically reside in nursing homes and assisting living</text>
<text top="896" left="483" width="318" height="12" font="2">facilities, are unable to live independently in the</text>
<text top="914" left="483" width="309" height="12" font="2">community, and have not been represented in RCTs.</text>
<text top="958" left="468" width="172" height="11" font="2">10.3.2. Children and Adolescents</text>
<text top="980" left="468" width="333" height="12" font="2">Pediatric guidelines are available from other organiza-</text>
<text top="998" left="468" width="29" height="12" font="2">tions</text>
<text top="998" left="503" width="113" height="12" font="5"><a href="e127.full.html#107">(S10.3.2-1,S10.3.2-2)</a></text>
<text top="998" left="617" width="184" height="12" font="2">. The 2011 report updates the</text>
<text top="1015" left="468" width="333" height="12" font="2">2004 report for publications through 2008 (antihyper-</text>
<text top="1033" left="468" width="333" height="12" font="2">tensive medication trials, normative data on pediatric BP)</text>
<text top="1051" left="468" width="333" height="12" font="2">but is otherwise unchanged. In the 2011 guideline</text>
<text top="1069" left="468" width="59" height="12" font="5"><a href="e127.full.html#107">(S10.3.2-3)</a></text>
<text top="1069" left="528" width="3" height="12" font="2"><a href="e127.full.html#107">,</a></text>
<text top="1069" left="546" width="15" height="12" font="2">BP</text>
<text top="1069" left="576" width="22" height="12" font="2">was</text>
<text top="1069" left="613" width="30" height="12" font="2">strati</text>
<text top="1067" left="643" width="158" height="15" font="2">ﬁed into normal, pre-</text>
<text top="1087" left="468" width="333" height="12" font="2">hypertension (90th percentile to 95th percentile), stage 1</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e192</text>
</page>
<page number="67" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="193" height="12" font="2">hypertension (95th percentile to</text>
<text top="141" left="262" width="134" height="15" font="2">&gt;99th percentile), and</text>
<text top="161" left="63" width="333" height="12" font="2">stage 2 hypertension (above stage 1) by using age-, sex-,</text>
<text top="178" left="63" width="333" height="12" font="2">and height-based tables beginning at 1 year of age, which</text>
<text top="196" left="63" width="231" height="12" font="2">were based on the distribution of BP in</text>
<text top="195" left="298" width="98" height="15" font="2">&gt;60,000 healthy</text>
<text top="214" left="63" width="266" height="12" font="2">children in various population-based studies</text>
<text top="214" left="334" width="58" height="12" font="5"><a href="e127.full.html#107">(S10.3.2-1)</a></text>
<text top="214" left="393" width="3" height="12" font="2"><a href="e127.full.html#107">.</a></text>
<text top="232" left="63" width="52" height="12" font="2">These de</text>
<text top="230" left="115" width="281" height="15" font="2">ﬁnitions were designed to be analogous to deﬁ-</text>
<text top="250" left="63" width="333" height="12" font="2">nitions in the extant JNC 7 report; for older adolescents</text>
<text top="268" left="63" width="4" height="12" font="2">(</text>
<text top="266" left="67" width="277" height="15" font="2">$14 years), the JNC 7 thresholds generally apply</text>
<text top="268" left="347" width="49" height="12" font="5"><a href="e127.full.html#107">(S10.3.2-</a></text>
<text top="286" left="63" width="11" height="12" font="5"><a href="e127.full.html#107">4)</a></text>
<text top="286" left="75" width="322" height="12" font="2"><a href="e127.full.html#107">. </a>Treatment recommendations are based on hyperten-</text>
<text top="304" left="63" width="333" height="12" font="2">sion severity, published short-term clinical trials of</text>
<text top="322" left="63" width="333" height="12" font="2">antihypertensive treatment, age, coexisting CVD risk</text>
<text top="340" left="63" width="137" height="12" font="2">factors, and risk strati</text>
<text top="338" left="201" width="196" height="15" font="2">ﬁcation by presence of LVH on</text>
<text top="143" left="423" width="333" height="12" font="2">echocardiogram. The treatment goal is to achieve</text>
<text top="161" left="423" width="15" height="12" font="2">BP</text>
<text top="159" left="443" width="313" height="15" font="2">&lt;90th percentile. New tables for ambulatory BP dis-</text>
<text top="178" left="423" width="308" height="12" font="2">tribution in children have been developed. A classi</text>
<text top="177" left="732" width="25" height="15" font="2">ﬁca-</text>
<text top="196" left="423" width="333" height="12" font="2">tion of BP that is based on these ambulatory BP results has</text>
<text top="214" left="423" width="87" height="12" font="2">been proposed</text>
<text top="214" left="516" width="115" height="12" font="5"><a href="e127.full.html#107">(S10.3.2-5,S10.3.2-6)</a></text>
<text top="214" left="632" width="125" height="12" font="2"><a href="e127.full.html#107">. </a>A new pediatric BP</text>
<text top="232" left="423" width="212" height="12" font="2">guideline was published in late 2017</text>
<text top="232" left="639" width="59" height="12" font="5"><a href="e127.full.html#107">(S10.3.2-7)</a></text>
<text top="232" left="699" width="3" height="12" font="2"><a href="e127.full.html#107">.</a></text>
<text top="262" left="423" width="194" height="16" font="14">11. OTHER CONSIDERATIONS</text>
<text top="301" left="423" width="149" height="11" font="12">11.1. Resistant Hypertension</text>
<text top="322" left="423" width="333" height="12" font="2">The diagnosis of resistant hypertension is made when a</text>
<text top="340" left="423" width="333" height="12" font="2">patient takes 3 antihypertensive medications with com-</text>
<text top="389" left="80" width="51" height="11" font="22">FIGURE 10</text>
<text top="390" left="139" width="274" height="9" font="23">Resistant Hypertension: Diagnosis, Evaluation, and Treatment</text>
<text top="1032" left="80" width="106" height="9" font="13">*See additional details in</text>
<text top="1032" left="190" width="40" height="9" font="17"><a href="e127.full.html#28">Section 6</a></text>
<text top="1032" left="230" width="150" height="9" font="13"><a href="e127.full.html#28">, </a>Nonpharmacological Intervention.</text>
<text top="1030" left="383" width="20" height="12" font="13">†See</text>
<text top="1032" left="406" width="113" height="9" font="17"><a href="">Section 5.4.1 </a>and <a href="e127.full.html#25">Table 14</a></text>
<text top="1032" left="522" width="181" height="9" font="13">for complete list of drugs that elevate BP.</text>
<text top="1030" left="707" width="20" height="12" font="13">‡See</text>
<text top="1047" left="80" width="106" height="9" font="17"><a href="e127.full.html#22">Section 5.4 </a>and <a href="e127.full.html#23">Table 13</a></text>
<text top="1047" left="190" width="527" height="9" font="13">for secondary hypertension. BP indicates blood pressure; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR,</text>
<text top="1062" left="80" width="90" height="9" font="13">estimated glomerular</text>
<text top="1060" left="173" width="565" height="12" font="13">ﬁltration rate; NSAIDs, nonsteroidal anti-inﬂammatory drugs; and SBP, systolic blood pressure. Adapted with permission from Calhoun</text>
<text top="1077" left="80" width="22" height="9" font="13">et al.</text>
<text top="1077" left="106" width="34" height="9" font="17"><a href="e127.full.html#107">(S11.1-1)</a></text>
<text top="1077" left="143" width="147" height="9" font="13">(American Heart Association, Inc.).</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="19" height="9" font="4">e193</text>
</page>
<page number="68" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="333" height="12" font="2">plementary mechanisms of action (a diuretic should be 1</text>
<text top="161" left="108" width="333" height="12" font="2">component) but does not achieve control or when BP</text>
<text top="178" left="108" width="185" height="12" font="2">control is achieved but requires</text>
<text top="177" left="297" width="91" height="15" font="2">$4 medications</text>
<text top="178" left="392" width="45" height="12" font="5"><a href="e127.full.html#107">(S11.1-1)</a></text>
<text top="178" left="437" width="3" height="12" font="2">.</text>
<text top="196" left="108" width="333" height="12" font="2">On the basis of the previous cutoff of 140/90 mm Hg, the</text>
<text top="214" left="108" width="333" height="12" font="2">prevalence of resistant hypertension is approximately</text>
<text top="232" left="108" width="177" height="12" font="2">13% in the adult population</text>
<text top="232" left="293" width="87" height="12" font="5"><a href="e127.full.html#107">(S11.1-2,S11.1-3)</a></text>
<text top="232" left="381" width="60" height="12" font="2"><a href="e127.full.html#107">. </a>Multiple</text>
<text top="250" left="108" width="333" height="12" font="2">single-cohort studies have indicated that common risk</text>
<text top="268" left="108" width="333" height="12" font="2">factors for resistant hypertension include older age,</text>
<text top="286" left="108" width="333" height="12" font="2">obesity, CKD, black race, and DM. Estimates suggest the</text>
<text top="304" left="108" width="333" height="12" font="2">prevalence would be about 4% higher with the newly</text>
<text top="322" left="108" width="183" height="12" font="2">recommended control target of</text>
<text top="320" left="296" width="145" height="15" font="2">&lt;130/80 mm Hg (subject</text>
<text top="340" left="108" width="333" height="12" font="2">to validation in future study). The prognosis of resistant</text>
<text top="358" left="108" width="77" height="12" font="2">hypertension</text>
<text top="358" left="196" width="18" height="12" font="2">(by</text>
<text top="358" left="226" width="19" height="12" font="2">the</text>
<text top="358" left="257" width="50" height="12" font="2">previous</text>
<text top="358" left="319" width="14" height="12" font="2">de</text>
<text top="356" left="334" width="47" height="15" font="2">ﬁnition)</text>
<text top="358" left="392" width="45" height="12" font="5"><a href="e127.full.html#107">(S11.1-1)</a></text>
<text top="358" left="437" width="3" height="12" font="2">,</text>
<text top="376" left="108" width="333" height="12" font="2">compared with the prognosis of those who more readily</text>
<text top="394" left="108" width="333" height="12" font="2">achieve control, has not been fully ascertained; however,</text>
<text top="412" left="108" width="333" height="12" font="2">risk of MI, stroke, ESRD, and death in adults with resistant</text>
<text top="430" left="108" width="333" height="12" font="2">hypertension and CHD may be 2- to 6-fold higher than in</text>
<text top="447" left="108" width="76" height="12" font="2">hypertensive</text>
<text top="447" left="196" width="36" height="12" font="2">adults</text>
<text top="447" left="244" width="45" height="12" font="2">without</text>
<text top="447" left="302" width="50" height="12" font="2">resistant</text>
<text top="447" left="364" width="77" height="12" font="2">hypertension</text>
<text top="465" left="108" width="43" height="12" font="5"><a href="e127.full.html#107">(S11.1-4</a></text>
<text top="464" left="151" width="51" height="15" font="5"><a href="e127.full.html#107">—S11.1-6)</a></text>
<text top="465" left="202" width="238" height="12" font="2">. The evaluation of resistant hyperten-</text>
<text top="483" left="108" width="333" height="12" font="2">sion involves consideration of many patient characteris-</text>
<text top="501" left="108" width="24" height="12" font="2">tics,</text>
<text top="501" left="146" width="100" height="12" font="2">pseudoresistance</text>
<text top="501" left="260" width="19" height="12" font="2">(BP</text>
<text top="501" left="294" width="62" height="12" font="2">technique,</text>
<text top="501" left="370" width="33" height="12" font="2">white</text>
<text top="501" left="417" width="24" height="12" font="2">coat</text>
<text top="519" left="108" width="333" height="12" font="2">hypertension, and medication compliance), and screening</text>
<text top="537" left="108" width="229" height="12" font="2">for secondary causes of hypertension (</text>
<text top="537" left="337" width="53" height="11" font="5"><a href="e127.full.html#67">Figure 10</a></text>
<text top="537" left="390" width="4" height="12" font="2">;</text>
<text top="537" left="399" width="42" height="12" font="5"><a href="e127.full.html#22">Section</a></text>
<text top="555" left="108" width="17" height="12" font="5"><a href="e127.full.html#22">5.4</a></text>
<text top="555" left="125" width="4" height="12" font="2">;</text>
<text top="555" left="136" width="49" height="11" font="5"><a href="e127.full.html#23">Table 13</a></text>
<text top="555" left="185" width="70" height="12" font="2"><a href="e127.full.html#23">). </a>The term</text>
<text top="553" left="262" width="179" height="15" font="2">“refractory hypertension” has</text>
<text top="573" left="108" width="333" height="12" font="2">been used to refer to an extreme phenotype of antihy-</text>
<text top="591" left="108" width="186" height="12" font="2">pertensive treatment failure, de</text>
<text top="589" left="294" width="147" height="15" font="2">ﬁned as failure to control</text>
<text top="609" left="108" width="333" height="12" font="2">BP despite use of at least 5 antihypertensive agents of</text>
<text top="627" left="108" width="333" height="12" font="2">different classes, including a long-acting thiazide-type</text>
<text top="645" left="108" width="333" height="12" font="2">diuretic, such as chlorthalidone, and a mineralocorticoid</text>
<text top="663" left="108" width="254" height="12" font="2">receptor antagonist, such as spironolactone</text>
<text top="663" left="365" width="46" height="12" font="5"><a href="e127.full.html#107">(S11.1-7)</a></text>
<text top="663" left="412" width="29" height="12" font="2"><a href="e127.full.html#107">. </a>The</text>
<text top="681" left="108" width="333" height="12" font="2">prevalence of refractory hypertension is low; patients</text>
<text top="698" left="108" width="333" height="12" font="2">with refractory hypertension experience high rates of</text>
<text top="716" left="108" width="299" height="12" font="2">CVD complications, including LVH, HF, and stroke.</text>
<text top="734" left="123" width="61" height="12" font="2">Treatment</text>
<text top="734" left="201" width="11" height="12" font="2">of</text>
<text top="734" left="230" width="50" height="12" font="2">resistant</text>
<text top="734" left="298" width="77" height="12" font="2">hypertension</text>
<text top="734" left="392" width="49" height="12" font="2">involves</text>
<text top="752" left="108" width="333" height="12" font="2">improving medication adherence, improving detection</text>
<text top="143" left="468" width="333" height="12" font="2">and correction of secondary hypertension, and address-</text>
<text top="161" left="468" width="188" height="12" font="2">ing other patient characteristics</text>
<text top="161" left="661" width="43" height="12" font="5"><a href="e127.full.html#107">(S11.1-8</a></text>
<text top="159" left="704" width="57" height="15" font="5"><a href="e127.full.html#107">—S11.1-10)</a></text>
<text top="161" left="762" width="39" height="12" font="2"><a href="e127.full.html#107">. </a>Phar-</text>
<text top="178" left="468" width="333" height="12" font="2">macological therapy with combinations of medications</text>
<text top="196" left="468" width="333" height="12" font="2">with complementary mechanisms of action provides an</text>
<text top="214" left="468" width="333" height="12" font="2">empirical approach that enhances BP control while</text>
<text top="232" left="468" width="333" height="12" font="2">mitigating untoward effects of potent vasodilators (e.g.,</text>
<text top="248" left="468" width="333" height="15" font="2">ﬂuid retention and reﬂex tachycardia). CCBs, inhibitors</text>
<text top="268" left="468" width="333" height="12" font="2">of RAS, and chlorthalidone comprise a common 3-drug</text>
<text top="286" left="468" width="47" height="12" font="2">regimen</text>
<text top="286" left="521" width="50" height="12" font="5"><a href="e127.full.html#107">(S11.1-11)</a></text>
<text top="286" left="572" width="230" height="12" font="2"><a href="e127.full.html#107">. </a>Considerable evidence indicates that</text>
<text top="304" left="468" width="333" height="12" font="2">the addition of spironolactone to multidrug regimens</text>
<text top="322" left="468" width="50" height="12" font="2">provides</text>
<text top="322" left="531" width="64" height="12" font="2">substantial</text>
<text top="322" left="608" width="15" height="12" font="2">BP</text>
<text top="322" left="636" width="56" height="12" font="2">reduction</text>
<text top="322" left="705" width="51" height="12" font="5"><a href="e127.full.html#107">(S11.1-12)</a></text>
<text top="322" left="770" width="32" height="12" font="2">when</text>
<text top="340" left="468" width="333" height="12" font="2">compared with placebo. Substantial data also demon-</text>
<text top="358" left="468" width="333" height="12" font="2">strate the advantage of spironolactone as compared with</text>
<text top="376" left="468" width="112" height="12" font="2">other active drugs</text>
<text top="376" left="587" width="89" height="12" font="5"><a href="e127.full.html#107">(S11.1-8,S11.1-13</a></text>
<text top="374" left="677" width="56" height="15" font="5"><a href="e127.full.html#107">—S11.1-15)</a></text>
<text top="376" left="733" width="68" height="12" font="2">. In partic-</text>
<text top="394" left="468" width="333" height="12" font="2">ular, the recent PATHWAY-2 (Optimum Treatment for</text>
<text top="412" left="468" width="333" height="12" font="2">Drug-Resistant Hypertension) RCT demonstrated the</text>
<text top="430" left="468" width="333" height="12" font="2">superiority of spironolactone over alpha and beta</text>
<text top="447" left="468" width="48" height="12" font="2">blockers</text>
<text top="447" left="523" width="51" height="12" font="5"><a href="e127.full.html#107">(S11.1-13)</a></text>
<text top="447" left="574" width="227" height="12" font="2">. There is also clinical trial evidence</text>
<text top="465" left="468" width="333" height="12" font="2">that the addition of hydralazine or minoxidil is effective</text>
<text top="483" left="468" width="333" height="12" font="2">in achieving BP control in patients resistant to usual</text>
<text top="501" left="468" width="73" height="12" font="2">combination</text>
<text top="501" left="555" width="44" height="12" font="2">therapy</text>
<text top="501" left="615" width="89" height="12" font="5"><a href="e127.full.html#107">(S11.1-8,S11.1-12</a></text>
<text top="499" left="704" width="57" height="15" font="5"><a href="e127.full.html#107">—S11.1-16)</a></text>
<text top="501" left="761" width="3" height="12" font="2">.</text>
<text top="501" left="780" width="22" height="12" font="2">The</text>
<text top="519" left="468" width="333" height="12" font="2">dosing of multidrug regimens, occasionally including</text>
<text top="537" left="468" width="333" height="12" font="2">nighttime dosing, may be best optimized by hyperten-</text>
<text top="555" left="468" width="92" height="12" font="2">sion specialists.</text>
<text top="573" left="483" width="318" height="12" font="2">Several studies have investigated devices that inter-</text>
<text top="591" left="468" width="333" height="12" font="2">rupt sympathetic nerve activity (carotid baroreceptor</text>
<text top="609" left="468" width="333" height="12" font="2">pacing and catheter ablation of renal sympathetic nerves);</text>
<text top="627" left="468" width="270" height="12" font="2">however, these studies have not provided suf</text>
<text top="625" left="738" width="63" height="15" font="2">ﬁcient evi-</text>
<text top="645" left="468" width="333" height="12" font="2">dence to recommend the use of these device in managing</text>
<text top="663" left="468" width="132" height="12" font="2">resistant hypertension</text>
<text top="663" left="605" width="42" height="12" font="5"><a href="e127.full.html#107">(S11.1-8</a></text>
<text top="661" left="647" width="57" height="15" font="5"><a href="e127.full.html#107">—S11.1-10)</a></text>
<text top="663" left="705" width="96" height="12" font="2"><a href="e127.full.html#107">. </a>In particular, 2</text>
<text top="681" left="468" width="333" height="12" font="2">RCTS of renal sympathetic nerve ablation have been</text>
<text top="698" left="468" width="49" height="12" font="2">negative</text>
<text top="698" left="522" width="89" height="12" font="5"><a href="e127.full.html#107">(S11.1-8,S11.1-9)</a></text>
<text top="698" left="611" width="3" height="12" font="2"><a href="e127.full.html#107">.</a></text>
<text top="752" left="468" width="132" height="11" font="12">11.2. Hypertensive Crises</text>
<text top="750" left="600" width="154" height="15" font="12">—Emergencies and Urgencies</text>
<text top="794" left="63" width="335" height="11" font="19">Recommendations for Hypertensive Crises and Emergencies</text>
<text top="808" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="808" left="412" width="152" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 55</a></text>
<text top="808" left="565" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="849" left="89" width="19" height="10" font="13">COR</text>
<text top="849" left="161" width="18" height="10" font="13">LOE</text>
<text top="849" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="886" left="97" width="3" height="9" font="4">I</text>
<text top="886" left="160" width="21" height="9" font="4">B-NR</text>
<text top="874" left="234" width="532" height="11" font="12">1. In adults with a hypertensive emergency, admission to an intensive care unit is recommended for</text>
<text top="889" left="246" width="555" height="11" font="12">continuous monitoring of BP and target organ damage and for parenteral administration of an appropriate</text>
<text top="905" left="246" width="38" height="11" font="12">agent (</text>
<text top="905" left="285" width="50" height="11" font="5"><a href="e127.full.html#70">Tables 19</a></text>
<text top="905" left="339" width="19" height="11" font="12">and</text>
<text top="905" left="362" width="14" height="11" font="5"><a href="e127.full.html#71">20</a></text>
<text top="905" left="376" width="4" height="11" font="12">)</text>
<text top="905" left="384" width="86" height="11" font="5"><a href="e127.full.html#108">(S11.2-1,S11.2-2)</a></text>
<text top="905" left="470" width="3" height="11" font="12">.</text>
<text top="950" left="97" width="3" height="9" font="4">I</text>
<text top="950" left="160" width="20" height="9" font="4">C-EO</text>
<text top="937" left="234" width="542" height="11" font="12">2. For adults with a compelling condition (i.e., aortic dissection, severe preeclampsia or eclampsia, or</text>
<text top="953" left="248" width="460" height="11" font="12">pheochromocytoma crisis), SBP should be reduced to less than 140 mm Hg during the</text>
<text top="951" left="712" width="87" height="15" font="12">ﬁrst hour and to</text>
<text top="969" left="248" width="220" height="11" font="12">less than 120 mm Hg in aortic dissection.</text>
<text top="1015" left="97" width="3" height="9" font="4">I</text>
<text top="1015" left="160" width="20" height="9" font="4">C-EO</text>
<text top="1003" left="234" width="543" height="11" font="12">3. For adults without a compelling condition, SBP should be reduced by no more than 25% within the</text>
<text top="1001" left="781" width="21" height="15" font="12">ﬁrst</text>
<text top="1018" left="248" width="554" height="11" font="12">hour; then, if stable, to 160/100 mm Hg within the next 2 to 6 hours; and then cautiously to normal during</text>
<text top="1034" left="248" width="158" height="11" font="12">the following 24 to 48 hours.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e194</text>
</page>
<page number="69" position="absolute" top="0" left="0" height="1160" width="864">
<text top="776" left="63" width="52" height="12" font="2">Synopsis</text>
<text top="794" left="78" width="193" height="12" font="2">Hypertensive emergencies are de</text>
<text top="792" left="271" width="125" height="15" font="2">ﬁned as severe eleva-</text>
<text top="812" left="63" width="69" height="12" font="2">tions in BP (</text>
<text top="810" left="132" width="264" height="15" font="2">&gt;180/120 mm Hg) associated with evidence of</text>
<text top="829" left="63" width="230" height="12" font="2">new or worsening target organ damage</text>
<text top="829" left="297" width="43" height="12" font="5"><a href="e127.full.html#108">(S11.2-3</a></text>
<text top="828" left="340" width="53" height="15" font="5"><a href="e127.full.html#108">—S11.2-6)</a></text>
<text top="829" left="393" width="3" height="12" font="2"><a href="e127.full.html#108">.</a></text>
<text top="847" left="63" width="333" height="12" font="2">The 1-year death rate associated with hypertensive emer-</text>
<text top="865" left="63" width="55" height="12" font="2">gencies is</text>
<text top="864" left="121" width="275" height="15" font="2">&gt;79%, and the median survival is 10.4 months if</text>
<text top="883" left="63" width="189" height="12" font="2">the emergency is left untreated</text>
<text top="883" left="257" width="47" height="12" font="5"><a href="e127.full.html#108">(S11.2-7)</a></text>
<text top="883" left="305" width="92" height="12" font="2"><a href="e127.full.html#108">. </a>The actual BP</text>
<text top="901" left="63" width="333" height="12" font="2">level may not be as important as the rate of BP rise; patients</text>
<text top="919" left="63" width="333" height="12" font="2">with chronic hypertension can often tolerate higher BP</text>
<text top="937" left="63" width="333" height="12" font="2">levels than previously normotensive individuals. Hyper-</text>
<text top="955" left="63" width="333" height="12" font="2">tensive emergencies demand immediate reduction of BP</text>
<text top="973" left="63" width="333" height="12" font="2">(not necessarily to normal) to prevent or limit further</text>
<text top="991" left="63" width="333" height="12" font="2">target organ damage. Examples of target organ damage</text>
<text top="1009" left="63" width="333" height="12" font="2">include hypertensive encephalopathy, ICH, acute ischemic</text>
<text top="1027" left="63" width="333" height="12" font="2">stroke, acute MI, acute LV failure with pulmonary edema,</text>
<text top="1045" left="63" width="333" height="12" font="2">unstable angina pectoris, dissecting aortic aneurysm,</text>
<text top="1063" left="63" width="333" height="12" font="2">acute renal failure, and eclampsia. In general, use of oral</text>
<text top="1080" left="63" width="333" height="12" font="2">therapy is discouraged for hypertensive emergencies.</text>
<text top="776" left="423" width="333" height="12" font="2">Hypertensive emergencies in patients with acute ICH and</text>
<text top="794" left="423" width="220" height="12" font="2">acute ischemic stroke are discussed in</text>
<text top="794" left="646" width="64" height="12" font="5"><a href="e127.full.html#52">Section 9.4</a></text>
<text top="794" left="711" width="3" height="12" font="2"><a href="e127.full.html#52">.</a></text>
<text top="812" left="438" width="318" height="12" font="2">In contrast, hypertensive urgencies are situations</text>
<text top="829" left="423" width="333" height="12" font="2">associated with severe BP elevation in otherwise stable</text>
<text top="847" left="423" width="333" height="12" font="2">patients without acute or impending change in target</text>
<text top="865" left="423" width="333" height="12" font="2">organ damage or dysfunction. Many of these patients</text>
<text top="883" left="423" width="333" height="12" font="2">have withdrawn from or are noncompliant with antihy-</text>
<text top="901" left="423" width="333" height="12" font="2">pertensive therapy and do not have clinical or laboratory</text>
<text top="919" left="423" width="333" height="12" font="2">evidence of acute target organ damage. These patients</text>
<text top="937" left="423" width="333" height="12" font="2">should not be considered as having a hypertensive</text>
<text top="955" left="423" width="333" height="12" font="2">emergency and instead are treated by reinstitution or</text>
<text top="973" left="423" width="40" height="12" font="2">intensi</text>
<text top="971" left="463" width="293" height="15" font="2">ﬁcation of antihypertensive drug therapy and</text>
<text top="991" left="423" width="333" height="12" font="2">treatment of anxiety as applicable. There is no indication</text>
<text top="1009" left="423" width="333" height="12" font="2">for referral to the emergency department, immediate</text>
<text top="1027" left="423" width="333" height="12" font="2">reduction in BP in the emergency department, or hospi-</text>
<text top="1045" left="423" width="161" height="12" font="2">talization for such patients.</text>
<text top="1063" left="438" width="49" height="11" font="5"><a href="e127.full.html#69">Figure 11</a></text>
<text top="1063" left="491" width="266" height="12" font="2">is an algorithm on diagnosis and management</text>
<text top="1080" left="423" width="149" height="12" font="2">of a hypertensive crisis.</text>
<text top="1081" left="580" width="106" height="11" font="5"><a href="e127.full.html#70">Tables 19 </a>and <a href="e127.full.html#71">20</a></text>
<text top="1080" left="693" width="64" height="12" font="2">summarize</text>
<text top="153" left="80" width="48" height="11" font="22">FIGURE 11</text>
<text top="154" left="136" width="230" height="9" font="23">Diagnosis and Management of a Hypertensive Crisis</text>
<text top="698" left="80" width="212" height="9" font="13">Colors correspond to Class of Recommendation in</text>
<text top="698" left="295" width="31" height="9" font="17"><a href="e127.full.html#6">Table 1</a></text>
<text top="698" left="326" width="83" height="9" font="13"><a href="e127.full.html#6">. </a>*Use drug(s) speci</text>
<text top="696" left="409" width="26" height="12" font="13">ﬁed in</text>
<text top="698" left="438" width="37" height="9" font="17"><a href="e127.full.html#70">Table 19</a></text>
<text top="698" left="475" width="3" height="9" font="13"><a href="e127.full.html#70">.</a></text>
<text top="696" left="480" width="258" height="12" font="13">†If other comorbidities are present, select a drug speciﬁed in</text>
<text top="713" left="80" width="38" height="9" font="17"><a href="e127.full.html#71">Table 20</a></text>
<text top="713" left="119" width="507" height="9" font="13"><a href="e127.full.html#71">. </a>BP indicates blood pressure; DBP, diastolic blood pressure; ICU, intensive care unit; and SBP, systolic blood pressure.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="19" height="9" font="4">e195</text>
</page>
<page number="70" position="absolute" top="0" left="0" height="1160" width="864">
<text top="842" left="108" width="333" height="12" font="2">intravenous antihypertensive drugs for treatment of</text>
<text top="860" left="108" width="156" height="12" font="2">hypertensive emergencies.</text>
<text top="887" left="108" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="885" left="247" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="914" left="109" width="332" height="12" font="2">1. There is no RCT evidence that antihypertensive drugs</text>
<text top="932" left="123" width="318" height="12" font="2">reduce morbidity or mortality in patients with hyper-</text>
<text top="950" left="123" width="120" height="12" font="2">tensive emergencies</text>
<text top="950" left="248" width="48" height="12" font="5"><a href="e127.full.html#108">(S11.2-8)</a></text>
<text top="950" left="296" width="145" height="12" font="2">. However, from clinical</text>
<text top="968" left="123" width="318" height="12" font="2">experience, it is highly likely that antihypertensive</text>
<text top="985" left="123" width="157" height="12" font="2">therapy is an overall bene</text>
<text top="984" left="280" width="161" height="15" font="2">ﬁt in a hypertensive emer-</text>
<text top="1003" left="123" width="34" height="12" font="2">gency</text>
<text top="1003" left="161" width="48" height="12" font="5"><a href="e127.full.html#108">(S11.2-9)</a></text>
<text top="1003" left="209" width="232" height="12" font="2">. There is also no high-quality RCT evi-</text>
<text top="1021" left="123" width="259" height="12" font="2">dence to inform clinicians as to which</text>
<text top="1020" left="391" width="50" height="15" font="2">ﬁrst-line</text>
<text top="1039" left="123" width="276" height="12" font="2">antihypertensive drug class provides more bene</text>
<text top="1037" left="399" width="42" height="15" font="2">ﬁt than</text>
<text top="1057" left="123" width="204" height="12" font="2">harm in hypertensive emergencies</text>
<text top="1057" left="332" width="48" height="12" font="5"><a href="e127.full.html#108">(S11.2-8)</a></text>
<text top="1057" left="380" width="61" height="12" font="2"><a href="e127.full.html#108">. </a>This lack</text>
<text top="1075" left="123" width="318" height="12" font="2">of evidence is related to the small size of trials, the lack</text>
<text top="1093" left="123" width="318" height="12" font="2">of long-term follow-up, and failure to report outcomes.</text>
<text top="842" left="483" width="318" height="12" font="2">However, 2 trials have demonstrated that nicardipine</text>
<text top="860" left="483" width="318" height="12" font="2">may be better than labetalol in achieving the short-</text>
<text top="878" left="483" width="84" height="12" font="2">term BP target</text>
<text top="878" left="572" width="90" height="12" font="5"><a href="e127.full.html#108">(S11.2-1,S11.2-10</a></text>
<text top="876" left="663" width="57" height="15" font="5"><a href="e127.full.html#108">—S11.2-12)</a></text>
<text top="878" left="720" width="81" height="12" font="2">. Several anti-</text>
<text top="896" left="483" width="318" height="12" font="2">hypertensive agents in various pharmacological classes</text>
<text top="914" left="483" width="318" height="12" font="2">are available for the treatment of hypertensive emer-</text>
<text top="932" left="483" width="54" height="12" font="2">gencies (</text>
<text top="932" left="537" width="50" height="11" font="5"><a href="e127.full.html#70">Table 19</a></text>
<text top="932" left="588" width="214" height="12" font="2"><a href="e127.full.html#70">). </a>Because autoregulation of tissue</text>
<text top="950" left="483" width="318" height="12" font="2">perfusion is disturbed in hypertensive emergencies,</text>
<text top="968" left="483" width="318" height="12" font="2">continuous infusion of short-acting titratable antihy-</text>
<text top="985" left="483" width="318" height="12" font="2">pertensive agents is often preferable to prevent further</text>
<text top="1003" left="483" width="121" height="12" font="2">target organ damage</text>
<text top="1003" left="608" width="90" height="12" font="5"><a href="e127.full.html#108">(S11.2-5,S11.2-6)</a></text>
<text top="1003" left="699" width="102" height="12" font="2"><a href="e127.full.html#108">. </a>The selection of</text>
<text top="1021" left="483" width="318" height="12" font="2">an antihypertensive agent should be based on the</text>
<text top="1039" left="483" width="27" height="12" font="2">drug</text>
<text top="1037" left="510" width="291" height="15" font="2">’s pharmacology, pathophysiological factors un-</text>
<text top="1057" left="483" width="114" height="12" font="2">derlying the patient</text>
<text top="1055" left="598" width="204" height="15" font="2">’s hypertension (as well as they can</text>
<text top="1075" left="483" width="318" height="12" font="2">be rapidly determined), degree of progression of target</text>
<text top="1093" left="483" width="318" height="12" font="2">organ damage, the desirable rate of BP decline, and the</text>
<text top="149" left="112" width="53" height="10" font="15">T A B L E 1 9</text>
<text top="149" left="179" width="430" height="10" font="16">Intravenous Antihypertensive Drugs for Treatment of Hypertensive Emergencies</text>
<text top="173" left="108" width="23" height="9" font="13">Class</text>
<text top="173" left="229" width="35" height="9" font="13">Drug(s)</text>
<text top="173" left="361" width="83" height="9" font="13">Usual Dose Range</text>
<text top="173" left="638" width="48" height="9" font="13">Comments</text>
<text top="192" left="108" width="17" height="9" font="13">CCB</text>
<text top="191" left="124" width="7" height="12" font="13">—</text>
<text top="204" left="120" width="69" height="9" font="13">dihydropyridines</text>
<text top="192" left="210" width="46" height="9" font="13">Nicardipine</text>
<text top="192" left="295" width="215" height="9" font="13">Initial 5 mg/h, increasing every 5 min by 2.5 mg/h to</text>
<text top="204" left="310" width="80" height="9" font="13">maximum 15 mg/h.</text>
<text top="192" left="523" width="270" height="9" font="13">Contraindicated in advanced aortic stenosis; no dose adjustment</text>
<text top="204" left="538" width="80" height="9" font="13">needed for elderly.</text>
<text top="224" left="210" width="45" height="9" font="13">Clevidipine</text>
<text top="224" left="295" width="30" height="9" font="13">Initial 1</text>
<text top="222" left="325" width="161" height="12" font="13">–2 mg/h, doubling every 90 s until BP</text>
<text top="236" left="310" width="199" height="9" font="13">approaches target, then increasing by less than</text>
<text top="248" left="310" width="61" height="9" font="13">double every 5</text>
<text top="246" left="371" width="139" height="12" font="13">–10 min; maximum dose 32 mg/h;</text>
<text top="260" left="310" width="102" height="9" font="13">maximum duration 72 h.</text>
<text top="224" left="523" width="278" height="9" font="13">Contraindicated in patients with soybean, soy product, egg, and egg</text>
<text top="236" left="538" width="263" height="9" font="13">product allergy and in patients with defective lipid metabolism</text>
<text top="248" left="538" width="248" height="9" font="13">(e.g., pathological hyperlipidemia, lipoid nephrosis or acute</text>
<text top="260" left="538" width="244" height="9" font="13">pancreatitis). Use low-end dose range for elderly patients.</text>
<text top="279" left="108" width="51" height="9" font="13">Vasodilators</text>
<text top="277" left="159" width="33" height="12" font="13">—Nitric-</text>
<text top="291" left="120" width="70" height="9" font="13">oxide dependent</text>
<text top="279" left="210" width="31" height="9" font="13">Sodium</text>
<text top="291" left="225" width="54" height="9" font="13">nitroprusside</text>
<text top="279" left="295" width="40" height="9" font="13">Initial 0.3</text>
<text top="277" left="335" width="170" height="12" font="13">–0.5 mcg/kg/min; increase in increments</text>
<text top="291" left="310" width="171" height="9" font="13">of 0.5 mcg/kg/min to achieve BP target;</text>
<text top="303" left="310" width="182" height="9" font="13">maximum dose 10 mcg/kg/min; duration of</text>
<text top="315" left="310" width="182" height="9" font="13">treatment as short as possible. For infusion</text>
<text top="327" left="310" width="21" height="9" font="13">rates</text>
<text top="325" left="333" width="173" height="12" font="13">$4–10 mcg/kg/min or duration &gt;30 min,</text>
<text top="339" left="310" width="189" height="9" font="13">thiosulfate can be coadministered to prevent</text>
<text top="350" left="310" width="68" height="9" font="13">cyanide toxicity.</text>
<text top="279" left="523" width="223" height="9" font="13">Intra-arterial BP monitoring recommended to prevent</text>
<text top="277" left="749" width="52" height="12" font="13">“overshoot.”</text>
<text top="291" left="538" width="254" height="9" font="13">Lower dosing adjustment required for elderly. Tachyphylaxis</text>
<text top="303" left="538" width="119" height="9" font="13">common with extended use.</text>
<text top="315" left="523" width="255" height="9" font="13">Cyanide toxicity with prolonged use can result in irreversible</text>
<text top="327" left="538" width="168" height="9" font="13">neurological changes and cardiac arrest.</text>
<text top="370" left="210" width="54" height="9" font="13">Nitroglycerin</text>
<text top="370" left="295" width="214" height="9" font="13">Initial 5 mcg/min; increase in increments of 5 mcg/</text>
<text top="382" left="310" width="47" height="9" font="13">min every 3</text>
<text top="380" left="357" width="153" height="12" font="13">–5 min to a maximum of 20 mcg/min.</text>
<text top="370" left="523" width="270" height="9" font="13">Use only in patients with acute coronary syndrome and/or acute</text>
<text top="382" left="538" width="251" height="9" font="13">pulmonary edema. Do not use in volume-depleted patients.</text>
<text top="401" left="108" width="51" height="9" font="13">Vasodilators</text>
<text top="399" left="159" width="31" height="12" font="13">—direct</text>
<text top="401" left="210" width="49" height="9" font="13">Hydralazine</text>
<text top="401" left="295" width="210" height="9" font="13">Initial 10 mg via slow IV infusion (maximum initial</text>
<text top="413" left="310" width="121" height="9" font="13">dose 20 mg); repeat every 4</text>
<text top="411" left="431" width="66" height="12" font="13">–6 h as needed.</text>
<text top="401" left="523" width="135" height="9" font="13">BP begins to decrease within 10</text>
<text top="399" left="658" width="139" height="12" font="13">–30 min, and the fall lasts 2–4 h.</text>
<text top="413" left="538" width="261" height="9" font="13">Unpredictability of response and prolonged duration of action</text>
<text top="425" left="538" width="152" height="9" font="13">do not make hydralazine a desirable</text>
<text top="423" left="693" width="103" height="12" font="13">ﬁrst-line agent for acute</text>
<text top="437" left="538" width="115" height="9" font="13">treatment in most patients.</text>
<text top="456" left="108" width="83" height="9" font="13">Adrenergic blockers</text>
<text top="454" left="190" width="7" height="12" font="13">—</text>
<text top="468" left="123" width="18" height="9" font="13">beta</text>
<text top="472" left="141" width="3" height="6" font="25">1</text>
<text top="468" left="147" width="35" height="9" font="13">receptor</text>
<text top="480" left="123" width="36" height="9" font="13">selective</text>
<text top="492" left="123" width="44" height="9" font="13">antagonist</text>
<text top="456" left="210" width="33" height="9" font="13">Esmolol</text>
<text top="456" left="295" width="76" height="9" font="13">Loading dose 500</text>
<text top="454" left="371" width="127" height="12" font="13">–1000 mcg/kg/min over 1 min</text>
<text top="468" left="310" width="181" height="9" font="13">followed by a 50-mcg/kg/min infusion. For</text>
<text top="480" left="310" width="189" height="9" font="13">additional dosing, the bolus dose is repeated</text>
<text top="492" left="310" width="189" height="9" font="13">and the infusion increased in 50-mcg/kg/min</text>
<text top="504" left="310" width="187" height="9" font="13">increments as needed to a maximum of 200</text>
<text top="516" left="310" width="53" height="9" font="13">mcg/kg/min.</text>
<text top="456" left="523" width="276" height="9" font="13">Contraindicated in patients with concurrent beta-blocker therapy,</text>
<text top="468" left="538" width="149" height="9" font="13">bradycardia, or decompensated HF.</text>
<text top="480" left="523" width="102" height="9" font="13">Monitor for bradycardia.</text>
<text top="492" left="523" width="68" height="9" font="13">May worsen HF.</text>
<text top="504" left="523" width="118" height="9" font="13">Higher doses may block beta</text>
<text top="508" left="641" width="4" height="6" font="25">2</text>
<text top="504" left="647" width="154" height="9" font="13">receptors and impact lung function in</text>
<text top="516" left="538" width="99" height="9" font="13">reactive airway disease.</text>
<text top="535" left="108" width="83" height="9" font="13">Adrenergic blockers</text>
<text top="533" left="190" width="7" height="12" font="13">—</text>
<text top="547" left="123" width="66" height="9" font="13">combined alpha</text>
<text top="551" left="189" width="3" height="6" font="25">1</text>
<text top="559" left="123" width="71" height="9" font="13">and nonselective</text>
<text top="571" left="123" width="57" height="9" font="13">beta receptor</text>
<text top="583" left="123" width="44" height="9" font="13">antagonist</text>
<text top="535" left="210" width="39" height="9" font="13">Labetalol</text>
<text top="535" left="295" width="40" height="9" font="13">Initial 0.3</text>
<text top="533" left="335" width="173" height="12" font="13">–1.0-mg/kg dose (maximum 20 mg) slow</text>
<text top="547" left="310" width="132" height="9" font="13">IV injection every 10 min or 0.4</text>
<text top="545" left="442" width="68" height="12" font="13">–1.0-mg/kg/h IV</text>
<text top="559" left="310" width="200" height="9" font="13">infusion up to 3 mg/kg/h. Adjust rate up to total</text>
<text top="571" left="310" width="193" height="9" font="13">cumulative dose of 300 mg. This dose can be</text>
<text top="583" left="310" width="71" height="9" font="13">repeated every 4</text>
<text top="581" left="381" width="21" height="12" font="13">–6 h.</text>
<text top="535" left="523" width="274" height="9" font="13">Contraindicated in reactive airways disease or chronic obstructive</text>
<text top="547" left="538" width="234" height="9" font="13">pulmonary disease. Especially useful in hyperadrenergic</text>
<text top="559" left="538" width="263" height="9" font="13">syndromes. May worsen HF and should not be given in patients</text>
<text top="571" left="538" width="237" height="9" font="13">with second- or third-degree heart block or bradycardia.</text>
<text top="602" left="108" width="83" height="9" font="13">Adrenergic blockers</text>
<text top="600" left="190" width="7" height="12" font="13">—</text>
<text top="614" left="123" width="52" height="9" font="13">nonselective</text>
<text top="626" left="123" width="61" height="9" font="13">alpha receptor</text>
<text top="638" left="123" width="44" height="9" font="13">antagonist</text>
<text top="602" left="210" width="57" height="9" font="13">Phentolamine</text>
<text top="602" left="295" width="215" height="9" font="13">IV bolus dose 5 mg. Additional bolus doses every 10</text>
<text top="614" left="310" width="156" height="9" font="13">min as needed to lower BP to target.</text>
<text top="602" left="523" width="278" height="9" font="13">Used in hypertensive emergencies induced by catecholamine excess</text>
<text top="614" left="538" width="226" height="9" font="13">(pheochromocytoma, interactions between monamine</text>
<text top="626" left="538" width="250" height="9" font="13">oxidase inhibitors and other drugs or food, cocaine toxicity,</text>
<text top="638" left="538" width="208" height="9" font="13">amphetamine overdose, or clonidine withdrawal).</text>
<text top="657" left="108" width="42" height="9" font="13">Dopamine</text>
<text top="661" left="149" width="3" height="6" font="25">1</text>
<text top="657" left="152" width="39" height="9" font="13">-receptor</text>
<text top="669" left="123" width="70" height="9" font="13">selective agonist</text>
<text top="657" left="210" width="52" height="9" font="13">Fenoldopam</text>
<text top="657" left="295" width="39" height="9" font="13">Initial 0.1</text>
<text top="655" left="334" width="160" height="12" font="13">–0.3 mcg/kg/min; may be increased in</text>
<text top="669" left="310" width="81" height="9" font="13">increments of 0.05</text>
<text top="667" left="391" width="108" height="12" font="13">–0.1 mcg/kg/min every 15</text>
<text top="681" left="310" width="171" height="9" font="13">min until target BP is reached. Maximum</text>
<text top="693" left="310" width="124" height="9" font="13">infusion rate 1.6 mcg/kg/min.</text>
<text top="657" left="523" width="278" height="9" font="13">Contraindicated in patients at risk of increased intraocular pressure</text>
<text top="669" left="538" width="227" height="9" font="13">(glaucoma) or intracranial pressure and those with sul</text>
<text top="667" left="765" width="14" height="12" font="13">ﬁte</text>
<text top="681" left="538" width="31" height="9" font="13">allergy.</text>
<text top="712" left="108" width="55" height="9" font="13">ACE inhibitor</text>
<text top="712" left="210" width="45" height="9" font="13">Enalaprilat</text>
<text top="712" left="295" width="206" height="9" font="13">Initial 1.25 mg over a 5-min period. Doses can be</text>
<text top="724" left="310" width="189" height="9" font="13">increased up to 5 mg every 6 h as needed to</text>
<text top="736" left="310" width="77" height="9" font="13">achieve BP target.</text>
<text top="712" left="523" width="278" height="9" font="13">Contraindicated in pregnancy and should not be used in acute MI or</text>
<text top="724" left="538" width="125" height="9" font="13">bilateral renal artery stenosis.</text>
<text top="736" left="523" width="267" height="9" font="13">Mainly useful in hypertensive emergencies associated with high</text>
<text top="748" left="538" width="89" height="9" font="13">plasma renin activity.</text>
<text top="760" left="523" width="105" height="9" font="13">Dose not easily adjusted.</text>
<text top="772" left="523" width="278" height="9" font="13">Relatively slow onset of action (15 min) and unpredictability of BP</text>
<text top="784" left="538" width="40" height="9" font="13">response.</text>
<text top="807" left="108" width="477" height="8" font="4">BP indicates blood pressure; CCB, calcium channel blocker; HF, heart failure; IV, intravenous; and MI, myocardial infarction.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="20" height="9" font="4">e196</text>
</page>
<page number="71" position="absolute" top="0" left="0" height="1160" width="864">
<text top="662" left="78" width="161" height="12" font="2">presence of comorbidities (</text>
<text top="663" left="240" width="50" height="11" font="5"><a href="e127.full.html#71">Table 20</a></text>
<text top="662" left="290" width="106" height="12" font="2"><a href="e127.full.html#71">). </a>The therapeutic</text>
<text top="680" left="78" width="318" height="12" font="2">goal is to minimize target organ damage safely by rapid</text>
<text top="698" left="78" width="318" height="12" font="2">recognition of the problem and early initiation of</text>
<text top="716" left="78" width="235" height="12" font="2">appropriate antihypertensive treatment.</text>
<text top="734" left="63" width="333" height="12" font="2">2. Compelling conditions requiring rapid lowering of SBP,</text>
<text top="752" left="78" width="58" height="12" font="2">usually to</text>
<text top="750" left="140" width="256" height="15" font="2">&lt;140 mm Hg, in the ﬁrst hour of treatment</text>
<text top="770" left="78" width="318" height="12" font="2">include aortic dissection, severe preeclampsia or</text>
<text top="788" left="78" width="318" height="12" font="2">eclampsia, and pheochromocytoma with hypertensive</text>
<text top="806" left="78" width="33" height="12" font="2">crisis.</text>
<text top="824" left="63" width="333" height="12" font="2">3. There is no RCT evidence comparing different strate-</text>
<text top="842" left="78" width="277" height="12" font="2">gies to reduce BP, except in patients with ICH</text>
<text top="842" left="360" width="36" height="12" font="5"><a href="e127.full.html#108">(S11.2-</a></text>
<text top="860" left="78" width="59" height="12" font="5"><a href="e127.full.html#108">9,S11.2-13)</a></text>
<text top="860" left="137" width="259" height="12" font="2">. Neither is there RCT evidence to suggest</text>
<text top="662" left="438" width="318" height="12" font="2">how rapidly or how much BP should be lowered in a</text>
<text top="680" left="438" width="147" height="12" font="2">hypertensive emergency</text>
<text top="680" left="592" width="48" height="12" font="5"><a href="e127.full.html#108">(S11.2-9)</a></text>
<text top="680" left="641" width="116" height="12" font="2"><a href="e127.full.html#108">. </a>However, clinical</text>
<text top="698" left="438" width="318" height="12" font="2">experience indicates that excessive reduction of BP</text>
<text top="716" left="438" width="318" height="12" font="2">may cause or contribute to renal, cerebral, or coronary</text>
<text top="734" left="438" width="318" height="12" font="2">ischemia and should be avoided. Thus, comprehensive</text>
<text top="752" left="438" width="318" height="12" font="2">dosing of intravenous or even oral antihypertensive</text>
<text top="770" left="438" width="318" height="12" font="2">agents to rapidly lower BP is not without risk. Oral</text>
<text top="788" left="438" width="318" height="12" font="2">loading doses of antihypertensive agents can engender</text>
<text top="806" left="438" width="65" height="12" font="2">cumulative</text>
<text top="806" left="520" width="42" height="12" font="2">effects,</text>
<text top="806" left="579" width="44" height="12" font="2">causing</text>
<text top="806" left="640" width="72" height="12" font="2">hypotension</text>
<text top="806" left="729" width="27" height="12" font="2">after</text>
<text top="824" left="438" width="304" height="12" font="2">discharge from the emergency department or clinic.</text>
<text top="860" left="423" width="197" height="11" font="12">11.3. Cognitive Decline and Dementia</text>
<text top="156" left="67" width="55" height="10" font="15">T A B L E 2 0</text>
<text top="149" left="135" width="568" height="10" font="16">Intravenous Antihypertensive Drugs for Treatment of Hypertensive Emergencies in Patients With Selected</text>
<text top="163" left="135" width="73" height="10" font="16">Comorbidities</text>
<text top="187" left="63" width="57" height="9" font="13">Comorbidity</text>
<text top="187" left="258" width="83" height="9" font="13">Preferred Drug(s)</text>
<text top="187" left="342" width="4" height="9" font="17"><a href="e127.full.html#71">*</a></text>
<text top="187" left="553" width="48" height="9" font="13">Comments</text>
<text top="207" left="63" width="95" height="9" font="13">Acute aortic dissection</text>
<text top="207" left="230" width="75" height="9" font="13">Esmolol, labetalol</text>
<text top="207" left="398" width="142" height="9" font="13">Requires rapid lowering of SBP to</text>
<text top="205" left="543" width="59" height="12" font="13">#120 mm Hg.</text>
<text top="219" left="398" width="320" height="9" font="13">Beta blockade should precede vasodilator (e.g., nicardipine or nitroprusside)</text>
<text top="231" left="413" width="229" height="9" font="13">administration, if needed for BP control or to prevent re</text>
<text top="229" left="642" width="115" height="12" font="13">ﬂex tachycardia or inotropic</text>
<text top="242" left="413" width="46" height="9" font="13">effect; SBP</text>
<text top="241" left="462" width="205" height="12" font="13">#120 mm Hg should be achieved within 20 min.</text>
<text top="262" left="63" width="102" height="9" font="13">Acute pulmonary edema</text>
<text top="262" left="230" width="106" height="9" font="13">Clevidipine, nitroglycerin,</text>
<text top="274" left="245" width="54" height="9" font="13">nitroprusside</text>
<text top="262" left="398" width="127" height="9" font="13">Beta blockers contraindicated.</text>
<text top="293" left="63" width="111" height="9" font="13">Acute coronary syndromes</text>
<text top="293" left="230" width="36" height="9" font="13"><a href="e127.full.html#71">Esmolol,</a></text>
<text top="291" left="266" width="5" height="12" font="17"><a href="e127.full.html#71">†</a></text>
<text top="293" left="274" width="90" height="9" font="13">labetalol, nicardipine,</text>
<text top="305" left="245" width="53" height="9" font="13">nitroglycerin</text>
<text top="303" left="298" width="5" height="12" font="17"><a href="e127.full.html#71">†</a></text>
<text top="293" left="398" width="358" height="9" font="13">Nitrates given in the presence of PDE-5 inhibitors may induce profound hypotension.</text>
<text top="305" left="413" width="327" height="9" font="13">Contraindications to beta blockers include moderate-to-severe LV failure with</text>
<text top="317" left="413" width="134" height="9" font="13">pulmonary edema, bradycardia (</text>
<text top="315" left="547" width="210" height="12" font="13">&lt;60 bpm), hypotension (SBP &lt;100 mm Hg), poor</text>
<text top="329" left="413" width="331" height="9" font="13">peripheral perfusion, second- or third-degree heart block, and reactive airways</text>
<text top="341" left="413" width="33" height="9" font="13">disease.</text>
<text top="360" left="63" width="77" height="9" font="13">Acute renal failure</text>
<text top="360" left="230" width="104" height="9" font="13">Clevidipine, fenoldopam,</text>
<text top="372" left="245" width="45" height="9" font="13">nicardipine</text>
<text top="360" left="398" width="16" height="9" font="13">N/A</text>
<text top="391" left="63" width="110" height="9" font="13">Eclampsia or preeclampsia</text>
<text top="391" left="230" width="142" height="9" font="13">Hydralazine, labetalol, nicardipine</text>
<text top="391" left="398" width="116" height="9" font="13">Requires rapid BP lowering.</text>
<text top="403" left="398" width="303" height="9" font="13">ACE inhibitors, ARBs, renin inhibitors, and nitroprusside contraindicated.</text>
<text top="422" left="63" width="112" height="9" font="13">Perioperative hypertension</text>
<text top="434" left="78" width="14" height="9" font="13">(BP</text>
<text top="432" left="95" width="104" height="12" font="13">$160/90 mm Hg or SBP</text>
<text top="446" left="78" width="38" height="9" font="13">elevation</text>
<text top="444" left="119" width="56" height="12" font="13">$20% of the</text>
<text top="458" left="78" width="98" height="9" font="13">preoperative value that</text>
<text top="470" left="78" width="47" height="9" font="13">persists for</text>
<text top="468" left="128" width="38" height="12" font="13">&gt;15 min)</text>
<text top="422" left="230" width="137" height="9" font="13">Clevidipine, esmolol, nicardipine,</text>
<text top="434" left="245" width="53" height="9" font="13">nitroglycerin</text>
<text top="422" left="398" width="354" height="9" font="13">Intraoperative hypertension is most frequently seen during anesthesia induction and</text>
<text top="434" left="413" width="87" height="9" font="13">airway manipulation.</text>
<text top="489" left="63" width="132" height="9" font="13">Acute sympathetic discharge or</text>
<text top="501" left="78" width="118" height="9" font="13">catecholamine excess states</text>
<text top="513" left="78" width="110" height="9" font="13">(e.g., pheochromocytoma,</text>
<text top="525" left="78" width="120" height="9" font="13">post-carotid endarterectomy</text>
<text top="537" left="78" width="28" height="9" font="13">status)</text>
<text top="489" left="230" width="99" height="9" font="13">Clevidipine, nicardipine,</text>
<text top="501" left="245" width="57" height="9" font="13">phentolamine</text>
<text top="489" left="398" width="128" height="9" font="13">Requires rapid lowering of BP.</text>
<text top="556" left="63" width="42" height="9" font="13">Acute ICH</text>
<text top="556" left="230" width="54" height="9" font="17"><a href="e127.full.html#52">Section 9.4.1</a></text>
<text top="556" left="398" width="54" height="9" font="17"><a href="e127.full.html#52">Section 9.4.1</a></text>
<text top="576" left="63" width="91" height="9" font="13">Acute ischemic stroke</text>
<text top="576" left="230" width="55" height="9" font="17"><a href="e127.full.html#54">Section 9.4.2</a></text>
<text top="576" left="398" width="55" height="9" font="17"><a href="e127.full.html#54">Section 9.4.2</a></text>
<text top="601" left="63" width="260" height="8" font="4">*Agents are listed in alphabetical order, not in order of preference.</text>
<text top="599" left="325" width="185" height="11" font="4">†Agent of choice for acute coronary syndromes.</text>
<text top="615" left="71" width="686" height="8" font="4">ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; bpm, beats per minute; ICH, intracerebral hemorrhage; LV, left ventricular;</text>
<text top="627" left="63" width="262" height="8" font="4">PDE-5, phosphodiesterase type-5; and SBP, systolic blood pressure.</text>
<text top="917" left="63" width="379" height="11" font="19">Recommendation for Prevention of Cognitive Decline and Dementia</text>
<text top="932" left="63" width="362" height="11" font="19">References that support the recommendation are summarized in</text>
<text top="932" left="429" width="153" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 56</a></text>
<text top="932" left="583" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="973" left="89" width="19" height="10" font="13">COR</text>
<text top="973" left="161" width="18" height="10" font="13">LOE</text>
<text top="973" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="1009" left="94" width="10" height="9" font="4">IIa</text>
<text top="1009" left="163" width="15" height="9" font="4">B-R</text>
<text top="997" left="234" width="533" height="11" font="12">1. In adults with hypertension, BP lowering is reasonable to prevent cognitive decline and dementia</text>
<text top="1013" left="246" width="40" height="11" font="5"><a href="e127.full.html#108">(S11.3-1</a></text>
<text top="1011" left="287" width="51" height="15" font="5"><a href="e127.full.html#108">—S11.3-6)</a></text>
<text top="1013" left="338" width="3" height="11" font="12">.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="19" height="9" font="4">e197</text>
</page>
<page number="72" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="161" left="123" width="318" height="12" font="2">Dementia is a leading cause of mortality and placement</text>
<text top="178" left="108" width="333" height="12" font="2">into nursing homes and assisted living facilities, affecting</text>
<text top="195" left="108" width="333" height="15" font="2">&gt;46 million individuals globally and 5 million persons in</text>
<text top="214" left="108" width="333" height="12" font="2">the United States, a number that is expected to double by</text>
<text top="232" left="108" width="28" height="12" font="2">2050</text>
<text top="232" left="139" width="47" height="12" font="5"><a href="e127.full.html#108">(S11.3-7)</a></text>
<text top="232" left="186" width="255" height="12" font="2">. A 5-year delay in onset of dementia would</text>
<text top="250" left="108" width="333" height="12" font="2">likely decrease the number of cases of incident dementia</text>
<text top="268" left="108" width="219" height="12" font="2">by about 50% after several decades</text>
<text top="268" left="333" width="48" height="12" font="5"><a href="e127.full.html#108">(S11.3-8)</a></text>
<text top="268" left="381" width="60" height="12" font="2">. Vascular</text>
<text top="286" left="108" width="333" height="12" font="2">disease and its risk factors are implicated in a large pro-</text>
<text top="304" left="108" width="333" height="12" font="2">portion of patients with dementia, including those with</text>
<text top="322" left="108" width="59" height="12" font="2">Alzheimer</text>
<text top="320" left="167" width="68" height="15" font="2">’s dementia</text>
<text top="322" left="240" width="43" height="12" font="5"><a href="e127.full.html#108">(S11.3-9</a></text>
<text top="320" left="284" width="56" height="15" font="5"><a href="e127.full.html#108">—S11.3-11)</a></text>
<text top="322" left="340" width="101" height="12" font="2">. Hypertension is</text>
<text top="340" left="108" width="23" height="12" font="2">also</text>
<text top="340" left="148" width="19" height="12" font="2">the</text>
<text top="340" left="184" width="46" height="12" font="2">primary</text>
<text top="340" left="247" width="21" height="12" font="2">risk</text>
<text top="340" left="285" width="33" height="12" font="2">factor</text>
<text top="340" left="336" width="16" height="12" font="2">for</text>
<text top="340" left="370" width="71" height="12" font="2">small-vessel</text>
<text top="358" left="108" width="333" height="12" font="2">ischemic disease and cortical white matter abnormalities</text>
<text top="376" left="108" width="48" height="12" font="5"><a href="e127.full.html#108">(S11.3-12</a></text>
<text top="374" left="156" width="57" height="15" font="5"><a href="e127.full.html#108">—S11.3-15)</a></text>
<text top="376" left="213" width="3" height="12" font="2">.</text>
<text top="376" left="229" width="28" height="12" font="2">Most</text>
<text top="376" left="269" width="78" height="12" font="2">observational</text>
<text top="376" left="360" width="41" height="12" font="2">studies</text>
<text top="376" left="413" width="28" height="12" font="2">have</text>
<text top="394" left="108" width="333" height="12" font="2">suggested that better control of SBP may reduce</text>
<text top="412" left="108" width="59" height="12" font="2">Alzheimer</text>
<text top="410" left="167" width="274" height="15" font="2">’s disease and other dementias, and the evi-</text>
<text top="430" left="108" width="333" height="12" font="2">dence is stronger for BP lowering in middle age than in</text>
<text top="447" left="108" width="70" height="12" font="2">older adults</text>
<text top="447" left="181" width="96" height="12" font="5"><a href="e127.full.html#108">(S11.3-9,S11.3-16)</a></text>
<text top="447" left="278" width="163" height="12" font="2">. Clinical trials with demen-</text>
<text top="465" left="108" width="333" height="12" font="2">tia assessment have evaluated all-cause dementia but not</text>
<text top="483" left="108" width="59" height="12" font="2">Alzheimer</text>
<text top="482" left="167" width="274" height="15" font="2">’s disease speciﬁcally. However, all of these</text>
<text top="501" left="108" width="333" height="12" font="2">trials have methodological issues, such as low power,</text>
<text top="519" left="108" width="29" height="12" font="2">insuf</text>
<text top="517" left="137" width="304" height="15" font="2">ﬁcient follow-up length, and inadequately designed</text>
<text top="537" left="108" width="183" height="12" font="2">dementia assessment batteries.</text>
<text top="555" left="108" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="553" left="247" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="582" left="108" width="333" height="12" font="2">1. Five clinical trials of BP lowering have included</text>
<text top="600" left="122" width="319" height="12" font="2">assessment for incident dementia. Of these 5 trials, 4</text>
<text top="618" left="122" width="319" height="12" font="2">demonstrated a reduction in dementia incidence, with</text>
<text top="636" left="122" width="245" height="12" font="2">2 of these 4 demonstrating statistical signi</text>
<text top="634" left="367" width="74" height="15" font="2">ﬁcance (746-</text>
<text top="654" left="122" width="319" height="12" font="2">751). SYST-EUR (Systolic Hypertension in Europe)</text>
<text top="672" left="122" width="52" height="12" font="5"><a href="e127.full.html#108">(S11.3-17)</a></text>
<text top="672" left="187" width="21" height="12" font="2">and</text>
<text top="672" left="222" width="62" height="12" font="2">PROGRESS</text>
<text top="672" left="298" width="69" height="12" font="2">(Perindopril</text>
<text top="672" left="381" width="60" height="12" font="2">Protection</text>
<text top="690" left="122" width="152" height="12" font="2">Against Recurrent Stroke)</text>
<text top="690" left="280" width="53" height="12" font="5"><a href="e127.full.html#108">(S11.3-18)</a></text>
<text top="690" left="338" width="103" height="12" font="2">both showed sta-</text>
<text top="708" left="122" width="83" height="12" font="2">tistically signi</text>
<text top="706" left="205" width="236" height="15" font="2">ﬁcant reductions in incident dementia.</text>
<text top="725" left="122" width="319" height="12" font="2">SYST-EUR achieved an SBP of 152 mm Hg in the treat-</text>
<text top="743" left="122" width="319" height="12" font="2">ment arm (8.3 mm Hg lower than placebo arm) during</text>
<text top="761" left="122" width="319" height="12" font="2">its blinded phase and an SBP of 149 mm Hg (7.0 mm Hg</text>
<text top="779" left="122" width="319" height="12" font="2">lower than comparison group) during its open-label</text>
<text top="797" left="122" width="95" height="12" font="2">follow-up phase</text>
<text top="797" left="222" width="90" height="12" font="5"><a href="e127.full.html#108">(S11.3-2,S11.3-3)</a></text>
<text top="797" left="312" width="129" height="12" font="2">. PROGRESS achieved</text>
<text top="815" left="122" width="319" height="12" font="2">an SBP of 138 mm Hg in the treatment group (9 mm Hg</text>
<text top="833" left="122" width="319" height="12" font="2">lower than the placebo group) and demonstrated de-</text>
<text top="851" left="122" width="319" height="12" font="2">mentia prevention in patients with a recent stroke</text>
<text top="869" left="122" width="47" height="12" font="5"><a href="e127.full.html#108">(S11.3-5)</a></text>
<text top="869" left="169" width="163" height="12" font="2"><a href="e127.full.html#108">. </a>The trial showing no bene</text>
<text top="867" left="333" width="108" height="15" font="2">ﬁt in the direction</text>
<text top="887" left="122" width="319" height="12" font="2">of dementia reduction achieved an SBP reduction of</text>
<text top="905" left="122" width="319" height="12" font="2">only 3.2 mm Hg, whereas the other 4 trials achieved</text>
<text top="923" left="122" width="319" height="12" font="2">SBP reductions of 7 to 15 mm Hg (746-751). When the</text>
<text top="941" left="122" width="319" height="12" font="2">rate of cognitive decline (not dementia) has been a trial</text>
<text top="959" left="122" width="319" height="12" font="2">outcome, 7 clinical trials of BP-lowering therapy have</text>
<text top="976" left="122" width="307" height="12" font="2">been completed, and 2 of these have shown bene</text>
<text top="975" left="429" width="12" height="15" font="2">ﬁt</text>
<text top="994" left="122" width="44" height="12" font="5"><a href="e127.full.html#108">(S11.3-4</a></text>
<text top="993" left="166" width="155" height="15" font="5"><a href="e127.full.html#108">—S11.3-6,S11.3-19—S11.3-22)</a></text>
<text top="994" left="321" width="3" height="12" font="2">.</text>
<text top="994" left="340" width="16" height="12" font="2">No</text>
<text top="994" left="372" width="69" height="12" font="2">randomized</text>
<text top="1012" left="122" width="319" height="12" font="2">trial of BP lowering has demonstrated an adverse</text>
<text top="143" left="482" width="319" height="12" font="2">impact on dementia incidence or cognitive function.</text>
<text top="161" left="482" width="293" height="12" font="2">However, the anticipated results from SPRINT, the</text>
<text top="159" left="778" width="23" height="15" font="2">ﬁrst</text>
<text top="178" left="482" width="319" height="12" font="2">adequately powered RCT to test whether intensive BP</text>
<text top="196" left="482" width="319" height="12" font="2">control reduces dementia, may help clarify this issue in</text>
<text top="214" left="482" width="92" height="12" font="2">the near future.</text>
<text top="253" left="468" width="228" height="11" font="12">11.4. Sexual Dysfunction and Hypertension</text>
<text top="274" left="468" width="333" height="12" font="2">An association among sexual dysfunction, atheroscle-</text>
<text top="292" left="468" width="333" height="12" font="2">rosis, and hypertension can be constructed from several</text>
<text top="310" left="468" width="333" height="12" font="2">epidemiology surveys, clinical trials, and cohort studies.</text>
<text top="328" left="468" width="333" height="12" font="2">Although these data converge to suggest that endothelial</text>
<text top="346" left="468" width="333" height="12" font="2">dysfunction is a common denominator, the story is</text>
<text top="364" left="468" width="333" height="12" font="2">incomplete. Sexual dysfunction represents several do-</text>
<text top="382" left="468" width="333" height="12" font="2">mains in desire or interest, as well as physical limitations</text>
<text top="400" left="468" width="333" height="12" font="2">such as erectile dysfunction. In addition, beta blockers,</text>
<text top="418" left="468" width="333" height="12" font="2">mineralocorticoid receptor antagonists, and other anti-</text>
<text top="436" left="468" width="333" height="12" font="2">hypertensive drugs can have negative effects on libido</text>
<text top="454" left="468" width="333" height="12" font="2">and erectile function. There are emerging data on the</text>
<text top="472" left="468" width="64" height="12" font="2">association</text>
<text top="472" left="545" width="49" height="12" font="2">between</text>
<text top="472" left="606" width="43" height="12" font="2">erectile</text>
<text top="472" left="661" width="69" height="12" font="2">dysfunction</text>
<text top="472" left="743" width="21" height="12" font="2">and</text>
<text top="472" left="776" width="25" height="12" font="2">CVD</text>
<text top="489" left="468" width="333" height="12" font="2">compared with other domains of sexual dysfunction.</text>
<text top="507" left="468" width="333" height="12" font="2">Experimental and clinical studies describe a role for</text>
<text top="525" left="468" width="287" height="12" font="2">angiotensin II, endothelin, and hydrogen sul</text>
<text top="523" left="756" width="46" height="15" font="2">ﬁde on</text>
<text top="543" left="468" width="149" height="12" font="2">cavernous tissue function</text>
<text top="543" left="621" width="47" height="12" font="5"><a href="e127.full.html#108">(S11.4-1)</a></text>
<text top="543" left="668" width="133" height="12" font="2">. Many of the signaling</text>
<text top="561" left="468" width="333" height="12" font="2">pathways for the increased production of oxidative stress</text>
<text top="579" left="468" width="333" height="12" font="2">and the subsequent deleterious effects of oxidative stress</text>
<text top="597" left="468" width="333" height="12" font="2">on vascular tissue have been described. Accordingly, it is</text>
<text top="615" left="468" width="333" height="12" font="2">reasonable to suggest that hypertension might lead to</text>
<text top="633" left="468" width="333" height="12" font="2">vascular changes that cause erectile dysfunction but,</text>
<text top="651" left="468" width="333" height="12" font="2">conversely, erectile dysfunction may be part of the causal</text>
<text top="669" left="468" width="97" height="12" font="2">pathway to CVD</text>
<text top="669" left="570" width="47" height="12" font="5"><a href="e127.full.html#108">(S11.4-1)</a></text>
<text top="669" left="617" width="147" height="12" font="2">. Although there is insuf</text>
<text top="667" left="765" width="36" height="15" font="2">ﬁcient</text>
<text top="687" left="468" width="333" height="12" font="2">evidence to recommend screening for CVD risk factors in</text>
<text top="705" left="468" width="333" height="12" font="2">all men with erectile dysfunction, it has been reported as</text>
<text top="723" left="468" width="187" height="12" font="2">a sole precursor for CVD in men</text>
<text top="723" left="659" width="44" height="12" font="5"><a href="e127.full.html#108">(S11.4-2</a></text>
<text top="721" left="703" width="54" height="15" font="5"><a href="e127.full.html#108">—S11.4-6)</a></text>
<text top="723" left="757" width="3" height="12" font="2"><a href="e127.full.html#108">.</a></text>
<text top="741" left="483" width="318" height="12" font="2">With the introduction of the phosphodiesterase-5 in-</text>
<text top="758" left="468" width="333" height="12" font="2">hibitors, which can be coadministered with antihyper-</text>
<text top="776" left="468" width="333" height="12" font="2">tensive medications, there is now effective therapy for</text>
<text top="794" left="468" width="333" height="12" font="2">erectile dysfunction that has implications for systemic</text>
<text top="812" left="468" width="98" height="12" font="2">vascular disease</text>
<text top="812" left="575" width="48" height="12" font="5"><a href="e127.full.html#108">(S11.4-7)</a></text>
<text top="812" left="623" width="178" height="12" font="2"><a href="e127.full.html#108">. </a>These drugs have additive</text>
<text top="830" left="468" width="333" height="12" font="2">effects on lowering BP and are recommended as a pri-</text>
<text top="848" left="468" width="270" height="12" font="2">mary therapy for pulmonary hypertension</text>
<text top="848" left="748" width="49" height="12" font="5"><a href="e127.full.html#108">(S11.4-8)</a></text>
<text top="848" left="798" width="3" height="12" font="2"><a href="e127.full.html#108">.</a></text>
<text top="866" left="468" width="333" height="12" font="2">Although data are available to suggest that some anti-</text>
<text top="884" left="468" width="333" height="12" font="2">hypertensive medications affect erectile dysfunction</text>
<text top="902" left="468" width="333" height="12" font="2">more than others, the use of phosphodiesterase-5 in-</text>
<text top="920" left="468" width="44" height="12" font="2">hibitors</text>
<text top="920" left="525" width="31" height="12" font="2">make</text>
<text top="920" left="569" width="27" height="12" font="2">drug</text>
<text top="920" left="608" width="27" height="12" font="2">class</text>
<text top="920" left="648" width="68" height="12" font="2">distinctions</text>
<text top="920" left="729" width="16" height="12" font="2">for</text>
<text top="920" left="758" width="43" height="12" font="2">erectile</text>
<text top="938" left="468" width="69" height="12" font="2">dysfunction</text>
<text top="938" left="550" width="21" height="12" font="2">less</text>
<text top="938" left="584" width="48" height="12" font="2">relevant</text>
<text top="938" left="644" width="49" height="12" font="5"><a href="e127.full.html#108">(S11.4-9)</a></text>
<text top="938" left="693" width="3" height="12" font="2">.</text>
<text top="938" left="710" width="22" height="12" font="2">The</text>
<text top="938" left="744" width="57" height="12" font="2">long-term</text>
<text top="956" left="468" width="35" height="12" font="2">safety</text>
<text top="956" left="516" width="21" height="12" font="2">and</text>
<text top="956" left="551" width="11" height="12" font="2">ef</text>
<text top="954" left="563" width="239" height="15" font="2">ﬁcacy of chronic administration of</text>
<text top="974" left="468" width="333" height="12" font="2">phosphodiesterase-5 inhibitors for the mitigation of CVD</text>
<text top="992" left="468" width="333" height="12" font="2">has yet to be determined and represents an important</text>
<text top="1009" left="468" width="92" height="12" font="2">knowledge gap.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="20" height="9" font="4">e198</text>
</page>
<page number="73" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="245" height="11" font="12">11.5. Patients Undergoing Surgical Procedures</text>
<text top="733" left="63" width="52" height="12" font="2">Synopsis</text>
<text top="751" left="78" width="318" height="12" font="2">Hypertension in the perioperative period increases</text>
<text top="769" left="63" width="333" height="12" font="2">the risk of CVD, cerebrovascular events, and bleeding</text>
<text top="787" left="63" width="101" height="12" font="5"><a href="e127.full.html#109">(S11.5-15,S11.5-16)</a></text>
<text top="787" left="164" width="232" height="12" font="2"><a href="e127.full.html#109">. </a>As many as 25% of patients who un-</text>
<text top="805" left="63" width="194" height="12" font="2">dergo major noncardiac surgery</text>
<text top="805" left="264" width="52" height="12" font="5"><a href="e127.full.html#109">(S11.5-17)</a></text>
<text top="805" left="324" width="73" height="12" font="2">and 80% of</text>
<text top="823" left="63" width="333" height="12" font="2">patients who have cardiac surgery experience periop-</text>
<text top="841" left="63" width="40" height="12" font="2">erative</text>
<text top="841" left="116" width="77" height="12" font="2">hypertension</text>
<text top="841" left="206" width="102" height="12" font="5"><a href="e127.full.html#109">(S11.5-16,S11.5-18)</a></text>
<text top="841" left="308" width="3" height="12" font="2"><a href="e127.full.html#109">.</a></text>
<text top="841" left="325" width="12" height="12" font="2">In</text>
<text top="841" left="350" width="47" height="12" font="2">general,</text>
<text top="859" left="63" width="333" height="12" font="2">the level of risk is related to the severity of the</text>
<text top="877" left="63" width="80" height="12" font="2">hypertension.</text>
<text top="895" left="78" width="203" height="12" font="2">No high-quality RCTs were identi</text>
<text top="893" left="281" width="115" height="15" font="2">ﬁed relating to the</text>
<text top="913" left="63" width="333" height="12" font="2">treatment of hypertension in patients undergoing major</text>
<text top="931" left="63" width="333" height="12" font="2">surgical procedures. One analysis evaluated data from 3</text>
<text top="949" left="63" width="333" height="12" font="2">prospective, randomized, open-label, parallel-compari-</text>
<text top="967" left="63" width="333" height="12" font="2">son studies in patients undergoing cardiac surgery and</text>
<text top="984" left="63" width="333" height="12" font="2">concluded that clevidipine is a safe and effective treat-</text>
<text top="1002" left="63" width="333" height="12" font="2">ment for acute hypertension in patients undergoing car-</text>
<text top="1020" left="63" width="74" height="12" font="2">diac surgery</text>
<text top="1020" left="143" width="53" height="12" font="5"><a href="e127.full.html#109">(S11.5-19)</a></text>
<text top="1020" left="197" width="200" height="12" font="2"><a href="e127.full.html#109">. </a>Another systematic review and</text>
<text top="1038" left="63" width="333" height="12" font="2">meta-analysis, including 4 studies, concluded that clevi-</text>
<text top="1056" left="63" width="333" height="12" font="2">dipine is more effective than other antihypertensive</text>
<text top="1074" left="63" width="333" height="12" font="2">drugs in the management of perioperative hypertension</text>
<text top="1092" left="63" width="45" height="12" font="2">without</text>
<text top="1092" left="121" width="45" height="12" font="2">adverse</text>
<text top="1092" left="178" width="38" height="12" font="2">events</text>
<text top="1092" left="228" width="54" height="12" font="5"><a href="e127.full.html#109">(S11.5-20)</a></text>
<text top="1092" left="283" width="3" height="12" font="2">.</text>
<text top="1092" left="299" width="42" height="12" font="2">Several</text>
<text top="1092" left="353" width="43" height="12" font="2">general</text>
<text top="733" left="423" width="333" height="12" font="2">strategies and principles based on experience and obser-</text>
<text top="751" left="423" width="333" height="12" font="2">vation are recommended for this section. In the man-</text>
<text top="769" left="423" width="333" height="12" font="2">agement of patients with perioperative hypertension, it is</text>
<text top="787" left="423" width="333" height="12" font="2">important to assess other potential contributing factors,</text>
<text top="805" left="423" width="333" height="12" font="2">such as volume status, pain control, oxygenation, and</text>
<text top="823" left="423" width="333" height="12" font="2">bladder distention, when the use of pharmacological</text>
<text top="841" left="423" width="333" height="12" font="2">therapy to control BP is under consideration. Uncon-</text>
<text top="859" left="423" width="333" height="12" font="2">trolled hypertension is associated with increased periop-</text>
<text top="877" left="423" width="40" height="12" font="2">erative</text>
<text top="877" left="480" width="21" height="12" font="2">and</text>
<text top="877" left="518" width="79" height="12" font="2">postoperative</text>
<text top="877" left="614" width="84" height="12" font="2">complications.</text>
<text top="877" left="714" width="42" height="12" font="2">Certain</text>
<text top="895" left="423" width="333" height="12" font="2">medications (e.g., beta blockers, clonidine) may be asso-</text>
<text top="913" left="423" width="35" height="12" font="2">ciated</text>
<text top="913" left="471" width="26" height="12" font="2">with</text>
<text top="913" left="509" width="48" height="12" font="2">rebound</text>
<text top="913" left="570" width="77" height="12" font="2">hypertension</text>
<text top="913" left="660" width="8" height="12" font="2">if</text>
<text top="913" left="681" width="76" height="12" font="2">discontinued</text>
<text top="931" left="423" width="49" height="12" font="2">abruptly</text>
<text top="931" left="478" width="52" height="12" font="5"><a href="e127.full.html#109">(S11.5-13)</a></text>
<text top="931" left="530" width="226" height="12" font="2">. Therefore, several general strategies</text>
<text top="949" left="423" width="333" height="12" font="2">and principles based on experience and observation are</text>
<text top="967" left="423" width="178" height="12" font="2">recommended for this section.</text>
<text top="984" left="438" width="319" height="12" font="2">These recommendations for beta blockers, ACE in-</text>
<text top="1002" left="423" width="297" height="12" font="2">hibitors, and ARBs are generally consistent with the</text>
<text top="1001" left="724" width="33" height="15" font="2">“2014</text>
<text top="1020" left="423" width="333" height="12" font="2">ACC/AHA Guideline on Perioperative Cardiovascular</text>
<text top="1038" left="423" width="333" height="12" font="2">Evaluation and Management of Patients Undergoing</text>
<text top="1056" left="423" width="116" height="12" font="2">Noncardiac Surgery</text>
<text top="1054" left="539" width="217" height="15" font="2">” and are provided to assist in the</text>
<text top="1074" left="423" width="333" height="12" font="2">management of patients undergoing major noncardiac</text>
<text top="1092" left="423" width="113" height="12" font="2">surgical procedures</text>
<text top="1092" left="541" width="52" height="12" font="5"><a href="e127.full.html#109">(S11.5-21)</a></text>
<text top="1092" left="593" width="3" height="12" font="2">.</text>
<text top="176" left="63" width="526" height="11" font="19">Recommendations for Treatment of Hypertension in Patients Undergoing Surgical Procedures</text>
<text top="190" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="190" left="412" width="200" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplements 57 and 58</a></text>
<text top="190" left="612" width="3" height="11" font="19">.</text>
<text top="228" left="399" width="67" height="11" font="12">Preoperative</text>
<text top="262" left="89" width="19" height="10" font="13">COR</text>
<text top="262" left="161" width="18" height="10" font="13">LOE</text>
<text top="262" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="299" left="97" width="3" height="9" font="4">I</text>
<text top="299" left="160" width="21" height="9" font="4">B-NR</text>
<text top="287" left="234" width="568" height="11" font="12">1. In patients with hypertension undergoing major surgery who have been on beta blockers chronically, beta</text>
<text top="303" left="246" width="156" height="11" font="12">blockers should be continued</text>
<text top="303" left="407" width="40" height="11" font="5"><a href="e127.full.html#108">(S11.5-1</a></text>
<text top="301" left="447" width="50" height="15" font="5"><a href="e127.full.html#108">—S11.5-7)</a></text>
<text top="303" left="497" width="3" height="11" font="12">.</text>
<text top="347" left="94" width="10" height="9" font="4">IIa</text>
<text top="347" left="160" width="20" height="9" font="4">C-EO</text>
<text top="335" left="234" width="556" height="11" font="12">2. In patients with hypertension undergoing planned elective major surgery, it is reasonable to continue</text>
<text top="351" left="248" width="252" height="11" font="12">medical therapy for hypertension until surgery.</text>
<text top="397" left="94" width="10" height="9" font="4">IIb</text>
<text top="397" left="160" width="21" height="9" font="4">B-NR</text>
<text top="385" left="234" width="566" height="11" font="12">3. In patients with hypertension undergoing major surgery, discontinuation of ACE inhibitors or ARBs per-</text>
<text top="400" left="248" width="166" height="11" font="12">ioperatively may be considered</text>
<text top="400" left="417" width="43" height="11" font="5"><a href="e127.full.html#109">(S11.5-8</a></text>
<text top="398" left="460" width="57" height="15" font="5"><a href="e127.full.html#109">—S11.5-10)</a></text>
<text top="400" left="517" width="3" height="11" font="12">.</text>
<text top="446" left="94" width="10" height="9" font="4">IIb</text>
<text top="446" left="160" width="20" height="9" font="4">C-LD</text>
<text top="434" left="234" width="568" height="11" font="12">4. In patients with planned elective major surgery and SBP of 180 mm Hg or higher or DBP of 110 mm Hg or</text>
<text top="450" left="249" width="236" height="11" font="12">higher, deferring surgery may be considered</text>
<text top="450" left="489" width="96" height="11" font="5"><a href="e127.full.html#109">(S11.5-11,S11.5-12)</a></text>
<text top="450" left="585" width="3" height="11" font="12"><a href="e127.full.html#109">.</a></text>
<text top="496" left="81" width="35" height="9" font="4">III: Harm</text>
<text top="496" left="160" width="21" height="9" font="4">B-NR</text>
<text top="484" left="234" width="553" height="11" font="12">5. For patients undergoing surgery, abrupt preoperative discontinuation of beta blockers or clonidine is</text>
<text top="499" left="248" width="103" height="11" font="12">potentially harmful</text>
<text top="499" left="354" width="92" height="11" font="5"><a href="e127.full.html#108">(S11.5-2,S11.5-13)</a></text>
<text top="499" left="447" width="3" height="11" font="12"><a href="e127.full.html#108">.</a></text>
<text top="545" left="81" width="35" height="9" font="4">III: Harm</text>
<text top="545" left="160" width="21" height="9" font="4">B-NR</text>
<text top="533" left="234" width="408" height="11" font="12">6. Beta blockers should not be started on the day of surgery in beta blocker</text>
<text top="531" left="642" width="80" height="15" font="12">–naïve patients</text>
<text top="533" left="726" width="52" height="11" font="5"><a href="e127.full.html#109">(S11.5-14)</a></text>
<text top="533" left="778" width="3" height="11" font="12">.</text>
<text top="591" left="395" width="74" height="11" font="12">Intraoperative</text>
<text top="625" left="89" width="19" height="10" font="13">COR</text>
<text top="625" left="161" width="18" height="10" font="13">LOE</text>
<text top="625" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="662" left="97" width="3" height="9" font="4">I</text>
<text top="662" left="160" width="20" height="9" font="4">C-EO</text>
<text top="650" left="234" width="511" height="11" font="12">7. Patients with intraoperative hypertension should be managed with intravenous medications (</text>
<text top="650" left="745" width="45" height="11" font="5"><a href="e127.full.html#70">Table 19</a></text>
<text top="650" left="790" width="4" height="11" font="12"><a href="e127.full.html#70">)</a></text>
<text top="666" left="247" width="277" height="11" font="12">until such time as oral medications can be resumed.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="788" width="20" height="9" font="4">e199</text>
</page>
<page number="74" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="141" left="247" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="169" left="110" width="331" height="12" font="2">1. If well tolerated, beta blockers should be continued in</text>
<text top="187" left="124" width="317" height="12" font="2">patients who are currently receiving them for longitu-</text>
<text top="205" left="124" width="317" height="12" font="2">dinal reasons, particularly when longitudinal treat-</text>
<text top="223" left="124" width="317" height="12" font="2">ment is provided according to GDMT, such as for MI</text>
<text top="241" left="124" width="53" height="12" font="5"><a href="e127.full.html#109">(S11.5-22)</a></text>
<text top="241" left="177" width="264" height="12" font="2">. Multiple observational studies support the</text>
<text top="259" left="124" width="28" height="12" font="2">bene</text>
<text top="257" left="152" width="289" height="15" font="2">ﬁts of continuing beta blockers in patients who are</text>
<text top="277" left="124" width="317" height="12" font="2">undergoing surgery and who are on these agents for</text>
<text top="295" left="124" width="139" height="12" font="2">longitudinal indications</text>
<text top="295" left="267" width="41" height="12" font="5"><a href="e127.full.html#108">(S11.5-1</a></text>
<text top="293" left="309" width="52" height="15" font="5"><a href="e127.full.html#108">—S11.5-7)</a></text>
<text top="295" left="361" width="3" height="12" font="2"><a href="e127.full.html#108">.</a></text>
<text top="313" left="109" width="332" height="12" font="2">2. In the absence of conclusive RCTs, the expert opinion</text>
<text top="331" left="124" width="317" height="12" font="2">of this writing committee is that control of BP to levels</text>
<text top="349" left="124" width="263" height="12" font="2">recommended by the present guideline (BP</text>
<text top="347" left="393" width="47" height="15" font="2">&lt;130/80</text>
<text top="367" left="124" width="205" height="12" font="2">mm Hg) or other target levels speci</text>
<text top="365" left="329" width="112" height="15" font="2">ﬁed for a particular</text>
<text top="385" left="124" width="317" height="12" font="2">individual is reasonable before undertaking major</text>
<text top="403" left="124" width="317" height="12" font="2">elective procedures in either the inpatient or outpa-</text>
<text top="421" left="124" width="317" height="12" font="2">tient setting. If the patient is unable to take oral med-</text>
<text top="439" left="124" width="49" height="12" font="2">ications,</text>
<text top="439" left="187" width="8" height="12" font="2">it</text>
<text top="439" left="210" width="9" height="12" font="2">is</text>
<text top="439" left="234" width="62" height="12" font="2">reasonable</text>
<text top="439" left="311" width="11" height="12" font="2">to</text>
<text top="439" left="337" width="20" height="12" font="2">use</text>
<text top="439" left="372" width="69" height="12" font="2">intravenous</text>
<text top="456" left="124" width="82" height="12" font="2">medications <a href="e127.full.html#70">(</a></text>
<text top="457" left="206" width="51" height="11" font="5"><a href="e127.full.html#70">Table 19</a></text>
<text top="456" left="258" width="183" height="12" font="2"><a href="e127.full.html#70">) </a>as necessary to control BP.</text>
<text top="474" left="124" width="317" height="12" font="2">Special consideration of parenteral therapy usually</text>
<text top="492" left="124" width="317" height="12" font="2">occurs for patients taking clonidine or beta blockers</text>
<text top="510" left="124" width="317" height="12" font="2">because of the risk of stopping these medications</text>
<text top="528" left="124" width="292" height="12" font="2">acutely. Withdrawal syndromes, accompanied</text>
<text top="528" left="427" width="14" height="12" font="2">by</text>
<text top="546" left="124" width="317" height="12" font="2">sympathetic discharge and acute hypertension, can</text>
<text top="564" left="124" width="200" height="12" font="2">occur on cessation of these agents</text>
<text top="564" left="328" width="52" height="12" font="5"><a href="e127.full.html#109">(S11.5-13)</a></text>
<text top="564" left="381" width="3" height="12" font="2"><a href="e127.full.html#109">.</a></text>
<text top="582" left="109" width="217" height="12" font="2">3. Data on the potential risk and bene</text>
<text top="580" left="327" width="114" height="15" font="2">ﬁt of ACE inhibitors</text>
<text top="600" left="124" width="317" height="12" font="2">in the perioperative setting are limited to observational</text>
<text top="618" left="124" width="317" height="12" font="2">analyses, and this area is controversial. Recent evi-</text>
<text top="636" left="124" width="317" height="12" font="2">dence from a large cohort study demonstrates that</text>
<text top="654" left="124" width="317" height="12" font="2">patients who stopped their ACE inhibitors or ARBs 24</text>
<text top="672" left="124" width="317" height="12" font="2">hours before noncardiac surgery were less likely to</text>
<text top="690" left="124" width="317" height="12" font="2">suffer the primary composite outcome (all-cause</text>
<text top="708" left="124" width="317" height="12" font="2">death, stroke, or myocardial injury) and intraoperative</text>
<text top="725" left="124" width="317" height="12" font="2">hypotension than were those continuing these medi-</text>
<text top="743" left="124" width="120" height="12" font="2">cations until surgery</text>
<text top="743" left="248" width="53" height="12" font="5"><a href="e127.full.html#109">(S11.5-10)</a></text>
<text top="743" left="302" width="3" height="12" font="2"><a href="e127.full.html#109">.</a></text>
<text top="761" left="108" width="48" height="12" font="2">4. JNC 6</text>
<text top="761" left="160" width="53" height="12" font="5"><a href="e127.full.html#109">(S11.5-23)</a></text>
<text top="761" left="217" width="58" height="12" font="2">noted con</text>
<text top="759" left="275" width="166" height="15" font="2">ﬂicting evidence for patients</text>
<text top="779" left="124" width="57" height="12" font="2">with DBP</text>
<text top="777" left="187" width="254" height="15" font="2">&gt;110 mm Hg and recommended delay of</text>
<text top="797" left="124" width="317" height="12" font="2">surgery for gradual reduction in DBP before proceeding</text>
<text top="815" left="124" width="317" height="12" font="2">with surgery. In a systematic review and meta-analysis</text>
<text top="833" left="124" width="317" height="12" font="2">of 30 observational studies, preoperative hypertension</text>
<text top="851" left="124" width="317" height="12" font="2">was associated with a 35% increase in cardiovascular</text>
<text top="869" left="124" width="81" height="12" font="2">complications</text>
<text top="869" left="209" width="52" height="12" font="5"><a href="e127.full.html#109">(S11.5-12)</a></text>
<text top="869" left="261" width="180" height="12" font="2">. An increase in complications,</text>
<text top="887" left="124" width="55" height="12" font="2">including</text>
<text top="887" left="192" width="83" height="12" font="2">dysrhythmias,</text>
<text top="887" left="288" width="64" height="12" font="2">myocardial</text>
<text top="887" left="365" width="51" height="12" font="2">ischemia</text>
<text top="887" left="429" width="12" height="12" font="2">or</text>
<text top="905" left="124" width="317" height="12" font="2">infarction, neurological complications, and renal fail-</text>
<text top="923" left="124" width="282" height="12" font="2">ure, has been reported in patients with DBP</text>
<text top="921" left="414" width="27" height="15" font="2">$110</text>
<text top="941" left="124" width="228" height="12" font="2">mm Hg immediately before surgery</text>
<text top="941" left="361" width="54" height="12" font="5"><a href="e127.full.html#109">(S11.5-24)</a></text>
<text top="941" left="416" width="25" height="12" font="2">. In</text>
<text top="959" left="124" width="158" height="12" font="2">contrast, patients with DBP</text>
<text top="957" left="285" width="156" height="15" font="2">&lt;110 mm Hg do not appear</text>
<text top="976" left="124" width="87" height="12" font="2">to be at signi</text>
<text top="975" left="211" width="135" height="15" font="2">ﬁcantly increased risk</text>
<text top="976" left="354" width="53" height="12" font="5"><a href="e127.full.html#109">(S11.5-25)</a></text>
<text top="976" left="408" width="33" height="12" font="2"><a href="e127.full.html#109">. </a>The</text>
<text top="994" left="124" width="317" height="12" font="2">relationship of systolic hypertension to surgical risk is</text>
<text top="1012" left="124" width="317" height="12" font="2">less certain. Among patients undergoing carotid</text>
<text top="1030" left="124" width="317" height="12" font="2">endarterectomy, increased risk of postoperative hy-</text>
<text top="1048" left="124" width="317" height="12" font="2">pertension and neurological defects were observed</text>
<text top="1066" left="124" width="54" height="12" font="5"><a href="e127.full.html#109">(S11.5-26)</a></text>
<text top="1066" left="178" width="263" height="12" font="2">, and an increased risk of CVD morbidity after</text>
<text top="1084" left="124" width="317" height="12" font="2">coronary artery bypass graft surgery has been observed</text>
<text top="143" left="484" width="276" height="12" font="2">in patients with isolated systolic hypertension</text>
<text top="143" left="765" width="36" height="12" font="5"><a href="e127.full.html#109">(S11.5-</a></text>
<text top="161" left="484" width="17" height="12" font="5"><a href="e127.full.html#109">27)</a></text>
<text top="161" left="501" width="300" height="12" font="2"><a href="e127.full.html#109">. </a>During induction of anesthesia for surgery, sym-</text>
<text top="178" left="484" width="202" height="12" font="2">pathetic action can result in a 20</text>
<text top="177" left="687" width="114" height="15" font="2">– to 30–mm Hg in-</text>
<text top="196" left="484" width="317" height="12" font="2">crease in BP and a 15- to 20-bpm increase in heart rate</text>
<text top="214" left="484" width="181" height="12" font="2">among patients with normal BP</text>
<text top="214" left="668" width="54" height="12" font="5"><a href="e127.full.html#109">(S11.5-24)</a></text>
<text top="214" left="723" width="78" height="12" font="2">. Exaggerated</text>
<text top="232" left="484" width="317" height="12" font="2">responses may occur in patients with poorly treated or</text>
<text top="250" left="484" width="317" height="12" font="2">untreated hypertension by as much as 90 mm Hg and</text>
<text top="268" left="484" width="51" height="12" font="2">40 bpm</text>
<text top="268" left="546" width="54" height="12" font="5"><a href="e127.full.html#109">(S11.5-24)</a></text>
<text top="268" left="601" width="200" height="12" font="2">. With further anesthesia, the</text>
<text top="286" left="484" width="317" height="12" font="2">accompanying inhibition of the sympathetic nervous</text>
<text top="304" left="484" width="317" height="12" font="2">system and loss of baroreceptor control may result in</text>
<text top="322" left="484" width="317" height="12" font="2">intraoperative hypotension. Lability in BP appears</text>
<text top="340" left="484" width="317" height="12" font="2">more likely in patients with poorly controlled hyper-</text>
<text top="358" left="484" width="43" height="12" font="2">tension</text>
<text top="358" left="531" width="53" height="12" font="5"><a href="e127.full.html#109">(S11.5-25)</a></text>
<text top="358" left="585" width="216" height="12" font="2"><a href="e127.full.html#109">, </a>whereas studies have observed that</text>
<text top="376" left="484" width="317" height="12" font="2">patients with controlled hypertension respond simi-</text>
<text top="394" left="484" width="218" height="12" font="2">larly to those who are normotensive</text>
<text top="394" left="708" width="54" height="12" font="5"><a href="e127.full.html#109">(S11.5-28)</a></text>
<text top="394" left="763" width="39" height="12" font="2"><a href="e127.full.html#109">. </a>Early</text>
<text top="412" left="484" width="317" height="12" font="2">work indicated that patients with severe hypertension</text>
<text top="430" left="484" width="26" height="12" font="2">(SBP</text>
<text top="428" left="516" width="285" height="15" font="2">&gt;210 mm Hg and DBP &gt;105 mm Hg) had exag-</text>
<text top="447" left="484" width="317" height="12" font="2">gerated responses in BP during the induction of anes-</text>
<text top="465" left="484" width="35" height="12" font="2">thesia</text>
<text top="465" left="523" width="54" height="12" font="5"><a href="e127.full.html#109">(S11.5-28)</a></text>
<text top="465" left="577" width="3" height="12" font="2">.</text>
<text top="483" left="469" width="332" height="12" font="2">5. Although few studies describe risks of withdrawing</text>
<text top="501" left="484" width="276" height="12" font="2">beta blockers in the perioperative time period</text>
<text top="501" left="765" width="36" height="12" font="5"><a href="e127.full.html#108">(S11.5-</a></text>
<text top="519" left="484" width="53" height="12" font="5"><a href="e127.full.html#108">2,S11.5-5)</a></text>
<text top="519" left="537" width="264" height="12" font="2">, longstanding evidence from other settings</text>
<text top="537" left="484" width="317" height="12" font="2">suggests that abrupt withdrawal of long-term beta</text>
<text top="555" left="484" width="110" height="12" font="2">blockers is harmful</text>
<text top="555" left="597" width="50" height="12" font="5"><a href="e127.full.html#109">(S11.5-29</a></text>
<text top="553" left="647" width="57" height="15" font="5"><a href="e127.full.html#109">—S11.5-31)</a></text>
<text top="555" left="704" width="97" height="12" font="2">. There are fewer</text>
<text top="573" left="484" width="317" height="12" font="2">data to describe whether short-term (1 to 2 days) peri-</text>
<text top="591" left="484" width="317" height="12" font="2">operative use of beta blockers, followed by rapid</text>
<text top="609" left="484" width="95" height="12" font="2">discontinuation,</text>
<text top="609" left="592" width="9" height="12" font="2">is</text>
<text top="609" left="614" width="46" height="12" font="2">harmful</text>
<text top="609" left="674" width="128" height="12" font="5"><a href="e127.full.html#109">(S11.5-5,S11.5-14,S11.5-</a></text>
<text top="627" left="484" width="66" height="12" font="5"><a href="e127.full.html#109">21,S11.5-30)</a></text>
<text top="627" left="550" width="3" height="12" font="2">.</text>
<text top="645" left="469" width="297" height="12" font="2">6. The 2014 ACC/AHA perioperative guideline speci</text>
<text top="643" left="767" width="35" height="15" font="2">ﬁcally</text>
<text top="663" left="484" width="317" height="12" font="2">recommends against starting beta blockers on the day</text>
<text top="681" left="484" width="147" height="12" font="2">of surgery in beta-blocker</text>
<text top="679" left="632" width="87" height="15" font="2">–naive patients</text>
<text top="681" left="722" width="79" height="12" font="5"><a href="e127.full.html#109">(S11.5-5,S11.5-</a></text>
<text top="698" left="484" width="66" height="12" font="5"><a href="e127.full.html#109">21,S11.5-30)</a></text>
<text top="698" left="550" width="251" height="12" font="2">, particularly at high initial doses, in</text>
<text top="716" left="484" width="317" height="12" font="2">long-acting form, and if there are no plans for dose</text>
<text top="734" left="484" width="317" height="12" font="2">titration or monitoring for adverse events. Data from</text>
<text top="752" left="484" width="317" height="12" font="2">the POISE (Perioperative Ischemic Evaluation) study</text>
<text top="770" left="484" width="317" height="12" font="2">demonstrate the risk of initiating long-acting beta</text>
<text top="788" left="484" width="177" height="12" font="2">blockers on the day of surgery</text>
<text top="788" left="665" width="53" height="12" font="5"><a href="e127.full.html#109">(S11.5-14)</a></text>
<text top="788" left="719" width="3" height="12" font="2">.</text>
<text top="806" left="470" width="332" height="12" font="2">7. Several antihypertensive agents in a variety of phar-</text>
<text top="824" left="484" width="317" height="12" font="2">macological classes are available for the treatment of</text>
<text top="842" left="484" width="160" height="12" font="2">hypertensive emergencies (</text>
<text top="842" left="645" width="47" height="11" font="5"><a href="e127.full.html#70">Table 19</a></text>
<text top="842" left="692" width="8" height="12" font="2">).</text>
<text top="885" left="468" width="307" height="16" font="14">12. STRATEGIES TO IMPROVE HYPERTENSION</text>
<text top="903" left="468" width="187" height="16" font="14">TREATMENT AND CONTROL</text>
<text top="941" left="468" width="333" height="12" font="2">In addition to promoting pharmacological and non-</text>
<text top="959" left="468" width="333" height="12" font="2">pharmacological treatment adherence in individual pa-</text>
<text top="976" left="468" width="33" height="12" font="2">tients</text>
<text top="976" left="514" width="26" height="12" font="2">with</text>
<text top="976" left="553" width="80" height="12" font="2">hypertension,</text>
<text top="976" left="646" width="41" height="12" font="2">several</text>
<text top="976" left="700" width="101" height="12" font="2">population-based</text>
<text top="994" left="468" width="333" height="12" font="2">systems approaches can play an important role in treat-</text>
<text top="1012" left="468" width="67" height="12" font="2">ment goals.</text>
<text top="1046" left="468" width="309" height="11" font="12">12.1. Adherence Strategies for Treatment of Hypertension</text>
<text top="1067" left="468" width="333" height="12" font="2">Therapeutic nonadherence (not following recommended</text>
<text top="1085" left="468" width="276" height="12" font="2">medical or health advice, including failure to</text>
<text top="1084" left="750" width="51" height="15" font="2">“persist”</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="22" height="9" font="4">e200</text>
</page>
<page number="75" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="308" height="12" font="2">with medications and recommended lifestyle modi</text>
<text top="141" left="371" width="25" height="15" font="2">ﬁca-</text>
<text top="161" left="63" width="333" height="12" font="2">tions) is a major contributor to poor control of hyperten-</text>
<text top="178" left="63" width="333" height="12" font="2">sion and a key barrier to reducing CVD deaths. Adherence</text>
<text top="196" left="63" width="333" height="12" font="2">rates vary substantially in different populations and, in</text>
<text top="143" left="423" width="333" height="12" font="2">general, are lower for lifestyle change and more behav-</text>
<text top="161" left="423" width="167" height="12" font="2">iorally demanding regimens.</text>
<text top="197" left="423" width="297" height="11" font="2">12.1.1. Antihypertensive Medication Adherence Strategies</text>
<text top="245" left="63" width="411" height="11" font="19">Recommendations for Antihypertensive Medication Adherence Strategies</text>
<text top="259" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="259" left="412" width="202" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplements 59 and 60</a></text>
<text top="259" left="615" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="300" left="89" width="19" height="10" font="13">COR</text>
<text top="300" left="161" width="18" height="10" font="13">LOE</text>
<text top="300" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="337" left="97" width="3" height="9" font="4">I</text>
<text top="337" left="163" width="15" height="9" font="4">B-R</text>
<text top="325" left="234" width="568" height="11" font="12">1. In adults with hypertension, dosing of antihypertensive medication once daily rather than multiple times</text>
<text top="340" left="246" width="66" height="11" font="12">daily is bene</text>
<text top="338" left="313" width="145" height="15" font="12">ﬁcial to improve adherence</text>
<text top="340" left="462" width="49" height="11" font="5"><a href="e127.full.html#109">(S12.1.1-1</a></text>
<text top="338" left="511" width="58" height="15" font="5"><a href="e127.full.html#109">—S12.1.1-3)</a></text>
<text top="340" left="570" width="3" height="11" font="12"><a href="e127.full.html#109">.</a></text>
<text top="385" left="94" width="10" height="9" font="4">IIa</text>
<text top="385" left="160" width="21" height="9" font="4">B-NR</text>
<text top="373" left="234" width="565" height="11" font="12">2. Use of combination pills rather than free individual components can be useful to improve adherence to</text>
<text top="388" left="248" width="132" height="11" font="12">antihypertensive therapy</text>
<text top="388" left="384" width="51" height="11" font="5"><a href="e127.full.html#109">(S12.1.1-4</a></text>
<text top="386" left="436" width="58" height="15" font="5"><a href="e127.full.html#109">—S12.1.1-7)</a></text>
<text top="388" left="494" width="3" height="11" font="12">.</text>
<text top="485" left="63" width="52" height="12" font="2">Synopsis</text>
<text top="503" left="78" width="162" height="12" font="2">Up to 25% of patients do not</text>
<text top="501" left="243" width="156" height="15" font="2">ﬁll their initial prescription</text>
<text top="521" left="63" width="166" height="12" font="2">for antihypertensive therapy</text>
<text top="521" left="232" width="53" height="12" font="5"><a href="e127.full.html#109">(S12.1.1-8</a></text>
<text top="519" left="285" width="67" height="15" font="5"><a href="e127.full.html#109">—S12.1.1-10)</a></text>
<text top="521" left="353" width="46" height="12" font="2"><a href="e127.full.html#109">. </a>During</text>
<text top="538" left="63" width="19" height="12" font="2">the</text>
<text top="537" left="91" width="308" height="15" font="2">ﬁrst year of treatment, the average patient has</text>
<text top="556" left="63" width="336" height="12" font="2">possession of antihypertensive medications only 50% of</text>
<text top="574" left="63" width="257" height="12" font="2">the time, and only 1 in 5 patients has suf</text>
<text top="573" left="320" width="79" height="15" font="2">ﬁciently high</text>
<text top="592" left="63" width="191" height="12" font="2">adherence to achieve the bene</text>
<text top="590" left="254" width="145" height="15" font="2">ﬁts observed in clinical</text>
<text top="610" left="63" width="29" height="12" font="2">trials</text>
<text top="610" left="96" width="117" height="12" font="5"><a href="e127.full.html#109">(S12.1.1-11,S12.1.1-12)</a></text>
<text top="610" left="214" width="3" height="12" font="2"><a href="e127.full.html#109">.</a></text>
<text top="628" left="78" width="321" height="12" font="2">Factors contributing to poor adherence are myriad,</text>
<text top="646" left="63" width="149" height="12" font="2">complex, and multilevel</text>
<text top="646" left="220" width="175" height="12" font="5"><a href="e127.full.html#109">(S12.1.1-11,S12.1.1-13,S12.1.1-14)</a></text>
<text top="646" left="395" width="3" height="12" font="2">.</text>
<text top="664" left="63" width="336" height="12" font="2">Therefore, solutions to improve adherence may be intro-</text>
<text top="682" left="63" width="336" height="12" font="2">duced at patient, provider, and healthcare system levels</text>
<text top="700" left="63" width="176" height="12" font="5"><a href="e127.full.html#109">(S12.1.1-13,S12.1.1-15,S12.1.1-16)</a></text>
<text top="700" left="239" width="3" height="12" font="2">.</text>
<text top="700" left="255" width="42" height="12" font="2">Several</text>
<text top="700" left="309" width="62" height="12" font="2">systematic</text>
<text top="700" left="383" width="16" height="12" font="2">re-</text>
<text top="718" left="63" width="336" height="12" font="2">views and meta-analyses have assessed the impact of in-</text>
<text top="736" left="63" width="66" height="12" font="2">terventions</text>
<text top="736" left="151" width="14" height="12" font="2">on</text>
<text top="736" left="186" width="60" height="12" font="2">adherence</text>
<text top="736" left="268" width="11" height="12" font="2">to</text>
<text top="736" left="301" width="98" height="12" font="2">antihypertensive</text>
<text top="754" left="63" width="171" height="12" font="2">medications, including modi</text>
<text top="752" left="234" width="165" height="15" font="2">ﬁcation of antihypertensive</text>
<text top="772" left="63" width="44" height="12" font="2">therapy</text>
<text top="772" left="113" width="51" height="12" font="5"><a href="e127.full.html#109">(S12.1.1-1</a></text>
<text top="770" left="164" width="231" height="15" font="5"><a href="e127.full.html#109">—S12.1.1-7,S12.1.1-11,S12.1.1-15,S12.1.1-16)</a></text>
<text top="772" left="395" width="3" height="12" font="2">.</text>
<text top="790" left="63" width="336" height="12" font="2">No single intervention is uniquely effective, and a sus-</text>
<text top="807" left="63" width="336" height="12" font="2">tained, coordinated effort that targets all barriers to</text>
<text top="825" left="63" width="336" height="12" font="2">adherence in an individual is likely to be the most effec-</text>
<text top="843" left="63" width="108" height="12" font="2">tive approach. See</text>
<text top="843" left="175" width="155" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement F</a></text>
<text top="843" left="334" width="65" height="12" font="2">for barriers</text>
<text top="861" left="63" width="11" height="12" font="2">to</text>
<text top="861" left="86" width="65" height="12" font="2">medication</text>
<text top="861" left="163" width="60" height="12" font="2">adherence</text>
<text top="861" left="235" width="21" height="12" font="2">and</text>
<text top="861" left="269" width="19" height="12" font="2">the</text>
<text top="861" left="299" width="28" height="12" font="2">most</text>
<text top="861" left="340" width="59" height="12" font="2">successful</text>
<text top="879" left="63" width="82" height="12" font="2">interventions.</text>
<text top="897" left="78" width="321" height="12" font="2">The creation of an encouraging, blame-free environ-</text>
<text top="915" left="63" width="336" height="12" font="2">ment in which patients are recognized for achieving</text>
<text top="933" left="63" width="155" height="12" font="2">treatment goals and given</text>
<text top="931" left="223" width="176" height="15" font="2">“permission” to answer ques-</text>
<text top="951" left="63" width="336" height="12" font="2">tions related to their treatment honestly is essential to</text>
<text top="969" left="63" width="336" height="12" font="2">identify and address nonadherence. Patient medication</text>
<text top="987" left="63" width="165" height="12" font="2">adherence assessment tools</text>
<text top="987" left="234" width="61" height="12" font="5"><a href="e127.full.html#109">(S12.1.1-17)</a></text>
<text top="987" left="301" width="98" height="12" font="2">are presented in</text>
<text top="485" left="420" width="155" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement A</a></text>
<text top="485" left="576" width="181" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">. </a>Members of the hypertension</text>
<text top="503" left="420" width="336" height="12" font="2">care team may use these self-report tools in a nonthreat-</text>
<text top="521" left="420" width="336" height="12" font="2">ening fashion to identify barriers and facilitate behaviors</text>
<text top="538" left="420" width="336" height="12" font="2">associated with improved adherence to antihypertensive</text>
<text top="556" left="420" width="336" height="12" font="2">medications. Use of more objective methods (e.g., pill</text>
<text top="574" left="420" width="184" height="12" font="2">counts, data on medication re</text>
<text top="573" left="605" width="152" height="15" font="2">ﬁlls) to assess adherence</text>
<text top="592" left="420" width="247" height="12" font="2">along with self-report methods is optimal.</text>
<text top="637" left="420" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="635" left="559" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="664" left="422" width="335" height="12" font="2">1. Remembering to take medication is often challenging,</text>
<text top="682" left="435" width="321" height="12" font="2">particularly for regimens that must be dosed several</text>
<text top="700" left="435" width="32" height="12" font="2">times</text>
<text top="700" left="482" width="32" height="12" font="2">daily.</text>
<text top="700" left="529" width="39" height="12" font="2">Taking</text>
<text top="700" left="583" width="70" height="12" font="2">medications</text>
<text top="700" left="669" width="41" height="12" font="2">several</text>
<text top="700" left="725" width="32" height="12" font="2">times</text>
<text top="718" left="435" width="321" height="12" font="2">throughout the day requires greater attention to</text>
<text top="736" left="435" width="321" height="12" font="2">scheduling, as well as additional issues such as trans-</text>
<text top="754" left="435" width="321" height="12" font="2">portation or storage, which can be challenging for some</text>
<text top="772" left="435" width="321" height="12" font="2">patients. The impact of once-daily dosing of antihy-</text>
<text top="790" left="435" width="321" height="12" font="2">pertensive drugs versus dosing multiple times daily has</text>
<text top="808" left="435" width="253" height="12" font="2">been evaluated in several meta-analyses</text>
<text top="808" left="697" width="51" height="12" font="5"><a href="e127.full.html#109">(S12.1.1-1</a></text>
<text top="806" left="748" width="9" height="15" font="5"><a href="e127.full.html#109">—</a></text>
<text top="825" left="435" width="52" height="12" font="5"><a href="e127.full.html#109">S12.1.1-3)</a></text>
<text top="825" left="487" width="269" height="12" font="2">. Medication adherence was greatest with</text>
<text top="843" left="435" width="321" height="12" font="2">once-daily dosing (range 71% to 94%) and declined as</text>
<text top="861" left="435" width="160" height="12" font="2">dosing frequency increased</text>
<text top="861" left="599" width="107" height="12" font="5"><a href="e127.full.html#109">(S12.1.1-1,S12.1.1-2)</a></text>
<text top="861" left="706" width="3" height="12" font="2">.</text>
<text top="879" left="421" width="195" height="12" font="2">2. Assessment and possible modi</text>
<text top="877" left="616" width="141" height="15" font="2">ﬁcation of drug therapy</text>
<text top="897" left="435" width="321" height="12" font="2">regimens can improve suboptimal adherence. Simpli-</text>
<text top="915" left="435" width="321" height="12" font="2">fying medication regimens, either by less frequent</text>
<text top="933" left="435" width="321" height="12" font="2">dosing (i.e., once daily versus multiple times daily) or</text>
<text top="951" left="435" width="321" height="12" font="2">use of combination drug therapy, improves adherence.</text>
<text top="969" left="435" width="54" height="12" font="2">Available</text>
<text top="967" left="492" width="264" height="15" font="2">ﬁxed-dose combination drug therapy is listed</text>
<text top="987" left="435" width="11" height="12" font="2">in</text>
<text top="987" left="451" width="155" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement D</a></text>
<text top="987" left="606" width="3" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="788" width="19" height="9" font="4">e201</text>
</page>
<page number="76" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="229" height="11" font="2">12.1.2. Strategies to Promote Lifestyle Modi</text>
<text top="141" left="336" width="38" height="15" font="2">ﬁcation</text>
<text top="348" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="366" left="123" width="161" height="12" font="2">The primary lifestyle modi</text>
<text top="364" left="284" width="157" height="15" font="2">ﬁcation interventions that</text>
<text top="384" left="108" width="226" height="12" font="2">can help reduce high BP are outlined in</text>
<text top="384" left="337" width="53" height="12" font="5"><a href="e127.full.html#28">Section 6</a></text>
<text top="384" left="393" width="48" height="12" font="2">(healthy</text>
<text top="402" left="108" width="333" height="12" font="2">diet, weight loss, exercise and moderate alcohol intake).</text>
<text top="420" left="108" width="333" height="12" font="2">In addition, tobacco cessation is crucial for CVD risk</text>
<text top="438" left="108" width="131" height="12" font="2">reduction. These modi</text>
<text top="436" left="239" width="202" height="15" font="2">ﬁcations are central to good health</text>
<text top="456" left="108" width="108" height="12" font="2">and require speci</text>
<text top="454" left="216" width="225" height="15" font="2">ﬁc motivational and cognitive inter-</text>
<text top="474" left="108" width="333" height="12" font="2">vention strategies designed to promote adherence to</text>
<text top="492" left="108" width="333" height="12" font="2">these healthy behaviors. High-quality evidence support-</text>
<text top="510" left="108" width="258" height="12" font="2">ing some of these strategies is provided in</text>
<text top="510" left="371" width="70" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data</a></text>
<text top="528" left="108" width="84" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Supplement G</a></text>
<text top="528" left="192" width="249" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">. </a>Additionally, interventions such as goal</text>
<text top="546" left="108" width="333" height="12" font="2">setting, provision of feedback, self-monitoring, follow-</text>
<text top="564" left="108" width="19" height="12" font="2">up,</text>
<text top="564" left="140" width="74" height="12" font="2">motivational</text>
<text top="564" left="228" width="77" height="12" font="2">interviewing,</text>
<text top="564" left="320" width="21" height="12" font="2">and</text>
<text top="564" left="355" width="61" height="12" font="2">promotion</text>
<text top="564" left="430" width="11" height="12" font="2">of</text>
<text top="581" left="108" width="43" height="12" font="2">self-suf</text>
<text top="580" left="151" width="290" height="15" font="2">ﬁciency are most effective when combined. Most</text>
<text top="599" left="108" width="333" height="12" font="2">individuals have clear expectations about what a new</text>
<text top="617" left="108" width="333" height="12" font="2">lifestyle will provide; if their experiences do not match</text>
<text top="635" left="108" width="252" height="12" font="2">these expectations, they will be dissatis</text>
<text top="634" left="360" width="81" height="15" font="2">ﬁed and less</text>
<text top="653" left="108" width="333" height="12" font="2">motivated to maintain a lifestyle change, particularly in</text>
<text top="671" left="108" width="333" height="12" font="2">environments that do not support healthy choices. Other</text>
<text top="689" left="108" width="112" height="12" font="2">factors that may in</text>
<text top="687" left="220" width="221" height="15" font="2">ﬂuence adoption and maintenance of</text>
<text top="707" left="108" width="333" height="12" font="2">new physical activity or dietary behaviors include age,</text>
<text top="725" left="108" width="333" height="12" font="2">sex, baseline health status, and body mass index, as well</text>
<text top="743" left="108" width="333" height="12" font="2">as the presence of comorbid conditions and depression,</text>
<text top="761" left="108" width="333" height="12" font="2">which negatively affect adherence to most lifestyle</text>
<text top="779" left="108" width="101" height="12" font="2">change regimens</text>
<text top="779" left="216" width="56" height="12" font="5"><a href="e127.full.html#110">(S12.1.2-1)</a></text>
<text top="779" left="272" width="169" height="12" font="2">. Primary strategies include</text>
<text top="797" left="108" width="333" height="12" font="2">cognitive-behavioral strategies for promoting behavior</text>
<text top="815" left="108" width="333" height="12" font="2">change, intervention processes and delivery strategies,</text>
<text top="833" left="108" width="333" height="12" font="2">and addressing cultural and social context variables that</text>
<text top="850" left="108" width="11" height="12" font="2">in</text>
<text top="849" left="119" width="156" height="15" font="2">ﬂuence behavioral change.</text>
<text top="886" left="108" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="885" left="247" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="913" left="108" width="333" height="12" font="2">1. It is crucial to translate and implement into practice the</text>
<text top="931" left="122" width="319" height="12" font="2">most effective evidence-based strategies for adherence</text>
<text top="949" left="122" width="319" height="12" font="2">to nonpharmacological treatment for hypertension.</text>
<text top="967" left="122" width="319" height="12" font="2">Both adoption and maintenance of new CVD risk-</text>
<text top="985" left="122" width="319" height="12" font="2">reducing behaviors pose challenges for many in-</text>
<text top="1003" left="122" width="319" height="12" font="2">dividuals. Success requires consideration of race,</text>
<text top="1021" left="122" width="319" height="12" font="2">ethnicity, and socioeconomic status, as well as indi-</text>
<text top="1039" left="122" width="319" height="12" font="2">vidual, provider, and environmental factors that may</text>
<text top="1057" left="122" width="11" height="12" font="2">in</text>
<text top="1055" left="133" width="242" height="15" font="2">ﬂuence the design of such interventions</text>
<text top="1057" left="381" width="56" height="12" font="5"><a href="e127.full.html#110">(S12.1.2-1)</a></text>
<text top="1057" left="437" width="3" height="12" font="2">.</text>
<text top="1075" left="122" width="319" height="12" font="2">High-quality evidence has shown that even modest</text>
<text top="1093" left="122" width="319" height="12" font="2">sustained lifestyle changes can substantially reduce</text>
<text top="348" left="482" width="169" height="12" font="2">CVD morbidity and mortality</text>
<text top="348" left="654" width="56" height="12" font="5"><a href="e127.full.html#110">(S12.1.2-1)</a></text>
<text top="348" left="711" width="90" height="12" font="2"><a href="e127.full.html#110">. </a>Because many</text>
<text top="366" left="482" width="28" height="12" font="2">bene</text>
<text top="364" left="510" width="291" height="15" font="2">ﬁcial effects of lifestyle changes accrue over time,</text>
<text top="384" left="482" width="319" height="12" font="2">long-term adherence maximizes individual and popu-</text>
<text top="402" left="482" width="65" height="12" font="2">lation bene</text>
<text top="400" left="548" width="254" height="15" font="2">ﬁts. Interventions targeting sodium restric-</text>
<text top="420" left="482" width="319" height="12" font="2">tion, other dietary patterns, weight reduction, and new</text>
<text top="438" left="482" width="319" height="12" font="2">physical activity habits often result in impressive rates</text>
<text top="456" left="482" width="319" height="12" font="2">of initial behavior changes but frequently are not</text>
<text top="474" left="482" width="295" height="12" font="2">translated into long-term behavioral maintenance.</text>
<text top="516" left="468" width="307" height="11" font="2">12.1.3. Improving Quality of Care for Resource-Constrained</text>
<text top="534" left="505" width="61" height="11" font="2">Populations</text>
<text top="555" left="468" width="110" height="12" font="2">The availability of</text>
<text top="553" left="585" width="217" height="15" font="2">ﬁnancial, informational, and instru-</text>
<text top="573" left="468" width="333" height="12" font="2">mental support resources can be important though not</text>
<text top="591" left="468" width="275" height="12" font="2">sole determinants of hypertension control</text>
<text top="591" left="755" width="47" height="12" font="5"><a href="e127.full.html#110">(S12.1.3-</a></text>
<text top="609" left="468" width="62" height="12" font="5"><a href="e127.full.html#110">1,S12.1.3-2)</a></text>
<text top="609" left="530" width="3" height="12" font="2">.</text>
<text top="609" left="548" width="22" height="12" font="2">The</text>
<text top="609" left="584" width="75" height="12" font="2">management</text>
<text top="609" left="673" width="11" height="12" font="2">of</text>
<text top="609" left="699" width="77" height="12" font="2">hypertension</text>
<text top="609" left="790" width="11" height="12" font="2">in</text>
<text top="627" left="468" width="333" height="12" font="2">resource-constrained populations poses a challenge that</text>
<text top="645" left="468" width="333" height="12" font="2">will require the implementation of all recommendations</text>
<text top="663" left="468" width="71" height="12" font="2">discussed in</text>
<text top="663" left="542" width="57" height="12" font="5"><a href="e127.full.html#81">Section 13</a></text>
<text top="663" left="603" width="4" height="12" font="2"><a href="e127.full.html#82">(</a></text>
<text top="663" left="607" width="46" height="11" font="5"><a href="e127.full.html#82">Table 21</a></text>
<text top="663" left="653" width="70" height="12" font="2">), with speci</text>
<text top="661" left="724" width="77" height="15" font="2">ﬁc sensitivity</text>
<text top="681" left="468" width="204" height="12" font="2">to challenges posed by limited</text>
<text top="679" left="682" width="119" height="15" font="2">ﬁnancial resources,</text>
<text top="699" left="468" width="333" height="12" font="2">including those related to health literacy, alignment of</text>
<text top="716" left="468" width="333" height="12" font="2">and potential need to realign healthcare priorities by</text>
<text top="734" left="468" width="51" height="12" font="2">patients,</text>
<text top="734" left="531" width="19" height="12" font="2">the</text>
<text top="734" left="562" width="73" height="12" font="2">convenience</text>
<text top="734" left="648" width="22" height="12" font="2">and</text>
<text top="734" left="682" width="65" height="12" font="2">complexity</text>
<text top="734" left="759" width="11" height="12" font="2">of</text>
<text top="734" left="783" width="19" height="12" font="2">the</text>
<text top="752" left="468" width="333" height="12" font="2">management strategy, accessibility to health care, and</text>
<text top="770" left="468" width="333" height="12" font="2">health-related costs (including medications). Resource-</text>
<text top="788" left="468" width="333" height="12" font="2">constrained populations are also populations with high</text>
<text top="806" left="468" width="333" height="12" font="2">representation of groups most likely to manifest health</text>
<text top="824" left="468" width="333" height="12" font="2">disparities, including racial and ethnic minorities (see</text>
<text top="842" left="468" width="69" height="12" font="5"><a href="e127.full.html#62">Section 10.1</a></text>
<text top="842" left="538" width="264" height="12" font="2"><a href="e127.full.html#62">), </a>residents located in rural areas, and older</text>
<text top="860" left="468" width="333" height="12" font="2">adults. The more comprehensive BP targets proposed in</text>
<text top="878" left="468" width="333" height="12" font="2">the present guideline will present added challenges in</text>
<text top="896" left="468" width="108" height="12" font="2">these populations.</text>
<text top="914" left="483" width="318" height="12" font="2">It is crucial to invest in measures to enhance health</text>
<text top="932" left="468" width="333" height="12" font="2">literacy and reinforce the importance of adhering to</text>
<text top="950" left="468" width="333" height="12" font="2">treatment strategies, while paying attention to cultural</text>
<text top="968" left="468" width="290" height="12" font="2">sensitivities. These measures may include identi</text>
<text top="966" left="758" width="43" height="15" font="2">ﬁcation</text>
<text top="985" left="468" width="333" height="12" font="2">of and partnering with community resources and organi-</text>
<text top="1003" left="468" width="333" height="12" font="2">zations devoted to hypertension control and cardiovas-</text>
<text top="1021" left="468" width="333" height="12" font="2">cular health. Although comparative-effectiveness data</text>
<text top="1039" left="468" width="77" height="12" font="2">documenting</text>
<text top="1039" left="557" width="11" height="12" font="2">ef</text>
<text top="1037" left="568" width="233" height="15" font="2">ﬁcacy of various interventions are</text>
<text top="1057" left="468" width="190" height="12" font="2">limited, multidisciplinary team</text>
<text top="1055" left="658" width="143" height="15" font="2">–based approaches and</text>
<text top="1075" left="468" width="247" height="12" font="2">the use of community health workers (see</text>
<text top="1075" left="719" width="82" height="12" font="5"><a href="e127.full.html#75">Sections 12.1.1</a></text>
<text top="1093" left="468" width="50" height="12" font="5">and <a href="e127.full.html#77">12.2</a></text>
<text top="1093" left="518" width="283" height="12" font="2">) have shown some utility, as has the use of</text>
<text top="179" left="63" width="328" height="11" font="19">Recommendation for Strategies to Promote Lifestyle Modi</text>
<text top="177" left="391" width="41" height="15" font="19">ﬁcation</text>
<text top="194" left="63" width="362" height="11" font="19">References that support the recommendation are summarized in</text>
<text top="194" left="429" width="152" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 61</a></text>
<text top="194" left="581" width="3" height="11" font="19">.</text>
<text top="235" left="89" width="19" height="10" font="13">COR</text>
<text top="235" left="161" width="18" height="10" font="13">LOE</text>
<text top="235" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="272" left="97" width="3" height="9" font="4">I</text>
<text top="272" left="160" width="20" height="9" font="4">C-EO</text>
<text top="259" left="234" width="556" height="11" font="12">1. Effective behavioral and motivational strategies to achieve a healthy lifestyle (i.e., tobacco cessation,</text>
<text top="275" left="246" width="521" height="11" font="12">weight loss, moderation in alcohol intake, increased physical activity, reduced sodium intake, and</text>
<text top="291" left="246" width="419" height="11" font="12">consumption of a healthy diet) are recommended for adults with hypertension</text>
<text top="291" left="669" width="106" height="11" font="5"><a href="e127.full.html#110">(S12.1.2-1,S12.1.2-2)</a></text>
<text top="291" left="775" width="3" height="11" font="12">.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="20" height="9" font="4">e202</text>
</page>
<page number="77" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="52" height="12" font="2">out-of-of</text>
<text top="141" left="115" width="281" height="15" font="2">ﬁce BP monitoring (or no-cost BP control visits),</text>
<text top="161" left="63" width="67" height="12" font="2">particularly</text>
<text top="161" left="142" width="39" height="12" font="2">among</text>
<text top="161" left="193" width="122" height="12" font="2">resource-constrained</text>
<text top="161" left="327" width="69" height="12" font="2">populations</text>
<text top="178" left="63" width="53" height="12" font="5"><a href="e127.full.html#110">(S12.1.3-3</a></text>
<text top="177" left="116" width="62" height="15" font="5"><a href="e127.full.html#110">—S12.1.3-5)</a></text>
<text top="178" left="178" width="218" height="12" font="2">. Long-acting once-daily medications</text>
<text top="196" left="63" width="333" height="12" font="2">(e.g., chlorthalidone, amlodipine) that are now available</text>
<text top="214" left="63" width="333" height="12" font="2">generically and often on discount formularies can often</text>
<text top="232" left="63" width="333" height="12" font="2">be used to reduce complexity of the regimen and promote</text>
<text top="250" left="63" width="333" height="12" font="2">adherence by decreasing the effect of missed medication</text>
<text top="268" left="63" width="333" height="12" font="2">dosages. When possible, prescriptions requiring longer</text>
<text top="143" left="423" width="83" height="12" font="2">than 30-day re</text>
<text top="141" left="506" width="250" height="15" font="2">ﬁlls should be considered, especially once a</text>
<text top="161" left="423" width="333" height="12" font="2">stable regimen is achieved. Where appropriate, using</text>
<text top="178" left="423" width="333" height="12" font="2">scored tablets and pill cutters can decrease the cost of</text>
<text top="196" left="423" width="140" height="12" font="2">medication for patients.</text>
<text top="250" left="423" width="277" height="11" font="12">12.2. Structured, Team-Based Care Interventions for</text>
<text top="268" left="452" width="114" height="11" font="12">Hypertension Control</text>
<text top="317" left="63" width="506" height="11" font="19">Recommendation for Structured, Team-Based Care Interventions for Hypertension Control</text>
<text top="331" left="63" width="362" height="11" font="19">References that support the recommendation are summarized in</text>
<text top="331" left="429" width="153" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 62</a></text>
<text top="331" left="583" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="372" left="89" width="19" height="10" font="13">COR</text>
<text top="372" left="161" width="18" height="10" font="13">LOE</text>
<text top="372" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="409" left="97" width="3" height="9" font="4">I</text>
<text top="409" left="168" width="6" height="9" font="4">A</text>
<text top="397" left="234" width="411" height="11" font="12">1. A team-based care approach is recommended for adults with hypertension</text>
<text top="397" left="648" width="42" height="11" font="5"><a href="e127.full.html#110">(S12.2-1</a></text>
<text top="395" left="690" width="51" height="15" font="5"><a href="e127.full.html#110">—S12.2-7)</a></text>
<text top="397" left="742" width="3" height="11" font="12"><a href="e127.full.html#110">.</a></text>
<text top="536" left="63" width="52" height="12" font="2">Synopsis</text>
<text top="554" left="78" width="321" height="12" font="2">Team-based care to improve BP control is a health</text>
<text top="572" left="63" width="46" height="12" font="2">systems</text>
<text top="571" left="109" width="290" height="15" font="2">–level, organizational intervention that in-</text>
<text top="590" left="63" width="336" height="12" font="2">corporates a multidisciplinary team to improve the</text>
<text top="608" left="63" width="243" height="12" font="2">quality of hypertension care for patients</text>
<text top="608" left="312" width="45" height="12" font="5"><a href="e127.full.html#110">(S12.2-8</a></text>
<text top="606" left="357" width="42" height="15" font="5"><a href="e127.full.html#110">—S12.2-</a></text>
<text top="626" left="63" width="17" height="12" font="5"><a href="e127.full.html#110">10)</a></text>
<text top="626" left="80" width="319" height="12" font="2">. Various team-based hypertension care models have</text>
<text top="644" left="63" width="336" height="12" font="2">been demonstrated to increase the proportion of in-</text>
<text top="662" left="63" width="336" height="12" font="2">dividuals with controlled BP and to reduce both SBP and</text>
<text top="680" left="63" width="24" height="12" font="2">DBP</text>
<text top="680" left="91" width="43" height="12" font="5"><a href="e127.full.html#110">(S12.2-1</a></text>
<text top="678" left="134" width="149" height="15" font="5"><a href="e127.full.html#110">—S12.2-7,S12.2-11,S12.2-12)</a></text>
<text top="680" left="284" width="115" height="12" font="2"><a href="e127.full.html#110">. </a>A team-based care</text>
<text top="698" left="63" width="336" height="12" font="2">approach is patient centered and is frequently imple-</text>
<text top="716" left="63" width="336" height="12" font="2">mented as part of a multifaceted approach, with systems</text>
<text top="734" left="63" width="336" height="12" font="2">support for clinical decision making (i.e., treatment al-</text>
<text top="752" left="63" width="60" height="12" font="2">gorithms),</text>
<text top="752" left="139" width="80" height="12" font="2">collaboration,</text>
<text top="752" left="235" width="60" height="12" font="2">adherence</text>
<text top="752" left="311" width="11" height="12" font="2">to</text>
<text top="752" left="338" width="60" height="12" font="2">prescribed</text>
<text top="770" left="63" width="336" height="12" font="2">regimen, BP monitoring, and patient self-management.</text>
<text top="788" left="63" width="336" height="12" font="2">Team-based care for hypertension includes the patient,</text>
<text top="805" left="63" width="70" height="12" font="2">the patient</text>
<text top="804" left="133" width="266" height="15" font="2">’s primary care provider, and other pro-</text>
<text top="823" left="63" width="336" height="12" font="2">fessionals, such as cardiologists, nurses, pharmacists,</text>
<text top="841" left="63" width="336" height="12" font="2">physician assistants, dietitians, social workers, and</text>
<text top="859" left="63" width="336" height="12" font="2">community health workers. These professionals com-</text>
<text top="877" left="63" width="336" height="12" font="2">plement the activities of the primary care provider by</text>
<text top="895" left="63" width="56" height="12" font="2">providing</text>
<text top="895" left="134" width="43" height="12" font="2">process</text>
<text top="895" left="193" width="45" height="12" font="2">support</text>
<text top="895" left="254" width="21" height="12" font="2">and</text>
<text top="895" left="291" width="43" height="12" font="2">sharing</text>
<text top="895" left="349" width="19" height="12" font="2">the</text>
<text top="895" left="383" width="16" height="12" font="2">re-</text>
<text top="913" left="63" width="207" height="12" font="2">sponsibilities of hypertension care.</text>
<text top="913" left="275" width="59" height="12" font="5"><a href="e127.full.html#81">Section 13</a></text>
<text top="913" left="339" width="60" height="12" font="2">contains a</text>
<text top="931" left="63" width="92" height="12" font="2">comprehensive,</text>
<text top="931" left="168" width="97" height="12" font="2">patient-centered</text>
<text top="931" left="277" width="25" height="12" font="2">plan</text>
<text top="931" left="315" width="11" height="12" font="2">of</text>
<text top="931" left="339" width="24" height="12" font="2">care</text>
<text top="931" left="376" width="23" height="12" font="2">that</text>
<text top="949" left="63" width="39" height="12" font="2">should</text>
<text top="949" left="115" width="13" height="12" font="2">be</text>
<text top="949" left="141" width="19" height="12" font="2">the</text>
<text top="949" left="173" width="28" height="12" font="2">basis</text>
<text top="949" left="215" width="11" height="12" font="2">of</text>
<text top="949" left="239" width="14" height="12" font="2">all</text>
<text top="949" left="266" width="67" height="12" font="2">team-based</text>
<text top="949" left="346" width="24" height="12" font="2">care</text>
<text top="949" left="383" width="16" height="12" font="2">for</text>
<text top="967" left="63" width="80" height="12" font="2">hypertension.</text>
<text top="985" left="78" width="321" height="12" font="2">Team-based care aims to achieve effective control of</text>
<text top="1003" left="63" width="336" height="12" font="2">hypertension by application of the strategies outlined in</text>
<text top="1021" left="63" width="212" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement H </a><a href="e127.full.html#110">(S12.2-3)</a></text>
<text top="1021" left="275" width="124" height="12" font="2"><a href="e127.full.html#110">. </a>Delineation of indi-</text>
<text top="1039" left="63" width="336" height="12" font="2">vidual team member roles on the basis of knowledge, skill</text>
<text top="1057" left="63" width="245" height="12" font="2">set, and availability, as well as the patient</text>
<text top="1055" left="308" width="91" height="15" font="2">’s needs, allows</text>
<text top="536" left="420" width="336" height="12" font="2">the primary care provider to delegate routine matters to</text>
<text top="554" left="420" width="336" height="12" font="2">the team, thereby permitting more time to manage com-</text>
<text top="572" left="420" width="336" height="12" font="2">plex and critical patient-care issues. Important imple-</text>
<text top="590" left="420" width="336" height="12" font="2">mentation aspects, such as type of team member added,</text>
<text top="608" left="420" width="336" height="12" font="2">role of team members related to medication management,</text>
<text top="626" left="420" width="209" height="12" font="2">and number of team members, in</text>
<text top="624" left="630" width="127" height="15" font="2">ﬂuence BP outcomes</text>
<text top="644" left="420" width="97" height="12" font="5"><a href="e127.full.html#110">(S12.2-3,S12.2-13)</a></text>
<text top="644" left="517" width="239" height="12" font="2">. Team member roles should be clear to</text>
<text top="662" left="420" width="276" height="12" font="2">all team members and to patients and families.</text>
<text top="680" left="435" width="321" height="12" font="2">Team-based care often requires organizational change</text>
<text top="698" left="420" width="169" height="12" font="2">and reallocation of resources</text>
<text top="698" left="593" width="103" height="12" font="5"><a href="e127.full.html#110">(S12.2-14,S12.2-15)</a></text>
<text top="698" left="697" width="60" height="12" font="2"><a href="e127.full.html#110">. </a>Systems-</text>
<text top="716" left="420" width="336" height="12" font="2">level support, such as use of electronic health records</text>
<text top="734" left="420" width="62" height="12" font="2">(EHR) (see</text>
<text top="734" left="488" width="78" height="12" font="5"><a href="e127.full.html#78">Section 12.3.1</a></text>
<text top="734" left="567" width="190" height="12" font="2"><a href="e127.full.html#78">), </a>clinical decision support (i.e.,</text>
<text top="752" left="420" width="336" height="12" font="2">treatment algorithms), technology-based remote moni-</text>
<text top="770" left="420" width="61" height="12" font="2">toring (see</text>
<text top="770" left="484" width="77" height="12" font="5"><a href="e127.full.html#78">Section 12.3.2</a></text>
<text top="770" left="562" width="195" height="12" font="2"><a href="e127.full.html#78">), </a>self-management support tools,</text>
<text top="788" left="420" width="336" height="12" font="2">and monitoring of performance, are likely to augment and</text>
<text top="805" left="420" width="304" height="12" font="2">intensify team-based care efforts to reduce high BP.</text>
<text top="832" left="420" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="831" left="559" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="859" left="421" width="336" height="12" font="2">1. RCTs and meta-analyses of RCTs of team-based</text>
<text top="877" left="434" width="76" height="12" font="2">hypertension</text>
<text top="877" left="523" width="24" height="12" font="2">care</text>
<text top="877" left="558" width="55" height="12" font="2">involving</text>
<text top="877" left="625" width="32" height="12" font="2">nurse</text>
<text top="877" left="669" width="12" height="12" font="2">or</text>
<text top="877" left="692" width="64" height="12" font="2">pharmacist</text>
<text top="895" left="434" width="322" height="12" font="2">intervention demonstrated reductions in SBP and</text>
<text top="913" left="434" width="322" height="12" font="2">DBP and/or greater achievement of BP goals when</text>
<text top="931" left="434" width="57" height="12" font="2">compared</text>
<text top="931" left="507" width="26" height="12" font="2">with</text>
<text top="931" left="548" width="31" height="12" font="2">usual</text>
<text top="931" left="594" width="24" height="12" font="2">care</text>
<text top="931" left="633" width="123" height="12" font="5"><a href="e127.full.html#110">(S12.2-1,S12.2-2,S12.2-</a></text>
<text top="949" left="434" width="55" height="12" font="5"><a href="e127.full.html#110">4,S12.2-5)</a></text>
<text top="949" left="490" width="267" height="12" font="2"><a href="e127.full.html#110">. </a>Similarly, systematic reviews of team-</text>
<text top="967" left="434" width="33" height="12" font="2">based</text>
<text top="967" left="480" width="28" height="12" font="2">care,</text>
<text top="967" left="519" width="55" height="12" font="2">including</text>
<text top="967" left="586" width="6" height="12" font="2">a</text>
<text top="967" left="605" width="39" height="12" font="2">review</text>
<text top="967" left="656" width="11" height="12" font="2">of</text>
<text top="967" left="680" width="41" height="12" font="2">studies</text>
<text top="967" left="733" width="23" height="12" font="2">that</text>
<text top="985" left="434" width="322" height="12" font="2">included community health workers, for patients with</text>
<text top="1003" left="434" width="322" height="12" font="2">primary hypertension showed reductions in SBP and</text>
<text top="1021" left="434" width="322" height="12" font="2">DBP and improvements in BP control, appointment</text>
<text top="1039" left="434" width="322" height="12" font="2">keeping, and hypertension medication adherence as</text>
<text top="1057" left="434" width="153" height="12" font="2">compared with usual care</text>
<text top="1057" left="593" width="97" height="12" font="5"><a href="e127.full.html#110">(S12.2-3,S12.2-12)</a></text>
<text top="1057" left="690" width="3" height="12" font="2">.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="787" width="20" height="9" font="4">e203</text>
</page>
<page number="78" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="195" height="11" font="12">12.3. Health Information Technology</text>
<text top="141" left="303" width="109" height="15" font="12">–Based Strategies to</text>
<text top="161" left="136" width="163" height="11" font="12">Promote Hypertension Control</text>
<text top="183" left="108" width="176" height="11" font="2">12.3.1. EHR and Patient Registries</text>
<text top="415" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="433" left="123" width="318" height="12" font="2">A growing number of health systems are developing or</text>
<text top="451" left="108" width="333" height="12" font="2">using registries and EHR that permit large-scale queries to</text>
<text top="469" left="108" width="333" height="12" font="2">support population health management strategies to</text>
<text top="487" left="108" width="333" height="12" font="2">identify undiagnosed or undertreated hypertension. Such</text>
<text top="505" left="108" width="69" height="12" font="2">innovations</text>
<text top="505" left="190" width="18" height="12" font="2">are</text>
<text top="505" left="222" width="77" height="12" font="2">implemented</text>
<text top="505" left="314" width="12" height="12" font="2">as</text>
<text top="505" left="340" width="47" height="12" font="2">ongoing</text>
<text top="505" left="400" width="40" height="12" font="2">quality</text>
<text top="523" left="108" width="333" height="12" font="2">improvement initiatives in clinical practice. To reduce</text>
<text top="541" left="108" width="333" height="12" font="2">undiagnosed hypertension and improve hypertension</text>
<text top="559" left="108" width="333" height="12" font="2">management, a multipronged approach may include 1)</text>
<text top="577" left="108" width="333" height="12" font="2">application of hypertension screening algorithms to EHR</text>
<text top="595" left="108" width="333" height="12" font="2">databases to identify at-risk patients, 2) contacting at-risk</text>
<text top="613" left="108" width="333" height="12" font="2">patients to schedule BP measurements, 3) monthly writ-</text>
<text top="630" left="108" width="333" height="12" font="2">ten feedback to clinicians about at-risk patients who have</text>
<text top="648" left="108" width="333" height="12" font="2">yet to complete a BP measurement, and 4) electronic</text>
<text top="666" left="108" width="333" height="12" font="2">prompts for BP measurements whenever at-risk patients</text>
<text top="684" left="108" width="83" height="12" font="2">visit the clinic</text>
<text top="684" left="194" width="109" height="12" font="5"><a href="e127.full.html#110">(S12.3.1-1,S12.3.1-2)</a></text>
<text top="684" left="304" width="3" height="12" font="2"><a href="e127.full.html#110">.</a></text>
<text top="412" left="468" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="410" left="607" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="439" left="469" width="332" height="12" font="2">1. A growing number of health systems have imple-</text>
<text top="457" left="483" width="318" height="12" font="2">mented secure EHR and are developing databases</text>
<text top="475" left="483" width="318" height="12" font="2">that permit large-scale queries to support population</text>
<text top="493" left="483" width="318" height="12" font="2">health management strategies for more effective and</text>
<text top="511" left="483" width="89" height="12" font="2">accurate identi</text>
<text top="509" left="572" width="229" height="15" font="2">ﬁcation of patients with hypertension</text>
<text top="529" left="483" width="52" height="12" font="5"><a href="e127.full.html#110">(S12.3.1-1</a></text>
<text top="527" left="535" width="62" height="15" font="5"><a href="e127.full.html#110">—S12.3.1-3)</a></text>
<text top="529" left="597" width="3" height="12" font="2">.</text>
<text top="547" left="468" width="333" height="12" font="2">2. A growing number of health systems have imple-</text>
<text top="565" left="483" width="318" height="12" font="2">mented secure EHR and are developing databases that</text>
<text top="583" left="483" width="313" height="12" font="2">permit large-scale quality improvement initiative</text>
<text top="581" left="796" width="5" height="15" font="2">–</text>
<text top="601" left="483" width="318" height="12" font="2">designed queries to support population health man-</text>
<text top="618" left="483" width="318" height="12" font="2">agement strategies for more effective management and</text>
<text top="636" left="483" width="137" height="12" font="2">control of hypertension</text>
<text top="636" left="624" width="52" height="12" font="5"><a href="e127.full.html#110">(S12.3.1-1</a></text>
<text top="635" left="677" width="62" height="15" font="5"><a href="e127.full.html#110">—S12.3.1-3)</a></text>
<text top="636" left="739" width="3" height="12" font="2"><a href="e127.full.html#110">.</a></text>
<text top="666" left="468" width="226" height="11" font="2">12.3.2. Telehealth Interventions to Improve</text>
<text top="684" left="506" width="111" height="11" font="2">Hypertension Control</text>
<text top="217" left="63" width="277" height="11" font="19">Recommendations for EHR and Patient Registries</text>
<text top="231" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="231" left="412" width="153" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 63</a></text>
<text top="231" left="566" width="3" height="11" font="19">.</text>
<text top="274" left="89" width="19" height="10" font="13">COR</text>
<text top="274" left="161" width="18" height="10" font="13">LOE</text>
<text top="274" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="309" left="97" width="3" height="9" font="4">I</text>
<text top="309" left="160" width="21" height="9" font="4">B-NR</text>
<text top="295" left="234" width="253" height="11" font="12">1. Use of the EHR and patient registries is bene</text>
<text top="293" left="487" width="292" height="15" font="12">ﬁcial for identiﬁcation of patients with undiagnosed or</text>
<text top="311" left="246" width="142" height="11" font="12">undertreated hypertension</text>
<text top="311" left="392" width="50" height="11" font="5"><a href="e127.full.html#110">(S12.3.1-1</a></text>
<text top="309" left="443" width="60" height="15" font="5"><a href="e127.full.html#110">—S12.3.1-3)</a></text>
<text top="311" left="503" width="3" height="11" font="12"><a href="e127.full.html#110">.</a></text>
<text top="360" left="97" width="3" height="9" font="4">I</text>
<text top="360" left="160" width="21" height="9" font="4">B-NR</text>
<text top="347" left="234" width="254" height="11" font="12">2. Use of the EHR and patient registries is bene</text>
<text top="345" left="488" width="307" height="15" font="12">ﬁcial for guiding quality improvement efforts designed to</text>
<text top="362" left="248" width="157" height="11" font="12">improve hypertension control</text>
<text top="362" left="409" width="50" height="11" font="5"><a href="e127.full.html#110">(S12.3.1-1</a></text>
<text top="360" left="460" width="60" height="15" font="5"><a href="e127.full.html#110">—S12.3.1-3)</a></text>
<text top="362" left="520" width="3" height="11" font="12"><a href="e127.full.html#110">.</a></text>
<text top="738" left="63" width="448" height="11" font="19">Recommendation for Telehealth Interventions to Improve Hypertension Control</text>
<text top="753" left="63" width="362" height="11" font="19">References that support the recommendation are summarized in</text>
<text top="753" left="429" width="155" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 64</a></text>
<text top="753" left="584" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="794" left="89" width="19" height="10" font="13">COR</text>
<text top="794" left="161" width="18" height="10" font="13">LOE</text>
<text top="794" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="830" left="94" width="10" height="9" font="4">IIa</text>
<text top="830" left="168" width="6" height="9" font="4">A</text>
<text top="818" left="234" width="529" height="11" font="12">1. Telehealth strategies can be useful adjuncts to interventions shown to reduce BP for adults with</text>
<text top="834" left="246" width="69" height="11" font="12">hypertension</text>
<text top="834" left="319" width="51" height="11" font="5"><a href="e127.full.html#110">(S12.3.2-1</a></text>
<text top="832" left="371" width="61" height="15" font="5"><a href="e127.full.html#110">—S12.3.2-5)</a></text>
<text top="834" left="433" width="3" height="11" font="12"><a href="e127.full.html#110">.</a></text>
<text top="906" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="924" left="123" width="321" height="12" font="2">Telehealth strategies, such as telemedicine, digital</text>
<text top="942" left="108" width="48" height="12" font="2">health (</text>
<text top="940" left="156" width="288" height="15" font="2">“eHealth”), and use of mobile computing and</text>
<text top="960" left="108" width="181" height="12" font="2">communication technologies (</text>
<text top="958" left="289" width="154" height="15" font="2">“mHealth”), are new and</text>
<text top="978" left="108" width="336" height="12" font="2">innovative tools to facilitate improvements in managing</text>
<text top="996" left="108" width="336" height="12" font="2">patients with hypertension. mHealth interventions show</text>
<text top="1014" left="108" width="336" height="12" font="2">promise in reducing SBP in patients with hypertension but</text>
<text top="1032" left="108" width="336" height="12" font="2">with large variability in behavioral targets, intervention</text>
<text top="1050" left="108" width="336" height="12" font="2">components, delivery modalities, and patient engagement</text>
<text top="1068" left="108" width="58" height="12" font="5"><a href="e127.full.html#110">(S12.3.2-5)</a></text>
<text top="1068" left="166" width="278" height="12" font="2">. In addition, there are important implications</text>
<text top="1086" left="108" width="336" height="12" font="2">for the role of social networks, social media, and electronic</text>
<text top="906" left="465" width="336" height="12" font="2">technology as viable components of weight management</text>
<text top="924" left="465" width="141" height="12" font="2">and other lifestyle modi</text>
<text top="922" left="606" width="195" height="15" font="2">ﬁcation and disease management</text>
<text top="942" left="465" width="54" height="12" font="2">programs</text>
<text top="942" left="523" width="59" height="12" font="5"><a href="e127.full.html#110">(S12.3.2-6)</a></text>
<text top="942" left="583" width="3" height="12" font="2"><a href="e127.full.html#110">.</a></text>
<text top="960" left="480" width="321" height="12" font="2">Commonly used telehealth interventions for hyperten-</text>
<text top="978" left="465" width="177" height="12" font="2">sion management are listed in</text>
<text top="978" left="646" width="151" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement I</a></text>
<text top="978" left="798" width="3" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="996" left="465" width="138" height="12" font="2">Wireless technologies (</text>
<text top="996" left="604" width="156" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement I</a></text>
<text top="996" left="760" width="41" height="12" font="2">) allow</text>
<text top="1014" left="465" width="336" height="12" font="2">linking BP devices and other measurement devices</text>
<text top="1032" left="465" width="336" height="12" font="2">to telephone- or Internet-based transmission systems or to</text>
<text top="1050" left="465" width="237" height="12" font="2">Wi-Fi access points available in users</text>
<text top="1048" left="703" width="98" height="15" font="2">’ homes and in</text>
<text top="1068" left="465" width="336" height="12" font="2">communities. Some systems require patients to manually</text>
<text top="1086" left="465" width="336" height="12" font="2">enter data, which is then forwarded to a remote computer</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="21" height="9" font="4">e204</text>
</page>
<page number="79" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="333" height="12" font="2">or the mobile device of the telehealth provider through a</text>
<text top="161" left="63" width="176" height="12" font="2">telephone line or the Internet</text>
<text top="161" left="244" width="58" height="12" font="5"><a href="e127.full.html#110">(S12.3.2-7)</a></text>
<text top="161" left="302" width="94" height="12" font="2">. When data are</text>
<text top="178" left="63" width="333" height="12" font="2">received, they are stored and analyzed, and reports are</text>
<text top="196" left="63" width="333" height="12" font="2">generated, including variations and averages in BP and</text>
<text top="214" left="63" width="257" height="12" font="2">other parameters over the recording period.</text>
<text top="250" left="63" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="248" left="202" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="277" left="63" width="333" height="12" font="2">1. Meta-analyses of RCTs of different telehealth in-</text>
<text top="295" left="77" width="320" height="12" font="2">terventions have demonstrated greater SBP and DBP</text>
<text top="313" left="77" width="62" height="12" font="2">reductions</text>
<text top="313" left="146" width="166" height="12" font="5"><a href="e127.full.html#110">(S12.3.2-1,S12.3.2-2,S12.3.2-4)</a></text>
<text top="313" left="320" width="76" height="12" font="2">and a larger</text>
<text top="331" left="77" width="256" height="12" font="2">proportion of patients achieving BP control</text>
<text top="331" left="338" width="58" height="12" font="5"><a href="e127.full.html#110">(S12.3.2-2)</a></text>
<text top="349" left="77" width="319" height="12" font="2">than those achieved with usual care without tele-</text>
<text top="367" left="77" width="319" height="12" font="2">health. The effect of various telehealth interventions</text>
<text top="143" left="437" width="143" height="12" font="2">on BP lowering was signi</text>
<text top="141" left="580" width="176" height="15" font="2">ﬁcantly greater than that of BP</text>
<text top="161" left="437" width="319" height="12" font="2">self-monitoring without transmission of BP data, which</text>
<text top="178" left="437" width="319" height="12" font="2">suggests a possible added value of the teletransmission</text>
<text top="196" left="437" width="53" height="12" font="2">approach</text>
<text top="196" left="498" width="111" height="12" font="5"><a href="e127.full.html#110">(S12.3.2-1,S12.3.2-3)</a></text>
<text top="196" left="610" width="147" height="12" font="2"><a href="e127.full.html#110">. </a>Although mHealth in-</text>
<text top="214" left="437" width="319" height="12" font="2">terventions in general showed promise in reducing SBP</text>
<text top="232" left="437" width="319" height="12" font="2">in patients with hypertension, results were inconsis-</text>
<text top="250" left="437" width="23" height="12" font="2">tent</text>
<text top="250" left="465" width="58" height="12" font="5"><a href="e127.full.html#110">(S12.3.2-5)</a></text>
<text top="250" left="523" width="233" height="12" font="2">. It is unclear which combination of tel-</text>
<text top="268" left="437" width="319" height="12" font="2">ehealth intervention features is most effective, and</text>
<text top="286" left="437" width="319" height="12" font="2">telehealth has not been demonstrated to be effective as</text>
<text top="304" left="437" width="319" height="12" font="2">a standalone strategy for improving hypertension</text>
<text top="322" left="437" width="45" height="12" font="2">control.</text>
<text top="345" left="423" width="333" height="11" font="12">12.4. Improving Quality of Care for Patients With Hypertension</text>
<text top="367" left="423" width="155" height="11" font="2">12.4.1. Performance Measures</text>
<text top="415" left="63" width="248" height="11" font="19">Recommendation for Performance Measures</text>
<text top="429" left="63" width="362" height="11" font="19">References that support the recommendation are summarized in</text>
<text top="429" left="429" width="153" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 65</a></text>
<text top="429" left="583" width="3" height="11" font="19"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="470" left="89" width="19" height="10" font="13">COR</text>
<text top="470" left="161" width="18" height="10" font="13">LOE</text>
<text top="470" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="507" left="94" width="10" height="9" font="4">IIa</text>
<text top="507" left="160" width="21" height="9" font="4">B-NR</text>
<text top="495" left="234" width="547" height="11" font="12">1. Use of performance measures in combination with other quality improvement strategies at patient-,</text>
<text top="510" left="246" width="485" height="11" font="12">provider-, and system-based levels is reasonable to facilitate optimal hypertension control</text>
<text top="526" left="246" width="51" height="11" font="5"><a href="e127.full.html#110">(S12.4.1-1</a></text>
<text top="524" left="298" width="61" height="15" font="5"><a href="e127.full.html#110">—S12.4.1-3)</a></text>
<text top="526" left="359" width="3" height="11" font="12"><a href="e127.full.html#110">.</a></text>
<text top="574" left="63" width="52" height="12" font="2">Synopsis</text>
<text top="592" left="78" width="321" height="12" font="2">Efforts to improve suboptimal medical care include the</text>
<text top="610" left="63" width="285" height="12" font="2">use of performance measures, which are de</text>
<text top="608" left="348" width="51" height="15" font="2">ﬁned as</text>
<text top="628" left="63" width="336" height="12" font="2">standardized, validated approaches to assess whether</text>
<text top="646" left="63" width="336" height="12" font="2">correct healthcare processes are being performed and</text>
<text top="664" left="63" width="23" height="12" font="2">that</text>
<text top="664" left="98" width="42" height="12" font="2">desired</text>
<text top="664" left="153" width="41" height="12" font="2">patient</text>
<text top="664" left="206" width="56" height="12" font="2">outcomes</text>
<text top="664" left="274" width="18" height="12" font="2">are</text>
<text top="664" left="304" width="32" height="12" font="2">being</text>
<text top="664" left="347" width="52" height="12" font="2">achieved</text>
<text top="682" left="63" width="59" height="12" font="5"><a href="e127.full.html#110">(S12.4.1-4)</a></text>
<text top="682" left="122" width="277" height="12" font="2">. Performance measures are often combined</text>
<text top="700" left="63" width="336" height="12" font="2">with other quality improvement strategies, such as cer-</text>
<text top="718" left="63" width="8" height="12" font="2">ti</text>
<text top="716" left="71" width="328" height="15" font="2">ﬁcation or ﬁnancial incentives tied to higher-quality</text>
<text top="735" left="63" width="24" height="12" font="2">care</text>
<text top="735" left="97" width="58" height="12" font="5"><a href="e127.full.html#110">(S12.4.1-5)</a></text>
<text top="735" left="156" width="135" height="12" font="2"><a href="e127.full.html#110">. </a>Guidelines help de</text>
<text top="734" left="291" width="108" height="15" font="2">ﬁne clinical care</text>
<text top="753" left="63" width="336" height="12" font="2">standards that can be used to develop performance</text>
<text top="771" left="63" width="336" height="12" font="2">measures. As guidelines evolve over time to incorporate</text>
<text top="789" left="63" width="336" height="12" font="2">new evidence, related performance measures may also</text>
<text top="807" left="63" width="42" height="12" font="2">evolve.</text>
<text top="825" left="78" width="92" height="12" font="2">Because identi</text>
<text top="823" left="170" width="229" height="15" font="2">ﬁcation, treatment, and control of</text>
<text top="843" left="63" width="336" height="12" font="2">hypertension are suboptimal, performance measures for</text>
<text top="861" left="63" width="336" height="12" font="2">hypertension control have been developed and recom-</text>
<text top="879" left="63" width="336" height="12" font="2">mended for use in quality improvement projects aimed at</text>
<text top="897" left="63" width="336" height="12" font="2">improving hypertension control and related outcomes in</text>
<text top="915" left="63" width="91" height="12" font="2">clinical practice</text>
<text top="915" left="157" width="55" height="12" font="5"><a href="e127.full.html#110">(S12.4.1-6</a></text>
<text top="913" left="212" width="64" height="15" font="5"><a href="e127.full.html#110">—S12.4.1-8)</a></text>
<text top="915" left="276" width="109" height="12" font="2">. Because the speci</text>
<text top="913" left="385" width="13" height="15" font="2">ﬁc</text>
<text top="933" left="63" width="336" height="12" font="2">methods used in performance measures can have an</text>
<text top="574" left="420" width="336" height="12" font="2">impact on their accuracy and ultimate impact (e.g., the</text>
<text top="592" left="420" width="336" height="12" font="2">method of BP measurement used in the assessment), they</text>
<text top="610" left="420" width="336" height="12" font="2">should be developed, tested, and implemented according</text>
<text top="628" left="420" width="146" height="12" font="2">to published standards</text>
<text top="628" left="577" width="59" height="12" font="5"><a href="e127.full.html#111">(S12.4.1-9)</a></text>
<text top="628" left="637" width="34" height="12" font="2"><a href="e127.full.html#111">. </a>See</text>
<text top="628" left="681" width="75" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data</a></text>
<text top="646" left="420" width="83" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Supplement J</a></text>
<text top="646" left="510" width="246" height="12" font="2">for publicly available performance mea-</text>
<text top="664" left="420" width="336" height="12" font="2">sures to assess the quality of hypertension care (generally</text>
<text top="682" left="420" width="121" height="12" font="2">using JNC 7 criteria).</text>
<text top="718" left="420" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="716" left="559" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="744" left="421" width="336" height="12" font="2">1. RCTs on the impact of performance measures on hy-</text>
<text top="762" left="434" width="62" height="12" font="2">pertension</text>
<text top="762" left="509" width="41" height="12" font="2">control</text>
<text top="762" left="562" width="18" height="12" font="2">are</text>
<text top="762" left="592" width="45" height="12" font="2">lacking;</text>
<text top="762" left="650" width="29" height="12" font="2">RCTs</text>
<text top="762" left="692" width="11" height="12" font="2">of</text>
<text top="762" left="716" width="40" height="12" font="2">quality</text>
<text top="780" left="434" width="322" height="12" font="2">improvement protocols have shown improvements in</text>
<text top="798" left="434" width="122" height="12" font="2">hypertension control</text>
<text top="798" left="560" width="111" height="12" font="5"><a href="e127.full.html#110">(S12.4.1-1,S12.4.1-2)</a></text>
<text top="798" left="671" width="85" height="12" font="2">. Furthermore,</text>
<text top="816" left="434" width="322" height="12" font="2">a large observational study showed that a systematic</text>
<text top="834" left="434" width="322" height="12" font="2">approach to hypertension control, including the use of</text>
<text top="852" left="434" width="289" height="12" font="2">performance measures, was associated with signi</text>
<text top="850" left="724" width="32" height="15" font="2">ﬁcant</text>
<text top="870" left="434" width="322" height="12" font="2">improvement in hypertension control compared with</text>
<text top="888" left="434" width="142" height="12" font="2">historical control groups</text>
<text top="888" left="581" width="58" height="12" font="5"><a href="e127.full.html#110">(S12.4.1-3)</a></text>
<text top="888" left="639" width="3" height="12" font="2">.</text>
<text top="933" left="420" width="204" height="11" font="2">12.4.2. Quality Improvement Strategies</text>
<text top="975" left="63" width="300" height="11" font="19">Recommendation for Quality Improvement Strategies</text>
<text top="989" left="63" width="362" height="11" font="19">References that support the recommendation are summarized in</text>
<text top="989" left="429" width="202" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplements 66 and 67</a></text>
<text top="989" left="631" width="3" height="11" font="19">.</text>
<text top="1030" left="89" width="19" height="10" font="13">COR</text>
<text top="1030" left="161" width="18" height="10" font="13">LOE</text>
<text top="1030" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="1067" left="94" width="10" height="9" font="4">IIa</text>
<text top="1067" left="163" width="15" height="9" font="4">B-R</text>
<text top="1055" left="234" width="547" height="11" font="12">1. Use of quality improvement strategies at the health system, provider, and patient levels to improve</text>
<text top="1071" left="246" width="30" height="11" font="12">identi</text>
<text top="1069" left="277" width="281" height="15" font="12">ﬁcation and control of hypertension can be effective</text>
<text top="1071" left="562" width="52" height="11" font="5"><a href="e127.full.html#111">(S12.4.2-1</a></text>
<text top="1069" left="614" width="63" height="15" font="5"><a href="e127.full.html#111">—S12.4.2-8)</a></text>
<text top="1071" left="678" width="3" height="11" font="12"><a href="e127.full.html#111">.</a></text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="787" width="20" height="9" font="4">e205</text>
</page>
<page number="80" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="161" left="123" width="318" height="12" font="2">High-quality BP management is multifactorial and</text>
<text top="178" left="108" width="333" height="12" font="2">requires the engagement of patients, families, pro-</text>
<text top="196" left="108" width="237" height="12" font="2">viders, and healthcare delivery systems</text>
<text top="196" left="350" width="60" height="12" font="5"><a href="e127.full.html#111">(S12.4.2-9)</a></text>
<text top="196" left="410" width="31" height="12" font="2">. The</text>
<text top="214" left="108" width="333" height="12" font="2">difference between patient outcomes achieved with</text>
<text top="232" left="108" width="333" height="12" font="2">current hypertension treatment methods and patient</text>
<text top="250" left="108" width="333" height="12" font="2">outcomes thought to be possible with best-practice</text>
<text top="268" left="108" width="333" height="12" font="2">treatment methods is known as a quality gap, and</text>
<text top="286" left="108" width="333" height="12" font="2">such gaps are at least partly responsible for the loss of</text>
<text top="304" left="108" width="173" height="12" font="2">thousands of lives each year</text>
<text top="304" left="286" width="66" height="12" font="5"><a href="e127.full.html#111">(S12.4.2-10)</a></text>
<text top="304" left="352" width="89" height="12" font="2">. This includes</text>
<text top="322" left="108" width="333" height="12" font="2">expanding patient and healthcare provider awareness,</text>
<text top="340" left="108" width="67" height="12" font="2">appropriate</text>
<text top="340" left="187" width="46" height="12" font="2">lifestyle</text>
<text top="340" left="246" width="29" height="12" font="2">modi</text>
<text top="338" left="276" width="165" height="15" font="2">ﬁcations, access to care,</text>
<text top="358" left="108" width="333" height="12" font="2">evidence-based treatment, a high level of medication</text>
<text top="376" left="108" width="214" height="12" font="2">adherence, and adequate follow-up</text>
<text top="376" left="328" width="60" height="12" font="5"><a href="e127.full.html#111">(S12.4.2-9)</a></text>
<text top="376" left="389" width="52" height="12" font="2"><a href="e127.full.html#111">. </a>Quality</text>
<text top="394" left="108" width="78" height="12" font="2">improvement</text>
<text top="394" left="198" width="56" height="12" font="2">strategies</text>
<text top="394" left="267" width="12" height="12" font="2">or</text>
<text top="394" left="291" width="78" height="12" font="2">interventions</text>
<text top="394" left="382" width="35" height="12" font="2">aimed</text>
<text top="394" left="430" width="11" height="12" font="2">at</text>
<text top="412" left="108" width="333" height="12" font="2">reducing the quality gap for a group of patients who are</text>
<text top="430" left="108" width="333" height="12" font="2">representative of those encountered in routine practice</text>
<text top="447" left="108" width="333" height="12" font="2">have been effective in improving the hypertension</text>
<text top="465" left="108" width="333" height="12" font="2">care and outcomes across a wide variety of clinic</text>
<text top="483" left="108" width="150" height="12" font="2">and community settings</text>
<text top="483" left="266" width="54" height="12" font="5"><a href="e127.full.html#111">(S12.4.2-1</a></text>
<text top="482" left="321" width="120" height="15" font="5"><a href="e127.full.html#111">—S12.4.2-4,S12.4.2-6,</a></text>
<text top="501" left="108" width="117" height="12" font="5"><a href="e127.full.html#111">S12.4.2-8,S12.4.2-10)</a></text>
<text top="501" left="225" width="3" height="12" font="2">.</text>
<text top="519" left="123" width="318" height="12" font="2">Hypertension quality improvement strategies, with</text>
<text top="537" left="108" width="333" height="12" font="2">examples of substrategies that have been demonstrated</text>
<text top="555" left="108" width="262" height="12" font="2">to reduce BP and improve BP, are provided in</text>
<text top="555" left="373" width="68" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data</a></text>
<text top="573" left="108" width="81" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Supplement E</a></text>
<text top="573" left="189" width="252" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">. </a>Because the effects of the different quality</text>
<text top="591" left="108" width="333" height="12" font="2">improvement strategies varied across trials, and most</text>
<text top="609" left="108" width="84" height="12" font="2">trials included</text>
<text top="607" left="196" width="245" height="15" font="2">&gt;1 quality improvement strategy, it is not</text>
<text top="627" left="108" width="189" height="12" font="2">possible to discern which speci</text>
<text top="625" left="297" width="144" height="15" font="2">ﬁc quality improvement</text>
<text top="143" left="468" width="333" height="12" font="2">strategies have the greatest effects. Team-based care</text>
<text top="161" left="468" width="23" height="12" font="2">(see</text>
<text top="161" left="495" width="70" height="12" font="5"><a href="e127.full.html#79">Section 12.4</a></text>
<text top="161" left="565" width="236" height="12" font="2">) and an organized system of regular re-</text>
<text top="178" left="468" width="333" height="12" font="2">view, with antihypertensive drug therapy implemented</text>
<text top="196" left="468" width="300" height="12" font="2">via a stepped-care protocol, had a clinically signi</text>
<text top="195" left="769" width="32" height="15" font="2">ﬁcant</text>
<text top="214" left="468" width="333" height="12" font="2">effect on reducing SBP and DBP and improving BP control.</text>
<text top="232" left="468" width="149" height="12" font="2">The assessed strategies in</text>
<text top="232" left="621" width="152" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement E</a></text>
<text top="232" left="777" width="24" height="12" font="2">may</text>
<text top="250" left="468" width="47" height="12" font="2">be bene</text>
<text top="248" left="515" width="286" height="15" font="2">ﬁcial under some circumstances and in varying</text>
<text top="268" left="468" width="78" height="12" font="2">combinations</text>
<text top="268" left="555" width="54" height="12" font="5"><a href="e127.full.html#111">(S12.4.2-1</a></text>
<text top="266" left="609" width="64" height="15" font="5"><a href="e127.full.html#111">—S12.4.2-5)</a></text>
<text top="268" left="674" width="128" height="12" font="2"><a href="e127.full.html#111">. </a>National initiatives</text>
<text top="286" left="468" width="333" height="12" font="2">such as Million Hearts Make Control Your Goal Blood</text>
<text top="304" left="468" width="333" height="12" font="2">Pressure Toolkit and Team Up Pressure Down provide</text>
<text top="322" left="468" width="333" height="12" font="2">quality improvement tools to support hypertension care</text>
<text top="340" left="468" width="207" height="12" font="2">in communities and clinical settings</text>
<text top="340" left="678" width="64" height="12" font="5"><a href="e127.full.html#111">(S12.4.2-11)</a></text>
<text top="340" left="742" width="60" height="12" font="2"><a href="e127.full.html#111">. </a>For other</text>
<text top="358" left="468" width="333" height="12" font="2">national and regional initiatives to improve hypertension,</text>
<text top="376" left="468" width="19" height="12" font="2">see</text>
<text top="376" left="491" width="155" height="12" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement G</a></text>
<text top="376" left="646" width="3" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">.</a></text>
<text top="412" left="468" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="410" left="607" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="439" left="468" width="333" height="12" font="2">1. Systematic review and meta-analyses of trials of quality</text>
<text top="456" left="482" width="319" height="12" font="2">improvement interventions at health system, provider,</text>
<text top="474" left="482" width="319" height="12" font="2">and patient levels have demonstrated greater SBP and</text>
<text top="492" left="482" width="319" height="12" font="2">DBP reductions and a larger proportion of patients</text>
<text top="510" left="482" width="319" height="12" font="2">achieving BP control than those observed with no</text>
<text top="528" left="482" width="139" height="12" font="2">intervention or usual</text>
<text top="528" left="632" width="136" height="12" font="2">care. Multicomponent</text>
<text top="528" left="780" width="21" height="12" font="2">and</text>
<text top="546" left="482" width="320" height="12" font="2">multilevel strategies at the local community and</text>
<text top="564" left="482" width="319" height="12" font="2">healthcare delivery system levels have been shown to</text>
<text top="582" left="482" width="112" height="12" font="2">improve BP control</text>
<text top="582" left="598" width="115" height="12" font="5"><a href="e127.full.html#111">(S12.4.2-6,S12.4.2-7)</a></text>
<text top="582" left="714" width="3" height="12" font="2"><a href="e127.full.html#111">.</a></text>
<text top="627" left="468" width="132" height="11" font="12">12.5. Financial Incentives</text>
<text top="675" left="63" width="236" height="11" font="19">Recommendations for Financial Incentives</text>
<text top="689" left="63" width="345" height="11" font="19">References that support recommendations are summarized in</text>
<text top="689" left="412" width="154" height="11" font="5"><a href="http://jaccjacc.acc.org/Clinical_Document/2017_HBP_FT_DATA_SUPPLEMENT.pdf">Online Data Supplement 68</a></text>
<text top="689" left="567" width="3" height="11" font="19">.</text>
<text top="730" left="89" width="19" height="10" font="13">COR</text>
<text top="730" left="161" width="18" height="10" font="13">LOE</text>
<text top="730" left="233" width="96" height="10" font="13">RECOMMENDATIONS</text>
<text top="767" left="94" width="10" height="9" font="4">IIa</text>
<text top="767" left="163" width="15" height="9" font="4">B-R</text>
<text top="755" left="234" width="525" height="11" font="12">1. Financial incentives paid to providers can be useful in achieving improvements in treatment and</text>
<text top="770" left="246" width="291" height="11" font="12">management of patient populations with hypertension</text>
<text top="770" left="541" width="42" height="11" font="5"><a href="e127.full.html#111">(S12.5-1</a></text>
<text top="768" left="583" width="51" height="15" font="5"><a href="e127.full.html#111">—S12.5-3)</a></text>
<text top="770" left="635" width="3" height="11" font="12"><a href="e127.full.html#111">.</a></text>
<text top="821" left="94" width="10" height="9" font="4">IIa</text>
<text top="821" left="160" width="21" height="9" font="4">B-NR</text>
<text top="809" left="234" width="89" height="11" font="12">2. Health system</text>
<text top="807" left="326" width="474" height="15" font="12">ﬁnancing strategies (e.g., insurance coverage and copayment beneﬁt design) can be useful</text>
<text top="825" left="248" width="487" height="11" font="12">in facilitating improved medication adherence and BP control in patients with hypertension</text>
<text top="825" left="739" width="48" height="11" font="5"><a href="e127.full.html#111">(S12.5-4)</a></text>
<text top="825" left="787" width="3" height="11" font="12">.</text>
<text top="885" left="108" width="52" height="12" font="2">Synopsis</text>
<text top="903" left="123" width="321" height="12" font="2">With the evolution of the U.S. health system to reward</text>
<text top="919" left="108" width="336" height="15" font="2">“value over volume,” payment systems have focused on</text>
<text top="937" left="108" width="336" height="15" font="2">ﬁnancial incentives to improve quality of care. Use of</text>
<text top="957" left="108" width="336" height="12" font="2">performance measures promulgated by national organi-</text>
<text top="975" left="108" width="336" height="12" font="2">zations, governmental payers, and commercial payers</text>
<text top="993" left="108" width="336" height="12" font="2">have fostered greater attention to control of high BP</text>
<text top="1011" left="108" width="336" height="12" font="2">among healthcare providers and their patients. These</text>
<text top="1029" left="108" width="336" height="12" font="2">performance measures have formed the basis for deter-</text>
<text top="1046" left="108" width="41" height="12" font="2">mining</text>
<text top="1045" left="154" width="290" height="15" font="2">ﬁnancial incentives for pay for performance ini-</text>
<text top="1064" left="108" width="171" height="12" font="2">tiatives, commercial insurer</text>
<text top="1063" left="287" width="156" height="15" font="2">“pay-for-value” contracts,</text>
<text top="1082" left="108" width="336" height="12" font="2">and the Medicare Shared Savings Programs developed by</text>
<text top="885" left="465" width="336" height="12" font="2">the Centers for Medicare &amp; Medicaid Services Innovation</text>
<text top="903" left="465" width="336" height="12" font="2">for Accountable Care Organizations. In addition, the Cen-</text>
<text top="921" left="465" width="336" height="12" font="2">ters for Medicare and Medicaid Services has developed</text>
<text top="939" left="465" width="336" height="12" font="2">The Million Hearts: Cardiovascular Disease Risk Reduction</text>
<text top="957" left="465" width="336" height="12" font="2">Model, which is an RCT designed to identify and test</text>
<text top="975" left="465" width="336" height="12" font="2">scalable models of care delivery that reduce CVD risk</text>
<text top="993" left="465" width="48" height="12" font="5"><a href="e127.full.html#111">(S12.5-5)</a></text>
<text top="993" left="513" width="3" height="12" font="2">.</text>
<text top="1011" left="480" width="259" height="12" font="2">Greater attention is being paid to the in</text>
<text top="1009" left="740" width="61" height="15" font="2">ﬂuence of</text>
<text top="1029" left="465" width="221" height="12" font="2">health insurance coverage and bene</text>
<text top="1027" left="687" width="115" height="15" font="2">ﬁt designs focused</text>
<text top="1046" left="465" width="336" height="12" font="2">on reducing patient copayments for antihypertensive</text>
<text top="1064" left="465" width="74" height="12" font="2">medications.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="21" height="9" font="4">e206</text>
</page>
<page number="81" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="141" left="202" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="169" left="64" width="332" height="12" font="2">1. Moderate-quality evidence with mixed results suggests</text>
<text top="187" left="78" width="318" height="12" font="2">that population-based payment incentive programs</text>
<text top="205" left="78" width="318" height="12" font="2">can play an important role in achieving better BP con-</text>
<text top="223" left="78" width="20" height="12" font="2">trol</text>
<text top="223" left="102" width="43" height="12" font="5"><a href="e127.full.html#111">(S12.5-1</a></text>
<text top="221" left="145" width="53" height="15" font="5"><a href="e127.full.html#111">—S12.5-3)</a></text>
<text top="223" left="198" width="3" height="12" font="2">.</text>
<text top="241" left="63" width="333" height="12" font="2">2. Reduced copayments for health care, including for</text>
<text top="259" left="78" width="318" height="12" font="2">medications, and improved outcomes of hypertension</text>
<text top="277" left="78" width="124" height="12" font="2">care have been identi</text>
<text top="275" left="202" width="194" height="15" font="2">ﬁed in several U.S. studies and in</text>
<text top="295" left="78" width="259" height="12" font="2">single studies in Finland, Israel, and Brazil</text>
<text top="295" left="343" width="49" height="12" font="5"><a href="e127.full.html#111">(S12.5-4)</a></text>
<text top="295" left="393" width="3" height="12" font="2"><a href="e127.full.html#111">.</a></text>
<text top="143" left="438" width="318" height="12" font="2">This is consistent with other evidence on how copay-</text>
<text top="161" left="438" width="318" height="12" font="2">ments reduce uptake of care and has implications for</text>
<text top="178" left="438" width="318" height="12" font="2">policy makers, particularly because the balance of ev-</text>
<text top="196" left="438" width="318" height="12" font="2">idence does not suggest that reducing medication</text>
<text top="214" left="438" width="318" height="12" font="2">copayments leads to an increase in overall healthcare</text>
<text top="232" left="438" width="74" height="12" font="2">expenditure.</text>
<text top="272" left="423" width="297" height="16" font="14">13. THE PLAN OF CARE FOR HYPERTENSION</text>
<text top="334" left="63" width="310" height="11" font="19">Recommendation for the Plan of Care for Hypertension</text>
<text top="375" left="89" width="19" height="10" font="13">COR</text>
<text top="375" left="161" width="18" height="10" font="13">LOE</text>
<text top="375" left="233" width="91" height="10" font="13">RECOMMENDATION</text>
<text top="412" left="97" width="3" height="9" font="4">I</text>
<text top="412" left="160" width="20" height="9" font="4">C-EO</text>
<text top="400" left="234" width="566" height="11" font="12">1. Every adult with hypertension should have a clear, detailed, and current evidence-based plan of care that</text>
<text top="415" left="246" width="553" height="11" font="12">ensures the achievement of treatment and self-management goals, encourages effective management of</text>
<text top="431" left="246" width="539" height="11" font="12">comorbid conditions, prompts timely follow-up with the healthcare team, and adheres to CVD GDMT</text>
<text top="447" left="246" width="4" height="11" font="12">(</text>
<text top="447" left="251" width="45" height="11" font="5"><a href="e127.full.html#82">Table 22</a></text>
<text top="447" left="296" width="7" height="11" font="12">).</text>
<text top="497" left="63" width="52" height="12" font="2">Synopsis</text>
<text top="515" left="78" width="41" height="12" font="2">A speci</text>
<text top="514" left="119" width="279" height="15" font="2">ﬁc plan of care for hypertension is essential and</text>
<text top="533" left="63" width="56" height="12" font="2">should re</text>
<text top="532" left="119" width="280" height="15" font="2">ﬂect understanding of the modiﬁable and non-</text>
<text top="551" left="63" width="29" height="12" font="2">modi</text>
<text top="549" left="93" width="306" height="15" font="2">ﬁable determinants of health behaviors, including</text>
<text top="569" left="63" width="327" height="12" font="2">the social determinants of risk and outcomes. A clinician</text>
<text top="567" left="390" width="9" height="15" font="2">’s</text>
<text top="587" left="63" width="60" height="12" font="2">sequential</text>
<text top="585" left="128" width="271" height="15" font="2">ﬂow chart for management of hypertension is</text>
<text top="605" left="63" width="74" height="12" font="2">presented in</text>
<text top="605" left="142" width="47" height="11" font="5"><a href="e127.full.html#82">Table 21</a></text>
<text top="605" left="189" width="210" height="12" font="2">. Detailed evidence-based elements</text>
<text top="623" left="63" width="176" height="12" font="2">of the plan of care are listed in</text>
<text top="623" left="242" width="47" height="11" font="5"><a href="e127.full.html#82">Table 22</a></text>
<text top="623" left="289" width="110" height="12" font="2">. The determinants</text>
<text top="641" left="63" width="270" height="12" font="2">will vary among demographic subgroups (see</text>
<text top="641" left="339" width="60" height="12" font="5"><a href="e127.full.html#62">Section 10</a></text>
<text top="659" left="63" width="161" height="12" font="2">for additional information).</text>
<text top="695" left="63" width="139" height="12" font="2">Recommendation-Speci</text>
<text top="693" left="202" width="113" height="15" font="2">ﬁc Supportive Text</text>
<text top="722" left="63" width="336" height="12" font="2">1. Studies demonstrate that implementation of a plan of</text>
<text top="740" left="77" width="322" height="12" font="2">care for hypertension can lead to sustained reduction of</text>
<text top="758" left="77" width="322" height="12" font="2">BP and attainment of BP targets over several years</text>
<text top="775" left="77" width="32" height="12" font="5"><a href="e127.full.html#111">(S13-1</a></text>
<text top="774" left="109" width="43" height="15" font="5"><a href="e127.full.html#111">—S13-6)</a></text>
<text top="775" left="158" width="241" height="12" font="2">Meta-analysis of RCTs shows reductions</text>
<text top="793" left="77" width="322" height="12" font="2">in BP of patients with hypertension and achievement of</text>
<text top="811" left="77" width="322" height="12" font="2">BP goals at 6 months and 1 year when compared with</text>
<text top="829" left="77" width="63" height="12" font="2">usual care.</text>
<text top="869" left="63" width="108" height="11" font="12">13.1. Health Literacy</text>
<text top="891" left="63" width="336" height="12" font="2">Communicating alternative behaviors that support self-</text>
<text top="909" left="63" width="336" height="12" font="2">management of healthy BP in addition to medication</text>
<text top="926" left="63" width="336" height="12" font="2">adherence is important. This should be done both verbally</text>
<text top="944" left="63" width="336" height="12" font="2">and in writing. Today, mobile phones have a recording</text>
<text top="962" left="63" width="336" height="12" font="2">option. For patients with mobile phones, the phone can be</text>
<text top="980" left="63" width="336" height="12" font="2">used to inform patients and family members of medical</text>
<text top="998" left="63" width="166" height="12" font="2">instructions after the doctor</text>
<text top="996" left="229" width="170" height="15" font="2">’s visit as an additional level</text>
<text top="1016" left="63" width="336" height="12" font="2">of communication. Inclusion of a family member or friend</text>
<text top="1034" left="63" width="336" height="12" font="2">that can help interpret and encourage self-management</text>
<text top="1052" left="63" width="336" height="12" font="2">treatment goals is suggested when appropriate. Exam-</text>
<text top="1070" left="63" width="336" height="12" font="2">ples of needed communication for alternative behaviors</text>
<text top="1088" left="63" width="88" height="12" font="2">include a speci</text>
<text top="1086" left="151" width="248" height="15" font="2">ﬁc regimen relating to physical activity; a</text>
<text top="497" left="420" width="29" height="12" font="2">speci</text>
<text top="496" left="450" width="307" height="15" font="2">ﬁc sodium-reduced meal plan indicating selections</text>
<text top="515" left="420" width="336" height="12" font="2">for breakfast, lunch, and dinner; lifestyle recommenda-</text>
<text top="533" left="420" width="290" height="12" font="2">tions relating to sleep, rest, and relaxation; and</text>
<text top="532" left="716" width="40" height="15" font="2">ﬁnally,</text>
<text top="551" left="420" width="336" height="12" font="2">suggestions and alternatives to environmental barriers,</text>
<text top="569" left="420" width="336" height="12" font="2">such as barriers that prevent healthy food shopping or</text>
<text top="587" left="420" width="336" height="12" font="2">limit reliable transportation to and from appointments</text>
<text top="605" left="420" width="251" height="12" font="2">with health providers and pharmacy visits.</text>
<text top="636" left="420" width="257" height="11" font="12">13.2. Access to Health Insurance and Medication</text>
<text top="654" left="449" width="87" height="11" font="12">Assistance Plans</text>
<text top="675" left="420" width="336" height="12" font="2">Health insurance and medication plan assistance for</text>
<text top="693" left="420" width="336" height="12" font="2">patients is especially important to improving access to</text>
<text top="711" left="420" width="336" height="12" font="2">and affordability of medical care and BP medications.</text>
<text top="729" left="420" width="170" height="12" font="2">Learning how the patient</text>
<text top="727" left="600" width="156" height="15" font="2">ﬁnancially supports and</text>
<text top="747" left="420" width="336" height="12" font="2">budgets for his or her medical care and medications</text>
<text top="765" left="420" width="336" height="12" font="2">offers the opportunity to share additional insight</text>
<text top="783" left="420" width="336" height="12" font="2">relating to cost reductions, including restructured pay-</text>
<text top="801" left="420" width="327" height="12" font="2">ment plans. Ideally, this would improve the patient</text>
<text top="799" left="747" width="9" height="15" font="2">’s</text>
<text top="819" left="420" width="336" height="12" font="2">compliance with medication adherence and treatment</text>
<text top="837" left="420" width="34" height="12" font="2">goals.</text>
<text top="869" left="420" width="193" height="11" font="12">13.3. Social and Community Services</text>
<text top="890" left="420" width="336" height="12" font="2">Health care can be strengthened through local partner-</text>
<text top="908" left="420" width="336" height="12" font="2">ships. Hypertensive patients, particularly patients with</text>
<text top="926" left="420" width="336" height="12" font="2">lower incomes, have more opportunity to achieve treat-</text>
<text top="944" left="420" width="336" height="12" font="2">ment goals with the assistance of strong local partner-</text>
<text top="962" left="420" width="34" height="12" font="2">ships.</text>
<text top="962" left="467" width="12" height="12" font="2">In</text>
<text top="962" left="491" width="47" height="12" font="2">patients</text>
<text top="962" left="551" width="26" height="12" font="2">with</text>
<text top="962" left="590" width="21" height="12" font="2">low</text>
<text top="962" left="624" width="85" height="12" font="2">socioeconomic</text>
<text top="962" left="722" width="35" height="12" font="2">status</text>
<text top="980" left="420" width="336" height="12" font="2">or patients who are challenged by social situations,</text>
<text top="998" left="420" width="336" height="12" font="2">integration of social and community services offers</text>
<text top="1016" left="420" width="314" height="12" font="2">complementary reinforcement of clinically identi</text>
<text top="1014" left="735" width="22" height="15" font="2">ﬁed</text>
<text top="1033" left="420" width="336" height="12" font="2">treatment goals. Social and community services are help-</text>
<text top="1051" left="420" width="336" height="12" font="2">ful when explicitly related to medical care. However,</text>
<text top="1069" left="420" width="59" height="12" font="2">additional</text>
<text top="1068" left="487" width="269" height="15" font="2">ﬁnancial support and ﬁnancial services are</text>
<text top="1087" left="420" width="94" height="12" font="2">incredibly bene</text>
<text top="1085" left="515" width="242" height="15" font="2">ﬁcial to patients, some of whom may</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="787" width="20" height="9" font="4">e207</text>
</page>
<page number="82" position="absolute" top="0" left="0" height="1160" width="864">
<text top="821" left="468" width="132" height="12" font="2">choose to skip a doctor</text>
<text top="819" left="600" width="201" height="15" font="2">’s appointment to pay a residential</text>
<text top="839" left="468" width="62" height="12" font="2">utility bill.</text>
<text top="865" left="468" width="316" height="16" font="14">14. SUMMARY OF BP THRESHOLDS AND GOALS</text>
<text top="883" left="468" width="240" height="16" font="14">FOR PHARMACOLOGICAL THERAPY</text>
<text top="921" left="468" width="333" height="12" font="2">Several different BP thresholds and goals for the long-</text>
<text top="939" left="468" width="333" height="12" font="2">term treatment of hypertension with pharmacological</text>
<text top="957" left="468" width="333" height="12" font="2">therapy are recommended in this guideline. To provide</text>
<text top="975" left="468" width="333" height="12" font="2">a quick reference for practicing clinicians, these are</text>
<text top="993" left="468" width="333" height="12" font="2">summarized for hypertensive patients in general and for</text>
<text top="1011" left="468" width="95" height="12" font="2">those with speci</text>
<text top="1009" left="563" width="112" height="15" font="2">ﬁc comorbidities in</text>
<text top="1011" left="680" width="48" height="11" font="5"><a href="e127.full.html#83">Table 23</a></text>
<text top="1011" left="728" width="3" height="12" font="2"><a href="e127.full.html#83">.</a></text>
<text top="1037" left="468" width="314" height="16" font="14">15. EVIDENCE GAPS AND FUTURE DIRECTIONS</text>
<text top="1075" left="468" width="333" height="12" font="2">In the present guideline, the writing committee was able</text>
<text top="1093" left="468" width="333" height="12" font="2">to call on the large body of literature on BP and</text>
<text top="156" left="113" width="52" height="10" font="15">T A B L E 2 1</text>
<text top="149" left="179" width="44" height="10" font="16">Clinician</text>
<text top="147" left="224" width="169" height="14" font="16">’s Sequential Flow Chart for the</text>
<text top="163" left="179" width="157" height="10" font="16">Management of Hypertension</text>
<text top="187" left="108" width="39" height="9" font="13">Clinician</text>
<text top="186" left="147" width="290" height="12" font="13">’s Sequential Flow Chart for the Management of Hypertension</text>
<text top="207" left="108" width="47" height="9" font="13">Measure of</text>
<text top="205" left="154" width="75" height="12" font="13">ﬁce BP accurately</text>
<text top="207" left="366" width="39" height="9" font="17"><a href="e127.full.html#14">Section 4</a></text>
<text top="226" left="108" width="235" height="9" font="13">Detect white coat hypertension or masked hypertension</text>
<text top="238" left="123" width="110" height="9" font="13">by using ABPM and HBPM</text>
<text top="226" left="366" width="39" height="9" font="17"><a href="e127.full.html#14">Section 4</a></text>
<text top="257" left="108" width="153" height="9" font="13">Evaluate for secondary hypertension</text>
<text top="257" left="366" width="39" height="9" font="17"><a href="e127.full.html#20">Section 5</a></text>
<text top="276" left="108" width="123" height="9" font="13">Identify target organ damage</text>
<text top="276" left="366" width="69" height="9" font="17"><a href="e127.full.html#20">Sections 5 </a>and <a href="e127.full.html#32">7</a></text>
<text top="295" left="108" width="134" height="9" font="13">Introduce lifestyle interventions</text>
<text top="295" left="366" width="39" height="9" font="17"><a href="e127.full.html#28">Section 6</a></text>
<text top="315" left="108" width="153" height="9" font="13">Identify and discuss treatment goals</text>
<text top="315" left="366" width="70" height="9" font="17"><a href="e127.full.html#32">Sections 7 </a>and <a href="e127.full.html#34">8</a></text>
<text top="334" left="108" width="221" height="9" font="13">Use ASCVD risk estimation to guide BP threshold for</text>
<text top="346" left="123" width="54" height="9" font="13">drug therapy</text>
<text top="334" left="366" width="54" height="9" font="17"><a href="e127.full.html#34">Section 8.1.2</a></text>
<text top="365" left="108" width="181" height="9" font="13">Align treatment options with comorbidities</text>
<text top="365" left="366" width="39" height="9" font="17"><a href="e127.full.html#45">Section 9</a></text>
<text top="384" left="108" width="203" height="9" font="13">Account for age, race, ethnicity, sex, and special</text>
<text top="396" left="123" width="186" height="9" font="13">circumstances in antihypertensive treatment</text>
<text top="384" left="366" width="66" height="9" font="17"><a href="e127.full.html#62">Sections 10 </a>and</text>
<text top="396" left="381" width="8" height="9" font="17"><a href="e127.full.html#67">11</a></text>
<text top="415" left="108" width="207" height="9" font="13">Initiate antihypertensive pharmacological therapy</text>
<text top="415" left="366" width="39" height="9" font="17"><a href="e127.full.html#34">Section 8</a></text>
<text top="435" left="108" width="121" height="9" font="13">Insure appropriate follow-up</text>
<text top="435" left="366" width="39" height="9" font="17"><a href="e127.full.html#34">Section 8</a></text>
<text top="454" left="108" width="88" height="9" font="13">Use team-based care</text>
<text top="454" left="366" width="43" height="9" font="17"><a href="e127.full.html#74">Section 12</a></text>
<text top="473" left="108" width="175" height="9" font="13">Connect patient to clinician via telehealth</text>
<text top="473" left="366" width="43" height="9" font="17"><a href="e127.full.html#74">Section 12</a></text>
<text top="492" left="108" width="141" height="9" font="13">Detect and reverse nonadherence</text>
<text top="492" left="366" width="43" height="9" font="17"><a href="e127.full.html#74">Section 12</a></text>
<text top="511" left="108" width="205" height="9" font="13">Detect white coat effect or masked uncontrolled</text>
<text top="523" left="123" width="54" height="9" font="13">hypertension</text>
<text top="511" left="366" width="39" height="9" font="17"><a href="e127.full.html#14">Section 4</a></text>
<text top="543" left="108" width="194" height="9" font="13">Use health information technology for remote</text>
<text top="555" left="123" width="158" height="9" font="13">monitoring and self-monitoring of BP</text>
<text top="543" left="366" width="43" height="9" font="17"><a href="e127.full.html#74">Section 12</a></text>
<text top="578" left="108" width="334" height="8" font="4">ABPM indicates ambulatory blood pressure monitoring; ASCVD, atherosclerotic cardio-</text>
<text top="590" left="108" width="313" height="8" font="4">vascular disease; BP, blood pressure; and HBPM, home blood pressure monitoring.</text>
<text top="633" left="112" width="53" height="10" font="15">T A B L E 2 2</text>
<text top="626" left="179" width="253" height="10" font="16">Evidence-Based Elements of the Plan of Care for</text>
<text top="641" left="179" width="147" height="10" font="16">Patients With Hypertension</text>
<text top="689" left="108" width="57" height="9" font="13">Plan of Care</text>
<text top="665" left="327" width="113" height="9" font="13">Associated Section(s) of</text>
<text top="677" left="337" width="93" height="9" font="13">Guideline and Other</text>
<text top="689" left="354" width="59" height="9" font="13">Reference(s)</text>
<text top="708" left="108" width="230" height="9" font="18">Pharmacological and nonpharmacological treatments</text>
<text top="727" left="117" width="174" height="9" font="13">Medication selection (initial and ongoing)</text>
<text top="727" left="326" width="46" height="9" font="17"><a href="">Section 8.1</a></text>
<text top="746" left="117" width="192" height="9" font="13">Monitoring for adverse effects and adherence</text>
<text top="746" left="326" width="112" height="9" font="17"><a href="e127.full.html#44">Sections 8.3.1, </a><a href="e127.full.html#45">8.3.2</a>, <a href="e127.full.html#75">12.1.1</a></text>
<text top="769" left="117" width="151" height="9" font="13">Nonpharmacological interventions</text>
<text top="784" left="118" width="6" height="10" font="21">n</text>
<text top="785" left="132" width="18" height="9" font="13">Diet</text>
<text top="800" left="118" width="6" height="10" font="21">n</text>
<text top="801" left="132" width="36" height="9" font="13">Exercise</text>
<text top="815" left="118" width="6" height="10" font="21">n</text>
<text top="816" left="132" width="113" height="9" font="13">Weight loss if overweight</text>
<text top="831" left="118" width="6" height="10" font="21">n</text>
<text top="832" left="132" width="137" height="9" font="13">Moderate alcohol consumption</text>
<text top="765" left="326" width="111" height="9" font="17"><a href="e127.full.html#28">Sections 6, </a><a href="">12.1.2 </a><a href="e127.full.html#111">(S13.1-2)</a></text>
<text top="851" left="108" width="236" height="9" font="18">Management of common comorbidities and conditions</text>
<text top="870" left="117" width="94" height="9" font="13">Ischemic heart disease</text>
<text top="870" left="326" width="84" height="9" font="17"><a href="">Section 9.1 </a><a href="e127.full.html#111">(S13.1-3,</a></text>
<text top="882" left="341" width="33" height="9" font="17"><a href="e127.full.html#111">S13.1-4)</a></text>
<text top="905" left="117" width="56" height="9" font="13">Heart failure</text>
<text top="920" left="118" width="6" height="10" font="21">n</text>
<text top="921" left="132" width="113" height="9" font="13">Reduced ejection fraction</text>
<text top="936" left="118" width="6" height="10" font="21">n</text>
<text top="937" left="132" width="119" height="9" font="13">Preserved ejection fraction</text>
<text top="902" left="326" width="86" height="9" font="17"><a href="e127.full.html#47">Section 9.2 </a><a href="e127.full.html#111">(S13.1-5)</a></text>
<text top="956" left="117" width="72" height="9" font="13">Diabetes mellitus</text>
<text top="956" left="326" width="89" height="9" font="17"><a href="e127.full.html#58">Section 9.6 </a><a href="e127.full.html#111">(S13.3-6)</a></text>
<text top="975" left="117" width="95" height="9" font="13">Chronic kidney disease</text>
<text top="975" left="326" width="47" height="9" font="17"><a href="e127.full.html#49">Section 9.3</a></text>
<text top="994" left="117" width="100" height="9" font="13">Cerebrovascular disease</text>
<text top="994" left="326" width="48" height="9" font="17"><a href="e127.full.html#52">Section 9.4</a></text>
<text top="1014" left="117" width="103" height="9" font="13">Peripheral artery disease</text>
<text top="1014" left="326" width="47" height="9" font="17"><a href="e127.full.html#58">Section 9.5</a></text>
<text top="1033" left="117" width="23" height="9" font="13">Atrial</text>
<text top="1031" left="143" width="43" height="12" font="13">ﬁbrillation</text>
<text top="1033" left="326" width="48" height="9" font="17"><a href="e127.full.html#60">Section 9.8</a></text>
<text top="1052" left="117" width="92" height="9" font="13">Valvular heart disease</text>
<text top="1052" left="326" width="48" height="9" font="17"><a href="e127.full.html#61">Section 9.9</a></text>
<text top="1071" left="117" width="119" height="9" font="13">Left ventricular hypertrophy</text>
<text top="1071" left="326" width="46" height="9" font="13">Section 7.3</text>
<text top="1089" left="117" width="95" height="9" font="13">Thoracic aortic disease</text>
<text top="1089" left="326" width="52" height="9" font="17"><a href="">Section 9.10</a></text>
<text top="1109" left="336" width="105" height="8" font="4">Continued on the next page</text>
<text top="148" left="472" width="53" height="10" font="15">T A B L E 2 2</text>
<text top="148" left="540" width="53" height="10" font="16">Continued</text>
<text top="195" left="468" width="53" height="9" font="13">Plan of Care</text>
<text top="171" left="687" width="113" height="9" font="13">Associated Section(s) of</text>
<text top="183" left="697" width="93" height="9" font="13">Guideline and Other</text>
<text top="195" left="714" width="59" height="9" font="13">Reference(s)</text>
<text top="215" left="468" width="125" height="9" font="18">Patient and family education</text>
<text top="234" left="477" width="173" height="9" font="13">Achieving BP control and self-monitoring</text>
<text top="234" left="686" width="70" height="9" font="17"><a href="e127.full.html#15">Sections 4.2</a>, <a href="e127.full.html#43">8.2</a></text>
<text top="253" left="477" width="129" height="9" font="13">Risk assessment and prognosis</text>
<text top="253" left="686" width="54" height="9" font="17"><a href="e127.full.html#34">Section 8.1.2</a></text>
<text top="272" left="477" width="130" height="9" font="13">Sexual activity and dysfunction</text>
<text top="272" left="686" width="50" height="9" font="17"><a href="e127.full.html#72">Section 11.4</a></text>
<text top="291" left="468" width="97" height="9" font="18">Special patient groups</text>
<text top="311" left="477" width="43" height="9" font="13">Pregnancy</text>
<text top="311" left="686" width="59" height="9" font="17"><a href="e127.full.html#64">Section 10.2.2</a></text>
<text top="330" left="477" width="58" height="9" font="13">Older persons</text>
<text top="330" left="686" width="58" height="9" font="17"><a href="e127.full.html#65">Section 10.3.1</a></text>
<text top="349" left="477" width="105" height="9" font="13">Children and adolescents</text>
<text top="349" left="686" width="59" height="9" font="17"><a href="e127.full.html#66">Section 10.3.2</a></text>
<text top="368" left="477" width="85" height="9" font="13">Metabolic syndrome</text>
<text top="368" left="686" width="47" height="9" font="17"><a href="e127.full.html#59">Section 9.7</a></text>
<text top="387" left="477" width="178" height="9" font="13">Possible secondary causes of hypertension</text>
<text top="387" left="686" width="47" height="9" font="17"><a href="e127.full.html#22">Section 5.4</a></text>
<text top="407" left="477" width="95" height="9" font="13">Resistant hypertension</text>
<text top="407" left="686" width="48" height="9" font="17"><a href="e127.full.html#67">Section 11.1</a></text>
<text top="426" left="477" width="197" height="9" font="13">Patients with hypertension undergoing surgery</text>
<text top="426" left="686" width="49" height="9" font="17"><a href="e127.full.html#73">Section 11.5</a></text>
<text top="445" left="477" width="90" height="9" font="13">Renal transplantation</text>
<text top="445" left="686" width="54" height="9" font="17"><a href="e127.full.html#51">Section 9.3.1</a></text>
<text top="464" left="468" width="88" height="9" font="18">Psychosocial factors</text>
<text top="483" left="477" width="39" height="9" font="13">Sex-speci</text>
<text top="482" left="516" width="37" height="12" font="13">ﬁc issues</text>
<text top="483" left="686" width="51" height="9" font="17"><a href="e127.full.html#63">Section 10.2</a></text>
<text top="503" left="477" width="192" height="9" font="13">Culturally sensitive issues (race and ethnicity)</text>
<text top="503" left="686" width="50" height="9" font="17"><a href="e127.full.html#62">Section 10.1</a></text>
<text top="522" left="477" width="87" height="9" font="13">Resource constraints</text>
<text top="522" left="686" width="50" height="9" font="17"><a href="e127.full.html#80">Section 12.5</a></text>
<text top="541" left="468" width="233" height="9" font="18">Clinician follow-up, monitoring, and care coordination</text>
<text top="560" left="477" width="67" height="9" font="13">Follow-up visits</text>
<text top="560" left="686" width="110" height="9" font="17"><a href="e127.full.html#37">Sections 8.1.3</a>, <a href="e127.full.html#44">8.3.1, </a><a href="e127.full.html#45">8.3.2</a></text>
<text top="579" left="477" width="71" height="9" font="13">Team-based care</text>
<text top="579" left="686" width="50" height="9" font="17"><a href="e127.full.html#77">Section 12.2</a></text>
<text top="599" left="477" width="100" height="9" font="13">Electronic health record</text>
<text top="599" left="686" width="57" height="9" font="17"><a href="e127.full.html#78">Section 12.3.1</a></text>
<text top="618" left="477" width="201" height="9" font="13">Health information technology tools for remote</text>
<text top="630" left="499" width="83" height="9" font="13">and self-monitoring</text>
<text top="618" left="686" width="58" height="9" font="17"><a href="e127.full.html#78">Section 12.3.2</a></text>
<text top="649" left="468" width="151" height="9" font="18">Socioeconomic and cultural factors</text>
<text top="668" left="477" width="61" height="9" font="13">Health literacy</text>
<text top="668" left="686" width="57" height="9" font="13">Section 13.1.3</text>
<text top="687" left="477" width="178" height="9" font="13">Access to health insurance and medication</text>
<text top="699" left="499" width="67" height="9" font="13">assistance plans</text>
<text top="687" left="686" width="57" height="9" font="13">Section 13.1.3</text>
<text top="719" left="477" width="60" height="9" font="13">Social services</text>
<text top="719" left="686" width="57" height="9" font="13">Section 13.1.3</text>
<text top="738" left="477" width="83" height="9" font="13">Community services</text>
<text top="738" left="686" width="57" height="9" font="13">Section 13.1.3</text>
<text top="761" left="468" width="109" height="8" font="4">BP indicates blood pressure.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="21" height="9" font="4">e208</text>
</page>
<page number="83" position="absolute" top="0" left="0" height="1160" width="864">
<text top="555" left="63" width="333" height="12" font="2">hypertension to make strong recommendations across a</text>
<text top="573" left="63" width="321" height="12" font="2">broad range of medical conditions. Nonetheless, signi</text>
<text top="571" left="384" width="12" height="15" font="2">ﬁ-</text>
<text top="591" left="63" width="173" height="12" font="2">cant gaps in knowledge exist.</text>
<text top="609" left="78" width="318" height="12" font="2">Importantly, there are areas where epidemiological and</text>
<text top="627" left="63" width="333" height="12" font="2">natural history studies suggest that hypertension pre-</text>
<text top="645" left="63" width="333" height="12" font="2">vention or earlier treatment of hypertension might sub-</text>
<text top="663" left="63" width="333" height="12" font="2">stantially improve outcomes, but clinical trials are lacking</text>
<text top="681" left="63" width="333" height="12" font="2">to provide guidance. The combination of epidemiological</text>
<text top="699" left="63" width="333" height="12" font="2">data showing a graded relationship between BP and out-</text>
<text top="716" left="63" width="333" height="12" font="2">comes, particularly above a BP of 120/80 mm Hg, and the</text>
<text top="734" left="63" width="263" height="12" font="2">results of the SPRINT trial showing bene</text>
<text top="733" left="326" width="70" height="15" font="2">ﬁt of more</text>
<text top="752" left="63" width="277" height="12" font="2">comprehensive treatment to a target BP of</text>
<text top="751" left="349" width="47" height="15" font="2">&lt;120/80</text>
<text top="770" left="63" width="333" height="12" font="2">mm Hg, suggests that a lifelong BP below that level will</text>
<text top="788" left="63" width="333" height="12" font="2">substantially lower CVD and CKD incidence. This is</text>
<text top="806" left="63" width="333" height="12" font="2">especially the case for younger individuals, those with</text>
<text top="824" left="63" width="333" height="12" font="2">DM, and those with high lifetime CVD risk based on the</text>
<text top="842" left="63" width="333" height="12" font="2">presence of multiple risk factors, including high BP.</text>
<text top="860" left="63" width="333" height="12" font="2">If hard, cardiovascular outcome clinical trials remain</text>
<text top="878" left="63" width="333" height="12" font="2">the sole driver of evidence-based guidelines, then deter-</text>
<text top="896" left="63" width="119" height="12" font="2">mining the full bene</text>
<text top="894" left="182" width="214" height="15" font="2">ﬁt of earlier intervention may not be</text>
<text top="914" left="63" width="333" height="12" font="2">possible because of the cost and length of time needed</text>
<text top="932" left="63" width="333" height="12" font="2">for intervention. Outcomes may be different if antihy-</text>
<text top="950" left="63" width="333" height="12" font="2">pertensive treatment is initiated earlier in the natural</text>
<text top="968" left="63" width="333" height="12" font="2">history of CVD. DM may provide a population in whom to</text>
<text top="985" left="63" width="333" height="12" font="2">test this hypothesis. Composite outcomes that include</text>
<text top="1003" left="63" width="333" height="12" font="2">both prevention of events and surrogates, such as pre-</text>
<text top="1021" left="63" width="333" height="12" font="2">vention of decline in renal function or amelioration of</text>
<text top="1039" left="63" width="333" height="12" font="2">measures of subclinical atherosclerosis, vascular stiff-</text>
<text top="1057" left="63" width="333" height="12" font="2">ness, or LV structure and function, should be considered.</text>
<text top="1075" left="63" width="333" height="12" font="2">Otherwise, these younger individuals may be under-</text>
<text top="1093" left="63" width="333" height="12" font="2">treated and experience mortality or CVD events before</text>
<text top="143" left="423" width="253" height="12" font="2">being old enough to enter hard outcome</text>
<text top="141" left="677" width="79" height="15" font="2">–driven trials</text>
<text top="161" left="423" width="333" height="12" font="2">such as SPRINT. Replication of SPRINT, especially in</text>
<text top="178" left="423" width="333" height="12" font="2">younger patients with DM and in countries where</text>
<text top="196" left="423" width="333" height="12" font="2">nonischemic stroke is the predominant cause of CVD, is</text>
<text top="214" left="423" width="333" height="12" font="2">highly desirable. Likewise, implementation studies that</text>
<text top="232" left="423" width="333" height="12" font="2">demonstrate the practicality of SPRINT-like interventions</text>
<text top="250" left="423" width="310" height="12" font="2">in resource-constrained practice settings are needed.</text>
<text top="268" left="438" width="318" height="12" font="2">More information is urgently needed relating hyper-</text>
<text top="286" left="423" width="333" height="12" font="2">tensive target organ damage to CVD risk and outcomes.</text>
<text top="304" left="423" width="101" height="12" font="2">Should the identi</text>
<text top="302" left="525" width="232" height="15" font="2">ﬁcation of target organ damage and hy-</text>
<text top="322" left="423" width="333" height="12" font="2">pertensive heart disease prompt more aggressive BP</text>
<text top="340" left="423" width="333" height="12" font="2">management (i.e., increase the rationale for instituting</text>
<text top="358" left="423" width="333" height="12" font="2">pharmacological therapy earlier or more intensively?</text>
<text top="376" left="423" width="334" height="12" font="2">Should all patients with hypertension be screened with</text>
<text top="394" left="423" width="333" height="12" font="2">echocardiogram for LVH? Should echocardiography be</text>
<text top="412" left="423" width="333" height="12" font="2">repeated once LVH is noted? Is it important to document</text>
<text top="430" left="423" width="333" height="12" font="2">LVH regression? At present, there are no RCT data to</text>
<text top="447" left="423" width="210" height="12" font="2">inform guideline recommendations.</text>
<text top="465" left="438" width="318" height="12" font="2">ABPM and HBPM provide enhanced ability to both</text>
<text top="483" left="423" width="333" height="12" font="2">diagnose hypertension and monitor treatment. Although</text>
<text top="501" left="423" width="88" height="12" font="2">evidence is suf</text>
<text top="499" left="512" width="245" height="15" font="2">ﬁcient to recommend incorporating these</text>
<text top="519" left="423" width="333" height="12" font="2">tools into clinical practice, more knowledge about them is</text>
<text top="537" left="423" width="333" height="12" font="2">required. Areas of inquiry include closer mapping of the</text>
<text top="555" left="423" width="333" height="12" font="2">relationship of outcomes to ambulatory and home BP</text>
<text top="573" left="423" width="157" height="12" font="2">measurements, so that de</text>
<text top="571" left="580" width="176" height="15" font="2">ﬁnitions of hypertension and</text>
<text top="591" left="423" width="333" height="12" font="2">hypertension severity based on these measures can</text>
<text top="609" left="423" width="333" height="12" font="2">be developed, including the importance of masked</text>
<text top="627" left="423" width="333" height="12" font="2">hypertension, white coat hypertension, and nocturnal</text>
<text top="645" left="423" width="333" height="12" font="2">hypertension. Reproducibility of ambulatory and home</text>
<text top="663" left="423" width="333" height="12" font="2">BPs must be studied, and cohorts should include a</text>
<text top="681" left="423" width="333" height="12" font="2">broader range of ethnicities. Trials with entry criteria and</text>
<text top="698" left="423" width="333" height="12" font="2">treatment goals based on ambulatory or home BP mea-</text>
<text top="716" left="423" width="333" height="12" font="2">sures should be conducted, including studies of masked</text>
<text top="734" left="423" width="333" height="12" font="2">and white coat hypertension. The practicality and cost of</text>
<text top="752" left="423" width="333" height="12" font="2">incorporating ABPM into EHR and routine care should be</text>
<text top="770" left="423" width="333" height="12" font="2">assessed. The existence of these techniques should not</text>
<text top="788" left="423" width="333" height="12" font="2">hamper efforts to investigate ways to improve accuracy in</text>
<text top="806" left="423" width="333" height="12" font="2">the measurement of clinic BP. Further research on</text>
<text top="824" left="423" width="144" height="12" font="2">improving accuracy of of</text>
<text top="822" left="567" width="189" height="15" font="2">ﬁce BP measurements, including</text>
<text top="842" left="423" width="45" height="12" font="2">number</text>
<text top="842" left="483" width="11" height="12" font="2">of</text>
<text top="842" left="509" width="89" height="12" font="2">measurements,</text>
<text top="842" left="612" width="46" height="12" font="2">training</text>
<text top="842" left="673" width="11" height="12" font="2">of</text>
<text top="842" left="699" width="57" height="12" font="2">personnel</text>
<text top="860" left="423" width="333" height="12" font="2">measuring BP, and device comparisons, will help stan-</text>
<text top="878" left="423" width="333" height="12" font="2">dardize care and thus improve outcomes. Technology for</text>
<text top="896" left="423" width="333" height="12" font="2">measurement of BP continues to evolve with the emer-</text>
<text top="914" left="423" width="69" height="12" font="2">gence of cuf</text>
<text top="912" left="493" width="264" height="15" font="2">ﬂess devices and other strategies that provide</text>
<text top="932" left="423" width="333" height="12" font="2">the opportunity for continuous noninvasive assessment</text>
<text top="950" left="423" width="333" height="12" font="2">of BP. The accuracy, cost, and usefulness of these new</text>
<text top="967" left="423" width="222" height="12" font="2">technologies will need to be assessed.</text>
<text top="985" left="438" width="318" height="12" font="2">The contemporary healthcare environment is dramati-</text>
<text top="1003" left="423" width="333" height="12" font="2">cally different from the era in which awareness of hy-</text>
<text top="1021" left="423" width="207" height="12" font="2">pertension as a risk factor and bene</text>
<text top="1020" left="630" width="126" height="15" font="2">ﬁts of treatment were</text>
<text top="1039" left="423" width="333" height="12" font="2">discovered. With the advent of the EHR, complex calcu-</text>
<text top="1057" left="423" width="333" height="12" font="2">lations of CVD risk and renal function can be incorporated</text>
<text top="1075" left="423" width="333" height="12" font="2">into routine reports, and many new avenues to support</text>
<text top="1093" left="423" width="72" height="12" font="2">intervention</text>
<text top="1093" left="508" width="56" height="12" font="2">strategies</text>
<text top="1093" left="577" width="18" height="12" font="2">are</text>
<text top="1093" left="608" width="52" height="12" font="2">available</text>
<text top="1093" left="673" width="11" height="12" font="2">to</text>
<text top="1093" left="698" width="59" height="12" font="2">clinicians.</text>
<text top="166" left="67" width="53" height="10" font="15">T A B L E 2 3</text>
<text top="154" left="135" width="253" height="10" font="16">BP Thresholds for and Goals of Pharmacological</text>
<text top="169" left="135" width="207" height="10" font="16">Therapy in Patients With Hypertension</text>
<text top="183" left="135" width="169" height="10" font="16">According to Clinical Conditions</text>
<text top="218" left="63" width="94" height="9" font="13">Clinical Condition(s)</text>
<text top="206" left="272" width="65" height="9" font="13">BP Threshold,</text>
<text top="218" left="288" width="33" height="9" font="13">mm Hg</text>
<text top="206" left="351" width="39" height="9" font="13">BP Goal,</text>
<text top="218" left="354" width="33" height="9" font="13">mm Hg</text>
<text top="234" left="63" width="33" height="9" font="18">General</text>
<text top="254" left="72" width="146" height="9" font="13">Clinical CVD or 10-year ASCVD risk</text>
<text top="252" left="221" width="27" height="12" font="13">$10%</text>
<text top="252" left="285" width="39" height="12" font="13">$130/80</text>
<text top="252" left="351" width="38" height="12" font="13">&lt;130/80</text>
<text top="273" left="72" width="164" height="9" font="13">No clinical CVD and 10-year ASCVD risk</text>
<text top="271" left="239" width="26" height="12" font="13">&lt;10%</text>
<text top="271" left="285" width="39" height="12" font="13">$140/90</text>
<text top="271" left="351" width="38" height="12" font="13">&lt;130/80</text>
<text top="292" left="72" width="65" height="9" font="13">Older persons (</text>
<text top="290" left="137" width="76" height="12" font="13">$65 years of age;</text>
<text top="304" left="93" width="138" height="9" font="13">noninstitutionalized, ambulatory,</text>
<text top="316" left="93" width="105" height="9" font="13">community-living adults)</text>
<text top="290" left="280" width="49" height="12" font="13">$130 (SBP)</text>
<text top="290" left="346" width="48" height="12" font="13">&lt;130 (SBP)</text>
<text top="335" left="63" width="22" height="9" font="18">Speci</text>
<text top="333" left="85" width="71" height="12" font="18">ﬁc comorbidities</text>
<text top="354" left="72" width="72" height="9" font="13">Diabetes mellitus</text>
<text top="353" left="285" width="39" height="12" font="13">$130/80</text>
<text top="353" left="351" width="38" height="12" font="13">&lt;130/80</text>
<text top="373" left="72" width="95" height="9" font="13">Chronic kidney disease</text>
<text top="372" left="285" width="39" height="12" font="13">$130/80</text>
<text top="372" left="351" width="38" height="12" font="13">&lt;130/80</text>
<text top="393" left="72" width="142" height="9" font="13">Chronic kidney disease after renal</text>
<text top="405" left="93" width="64" height="9" font="13">transplantation</text>
<text top="391" left="285" width="39" height="12" font="13">$130/80</text>
<text top="391" left="351" width="38" height="12" font="13">&lt;130/80</text>
<text top="424" left="72" width="53" height="9" font="13">Heart failure</text>
<text top="422" left="285" width="39" height="12" font="13">$130/80</text>
<text top="422" left="351" width="38" height="12" font="13">&lt;130/80</text>
<text top="443" left="72" width="122" height="9" font="13">Stable ischemic heart disease</text>
<text top="441" left="285" width="39" height="12" font="13">$130/80</text>
<text top="441" left="351" width="38" height="12" font="13">&lt;130/80</text>
<text top="462" left="72" width="120" height="9" font="13">Secondary stroke prevention</text>
<text top="461" left="285" width="39" height="12" font="13">$140/90</text>
<text top="461" left="351" width="38" height="12" font="13">&lt;130/80</text>
<text top="481" left="72" width="103" height="9" font="13">Peripheral artery disease</text>
<text top="480" left="285" width="39" height="12" font="13">$130/80</text>
<text top="480" left="351" width="38" height="12" font="13">&lt;130/80</text>
<text top="505" left="63" width="312" height="8" font="4">ASCVD indicates atherosclerotic cardiovascular disease; BP, blood pressure; CVD,</text>
<text top="517" left="63" width="218" height="8" font="4">cardiovascular disease; and SBP, systolic blood pressure.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="786" width="21" height="9" font="4">e209</text>
</page>
<page number="84" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="333" height="12" font="2">Optimizing these approaches will require continued</text>
<text top="161" left="108" width="333" height="12" font="2">focused research. Recognition that simply applying what</text>
<text top="178" left="108" width="333" height="12" font="2">we know about BP control would have a large impact on</text>
<text top="196" left="108" width="249" height="12" font="2">population health, observations on inef</text>
<text top="195" left="357" width="84" height="15" font="2">ﬁciencies and</text>
<text top="214" left="108" width="333" height="12" font="2">excessive cost in the U.S. healthcare system, and the</text>
<text top="232" left="108" width="333" height="12" font="2">growth of information technology have led to promising</text>
<text top="250" left="108" width="333" height="12" font="2">studies of ways to improve and monitor hypertension</text>
<text top="268" left="108" width="210" height="12" font="2">care. Results of this research are re</text>
<text top="266" left="318" width="123" height="15" font="2">ﬂected in this guide-</text>
<text top="286" left="108" width="333" height="12" font="2">line, but further work is required. Examples for study</text>
<text top="304" left="108" width="333" height="12" font="2">include the effectiveness of multidisciplinary healthcare</text>
<text top="322" left="108" width="333" height="12" font="2">teams to achieve BP treatment goals at lower cost, social</text>
<text top="340" left="108" width="333" height="12" font="2">media to maintain contact with patients, information</text>
<text top="358" left="108" width="333" height="12" font="2">technology to monitor outcomes and decrease practice</text>
<text top="376" left="108" width="333" height="12" font="2">variability, and incentives to providers to achieve better</text>
<text top="394" left="108" width="333" height="12" font="2">outcomes for patients. A key goal of these efforts should</text>
<text top="412" left="108" width="333" height="12" font="2">be to demonstrate reduction in healthcare disparities</text>
<text top="430" left="108" width="333" height="12" font="2">across ethnicity, sex, social and economic class, and age</text>
<text top="447" left="108" width="48" height="12" font="2">barriers.</text>
<text top="465" left="123" width="319" height="12" font="2">More research on the prevention of the development of</text>
<text top="483" left="108" width="155" height="12" font="2">hypertension and the bene</text>
<text top="482" left="263" width="178" height="15" font="2">ﬁt of lifetime low BP should be</text>
<text top="501" left="108" width="333" height="12" font="2">conducted. In this regard, elucidation of genetic expres-</text>
<text top="519" left="108" width="333" height="12" font="2">sion, epigenetic effects, transcriptomics, and proteomics</text>
<text top="537" left="108" width="333" height="12" font="2">that link genotypes with longitudinal databases may add</text>
<text top="555" left="108" width="222" height="12" font="2">considerable knowledge about bene</text>
<text top="553" left="330" width="111" height="15" font="2">ﬁcial outcomes of</text>
<text top="573" left="108" width="333" height="12" font="2">lifelong lower BP, determinants of rise in BP over time,</text>
<text top="591" left="108" width="61" height="12" font="2">and identi</text>
<text top="589" left="169" width="272" height="15" font="2">ﬁcation of new treatment targets through un-</text>
<text top="609" left="108" width="333" height="12" font="2">derstanding the underlying pathophysiological mecha-</text>
<text top="627" left="108" width="38" height="12" font="2">nisms.</text>
<text top="627" left="159" width="52" height="12" font="2">Research</text>
<text top="627" left="225" width="39" height="12" font="2">should</text>
<text top="627" left="279" width="13" height="12" font="2">be</text>
<text top="627" left="306" width="48" height="12" font="2">directed</text>
<text top="627" left="368" width="41" height="12" font="2">toward</text>
<text top="627" left="422" width="19" height="12" font="2">the</text>
<text top="645" left="108" width="333" height="12" font="2">development of therapies that directly counteract the</text>
<text top="663" left="108" width="333" height="12" font="2">mechanisms accounting for the development of hyper-</text>
<text top="681" left="108" width="333" height="12" font="2">tension and disease progression. Additional research</text>
<text top="698" left="108" width="333" height="12" font="2">aimed at development of practical approaches to imple-</text>
<text top="716" left="108" width="333" height="12" font="2">mentation of clinical and population-based strategies to</text>
<text top="734" left="108" width="207" height="12" font="2">prevent obesity, increase physical</text>
<text top="733" left="322" width="119" height="15" font="2">ﬁtness, and control</text>
<text top="752" left="108" width="261" height="12" font="2">excess salt and sugar intake could have signi</text>
<text top="751" left="369" width="72" height="15" font="2">ﬁcant public</text>
<text top="770" left="108" width="333" height="12" font="2">health impact. In addition, there are minimal, if any, data</text>
<text top="788" left="108" width="333" height="12" font="2">on whether treatment of hypertension during pregnancy</text>
<text top="806" left="108" width="333" height="12" font="2">mitigates risk; thus, there is a need for further research in</text>
<text top="824" left="108" width="333" height="12" font="2">this area, considering both proximate (during the preg-</text>
<text top="842" left="108" width="333" height="12" font="2">nancy and postpartum period) and distant (CVD preven-</text>
<text top="860" left="108" width="87" height="12" font="2">tion) outcomes</text>
<text top="860" left="199" width="37" height="12" font="5"><a href="e127.full.html#111">(S15-1)</a></text>
<text top="860" left="236" width="3" height="12" font="2">.</text>
<text top="878" left="123" width="318" height="12" font="2">In the very old, frailty and higher risk of medication</text>
<text top="896" left="108" width="333" height="12" font="2">side effects complicate treatment. Additional knowledge</text>
<text top="914" left="108" width="333" height="12" font="2">of the effects of antihypertensive treatment for patients</text>
<text top="932" left="108" width="333" height="12" font="2">with dementia and patients who reside in long-term-care</text>
<text top="950" left="108" width="333" height="12" font="2">facility settings is needed. The best approach to older</text>
<text top="967" left="108" width="333" height="12" font="2">persons who have supine hypertension but postural</text>
<text top="985" left="108" width="172" height="12" font="2">hypotension needs to be clari</text>
<text top="984" left="280" width="26" height="15" font="2">ﬁed.</text>
<text top="1003" left="123" width="318" height="12" font="2">Further research related to shared decision-making</text>
<text top="1021" left="108" width="333" height="12" font="2">with patients and their families is needed. Examples</text>
<text top="143" left="468" width="333" height="12" font="2">include areas where evidence does not clearly identify</text>
<text top="161" left="468" width="333" height="12" font="2">one treatment or goal as substantially better than</text>
<text top="178" left="468" width="49" height="12" font="2">another,</text>
<text top="178" left="531" width="36" height="12" font="2">where</text>
<text top="178" left="582" width="55" height="12" font="2">improved</text>
<text top="178" left="652" width="41" height="12" font="2">patient</text>
<text top="178" left="708" width="63" height="12" font="2">knowledge</text>
<text top="178" left="785" width="16" height="12" font="2">(or</text>
<text top="196" left="468" width="273" height="12" font="2">improved provider knowledge of the patient</text>
<text top="195" left="741" width="60" height="15" font="2">’s circum-</text>
<text top="214" left="468" width="333" height="12" font="2">stances) might improve compliance, where reliance on</text>
<text top="232" left="468" width="333" height="12" font="2">patient collaboration improves achievement of outcomes</text>
<text top="250" left="468" width="333" height="12" font="2">(e.g., HBPM, use of social media), and where there are</text>
<text top="268" left="468" width="333" height="12" font="2">competing health concerns (e.g., older individuals with</text>
<text top="286" left="468" width="43" height="12" font="2">frailty).</text>
<text top="304" left="483" width="318" height="12" font="2">Finally, clinical guidelines are increasingly required to</text>
<text top="322" left="468" width="333" height="12" font="2">manage the large body of accumulated knowledge related</text>
<text top="340" left="468" width="333" height="12" font="2">to diagnosis and management of high BP. However,</text>
<text top="358" left="468" width="333" height="12" font="2">guidelines often cause controversy and confusion when</text>
<text top="376" left="468" width="333" height="12" font="2">competing recommendations are made by different</text>
<text top="392" left="468" width="333" height="15" font="2">“expert” groups or when changes in deﬁnitions, treat-</text>
<text top="412" left="468" width="333" height="12" font="2">ments, or treatment goals are introduced. Now may be the</text>
<text top="430" left="468" width="333" height="12" font="2">time to begin the investigation of the impact of guidelines</text>
<text top="447" left="468" width="333" height="12" font="2">on clinical practice, costs, and patient outcomes, as well</text>
<text top="465" left="468" width="333" height="12" font="2">as ways to facilitate communication and collaboration</text>
<text top="483" left="468" width="333" height="12" font="2">between different guideline-developing organizations.</text>
<text top="501" left="468" width="333" height="12" font="2">This document is, as its name implies, a guide. In man-</text>
<text top="519" left="468" width="240" height="12" font="2">aging patients, the responsible clinician</text>
<text top="517" left="708" width="93" height="15" font="2">’s judgment re-</text>
<text top="537" left="468" width="106" height="12" font="2">mains paramount.</text>
<text top="589" left="468" width="166" height="16" font="14">PRESIDENTS AND STAFF</text>
<text top="627" left="468" width="188" height="12" font="2">American College of Cardiology</text>
<text top="645" left="468" width="245" height="12" font="2">Mary Norine Walsh, MD, MACC, President</text>
<text top="663" left="468" width="225" height="12" font="2">Shalom Jacobovitz, Chief Executive Of</text>
<text top="661" left="693" width="25" height="15" font="2">ﬁcer</text>
<text top="681" left="468" width="299" height="12" font="2">William J. Oetgen, MD, MBA, FACC, Executive Vice</text>
<text top="698" left="483" width="317" height="12" font="2">President, Science, Education, Quality, and Publishing</text>
<text top="716" left="468" width="279" height="12" font="2">MaryAnne Elma, MPH, Senior Director, Science,</text>
<text top="734" left="483" width="204" height="12" font="2">Education, Quality, and Publishing</text>
<text top="752" left="468" width="306" height="12" font="2">Amelia Scholtz, PhD, Publications Manager, Science,</text>
<text top="770" left="483" width="204" height="12" font="2">Education, Quality, and Publishing</text>
<text top="788" left="468" width="333" height="12" font="2">American College of Cardiology/American Heart Association</text>
<text top="806" left="468" width="328" height="12" font="2">Katherine A. Sheehan, PhD, Director, Guideline Strategy</text>
<text top="824" left="483" width="89" height="12" font="2">and Operations</text>
<text top="842" left="468" width="317" height="12" font="2">Abdul R. Abdullah, MD, Science and Medicine Advisor</text>
<text top="860" left="468" width="271" height="12" font="2">Naira Tahir, MPH, Associate Guideline Advisor</text>
<text top="878" left="468" width="168" height="12" font="2">American Heart Association</text>
<text top="896" left="468" width="177" height="12" font="2">John J. Warner, MD, President</text>
<text top="914" left="468" width="195" height="12" font="2">Nancy Brown, Chief Executive Of</text>
<text top="912" left="663" width="25" height="15" font="2">ﬁcer</text>
<text top="932" left="468" width="308" height="12" font="2">Rose Marie Robertson, MD, FAHA, Chief Science and</text>
<text top="950" left="483" width="70" height="12" font="2">Medicine Of</text>
<text top="948" left="554" width="25" height="15" font="2">ﬁcer</text>
<text top="967" left="468" width="318" height="12" font="2">Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice</text>
<text top="985" left="483" width="76" height="12" font="2">President, Of</text>
<text top="984" left="559" width="150" height="15" font="2">ﬁce of Science Operations</text>
<text top="1003" left="468" width="307" height="12" font="2">Jody Hundley, Manager, Production and Operations,</text>
<text top="1021" left="483" width="39" height="12" font="2">Scienti</text>
<text top="1020" left="522" width="261" height="15" font="2">ﬁc Publications, Ofﬁce of Science Operations</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e210</text>
</page>
<page number="85" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="26" size="7" family="Times" color="#e3202b"/>
<text top="157" left="63" width="82" height="12" font="26">R E F E R E N C E S</text>
<text top="204" left="63" width="67" height="12" font="26">P R E A M B L E</text>
<text top="238" left="63" width="15" height="9" font="4">P-1.</text>
<text top="238" left="81" width="199" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1">Gibbons GH, Harold JG, Jessup M, et al. The</a></text>
<text top="251" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1">next steps in developing clinical practice guide-</a></text>
<text top="265" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1">lines for prevention. J Am Coll Cardiol. 2013;62:</a></text>
<text top="278" left="63" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1">1399</a></text>
<text top="276" left="84" width="22" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1">–400</a></text>
<text top="278" left="106" width="3" height="9" font="4">.</text>
<text top="298" left="63" width="16" height="9" font="4">P-2.</text>
<text top="298" left="82" width="198" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref2">Gibbons GH, Shurin SB, Mensah GA, et al.</a></text>
<text top="312" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref2">Refocusing the agenda on cardiovascular guidelines:</a></text>
<text top="325" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref2">an announcement from the National Heart, Lung,</a></text>
<text top="339" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref2">and Blood Institute. J Am Coll Cardiol. 2013;62:</a></text>
<text top="352" left="63" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref2">1396</a></text>
<text top="351" left="83" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref2">–8</a></text>
<text top="352" left="93" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref2">.</a></text>
<text top="372" left="63" width="16" height="9" font="4">P-3.</text>
<text top="372" left="82" width="198" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref3">Committee on Standards for Developing Trust-</a></text>
<text top="386" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref3">worthy Clinical Practice Guidelines, Institute of Medi-</a></text>
<text top="399" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref3">cine (U.S.). Clinical Practice Guidelines We Can Trust.</a></text>
<text top="413" left="63" width="196" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref3">Washington, DC: National Academies Press; 2011</a></text>
<text top="413" left="259" width="3" height="9" font="4">.</text>
<text top="433" left="63" width="17" height="9" font="4">P-4.</text>
<text top="433" left="83" width="197" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref4">Committee on Standards for Systematic Reviews</a></text>
<text top="446" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref4">of Comparative Effectiveness Research, Institute of</a></text>
<text top="460" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref4">Medicine (U.S.). Finding What Works in Health Care:</a></text>
<text top="473" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref4">Standards for Systematic Reviews. Washington, DC:</a></text>
<text top="487" left="63" width="127" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref4">National Academies Press; 2011</a></text>
<text top="487" left="189" width="3" height="9" font="4">.</text>
<text top="507" left="63" width="16" height="9" font="4">P-5.</text>
<text top="507" left="82" width="198" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref5">Anderson JL, Heidenreich PA, Barnett PG,</a></text>
<text top="521" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref5">et al. ACC/AHA statement on cost/value method-</a></text>
<text top="534" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref5">ology in clinical practice guidelines and perfor-</a></text>
<text top="547" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref5">mance measures: a report of the American College</a></text>
<text top="561" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref5">of Cardiology/American Heart Association Task</a></text>
<text top="574" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref5">Force on Performance Measures and Task Force on</a></text>
<text top="588" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref5">Practice Guidelines. J Am Coll Cardiol. 2014;63:</a></text>
<text top="601" left="63" width="22" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref5">2304</a></text>
<text top="600" left="85" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref5">–22</a></text>
<text top="601" left="100" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref5">.</a></text>
<text top="621" left="63" width="217" height="9" font="4">P-6. ACCF/AHA Task Force on Practice Guidelines.</text>
<text top="635" left="63" width="53" height="9" font="4">Methodology</text>
<text top="635" left="127" width="29" height="9" font="4">Manual</text>
<text top="635" left="168" width="15" height="9" font="4">and</text>
<text top="635" left="194" width="30" height="9" font="4">Policies</text>
<text top="635" left="235" width="21" height="9" font="4">From</text>
<text top="635" left="267" width="13" height="9" font="4">the</text>
<text top="648" left="63" width="42" height="9" font="4">ACCF/AHA</text>
<text top="648" left="115" width="18" height="9" font="4">Task</text>
<text top="648" left="143" width="22" height="9" font="4">Force</text>
<text top="648" left="175" width="10" height="9" font="4">on</text>
<text top="648" left="195" width="32" height="9" font="4">Practice</text>
<text top="648" left="236" width="44" height="9" font="4">Guidelines.</text>
<text top="662" left="63" width="217" height="9" font="4">American College of Cardiology and American Heart</text>
<text top="675" left="63" width="48" height="9" font="4">Association,</text>
<text top="675" left="122" width="23" height="9" font="4">2010.</text>
<text top="675" left="156" width="36" height="9" font="4">Available</text>
<text top="675" left="204" width="11" height="9" font="4">at:</text>
<text top="675" left="226" width="53" height="9" font="8"><a href="http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf">http://assets.</a></text>
<text top="689" left="63" width="216" height="9" font="8"><a href="http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf">cardiosource.com/Methodology_Manual_for_ACC_AHA_</a></text>
<text top="702" left="63" width="95" height="9" font="8"><a href="http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf">Writing_Committees.pdf</a></text>
<text top="702" left="161" width="15" height="9" font="4">and</text>
<text top="702" left="179" width="101" height="9" font="8"><a href="http://professional.heart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf">http://professional.heart.</a></text>
<text top="716" left="63" width="217" height="9" font="8"><a href="http://professional.heart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf">org/idc/groups/ahamah-public/@wcm/@sop/documents/</a></text>
<text top="729" left="63" width="123" height="9" font="8"><a href="http://professional.heart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf">downloadable/ucm_319826.pdf</a></text>
<text top="729" left="186" width="94" height="9" font="4"><a href="http://professional.heart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf">. </a>Accessed September</text>
<text top="743" left="63" width="37" height="9" font="4">15, 2017.</text>
<text top="763" left="63" width="16" height="9" font="4">P-7.</text>
<text top="763" left="82" width="198" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref7">Halperin JL, Levine GN, Al-Khatib SM, et al.</a></text>
<text top="776" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref7">Further evolution of the ACC/AHA clinical practice</a></text>
<text top="790" left="63" width="139" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref7">guideline recommendation classi</a></text>
<text top="788" left="201" width="78" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref7">ﬁcation system: a</a></text>
<text top="803" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref7">report of the American College of Cardiology Foun-</a></text>
<text top="817" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref7">dation/American Heart Association Task Force on</a></text>
<text top="830" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref7">Clinical Practice Guidelines. J Am Coll Cardiol. 2016;</a></text>
<text top="844" left="63" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref7">67:1572</a></text>
<text top="842" left="94" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref7">–4</a></text>
<text top="844" left="103" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref7">.</a></text>
<text top="864" left="63" width="17" height="9" font="4">P-8.</text>
<text top="864" left="83" width="197" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref8">Jacobs AK, Kushner FG, Ettinger SM. ACCF/AHA</a></text>
<text top="877" left="63" width="27" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref8">clinical</a></text>
<text top="877" left="100" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref8">practice</a></text>
<text top="877" left="141" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref8">guideline</a></text>
<text top="877" left="187" width="53" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref8">methodology</a></text>
<text top="877" left="250" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref8">summit</a></text>
<text top="891" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref8">report: a report of the American College of Cardiol-</a></text>
<text top="904" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref8">ogy Foundation/American Heart Association Task</a></text>
<text top="918" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref8">Force on Practice Guidelines. J Am Coll Cardiol. 2013;</a></text>
<text top="931" left="63" width="25" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref8">61:213</a></text>
<text top="929" left="88" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref8">–65</a></text>
<text top="931" left="102" width="3" height="9" font="4">.</text>
<text top="951" left="63" width="17" height="9" font="4">P-9.</text>
<text top="951" left="83" width="197" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref9">Jacobs AK, Anderson JL, Halperin JL. The evolu-</a></text>
<text top="965" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref9">tion and future of ACC/AHA clinical practice guidelines:</a></text>
<text top="978" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref9">a 30-year journey: a report of the American College</a></text>
<text top="992" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref9">of Cardiology/American Heart Association Task Force</a></text>
<text top="1005" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref9">on Practice Guidelines. J Am Coll Cardiol. 2014;64:</a></text>
<text top="1019" left="63" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref9">1373</a></text>
<text top="1017" left="81" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref9">–84</a></text>
<text top="1019" left="96" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref9">.</a></text>
<text top="1039" left="63" width="21" height="9" font="4">P-10.</text>
<text top="1039" left="87" width="193" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref10">Arnett DK, Goodman RA, Halperin JL, et al. AHA/</a></text>
<text top="1052" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref10">ACC/HHS strategies to enhance application of clinical</a></text>
<text top="1066" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref10">practice guidelines in patients with cardiovascular</a></text>
<text top="1079" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref10">disease and comorbid conditions: from the American</a></text>
<text top="1093" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref10">Heart Association, American College of Cardiology,</a></text>
<text top="191" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref10">and U.S. Department of Health and Human Services.</a></text>
<text top="205" left="301" width="129" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref10">J Am Coll Cardiol. 2014;64:1851</a></text>
<text top="203" left="430" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref10">–6</a></text>
<text top="205" left="440" width="3" height="9" font="4">.</text>
<text top="245" left="301" width="110" height="12" font="26">1 . I N T R O D U C T I O N</text>
<text top="278" left="301" width="25" height="9" font="4">S1.5-1.</text>
<text top="278" left="330" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref11">Society</a></text>
<text top="278" left="369" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref11">of</a></text>
<text top="278" left="388" width="39" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref11">Actuaries.</a></text>
<text top="278" left="438" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref11">Build</a></text>
<text top="278" left="469" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref11">and</a></text>
<text top="278" left="495" width="23" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref11">Blood</a></text>
<text top="291" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref11">Pressure Study, Vol 1. Ann Arbor, MI: The University of</a></text>
<text top="305" left="301" width="61" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref11">Michigan; 1959</a></text>
<text top="305" left="362" width="3" height="9" font="4">.</text>
<text top="324" left="301" width="26" height="9" font="4">S1.5-2.</text>
<text top="324" left="330" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref12">Dawber TR. The Framingham Study: The</a></text>
<text top="338" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref12">Epidemiology of Atherosclerotic Disease. Cambridge,</a></text>
<text top="351" left="301" width="144" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref12">MA: Harvard University Press; 1980</a></text>
<text top="351" left="445" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref12">.</a></text>
<text top="371" left="301" width="26" height="9" font="4">S1.5-3.</text>
<text top="371" left="330" width="28" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref13">Effects</a></text>
<text top="371" left="369" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref13">of</a></text>
<text top="371" left="389" width="40" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref13">treatment</a></text>
<text top="371" left="440" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref13">on</a></text>
<text top="371" left="461" width="38" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref13">morbidity</a></text>
<text top="371" left="511" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref13">in</a></text>
<text top="384" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref13">hypertension. I. Results in patients with diastolic blood</a></text>
<text top="398" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref13">pressures averaging 115 through 129 mm Hg. JAMA.</a></text>
<text top="411" left="301" width="61" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref13">1967;202:1028</a></text>
<text top="409" left="362" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref13">–34</a></text>
<text top="411" left="376" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref13">.</a></text>
<text top="431" left="301" width="27" height="9" font="4">S1.5-4.</text>
<text top="431" left="331" width="28" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref14">Effects</a></text>
<text top="431" left="370" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref14">of</a></text>
<text top="431" left="389" width="40" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref14">treatment</a></text>
<text top="431" left="441" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref14">on</a></text>
<text top="431" left="462" width="38" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref14">morbidity</a></text>
<text top="431" left="511" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref14">in</a></text>
<text top="444" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref14">hypertension. II. Results in patients with diastolic</a></text>
<text top="458" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref14">blood pressure averaging 90 through 114 mm Hg.</a></text>
<text top="471" left="301" width="85" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref14">JAMA. 1970;213:1143</a></text>
<text top="469" left="386" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref14">–52</a></text>
<text top="471" left="399" width="3" height="9" font="4">.</text>
<text top="491" left="301" width="26" height="9" font="4">S1.5-5.</text>
<text top="491" left="330" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref15">Report of the Joint National Committee on</a></text>
<text top="504" left="301" width="41" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref15">Detection,</a></text>
<text top="504" left="352" width="45" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref15">Evaluation,</a></text>
<text top="504" left="406" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref15">and</a></text>
<text top="504" left="430" width="42" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref15">Treatment</a></text>
<text top="504" left="482" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref15">of</a></text>
<text top="504" left="500" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref15">High</a></text>
<text top="518" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref15">Blood Pressure. A cooperative study. JAMA. 1977;237:</a></text>
<text top="531" left="301" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref15">255</a></text>
<text top="529" left="316" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref15">–61</a></text>
<text top="531" left="329" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref15">.</a></text>
<text top="551" left="301" width="27" height="9" font="4">S1.5-6.</text>
<text top="551" left="331" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref16">Moser M, Roccella EJ. The treatment of</a></text>
<text top="564" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref16">hypertension: a remarkable success story. J Clin</a></text>
<text top="578" left="301" width="142" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref16">Hypertens (Greenwich). 2013;15:88</a></text>
<text top="576" left="443" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref16">–91</a></text>
<text top="578" left="456" width="3" height="9" font="4">.</text>
<text top="597" left="301" width="26" height="9" font="4">S1.5-7.</text>
<text top="597" left="330" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref17">Chobanian AV, Bakris GL, Black HR, et al., the</a></text>
<text top="611" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref17">National High Blood Pressure Education Program</a></text>
<text top="624" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref17">Coordinating Committee. Seventh Report of the</a></text>
<text top="638" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref17">Joint National Committee on Prevention, Detection,</a></text>
<text top="651" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref17">Evaluation, and Treatment of High Blood Pressure.</a></text>
<text top="664" left="301" width="116" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref17">Hypertension. 2003;42:1206</a></text>
<text top="663" left="417" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref17">–52</a></text>
<text top="664" left="431" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref17">.</a></text>
<text top="684" left="301" width="27" height="9" font="4">S1.5-8.</text>
<text top="684" left="331" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref18">Reboussin DM, Allen NB, Griswold ME, et al.</a></text>
<text top="697" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref18">Systematic review for the 2017 ACC/AHA/AAPA/ABC/</a></text>
<text top="711" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref18">ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for</a></text>
<text top="724" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref18">the prevention, detection, evaluation, and manage-</a></text>
<text top="738" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref18">ment of high blood pressure in adults: a report of</a></text>
<text top="751" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref18">the American College of Cardiology/American Heart</a></text>
<text top="765" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref18">Association Task Force on Clinical Practice Guidelines.</a></text>
<text top="778" left="301" width="128" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref18">J Am Coll Cardiol. 2018;71:2176</a></text>
<text top="777" left="429" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref18">–98</a></text>
<text top="778" left="444" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref18">.</a></text>
<text top="798" left="301" width="27" height="9" font="4">S1.5-9.</text>
<text top="798" left="331" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref19">Fihn SD, Gardin JM, Abrams J, et al. 2012</a></text>
<text top="811" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref19">ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for</a></text>
<text top="825" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref19">the diagnosis and management of patients with stable</a></text>
<text top="838" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref19">ischemic heart disease: a report of the American</a></text>
<text top="852" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref19">College of Cardiology Foundation/American Heart</a></text>
<text top="865" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref19">Association Task Force on Practice Guidelines, and the</a></text>
<text top="878" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref19">American College of Physicians, American Association</a></text>
<text top="892" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref19">for Thoracic Surgery, Preventive Cardiovascular Nurses</a></text>
<text top="905" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref19">Association, Society for Cardiovascular Angiography</a></text>
<text top="919" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref19">and Interventions, and Society of Thoracic Surgeons.</a></text>
<text top="932" left="301" width="127" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref19">J Am Coll Cardiol. 2012;60:e44</a></text>
<text top="931" left="428" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref19">–164</a></text>
<text top="932" left="447" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref19">.</a></text>
<text top="952" left="301" width="31" height="9" font="4">S1.5-10.</text>
<text top="952" left="335" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref20">Yancy CW, Jessup M, Bozkurt B, et al. 2013</a></text>
<text top="965" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref20">ACCF/AHA guideline for the management of heart</a></text>
<text top="979" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref20">failure: a report of the American College of Cardiology</a></text>
<text top="992" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref20">Foundation/American Heart Association Task Force</a></text>
<text top="1006" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref20">on Practice Guidelines. J Am Coll Cardiol. 2013;62:</a></text>
<text top="1019" left="301" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref20">e147</a></text>
<text top="1018" left="319" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref20">–239</a></text>
<text top="1019" left="339" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref20">.</a></text>
<text top="1039" left="301" width="29" height="9" font="4">S1.5-11.</text>
<text top="1039" left="333" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref21">Gerhard-Herman MD, Gornik HL, Barrett C,</a></text>
<text top="1052" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref21">et al. 2016 AHA/ACC guideline on the management of</a></text>
<text top="1066" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref21">patients with lower extremity peripheral artery</a></text>
<text top="1079" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref21">disease: a report of the American College of</a></text>
<text top="1093" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref21">Cardiology/American Heart Association Task Force on</a></text>
<text top="191" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref21">Clinical Practice Guidelines. J Am Coll Cardiol. 2017;</a></text>
<text top="205" left="539" width="27" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref21">69:e71</a></text>
<text top="203" left="566" width="18" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref21">–126</a></text>
<text top="205" left="584" width="3" height="9" font="4">.</text>
<text top="224" left="539" width="30" height="9" font="4">S1.5-12.</text>
<text top="224" left="573" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref22">Funder JW, Carey RM, Mantero F, et al.</a></text>
<text top="237" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref22">The management of primary aldosteronism: case</a></text>
<text top="250" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref22">detection, diagnosis, and treatment: an Endocrine</a></text>
<text top="264" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref22">Society clinical practice guideline. J Clin Endocrinol</a></text>
<text top="277" left="539" width="90" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref22">Metab. 2016;101:1889</a></text>
<text top="276" left="630" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref22">–916</a></text>
<text top="277" left="649" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref22">.</a></text>
<text top="296" left="539" width="30" height="9" font="4">S1.5-13.</text>
<text top="296" left="573" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref23">Fihn SD, Blankenship JC, Alexander KP, et al.</a></text>
<text top="310" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref23">2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update</a></text>
<text top="323" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref23">of the guideline for the diagnosis and management of</a></text>
<text top="337" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref23">patients with stable ischemic heart disease: a report of</a></text>
<text top="350" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref23">the American College of Cardiology/American Heart</a></text>
<text top="363" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref23">Association Task Force on Practice Guidelines, and</a></text>
<text top="377" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref23">the American Association for Thoracic Surgery,</a></text>
<text top="390" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref23">Preventive Cardiovascular Nurses Association, Society</a></text>
<text top="404" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref23">for Cardiovascular Angiography and Interventions, and</a></text>
<text top="417" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref23">Society of Thoracic Surgeons. J Am Coll Cardiol. 2014;</a></text>
<text top="431" left="539" width="33" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref23">64:1929</a></text>
<text top="429" left="573" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref23">–49</a></text>
<text top="431" left="588" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref23">.</a></text>
<text top="450" left="539" width="31" height="9" font="4">S1.5-14.</text>
<text top="450" left="574" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref24">Lenders JWM, Duh Q-Y, Eisenhofer G, et al.</a></text>
<text top="463" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref24">Pheochromocytoma and paraganglioma: an Endocrine</a></text>
<text top="476" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref24">Society clinical practice guideline. J Clin Endocrinol</a></text>
<text top="490" left="539" width="85" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref24">Metab. 2014;99:1915</a></text>
<text top="488" left="624" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref24">–42</a></text>
<text top="490" left="639" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref24">.</a></text>
<text top="509" left="539" width="30" height="9" font="4">S1.5-15.</text>
<text top="509" left="573" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref25">January CT, Wann LS, Alpert JS, et al. 2014</a></text>
<text top="522" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref25">AHA/ACC/HRS guideline for the management of</a></text>
<text top="536" left="539" width="74" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref25">patients with atrial</a></text>
<text top="534" left="615" width="141" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref25">ﬁbrillation: a report of the American</a></text>
<text top="549" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref25">College of Cardiology/American Heart Association Task</a></text>
<text top="563" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref25">Force on Practice Guidelines and the Heart Rhythm</a></text>
<text top="576" left="539" width="151" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref25">Society. J Am Coll Cardiol. 2014;64:e1</a></text>
<text top="574" left="690" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref25">–76</a></text>
<text top="576" left="705" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref25">.</a></text>
<text top="595" left="539" width="31" height="9" font="4">S1.5-16.</text>
<text top="595" left="574" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref26">Nishimura RA, Otto CM, Bonow RO, et al. 2017</a></text>
<text top="608" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref26">AHA/ACC focused update of the 2014 AHA/ACC</a></text>
<text top="622" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref26">Guideline for the Management of Patients With</a></text>
<text top="635" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref26">Valvular Heart Disease: a report of the American</a></text>
<text top="649" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref26">College of Cardiology/American Heart Association Task</a></text>
<text top="662" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref26">Force on Clinical Practice Guidelines. Circulation. 2017;</a></text>
<text top="676" left="539" width="39" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref26">135:e1159</a></text>
<text top="674" left="578" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref26">–95</a></text>
<text top="676" left="592" width="3" height="9" font="4">.</text>
<text top="694" left="539" width="30" height="9" font="4">S1.5-17.</text>
<text top="694" left="573" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref27">Goff DC Jr., Lloyd-Jones DM, Bennett G, et al.</a></text>
<text top="708" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref27">2013 ACC/AHA guideline on the assessment of</a></text>
<text top="721" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref27">cardiovascular risk: a report of the American College</a></text>
<text top="735" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref27">of Cardiology/American Heart Association Task Force</a></text>
<text top="748" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref27">on Practice Guidelines. J Am Coll Cardiol. 2014;63:</a></text>
<text top="762" left="539" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref27">2935</a></text>
<text top="760" left="559" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref27">–59</a></text>
<text top="762" left="574" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref27">.</a></text>
<text top="780" left="539" width="31" height="9" font="4">S1.5-18.</text>
<text top="780" left="574" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref28">American</a></text>
<text top="780" left="621" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref28">College</a></text>
<text top="780" left="661" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref28">of</a></text>
<text top="780" left="680" width="52" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref28">Obstetricians</a></text>
<text top="780" left="742" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref28">and</a></text>
<text top="794" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref28">Gynecologists, Task Force on Hypertension in Preg-</a></text>
<text top="807" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref28">nancy. Hypertension in pregnancy. Report of the</a></text>
<text top="821" left="539" width="215" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref28">American College of Obstetricians and Gynecologists</a></text>
<text top="819" left="754" width="2" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref28">’</a></text>
<text top="834" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref28">Task Force on Hypertension in Pregnancy. Obstet</a></text>
<text top="848" left="539" width="93" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref28">Gynecol. 2013;122:1122</a></text>
<text top="846" left="632" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref28">–31</a></text>
<text top="848" left="645" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref28">.</a></text>
<text top="867" left="539" width="31" height="9" font="4">S1.5-19.</text>
<text top="867" left="574" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref29">Yancy CW, Jessup M, Bozkurt B, et al. 2017</a></text>
<text top="880" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref29">ACC/AHA/HFSA focused update of the 2013 ACCF/AHA</a></text>
<text top="894" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref29">guideline for the management of heart failure: a report</a></text>
<text top="907" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref29">of the American College of Cardiology/American Heart</a></text>
<text top="920" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref29">Association Task Force on Clinical Practice Guidelines</a></text>
<text top="934" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref29">and the Heart Failure Society of America. J Am Coll</a></text>
<text top="947" left="539" width="83" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref29">Cardiol. 2017;70:776</a></text>
<text top="946" left="623" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref29">–803</a></text>
<text top="947" left="643" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref29">.</a></text>
<text top="966" left="539" width="32" height="9" font="4">S1.5-20.</text>
<text top="966" left="575" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref30">Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/</a></text>
<text top="980" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref30">ACC guideline on lifestyle management to reduce</a></text>
<text top="993" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref30">cardiovascular risk: a report of the American College of</a></text>
<text top="1006" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref30">Cardiology/American Heart Association Task Force</a></text>
<text top="1020" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref30">on Practice Guidelines. J Am Coll Cardiol. 2014;63:</a></text>
<text top="1033" left="539" width="22" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref30">2960</a></text>
<text top="1032" left="561" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref30">–84</a></text>
<text top="1033" left="576" width="3" height="9" font="4">.</text>
<text top="1052" left="539" width="30" height="9" font="4">S1.5-21.</text>
<text top="1052" left="573" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref31">Mancia G, Fagard R, Narkiewicz K, et al. 2013</a></text>
<text top="1066" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref31">ESH/ESC guidelines for the management of arterial</a></text>
<text top="1079" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref31">hypertension: the Task Force for the Management of</a></text>
<text top="1093" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref31">Arterial Hypertension of the European Society of</a></text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="791" width="17" height="9" font="4">e211</text>
</page>
<page number="86" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref31">Hypertension (ESH) and of the European Society of</a></text>
<text top="156" left="108" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref31">Cardiology (ESC). Eur Heart J. 2013;34:2159</a></text>
<text top="155" left="285" width="18" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref31">–219</a></text>
<text top="156" left="303" width="3" height="9" font="4">.</text>
<text top="175" left="108" width="31" height="9" font="4">S1.5-22.</text>
<text top="175" left="142" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref32">Jensen MD, Ryan DH, Apovian CM, et al. 2013</a></text>
<text top="188" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref32">AHA/ACC/TOS guideline for the management of</a></text>
<text top="202" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref32">overweight and obesity in adults: a report of</a></text>
<text top="215" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref32">the American College of Cardiology/American Heart</a></text>
<text top="229" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref32">Association Task Force on Practice Guidelines and</a></text>
<text top="242" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref32">The Obesity Society. Circulation. 2014;129 suppl 2:</a></text>
<text top="256" left="108" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref32">S102</a></text>
<text top="254" left="127" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref32">–38</a></text>
<text top="256" left="141" width="3" height="9" font="4">.</text>
<text top="275" left="108" width="31" height="9" font="4">S1.5-23.</text>
<text top="275" left="142" width="6" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref33">O</a></text>
<text top="273" left="148" width="177" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref33">’Gara PT, Kushner FG, Ascheim DD, et al.</a></text>
<text top="288" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref33">2013 ACCF/AHA guideline for the management of</a></text>
<text top="302" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref33">ST-elevation myocardial infarction: a report of the</a></text>
<text top="315" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref33">American College of Cardiology Foundation/American</a></text>
<text top="329" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref33">Heart Association Task Force on Practice Guidelines.</a></text>
<text top="342" left="108" width="124" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref33">J Am Coll Cardiol. 2013;61:e78</a></text>
<text top="341" left="232" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref33">–140</a></text>
<text top="342" left="251" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref33">.</a></text>
<text top="361" left="108" width="32" height="9" font="4">S1.5-24.</text>
<text top="361" left="143" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref34">Stone NJ, Robinson JG, Lichtenstein AH, et al.</a></text>
<text top="375" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref34">2013 ACC/AHA guideline on the treatment of blood</a></text>
<text top="388" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref34">cholesterol to reduce atherosclerotic cardiovascular</a></text>
<text top="402" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref34">risk in adults: a report of the American College of</a></text>
<text top="415" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref34">Cardiology/American Heart Association Task Force</a></text>
<text top="429" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref34">on Practice Guidelines. J Am Coll Cardiol. 2014;63:</a></text>
<text top="442" left="108" width="22" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref34">2889</a></text>
<text top="441" left="129" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref34">–934</a></text>
<text top="442" left="149" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref34">.</a></text>
<text top="461" left="108" width="31" height="9" font="4">S1.5-25.</text>
<text top="461" left="142" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref35">Regitz-Zagrosek V, Blomstrom Lundqvist C,</a></text>
<text top="474" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref35">Borghi C, et al. ESC guidelines on the management of</a></text>
<text top="488" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref35">cardiovascular diseases during pregnancy: the Task</a></text>
<text top="501" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref35">Force on the Management of Cardiovascular Diseases</a></text>
<text top="515" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref35">During Pregnancy of the European Society of Cardiol-</a></text>
<text top="528" left="108" width="147" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref35">ogy (ESC). Eur Heart J. 2011;32:3147</a></text>
<text top="526" left="255" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref35">–97</a></text>
<text top="528" left="269" width="3" height="9" font="4">.</text>
<text top="547" left="108" width="32" height="9" font="4">S1.5-26.</text>
<text top="547" left="143" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref36">Mosca L, Benjamin EJ, Berra K, et al.</a></text>
<text top="560" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref36">Effectiveness-based guidelines for the prevention of</a></text>
<text top="573" left="108" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref36">cardiovascular</a></text>
<text top="573" left="174" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref36">disease</a></text>
<text top="573" left="213" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref36">in</a></text>
<text top="573" left="230" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref36">women</a></text>
<text top="572" left="259" width="65" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref36">—2011 update:</a></text>
<text top="587" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref36">a guideline from the American Heart Association.</a></text>
<text top="600" left="108" width="104" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref36">Circulation. 2011;123:1243</a></text>
<text top="599" left="211" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref36">–62</a></text>
<text top="600" left="226" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref36">.</a></text>
<text top="620" left="108" width="31" height="9" font="4">S1.5-27.</text>
<text top="620" left="142" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref37">Smith SC Jr., Benjamin EJ, Bonow RO, et al.</a></text>
<text top="633" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref37">AHA/ACCF secondary prevention and risk reduction</a></text>
<text top="646" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref37">therapy for patients with coronary and other athero-</a></text>
<text top="660" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref37">sclerotic vascular disease: 2011 update: a guideline</a></text>
<text top="673" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref37">from the American Heart Association and American</a></text>
<text top="687" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref37">College of Cardiology Foundation endorsed by the</a></text>
<text top="700" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref37">World Heart Federation and the Preventive Cardio-</a></text>
<text top="714" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref37">vascular Nurses Association. J Am Coll Cardiol. 2011;</a></text>
<text top="727" left="108" width="33" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref37">58:2432</a></text>
<text top="726" left="140" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref37">–46</a></text>
<text top="727" left="156" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref37">.</a></text>
<text top="746" left="108" width="32" height="9" font="4">S1.5-28.</text>
<text top="746" left="143" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref38">Greenland P, Alpert JS, Beller GA, et al. 2010</a></text>
<text top="760" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref38">ACCF/AHA guideline for assessment of cardiovascular</a></text>
<text top="773" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref38">risk in asymptomatic adults: a report of the American</a></text>
<text top="787" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref38">College of Cardiology Foundation/American Heart As-</a></text>
<text top="800" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref38">sociation Task Force on Practice Guidelines. J Am Coll</a></text>
<text top="814" left="108" width="85" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref38">Cardiol. 2010;56:e50</a></text>
<text top="812" left="193" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref38">–103</a></text>
<text top="814" left="211" width="3" height="9" font="4">.</text>
<text top="833" left="108" width="32" height="9" font="4">S1.5-29.</text>
<text top="833" left="143" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">Hiratzka LF, Bakris GL, Beckman JA, et al.</a></text>
<text top="846" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/</a></text>
<text top="860" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">SVM guidelines for the diagnosis and management</a></text>
<text top="873" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">of patients with thoracic aortic disease: a report of</a></text>
<text top="887" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">the American College of Cardiology Foundation/</a></text>
<text top="900" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">American Heart Association Task Force on Practice</a></text>
<text top="914" left="108" width="45" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">Guidelines,</a></text>
<text top="914" left="163" width="38" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">American</a></text>
<text top="914" left="211" width="46" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">Association</a></text>
<text top="914" left="268" width="12" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">for</a></text>
<text top="914" left="290" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">Thoracic</a></text>
<text top="927" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">Surgery, American College of Radiology, American</a></text>
<text top="941" left="108" width="26" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">Stroke</a></text>
<text top="941" left="145" width="49" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">Association,</a></text>
<text top="941" left="205" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">Society</a></text>
<text top="941" left="246" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">of</a></text>
<text top="941" left="265" width="59" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">Cardiovascular</a></text>
<text top="954" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">Anesthesiologists, Society for Cardiovascular Angi-</a></text>
<text top="967" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">ography and Interventions, Society of Interventional</a></text>
<text top="981" left="108" width="43" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">Radiology,</a></text>
<text top="981" left="160" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">Society</a></text>
<text top="981" left="199" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">of</a></text>
<text top="981" left="217" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">Thoracic</a></text>
<text top="981" left="260" width="40" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">Surgeons,</a></text>
<text top="981" left="310" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">and</a></text>
<text top="994" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">Society for Vascular Medicine. J Am Coll Cardiol.</a></text>
<text top="1008" left="108" width="51" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">2010;55:e27</a></text>
<text top="1006" left="159" width="18" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref39">–129</a></text>
<text top="1008" left="177" width="3" height="9" font="4">.</text>
<text top="1027" left="108" width="32" height="9" font="4">S1.5-30.</text>
<text top="1027" left="143" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref40">National High Blood Pressure Education</a></text>
<text top="1041" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref40">Program Working Group on High Blood Pressure in</a></text>
<text top="1054" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref40">Children and Adolescents. The fourth report on the</a></text>
<text top="1067" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref40">diagnosis, evaluation, and treatment of high blood</a></text>
<text top="1081" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref40">pressure in children and adolescents. Pediatrics. 2004;</a></text>
<text top="1094" left="108" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref40">114:555</a></text>
<text top="1093" left="138" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref40">–76</a></text>
<text top="1094" left="152" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref40">.</a></text>
<text top="143" left="346" width="30" height="9" font="4">S1.5-31.</text>
<text top="143" left="379" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref41">Elijovich F, Weinberger MH, Anderson CAM,</a></text>
<text top="156" left="346" width="208" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref41">et al. Salt sensitivity of blood pressure: a scienti</a></text>
<text top="155" left="554" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref41">ﬁc</a></text>
<text top="170" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref41">statement from the American Heart Association.</a></text>
<text top="183" left="346" width="105" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref41">Hypertension. 2016;68:e7</a></text>
<text top="182" left="450" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref41">–46</a></text>
<text top="183" left="465" width="3" height="9" font="4">.</text>
<text top="202" left="346" width="31" height="9" font="4">S1.5-32.</text>
<text top="202" left="380" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref42">Brush JE Jr., Handberg EM, Biga C, et al. 2015</a></text>
<text top="216" left="346" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref42">ACC</a></text>
<text top="216" left="371" width="25" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref42">health</a></text>
<text top="216" left="405" width="73" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref42">policy statement</a></text>
<text top="216" left="487" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref42">on</a></text>
<text top="216" left="506" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref42">cardiovascular</a></text>
<text top="229" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref42">team-based care and the role of advanced practice</a></text>
<text top="243" left="346" width="171" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref42">providers. J Am Coll Cardiol. 2015;65:2118</a></text>
<text top="241" left="517" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref42">–36</a></text>
<text top="243" left="531" width="3" height="9" font="4">.</text>
<text top="262" left="346" width="31" height="9" font="4">S1.5-33.</text>
<text top="262" left="380" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref43">Rosendorff C, Lackland DT, Allison M, et al.</a></text>
<text top="275" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref43">Treatment of hypertension in patients with coronary</a></text>
<text top="289" left="346" width="110" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref43">artery disease: a scienti</a></text>
<text top="287" left="456" width="107" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref43">ﬁc statement from the</a></text>
<text top="302" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref43">American Heart Association, American College of</a></text>
<text top="315" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref43">Cardiology, and American Society of Hypertension.</a></text>
<text top="329" left="346" width="131" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref43">J Am Coll Cardiol. 2015;65:1998</a></text>
<text top="327" left="477" width="25" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref43">–2038</a></text>
<text top="329" left="502" width="3" height="9" font="4">.</text>
<text top="348" left="346" width="32" height="9" font="4">S1.5-34.</text>
<text top="348" left="381" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref44">Flynn JT, Daniels SR, Hayman LL, et al.</a></text>
<text top="361" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref44">Update: ambulatory blood pressure monitoring in</a></text>
<text top="375" left="346" width="141" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref44">children and adolescents: a scienti</a></text>
<text top="373" left="487" width="76" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref44">ﬁc statement from</a></text>
<text top="388" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref44">the American Heart Association. Hypertension. 2014;</a></text>
<text top="402" left="346" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref44">63:1116</a></text>
<text top="400" left="376" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref44">–35</a></text>
<text top="402" left="389" width="3" height="9" font="4">.</text>
<text top="421" left="346" width="31" height="9" font="4">S1.5-35.</text>
<text top="421" left="380" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref45">Go AS, Bauman MA, Coleman King SM, et al.</a></text>
<text top="434" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref45">An effective approach to high blood pressure control:</a></text>
<text top="447" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref45">a science advisory from the American Heart Associa-</a></text>
<text top="461" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref45">tion, the American College of Cardiology, and the</a></text>
<text top="474" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref45">Centers for Disease Control and Prevention. Hyper-</a></text>
<text top="488" left="346" width="86" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref45">tension. 2014;63:878</a></text>
<text top="486" left="432" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref45">–85</a></text>
<text top="488" left="446" width="3" height="9" font="4">.</text>
<text top="507" left="346" width="32" height="9" font="4">S1.5-36.</text>
<text top="507" left="381" width="6" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref46">O</a></text>
<text top="505" left="387" width="176" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref46">’Brien E, Parati G, Stergiou G, et al.</a></text>
<text top="520" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref46">European Society of Hypertension position paper on</a></text>
<text top="534" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref46">ambulatory blood pressure monitoring. J Hypertens.</a></text>
<text top="547" left="346" width="50" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref46">2013;31:1731</a></text>
<text top="546" left="396" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref46">–68</a></text>
<text top="547" left="411" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref46">.</a></text>
<text top="566" left="346" width="31" height="9" font="4">S1.5-37.</text>
<text top="566" left="380" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref47">Drozda J Jr., Messer JV, Spertus J, et al. ACCF/</a></text>
<text top="580" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref47">AHA/AMA-PCPI 2011 performance measures for adults</a></text>
<text top="593" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref47">with coronary artery disease and hypertension: a</a></text>
<text top="606" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref47">report of the American College of Cardiology Foun-</a></text>
<text top="620" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref47">dation/American Heart Association Task Force on</a></text>
<text top="633" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref47">Performance Measures and the American Medical</a></text>
<text top="647" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref47">Association-Physician Consortium for Performance</a></text>
<text top="660" left="346" width="161" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref47">Improvement. Circulation. 2011;124:248</a></text>
<text top="659" left="506" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref47">–70</a></text>
<text top="660" left="521" width="3" height="9" font="4">.</text>
<text top="679" left="346" width="32" height="9" font="4">S1.5-38.</text>
<text top="679" left="381" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref48">Artinian NT, Fletcher GF, Mozaffarian D, et al.</a></text>
<text top="693" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref48">Interventions to promote physical activity and dietary</a></text>
<text top="706" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref48">lifestyle changes for cardiovascular risk factor reduc-</a></text>
<text top="720" left="346" width="89" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref48">tion in adults: a scienti</a></text>
<text top="718" left="435" width="128" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref48">ﬁc statement from the American</a></text>
<text top="733" left="346" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref48">Heart Association. Circulation. 2010;122:406</a></text>
<text top="731" left="526" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref48">–41</a></text>
<text top="733" left="539" width="3" height="9" font="4">.</text>
<text top="752" left="346" width="32" height="9" font="4">S1.5-39.</text>
<text top="752" left="381" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref49">Calhoun DA, Jones D, Textor S, et al.</a></text>
<text top="765" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref49">Resistant hypertension: diagnosis, evaluation, and</a></text>
<text top="779" left="346" width="78" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref49">treatment:a scienti</a></text>
<text top="777" left="424" width="139" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref49">ﬁc statement from the American</a></text>
<text top="792" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref49">Heart Association Professional Education Committee</a></text>
<text top="806" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref49">of the Council for High Blood Pressure Research.</a></text>
<text top="819" left="346" width="115" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref49">Hypertension. 2008;51:1403</a></text>
<text top="818" left="461" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref49">–19</a></text>
<text top="819" left="474" width="3" height="9" font="4">.</text>
<text top="859" left="346" width="124" height="12" font="26">2 . B P A N D C V D R I S K</text>
<text top="885" left="346" width="142" height="9" font="23">2.1. Observational Relationship</text>
<text top="909" left="346" width="25" height="9" font="4">S2.1-1.</text>
<text top="909" left="374" width="189" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref50">Lewington S, Clarke R, Qizilbash N, et al.</a></text>
<text top="923" left="346" width="39" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref50">Age-speci</a></text>
<text top="921" left="385" width="178" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref50">ﬁc relevance of usual blood pressure to</a></text>
<text top="936" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref50">vascular mortality: a meta-analysis of individual data</a></text>
<text top="950" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref50">for one million adults in 61 prospective studies. Lancet.</a></text>
<text top="963" left="346" width="64" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref50">2002;360:1903</a></text>
<text top="962" left="409" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref50">–13</a></text>
<text top="963" left="422" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref50">.</a></text>
<text top="982" left="346" width="26" height="9" font="4">S2.1-2.</text>
<text top="982" left="375" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref51">Rapsomaniki E, Timmis A, George J, et al. Blood</a></text>
<text top="996" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref51">pressure and incidence of twelve cardiovascular</a></text>
<text top="1009" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref51">diseases: lifetime risks, healthy life-years lost, and</a></text>
<text top="1023" left="346" width="38" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref51">age-speci</a></text>
<text top="1021" left="384" width="179" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref51">ﬁc associations in 1.25 million people. Lancet.</a></text>
<text top="1036" left="346" width="61" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref51">2014;383:1899</a></text>
<text top="1034" left="407" width="17" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref51">–911</a></text>
<text top="1036" left="424" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref51">.</a></text>
<text top="1058" left="346" width="91" height="9" font="23">2.2. BP Components</text>
<text top="1082" left="346" width="26" height="9" font="4">S2.2-1.</text>
<text top="1082" left="375" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref52">Lewington S, Clarke R, Qizilbash N, et al.</a></text>
<text top="1095" left="346" width="39" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref52">Age-speci</a></text>
<text top="1094" left="385" width="178" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref52">ﬁc relevance of usual blood pressure to</a></text>
<text top="143" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref52">vascular mortality: a meta-analysis of individual data</a></text>
<text top="156" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref52">for one million adults in 61 prospective studies. Lancet.</a></text>
<text top="170" left="584" width="64" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref52">2002;360:1903</a></text>
<text top="168" left="648" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref52">–13</a></text>
<text top="170" left="660" width="3" height="9" font="4">.</text>
<text top="188" left="584" width="27" height="9" font="4">S2.2-2.</text>
<text top="188" left="614" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref53">Rapsomaniki E, Timmis A, George J, et al.</a></text>
<text top="202" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref53">Blood pressure and incidence of twelve cardiovascular</a></text>
<text top="215" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref53">diseases: lifetime risks, healthy life-years lost, and</a></text>
<text top="229" left="584" width="38" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref53">age-speci</a></text>
<text top="227" left="622" width="179" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref53">ﬁc associations in 1.25 million people. Lancet.</a></text>
<text top="242" left="584" width="61" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref53">2014;383:1899</a></text>
<text top="241" left="645" width="17" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref53">–911</a></text>
<text top="242" left="662" width="3" height="9" font="4">.</text>
<text top="261" left="584" width="27" height="9" font="4">S2.2-3.</text>
<text top="261" left="614" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref54">Rutan GH, Kuller LH, Neaton JD, et al.</a></text>
<text top="274" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref54">Mortality associated with diastolic hypertension and</a></text>
<text top="288" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref54">isolated systolic hypertension among men screened</a></text>
<text top="301" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref54">for the Multiple Risk Factor Intervention Trial.</a></text>
<text top="315" left="584" width="99" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref54">Circulation. 1988;77:504</a></text>
<text top="313" left="683" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref54">–14</a></text>
<text top="315" left="697" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref54">.</a></text>
<text top="333" left="584" width="28" height="9" font="4">S2.2-4.</text>
<text top="333" left="615" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref55">Sesso HD, Stampfer MJ, Rosner B, et al.</a></text>
<text top="347" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref55">Systolic and diastolic blood pressure, pulse pressure,</a></text>
<text top="360" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref55">and mean arterial pressure as predictors of cardio-</a></text>
<text top="373" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref55">vascular disease risk in men. Hypertension. 2000;36:</a></text>
<text top="387" left="584" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref55">801</a></text>
<text top="385" left="600" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref55">–7</a></text>
<text top="387" left="608" width="3" height="9" font="4">.</text>
<text top="405" left="584" width="27" height="9" font="4">S2.2-5.</text>
<text top="405" left="614" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref56">Stamler J, Stamler R, Neaton JD. Blood pres-</a></text>
<text top="419" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref56">sure, systolic and diastolic, and cardiovascular risks. US</a></text>
<text top="432" left="584" width="194" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref56">population data. Arch Intern Med. 1993;153:598</a></text>
<text top="431" left="778" width="18" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref56">–615</a></text>
<text top="432" left="796" width="3" height="9" font="4">.</text>
<text top="451" left="584" width="28" height="9" font="4">S2.2-6.</text>
<text top="451" left="615" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref57">Benetos A, Thomas F, Bean K, et al. Prognostic</a></text>
<text top="464" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref57">value of systolic and diastolic blood pressure in treated</a></text>
<text top="478" left="584" width="201" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref57">hypertensive men. Arch Intern Med. 2002;162:577</a></text>
<text top="476" left="785" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref57">–81</a></text>
<text top="478" left="799" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref57">.</a></text>
<text top="496" left="584" width="27" height="9" font="4">S2.2-7.</text>
<text top="496" left="614" width="147" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref58">Lindenstrom E, Boysen G, Nyboe J. In</a></text>
<text top="495" left="762" width="40" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref58">ﬂuence of</a></text>
<text top="510" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref58">systolic and diastolic blood pressure on stroke risk: a</a></text>
<text top="523" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref58">prospective observational study. Am J. Epidemiol.</a></text>
<text top="537" left="584" width="58" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref58">1995;142:1279</a></text>
<text top="535" left="642" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref58">–90</a></text>
<text top="537" left="658" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref58">.</a></text>
<text top="555" left="584" width="28" height="9" font="4">S2.2-8.</text>
<text top="555" left="615" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref59">Zhao L, Song Y, Dong P, et al. Brachial pulse</a></text>
<text top="569" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref59">pressure and cardiovascular or all-cause mortality in</a></text>
<text top="582" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref59">the general population: a meta-analysis of prospective</a></text>
<text top="596" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref59">observational studies. J Clin Hypertens (Greenwich).</a></text>
<text top="609" left="584" width="50" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref59">2014;16:678</a></text>
<text top="607" left="635" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref59">–85</a></text>
<text top="609" left="649" width="3" height="9" font="4">.</text>
<text top="628" left="584" width="28" height="9" font="4">S2.2-9.</text>
<text top="628" left="615" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref60">Mosley WJ, Greenland P, Garside DB, et al.</a></text>
<text top="641" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref60">Predictive utility of pulse pressure and other blood</a></text>
<text top="654" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref60">pressure measures for cardiovascular outcomes. Hy-</a></text>
<text top="668" left="584" width="105" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref60">pertension. 2007;49:1256</a></text>
<text top="666" left="689" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref60">–64</a></text>
<text top="668" left="704" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref60">.</a></text>
<text top="687" left="584" width="32" height="9" font="4">S2.2-10.</text>
<text top="687" left="620" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref61">Franklin SS, Lopez VA, Wong ND, et al. Single</a></text>
<text top="701" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref61">versus combined blood pressure components and risk</a></text>
<text top="714" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref61">for cardiovascular disease: the Framingham Heart</a></text>
<text top="728" left="584" width="132" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref61">Study. Circulation. 2009;119:243</a></text>
<text top="726" left="716" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref61">–50</a></text>
<text top="728" left="731" width="3" height="9" font="4">.</text>
<text top="747" left="584" width="30" height="9" font="4">S2.2-11.</text>
<text top="747" left="617" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref62">Kodama S, Horikawa C, Fujihara K, et al. Meta-</a></text>
<text top="761" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref62">analysis of the quantitative relation between pulse</a></text>
<text top="774" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref62">pressure and mean arterial pressure and cardiovascular</a></text>
<text top="788" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref62">risk in patients with diabetes mellitus. Am J Cardiol.</a></text>
<text top="801" left="584" width="58" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref62">2014;113:1058</a></text>
<text top="800" left="642" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref62">–65</a></text>
<text top="801" left="656" width="3" height="9" font="4">.</text>
<text top="826" left="584" width="91" height="9" font="23">2.3. Population Risk</text>
<text top="851" left="584" width="26" height="9" font="4">S2.3-1.</text>
<text top="851" left="614" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref63">Lim SS, Vos T, Flaxman AD, et al. A comparative</a></text>
<text top="865" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref63">risk assessment of burden of disease and injury</a></text>
<text top="878" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref63">attributable to 67 risk factors and risk factor clusters in</a></text>
<text top="892" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref63">21 regions, 1990-2010: a systematic analysis for the</a></text>
<text top="905" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref63">Global Burden of Disease Study 2010. Lancet. 2012;</a></text>
<text top="918" left="584" width="39" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref63">380:2224</a></text>
<text top="917" left="623" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref63">–60</a></text>
<text top="918" left="639" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref63">.</a></text>
<text top="937" left="584" width="27" height="9" font="4">S2.3-2.</text>
<text top="937" left="614" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref64">Forouzanfar MH, Liu P, Roth GA, et al. Global</a></text>
<text top="950" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref64">burden of hypertension and systolic blood pressure of</a></text>
<text top="964" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref64">at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;</a></text>
<text top="977" left="584" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref64">317:165</a></text>
<text top="976" left="614" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref64">–82</a></text>
<text top="977" left="628" width="3" height="9" font="4">.</text>
<text top="996" left="584" width="27" height="9" font="4">S2.3-3.</text>
<text top="996" left="614" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref65">Danaei G, Ding EL, Mozaffarian D, et al. The</a></text>
<text top="1009" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref65">preventable causes of death in the United States:</a></text>
<text top="1023" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref65">comparative risk assessment of dietary, lifestyle, and</a></text>
<text top="1036" left="584" width="214" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref65">metabolic risk factors. PLoS Med. 2009;6:e1000058</a></text>
<text top="1036" left="798" width="3" height="9" font="4">.</text>
<text top="1055" left="584" width="28" height="9" font="4">S2.3-4.</text>
<text top="1055" left="615" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref66">Ford ES. Trends in mortality from all causes</a></text>
<text top="1068" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref66">and cardiovascular disease among hypertensive and</a></text>
<text top="1082" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref66">nonhypertensive adults in the United States. Circula-</a></text>
<text top="1095" left="584" width="76" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref66">tion. 2011;123:1737</a></text>
<text top="1094" left="660" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref66">–44</a></text>
<text top="1095" left="675" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref66">.</a></text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="18" height="9" font="4">e212</text>
</page>
<page number="87" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="27" height="9" font="4">S2.3-5.</text>
<text top="143" left="93" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref67">Cheng S, Claggett B, Correia AW, et al. Tem-</a></text>
<text top="156" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref67">poral trends in the population attributable risk for</a></text>
<text top="170" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref67">cardiovascular disease: the Atherosclerosis Risk in</a></text>
<text top="183" left="63" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref67">Communities Study. Circulation. 2014;130:820</a></text>
<text top="182" left="250" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref67">–8</a></text>
<text top="183" left="260" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref67">.</a></text>
<text top="203" left="63" width="28" height="9" font="4">S2.3-6.</text>
<text top="203" left="94" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref68">Willey JZ, Moon YP, Kahn E, et al. Population</a></text>
<text top="216" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref68">attributable risks of hypertension and diabetes for</a></text>
<text top="230" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref68">cardiovascular disease and stroke in the northern</a></text>
<text top="243" left="63" width="215" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref68">Manhattan study. J Am Heart Assoc. 2014;3:e001106</a></text>
<text top="243" left="277" width="3" height="9" font="4">.</text>
<text top="262" left="63" width="27" height="9" font="4">S2.3-7.</text>
<text top="262" left="93" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref69">Saran R, Li Y, Robinson B, et al. US Renal Data</a></text>
<text top="276" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref69">System 2014 annual data report: epidemiology of</a></text>
<text top="289" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref69">kidney disease in the United States. Am J Kidney Dis.</a></text>
<text top="303" left="63" width="61" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref69">2015;66 Svii:S1</a></text>
<text top="301" left="124" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref69">–305</a></text>
<text top="303" left="143" width="3" height="9" font="4">.</text>
<text top="324" left="63" width="217" height="9" font="23">2.4. Coexistence of Hypertension and Related</text>
<text top="338" left="63" width="88" height="9" font="23">Chronic Conditions</text>
<text top="361" left="63" width="27" height="9" font="4">S2.4-1.</text>
<text top="361" left="93" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref70">Wilson PW, Kannel WB, Silbershatz H, et al.</a></text>
<text top="375" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref70">Clustering of metabolic factors and coronary heart</a></text>
<text top="388" left="63" width="164" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref70">disease. Arch Intern Med. 1999;159:1104</a></text>
<text top="387" left="227" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref70">–9</a></text>
<text top="388" left="236" width="3" height="9" font="4">.</text>
<text top="408" left="63" width="28" height="9" font="4">S2.4-2.</text>
<text top="408" left="94" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref71">Berry JD, Dyer A, Cai X, et al. Lifetime risks of</a></text>
<text top="421" left="63" width="205" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref71">cardiovascular disease. N Engl J Med. 2012;366:321</a></text>
<text top="419" left="268" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref71">–9</a></text>
<text top="421" left="277" width="3" height="9" font="4">.</text>
<text top="440" left="63" width="28" height="9" font="4">S2.4-3.</text>
<text top="440" left="94" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref72">Egan BM, Li J, Hutchison FN, et al. Hyperten-</a></text>
<text top="454" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref72">sion in the United States, 1999 to 2012: progress to-</a></text>
<text top="467" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref72">ward Healthy People 2020 goals. Circulation. 2014;</a></text>
<text top="481" left="63" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref72">130:1692</a></text>
<text top="479" left="100" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref72">–9</a></text>
<text top="481" left="109" width="3" height="9" font="4">.</text>
<text top="500" left="63" width="29" height="9" font="4">S2.4-4.</text>
<text top="500" left="95" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref73">Centers for Disease Control and Prevention.</a></text>
<text top="514" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref73">National Diabetes Statistics Report: Estimates of Dia-</a></text>
<text top="527" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref73">betes and Its Burden in the United States. Atlanta, GA:</a></text>
<text top="541" left="63" width="215" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref73">U.S. Department of Health and Human Services; 2014</a></text>
<text top="541" left="277" width="3" height="9" font="4">.</text>
<text top="560" left="63" width="28" height="9" font="4">S2.4-5.</text>
<text top="560" left="94" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref74">Muntner P, Anderson A, Charleston J, et al.</a></text>
<text top="573" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref74">Hypertension awareness, treatment, and control in</a></text>
<text top="587" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref74">adults with CKD: results from the Chronic Renal</a></text>
<text top="600" left="63" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref74">Insuf</a></text>
<text top="599" left="82" width="197" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref74">ﬁciency Cohort (CRIC) Study. Am J Kidney Dis.</a></text>
<text top="614" left="63" width="50" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref74">2010;55:441</a></text>
<text top="612" left="113" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref74">–51</a></text>
<text top="614" left="126" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref74">.</a></text>
<text top="633" left="63" width="29" height="9" font="4">S2.4-6.</text>
<text top="633" left="95" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref75">Tanner RM, Calhoun DA, Bell EK, et al. Prev-</a></text>
<text top="646" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref75">alence of apparent treatment-resistant hypertension</a></text>
<text top="660" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref75">among individuals with CKD. Clin J Am Soc Nephrol.</a></text>
<text top="673" left="63" width="49" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref75">2013;8:1583</a></text>
<text top="672" left="112" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref75">–90</a></text>
<text top="673" left="128" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref75">.</a></text>
<text top="693" left="63" width="28" height="9" font="4">S2.4-7.</text>
<text top="693" left="94" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref76">Saydah S, Bullard KM, Cheng Y, et al. Trends in</a></text>
<text top="706" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref76">cardiovascular disease risk factors by obesity level in</a></text>
<text top="720" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref76">adults in the United States, NHANES 1999-2010.</a></text>
<text top="733" left="63" width="151" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref76">Obesity (Silver Spring). 2014;22:1888</a></text>
<text top="731" left="214" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref76">–95</a></text>
<text top="733" left="228" width="3" height="9" font="4">.</text>
<text top="752" left="63" width="29" height="9" font="4">S2.4-8.</text>
<text top="752" left="95" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref77">Castelli WP. Epidemiology of coronary heart</a></text>
<text top="766" left="63" width="213" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref77">disease: the Framingham study. Am J Med. 1984;76:4</a></text>
<text top="764" left="276" width="4" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref77">–</a></text>
<text top="779" left="63" width="9" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref77">12</a></text>
<text top="779" left="71" width="3" height="9" font="4">.</text>
<text top="799" left="63" width="29" height="9" font="4">S2.4-9.</text>
<text top="799" left="95" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref78">Sarzani R, Salvi F, Dessi-Fulgheri P, et al. Renin-</a></text>
<text top="812" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref78">angiotensin system, natriuretic peptides, obesity,</a></text>
<text top="826" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref78">metabolic syndrome, and hypertension: an integrated</a></text>
<text top="839" left="63" width="170" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref78">view in humans. J Hypertens. 2008;26:831</a></text>
<text top="837" left="233" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref78">–43</a></text>
<text top="839" left="247" width="3" height="9" font="4">.</text>
<text top="858" left="63" width="33" height="9" font="4">S2.4-10.</text>
<text top="858" left="99" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref79">Grassi G, Seravalle G, Cattaneo BM, et al.</a></text>
<text top="872" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref79">Sympathetic activation in obese normotensive sub-</a></text>
<text top="885" left="63" width="134" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref79">jects. Hypertension. 1995;25:560</a></text>
<text top="884" left="196" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref79">–3</a></text>
<text top="885" left="205" width="3" height="9" font="4">.</text>
<text top="905" left="63" width="31" height="9" font="4">S2.4-11.</text>
<text top="905" left="97" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref80">Kim J, Montagnani M, Koh KK, et al. Recip-</a></text>
<text top="918" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref80">rocal relationships between insulin resistance and</a></text>
<text top="932" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref80">endothelial dysfunction: molecular and pathophysio-</a></text>
<text top="945" left="63" width="192" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref80">logical mechanisms. Circulation. 2006;113:1888</a></text>
<text top="943" left="255" width="21" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref80">–904</a></text>
<text top="945" left="276" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref80">.</a></text>
<text top="964" left="63" width="32" height="9" font="4">S2.4-12.</text>
<text top="964" left="98" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref81">McEvoy RD, Antic NA, Heeley E, et al. CPAP</a></text>
<text top="978" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref81">for prevention of cardiovascular events in obstructive</a></text>
<text top="991" left="63" width="168" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref81">sleep apnea. N Engl J Med. 2016;375:919</a></text>
<text top="990" left="230" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref81">–31</a></text>
<text top="991" left="243" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref81">.</a></text>
<text top="1031" left="63" width="163" height="12" font="26">3 . C L A S S I F I C A T I O N O F B P</text>
<text top="1057" left="63" width="30" height="9" font="23">3.1. De</text>
<text top="1056" left="93" width="85" height="12" font="23">ﬁnition of High BP</text>
<text top="1082" left="63" width="25" height="9" font="4">S3.1-1.</text>
<text top="1082" left="91" width="189" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref82">Lewington S, Clarke R, Qizilbash N, et al. Age-</a></text>
<text top="1095" left="63" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref82">speci</a></text>
<text top="1094" left="83" width="197" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref82">ﬁc relevance of usual blood pressure to vascular</a></text>
<text top="143" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref82">mortality: a meta-analysis of individual data for one</a></text>
<text top="156" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref82">million adults in 61 prospective studies. Lancet. 2002;</a></text>
<text top="170" left="301" width="39" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref82">360:1903</a></text>
<text top="168" left="340" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref82">–13</a></text>
<text top="170" left="353" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref82">.</a></text>
<text top="189" left="301" width="26" height="9" font="4">S3.1-2.</text>
<text top="189" left="330" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref83">Rapsomaniki E, Timmis A, George J, et al. Blood</a></text>
<text top="203" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref83">pressure and incidence of twelve cardiovascular</a></text>
<text top="216" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref83">diseases: lifetime risks, healthy life-years lost, and</a></text>
<text top="229" left="301" width="38" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref83">age-speci</a></text>
<text top="228" left="339" width="179" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref83">ﬁc associations in 1$25 million people.</a></text>
<text top="243" left="301" width="93" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref83">Lancet. 2014;383:1899</a></text>
<text top="241" left="394" width="17" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref83">–911</a></text>
<text top="243" left="411" width="3" height="9" font="4">.</text>
<text top="262" left="301" width="26" height="9" font="4">S3.1-3.</text>
<text top="262" left="330" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref84">Ettehad D, Emdin CA, Kiran A, et al. Blood</a></text>
<text top="276" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref84">pressure lowering for prevention of cardiovascular</a></text>
<text top="289" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref84">disease and death: a systematic review and meta-</a></text>
<text top="302" left="301" width="124" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref84">analysis. Lancet. 2016;387:957</a></text>
<text top="301" left="425" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref84">–67</a></text>
<text top="302" left="439" width="3" height="9" font="4">.</text>
<text top="322" left="301" width="27" height="9" font="4">S3.1-4.</text>
<text top="322" left="331" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref85">Guo X, Zhang X, Guo L, et al. Association</a></text>
<text top="335" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref85">between pre-hypertension and cardiovascular out-</a></text>
<text top="348" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref85">comes: a systematic review and meta-analysis of pro-</a></text>
<text top="362" left="301" width="201" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref85">spective studies. Curr Hypertens Rep. 2013;15:703</a></text>
<text top="360" left="502" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref85">–16</a></text>
<text top="362" left="516" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref85">.</a></text>
<text top="381" left="301" width="26" height="9" font="4">S3.1-5.</text>
<text top="381" left="330" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref86">Guo</a></text>
<text top="381" left="358" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref86">X,</a></text>
<text top="381" left="378" width="25" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref86">Zhang</a></text>
<text top="381" left="414" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref86">X,</a></text>
<text top="381" left="434" width="25" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref86">Zheng</a></text>
<text top="381" left="470" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref86">L,</a></text>
<text top="381" left="489" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref86">et</a></text>
<text top="381" left="509" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref86">al.</a></text>
<text top="395" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref86">Prehypertension is not associated with all-cause</a></text>
<text top="408" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref86">mortality: a systematic review and meta-analysis of</a></text>
<text top="421" left="301" width="189" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref86">prospective studies. PLoS ONE. 2013;8:e61796</a></text>
<text top="421" left="490" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref86">.</a></text>
<text top="441" left="301" width="27" height="9" font="4">S3.1-6.</text>
<text top="441" left="331" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref87">Huang Y, Cai X, Li Y, et al. Prehypertension and</a></text>
<text top="454" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref87">the risk of stroke: a meta-analysis. Neurology. 2014;</a></text>
<text top="468" left="301" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref87">82:1153</a></text>
<text top="466" left="331" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref87">–61</a></text>
<text top="468" left="344" width="3" height="9" font="4">.</text>
<text top="487" left="301" width="26" height="9" font="4">S3.1-7.</text>
<text top="487" left="330" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref88">Huang Y, Cai X, Liu C, et al. Prehypertension</a></text>
<text top="500" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref88">and the risk of coronary heart disease in Asian and</a></text>
<text top="514" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref88">Western populations: a meta-analysis. J Am Heart</a></text>
<text top="527" left="301" width="93" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref88">Assoc. 2015;4:e001519</a></text>
<text top="527" left="394" width="3" height="9" font="4">.</text>
<text top="546" left="301" width="27" height="9" font="4">S3.1-8.</text>
<text top="546" left="331" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref89">Huang Y, Cai X, Zhang J, et al. Prehypertension</a></text>
<text top="560" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref89">and incidence of ESRD: a systematic review and meta-</a></text>
<text top="573" left="301" width="153" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref89">analysis. Am J Kidney Dis. 2014;63:76</a></text>
<text top="572" left="454" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref89">–83</a></text>
<text top="573" left="469" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref89">.</a></text>
<text top="592" left="301" width="27" height="9" font="4">S3.1-9.</text>
<text top="592" left="331" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref90">Huang Y, Su L, Cai X, et al. Association of all-</a></text>
<text top="606" left="301" width="22" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref90">cause</a></text>
<text top="606" left="334" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref90">and</a></text>
<text top="606" left="359" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref90">cardiovascular</a></text>
<text top="606" left="426" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref90">mortality</a></text>
<text top="606" left="473" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref90">with</a></text>
<text top="606" left="501" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref90">pre-</a></text>
<text top="619" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref90">hypertension: a meta-analysis. Am Heart J. 2014;167:</a></text>
<text top="633" left="301" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref90">160</a></text>
<text top="631" left="316" width="21" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref90">–8.e1</a></text>
<text top="633" left="337" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref90">.</a></text>
<text top="652" left="301" width="31" height="9" font="4">S3.1-10.</text>
<text top="652" left="335" width="26" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref91">Huang</a></text>
<text top="652" left="373" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref91">Y,</a></text>
<text top="652" left="392" width="23" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref91">Wang</a></text>
<text top="652" left="427" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref91">S,</a></text>
<text top="652" left="445" width="12" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref91">Cai</a></text>
<text top="652" left="469" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref91">X,</a></text>
<text top="652" left="489" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref91">et</a></text>
<text top="652" left="509" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref91">al.</a></text>
<text top="665" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref91">Prehypertension and incidence of cardiovascular dis-</a></text>
<text top="679" left="301" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref91">ease: a meta-analysis. BMC Med. 2013;11:177</a></text>
<text top="679" left="481" width="3" height="9" font="4">.</text>
<text top="698" left="301" width="29" height="9" font="4">S3.1-11.</text>
<text top="698" left="333" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref92">Law MR, Morris JK, Wald NJ. Use of blood</a></text>
<text top="711" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref92">pressure lowering drugs in the prevention of cardio-</a></text>
<text top="725" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref92">vascular disease: meta-analysis of 147 randomised</a></text>
<text top="738" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref92">trials in the context of expectations from prospective</a></text>
<text top="752" left="301" width="190" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref92">epidemiological studies. BMJ. 2009;338:b1665</a></text>
<text top="752" left="491" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref92">.</a></text>
<text top="771" left="301" width="30" height="9" font="4">S3.1-12.</text>
<text top="771" left="334" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref93">Lee M, Saver JL, Chang B, et al. Presence of</a></text>
<text top="784" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref93">baseline prehypertension and risk of incident stroke: a</a></text>
<text top="798" left="301" width="160" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref93">meta-analysis. Neurology. 2011;77:1330</a></text>
<text top="796" left="461" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref93">–7</a></text>
<text top="798" left="469" width="3" height="9" font="4">.</text>
<text top="817" left="301" width="30" height="9" font="4">S3.1-13.</text>
<text top="817" left="334" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref94">Shen L, Ma H, Xiang M-X, et al. Meta-analysis of</a></text>
<text top="830" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref94">cohort studies of baseline prehypertension and risk of</a></text>
<text top="844" left="301" width="202" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref94">coronary heart disease. Am J Cardiol. 2013;112:266</a></text>
<text top="842" left="503" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref94">–71</a></text>
<text top="844" left="515" width="3" height="9" font="4">.</text>
<text top="863" left="301" width="31" height="9" font="4">S3.1-14.</text>
<text top="863" left="335" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref95">Sundstrom J, Arima H, Jackson R, et al. Ef-</a></text>
<text top="876" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref95">fects of blood pressure reduction in mild hypertension:</a></text>
<text top="890" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref95">a systematic review and meta-analysis. Ann Intern</a></text>
<text top="903" left="301" width="77" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref95">Med. 2015;162:184</a></text>
<text top="902" left="377" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref95">–91</a></text>
<text top="903" left="391" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref95">.</a></text>
<text top="923" left="301" width="30" height="9" font="4">S3.1-15.</text>
<text top="923" left="334" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref96">Thomopoulos C, Parati G, Zanchetti A. Effects</a></text>
<text top="936" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref96">of blood pressure lowering on outcome incidence in</a></text>
<text top="949" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref96">hypertension: 2. Effects at different baseline and</a></text>
<text top="963" left="301" width="129" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref96">achieved blood pressure levels</a></text>
<text top="961" left="430" width="88" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref96">–overview and meta-</a></text>
<text top="976" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref96">analyses of randomized trials. J Hypertens. 2014;32:</a></text>
<text top="990" left="301" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref96">2296</a></text>
<text top="988" left="322" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref96">–304</a></text>
<text top="990" left="342" width="3" height="9" font="4">.</text>
<text top="1009" left="301" width="31" height="9" font="4">S3.1-16.</text>
<text top="1009" left="335" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref97">Wang S, Wu H, Zhang Q, et al. Impact of</a></text>
<text top="1022" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref97">baseline prehypertension on cardiovascular events and</a></text>
<text top="1036" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref97">all-cause mortality in the general population: a meta-</a></text>
<text top="1049" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref97">analysis of prospective cohort studies. Int J Cardiol.</a></text>
<text top="1063" left="301" width="60" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref97">2013;168:4857</a></text>
<text top="1061" left="361" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref97">–60</a></text>
<text top="1063" left="377" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref97">.</a></text>
<text top="1082" left="301" width="30" height="9" font="4">S3.1-17.</text>
<text top="1082" left="334" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref98">Xie X, Atkins E, Lv J, et al. Effects of intensive</a></text>
<text top="1095" left="301" width="23" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref98">blood</a></text>
<text top="1095" left="333" width="77" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref98">pressure lowering</a></text>
<text top="1095" left="419" width="99" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref98">on cardiovascular and</a></text>
<text top="143" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref98">renal outcomes: updated systematic review and meta-</a></text>
<text top="156" left="539" width="124" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref98">analysis. Lancet. 2016;387:435</a></text>
<text top="155" left="663" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref98">–43</a></text>
<text top="156" left="678" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref98">.</a></text>
<text top="176" left="539" width="31" height="9" font="4">S3.1-18.</text>
<text top="176" left="574" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref99">Cushman WC, Ford CE, Cutler JA, et al.</a></text>
<text top="189" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref99">Success and predictors of blood pressure control in</a></text>
<text top="203" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref99">diverse North American settings: the antihypertensive</a></text>
<text top="216" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref99">and lipid-lowering treatment to prevent heart attack</a></text>
<text top="230" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref99">trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:</a></text>
<text top="243" left="539" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref99">393</a></text>
<text top="241" left="554" width="21" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref99">–404</a></text>
<text top="243" left="575" width="3" height="9" font="4">.</text>
<text top="262" left="539" width="31" height="9" font="4">S3.1-19.</text>
<text top="262" left="574" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref100">Dahlof B, Devereux RB, Kjeldsen SE, et al.</a></text>
<text top="276" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref100">Cardiovascular morbidity and mortality in the Losartan</a></text>
<text top="289" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref100">Intervention For Endpoint reduction in hypertension</a></text>
<text top="303" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref100">study (LIFE): a randomised trial against atenolol.</a></text>
<text top="316" left="539" width="90" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref100">Lancet. 2002;359:995</a></text>
<text top="314" left="630" width="25" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref100">–1003</a></text>
<text top="316" left="654" width="3" height="9" font="4">.</text>
<text top="335" left="539" width="32" height="9" font="4">S3.1-20.</text>
<text top="335" left="575" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref101">Wald DS, Law M, Morris JK, et al. Combination</a></text>
<text top="349" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref101">therapy versus monotherapy in reducing blood</a></text>
<text top="362" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref101">pressure: meta-analysis on 11,000 participants from</a></text>
<text top="376" left="539" width="142" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref101">42 trials. Am J Med. 2009;122:290</a></text>
<text top="374" left="682" width="21" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref101">–300</a></text>
<text top="376" left="703" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref101">.</a></text>
<text top="395" left="539" width="30" height="9" font="4">S3.1-21.</text>
<text top="395" left="573" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref102">Chobanian AV, Bakris GL, Black HR, et al., the</a></text>
<text top="408" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref102">National High Blood Pressure Education Program</a></text>
<text top="422" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref102">Coordinating Committee. Seventh Report of the</a></text>
<text top="435" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref102">Joint National Committee on Prevention, Detection,</a></text>
<text top="449" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref102">Evaluation, and Treatment of High Blood Pressure.</a></text>
<text top="462" left="539" width="116" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref102">Hypertension. 2003;42:1206</a></text>
<text top="460" left="655" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref102">–52</a></text>
<text top="462" left="669" width="3" height="9" font="4">.</text>
<text top="481" left="539" width="31" height="9" font="4">S3.1-22.</text>
<text top="481" left="574" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref103">Yoon SS, Gu Q, Nwankwo T, et al. Trends in</a></text>
<text top="495" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref103">blood pressure among adults with hypertension: United</a></text>
<text top="508" left="539" width="192" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref103">States, 2003 to 2012. Hypertension. 2015;65:54</a></text>
<text top="507" left="732" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref103">–61</a></text>
<text top="508" left="745" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref103">.</a></text>
<text top="530" left="539" width="156" height="9" font="23">3.2. Lifetime Risk of Hypertension</text>
<text top="553" left="539" width="26" height="9" font="4">S3.2-1.</text>
<text top="553" left="569" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref104">Muntner P, Woodward M, Mann DM, et al.</a></text>
<text top="566" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref104">Comparison of the Framingham Heart Study hyper-</a></text>
<text top="580" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref104">tension model with blood pressure alone in the pre-</a></text>
<text top="593" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref104">diction of risk of hypertension: the Multi-Ethnic Study</a></text>
<text top="607" left="539" width="191" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref104">of Atherosclerosis. Hypertension. 2010;55:1339</a></text>
<text top="605" left="730" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref104">–45</a></text>
<text top="607" left="744" width="3" height="9" font="4">.</text>
<text top="626" left="539" width="27" height="9" font="4">S3.2-2.</text>
<text top="626" left="570" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref105">Parikh NI, Pencina MJ, Wang TJ, et al. A risk</a></text>
<text top="639" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref105">score for predicting near-term incidence of hyperten-</a></text>
<text top="653" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref105">sion: the Framingham Heart Study. Ann Intern Med.</a></text>
<text top="666" left="539" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref105">2008;148:102</a></text>
<text top="665" left="597" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref105">–10</a></text>
<text top="666" left="610" width="3" height="9" font="4">.</text>
<text top="686" left="539" width="27" height="9" font="4">S3.2-3.</text>
<text top="686" left="570" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref106">Carson AP, Howard G, Burke GL, et al. Ethnic</a></text>
<text top="699" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref106">differences in hypertension incidence among middle-</a></text>
<text top="712" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref106">aged and older adults: the multi-ethnic study of</a></text>
<text top="726" left="539" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref106">atherosclerosis. Hypertension. 2011;57:1101</a></text>
<text top="724" left="713" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref106">–7</a></text>
<text top="726" left="722" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref106">.</a></text>
<text top="745" left="539" width="28" height="9" font="4">S3.2-4.</text>
<text top="745" left="571" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref107">Vasan RS, Beiser A, Seshadri S, et al. Residual</a></text>
<text top="759" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref107">lifetime risk for developing hypertension in middle-</a></text>
<text top="772" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref107">aged women and men: the Framingham Heart Study.</a></text>
<text top="785" left="539" width="91" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref107">JAMA. 2002;287:1003</a></text>
<text top="784" left="631" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref107">–10</a></text>
<text top="785" left="644" width="3" height="9" font="4">.</text>
<text top="805" left="539" width="27" height="9" font="4">S3.2-5.</text>
<text top="805" left="570" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref108">Shihab HM, Meoni LA, Chu AY, et al. Body</a></text>
<text top="818" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref108">mass index and risk of incident hypertension over</a></text>
<text top="832" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref108">the life course: the Johns Hopkins Precursors Study.</a></text>
<text top="845" left="539" width="108" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref108">Circulation. 2012;126:2983</a></text>
<text top="843" left="647" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref108">–9</a></text>
<text top="845" left="657" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref108">.</a></text>
<text top="867" left="539" width="120" height="9" font="23">3.3. Prevalence of High BP</text>
<text top="890" left="539" width="26" height="9" font="4">S3.3-1.</text>
<text top="890" left="569" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref109">Whelton PK. The elusiveness of population-</a></text>
<text top="903" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref109">wide high blood pressure control. Annu Rev Public</a></text>
<text top="917" left="539" width="82" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref109">Health. 2015;36:109</a></text>
<text top="915" left="622" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref109">–30</a></text>
<text top="917" left="637" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref109">.</a></text>
<text top="936" left="539" width="27" height="9" font="4">S3.3-2.</text>
<text top="936" left="570" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref110">Crim MT, Yoon SSS, Ortiz E, et al. National</a></text>
<text top="949" left="539" width="62" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref110">surveillance de</a></text>
<text top="948" left="602" width="155" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref110">ﬁnitions for hypertension prevalence</a></text>
<text top="963" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref110">and control among adults. Circ Cardiovasc Qual Out-</a></text>
<text top="976" left="539" width="75" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref110">comes. 2012;5:343</a></text>
<text top="975" left="615" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref110">–51</a></text>
<text top="976" left="627" width="3" height="9" font="4">.</text>
<text top="995" left="539" width="27" height="9" font="4">S3.3-3.</text>
<text top="995" left="570" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref111">Chobanian AV, Bakris GL, Black HR, et al., the</a></text>
<text top="1009" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref111">National High Blood Pressure Education Program</a></text>
<text top="1022" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref111">Coordinating Committee. Seventh Report of the Joint</a></text>
<text top="1036" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref111">National Committee on Prevention, Detection, Evalu-</a></text>
<text top="1049" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref111">ation, and Treatment of High Blood Pressure. Hyper-</a></text>
<text top="1063" left="539" width="92" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref111">tension. 2003;42:1206</a></text>
<text top="1061" left="632" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref111">–52</a></text>
<text top="1063" left="645" width="3" height="9" font="4">.</text>
<text top="1082" left="539" width="28" height="9" font="4">S3.3-4.</text>
<text top="1082" left="571" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref112">Report of the Joint National Committee</a></text>
<text top="1095" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref112">on Detection, Evaluation, and Treatment of High</a></text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="790" width="18" height="9" font="4">e213</text>
</page>
<page number="88" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref112">Blood Pressure. A cooperative study. JAMA. 1977;</a></text>
<text top="156" left="108" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref112">237:255</a></text>
<text top="155" left="139" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref112">–61</a></text>
<text top="156" left="152" width="3" height="9" font="4">.</text>
<text top="175" left="108" width="27" height="9" font="4">S3.3-5.</text>
<text top="175" left="138" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref113">The</a></text>
<text top="173" left="162" width="163" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref113">ﬁfth report of the Joint National</a></text>
<text top="188" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref113">Committee on Detection, Evaluation, and Treatment of</a></text>
<text top="202" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref113">High Blood Pressure (JNC V). Arch Intern Med. 1993;</a></text>
<text top="215" left="108" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref113">153:154</a></text>
<text top="214" left="138" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref113">–83</a></text>
<text top="215" left="152" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref113">.</a></text>
<text top="234" left="108" width="28" height="9" font="4">S3.3-6.</text>
<text top="234" left="139" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref114">Burt VL, Whelton P, Roccella EJ, et al.</a></text>
<text top="247" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref114">Prevalence of hypertension in the US adult population.</a></text>
<text top="261" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref114">Results from the Third National Health and Nutrition</a></text>
<text top="274" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref114">Examination Survey, 1988-1991. Hypertension. 1995;</a></text>
<text top="288" left="108" width="28" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref114">25:305</a></text>
<text top="286" left="136" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref114">–13</a></text>
<text top="288" left="148" width="3" height="9" font="4">.</text>
<text top="306" left="108" width="27" height="9" font="4">S3.3-7.</text>
<text top="306" left="138" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref115">Gee ME, Campbell N, Sarrafzadegan N, et al.</a></text>
<text top="320" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref115">Standards for the uniform reporting of hypertension in</a></text>
<text top="333" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref115">adults using population survey data: recommendations</a></text>
<text top="347" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref115">from the World Hypertension League Expert Commit-</a></text>
<text top="360" left="108" width="190" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref115">tee. J Clin Hypertens (Greenwich). 2014;16:773</a></text>
<text top="358" left="297" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref115">–81</a></text>
<text top="360" left="310" width="3" height="9" font="4">.</text>
<text top="386" left="108" width="182" height="9" font="23">3.4. Awareness, Treatment, and Control</text>
<text top="411" left="108" width="27" height="9" font="4">S3.4-1.</text>
<text top="411" left="138" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref116">Burt VL, Cutler JA, Higgins M, et al. Trends in</a></text>
<text top="425" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref116">the prevalence, awareness, treatment, and control of</a></text>
<text top="438" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref116">hypertension in the adult US population. Data from the</a></text>
<text top="452" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref116">Health Examination Surveys, 1960 to 1991. Hyper-</a></text>
<text top="465" left="108" width="82" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref116">tension. 1995;26:60</a></text>
<text top="464" left="189" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref116">–9</a></text>
<text top="465" left="199" width="3" height="9" font="4">.</text>
<text top="484" left="108" width="28" height="9" font="4">S3.4-2.</text>
<text top="484" left="139" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref117">Hajjar I, Kotchen TA. Trends in prevalence,</a></text>
<text top="497" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref117">awareness, treatment, and control of hypertension</a></text>
<text top="511" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref117">in the United States, 1988-2000. JAMA. 2003;290:</a></text>
<text top="524" left="108" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref117">199</a></text>
<text top="522" left="123" width="21" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref117">–206</a></text>
<text top="524" left="143" width="3" height="9" font="4">.</text>
<text top="543" left="108" width="28" height="9" font="4">S3.4-3.</text>
<text top="543" left="139" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref118">Egan BM, Li J, Hutchison FN, et al. Hyperten-</a></text>
<text top="556" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref118">sion in the United States, 1999 to 2012: progress</a></text>
<text top="570" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref118">toward Healthy People 2020 goals. Circulation. 2014;</a></text>
<text top="583" left="108" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref118">130:1692</a></text>
<text top="581" left="144" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref118">–9</a></text>
<text top="583" left="154" width="3" height="9" font="4">.</text>
<text top="601" left="108" width="29" height="9" font="4">S3.4-4.</text>
<text top="601" left="140" width="39" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref119">Nwankwo</a></text>
<text top="601" left="188" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref119">T,</a></text>
<text top="601" left="204" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref119">Yoon</a></text>
<text top="601" left="234" width="12" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref119">SS,</a></text>
<text top="601" left="255" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref119">Burt</a></text>
<text top="601" left="281" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref119">V,</a></text>
<text top="601" left="298" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref119">et</a></text>
<text top="601" left="315" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref119">al.</a></text>
<text top="615" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref119">Hypertension among adults in the United States:</a></text>
<text top="628" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref119">National Health and Nutrition Examination Survey,</a></text>
<text top="642" left="108" width="144" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref119">2011-2012. NCHS Data Brief; 2013:1</a></text>
<text top="640" left="252" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref119">–8</a></text>
<text top="642" left="261" width="3" height="9" font="4">.</text>
<text top="660" left="108" width="28" height="9" font="4">S3.4-5.</text>
<text top="660" left="139" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref120">National Center for Health Statistics (U.S.).</a></text>
<text top="674" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref120">Health, United States, 2013: With Special Feature on</a></text>
<text top="687" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref120">Prescription Drugs. Hyattsville, MD: National Center</a></text>
<text top="701" left="108" width="131" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref120">for Health Statistics (U.S.), 2014</a></text>
<text top="701" left="238" width="3" height="9" font="4">.</text>
<text top="719" left="108" width="29" height="9" font="4">S3.4-6.</text>
<text top="719" left="140" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref121">Brom</a></text>
<text top="718" left="161" width="164" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref121">ﬁeld SG, Bowling CB, Tanner RM, et al.</a></text>
<text top="733" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref121">Trends in hypertension prevalence, awareness, treat-</a></text>
<text top="746" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref121">ment, and control among US adults 80 years and</a></text>
<text top="760" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref121">older, 1988-2010. J Clin Hypertens (Greenwich). 2014;</a></text>
<text top="773" left="108" width="27" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref121">16:270</a></text>
<text top="771" left="135" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref121">–6</a></text>
<text top="773" left="145" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref121">.</a></text>
<text top="792" left="108" width="28" height="9" font="4">S3.4-7.</text>
<text top="792" left="139" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref122">Cushman WC, Evans GW, Byington RP, et al.</a></text>
<text top="805" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref122">Effects of intensive blood-pressure control in type 2</a></text>
<text top="819" left="108" width="193" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref122">diabetes mellitus. N Engl J Med. 2010;362:1575</a></text>
<text top="817" left="301" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref122">–85</a></text>
<text top="819" left="315" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref122">.</a></text>
<text top="837" left="108" width="29" height="9" font="4">S3.4-8.</text>
<text top="837" left="140" width="62" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref123">The ALLHAT Of</a></text>
<text top="835" left="202" width="123" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref123">ﬁcers and Coordinators for the</a></text>
<text top="850" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref123">ALLHAT Collaborative Research Group. Major out-</a></text>
<text top="864" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref123">comes in high-risk hypertensive patients randomized</a></text>
<text top="877" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref123">to angiotensin-converting enzyme inhibitor or calcium</a></text>
<text top="891" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref123">channel blocker vs diuretic: the Antihypertensive and</a></text>
<text top="904" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref123">Lipid-Lowering Treatment to Prevent Heart Attack</a></text>
<text top="918" left="108" width="156" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref123">Trial (ALLHAT). JAMA. 2002;288:2981</a></text>
<text top="916" left="263" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref123">–97</a></text>
<text top="918" left="278" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref123">.</a></text>
<text top="936" left="108" width="29" height="9" font="4">S3.4-9.</text>
<text top="936" left="140" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref124">Williamson JD, Supiano MA, Applegate WB, et al.</a></text>
<text top="950" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref124">Intensive vs standard blood pressure control and car-</a></text>
<text top="963" left="108" width="168" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref124">diovascular disease outcomes in adults aged</a></text>
<text top="962" left="277" width="47" height="12" font="8">$<a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref124">75 years: a</a></text>
<text top="977" left="108" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref124">randomized clinical trial. JAMA. 2016;315:2673</a></text>
<text top="975" left="289" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref124">–82</a></text>
<text top="977" left="304" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref124">.</a></text>
<text top="995" left="108" width="33" height="9" font="4">S3.4-10.</text>
<text top="995" left="144" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref125">Fletcher RD, Amdur RL, Kolodner R, et al.</a></text>
<text top="1009" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref125">Blood pressure control among US veterans: a large</a></text>
<text top="1022" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref125">multiyear analysis of blood pressure data from the</a></text>
<text top="1035" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref125">Veterans Administration health data repository. Cir-</a></text>
<text top="1049" left="108" width="96" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref125">culation. 2012;125:2462</a></text>
<text top="1047" left="204" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref125">–8</a></text>
<text top="1049" left="213" width="3" height="9" font="4">.</text>
<text top="1067" left="108" width="31" height="9" font="4">S3.4-11.</text>
<text top="1067" left="142" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref126">Jaffe MG, Lee GA, Young JD, et al. Improved</a></text>
<text top="1081" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref126">blood pressure control associated with a large-scale</a></text>
<text top="1094" left="108" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref126">hypertension program. JAMA. 2013;310:699</a></text>
<text top="1093" left="286" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref126">–705</a></text>
<text top="1094" left="306" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref126">.</a></text>
<text top="143" left="346" width="32" height="9" font="4">S3.4-12.</text>
<text top="143" left="381" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref127">Jaffe MG, Young JD. The Kaiser Permanente</a></text>
<text top="156" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref127">Northern California story: improving hypertension</a></text>
<text top="170" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref127">control from 44% to 90% in 13 years (2000 to 2013).</a></text>
<text top="183" left="346" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref127">J Clin Hypertens (Greenwich). 2016;18:260</a></text>
<text top="182" left="520" width="8" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref127">–1</a></text>
<text top="183" left="528" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref127">.</a></text>
<text top="223" left="346" width="151" height="12" font="26">4 . M E A S U R E M E N T O F B P</text>
<text top="254" left="346" width="194" height="9" font="23">4.1. Accurate Measurement of BP in the Of</text>
<text top="253" left="541" width="16" height="12" font="23">ﬁce</text>
<text top="269" left="346" width="26" height="9" font="4">S4.1-1.</text>
<text top="269" left="375" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref128">Leung AA, Daskalopoulou SS, Dasgupta K, et al.</a></text>
<text top="282" left="346" width="86" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref128">Hypertension Canada</a></text>
<text top="281" left="432" width="131" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref128">’s 2017 guidelines for diagnosis,</a></text>
<text top="296" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref128">risk assessment, prevention, and treatment of hyper-</a></text>
<text top="309" left="346" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref128">tension in adults. Can J Cardiol. 2017;33:557</a></text>
<text top="307" left="525" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref128">–76</a></text>
<text top="309" left="539" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref128">.</a></text>
<text top="328" left="346" width="27" height="9" font="4">S4.1-2.</text>
<text top="328" left="376" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref129">Pickering TG, Hall JE, Appel LJ, et al.</a></text>
<text top="341" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref129">Recommendations for blood pressure measurement in</a></text>
<text top="355" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref129">humans and experimental animals: part 1: blood</a></text>
<text top="368" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref129">pressure measurement in humans: a statement for</a></text>
<text top="381" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref129">professionals from the Subcommittee of Professional</a></text>
<text top="395" left="346" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref129">and</a></text>
<text top="395" left="370" width="24" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref129">Public</a></text>
<text top="395" left="404" width="40" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref129">Education</a></text>
<text top="395" left="453" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref129">of</a></text>
<text top="395" left="471" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref129">the</a></text>
<text top="395" left="494" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref129">American</a></text>
<text top="395" left="541" width="22" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref129">Heart</a></text>
<text top="408" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref129">Association Council on High Blood Pressure Research.</a></text>
<text top="422" left="346" width="102" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref129">Circulation. 2005;111:697</a></text>
<text top="420" left="448" width="18" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref129">–716</a></text>
<text top="422" left="466" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref129">.</a></text>
<text top="440" left="346" width="27" height="9" font="4">S4.1-3.</text>
<text top="440" left="376" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref130">Mancia G, Fagard R, Narkiewicz K, et al. 2013</a></text>
<text top="454" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref130">ESH/ESC guidelines for the management of arterial</a></text>
<text top="467" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref130">hypertension: the Task Force for the Management of</a></text>
<text top="481" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref130">Arterial Hypertension of the European Society of</a></text>
<text top="494" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref130">Hypertension (ESH) and of the European Society</a></text>
<text top="508" left="346" width="189" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref130">of Cardiology (ESC). Eur Heart J. 2013;34:2159</a></text>
<text top="506" left="535" width="18" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref130">–219</a></text>
<text top="508" left="553" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref130">.</a></text>
<text top="526" left="346" width="28" height="9" font="4">S4.1-4.</text>
<text top="526" left="377" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref131">Weir MR. In the clinic: hypertension. Ann</a></text>
<text top="540" left="346" width="105" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref131">Intern Med. 2014;161:ITC1</a></text>
<text top="538" left="451" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref131">–15</a></text>
<text top="540" left="463" width="3" height="9" font="4">.</text>
<text top="558" left="346" width="27" height="9" font="4">S4.1-5.</text>
<text top="558" left="376" width="41" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref132">Liu C, Grif</a></text>
<text top="556" left="417" width="146" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref132">ﬁths C, Murray A, et al. Comparison</a></text>
<text top="572" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref132">of stethoscope bell and diaphragm, and of stetho-</a></text>
<text top="585" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref132">scope tube length, for clinical blood pressure</a></text>
<text top="598" left="346" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref132">measurement. Blood Press Monit. 2016;21:178</a></text>
<text top="597" left="532" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref132">–83</a></text>
<text top="598" left="547" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref132">.</a></text>
<text top="617" left="346" width="28" height="9" font="4">S4.1-6.</text>
<text top="617" left="377" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref133">Kantola I, Vesalainen R, Kangassalo K, et al.</a></text>
<text top="630" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref133">Bell or diaphragm in the measurement of blood</a></text>
<text top="644" left="346" width="147" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref133">pressure? J Hypertens. 2005;23:499</a></text>
<text top="642" left="493" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref133">–503</a></text>
<text top="644" left="513" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref133">.</a></text>
<text top="666" left="346" width="63" height="9" font="23">4.2. Out-of-Of</text>
<text top="664" left="409" width="137" height="12" font="23">ﬁce and Self-Monitoring of BP</text>
<text top="689" left="346" width="27" height="9" font="4">S4.2-1.</text>
<text top="689" left="376" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref134">Uhlig K, Balk EM, Patel K, et al. Self-Measured</a></text>
<text top="703" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref134">Blood Pressure Monitoring: Comparative Effective-</a></text>
<text top="716" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref134">ness. Rockville, MD: Agency for Healthcare Research</a></text>
<text top="730" left="346" width="96" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref134">and Quality (U.S.); 2012</a></text>
<text top="730" left="442" width="3" height="9" font="4">.</text>
<text top="748" left="346" width="28" height="9" font="4">S4.2-2.</text>
<text top="748" left="377" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref135">Margolis KL, Asche SE, Bergdall AR, et al. Effect</a></text>
<text top="762" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref135">of home blood pressure telemonitoring and pharmacist</a></text>
<text top="775" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref135">management on blood pressure control: a cluster ran-</a></text>
<text top="789" left="346" width="165" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref135">domized clinical trial. JAMA. 2013;310:46</a></text>
<text top="787" left="510" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref135">–56</a></text>
<text top="789" left="525" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref135">.</a></text>
<text top="807" left="346" width="28" height="9" font="4">S4.2-3.</text>
<text top="807" left="377" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref136">McManus RJ, Mant J, Haque MS, et al. Effect of</a></text>
<text top="821" left="346" width="62" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref136">self-monitoring</a></text>
<text top="821" left="417" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref136">and</a></text>
<text top="821" left="441" width="44" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref136">medication</a></text>
<text top="821" left="493" width="51" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref136">self-titration</a></text>
<text top="821" left="553" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref136">on</a></text>
<text top="834" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref136">systolic blood pressure in hypertensive patients at</a></text>
<text top="847" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref136">high risk of cardiovascular disease: the TASMIN-SR</a></text>
<text top="861" left="346" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref136">randomized clinical trial. JAMA. 2014;312:799</a></text>
<text top="859" left="530" width="21" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref136">–808</a></text>
<text top="861" left="551" width="3" height="9" font="4">.</text>
<text top="879" left="346" width="29" height="9" font="4">S4.2-4.</text>
<text top="879" left="378" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref137">Siu AL. Screening for high blood pressure in</a></text>
<text top="893" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref137">adults: U.S. Preventive Services Task Force recommen-</a></text>
<text top="906" left="346" width="189" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref137">dation statement. Ann Intern Med. 2015;163:778</a></text>
<text top="905" left="535" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref137">–86</a></text>
<text top="906" left="550" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref137">.</a></text>
<text top="925" left="346" width="28" height="9" font="4">S4.2-5.</text>
<text top="925" left="377" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref138">Yi SS, Tabaei BP, Angell SY, et al. Self-blood</a></text>
<text top="938" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref138">pressure monitoring in an urban, ethnically diverse</a></text>
<text top="952" left="346" width="46" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref138">population:</a></text>
<text top="952" left="401" width="4" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref138">a</a></text>
<text top="952" left="414" width="47" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref138">randomized</a></text>
<text top="952" left="470" width="27" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref138">clinical</a></text>
<text top="952" left="506" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref138">trial</a></text>
<text top="952" left="531" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref138">utilizing</a></text>
<text top="965" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref138">the electronic health record. Circ Cardiovasc Qual</a></text>
<text top="979" left="346" width="90" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref138">Outcomes. 2015;8:138</a></text>
<text top="977" left="436" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref138">–45</a></text>
<text top="979" left="450" width="3" height="9" font="4">.</text>
<text top="997" left="346" width="29" height="9" font="4">S4.2-6.</text>
<text top="997" left="378" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref139">Agarwal R, Bills JE, Hecht TJW, et al. Role of</a></text>
<text top="1011" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref139">home blood pressure monitoring in overcoming ther-</a></text>
<text top="1024" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref139">apeutic inertia and improving hypertension control: a</a></text>
<text top="1037" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref139">systematic review and meta-analysis. Hypertension.</a></text>
<text top="1051" left="346" width="43" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref139">2011;57:29</a></text>
<text top="1049" left="389" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref139">–38</a></text>
<text top="1051" left="404" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref139">.</a></text>
<text top="1068" left="346" width="28" height="9" font="4">S4.2-7.</text>
<text top="1068" left="377" width="6" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref140">O</a></text>
<text top="1066" left="383" width="180" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref140">’Brien E, Stergiou GS. The pursuit of accurate</a></text>
<text top="1081" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref140">blood pressure measurement: a 35-year travail. J Clin</a></text>
<text top="1095" left="346" width="147" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref140">Hypertens (Greenwich). 2017;19:746</a></text>
<text top="1093" left="493" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref140">–52</a></text>
<text top="1095" left="506" width="3" height="9" font="4">.</text>
<text top="143" left="584" width="29" height="9" font="4">S4.2-8.</text>
<text top="143" left="616" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref141">Mancia G, Fagard R, Narkiewicz K, et al. 2013</a></text>
<text top="156" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref141">ESH/ESC guidelines for the management of arterial</a></text>
<text top="170" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref141">hypertension: the Task Force for the Management of</a></text>
<text top="183" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref141">Arterial Hypertension of the European Society of</a></text>
<text top="197" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref141">Hypertension (ESH) and of the European Society</a></text>
<text top="210" left="584" width="189" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref141">of Cardiology (ESC). Eur Heart J. 2013;34:2159</a></text>
<text top="209" left="773" width="18" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref141">–219</a></text>
<text top="210" left="791" width="3" height="9" font="4">.</text>
<text top="229" left="584" width="29" height="9" font="4">S4.2-9.</text>
<text top="229" left="616" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref142">Pickering TG, Miller NH, Ogedegbe G, et al.</a></text>
<text top="243" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref142">Call to action on use and reimbursement for home</a></text>
<text top="256" left="584" width="164" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref142">blood pressure monitoring: a joint scienti</a></text>
<text top="255" left="749" width="53" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref142">ﬁc statement</a></text>
<text top="270" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref142">from the American Heart Association, American Soci-</a></text>
<text top="283" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref142">ety of Hypertension, and Preventive Cardiovascular</a></text>
<text top="297" left="584" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref142">Nurses Association. Hypertension. 2008;52:10</a></text>
<text top="295" left="771" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref142">–29</a></text>
<text top="297" left="785" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref142">.</a></text>
<text top="316" left="584" width="33" height="9" font="4">S4.2-10.</text>
<text top="316" left="620" width="33" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref143">National</a></text>
<text top="316" left="663" width="28" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref143">Clinical</a></text>
<text top="316" left="700" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref143">Guideline</a></text>
<text top="316" left="746" width="26" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref143">Centre</a></text>
<text top="316" left="781" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref143">(UK).</a></text>
<text top="329" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref143">Hypertension: The Clinical Management of Primary Hy-</a></text>
<text top="342" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref143">pertension in Adults: Update of Clinical Guidelines 18 and</a></text>
<text top="356" left="584" width="214" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref143">34. London, UK: Royal College of Physicians (UK); 2011</a></text>
<text top="356" left="798" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref143">.</a></text>
<text top="378" left="584" width="143" height="9" font="23">4.3. Ambulatory BP Monitoring</text>
<text top="402" left="584" width="27" height="9" font="4">S4.3-1.</text>
<text top="402" left="614" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref144">Pickering TG, Shimbo D, Haas D. Ambulatory</a></text>
<text top="415" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref144">blood-pressure monitoring. N Engl J Med. 2006;354:</a></text>
<text top="429" left="584" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref144">2368</a></text>
<text top="427" left="605" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref144">–74</a></text>
<text top="429" left="619" width="3" height="9" font="4">.</text>
<text top="448" left="584" width="217" height="9" font="4">S4.3-2. Tunis SR. Decision Memo for Ambulatory Blood</text>
<text top="461" left="584" width="217" height="9" font="4">Pressure Monitoring (CAG-00067N). Centers for</text>
<text top="475" left="584" width="205" height="9" font="4">Medicare and Medicaid Services; October 17, 2001.</text>
<text top="494" left="584" width="28" height="9" font="4">S4.3-3.</text>
<text top="494" left="615" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref146">Shimbo D, Kent ST, Diaz KM, et al. The use of</a></text>
<text top="507" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref146">ambulatory blood pressure monitoring among Medi-</a></text>
<text top="521" left="584" width="39" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref146">care bene</a></text>
<text top="519" left="623" width="178" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref146">ﬁciaries in 2007-2010. J Am Soc Hypertens.</a></text>
<text top="534" left="584" width="46" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref146">2014;8:891</a></text>
<text top="532" left="630" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref146">–7</a></text>
<text top="534" left="639" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref146">.</a></text>
<text top="553" left="584" width="29" height="9" font="4">S4.3-4.</text>
<text top="553" left="616" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref147">Kent ST, Shimbo D, Huang L, et al. Rates,</a></text>
<text top="567" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref147">amounts, and determinants of ambulatory blood</a></text>
<text top="580" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref147">pressure monitoring claim reimbursements among</a></text>
<text top="593" left="584" width="59" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref147">Medicare bene</a></text>
<text top="592" left="644" width="158" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref147">ﬁciaries. J Am Soc Hypertens. 2014;8:</a></text>
<text top="607" left="584" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref147">898</a></text>
<text top="605" left="601" width="21" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref147">–908</a></text>
<text top="607" left="622" width="3" height="9" font="4">.</text>
<text top="626" left="584" width="50" height="9" font="4">S4.3-5. Dabl</text>
<text top="626" left="644" width="47" height="9" font="4">Educational</text>
<text top="626" left="701" width="23" height="9" font="4">Trust.</text>
<text top="626" left="734" width="47" height="9" font="4">Information</text>
<text top="626" left="791" width="10" height="9" font="4">on</text>
<text top="639" left="584" width="217" height="9" font="4">validated blood pressure devices and monitors. Avail-</text>
<text top="653" left="584" width="35" height="9" font="4">able at:</text>
<text top="653" left="626" width="129" height="9" font="8"><a href="http://www.dableducational.org">http://www.dableducational.org</a></text>
<text top="653" left="755" width="46" height="9" font="4">. Accessed</text>
<text top="666" left="584" width="82" height="9" font="4">September 17, 2017.</text>
<text top="685" left="584" width="217" height="9" font="4">S4.3-6. British Hypertension Society. BP Monitors.</text>
<text top="699" left="584" width="52" height="9" font="4">Available at:</text>
<text top="699" left="642" width="159" height="9" font="8"><a href="http://www.bhsoc.org/bp-monitors/bp-monitors">http://www.bhsoc.org/bp-monitors/bp-</a></text>
<text top="712" left="584" width="35" height="9" font="8"><a href="http://www.bhsoc.org/bp-monitors/bp-monitors">monitors</a></text>
<text top="712" left="620" width="127" height="9" font="4"><a href="http://www.bhsoc.org/bp-monitors/bp-monitors">. </a>Accessed September 17, 2017.</text>
<text top="731" left="584" width="28" height="9" font="4">S4.3-7.</text>
<text top="731" left="615" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref150">Pickering TG, White WB, American Society of</a></text>
<text top="745" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref150">Hypertension Writing Group. ASH position paper:</a></text>
<text top="758" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref150">home and ambulatory blood pressure monitoring.</a></text>
<text top="772" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref150">When and how to use self (home) and ambulatory</a></text>
<text top="785" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref150">blood pressure monitoring. J Clin Hypertens (Green-</a></text>
<text top="799" left="584" width="81" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref150">wich). 2008;10:850</a></text>
<text top="797" left="665" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref150">–5</a></text>
<text top="799" left="674" width="3" height="9" font="4">.</text>
<text top="817" left="584" width="29" height="9" font="4">S4.3-8.</text>
<text top="817" left="616" width="6" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref151">O</a></text>
<text top="816" left="622" width="179" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref151">’Brien E, Parati G, Stergiou G, et al. European</a></text>
<text top="831" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref151">Society of Hypertension position paper on ambulatory</a></text>
<text top="844" left="584" width="213" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref151">blood pressure monitoring. J Hypertens. 2013;31:1731</a></text>
<text top="843" left="797" width="4" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref151">–</a></text>
<text top="858" left="584" width="11" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref151">68</a></text>
<text top="858" left="595" width="3" height="9" font="4">.</text>
<text top="877" left="584" width="29" height="9" font="4">S4.3-9.</text>
<text top="877" left="616" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref152">Kikuya M, Hansen TW, Thijs L, et al. Diagnostic</a></text>
<text top="890" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref152">thresholds for ambulatory blood pressure monitoring</a></text>
<text top="904" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref152">based on 10-year cardiovascular risk. Circulation.</a></text>
<text top="917" left="584" width="58" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref152">2007;115:2145</a></text>
<text top="916" left="642" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref152">–52</a></text>
<text top="917" left="656" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref152">.</a></text>
<text top="936" left="584" width="33" height="9" font="4">S4.3-10.</text>
<text top="936" left="620" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref153">Niiranen TJ, Asayama K, Thijs L, et al.</a></text>
<text top="950" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref153">Outcome-driven thresholds for home blood pressure</a></text>
<text top="963" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref153">measurement: international database of home blood</a></text>
<text top="977" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref153">pressure in relation to cardiovascular outcome. Hy-</a></text>
<text top="990" left="584" width="91" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref153">pertension. 2013;61:27</a></text>
<text top="988" left="675" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref153">–34</a></text>
<text top="990" left="689" width="3" height="9" font="4">.</text>
<text top="1009" left="584" width="31" height="9" font="4">S4.3-11.</text>
<text top="1009" left="618" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref154">Head GA, Mihailidou AS, Duggan KA, et al.</a></text>
<text top="1023" left="584" width="11" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref154">De</a></text>
<text top="1021" left="595" width="206" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref154">ﬁnition of ambulatory blood pressure targets for</a></text>
<text top="1036" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref154">diagnosis and treatment of hypertension in relation to</a></text>
<text top="1049" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref154">clinic blood pressure: prospective cohort study. BMJ.</a></text>
<text top="1063" left="584" width="65" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref154">2010;340:c1104</a></text>
<text top="1063" left="649" width="3" height="9" font="4">.</text>
<text top="1082" left="584" width="32" height="9" font="4">S4.3-12.</text>
<text top="1082" left="619" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref155">Hansen TW, Kikuya M, Thijs L, et al. Diag-</a></text>
<text top="1095" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref155">nostic thresholds for ambulatory blood pressure</a></text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e214</text>
</page>
<page number="89" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref155">moving lower: a review based on a meta-analysis-</a></text>
<text top="156" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref155">clinical implications. J Clin Hypertens (Greenwich).</a></text>
<text top="170" left="63" width="52" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref155">2008;10:377</a></text>
<text top="168" left="114" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref155">–81</a></text>
<text top="170" left="128" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref155">.</a></text>
<text top="189" left="63" width="32" height="9" font="4">S4.3-13.</text>
<text top="189" left="98" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref156">Ravenell J, Shimbo D, Booth JN 3rd, et al.</a></text>
<text top="202" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref156">Thresholds for ambulatory blood pressure among</a></text>
<text top="215" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref156">African Americans in the Jackson Heart Study.</a></text>
<text top="229" left="63" width="107" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref156">Circulation. 2017;135:2470</a></text>
<text top="227" left="169" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref156">–80</a></text>
<text top="229" left="185" width="3" height="9" font="4">.</text>
<text top="248" left="63" width="33" height="9" font="4">S4.3-14.</text>
<text top="248" left="99" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref157">Hansen TW, Kikuya M, Thijs L, et al.</a></text>
<text top="261" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref157">Prognostic superiority of daytime ambulatory over</a></text>
<text top="275" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref157">conventional blood pressure in four populations: a</a></text>
<text top="288" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref157">meta-analysis of 7,030 individuals. J Hypertens. 2007;</a></text>
<text top="301" left="63" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref157">25:1554</a></text>
<text top="300" left="94" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref157">–64</a></text>
<text top="301" left="109" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref157">.</a></text>
<text top="320" left="63" width="32" height="9" font="4">S4.3-15.</text>
<text top="320" left="98" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref158">Roush GC, Fagard RH, Salles GF, et al.</a></text>
<text top="334" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref158">Prognostic impact from clinic, daytime, and night-time</a></text>
<text top="347" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref158">systolic blood pressure in nine cohorts of 13,844</a></text>
<text top="360" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref158">patients with hypertension. J Hypertens. 2014;32:</a></text>
<text top="374" left="63" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref158">2332</a></text>
<text top="372" left="82" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref158">–40</a></text>
<text top="374" left="97" width="3" height="9" font="4">.</text>
<text top="393" left="63" width="33" height="9" font="4">S4.3-16.</text>
<text top="393" left="99" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref159">Mancia G, Bombelli M, Facchetti R, et al.</a></text>
<text top="406" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref159">Long-term risk of sustained hypertension in white-</a></text>
<text top="419" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref159">coat or masked hypertension. Hypertension. 2009;</a></text>
<text top="433" left="63" width="28" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref159">54:226</a></text>
<text top="431" left="91" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref159">–32</a></text>
<text top="433" left="105" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref159">.</a></text>
<text top="451" left="63" width="32" height="9" font="4">S4.3-17.</text>
<text top="451" left="98" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref160">Ben-Dov IZ, Ben-Arie L, Mekler J, et al.</a></text>
<text top="465" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref160">Reproducibility of white-coat and masked hyperten-</a></text>
<text top="478" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref160">sion in ambulatory BP monitoring. Int J Cardiol. 2007;</a></text>
<text top="492" left="63" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref160">117:355</a></text>
<text top="490" left="92" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref160">–9</a></text>
<text top="492" left="101" width="3" height="9" font="4">.</text>
<text top="510" left="63" width="33" height="9" font="4">S4.3-18.</text>
<text top="510" left="99" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref161">Bidlingmeyer I, Burnier M, Bidlingmeyer M,</a></text>
<text top="524" left="63" width="69" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref161">et al. Isolated of</a></text>
<text top="522" left="132" width="148" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref161">ﬁce hypertension: a prehypertensive</a></text>
<text top="537" left="63" width="129" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref161">state? J Hypertens. 1996;14:327</a></text>
<text top="536" left="192" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref161">–32</a></text>
<text top="537" left="206" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref161">.</a></text>
<text top="556" left="63" width="33" height="9" font="4">S4.3-19.</text>
<text top="556" left="99" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref162">Muxfeldt ES, Fiszman R, de Souza F, et al.</a></text>
<text top="570" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref162">Appropriate time interval to repeat ambulatory blood</a></text>
<text top="583" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref162">pressure monitoring in patients with white-coat</a></text>
<text top="596" left="63" width="204" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref162">resistant hypertension. Hypertension. 2012;59:384</a></text>
<text top="595" left="267" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref162">–9</a></text>
<text top="596" left="277" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref162">.</a></text>
<text top="615" left="63" width="34" height="9" font="4">S4.3-20.</text>
<text top="615" left="100" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref163">Palatini P, Winnicki M, Santonastaso M, et al.</a></text>
<text top="629" left="63" width="114" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref163">Prevalence and clinical signi</a></text>
<text top="627" left="177" width="103" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref163">ﬁcance of isolated ambu-</a></text>
<text top="642" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref163">latory hypertension in young subjects screened for</a></text>
<text top="655" left="63" width="200" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref163">stage 1 hypertension. Hypertension. 2004;44:170</a></text>
<text top="654" left="263" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref163">–4</a></text>
<text top="655" left="272" width="3" height="9" font="4">.</text>
<text top="674" left="63" width="32" height="9" font="4">S4.3-21.</text>
<text top="674" left="98" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref164">Trudel X, Milot A, Brisson C. Persistence and</a></text>
<text top="688" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref164">progression of masked hypertension: a 5-year pro-</a></text>
<text top="701" left="63" width="206" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref164">spective study. Int J Hypertens. 2013;2013:836387</a></text>
<text top="701" left="268" width="3" height="9" font="4">.</text>
<text top="720" left="63" width="33" height="9" font="4">S4.3-22.</text>
<text top="720" left="99" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref165">Ugajin T, Hozawa A, Ohkubo T, et al. White-</a></text>
<text top="733" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref165">coat hypertension as a risk factor for the development</a></text>
<text top="747" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref165">of home hypertension: the Ohasama study. Arch Intern</a></text>
<text top="760" left="63" width="82" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref165">Med. 2005;165:1541</a></text>
<text top="758" left="144" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref165">–6</a></text>
<text top="760" left="154" width="3" height="9" font="4">.</text>
<text top="782" left="63" width="194" height="9" font="23">4.4. Masked and White Coat Hypertension</text>
<text top="806" left="63" width="28" height="9" font="4">S4.4-1.</text>
<text top="806" left="94" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref166">Pickering TG, James GD, Boddie C, et al. How</a></text>
<text top="819" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref166">common is white coat hypertension? JAMA. 1988;259:</a></text>
<text top="832" left="63" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref166">225</a></text>
<text top="831" left="77" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref166">–8</a></text>
<text top="832" left="87" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref166">.</a></text>
<text top="851" left="63" width="29" height="9" font="4">S4.4-2.</text>
<text top="851" left="95" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref167">Piper MA, Evans CV, Burda BU, et al. Diag-</a></text>
<text top="865" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref167">nostic and predictive accuracy of blood pressure</a></text>
<text top="878" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref167">screening methods with consideration of rescreening</a></text>
<text top="891" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref167">intervals: a systematic review for the U.S. Preventive</a></text>
<text top="905" left="63" width="213" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref167">Services Task Force. Ann Intern Med. 2015;162:192</a></text>
<text top="903" left="276" width="4" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref167">–</a></text>
<text top="918" left="63" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref167">204</a></text>
<text top="918" left="79" width="3" height="9" font="4">.</text>
<text top="937" left="63" width="29" height="9" font="4">S4.4-3.</text>
<text top="937" left="95" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref168">Ohkubo T, Kikuya M, Metoki H, et al. Prognosis</a></text>
<text top="950" left="63" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref168">of</a></text>
<text top="949" left="77" width="203" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref168">“masked” hypertension and “white-coat” hyper-</a></text>
<text top="964" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref168">tension detected by 24-h ambulatory blood pressure</a></text>
<text top="977" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref168">monitoring 10-year follow-up from the Ohasama</a></text>
<text top="991" left="63" width="157" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref168">study. J Am Coll Cardiol. 2005;46:508</a></text>
<text top="989" left="220" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref168">–15</a></text>
<text top="991" left="233" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref168">.</a></text>
<text top="1010" left="63" width="30" height="9" font="4">S4.4-4.</text>
<text top="1009" left="96" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref169">Fagard RH, Cornelissen VA. Incidence of</a></text>
<text top="1023" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref169">cardiovascular events in white-coat, masked and</a></text>
<text top="1036" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref169">sustained hypertension versus true normotension: a</a></text>
<text top="1050" left="63" width="169" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref169">meta-analysis. J Hypertens. 2007;25:2193</a></text>
<text top="1048" left="232" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref169">–8</a></text>
<text top="1050" left="242" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref169">.</a></text>
<text top="1069" left="63" width="29" height="9" font="4">S4.4-5.</text>
<text top="1069" left="95" width="33" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref170">National</a></text>
<text top="1069" left="138" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref170">Clinical</a></text>
<text top="1069" left="176" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref170">Guideline</a></text>
<text top="1069" left="223" width="26" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref170">Centre</a></text>
<text top="1069" left="259" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref170">(UK).</a></text>
<text top="1082" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref170">Hypertension: The Clinical Management of Primary</a></text>
<text top="1095" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref170">Hypertension in Adults: Update of Clinical Guidelines</a></text>
<text top="143" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref170">18 and 34. London, UK: Royal College of Physicians</a></text>
<text top="156" left="301" width="42" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref170">(UK); 2011</a></text>
<text top="156" left="343" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref170">.</a></text>
<text top="176" left="301" width="30" height="9" font="4">S4.4-6.</text>
<text top="176" left="334" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref171">Asayama K, Thijs L, Li Y, et al. Setting</a></text>
<text top="189" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref171">thresholds to varying blood pressure monitoring in-</a></text>
<text top="203" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref171">tervals differentially affects risk estimates associated</a></text>
<text top="216" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref171">with white-coat and masked hypertension in the</a></text>
<text top="229" left="301" width="159" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref171">population. Hypertension. 2014;64:935</a></text>
<text top="228" left="460" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref171">–42</a></text>
<text top="229" left="474" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref171">.</a></text>
<text top="249" left="301" width="29" height="9" font="4">S4.4-7.</text>
<text top="249" left="333" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref172">Mancia G, Bombelli M, Brambilla G, et al.</a></text>
<text top="262" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref172">Long-term prognostic value of white coat hyperten-</a></text>
<text top="276" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref172">sion: an insight from diagnostic use of both ambula-</a></text>
<text top="289" left="301" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref172">tory</a></text>
<text top="289" left="327" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref172">and</a></text>
<text top="289" left="351" width="22" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref172">home</a></text>
<text top="289" left="382" width="23" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref172">blood</a></text>
<text top="289" left="414" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref172">pressure</a></text>
<text top="289" left="458" width="61" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref172">measurements.</a></text>
<text top="302" left="301" width="109" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref172">Hypertension. 2013;62:168</a></text>
<text top="301" left="410" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref172">–74</a></text>
<text top="302" left="424" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref172">.</a></text>
<text top="322" left="301" width="30" height="9" font="4">S4.4-8.</text>
<text top="322" left="334" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref173">Pierdomenico SD, Cuccurullo F. Prognostic</a></text>
<text top="335" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref173">value of white-coat and masked hypertension diag-</a></text>
<text top="348" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref173">nosed by ambulatory monitoring in initially untreated</a></text>
<text top="362" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref173">subjects: an updated meta analysis. Am J Hypertens.</a></text>
<text top="375" left="301" width="44" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref173">2011;24:52</a></text>
<text top="374" left="345" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref173">–8</a></text>
<text top="375" left="354" width="3" height="9" font="4">.</text>
<text top="395" left="301" width="30" height="9" font="4">S4.4-9.</text>
<text top="395" left="334" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref174">Viera AJ, Hinderliter AL, Kshirsagar AV, et al.</a></text>
<text top="408" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref174">Reproducibility of masked hypertension in adults with</a></text>
<text top="421" left="301" width="96" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref174">untreated borderline of</a></text>
<text top="420" left="397" width="121" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref174">ﬁce blood pressure: compari-</a></text>
<text top="435" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref174">son of ambulatory and home monitoring. Am J</a></text>
<text top="448" left="301" width="101" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref174">Hypertens. 2010;23:1190</a></text>
<text top="447" left="402" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref174">–7</a></text>
<text top="448" left="411" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref174">.</a></text>
<text top="468" left="301" width="34" height="9" font="4">S4.4-10.</text>
<text top="468" left="338" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref175">Viera AJ, Lin F-C, Tuttle LA, et al. Repro-</a></text>
<text top="481" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref175">ducibility of masked hypertension among adults 30</a></text>
<text top="494" left="301" width="191" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref175">years or older. Blood Press Monit. 2014;19:208</a></text>
<text top="493" left="492" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref175">–15</a></text>
<text top="494" left="505" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref175">.</a></text>
<text top="514" left="301" width="32" height="9" font="4">S4.4-11.</text>
<text top="514" left="336" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref176">Stergiou GS, Asayama K, Thijs L, et al. Prognosis</a></text>
<text top="527" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref176">of white-coat and masked hypertension: International</a></text>
<text top="541" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref176">Database of Home Blood Pressure in Relation to Car-</a></text>
<text top="554" left="301" width="193" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref176">diovascular Outcome. Hypertension. 2014;63:675</a></text>
<text top="552" left="494" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref176">–82</a></text>
<text top="554" left="508" width="3" height="9" font="4">.</text>
<text top="573" left="301" width="33" height="9" font="4">S4.4-12.</text>
<text top="573" left="337" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref177">Tomiyama M, Horio T, Yoshii M, et al. Masked</a></text>
<text top="587" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref177">hypertension and target organ damage in treated hy-</a></text>
<text top="600" left="301" width="205" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref177">pertensive patients. Am J Hypertens. 2006;19:880</a></text>
<text top="598" left="506" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref177">–6</a></text>
<text top="600" left="516" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref177">.</a></text>
<text top="619" left="301" width="33" height="9" font="4">S4.4-13.</text>
<text top="619" left="337" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref178">Perloff D, Sokolow M, Cowan R. The prog-</a></text>
<text top="633" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref178">nostic value of ambulatory blood pressures. JAMA.</a></text>
<text top="646" left="301" width="61" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref178">1983;249:2792</a></text>
<text top="645" left="362" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref178">–8</a></text>
<text top="646" left="371" width="3" height="9" font="4">.</text>
<text top="665" left="301" width="34" height="9" font="4">S4.4-14.</text>
<text top="665" left="338" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref179">Pickering TG, Davidson K, Gerin W, et al.</a></text>
<text top="679" left="301" width="203" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref179">Masked hypertension. Hypertension. 2002;40:795</a></text>
<text top="677" left="504" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref179">–6</a></text>
<text top="679" left="513" width="3" height="9" font="4">.</text>
<text top="698" left="301" width="33" height="9" font="4">S4.4-15.</text>
<text top="698" left="337" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref180">Banegas JR, Ruilope LM, de la Sierra A, et al.</a></text>
<text top="711" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref180">High prevalence of masked uncontrolled hypertension</a></text>
<text top="725" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref180">in people with treated hypertension. Eur Heart J. 2014;</a></text>
<text top="738" left="301" width="33" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref180">35:3304</a></text>
<text top="737" left="334" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref180">–12</a></text>
<text top="738" left="347" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref180">.</a></text>
<text top="757" left="301" width="34" height="9" font="4">S4.4-16.</text>
<text top="757" left="338" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref181">Gorostidi M, Vinyoles E, Banegas JR, et al.</a></text>
<text top="771" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref181">Prevalence of white-coat and masked hypertension in</a></text>
<text top="784" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref181">national and international registries. Hypertens Res.</a></text>
<text top="798" left="301" width="39" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref181">2015;38:1</a></text>
<text top="796" left="340" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref181">–7</a></text>
<text top="798" left="348" width="3" height="9" font="4">.</text>
<text top="817" left="301" width="33" height="9" font="4">S4.4-17.</text>
<text top="817" left="337" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref182">Calhoun DA, Jones D, Textor S, et al. Resis-</a></text>
<text top="830" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref182">tant hypertension: diagnosis, evaluation, and treat-</a></text>
<text top="844" left="301" width="60" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref182">ment: a scienti</a></text>
<text top="842" left="361" width="157" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref182">ﬁc statement from the American Heart</a></text>
<text top="857" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref182">Association Professional Education Committee of the</a></text>
<text top="871" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref182">Council for High Blood Pressure Research. Hyperten-</a></text>
<text top="884" left="301" width="78" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref182">sion. 2008;51:1403</a></text>
<text top="883" left="379" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref182">–19</a></text>
<text top="884" left="392" width="3" height="9" font="4">.</text>
<text top="903" left="301" width="34" height="9" font="4">S4.4-18.</text>
<text top="903" left="338" width="6" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref183">O</a></text>
<text top="902" left="344" width="174" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref183">’Brien E, Parati G, Stergiou G, et al. Euro-</a></text>
<text top="917" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref183">pean Society of Hypertension position paper on</a></text>
<text top="930" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref183">ambulatory blood pressure monitoring. J Hypertens.</a></text>
<text top="944" left="301" width="50" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref183">2013;31:1731</a></text>
<text top="942" left="351" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref183">–68</a></text>
<text top="944" left="366" width="3" height="9" font="4">.</text>
<text top="963" left="301" width="34" height="9" font="4">S4.4-19.</text>
<text top="963" left="338" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref184">Wang YC, Shimbo D, Muntner P, et al. Prev-</a></text>
<text top="976" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref184">alence of masked hypertension among US Adults with</a></text>
<text top="990" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref184">nonelevated clinic blood pressure. Am J Epidemiol.</a></text>
<text top="1003" left="301" width="53" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref184">2017;185:194</a></text>
<text top="1002" left="354" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref184">–202</a></text>
<text top="1003" left="374" width="3" height="9" font="4">.</text>
<text top="1022" left="301" width="35" height="9" font="4">S4.4-20.</text>
<text top="1022" left="339" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref185">Peacock J, Diaz KM, Viera AJ, et al.</a></text>
<text top="1036" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref185">Unmasking masked hypertension: prevalence, clinical</a></text>
<text top="1049" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref185">implications, diagnosis, correlates and future di-</a></text>
<text top="1063" left="301" width="162" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref185">rections. J Hum Hypertens. 2014;28:521</a></text>
<text top="1061" left="463" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref185">–8</a></text>
<text top="1063" left="472" width="3" height="9" font="4">.</text>
<text top="1082" left="301" width="33" height="9" font="4">S4.4-21.</text>
<text top="1082" left="337" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref186">Conen D, Aeschbacher S, Thijs L, et al. Age-</a></text>
<text top="1095" left="301" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref186">speci</a></text>
<text top="1094" left="321" width="197" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref186">ﬁc differences between conventional and</a></text>
<text top="143" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref186">ambulatory daytime blood pressure values. Hyper-</a></text>
<text top="156" left="539" width="90" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref186">tension. 2014;64:1073</a></text>
<text top="155" left="629" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref186">–9</a></text>
<text top="156" left="639" width="3" height="9" font="4">.</text>
<text top="173" left="539" width="34" height="9" font="4">S4.4-22.</text>
<text top="173" left="576" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref187">Alwan H, Pruijm M, Ponte B, et al. Epidemi-</a></text>
<text top="187" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref187">ology of masked and white-coat hypertension: the</a></text>
<text top="200" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref187">family-based SKIPOGH study. PLoS ONE. 2014;9:</a></text>
<text top="214" left="539" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref187">e92522</a></text>
<text top="214" left="569" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref187">.</a></text>
<text top="231" left="539" width="34" height="9" font="4">S4.4-23.</text>
<text top="231" left="576" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref188">Shimbo D, Newman JD, Schwartz JE. Masked</a></text>
<text top="244" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref188">hypertension and prehypertension: diagnostic overlap</a></text>
<text top="258" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref188">and interrelationships with left ventricular mass: the</a></text>
<text top="271" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref188">Masked Hypertension Study. Am J Hypertens. 2012;25:</a></text>
<text top="285" left="539" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref188">664</a></text>
<text top="283" left="556" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref188">–71</a></text>
<text top="285" left="568" width="3" height="9" font="4">.</text>
<text top="302" left="539" width="35" height="9" font="4">S4.4-24.</text>
<text top="302" left="577" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref189">Franklin SS, Thijs L, Asayama K, et al. The</a></text>
<text top="315" left="539" width="113" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref189">cardiovascular risk of white</a></text>
<text top="314" left="652" width="105" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref189">–coat hypertension. J Am</a></text>
<text top="329" left="539" width="109" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref189">Coll Cardiol. 2016;68:2033</a></text>
<text top="327" left="648" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref189">–43</a></text>
<text top="329" left="663" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref189">.</a></text>
<text top="346" left="539" width="34" height="9" font="4">S4.4-25.</text>
<text top="346" left="576" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref190">Tientcheu D, Ayers C, Das SR, et al. Target</a></text>
<text top="359" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref190">organ complications and cardiovascular events asso-</a></text>
<text top="373" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref190">ciated with masked hypertension and white-coat hy-</a></text>
<text top="386" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref190">pertension: analysis from the Dallas Heart Study. J Am</a></text>
<text top="399" left="539" width="107" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref190">Coll Cardiol. 2015;66:2159</a></text>
<text top="398" left="646" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref190">–69</a></text>
<text top="399" left="661" width="3" height="9" font="4">.</text>
<text top="418" left="539" width="35" height="9" font="4">S4.4-26.</text>
<text top="418" left="577" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref191">Briasoulis A, Androulakis E, Palla M, et al.</a></text>
<text top="431" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref191">White-coat hypertension and cardiovascular events: a</a></text>
<text top="445" left="539" width="165" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref191">meta-analysis. J Hypertens. 2016;34:593</a></text>
<text top="443" left="704" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref191">–9</a></text>
<text top="445" left="714" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref191">.</a></text>
<text top="463" left="539" width="34" height="9" font="4">S4.4-27.</text>
<text top="463" left="576" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref192">Siu AL, U.S. Preventive Services Task Force.</a></text>
<text top="477" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref192">Screening for high blood pressure in adults: U.S. Pre-</a></text>
<text top="490" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref192">ventive Services Task Force recommendation state-</a></text>
<text top="504" left="539" width="148" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref192">ment. Ann Intern Med. 2015;163:778</a></text>
<text top="502" left="688" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref192">–86</a></text>
<text top="504" left="703" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref192">.</a></text>
<text top="521" left="539" width="35" height="9" font="4">S4.4-28.</text>
<text top="521" left="577" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref193">Bayo J, Cos FX, Roca C, et al. Home blood</a></text>
<text top="534" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref193">pressure self-monitoring: diagnostic performance in</a></text>
<text top="548" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref193">white-coat hypertension. Blood Press Monit. 2006;11:</a></text>
<text top="561" left="539" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref193">47</a></text>
<text top="560" left="549" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref193">–52</a></text>
<text top="561" left="563" width="3" height="9" font="4">.</text>
<text top="578" left="539" width="35" height="9" font="4">S4.4-29.</text>
<text top="578" left="577" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref194">Nasothimiou EG, Tzamouranis D, Rarra V,</a></text>
<text top="592" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref194">et al. Diagnostic accuracy of home vs. ambulatory</a></text>
<text top="605" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref194">blood pressure monitoring in untreated and treated</a></text>
<text top="619" left="539" width="171" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref194">hypertension. Hypertens Res. 2012;35:750</a></text>
<text top="617" left="710" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref194">–5</a></text>
<text top="619" left="719" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref194">.</a></text>
<text top="636" left="539" width="35" height="9" font="4">S4.4-30.</text>
<text top="636" left="578" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref195">Sega R, Trocino G, Lanzarotti A, et al. Alter-</a></text>
<text top="649" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref195">ations of cardiac structure in patients with isolated</a></text>
<text top="662" left="539" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref195">of</a></text>
<text top="661" left="548" width="209" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref195">ﬁce, ambulatory, or home hypertension: data from</a></text>
<text top="676" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref195">the general population (Pressione Arteriose Moni-</a></text>
<text top="689" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref195">torate E Loro Associazioni [PAMELA] Study). Circula-</a></text>
<text top="703" left="539" width="81" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref195">tion. 2001;104:1385</a></text>
<text top="701" left="621" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref195">–92</a></text>
<text top="703" left="635" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref195">.</a></text>
<text top="720" left="539" width="33" height="9" font="4">S4.4-31.</text>
<text top="720" left="575" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref196">Hansen TW, Kikuya M, Thijs L, et al.</a></text>
<text top="733" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref196">Prognostic superiority of daytime ambulatory over</a></text>
<text top="747" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref196">conventional blood pressure in four populations: a</a></text>
<text top="760" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref196">meta-analysis of 7,030 individuals. J Hypertens. 2007;</a></text>
<text top="774" left="539" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref196">25:1554</a></text>
<text top="772" left="571" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref196">–64</a></text>
<text top="774" left="585" width="3" height="9" font="4">.</text>
<text top="791" left="539" width="34" height="9" font="4">S4.4-32.</text>
<text top="791" left="576" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref197">Diaz KM, Veerabhadrappa P, Brown MD, et al.</a></text>
<text top="804" left="539" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref197">Prevalence, determinants, and clinical signi</a></text>
<text top="803" left="716" width="40" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref197">ﬁcance of</a></text>
<text top="818" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref197">masked hypertension in a population-based sample of</a></text>
<text top="831" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref197">African Americans: the Jackson Heart Study. Am J</a></text>
<text top="845" left="539" width="99" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref197">Hypertens. 2015;28:900</a></text>
<text top="843" left="639" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref197">–8</a></text>
<text top="845" left="648" width="3" height="9" font="4">.</text>
<text top="862" left="539" width="34" height="9" font="4">S4.4-33.</text>
<text top="862" left="576" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref198">Andalib A, Akhtari S, Rigal R, et al. De-</a></text>
<text top="875" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref198">terminants of masked hypertension in hypertensive</a></text>
<text top="888" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref198">patients treated in a primary care setting. Intern Med J.</a></text>
<text top="902" left="539" width="52" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref198">2012;42:260</a></text>
<text top="900" left="591" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref198">–6</a></text>
<text top="902" left="600" width="3" height="9" font="4">.</text>
<text top="919" left="539" width="35" height="9" font="4">S4.4-34.</text>
<text top="919" left="577" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref199">Terawaki H, Metoki H, Nakayama M, et al.</a></text>
<text top="932" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref199">Masked hypertension determined by self-measured</a></text>
<text top="946" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref199">blood pressure at home and chronic kidney disease in</a></text>
<text top="959" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref199">the Japanese general population: the Ohasama study.</a></text>
<text top="973" left="539" width="119" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref199">Hypertens Res. 2008;31:2129</a></text>
<text top="971" left="658" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref199">–35</a></text>
<text top="973" left="672" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref199">.</a></text>
<text top="1013" left="539" width="187" height="12" font="26">5 . C A U S E S O F H Y P E R T E N S I O N</text>
<text top="1043" left="539" width="121" height="9" font="23">5.1. Genetic Predisposition</text>
<text top="1067" left="539" width="25" height="9" font="4">S5.1-1.</text>
<text top="1067" left="568" width="189" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref200">Kaplan NM. Primary hypertension: pathogen-</a></text>
<text top="1081" left="539" width="63" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref200">esis. In: Kaplan</a></text>
<text top="1079" left="602" width="154" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref200">’s Clinical Hypertension. Philadelphia,</a></text>
<text top="1094" left="539" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref200">PA: Lippincott Williams &amp; Wilkins; 2006:50</a></text>
<text top="1092" left="715" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref200">–121</a></text>
<text top="1094" left="731" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref200">.</a></text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="18" height="9" font="4">e215</text>
</page>
<page number="90" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="26" height="9" font="4">S5.1-2.</text>
<text top="143" left="137" width="89" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref201">Padmanabhan S, Caul</a></text>
<text top="141" left="226" width="99" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref201">ﬁeld M, Dominiczak AF.</a></text>
<text top="156" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref201">Genetic and molecular aspects of hypertension. Circ</a></text>
<text top="170" left="108" width="72" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref201">Res. 2015;116:937</a></text>
<text top="168" left="180" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref201">–59</a></text>
<text top="170" left="194" width="3" height="9" font="4">.</text>
<text top="188" left="108" width="26" height="9" font="4">S5.1-3.</text>
<text top="188" left="137" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref202">Lifton RP, Gharavi AG, Geller DS. Molecular</a></text>
<text top="202" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref202">mechanisms of human hypertension. Cell. 2001;104:</a></text>
<text top="215" left="108" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref202">545</a></text>
<text top="214" left="123" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref202">–56</a></text>
<text top="215" left="137" width="3" height="9" font="4">.</text>
<text top="234" left="108" width="27" height="9" font="4">S5.1-4.</text>
<text top="234" left="138" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref203">Dominiczak AF, Kuo D. Hypertension: update</a></text>
<text top="247" left="108" width="124" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref203">2017. Hypertension. 2017;69:3</a></text>
<text top="246" left="231" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref203">–4</a></text>
<text top="247" left="241" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref203">.</a></text>
<text top="266" left="108" width="26" height="9" font="4">S5.1-5.</text>
<text top="266" left="137" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref204">Ference BA, Julius S, Mahajan N, et al. Clinical</a></text>
<text top="279" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref204">effect of naturally random allocation to lower systolic</a></text>
<text top="293" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref204">blood pressure beginning before the development of</a></text>
<text top="306" left="108" width="170" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref204">hypertension. Hypertension. 2014;63:1182</a></text>
<text top="305" left="277" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref204">–8</a></text>
<text top="306" left="287" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref204">.</a></text>
<text top="328" left="108" width="146" height="9" font="23">5.2. Environmental Risk Factors</text>
<text top="352" left="108" width="26" height="9" font="4">S5.2-1.</text>
<text top="352" left="137" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref205">Savica V, Bellinghieri G, Kopple JD. The effect</a></text>
<text top="365" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref205">of nutrition on blood pressure. Annu Rev Nutr. 2010;</a></text>
<text top="379" left="108" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref205">30:365</a></text>
<text top="377" left="136" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref205">–401</a></text>
<text top="379" left="155" width="3" height="9" font="4">.</text>
<text top="397" left="108" width="27" height="9" font="4">S5.2-2.</text>
<text top="397" left="138" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref206">Chan Q, Stamler J, Griep LMO, et al. An update</a></text>
<text top="410" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref206">on nutrients and blood pressure. J Atheroscler</a></text>
<text top="424" left="108" width="87" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref206">Thromb. 2016;23:276</a></text>
<text top="422" left="194" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref206">–89</a></text>
<text top="424" left="209" width="3" height="9" font="4">.</text>
<text top="443" left="108" width="27" height="9" font="4">S5.2-3.</text>
<text top="443" left="138" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref207">Tang WHW, Kitai T, Hazen SL. Gut microbiota in</a></text>
<text top="456" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref207">cardiovascular health and disease. Circ Res. 2017;120:</a></text>
<text top="469" left="108" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref207">1183</a></text>
<text top="468" left="125" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref207">–96</a></text>
<text top="469" left="141" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref207">.</a></text>
<text top="491" left="108" width="136" height="9" font="4">5.2.1. Overweight and Obesity</text>
<text top="506" left="108" width="34" height="9" font="4">S5.2.5-1.</text>
<text top="506" left="144" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref208">Bray GA. Life insurance and overweight. Obes</a></text>
<text top="519" left="108" width="60" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref208">Res. 1995;3:97</a></text>
<text top="518" left="167" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref208">–9</a></text>
<text top="519" left="177" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref208">.</a></text>
<text top="538" left="108" width="35" height="9" font="4">S5.2.5-2.</text>
<text top="538" left="145" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref209">Harsha DW, Bray GA. Weight loss and blood</a></text>
<text top="551" left="108" width="206" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref209">pressure control (Pro). Hypertension. 2008;51:1420</a></text>
<text top="550" left="313" width="11" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref209">–5;</a></text>
<text top="565" left="108" width="62" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref209">discussion 1425</a></text>
<text top="565" left="170" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref209">.</a></text>
<text top="583" left="108" width="35" height="9" font="4">S5.2.5-3.</text>
<text top="583" left="145" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref210">Hubert HB, Feinleib M, McNamara PM, et al.</a></text>
<text top="597" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref210">Obesity as an independent risk factor for cardiovascular</a></text>
<text top="610" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref210">disease: a 26-year follow-up of participants in the</a></text>
<text top="624" left="108" width="201" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref210">Framingham Heart Study. Circulation. 1983;67:968</a></text>
<text top="622" left="309" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref210">–77</a></text>
<text top="624" left="322" width="3" height="9" font="4">.</text>
<text top="642" left="108" width="35" height="9" font="4">S5.2.5-4.</text>
<text top="642" left="146" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref211">Huang Z, Willett WC, Manson JE, et al. Body</a></text>
<text top="656" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref211">weight, weight change, and risk for hypertension in</a></text>
<text top="669" left="108" width="152" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref211">women. Ann Intern Med. 1998;128:81</a></text>
<text top="667" left="260" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref211">–8</a></text>
<text top="669" left="270" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref211">.</a></text>
<text top="688" left="108" width="35" height="9" font="4">S5.2.5-5.</text>
<text top="688" left="145" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref212">Hall JE. The kidney, hypertension, and</a></text>
<text top="701" left="108" width="144" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref212">obesity. Hypertension. 2003;41:625</a></text>
<text top="699" left="252" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref212">–33</a></text>
<text top="701" left="265" width="3" height="9" font="4">.</text>
<text top="720" left="108" width="35" height="9" font="4">S5.2.5-6.</text>
<text top="720" left="146" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref213">Jones DW, Kim JS, Andrew ME, et al. Body</a></text>
<text top="733" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref213">mass index and blood pressure in Korean men and</a></text>
<text top="746" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref213">women: the Korean National Blood Pressure Survey.</a></text>
<text top="760" left="108" width="106" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref213">J Hypertens. 1994;12:1433</a></text>
<text top="758" left="214" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref213">–7</a></text>
<text top="760" left="222" width="3" height="9" font="4">.</text>
<text top="778" left="108" width="35" height="9" font="4">S5.2.5-7.</text>
<text top="778" left="145" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref214">Mertens IL, Van Gaal LF. Overweight, obesity,</a></text>
<text top="792" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref214">and blood pressure: the effects of modest weight</a></text>
<text top="805" left="108" width="135" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref214">reduction. Obes Res. 2000;8:270</a></text>
<text top="804" left="243" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref214">–8</a></text>
<text top="805" left="252" width="3" height="9" font="4">.</text>
<text top="824" left="108" width="35" height="9" font="4">S5.2.5-8.</text>
<text top="824" left="146" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref215">Garrison RJ, Kannel WB, Stokes J 3rd, et al.</a></text>
<text top="837" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref215">Incidence and precursors of hypertension in young</a></text>
<text top="851" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref215">adults: the Framingham Offspring Study. Prev Med.</a></text>
<text top="864" left="108" width="49" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref215">1987;16:235</a></text>
<text top="863" left="156" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref215">–51</a></text>
<text top="864" left="169" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref215">.</a></text>
<text top="883" left="108" width="35" height="9" font="4">S5.2.5-9.</text>
<text top="883" left="146" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref216">Forman JP, Stampfer MJ, Curhan GC. Diet</a></text>
<text top="896" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref216">and lifestyle risk factors associated with incident hy-</a></text>
<text top="910" left="108" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref216">pertension in women. JAMA. 2009;302:401</a></text>
<text top="908" left="285" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref216">–11</a></text>
<text top="910" left="296" width="3" height="9" font="4">.</text>
<text top="928" left="108" width="40" height="9" font="4">S5.2.5-10.</text>
<text top="928" left="150" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref217">Juonala M, Magnussen CG, Berenson GS,</a></text>
<text top="942" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref217">et al. Childhood adiposity, adult adiposity, and cardio-</a></text>
<text top="955" left="108" width="199" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref217">vascular risk factors. N Engl J Med. 2011;365:1876</a></text>
<text top="953" left="306" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref217">–85</a></text>
<text top="955" left="321" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref217">.</a></text>
<text top="977" left="108" width="93" height="9" font="4">5.2.2. Sodium Intake</text>
<text top="992" left="108" width="37" height="9" font="4">S5.2.5-11.</text>
<text top="992" left="148" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref218">Klag MJ, He J, Coresh J, et al. The contri-</a></text>
<text top="1005" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref218">bution of urinary cations to the blood pressure dif-</a></text>
<text top="1018" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref218">ferences associated with migration. Am J Epidemiol.</a></text>
<text top="1032" left="108" width="54" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref218">1995;142:295</a></text>
<text top="1030" left="162" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref218">–303</a></text>
<text top="1032" left="181" width="3" height="9" font="4">.</text>
<text top="1050" left="108" width="38" height="9" font="4">S5.2.5-12.</text>
<text top="1050" left="149" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref219">Intersalt: an international study of electro-</a></text>
<text top="1064" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref219">lyte excretion and blood pressure. Results for 24 hour</a></text>
<text top="1077" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref219">urinary sodium and potassium excretion. Intersalt</a></text>
<text top="1091" left="108" width="197" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref219">Cooperative Research Group. BMJ. 1988;297:319</a></text>
<text top="1089" left="304" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref219">–28</a></text>
<text top="1091" left="319" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref219">.</a></text>
<text top="143" left="346" width="38" height="9" font="4">S5.2.5-13.</text>
<text top="143" left="387" width="45" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref220">Mente A, O</a></text>
<text top="141" left="433" width="130" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref220">’Donnell MJ, Rangarajan S, et al.</a></text>
<text top="156" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref220">Association of urinary sodium and potassium excretion</a></text>
<text top="170" left="346" width="199" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref220">with blood pressure. N Engl J Med. 2014;371:601</a></text>
<text top="168" left="545" width="11" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref220">–11</a></text>
<text top="170" left="557" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref220">.</a></text>
<text top="187" left="346" width="39" height="9" font="4">S5.2.5-14.</text>
<text top="187" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref221">Elliott P, Stamler J, Nichols R, et al. Intersalt</a></text>
<text top="200" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref221">revisited: further analyses of 24 hour sodium excretion</a></text>
<text top="214" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref221">and blood pressure within and across populations.</a></text>
<text top="227" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref221">Intersalt Cooperative Research Group. BMJ. 1996;312:</a></text>
<text top="241" left="346" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref221">1249</a></text>
<text top="239" left="365" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref221">–53</a></text>
<text top="241" left="379" width="3" height="9" font="4">.</text>
<text top="258" left="346" width="38" height="9" font="4">S5.2.5-15.</text>
<text top="258" left="387" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref222">Takase H, Sugiura T, Kimura G, et al. Dietary</a></text>
<text top="271" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref222">sodium consumption predicts future blood pressure and</a></text>
<text top="285" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref222">incident hypertension in the Japanese normotensive</a></text>
<text top="298" left="346" width="215" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref222">general population. J Am Heart Assoc. 2015;4:e001959</a></text>
<text top="298" left="560" width="3" height="9" font="4">.</text>
<text top="315" left="346" width="39" height="9" font="4">S5.2.5-16.</text>
<text top="315" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref223">Stamler J. The INTERSALT study: back-</a></text>
<text top="329" left="346" width="71" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref223">ground, methods,</a></text>
<text top="327" left="419" width="144" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref223">ﬁndings, and implications. Am J Clin</a></text>
<text top="342" left="346" width="79" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref223">Nutr. 1997;65:626S</a></text>
<text top="340" left="425" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref223">–42S</a></text>
<text top="342" left="444" width="3" height="9" font="4">.</text>
<text top="359" left="346" width="38" height="9" font="4">S5.2.5-17.</text>
<text top="359" left="387" width="58" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref224">Strazzullo P, D</a></text>
<text top="357" left="446" width="117" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref224">’Elia L, Kandala NB, et al. Salt</a></text>
<text top="373" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref224">intake, stroke, and cardiovascular disease: meta-</a></text>
<text top="386" left="346" width="215" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref224">analysis of prospective studies. BMJ. 2009;339:b4567</a></text>
<text top="386" left="560" width="3" height="9" font="4">.</text>
<text top="405" left="346" width="39" height="9" font="4">S5.2.5-18.</text>
<text top="405" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref225">Whelton PK. Sodium, potassium, blood</a></text>
<text top="418" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref225">pressure, and cardiovascular disease in humans. Curr</a></text>
<text top="431" left="346" width="115" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref225">Hypertens Rep. 2014;16:465</a></text>
<text top="431" left="461" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref225">.</a></text>
<text top="450" left="346" width="39" height="9" font="4">S5.2.5-19.</text>
<text top="450" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref226">Whelton PK, Appel LJ, Sacco RL, et al.</a></text>
<text top="463" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref226">Sodium, blood pressure, and cardiovascular disease:</a></text>
<text top="477" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref226">further evidence supporting the American Heart</a></text>
<text top="490" left="346" width="45" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref226">Association</a></text>
<text top="490" left="402" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref226">sodium</a></text>
<text top="490" left="441" width="38" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref226">reduction</a></text>
<text top="490" left="489" width="74" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref226">recommendations.</a></text>
<text top="504" left="346" width="109" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref226">Circulation. 2012;126:2880</a></text>
<text top="502" left="455" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref226">–9</a></text>
<text top="504" left="465" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref226">.</a></text>
<text top="522" left="346" width="40" height="9" font="4">S5.2.5-20.</text>
<text top="522" left="389" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref227">Institute of Medicine. Dietary Reference</a></text>
<text top="536" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref227">Intakes for Water, Potassium, Sodium, Chloride, and</a></text>
<text top="549" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref227">Sulfate. Washington, DC: The National Academies</a></text>
<text top="563" left="346" width="48" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref227">Press, 2005</a></text>
<text top="563" left="394" width="3" height="9" font="4">.</text>
<text top="581" left="346" width="38" height="9" font="4">S5.2.5-21.</text>
<text top="581" left="387" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref228">Weinberger MH, Miller JZ, Luft FC, et al.</a></text>
<text top="595" left="346" width="11" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref228">De</a></text>
<text top="593" left="357" width="206" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref228">ﬁnitions and characteristics of sodium sensitivity</a></text>
<text top="608" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref228">and blood pressure resistance. Hypertension. 1986;8:</a></text>
<text top="622" left="346" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref228">II127</a></text>
<text top="620" left="364" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref228">–I134</a></text>
<text top="622" left="384" width="3" height="9" font="4">.</text>
<text top="640" left="346" width="39" height="9" font="4">S5.2.5-22.</text>
<text top="640" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref229">Sanada H, Jones JE, Jose PA. Genetics of</a></text>
<text top="654" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref229">salt-sensitive hypertension. Curr Hypertens Rep. 2011;</a></text>
<text top="667" left="346" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref229">13:55</a></text>
<text top="665" left="367" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref229">–66</a></text>
<text top="667" left="382" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref229">.</a></text>
<text top="687" left="346" width="39" height="9" font="4">S5.2.5-23.</text>
<text top="687" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref230">Carey RM, Schoeffel CD, Gildea JJ, et al. Salt</a></text>
<text top="700" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref230">sensitivity of blood pressure is associated with poly-</a></text>
<text top="714" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref230">morphisms in the sodium-bicarbonate cotransporter.</a></text>
<text top="727" left="346" width="114" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref230">Hypertension. 2012;60:1359</a></text>
<text top="726" left="460" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref230">–66</a></text>
<text top="727" left="475" width="3" height="9" font="4">.</text>
<text top="747" left="346" width="40" height="9" font="4">S5.2.5-24.</text>
<text top="747" left="389" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref231">Elijovich F, Weinberger MH, Anderson CAM.</a></text>
<text top="761" left="346" width="165" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref231">Salt sensitivity of blood pressure: a scienti</a></text>
<text top="759" left="511" width="52" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref231">ﬁc statement</a></text>
<text top="774" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref231">from the American Heart Association. Hypertension.</a></text>
<text top="788" left="346" width="46" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref231">2016;68:e7</a></text>
<text top="786" left="392" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref231">–46</a></text>
<text top="788" left="407" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref231">.</a></text>
<text top="808" left="346" width="39" height="9" font="4">S5.2.5-25.</text>
<text top="808" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref232">Weinberger MH. Salt sensitivity of blood</a></text>
<text top="821" left="346" width="192" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref232">pressure in humans. Hypertension. 1996;27:481</a></text>
<text top="820" left="538" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref232">–90</a></text>
<text top="821" left="553" width="3" height="9" font="4">.</text>
<text top="840" left="346" width="40" height="9" font="4">S5.2.5-26.</text>
<text top="840" left="389" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref233">Cogswell ME, Zhang Z, Carriquiry AL, et al.</a></text>
<text top="853" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref233">Sodium and potassium intakes among US adults:</a></text>
<text top="867" left="346" width="201" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref233">NHANES 2003-2008. Am J Clin Nutr. 2012;96:647</a></text>
<text top="865" left="547" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref233">–57</a></text>
<text top="867" left="560" width="3" height="9" font="4">.</text>
<text top="885" left="346" width="39" height="9" font="4">S5.2.5-27.</text>
<text top="885" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref234">Weinberger MH, Fineberg NS, Fineberg SE,</a></text>
<text top="899" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref234">et al. Salt sensitivity, pulse pressure, and death in</a></text>
<text top="912" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref234">normal and hypertensive humans. Hypertension. 2001;</a></text>
<text top="925" left="346" width="28" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref234">37:429</a></text>
<text top="924" left="374" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref234">–32</a></text>
<text top="925" left="387" width="3" height="9" font="4">.</text>
<text top="944" left="346" width="40" height="9" font="4">S5.2.5-28.</text>
<text top="944" left="389" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref235">Morimoto A, Uzu T, Fujii T, et al. Sodium</a></text>
<text top="957" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref235">sensitivity and cardiovascular events in patients with</a></text>
<text top="971" left="346" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref235">essential hypertension. Lancet. 1997;350:1734</a></text>
<text top="969" left="532" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref235">–7</a></text>
<text top="971" left="541" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref235">.</a></text>
<text top="989" left="346" width="40" height="9" font="4">S5.2.5-29.</text>
<text top="989" left="389" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref236">Gu D, Zhao Q, Chen J, et al. Reproducibility</a></text>
<text top="1003" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref236">of blood pressure responses to dietary sodium and</a></text>
<text top="1016" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref236">potassium interventions: the GenSalt study. Hyper-</a></text>
<text top="1030" left="346" width="86" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref236">tension. 2013;62:499</a></text>
<text top="1028" left="432" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref236">–505</a></text>
<text top="1030" left="452" width="3" height="9" font="4">.</text>
<text top="1053" left="346" width="74" height="9" font="4">5.2.3. Potassium</text>
<text top="1068" left="346" width="40" height="9" font="4">S5.2.5-30.</text>
<text top="1068" left="389" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref237">Poulter N, Khaw KT, Hopwood BE, et al.</a></text>
<text top="1081" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref237">Blood pressure and associated factors in a rural Kenyan</a></text>
<text top="1095" left="346" width="155" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref237">community. Hypertension. 1984;6:810</a></text>
<text top="1093" left="501" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref237">–3</a></text>
<text top="1095" left="510" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref237">.</a></text>
<text top="143" left="584" width="38" height="9" font="4">S5.2.5-31.</text>
<text top="143" left="626" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref238">He J, Tell GS, Tang YC, et al. Relation of</a></text>
<text top="156" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref238">electrolytes to blood pressure in men. The Yi people</a></text>
<text top="170" left="584" width="133" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref238">study. Hypertension. 1991;17:378</a></text>
<text top="168" left="717" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref238">–85</a></text>
<text top="170" left="732" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref238">.</a></text>
<text top="189" left="584" width="39" height="9" font="4">S5.2.5-32.</text>
<text top="189" left="627" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref239">Zhang Z, Cogswell ME, Gillespie C, et al. As-</a></text>
<text top="203" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref239">sociation between usual sodium and potassium intake</a></text>
<text top="216" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref239">and blood pressure and hypertension among U.S. adults:</a></text>
<text top="230" left="584" width="58" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref239">NHANES 2005</a></text>
<text top="228" left="642" width="132" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref239">–2010. PLoS ONE. 2013;8:e75289</a></text>
<text top="230" left="773" width="3" height="9" font="4">.</text>
<text top="249" left="584" width="39" height="9" font="4">S5.2.5-33.</text>
<text top="249" left="627" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref240">Kieneker LM, Gansevoort RT, Mukamal KJ,</a></text>
<text top="263" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref240">et al. Urinary potassium excretion and risk of devel-</a></text>
<text top="276" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref240">oping hypertension: the prevention of renal and</a></text>
<text top="290" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref240">vascular end-stage disease study. Hypertension. 2014;</a></text>
<text top="303" left="584" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref240">64:769</a></text>
<text top="301" left="614" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref240">–76</a></text>
<text top="303" left="628" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref240">.</a></text>
<text top="322" left="584" width="40" height="9" font="4">S5.2.5-34.</text>
<text top="322" left="627" width="6" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref241">D</a></text>
<text top="321" left="634" width="168" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref241">’Elia L, Barba G, Cappuccio FP, et al. Po-</a></text>
<text top="336" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref241">tassium intake, stroke, and cardiovascular disease a</a></text>
<text top="349" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref241">meta-analysis of prospective studies. J Am Coll Car-</a></text>
<text top="363" left="584" width="72" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref241">diol. 2011;57:1210</a></text>
<text top="361" left="656" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref241">–9</a></text>
<text top="363" left="666" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref241">.</a></text>
<text top="382" left="584" width="39" height="9" font="4">S5.2.5-35.</text>
<text top="382" left="627" width="6" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref242">D</a></text>
<text top="381" left="633" width="169" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref242">’Elia L, Iannotta C, Sabino P, et al. Potas-</a></text>
<text top="396" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref242">sium-rich diet and risk of stroke: updated meta-anal-</a></text>
<text top="409" left="584" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref242">ysis. Nutr Metab Cardiovasc Dis. 2014;24:585</a></text>
<text top="408" left="767" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref242">–7</a></text>
<text top="409" left="776" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref242">.</a></text>
<text top="429" left="584" width="40" height="9" font="4">S5.2.5-36.</text>
<text top="429" left="627" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref243">Vinceti M, Filippini T, Crippa A, et al. Meta-</a></text>
<text top="442" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref243">analysis of potassium intake and the risk of stroke.</a></text>
<text top="455" left="584" width="144" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref243">J Am Heart Assoc. 2016;5:e004210</a></text>
<text top="455" left="728" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref243">.</a></text>
<text top="475" left="584" width="39" height="9" font="4">S5.2.5-37.</text>
<text top="475" left="627" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref244">Rodrigues SL, Baldo MP, Machado RC, et al.</a></text>
<text top="488" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref244">High potassium intake blunts the effect of elevated</a></text>
<text top="502" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref244">sodium intake on blood pressure levels. J Am Soc</a></text>
<text top="515" left="584" width="92" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref244">Hypertens. 2014;8:232</a></text>
<text top="514" left="676" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref244">–8</a></text>
<text top="515" left="686" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref244">.</a></text>
<text top="535" left="584" width="40" height="9" font="4">S5.2.5-38.</text>
<text top="535" left="627" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref245">Khaw KT, Barrett-Connor E. The association</a></text>
<text top="548" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref245">between blood pressure, age, and dietary sodium and</a></text>
<text top="562" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref245">potassium: a population study. Circulation. 1988;77:</a></text>
<text top="575" left="584" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref245">53</a></text>
<text top="573" left="594" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref245">–61</a></text>
<text top="575" left="607" width="3" height="9" font="4">.</text>
<text top="595" left="584" width="40" height="9" font="4">S5.2.5-39.</text>
<text top="595" left="627" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref246">Cook NR, Obarzanek E, Cutler JA, et al.</a></text>
<text top="608" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref246">Joint effects of sodium and potassium intake on sub-</a></text>
<text top="621" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref246">sequent cardiovascular disease: the Trials of Hyper-</a></text>
<text top="635" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref246">tension Prevention follow-up study. Arch Intern Med.</a></text>
<text top="648" left="584" width="52" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref246">2009;169:32</a></text>
<text top="647" left="637" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref246">–40</a></text>
<text top="648" left="652" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref246">.</a></text>
<text top="670" left="584" width="101" height="9" font="4">5.2.4. Physical Fitness</text>
<text top="686" left="584" width="41" height="9" font="4">S5.2.5-40.</text>
<text top="686" left="629" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref247">Lesniak KT, Dubbert PM. Exercise and hy-</a></text>
<text top="699" left="584" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref247">pertension. Curr Opin Cardiol. 2001;16:356</a></text>
<text top="698" left="757" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref247">–9</a></text>
<text top="699" left="767" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref247">.</a></text>
<text top="719" left="584" width="39" height="9" font="4">S5.2.5-41.</text>
<text top="719" left="627" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref248">Hayashi T, Tsumura K, Suematsu C, et al.</a></text>
<text top="732" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref248">Walking to work and the risk for hypertension in men:</a></text>
<text top="746" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref248">the Osaka Health Survey. Ann Intern Med. 1999;131:</a></text>
<text top="759" left="584" width="9" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref248">21</a></text>
<text top="757" left="593" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref248">–6</a></text>
<text top="759" left="602" width="3" height="9" font="4">.</text>
<text top="778" left="584" width="40" height="9" font="4">S5.2.5-42.</text>
<text top="778" left="627" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref249">Leary AC, Donnan PT, MacDonald TM, et al.</a></text>
<text top="792" left="584" width="25" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref249">The in</a></text>
<text top="790" left="609" width="192" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref249">ﬂuence of physical activity on the variability of</a></text>
<text top="805" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref249">ambulatory blood pressure. Am J Hypertens. 2000;13:</a></text>
<text top="819" left="584" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref249">1067</a></text>
<text top="817" left="604" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref249">–73</a></text>
<text top="819" left="617" width="3" height="9" font="4">.</text>
<text top="838" left="584" width="40" height="9" font="4">S5.2.5-43.</text>
<text top="838" left="627" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref250">Carnethon MR, Gidding SS, Nehgme R, et al.</a></text>
<text top="852" left="584" width="68" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref250">Cardiorespiratory</a></text>
<text top="850" left="656" width="145" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref250">ﬁtness in young adulthood and the</a></text>
<text top="865" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref250">development of cardiovascular disease risk factors.</a></text>
<text top="879" left="584" width="93" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref250">JAMA. 2003;290:3092</a></text>
<text top="877" left="677" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref250">–100</a></text>
<text top="879" left="697" width="3" height="9" font="4">.</text>
<text top="898" left="584" width="41" height="9" font="4">S5.2.5-44.</text>
<text top="898" left="628" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref251">Liu J, Sui X, Lavie CJ, et al. Effects of</a></text>
<text top="911" left="584" width="67" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref251">cardiorespiratory</a></text>
<text top="910" left="655" width="146" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref251">ﬁtness on blood pressure trajectory</a></text>
<text top="925" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref251">with aging in a cohort of healthy men. J Am Coll</a></text>
<text top="938" left="584" width="89" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref251">Cardiol. 2014;64:1245</a></text>
<text top="937" left="673" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref251">–53</a></text>
<text top="938" left="686" width="3" height="9" font="4">.</text>
<text top="960" left="584" width="61" height="9" font="4">5.2.5. Alcohol</text>
<text top="976" left="584" width="40" height="9" font="4">S5.2.5-45.</text>
<text top="976" left="627" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref252">Lian C. L</a></text>
<text top="974" left="663" width="138" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref252">’alcoholisme cause d’hypertension</a></text>
<text top="989" left="584" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref252">arterielle. Bull Acad Med (Paris). 1915;74:525</a></text>
<text top="988" left="765" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref252">–8</a></text>
<text top="989" left="775" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref252">.</a></text>
<text top="1009" left="584" width="41" height="9" font="4">S5.2.5-46.</text>
<text top="1009" left="628" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref253">Klatsky AL. Alcohol and cardiovascular</a></text>
<text top="1022" left="584" width="154" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref253">mortality: common sense and scienti</a></text>
<text top="1020" left="738" width="63" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref253">ﬁc truth. J Am</a></text>
<text top="1036" left="584" width="106" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref253">Coll Cardiol. 2010;55:1336</a></text>
<text top="1034" left="691" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref253">–8</a></text>
<text top="1036" left="700" width="3" height="9" font="4">.</text>
<text top="1057" left="584" width="203" height="9" font="23">5.3. Childhood Risk Factors and BP Tracking</text>
<text top="1082" left="584" width="26" height="9" font="4">S5.3-1.</text>
<text top="1082" left="614" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref254">Chen X, Wang Y. Tracking of blood pressure</a></text>
<text top="1095" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref254">from childhood to adulthood: a systematic review</a></text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e216</text>
</page>
<page number="91" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref254">and meta-regression analysis. Circulation. 2008;117:</a></text>
<text top="156" left="63" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref254">3171</a></text>
<text top="155" left="80" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref254">–80</a></text>
<text top="156" left="95" width="3" height="9" font="4">.</text>
<text top="175" left="63" width="27" height="9" font="4">S5.3-2.</text>
<text top="175" left="93" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref255">Juhola J, Oikonen M, Magnussen CG, et al.</a></text>
<text top="188" left="63" width="40" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref255">Childhood</a></text>
<text top="188" left="113" width="35" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref255">physical,</a></text>
<text top="188" left="157" width="60" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref255">environmental,</a></text>
<text top="188" left="226" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref255">and</a></text>
<text top="188" left="251" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref255">genetic</a></text>
<text top="202" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref255">predictors of adult hypertension: the cardiovascular</a></text>
<text top="215" left="63" width="205" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref255">risk in young Finns study. Circulation. 2012;126:402</a></text>
<text top="214" left="268" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref255">–9</a></text>
<text top="215" left="277" width="3" height="9" font="4">.</text>
<text top="234" left="63" width="27" height="9" font="4">S5.3-3.</text>
<text top="234" left="93" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref256">Parkinson JRC, Hyde MJ, Gale C, et al. Preterm</a></text>
<text top="247" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref256">birth and the metabolic syndrome in adult life: a</a></text>
<text top="261" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref256">systematic review and meta-analysis. Pediatrics. 2013;</a></text>
<text top="274" left="63" width="40" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref256">131:e1240</a></text>
<text top="273" left="102" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref256">–63</a></text>
<text top="274" left="117" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref256">.</a></text>
<text top="293" left="63" width="28" height="9" font="4">S5.3-4.</text>
<text top="293" left="94" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref257">de Jong F, Monuteaux MC, van Elburg RM,</a></text>
<text top="306" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref257">et al. Systematic review and meta-analysis of preterm</a></text>
<text top="320" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref257">birth and later systolic blood pressure. Hypertension.</a></text>
<text top="333" left="63" width="50" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref257">2012;59:226</a></text>
<text top="331" left="113" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref257">–34</a></text>
<text top="333" left="127" width="3" height="9" font="4">.</text>
<text top="355" left="63" width="175" height="9" font="23">5.4. Secondary Forms of Hypertension</text>
<text top="379" left="63" width="27" height="9" font="4">S5.4-1.</text>
<text top="379" left="93" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref258">Calhoun DA, Jones D, Textor S, et al. Resistant</a></text>
<text top="392" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref258">hypertension: diagnosis, evaluation, and treatment: a</a></text>
<text top="405" left="63" width="26" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref258">scienti</a></text>
<text top="404" left="88" width="192" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref258">ﬁc statement from the American Heart Associ-</a></text>
<text top="419" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref258">ation Professional Education Committee of the Council</a></text>
<text top="432" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref258">for High Blood Pressure Research. Hypertension.</a></text>
<text top="446" left="63" width="56" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref258">2008;51:1403</a></text>
<text top="444" left="119" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref258">–19</a></text>
<text top="446" left="132" width="3" height="9" font="4">.</text>
<text top="464" left="63" width="28" height="9" font="4">S5.4-2.</text>
<text top="464" left="94" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref259">Selassie A, Wagner CS, Laken ML, et al. Pro-</a></text>
<text top="478" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref259">gression is accelerated from prehypertension to hy-</a></text>
<text top="491" left="63" width="193" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref259">pertension in blacks. Hypertension. 2011;58:579</a></text>
<text top="490" left="256" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref259">–87</a></text>
<text top="491" left="270" width="3" height="9" font="4">.</text>
<text top="510" left="63" width="28" height="9" font="4">S5.4-3.</text>
<text top="510" left="94" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref260">Levey AS, Bosch JP, Lewis JB, et al. A more</a></text>
<text top="523" left="63" width="161" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref260">accurate method to estimate glomerular</a></text>
<text top="522" left="227" width="53" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref260">ﬁltration rate</a></text>
<text top="537" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref260">from serum creatinine: a new prediction equation.</a></text>
<text top="550" left="63" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref260">Modi</a></text>
<text top="548" left="83" width="197" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref260">ﬁcation of Diet in Renal Disease Study Group. Ann</a></text>
<text top="564" left="63" width="105" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref260">Intern Med. 1999;130:461</a></text>
<text top="562" left="168" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref260">–70</a></text>
<text top="564" left="182" width="3" height="9" font="4">.</text>
<text top="582" left="63" width="29" height="9" font="4">S5.4-4.</text>
<text top="582" left="95" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref261">Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA</a></text>
<text top="596" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref261">2005 practice guidelines for the management of pa-</a></text>
<text top="609" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref261">tients with peripheral arterial disease (lower extremity,</a></text>
<text top="622" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref261">renal, mesenteric, and abdominal aortic): a collaborative</a></text>
<text top="636" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref261">report from the American Association for Vascular</a></text>
<text top="649" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref261">Surgery/Society for Vascular Surgery, Society for Car-</a></text>
<text top="663" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref261">diovascular Angiography and Interventions, Society for</a></text>
<text top="676" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref261">Vascular Medicine and Biology, Society of Interventional</a></text>
<text top="690" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref261">Radiology, and the ACC/AHA Task Force on Practice</a></text>
<text top="703" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref261">Guidelines (Writing Committee to Develop Guidelines for</a></text>
<text top="717" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref261">the Management of Patients With Peripheral Arterial</a></text>
<text top="730" left="63" width="143" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref261">Disease). Circulation. 2006;113:e463</a></text>
<text top="728" left="206" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref261">–654</a></text>
<text top="730" left="225" width="3" height="9" font="4">.</text>
<text top="749" left="63" width="28" height="9" font="4">S5.4-5.</text>
<text top="749" left="94" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref262">Funder JW, Carey RM, Fardella C, et al. Case</a></text>
<text top="762" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref262">detection, diagnosis, and treatment of patients with</a></text>
<text top="775" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref262">primary aldosteronism: an Endocrine Society clinical</a></text>
<text top="789" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref262">practice guideline. J Clin Endocrinol Metab. 2008;93:</a></text>
<text top="802" left="63" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref262">3266</a></text>
<text top="801" left="84" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref262">–81</a></text>
<text top="802" left="97" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref262">.</a></text>
<text top="821" left="63" width="29" height="9" font="4">S5.4-6.</text>
<text top="821" left="95" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref263">Funder JW, Carey RM, Mantero F, et al. The</a></text>
<text top="834" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref263">management of primary aldosteronism: case detec-</a></text>
<text top="848" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref263">tion, diagnosis, and treatment: an Endocrine Society</a></text>
<text top="861" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref263">clinical practice guideline. J Clin Endocrinol Metab.</a></text>
<text top="875" left="63" width="60" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref263">2016;101:1889</a></text>
<text top="873" left="122" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref263">–916</a></text>
<text top="875" left="141" width="3" height="9" font="4">.</text>
<text top="893" left="63" width="28" height="9" font="4">S5.4-7.</text>
<text top="893" left="94" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref264">Pedrosa RP, Drager LF, Gonzaga CC, et al.</a></text>
<text top="907" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref264">Obstructive sleep apnea: the most common secondary</a></text>
<text top="920" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref264">cause of hypertension associated with resistant hy-</a></text>
<text top="934" left="63" width="154" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref264">pertension. Hypertension. 2011;58:811</a></text>
<text top="932" left="216" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref264">–7</a></text>
<text top="934" left="225" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref264">.</a></text>
<text top="952" left="63" width="29" height="9" font="4">S5.4-8.</text>
<text top="952" left="95" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref265">Kump K, Whalen C, Tishler PV, et al. Assess-</a></text>
<text top="966" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref265">ment of the validity and utility of a sleep-symptom</a></text>
<text top="979" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref265">questionnaire. Am J. Respir Crit Care Med. 1994;150:</a></text>
<text top="992" left="63" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref265">735</a></text>
<text top="991" left="77" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref265">–41</a></text>
<text top="992" left="90" width="3" height="9" font="4">.</text>
<text top="1011" left="63" width="29" height="9" font="4">S5.4-9.</text>
<text top="1011" left="95" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref266">Johns MW. A new method for measuring</a></text>
<text top="1024" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref266">daytime sleepiness: the Epworth sleepiness scale.</a></text>
<text top="1038" left="63" width="77" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref266">Sleep. 1991;14:540</a></text>
<text top="1036" left="139" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref266">–5</a></text>
<text top="1038" left="148" width="3" height="9" font="4">.</text>
<text top="1056" left="63" width="33" height="9" font="4">S5.4-10.</text>
<text top="1056" left="99" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref267">Grossman E, Messerli FH. Drug-induced hy-</a></text>
<text top="1070" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref267">pertension: an unappreciated cause of secondary hy-</a></text>
<text top="1083" left="63" width="141" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref267">pertension. Am J Med. 2012;125:14</a></text>
<text top="1082" left="204" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref267">–22</a></text>
<text top="1083" left="218" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref267">.</a></text>
<text top="143" left="301" width="31" height="9" font="4">S5.4-11.</text>
<text top="143" left="335" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref268">Lenders JWM, Duh Q-Y, Eisenhofer G, et al.</a></text>
<text top="156" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref268">Pheochromocytoma and paraganglioma: an Endocrine</a></text>
<text top="170" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref268">Society clinical practice guideline. J Clin Endocrinol</a></text>
<text top="183" left="301" width="85" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref268">Metab. 2014;99:1915</a></text>
<text top="182" left="386" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref268">–42</a></text>
<text top="183" left="400" width="3" height="9" font="4">.</text>
<text top="202" left="301" width="32" height="9" font="4">S5.4-12.</text>
<text top="202" left="336" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref269">Nieman LK, Biller BMK, Findling JW, et al. The</a></text>
<text top="215" left="301" width="82" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref269">diagnosis of Cushing</a></text>
<text top="214" left="383" width="135" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref269">’s syndrome: an Endocrine Society</a></text>
<text top="229" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref269">clinical practice guideline. J Clin Endocrinol Metab.</a></text>
<text top="242" left="301" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref269">2008;93:1526</a></text>
<text top="241" left="358" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref269">–40</a></text>
<text top="242" left="374" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref269">.</a></text>
<text top="261" left="301" width="32" height="9" font="4">S5.4-13.</text>
<text top="261" left="336" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref270">Lurbe E, Cifkova R, Cruickshank JK, et al.</a></text>
<text top="274" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref270">Management of high blood pressure in children and</a></text>
<text top="288" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref270">adolescents: recommendations of the European Soci-</a></text>
<text top="301" left="301" width="194" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref270">ety of Hypertension. J Hypertens. 2009;27:1719</a></text>
<text top="299" left="495" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref270">–42</a></text>
<text top="301" left="509" width="3" height="9" font="4">.</text>
<text top="320" left="301" width="33" height="9" font="4">S5.4-14.</text>
<text top="320" left="337" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref271">Berglund G, Andersson O, Wilhelmsen L.</a></text>
<text top="333" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref271">Prevalence of primary and secondary hypertension:</a></text>
<text top="347" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref271">studies in a random population sample. Br Med J.</a></text>
<text top="360" left="301" width="45" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref271">1976;2:554</a></text>
<text top="358" left="346" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref271">–6</a></text>
<text top="360" left="355" width="3" height="9" font="4">.</text>
<text top="379" left="301" width="32" height="9" font="4">S5.4-15.</text>
<text top="379" left="336" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref272">Hassan-Smith Z, Stewart PM. Inherited forms</a></text>
<text top="392" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref272">of mineralocorticoid hypertension. Curr Opin Endo-</a></text>
<text top="405" left="301" width="134" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref272">crinol Diabetes Obes. 2011;18:177</a></text>
<text top="404" left="435" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref272">–85</a></text>
<text top="405" left="449" width="3" height="9" font="4">.</text>
<text top="424" left="301" width="33" height="9" font="4">S5.4-16.</text>
<text top="424" left="337" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref273">Katznelson L, Laws ER Jr., Melmed S, et al.</a></text>
<text top="437" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref273">Acromegaly: an Endocrine Society clinical practice</a></text>
<text top="451" left="301" width="200" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref273">guideline. J Clin Endocrinol Metab. 2014;99:3933</a></text>
<text top="449" left="501" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref273">–51</a></text>
<text top="451" left="513" width="3" height="9" font="4">.</text>
<text top="472" left="301" width="24" height="9" font="4">5.4.1.</text>
<text top="472" left="335" width="26" height="9" font="4">Drugs</text>
<text top="472" left="372" width="17" height="9" font="4">and</text>
<text top="472" left="399" width="25" height="9" font="4">Other</text>
<text top="472" left="435" width="50" height="9" font="4">Substances</text>
<text top="472" left="496" width="22" height="9" font="4">With</text>
<text top="486" left="301" width="139" height="9" font="4">Potential to Impair BP Control</text>
<text top="500" left="301" width="34" height="9" font="4">S5.4.1-1.</text>
<text top="500" left="338" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref274">The</a></text>
<text top="498" left="356" width="162" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref274">ﬁfth report of the Joint National Com-</a></text>
<text top="513" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref274">mittee on Detection, Evaluation, and Treatment of</a></text>
<text top="527" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref274">High Blood Pressure (JNC V). Arch Intern Med. 1993;</a></text>
<text top="540" left="301" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref274">153:154</a></text>
<text top="538" left="331" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref274">–83</a></text>
<text top="540" left="345" width="3" height="9" font="4">.</text>
<text top="559" left="301" width="35" height="9" font="4">S5.4.1-2.</text>
<text top="559" left="339" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref275">Grossman E, Messerli FH. Drug-induced hy-</a></text>
<text top="572" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref275">pertension: an unappreciated cause of secondary hy-</a></text>
<text top="585" left="301" width="141" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref275">pertension. Am J Med. 2012;125:14</a></text>
<text top="584" left="442" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref275">–22</a></text>
<text top="585" left="456" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref275">.</a></text>
<text top="604" left="301" width="35" height="9" font="4">S5.4.1-3.</text>
<text top="604" left="339" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref276">Ong SLH, Whitworth JA. How do glucocorti-</a></text>
<text top="617" left="301" width="208" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref276">coids cause hypertension: role of nitric oxide de</a></text>
<text top="616" left="509" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref276">ﬁ-</a></text>
<text top="631" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref276">ciency, oxidative stress, and eicosanoids. Endocrinol</a></text>
<text top="644" left="301" width="141" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref276">Metab Clin North Am. 2011;40:393</a></text>
<text top="643" left="442" width="32" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref276">–407, ix</a></text>
<text top="644" left="474" width="3" height="9" font="4">.</text>
<text top="663" left="301" width="35" height="9" font="4">S5.4.1-4.</text>
<text top="663" left="339" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref277">Rossi GP, Seccia TM, Maniero C, et al. Drug-</a></text>
<text top="676" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref277">related hypertension and resistance to antihyperten-</a></text>
<text top="690" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref277">sive treatment: a call for action. J Hypertens. 2011;29:</a></text>
<text top="703" left="301" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref277">2295</a></text>
<text top="702" left="321" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref277">–309</a></text>
<text top="703" left="342" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref277">.</a></text>
<text top="722" left="301" width="35" height="9" font="4">S5.4.1-5.</text>
<text top="722" left="339" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref278">Tachjian A, Maria V, Jahangir A. Use of herbal</a></text>
<text top="735" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref278">products and potential interactions in patients with</a></text>
<text top="749" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref278">cardiovascular diseases. J Am Coll Cardiol. 2010;55:</a></text>
<text top="762" left="301" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref278">515</a></text>
<text top="760" left="314" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref278">–25</a></text>
<text top="762" left="328" width="3" height="9" font="4">.</text>
<text top="781" left="301" width="35" height="9" font="4">S5.4.1-6.</text>
<text top="781" left="339" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref279">Grossman E, Messerli FH. Secondary hyper-</a></text>
<text top="794" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref279">tension: interfering substances. J Clin Hypertens</a></text>
<text top="808" left="301" width="107" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref279">(Greenwich). 2008;10:556</a></text>
<text top="806" left="408" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref279">–66</a></text>
<text top="808" left="423" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref279">.</a></text>
<text top="826" left="301" width="35" height="9" font="4">S5.4.1-7.</text>
<text top="826" left="339" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref280">Goldstein LB, Bushnell CD, Adams RJ, et al.</a></text>
<text top="840" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref280">Guidelines for the primary prevention of stroke: a</a></text>
<text top="853" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref280">guideline for healthcare professionals from the</a></text>
<text top="866" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref280">American Heart Association/American Stroke Associa-</a></text>
<text top="880" left="301" width="99" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref280">tion. Stroke. 2011;42:517</a></text>
<text top="878" left="400" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref280">–84</a></text>
<text top="880" left="415" width="3" height="9" font="4">.</text>
<text top="898" left="301" width="35" height="9" font="4">S5.4.1-8.</text>
<text top="898" left="339" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref281">Cortese S, Holtmann M, Banaschewski T,</a></text>
<text top="912" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref281">et al. Practitioner review: current best practice in the</a></text>
<text top="925" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref281">management of adverse events during treatment with</a></text>
<text top="939" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref281">ADHD medications in children and adolescents. J Child</a></text>
<text top="952" left="301" width="129" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref281">Psychol Psychiatry. 2013;54:227</a></text>
<text top="951" left="430" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref281">–46</a></text>
<text top="952" left="445" width="3" height="9" font="4">.</text>
<text top="971" left="301" width="35" height="9" font="4">S5.4.1-9.</text>
<text top="971" left="339" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref282">Wolraich M, Brown L, Brown RT, et al. ADHD:</a></text>
<text top="984" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref282">clinical practice guideline for the diagnosis, evaluation,</a></text>
<text top="998" left="301" width="127" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref282">and treatment of attention-de</a></text>
<text top="996" left="428" width="90" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref282">ﬁcit/hyperactivity dis-</a></text>
<text top="1011" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref282">order in children and adolescents. Pediatrics. 2011;128:</a></text>
<text top="1024" left="301" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref282">1007</a></text>
<text top="1023" left="321" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref282">–22</a></text>
<text top="1024" left="335" width="3" height="9" font="4">.</text>
<text top="1043" left="301" width="40" height="9" font="4">S5.4.1-10.</text>
<text top="1043" left="344" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref283">Newcomer JW. Metabolic considerations in</a></text>
<text top="1056" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref283">the use of antipsychotic medications: a review of</a></text>
<text top="1070" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref283">recent evidence. J Clin Psychiatry. 2007;68 suppl 1:</a></text>
<text top="1083" left="301" width="11" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref283">20</a></text>
<text top="1082" left="312" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref283">–7</a></text>
<text top="1083" left="321" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref283">.</a></text>
<text top="143" left="539" width="37" height="9" font="4">S5.4.1-11.</text>
<text top="143" left="580" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref284">Willey JZ, Moon YP, Kahn E, et al.</a></text>
<text top="156" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref284">Population attributable risks of hypertension and dia-</a></text>
<text top="170" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref284">betes for cardiovascular disease and stroke in the</a></text>
<text top="183" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref284">northern Manhattan study. J Am Heart Assoc. 2014;3:</a></text>
<text top="197" left="539" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref284">e001106</a></text>
<text top="197" left="575" width="3" height="9" font="4">.</text>
<text top="215" left="539" width="38" height="9" font="4">S5.4.1-12.</text>
<text top="215" left="581" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref285">Mesas AE, Leon-Munoz LM, Rodriguez-</a></text>
<text top="229" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref285">Artalejo F, et al. The effect of coffee on blood pressure</a></text>
<text top="242" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref285">and cardiovascular disease in hypertensive individuals:</a></text>
<text top="256" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref285">a systematic review and meta-analysis. Am J Clin Nutr.</a></text>
<text top="269" left="539" width="51" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref285">2011;94:1113</a></text>
<text top="268" left="590" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref285">–26</a></text>
<text top="269" left="604" width="3" height="9" font="4">.</text>
<text top="288" left="539" width="38" height="9" font="4">S5.4.1-13.</text>
<text top="288" left="581" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref286">Liu Y, Yang M-S, Yuan J-Y. Immunosup-</a></text>
<text top="301" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref286">pressant utilization and cardiovascular complications</a></text>
<text top="315" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref286">among Chinese patients after kidney transplantation: a</a></text>
<text top="328" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref286">systematic review and analysis. Int Urol Nephrol. 2013;</a></text>
<text top="342" left="539" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref286">45:885</a></text>
<text top="340" left="568" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref286">–92</a></text>
<text top="342" left="583" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref286">.</a></text>
<text top="360" left="539" width="39" height="9" font="4">S5.4.1-14.</text>
<text top="360" left="582" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref287">Penninga L, Penninga EI, Moller CH, et al.</a></text>
<text top="373" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref287">Tacrolimus versus cyclosporin as primary immuno-</a></text>
<text top="387" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref287">suppression for lung transplant recipients. Cochrane</a></text>
<text top="400" left="539" width="152" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref287">Database Syst Rev. 2013;5:CD008817</a></text>
<text top="400" left="691" width="3" height="9" font="4">.</text>
<text top="419" left="539" width="38" height="9" font="4">S5.4.1-15.</text>
<text top="419" left="581" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref288">Xue W, Zhang Q, Xu Y, et al. Effects of</a></text>
<text top="432" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref288">tacrolimus and cyclosporine treatment on metabolic</a></text>
<text top="446" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref288">syndrome and cardiovascular risk factors after renal</a></text>
<text top="459" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref288">transplantation: a meta-analysis. Chin Med J. 2014;</a></text>
<text top="473" left="539" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref288">127:2376</a></text>
<text top="471" left="575" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref288">–81</a></text>
<text top="473" left="588" width="3" height="9" font="4">.</text>
<text top="491" left="539" width="39" height="9" font="4">S5.4.1-16.</text>
<text top="491" left="582" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref289">Mancia G, Fagard R, Narkiewicz K, et al.</a></text>
<text top="505" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref289">2013 ESH/ESC guidelines for the management of</a></text>
<text top="518" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref289">arterial hypertension: the Task Force for the Manage-</a></text>
<text top="532" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref289">ment of Arterial Hypertension of the European Society</a></text>
<text top="545" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref289">of Hypertension (ESH) and of the European Society of</a></text>
<text top="558" left="539" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref289">Cardiology (ESC). Eur Heart J. 2013;34:2159</a></text>
<text top="557" left="717" width="18" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref289">–219</a></text>
<text top="558" left="735" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref289">.</a></text>
<text top="579" left="539" width="133" height="9" font="4">5.4.2. Primary Aldosteronism</text>
<text top="593" left="539" width="35" height="9" font="4">S5.4.2-1.</text>
<text top="593" left="577" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref290">Montori VM, Young WF Jr. Use of plasma</a></text>
<text top="607" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref290">aldosterone concentration-to-plasma renin activity</a></text>
<text top="620" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref290">ratio as a screening test for primary aldosteronism. A</a></text>
<text top="634" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref290">systematic review of the literature. Endocrinol Metab</a></text>
<text top="647" left="539" width="113" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref290">Clin North Am. 2002;31:619</a></text>
<text top="646" left="653" width="26" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref290">–32, xi</a></text>
<text top="647" left="678" width="3" height="9" font="4">.</text>
<text top="666" left="539" width="35" height="9" font="4">S5.4.2-2.</text>
<text top="666" left="578" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref291">Funder JW, Carey RM, Fardella C, et al. Case</a></text>
<text top="679" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref291">detection, diagnosis, and treatment of patients with</a></text>
<text top="693" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref291">primary aldosteronism: an Endocrine Society clinical</a></text>
<text top="706" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref291">practice guideline. J Clin Endocrinol Metab. 2008;93:</a></text>
<text top="720" left="539" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref291">3266</a></text>
<text top="718" left="560" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref291">–81</a></text>
<text top="720" left="574" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref291">.</a></text>
<text top="738" left="539" width="35" height="9" font="4">S5.4.2-3.</text>
<text top="738" left="578" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref292">Funder JW, Carey RM, Mantero F, et al. The</a></text>
<text top="752" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref292">management of primary aldosteronism: case detec-</a></text>
<text top="765" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref292">tion, diagnosis, and treatment: an Endocrine Society</a></text>
<text top="778" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref292">clinical practice guideline. J Clin Endocrinol Metab.</a></text>
<text top="792" left="539" width="60" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref292">2016;101:1889</a></text>
<text top="790" left="599" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref292">–916</a></text>
<text top="792" left="618" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref292">.</a></text>
<text top="810" left="539" width="36" height="9" font="4">S5.4.2-4.</text>
<text top="810" left="579" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref293">Mulatero P, Stowasser M, Loh K-C, et al.</a></text>
<text top="824" left="539" width="38" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref293">Increased</a></text>
<text top="824" left="588" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref293">diagnosis</a></text>
<text top="824" left="637" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref293">of</a></text>
<text top="824" left="656" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref293">primary</a></text>
<text top="824" left="698" width="59" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref293">aldosteronism,</a></text>
<text top="837" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref293">including surgically correctable forms, in centers from</a></text>
<text top="849" left="539" width="217" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref293">ﬁve continents. J Clin Endocrinol Metab. 2004;89:</a></text>
<text top="864" left="539" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref293">1045</a></text>
<text top="863" left="559" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref293">–50</a></text>
<text top="864" left="574" width="3" height="9" font="4">.</text>
<text top="883" left="539" width="35" height="9" font="4">S5.4.2-5.</text>
<text top="883" left="578" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref294">Hannemann A, Wallaschofski H. Prevalence</a></text>
<text top="896" left="539" width="147" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref294">of primary aldosteronism in patient</a></text>
<text top="895" left="686" width="70" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref294">’s cohorts and in</a></text>
<text top="910" left="539" width="105" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref294">population-based studies</a></text>
<text top="908" left="644" width="112" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref294">–a review of the current</a></text>
<text top="923" left="539" width="164" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref294">literature. Horm Metab Res. 2012;44:157</a></text>
<text top="921" left="703" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref294">–62</a></text>
<text top="923" left="718" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref294">.</a></text>
<text top="942" left="539" width="36" height="9" font="4">S5.4.2-6.</text>
<text top="942" left="579" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref295">Rossi GP, Bernini G, Desideri G, et al. Renal</a></text>
<text top="955" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref295">damage in primary aldosteronism: results of the PAPY</a></text>
<text top="969" left="539" width="140" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref295">Study. Hypertension. 2006;48:232</a></text>
<text top="967" left="680" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref295">–8</a></text>
<text top="969" left="689" width="3" height="9" font="4">.</text>
<text top="987" left="539" width="35" height="9" font="4">S5.4.2-7.</text>
<text top="987" left="578" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref296">Milliez P, Girerd X, Plouin P-F, et al. Evidence</a></text>
<text top="1000" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref296">for an increased rate of cardiovascular events in pa-</a></text>
<text top="1014" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref296">tients with primary aldosteronism. J Am Coll Cardiol.</a></text>
<text top="1027" left="539" width="56" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref296">2005;45:1243</a></text>
<text top="1026" left="595" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref296">–8</a></text>
<text top="1027" left="605" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref296">.</a></text>
<text top="1044" left="539" width="36" height="9" font="4">S5.4.2-8.</text>
<text top="1044" left="579" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref297">Mulatero P, Monticone S, Bertello C, et al.</a></text>
<text top="1058" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref297">Long-term cardio- and cerebrovascular events in pa-</a></text>
<text top="1071" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref297">tients with primary aldosteronism. J Clin Endocrinol</a></text>
<text top="1085" left="539" width="88" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref297">Metab. 2013;98:4826</a></text>
<text top="1083" left="627" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref297">–33</a></text>
<text top="1085" left="641" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref297">.</a></text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="790" width="18" height="9" font="4">e217</text>
</page>
<page number="92" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="36" height="9" font="4">S5.4.2-9.</text>
<text top="143" left="147" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref298">Rossi GP, Cesari M, Cuspidi C, et al. Long-</a></text>
<text top="156" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref298">term control of arterial hypertension and regression of</a></text>
<text top="170" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref298">left ventricular hypertrophy with treatment of primary</a></text>
<text top="183" left="108" width="166" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref298">aldosteronism. Hypertension. 2013;62:62</a></text>
<text top="182" left="273" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref298">–9</a></text>
<text top="183" left="283" width="3" height="9" font="4">.</text>
<text top="202" left="108" width="40" height="9" font="4">S5.4.2-10.</text>
<text top="202" left="151" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref299">Fourkiotis V, Vonend O, Diederich S, et al.</a></text>
<text top="215" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref299">Effectiveness of eplerenone or spironolactone treat-</a></text>
<text top="229" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref299">ment in preserving renal function in primary aldoste-</a></text>
<text top="242" left="108" width="153" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref299">ronism. Eur J Endocrinol. 2013;168:75</a></text>
<text top="241" left="260" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref299">–81</a></text>
<text top="242" left="274" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref299">.</a></text>
<text top="264" left="108" width="126" height="9" font="4">5.4.3. Renal Artery Stenosis</text>
<text top="279" left="108" width="35" height="9" font="4">S5.4.3-1.</text>
<text top="279" left="145" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref300">Cooper CJ, Murphy TP, Cutlip DE, et al.</a></text>
<text top="292" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref300">Stenting and medical therapy for atherosclerotic renal-</a></text>
<text top="306" left="108" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref300">artery stenosis. N Engl J Med. 2014;370:13</a></text>
<text top="304" left="281" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref300">–22</a></text>
<text top="306" left="295" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref300">.</a></text>
<text top="324" left="108" width="35" height="9" font="4">S5.4.3-2.</text>
<text top="324" left="146" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref301">Riaz IB, Husnain M, Riaz H, et al. Meta-</a></text>
<text top="338" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref301">analysis of revascularization versus medical therapy for</a></text>
<text top="351" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref301">atherosclerotic renal artery stenosis. Am J Cardiol.</a></text>
<text top="365" left="108" width="55" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref301">2014;114:1116</a></text>
<text top="363" left="163" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref301">–23</a></text>
<text top="365" left="176" width="3" height="9" font="4">.</text>
<text top="383" left="108" width="35" height="9" font="4">S5.4.3-3.</text>
<text top="383" left="146" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref302">Olin JW, Froehlich J, Gu X, et al. The United</a></text>
<text top="397" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref302">States Registry for Fibromuscular Dysplasia: results in</a></text>
<text top="410" left="108" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref302">the</a></text>
<text top="409" left="124" width="196" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref302">ﬁrst 447 patients. Circulation. 2012;125:3182–90</a></text>
<text top="410" left="319" width="3" height="9" font="4">.</text>
<text top="429" left="108" width="36" height="9" font="4">S5.4.3-4.</text>
<text top="429" left="147" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref303">Lamawansa MD, Bell R, House AK. Short-</a></text>
<text top="442" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref303">term and long-term outcome following renovascular</a></text>
<text top="456" left="108" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref303">reconstruction. Cardiovasc Surg. 1995;3:50</a></text>
<text top="454" left="280" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref303">–5</a></text>
<text top="456" left="289" width="3" height="9" font="4">.</text>
<text top="474" left="108" width="35" height="9" font="4">S5.4.3-5.</text>
<text top="474" left="146" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref304">Trinquart L, Mounier-Vehier C, Sapoval M,</a></text>
<text top="488" left="108" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref304">et al. Ef</a></text>
<text top="486" left="144" width="180" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref304">ﬁcacy of revascularization for renal artery</a></text>
<text top="501" left="108" width="75" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref304">stenosis caused by</a></text>
<text top="500" left="186" width="139" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref304">ﬁbromuscular dysplasia: a system-</a></text>
<text top="515" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref304">atic review and meta-analysis. Hypertension. 2010;56:</a></text>
<text top="528" left="108" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref304">525</a></text>
<text top="526" left="122" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref304">–32</a></text>
<text top="528" left="136" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref304">.</a></text>
<text top="548" left="108" width="140" height="9" font="4">5.4.4. Obstructive Sleep Apnea</text>
<text top="563" left="108" width="35" height="9" font="4">S5.4.4-1.</text>
<text top="563" left="146" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref305">Barbe F, Duran-Cantolla J, Capote F, et al.</a></text>
<text top="577" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref305">Long-term effect of continuous positive airway pres-</a></text>
<text top="590" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref305">sure in hypertensive patients with sleep apnea. Am J</a></text>
<text top="604" left="108" width="141" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref305">Respir Crit Care Med. 2010;181:718</a></text>
<text top="602" left="249" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref305">–26</a></text>
<text top="604" left="263" width="3" height="9" font="4">.</text>
<text top="622" left="108" width="36" height="9" font="4">S5.4.4-2.</text>
<text top="622" left="147" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref306">Martinez-Garcia MA, Capote F, Campos-</a></text>
<text top="636" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref306">Rodriguez F, et al. Effect of CPAP on blood pressure in</a></text>
<text top="649" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref306">patients with obstructive sleep apnea and resistant</a></text>
<text top="662" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref306">hypertension: the HIPARCO randomized clinical trial.</a></text>
<text top="676" left="108" width="89" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref306">JAMA. 2013;310:2407</a></text>
<text top="674" left="196" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref306">–15</a></text>
<text top="676" left="209" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref306">.</a></text>
<text top="695" left="108" width="36" height="9" font="4">S5.4.4-3.</text>
<text top="695" left="147" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref307">Lozano L, Tovar JL, Sampol G, et al. Contin-</a></text>
<text top="708" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref307">uous positive airway pressure treatment in sleep apnea</a></text>
<text top="721" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref307">patients with resistant hypertension: a randomized,</a></text>
<text top="735" left="108" width="170" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref307">controlled trial. J Hypertens. 2010;28:2161</a></text>
<text top="733" left="278" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref307">–8</a></text>
<text top="735" left="287" width="3" height="9" font="4">.</text>
<text top="753" left="108" width="37" height="9" font="4">S5.4.4-4.</text>
<text top="753" left="148" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref308">Muxfeldt ES, Margallo V, Costa LMS, et al.</a></text>
<text top="767" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref308">Effects of continuous positive airway pressure treat-</a></text>
<text top="780" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref308">ment on clinic and ambulatory blood pressures in pa-</a></text>
<text top="794" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref308">tients with obstructive sleep apnea and resistant</a></text>
<text top="807" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref308">hypertension: a randomized controlled trial. Hyper-</a></text>
<text top="821" left="108" width="143" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref308">tension. Hypertension. 2015;65:736</a></text>
<text top="819" left="251" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref308">–42</a></text>
<text top="821" left="265" width="3" height="9" font="4">.</text>
<text top="839" left="108" width="36" height="9" font="4">S5.4.4-5.</text>
<text top="839" left="147" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref309">Pedrosa RP, Drager LF, de Paula LKG, et al.</a></text>
<text top="853" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref309">Effects of OSA treatment on BP in patients with</a></text>
<text top="866" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref309">resistant hypertension: a randomized trial. Chest.</a></text>
<text top="880" left="108" width="59" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref309">2013;144:1487</a></text>
<text top="878" left="166" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref309">–94</a></text>
<text top="880" left="181" width="3" height="9" font="4">.</text>
<text top="897" left="108" width="37" height="9" font="4">S5.4.4-6.</text>
<text top="897" left="148" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref310">Parati G, Lombardi C, Hedner J, et al. Posi-</a></text>
<text top="910" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref310">tion paper on the management of patients with</a></text>
<text top="924" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref310">obstructive sleep apnea and hypertension: joint rec-</a></text>
<text top="937" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref310">ommendations by the European Society of Hyperten-</a></text>
<text top="951" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref310">sion, by the European Respiratory Society and by the</a></text>
<text top="964" left="108" width="208" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref310">members of European COST (COoperation in Scienti</a></text>
<text top="962" left="315" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref310">ﬁc</a></text>
<text top="977" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref310">and Technological research) ACTION B26 on obstruc-</a></text>
<text top="991" left="108" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref310">tive sleep apnea. J Hypertens. 2012;30:633</a></text>
<text top="989" left="283" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref310">–46</a></text>
<text top="991" left="298" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref310">.</a></text>
<text top="1010" left="108" width="36" height="9" font="4">S5.4.4-7.</text>
<text top="1009" left="147" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref311">Marin JM, Carrizo SJ, Vicente E, et al. Long-</a></text>
<text top="1023" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref311">term cardiovascular outcomes in men with obstructive</a></text>
<text top="1036" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref311">sleep apnoea-hypopnoea with or without treatment</a></text>
<text top="1050" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref311">with continuous positive airway pressure: an observa-</a></text>
<text top="1063" left="108" width="148" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref311">tional study. Lancet. 2005;365:1046</a></text>
<text top="1062" left="256" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref311">–53</a></text>
<text top="1063" left="269" width="3" height="9" font="4">.</text>
<text top="1082" left="108" width="37" height="9" font="4">S5.4.4-8.</text>
<text top="1082" left="148" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref312">Marshall NS, Wong KKH, Liu PY, et al. Sleep</a></text>
<text top="1095" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref312">apnea as an independent risk factor for all-cause</a></text>
<text top="143" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref312">mortality: the Busselton Health Study. Sleep. 2008;</a></text>
<text top="156" left="346" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref312">31:1079</a></text>
<text top="155" left="377" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref312">–85</a></text>
<text top="156" left="391" width="3" height="9" font="4">.</text>
<text top="175" left="346" width="37" height="9" font="4">S5.4.4-9.</text>
<text top="175" left="386" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref313">Nieto FJ, Young TB, Lind BK, et al.</a></text>
<text top="189" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref313">Association of sleep-disordered breathing, sleep ap-</a></text>
<text top="202" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref313">nea, and hypertension in a large community-based</a></text>
<text top="215" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref313">study. Sleep Heart Health Study. JAMA. 2000;283:</a></text>
<text top="229" left="346" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref313">1829</a></text>
<text top="227" left="366" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref313">–36</a></text>
<text top="229" left="380" width="3" height="9" font="4">.</text>
<text top="248" left="346" width="41" height="9" font="4">S5.4.4-10.</text>
<text top="248" left="390" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref314">Peppard PE, Young T, Palta M, et al.</a></text>
<text top="261" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref314">Prospective study of the association between sleep-</a></text>
<text top="275" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref314">disordered breathing and hypertension. N Engl J</a></text>
<text top="288" left="346" width="85" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref314">Med. 2000;342:1378</a></text>
<text top="286" left="431" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref314">–84</a></text>
<text top="288" left="446" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref314">.</a></text>
<text top="307" left="346" width="39" height="9" font="4">S5.4.4-11.</text>
<text top="307" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref315">Marin JM, Agusti A, Villar I, et al.</a></text>
<text top="320" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref315">Association between treated and untreated obstruc-</a></text>
<text top="334" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref315">tive sleep apnea and risk of hypertension. JAMA. 2012;</a></text>
<text top="347" left="346" width="38" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref315">307:2169</a></text>
<text top="345" left="384" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref315">–76</a></text>
<text top="347" left="398" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref315">.</a></text>
<text top="366" left="346" width="40" height="9" font="4">S5.4.4-12.</text>
<text top="366" left="389" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref316">Pedrosa RP, Drager LF, Gonzaga CC, et al.</a></text>
<text top="379" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref316">Obstructive sleep apnea: the most common secondary</a></text>
<text top="393" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref316">cause of hypertension associated with resistant hy-</a></text>
<text top="406" left="346" width="154" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref316">pertension. Hypertension. 2011;58:811</a></text>
<text top="404" left="499" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref316">–7</a></text>
<text top="406" left="508" width="3" height="9" font="4">.</text>
<text top="425" left="346" width="40" height="9" font="4">S5.4.4-13.</text>
<text top="425" left="389" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref317">Muxfeldt ES, Margallo VS, Guimaraes GM,</a></text>
<text top="438" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref317">et al. Prevalence and associated factors of obstructive</a></text>
<text top="452" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref317">sleep apnea in patients with resistant hypertension.</a></text>
<text top="465" left="346" width="125" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref317">Am J Hypertens. 2014;27:1069</a></text>
<text top="463" left="471" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref317">–78</a></text>
<text top="465" left="485" width="3" height="9" font="4">.</text>
<text top="484" left="346" width="41" height="9" font="4">S5.4.4-14.</text>
<text top="484" left="390" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref318">McEvoy RD, Antic NA, Heeley E, et al. CPAP</a></text>
<text top="497" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref318">for prevention of cardiovascular events in obstructive</a></text>
<text top="511" left="346" width="168" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref318">sleep apnea. N Engl J Med. 2016;375:919</a></text>
<text top="509" left="514" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref318">–31</a></text>
<text top="511" left="526" width="3" height="9" font="4">.</text>
<text top="551" left="346" width="171" height="12" font="26">6 . N O N P H A R M A C O L O G I C A L</text>
<text top="564" left="346" width="103" height="12" font="26">I N T E R V E N T I O N S</text>
<text top="596" left="346" width="20" height="9" font="4">S6-1.</text>
<text top="596" left="369" width="194" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref319">Whelton PK, He J, Appel LJ, et al. Primary pre-</a></text>
<text top="610" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref319">vention of hypertension: clinical and public health</a></text>
<text top="623" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref319">advisory from the National High Blood Pressure Edu-</a></text>
<text top="637" left="346" width="158" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref319">cation Program. JAMA. 2002;288:1882</a></text>
<text top="635" left="504" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref319">–8</a></text>
<text top="637" left="514" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref319">.</a></text>
<text top="655" left="346" width="21" height="9" font="4">S6-2.</text>
<text top="655" left="370" width="193" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref320">National High Blood Pressure Education Program</a></text>
<text top="669" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref320">Working Group report on primary prevention of</a></text>
<text top="682" left="346" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref320">hypertension. Arch Intern Med. 1993;153:186</a></text>
<text top="681" left="527" width="21" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref320">–208</a></text>
<text top="682" left="548" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref320">.</a></text>
<text top="701" left="346" width="21" height="9" font="4">S6-3.</text>
<text top="701" left="370" width="193" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref321">Whelton PK. Hypertension curriculum review:</a></text>
<text top="714" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref321">epidemiology and the prevention of hypertension.</a></text>
<text top="728" left="346" width="172" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref321">J Clin Hypertens (Greenwich). 2004;6:636</a></text>
<text top="726" left="518" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref321">–42</a></text>
<text top="728" left="532" width="3" height="9" font="4">.</text>
<text top="746" left="346" width="22" height="9" font="4">S6-4.</text>
<text top="746" left="371" width="192" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref322">Whelton PK, Appel LJ, Espeland MA, et al. So-</a></text>
<text top="760" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref322">dium reduction and weight loss in the treatment of</a></text>
<text top="773" left="346" width="52" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref322">hypertension</a></text>
<text top="773" left="408" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref322">in</a></text>
<text top="773" left="426" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref322">older</a></text>
<text top="773" left="457" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref322">persons:</a></text>
<text top="773" left="501" width="4" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref322">a</a></text>
<text top="773" left="516" width="47" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref322">randomized</a></text>
<text top="787" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref322">controlled trial of nonpharmacologic interventions in</a></text>
<text top="800" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref322">the elderly (TONE). TONE Collaborative Research</a></text>
<text top="814" left="346" width="115" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref322">Group. JAMA. 1998;279:839</a></text>
<text top="812" left="461" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref322">–46</a></text>
<text top="814" left="476" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref322">.</a></text>
<text top="832" left="346" width="21" height="9" font="4">S6-5.</text>
<text top="832" left="370" width="193" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref323">Whelton PK. The elusiveness of population-wide</a></text>
<text top="846" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref323">high blood pressure control. Annu Rev Public Health.</a></text>
<text top="859" left="346" width="50" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref323">2015;36:109</a></text>
<text top="858" left="396" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref323">–30</a></text>
<text top="859" left="411" width="3" height="9" font="4">.</text>
<text top="881" left="346" width="64" height="9" font="23">6.1. Strategies</text>
<text top="905" left="346" width="26" height="9" font="4">S6.1-1.</text>
<text top="905" left="375" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref324">National High Blood Pressure Education Pro-</a></text>
<text top="918" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref324">gram Working Group report on primary prevention of</a></text>
<text top="932" left="346" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref324">hypertension. Arch Intern Med. 1993;153:186</a></text>
<text top="930" left="527" width="21" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref324">–208</a></text>
<text top="932" left="548" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref324">.</a></text>
<text top="950" left="346" width="27" height="9" font="4">S6.1-2.</text>
<text top="950" left="376" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref325">Cook NR, Cutler JA, Obarzanek E, et al. Long</a></text>
<text top="964" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref325">term effects of dietary sodium reduction on cardio-</a></text>
<text top="977" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref325">vascular disease outcomes: observational follow-up of</a></text>
<text top="991" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref325">the Trials of Hypertension Prevention (TOHP). BMJ.</a></text>
<text top="1004" left="346" width="58" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref325">2007;334:885</a></text>
<text top="1003" left="404" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref325">–8</a></text>
<text top="1004" left="413" width="3" height="9" font="4">.</text>
<text top="1023" left="346" width="27" height="9" font="4">S6.1-3.</text>
<text top="1023" left="376" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref326">Rodgers A, MacMahon S. Blood pressure and</a></text>
<text top="1036" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref326">the global burden of cardiovascular disease. Clin Exp</a></text>
<text top="1050" left="346" width="96" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref326">Hypertens. 1999;21:543</a></text>
<text top="1048" left="442" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref326">–52</a></text>
<text top="1050" left="455" width="3" height="9" font="4">.</text>
<text top="1068" left="346" width="28" height="9" font="4">S6.1-4.</text>
<text top="1068" left="377" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref327">Qin X, Jackson R, Marshall R, et al. Modelling</a></text>
<text top="1082" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref327">the potential impact of population-wide and targeted</a></text>
<text top="1095" left="346" width="35" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref327">high-risk</a></text>
<text top="1095" left="390" width="23" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref327">blood</a></text>
<text top="1095" left="423" width="72" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref327">pressure-lowering</a></text>
<text top="1095" left="504" width="39" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref327">strategies</a></text>
<text top="1095" left="553" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref327">on</a></text>
<text top="143" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref327">cardiovascular disease in China. Eur J Cardiovasc Prev</a></text>
<text top="156" left="584" width="83" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref327">Rehabil. 2009;16:96</a></text>
<text top="155" left="668" width="18" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref327">–101</a></text>
<text top="156" left="685" width="3" height="9" font="4">.</text>
<text top="175" left="584" width="27" height="9" font="4">S6.1-5.</text>
<text top="175" left="614" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref328">Zulman DM, Vijan S, Omenn GS, et al. The</a></text>
<text top="188" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref328">relative merits of population-based and targeted pre-</a></text>
<text top="202" left="584" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref328">vention strategies. Milbank Q. 2008;86:557</a></text>
<text top="200" left="761" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref328">–80</a></text>
<text top="202" left="777" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref328">.</a></text>
<text top="224" left="584" width="178" height="9" font="23">6.2. Nonpharmacological Interventions</text>
<text top="247" left="584" width="27" height="9" font="4">S6.2-1.</text>
<text top="247" left="614" width="146" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref329">Neter JE, Stam BE, Kok FJ, et al. In</a></text>
<text top="246" left="760" width="41" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref329">ﬂuence of</a></text>
<text top="261" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref329">weight reduction on blood pressure: a meta-analysis of</a></text>
<text top="274" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref329">randomized controlled trials. Hypertension. 2003;42:</a></text>
<text top="288" left="584" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref329">878</a></text>
<text top="286" left="600" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref329">–84</a></text>
<text top="288" left="615" width="3" height="9" font="4">.</text>
<text top="306" left="584" width="28" height="9" font="4">S6.2-2.</text>
<text top="306" left="615" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref330">Whelton PK, Kumanyika SK, Cook NR, et al.</a></text>
<text top="320" left="584" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref330">Ef</a></text>
<text top="318" left="593" width="209" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref330">ﬁcacy of nonpharmacologic interventions in adults</a></text>
<text top="333" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref330">with high-normal blood pressure: results from phase 1</a></text>
<text top="347" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref330">of the Trials of Hypertension Prevention. Trials of</a></text>
<text top="360" left="584" width="53" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref330">Hypertension</a></text>
<text top="360" left="648" width="43" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref330">Prevention</a></text>
<text top="360" left="702" width="53" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref330">Collaborative</a></text>
<text top="360" left="766" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref330">Research</a></text>
<text top="373" left="584" width="150" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref330">Group. Am J Clin Nutr. 1997;65:652S</a></text>
<text top="372" left="734" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref330">–60S</a></text>
<text top="373" left="754" width="3" height="9" font="4">.</text>
<text top="392" left="584" width="28" height="9" font="4">S6.2-3.</text>
<text top="392" left="615" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref331">The effects of nonpharmacologic interventions</a></text>
<text top="405" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref331">on blood pressure of persons with high normal levels.</a></text>
<text top="419" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref331">Results of the Trials of Hypertension Prevention, Phase</a></text>
<text top="432" left="584" width="94" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref331">I. JAMA. 1992;267:1213</a></text>
<text top="431" left="678" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref331">–20</a></text>
<text top="432" left="693" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref331">.</a></text>
<text top="451" left="584" width="29" height="9" font="4">S6.2-4.</text>
<text top="451" left="616" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref332">Effects of weight loss and sodium reduction</a></text>
<text top="464" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref332">intervention on blood pressure and hypertension</a></text>
<text top="478" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref332">incidence in overweight people with high-normal</a></text>
<text top="491" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref332">blood pressure. The Trials of Hypertension Preven-</a></text>
<text top="505" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref332">tion, phase II. The Trials of Hypertension Prevention</a></text>
<text top="518" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref332">Collaborative Research Group. Arch Intern Med. 1997;</a></text>
<text top="532" left="584" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref332">157:657</a></text>
<text top="530" left="615" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref332">–67</a></text>
<text top="532" left="629" width="3" height="9" font="4">.</text>
<text top="552" left="584" width="28" height="9" font="4">S6.2-5.</text>
<text top="552" left="615" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref333">Sacks FM, Svetkey LP, Vollmer WM, et al. Ef-</a></text>
<text top="565" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref333">fects on blood pressure of reduced dietary sodium and</a></text>
<text top="579" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref333">the Dietary Approaches to Stop Hypertension (DASH)</a></text>
<text top="592" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref333">diet. DASH-Sodium Collaborative Research Group.</a></text>
<text top="605" left="584" width="106" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref333">N Engl J Med. 2001;344:3</a></text>
<text top="604" left="690" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref333">–10</a></text>
<text top="605" left="704" width="3" height="9" font="4">.</text>
<text top="625" left="584" width="29" height="9" font="4">S6.2-6.</text>
<text top="625" left="616" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref334">Appel LJ, Champagne CM, Harsha DW, et al.</a></text>
<text top="638" left="584" width="171" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref334">Effects of comprehensive lifestyle modi</a></text>
<text top="637" left="756" width="46" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref334">ﬁcation on</a></text>
<text top="652" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref334">blood pressure control: main results of the PREMIER</a></text>
<text top="665" left="584" width="145" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref334">clinical trial. JAMA. 2003;289:2083</a></text>
<text top="663" left="729" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref334">–93</a></text>
<text top="665" left="743" width="3" height="9" font="4">.</text>
<text top="684" left="584" width="28" height="9" font="4">S6.2-7.</text>
<text top="684" left="615" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref335">Appel LJ, Moore TJ, Obarzanek E, et al.</a></text>
<text top="697" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref335">A clinical trial of the effects of dietary patterns on</a></text>
<text top="710" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref335">blood pressure. DASH Collaborative Research Group.</a></text>
<text top="724" left="584" width="116" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref335">N Engl J Med. 1997;336:1117</a></text>
<text top="722" left="700" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref335">–24</a></text>
<text top="724" left="714" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref335">.</a></text>
<text top="742" left="584" width="29" height="9" font="4">S6.2-8.</text>
<text top="742" left="616" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref336">Mozaffarian D, Fahimi S, Singh GM, et al.</a></text>
<text top="756" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref336">Global sodium consumption and death from cardio-</a></text>
<text top="769" left="584" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref336">vascular causes. N Engl J Med. 2014;371:624</a></text>
<text top="768" left="765" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref336">–34</a></text>
<text top="769" left="780" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref336">.</a></text>
<text top="788" left="584" width="29" height="9" font="4">S6.2-9.</text>
<text top="788" left="616" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref337">Aburto NJ, Ziolkovska A, Hooper L, et al. Ef-</a></text>
<text top="801" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref337">fect of lower sodium intake on health: systematic re-</a></text>
<text top="815" left="584" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref337">view and meta-analyses. BMJ. 2013;346:f1326</a></text>
<text top="815" left="771" width="3" height="9" font="4">.</text>
<text top="833" left="584" width="33" height="9" font="4">S6.2-10.</text>
<text top="833" left="620" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref338">He FJ, Li J, MacGregor GA. Effect of longer</a></text>
<text top="847" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref338">term modest salt reduction on blood pressure:</a></text>
<text top="860" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref338">Cochrane systematic review and meta-analysis of</a></text>
<text top="874" left="584" width="159" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref338">randomised trials. BMJ. 2013;346:f1325</a></text>
<text top="874" left="743" width="3" height="9" font="4">.</text>
<text top="894" left="584" width="31" height="9" font="4">S6.2-11.</text>
<text top="894" left="618" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref339">Graudal NA, Hubeck-Graudal T, Jurgens G.</a></text>
<text top="907" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref339">Effects of low-sodium diet vs. high-sodium diet on</a></text>
<text top="921" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref339">blood pressure, renin, aldosterone, catecholamines,</a></text>
<text top="934" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref339">cholesterol, and triglyceride (Cochrane Review). Am J</a></text>
<text top="947" left="584" width="85" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref339">Hypertens. 2012;25:1</a></text>
<text top="946" left="669" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref339">–15</a></text>
<text top="947" left="681" width="3" height="9" font="4">.</text>
<text top="967" left="584" width="32" height="9" font="4">S6.2-12.</text>
<text top="967" left="619" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref340">Whelton PK, Appel LJ, Espeland MA, et al.</a></text>
<text top="981" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref340">Sodium reduction and weight loss in the treatment of</a></text>
<text top="994" left="584" width="52" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref340">hypertension</a></text>
<text top="994" left="647" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref340">in</a></text>
<text top="994" left="664" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref340">older</a></text>
<text top="994" left="696" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref340">persons:</a></text>
<text top="994" left="740" width="4" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref340">a</a></text>
<text top="994" left="755" width="47" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref340">randomized</a></text>
<text top="1008" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref340">controlled trial of nonpharmacologic interventions in</a></text>
<text top="1021" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref340">the elderly (TONE). TONE Collaborative Research</a></text>
<text top="1035" left="584" width="115" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref340">Group. JAMA. 1998;279:839</a></text>
<text top="1033" left="699" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref340">–46</a></text>
<text top="1035" left="714" width="3" height="9" font="4">.</text>
<text top="1055" left="584" width="32" height="9" font="4">S6.2-13.</text>
<text top="1055" left="619" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref341">Whelton PK, He J, Cutler JA, et al. Effects of</a></text>
<text top="1068" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref341">oral potassium on blood pressure. Meta-analysis of</a></text>
<text top="1082" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref341">randomized controlled clinical trials. JAMA. 1997;277:</a></text>
<text top="1095" left="584" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref341">1624</a></text>
<text top="1094" left="604" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref341">–32</a></text>
<text top="1095" left="617" width="3" height="9" font="4">.</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e218</text>
</page>
<page number="93" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="33" height="9" font="4">S6.2-14.</text>
<text top="143" left="99" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref342">Geleijnse</a></text>
<text top="143" left="146" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref342">JM,</a></text>
<text top="143" left="172" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref342">Kok</a></text>
<text top="143" left="198" width="12" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref342">FJ,</a></text>
<text top="143" left="220" width="35" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref342">Grobbee</a></text>
<text top="143" left="266" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref342">DE.</a></text>
<text top="156" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref342">Blood pressure response to changes in sodium</a></text>
<text top="170" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref342">and potassium intake: a metaregression analysis</a></text>
<text top="183" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref342">of randomised trials. J Hum Hypertens. 2003;17:</a></text>
<text top="197" left="63" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref342">471</a></text>
<text top="195" left="77" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref342">–80</a></text>
<text top="197" left="93" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref342">.</a></text>
<text top="215" left="63" width="32" height="9" font="4">S6.2-15.</text>
<text top="215" left="98" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref343">World Health Organization. Guideline: Potas-</a></text>
<text top="229" left="63" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref343">sium</a></text>
<text top="229" left="90" width="25" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref343">Intake</a></text>
<text top="229" left="124" width="12" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref343">for</a></text>
<text top="229" left="145" width="26" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref343">Adults</a></text>
<text top="229" left="179" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref343">and</a></text>
<text top="229" left="203" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref343">Children.</a></text>
<text top="229" left="248" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref343">Geneva,</a></text>
<text top="242" left="63" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref343">Switzerland: World Health Organization; 2012</a></text>
<text top="242" left="247" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref343">.</a></text>
<text top="261" left="63" width="33" height="9" font="4">S6.2-16.</text>
<text top="261" left="99" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref344">Whelton PK, He J. Health effects of sodium</a></text>
<text top="274" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref344">and potassium in humans. Curr Opin Lipidol. 2014;25:</a></text>
<text top="288" left="63" width="9" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref344">75</a></text>
<text top="286" left="72" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref344">–9</a></text>
<text top="288" left="82" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref344">.</a></text>
<text top="306" left="63" width="32" height="9" font="4">S6.2-17.</text>
<text top="306" left="98" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref345">Aburto NJ, Hanson S, Gutierrez H, et al. Effect</a></text>
<text top="320" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref345">of increased potassium intake on cardiovascular risk</a></text>
<text top="333" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref345">factors and disease: systematic review and meta-ana-</a></text>
<text top="347" left="63" width="110" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref345">lyses. BMJ. 2013;346:f1378</a></text>
<text top="347" left="173" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref345">.</a></text>
<text top="365" left="63" width="33" height="9" font="4">S6.2-18.</text>
<text top="365" left="99" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref346">Cornelissen VA, Smart NA. Exercise training</a></text>
<text top="379" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref346">for blood pressure: a systematic review and meta-</a></text>
<text top="392" left="63" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref346">analysis. J Am Heart Assoc. 2013;2:e004473</a></text>
<text top="392" left="242" width="3" height="9" font="4">.</text>
<text top="410" left="63" width="33" height="9" font="4">S6.2-19.</text>
<text top="410" left="99" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref347">Carlson DJ, Dieberg G, Hess NC, et al. Iso-</a></text>
<text top="424" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref347">metric exercise training for blood pressure manage-</a></text>
<text top="437" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref347">ment: a systematic review and meta-analysis. Mayo</a></text>
<text top="451" left="63" width="92" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref347">Clin Proc. 2014;89:327</a></text>
<text top="449" left="155" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref347">–34</a></text>
<text top="451" left="169" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref347">.</a></text>
<text top="469" left="63" width="34" height="9" font="4">S6.2-20.</text>
<text top="469" left="100" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref348">Garcia-Hermoso A, Saavedra JM, Escalante Y.</a></text>
<text top="483" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref348">Effects of exercise on resting blood pressure in obese</a></text>
<text top="496" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref348">children: a meta-analysis of randomized controlled</a></text>
<text top="510" left="63" width="117" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref348">trials. Obes Rev. 2013;14:919</a></text>
<text top="508" left="180" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref348">–28</a></text>
<text top="510" left="194" width="3" height="9" font="4">.</text>
<text top="528" left="63" width="32" height="9" font="4">S6.2-21.</text>
<text top="528" left="98" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref349">Rossi AM, Moullec G, Lavoie KL, et al. The</a></text>
<text top="542" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref349">evolution of a Canadian Hypertension Education Pro-</a></text>
<text top="555" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref349">gram recommendation: the impact of resistance</a></text>
<text top="569" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref349">training on resting blood pressure in adults as an</a></text>
<text top="582" left="63" width="148" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref349">example. Can J Cardiol. 2013;29:622</a></text>
<text top="580" left="210" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref349">–7</a></text>
<text top="582" left="219" width="3" height="9" font="4">.</text>
<text top="601" left="63" width="33" height="9" font="4">S6.2-22.</text>
<text top="601" left="99" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref350">Whelton SP, Chin A, Xin X, et al. Effect of</a></text>
<text top="614" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref350">aerobic exercise on blood pressure: a meta-analysis of</a></text>
<text top="628" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref350">randomized, controlled trials. Ann Intern Med. 2002;</a></text>
<text top="641" left="63" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref350">136:493</a></text>
<text top="639" left="95" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref350">–503</a></text>
<text top="641" left="115" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref350">.</a></text>
<text top="659" left="63" width="33" height="9" font="4">S6.2-23.</text>
<text top="659" left="99" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref351">Xin X, He J, Frontini MG, et al. Effects of</a></text>
<text top="673" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref351">alcohol reduction on blood pressure: a meta-analysis</a></text>
<text top="686" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref351">of randomized controlled trials. Hypertension. 2001;</a></text>
<text top="700" left="63" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref351">38:1112</a></text>
<text top="698" left="92" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref351">–7</a></text>
<text top="700" left="100" width="3" height="9" font="4">.</text>
<text top="718" left="63" width="34" height="9" font="4">S6.2-24.</text>
<text top="718" left="100" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref352">Roerecke M, Kaczorowski J, Tobe SW, et al.</a></text>
<text top="732" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref352">The effect of a reduction in alcohol consumption on</a></text>
<text top="745" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref352">blood pressure: a systematic review and meta-analysis.</a></text>
<text top="759" left="63" width="138" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref352">Lancet Public Health. 2017;2:e108</a></text>
<text top="757" left="201" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref352">–20</a></text>
<text top="759" left="216" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref352">.</a></text>
<text top="777" left="63" width="33" height="9" font="4">S6.2-25.</text>
<text top="777" left="99" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref353">Stewart SH, Latham PK, Miller PM, et al.</a></text>
<text top="791" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref353">Blood pressure reduction during treatment for alcohol</a></text>
<text top="804" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref353">dependence: results from the Combining Medications</a></text>
<text top="818" left="63" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref353">and</a></text>
<text top="818" left="90" width="42" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref353">Behavioral</a></text>
<text top="818" left="145" width="53" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref353">Interventions</a></text>
<text top="818" left="211" width="12" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref353">for</a></text>
<text top="818" left="236" width="44" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref353">Alcoholism</a></text>
<text top="831" left="63" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref353">(COMBINE) study. Addiction. 2008;103:1622</a></text>
<text top="829" left="243" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref353">–8</a></text>
<text top="831" left="252" width="3" height="9" font="4">.</text>
<text top="850" left="63" width="34" height="9" font="4">S6.2-26.</text>
<text top="850" left="100" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref354">Dickinson HO, Mason JM, Nicolson DJ, et al.</a></text>
<text top="863" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref354">Lifestyle interventions to reduce raised blood pres-</a></text>
<text top="876" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref354">sure: a systematic review of randomized controlled</a></text>
<text top="890" left="63" width="130" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref354">trials. J Hypertens. 2006;24:215</a></text>
<text top="888" left="193" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref354">–33</a></text>
<text top="890" left="207" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref354">.</a></text>
<text top="908" left="63" width="33" height="9" font="4">S6.2-27.</text>
<text top="908" left="99" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref355">Wallace P, Cutler S, Haines A. Randomised</a></text>
<text top="922" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref355">controlled trial of general practitioner intervention in</a></text>
<text top="935" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref355">patients with excessive alcohol consumption. BMJ.</a></text>
<text top="949" left="63" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref355">1988;297:663</a></text>
<text top="947" left="119" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref355">–8</a></text>
<text top="949" left="129" width="3" height="9" font="4">.</text>
<text top="967" left="63" width="34" height="9" font="4">S6.2-28.</text>
<text top="967" left="100" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref356">Lang T, Nicaud V, Darne B, et al. Improving</a></text>
<text top="981" left="63" width="52" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref356">hypertension</a></text>
<text top="981" left="125" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref356">control</a></text>
<text top="981" left="165" width="27" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref356">among</a></text>
<text top="981" left="203" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref356">excessive</a></text>
<text top="981" left="251" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref356">alcohol</a></text>
<text top="994" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref356">drinkers: a randomised controlled trial in France. The</a></text>
<text top="1008" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref356">WALPA Group. J Epidemiol Community Health. 1995;</a></text>
<text top="1021" left="63" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref356">49:610</a></text>
<text top="1020" left="92" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref356">–6</a></text>
<text top="1021" left="101" width="3" height="9" font="4">.</text>
<text top="1040" left="63" width="217" height="9" font="4">S6.2-29. National Institute on Alcohol Abuse and</text>
<text top="1053" left="63" width="217" height="9" font="4">Alcoholism (NIAAA). What Is A Standard Drink? Avail-</text>
<text top="1067" left="63" width="17" height="9" font="4">able</text>
<text top="1067" left="89" width="11" height="9" font="4">at:</text>
<text top="1067" left="109" width="171" height="9" font="8"><a href="https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/what-standard-drink">https://www.niaaa.nih.gov/alcohol-health/</a></text>
<text top="1080" left="63" width="210" height="9" font="8"><a href="https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/what-standard-drink">overview-alcohol-consumption/what-standard-drink</a></text>
<text top="1080" left="272" width="3" height="9" font="4">.</text>
<text top="1093" left="63" width="107" height="9" font="4">Accessed August 16, 2017.</text>
<text top="143" left="301" width="34" height="9" font="4">S6.2-30.</text>
<text top="143" left="338" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref358">Blumenthal JA, Babyak MA, Hinderliter A,</a></text>
<text top="156" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref358">et al. Effects of the DASH diet alone and in combina-</a></text>
<text top="170" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref358">tion with exercise and weight loss on blood pressure</a></text>
<text top="183" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref358">and cardiovascular biomarkers in men and women with</a></text>
<text top="197" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref358">high blood pressure: the ENCORE study. Arch Intern</a></text>
<text top="210" left="301" width="77" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref358">Med. 2010;170:126</a></text>
<text top="209" left="378" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref358">–35</a></text>
<text top="210" left="392" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref358">.</a></text>
<text top="230" left="301" width="32" height="9" font="4">S6.2-31.</text>
<text top="230" left="336" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref359">Inder JD, Carlson DJ, Dieberg G, et al. Iso-</a></text>
<text top="243" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref359">metric exercise training for blood pressure manage-</a></text>
<text top="257" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref359">ment: a systematic review and meta-analysis to</a></text>
<text top="270" left="301" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref359">optimize bene</a></text>
<text top="269" left="358" width="140" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref359">ﬁt. Hypertens Res. 2016;39:88–94</a></text>
<text top="270" left="497" width="3" height="9" font="4">.</text>
<text top="290" left="301" width="33" height="9" font="4">S6.2-32.</text>
<text top="290" left="337" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref360">Khalesi S, Sun J, Buys N, et al. Effect of</a></text>
<text top="303" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref360">probiotics on blood pressure: a systematic review and</a></text>
<text top="317" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref360">meta-analysis of randomized, controlled trials. Hy-</a></text>
<text top="330" left="301" width="100" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref360">pertension. 2014;64:897</a></text>
<text top="328" left="401" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref360">–903</a></text>
<text top="330" left="421" width="3" height="9" font="4">.</text>
<text top="350" left="301" width="33" height="9" font="4">S6.2-33.</text>
<text top="350" left="337" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref361">Dong J-Y, Szeto IMY, Makinen K, et al. Effect</a></text>
<text top="363" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref361">of probiotic fermented milk on blood pressure: a meta-</a></text>
<text top="377" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref361">analysis of randomised controlled trials. Br J Nutr.</a></text>
<text top="390" left="301" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref361">2013;110:1188</a></text>
<text top="388" left="358" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref361">–94</a></text>
<text top="390" left="373" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref361">.</a></text>
<text top="410" left="301" width="34" height="9" font="4">S6.2-34.</text>
<text top="410" left="338" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref362">Cicero AFG, Gerocarni B, Laghi L, et al. Blood</a></text>
<text top="423" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref362">pressure lowering effect of lactotripeptides assumed</a></text>
<text top="436" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref362">as functional foods: a meta-analysis of current avail-</a></text>
<text top="450" left="301" width="199" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref362">able clinical trials. J Hum Hypertens. 2011;25:425</a></text>
<text top="448" left="500" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref362">–36</a></text>
<text top="450" left="514" width="3" height="9" font="4">.</text>
<text top="469" left="301" width="33" height="9" font="4">S6.2-35.</text>
<text top="469" left="337" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref363">Rebholz CM, Friedman EE, Powers LJ, et al.</a></text>
<text top="483" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref363">Dietary protein intake and blood pressure: a meta-</a></text>
<text top="496" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref363">analysis of randomized controlled trials. Am J Epi-</a></text>
<text top="510" left="301" width="118" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref363">demiol. 2012;176 suppl 7:S27</a></text>
<text top="508" left="419" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref363">–43</a></text>
<text top="510" left="433" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref363">.</a></text>
<text top="529" left="301" width="34" height="9" font="4">S6.2-36.</text>
<text top="529" left="338" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref364">Tielemans SMaJ, Altorf-van der Kuil W,</a></text>
<text top="543" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref364">Engberink MF, et al. Intake of total protein, plant</a></text>
<text top="556" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref364">protein and animal protein in relation to blood pres-</a></text>
<text top="570" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref364">sure: a meta-analysis of observational and intervention</a></text>
<text top="583" left="301" width="159" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref364">studies. J Hum Hypertens. 2013;27:564</a></text>
<text top="581" left="460" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref364">–71</a></text>
<text top="583" left="472" width="3" height="9" font="4">.</text>
<text top="603" left="301" width="33" height="9" font="4">S6.2-37.</text>
<text top="603" left="337" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref365">Dong J-Y, Zhang Z-L, Wang P-Y, et al. Effects</a></text>
<text top="616" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref365">of high-protein diets on body weight, glycaemic con-</a></text>
<text top="630" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref365">trol, blood lipids and blood pressure in type 2 diabetes:</a></text>
<text top="643" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref365">meta-analysis of randomised controlled trials. Br J</a></text>
<text top="657" left="301" width="75" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref365">Nutr. 2013;110:781</a></text>
<text top="655" left="376" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref365">–9</a></text>
<text top="657" left="386" width="3" height="9" font="4">.</text>
<text top="676" left="301" width="34" height="9" font="4">S6.2-38.</text>
<text top="676" left="338" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref366">Whelton SP, Hyre AD, Pedersen B, et al. Ef-</a></text>
<text top="689" left="301" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref366">fect of dietary</a></text>
<text top="688" left="361" width="157" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref366">ﬁber intake on blood pressure: a meta-</a></text>
<text top="703" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref366">analysis of randomized, controlled clinical trials.</a></text>
<text top="716" left="301" width="105" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref366">J Hypertens. 2005;23:475</a></text>
<text top="715" left="406" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref366">–81</a></text>
<text top="716" left="419" width="3" height="9" font="4">.</text>
<text top="736" left="301" width="34" height="9" font="4">S6.2-39.</text>
<text top="736" left="338" width="117" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref367">Streppel MT, Arends LR, van</a></text>
<text top="734" left="455" width="63" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref367">’t Veer P, et al.</a></text>
<text top="749" left="301" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref367">Dietary</a></text>
<text top="748" left="334" width="184" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref367">ﬁber and blood pressure: a meta-analysis of</a></text>
<text top="763" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref367">randomized placebo-controlled trials. Arch Intern</a></text>
<text top="776" left="301" width="79" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref367">Med. 2005;165:150</a></text>
<text top="775" left="380" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref367">–6</a></text>
<text top="776" left="389" width="3" height="9" font="4">.</text>
<text top="796" left="301" width="35" height="9" font="4">S6.2-40.</text>
<text top="796" left="339" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref368">Rodriguez-Leyva D, Weighell W, Edel AL,</a></text>
<text top="809" left="301" width="195" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref368">et al. Potent antihypertensive action of dietary</a></text>
<text top="808" left="500" width="18" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref368">ﬂax-</a></text>
<text top="823" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref368">seed in hypertensive patients. Hypertension. 2013;62:</a></text>
<text top="836" left="301" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref368">1081</a></text>
<text top="835" left="320" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref368">–9</a></text>
<text top="836" left="330" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref368">.</a></text>
<text top="856" left="301" width="33" height="9" font="4">S6.2-41.</text>
<text top="856" left="337" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref369">Campbell F, Dickinson HO, Critchley JA, et al.</a></text>
<text top="869" left="301" width="96" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref369">A systematic review of</a></text>
<text top="868" left="401" width="117" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref369">ﬁsh-oil supplements for the</a></text>
<text top="883" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref369">prevention and treatment of hypertension. Eur J Prev</a></text>
<text top="896" left="301" width="83" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref369">Cardiol. 2013;20:107</a></text>
<text top="895" left="384" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref369">–20</a></text>
<text top="896" left="399" width="3" height="9" font="4">.</text>
<text top="916" left="301" width="34" height="9" font="4">S6.2-42.</text>
<text top="916" left="338" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref370">van Mierlo L a J, Arends LR, Streppel MT,</a></text>
<text top="929" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref370">et al. Blood pressure response to calcium supple-</a></text>
<text top="943" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref370">mentation: a meta-analysis of randomized controlled</a></text>
<text top="956" left="301" width="152" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref370">trials. J Hum Hypertens. 2006;20:571</a></text>
<text top="954" left="453" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref370">–80</a></text>
<text top="956" left="469" width="3" height="9" font="4">.</text>
<text top="976" left="301" width="34" height="9" font="4">S6.2-43.</text>
<text top="976" left="338" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref371">Cormick G, Ciapponi A, Cafferata ML, et al.</a></text>
<text top="989" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref371">Calcium supplementation for prevention of primary</a></text>
<text top="1002" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref371">hypertension. Cochrane Database Syst Rev. 2015;6:</a></text>
<text top="1016" left="301" width="43" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref371">CD010037</a></text>
<text top="1016" left="344" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref371">.</a></text>
<text top="1035" left="301" width="35" height="9" font="4">S6.2-44.</text>
<text top="1035" left="339" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref372">Kass L, Weekes J, Carpenter L. Effect of</a></text>
<text top="1049" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref372">magnesium supplementation on blood pressure: a</a></text>
<text top="1062" left="301" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref372">meta-analysis. Eur J Clin Nutr. 2012;66:411</a></text>
<text top="1061" left="475" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref372">–8</a></text>
<text top="1062" left="485" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref372">.</a></text>
<text top="1082" left="301" width="34" height="9" font="4">S6.2-45.</text>
<text top="1082" left="338" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref373">Zhang X, Li Y, Del Gobbo LC, et al. Effects of</a></text>
<text top="1095" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref373">magnesium supplementation on blood pressure: a</a></text>
<text top="143" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref373">meta-analysis of randomized double-blind placebo-</a></text>
<text top="156" left="539" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref373">controlled trials. Hypertension. 2016;68:324</a></text>
<text top="155" left="719" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref373">–33</a></text>
<text top="156" left="732" width="3" height="9" font="4">.</text>
<text top="177" left="539" width="35" height="9" font="4">S6.2-46.</text>
<text top="177" left="577" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref374">Bazzano LA, Hu T, Reynolds K, et al. Effects</a></text>
<text top="190" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref374">of low-carbohydrate and low-fat diets: a randomized</a></text>
<text top="203" left="539" width="145" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref374">trial. Ann Intern Med. 2014;161:309</a></text>
<text top="202" left="684" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref374">–18</a></text>
<text top="203" left="697" width="3" height="9" font="4">.</text>
<text top="223" left="539" width="34" height="9" font="4">S6.2-47.</text>
<text top="223" left="576" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref375">Nordmann AJ, Nordmann A, Briel M, et al.</a></text>
<text top="237" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref375">Effects of low-carbohydrate vs low-fat diets on weight</a></text>
<text top="250" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref375">loss and cardiovascular risk factors: a meta-analysis of</a></text>
<text top="264" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref375">randomized controlled trials. Arch Intern Med. 2006;</a></text>
<text top="277" left="539" width="33" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref375">166:285</a></text>
<text top="276" left="572" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref375">–93</a></text>
<text top="277" left="587" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref375">.</a></text>
<text top="296" left="539" width="35" height="9" font="4">S6.2-48.</text>
<text top="296" left="577" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref376">Yokoyama Y, Nishimura K, Barnard ND, et al.</a></text>
<text top="309" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref376">Vegetarian diets and blood pressure: a meta-analysis.</a></text>
<text top="323" left="539" width="129" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref376">JAMA Intern Med. 2014;174:577</a></text>
<text top="321" left="668" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref376">–87</a></text>
<text top="323" left="682" width="3" height="9" font="4">.</text>
<text top="341" left="539" width="35" height="9" font="4">S6.2-49.</text>
<text top="341" left="577" width="42" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref377">Nordmann</a></text>
<text top="341" left="632" width="12" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref377">AJ,</a></text>
<text top="341" left="658" width="77" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref377">Suter-Zimmermann</a></text>
<text top="341" left="748" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref377">K,</a></text>
<text top="355" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref377">Bucher HC, et al. Meta-analysis comparing Mediterra-</a></text>
<text top="368" left="539" width="118" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref377">nean to low-fat diets for modi</a></text>
<text top="366" left="658" width="99" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref377">ﬁcation of cardiovascular</a></text>
<text top="382" left="539" width="148" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref377">risk factors. Am J Med. 2011;124:841</a></text>
<text top="380" left="688" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref377">–51</a></text>
<text top="382" left="700" width="3" height="9" font="4">.</text>
<text top="400" left="539" width="34" height="9" font="4">S6.2-50.</text>
<text top="400" left="576" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref378">Rossi GP, Seccia TM, Maniero C, et al. Drug-</a></text>
<text top="414" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref378">related hypertension and resistance to antihyperten-</a></text>
<text top="427" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref378">sive treatment: a call for action. J Hypertens. 2011;29:</a></text>
<text top="440" left="539" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref378">2295</a></text>
<text top="439" left="559" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref378">–309</a></text>
<text top="440" left="580" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref378">.</a></text>
<text top="459" left="539" width="32" height="9" font="4">S6.2-51.</text>
<text top="459" left="574" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref379">Nagele E, Jeitler K, Horvath K, et al. Clinical</a></text>
<text top="472" left="539" width="53" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref379">effectiveness</a></text>
<text top="472" left="602" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref379">of</a></text>
<text top="472" left="621" width="65" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref379">stress-reduction</a></text>
<text top="472" left="696" width="43" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref379">techniques</a></text>
<text top="472" left="749" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref379">in</a></text>
<text top="486" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref379">patients with hypertension: systematic review and</a></text>
<text top="499" left="539" width="169" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref379">meta-analysis. J Hypertens. 2014;32:1936</a></text>
<text top="498" left="708" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref379">–44</a></text>
<text top="499" left="723" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref379">.</a></text>
<text top="518" left="539" width="33" height="9" font="4">S6.2-52.</text>
<text top="518" left="575" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref380">Rohner A, Ried K, Sobenin IA, et al.</a></text>
<text top="531" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref380">A systematic review and metaanalysis on the effects of</a></text>
<text top="545" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref380">garlic preparations on blood pressure in individuals</a></text>
<text top="558" left="539" width="197" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref380">with hypertension. Am J Hypertens. 2015;28:414</a></text>
<text top="557" left="737" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref380">–23</a></text>
<text top="558" left="750" width="3" height="9" font="4">.</text>
<text top="577" left="539" width="33" height="9" font="4">S6.2-53.</text>
<text top="577" left="575" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref381">Egan BM, Laken MA, Donovan JL, et al. Does</a></text>
<text top="590" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref381">dark chocolate have a role in the prevention and</a></text>
<text top="604" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref381">management of hypertension? Commentary on the</a></text>
<text top="617" left="539" width="155" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref381">evidence. Hypertension. 2010;55:1289</a></text>
<text top="615" left="694" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref381">–95</a></text>
<text top="617" left="708" width="3" height="9" font="4">.</text>
<text top="636" left="539" width="34" height="9" font="4">S6.2-54.</text>
<text top="636" left="576" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref382">Ried K, Sullivan T, Fakler P, et al. Does</a></text>
<text top="649" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref382">chocolate reduce blood pressure? A meta-analysis.</a></text>
<text top="662" left="539" width="86" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref382">BMC Med. 2010;8:39</a></text>
<text top="662" left="625" width="3" height="9" font="4">.</text>
<text top="681" left="539" width="33" height="9" font="4">S6.2-55.</text>
<text top="681" left="575" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref383">Liu G, Mi X-N, Zheng X-X, et al. Effects of tea</a></text>
<text top="694" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref383">intake on blood pressure: a meta-analysis of rando-</a></text>
<text top="708" left="539" width="195" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref383">mised controlled trials. Br J Nutr. 2014;112:1043</a></text>
<text top="706" left="735" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref383">–54</a></text>
<text top="708" left="749" width="3" height="9" font="4">.</text>
<text top="726" left="539" width="34" height="9" font="4">S6.2-56.</text>
<text top="726" left="576" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref384">Steffen M, Kuhle C, Hensrud D, et al. The</a></text>
<text top="740" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref384">effect of coffee consumption on blood pressure and</a></text>
<text top="753" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref384">the development of hypertension: a systematic review</a></text>
<text top="767" left="539" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref384">and meta-analysis. J Hypertens. 2012;30:2245</a></text>
<text top="765" left="726" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref384">–54</a></text>
<text top="767" left="741" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref384">.</a></text>
<text top="785" left="539" width="33" height="9" font="4">S6.2-57.</text>
<text top="785" left="575" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref385">Wang J, Xiong X, Liu W. Yoga for essential</a></text>
<text top="799" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref385">hypertension: a systematic review. PLoS ONE. 2013;8:</a></text>
<text top="812" left="539" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref385">e76357</a></text>
<text top="812" left="568" width="3" height="9" font="4">.</text>
<text top="831" left="539" width="34" height="9" font="4">S6.2-58.</text>
<text top="831" left="576" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref386">Dickinson H, Campbell F, Beyer F, et al.</a></text>
<text top="844" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref386">Relaxation therapies for the management of primary</a></text>
<text top="858" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref386">hypertension in adults: a Cochrane review. J Hum</a></text>
<text top="871" left="539" width="101" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref386">Hypertens. 2008;22:809</a></text>
<text top="869" left="641" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref386">–20</a></text>
<text top="871" left="655" width="3" height="9" font="4">.</text>
<text top="890" left="539" width="34" height="9" font="4">S6.2-59.</text>
<text top="890" left="576" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref387">Lee MS, Pittler MH, Guo R, et al. Qigong for</a></text>
<text top="903" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref387">hypertension: a systematic review of randomized</a></text>
<text top="917" left="539" width="164" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref387">clinical trials. J Hypertens. 2007;25:1525</a></text>
<text top="915" left="703" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref387">–32</a></text>
<text top="917" left="717" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref387">.</a></text>
<text top="935" left="539" width="35" height="9" font="4">S6.2-60.</text>
<text top="935" left="577" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref388">Yeh GY, Wang C, Wayne PM, et al. The effect</a></text>
<text top="949" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref388">of tai chi exercise on blood pressure: a systematic</a></text>
<text top="962" left="539" width="132" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref388">review. Prev Cardiol. 2008;11:82</a></text>
<text top="960" left="671" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref388">–9</a></text>
<text top="962" left="681" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref388">.</a></text>
<text top="980" left="539" width="33" height="9" font="4">S6.2-61.</text>
<text top="980" left="575" width="105" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref389">Canter PH, Ernst E. Insuf</a></text>
<text top="979" left="680" width="77" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref389">ﬁcient evidence to</a></text>
<text top="994" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref389">conclude whether or not transcendental meditation</a></text>
<text top="1007" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref389">decreases blood pressure: results of a systematic</a></text>
<text top="1021" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref389">review of randomized clinical trials. J Hypertens.</a></text>
<text top="1034" left="539" width="59" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref389">2004;22:2049</a></text>
<text top="1033" left="599" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref389">–54</a></text>
<text top="1034" left="613" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref389">.</a></text>
<text top="1053" left="539" width="34" height="9" font="4">S6.2-62.</text>
<text top="1053" left="576" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref390">Whelton PK, He J, Appel LJ, et al. Primary</a></text>
<text top="1066" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref390">prevention of hypertension: clinical and public health</a></text>
<text top="1080" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref390">advisory from the National High Blood Pressure</a></text>
<text top="1093" left="539" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref390">Education Program. JAMA. 2002;288:1882</a></text>
<text top="1092" left="713" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref390">–8</a></text>
<text top="1093" left="722" width="3" height="9" font="4">.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="19" height="9" font="4">e219</text>
</page>
<page number="94" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="34" height="9" font="4">S6.2-63.</text>
<text top="143" left="144" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref391">Estruch R, Ros E, Martinez-Gonzalez MA.</a></text>
<text top="156" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref391">Mediterranean diet for primary prevention of</a></text>
<text top="170" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref391">cardiovascular disease. N Engl J Med. 2013;369:</a></text>
<text top="183" left="108" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref391">676</a></text>
<text top="182" left="124" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref391">–7</a></text>
<text top="183" left="133" width="3" height="9" font="4">.</text>
<text top="201" left="108" width="35" height="9" font="4">S6.2-64.</text>
<text top="201" left="145" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref392">Look AHEAD Research Group, Wing RR,</a></text>
<text top="214" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref392">Bolin P, et al. Cardiovascular effects of intensive life-</a></text>
<text top="228" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref392">style intervention in type 2 diabetes. N Engl J Med.</a></text>
<text top="241" left="108" width="55" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref392">2013;369:145</a></text>
<text top="240" left="162" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref392">–54</a></text>
<text top="241" left="176" width="3" height="9" font="4">.</text>
<text top="259" left="108" width="34" height="9" font="4">S6.2-65.</text>
<text top="259" left="144" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref393">Aucott L, Rothnie H, McIntyre L, et al. Long-</a></text>
<text top="272" left="108" width="204" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref393">term weight loss from lifestyle intervention bene</a></text>
<text top="271" left="312" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref393">ﬁts</a></text>
<text top="286" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref393">blood pressure? A systematic review. Hypertension.</a></text>
<text top="299" left="108" width="53" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref393">2009;54:756</a></text>
<text top="298" left="161" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref393">–62</a></text>
<text top="299" left="175" width="3" height="9" font="4">.</text>
<text top="317" left="108" width="35" height="9" font="4">S6.2-66.</text>
<text top="317" left="145" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref394">Straznicky N, Grassi G, Esler M, et al.</a></text>
<text top="330" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref394">European Society of Hypertension Working Group on</a></text>
<text top="344" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref394">Obesity Antihypertensive effects of weight loss: myth</a></text>
<text top="357" left="108" width="148" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref394">or reality? J Hypertens. 2010;28:637</a></text>
<text top="355" left="256" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref394">–43</a></text>
<text top="357" left="270" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref394">.</a></text>
<text top="375" left="108" width="34" height="9" font="4">S6.2-67.</text>
<text top="375" left="144" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref395">Jensen MD, Ryan DH, Apovian CM, et al. 2013</a></text>
<text top="388" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref395">AHA/ACC/TOS guideline for the management of</a></text>
<text top="402" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref395">overweight and obesity in adults: a report of the</a></text>
<text top="415" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref395">American College of Cardiology/American Heart As-</a></text>
<text top="428" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref395">sociation Task Force on Practice Guidelines and The</a></text>
<text top="442" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref395">Obesity Society. J Am Coll Cardiol. 2014;63 25 Pt B:</a></text>
<text top="455" left="108" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref395">2985</a></text>
<text top="454" left="128" width="24" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref395">–3023</a></text>
<text top="455" left="153" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref395">.</a></text>
<text top="474" left="108" width="35" height="9" font="4">S6.2-68.</text>
<text top="474" left="145" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref396">Ryan DH. The pharmacological and surgical</a></text>
<text top="488" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref396">management of adults with obesity. J Fam Pract.</a></text>
<text top="501" left="108" width="49" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref396">2014;63:S21</a></text>
<text top="500" left="157" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref396">–6</a></text>
<text top="501" left="166" width="3" height="9" font="4">.</text>
<text top="520" left="108" width="35" height="9" font="4">S6.2-69.</text>
<text top="520" left="145" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref397">Chang S-H, Stoll CRT, Song J, et al. The</a></text>
<text top="534" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref397">effectiveness and risks of bariatric surgery: an updated</a></text>
<text top="547" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref397">systematic review and meta-analysis, 2003-2012.</a></text>
<text top="561" left="108" width="104" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref397">JAMA Surg. 2014;149:275</a></text>
<text top="559" left="211" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref397">–87</a></text>
<text top="561" left="226" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref397">.</a></text>
<text top="580" left="108" width="34" height="9" font="4">S6.2-70.</text>
<text top="580" left="145" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref398">Svetkey LP, Simons-Morton D, Vollmer WM,</a></text>
<text top="593" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref398">et al. Effects of dietary patterns on blood pressure:</a></text>
<text top="607" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref398">subgroup analysis of the Dietary Approaches to Stop</a></text>
<text top="620" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref398">Hypertension (DASH) randomized clinical trial. Arch</a></text>
<text top="634" left="108" width="105" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref398">Intern Med. 1999;159:285</a></text>
<text top="632" left="213" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref398">–93</a></text>
<text top="634" left="227" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref398">.</a></text>
<text top="651" left="108" width="32" height="9" font="4">S6.2-71.</text>
<text top="651" left="143" width="104" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref399">Filippini T, Violi F, D</a></text>
<text top="650" left="247" width="78" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref399">’Amico R, et al.</a></text>
<text top="665" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref399">The effect of potassium supplementation on blood</a></text>
<text top="678" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref399">pressure in hypertensive subjects: a systematic</a></text>
<text top="691" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref399">review and meta-analysis. Int J Cardiol. 2017;230:</a></text>
<text top="705" left="108" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref399">127</a></text>
<text top="703" left="121" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref399">–35</a></text>
<text top="705" left="134" width="3" height="9" font="4">.</text>
<text top="724" left="108" width="217" height="9" font="4">S6.2-72. National Heart, Lung, and Blood Institute.</text>
<text top="737" left="108" width="217" height="9" font="4">Your Guide to Lowering Your Blood Pressure With</text>
<text top="751" left="108" width="23" height="9" font="4">DASH</text>
<text top="749" left="130" width="161" height="12" font="4">–How Do I Make the DASH? Available at:</text>
<text top="751" left="294" width="31" height="9" font="8"><a href="https://www.nhlbi.nih.gov/health/resources/heart/hbp-dash-how-to">https://</a></text>
<text top="764" left="108" width="217" height="9" font="8"><a href="https://www.nhlbi.nih.gov/health/resources/heart/hbp-dash-how-to">www.nhlbi.nih.gov/health/resources/heart/hbp-dash-</a></text>
<text top="778" left="108" width="29" height="9" font="8"><a href="https://www.nhlbi.nih.gov/health/resources/heart/hbp-dash-how-to">how-to</a></text>
<text top="778" left="137" width="128" height="9" font="4">. Accessed September 18, 2017.</text>
<text top="797" left="108" width="187" height="9" font="4">S6.2-73. Top 10 DASH Diet Tips. Available at:</text>
<text top="797" left="298" width="27" height="9" font="8"><a href="http://dashdiet.org/dash_diet_tips.asp">http://</a></text>
<text top="810" left="108" width="124" height="9" font="8"><a href="http://dashdiet.org/dash_diet_tips.asp">dashdiet.org/dash_diet_tips.asp</a></text>
<text top="810" left="232" width="93" height="9" font="4"><a href="http://dashdiet.org/dash_diet_tips.asp">. </a>Accessed September</text>
<text top="824" left="108" width="37" height="9" font="4">18, 2017.</text>
<text top="843" left="108" width="34" height="9" font="4">S6.2-74.</text>
<text top="843" left="144" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref402">van Bommel E, Cleophas T. Potassium treat-</a></text>
<text top="856" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref402">ment for hypertension in patients with high salt intake:</a></text>
<text top="870" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref402">a meta-analysis. Int J Clin Pharmacol Ther. 2012;50:</a></text>
<text top="883" left="108" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref402">478</a></text>
<text top="882" left="123" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref402">–82</a></text>
<text top="883" left="138" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref402">.</a></text>
<text top="902" left="108" width="33" height="9" font="4">S6.2-75.</text>
<text top="902" left="144" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref403">He J, Wofford MR, Reynolds K, et al. Effect of</a></text>
<text top="916" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref403">dietary protein supplementation on blood pressure.</a></text>
<text top="929" left="108" width="102" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref403">Circulation. 2011;124:589</a></text>
<text top="928" left="209" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref403">–95</a></text>
<text top="929" left="224" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref403">.</a></text>
<text top="948" left="108" width="34" height="9" font="4">S6.2-76.</text>
<text top="948" left="144" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref404">Cook NR, Appel LJ, Whelton PK. Lower levels</a></text>
<text top="962" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref404">of sodium intake and reduced cardiovascular risk. Cir-</a></text>
<text top="975" left="108" width="92" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref404">culation. 2014;129:981</a></text>
<text top="973" left="199" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref404">–9</a></text>
<text top="975" left="209" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref404">.</a></text>
<text top="994" left="108" width="33" height="9" font="4">S6.2-77.</text>
<text top="994" left="144" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref405">Cook NR, Cutler JA, Obarzanek E, et al. Long</a></text>
<text top="1008" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref405">term effects of dietary sodium reduction on cardio-</a></text>
<text top="1021" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref405">vascular disease outcomes: observational follow-up of</a></text>
<text top="1034" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref405">the Trials of Hypertension Orevention (TOHP). BMJ.</a></text>
<text top="1048" left="108" width="58" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref405">2007;334:885</a></text>
<text top="1046" left="165" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref405">–8</a></text>
<text top="1048" left="175" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref405">.</a></text>
<text top="1068" left="108" width="34" height="9" font="4">S6.2-78.</text>
<text top="1068" left="144" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref406">Pimenta E, Gaddam KK, Oparil S, et al.</a></text>
<text top="1082" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref406">Effects of dietary sodium reduction on blood pres-</a></text>
<text top="1095" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref406">sure in subjects with resistant hypertension: results</a></text>
<text top="143" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref406">from a randomized trial. Hypertension. 2009;54:</a></text>
<text top="156" left="346" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref406">475</a></text>
<text top="155" left="361" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref406">–81</a></text>
<text top="156" left="375" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref406">.</a></text>
<text top="175" left="346" width="34" height="9" font="4">S6.2-79.</text>
<text top="175" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref407">Huggins CE, Margerison C, Worsley A, et al.</a></text>
<text top="189" left="346" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref407">In</a></text>
<text top="187" left="353" width="210" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref407">ﬂuence of dietary modiﬁcations on the blood</a></text>
<text top="202" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref407">pressure response to antihypertensive medication. Br J</a></text>
<text top="215" left="346" width="78" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref407">Nutr. 2011;105:248</a></text>
<text top="214" left="423" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref407">–55</a></text>
<text top="215" left="437" width="3" height="9" font="4">.</text>
<text top="234" left="346" width="35" height="9" font="4">S6.2-80.</text>
<text top="234" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref408">He FJ, Fan S, Macgregor GA, et al.</a></text>
<text top="248" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref408">Plasma sodium and blood pressure in individuals on</a></text>
<text top="261" left="346" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref408">haemodialysis. J Hum Hypertens. 2013;27:85</a></text>
<text top="259" left="527" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref408">–9</a></text>
<text top="261" left="536" width="3" height="9" font="4">.</text>
<text top="280" left="346" width="33" height="9" font="4">S6.2-81.</text>
<text top="280" left="382" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref409">Whelton</a></text>
<text top="280" left="425" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref409">PK.</a></text>
<text top="280" left="447" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref409">Sodium,</a></text>
<text top="280" left="488" width="43" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref409">potassium,</a></text>
<text top="280" left="540" width="23" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref409">blood</a></text>
<text top="293" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref409">pressure, and cardiovascular disease in humans.</a></text>
<text top="307" left="346" width="135" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref409">Curr Hypertens Rep. 2014;16:465</a></text>
<text top="307" left="481" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref409">.</a></text>
<text top="325" left="346" width="34" height="9" font="4">S6.2-82.</text>
<text top="325" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref410">Weinberger MH, Miller JZ, Luft FC, et al.</a></text>
<text top="339" left="346" width="11" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref410">De</a></text>
<text top="337" left="357" width="206" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref410">ﬁnitions and characteristics of sodium sensitivity</a></text>
<text top="352" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref410">and blood pressure resistance. Hypertension. 1986;8:</a></text>
<text top="366" left="346" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref410">II127</a></text>
<text top="364" left="364" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref410">–I134</a></text>
<text top="366" left="384" width="3" height="9" font="4">.</text>
<text top="384" left="346" width="34" height="9" font="4">S6.2-83.</text>
<text top="384" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref411">Mattes RD, Donnelly D. Relative contribu-</a></text>
<text top="398" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref411">tions of dietary sodium sources. J Am Coll Nutr. 1991;</a></text>
<text top="411" left="346" width="28" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref411">10:383</a></text>
<text top="410" left="373" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref411">–93</a></text>
<text top="411" left="388" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref411">.</a></text>
<text top="430" left="346" width="35" height="9" font="4">S6.2-84.</text>
<text top="430" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref412">Anderson CAM, Appel LJ, Okuda N, et al.</a></text>
<text top="443" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref412">Dietary sources of sodium in China, Japan, the United</a></text>
<text top="457" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref412">Kingdom, and the United States, women and men aged</a></text>
<text top="470" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref412">40 to 59 years: the INTERMAP study. J Am Diet Assoc.</a></text>
<text top="484" left="346" width="54" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref412">2010;110:736</a></text>
<text top="482" left="400" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref412">–45</a></text>
<text top="484" left="414" width="3" height="9" font="4">.</text>
<text top="502" left="346" width="34" height="9" font="4">S6.2-85.</text>
<text top="502" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref413">Whelton PK, Appel LJ, Sacco RL, et al. So-</a></text>
<text top="516" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref413">dium, blood pressure, and cardiovascular disease:</a></text>
<text top="529" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref413">further evidence supporting the American Heart As-</a></text>
<text top="543" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref413">sociation sodium reduction recommendations. Circu-</a></text>
<text top="556" left="346" width="89" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref413">lation. 2012;126:2880</a></text>
<text top="554" left="435" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref413">–9</a></text>
<text top="556" left="445" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref413">.</a></text>
<text top="575" left="346" width="35" height="9" font="4">S6.2-86.</text>
<text top="575" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref414">Cobb LK, Appel LJ, Anderson CAM. Strategies</a></text>
<text top="588" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref414">to reduce dietary sodium intake. Curr Treat Options</a></text>
<text top="602" left="346" width="117" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref414">Cardiovasc Med. 2012;14:425</a></text>
<text top="600" left="463" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref414">–34</a></text>
<text top="602" left="477" width="3" height="9" font="4">.</text>
<text top="620" left="346" width="34" height="9" font="4">S6.2-87.</text>
<text top="620" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref415">McGuire S, Institute of Medicine. 2010.</a></text>
<text top="634" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref415">Strategies to Reduce Sodium Intake in the United</a></text>
<text top="647" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref415">States. Washington, DC: The National Academies</a></text>
<text top="661" left="346" width="103" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref415">Press. Adv Nutr. 2010:49</a></text>
<text top="659" left="448" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref415">–50</a></text>
<text top="661" left="463" width="3" height="9" font="4">.</text>
<text top="679" left="346" width="35" height="9" font="4">S6.2-88.</text>
<text top="679" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref416">He J, Tell GS, Tang YC, et al. Effect of</a></text>
<text top="693" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref416">migration on blood pressure: the Yi People Study.</a></text>
<text top="706" left="346" width="100" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref416">Epidemiology. 1991;2:88</a></text>
<text top="705" left="446" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref416">–97</a></text>
<text top="706" left="460" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref416">.</a></text>
<text top="725" left="346" width="35" height="9" font="4">S6.2-89.</text>
<text top="725" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref417">Stamler J. The INTERSALT Study: back-</a></text>
<text top="738" left="346" width="71" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref417">ground, methods,</a></text>
<text top="737" left="419" width="144" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref417">ﬁndings, and implications. Am J Clin</a></text>
<text top="752" left="346" width="79" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref417">Nutr. 1997;65:626S</a></text>
<text top="750" left="425" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref417">–42S</a></text>
<text top="752" left="444" width="3" height="9" font="4">.</text>
<text top="770" left="346" width="35" height="9" font="4">S6.2-90.</text>
<text top="770" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref418">Zhang Z, Cogswell ME, Gillespie C, et al.</a></text>
<text top="784" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref418">Association between usual sodium and potassium</a></text>
<text top="797" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref418">intake and blood pressure and hypertension among U.</a></text>
<text top="811" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref418">S. adults: NHANES 2005-2010. PLoS ONE. 2013;8:</a></text>
<text top="824" left="346" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref418">e75289</a></text>
<text top="824" left="376" width="3" height="9" font="4">.</text>
<text top="843" left="346" width="33" height="9" font="4">S6.2-91.</text>
<text top="843" left="382" width="47" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref419">Mente A, O</a></text>
<text top="841" left="429" width="134" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref419">’Donnell MJ, Rangarajan S, et al.</a></text>
<text top="856" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref419">Association of urinary sodium and potassium excretion</a></text>
<text top="870" left="346" width="199" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref419">with blood pressure. N Engl J Med. 2014;371:601</a></text>
<text top="868" left="545" width="11" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref419">–11</a></text>
<text top="870" left="557" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref419">.</a></text>
<text top="890" left="346" width="34" height="9" font="4">S6.2-92.</text>
<text top="890" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref420">Kieneker LM, Gansevoort RT, Mukamal KJ,</a></text>
<text top="903" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref420">et al. Urinary potassium excretion and risk of developing</a></text>
<text top="917" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref420">hypertension: the prevention of renal and vascular end-</a></text>
<text top="930" left="346" width="192" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref420">stage disease study. Hypertension. 2014;64:769</a></text>
<text top="929" left="538" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref420">–76</a></text>
<text top="930" left="552" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref420">.</a></text>
<text top="950" left="346" width="34" height="9" font="4">S6.2-93.</text>
<text top="950" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref421">Bazzano LA, He J, Ogden LG, et al. Dietary</a></text>
<text top="964" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref421">potassium intake and risk of stroke in US men and</a></text>
<text top="977" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref421">women: National Health and Nutrition Examination</a></text>
<text top="991" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref421">Survey I epidemiologic follow-up study. Stroke. 2001;</a></text>
<text top="1004" left="346" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref421">32:1473</a></text>
<text top="1003" left="377" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref421">–80</a></text>
<text top="1004" left="392" width="3" height="9" font="4">.</text>
<text top="1023" left="346" width="35" height="9" font="4">S6.2-94.</text>
<text top="1023" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref422">Ascherio A, Rimm EB, Hernan MA, et al.</a></text>
<text top="1036" left="346" width="194" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref422">Intake of potassium, magnesium, calcium, and</a></text>
<text top="1035" left="545" width="18" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref422">ﬁber</a></text>
<text top="1050" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref422">and risk of stroke among US men. Circulation. 1998;</a></text>
<text top="1063" left="346" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref422">98:1198</a></text>
<text top="1062" left="378" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref422">–204</a></text>
<text top="1063" left="399" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref422">.</a></text>
<text top="1082" left="346" width="34" height="9" font="4">S6.2-95.</text>
<text top="1082" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref423">Seth A, Mossavar-Rahmani Y, Kamensky V,</a></text>
<text top="1095" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref423">et al. Potassium intake and risk of stroke in</a></text>
<text top="143" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref423">women with hypertension and nonhypertension in</a></text>
<text top="156" left="584" width="51" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref423">the Women</a></text>
<text top="155" left="636" width="166" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref423">’s Health Initiative. Stroke. 2014;45:</a></text>
<text top="170" left="584" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref423">2874</a></text>
<text top="168" left="605" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref423">–80</a></text>
<text top="170" left="621" width="3" height="9" font="4">.</text>
<text top="188" left="584" width="35" height="9" font="4">S6.2-96.</text>
<text top="188" left="622" width="6" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref424">D</a></text>
<text top="187" left="628" width="173" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref424">’Elia L, Barba G, Cappuccio FP, et al.</a></text>
<text top="202" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref424">Potassium intake, stroke, and cardiovascular disease</a></text>
<text top="215" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref424">a meta-analysis of prospective studies. J Am Coll</a></text>
<text top="229" left="584" width="85" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref424">Cardiol. 2011;57:1210</a></text>
<text top="227" left="669" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref424">–9</a></text>
<text top="229" left="679" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref424">.</a></text>
<text top="247" left="584" width="34" height="9" font="4">S6.2-97.</text>
<text top="247" left="621" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref425">Bazzano LA, He J, Ogden LG, et al. Fruit and</a></text>
<text top="261" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref425">vegetable intake and risk of cardiovascular disease in</a></text>
<text top="274" left="584" width="62" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref425">US adults: the</a></text>
<text top="273" left="652" width="149" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref425">ﬁrst National Health and Nutrition</a></text>
<text top="288" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref425">Examination Survey Epidemiologic Follow-up Study.</a></text>
<text top="301" left="584" width="112" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref425">Am J Clin Nutr. 2002;76:93</a></text>
<text top="300" left="696" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref425">–9</a></text>
<text top="301" left="706" width="3" height="9" font="4">.</text>
<text top="320" left="584" width="35" height="9" font="4">S6.2-98.</text>
<text top="320" left="622" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref426">Gu D, Zhao Q, Chen J, et al. Reproducibility</a></text>
<text top="333" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref426">of blood pressure responses to dietary sodium</a></text>
<text top="347" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref426">and potassium interventions: the GenSalt study.</a></text>
<text top="360" left="584" width="110" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref426">Hypertension. 2013;62:499</a></text>
<text top="358" left="694" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref426">–505</a></text>
<text top="360" left="714" width="3" height="9" font="4">.</text>
<text top="379" left="584" width="35" height="9" font="4">S6.2-99.</text>
<text top="379" left="622" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref427">Cook NR, Obarzanek E, Cutler JA, et al. Joint</a></text>
<text top="392" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref427">effects of sodium and potassium intake on subsequent</a></text>
<text top="406" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref427">cardiovascular disease: the Trials of Hypertension</a></text>
<text top="419" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref427">Prevention follow-up study. Arch Intern Med. 2009;</a></text>
<text top="432" left="584" width="27" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref427">169:32</a></text>
<text top="431" left="611" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref427">–40</a></text>
<text top="432" left="627" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref427">.</a></text>
<text top="451" left="584" width="39" height="9" font="4">S6.2-100.</text>
<text top="451" left="626" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref428">Whelton PK, Buring J, Borhani NO, et al.</a></text>
<text top="464" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref428">The effect of potassium supplementation in persons</a></text>
<text top="478" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref428">with a high-normal blood pressure. Results from</a></text>
<text top="491" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref428">phase I of the Trials of Hypertension Prevention</a></text>
<text top="505" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref428">(TOHP). Trials of Hypertension Prevention (TOHP)</a></text>
<text top="518" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref428">Collaborative Research Group. Ann Epidemiol. 1995;</a></text>
<text top="532" left="584" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref428">5:85</a></text>
<text top="530" left="602" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref428">–95</a></text>
<text top="532" left="617" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref428">.</a></text>
<text top="550" left="584" width="37" height="9" font="4">S6.2-101.</text>
<text top="550" left="624" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref429">Dietary Guidelines Advisory Committee.</a></text>
<text top="564" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref429">Dietary Guidelines for Americans, 2015-2020. Wash-</a></text>
<text top="577" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref429">ington, DC: Department of Health and Human Services</a></text>
<text top="591" left="584" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref429">(U.S.), Department of Agriculture (U.S); 2015</a></text>
<text top="591" left="766" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref429">.</a></text>
<text top="609" left="584" width="38" height="9" font="4">S6.2-102.</text>
<text top="609" left="625" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref430">Institute of Medicine. Dietary Reference</a></text>
<text top="623" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref430">Intakes for Water, Potassium, Sodium, Chloride, and</a></text>
<text top="636" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref430">Sulfate. Washington, DC: The National Academies</a></text>
<text top="650" left="584" width="48" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref430">Press; 2005</a></text>
<text top="650" left="633" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref430">.</a></text>
<text top="668" left="584" width="38" height="9" font="4">S6.2-103.</text>
<text top="668" left="625" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref431">Cornelissen VA, Arnout J, Holvoet P, et al.</a></text>
<text top="682" left="584" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref431">In</a></text>
<text top="680" left="592" width="210" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref431">ﬂuence of exercise at lower and higher intensity on</a></text>
<text top="695" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref431">blood pressure and cardiovascular risk factors at older</a></text>
<text top="708" left="584" width="125" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref431">age. J Hypertens. 2009;27:753</a></text>
<text top="707" left="709" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref431">–62</a></text>
<text top="708" left="723" width="3" height="9" font="4">.</text>
<text top="727" left="584" width="39" height="9" font="4">S6.2-104.</text>
<text top="727" left="626" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref432">Klatsky AL, Gunderson E. Alcohol and hy-</a></text>
<text top="740" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref432">pertension: a review. J Am Soc Hypertens. 2008;2:</a></text>
<text top="754" left="584" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref432">307</a></text>
<text top="752" left="600" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref432">–17</a></text>
<text top="754" left="612" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref432">.</a></text>
<text top="772" left="584" width="217" height="9" font="4">S6.2-105. National Institute on Alcohol Abuse and Alco-</text>
<text top="786" left="584" width="217" height="9" font="4">holism (NIAAA). A Pocket Guide for Alcohol Screening and</text>
<text top="799" left="584" width="217" height="9" font="4">Brief Intervention. Rockville, MD: NIAAA, 2005. Available</text>
<text top="813" left="584" width="10" height="9" font="4">at:</text>
<text top="813" left="599" width="203" height="9" font="8"><a href="https://pubs.niaaa.nih.gov/publications/practitioner/pocketguide/pocket_guide.htm">https://pubs.niaaa.nih.gov/publications/practitioner/</a></text>
<text top="826" left="584" width="119" height="9" font="8"><a href="https://pubs.niaaa.nih.gov/publications/practitioner/pocketguide/pocket_guide.htm">pocketguide/pocket_guide.htm</a></text>
<text top="826" left="703" width="98" height="9" font="4">. Accessed September</text>
<text top="840" left="584" width="35" height="9" font="4">18, 2017.</text>
<text top="858" left="584" width="39" height="9" font="4">S6.2-106.</text>
<text top="858" left="626" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref434">Cushman WC, Cutler JA, Hanna E, et al.</a></text>
<text top="872" left="584" width="44" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref434">Prevention</a></text>
<text top="872" left="642" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref434">and</a></text>
<text top="872" left="670" width="42" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref434">Treatment</a></text>
<text top="872" left="725" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref434">of</a></text>
<text top="872" left="747" width="54" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref434">Hypertension</a></text>
<text top="885" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref434">Study (PATHS): effects of an alcohol treatment</a></text>
<text top="899" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref434">program on blood pressure. Arch Intern Med. 1998;</a></text>
<text top="912" left="584" width="35" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref434">158:1197</a></text>
<text top="910" left="619" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref434">–207</a></text>
<text top="912" left="639" width="3" height="9" font="4">.</text>
<text top="931" left="584" width="38" height="9" font="4">S6.2-107.</text>
<text top="931" left="625" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref435">Rimm EB, Williams P, Fosher K, et al. Mod-</a></text>
<text top="944" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref435">erate alcohol intake and lower risk of coronary heart</a></text>
<text top="958" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref435">disease: meta-analysis of effects on lipids and hae-</a></text>
<text top="971" left="584" width="151" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref435">mostatic factors. BMJ. 1999;319:1523</a></text>
<text top="969" left="735" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref435">–8</a></text>
<text top="971" left="745" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref435">.</a></text>
<text top="990" left="584" width="39" height="9" font="4">S6.2-108.</text>
<text top="990" left="626" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref436">Mukamal KJ. Understanding the mecha-</a></text>
<text top="1003" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref436">nisms that link alcohol and lower risk of coronary heart</a></text>
<text top="1016" left="584" width="132" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref436">disease. Clin Chem. 2012;58:664</a></text>
<text top="1015" left="716" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref436">–6</a></text>
<text top="1016" left="726" width="3" height="9" font="4">.</text>
<text top="1035" left="584" width="39" height="9" font="4">S6.2-109.</text>
<text top="1035" left="626" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref437">Klatsky AL. Alcohol and cardiovascular</a></text>
<text top="1048" left="584" width="154" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref437">mortality: common sense and scienti</a></text>
<text top="1047" left="738" width="63" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref437">ﬁc truth. J Am</a></text>
<text top="1062" left="584" width="106" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref437">Coll Cardiol. 2010;55:1336</a></text>
<text top="1060" left="691" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref437">–8</a></text>
<text top="1062" left="700" width="3" height="9" font="4">.</text>
<text top="1082" left="584" width="37" height="9" font="4">S6.2-110.</text>
<text top="1082" left="624" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref438">Mukamal KJ, Chen CM, Rao SR, et al. Alcohol</a></text>
<text top="1095" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref438">consumption and cardiovascular mortality among U.S.</a></text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="20" height="9" font="4">e220</text>
</page>
<page number="95" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref438">adults, 1987 to 2002. J Am Coll Cardiol. 2010;55:</a></text>
<text top="156" left="63" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref438">1328</a></text>
<text top="155" left="82" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref438">–35</a></text>
<text top="156" left="95" width="3" height="9" font="4">.</text>
<text top="200" left="63" width="156" height="12" font="26">7 . P A T I E N T E V A L U A T I O N</text>
<text top="230" left="63" width="217" height="9" font="23">7.1. Laboratory Tests and Other Diagnostic</text>
<text top="243" left="63" width="51" height="9" font="23">Procedures</text>
<text top="267" left="63" width="25" height="9" font="4">S7.1-1.</text>
<text top="267" left="91" width="189" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref439">Chang AR, Sang Y, Leddy J, et al. Antihyper-</a></text>
<text top="280" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref439">tensive medications and the prevalence of hyper-</a></text>
<text top="294" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref439">kalemia in a large health system. Hypertension. 2016;</a></text>
<text top="307" left="63" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref439">67:1181</a></text>
<text top="306" left="92" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref439">–8</a></text>
<text top="307" left="102" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref439">.</a></text>
<text top="329" left="63" width="188" height="9" font="23">7.2. Cardiovascular Target Organ Damage</text>
<text top="353" left="63" width="26" height="9" font="4">S7.2-1.</text>
<text top="353" left="92" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref440">Persu A, De Plaen J-F. Recent insights in the</a></text>
<text top="367" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref440">development of organ damage caused by hyperten-</a></text>
<text top="380" left="63" width="130" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref440">sion. Acta Cardiol. 2004;59:369</a></text>
<text top="379" left="193" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref440">–81</a></text>
<text top="380" left="206" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref440">.</a></text>
<text top="400" left="63" width="27" height="9" font="4">S7.2-2.</text>
<text top="400" left="93" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref441">Allen NB, Siddique J, Wilkins JT, et al. Blood</a></text>
<text top="413" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref441">pressure trajectories in early adulthood and subclinical</a></text>
<text top="426" left="63" width="206" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref441">atherosclerosis in middle age. JAMA. 2014;311:490</a></text>
<text top="425" left="268" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref441">–7</a></text>
<text top="426" left="277" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref441">.</a></text>
<text top="446" left="63" width="27" height="9" font="4">S7.2-3.</text>
<text top="446" left="93" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref442">Pletcher MJ, Bibbins-Domingo K, Lewis CE, et al.</a></text>
<text top="459" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref442">Prehypertension during young adulthood and coronary</a></text>
<text top="473" left="63" width="198" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref442">calcium later in life. Ann Intern Med. 2008;149:91</a></text>
<text top="471" left="261" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref442">–9</a></text>
<text top="473" left="270" width="3" height="9" font="4">.</text>
<text top="492" left="63" width="28" height="9" font="4">S7.2-4.</text>
<text top="492" left="94" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref443">Juhola J, Magnussen CG, Berenson GS, et al.</a></text>
<text top="505" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref443">Combined effects of child and adult elevated blood</a></text>
<text top="519" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref443">pressure on subclinical atherosclerosis: the Interna-</a></text>
<text top="532" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref443">tional Childhood Cardiovascular Cohort Consortium.</a></text>
<text top="546" left="63" width="100" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref443">Circulation. 2013;128:217</a></text>
<text top="544" left="163" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref443">–24</a></text>
<text top="546" left="177" width="3" height="9" font="4">.</text>
<text top="565" left="63" width="27" height="9" font="4">S7.2-5.</text>
<text top="565" left="93" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref444">Santos M, Shah AM. Alterations in cardiac</a></text>
<text top="578" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref444">structure and function in hypertension. Curr Hypertens</a></text>
<text top="592" left="63" width="71" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref444">Rep. 2014;16:428</a></text>
<text top="592" left="134" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref444">.</a></text>
<text top="611" left="63" width="28" height="9" font="4">S7.2-6.</text>
<text top="611" left="94" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref445">Devereux RB, Roman MJ. Left ventricular</a></text>
<text top="624" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref445">hypertrophy in hypertension: stimuli, patterns, and</a></text>
<text top="638" left="63" width="164" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref445">consequences. Hypertens Res. 1999;22:1</a></text>
<text top="636" left="226" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref445">–9</a></text>
<text top="638" left="236" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref445">.</a></text>
<text top="657" left="63" width="27" height="9" font="4">S7.2-7.</text>
<text top="657" left="93" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref446">Gidding SS, Liu K, Colangelo LA, et al.</a></text>
<text top="671" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref446">Longitudinal determinants of left ventricular mass and</a></text>
<text top="684" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref446">geometry: the Coronary Artery Risk Development</a></text>
<text top="697" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref446">in Young Adults (CARDIA) Study. Circ Cardiovasc</a></text>
<text top="711" left="63" width="84" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref446">Imaging. 2013;6:769</a></text>
<text top="709" left="146" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref446">–75</a></text>
<text top="711" left="160" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref446">.</a></text>
<text top="730" left="63" width="28" height="9" font="4">S7.2-8.</text>
<text top="730" left="94" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref447">Fox ER, Musani SK, Samdarshi TE, et al. Clinical</a></text>
<text top="744" left="63" width="130" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref447">correlates and prognostic signi</a></text>
<text top="742" left="193" width="87" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref447">ﬁcance of change in</a></text>
<text top="757" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref447">standardized left ventricular mass in a community-</a></text>
<text top="771" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref447">based cohort of African Americans. J Am Heart</a></text>
<text top="784" left="63" width="94" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref447">Assoc. 2015;4:e001224</a></text>
<text top="784" left="157" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref447">.</a></text>
<text top="803" left="63" width="28" height="9" font="4">S7.2-9.</text>
<text top="803" left="94" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref448">Lieb W, Xanthakis V, Sullivan LM, et al.</a></text>
<text top="817" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref448">Longitudinal tracking of left ventricular mass over</a></text>
<text top="830" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref448">the adult life course: clinical correlates of short- and</a></text>
<text top="844" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref448">long-term change in the framingham offspring study.</a></text>
<text top="857" left="63" width="110" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref448">Circulation. 2009;119:3085</a></text>
<text top="855" left="173" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref448">–92</a></text>
<text top="857" left="187" width="3" height="9" font="4">.</text>
<text top="876" left="63" width="32" height="9" font="4">S7.2-10.</text>
<text top="876" left="98" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref449">Liebson PR, Grandits GA, Dianzumba S, et al.</a></text>
<text top="890" left="63" width="61" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref449">Comparison of</a></text>
<text top="888" left="129" width="151" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref449">ﬁve antihypertensive monotherapies</a></text>
<text top="903" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref449">and placebo for change in left ventricular mass in</a></text>
<text top="917" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref449">patients receiving nutritional-hygienic therapy in the</a></text>
<text top="930" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref449">Treatment of Mild Hypertension Study (TOMHS). Cir-</a></text>
<text top="944" left="63" width="88" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref449">culation. 1995;91:698</a></text>
<text top="942" left="151" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref449">–706</a></text>
<text top="944" left="171" width="3" height="9" font="4">.</text>
<text top="963" left="63" width="30" height="9" font="4">S7.2-11.</text>
<text top="963" left="96" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref450">Fagard RH, Celis H, Thijs L, et al. Regression of</a></text>
<text top="976" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref450">left ventricular mass by antihypertensive treatment: a</a></text>
<text top="990" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref450">meta-analysis of randomized comparative studies.</a></text>
<text top="1003" left="63" width="117" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref450">Hypertension. 2009;54:1084</a></text>
<text top="1002" left="180" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref450">–91</a></text>
<text top="1003" left="194" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref450">.</a></text>
<text top="1022" left="63" width="31" height="9" font="4">S7.2-12.</text>
<text top="1022" left="97" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref451">Norman JE Jr., Levy D. Improved electrocar-</a></text>
<text top="1036" left="63" width="42" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref451">diographic</a></text>
<text top="1036" left="115" width="38" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref451">detection</a></text>
<text top="1036" left="164" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref451">of</a></text>
<text top="1036" left="183" width="73" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref451">echocardiographic</a></text>
<text top="1036" left="266" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref451">left</a></text>
<text top="1049" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref451">ventricular hypertrophy: results of a correlated data</a></text>
<text top="1063" left="63" width="194" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref451">base approach. J Am Coll Cardiol. 1995;26:1022</a></text>
<text top="1061" left="256" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref451">–9</a></text>
<text top="1063" left="266" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref451">.</a></text>
<text top="1082" left="63" width="31" height="9" font="4">S7.2-13.</text>
<text top="1082" left="97" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref452">da Costa W, Riera ARP, Costa F de A, et al.</a></text>
<text top="1095" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref452">Correlation of electrocardiographic left ventricular</a></text>
<text top="143" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref452">hypertrophy criteria with left ventricular mass by</a></text>
<text top="156" left="301" width="64" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref452">echocardiogram</a></text>
<text top="156" left="374" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref452">in</a></text>
<text top="156" left="390" width="23" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref452">obese</a></text>
<text top="156" left="423" width="51" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref452">hypertensive</a></text>
<text top="156" left="483" width="35" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref452">patients.</a></text>
<text top="170" left="301" width="120" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref452">J Electrocardiol. 2008;41:724</a></text>
<text top="168" left="421" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref452">–9</a></text>
<text top="170" left="430" width="3" height="9" font="4">.</text>
<text top="187" left="301" width="32" height="9" font="4">S7.2-14.</text>
<text top="187" left="336" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref453">Bacharova L, Schocken D, Estes EH, et al.</a></text>
<text top="200" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref453">The role of ECG in the diagnosis of left ventricular</a></text>
<text top="214" left="301" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref453">hypertrophy. Curr Cardiol Rev. 2014;10:257</a></text>
<text top="212" left="476" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref453">–61</a></text>
<text top="214" left="489" width="3" height="9" font="4">.</text>
<text top="231" left="301" width="31" height="9" font="4">S7.2-15.</text>
<text top="231" left="335" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref454">Bang CN, Devereux RB, Okin PM. Regression</a></text>
<text top="244" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref454">of electrocardiographic left ventricular hypertrophy or</a></text>
<text top="258" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref454">strain is associated with lower incidence of cardiovas-</a></text>
<text top="271" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref454">cular morbidity and mortality in hypertensive patients</a></text>
<text top="285" left="301" width="171" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref454">independent of blood pressure reduction</a></text>
<text top="283" left="472" width="46" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref454">–a LIFE re-</a></text>
<text top="298" left="301" width="143" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref454">view. J Electrocardiol. 2014;47:630</a></text>
<text top="297" left="444" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref454">–5</a></text>
<text top="298" left="453" width="3" height="9" font="4">.</text>
<text top="317" left="301" width="32" height="9" font="4">S7.2-16.</text>
<text top="317" left="336" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref455">Pewsner D, Juni P, Egger M, et al. Accuracy of</a></text>
<text top="330" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref455">electrocardiography in diagnosis of left ventricular</a></text>
<text top="344" left="301" width="49" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref455">hypertrophy</a></text>
<text top="344" left="359" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref455">in</a></text>
<text top="344" left="375" width="28" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref455">arterial</a></text>
<text top="344" left="412" width="55" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref455">hypertension:</a></text>
<text top="344" left="476" width="42" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref455">systematic</a></text>
<text top="357" left="301" width="108" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref455">review. BMJ. 2007;335:711</a></text>
<text top="357" left="409" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref455">.</a></text>
<text top="376" left="301" width="31" height="9" font="4">S7.2-17.</text>
<text top="376" left="335" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref456">Rautaharju PM, Soliman EZ. Electrocardio-</a></text>
<text top="389" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref456">graphic left ventricular hypertrophy and the risk of</a></text>
<text top="402" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref456">adverse cardiovascular events: a critical appraisal.</a></text>
<text top="416" left="301" width="120" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref456">J Electrocardiol. 2014;47:649</a></text>
<text top="414" left="421" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref456">–54</a></text>
<text top="416" left="435" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref456">.</a></text>
<text top="434" left="301" width="32" height="9" font="4">S7.2-18.</text>
<text top="434" left="336" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref457">Armstrong AC, Gidding S, Gjesdal O, et al. LV</a></text>
<text top="448" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref457">mass assessed by echocardiography and CMR, cardio-</a></text>
<text top="461" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref457">vascular outcomes, and medical practice. J Am Coll</a></text>
<text top="475" left="301" width="96" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref457">Cardiol Img. 2012;5:837</a></text>
<text top="473" left="397" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref457">–48</a></text>
<text top="475" left="412" width="3" height="9" font="4">.</text>
<text top="493" left="301" width="32" height="9" font="4">S7.2-19.</text>
<text top="493" left="336" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref458">Greenland P, Alpert JS, Beller GA, et al. 2010</a></text>
<text top="507" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref458">ACCF/AHA guideline for assessment of cardiovascular</a></text>
<text top="520" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref458">risk in asymptomatic adults: a report of the American</a></text>
<text top="534" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref458">College of Cardiology Foundation/American Heart</a></text>
<text top="547" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref458">Association Task Force on Practice Guidelines. J Am</a></text>
<text top="561" left="301" width="104" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref458">Coll Cardiol. 2010;56:e50</a></text>
<text top="559" left="405" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref458">–103</a></text>
<text top="561" left="423" width="3" height="9" font="4">.</text>
<text top="579" left="301" width="33" height="9" font="4">S7.2-20.</text>
<text top="579" left="337" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref459">Devereux RB, Wachtell K, Gerdts E, et al.</a></text>
<text top="593" left="301" width="63" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref459">Prognostic signi</a></text>
<text top="591" left="364" width="154" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref459">ﬁcance of left ventricular mass change</a></text>
<text top="606" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref459">during treatment of hypertension. JAMA. 2004;292:</a></text>
<text top="620" left="301" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref459">2350</a></text>
<text top="618" left="322" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref459">–6</a></text>
<text top="620" left="331" width="3" height="9" font="4">.</text>
<text top="638" left="301" width="31" height="9" font="4">S7.2-21.</text>
<text top="638" left="335" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref460">Armstrong AC, Jacobs DR Jr., Gidding SS, et al.</a></text>
<text top="651" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref460">Framingham score and LV mass predict events in young</a></text>
<text top="665" left="301" width="196" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref460">adults: CARDIA study. Int J Cardiol. 2014;172:350</a></text>
<text top="663" left="497" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref460">–5</a></text>
<text top="665" left="505" width="3" height="9" font="4">.</text>
<text top="683" left="301" width="32" height="9" font="4">S7.2-22.</text>
<text top="683" left="336" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref461">Okwuosa TM, Soliman EZ, Lopez F, et al. Left</a></text>
<text top="697" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref461">ventricular hypertrophy and cardiovascular disease risk</a></text>
<text top="710" left="301" width="88" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref461">prediction and reclassi</a></text>
<text top="709" left="389" width="129" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref461">ﬁcation in blacks and whites: the</a></text>
<text top="724" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref461">Atherosclerosis Risk in Communities Study. Am Heart</a></text>
<text top="737" left="301" width="63" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref461">J. 2015;169:155</a></text>
<text top="736" left="364" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref461">–61</a></text>
<text top="737" left="377" width="3" height="9" font="4">.</text>
<text top="756" left="301" width="32" height="9" font="4">S7.2-23.</text>
<text top="756" left="336" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref462">Zalawadiya SK, Gunasekaran PC, Bavishi CP,</a></text>
<text top="769" left="301" width="208" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref462">et al. Left ventricular hypertrophy and risk reclassi</a></text>
<text top="768" left="509" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref462">ﬁ-</a></text>
<text top="783" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref462">cation for coronary events in multi-ethnic adults. Eur J</a></text>
<text top="796" left="301" width="104" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref462">Prev Cardiol. 2015;22:673</a></text>
<text top="795" left="405" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref462">–9</a></text>
<text top="796" left="414" width="3" height="9" font="4">.</text>
<text top="836" left="301" width="166" height="12" font="26">8 . T R E A T M E N T O F H I G H B P</text>
<text top="864" left="301" width="145" height="9" font="23">8.1. Pharmacological Treatment</text>
<text top="885" left="301" width="217" height="9" font="4">8.1.1. Initiation of Pharmacological BP Treat-</text>
<text top="898" left="301" width="186" height="9" font="4">ment in the Context of Overall CVD Risk</text>
<text top="912" left="301" width="33" height="9" font="4">S8.1.1-1.</text>
<text top="912" left="337" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref463">Lloyd-Jones DM, Evans JC, Levy D. Hyper-</a></text>
<text top="925" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref463">tension in adults across the age spectrum: current</a></text>
<text top="939" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref463">outcomes and control in the community. JAMA. 2005;</a></text>
<text top="952" left="301" width="35" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref463">294:466</a></text>
<text top="951" left="336" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref463">–72</a></text>
<text top="952" left="350" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref463">.</a></text>
<text top="969" left="301" width="33" height="9" font="4">S8.1.1-2.</text>
<text top="969" left="338" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref464">Ozyilmaz A, Bakker SJL, de Zeeuw D, et al.</a></text>
<text top="983" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref464">Screening for albuminuria with subsequent screening</a></text>
<text top="996" left="301" width="203" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref464">for hypertension and hypercholesterolaemia identi</a></text>
<text top="995" left="504" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref464">ﬁes</a></text>
<text top="1010" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref464">subjects in whom treatment is warranted to prevent</a></text>
<text top="1023" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref464">cardiovascular events. Nephrol Dial Transplant. 2013;</a></text>
<text top="1036" left="301" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref464">28:2805</a></text>
<text top="1035" left="335" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref464">–15</a></text>
<text top="1036" left="348" width="3" height="9" font="4">.</text>
<text top="1055" left="301" width="33" height="9" font="4">S8.1.1-3.</text>
<text top="1055" left="338" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref465">Peters SAE, Huxley RR, Woodward M. Com-</a></text>
<text top="1069" left="301" width="98" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref465">parison of the sex-speci</a></text>
<text top="1067" left="399" width="119" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref465">ﬁc associations between sys-</a></text>
<text top="1082" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref465">tolic blood pressure and the risk of cardiovascular</a></text>
<text top="1095" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref465">disease: a systematic review and meta-analysis of 124</a></text>
<text top="143" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref465">cohort studies, including 1.2 million individuals. Stroke.</a></text>
<text top="156" left="539" width="56" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref465">2013;44:2394</a></text>
<text top="155" left="595" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref465">–401</a></text>
<text top="156" left="615" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref465">.</a></text>
<text top="175" left="539" width="34" height="9" font="4">S8.1.1-4.</text>
<text top="175" left="577" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref466">Schoenfeld SR, Kasturi S, Costenbader KH.</a></text>
<text top="188" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref466">The epidemiology of atherosclerotic cardiovascular</a></text>
<text top="202" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref466">disease among patients with SLE: a systematic review.</a></text>
<text top="215" left="539" width="140" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref466">Semin Arthritis Rheum. 2013;43:77</a></text>
<text top="214" left="679" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref466">–95</a></text>
<text top="215" left="693" width="3" height="9" font="4">.</text>
<text top="234" left="539" width="33" height="9" font="4">S8.1.1-5.</text>
<text top="234" left="576" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref467">Lawes CMM, Bennett DA, Lewington S, et al.</a></text>
<text top="247" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref467">Blood pressure and coronary heart disease: a review of</a></text>
<text top="261" left="539" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref467">the evidence. Semin Vasc Med. 2002;2:355</a></text>
<text top="259" left="713" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref467">–68</a></text>
<text top="261" left="729" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref467">.</a></text>
<text top="279" left="539" width="34" height="9" font="4">S8.1.1-6.</text>
<text top="279" left="577" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref468">Lewington S, Clarke R, Qizilbash N, et al.</a></text>
<text top="293" left="539" width="39" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref468">Age-speci</a></text>
<text top="291" left="579" width="178" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref468">ﬁc relevance of usual blood pressure to</a></text>
<text top="306" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref468">vascular mortality: a meta-analysis of individual data</a></text>
<text top="320" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref468">for one million adults in 61 prospective studies. Lancet.</a></text>
<text top="333" left="539" width="64" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref468">2002;360:1903</a></text>
<text top="331" left="603" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref468">–13</a></text>
<text top="333" left="615" width="3" height="9" font="4">.</text>
<text top="352" left="539" width="33" height="9" font="4">S8.1.1-7.</text>
<text top="352" left="576" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref469">Takashima N, Ohkubo T, Miura K, et al.</a></text>
<text top="365" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref469">Long-term risk of BP values above normal for cardio-</a></text>
<text top="379" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref469">vascular mortality: a 24-year observation of Japanese</a></text>
<text top="392" left="539" width="194" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref469">aged 30 to 92 years. J Hypertens. 2012;30:2299</a></text>
<text top="390" left="733" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref469">–306</a></text>
<text top="392" left="754" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref469">.</a></text>
<text top="410" left="539" width="34" height="9" font="4">S8.1.1-8.</text>
<text top="410" left="577" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref470">Murakami Y. Meta-analyses using individual</a></text>
<text top="424" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref470">participant data from cardiovascular cohort studies in</a></text>
<text top="437" left="539" width="26" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref470">Japan:</a></text>
<text top="437" left="577" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref470">current</a></text>
<text top="437" left="617" width="24" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref470">status</a></text>
<text top="437" left="653" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref470">and</a></text>
<text top="437" left="679" width="25" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref470">future</a></text>
<text top="437" left="715" width="42" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref470">directions.</a></text>
<text top="451" left="539" width="99" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref470">J Epidemiol. 2014;24:96</a></text>
<text top="449" left="638" width="18" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref470">–101</a></text>
<text top="451" left="656" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref470">.</a></text>
<text top="469" left="539" width="34" height="9" font="4">S8.1.1-9.</text>
<text top="469" left="577" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref471">van Dieren S, Kengne AP, Chalmers J, et al.</a></text>
<text top="483" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref471">Effects of blood pressure lowering on cardiovascular</a></text>
<text top="496" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref471">outcomes in different cardiovascular risk groups</a></text>
<text top="510" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref471">among participants with type 2 diabetes. Diabetes Res</a></text>
<text top="523" left="539" width="90" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref471">Clin Pract. 2012;98:83</a></text>
<text top="522" left="630" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref471">–90</a></text>
<text top="523" left="645" width="3" height="9" font="4">.</text>
<text top="543" left="539" width="39" height="9" font="4">S8.1.1-10.</text>
<text top="543" left="581" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref472">Sundstrom J, Arima H, Woodward M, et al.</a></text>
<text top="557" left="539" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref472">Blood Pressure Lowering Treatment Trialists</a></text>
<text top="555" left="721" width="35" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref472">’ Collab-</a></text>
<text top="570" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref472">oration. Blood pressure-lowering treatment based</a></text>
<text top="584" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref472">on cardiovascular risk: a meta-analysis of individual</a></text>
<text top="597" left="539" width="142" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref472">patient data. Lancet. 2014;384:591</a></text>
<text top="595" left="681" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref472">–8</a></text>
<text top="597" left="691" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref472">.</a></text>
<text top="617" left="539" width="36" height="9" font="4">S8.1.1-11.</text>
<text top="617" left="579" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref473">Turnbull F, Neal B, Algert C, et al. Effects of</a></text>
<text top="630" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref473">different blood pressure-lowering regimens on major</a></text>
<text top="644" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref473">cardiovascular events in individuals with and without</a></text>
<text top="657" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref473">diabetes mellitus: results of prospectively designed</a></text>
<text top="671" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref473">overviews of randomized trials. Arch Intern Med.</a></text>
<text top="684" left="539" width="60" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref473">2005;165:1410</a></text>
<text top="683" left="600" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref473">–9</a></text>
<text top="684" left="609" width="3" height="9" font="4">.</text>
<text top="704" left="539" width="37" height="9" font="4">S8.1.1-12.</text>
<text top="704" left="580" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref474">Wang J-G, Staessen JA, Franklin SS, et al.</a></text>
<text top="718" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref474">Systolic and diastolic blood pressure lowering as de-</a></text>
<text top="731" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref474">terminants of cardiovascular outcome. Hypertension.</a></text>
<text top="745" left="539" width="54" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref474">2005;45:907</a></text>
<text top="743" left="593" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref474">–13</a></text>
<text top="745" left="605" width="3" height="9" font="4">.</text>
<text top="765" left="539" width="37" height="9" font="4">S8.1.1-13.</text>
<text top="765" left="580" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref475">Turnbull F, Woodward M, Neal B, et al.</a></text>
<text top="778" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref475">Do men and women respond differently to blood</a></text>
<text top="792" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref475">pressure-lowering treatment? Results of prospectively</a></text>
<text top="805" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref475">designed overviews of randomized trials. Eur Heart J.</a></text>
<text top="818" left="539" width="60" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref475">2008;29:2669</a></text>
<text top="817" left="599" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref475">–80</a></text>
<text top="818" left="615" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref475">.</a></text>
<text top="837" left="539" width="38" height="9" font="4">S8.1.1-14.</text>
<text top="837" left="581" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref476">Turnbull F, Neal B, Ninomiya T, et al. Effects</a></text>
<text top="850" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref476">of different regimens to lower blood pressure on major</a></text>
<text top="864" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref476">cardiovascular events in older and younger adults:</a></text>
<text top="877" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref476">meta-analysis of randomised trials. BMJ. 2008;336:</a></text>
<text top="891" left="539" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref476">1121</a></text>
<text top="889" left="555" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref476">–3</a></text>
<text top="891" left="564" width="3" height="9" font="4">.</text>
<text top="909" left="539" width="37" height="9" font="4">S8.1.1-15.</text>
<text top="909" left="580" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref477">Du X, Ninomiya T, de Galan B, et al. Risks of</a></text>
<text top="923" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref477">cardiovascular events and effects of routine blood</a></text>
<text top="936" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref477">pressure lowering among patients with type 2 diabetes</a></text>
<text top="950" left="539" width="39" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref477">and atrial</a></text>
<text top="948" left="582" width="175" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref477">ﬁbrillation: results of the ADVANCE study.</a></text>
<text top="963" left="539" width="107" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref477">Eur Heart J. 2009;30:1128</a></text>
<text top="962" left="647" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref477">–35</a></text>
<text top="963" left="660" width="3" height="9" font="4">.</text>
<text top="982" left="539" width="38" height="9" font="4">S8.1.1-16.</text>
<text top="982" left="581" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref478">Czernichow S, Ninomiya T, Huxley R, et al.</a></text>
<text top="995" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref478">Impact of blood pressure lowering on cardiovascular</a></text>
<text top="1009" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref478">outcomes in normal weight, overweight, and obese</a></text>
<text top="1022" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref478">individuals: the Perindopril Protection Against Recur-</a></text>
<text top="1035" left="539" width="205" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref478">rent Stroke Study trial. Hypertension. 2010;55:1193</a></text>
<text top="1034" left="744" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref478">–8</a></text>
<text top="1035" left="754" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref478">.</a></text>
<text top="1054" left="539" width="37" height="9" font="4">S8.1.1-17.</text>
<text top="1054" left="580" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref479">Heerspink HJL, Ninomiya T, Perkovic V, et al.</a></text>
<text top="1067" left="539" width="52" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref479">Effects of a</a></text>
<text top="1066" left="598" width="159" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref479">ﬁxed combination of perindopril and</a></text>
<text top="1081" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref479">indapamide in patients with type 2 diabetes and</a></text>
<text top="1094" left="539" width="199" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref479">chronic kidney disease. Eur Heart J. 2010;31:2888</a></text>
<text top="1093" left="739" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref479">–96</a></text>
<text top="1094" left="754" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref479">.</a></text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="18" height="9" font="4">e221</text>
</page>
<page number="96" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="38" height="9" font="4">S8.1.1-18.</text>
<text top="143" left="149" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref480">Ninomiya T, Zoungas S, Neal B, et al.</a></text>
<text top="156" left="108" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref480">Ef</a></text>
<text top="155" left="116" width="209" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref480">ﬁcacy and safety of routine blood pressure lowering</a></text>
<text top="170" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref480">in older patients with diabetes: results from the</a></text>
<text top="183" left="108" width="171" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref480">ADVANCE trial. J Hypertens. 2010;28:1141</a></text>
<text top="182" left="278" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref480">–9</a></text>
<text top="183" left="288" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref480">.</a></text>
<text top="202" left="108" width="38" height="9" font="4">S8.1.1-19.</text>
<text top="202" left="149" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref481">Collier DJ, Poulter NR, Dahlof B, et al.</a></text>
<text top="215" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref481">Impact of amlodipine-based therapy among older</a></text>
<text top="229" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref481">and younger patients in the Anglo-Scandinavian</a></text>
<text top="242" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref481">Cardiac Outcomes Trial-Blood Pressure Lowering Arm</a></text>
<text top="256" left="108" width="167" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref481">(ASCOT-BPLA). J Hypertens. 2011;29:583</a></text>
<text top="254" left="274" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref481">–91</a></text>
<text top="256" left="287" width="3" height="9" font="4">.</text>
<text top="274" left="108" width="39" height="9" font="4">S8.1.1-20.</text>
<text top="274" left="150" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref482">Ninomiya T, Perkovic V, Turnbull F, et al.</a></text>
<text top="288" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref482">Blood pressure lowering and major cardiovascular</a></text>
<text top="301" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref482">events in people with and without chronic kidney</a></text>
<text top="315" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref482">disease: meta-analysis of randomised controlled trials.</a></text>
<text top="328" left="108" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref482">Blood Pressure Lowering Treatment Trialists</a></text>
<text top="326" left="290" width="35" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref482">’ Collab-</a></text>
<text top="342" left="108" width="121" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref482">oration. BMJ. 2013;347:f5680</a></text>
<text top="342" left="229" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref482">.</a></text>
<text top="360" left="108" width="37" height="9" font="4">S8.1.1-21.</text>
<text top="360" left="148" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref483">Redon J, Mancia G, Sleight P, et al. Safety</a></text>
<text top="374" left="108" width="27" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref483">and ef</a></text>
<text top="372" left="134" width="190" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref483">ﬁcacy of low blood pressures among patients</a></text>
<text top="387" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref483">with diabetes: subgroup analyses from the ONTARGET</a></text>
<text top="400" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref483">(ONgoing Telmisartan Alone and in combination with</a></text>
<text top="414" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref483">Ramipril Global Endpoint Trial). J Am Coll Cardiol.</a></text>
<text top="427" left="108" width="45" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref483">2012;59:74</a></text>
<text top="426" left="153" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref483">–83</a></text>
<text top="427" left="167" width="3" height="9" font="4">.</text>
<text top="446" left="108" width="38" height="9" font="4">S8.1.1-22.</text>
<text top="446" left="149" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref484">Ogden LG, He J, Lydick E, et al. Long-term</a></text>
<text top="459" left="108" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref484">absolute bene</a></text>
<text top="458" left="164" width="160" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref484">ﬁt of lowering blood pressure in hyper-</a></text>
<text top="473" left="108" width="208" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref484">tensive patients according to the JNC VI risk strati</a></text>
<text top="471" left="316" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref484">ﬁ-</a></text>
<text top="486" left="108" width="142" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref484">cation. Hypertension. 2000;35:539</a></text>
<text top="485" left="249" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref484">–43</a></text>
<text top="486" left="263" width="3" height="9" font="4">.</text>
<text top="505" left="108" width="38" height="9" font="4">S8.1.1-23.</text>
<text top="505" left="149" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref485">van</a></text>
<text top="505" left="176" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref485">der</a></text>
<text top="505" left="203" width="26" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref485">Leeuw</a></text>
<text top="505" left="242" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref485">J,</a></text>
<text top="505" left="262" width="33" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref485">Visseren</a></text>
<text top="505" left="308" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref485">FLJ,</a></text>
<text top="518" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref485">Woodward M, et al. Predicting the effects of blood</a></text>
<text top="532" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref485">pressure-lowering treatment on major cardiovascular</a></text>
<text top="545" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref485">events for individual patients with type 2 diabetes</a></text>
<text top="559" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref485">mellitus: results from Action in Diabetes and Vascular</a></text>
<text top="572" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref485">Disease: Preterax and Diamicron MR Controlled Eval-</a></text>
<text top="585" left="108" width="137" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref485">uation. Hypertension. 2015;65:115</a></text>
<text top="584" left="244" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref485">–21</a></text>
<text top="585" left="257" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref485">.</a></text>
<text top="607" left="108" width="217" height="9" font="4">8.1.2. BP Treatment Threshold and the Use of</text>
<text top="621" left="108" width="217" height="9" font="4">CVD Risk Estimation to Guide Drug Treatment</text>
<text top="634" left="108" width="74" height="9" font="4">of Hypertension</text>
<text top="648" left="108" width="33" height="9" font="4">S8.1.2-1.</text>
<text top="648" left="144" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref486">Law MR, Morris JK, Wald NJ. Use of</a></text>
<text top="661" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref486">blood pressure lowering drugs in the prevention</a></text>
<text top="675" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref486">of cardiovascular disease: meta-analysis of 147</a></text>
<text top="688" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref486">randomised trials in the context of expectations from</a></text>
<text top="702" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref486">prospective epidemiological studies. BMJ. 2009;338:</a></text>
<text top="715" left="108" width="25" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref486">b1665</a></text>
<text top="715" left="132" width="3" height="9" font="4">.</text>
<text top="734" left="108" width="34" height="9" font="4">S8.1.2-2.</text>
<text top="734" left="145" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref487">Ettehad D, Emdin CA, Kiran A, et al.</a></text>
<text top="747" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref487">Blood pressure lowering for prevention of cardiovas-</a></text>
<text top="761" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref487">cular disease and death: a systematic review and</a></text>
<text top="774" left="108" width="148" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref487">meta-analysis. Lancet. 2016;387:957</a></text>
<text top="772" left="256" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref487">–67</a></text>
<text top="774" left="270" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref487">.</a></text>
<text top="792" left="108" width="34" height="9" font="4">S8.1.2-3.</text>
<text top="792" left="145" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref488">Sundstrom J, Arima H, Woodward M, et al.</a></text>
<text top="806" left="108" width="23" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref488">Blood</a></text>
<text top="806" left="143" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref488">Pressure</a></text>
<text top="806" left="189" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref488">Lowering</a></text>
<text top="806" left="238" width="42" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref488">Treatment</a></text>
<text top="806" left="292" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref488">Trialists</a></text>
<text top="804" left="322" width="2" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref488">’</a></text>
<text top="819" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref488">Collaboration. Blood pressure-lowering treatment</a></text>
<text top="833" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref488">based on cardiovascular risk: a meta-analysis of</a></text>
<text top="846" left="108" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref488">individual patient data. Lancet. 2014;384:591</a></text>
<text top="845" left="291" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref488">–8</a></text>
<text top="846" left="300" width="3" height="9" font="4">.</text>
<text top="865" left="108" width="35" height="9" font="4">S8.1.2-4.</text>
<text top="865" left="146" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref489">Thomopoulos C, Parati G, Zanchetti A.</a></text>
<text top="878" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref489">Effects of blood pressure lowering on outcome inci-</a></text>
<text top="892" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref489">dence in hypertension: 2. Effects at different baseline</a></text>
<text top="905" left="108" width="156" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref489">and achieved blood pressure levels</a></text>
<text top="904" left="263" width="61" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref489">–overview and</a></text>
<text top="919" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref489">meta-analyses of randomized trials. J Hypertens.</a></text>
<text top="932" left="108" width="56" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref489">2014;32:2296</a></text>
<text top="930" left="163" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref489">–304</a></text>
<text top="932" left="184" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref489">.</a></text>
<text top="951" left="108" width="34" height="9" font="4">S8.1.2-5.</text>
<text top="951" left="145" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref490">Sundstrom J, Arima H, Jackson R, et al. Ef-</a></text>
<text top="964" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref490">fects of blood pressure reduction in mild hypertension:</a></text>
<text top="978" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref490">a systematic review and meta-analysis. Ann Intern</a></text>
<text top="991" left="108" width="77" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref490">Med. 2015;162:184</a></text>
<text top="989" left="184" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref490">–91</a></text>
<text top="991" left="197" width="3" height="9" font="4">.</text>
<text top="1010" left="108" width="35" height="9" font="4">S8.1.2-6.</text>
<text top="1010" left="146" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref491">Thompson AM, Hu T, Eshelbrenner CL, et al.</a></text>
<text top="1023" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref491">Antihypertensive treatment and secondary prevention</a></text>
<text top="1036" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref491">of cardiovascular disease events among persons</a></text>
<text top="1050" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref491">without hypertension: a meta-analysis. JAMA. 2011;</a></text>
<text top="1063" left="108" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref491">305:913</a></text>
<text top="1062" left="140" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref491">–22</a></text>
<text top="1063" left="154" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref491">.</a></text>
<text top="1082" left="108" width="34" height="9" font="4">S8.1.2-7.</text>
<text top="1082" left="145" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref492">Xie X, Atkins E, Lv J, et al. Effects of</a></text>
<text top="1095" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref492">intensive blood pressure lowering on cardiovascular</a></text>
<text top="143" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref492">and renal outcomes: updated systematic review and</a></text>
<text top="156" left="346" width="148" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref492">meta-analysis. Lancet. 2016;387:435</a></text>
<text top="155" left="494" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref492">–43</a></text>
<text top="156" left="508" width="3" height="9" font="4">.</text>
<text top="175" left="346" width="35" height="9" font="4">S8.1.2-8.</text>
<text top="175" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref493">Wright JT Jr., Williamson JD, Whelton PK,</a></text>
<text top="189" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref493">et al. A randomized trial of intensive versus standard</a></text>
<text top="202" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref493">blood-pressure control. SPRINT Research Group.</a></text>
<text top="215" left="346" width="118" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref493">N Engl J Med. 2015;373:2103</a></text>
<text top="214" left="464" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref493">–16</a></text>
<text top="215" left="477" width="3" height="9" font="4">.</text>
<text top="234" left="346" width="35" height="9" font="4">S8.1.2-9.</text>
<text top="234" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref494">Czernichow S, Zanchetti A, Turnbull F, et al.</a></text>
<text top="248" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref494">The effects of blood pressure reduction and of</a></text>
<text top="261" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref494">different blood pressure-lowering regimens on major</a></text>
<text top="275" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref494">cardiovascular events according to baseline blood</a></text>
<text top="288" left="346" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref494">pressure:</a></text>
<text top="288" left="394" width="55" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref494">meta-analysis</a></text>
<text top="288" left="461" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref494">of</a></text>
<text top="288" left="482" width="47" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref494">randomized</a></text>
<text top="288" left="541" width="22" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref494">trials.</a></text>
<text top="301" left="346" width="93" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref494">J Hypertens. 2011;29:4</a></text>
<text top="300" left="439" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref494">–16</a></text>
<text top="301" left="452" width="3" height="9" font="4">.</text>
<text top="320" left="346" width="39" height="9" font="4">S8.1.2-10.</text>
<text top="320" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref495">Lewington S, Clarke R, Qizilbash N, et al.</a></text>
<text top="334" left="346" width="39" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref495">Age-speci</a></text>
<text top="332" left="385" width="178" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref495">ﬁc relevance of usual blood pressure to</a></text>
<text top="347" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref495">vascular mortality: a meta-analysis of individual data</a></text>
<text top="360" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref495">for one million adults in 61 prospective studies. Lancet.</a></text>
<text top="374" left="346" width="64" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref495">2002;360:1903</a></text>
<text top="372" left="409" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref495">–13</a></text>
<text top="374" left="422" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref495">.</a></text>
<text top="393" left="346" width="37" height="9" font="4">S8.1.2-11.</text>
<text top="393" left="386" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref496">van Dieren S, Kengne AP, Chalmers J, et al.</a></text>
<text top="406" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref496">Effects of blood pressure lowering on cardiovascular</a></text>
<text top="419" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref496">outcomes in different cardiovascular risk groups</a></text>
<text top="433" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref496">among participants with type 2 diabetes. Diabetes Res</a></text>
<text top="446" left="346" width="91" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref496">Clin Pract. 2012;98:83</a></text>
<text top="445" left="436" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref496">–90</a></text>
<text top="446" left="452" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref496">.</a></text>
<text top="465" left="346" width="38" height="9" font="4">S8.1.2-12.</text>
<text top="465" left="387" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref497">Montgomery AA, Fahey T, Ben-Shlomo Y,</a></text>
<text top="478" left="346" width="54" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref497">et al. The in</a></text>
<text top="477" left="400" width="163" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref497">ﬂuence of absolute cardiovascular risk,</a></text>
<text top="492" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref497">patient utilities, and costs on the decision to treat</a></text>
<text top="505" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref497">hypertension: a Markov decision analysis. J Hypertens.</a></text>
<text top="519" left="346" width="53" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref497">2003;21:1753</a></text>
<text top="517" left="399" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref497">–9</a></text>
<text top="519" left="409" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref497">.</a></text>
<text top="537" left="346" width="38" height="9" font="4">S8.1.2-13.</text>
<text top="537" left="387" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref498">Kassai B, Boissel J-P, Cucherat M, et al.</a></text>
<text top="551" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref498">Treatment of high blood pressure and gain in event-</a></text>
<text top="564" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref498">free life expectancy. Vasc Health Risk Manag. 2005;</a></text>
<text top="578" left="346" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref498">1:163</a></text>
<text top="576" left="366" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref498">–9</a></text>
<text top="578" left="376" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref498">.</a></text>
<text top="596" left="346" width="217" height="9" font="4">S8.1.2-13a. ACC/AHA Pooled Cohort Equations. Avail-</text>
<text top="610" left="346" width="40" height="9" font="4">able at: <a href="http://tools.acc.org/ASCVD-Risk-Estimator/">(</a></text>
<text top="610" left="386" width="174" height="9" font="8"><a href="http://tools.acc.org/ASCVD-Risk-Estimator/">http://tools.acc.org/ASCVD-Risk-Estimator/</a></text>
<text top="610" left="560" width="3" height="9" font="4">.</text>
<text top="623" left="346" width="116" height="9" font="4">Accessed November 3, 2017.</text>
<text top="642" left="346" width="39" height="9" font="4">S8.1.2-14.</text>
<text top="642" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref500">Rubinstein A, Colantonio L, Bardach A, et al.</a></text>
<text top="655" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref500">Estimation of the burden of cardiovascular disease</a></text>
<text top="669" left="346" width="90" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref500">attributable to modi</a></text>
<text top="667" left="436" width="127" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref500">ﬁable risk factors and cost-</a></text>
<text top="682" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref500">effectiveness analysis of preventative interventions</a></text>
<text top="696" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref500">to reduce this burden in Argentina. BMC Public Health.</a></text>
<text top="709" left="346" width="51" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref500">2010;10:627</a></text>
<text top="709" left="397" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref500">.</a></text>
<text top="728" left="346" width="38" height="9" font="4">S8.1.2-15.</text>
<text top="728" left="387" width="22" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref501">Baker</a></text>
<text top="728" left="419" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref501">S,</a></text>
<text top="728" left="435" width="23" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref501">Priest</a></text>
<text top="728" left="467" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref501">P,</a></text>
<text top="728" left="483" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref501">Jackson</a></text>
<text top="728" left="524" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref501">R.</a></text>
<text top="728" left="541" width="22" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref501">Using</a></text>
<text top="741" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref501">thresholds based on risk of cardiovascular disease to</a></text>
<text top="755" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref501">target treatment for hypertension: modelling events</a></text>
<text top="768" left="346" width="203" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref501">averted and number treated. BMJ. 2000;320:680</a></text>
<text top="767" left="549" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref501">–5</a></text>
<text top="768" left="558" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref501">.</a></text>
<text top="787" left="346" width="39" height="9" font="4">S8.1.2-16.</text>
<text top="787" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref502">Gaziano TA, Steyn K, Cohen DJ, et al.</a></text>
<text top="800" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref502">Cost-effectiveness analysis of hypertension guidelines</a></text>
<text top="814" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref502">in South Africa: absolute risk versus blood pressure</a></text>
<text top="827" left="346" width="133" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref502">level. Circulation. 2005;112:3569</a></text>
<text top="826" left="479" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref502">–76</a></text>
<text top="827" left="493" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref502">.</a></text>
<text top="846" left="346" width="38" height="9" font="4">S8.1.2-17.</text>
<text top="846" left="387" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref503">Eddy DM, Adler J, Patterson B, et al.</a></text>
<text top="859" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref503">Individualized guidelines: the potential for increasing</a></text>
<text top="873" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref503">quality and reducing costs. Ann Intern Med. 2011;154:</a></text>
<text top="886" left="346" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref503">627</a></text>
<text top="885" left="361" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref503">–34</a></text>
<text top="886" left="375" width="3" height="9" font="4">.</text>
<text top="905" left="346" width="39" height="9" font="4">S8.1.2-18.</text>
<text top="905" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref504">Marchant I, Nony P, Cucherat M, et al.</a></text>
<text top="918" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref504">The global risk approach should be better applied in French</a></text>
<text top="932" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref504">hypertensive patients: a comparison between simulation</a></text>
<text top="945" left="346" width="191" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref504">and observation studies. PLoS ONE. 2011;6:e17508</a></text>
<text top="945" left="536" width="3" height="9" font="4">.</text>
<text top="964" left="346" width="39" height="9" font="4">S8.1.2-19.</text>
<text top="964" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref505">Cadilhac DA, Carter R, Thrift AG, et al.</a></text>
<text top="977" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref505">Organized blood pressure control programs to prevent</a></text>
<text top="991" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref505">stroke in Australia: would they be cost-effective?</a></text>
<text top="1004" left="346" width="85" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref505">Stroke. 2012;43:1370</a></text>
<text top="1003" left="431" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref505">–5</a></text>
<text top="1004" left="440" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref505">.</a></text>
<text top="1023" left="346" width="40" height="9" font="4">S8.1.2-20.</text>
<text top="1023" left="389" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref506">Cobiac LJ, Magnus A, Barendregt JJ, et al.</a></text>
<text top="1036" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref506">Improving the cost-effectiveness of cardiovascular</a></text>
<text top="1050" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref506">disease prevention in Australia: a modelling study.</a></text>
<text top="1063" left="346" width="130" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref506">BMC Public Health. 2012;12:398</a></text>
<text top="1063" left="476" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref506">.</a></text>
<text top="1082" left="346" width="38" height="9" font="4">S8.1.2-21.</text>
<text top="1082" left="387" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref507">Cobiac LJ, Magnus A, Lim S, et al. Which</a></text>
<text top="1095" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref507">interventions offer best value for money in primary</a></text>
<text top="143" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref507">prevention of cardiovascular disease? PLoS ONE. 2012;</a></text>
<text top="156" left="584" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref507">7:e41842</a></text>
<text top="156" left="621" width="3" height="9" font="4">.</text>
<text top="175" left="584" width="39" height="9" font="4">S8.1.2-22.</text>
<text top="175" left="626" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref508">Karmali KN, Lloyd-Jones DM. Global risk</a></text>
<text top="188" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref508">assessment to guide blood pressure management in</a></text>
<text top="202" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref508">cardiovascular disease prevention. Hypertension. 2017;</a></text>
<text top="215" left="584" width="23" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref508">69:e2</a></text>
<text top="214" left="608" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref508">–9</a></text>
<text top="215" left="617" width="3" height="9" font="4">.</text>
<text top="234" left="584" width="39" height="9" font="4">S8.1.2-23.</text>
<text top="234" left="626" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref509">Muntner P, Whelton PK. Using predicted</a></text>
<text top="247" left="584" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref509">cardiovascular</a></text>
<text top="247" left="650" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref509">disease</a></text>
<text top="247" left="688" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref509">risk</a></text>
<text top="247" left="712" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref509">in</a></text>
<text top="247" left="728" width="46" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref509">conjunction</a></text>
<text top="247" left="784" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref509">with</a></text>
<text top="261" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref509">blood pressure to guide antihypertensive medication</a></text>
<text top="274" left="584" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref509">treatment. J Am Coll Cardiol. 2017;69:2446</a></text>
<text top="273" left="762" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref509">–56</a></text>
<text top="274" left="776" width="3" height="9" font="4">.</text>
<text top="293" left="584" width="40" height="9" font="4">S8.1.2-24.</text>
<text top="293" left="627" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref510">Sussman J, Vijan S, Hayward R. Using</a></text>
<text top="306" left="584" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref510">bene</a></text>
<text top="305" left="604" width="198" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref510">ﬁt-based tailored treatment to improve the use of</a></text>
<text top="320" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref510">antihypertensive medications. Circulation. 2013;128:</a></text>
<text top="333" left="584" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref510">2309</a></text>
<text top="332" left="605" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref510">–17</a></text>
<text top="333" left="618" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref510">.</a></text>
<text top="352" left="584" width="39" height="9" font="4">S8.1.2-25.</text>
<text top="352" left="626" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref511">van der Leeuw J, Ridker PM, van der</a></text>
<text top="365" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref511">Graaf Y, et al. Personalized cardiovascular disease</a></text>
<text top="379" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref511">prevention by applying individualized prediction of</a></text>
<text top="392" left="584" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref511">treatment effects. Eur Heart J. 2014;35:837</a></text>
<text top="390" left="761" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref511">–43</a></text>
<text top="392" left="775" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref511">.</a></text>
<text top="411" left="584" width="40" height="9" font="4">S8.1.2-26.</text>
<text top="411" left="627" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref512">Mendis S, Lindholm LH, Mancia G, et al.</a></text>
<text top="424" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref512">World Health Organization (WHO) and International</a></text>
<text top="438" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref512">Society of Hypertension (ISH) risk prediction charts:</a></text>
<text top="451" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref512">assessment of cardiovascular risk for prevention</a></text>
<text top="464" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref512">and control of cardiovascular disease in low and</a></text>
<text top="478" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref512">middle-income countries. J Hypertens. 2007;25:</a></text>
<text top="491" left="584" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref512">1578</a></text>
<text top="490" left="604" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref512">–82</a></text>
<text top="491" left="618" width="3" height="9" font="4">.</text>
<text top="510" left="584" width="39" height="9" font="4">S8.1.2-27.</text>
<text top="510" left="626" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref513">van Dis I, Geleijnse JM, Verschuren WMM,</a></text>
<text top="523" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref513">et al. Cardiovascular risk management of hypertension</a></text>
<text top="537" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref513">and hypercholesterolaemia in the Netherlands: from</a></text>
<text top="550" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref513">unifactorial to multifactorial approach. Neth Heart J.</a></text>
<text top="564" left="584" width="51" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref513">2012;20:320</a></text>
<text top="562" left="635" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref513">–5</a></text>
<text top="564" left="644" width="3" height="9" font="4">.</text>
<text top="582" left="584" width="40" height="9" font="4">S8.1.2-28.</text>
<text top="582" left="627" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref514">Nelson MR, Doust JA. Primary prevention of</a></text>
<text top="596" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref514">cardiovascular disease: new guidelines, technologies</a></text>
<text top="609" left="584" width="167" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref514">and therapies. Med J Aust. 2013;198:606</a></text>
<text top="608" left="752" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref514">–10</a></text>
<text top="609" left="765" width="3" height="9" font="4">.</text>
<text top="628" left="584" width="40" height="9" font="4">S8.1.2-29.</text>
<text top="628" left="627" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref515">JBS3</a></text>
<text top="628" left="658" width="26" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref515">Board.</a></text>
<text top="628" left="696" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref515">Joint</a></text>
<text top="628" left="727" width="25" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref515">British</a></text>
<text top="628" left="764" width="35" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref515">Societies</a></text>
<text top="626" left="799" width="2" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref515">’</a></text>
<text top="641" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref515">consensus recommendations for the prevention of</a></text>
<text top="655" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref515">cardiovascular disease (JBS3). Heart. 2014;100 suppl</a></text>
<text top="668" left="584" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref515">2:ii1</a></text>
<text top="666" left="600" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref515">–67</a></text>
<text top="668" left="614" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref515">.</a></text>
<text top="687" left="584" width="40" height="9" font="4">S8.1.2-30.</text>
<text top="687" left="628" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref516">World Health Organization. Prevention of</a></text>
<text top="700" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref516">Cardiovascular Disease. Guidelines for Assessment and</a></text>
<text top="714" left="584" width="52" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref516">Management</a></text>
<text top="714" left="648" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref516">of</a></text>
<text top="714" left="669" width="58" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref516">Cardiovascular</a></text>
<text top="714" left="739" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref516">Risk.</a></text>
<text top="714" left="769" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref516">Geneva,</a></text>
<text top="727" left="584" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref516">Switzerland: World Health Organization; 2007</a></text>
<text top="727" left="770" width="3" height="9" font="4">.</text>
<text top="746" left="584" width="38" height="9" font="4">S8.1.2-31.</text>
<text top="746" left="625" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref517">Anderson JL, Heidenreich PA, Barnett PG,</a></text>
<text top="759" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref517">et al. ACC/AHA statement on cost/value methodol-</a></text>
<text top="772" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref517">ogy in clinical practice guidelines and performance</a></text>
<text top="786" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref517">measures: a report of the American College of</a></text>
<text top="799" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref517">Cardiology/American Heart Association Task Force on</a></text>
<text top="813" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref517">Performance Measures and Task Force on Practice</a></text>
<text top="826" left="584" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref517">Guidelines. J Am Coll Cardiol. 2014;63:2304</a></text>
<text top="825" left="767" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref517">–22</a></text>
<text top="826" left="781" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref517">.</a></text>
<text top="845" left="584" width="39" height="9" font="4">S8.1.2-32.</text>
<text top="845" left="626" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref518">Sheridan SL, Crespo E. Does the routine use</a></text>
<text top="858" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref518">of global coronary heart disease risk scores translate</a></text>
<text top="872" left="584" width="68" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref518">into clinical bene</a></text>
<text top="870" left="652" width="149" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref518">ﬁts or harms? A systematic review of</a></text>
<text top="885" left="584" width="194" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref518">the literature. BMC Health Serv Res. 2008;8:60</a></text>
<text top="885" left="778" width="3" height="9" font="4">.</text>
<text top="904" left="584" width="39" height="9" font="4">S8.1.2-33.</text>
<text top="904" left="626" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref519">Sheridan SL, Viera AJ, Krantz MJ, et al.</a></text>
<text top="917" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref519">The effect of giving global coronary risk information to</a></text>
<text top="931" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref519">adults: a systematic review. Arch Intern Med. 2010;</a></text>
<text top="944" left="584" width="33" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref519">170:230</a></text>
<text top="942" left="617" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref519">–9</a></text>
<text top="944" left="626" width="3" height="9" font="4">.</text>
<text top="963" left="584" width="40" height="9" font="4">S8.1.2-34.</text>
<text top="963" left="627" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref520">Viera AJ, Sheridan SL. Global risk of</a></text>
<text top="976" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref520">coronary heart disease: assessment and application.</a></text>
<text top="990" left="584" width="130" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref520">Am Fam Physician. 2010;82:265</a></text>
<text top="988" left="714" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref520">–74</a></text>
<text top="990" left="728" width="3" height="9" font="4">.</text>
<text top="1008" left="584" width="39" height="9" font="4">S8.1.2-35.</text>
<text top="1008" left="626" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref521">Sheridan SL, Draeger LB, Pignone MP, et al.</a></text>
<text top="1021" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref521">A randomized trial of an intervention to improve use</a></text>
<text top="1035" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref521">and adherence to effective coronary heart disease</a></text>
<text top="1048" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref521">prevention strategies. BMC Health Serv Res. 2011;11:</a></text>
<text top="1062" left="584" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref521">331</a></text>
<text top="1062" left="597" width="3" height="9" font="4">.</text>
<text top="1082" left="584" width="40" height="9" font="4">S8.1.2-36.</text>
<text top="1082" left="627" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref522">Brett T, Arnold-Reed D, Phan C, et al. The</a></text>
<text top="1095" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref522">Fremantle Primary Prevention Study: a multicentre</a></text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e222</text>
</page>
<page number="97" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref522">randomised trial of absolute cardiovascular risk</a></text>
<text top="156" left="63" width="156" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref522">reduction. Br J Gen Pract. 2012;62:e22</a></text>
<text top="155" left="219" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref522">–8</a></text>
<text top="156" left="229" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref522">.</a></text>
<text top="175" left="63" width="39" height="9" font="4">S8.1.2-37.</text>
<text top="175" left="105" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref523">Sekaran NK, Sussman JB, Xu A, et al.</a></text>
<text top="188" left="63" width="143" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref523">Providing clinicians with a patient</a></text>
<text top="187" left="206" width="74" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref523">’s 10-year cardio-</a></text>
<text top="202" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref523">vascular risk improves their statin prescribing: a true</a></text>
<text top="215" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref523">experiment using clinical vignettes. BMC Cardiovasc</a></text>
<text top="229" left="63" width="76" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref523">Disord. 2013;13:90</a></text>
<text top="229" left="139" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref523">.</a></text>
<text top="247" left="63" width="40" height="9" font="4">S8.1.2-38.</text>
<text top="247" left="106" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref524">Sheridan SL, Draeger LB, Pignone MP, et al.</a></text>
<text top="261" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref524">The effect of a decision aid intervention on decision</a></text>
<text top="274" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref524">making about coronary heart disease risk reduction:</a></text>
<text top="288" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref524">secondary analyses of a randomized trial. BMC Med</a></text>
<text top="301" left="63" width="119" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref524">Inform Decis Mak. 2014;14:14</a></text>
<text top="301" left="182" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref524">.</a></text>
<text top="320" left="63" width="40" height="9" font="4">S8.1.2-39.</text>
<text top="320" left="106" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref525">Jansen J, Bonner C, McKinn S, et al.</a></text>
<text top="333" left="63" width="87" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref525">General practitioners</a></text>
<text top="331" left="150" width="130" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref525">’ use of absolute risk versus</a></text>
<text top="347" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref525">individual risk factors in cardiovascular disease pre-</a></text>
<text top="360" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref525">vention: an experimental study. BMJ Open. 2014;4:</a></text>
<text top="373" left="63" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref525">e004812</a></text>
<text top="373" left="99" width="3" height="9" font="4">.</text>
<text top="392" left="63" width="41" height="9" font="4">S8.1.2-40.</text>
<text top="392" left="107" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref526">Vagholkar S, Zwar N, Jayasinghe UW, et al.</a></text>
<text top="405" left="63" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref526">In</a></text>
<text top="404" left="70" width="209" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref526">ﬂuence of cardiovascular absolute risk assessment</a></text>
<text top="419" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref526">on prescribing of antihypertensive and lipid-lowering</a></text>
<text top="432" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref526">medications: a cluster randomized controlled trial.</a></text>
<text top="446" left="63" width="101" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref526">Am Heart J. 2014;167:28</a></text>
<text top="444" left="163" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref526">–35</a></text>
<text top="446" left="177" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref526">.</a></text>
<text top="464" left="63" width="39" height="9" font="4">S8.1.2-41.</text>
<text top="464" left="105" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref527">Rafter N, Connor J, Hall J, et al. Cardio-</a></text>
<text top="478" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref527">vascular medications in primary care: treatment gaps</a></text>
<text top="491" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref527">and targeting by absolute risk. N Z Med J. 2005;118:</a></text>
<text top="505" left="63" width="26" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref527">U1676</a></text>
<text top="505" left="88" width="3" height="9" font="4">.</text>
<text top="523" left="63" width="40" height="9" font="4">S8.1.2-42.</text>
<text top="523" left="106" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref528">Yong TY, Phillipov G, Phillips PJ. Manage-</a></text>
<text top="537" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref528">ment outcomes of patients with type 2 diabetes: tar-</a></text>
<text top="550" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref528">geting the 10-year absolute risk of coronary heart</a></text>
<text top="564" left="63" width="142" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref528">disease. Med J Aust. 2007;186:622</a></text>
<text top="562" left="205" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref528">–4</a></text>
<text top="564" left="214" width="3" height="9" font="4">.</text>
<text top="582" left="63" width="40" height="9" font="4">S8.1.2-43.</text>
<text top="582" left="106" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref529">Webster RJ, Heeley EL, Peiris DP, et al.</a></text>
<text top="596" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref529">Gaps in cardiovascular disease risk management in</a></text>
<text top="609" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref529">Australian general practice. Med J Aust. 2009;191:</a></text>
<text top="622" left="63" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref529">324</a></text>
<text top="621" left="78" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref529">–9</a></text>
<text top="622" left="87" width="3" height="9" font="4">.</text>
<text top="641" left="63" width="41" height="9" font="4">S8.1.2-44.</text>
<text top="641" left="107" width="60" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref530">Frikke-Schmidt</a></text>
<text top="641" left="177" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref530">R,</a></text>
<text top="641" left="196" width="66" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref530">Tybjærg-Hansen</a></text>
<text top="641" left="272" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref530">A,</a></text>
<text top="654" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref530">Schnohr P, et al. Common clinical practice versus new</a></text>
<text top="668" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref530">PRIM score in predicting coronary heart disease risk.</a></text>
<text top="681" left="63" width="120" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref530">Atherosclerosis. 2010;213:532</a></text>
<text top="680" left="183" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref530">–8</a></text>
<text top="681" left="192" width="3" height="9" font="4">.</text>
<text top="700" left="63" width="40" height="9" font="4">S8.1.2-45.</text>
<text top="700" left="106" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref531">Heeley EL, Peiris DP, Patel AA, et al.</a></text>
<text top="713" left="63" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref531">Cardiovascular risk perception and evidence</a></text>
<text top="712" left="244" width="36" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref531">–practice</a></text>
<text top="727" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref531">gaps in Australian general practice (the AusHEART</a></text>
<text top="740" left="63" width="137" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref531">study). Med J Aust. 2010;192:254</a></text>
<text top="739" left="199" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref531">–9</a></text>
<text top="740" left="209" width="3" height="9" font="4">.</text>
<text top="759" left="63" width="41" height="9" font="4">S8.1.2-46.</text>
<text top="759" left="107" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref532">Shillinglaw B, Viera AJ, Edwards T, et al.</a></text>
<text top="772" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref532">Use of global coronary heart disease risk assessment in</a></text>
<text top="786" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref532">practice: a cross-sectional survey of a sample of U.S.</a></text>
<text top="799" left="63" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref532">physicians. BMC Health Serv Res. 2012;12:20</a></text>
<text top="799" left="244" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref532">.</a></text>
<text top="818" left="63" width="40" height="9" font="4">S8.1.2-47.</text>
<text top="818" left="106" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref533">Game FL, Bartlett WA, Bayly GR, et al.</a></text>
<text top="831" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref533">Comparative accuracy of cardiovascular risk prediction</a></text>
<text top="845" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref533">methods in patients with diabetes mellitus. Diabetes</a></text>
<text top="858" left="63" width="99" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref533">Obes Metab. 2001;3:279</a></text>
<text top="856" left="162" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref533">–86</a></text>
<text top="858" left="177" width="3" height="9" font="4">.</text>
<text top="876" left="63" width="41" height="9" font="4">S8.1.2-48.</text>
<text top="876" left="107" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref534">Bastuji-Garin S, Deverly A, Moyse D, et al.</a></text>
<text top="890" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref534">The Framingham prediction rule is not valid in a</a></text>
<text top="903" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref534">European population of treated hypertensive patients.</a></text>
<text top="917" left="63" width="110" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref534">J Hypertens. 2002;20:1973</a></text>
<text top="915" left="173" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref534">–80</a></text>
<text top="917" left="189" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref534">.</a></text>
<text top="935" left="63" width="41" height="9" font="4">S8.1.2-49.</text>
<text top="935" left="107" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref535">Menotti A, Puddu PE, Lanti M. The estimate</a></text>
<text top="949" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref535">of cardiovascular risk. Theory, tools and problems. Ann</a></text>
<text top="962" left="63" width="98" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref535">Ital Med Int. 2002;17:81</a></text>
<text top="961" left="160" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref535">–94</a></text>
<text top="962" left="175" width="3" height="9" font="4">.</text>
<text top="981" left="63" width="40" height="9" font="4">S8.1.2-50.</text>
<text top="981" left="106" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref536">de Visser CL, Bilo HJG, Thomsen TF, et al.</a></text>
<text top="994" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref536">Prediction of coronary heart disease: a comparison</a></text>
<text top="1008" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref536">between the Copenhagen risk score and the Framing-</a></text>
<text top="1021" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref536">ham risk score applied to a Dutch population. J Intern</a></text>
<text top="1035" left="63" width="79" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref536">Med. 2003;253:553</a></text>
<text top="1033" left="141" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref536">–62</a></text>
<text top="1035" left="156" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref536">.</a></text>
<text top="1053" left="63" width="38" height="9" font="4">S8.1.2-51.</text>
<text top="1053" left="104" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref537">Persson M, Carlberg B, Weinehall L, et al.</a></text>
<text top="1067" left="63" width="42" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref537">Risk strati</a></text>
<text top="1065" left="105" width="175" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref537">ﬁcation by guidelines compared with risk</a></text>
<text top="1080" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref537">assessment by risk equations applied to a MONICA</a></text>
<text top="1093" left="63" width="144" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref537">sample. J Hypertens. 2003;21:1089</a></text>
<text top="1092" left="207" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref537">–95</a></text>
<text top="1093" left="221" width="3" height="9" font="4">.</text>
<text top="143" left="301" width="39" height="9" font="4">S8.1.2-52.</text>
<text top="143" left="343" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref538">Doust J, Sanders S, Shaw J, et al. Prioritising</a></text>
<text top="156" left="301" width="95" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref538">CVD prevention therapy</a></text>
<text top="155" left="396" width="122" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref538">–absolute risk versus individual</a></text>
<text top="170" left="301" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref538">risk factors. Aust Fam Physician. 2012;41:805</a></text>
<text top="168" left="484" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref538">–9</a></text>
<text top="170" left="494" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref538">.</a></text>
<text top="189" left="301" width="39" height="9" font="4">S8.1.2-53.</text>
<text top="189" left="343" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref539">Allan GM, Nouri F, Korownyk C, et al.</a></text>
<text top="202" left="301" width="44" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref539">Agreement</a></text>
<text top="202" left="357" width="27" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref539">among</a></text>
<text top="202" left="396" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref539">cardiovascular</a></text>
<text top="202" left="464" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref539">disease</a></text>
<text top="202" left="504" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref539">risk</a></text>
<text top="216" left="301" width="155" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref539">calculators. Circulation. 2013;127:1948</a></text>
<text top="214" left="456" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref539">–56</a></text>
<text top="216" left="470" width="3" height="9" font="4">.</text>
<text top="235" left="301" width="40" height="9" font="4">S8.1.2-54.</text>
<text top="235" left="344" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref540">Diverse Populations Collaborative Group.</a></text>
<text top="248" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref540">Prediction of mortality from coronary heart disease</a></text>
<text top="262" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref540">among diverse populations: is there a common</a></text>
<text top="275" left="301" width="163" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref540">predictive function? Heart. 2002;88:222</a></text>
<text top="274" left="464" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref540">–8</a></text>
<text top="275" left="473" width="3" height="9" font="4">.</text>
<text top="294" left="301" width="39" height="9" font="4">S8.1.2-55.</text>
<text top="294" left="343" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref541">van</a></text>
<text top="294" left="369" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref541">den</a></text>
<text top="294" left="396" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref541">Hoogen</a></text>
<text top="294" left="438" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref541">PC,</a></text>
<text top="294" left="463" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref541">Feskens</a></text>
<text top="294" left="506" width="12" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref541">EJ,</a></text>
<text top="308" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref541">Nagelkerke NJ, et al. The relation between blood</a></text>
<text top="321" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref541">pressure and mortality due to coronary heart disease</a></text>
<text top="335" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref541">among men in different parts of the world. Seven</a></text>
<text top="348" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref541">Countries Study Research Group. N Engl J Med. 2000;</a></text>
<text top="362" left="301" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref541">342:1</a></text>
<text top="360" left="322" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref541">–8</a></text>
<text top="362" left="332" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref541">.</a></text>
<text top="381" left="301" width="40" height="9" font="4">S8.1.2-56.</text>
<text top="381" left="344" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref542">Goff DC Jr., Lloyd-Jones DM, Bennett G,</a></text>
<text top="394" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref542">et al. 2013 ACC/AHA guideline on the assessment of</a></text>
<text top="408" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref542">cardiovascular risk: a report of the American College</a></text>
<text top="421" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref542">of Cardiology/American Heart Association Task Force</a></text>
<text top="435" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref542">on Practice Guidelines. J Am Coll Cardiol. 2014;63:</a></text>
<text top="448" left="301" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref542">2935</a></text>
<text top="447" left="321" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref542">–59</a></text>
<text top="448" left="336" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref542">.</a></text>
<text top="467" left="301" width="39" height="9" font="4">S8.1.2-57.</text>
<text top="467" left="343" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref543">Stone NJ, Robinson JG, Lichtenstein AH,</a></text>
<text top="481" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref543">et al. 2013 ACC/AHA guideline on the treatment</a></text>
<text top="494" left="301" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref543">of</a></text>
<text top="494" left="319" width="23" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref543">blood</a></text>
<text top="494" left="351" width="44" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref543">cholesterol</a></text>
<text top="494" left="405" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref543">to</a></text>
<text top="494" left="423" width="27" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref543">reduce</a></text>
<text top="494" left="459" width="59" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref543">atherosclerotic</a></text>
<text top="508" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref543">cardiovascular risk in adults: a report of the American</a></text>
<text top="521" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref543">College of Cardiology/American Heart Association Task</a></text>
<text top="534" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref543">Force on Practice Guidelines. J Am Coll Cardiol. 2014;</a></text>
<text top="548" left="301" width="35" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref543">63:2889</a></text>
<text top="546" left="336" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref543">–934</a></text>
<text top="548" left="355" width="3" height="9" font="4">.</text>
<text top="567" left="301" width="40" height="9" font="4">S8.1.2-58.</text>
<text top="567" left="344" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref544">Thomopoulos C, Parati G, Zanchetti A.</a></text>
<text top="580" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref544">Effects of blood pressure lowering on outcome</a></text>
<text top="594" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref544">incidence in hypertension: 3. Effects in patients at</a></text>
<text top="607" left="301" width="157" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref544">different levels of cardiovascular risk</a></text>
<text top="606" left="458" width="60" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref544">–overview and</a></text>
<text top="621" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref544">meta-analyses of randomized trials. J Hypertens.</a></text>
<text top="634" left="301" width="55" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref544">2014;32:2305</a></text>
<text top="633" left="356" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref544">–14</a></text>
<text top="634" left="370" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref544">.</a></text>
<text top="653" left="301" width="40" height="9" font="4">S8.1.2-59.</text>
<text top="653" left="344" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref545">Julius S, Nesbitt SD, Egan BM, et al. Feasi-</a></text>
<text top="667" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref545">bility of treating prehypertension with an angiotensin-</a></text>
<text top="680" left="301" width="194" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref545">receptor blocker. N Engl J Med. 2006;354:1685</a></text>
<text top="679" left="495" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref545">–97</a></text>
<text top="680" left="509" width="3" height="9" font="4">.</text>
<text top="699" left="301" width="41" height="9" font="4">S8.1.2-60.</text>
<text top="699" left="345" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref546">Julius S, Kaciroti N, Egan BM, et al. TROPHY</a></text>
<text top="713" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref546">study: outcomes based on the Seventh Report of the</a></text>
<text top="726" left="301" width="189" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref546">Joint National Committee on Hypertension de</a></text>
<text top="725" left="490" width="28" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref546">ﬁnition</a></text>
<text top="740" left="301" width="198" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref546">of hypertension. J Am Soc Hypertens. 2008;2:39</a></text>
<text top="738" left="499" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref546">–43</a></text>
<text top="740" left="513" width="3" height="9" font="4">.</text>
<text top="759" left="301" width="39" height="9" font="4">S8.1.2-61.</text>
<text top="759" left="343" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref547">Luders S, Schrader J, Berger J, et al. The</a></text>
<text top="772" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref547">PHARAO study: prevention of hypertension with the</a></text>
<text top="786" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref547">angiotensin-converting enzyme inhibitor ramipril in</a></text>
<text top="799" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref547">patients with high-normal blood pressure: a prospec-</a></text>
<text top="813" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref547">tive, randomized, controlled prevention trial of the</a></text>
<text top="826" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref547">German Hypertension League. J Hypertens. 2008;26:</a></text>
<text top="840" left="301" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref547">1487</a></text>
<text top="838" left="320" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref547">–96</a></text>
<text top="840" left="336" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref547">.</a></text>
<text top="859" left="301" width="40" height="9" font="4">S8.1.2-62.</text>
<text top="859" left="344" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref548">Fuchs SC, Poli-de-Figueiredo CE, Figueiredo</a></text>
<text top="872" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref548">Neto JA, et al. Effectiveness of chlorthalidone plus</a></text>
<text top="886" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref548">amiloride for the prevention of hypertension: the</a></text>
<text top="899" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref548">PREVER Prevention Randomized Clinical Trial. J Am</a></text>
<text top="912" left="301" width="122" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref548">Heart Assoc. 2016;5:e004248</a></text>
<text top="912" left="423" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref548">.</a></text>
<text top="932" left="301" width="40" height="9" font="4">S8.1.2-63.</text>
<text top="932" left="344" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref549">Lonn EM, Bosch J, Lopez-Jaramillo P, et al.</a></text>
<text top="945" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref549">Blood-pressure lowering in intermediate-risk persons</a></text>
<text top="958" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref549">without cardiovascular disease. N Engl J Med. 2016;</a></text>
<text top="972" left="301" width="40" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref549">374:2009</a></text>
<text top="970" left="341" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref549">–20</a></text>
<text top="972" left="356" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref549">.</a></text>
<text top="994" left="301" width="198" height="9" font="4">8.1.3. Follow-Up After Initial BP Evaluation</text>
<text top="1009" left="301" width="33" height="9" font="4">S8.1.3-1.</text>
<text top="1009" left="338" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref550">Ambrosius WT, Sink KM, Foy CG, et al. The</a></text>
<text top="1022" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref550">design and rationale of a multicenter clinical trial</a></text>
<text top="1036" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref550">comparing two strategies for control of systolic blood</a></text>
<text top="1049" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref550">pressure: the Systolic Blood Pressure Intervention Trial</a></text>
<text top="1063" left="301" width="133" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref550">(SPRINT). Clin Trials. 2014;11:532</a></text>
<text top="1061" left="434" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref550">–46</a></text>
<text top="1063" left="449" width="3" height="9" font="4">.</text>
<text top="1082" left="301" width="34" height="9" font="4">S8.1.3-2.</text>
<text top="1082" left="338" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref551">Cushman WC, Grimm RH Jr., Cutler JA, et al.</a></text>
<text top="1095" left="301" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref551">Rationale</a></text>
<text top="1095" left="348" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref551">and</a></text>
<text top="1095" left="372" width="26" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref551">design</a></text>
<text top="1095" left="408" width="12" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref551">for</a></text>
<text top="1095" left="429" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref551">the</a></text>
<text top="1095" left="452" width="23" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref551">blood</a></text>
<text top="1095" left="484" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref551">pressure</a></text>
<text top="143" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref551">intervention of the Action to Control Cardiovascular</a></text>
<text top="156" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref551">Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;</a></text>
<text top="170" left="539" width="27" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref551">99:44i</a></text>
<text top="168" left="566" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref551">–55i</a></text>
<text top="170" left="582" width="3" height="9" font="4">.</text>
<text top="188" left="539" width="34" height="9" font="4">S8.1.3-3.</text>
<text top="188" left="577" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref552">Carson AP, Howard G, Burke GL, et al. Ethnic</a></text>
<text top="202" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref552">differences in hypertension incidence among middle-</a></text>
<text top="215" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref552">aged and older adults: the Multi-Ethnic study of</a></text>
<text top="229" left="539" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref552">Atherosclerosis. Hypertension. 2011;57:1101</a></text>
<text top="227" left="715" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref552">–7</a></text>
<text top="229" left="723" width="3" height="9" font="4">.</text>
<text top="256" left="539" width="189" height="9" font="4">8.1.4. General Principles of Drug Therapy</text>
<text top="271" left="539" width="34" height="9" font="4">S8.1.4-1.</text>
<text top="271" left="577" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref553">Yusuf S, Teo KK, Pogue J, et al. Telmisartan,</a></text>
<text top="285" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref553">ramipril, or both in patients at high risk for vascular</a></text>
<text top="298" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref553">events. ONTARGET Investigators. N Engl J Med. 2008;</a></text>
<text top="312" left="539" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref553">358:1547</a></text>
<text top="310" left="576" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref553">–59</a></text>
<text top="312" left="590" width="3" height="9" font="4">.</text>
<text top="330" left="539" width="35" height="9" font="4">S8.1.4-2.</text>
<text top="330" left="578" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref554">Parving H-H, Brenner BM, McMurray JJV,</a></text>
<text top="344" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref554">et al. Cardiorenal end points in a trial of aliskiren for</a></text>
<text top="357" left="539" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref554">type 2 diabetes. N Engl J Med. 2012;367:2204</a></text>
<text top="355" left="728" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref554">–13</a></text>
<text top="357" left="740" width="3" height="9" font="4">.</text>
<text top="376" left="539" width="35" height="9" font="4">S8.1.4-3.</text>
<text top="376" left="578" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref555">Fried LF, Emanuele N, Zhang JH, et al.</a></text>
<text top="389" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref555">Combined angiotensin inhibition for the treatment of</a></text>
<text top="402" left="539" width="213" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref555">diabetic nephropathy. N Engl J Med. 2013;369:1892</a></text>
<text top="401" left="752" width="4" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref555">–</a></text>
<text top="416" left="539" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref555">903</a></text>
<text top="416" left="556" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref555">.</a></text>
<text top="434" left="539" width="36" height="9" font="4">S8.1.4-4.</text>
<text top="434" left="579" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref556">Effects of treatment on morbidity in hyper-</a></text>
<text top="448" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref556">tension. Results in patients with diastolic blood pres-</a></text>
<text top="461" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref556">sures averaging 115 through 129 mm Hg. JAMA. 1967;</a></text>
<text top="475" left="539" width="39" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref556">202:1028</a></text>
<text top="473" left="578" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref556">–34</a></text>
<text top="475" left="592" width="3" height="9" font="4">.</text>
<text top="493" left="539" width="35" height="9" font="4">S8.1.4-5.</text>
<text top="493" left="578" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref557">Five-year</a></text>
<text top="492" left="624" width="133" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref557">ﬁndings of the hypertension</a></text>
<text top="507" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref557">detection and follow-up program. I. Reduction in</a></text>
<text top="520" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref557">mortality of persons with high blood pressure,</a></text>
<text top="534" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref557">including mild hypertension. Hypertension Detection</a></text>
<text top="547" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref557">and Follow-up Program Cooperative Group. JAMA.</a></text>
<text top="561" left="539" width="60" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref557">1979;242:2562</a></text>
<text top="559" left="599" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref557">–71</a></text>
<text top="561" left="612" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref557">.</a></text>
<text top="579" left="539" width="36" height="9" font="4">S8.1.4-6.</text>
<text top="579" left="579" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref558">Prevention of stroke by antihypertensive</a></text>
<text top="593" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref558">drug treatment in older persons with isolated systolic</a></text>
<text top="606" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref558">hypertension. Final results of the Systolic Hyperten-</a></text>
<text top="619" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref558">sion in the Elderly Program (SHEP). SHEP Cooperative</a></text>
<text top="633" left="539" width="155" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref558">Research Group. JAMA. 1991;265:3255</a></text>
<text top="631" left="695" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref558">–64</a></text>
<text top="633" left="710" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref558">.</a></text>
<text top="651" left="539" width="35" height="9" font="4">S8.1.4-7.</text>
<text top="651" left="578" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref559">Kostis JB, Cabrera J, Cheng JQ, et al.</a></text>
<text top="665" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref559">Association between chlorthalidone treatment of</a></text>
<text top="678" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref559">systolic hypertension and long-term survival. JAMA.</a></text>
<text top="692" left="539" width="61" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref559">2011;306:2588</a></text>
<text top="690" left="600" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref559">–93</a></text>
<text top="692" left="615" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref559">.</a></text>
<text top="710" left="539" width="36" height="9" font="4">S8.1.4-8.</text>
<text top="710" left="579" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref560">Law MR, Morris JK, Wald NJ. Use of blood</a></text>
<text top="724" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref560">pressure lowering drugs in the prevention of cardio-</a></text>
<text top="737" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref560">vascular disease: meta-analysis of 147 randomised</a></text>
<text top="751" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref560">trials in the context of expectations from prospective</a></text>
<text top="764" left="539" width="190" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref560">epidemiological studies. BMJ. 2009;338:b1665</a></text>
<text top="764" left="729" width="3" height="9" font="4">.</text>
<text top="783" left="539" width="36" height="9" font="4">S8.1.4-9.</text>
<text top="783" left="579" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref561">Thomopoulos C, Parati G, Zanchetti A.</a></text>
<text top="796" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref561">Effects of blood pressure lowering on outcome</a></text>
<text top="809" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref561">incidence in hypertension: 2. Effects at different</a></text>
<text top="823" left="539" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref561">baseline and achieved blood pressure levels</a></text>
<text top="821" left="716" width="40" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref561">–overview</a></text>
<text top="836" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref561">and meta-analyses of randomized trials. J Hypertens.</a></text>
<text top="850" left="539" width="56" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref561">2014;32:2296</a></text>
<text top="848" left="595" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref561">–304</a></text>
<text top="850" left="615" width="3" height="9" font="4">.</text>
<text top="868" left="539" width="40" height="9" font="4">S8.1.4-10.</text>
<text top="868" left="583" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref562">Czernichow S, Zanchetti A, Turnbull F, et al.</a></text>
<text top="882" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref562">The effects of blood pressure reduction and of</a></text>
<text top="895" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref562">different blood pressure-lowering regimens on major</a></text>
<text top="909" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref562">cardiovascular events according to baseline blood</a></text>
<text top="922" left="539" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref562">pressure:</a></text>
<text top="922" left="588" width="55" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref562">meta-analysis</a></text>
<text top="922" left="655" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref562">of</a></text>
<text top="922" left="675" width="47" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref562">randomized</a></text>
<text top="922" left="734" width="22" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref562">trials.</a></text>
<text top="936" left="539" width="93" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref562">J Hypertens. 2011;29:4</a></text>
<text top="934" left="632" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref562">–16</a></text>
<text top="936" left="646" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref562">.</a></text>
<text top="954" left="539" width="38" height="9" font="4">S8.1.4-11.</text>
<text top="954" left="581" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref563">Fretheim A, Odgaard-Jensen J, Brors O,</a></text>
<text top="968" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref563">et al. Comparative effectiveness of antihypertensive</a></text>
<text top="981" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref563">medication for primary prevention of cardiovascular</a></text>
<text top="995" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref563">disease: systematic review and multiple treatments</a></text>
<text top="1008" left="539" width="149" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref563">meta-analysis. BMC Med. 2012;10:33</a></text>
<text top="1008" left="688" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref563">.</a></text>
<text top="1027" left="539" width="39" height="9" font="4">S8.1.4-12.</text>
<text top="1027" left="582" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref564">Cushman WC, Ford CE, Cutler JA, et al.</a></text>
<text top="1040" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref564">Success and predictors of blood pressure control in</a></text>
<text top="1053" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref564">diverse North American settings: the Antihypertensive</a></text>
<text top="1067" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref564">and Lipid-Lowering Treatment to Prevent Heart Attack</a></text>
<text top="1080" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref564">Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:</a></text>
<text top="1094" left="539" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref564">393</a></text>
<text top="1092" left="554" width="21" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref564">–404</a></text>
<text top="1094" left="575" width="3" height="9" font="4">.</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="788" width="19" height="9" font="4">e223</text>
</page>
<page number="98" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="39" height="9" font="4">S8.1.4-13.</text>
<text top="143" left="150" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref565">Gradman AH, Basile JN, Carter BL, et al.</a></text>
<text top="156" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref565">Combination therapy in hypertension. J Clin Hypertens</a></text>
<text top="170" left="108" width="101" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref565">(Greenwich). 2011;13:146</a></text>
<text top="168" left="208" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref565">–54</a></text>
<text top="170" left="222" width="3" height="9" font="4">.</text>
<text top="189" left="108" width="40" height="9" font="4">S8.1.4-14.</text>
<text top="189" left="151" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref566">Cushman WC, Evans GW, Byington RP, et al.</a></text>
<text top="203" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref566">Effects of intensive blood-pressure control in type 2</a></text>
<text top="216" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref566">diabetes mellitus. ACCORD Study Group. N Engl J Med.</a></text>
<text top="230" left="108" width="59" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref566">2010;362:1575</a></text>
<text top="228" left="167" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref566">–85</a></text>
<text top="230" left="181" width="3" height="9" font="4">.</text>
<text top="248" left="108" width="39" height="9" font="4">S8.1.4-15.</text>
<text top="248" left="150" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref567">Chobanian AV, Bakris GL, Black HR, et al.,</a></text>
<text top="261" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref567">the National High Blood Pressure Education Program</a></text>
<text top="275" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref567">Coordinating Committee. Seventh Report of the</a></text>
<text top="288" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref567">Joint National Committee on Prevention, Detection,</a></text>
<text top="302" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref567">Evaluation, and Treatment of High Blood Pressure.</a></text>
<text top="315" left="108" width="116" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref567">Hypertension. 2003;42:1206</a></text>
<text top="314" left="224" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref567">–52</a></text>
<text top="315" left="237" width="3" height="9" font="4">.</text>
<text top="337" left="108" width="208" height="9" font="4">8.1.5. BP Goal for Patients With Hypertension</text>
<text top="352" left="108" width="33" height="9" font="4">S8.1.5-1.</text>
<text top="352" left="144" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref568">Thomopoulos C, Parati G, Zanchetti A. Effects</a></text>
<text top="365" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref568">of blood pressure lowering on outcome incidence in</a></text>
<text top="379" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref568">hypertension: 7. Effects of more vs. less intensive</a></text>
<text top="392" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref568">blood pressure lowering and different achieved blood</a></text>
<text top="406" left="108" width="61" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref568">pressure levels</a></text>
<text top="404" left="168" width="156" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref568">–updated overview and meta-analyses</a></text>
<text top="419" left="108" width="189" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref568">of randomized trials. J Hypertens. 2016;34:613</a></text>
<text top="417" left="297" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref568">–22</a></text>
<text top="419" left="311" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref568">.</a></text>
<text top="438" left="108" width="34" height="9" font="4">S8.1.5-2.</text>
<text top="438" left="145" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref569">Xie X, Atkins E, Lv J, et al. Effects of</a></text>
<text top="451" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref569">intensive blood pressure lowering on cardiovascular</a></text>
<text top="464" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref569">and renal outcomes: updated systematic review and</a></text>
<text top="478" left="108" width="148" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref569">meta-analysis. Lancet. 2016;387:435</a></text>
<text top="476" left="256" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref569">–43</a></text>
<text top="478" left="270" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref569">.</a></text>
<text top="496" left="108" width="34" height="9" font="4">S8.1.5-3.</text>
<text top="496" left="145" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref570">Verdecchia P, Angeli F, Gentile G, et al.</a></text>
<text top="510" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref570">More versus less intensive blood pressure-lowering</a></text>
<text top="523" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref570">strategy: cumulative evidence and trial sequential</a></text>
<text top="537" left="108" width="148" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref570">analysis. Hypertension. 2016;68:642</a></text>
<text top="535" left="255" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref570">–53</a></text>
<text top="537" left="269" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref570">.</a></text>
<text top="555" left="108" width="35" height="9" font="4">S8.1.5-4.</text>
<text top="555" left="146" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref571">Bangalore S, Toklu B, Gianos E, et al. Optimal</a></text>
<text top="569" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref571">systolic blood pressure target after SPRINT: insights</a></text>
<text top="582" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref571">from a network meta-analysis of randomized trials.</a></text>
<text top="596" left="108" width="97" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref571">Am J Med. 2017;30:707</a></text>
<text top="594" left="204" width="26" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref571">–19.e8</a></text>
<text top="596" left="230" width="3" height="9" font="4">.</text>
<text top="614" left="108" width="34" height="9" font="4">S8.1.5-5.</text>
<text top="614" left="145" width="26" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref572">Bundy</a></text>
<text top="614" left="180" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref572">JD,</a></text>
<text top="614" left="203" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref572">Li</a></text>
<text top="614" left="220" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref572">C,</a></text>
<text top="614" left="237" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref572">Stuchlik</a></text>
<text top="614" left="279" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref572">P,</a></text>
<text top="614" left="297" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref572">et</a></text>
<text top="614" left="315" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref572">al.</a></text>
<text top="628" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref572">Systolic blood pressure reduction and risk of</a></text>
<text top="641" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref572">cardiovascular disease and mortality: a systematic</a></text>
<text top="655" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref572">review and network meta-analysis. JAMA Cardiol.</a></text>
<text top="668" left="108" width="44" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref572">2017;2:775</a></text>
<text top="666" left="152" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref572">–81</a></text>
<text top="668" left="166" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref572">.</a></text>
<text top="687" left="108" width="35" height="9" font="4">S8.1.5-6.</text>
<text top="687" left="146" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref573">Julius S, Nesbitt SD, Egan BM, et al.</a></text>
<text top="700" left="108" width="40" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref573">Feasibility</a></text>
<text top="700" left="157" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref573">of</a></text>
<text top="700" left="174" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref573">treating</a></text>
<text top="700" left="215" width="65" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref573">prehypertension</a></text>
<text top="700" left="289" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref573">with</a></text>
<text top="700" left="315" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref573">an</a></text>
<text top="713" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref573">angiotensin-receptor blocker. N Engl J Med. 2006;</a></text>
<text top="727" left="108" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref573">354:1685</a></text>
<text top="725" left="145" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref573">–97</a></text>
<text top="727" left="159" width="3" height="9" font="4">.</text>
<text top="745" left="108" width="34" height="9" font="4">S8.1.5-7.</text>
<text top="745" left="145" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref574">Lawes CMM, Bennett DA, Lewington S, et al.</a></text>
<text top="759" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref574">Blood pressure and coronary heart disease: a review of</a></text>
<text top="772" left="108" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref574">the evidence. Semin Vasc Med. 2002;2:355</a></text>
<text top="771" left="282" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref574">–68</a></text>
<text top="772" left="297" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref574">.</a></text>
<text top="791" left="108" width="35" height="9" font="4">S8.1.5-8.</text>
<text top="791" left="146" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref575">Lonn EM, Bosch J, Lopez-Jaramillo P, et al.</a></text>
<text top="804" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref575">Blood-pressure lowering in intermediate-risk persons</a></text>
<text top="818" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref575">without cardiovascular disease. N Engl J Med. 2016;</a></text>
<text top="831" left="108" width="40" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref575">374:2009</a></text>
<text top="830" left="148" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref575">–20</a></text>
<text top="831" left="162" width="3" height="9" font="4">.</text>
<text top="850" left="108" width="35" height="9" font="4">S8.1.5-9.</text>
<text top="850" left="146" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref576">Neaton JD, Grimm RH Jr., Prineas RJ, et al.</a></text>
<text top="863" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref576">Treatment of Mild Hypertension Study. Final results.</a></text>
<text top="877" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref576">Treatment of Mild Hypertension Study Research</a></text>
<text top="890" left="108" width="112" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref576">Group. JAMA. 1993;270:713</a></text>
<text top="888" left="219" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref576">–24</a></text>
<text top="890" left="234" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref576">.</a></text>
<text top="909" left="108" width="39" height="9" font="4">S8.1.5-10.</text>
<text top="909" left="150" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref577">Reboussin DM, Allen NB, Griswold ME, et al.</a></text>
<text top="922" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref577">Systematic review for the 2017 ACC/AHA/AAPA/ABC/</a></text>
<text top="936" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref577">ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for</a></text>
<text top="949" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref577">the prevention, detection, evaluation, and manage-</a></text>
<text top="962" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref577">ment of high blood pressure in adults. J Am Coll Car-</a></text>
<text top="976" left="108" width="73" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref577">diol. 2018;71:2176</a></text>
<text top="974" left="180" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref577">–98</a></text>
<text top="976" left="196" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref577">.</a></text>
<text top="994" left="108" width="37" height="9" font="4">S8.1.5-11.</text>
<text top="994" left="148" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref578">Brunstrom M, Carlberg B. Effect of antihy-</a></text>
<text top="1008" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref578">pertensive treatment at different blood pressure levels</a></text>
<text top="1021" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref578">in patients with diabetes mellitus: systematic review</a></text>
<text top="1035" left="108" width="158" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref578">and meta-analyses. BMJ. 2016;352:i717</a></text>
<text top="1035" left="266" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref578">.</a></text>
<text top="1053" left="108" width="38" height="9" font="4">S8.1.5-12.</text>
<text top="1053" left="149" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref579">Ettehad D, Emdin CA, Kiran A, et al. Blood</a></text>
<text top="1067" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref579">pressure lowering for prevention of cardiovascular</a></text>
<text top="1080" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref579">disease and death: a systematic review and meta-</a></text>
<text top="1094" left="108" width="124" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref579">analysis. Lancet. 2016;387:957</a></text>
<text top="1092" left="232" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref579">–67</a></text>
<text top="1094" left="246" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref579">.</a></text>
<text top="143" left="346" width="38" height="9" font="4">S8.1.5-13.</text>
<text top="143" left="387" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref580">Lv J, Ehteshami P, Sarnak MJ, et al. Effects</a></text>
<text top="156" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref580">of intensive blood pressure lowering on the progres-</a></text>
<text top="170" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref580">sion of chronic kidney disease: a systematic review and</a></text>
<text top="183" left="346" width="144" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref580">meta-analysis. CMAJ. 2013;185:949</a></text>
<text top="182" left="490" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref580">–57</a></text>
<text top="183" left="503" width="3" height="9" font="4">.</text>
<text top="202" left="346" width="39" height="9" font="4">S8.1.5-14.</text>
<text top="202" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref581">Cushman WC, Evans GW, Byington RP, et al.</a></text>
<text top="215" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref581">Effects of intensive blood-pressure control in type 2</a></text>
<text top="229" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref581">diabetes mellitus. ACCORD Study. N Engl J Med. 2010;</a></text>
<text top="242" left="346" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref581">362:1575</a></text>
<text top="241" left="382" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref581">–85</a></text>
<text top="242" left="396" width="3" height="9" font="4">.</text>
<text top="261" left="346" width="38" height="9" font="4">S8.1.5-15.</text>
<text top="261" left="387" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref582">Wright JT Jr., Williamson JD, Whelton PK,</a></text>
<text top="274" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref582">et al. A randomized trial of intensive versus standard</a></text>
<text top="288" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref582">blood-pressure control. SPRINT Research Group.</a></text>
<text top="301" left="346" width="118" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref582">N Engl J Med. 2015;373:2103</a></text>
<text top="299" left="464" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref582">–16</a></text>
<text top="301" left="477" width="3" height="9" font="4">.</text>
<text top="320" left="346" width="39" height="9" font="4">S8.1.5-16.</text>
<text top="320" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref583">SPS3 Study Group. Blood-pressure targets</a></text>
<text top="333" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref583">in patients with recent lacunar stroke: the SPS3</a></text>
<text top="347" left="346" width="158" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref583">randomised trial. Lancet. 2013;382:507</a></text>
<text top="345" left="504" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref583">–15</a></text>
<text top="347" left="517" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref583">.</a></text>
<text top="365" left="346" width="38" height="9" font="4">S8.1.5-17.</text>
<text top="365" left="387" width="122" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref584">Perkovic V, Rodgers A. Rede</a></text>
<text top="363" left="509" width="54" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref584">ﬁning blood-</a></text>
<text top="379" left="346" width="66" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref584">pressure targets</a></text>
<text top="377" left="412" width="151" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref584">–SPRINT starts the marathon. N Engl</a></text>
<text top="392" left="346" width="87" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref584">J Med. 2015;373:2175</a></text>
<text top="390" left="433" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref584">–8</a></text>
<text top="392" left="442" width="3" height="9" font="4">.</text>
<text top="410" left="346" width="39" height="9" font="4">S8.1.5-18.</text>
<text top="410" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref585">Lawes CMM, Rodgers A, Bennett DA, et al.</a></text>
<text top="424" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref585">Blood pressure and cardiovascular disease in the Asia</a></text>
<text top="437" left="346" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref585">Paci</a></text>
<text top="436" left="362" width="161" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref585">ﬁc region. J Hypertens. 2003;21:707–16</a></text>
<text top="437" left="523" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref585">.</a></text>
<text top="457" left="346" width="39" height="9" font="4">S8.1.5-19.</text>
<text top="457" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref586">Allen NB, Siddique J, Wilkins JT, et al. Blood</a></text>
<text top="470" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref586">pressure trajectories in early adulthood and subclinical</a></text>
<text top="484" left="346" width="206" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref586">atherosclerosis in middle age. JAMA. 2014;311:490</a></text>
<text top="482" left="552" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref586">–7</a></text>
<text top="484" left="560" width="3" height="9" font="4">.</text>
<text top="503" left="346" width="40" height="9" font="4">S8.1.5-20.</text>
<text top="503" left="389" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref587">Ference BA, Julius S, Mahajan N, et al.</a></text>
<text top="516" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref587">Clinical effect of naturally random allocation to lower</a></text>
<text top="530" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref587">systolic blood pressure beginning before the devel-</a></text>
<text top="543" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref587">opment of hypertension. Hypertension. 2014;63:</a></text>
<text top="557" left="346" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref587">1182</a></text>
<text top="555" left="364" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref587">–8</a></text>
<text top="557" left="373" width="3" height="9" font="4">.</text>
<text top="578" left="346" width="155" height="9" font="4">8.1.6. Choice of Initial Medication</text>
<text top="593" left="346" width="34" height="9" font="4">S8.1.6-1.</text>
<text top="593" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref588">Reboussin DM, Allen NB, Griswold ME, et al.</a></text>
<text top="607" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref588">Systematic review for the 2017 ACC/AHA/AAPA/ABC/</a></text>
<text top="620" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref588">ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for</a></text>
<text top="633" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref588">the prevention, detection, evaluation, and manage-</a></text>
<text top="647" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref588">ment of high blood pressure in adults: a report of</a></text>
<text top="660" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref588">the American College of Cardiology/American Heart</a></text>
<text top="674" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref588">Association Task Force on Clinical Practice Guidelines.</a></text>
<text top="687" left="346" width="128" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref588">J Am Coll Cardiol. 2018;71:2176</a></text>
<text top="686" left="474" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref588">–98</a></text>
<text top="687" left="489" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref588">.</a></text>
<text top="706" left="346" width="35" height="9" font="4">S8.1.6-2.</text>
<text top="706" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref589">Psaty BM, Lumley T, Furberg CD, et al.</a></text>
<text top="719" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref589">Health outcomes associated with various antihyper-</a></text>
<text top="733" left="346" width="103" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref589">tensive therapies used as</a></text>
<text top="731" left="452" width="111" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref589">ﬁrst-line agents: a network</a></text>
<text top="746" left="346" width="152" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref589">meta-analysis. JAMA. 2003;289:2534</a></text>
<text top="745" left="498" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref589">–44</a></text>
<text top="746" left="513" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref589">.</a></text>
<text top="765" left="346" width="35" height="9" font="4">S8.1.6-3.</text>
<text top="765" left="384" width="47" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref590">ALLHAT Of</a></text>
<text top="763" left="431" width="132" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref590">ﬁcers and Coordinators for the</a></text>
<text top="778" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref590">ALLHAT Collaborative Research Group. Major out-</a></text>
<text top="792" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref590">comes in high-risk hypertensive patients randomized</a></text>
<text top="805" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref590">to angiotensin-converting enzyme inhibitor or calcium</a></text>
<text top="819" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref590">channel blocker vs diuretic: the Antihypertensive and</a></text>
<text top="832" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref590">Lipid-Lowering Treatment to Prevent Heart Attack</a></text>
<text top="845" left="346" width="156" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref590">Trial (ALLHAT). JAMA. 2002;288:2981</a></text>
<text top="844" left="502" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref590">–97</a></text>
<text top="845" left="516" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref590">.</a></text>
<text top="864" left="346" width="36" height="9" font="4">S8.1.6-4.</text>
<text top="864" left="385" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref591">Ferrucci L, Guralnik JM, Pahor M, et al.</a></text>
<text top="877" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref591">Hospital diagnoses, Medicare charges, and nursing</a></text>
<text top="891" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref591">home admissions in the year when older persons</a></text>
<text top="904" left="346" width="191" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref591">become severely disabled. JAMA. 1997;277:728</a></text>
<text top="903" left="537" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref591">–34</a></text>
<text top="904" left="551" width="3" height="9" font="4">.</text>
<text top="923" left="346" width="35" height="9" font="4">S8.1.6-5.</text>
<text top="923" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref592">Curtis LH, Whellan DJ, Hammill BG, et al.</a></text>
<text top="936" left="346" width="38" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref592">Incidence</a></text>
<text top="936" left="393" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref592">and</a></text>
<text top="936" left="418" width="43" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref592">prevalence</a></text>
<text top="936" left="471" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref592">of</a></text>
<text top="936" left="490" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref592">heart</a></text>
<text top="936" left="520" width="25" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref592">failure</a></text>
<text top="936" left="556" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref592">in</a></text>
<text top="950" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref592">elderly persons, 1994-2003. Arch Intern Med. 2008;</a></text>
<text top="963" left="346" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref592">168:418</a></text>
<text top="962" left="378" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref592">–24</a></text>
<text top="963" left="392" width="3" height="9" font="4">.</text>
<text top="982" left="346" width="36" height="9" font="4">S8.1.6-6.</text>
<text top="982" left="385" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref593">Bleumink GS, Knetsch AM, Sturkenboom MCJM,</a></text>
<text top="995" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref593">et al. Quantifying the heart failure epidemic: preva-</a></text>
<text top="1009" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref593">lence, incidence rate, lifetime risk and prognosis of</a></text>
<text top="1022" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref593">heart failure The Rotterdam Study. Eur Heart J. 2004;</a></text>
<text top="1035" left="346" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref593">25:1614</a></text>
<text top="1034" left="378" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref593">–9</a></text>
<text top="1035" left="388" width="3" height="9" font="4">.</text>
<text top="1054" left="346" width="35" height="9" font="4">S8.1.6-7.</text>
<text top="1054" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref594">Bertoni AG, Hundley WG, Massing MW, et al.</a></text>
<text top="1067" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref594">Heart failure prevalence, incidence, and mortality in</a></text>
<text top="1081" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref594">the elderly with diabetes. Diabetes Care. 2004;27:</a></text>
<text top="1094" left="346" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref594">699</a></text>
<text top="1093" left="363" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref594">–703</a></text>
<text top="1094" left="382" width="3" height="9" font="4">.</text>
<text top="143" left="584" width="36" height="9" font="4">S8.1.6-8.</text>
<text top="143" left="623" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref595">Ogedegbe G, Shah NR, Phillips C, et al.</a></text>
<text top="156" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref595">Comparative effectiveness of angiotensin-converting</a></text>
<text top="170" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref595">enzyme inhibitor-based treatment on cardiovascular</a></text>
<text top="183" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref595">outcomes in hypertensive blacks versus whites. J Am</a></text>
<text top="197" left="584" width="107" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref595">Coll Cardiol. 2015;66:1224</a></text>
<text top="195" left="691" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref595">–33</a></text>
<text top="197" left="704" width="3" height="9" font="4">.</text>
<text top="215" left="584" width="36" height="9" font="4">S8.1.6-9.</text>
<text top="215" left="623" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref596">Leenen FHH, Nwachuku CE, Black HR, et al.</a></text>
<text top="229" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref596">Clinical events in high-risk hypertensive patients</a></text>
<text top="242" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref596">randomly assigned to calcium channel blocker versus</a></text>
<text top="256" left="584" width="91" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref596">angiotensin-converting</a></text>
<text top="256" left="686" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref596">enzyme</a></text>
<text top="256" left="727" width="33" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref596">inhibitor</a></text>
<text top="256" left="770" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref596">in</a></text>
<text top="256" left="788" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref596">the</a></text>
<text top="269" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref596">Antihypertensive and Lipid-Lowering Treatment to Pre-</a></text>
<text top="283" left="584" width="200" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref596">vent Heart Attack Trial. Hypertension. 2006;48:374</a></text>
<text top="281" left="784" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref596">–84</a></text>
<text top="283" left="799" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref596">.</a></text>
<text top="301" left="584" width="40" height="9" font="4">S8.1.6-10.</text>
<text top="301" left="627" width="68" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref597">Antihypertensive</a></text>
<text top="301" left="711" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref597">and</a></text>
<text top="301" left="741" width="60" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref597">Lipid-Lowering</a></text>
<text top="315" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref597">Treatment to Prevent Heart Attack Trial Collaborative</a></text>
<text top="328" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref597">Research Group. Diuretic versus alpha-blocker as</a></text>
<text top="340" left="584" width="217" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref597">ﬁrst-step antihypertensive therapy: ﬁnal results from</a></text>
<text top="355" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref597">the Antihypertensive and Lipid-Lowering Treatment to</a></text>
<text top="368" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref597">Prevent Heart Attack Trial (ALLHAT). Hypertension.</a></text>
<text top="382" left="584" width="52" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref597">2003;42:239</a></text>
<text top="380" left="637" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref597">–46</a></text>
<text top="382" left="652" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref597">.</a></text>
<text top="400" left="584" width="38" height="9" font="4">S8.1.6-11.</text>
<text top="400" left="625" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref598">Law MR, Morris JK, Wald NJ. Use of blood</a></text>
<text top="414" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref598">pressure lowering drugs in the prevention of cardio-</a></text>
<text top="427" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref598">vascular disease: meta-analysis of 147 randomised</a></text>
<text top="441" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref598">trials in the context of expectations from prospective</a></text>
<text top="454" left="584" width="190" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref598">epidemiological studies. BMJ. 2009;338:b1665</a></text>
<text top="454" left="774" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref598">.</a></text>
<text top="473" left="584" width="39" height="9" font="4">S8.1.6-12.</text>
<text top="473" left="626" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref599">Thomopoulos C, Parati G, Zanchetti A.</a></text>
<text top="486" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref599">Effects of blood pressure-lowering on outcome inci-</a></text>
<text top="500" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref599">dence in hypertension: 5. Head-to-head comparisons</a></text>
<text top="513" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref599">of various classes of antihypertensive drugs-overview</a></text>
<text top="526" left="584" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref599">and meta-analyses. J Hypertens. 2015;33:1321</a></text>
<text top="525" left="770" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref599">–41</a></text>
<text top="526" left="783" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref599">.</a></text>
<text top="545" left="584" width="39" height="9" font="4">S8.1.6-13.</text>
<text top="545" left="626" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref600">Zhang Y, Sun N, Jiang X, et al. Comparative</a></text>
<text top="558" left="584" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref600">ef</a></text>
<text top="557" left="592" width="34" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref600">ﬁcacy of</a></text>
<text top="556" left="629" width="5" height="13" font="7"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref600">b</a></text>
<text top="558" left="634" width="167" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref600">-blockers on mortality and cardiovascular</a></text>
<text top="572" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref600">outcomes in patients with hypertension: a systematic</a></text>
<text top="585" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref600">review and network meta-analysis. J Am Soc. Hyper-</a></text>
<text top="599" left="584" width="70" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref600">tens. 2017;11:394</a></text>
<text top="597" left="654" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref600">–401</a></text>
<text top="599" left="674" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref600">.</a></text>
<text top="617" left="584" width="40" height="9" font="4">S8.1.6-14.</text>
<text top="617" left="627" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref601">Larochelle P, Tobe SW, Lacourciere Y.</a></text>
<text top="628" left="584" width="5" height="13" font="7"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref601">b</a></text>
<text top="631" left="589" width="212" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref601">-Blockers in hypertension: studies and meta-analyses</a></text>
<text top="644" left="584" width="172" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref601">over the years. Can J Cardiol. 2014;30:S16</a></text>
<text top="643" left="756" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref601">–22</a></text>
<text top="644" left="769" width="3" height="9" font="4">.</text>
<text top="666" left="584" width="217" height="9" font="4">8.1.6.1. Choice of Initial Monotherapy Versus</text>
<text top="679" left="584" width="155" height="9" font="4">Initial Combination Drug Therapy</text>
<text top="693" left="584" width="41" height="9" font="4">S8.1.6.1-1.</text>
<text top="693" left="628" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref602">Chobanian AV, Bakris GL, Black HR, et al.,</a></text>
<text top="707" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref602">the National High Blood Pressure Education Program</a></text>
<text top="720" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref602">Coordinating Committee. Seventh Report of the Joint</a></text>
<text top="733" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref602">National Committee on Prevention, Detection, Evalu-</a></text>
<text top="747" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref602">ation, and Treatment of High Blood Pressure. Hyper-</a></text>
<text top="760" left="584" width="92" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref602">tension. 2003;42:1206</a></text>
<text top="759" left="676" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref602">–52</a></text>
<text top="760" left="690" width="3" height="9" font="4">.</text>
<text top="779" left="584" width="42" height="9" font="4">S8.1.6.1-2.</text>
<text top="779" left="629" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref603">Law MR, Wald NJ, Morris JK, et al. Value of</a></text>
<text top="792" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref603">low dose combination treatment with blood pressure</a></text>
<text top="806" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref603">lowering drugs: analysis of 354 randomised trials.</a></text>
<text top="819" left="584" width="83" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref603">BMJ. 2003;326:1427</a></text>
<text top="819" left="668" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref603">.</a></text>
<text top="838" left="584" width="42" height="9" font="4">S8.1.6.1-3.</text>
<text top="838" left="629" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref604">Bangalore S, Kamalakkannan G, Parkar S,</a></text>
<text top="851" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref604">et al. Fixed-dose combinations improve medication</a></text>
<text top="865" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref604">compliance: a meta-analysis. Am J Med. 2007;120:</a></text>
<text top="878" left="584" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref604">713</a></text>
<text top="876" left="597" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref604">–9</a></text>
<text top="878" left="607" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref604">.</a></text>
<text top="897" left="584" width="42" height="9" font="4">S8.1.6.1-4.</text>
<text top="897" left="630" width="172" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref605">Jamerson K, Weber MA, Bakris GL, et al.</a></text>
<text top="910" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref605">Benazepril plus amlodipine or hydrochlorothiazide for</a></text>
<text top="923" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref605">hypertension in high-risk patients. N Engl J Med.</a></text>
<text top="937" left="584" width="62" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref605">2008;359:2417</a></text>
<text top="935" left="646" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref605">–28</a></text>
<text top="937" left="660" width="3" height="9" font="4">.</text>
<text top="955" left="584" width="42" height="9" font="4">S8.1.6.1-5.</text>
<text top="955" left="629" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref606">Sundstrom J, Arima H, Jackson R, et al.</a></text>
<text top="969" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref606">Effects of blood pressure reduction in mild hyperten-</a></text>
<text top="982" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref606">sion: a systematic review and meta-analysis. Ann</a></text>
<text top="996" left="584" width="103" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref606">Intern Med. 2015;162:184</a></text>
<text top="994" left="688" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref606">–91</a></text>
<text top="996" left="701" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref606">.</a></text>
<text top="1014" left="584" width="42" height="9" font="4">S8.1.6.1-6.</text>
<text top="1014" left="630" width="172" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref607">Luders S, Schrader J, Berger J, et al.</a></text>
<text top="1028" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref607">The PHARAO study: prevention of hypertension with</a></text>
<text top="1041" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref607">the angiotensin-converting enzyme inhibitor ramipril</a></text>
<text top="1055" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref607">in patients with high-normal blood pressure: a pro-</a></text>
<text top="1068" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref607">spective, randomized, controlled prevention trial of</a></text>
<text top="1082" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref607">the German Hypertension League. J Hypertens. 2008;</a></text>
<text top="1095" left="584" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref607">26:1487</a></text>
<text top="1093" left="617" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref607">–96</a></text>
<text top="1095" left="632" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref607">.</a></text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="20" height="9" font="4">e224</text>
</page>
<page number="99" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="42" height="9" font="4">S8.1.6.1-7.</text>
<text top="143" left="107" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref608">Report of the Joint National Committee</a></text>
<text top="156" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref608">on Detection, Evaluation, and Treatment of High</a></text>
<text top="170" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref608">Blood Pressure. A cooperative study. JAMA. 1977;237:</a></text>
<text top="183" left="63" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref608">255</a></text>
<text top="182" left="77" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref608">–61</a></text>
<text top="183" left="91" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref608">.</a></text>
<text top="206" left="63" width="217" height="9" font="23">8.2. Achieving BP Control in Individual Patients</text>
<text top="230" left="63" width="27" height="9" font="4">S8.2-1.</text>
<text top="230" left="93" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref609">Neaton JD, Grimm RH Jr., Prineas RJ, et al.</a></text>
<text top="244" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref609">Treatment of Mild Hypertension Study. Final results.</a></text>
<text top="257" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref609">Treatment of Mild Hypertension Study Research</a></text>
<text top="271" left="63" width="112" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref609">Group. JAMA. 1993;270:713</a></text>
<text top="269" left="175" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref609">–24</a></text>
<text top="271" left="189" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref609">.</a></text>
<text top="291" left="63" width="28" height="9" font="4">S8.2-2.</text>
<text top="291" left="94" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref610">Senn S. Individual response to treatment: is it a</a></text>
<text top="304" left="63" width="157" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref610">valid assumption? BMJ. 2004;329:966</a></text>
<text top="303" left="219" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref610">–8</a></text>
<text top="304" left="229" width="3" height="9" font="4">.</text>
<text top="328" left="63" width="217" height="9" font="23">8.3. Follow-Up of BP During Antihypertensive</text>
<text top="341" left="63" width="63" height="9" font="23">Drug Therapy</text>
<text top="365" left="63" width="27" height="9" font="4">S8.3-1.</text>
<text top="365" left="93" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref611">Ambrosius WT, Sink KM, Foy CG, et al. The</a></text>
<text top="379" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref611">design and rationale of a multicenter clinical trial</a></text>
<text top="392" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref611">comparing two strategies for control of systolic blood</a></text>
<text top="406" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref611">pressure: the Systolic Blood Pressure Intervention Trial</a></text>
<text top="419" left="63" width="133" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref611">(SPRINT). Clin Trials. 2014;11:532</a></text>
<text top="418" left="196" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref611">–46</a></text>
<text top="419" left="211" width="3" height="9" font="4">.</text>
<text top="439" left="63" width="28" height="9" font="4">S8.3-2.</text>
<text top="439" left="94" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref612">Cushman WC, Grimm RH Jr., Cutler JA, et al.</a></text>
<text top="453" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref612">Rationale and design for the blood pressure interven-</a></text>
<text top="466" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref612">tion of the Action to Control Cardiovascular Risk</a></text>
<text top="480" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref612">in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99:</a></text>
<text top="493" left="63" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref612">44i</a></text>
<text top="492" left="76" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref612">–55i</a></text>
<text top="493" left="92" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref612">.</a></text>
<text top="516" left="63" width="217" height="9" font="4">8.3.1. Follow-Up After Initiating Antihyperten-</text>
<text top="530" left="63" width="84" height="9" font="4">sive Drug Therapy</text>
<text top="544" left="63" width="33" height="9" font="4">S8.3.1-1.</text>
<text top="544" left="99" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref613">Ambrosius WT, Sink KM, Foy CG, et al. The</a></text>
<text top="557" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref613">design and rationale of a multicenter clinical trial</a></text>
<text top="570" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref613">comparing two strategies for control of systolic blood</a></text>
<text top="584" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref613">pressure: the Systolic Blood Pressure Intervention Trial</a></text>
<text top="597" left="63" width="133" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref613">(SPRINT). Clin Trials. 2014;11:532</a></text>
<text top="596" left="196" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref613">–46</a></text>
<text top="597" left="211" width="3" height="9" font="4">.</text>
<text top="617" left="63" width="34" height="9" font="4">S8.3.1-2.</text>
<text top="617" left="100" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref614">Cushman WC, Grimm RH Jr., Cutler JA, et al.</a></text>
<text top="630" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref614">Rationale and design for the blood pressure interven-</a></text>
<text top="644" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref614">tion of the Action to Control Cardiovascular Risk</a></text>
<text top="657" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref614">in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99:</a></text>
<text top="671" left="63" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref614">44i</a></text>
<text top="669" left="76" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref614">–55i</a></text>
<text top="671" left="92" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref614">.</a></text>
<text top="689" left="63" width="34" height="9" font="4">S8.3.1-3.</text>
<text top="689" left="100" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref615">Xu W, Goldberg SI, Shubina M, et al. Optimal</a></text>
<text top="703" left="63" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref615">systolic blood pressure target, time to intensi</a></text>
<text top="701" left="248" width="32" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref615">ﬁcation,</a></text>
<text top="716" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref615">and time to follow-up in treatment of hypertension:</a></text>
<text top="730" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref615">population based retrospective cohort study. BMJ.</a></text>
<text top="743" left="63" width="60" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref615">2015;350:h158</a></text>
<text top="743" left="122" width="3" height="9" font="4">.</text>
<text top="765" left="63" width="217" height="9" font="4">8.3.2. Monitoring Strategies to Improve Control</text>
<text top="778" left="63" width="212" height="9" font="4">of BP in Patients on Drug Therapy for High BP</text>
<text top="792" left="63" width="34" height="9" font="4">S8.3.2-1.</text>
<text top="792" left="100" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref616">Brennan T, Spettell C, Villagra V, et al. Dis-</a></text>
<text top="805" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref616">ease management to promote blood pressure control</a></text>
<text top="819" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref616">among African Americans. Popul Health Manag. 2010;</a></text>
<text top="832" left="63" width="22" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref616">13:65</a></text>
<text top="831" left="84" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref616">–72</a></text>
<text top="832" left="98" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref616">.</a></text>
<text top="851" left="63" width="35" height="9" font="4">S8.3.2-2.</text>
<text top="851" left="101" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref617">Bosworth HB, Olsen MK, Grubber JM, et al.</a></text>
<text top="865" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref617">Two self-management interventions to improve hy-</a></text>
<text top="878" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref617">pertension control: a randomized trial. Ann Intern</a></text>
<text top="891" left="63" width="79" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref617">Med. 2009;151:687</a></text>
<text top="890" left="141" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref617">–95</a></text>
<text top="891" left="156" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref617">.</a></text>
<text top="910" left="63" width="35" height="9" font="4">S8.3.2-3.</text>
<text top="910" left="101" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref618">Bosworth HB, Powers BJ, Olsen MK, et al.</a></text>
<text top="924" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref618">Home blood pressure management and improved</a></text>
<text top="937" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref618">blood pressure control: results from a randomized</a></text>
<text top="950" left="63" width="189" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref618">controlled trial. Arch Intern Med. 2011;171:1173</a></text>
<text top="949" left="251" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref618">–80</a></text>
<text top="950" left="267" width="3" height="9" font="4">.</text>
<text top="969" left="63" width="36" height="9" font="4">S8.3.2-4.</text>
<text top="969" left="102" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref619">Green BB, Cook AJ, Ralston JD, et al. Effec-</a></text>
<text top="983" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref619">tiveness of home blood pressure monitoring, Web</a></text>
<text top="996" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref619">communication, and pharmacist care on hypertension</a></text>
<text top="1009" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref619">control: a randomized controlled trial. JAMA. 2008;</a></text>
<text top="1023" left="63" width="39" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref619">299:2857</a></text>
<text top="1021" left="101" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref619">–67</a></text>
<text top="1023" left="115" width="3" height="9" font="4">.</text>
<text top="1042" left="63" width="35" height="9" font="4">S8.3.2-5.</text>
<text top="1042" left="101" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref620">Heisler M, Hofer TP, Schmittdiel JA, et al.</a></text>
<text top="1055" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref620">Improving blood pressure control through a clinical</a></text>
<text top="1068" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref620">pharmacist outreach program in patients with diabetes</a></text>
<text top="1082" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref620">mellitus in 2 high-performing health systems: the</a></text>
<text top="1095" left="63" width="91" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref620">adherence and intensi</a></text>
<text top="1094" left="154" width="126" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref620">ﬁcation of medications cluster</a></text>
<text top="143" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref620">randomized, controlled pragmatic trial. Circulation.</a></text>
<text top="156" left="301" width="59" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref620">2012;125:2863</a></text>
<text top="155" left="360" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref620">–72</a></text>
<text top="156" left="373" width="3" height="9" font="4">.</text>
<text top="177" left="301" width="36" height="9" font="4">S8.3.2-6.</text>
<text top="177" left="340" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref621">Margolis KL, Asche SE, Bergdall AR, et al.</a></text>
<text top="191" left="301" width="24" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref621">Effect</a></text>
<text top="191" left="334" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref621">of</a></text>
<text top="191" left="352" width="22" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref621">home</a></text>
<text top="191" left="384" width="23" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref621">blood</a></text>
<text top="191" left="416" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref621">pressure</a></text>
<text top="191" left="459" width="59" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref621">telemonitoring</a></text>
<text top="204" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref621">and pharmacist management on blood pressure</a></text>
<text top="218" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref621">control: a cluster randomized clinical trial. JAMA.</a></text>
<text top="231" left="301" width="50" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref621">2013;310:46</a></text>
<text top="229" left="351" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref621">–56</a></text>
<text top="231" left="366" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref621">.</a></text>
<text top="271" left="301" width="197" height="12" font="26">9 . H Y P E R T E N S I O N I N P A T I E N T S</text>
<text top="285" left="301" width="138" height="12" font="26">W I T H C O M O R B I D I T I E S</text>
<text top="318" left="301" width="20" height="9" font="4">S9-1.</text>
<text top="318" left="324" width="194" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref622">Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA</a></text>
<text top="332" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref622">2011 expert consensus document on hypertension</a></text>
<text top="345" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref622">in the elderly: a report of the American College of</a></text>
<text top="359" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref622">Cardiology Foundation Task Force on Clinical Expert</a></text>
<text top="372" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref622">Consensus Documents. Developed in collaboration</a></text>
<text top="386" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref622">with the American Academy of Neurology, American</a></text>
<text top="399" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref622">Geriatrics Society, American Society for Preventive</a></text>
<text top="413" left="301" width="45" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref622">Cardiology,</a></text>
<text top="413" left="357" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref622">American</a></text>
<text top="413" left="404" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref622">Society</a></text>
<text top="413" left="444" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref622">of</a></text>
<text top="413" left="462" width="56" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref622">Hypertension,</a></text>
<text top="426" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref622">American Society of Nephrology, Association of Black</a></text>
<text top="440" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref622">Cardiologists, and European Society of Hypertension.</a></text>
<text top="453" left="301" width="129" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref622">J Am Coll Cardiol. 2011;57:2037</a></text>
<text top="451" left="430" width="17" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref622">–114</a></text>
<text top="453" left="446" width="3" height="9" font="4">.</text>
<text top="474" left="301" width="21" height="9" font="4">S9-2.</text>
<text top="474" left="325" width="193" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref623">Yancy CW, Jessup M, Bozkurt B, et al. 2013</a></text>
<text top="487" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref623">ACCF/AHA guideline for the management of heart</a></text>
<text top="501" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref623">failure: a report of the American College of Cardiology</a></text>
<text top="514" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref623">Foundation/American Heart Association Task Force</a></text>
<text top="527" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref623">on Practice Guidelines. J Am Coll Cardiol. 2013;62:</a></text>
<text top="541" left="301" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref623">e147</a></text>
<text top="539" left="319" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref623">–239</a></text>
<text top="541" left="339" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref623">.</a></text>
<text top="562" left="301" width="21" height="9" font="4">S9-3.</text>
<text top="562" left="325" width="193" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref624">Fihn SD, Blankenship JC, Alexander KP, et al.</a></text>
<text top="575" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref624">2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update</a></text>
<text top="588" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref624">of the guideline for the diagnosis and management of</a></text>
<text top="602" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref624">patients with stable ischemic heart disease: a report of</a></text>
<text top="615" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref624">the American College of Cardiology/American Heart</a></text>
<text top="629" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref624">Association Task Force on Practice Guidelines, and the</a></text>
<text top="642" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref624">American Association for Thoracic Surgery, Preventive</a></text>
<text top="656" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref624">Cardiovascular Nurses Association, Society for Cardio-</a></text>
<text top="669" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref624">vascular Angiography and Interventions, and Society</a></text>
<text top="683" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref624">of Thoracic Surgeons. J Am Coll Cardiol. 2014;64:</a></text>
<text top="696" left="301" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref624">1929</a></text>
<text top="695" left="321" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref624">–49</a></text>
<text top="696" left="336" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref624">.</a></text>
<text top="717" left="301" width="22" height="9" font="4">S9-4.</text>
<text top="717" left="326" width="192" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref625">Gerhard-Herman MD, Gornik HL, Barrett C, et al.</a></text>
<text top="730" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref625">2016 AHA/ACC guideline on the management of</a></text>
<text top="744" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref625">patients with lower extremity peripheral artery dis-</a></text>
<text top="757" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref625">ease: a report of the American College of Cardiology/</a></text>
<text top="771" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref625">American Heart Association Task Force on Clinical</a></text>
<text top="784" left="301" width="213" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref625">Practice Guidelines. J Am Coll Cardiol. 2017;69:e71</a></text>
<text top="782" left="514" width="4" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref625">–</a></text>
<text top="797" left="301" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref625">126</a></text>
<text top="797" left="315" width="3" height="9" font="4">.</text>
<text top="819" left="301" width="156" height="9" font="23">9.1. Stable Ischemic Heart Disease</text>
<text top="845" left="301" width="26" height="9" font="4">S9.1-1.</text>
<text top="845" left="330" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref626">Wright JT Jr., Williamson JD, Whelton PK, et al.</a></text>
<text top="858" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref626">A randomized trial of intensive versus standard blood-</a></text>
<text top="872" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref626">pressure control. SPRINT Research Group. N Engl J</a></text>
<text top="885" left="301" width="81" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref626">Med. 2015;373:2103</a></text>
<text top="884" left="382" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref626">–16</a></text>
<text top="885" left="395" width="3" height="9" font="4">.</text>
<text top="906" left="301" width="27" height="9" font="4">S9.1-2.</text>
<text top="906" left="331" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref627">Bundy JD, Li C, Stuchlik P, et al. Systolic blood</a></text>
<text top="920" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref627">pressure reduction and risk of cardiovascular disease</a></text>
<text top="933" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref627">and mortality: a systematic review and network meta-</a></text>
<text top="946" left="301" width="139" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref627">analysis. JAMA Cardiol. 2017;2:775</a></text>
<text top="945" left="440" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref627">–81</a></text>
<text top="946" left="454" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref627">.</a></text>
<text top="967" left="301" width="27" height="9" font="4">S9.1-3.</text>
<text top="967" left="331" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref628">Leenen FHH, Nwachuku CE, Black HR,</a></text>
<text top="981" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref628">et al. Clinical events in high-risk hypertensive</a></text>
<text top="994" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref628">patients randomly assigned to calcium channel</a></text>
<text top="1007" left="301" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref628">blocker</a></text>
<text top="1007" left="342" width="27" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref628">versus</a></text>
<text top="1007" left="378" width="98" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref628">angiotensin-converting</a></text>
<text top="1007" left="486" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref628">enzyme</a></text>
<text top="1021" left="301" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref628">inhibitor</a></text>
<text top="1021" left="347" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref628">in</a></text>
<text top="1021" left="365" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref628">the</a></text>
<text top="1021" left="389" width="71" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref628">antihypertensive</a></text>
<text top="1021" left="470" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref628">and</a></text>
<text top="1021" left="496" width="22" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref628">lipid-</a></text>
<text top="1034" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref628">lowering treatment to prevent heart attack trial.</a></text>
<text top="1048" left="301" width="120" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref628">Hypertension. 2006;48:374</a></text>
<text top="1046" left="421" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref628">–84</a></text>
<text top="1048" left="437" width="3" height="9" font="4">.</text>
<text top="1069" left="301" width="28" height="9" font="4">S9.1-4.</text>
<text top="1069" left="332" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref629">Zanchetti A, Julius S, Kjeldsen S, et al.</a></text>
<text top="1082" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref629">Outcomes in subgroups of hypertensive patients</a></text>
<text top="1095" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref629">treated with regimens based on valsartan and</a></text>
<text top="143" left="539" width="108" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref629">amlodipine: an analysis of</a></text>
<text top="141" left="652" width="104" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref629">ﬁndings from the VALUE</a></text>
<text top="156" left="539" width="132" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref629">trial. J Hypertens. 2006;24:2163</a></text>
<text top="155" left="671" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref629">–8</a></text>
<text top="156" left="681" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref629">.</a></text>
<text top="175" left="539" width="27" height="9" font="4">S9.1-5.</text>
<text top="175" left="570" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref630">Antihypertensive and Lipid-Lowering Treat-</a></text>
<text top="188" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref630">ment to Prevent Heart Attack Trial Collaborative</a></text>
<text top="202" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref630">Research Group. Diuretic versus alpha-blocker as</a></text>
<text top="214" left="539" width="217" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref630">ﬁrst-step antihypertensive therapy: ﬁnal results from</a></text>
<text top="229" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref630">the Antihypertensive and Lipid-Lowering Treatment to</a></text>
<text top="242" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref630">Prevent Heart Attack Trial (ALLHAT). Hypertension.</a></text>
<text top="256" left="539" width="52" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref630">2003;42:239</a></text>
<text top="254" left="592" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref630">–46</a></text>
<text top="256" left="607" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref630">.</a></text>
<text top="274" left="539" width="28" height="9" font="4">S9.1-6.</text>
<text top="274" left="570" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref631">Fihn SD, Blankenship JC, Alexander KP, et al.</a></text>
<text top="287" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref631">2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update</a></text>
<text top="301" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref631">of the Guideline for the diagnosis and management of</a></text>
<text top="314" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref631">patients with stable ischemic heart disease: a report of</a></text>
<text top="328" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref631">the American College of Cardiology/American Heart</a></text>
<text top="341" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref631">Association Task Force on Practice Guidelines, and the</a></text>
<text top="355" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref631">American Association for Thoracic Surgery, Preventive</a></text>
<text top="368" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref631">Cardiovascular Nurses Association, Society for Cardio-</a></text>
<text top="381" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref631">vascular Angiography and Interventions, and Society</a></text>
<text top="395" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref631">of Thoracic Surgeons. J Am Coll Cardiol. 2014;64:</a></text>
<text top="408" left="539" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref631">1929</a></text>
<text top="407" left="559" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref631">–49</a></text>
<text top="408" left="574" width="3" height="9" font="4">.</text>
<text top="427" left="539" width="27" height="9" font="4">S9.1-7.</text>
<text top="427" left="570" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref632">Fox KM. EURopean trial On reduction of cardiac</a></text>
<text top="440" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref632">events with Perindopril in stable coronary Artery dis-</a></text>
<text top="454" left="539" width="86" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref632">ease Investigators. Ef</a></text>
<text top="452" left="625" width="131" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref632">ﬁcacy of perindopril in reduction</a></text>
<text top="467" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref632">of cardiovascular events among patients with stable</a></text>
<text top="481" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref632">coronary artery disease: randomised, double-blind,</a></text>
<text top="494" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref632">placebo-controlled, multicentre trial (the EUROPA</a></text>
<text top="508" left="539" width="120" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref632">study). Lancet. 2003;362:782</a></text>
<text top="506" left="659" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref632">–8</a></text>
<text top="508" left="669" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref632">.</a></text>
<text top="526" left="539" width="28" height="9" font="4">S9.1-8.</text>
<text top="526" left="570" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref633">Law MR, Morris JK, Wald NJ. Use of blood</a></text>
<text top="539" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref633">pressure lowering drugs in the prevention of</a></text>
<text top="553" left="539" width="61" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref633">cardiovascular</a></text>
<text top="553" left="610" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref633">disease:</a></text>
<text top="553" left="654" width="59" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref633">meta-analysis</a></text>
<text top="553" left="723" width="9" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref633">of</a></text>
<text top="553" left="742" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref633">147</a></text>
<text top="566" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref633">randomised trials in the context of expectations</a></text>
<text top="580" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref633">from prospective epidemiological studies. BMJ.</a></text>
<text top="593" left="539" width="72" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref633">2009;338:b1665</a></text>
<text top="593" left="612" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref633">.</a></text>
<text top="613" left="539" width="28" height="9" font="4">S9.1-9.</text>
<text top="613" left="570" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref634">Pfeffer MA, Braunwald E, Moye LA, et al. Ef-</a></text>
<text top="626" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref634">fect of captopril on mortality and morbidity in patients</a></text>
<text top="640" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref634">with left ventricular dysfunction after myocardial</a></text>
<text top="653" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref634">infarction. Results of the survival and ventricular</a></text>
<text top="667" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref634">enlargement trial. The SAVE Investigators. N Engl J</a></text>
<text top="680" left="539" width="79" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref634">Med. 1992;327:669</a></text>
<text top="679" left="618" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref634">–77</a></text>
<text top="680" left="631" width="3" height="9" font="4">.</text>
<text top="700" left="539" width="32" height="9" font="4">S9.1-10.</text>
<text top="700" left="575" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref635">Yusuf S, Sleight P, Pogue J, et al. Effects of an</a></text>
<text top="714" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref635">angiotensin-converting-enzyme inhibitor, ramipril, on</a></text>
<text top="727" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref635">cardiovascular events in high-risk patients. The Heart</a></text>
<text top="740" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref635">Outcomes Prevention Evaluation Study Investigators.</a></text>
<text top="754" left="539" width="117" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref635">N Engl J Med. 2000;342:145</a></text>
<text top="752" left="657" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref635">–53</a></text>
<text top="754" left="670" width="3" height="9" font="4">.</text>
<text top="774" left="539" width="30" height="9" font="4">S9.1-11.</text>
<text top="774" left="573" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref636">Leon MB, Rosing DR, Bonow RO, et al. Clinical</a></text>
<text top="787" left="539" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref636">ef</a></text>
<text top="786" left="547" width="209" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref636">ﬁcacy of verapamil alone and combined with pro-</a></text>
<text top="801" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref636">pranolol in treating patients with chronic stable angina</a></text>
<text top="814" left="539" width="141" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref636">pectoris. Am J Cardiol. 1981;48:131</a></text>
<text top="813" left="680" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref636">–9</a></text>
<text top="814" left="690" width="3" height="9" font="4">.</text>
<text top="834" left="539" width="31" height="9" font="4">S9.1-12.</text>
<text top="834" left="574" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref637">Staessen JA, Fagard R, Thijs L, et al.</a></text>
<text top="847" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref637">Randomised double-blind comparison of placebo</a></text>
<text top="861" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref637">and active treatment for older patients with isolated</a></text>
<text top="874" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref637">systolic hypertension. The Systolic Hypertension in</a></text>
<text top="888" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref637">Europe (Syst-Eur) Trial Investigators. Lancet. 1997;</a></text>
<text top="901" left="539" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref637">350:757</a></text>
<text top="900" left="572" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref637">–64</a></text>
<text top="901" left="587" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref637">.</a></text>
<text top="921" left="539" width="31" height="9" font="4">S9.1-13.</text>
<text top="921" left="574" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref638">Freemantle N, Cleland J, Young P, et al. Beta</a></text>
<text top="935" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref638">Blockade after myocardial infarction: systematic re-</a></text>
<text top="948" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref638">view and meta regression analysis. BMJ. 1999;318:</a></text>
<text top="961" left="539" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref638">1730</a></text>
<text top="960" left="558" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref638">–7</a></text>
<text top="961" left="567" width="3" height="9" font="4">.</text>
<text top="981" left="539" width="32" height="9" font="4">S9.1-14.</text>
<text top="981" left="574" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref639">de Peuter OR, Lussana F, Peters RJG, et al.</a></text>
<text top="995" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref639">A systematic review of selective and non-selective</a></text>
<text top="1008" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref639">beta blockers for prevention of vascular events in</a></text>
<text top="1022" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref639">patients with acute coronary syndrome or heart fail-</a></text>
<text top="1035" left="539" width="124" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref639">ure. Neth J Med. 2009;67:284</a></text>
<text top="1034" left="664" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref639">–94</a></text>
<text top="1035" left="679" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref639">.</a></text>
<text top="1055" left="539" width="31" height="9" font="4">S9.1-15.</text>
<text top="1055" left="574" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">Bavry AA, Anderson RD, Gong Y, et al.</a></text>
<text top="1068" left="539" width="42" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">Outcomes</a></text>
<text top="1068" left="591" width="28" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">among</a></text>
<text top="1068" left="629" width="55" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">hypertensive</a></text>
<text top="1068" left="694" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">patients</a></text>
<text top="1068" left="738" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">with</a></text>
<text top="1082" left="539" width="53" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">concomitant</a></text>
<text top="1082" left="603" width="43" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">peripheral</a></text>
<text top="1082" left="657" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">and</a></text>
<text top="1082" left="683" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">coronary</a></text>
<text top="1082" left="731" width="25" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">artery</a></text>
<text top="1095" left="539" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">disease:</a></text>
<text top="1094" left="588" width="33" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">ﬁndings</a></text>
<text top="1095" left="636" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">from</a></text>
<text top="1095" left="671" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">the</a></text>
<text top="1095" left="700" width="56" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">INternational</a></text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="788" width="19" height="9" font="4">e225</text>
</page>
<page number="100" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">VErapamil-SR/Trandolapril STudy. Hypertension.</a></text>
<text top="156" left="108" width="49" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">2010;55:48</a></text>
<text top="155" left="157" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">–53</a></text>
<text top="156" left="172" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref640">.</a></text>
<text top="176" left="108" width="32" height="9" font="4">S9.1-16.</text>
<text top="176" left="143" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref641">Piller LB, Simpson LM, Baraniuk S, et al.</a></text>
<text top="189" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref641">Characteristics and long-term follow-up of partici-</a></text>
<text top="203" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref641">pants with peripheral arterial disease during ALLHAT.</a></text>
<text top="216" left="108" width="130" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref641">J Gen Intern Med. 2014;29:1475</a></text>
<text top="215" left="237" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref641">–83</a></text>
<text top="216" left="252" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref641">.</a></text>
<text top="235" left="108" width="31" height="9" font="4">S9.1-17.</text>
<text top="235" left="142" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref642">Rosendorff C, Lackland DT, Allison M, et al.</a></text>
<text top="249" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref642">Treatment of hypertension in patients with coronary</a></text>
<text top="262" left="108" width="110" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref642">artery disease: a scienti</a></text>
<text top="261" left="218" width="107" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref642">ﬁc statement from the</a></text>
<text top="276" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref642">American Heart Association, American College of</a></text>
<text top="289" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref642">Cardiology, and American Society of Hypertension.</a></text>
<text top="303" left="108" width="131" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref642">J Am Coll Cardiol. 2015;65:1998</a></text>
<text top="301" left="239" width="25" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref642">–2038</a></text>
<text top="303" left="264" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref642">.</a></text>
<text top="322" left="108" width="32" height="9" font="4">S9.1-18.</text>
<text top="322" left="143" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref643">Ekelund LG, Olsson AG, Oro L, et al. Effects of</a></text>
<text top="335" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref643">the cardioselective beta-adrenergic receptor blocking</a></text>
<text top="349" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref643">agent metoprolol in angina pectoris. Subacute study</a></text>
<text top="362" left="108" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref643">with exercise tests. Br Heart J. 1976;38:155</a></text>
<text top="361" left="283" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref643">–61</a></text>
<text top="362" left="296" width="3" height="9" font="4">.</text>
<text top="382" left="108" width="32" height="9" font="4">S9.1-19.</text>
<text top="382" left="143" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref644">Aronow WS, Turbow M, Van Camp S, et al.</a></text>
<text top="395" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref644">The effect of timolol vs placebo on angina pectoris.</a></text>
<text top="409" left="108" width="95" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref644">Circulation. 1980;61:66</a></text>
<text top="407" left="202" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref644">–9</a></text>
<text top="409" left="212" width="3" height="9" font="4">.</text>
<text top="428" left="108" width="33" height="9" font="4">S9.1-20.</text>
<text top="428" left="144" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref645">Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/</a></text>
<text top="441" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref645">AHA 2011 expert consensus document on hypertension</a></text>
<text top="455" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref645">in the elderly: a report of the American College of</a></text>
<text top="468" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref645">Cardiology Foundation Task Force on Clinical Expert</a></text>
<text top="482" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref645">Consensus Documents. Developed in collaboration</a></text>
<text top="495" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref645">with the American Academy of Neurology, American</a></text>
<text top="509" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref645">Geriatrics Society, American Society for Preventive</a></text>
<text top="522" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref645">Cardiology, American Society of Hypertension, Amer-</a></text>
<text top="536" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref645">ican Society of Nephrology, Association of Black Car-</a></text>
<text top="549" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref645">diologists, and European Society of Hypertension.</a></text>
<text top="562" left="108" width="129" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref645">J Am Coll Cardiol. 2011;57:2037</a></text>
<text top="561" left="236" width="17" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref645">–114</a></text>
<text top="562" left="253" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref645">.</a></text>
<text top="582" left="108" width="31" height="9" font="4">S9.1-21.</text>
<text top="582" left="142" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref646">Aronow WS, Frishman WH. Angina pectoris in</a></text>
<text top="595" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref646">the elderly. In: Aronow WS, Fleg JL, Rich MW, editors.</a></text>
<text top="609" left="108" width="82" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref646">Tresch and Aronow</a></text>
<text top="607" left="190" width="135" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref646">’s Cardiovascular Disease in the</a></text>
<text top="622" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref646">Elderly. Boca Raton, FL: CRC Press, Taylor &amp; Francis</a></text>
<text top="636" left="108" width="65" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref646">Group; 2013:215</a></text>
<text top="634" left="173" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref646">–37</a></text>
<text top="636" left="186" width="3" height="9" font="4">.</text>
<text top="655" left="108" width="32" height="9" font="4">S9.1-22.</text>
<text top="655" left="143" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref647">Smith SC Jr., Benjamin EJ, Bonow RO, et al.</a></text>
<text top="668" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref647">AHA/ACCF secondary prevention and risk reduction</a></text>
<text top="682" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref647">therapy for patients with coronary and other athero-</a></text>
<text top="695" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref647">sclerotic vascular disease: 2011 update: a guideline</a></text>
<text top="709" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref647">from the American Heart Association and American</a></text>
<text top="722" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref647">College of Cardiology Foundation. J Am Coll Cardiol.</a></text>
<text top="736" left="108" width="54" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref647">2011;58:2432</a></text>
<text top="734" left="161" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref647">–46</a></text>
<text top="736" left="177" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref647">.</a></text>
<text top="755" left="108" width="32" height="9" font="4">S9.1-23.</text>
<text top="755" left="143" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref648">Carlberg B, Samuelsson O, Lindholm LH.</a></text>
<text top="768" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref648">Atenolol in hypertension: is it a wise choice? Lancet.</a></text>
<text top="782" left="108" width="64" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref648">2004;364:1684</a></text>
<text top="780" left="171" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref648">–9</a></text>
<text top="782" left="181" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref648">.</a></text>
<text top="801" left="108" width="33" height="9" font="4">S9.1-24.</text>
<text top="801" left="144" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref649">Mancia G, Fagard R, Narkiewicz K, et al.</a></text>
<text top="815" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref649">2013 ESH/ESC guidelines for the management</a></text>
<text top="828" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref649">of arterial hypertension: the Task Force for</a></text>
<text top="842" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref649">the Management of Arterial Hypertension of the</a></text>
<text top="855" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref649">European Society of Hypertension (ESH) and of the</a></text>
<text top="868" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref649">European Society of Cardiology (ESC). Eur Heart J.</a></text>
<text top="882" left="108" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref649">2013;34:2159</a></text>
<text top="880" left="165" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref649">–219</a></text>
<text top="882" left="185" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref649">.</a></text>
<text top="901" left="108" width="32" height="9" font="4">S9.1-25.</text>
<text top="901" left="143" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref650">Fihn SD, Gardin JM, Abrams J, et al. 2012</a></text>
<text top="915" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref650">ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for</a></text>
<text top="928" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref650">the diagnosis and management of patients with stable</a></text>
<text top="942" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref650">ischemic heart disease: a report of the American Col-</a></text>
<text top="955" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref650">lege of Cardiology Foundation/American Heart Asso-</a></text>
<text top="968" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref650">ciation Task Force on Practice Guidelines, and the</a></text>
<text top="982" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref650">American College of Physicians, American Association</a></text>
<text top="995" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref650">for Thoracic Surgery, Preventive Cardiovascular Nurses</a></text>
<text top="1009" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref650">Association, Society for Cardiovascular Angiography</a></text>
<text top="1022" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref650">and Interventions, and Society of Thoracic Surgeons.</a></text>
<text top="1036" left="108" width="127" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref650">J Am Coll Cardiol. 2012;60:e44</a></text>
<text top="1034" left="235" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref650">–164</a></text>
<text top="1036" left="253" width="3" height="9" font="4">.</text>
<text top="1057" left="108" width="80" height="9" font="23">9.2. Heart Failure</text>
<text top="1082" left="108" width="27" height="9" font="4">S9.2-1.</text>
<text top="1082" left="138" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref651">Lv J, Ehteshami P, Sarnak MJ, et al. Effects of</a></text>
<text top="1095" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref651">intensive blood pressure lowering on the progression</a></text>
<text top="143" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref651">of chronic kidney disease: a systematic review and</a></text>
<text top="156" left="346" width="144" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref651">meta-analysis. CMAJ. 2013;185:949</a></text>
<text top="155" left="490" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref651">–57</a></text>
<text top="156" left="503" width="3" height="9" font="4">.</text>
<text top="176" left="346" width="28" height="9" font="4">S9.2-2.</text>
<text top="176" left="377" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref652">Thomopoulos C, Parati G, Zanchetti A. Effects</a></text>
<text top="189" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref652">of blood pressure lowering on outcome incidence in</a></text>
<text top="203" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref652">hypertension: 7. Effects of more vs. less intensive</a></text>
<text top="216" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref652">blood pressure lowering and different achieved blood</a></text>
<text top="229" left="346" width="61" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref652">pressure levels</a></text>
<text top="228" left="407" width="156" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref652">–updated overview and meta-analyses</a></text>
<text top="243" left="346" width="189" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref652">of randomized trials. J Hypertens. 2016;34:613</a></text>
<text top="241" left="535" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref652">–22</a></text>
<text top="243" left="549" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref652">.</a></text>
<text top="262" left="346" width="28" height="9" font="4">S9.2-3.</text>
<text top="262" left="377" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref653">Xie X, Atkins E, Lv J, et al. Effects of intensive</a></text>
<text top="276" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref653">blood pressure lowering on cardiovascular and renal</a></text>
<text top="289" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref653">outcomes: updated systematic review and meta-anal-</a></text>
<text top="302" left="346" width="108" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref653">ysis. Lancet. 2016;387:435</a></text>
<text top="301" left="453" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref653">–43</a></text>
<text top="302" left="468" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref653">.</a></text>
<text top="322" left="346" width="29" height="9" font="4">S9.2-4.</text>
<text top="322" left="378" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref654">Yancy CW, Jessup M, Bozkurt B, et al. 2016</a></text>
<text top="335" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref654">ACC/AHA/HFSA focused update on new pharmaco-</a></text>
<text top="349" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref654">logical therapy for heart failure: an update of the 2013</a></text>
<text top="362" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref654">ACCF/AHA guideline for the management of heart</a></text>
<text top="375" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref654">failure: a report of the American College of Cardiology/</a></text>
<text top="389" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref654">American Heart Association Task Force on Clinical</a></text>
<text top="402" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref654">Practice Guidelines and the Heart Failure Society of</a></text>
<text top="416" left="346" width="169" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref654">America. J Am Coll Cardiol. 2016;68:1476</a></text>
<text top="414" left="515" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref654">–88</a></text>
<text top="416" left="530" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref654">.</a></text>
<text top="435" left="346" width="28" height="9" font="4">S9.2-5.</text>
<text top="435" left="377" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref655">Visser M, Langlois J, Guralnik JM, et al. High</a></text>
<text top="448" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref655">body fatness, but not low fat-free mass, predicts</a></text>
<text top="462" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref655">disability in older men and women: the Cardiovascular</a></text>
<text top="475" left="346" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref655">Health Study. Am J Clin Nutr. 1998;68:584</a></text>
<text top="474" left="521" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref655">–90</a></text>
<text top="475" left="537" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref655">.</a></text>
<text top="495" left="346" width="29" height="9" font="4">S9.2-6.</text>
<text top="495" left="378" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref656">Goodpaster BH, Park SW, Harris TB, et al.</a></text>
<text top="508" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref656">The loss of skeletal muscle strength, mass, and</a></text>
<text top="521" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref656">quality in older adults: the health, aging and body</a></text>
<text top="535" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref656">composition study. J Gerontol A Biol Sci Med Sci.</a></text>
<text top="548" left="346" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref656">2006;61:1059</a></text>
<text top="547" left="403" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref656">–64</a></text>
<text top="548" left="418" width="3" height="9" font="4">.</text>
<text top="568" left="346" width="28" height="9" font="4">S9.2-7.</text>
<text top="568" left="377" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref657">Butler J, Kalogeropoulos AP, Georgiopoulou VV,</a></text>
<text top="581" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref657">et al. Systolic blood pressure and incident heart failure</a></text>
<text top="595" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref657">in the elderly. The Cardiovascular Health Study and</a></text>
<text top="608" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref657">the Health, Ageing and Body Composition Study. Heart.</a></text>
<text top="621" left="346" width="54" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref657">2011;97:1304</a></text>
<text top="620" left="399" width="11" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref657">–11</a></text>
<text top="621" left="411" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref657">.</a></text>
<text top="641" left="346" width="29" height="9" font="4">S9.2-8.</text>
<text top="641" left="378" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref658">Yancy CW, Jessup M, Bozkurt B, et al. 2013</a></text>
<text top="654" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref658">ACCF/AHA guideline for the management of heart</a></text>
<text top="667" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref658">failure: a report of the American College of Cardiology</a></text>
<text top="681" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref658">Foundation/American Heart Association Task Force</a></text>
<text top="694" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref658">on Practice Guidelines. J Am Coll Cardiol. 2013;62:</a></text>
<text top="708" left="346" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref658">e147</a></text>
<text top="706" left="364" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref658">–239</a></text>
<text top="708" left="383" width="3" height="9" font="4">.</text>
<text top="727" left="346" width="29" height="9" font="4">S9.2-9.</text>
<text top="727" left="378" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref659">Wright JT Jr., Williamson JD, Whelton PK,</a></text>
<text top="740" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref659">et al. A randomized trial of intensive versus standard</a></text>
<text top="754" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref659">blood-pressure control. SPRINT Research Group.</a></text>
<text top="767" left="346" width="118" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref659">N Engl J Med. 2015;373:2103</a></text>
<text top="766" left="464" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref659">–16</a></text>
<text top="767" left="477" width="3" height="9" font="4">.</text>
<text top="787" left="346" width="33" height="9" font="4">S9.2-10.</text>
<text top="787" left="382" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref660">Ettehad D, Emdin CA, Kiran A, et al. Blood</a></text>
<text top="800" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref660">pressure lowering for prevention of cardiovascular</a></text>
<text top="813" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref660">disease and death: a systematic review and meta-</a></text>
<text top="827" left="346" width="124" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref660">analysis. Lancet. 2016;387:957</a></text>
<text top="825" left="470" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref660">–67</a></text>
<text top="827" left="484" width="3" height="9" font="4">.</text>
<text top="849" left="346" width="217" height="9" font="4">9.2.1. Heart Failure With Reduced Ejection</text>
<text top="862" left="346" width="38" height="9" font="4">Fraction</text>
<text top="876" left="346" width="33" height="9" font="4">S9.2.1-1.</text>
<text top="876" left="382" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref661">Goldstein RE, Boccuzzi SJ, Cruess D, et al.</a></text>
<text top="890" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref661">Diltiazem increases late-onset congestive heart failure</a></text>
<text top="903" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref661">in postinfarction patients with early reduction in</a></text>
<text top="917" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref661">ejection fraction. The Adverse Experience Committee;</a></text>
<text top="930" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref661">and the Multicenter Diltiazem Postinfarction Research</a></text>
<text top="944" left="346" width="122" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref661">Group. Circulation. 1991;83:52</a></text>
<text top="942" left="468" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref661">–60</a></text>
<text top="944" left="483" width="3" height="9" font="4">.</text>
<text top="963" left="346" width="34" height="9" font="4">S9.2.1-2.</text>
<text top="963" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref662">Aronow WS, Ahn C, Kronzon I. Normal left</a></text>
<text top="976" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref662">ventricular ejection fraction in older persons with</a></text>
<text top="990" left="346" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref662">congestive heart failure. Chest. 1998;113:867</a></text>
<text top="988" left="528" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref662">–9</a></text>
<text top="990" left="538" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref662">.</a></text>
<text top="1009" left="346" width="34" height="9" font="4">S9.2.1-3.</text>
<text top="1009" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref663">Aronow WS, Ahn C, Kronzon I. Comparison of</a></text>
<text top="1022" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref663">incidences of congestive heart failure in older African-</a></text>
<text top="1036" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref663">Americans, Hispanics, and whites. Am J Cardiol. 1999;</a></text>
<text top="1049" left="346" width="27" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref663">84:611</a></text>
<text top="1048" left="373" width="26" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref663">–2. A9</a></text>
<text top="1049" left="398" width="3" height="9" font="4">.</text>
<text top="1068" left="346" width="35" height="9" font="4">S9.2.1-4.</text>
<text top="1068" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref664">Gottdiener JS, McClelland RL, Marshall R,</a></text>
<text top="1082" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref664">et al. Outcome of congestive heart failure in elderly</a></text>
<text top="1095" left="346" width="44" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref664">persons: in</a></text>
<text top="1094" left="389" width="174" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref664">ﬂuence of left ventricular systolic function.</a></text>
<text top="143" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref664">The Cardiovascular Health Study. Ann Intern Med.</a></text>
<text top="156" left="584" width="54" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref664">2002;137:631</a></text>
<text top="155" left="638" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref664">–9</a></text>
<text top="156" left="648" width="3" height="9" font="4">.</text>
<text top="177" left="584" width="34" height="9" font="4">S9.2.1-5.</text>
<text top="177" left="622" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref665">Owan TE, Hodge DO, Herges RM, et al.</a></text>
<text top="190" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref665">Trends in prevalence and outcome of heart failure with</a></text>
<text top="203" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref665">preserved ejection fraction. N Engl J Med. 2006;355:</a></text>
<text top="217" left="584" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref665">251</a></text>
<text top="215" left="598" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref665">–9</a></text>
<text top="217" left="607" width="3" height="9" font="4">.</text>
<text top="237" left="584" width="35" height="9" font="4">S9.2.1-6.</text>
<text top="237" left="622" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref666">Vasan RS, Larson MG, Benjamin EJ, et al.</a></text>
<text top="250" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref666">Congestive heart failure in subjects with normal versus</a></text>
<text top="264" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref666">reduced left ventricular ejection fraction: prevalence</a></text>
<text top="277" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref666">and mortality in a population-based cohort. J Am Coll</a></text>
<text top="291" left="584" width="89" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref666">Cardiol. 1999;33:1948</a></text>
<text top="289" left="673" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref666">–55</a></text>
<text top="291" left="687" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref666">.</a></text>
<text top="311" left="584" width="34" height="9" font="4">S9.2.1-7.</text>
<text top="311" left="622" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref667">Yancy CW, Jessup M, Bozkurt B, et al. 2016</a></text>
<text top="324" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref667">ACC/AHA/HFSA focused update on new pharmaco-</a></text>
<text top="338" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref667">logical therapy for heart failure: an update of the 2013</a></text>
<text top="351" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref667">ACCF/AHA guideline for the management of heart</a></text>
<text top="364" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref667">failure: a report of the American College of Cardiology/</a></text>
<text top="378" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref667">American Heart Association Task Force on Clinical</a></text>
<text top="391" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref667">Practice Guidelines and the Heart Failure Society of</a></text>
<text top="405" left="584" width="169" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref667">America. J Am Coll Cardiol. 2016;68:1476</a></text>
<text top="403" left="753" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref667">–88</a></text>
<text top="405" left="768" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref667">.</a></text>
<text top="425" left="584" width="35" height="9" font="4">S9.2.1-8.</text>
<text top="425" left="622" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref668">Amery A, Birkenhager W, Brixko P, et al.</a></text>
<text top="438" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref668">Mortality and morbidity results from the European</a></text>
<text top="452" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref668">Working Party on High Blood Pressure in the Elderly</a></text>
<text top="465" left="584" width="102" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref668">trial. Lancet. 1985;1:1349</a></text>
<text top="464" left="686" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref668">–54</a></text>
<text top="465" left="700" width="3" height="9" font="4">.</text>
<text top="485" left="584" width="35" height="9" font="4">S9.2.1-9.</text>
<text top="485" left="622" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref669">Kostis JB, Davis BR, Cutler J, et al.</a></text>
<text top="499" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref669">Prevention of heart failure by antihypertensive drug</a></text>
<text top="512" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref669">treatment in older persons with isolated systolic</a></text>
<text top="526" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref669">hypertension. SHEP Cooperative Research Group.</a></text>
<text top="539" left="584" width="82" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref669">JAMA. 1997;278:212</a></text>
<text top="537" left="666" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref669">–6</a></text>
<text top="539" left="675" width="3" height="9" font="4">.</text>
<text top="559" left="584" width="39" height="9" font="4">S9.2.1-10.</text>
<text top="559" left="627" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref670">Beckett NS, Peters R, Fletcher AE, et al.</a></text>
<text top="572" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref670">Treatment of hypertension in patients 80 years of age</a></text>
<text top="586" left="584" width="160" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref670">or older. N Engl J Med. 2008;358:1887</a></text>
<text top="584" left="744" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref670">–98</a></text>
<text top="586" left="759" width="3" height="9" font="4">.</text>
<text top="606" left="584" width="37" height="9" font="4">S9.2.1-11.</text>
<text top="606" left="625" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref671">Law MR, Morris JK, Wald NJ. Use of blood</a></text>
<text top="619" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref671">pressure lowering drugs in the prevention of cardio-</a></text>
<text top="633" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref671">vascular disease: meta-analysis of 147 randomised</a></text>
<text top="646" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref671">trials in the context of expectations from prospective</a></text>
<text top="660" left="584" width="190" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref671">epidemiological studies. BMJ. 2009;338:b1665</a></text>
<text top="660" left="774" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref671">.</a></text>
<text top="680" left="584" width="38" height="9" font="4">S9.2.1-12.</text>
<text top="680" left="625" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref672">Davis BR, Kostis JB, Simpson LM, et al. Heart</a></text>
<text top="693" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref672">failure with preserved and reduced left ventricular</a></text>
<text top="707" left="584" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref672">ejection</a></text>
<text top="707" left="626" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref672">fraction</a></text>
<text top="707" left="668" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref672">in</a></text>
<text top="707" left="686" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref672">the</a></text>
<text top="707" left="710" width="66" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref672">antihypertensive</a></text>
<text top="707" left="787" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref672">and</a></text>
<text top="720" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref672">lipid-lowering treatment to prevent heart attack trial.</a></text>
<text top="734" left="584" width="109" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref672">Circulation. 2008;118:2259</a></text>
<text top="732" left="693" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref672">–67</a></text>
<text top="734" left="707" width="3" height="9" font="4">.</text>
<text top="752" left="584" width="38" height="9" font="4">S9.2.1-13.</text>
<text top="752" left="625" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref673">Piller LB, Baraniuk S, Simpson LM, et al.</a></text>
<text top="766" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref673">Long-term follow-up of participants with heart failure</a></text>
<text top="779" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref673">in the Antihypertensive and Lipid-Lowering Treatment</a></text>
<text top="792" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref673">to Prevent Heart Attack Trial (ALLHAT). Circulation.</a></text>
<text top="806" left="584" width="54" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref673">2011;124:1811</a></text>
<text top="804" left="639" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref673">–8</a></text>
<text top="806" left="648" width="3" height="9" font="4">.</text>
<text top="824" left="584" width="39" height="9" font="4">S9.2.1-14.</text>
<text top="824" left="626" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref674">Yancy CW, Jessup M, Bozkurt B, et al. 2017</a></text>
<text top="838" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref674">ACC/AHA/HFSA focused update of the 2013 ACCF/AHA</a></text>
<text top="851" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref674">Guideline for the Management of Heart Failure: a</a></text>
<text top="865" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref674">report of the American College of Cardiology/Amer-</a></text>
<text top="878" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref674">ican Heart Association Task Force on Clinical Practice</a></text>
<text top="892" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref674">Guidelines and the Heart Failure Society of America.</a></text>
<text top="905" left="584" width="125" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref674">J Am Coll Cardiol. 2017;70:776</a></text>
<text top="904" left="709" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref674">–803</a></text>
<text top="905" left="730" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref674">.</a></text>
<text top="927" left="584" width="217" height="9" font="4">9.2.2. Heart Failure With Preserved Ejection</text>
<text top="940" left="584" width="38" height="9" font="4">Fraction</text>
<text top="954" left="584" width="34" height="9" font="4">S9.2.2-1.</text>
<text top="954" left="622" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref675">Pfeffer MA, Claggett B, Assmann SF, et al.</a></text>
<text top="967" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref675">Regional variation in patients and outcomes in the</a></text>
<text top="981" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref675">Treatment of Preserved Cardiac Function Heart Failure</a></text>
<text top="994" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref675">With an Aldosterone Antagonist (TOPCAT) trial.</a></text>
<text top="1008" left="584" width="95" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref675">Circulation. 2015;131:34</a></text>
<text top="1006" left="679" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref675">–42</a></text>
<text top="1008" left="694" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref675">.</a></text>
<text top="1026" left="584" width="35" height="9" font="4">S9.2.2-2.</text>
<text top="1026" left="622" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref676">Yancy CW, Jessup M, Bozkurt B, et al. 2013</a></text>
<text top="1040" left="584" width="42" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref676">ACCF/AHA</a></text>
<text top="1040" left="637" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref676">guideline</a></text>
<text top="1040" left="684" width="12" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref676">for</a></text>
<text top="1040" left="706" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref676">the</a></text>
<text top="1040" left="730" width="52" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref676">management</a></text>
<text top="1040" left="793" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref676">of</a></text>
<text top="1053" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref676">heart failure: a report of the American College</a></text>
<text top="1067" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref676">of Cardiology Foundation/American Heart Association</a></text>
<text top="1080" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref676">Task Force on Practice Guidelines. J Am Coll Cardiol.</a></text>
<text top="1094" left="584" width="53" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref676">2013;62:e147</a></text>
<text top="1092" left="638" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref676">–239</a></text>
<text top="1094" left="657" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref676">.</a></text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="20" height="9" font="4">e226</text>
</page>
<page number="101" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="35" height="9" font="4">S9.2.2-3.</text>
<text top="143" left="101" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref677">Aronow WS, Ahn C, Kronzon I. Effect of</a></text>
<text top="156" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref677">propranolol versus no propranolol on total mortality</a></text>
<text top="170" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref677">plus nonfatal myocardial infarction in older patients</a></text>
<text top="183" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref677">with prior myocardial infarction, congestive heart</a></text>
<text top="197" left="63" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref677">failure, and left ventricular ejection fraction</a></text>
<text top="195" left="249" width="30" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref677">&gt; or ¼</a></text>
<text top="210" left="63" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref677">40%</a></text>
<text top="210" left="93" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref677">treated</a></text>
<text top="210" left="132" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref677">with</a></text>
<text top="210" left="159" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref677">diuretics</a></text>
<text top="210" left="203" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref677">plus</a></text>
<text top="210" left="230" width="50" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref677">angiotensin-</a></text>
<text top="224" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref677">converting enzyme inhibitors. Am J Cardiol. 1997;80:</a></text>
<text top="237" left="63" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref677">207</a></text>
<text top="236" left="78" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref677">–9</a></text>
<text top="237" left="88" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref677">.</a></text>
<text top="257" left="63" width="36" height="9" font="4">S9.2.2-4.</text>
<text top="257" left="102" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref678">van Veldhuisen DJ, Cohen-Solal A, Bohm M,</a></text>
<text top="270" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref678">et al. Beta-blockade with nebivolol in elderly heart</a></text>
<text top="284" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref678">failure patients with impaired and preserved left</a></text>
<text top="297" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref678">ventricular ejection fraction: Data From SENIORS</a></text>
<text top="310" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref678">(Study of Effects of Nebivolol Intervention on</a></text>
<text top="324" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref678">Outcomes and Rehospitalization in Seniors With Heart</a></text>
<text top="337" left="63" width="168" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref678">Failure). J Am Coll Cardiol. 2009;53:2150</a></text>
<text top="336" left="230" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref678">–8</a></text>
<text top="337" left="240" width="3" height="9" font="4">.</text>
<text top="357" left="63" width="35" height="9" font="4">S9.2.2-5.</text>
<text top="357" left="101" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref679">Yusuf S, Pfeffer MA, Swedberg K, et al.</a></text>
<text top="370" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref679">Effects of candesartan in patients with chronic</a></text>
<text top="384" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref679">heart failure and preserved left-ventricular ejection</a></text>
<text top="397" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref679">fraction: the CHARM-Preserved Trial. Lancet. 2003;</a></text>
<text top="411" left="63" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref679">362:777</a></text>
<text top="409" left="94" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref679">–81</a></text>
<text top="411" left="108" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref679">.</a></text>
<text top="430" left="63" width="36" height="9" font="4">S9.2.2-6.</text>
<text top="430" left="102" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref680">Massie BM, Carson PE, McMurray JJ, et al.</a></text>
<text top="443" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref680">Irbesartan in patients with heart failure and preserved</a></text>
<text top="457" left="63" width="194" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref680">ejection fraction. N Engl J Med. 2008;359:2456</a></text>
<text top="455" left="257" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref680">–67</a></text>
<text top="457" left="271" width="3" height="9" font="4">.</text>
<text top="476" left="63" width="35" height="9" font="4">S9.2.2-7.</text>
<text top="476" left="101" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref681">Aronow WS, Ahn C, Kronzon I. Normal left</a></text>
<text top="490" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref681">ventricular ejection fraction in older persons with</a></text>
<text top="503" left="63" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref681">congestive heart failure. Chest. 1998;113:867</a></text>
<text top="502" left="245" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref681">–9</a></text>
<text top="503" left="254" width="3" height="9" font="4">.</text>
<text top="523" left="63" width="36" height="9" font="4">S9.2.2-8.</text>
<text top="523" left="102" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref682">Aronow WS, Ahn C, Kronzon I. Comparison of</a></text>
<text top="536" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref682">incidences of congestive heart failure in older African-</a></text>
<text top="550" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref682">Americans, Hispanics, and whites. Am J Cardiol. 1999;</a></text>
<text top="563" left="63" width="27" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref682">84:611</a></text>
<text top="562" left="89" width="26" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref682">–2. A9</a></text>
<text top="563" left="115" width="3" height="9" font="4">.</text>
<text top="583" left="63" width="36" height="9" font="4">S9.2.2-9.</text>
<text top="583" left="102" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref683">Vasan RS, Larson MG, Benjamin EJ, et al.</a></text>
<text top="596" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref683">Congestive heart failure in subjects with normal versus</a></text>
<text top="609" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref683">reduced left ventricular ejection fraction: prevalence</a></text>
<text top="623" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref683">and mortality in a population-based cohort. J Am Coll</a></text>
<text top="636" left="63" width="89" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref683">Cardiol. 1999;33:1948</a></text>
<text top="635" left="152" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref683">–55</a></text>
<text top="636" left="165" width="3" height="9" font="4">.</text>
<text top="656" left="63" width="40" height="9" font="4">S9.2.2-10.</text>
<text top="656" left="106" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref684">Gottdiener JS, McClelland RL, Marshall R,</a></text>
<text top="669" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref684">et al. Outcome of congestive heart failure in elderly</a></text>
<text top="683" left="63" width="43" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref684">persons: in</a></text>
<text top="681" left="106" width="173" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref684">ﬂuence of left ventricular systolic function.</a></text>
<text top="696" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref684">The Cardiovascular Health Study. Ann Intern Med.</a></text>
<text top="710" left="63" width="54" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref684">2002;137:631</a></text>
<text top="708" left="117" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref684">–9</a></text>
<text top="710" left="127" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref684">.</a></text>
<text top="729" left="63" width="38" height="9" font="4">S9.2.2-11.</text>
<text top="729" left="104" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref685">Owan TE, Hodge DO, Herges RM, et al.</a></text>
<text top="743" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref685">Trends in prevalence and outcome of heart failure with</a></text>
<text top="756" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref685">preserved ejection fraction. N Engl J Med. 2006;355:</a></text>
<text top="769" left="63" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref685">251</a></text>
<text top="768" left="76" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref685">–9</a></text>
<text top="769" left="86" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref685">.</a></text>
<text top="789" left="63" width="39" height="9" font="4">S9.2.2-12.</text>
<text top="789" left="105" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref686">Lee DS, Gona P, Vasan RS, et al. Relation of</a></text>
<text top="802" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref686">disease pathogenesis and risk factors to heart failure</a></text>
<text top="816" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref686">with preserved or reduced ejection fraction: insights</a></text>
<text top="829" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref686">from the Framingham Heart Study of the National</a></text>
<text top="843" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref686">Heart, Lung, and Blood Institute. Circulation. 2009;</a></text>
<text top="856" left="63" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref686">119:3070</a></text>
<text top="855" left="100" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref686">–7</a></text>
<text top="856" left="108" width="3" height="9" font="4">.</text>
<text top="876" left="63" width="39" height="9" font="4">S9.2.2-13.</text>
<text top="876" left="105" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref687">Bhuiyan T, Maurer MS. Heart failure with</a></text>
<text top="889" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref687">preserved ejection fraction: persistent diagnosis, thera-</a></text>
<text top="903" left="63" width="204" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref687">peutic enigma. Curr Cardiovasc Risk Rep. 2011;5:440</a></text>
<text top="901" left="267" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref687">–9</a></text>
<text top="903" left="276" width="3" height="9" font="4">.</text>
<text top="922" left="63" width="40" height="9" font="4">S9.2.2-14.</text>
<text top="922" left="106" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref688">Kato S, Onishi K, Yamanaka T, et al. Exag-</a></text>
<text top="935" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref688">gerated hypertensive response to exercise in patients</a></text>
<text top="949" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref688">with diastolic heart failure. Hypertens Res. 2008;31:</a></text>
<text top="962" left="63" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref688">679</a></text>
<text top="961" left="78" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref688">–84</a></text>
<text top="962" left="94" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref688">.</a></text>
<text top="982" left="63" width="39" height="9" font="4">S9.2.2-15.</text>
<text top="982" left="105" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref689">St</a></text>
<text top="982" left="128" width="56" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref689">Gyalai-Korpos</a></text>
<text top="982" left="199" width="5" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref689">I,</a></text>
<text top="982" left="219" width="35" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref689">Tomescu</a></text>
<text top="982" left="270" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref689">M,</a></text>
<text top="995" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref689">Pogorevici A. Hypertensive acute pulmonary oedema</a></text>
<text top="1009" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref689">as expression of diastolic heart failure. Rom J Intern</a></text>
<text top="1022" left="63" width="75" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref689">Med. 2008;46:153</a></text>
<text top="1020" left="138" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref689">–7</a></text>
<text top="1022" left="146" width="3" height="9" font="4">.</text>
<text top="1042" left="63" width="40" height="9" font="4">S9.2.2-16.</text>
<text top="1042" left="106" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref690">Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/</a></text>
<text top="1055" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref690">AHA 2011 expert consensus document on hypertension</a></text>
<text top="1069" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref690">in the elderly: a report of the American College of</a></text>
<text top="1082" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref690">Cardiology Foundation Task Force on Clinical Expert</a></text>
<text top="1095" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref690">Consensus Documents. Developed in collaboration</a></text>
<text top="143" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref690">with the American Academy of Neurology, American</a></text>
<text top="156" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref690">Geriatrics Society, American Society for Preventive</a></text>
<text top="170" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref690">Cardiology, American Society of Hypertension, Amer-</a></text>
<text top="183" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref690">ican Society of Nephrology, Association of Black Car-</a></text>
<text top="197" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref690">diologists, and European Society of Hypertension.</a></text>
<text top="210" left="301" width="129" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref690">J Am Coll Cardiol. 2011;57:2037</a></text>
<text top="209" left="430" width="17" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref690">–114</a></text>
<text top="210" left="446" width="3" height="9" font="4">.</text>
<text top="230" left="301" width="39" height="9" font="4">S9.2.2-17.</text>
<text top="230" left="343" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref691">Kostis JB, Davis BR, Cutler J, et al. Preven-</a></text>
<text top="243" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref691">tion of heart failure by antihypertensive drug treat-</a></text>
<text top="256" left="301" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref691">ment</a></text>
<text top="256" left="332" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref691">in</a></text>
<text top="256" left="348" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref691">older</a></text>
<text top="256" left="379" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref691">persons</a></text>
<text top="256" left="420" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref691">with</a></text>
<text top="256" left="447" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref691">isolated</a></text>
<text top="256" left="488" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref691">systolic</a></text>
<text top="270" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref691">hypertension. SHEP Cooperative Research Group.</a></text>
<text top="283" left="301" width="82" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref691">JAMA. 1997;278:212</a></text>
<text top="282" left="383" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref691">–6</a></text>
<text top="283" left="392" width="3" height="9" font="4">.</text>
<text top="303" left="301" width="40" height="9" font="4">S9.2.2-18.</text>
<text top="303" left="344" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref692">Beckett NS, Peters R, Fletcher AE, et al.</a></text>
<text top="316" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref692">Treatment of hypertension in patients 80 years of age</a></text>
<text top="330" left="301" width="160" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref692">or older. N Engl J Med. 2008;358:1887</a></text>
<text top="328" left="461" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref692">–98</a></text>
<text top="330" left="476" width="3" height="9" font="4">.</text>
<text top="349" left="301" width="40" height="9" font="4">S9.2.2-19.</text>
<text top="349" left="344" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref693">Piller LB, Baraniuk S, Simpson LM, et al.</a></text>
<text top="362" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref693">Long-term follow-up of participants with heart failure</a></text>
<text top="376" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref693">in the antihypertensive and lipid-lowering treatment</a></text>
<text top="389" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref693">to prevent heart attack trial (ALLHAT). Circulation.</a></text>
<text top="403" left="301" width="54" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref693">2011;124:1811</a></text>
<text top="401" left="355" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref693">–8</a></text>
<text top="403" left="365" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref693">.</a></text>
<text top="422" left="301" width="41" height="9" font="4">S9.2.2-20.</text>
<text top="422" left="345" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref694">Davis BR, Kostis JB, Simpson LM, et al.</a></text>
<text top="436" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref694">Heart failure with preserved and reduced left ventric-</a></text>
<text top="449" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref694">ular ejection fraction in the antihypertensive and lipid-</a></text>
<text top="463" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref694">lowering treatment to prevent heart attack trial. Cir-</a></text>
<text top="476" left="301" width="98" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref694">culation. 2008;118:2259</a></text>
<text top="474" left="399" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref694">–67</a></text>
<text top="476" left="414" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref694">.</a></text>
<text top="495" left="301" width="39" height="9" font="4">S9.2.2-21.</text>
<text top="495" left="343" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref695">Red</a></text>
<text top="494" left="359" width="160" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref695">ﬁeld MM, Chen HH, Borlaug BA, et al.</a></text>
<text top="509" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref695">Effect of phosphodiesterase-5 inhibition on exercise</a></text>
<text top="522" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref695">capacity and clinical status in heart failure with pre-</a></text>
<text top="536" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref695">served ejection fraction: a randomized clinical trial.</a></text>
<text top="549" left="301" width="89" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref695">JAMA. 2013;309:1268</a></text>
<text top="547" left="390" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref695">–77</a></text>
<text top="549" left="404" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref695">.</a></text>
<text top="571" left="301" width="127" height="9" font="23">9.3. Chronic Kidney Disease</text>
<text top="595" left="301" width="27" height="9" font="4">S9.3-1.</text>
<text top="595" left="331" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref696">Klahr S, Levey AS, Beck GJ, et al. The effects of</a></text>
<text top="609" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref696">dietary protein restriction and blood-pressure control</a></text>
<text top="622" left="301" width="199" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref696">on the progression of chronic renal disease. Modi</a></text>
<text top="621" left="500" width="18" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref696">ﬁca-</a></text>
<text top="636" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref696">tion of Diet in Renal Disease Study Group. N Engl J</a></text>
<text top="649" left="301" width="79" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref696">Med. 1994;330:877</a></text>
<text top="647" left="380" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref696">–84</a></text>
<text top="649" left="395" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref696">.</a></text>
<text top="668" left="301" width="28" height="9" font="4">S9.3-2.</text>
<text top="668" left="332" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref697">Ruggenenti P, Perna A, Loriga G, et al. Blood-</a></text>
<text top="682" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref697">pressure control for renoprotection in patients with</a></text>
<text top="695" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref697">non-diabetic chronic renal disease (REIN-2): multi-</a></text>
<text top="709" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref697">centre, randomised controlled trial. Lancet. 2005;365:</a></text>
<text top="722" left="301" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref697">939</a></text>
<text top="721" left="317" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref697">–46</a></text>
<text top="722" left="332" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref697">.</a></text>
<text top="742" left="301" width="28" height="9" font="4">S9.3-3.</text>
<text top="742" left="332" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref698">Wright JT Jr., Bakris G, Greene T, et al. Effect</a></text>
<text top="755" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref698">of blood pressure lowering and antihypertensive drug</a></text>
<text top="769" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref698">class on progression of hypertensive kidney disease:</a></text>
<text top="782" left="301" width="202" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref698">results from the AASK trial. JAMA. 2002;288:2421</a></text>
<text top="780" left="503" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref698">–31</a></text>
<text top="782" left="516" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref698">.</a></text>
<text top="801" left="301" width="29" height="9" font="4">S9.3-4.</text>
<text top="801" left="333" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref699">Upadhyay A, Earley A, Haynes SM, et al. Sys-</a></text>
<text top="815" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref699">tematic review: blood pressure target in chronic kidney</a></text>
<text top="828" left="301" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref699">disease and proteinuria as an effect modi</a></text>
<text top="827" left="481" width="37" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref699">ﬁer. Ann</a></text>
<text top="842" left="301" width="101" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref699">Intern Med. 2011;154:541</a></text>
<text top="840" left="402" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref699">–8</a></text>
<text top="842" left="412" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref699">.</a></text>
<text top="861" left="301" width="28" height="9" font="4">S9.3-5.</text>
<text top="861" left="332" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref700">Lv J, Ehteshami P, Sarnak MJ, et al. Effects of</a></text>
<text top="874" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref700">intensive blood pressure lowering on the progression</a></text>
<text top="888" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref700">of chronic kidney disease: a systematic review and</a></text>
<text top="901" left="301" width="144" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref700">meta-analysis. CMAJ. 2013;185:949</a></text>
<text top="900" left="445" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref700">–57</a></text>
<text top="901" left="459" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref700">.</a></text>
<text top="921" left="301" width="29" height="9" font="4">S9.3-6.</text>
<text top="921" left="333" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref701">Jafar TH, Stark PC, Schmid CH, et al. Pro-</a></text>
<text top="934" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref701">gression of chronic kidney disease: the role of blood</a></text>
<text top="948" left="301" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref701">pressure</a></text>
<text top="948" left="345" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref701">control,</a></text>
<text top="948" left="387" width="46" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref701">proteinuria,</a></text>
<text top="948" left="443" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref701">and</a></text>
<text top="948" left="468" width="50" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref701">angiotensin-</a></text>
<text top="961" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref701">converting enzyme inhibition: a patient-level meta-</a></text>
<text top="974" left="301" width="162" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref701">analysis. Ann Intern Med. 2003;139:244</a></text>
<text top="973" left="463" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref701">–52</a></text>
<text top="974" left="477" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref701">.</a></text>
<text top="995" left="301" width="28" height="9" font="4">S9.3-7.</text>
<text top="995" left="332" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref702">Lambers Heerspink HJ, Brantsma AH, de</a></text>
<text top="1009" left="301" width="191" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref702">Zeeuw D, et al. Albuminuria assessed from</a></text>
<text top="1007" left="497" width="21" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref702">ﬁrst-</a></text>
<text top="1022" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref702">morning-void urine samples versus 24-hour urine</a></text>
<text top="1036" left="301" width="46" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref702">collections</a></text>
<text top="1036" left="357" width="9" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref702">as</a></text>
<text top="1036" left="376" width="4" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref702">a</a></text>
<text top="1036" left="390" width="38" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref702">predictor</a></text>
<text top="1036" left="439" width="9" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref702">of</a></text>
<text top="1036" left="458" width="60" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref702">cardiovascular</a></text>
<text top="1049" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref702">morbidity and mortality. Am J Epidemiol. 2008;</a></text>
<text top="1063" left="301" width="35" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref702">168:897</a></text>
<text top="1061" left="336" width="21" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref702">–905</a></text>
<text top="1063" left="358" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref702">.</a></text>
<text top="1082" left="301" width="29" height="9" font="4">S9.3-8.</text>
<text top="1082" left="333" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref703">Lambers</a></text>
<text top="1082" left="377" width="40" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref703">Heerspink</a></text>
<text top="1082" left="426" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref703">HJ,</a></text>
<text top="1082" left="449" width="46" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref703">Gansevoort</a></text>
<text top="1082" left="505" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref703">RT,</a></text>
<text top="1095" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref703">Brenner BM, et al. Comparison of different measures of</a></text>
<text top="143" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref703">urinary protein excretion for prediction of renal events.</a></text>
<text top="156" left="539" width="130" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref703">J Am Soc Nephrol. 2010;21:1355</a></text>
<text top="155" left="670" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref703">–60</a></text>
<text top="156" left="685" width="3" height="9" font="4">.</text>
<text top="176" left="539" width="29" height="9" font="4">S9.3-9.</text>
<text top="176" left="571" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref704">Contreras G, Greene T, Agodoa LY, et al. Blood</a></text>
<text top="189" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref704">pressure control, drug therapy, and kidney disease.</a></text>
<text top="203" left="539" width="108" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref704">Hypertension. 2005;46:44</a></text>
<text top="201" left="647" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref704">–50</a></text>
<text top="203" left="662" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref704">.</a></text>
<text top="222" left="539" width="33" height="9" font="4">S9.3-10.</text>
<text top="222" left="576" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref705">Esnault VLM, Brown EA, Apetrei E, et al. The</a></text>
<text top="236" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref705">effects of amlodipine and enalapril on renal function in</a></text>
<text top="249" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref705">adults with hypertension and nondiabetic nephropa-</a></text>
<text top="263" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref705">thies: a 3-year, randomized, multicenter, double-blind,</a></text>
<text top="276" left="539" width="199" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref705">placebo-controlled study. Clin Ther. 2008;30:482</a></text>
<text top="274" left="739" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref705">–98</a></text>
<text top="276" left="754" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref705">.</a></text>
<text top="296" left="539" width="31" height="9" font="4">S9.3-11.</text>
<text top="296" left="574" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref706">Marin R, Ruilope LM, Aljama P, et al. A random</a></text>
<text top="309" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref706">comparison of fosinopril and nifedipine GITS in</a></text>
<text top="322" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref706">patients with primary renal disease. J Hypertens. 2001;</a></text>
<text top="336" left="539" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref706">19:1871</a></text>
<text top="334" left="569" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref706">–6</a></text>
<text top="336" left="579" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref706">.</a></text>
<text top="355" left="539" width="32" height="9" font="4">S9.3-12.</text>
<text top="355" left="574" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref707">Giatras I, Lau J, Levey AS. Effect of</a></text>
<text top="369" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref707">angiotensin-converting enzyme inhibitors on the pro-</a></text>
<text top="382" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref707">gression of nondiabetic renal disease: a meta-analysis</a></text>
<text top="396" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref707">of randomized trials. Angiotensin-Converting-Enzyme</a></text>
<text top="409" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref707">Inhibition and Progressive Renal Disease Study</a></text>
<text top="423" left="539" width="150" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref707">Group. Ann Intern Med. 1997;127:337</a></text>
<text top="421" left="690" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref707">–45</a></text>
<text top="423" left="704" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref707">.</a></text>
<text top="442" left="539" width="32" height="9" font="4">S9.3-13.</text>
<text top="442" left="574" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref708">Reboussin DM, Allen NB, Griswold ME, et al.</a></text>
<text top="456" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref708">Systematic review for the 2017 ACC/AHA/AAPA/</a></text>
<text top="469" left="539" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref708">ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA</a></text>
<text top="469" left="731" width="26" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref708">guide-</a></text>
<text top="482" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref708">line for the prevention, detection, evaluation, and</a></text>
<text top="496" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref708">management of high blood pressure in adults. J Am</a></text>
<text top="509" left="539" width="104" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref708">Coll Cardiol. 2018;71:2176</a></text>
<text top="508" left="644" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref708">–98</a></text>
<text top="509" left="659" width="3" height="9" font="4">.</text>
<text top="529" left="539" width="33" height="9" font="4">S9.3-14.</text>
<text top="529" left="575" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref709">Muntner P, Anderson A, Charleston J, et al.</a></text>
<text top="542" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref709">Hypertension awareness, treatment, and control in</a></text>
<text top="556" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref709">adults with CKD: results from the Chronic Renal</a></text>
<text top="569" left="539" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref709">Insuf</a></text>
<text top="567" left="559" width="197" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref709">ﬁciency Cohort (CRIC) Study. Am J Kidney Dis.</a></text>
<text top="583" left="539" width="50" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref709">2010;55:441</a></text>
<text top="581" left="589" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref709">–51</a></text>
<text top="583" left="602" width="3" height="9" font="4">.</text>
<text top="602" left="539" width="32" height="9" font="4">S9.3-15.</text>
<text top="602" left="574" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref710">James PA, Oparil S, Carter BL, et al. 2014</a></text>
<text top="616" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref710">evidence-based guideline for the management of high</a></text>
<text top="629" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref710">blood pressure in adults: report from the panel</a></text>
<text top="642" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref710">members appointed to the Eighth Joint National</a></text>
<text top="656" left="539" width="164" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref710">Committee (JNC 8). JAMA. 2014;311:507</a></text>
<text top="654" left="704" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref710">–20</a></text>
<text top="656" left="719" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref710">.</a></text>
<text top="675" left="539" width="33" height="9" font="4">S9.3-16.</text>
<text top="675" left="575" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref711">National Clinical Guideline Centre (UK).</a></text>
<text top="689" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref711">Chronic Kidney Disease (Partial Update): Early Identi-</a></text>
<text top="701" left="539" width="217" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref711">ﬁcation and Management of Chronic Kidney Disease in</a></text>
<text top="716" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref711">Adults in Primary and Secondary Care. London, UK:</a></text>
<text top="729" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref711">National Institute for Health and Care Excellence (UK);</a></text>
<text top="743" left="539" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref711">2014</a></text>
<text top="743" left="559" width="3" height="9" font="4">.</text>
<text top="762" left="539" width="32" height="9" font="4">S9.3-17.</text>
<text top="762" left="574" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref712">Mancia G, Fagard R, Narkiewicz K, et al. 2013</a></text>
<text top="775" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref712">ESH/ESC guidelines for the management of arterial</a></text>
<text top="789" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref712">hypertension: the Task Force for the Management of</a></text>
<text top="802" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref712">Arterial Hypertension of the European Society of</a></text>
<text top="816" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref712">Hypertension (ESH) and of the European Society</a></text>
<text top="829" left="539" width="189" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref712">of Cardiology (ESC). Eur Heart J. 2013;34:2159</a></text>
<text top="828" left="728" width="18" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref712">–219</a></text>
<text top="829" left="746" width="3" height="9" font="4">.</text>
<text top="849" left="539" width="33" height="9" font="4">S9.3-18.</text>
<text top="849" left="575" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref713">KDIGO clinical practice guideline for the</a></text>
<text top="862" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref713">management of blood pressure in chronic kidney</a></text>
<text top="876" left="539" width="189" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref713">disease. Kidney Int Suppl (2011). 2012;2(5):337</a></text>
<text top="874" left="728" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref713">–414</a></text>
<text top="876" left="747" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref713">.</a></text>
<text top="895" left="539" width="33" height="9" font="4">S9.3-19.</text>
<text top="895" left="575" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref714">Kanno A, Metoki H, Kikuya M, et al.</a></text>
<text top="908" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref714">Usefulness of assessing masked and white-coat</a></text>
<text top="922" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref714">hypertension by ambulatory blood pressure moni-</a></text>
<text top="935" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref714">toring for determining prevalent risk of chronic kidney</a></text>
<text top="949" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref714">disease: the Ohasama study. Hypertens Res. 2010;33:</a></text>
<text top="962" left="539" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref714">1192</a></text>
<text top="961" left="557" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref714">–8</a></text>
<text top="962" left="567" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref714">.</a></text>
<text top="982" left="539" width="34" height="9" font="4">S9.3-20.</text>
<text top="982" left="576" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref715">Terawaki H, Metoki H, Nakayama M, et al.</a></text>
<text top="995" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref715">Masked hypertension determined by self-measured</a></text>
<text top="1009" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref715">blood pressure at home and chronic kidney disease</a></text>
<text top="1022" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref715">in the Japanese general population: the Ohasama</a></text>
<text top="1036" left="539" width="146" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref715">study. Hypertens Res. 2008;31:2129</a></text>
<text top="1034" left="686" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref715">–35</a></text>
<text top="1036" left="699" width="3" height="9" font="4">.</text>
<text top="1055" left="539" width="32" height="9" font="4">S9.3-21.</text>
<text top="1055" left="574" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref716">Minutolo R, Gabbai FB, Agarwal R, et al.</a></text>
<text top="1069" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref716">Assessment of achieved clinic and ambulatory blood</a></text>
<text top="1082" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref716">pressure recordings and outcomes during treatment</a></text>
<text top="1095" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref716">in hypertensive patients with CKD: a multicenter</a></text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="19" height="9" font="4">e227</text>
</page>
<page number="102" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref716">prospective cohort study. Am J Kidney Dis. 2014;64:</a></text>
<text top="156" left="108" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref716">744</a></text>
<text top="155" left="123" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref716">–52</a></text>
<text top="156" left="137" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref716">.</a></text>
<text top="175" left="108" width="33" height="9" font="4">S9.3-22.</text>
<text top="175" left="144" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref717">Drawz PE, Alper AB, Anderson AH, et al.</a></text>
<text top="189" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref717">Masked hypertension and elevated nighttime blood</a></text>
<text top="202" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref717">pressure in CKD: prevalence and association with</a></text>
<text top="215" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref717">target organ damage. Clin J Am Soc Nephrol. 2016;11:</a></text>
<text top="229" left="108" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref717">642</a></text>
<text top="227" left="123" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref717">–52</a></text>
<text top="229" left="137" width="3" height="9" font="4">.</text>
<text top="248" left="108" width="33" height="9" font="4">S9.3-23.</text>
<text top="248" left="144" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref718">Agarwal R, Andersen MJ. Prognostic impor-</a></text>
<text top="261" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref718">tance of ambulatory blood pressure recordings in</a></text>
<text top="275" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref718">patients with chronic kidney disease. Kidney Int. 2006;</a></text>
<text top="288" left="108" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref718">69:1175</a></text>
<text top="286" left="138" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref718">–80</a></text>
<text top="288" left="154" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref718">.</a></text>
<text top="307" left="108" width="34" height="9" font="4">S9.3-24.</text>
<text top="307" left="144" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref719">Navaneethan SD, Schold JD, Arrigain S, et al.</a></text>
<text top="320" left="108" width="47" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref719">Cause-speci</a></text>
<text top="318" left="155" width="170" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref719">ﬁc deaths in non-dialysis-dependent CKD.</a></text>
<text top="334" left="108" width="131" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref719">J Am Soc Nephrol. 2015;26:2512</a></text>
<text top="332" left="239" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref719">–20</a></text>
<text top="334" left="254" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref719">.</a></text>
<text top="352" left="108" width="33" height="9" font="4">S9.3-25.</text>
<text top="352" left="144" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref720">Matsushita K, van der Velde M, Astor BC,</a></text>
<text top="366" left="108" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref720">et al. Association of estimated glomerular</a></text>
<text top="364" left="290" width="35" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref720">ﬁltration</a></text>
<text top="379" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref720">rate and albuminuria with all-cause and cardiovascular</a></text>
<text top="393" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref720">mortality in general population cohorts: a collabora-</a></text>
<text top="406" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref720">tive meta-analysis. Chronic Kidney Disease Prognosis</a></text>
<text top="419" left="108" width="144" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref720">Consortium. Lancet. 2010;375:2073</a></text>
<text top="418" left="251" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref720">–81</a></text>
<text top="419" left="264" width="3" height="9" font="4">.</text>
<text top="438" left="108" width="34" height="9" font="4">S9.3-26.</text>
<text top="438" left="144" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref721">Wright JT Jr., Williamson JD, Whelton PK,</a></text>
<text top="451" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref721">et al. A randomized trial of intensive versus standard</a></text>
<text top="465" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref721">blood-pressure control. SPRINT Research Group.</a></text>
<text top="478" left="108" width="118" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref721">N Engl J Med. 2015;373:2103</a></text>
<text top="477" left="226" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref721">–16</a></text>
<text top="478" left="239" width="3" height="9" font="4">.</text>
<text top="497" left="108" width="33" height="9" font="4">S9.3-27.</text>
<text top="497" left="144" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref722">Cushman WC, Evans GW, Byington RP, et al.</a></text>
<text top="510" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref722">Effects of intensive blood-pressure control in type 2</a></text>
<text top="524" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref722">diabetes mellitus. ACCORD Study Group. N Engl J Med.</a></text>
<text top="537" left="108" width="59" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref722">2010;362:1575</a></text>
<text top="536" left="167" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref722">–85</a></text>
<text top="537" left="181" width="3" height="9" font="4">.</text>
<text top="556" left="108" width="34" height="9" font="4">S9.3-28.</text>
<text top="556" left="144" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref723">Goff DC Jr., Lloyd-Jones DM, Bennett G,</a></text>
<text top="570" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref723">et al. 2013 ACC/AHA guideline on the assessment of</a></text>
<text top="583" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref723">cardiovascular risk: a report of the American College of</a></text>
<text top="596" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref723">Cardiology/American Heart Association Task Force on</a></text>
<text top="610" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref723">Practice Guidelines. J Am Coll Cardiol. 2014;63 25 Pt B:</a></text>
<text top="623" left="108" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref723">2935</a></text>
<text top="622" left="128" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref723">–59</a></text>
<text top="623" left="142" width="3" height="9" font="4">.</text>
<text top="642" left="108" width="34" height="9" font="4">S9.3-29.</text>
<text top="642" left="144" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref724">Kovesdy CP, Alrifai A, Gosmanova EO, et al.</a></text>
<text top="655" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref724">Age and outcomes associated with BP in patients with</a></text>
<text top="669" left="108" width="200" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref724">incident CKD. Clin J Am Soc Nephrol. 2016;11:821</a></text>
<text top="667" left="308" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref724">–31</a></text>
<text top="669" left="320" width="3" height="9" font="4">.</text>
<text top="688" left="108" width="34" height="9" font="4">S9.3-30.</text>
<text top="688" left="145" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref725">Weiss JW, Peters D, Yang X, et al. Systolic BP</a></text>
<text top="701" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref725">and mortality in older adults with CKD. Clin J Am Soc</a></text>
<text top="714" left="108" width="90" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref725">Nephrol. 2015;10:1553</a></text>
<text top="713" left="198" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref725">–9</a></text>
<text top="714" left="207" width="3" height="9" font="4">.</text>
<text top="733" left="108" width="32" height="9" font="4">S9.3-31.</text>
<text top="733" left="143" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref726">Williamson JD, Supiano MA, Applegate WB,</a></text>
<text top="747" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref726">et al. Intensive vs standard blood pressure control and</a></text>
<text top="760" left="108" width="196" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref726">cardiovascular disease outcomes in adults aged</a></text>
<text top="758" left="308" width="17" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref726">$75</a></text>
<text top="773" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref726">years: a randomized clinical trial. JAMA. 2016;315:</a></text>
<text top="787" left="108" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref726">2673</a></text>
<text top="785" left="127" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref726">–82</a></text>
<text top="787" left="142" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref726">.</a></text>
<text top="806" left="108" width="33" height="9" font="4">S9.3-32.</text>
<text top="806" left="144" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref727">Holtkamp FA, de Zeeuw D, Thomas MC, et al.</a></text>
<text top="819" left="108" width="158" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref727">An acute fall in estimated glomerular</a></text>
<text top="817" left="270" width="55" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref727">ﬁltration rate</a></text>
<text top="832" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref727">during treatment with losartan predicts a slower</a></text>
<text top="846" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref727">decrease in long-term renal function. Kidney Int. 2011;</a></text>
<text top="859" left="108" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref727">80:282</a></text>
<text top="858" left="137" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref727">–7</a></text>
<text top="859" left="146" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref727">.</a></text>
<text top="878" left="108" width="33" height="9" font="4">S9.3-33.</text>
<text top="878" left="144" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref728">Hricik DE, Browning PJ, Kopelman R, et al.</a></text>
<text top="891" left="108" width="160" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref728">Captopril-induced functional renal insuf</a></text>
<text top="890" left="268" width="57" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref728">ﬁciency in pa-</a></text>
<text top="905" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref728">tients with bilateral renal-artery stenoses or renal-</a></text>
<text top="918" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref728">artery stenosis in a solitary kidney. N Engl J Med.</a></text>
<text top="932" left="108" width="55" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref728">1983;308:373</a></text>
<text top="930" left="163" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref728">–6</a></text>
<text top="932" left="173" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref728">.</a></text>
<text top="950" left="108" width="34" height="9" font="4">S9.3-34.</text>
<text top="950" left="144" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref729">Pfeffer MA, McMurray JJV, Velazquez EJ,</a></text>
<text top="964" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref729">et al. Valsartan, captopril, or both in myocardial</a></text>
<text top="977" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref729">infarction complicated by heart failure, left ventricular</a></text>
<text top="991" left="108" width="213" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref729">dysfunction, or both. N Engl J Med. 2003;349:1893</a></text>
<text top="989" left="321" width="4" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref729">–</a></text>
<text top="1004" left="108" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref729">906</a></text>
<text top="1004" left="125" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref729">.</a></text>
<text top="1023" left="108" width="33" height="9" font="4">S9.3-35.</text>
<text top="1023" left="144" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref730">Yusuf S, Teo KK, Pogue J, et al. Telmisartan,</a></text>
<text top="1036" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref730">ramipril, or both in patients at high risk for vascular</a></text>
<text top="1050" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref730">events. ONTARGET Investigators. N Engl J Med. 2008;</a></text>
<text top="1063" left="108" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref730">358:1547</a></text>
<text top="1062" left="144" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref730">–59</a></text>
<text top="1063" left="158" width="3" height="9" font="4">.</text>
<text top="1082" left="108" width="34" height="9" font="4">S9.3-36.</text>
<text top="1082" left="144" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref731">Fried LF, Emanuele N, Zhang JH, et al.</a></text>
<text top="1095" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref731">Combined angiotensin inhibition for the treatment of</a></text>
<text top="143" left="346" width="213" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref731">diabetic nephropathy. N Engl J Med. 2013;369:1892</a></text>
<text top="141" left="559" width="4" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref731">–</a></text>
<text top="156" left="346" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref731">903</a></text>
<text top="156" left="362" width="3" height="9" font="4">.</text>
<text top="175" left="346" width="33" height="9" font="4">S9.3-37.</text>
<text top="175" left="382" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref732">Parving H-H, Brenner BM, McMurray JJV,</a></text>
<text top="189" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref732">et al. Cardiorenal end points in a trial of aliskiren for</a></text>
<text top="202" left="346" width="188" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref732">type 2 diabetes. N Engl J Med. 2012;367:2204</a></text>
<text top="201" left="534" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref732">–13</a></text>
<text top="202" left="547" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref732">.</a></text>
<text top="221" left="346" width="34" height="9" font="4">S9.3-38.</text>
<text top="221" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref733">Peterson JC, Adler S, Burkart JM, et al. Blood</a></text>
<text top="235" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref733">pressure control, proteinuria, and the progression of</a></text>
<text top="248" left="346" width="93" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref733">renal disease. The Modi</a></text>
<text top="246" left="439" width="124" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref733">ﬁcation of Diet in Renal Disease</a></text>
<text top="261" left="346" width="150" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref733">Study. Ann Intern Med. 1995;123:754</a></text>
<text top="260" left="496" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref733">–62</a></text>
<text top="261" left="510" width="3" height="9" font="4">.</text>
<text top="280" left="346" width="34" height="9" font="4">S9.3-39.</text>
<text top="280" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref734">Appel LJ, Wright JT Jr., Greene T, et al.</a></text>
<text top="294" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref734">Intensive blood-pressure control in hypertensive</a></text>
<text top="307" left="346" width="213" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref734">chronic kidney disease. N Engl J Med. 2010;363:918</a></text>
<text top="306" left="559" width="4" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref734">–</a></text>
<text top="321" left="346" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref734">29</a></text>
<text top="321" left="356" width="3" height="9" font="4">.</text>
<text top="340" left="346" width="35" height="9" font="4">S9.3-40.</text>
<text top="340" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref735">Ettehad D, Emdin CA, Kiran A, et al. Blood</a></text>
<text top="353" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref735">pressure lowering for prevention of cardiovascular</a></text>
<text top="367" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref735">disease and death: a systematic review and meta-</a></text>
<text top="380" left="346" width="124" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref735">analysis. Lancet. 2016;387:957</a></text>
<text top="378" left="470" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref735">–67</a></text>
<text top="380" left="484" width="3" height="9" font="4">.</text>
<text top="399" left="346" width="33" height="9" font="4">S9.3-41.</text>
<text top="399" left="382" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref736">Thomopoulos C, Parati G, Zanchetti A. Ef-</a></text>
<text top="412" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref736">fects of blood pressure lowering on outcome inci-</a></text>
<text top="426" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref736">dence in hypertension: 7. Effects of more vs. less</a></text>
<text top="439" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref736">intensive blood pressure lowering and different ach-</a></text>
<text top="453" left="346" width="118" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref736">ieved blood pressure levels</a></text>
<text top="451" left="464" width="99" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref736">–updated overview and</a></text>
<text top="466" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref736">meta-analyses of randomized trials. J Hypertens.</a></text>
<text top="480" left="346" width="50" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref736">2016;34:613</a></text>
<text top="478" left="396" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref736">–22</a></text>
<text top="480" left="409" width="3" height="9" font="4">.</text>
<text top="498" left="346" width="34" height="9" font="4">S9.3-42.</text>
<text top="498" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref737">Xie X, Atkins E, Lv J, et al. Effects of intensive</a></text>
<text top="512" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref737">blood pressure lowering on cardiovascular and renal</a></text>
<text top="525" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref737">outcomes: updated systematic review and meta-anal-</a></text>
<text top="539" left="346" width="108" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref737">ysis. Lancet. 2016;387:435</a></text>
<text top="537" left="453" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref737">–43</a></text>
<text top="539" left="468" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref737">.</a></text>
<text top="558" left="346" width="34" height="9" font="4">S9.3-43.</text>
<text top="558" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref738">Ninomiya T, Perkovic V, Turnbull F, et al.</a></text>
<text top="571" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref738">Blood pressure lowering and major cardiovascular</a></text>
<text top="585" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref738">events in people with and without chronic kidney</a></text>
<text top="598" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref738">disease: meta-analysis of randomised controlled trials.</a></text>
<text top="612" left="346" width="87" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref738">BMJ. 2013;347:f5680</a></text>
<text top="612" left="433" width="3" height="9" font="4">.</text>
<text top="633" left="346" width="217" height="9" font="4">9.3.1. Hypertension After Renal Transplantation</text>
<text top="648" left="346" width="33" height="9" font="4">S9.3.1-1.</text>
<text top="648" left="382" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref739">Wright JT Jr., Williamson JD, Whelton PK,</a></text>
<text top="662" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref739">et al. A randomized trial of intensive versus standard</a></text>
<text top="675" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref739">blood-pressure control. SPRINT Research Group.</a></text>
<text top="689" left="346" width="118" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref739">N Engl J Med. 2015;373:2103</a></text>
<text top="687" left="464" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref739">–16</a></text>
<text top="689" left="477" width="3" height="9" font="4">.</text>
<text top="708" left="346" width="34" height="9" font="4">S9.3.1-2.</text>
<text top="708" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref740">Cross NB, Webster AC, Masson P, et al.</a></text>
<text top="721" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref740">Antihypertensive treatment for kidney transplant re-</a></text>
<text top="734" left="346" width="33" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref740">cipients.</a></text>
<text top="734" left="397" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref740">Cochrane</a></text>
<text top="734" left="453" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref740">Database</a></text>
<text top="734" left="508" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref740">Syst</a></text>
<text top="734" left="543" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref740">Rev..</a></text>
<text top="748" left="346" width="67" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref740">2009CD003598</a></text>
<text top="748" left="413" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref740">.</a></text>
<text top="767" left="346" width="34" height="9" font="4">S9.3.1-3.</text>
<text top="767" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref741">Cosio FG, Pelletier RP, Pesavento TE, et al.</a></text>
<text top="780" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref741">Elevated blood pressure predicts the risk of acute</a></text>
<text top="794" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref741">rejection in renal allograft recipients. Kidney Int. 2001;</a></text>
<text top="807" left="346" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref741">59:1158</a></text>
<text top="806" left="377" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref741">–64</a></text>
<text top="807" left="392" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref741">.</a></text>
<text top="826" left="346" width="35" height="9" font="4">S9.3.1-4.</text>
<text top="826" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref742">Peschke B, Scheuermann EH, Geiger H, et al.</a></text>
<text top="840" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref742">Hypertension is associated with hyperlipidemia, coro-</a></text>
<text top="853" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref742">nary heart disease and chronic graft failure in kidney</a></text>
<text top="866" left="346" width="194" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref742">transplant recipients. Clin Nephrol. 1999;51:290</a></text>
<text top="865" left="540" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref742">–5</a></text>
<text top="866" left="549" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref742">.</a></text>
<text top="885" left="346" width="34" height="9" font="4">S9.3.1-5.</text>
<text top="885" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref743">Mange KC, Cizman B, Joffe M, et al. Arterial</a></text>
<text top="899" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref743">hypertension and renal allograft survival. JAMA.</a></text>
<text top="912" left="346" width="59" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref743">2000;283:633</a></text>
<text top="911" left="404" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref743">–8</a></text>
<text top="912" left="414" width="3" height="9" font="4">.</text>
<text top="931" left="346" width="35" height="9" font="4">S9.3.1-6.</text>
<text top="931" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref744">Mange KC, Feldman HI, Joffe MM, et al. Blood</a></text>
<text top="945" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref744">pressure and the survival of renal allografts from living</a></text>
<text top="958" left="346" width="157" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref744">donors. J Am Soc Nephrol. 2004;15:187</a></text>
<text top="956" left="503" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref744">–93</a></text>
<text top="958" left="517" width="3" height="9" font="4">.</text>
<text top="977" left="346" width="34" height="9" font="4">S9.3.1-7.</text>
<text top="977" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref745">Taler SJ, Textor SC, Canzanello VJ, et al.</a></text>
<text top="990" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref745">Cyclosporin-induced hypertension: incidence, patho-</a></text>
<text top="1004" left="346" width="199" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref745">genesis and management. Drug Saf. 1999;20:437</a></text>
<text top="1002" left="545" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref745">–49</a></text>
<text top="1004" left="560" width="3" height="9" font="4">.</text>
<text top="1023" left="346" width="35" height="9" font="4">S9.3.1-8.</text>
<text top="1023" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref746">Taler SJ, Textor SC, Canzanello VJ, et al. Role</a></text>
<text top="1036" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref746">of steroid dose in hypertension early after liver</a></text>
<text top="1050" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref746">transplantation with tacrolimus (FK506) and cyclo-</a></text>
<text top="1063" left="346" width="159" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref746">sporine. Transplantation. 1996;62:1588</a></text>
<text top="1061" left="505" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref746">–92</a></text>
<text top="1063" left="519" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref746">.</a></text>
<text top="1082" left="346" width="35" height="9" font="4">S9.3.1-9.</text>
<text top="1082" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref747">Woodle ES, First MR, Pirsch J, et al.</a></text>
<text top="1095" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref747">A prospective, randomized, double-blind, placebo-</a></text>
<text top="143" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref747">controlled multicenter trial comparing early (7 day)</a></text>
<text top="156" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref747">corticosteroid cessation versus long-term, low-dose</a></text>
<text top="170" left="584" width="196" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref747">corticosteroid therapy. Ann Surg. 2008;248:564</a></text>
<text top="168" left="780" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref747">–77</a></text>
<text top="170" left="793" width="3" height="9" font="4">.</text>
<text top="188" left="584" width="39" height="9" font="4">S9.3.1-10.</text>
<text top="188" left="627" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref748">Vincenti F, Schena FP, Paraskevas S, et al.</a></text>
<text top="202" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref748">A randomized, multicenter study of steroid avoidance,</a></text>
<text top="215" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref748">early steroid withdrawal or standard steroid therapy in</a></text>
<text top="229" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref748">kidney transplant recipients. Am J Transplant. 2008;8:</a></text>
<text top="242" left="584" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref748">307</a></text>
<text top="241" left="600" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref748">–16</a></text>
<text top="242" left="613" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref748">.</a></text>
<text top="261" left="584" width="37" height="9" font="4">S9.3.1-11.</text>
<text top="261" left="625" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref749">Rostaing L, Vincenti F, Grinyo J, et al. Long-</a></text>
<text top="274" left="584" width="172" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref749">term belatacept exposure maintains ef</a></text>
<text top="273" left="757" width="45" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref749">ﬁcacy and</a></text>
<text top="288" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref749">safety at 5 years: results from the long-term extension</a></text>
<text top="301" left="584" width="213" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref749">of the BENEFIT study. Am J Transplant. 2013;13:2875</a></text>
<text top="300" left="797" width="4" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref749">–</a></text>
<text top="315" left="584" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref749">83</a></text>
<text top="315" left="595" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref749">.</a></text>
<text top="333" left="584" width="38" height="9" font="4">S9.3.1-12.</text>
<text top="333" left="625" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref750">Opelz G, Dohler B, Collaborative Transplant</a></text>
<text top="347" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref750">Study. Improved long-term outcomes after renal</a></text>
<text top="360" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref750">transplantation associated with blood pressure con-</a></text>
<text top="374" left="584" width="142" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref750">trol. Am J Transplant. 2005;5:2725</a></text>
<text top="372" left="726" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref750">–31</a></text>
<text top="374" left="739" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref750">.</a></text>
<text top="392" left="584" width="38" height="9" font="4">S9.3.1-13.</text>
<text top="392" left="625" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref751">Hillebrand U, Suwelack BM, Loley K, et al.</a></text>
<text top="406" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref751">Blood pressure, antihypertensive treatment, and graft</a></text>
<text top="419" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref751">survival in kidney transplant patients. Transpl Int.</a></text>
<text top="432" left="584" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref751">2009;22:1073</a></text>
<text top="431" left="641" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref751">–80</a></text>
<text top="432" left="656" width="3" height="9" font="4">.</text>
<text top="451" left="584" width="39" height="9" font="4">S9.3.1-14.</text>
<text top="451" left="626" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref752">Wadei HM, Amer H, Taler SJ, et al. Diurnal</a></text>
<text top="464" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref752">blood pressure changes one year after kidney trans-</a></text>
<text top="478" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref752">plantation: relationship to allograft function, histol-</a></text>
<text top="491" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref752">ogy, and resistive index. J Am Soc Nephrol. 2007;18:</a></text>
<text top="505" left="584" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref752">1607</a></text>
<text top="503" left="604" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref752">–15</a></text>
<text top="505" left="617" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref752">.</a></text>
<text top="523" left="584" width="38" height="9" font="4">S9.3.1-15.</text>
<text top="523" left="625" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref753">Ambrosi P, Kreitmann B, Habib G. Home</a></text>
<text top="537" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref753">blood pressure monitoring in heart transplant re-</a></text>
<text top="550" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref753">cipients: comparison with ambulatory blood pressure</a></text>
<text top="564" left="584" width="168" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref753">monitoring. Transplantation. 2014;97:363</a></text>
<text top="562" left="752" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref753">–7</a></text>
<text top="564" left="761" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref753">.</a></text>
<text top="582" left="584" width="39" height="9" font="4">S9.3.1-16.</text>
<text top="582" left="626" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref754">Haydar AA, Covic A, Jayawardene S, et al.</a></text>
<text top="596" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref754">Insights from ambulatory blood pressure monitoring:</a></text>
<text top="609" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref754">diagnosis of hypertension and diurnal blood pressure</a></text>
<text top="623" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref754">in renal transplant recipients. Transplantation. 2004;</a></text>
<text top="636" left="584" width="28" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref754">77:849</a></text>
<text top="634" left="613" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref754">–53</a></text>
<text top="636" left="626" width="3" height="9" font="4">.</text>
<text top="655" left="584" width="38" height="9" font="4">S9.3.1-17.</text>
<text top="655" left="625" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref755">Jennings DL, Taber DJ. Use of renin-</a></text>
<text top="668" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref755">angiotensin-aldosterone system inhibitors within the</a></text>
<text top="680" left="584" width="217" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref755">ﬁrst eight to twelve weeks after renal transplantation.</a></text>
<text top="695" left="584" width="131" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref755">Ann Pharmacother. 2008;42:116</a></text>
<text top="693" left="715" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref755">–20</a></text>
<text top="695" left="730" width="3" height="9" font="4">.</text>
<text top="717" left="584" width="131" height="9" font="23">9.4. Cerebrovascular Disease</text>
<text top="740" left="584" width="28" height="9" font="4">S9.4-1.</text>
<text top="740" left="615" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref756">Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart</a></text>
<text top="754" left="584" width="119" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref756">disease and stroke statistics</a></text>
<text top="752" left="703" width="98" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref756">–2017 update: a report</a></text>
<text top="767" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref756">from the American Heart Association. Circulation.</a></text>
<text top="781" left="584" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref756">2017;135:e146</a></text>
<text top="779" left="641" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref756">–603</a></text>
<text top="781" left="662" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref756">.</a></text>
<text top="799" left="584" width="29" height="9" font="4">S9.4-2.</text>
<text top="799" left="616" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref757">Boan AD, Lackland DT, Ovbiagele B. Lowering</a></text>
<text top="813" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref757">of blood pressure for recurrent stroke prevention.</a></text>
<text top="826" left="584" width="88" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref757">Stroke. 2014;45:2506</a></text>
<text top="825" left="672" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref757">–13</a></text>
<text top="826" left="685" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref757">.</a></text>
<text top="846" left="584" width="175" height="9" font="4">9.4.1. Acute Intracerebral Hemorrhage</text>
<text top="861" left="584" width="34" height="9" font="4">S9.4.1-1.</text>
<text top="861" left="622" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref758">Anderson CS, Heeley E, Huang Y, et al. Rapid</a></text>
<text top="875" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref758">blood-pressure lowering in patients with acute intra-</a></text>
<text top="888" left="584" width="200" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref758">cerebral hemorrhage. N Engl J Med. 2013;368:2355</a></text>
<text top="887" left="784" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref758">–65</a></text>
<text top="888" left="799" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref758">.</a></text>
<text top="907" left="584" width="35" height="9" font="4">S9.4.1-2.</text>
<text top="907" left="622" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref759">Qureshi AI, Palesch YY, Barsan WG, et al.</a></text>
<text top="920" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref759">Intensive blood-pressure lowering in patients with</a></text>
<text top="934" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref759">acute cerebral hemorrhage. N Engl J Med. 2016;375:</a></text>
<text top="947" left="584" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref759">1033</a></text>
<text top="945" left="604" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref759">–43</a></text>
<text top="947" left="618" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref759">.</a></text>
<text top="966" left="584" width="35" height="9" font="4">S9.4.1-3.</text>
<text top="966" left="622" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref760">Benjamin EJ, Blaha MJ, Chiuve SE, et al.</a></text>
<text top="979" left="584" width="148" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref760">Heart disease and stroke statistics</a></text>
<text top="977" left="732" width="69" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref760">–2017 update: a</a></text>
<text top="992" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref760">report from the American Heart Association. Circula-</a></text>
<text top="1006" left="584" width="78" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref760">tion. 2017;135:e146</a></text>
<text top="1004" left="662" width="21" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref760">–603</a></text>
<text top="1006" left="683" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref760">.</a></text>
<text top="1023" left="584" width="36" height="9" font="4">S9.4.1-4.</text>
<text top="1023" left="623" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref761">Zhang Y, Reilly KH, Tong W, et al. Blood</a></text>
<text top="1036" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref761">pressure and clinical outcome among patients with</a></text>
<text top="1050" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref761">acute stroke in Inner Mongolia. China J Hypertens.</a></text>
<text top="1063" left="584" width="58" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref761">2008;26:1446</a></text>
<text top="1062" left="643" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref761">–52</a></text>
<text top="1063" left="656" width="3" height="9" font="4">.</text>
<text top="1082" left="584" width="35" height="9" font="4">S9.4.1-5.</text>
<text top="1082" left="622" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref762">Rodriguez-Luna D, Pineiro S, Rubiera M, et al.</a></text>
<text top="1095" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref762">Impact of blood pressure changes and course on</a></text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="20" height="9" font="4">e228</text>
</page>
<page number="103" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref762">hematoma growth in acute intracerebral hemorrhage.</a></text>
<text top="156" left="63" width="109" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref762">Eur J Neurol. 2013;20:1277</a></text>
<text top="155" left="172" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref762">–83</a></text>
<text top="156" left="186" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref762">.</a></text>
<text top="175" left="63" width="36" height="9" font="4">S9.4.1-6.</text>
<text top="175" left="102" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref763">Sakamoto Y, Koga M, Yamagami H, et al.</a></text>
<text top="189" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref763">Systolic blood pressure after intravenous antihyper-</a></text>
<text top="202" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref763">tensive treatment and clinical outcomes in hyperacute</a></text>
<text top="216" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref763">intracerebral hemorrhage: the Stroke Acute Manage-</a></text>
<text top="229" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref763">ment With Urgent Risk-Factor Assessment and</a></text>
<text top="242" left="63" width="108" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref763">Improvement-Intracerebral</a></text>
<text top="242" left="188" width="49" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref763">Hemorrhage</a></text>
<text top="242" left="254" width="25" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref763">Study.</a></text>
<text top="256" left="63" width="87" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref763">Stroke. 2013;44:1846</a></text>
<text top="254" left="150" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref763">–51</a></text>
<text top="256" left="162" width="3" height="9" font="4">.</text>
<text top="275" left="63" width="35" height="9" font="4">S9.4.1-7.</text>
<text top="275" left="101" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref764">Tsivgoulis G, Katsanos AH, Butcher KS, et al.</a></text>
<text top="288" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref764">Intensive blood pressure reduction in acute intracere-</a></text>
<text top="301" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref764">bral hemorrhage: a meta-analysis. Neurology. 2014;</a></text>
<text top="315" left="63" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref764">83:1523</a></text>
<text top="313" left="94" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref764">–9</a></text>
<text top="315" left="103" width="3" height="9" font="4">.</text>
<text top="334" left="63" width="36" height="9" font="4">S9.4.1-8.</text>
<text top="334" left="102" width="68" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref765">Antihypertensive</a></text>
<text top="334" left="182" width="42" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref765">Treatment</a></text>
<text top="334" left="236" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref765">of</a></text>
<text top="334" left="257" width="23" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref765">Acute</a></text>
<text top="347" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref765">Cerebral Hemorrhage (ATACH) investigators. Antihy-</a></text>
<text top="361" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref765">pertensive treatment of acute cerebral hemorrhage.</a></text>
<text top="374" left="63" width="112" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref765">Crit Care Med. 2010;38:637</a></text>
<text top="372" left="175" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref765">–48</a></text>
<text top="374" left="190" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref765">.</a></text>
<text top="393" left="63" width="36" height="9" font="4">S9.4.1-9.</text>
<text top="393" left="102" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref766">Anderson CS, Huang Y, Wang JG, et al.</a></text>
<text top="406" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref766">Intensive blood pressure reduction in acute cerebral</a></text>
<text top="420" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref766">haemorrhage trial (INTERACT): a randomised pilot</a></text>
<text top="433" left="63" width="130" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref766">trial. Lancet Neurol. 2008;7:391</a></text>
<text top="431" left="192" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref766">–9</a></text>
<text top="433" left="202" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref766">.</a></text>
<text top="455" left="63" width="130" height="9" font="4">9.4.2. Acute Ischemic Stroke</text>
<text top="470" left="63" width="35" height="9" font="4">S9.4.2-1.</text>
<text top="470" left="101" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref767">National Institute of Neurological Disorders</a></text>
<text top="483" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref767">and Stroke rt-PA Stroke Study Group. Tissue plasmin-</a></text>
<text top="497" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref767">ogen activator for acute ischemic stroke. N Engl J Med.</a></text>
<text top="510" left="63" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref767">1995;333:1581</a></text>
<text top="508" left="120" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref767">–7</a></text>
<text top="510" left="128" width="3" height="9" font="4">.</text>
<text top="529" left="63" width="36" height="9" font="4">S9.4.2-2.</text>
<text top="529" left="102" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref768">Hacke W, Kaste M, Bluhmki E, et al.</a></text>
<text top="542" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref768">Thrombolysis with alteplase 3 to 4.5 hours after acute</a></text>
<text top="556" left="63" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref768">ischemic stroke. N Engl J Med. 2008;359:1317</a></text>
<text top="554" left="250" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref768">–29</a></text>
<text top="556" left="264" width="3" height="9" font="4">.</text>
<text top="574" left="63" width="36" height="9" font="4">S9.4.2-3.</text>
<text top="574" left="102" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref769">Ahmed N, Wahlgren N, Brainin M, et al.</a></text>
<text top="588" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref769">Relationship of blood pressure, antihypertensive</a></text>
<text top="601" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref769">therapy, and outcome in ischemic stroke treated</a></text>
<text top="615" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref769">with intravenous thrombolysis: retrospective analysis</a></text>
<text top="628" left="63" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref769">from</a></text>
<text top="628" left="92" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref769">Safe</a></text>
<text top="628" left="119" width="63" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref769">Implementation</a></text>
<text top="628" left="192" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref769">of</a></text>
<text top="628" left="210" width="53" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref769">Thrombolysis</a></text>
<text top="628" left="273" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref769">in</a></text>
<text top="642" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref769">Stroke-International Stroke Thrombolysis Register</a></text>
<text top="655" left="63" width="141" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref769">(SITS-ISTR). Stroke. 2009;40:2442</a></text>
<text top="653" left="204" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref769">–9</a></text>
<text top="655" left="214" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref769">.</a></text>
<text top="674" left="63" width="37" height="9" font="4">S9.4.2-4.</text>
<text top="674" left="103" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref770">Robinson TG, Potter JF, Ford GA, et al.</a></text>
<text top="687" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref770">Effects of antihypertensive treatment after acute</a></text>
<text top="701" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref770">stroke in the Continue or Stop Post-Stroke Antihy-</a></text>
<text top="714" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref770">pertensives Collaborative Study (COSSACS): a pro-</a></text>
<text top="728" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref770">spective, randomised, open, blinded-endpoint trial.</a></text>
<text top="741" left="63" width="108" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref770">Lancet Neurol. 2010;9:767</a></text>
<text top="739" left="171" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref770">–75</a></text>
<text top="741" left="184" width="3" height="9" font="4">.</text>
<text top="760" left="63" width="36" height="9" font="4">S9.4.2-5.</text>
<text top="760" left="102" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref771">He J, Zhang Y, Xu T, et al. Effects of</a></text>
<text top="773" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref771">immediate blood pressure reduction on death and</a></text>
<text top="787" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref771">major disability in patients with acute ischemic stroke:</a></text>
<text top="800" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref771">the CATIS randomized clinical trial. JAMA. 2014;311:</a></text>
<text top="814" left="63" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref771">479</a></text>
<text top="812" left="78" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref771">–89</a></text>
<text top="814" left="94" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref771">.</a></text>
<text top="832" left="63" width="37" height="9" font="4">S9.4.2-6.</text>
<text top="832" left="103" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref772">Wang H, Tang Y, Rong X, et al. Effects</a></text>
<text top="846" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref772">of early blood pressure lowering on early and</a></text>
<text top="859" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref772">long-term outcomes after acute stroke: an updated</a></text>
<text top="873" left="63" width="166" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref772">meta-analysis. PLoS ONE. 2014;9:e97917</a></text>
<text top="873" left="229" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref772">.</a></text>
<text top="891" left="63" width="36" height="9" font="4">S9.4.2-7.</text>
<text top="891" left="102" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref773">Zhao R, Liu F-D, Wang S, et al. Blood</a></text>
<text top="905" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref773">pressure reduction in the acute phase of an ischemic</a></text>
<text top="918" left="63" width="25" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref773">stroke</a></text>
<text top="918" left="97" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref773">does</a></text>
<text top="918" left="124" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref773">not</a></text>
<text top="918" left="147" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref773">improve</a></text>
<text top="918" left="189" width="24" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref773">short-</a></text>
<text top="918" left="222" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref773">or</a></text>
<text top="918" left="239" width="40" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref773">long-term</a></text>
<text top="932" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref773">dependency or mortality: a meta-analysis of current</a></text>
<text top="945" left="63" width="189" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref773">literature. Medicine (Baltimore). 2015;94:e896</a></text>
<text top="945" left="251" width="3" height="9" font="4">.</text>
<text top="964" left="63" width="37" height="9" font="4">S9.4.2-8.</text>
<text top="964" left="103" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref774">Bath PM, Krishnan K. Interventions for</a></text>
<text top="977" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref774">deliberately altering blood pressure in acute stroke.</a></text>
<text top="991" left="63" width="201" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref774">Cochrane Database Syst Rev. 2014;10:CD000039</a></text>
<text top="991" left="263" width="3" height="9" font="4">.</text>
<text top="1009" left="63" width="37" height="9" font="4">S9.4.2-9.</text>
<text top="1009" left="103" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref775">Sandset EC, Bath PMW, Boysen G, et al.</a></text>
<text top="1023" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref775">The angiotensin-receptor blocker candesartan for</a></text>
<text top="1036" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref775">treatment of acute stroke (SCAST): a randomised,</a></text>
<text top="1050" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref775">placebo-controlled, double-blind trial. Lancet. 2011;</a></text>
<text top="1063" left="63" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref775">377:741</a></text>
<text top="1062" left="93" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref775">–50</a></text>
<text top="1063" left="108" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref775">.</a></text>
<text top="1082" left="63" width="41" height="9" font="4">S9.4.2-10.</text>
<text top="1082" left="107" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref776">Qureshi AI, Ezzeddine MA, Nasar A, et al.</a></text>
<text top="1095" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref776">Prevalence of elevated blood pressure in 563,704</a></text>
<text top="143" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref776">adult patients with stroke presenting to the ED in the</a></text>
<text top="156" left="301" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref776">United States. Am J Emerg Med. 2007;25:32</a></text>
<text top="155" left="482" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref776">–8</a></text>
<text top="156" left="491" width="3" height="9" font="4">.</text>
<text top="176" left="301" width="39" height="9" font="4">S9.4.2-11.</text>
<text top="176" left="343" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref777">Leonardi-Bee J, Bath PM, Phillips SJ, et al.</a></text>
<text top="189" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref777">Blood pressure and clinical outcomes in the Interna-</a></text>
<text top="203" left="301" width="162" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref777">tional Stroke Trial. Stroke. 2002;33:1315</a></text>
<text top="201" left="463" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref777">–20</a></text>
<text top="203" left="478" width="3" height="9" font="4">.</text>
<text top="222" left="301" width="40" height="9" font="4">S9.4.2-12.</text>
<text top="222" left="344" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref778">Castillo J, Leira R, Garcia MM, et al. Blood</a></text>
<text top="235" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref778">pressure decrease during the acute phase of ischemic</a></text>
<text top="249" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref778">stroke is associated with brain injury and poor stroke</a></text>
<text top="262" left="301" width="125" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref778">outcome. Stroke. 2004;35:520</a></text>
<text top="261" left="425" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref778">–6</a></text>
<text top="262" left="435" width="3" height="9" font="4">.</text>
<text top="281" left="301" width="40" height="9" font="4">S9.4.2-13.</text>
<text top="281" left="344" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref779">Vemmos KN, Tsivgoulis G, Spengos K, et al.</a></text>
<text top="295" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref779">U-shaped relationship between mortality and admis-</a></text>
<text top="308" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref779">sion blood pressure in patients with acute stroke.</a></text>
<text top="322" left="301" width="113" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref779">J Intern Med. 2004;255:257</a></text>
<text top="320" left="414" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref779">–65</a></text>
<text top="322" left="429" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref779">.</a></text>
<text top="341" left="301" width="41" height="9" font="4">S9.4.2-14.</text>
<text top="341" left="345" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref780">Jauch EC, Saver JL, Adams HP Jr., et al.</a></text>
<text top="355" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref780">Guidelines for the early management of patients</a></text>
<text top="368" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref780">with acute ischemic stroke: a guideline for healthcare</a></text>
<text top="381" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref780">professionals from the American Heart Association/</a></text>
<text top="395" left="301" width="213" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref780">American Stroke Association. Stroke. 2013;44:870</a></text>
<text top="393" left="514" width="4" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref780">–</a></text>
<text top="408" left="301" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref780">947</a></text>
<text top="408" left="317" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref780">.</a></text>
<text top="430" left="301" width="161" height="9" font="4">9.4.3. Secondary Stroke Prevention</text>
<text top="446" left="301" width="35" height="9" font="4">S9.4.3-1.</text>
<text top="446" left="339" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref781">Liu L, Wang Z, Gong L, et al. Blood pressure</a></text>
<text top="459" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref781">reduction for the secondary prevention of stroke: a</a></text>
<text top="472" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref781">Chinese trial and a systematic review of the literature.</a></text>
<text top="486" left="301" width="120" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref781">Hypertens Res. 2009;32:1032</a></text>
<text top="484" left="421" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref781">–40</a></text>
<text top="486" left="437" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref781">.</a></text>
<text top="505" left="301" width="36" height="9" font="4">S9.4.3-2.</text>
<text top="505" left="340" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref782">Lakhan SE, Sapko MT. Blood pressure</a></text>
<text top="519" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref782">lowering treatment for preventing stroke recurrence: a</a></text>
<text top="532" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref782">systematic review and meta-analysis. Int Arch Med.</a></text>
<text top="546" left="301" width="43" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref782">2009;2:30</a></text>
<text top="546" left="344" width="3" height="9" font="4">.</text>
<text top="565" left="301" width="36" height="9" font="4">S9.4.3-3.</text>
<text top="565" left="340" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref783">PROGRESS Collaborative Group. Randomised</a></text>
<text top="578" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref783">trial of a perindopril-based blood-pressure-lowering</a></text>
<text top="592" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref783">regimen among 6,105 individuals with previous stroke</a></text>
<text top="605" left="301" width="213" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref783">or transient ischaemic attack. Lancet. 2001;358:1033</a></text>
<text top="603" left="514" width="4" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref783">–</a></text>
<text top="619" left="301" width="9" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref783">41</a></text>
<text top="619" left="310" width="3" height="9" font="4">.</text>
<text top="638" left="301" width="37" height="9" font="4">S9.4.3-4.</text>
<text top="638" left="341" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref784">PATS</a></text>
<text top="638" left="372" width="54" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref784">Collaborating</a></text>
<text top="638" left="435" width="27" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref784">Group.</a></text>
<text top="638" left="472" width="46" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref784">Post-stroke</a></text>
<text top="651" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref784">antihypertensive treatment study. A preliminary result.</a></text>
<text top="665" left="301" width="105" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref784">Chin Med J. 1995;108:710</a></text>
<text top="663" left="406" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref784">–7</a></text>
<text top="665" left="415" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref784">.</a></text>
<text top="684" left="301" width="36" height="9" font="4">S9.4.3-5.</text>
<text top="684" left="340" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref785">Lee M, Saver JL, Hong K-S, et al. Renin-</a></text>
<text top="697" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref785">angiotensin system modulators modestly reduce</a></text>
<text top="711" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref785">vascular risk in persons with prior stroke. Stroke. 2012;</a></text>
<text top="724" left="301" width="25" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref785">43:113</a></text>
<text top="723" left="326" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref785">–9</a></text>
<text top="724" left="336" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref785">.</a></text>
<text top="744" left="301" width="37" height="9" font="4">S9.4.3-6.</text>
<text top="744" left="341" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref786">Wang W-T, You L-K, Chiang C-E, et al.</a></text>
<text top="757" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref786">Comparative effectiveness of blood pressure-lowering</a></text>
<text top="770" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref786">drugs in patients who have already suffered from</a></text>
<text top="784" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref786">stroke: traditional and Bayesian network meta-analysis</a></text>
<text top="797" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref786">of randomized trials. Medicine (Baltimore). 2016;95:</a></text>
<text top="811" left="301" width="25" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref786">e3302</a></text>
<text top="811" left="326" width="3" height="9" font="4">.</text>
<text top="830" left="301" width="36" height="9" font="4">S9.4.3-7.</text>
<text top="830" left="340" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref787">Katsanos AH, Filippatou A, Manios E, et al.</a></text>
<text top="844" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref787">Blood pressure reduction and secondary stroke pre-</a></text>
<text top="857" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref787">vention: a systematic review and metaregression</a></text>
<text top="870" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref787">analysis of randomized clinical trials. Hypertension.</a></text>
<text top="884" left="301" width="48" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref787">2017;69:171</a></text>
<text top="882" left="349" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref787">–9</a></text>
<text top="884" left="358" width="3" height="9" font="4">.</text>
<text top="903" left="301" width="37" height="9" font="4">S9.4.3-8.</text>
<text top="903" left="341" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref788">Benavente OR, Coffey CS, Conwit R, et al.</a></text>
<text top="917" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref788">Blood-pressure targets in patients with recent lacunar</a></text>
<text top="930" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref788">stroke: the SPS3 randomised trial. SPS3 Study Group.</a></text>
<text top="943" left="301" width="87" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref788">Lancet. 2013;382:507</a></text>
<text top="942" left="388" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref788">–15</a></text>
<text top="943" left="401" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref788">.</a></text>
<text top="963" left="301" width="37" height="9" font="4">S9.4.3-9.</text>
<text top="963" left="341" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref789">Arima H, Chalmers J, Woodward M, et al.</a></text>
<text top="976" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref789">Lower target blood pressures are safe and effective for</a></text>
<text top="990" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref789">the prevention of recurrent stroke: the PROGRESS</a></text>
<text top="1003" left="301" width="131" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref789">trial. J Hypertens. 2006;24:1201</a></text>
<text top="1001" left="432" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref789">–8</a></text>
<text top="1003" left="442" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref789">.</a></text>
<text top="1022" left="301" width="41" height="9" font="4">S9.4.3-10.</text>
<text top="1022" left="345" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref790">Benjamin EJ, Blaha MJ, Chiuve SE, et al.</a></text>
<text top="1036" left="301" width="148" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref790">Heart disease and stroke statistics</a></text>
<text top="1034" left="449" width="69" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref790">–2017 update: a</a></text>
<text top="1049" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref790">report from the American Heart Association. Circula-</a></text>
<text top="1063" left="301" width="78" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref790">tion. 2017;135:e146</a></text>
<text top="1061" left="379" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref790">–603</a></text>
<text top="1063" left="400" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref790">.</a></text>
<text top="1082" left="301" width="39" height="9" font="4">S9.4.3-11.</text>
<text top="1082" left="343" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref791">Dhamoon MS, Sciacca RR, Rundek T, et al.</a></text>
<text top="1095" left="301" width="160" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref791">Recurrent stroke and cardiac risks after</a></text>
<text top="1094" left="465" width="53" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref791">ﬁrst ischemic</a></text>
<text top="143" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref791">stroke: the Northern Manhattan Study. Neurology.</a></text>
<text top="156" left="539" width="54" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref791">2006;66:641</a></text>
<text top="155" left="593" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref791">–6</a></text>
<text top="156" left="603" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref791">.</a></text>
<text top="176" left="539" width="40" height="9" font="4">S9.4.3-12.</text>
<text top="176" left="583" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref792">Hardie K, Hankey GJ, Jamrozik K, et al. Ten-</a></text>
<text top="190" left="539" width="47" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref792">year risk of</a></text>
<text top="188" left="590" width="166" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref792">ﬁrst recurrent stroke and disability after</a></text>
<text top="202" left="539" width="217" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref792">ﬁrst-ever stroke in the Perth Community Stroke Study.</a></text>
<text top="217" left="539" width="81" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref792">Stroke. 2004;35:731</a></text>
<text top="215" left="621" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref792">–5</a></text>
<text top="217" left="630" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref792">.</a></text>
<text top="237" left="539" width="40" height="9" font="4">S9.4.3-13.</text>
<text top="237" left="583" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref793">Lovett JK, Coull AJ, Rothwell PM. Early risk</a></text>
<text top="250" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref793">of recurrence by subtype of ischemic stroke in</a></text>
<text top="264" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref793">population-based incidence studies. Neurology. 2004;</a></text>
<text top="277" left="539" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref793">62:569</a></text>
<text top="276" left="568" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref793">–73</a></text>
<text top="277" left="582" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref793">.</a></text>
<text top="297" left="539" width="41" height="9" font="4">S9.4.3-14.</text>
<text top="297" left="583" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref794">Toschke AM, Gulliford MC, Wolfe CDA,</a></text>
<text top="311" left="539" width="159" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref794">et al. Antihypertensive treatment after</a></text>
<text top="309" left="701" width="55" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref794">ﬁrst stroke in</a></text>
<text top="324" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref794">primary care: results from the General Practitioner</a></text>
<text top="338" left="539" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref794">Research Database. J Hypertens. 2011;29:154</a></text>
<text top="336" left="722" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref794">–60</a></text>
<text top="338" left="737" width="3" height="9" font="4">.</text>
<text top="358" left="539" width="40" height="9" font="4">S9.4.3-15.</text>
<text top="358" left="583" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref795">Kernan WN, Ovbiagele B, Black HR, et al.</a></text>
<text top="371" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref795">Guidelines for the prevention of stroke in patients with</a></text>
<text top="384" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref795">stroke and transient ischemic attack: a guideline for</a></text>
<text top="398" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref795">healthcare professionals from the American Heart As-</a></text>
<text top="411" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref795">sociation/American Stroke Association. Stroke. 2014;</a></text>
<text top="425" left="539" width="33" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref795">45:2160</a></text>
<text top="423" left="572" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref795">–236</a></text>
<text top="425" left="592" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref795">.</a></text>
<text top="445" left="539" width="41" height="9" font="4">S9.4.3-16.</text>
<text top="445" left="583" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref796">Buse JB, Ginsberg HN, Bakris GL, et al.</a></text>
<text top="458" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref796">Primary prevention of cardiovascular diseases in peo-</a></text>
<text top="472" left="539" width="142" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref796">ple with diabetes mellitus: a scienti</a></text>
<text top="470" left="682" width="75" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref796">ﬁc statement from</a></text>
<text top="485" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref796">the American Heart Association and the American</a></text>
<text top="498" left="539" width="200" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref796">Diabetes Association. Diabetes Care. 2007;30:162</a></text>
<text top="497" left="740" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref796">–72</a></text>
<text top="498" left="753" width="3" height="9" font="4">.</text>
<text top="520" left="539" width="136" height="9" font="23">9.5. Peripheral Artery Disease</text>
<text top="545" left="539" width="27" height="9" font="4">S9.5-1.</text>
<text top="545" left="570" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref797">Ostergren J, Sleight P, Dagenais G, et al.</a></text>
<text top="559" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref797">Impact of ramipril in patients with evidence of clinical</a></text>
<text top="572" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref797">or subclinical peripheral arterial disease. Eur Heart J.</a></text>
<text top="586" left="539" width="46" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref797">2004;25:17</a></text>
<text top="584" left="585" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref797">–24</a></text>
<text top="586" left="599" width="3" height="9" font="4">.</text>
<text top="606" left="539" width="28" height="9" font="4">S9.5-2.</text>
<text top="606" left="571" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref798">Thompson AM, Hu T, Eshelbrenner CL, et al.</a></text>
<text top="619" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref798">Antihypertensive treatment and secondary prevention</a></text>
<text top="633" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref798">of cardiovascular disease events among persons</a></text>
<text top="646" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref798">without hypertension: a meta-analysis. JAMA. 2011;</a></text>
<text top="660" left="539" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref798">305:913</a></text>
<text top="658" left="572" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref798">–22</a></text>
<text top="660" left="585" width="3" height="9" font="4">.</text>
<text top="680" left="539" width="28" height="9" font="4">S9.5-3.</text>
<text top="680" left="571" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref799">Bavry AA, Anderson RD, Gong Y, et al.</a></text>
<text top="693" left="539" width="40" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref799">Outcomes</a></text>
<text top="693" left="592" width="27" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref799">among</a></text>
<text top="693" left="631" width="51" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref799">hypertensive</a></text>
<text top="693" left="694" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref799">patients</a></text>
<text top="693" left="739" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref799">with</a></text>
<text top="706" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref799">concomitant peripheral and coronary artery disease:</a></text>
<text top="718" left="539" width="217" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref799">ﬁndings from the INternational VErapamil-SR/</a></text>
<text top="733" left="539" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref799">Trandolapril STudy. Hypertension. 2010;55:48</a></text>
<text top="732" left="726" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref799">–53</a></text>
<text top="733" left="739" width="3" height="9" font="4">.</text>
<text top="753" left="539" width="29" height="9" font="4">S9.5-4.</text>
<text top="753" left="571" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref800">Zanchetti A, Julius S, Kjeldsen S, et al.</a></text>
<text top="767" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref800">Outcomes in subgroups of hypertensive patients</a></text>
<text top="780" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref800">treated with regimens based on valsartan and amlo-</a></text>
<text top="794" left="539" width="88" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref800">dipine: an analysis of</a></text>
<text top="792" left="631" width="125" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref800">ﬁndings from the VALUE trial.</a></text>
<text top="807" left="539" width="110" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref800">J Hypertens. 2006;24:2163</a></text>
<text top="805" left="650" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref800">–8</a></text>
<text top="807" left="659" width="3" height="9" font="4">.</text>
<text top="827" left="539" width="28" height="9" font="4">S9.5-5.</text>
<text top="827" left="571" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref801">Piller LB, Simpson LM, Baraniuk S, et al.</a></text>
<text top="841" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref801">Characteristics and long-term follow-up of partici-</a></text>
<text top="854" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref801">pants with peripheral arterial disease during ALLHAT.</a></text>
<text top="867" left="539" width="132" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref801">J Gen Intern. Med. 2014;29:1475</a></text>
<text top="866" left="672" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref801">–83</a></text>
<text top="867" left="686" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref801">.</a></text>
<text top="889" left="539" width="99" height="9" font="23">9.6. Diabetes Mellitus</text>
<text top="914" left="539" width="28" height="9" font="4">S9.6-1.</text>
<text top="914" left="570" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref802">Emdin CA, Rahimi K, Neal B, et al. Blood</a></text>
<text top="928" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref802">pressure lowering in type 2 diabetes: a systematic re-</a></text>
<text top="941" left="539" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref802">view and meta-analysis. JAMA. 2015;313:603</a></text>
<text top="940" left="722" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref802">–15</a></text>
<text top="941" left="734" width="3" height="9" font="4">.</text>
<text top="961" left="539" width="29" height="9" font="4">S9.6-2.</text>
<text top="961" left="571" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref803">Arguedas JA, Leiva V, Wright JM. Blood pres-</a></text>
<text top="975" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref803">sure targets for hypertension in people with diabetes</a></text>
<text top="988" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref803">mellitus. Cochrane Database Syst Rev. 2013;10:</a></text>
<text top="1002" left="539" width="43" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref803">CD008277</a></text>
<text top="1002" left="582" width="3" height="9" font="4">.</text>
<text top="1022" left="539" width="29" height="9" font="4">S9.6-3.</text>
<text top="1022" left="571" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref804">Cushman WC, Evans GW, Byington RP, et al.</a></text>
<text top="1035" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref804">Effects of intensive blood-pressure control in type 2</a></text>
<text top="1048" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref804">diabetes mellitus. ACCORD Study. N Engl J Med. 2010;</a></text>
<text top="1062" left="539" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref804">362:1575</a></text>
<text top="1060" left="575" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref804">–85</a></text>
<text top="1062" left="590" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref804">.</a></text>
<text top="1082" left="539" width="30" height="9" font="4">S9.6-4.</text>
<text top="1082" left="572" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref805">Xie X, Atkins E, Lv J, et al. Effects of intensive</a></text>
<text top="1095" left="539" width="109" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref805">blood pressure lowering</a></text>
<text top="1095" left="657" width="76" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref805">on cardiovascular</a></text>
<text top="1095" left="742" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref805">and</a></text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="788" width="20" height="9" font="4">e229</text>
</page>
<page number="104" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref805">renal outcomes: updated systematic review and meta-</a></text>
<text top="156" left="108" width="124" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref805">analysis. Lancet. 2016;387:435</a></text>
<text top="155" left="232" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref805">–43</a></text>
<text top="156" left="246" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref805">.</a></text>
<text top="177" left="108" width="29" height="9" font="4">S9.6-5.</text>
<text top="177" left="140" width="61" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref806">Margolis KL, O</a></text>
<text top="175" left="200" width="125" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref806">’Connor PJ, Morgan TM, et al.</a></text>
<text top="190" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref806">Outcomes of combined cardiovascular risk factor</a></text>
<text top="203" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref806">management strategies in type 2 diabetes: the</a></text>
<text top="217" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref806">ACCORD randomized trial. Diabetes Care. 2014;37:</a></text>
<text top="230" left="108" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref806">1721</a></text>
<text top="229" left="124" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref806">–8</a></text>
<text top="230" left="134" width="3" height="9" font="4">.</text>
<text top="250" left="108" width="30" height="9" font="4">S9.6-6.</text>
<text top="250" left="140" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref807">Soliman EZ, Byington RP, Bigger JT, et al.</a></text>
<text top="264" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref807">Effect of intensive blood pressure lowering on left</a></text>
<text top="277" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref807">ventricular hypertrophy in patients with diabetes</a></text>
<text top="291" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref807">mellitus: Action to Control Cardiovascular Risk in</a></text>
<text top="304" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref807">Diabetes Blood Pressure Trial. Hypertension. 2015;66:</a></text>
<text top="318" left="108" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref807">1123</a></text>
<text top="316" left="125" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref807">–9</a></text>
<text top="318" left="134" width="3" height="9" font="4">.</text>
<text top="338" left="108" width="29" height="9" font="4">S9.6-7.</text>
<text top="338" left="140" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref808">Lv J, Ehteshami P, Sarnak MJ, et al. Effects of</a></text>
<text top="351" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref808">intensive blood pressure lowering on the progression</a></text>
<text top="364" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref808">of chronic kidney disease: a systematic review and</a></text>
<text top="378" left="108" width="144" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref808">meta-analysis. CMAJ. 2013;185:949</a></text>
<text top="376" left="252" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref808">–57</a></text>
<text top="378" left="265" width="3" height="9" font="4">.</text>
<text top="398" left="108" width="30" height="9" font="4">S9.6-8.</text>
<text top="398" left="140" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref809">Bress AP, King JB, Kreider KE, et al. Effect of</a></text>
<text top="411" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref809">intensive versus standard blood pressure treatment</a></text>
<text top="425" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref809">according to baseline prediabetes status: a post hoc</a></text>
<text top="438" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref809">analysis of a randomized trial. Diabetes Care. 2017;40:</a></text>
<text top="452" left="108" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref809">1401</a></text>
<text top="450" left="127" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref809">–8</a></text>
<text top="452" left="136" width="3" height="9" font="4">.</text>
<text top="470" left="108" width="30" height="9" font="4">S9.6-9.</text>
<text top="470" left="140" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref810">Turnbull F, Neal B, Algert C, et al. Effects of</a></text>
<text top="484" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref810">different blood pressure-lowering regimens on major</a></text>
<text top="497" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref810">cardiovascular events in individuals with and without</a></text>
<text top="511" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref810">diabetes mellitus: results of prospectively designed</a></text>
<text top="524" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref810">overviews of randomized trials. Arch Intern Med.</a></text>
<text top="538" left="108" width="60" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref810">2005;165:1410</a></text>
<text top="536" left="168" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref810">–9</a></text>
<text top="538" left="177" width="3" height="9" font="4">.</text>
<text top="556" left="108" width="34" height="9" font="4">S9.6-10.</text>
<text top="556" left="145" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref811">Whelton PK, Barzilay J, Cushman WC, et al.</a></text>
<text top="570" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref811">Clinical outcomes in antihypertensive treatment of</a></text>
<text top="583" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref811">type 2 diabetes, impaired fasting glucose concentra-</a></text>
<text top="596" left="108" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref811">tion,</a></text>
<text top="596" left="135" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref811">and</a></text>
<text top="596" left="160" width="64" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref811">normoglycemia:</a></text>
<text top="596" left="233" width="68" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref811">Antihypertensive</a></text>
<text top="596" left="310" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref811">and</a></text>
<text top="610" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref811">Lipid-Lowering Treatment to Prevent Heart Attack</a></text>
<text top="623" left="108" width="196" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref811">Trial (ALLHAT). Arch Intern Med. 2005;165:1401</a></text>
<text top="622" left="303" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref811">–9</a></text>
<text top="623" left="313" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref811">.</a></text>
<text top="642" left="108" width="32" height="9" font="4">S9.6-11.</text>
<text top="642" left="143" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref812">Palmer SC, Mavridis D, Navarese E, et al.</a></text>
<text top="655" left="108" width="63" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref812">Comparative ef</a></text>
<text top="654" left="170" width="154" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref812">ﬁcacy and safety of blood pressure-</a></text>
<text top="669" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref812">lowering agents in adults with diabetes and kidney</a></text>
<text top="682" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref812">disease: a network meta-analysis. Lancet. 2015;385:</a></text>
<text top="696" left="108" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref812">2047</a></text>
<text top="694" left="128" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref812">–56</a></text>
<text top="696" left="143" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref812">.</a></text>
<text top="714" left="108" width="33" height="9" font="4">S9.6-12.</text>
<text top="714" left="143" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref813">Schmieder RE, Hilgers KF, Schlaich MP, et al.</a></text>
<text top="728" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref813">Renin-angiotensin system and cardiovascular risk.</a></text>
<text top="741" left="108" width="95" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref813">Lancet. 2007;369:1208</a></text>
<text top="739" left="203" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref813">–19</a></text>
<text top="741" left="216" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref813">.</a></text>
<text top="760" left="108" width="33" height="9" font="4">S9.6-13.</text>
<text top="760" left="143" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref814">Reboussin DM, Allen NB, Griswold ME, et al.</a></text>
<text top="773" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref814">Systematic review for the 2017 ACC/AHA/AAPA/ABC/</a></text>
<text top="787" left="108" width="162" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref814">ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA</a></text>
<text top="787" left="288" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref814">guideline</a></text>
<text top="800" left="108" width="12" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref814">for</a></text>
<text top="800" left="129" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref814">the</a></text>
<text top="800" left="151" width="46" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref814">prevention,</a></text>
<text top="800" left="207" width="40" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref814">detection,</a></text>
<text top="800" left="256" width="44" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref814">evaluation,</a></text>
<text top="800" left="310" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref814">and</a></text>
<text top="813" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref814">management of high blood pressure in adults. J Am</a></text>
<text top="827" left="108" width="104" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref814">Coll Cardiol. 2018;71:2176</a></text>
<text top="825" left="212" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref814">–98</a></text>
<text top="827" left="227" width="3" height="9" font="4">.</text>
<text top="845" left="108" width="34" height="9" font="4">S9.6-14.</text>
<text top="845" left="144" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref815">Kannel WB, Wilson PW, Zhang TJ. The</a></text>
<text top="859" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref815">epidemiology of impaired glucose tolerance and</a></text>
<text top="872" left="108" width="164" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref815">hypertension. Am Heart J. 1991;121:1268</a></text>
<text top="871" left="272" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref815">–73</a></text>
<text top="872" left="285" width="3" height="9" font="4">.</text>
<text top="891" left="108" width="33" height="9" font="4">S9.6-15.</text>
<text top="891" left="143" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref816">Tarnow L, Rossing P, Gall MA, et al. Prevalence</a></text>
<text top="904" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref816">of arterial hypertension in diabetic patients before and</a></text>
<text top="918" left="108" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref816">after the JNC-V. Diabetes Care. 1994;17:1247</a></text>
<text top="916" left="286" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref816">–51</a></text>
<text top="918" left="298" width="3" height="9" font="4">.</text>
<text top="936" left="108" width="34" height="9" font="4">S9.6-16.</text>
<text top="936" left="144" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref817">Adler AI, Stratton IM, Neil HA, et al.</a></text>
<text top="950" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref817">Association of systolic blood pressure with macro-</a></text>
<text top="963" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref817">vascular and microvascular complications of type 2</a></text>
<text top="977" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref817">diabetes (UKPDS 36): prospective observational study.</a></text>
<text top="990" left="108" width="78" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref817">BMJ. 2000;321:412</a></text>
<text top="988" left="186" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref817">–9</a></text>
<text top="990" left="195" width="3" height="9" font="4">.</text>
<text top="1009" left="108" width="33" height="9" font="4">S9.6-17.</text>
<text top="1009" left="143" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref818">Stamler J, Vaccaro O, Neaton JD, et al.</a></text>
<text top="1022" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref818">Diabetes, other risk factors, and 12-yr cardiovascular</a></text>
<text top="1035" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref818">mortality for men screened in the Multiple Risk Factor</a></text>
<text top="1049" left="108" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref818">Intervention Trial. Diabetes Care. 1993;16:434</a></text>
<text top="1047" left="293" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref818">–44</a></text>
<text top="1049" left="308" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref818">.</a></text>
<text top="1067" left="108" width="34" height="9" font="4">S9.6-18.</text>
<text top="1067" left="144" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref819">Do DV, Wang X, Vedula SS, et al. Blood</a></text>
<text top="1081" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref819">pressure control for diabetic retinopathy. Cochrane</a></text>
<text top="1094" left="108" width="150" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref819">Database Syst Rev. 2015;1:CD006127</a></text>
<text top="1094" left="258" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref819">.</a></text>
<text top="143" left="346" width="34" height="9" font="4">S9.6-19.</text>
<text top="143" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref820">Estacio RO, Jeffers BW, Gifford N, et al.</a></text>
<text top="156" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref820">Effect of blood pressure control on diabetic micro-</a></text>
<text top="170" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref820">vascular complications in patients with hypertension</a></text>
<text top="183" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref820">and type 2 diabetes. Diabetes Care. 2000;23 suppl 2:</a></text>
<text top="197" left="346" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref820">B54</a></text>
<text top="195" left="362" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref820">–64</a></text>
<text top="197" left="377" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref820">.</a></text>
<text top="215" left="346" width="35" height="9" font="4">S9.6-20.</text>
<text top="215" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref821">Estacio RO, Jeffers BW, Hiatt WR, et al.</a></text>
<text top="229" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref821">The effect of nisoldipine as compared with enalapril</a></text>
<text top="242" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref821">on cardiovascular outcomes in patients with non-</a></text>
<text top="256" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref821">insulin-dependent diabetes and hypertension. N Engl</a></text>
<text top="269" left="346" width="87" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref821">J Med. 1998;338:645</a></text>
<text top="268" left="432" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref821">–52</a></text>
<text top="269" left="446" width="3" height="9" font="4">.</text>
<text top="288" left="346" width="33" height="9" font="4">S9.6-21.</text>
<text top="288" left="382" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref822">Tight blood pressure control and risk of</a></text>
<text top="301" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref822">macrovascular and microvascular complications in type</a></text>
<text top="315" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref822">2 diabetes: UKPDS 38. UK Prospective Diabetes Study</a></text>
<text top="328" left="346" width="107" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref822">Group. BMJ. 1998;317:703</a></text>
<text top="326" left="452" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref822">–13</a></text>
<text top="328" left="465" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref822">.</a></text>
<text top="347" left="346" width="34" height="9" font="4">S9.6-22.</text>
<text top="347" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref823">Hansson L, Zanchetti A, Carruthers SG, et al.</a></text>
<text top="360" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref823">Effects of intensive blood-pressure lowering and low-</a></text>
<text top="373" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref823">dose aspirin in patients with hypertension: principal</a></text>
<text top="387" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref823">results of the Hypertension Optimal Treatment (HOT)</a></text>
<text top="400" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref823">randomised trial. HOT Study Group. Lancet. 1998;351:</a></text>
<text top="414" left="346" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref823">1755</a></text>
<text top="412" left="364" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref823">–62</a></text>
<text top="414" left="378" width="3" height="9" font="4">.</text>
<text top="432" left="346" width="34" height="9" font="4">S9.6-23.</text>
<text top="432" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref824">Reboldi G, Gentile G, Angeli F, et al. Effects</a></text>
<text top="446" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref824">of intensive blood pressure reduction on myocardial</a></text>
<text top="459" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref824">infarction and stroke in diabetes: a meta-analysis in 73,</a></text>
<text top="473" left="346" width="161" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref824">913 patients. J Hypertens. 2011;29:1253</a></text>
<text top="471" left="506" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref824">–69</a></text>
<text top="473" left="522" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref824">.</a></text>
<text top="491" left="346" width="35" height="9" font="4">S9.6-24.</text>
<text top="491" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref825">Ettehad D, Emdin CA, Kiran A, et al.</a></text>
<text top="505" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref825">Blood pressure lowering for prevention of cardiovas-</a></text>
<text top="518" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref825">cular disease and death: a systematic review and</a></text>
<text top="532" left="346" width="148" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref825">meta-analysis. Lancet. 2016;387:957</a></text>
<text top="530" left="494" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref825">–67</a></text>
<text top="532" left="508" width="3" height="9" font="4">.</text>
<text top="550" left="346" width="34" height="9" font="4">S9.6-25.</text>
<text top="550" left="383" width="42" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref826">Brunstrom</a></text>
<text top="550" left="435" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref826">M,</a></text>
<text top="550" left="456" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref826">Carlberg</a></text>
<text top="550" left="501" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref826">B.</a></text>
<text top="550" left="520" width="24" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref826">Effect</a></text>
<text top="550" left="555" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref826">of</a></text>
<text top="564" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref826">antihypertensive treatment at different blood pressure</a></text>
<text top="577" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref826">levels in patients with diabetes mellitus: systematic</a></text>
<text top="590" left="346" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref826">review and meta-analyses. BMJ. 2016;352:i717</a></text>
<text top="590" left="533" width="3" height="9" font="4">.</text>
<text top="609" left="346" width="35" height="9" font="4">S9.6-26.</text>
<text top="609" left="384" width="125" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref827">Perkovic V, Rodgers A. Rede</a></text>
<text top="607" left="508" width="55" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref827">ﬁning blood-</a></text>
<text top="622" left="346" width="66" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref827">pressure targets</a></text>
<text top="621" left="412" width="151" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref827">–SPRINT starts the marathon. N Engl</a></text>
<text top="636" left="346" width="87" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref827">J Med. 2015;373:2175</a></text>
<text top="634" left="433" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref827">–8</a></text>
<text top="636" left="442" width="3" height="9" font="4">.</text>
<text top="654" left="346" width="34" height="9" font="4">S9.6-27.</text>
<text top="654" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref828">Mancia G, Schumacher H, Redon J, et al.</a></text>
<text top="668" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref828">Blood pressure targets recommended by guidelines</a></text>
<text top="681" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref828">and incidence of cardiovascular and renal events in the</a></text>
<text top="695" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref828">Ongoing Telmisartan Alone and in Combination With</a></text>
<text top="708" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref828">Ramipril Global Endpoint Trial (ONTARGET). Circula-</a></text>
<text top="722" left="346" width="76" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref828">tion. 2011;124:1727</a></text>
<text top="720" left="422" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref828">–36</a></text>
<text top="722" left="437" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref828">.</a></text>
<text top="740" left="346" width="35" height="9" font="4">S9.6-28.</text>
<text top="740" left="384" width="86" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref829">Wright JT Jr., Probst</a></text>
<text top="739" left="470" width="93" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref829">ﬁeld JL, Cushman WC,</a></text>
<text top="754" left="346" width="61" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref829">et al. ALLHAT</a></text>
<text top="752" left="412" width="151" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref829">ﬁndings revisited in the context of</a></text>
<text top="767" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref829">subsequent analyses, other trials, and meta-analyses.</a></text>
<text top="780" left="346" width="129" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref829">Arch Intern Med. 2009;169:832</a></text>
<text top="779" left="475" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref829">–42</a></text>
<text top="780" left="489" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref829">.</a></text>
<text top="808" left="346" width="113" height="9" font="23">9.7. Metabolic Syndrome</text>
<text top="832" left="346" width="27" height="9" font="4">S9.7-1.</text>
<text top="832" left="376" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref830">Lim S, Eckel RH. Pharmacological treatment</a></text>
<text top="845" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref830">and therapeutic perspectives of metabolic syndrome.</a></text>
<text top="859" left="346" width="157" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref830">Rev Endocr Metab Disord. 2014;15:329</a></text>
<text top="857" left="503" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref830">–41</a></text>
<text top="859" left="516" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref830">.</a></text>
<text top="877" left="346" width="28" height="9" font="4">S9.7-2.</text>
<text top="877" left="377" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref831">Owen JG, Reisin E. Anti-hypertensive drug</a></text>
<text top="891" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref831">treatment of patients with and the metabolic syn-</a></text>
<text top="904" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref831">drome and obesity: a review of evidence, meta-</a></text>
<text top="918" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref831">analysis, post hoc and guidelines publications. Curr</a></text>
<text top="931" left="346" width="113" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref831">Hypertens Rep. 2015;17:558</a></text>
<text top="931" left="459" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref831">.</a></text>
<text top="950" left="346" width="28" height="9" font="4">S9.7-3.</text>
<text top="950" left="377" width="41" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref832">Ruderman</a></text>
<text top="950" left="429" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref832">NB,</a></text>
<text top="950" left="455" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref832">Shulman</a></text>
<text top="950" left="501" width="11" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref832">GI.</a></text>
<text top="950" left="524" width="39" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref832">Metabolic</a></text>
<text top="963" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref832">syndrome. In: Jameson JL, editor. Endocrinology:</a></text>
<text top="977" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref832">Adult &amp; Pediatric. Philadelphia, PA: Elsevier Saunders,</a></text>
<text top="990" left="346" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref832">2015:752</a></text>
<text top="988" left="382" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref832">–9</a></text>
<text top="990" left="392" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref832">.</a></text>
<text top="1009" left="346" width="29" height="9" font="4">S9.7-4.</text>
<text top="1009" left="378" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref833">Mozumdar A, Liguori G. Persistent increase of</a></text>
<text top="1022" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref833">prevalence of metabolic syndrome among U.S. adults:</a></text>
<text top="1035" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref833">NHANES III to NHANES 1999-2006. Diabetes Care.</a></text>
<text top="1049" left="346" width="48" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref833">2011;34:216</a></text>
<text top="1047" left="394" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref833">–9</a></text>
<text top="1049" left="403" width="3" height="9" font="4">.</text>
<text top="1067" left="346" width="28" height="9" font="4">S9.7-5.</text>
<text top="1067" left="377" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref834">Chen J, Muntner P, Hamm LL, et al. The</a></text>
<text top="1081" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref834">metabolic syndrome and chronic kidney disease in U.S.</a></text>
<text top="1094" left="346" width="155" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref834">adults. Ann Intern Med. 2004;140:167</a></text>
<text top="1093" left="501" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref834">–74</a></text>
<text top="1094" left="515" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref834">.</a></text>
<text top="143" left="584" width="29" height="9" font="4">S9.7-6.</text>
<text top="143" left="616" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref835">Chen J, Gu D, Chen C-S, et al. Association</a></text>
<text top="156" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref835">between the metabolic syndrome and chronic kidney</a></text>
<text top="170" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref835">disease in Chinese adults. Nephrol Dial Transplant.</a></text>
<text top="183" left="584" width="56" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref835">2007;22:1100</a></text>
<text top="182" left="640" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref835">–6</a></text>
<text top="183" left="650" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref835">.</a></text>
<text top="202" left="584" width="28" height="9" font="4">S9.7-7.</text>
<text top="202" left="615" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref836">Barzilay JI, Davis BR, Whelton PK. The</a></text>
<text top="216" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref836">glycemic effects of antihypertensive medications. Curr</a></text>
<text top="229" left="584" width="114" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref836">Hypertens Rep. 2014;16:410</a></text>
<text top="229" left="699" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref836">.</a></text>
<text top="248" left="584" width="29" height="9" font="4">S9.7-8.</text>
<text top="248" left="616" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref837">Kostis JB, Wilson AC, Freudenberger RS, et al.</a></text>
<text top="262" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref837">Long-term effect of diuretic-based therapy on fatal</a></text>
<text top="275" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref837">outcomes in subjects with isolated systolic hyperten-</a></text>
<text top="289" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref837">sion with and without diabetes. Am J Cardiol. 2005;</a></text>
<text top="302" left="584" width="24" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref837">95:29</a></text>
<text top="300" left="608" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref837">–35</a></text>
<text top="302" left="621" width="3" height="9" font="4">.</text>
<text top="320" left="584" width="29" height="9" font="4">S9.7-9.</text>
<text top="320" left="616" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref838">Wright JT Jr., Harris-Haywood S, Pressel S,</a></text>
<text top="333" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref838">et al. Clinical outcomes by race in hypertensive</a></text>
<text top="346" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref838">patients with and without the metabolic syndrome:</a></text>
<text top="360" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref838">Antihypertensive and Lipid-Lowering Treatment to</a></text>
<text top="373" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref838">Prevent Heart Attack Trial (ALLHAT). Arch Intern Med.</a></text>
<text top="387" left="584" width="58" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref838">2008;168:207</a></text>
<text top="385" left="642" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref838">–17</a></text>
<text top="387" left="655" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref838">.</a></text>
<text top="404" left="584" width="33" height="9" font="4">S9.7-10.</text>
<text top="404" left="620" width="87" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref839">Wright JT Jr., Probst</a></text>
<text top="403" left="708" width="94" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref839">ﬁeld JL, Cushman WC,</a></text>
<text top="418" left="584" width="61" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref839">et al. ALLHAT</a></text>
<text top="416" left="650" width="151" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref839">ﬁndings revisited in the context of</a></text>
<text top="431" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref839">subsequent analyses, other trials, and meta-analyses.</a></text>
<text top="445" left="584" width="129" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref839">Arch Intern Med. 2009;169:832</a></text>
<text top="443" left="713" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref839">–42</a></text>
<text top="445" left="727" width="3" height="9" font="4">.</text>
<text top="462" left="584" width="31" height="9" font="4">S9.7-11.</text>
<text top="462" left="618" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref840">Black HR, Davis B, Barzilay J, et al. Metabolic</a></text>
<text top="476" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref840">and clinical outcomes in nondiabetic individuals with</a></text>
<text top="489" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref840">the metabolic syndrome assigned to chlorthalidone,</a></text>
<text top="502" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref840">amlodipine, or lisinopril as initial treatment for</a></text>
<text top="516" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref840">hypertension: a report from the Antihypertensive and</a></text>
<text top="529" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref840">Lipid-Lowering Treatment to Prevent Heart Attack</a></text>
<text top="543" left="584" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref840">Trial (ALLHAT). Diabetes Care. 2008;31:353</a></text>
<text top="541" left="760" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref840">–60</a></text>
<text top="543" left="776" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref840">.</a></text>
<text top="560" left="584" width="32" height="9" font="4">S9.7-12.</text>
<text top="560" left="619" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref841">Laurent S, Boutouyrie P, Vascular Mechanism</a></text>
<text top="574" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref841">Collaboration. Dose-dependent arterial destiffening</a></text>
<text top="587" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref841">and inward remodeling after olmesartan in hyperten-</a></text>
<text top="601" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref841">sives with metabolic syndrome. Hypertension. 2014;</a></text>
<text top="614" left="584" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref841">64:709</a></text>
<text top="613" left="614" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref841">–16</a></text>
<text top="614" left="627" width="3" height="9" font="4">.</text>
<text top="632" left="584" width="32" height="9" font="4">S9.7-13.</text>
<text top="632" left="619" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref842">Reisin E, Owen J. Treatment: special condi-</a></text>
<text top="645" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref842">tions. Metabolic syndrome: obesity and the hyperten-</a></text>
<text top="659" left="584" width="205" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref842">sion connection. J Am Soc Hypertens. 2015;9:156</a></text>
<text top="657" left="789" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref842">–9;</a></text>
<text top="672" left="584" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref842">quiz 160</a></text>
<text top="672" left="618" width="3" height="9" font="4">.</text>
<text top="694" left="584" width="100" height="9" font="23">9.8. Atrial Fibrillation</text>
<text top="718" left="584" width="28" height="9" font="4">S9.8-1.</text>
<text top="718" left="615" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref843">Healey JS, Baranchuk A, Crystal E, et al.</a></text>
<text top="731" left="584" width="87" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref843">Prevention of atrial</a></text>
<text top="730" left="678" width="123" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref843">ﬁbrillation with angiotensin-</a></text>
<text top="745" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref843">converting enzyme inhibitors and angiotensin recep-</a></text>
<text top="758" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref843">tor blockers: a meta-analysis. J Am Coll Cardiol. 2005;</a></text>
<text top="772" left="584" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref843">45:1832</a></text>
<text top="770" left="616" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref843">–9</a></text>
<text top="772" left="626" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref843">.</a></text>
<text top="791" left="584" width="29" height="9" font="4">S9.8-2.</text>
<text top="791" left="616" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref844">Zhao D, Wang Z-M, Wang L-S. Prevention of</a></text>
<text top="804" left="584" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref844">atrial</a></text>
<text top="803" left="610" width="191" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref844">ﬁbrillation with renin-angiotensin system in-</a></text>
<text top="818" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref844">hibitors on essential hypertensive patients: a meta-</a></text>
<text top="831" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref844">analysis of randomized controlled trials. J Biomed</a></text>
<text top="845" left="584" width="70" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref844">Res. 2015;29:475</a></text>
<text top="843" left="654" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref844">–85</a></text>
<text top="845" left="668" width="3" height="9" font="4">.</text>
<text top="863" left="584" width="29" height="9" font="4">S9.8-3.</text>
<text top="863" left="616" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref845">Kistler PM, Sanders P, Fynn SP, et al. Elec-</a></text>
<text top="877" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref845">trophysiologic and electroanatomic changes in the</a></text>
<text top="890" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref845">human atrium associated with age. J Am Coll Cardiol.</a></text>
<text top="904" left="584" width="54" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref845">2004;44:109</a></text>
<text top="902" left="638" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref845">–16</a></text>
<text top="904" left="651" width="3" height="9" font="4">.</text>
<text top="923" left="584" width="30" height="9" font="4">S9.8-4.</text>
<text top="923" left="617" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref846">January CT, Wann LS, Alpert JS, et al. 2014</a></text>
<text top="936" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref846">AHA/ACC/HRS guideline for the management of pa-</a></text>
<text top="950" left="584" width="67" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref846">tients with atrial</a></text>
<text top="948" left="654" width="147" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref846">ﬁbrillation: a report of the American</a></text>
<text top="963" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref846">College of Cardiology/American Heart Association Task</a></text>
<text top="977" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref846">Force on Practice Guidelines and the Heart Rhythm</a></text>
<text top="990" left="584" width="154" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref846">Society. J Am Coll Cardiol. 2014;64:e1</a></text>
<text top="988" left="738" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref846">–76</a></text>
<text top="990" left="753" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref846">.</a></text>
<text top="1009" left="584" width="29" height="9" font="4">S9.8-5.</text>
<text top="1009" left="616" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref847">Olesen JB, Torp-Pedersen C, Hansen ML, et al.</a></text>
<text top="1023" left="584" width="194" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref847">The value of the CHA2DS2-VASc score for re</a></text>
<text top="1021" left="779" width="23" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref847">ﬁning</a></text>
<text top="1036" left="584" width="65" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref847">stroke risk strati</a></text>
<text top="1034" left="650" width="152" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref847">ﬁcation in patients with atrial ﬁbrilla-</a></text>
<text top="1049" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref847">tion with a CHADS2 score 0-1: a nationwide cohort</a></text>
<text top="1063" left="584" width="158" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref847">study. Thromb Haemost. 2012;107:1172</a></text>
<text top="1061" left="742" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref847">–9</a></text>
<text top="1063" left="752" width="3" height="9" font="4">.</text>
<text top="1082" left="584" width="30" height="9" font="4">S9.8-6.</text>
<text top="1082" left="617" width="134" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref848">Healey JS, Connolly SJ. Atrial</a></text>
<text top="1080" left="758" width="44" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref848">ﬁbrillation:</a></text>
<text top="1095" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref848">hypertension as a causative agent, risk factor for</a></text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="20" height="9" font="4">e230</text>
</page>
<page number="105" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref848">complications, and potential therapeutic target. Am J</a></text>
<text top="156" left="63" width="81" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref848">Cardiol. 2003;91:9G</a></text>
<text top="155" left="144" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref848">–14G</a></text>
<text top="156" left="163" width="3" height="9" font="4">.</text>
<text top="176" left="63" width="29" height="9" font="4">S9.8-7.</text>
<text top="176" left="95" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref849">Hansson L, Lindholm LH, Ekbom T, et al.</a></text>
<text top="189" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref849">Randomised trial of old and new antihypertensive</a></text>
<text top="203" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref849">drugs in elderly patients: cardiovascular mortality and</a></text>
<text top="216" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref849">morbidity. The Swedish Trial in Old Patients with</a></text>
<text top="230" left="63" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref849">Hypertension-2 study. Lancet. 1999;354:1751</a></text>
<text top="228" left="245" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref849">–6</a></text>
<text top="230" left="254" width="3" height="9" font="4">.</text>
<text top="249" left="63" width="30" height="9" font="4">S9.8-8.</text>
<text top="249" left="96" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref850">Julius S, Kjeldsen SE, Weber M, et al.</a></text>
<text top="263" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref850">Outcomes in hypertensive patients at high cardiovas-</a></text>
<text top="276" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref850">cular risk treated with regimens based on valsartan or</a></text>
<text top="290" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref850">amlodipine: the VALUE randomised trial. Lancet.</a></text>
<text top="303" left="63" width="63" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref850">2004;363:2022</a></text>
<text top="301" left="126" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref850">–31</a></text>
<text top="303" left="139" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref850">.</a></text>
<text top="322" left="63" width="30" height="9" font="4">S9.8-9.</text>
<text top="322" left="96" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref851">Wachtell K, Lehto M, Gerdts E, et al. Angio-</a></text>
<text top="336" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref851">tensin II receptor blockade reduces new-onset atrial</a></text>
<text top="348" left="63" width="217" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref851">ﬁbrillation and subsequent stroke compared to aten-</a></text>
<text top="363" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref851">olol: the Losartan Intervention For End Point Reduc-</a></text>
<text top="376" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref851">tion in Hypertension (LIFE) study. J Am Coll Cardiol.</a></text>
<text top="390" left="63" width="50" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref851">2005;45:712</a></text>
<text top="388" left="113" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref851">–9</a></text>
<text top="390" left="123" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref851">.</a></text>
<text top="409" left="63" width="34" height="9" font="4">S9.8-10.</text>
<text top="409" left="100" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref852">Haywood LJ, Ford CE, Crow RS, et al. Atrial</a></text>
<text top="421" left="63" width="217" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref852">ﬁbrillation at baseline and during follow-up in ALLHAT</a></text>
<text top="436" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref852">(Antihypertensive and Lipid-Lowering Treatment to</a></text>
<text top="450" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref852">Prevent Heart Attack Trial). J Am Coll Cardiol. 2009;</a></text>
<text top="463" left="63" width="33" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref852">54:2023</a></text>
<text top="461" left="96" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref852">–31</a></text>
<text top="463" left="109" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref852">.</a></text>
<text top="482" left="63" width="32" height="9" font="4">S9.8-11.</text>
<text top="482" left="98" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref853">Hansson L, Lindholm LH, Niskanen L, et al.</a></text>
<text top="496" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref853">Effect of angiotensin-converting-enzyme inhibition</a></text>
<text top="509" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref853">compared with conventional therapy on cardiovascular</a></text>
<text top="523" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref853">morbidity and mortality in hypertension: the Captopril</a></text>
<text top="536" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref853">Prevention Project (CAPPP) randomised trial. Lancet.</a></text>
<text top="550" left="63" width="53" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref853">1999;353:611</a></text>
<text top="548" left="116" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref853">–6</a></text>
<text top="550" left="126" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref853">.</a></text>
<text top="571" left="63" width="124" height="9" font="23">9.9. Valvular Heart Disease</text>
<text top="596" left="63" width="28" height="9" font="4">S9.9-1.</text>
<text top="596" left="94" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref854">Rieck ÅE, Cramariuc D, Boman K, et al. Hy-</a></text>
<text top="609" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref854">pertension in aortic stenosis: implications for left</a></text>
<text top="623" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref854">ventricular structure and cardiovascular events. Hy-</a></text>
<text top="636" left="63" width="96" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref854">pertension. 2012;60:90</a></text>
<text top="635" left="159" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref854">–7</a></text>
<text top="636" left="167" width="3" height="9" font="4">.</text>
<text top="656" left="63" width="29" height="9" font="4">S9.9-2.</text>
<text top="656" left="95" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref855">Eleid MF, Nishimura RA, Sorajja P, et al. Sys-</a></text>
<text top="669" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref855">temic hypertension in low-gradient severe aortic ste-</a></text>
<text top="683" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref855">nosis with preserved ejection fraction. Circulation.</a></text>
<text top="696" left="63" width="58" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref855">2013;128:1349</a></text>
<text top="695" left="121" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref855">–53</a></text>
<text top="696" left="135" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref855">.</a></text>
<text top="716" left="63" width="29" height="9" font="4">S9.9-3.</text>
<text top="716" left="95" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref856">Bull</a></text>
<text top="716" left="119" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref856">S,</a></text>
<text top="716" left="135" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref856">Loudon</a></text>
<text top="716" left="174" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref856">M,</a></text>
<text top="716" left="193" width="28" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref856">Francis</a></text>
<text top="716" left="230" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref856">JM,</a></text>
<text top="716" left="253" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref856">et</a></text>
<text top="716" left="270" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref856">al.</a></text>
<text top="729" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref856">A prospective, double-blind, randomized controlled</a></text>
<text top="743" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref856">trial of the angiotensin-converting enzyme inhibitor</a></text>
<text top="756" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref856">Ramipril In Aortic Stenosis (RIAS trial). Eur Heart J</a></text>
<text top="769" left="63" width="133" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref856">Cardiovasc Imaging. 2015;16:834</a></text>
<text top="768" left="196" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref856">–41</a></text>
<text top="769" left="209" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref856">.</a></text>
<text top="789" left="63" width="30" height="9" font="4">S9.9-4.</text>
<text top="789" left="96" width="56" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref857">Chockalingam</a></text>
<text top="789" left="174" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref857">A,</a></text>
<text top="789" left="204" width="46" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref857">Venkatesan</a></text>
<text top="789" left="273" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref857">S,</a></text>
<text top="802" left="63" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref857">Subramaniam T, et al. Safety and ef</a></text>
<text top="801" left="240" width="39" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref857">ﬁcacy of</a></text>
<text top="816" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref857">angiotensin-converting enzyme inhibitors in symp-</a></text>
<text top="829" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref857">tomatic severe aortic stenosis: Symptomatic Cardiac</a></text>
<text top="843" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref857">Obstruction-Pilot Study of Enalapril in Aortic Stenosis</a></text>
<text top="856" left="63" width="159" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref857">(SCOPE-AS). Am Heart J. 2004;147:E19</a></text>
<text top="856" left="222" width="3" height="9" font="4">.</text>
<text top="876" left="63" width="29" height="9" font="4">S9.9-5.</text>
<text top="876" left="95" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref858">Scognamiglio R, Rahimtoola SH, Fasoli G, et al.</a></text>
<text top="889" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref858">Nifedipine in asymptomatic patients with severe aortic</a></text>
<text top="903" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref858">regurgitation and normal left ventricular function.</a></text>
<text top="916" left="63" width="116" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref858">N Engl J Med. 1994;331:689</a></text>
<text top="914" left="178" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref858">–94</a></text>
<text top="916" left="193" width="3" height="9" font="4">.</text>
<text top="935" left="63" width="30" height="9" font="4">S9.9-6.</text>
<text top="935" left="96" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref859">Evangelista A, Tornos P, Sambola A, et al.</a></text>
<text top="949" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref859">Long-term vasodilator therapy in patients with severe</a></text>
<text top="962" left="63" width="203" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref859">aortic regurgitation. N Engl J Med. 2005;353:1342</a></text>
<text top="961" left="266" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref859">–9</a></text>
<text top="962" left="276" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref859">.</a></text>
<text top="984" left="63" width="90" height="9" font="23">9.10. Aortic Disease</text>
<text top="1009" left="63" width="32" height="9" font="4">S9.10-1.</text>
<text top="1009" left="98" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref860">Genoni M, Paul M, Jenni R, et al. Chronic</a></text>
<text top="1022" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref860">beta-blocker therapy improves outcome and reduces</a></text>
<text top="1036" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref860">treatment costs in chronic type B aortic dissection. Eur</a></text>
<text top="1049" left="63" width="137" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref860">J Cardiothorac Surg. 2001;19:606</a></text>
<text top="1047" left="200" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref860">–10</a></text>
<text top="1049" left="213" width="3" height="9" font="4">.</text>
<text top="1068" left="63" width="33" height="9" font="4">S9.10-2.</text>
<text top="1068" left="99" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref861">Suzuki T, Isselbacher EM, Nienaber CA, et al.</a></text>
<text top="1082" left="63" width="80" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref861">Type-selective bene</a></text>
<text top="1080" left="143" width="137" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref861">ﬁts of medications in treatment of</a></text>
<text top="1095" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref861">acute aortic dissection (from the International Registry</a></text>
<text top="143" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref861">of Acute Aortic Dissection [IRAD]). Am J Cardiol. 2012;</a></text>
<text top="156" left="301" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref861">109:122</a></text>
<text top="155" left="333" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref861">–7</a></text>
<text top="156" left="341" width="3" height="9" font="4">.</text>
<text top="175" left="301" width="33" height="9" font="4">S9.10-3.</text>
<text top="175" left="337" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref862">Masuda Y, Yamada Z, Morooka N, et al.</a></text>
<text top="188" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref862">Prognosis of patients with medically treated aortic</a></text>
<text top="202" left="301" width="144" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref862">dissections. Circulation. 1991;84:III7</a></text>
<text top="200" left="445" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref862">–13</a></text>
<text top="202" left="458" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref862">.</a></text>
<text top="220" left="301" width="34" height="9" font="4">S9.10-4.</text>
<text top="220" left="338" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref863">Rampoldi V, Trimarchi S, Eagle KA, et al.</a></text>
<text top="234" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref863">Simple risk models to predict surgical mortality</a></text>
<text top="247" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref863">in acute type A aortic dissection: the International</a></text>
<text top="261" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref863">Registry of Acute Aortic Dissection score. Ann Thorac</a></text>
<text top="274" left="301" width="70" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref863">Surg. 2007;83:55</a></text>
<text top="273" left="371" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref863">–61</a></text>
<text top="274" left="385" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref863">.</a></text>
<text top="293" left="301" width="33" height="9" font="4">S9.10-5.</text>
<text top="293" left="337" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref864">Suzuki T, Mehta RH, Ince H, et al. Clinical</a></text>
<text top="306" left="301" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref864">pro</a></text>
<text top="305" left="314" width="204" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref864">ﬁles and outcomes of acute type B aortic dissection</a></text>
<text top="320" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref864">in the current era: lessons from the International</a></text>
<text top="333" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref864">Registry of Aortic Dissection (IRAD). Circulation. 2003;</a></text>
<text top="347" left="301" width="68" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref864">108 suppl 1:II312</a></text>
<text top="345" left="369" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref864">–I317</a></text>
<text top="347" left="388" width="3" height="9" font="4">.</text>
<text top="365" left="301" width="34" height="9" font="4">S9.10-6.</text>
<text top="365" left="338" width="58" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref865">Mehta RH, O</a></text>
<text top="363" left="396" width="122" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref865">’Gara PT, Bossone E, et al.</a></text>
<text top="379" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref865">Acute type A aortic dissection in the elderly: clinical</a></text>
<text top="392" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref865">characteristics, management, and outcomes in the</a></text>
<text top="405" left="301" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref865">current era. J Am Coll Cardiol. 2002;40:685</a></text>
<text top="404" left="480" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref865">–92</a></text>
<text top="405" left="495" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref865">.</a></text>
<text top="424" left="301" width="33" height="9" font="4">S9.10-7.</text>
<text top="424" left="337" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref866">Chan KK, Lai P, Wright JM. First-line</a></text>
<text top="437" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref866">beta-blockers versus other antihypertensive medica-</a></text>
<text top="451" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref866">tions for chronic type B aortic dissection. Cochrane</a></text>
<text top="464" left="301" width="153" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref866">Database Syst Rev. 2014;2:CD010426</a></text>
<text top="464" left="454" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref866">.</a></text>
<text top="483" left="301" width="34" height="9" font="4">S9.10-8.</text>
<text top="483" left="338" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">Hiratzka LF, Bakris GL, Beckman JA, et al.</a></text>
<text top="496" left="301" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">2010</a></text>
<text top="496" left="333" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/</a></text>
<text top="510" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">SVM guidelines for the diagnosis and management of</a></text>
<text top="523" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">patients with thoracic aortic disease. a report of the</a></text>
<text top="537" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">American College of Cardiology Foundation/American</a></text>
<text top="550" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">Heart Association Task Force on Practice Guidelines,</a></text>
<text top="564" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">American Association for Thoracic Surgery, American</a></text>
<text top="577" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">College of Radiology, American Stroke Association,</a></text>
<text top="590" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">Society of Cardiovascular Anesthesiologists, Society</a></text>
<text top="604" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">for Cardiovascular Angiography and Interventions,</a></text>
<text top="617" left="301" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">Society</a></text>
<text top="617" left="339" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">of</a></text>
<text top="617" left="356" width="56" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">Interventional</a></text>
<text top="617" left="421" width="42" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">Radiology,</a></text>
<text top="617" left="472" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">Society</a></text>
<text top="617" left="510" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">of</a></text>
<text top="631" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">Thoracic Surgeons, and Society for Vascular Medicine.</a></text>
<text top="644" left="301" width="125" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">J Am Coll Cardiol. 2010;55:e27</a></text>
<text top="643" left="426" width="18" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref867">–129</a></text>
<text top="644" left="444" width="3" height="9" font="4">.</text>
<text top="663" left="301" width="34" height="9" font="4">S9.10-9.</text>
<text top="663" left="338" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref868">Gaddum NR, Keehn L, Guilcher A, et al.</a></text>
<text top="676" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref868">Altered dependence of aortic pulse wave velocity</a></text>
<text top="690" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref868">on transmural pressure in hypertension revealing</a></text>
<text top="703" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref868">structural change in the aortic wall. Hypertension.</a></text>
<text top="717" left="301" width="50" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref868">2015;65:362</a></text>
<text top="715" left="351" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref868">–9</a></text>
<text top="717" left="361" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref868">.</a></text>
<text top="735" left="301" width="38" height="9" font="4">S9.10-10.</text>
<text top="735" left="342" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref869">Zhang L, Tian W, Feng R, et al. Prognostic</a></text>
<text top="749" left="301" width="27" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref869">impact</a></text>
<text top="749" left="337" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref869">of</a></text>
<text top="749" left="354" width="23" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref869">blood</a></text>
<text top="749" left="386" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref869">pressure</a></text>
<text top="749" left="429" width="39" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref869">variability</a></text>
<text top="749" left="477" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref869">on</a></text>
<text top="749" left="496" width="23" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref869">aortic</a></text>
<text top="762" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref869">dissection patients after endovascular therapy. Medi-</a></text>
<text top="775" left="301" width="128" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref869">cine (Baltimore). 2015;94:e1591</a></text>
<text top="775" left="429" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref869">.</a></text>
<text top="825" left="301" width="189" height="12" font="26">1 0 . S P E C I A L P A T I E N T G R O U P S</text>
<text top="854" left="301" width="110" height="9" font="23">10.1. Race and Ethnicity</text>
<text top="877" left="301" width="31" height="9" font="4">S10.1-1.</text>
<text top="877" left="335" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref870">Yoon SSS, Carroll MD, Fryar CD. Hypertension</a></text>
<text top="891" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref870">prevalence and control among adults: United States,</a></text>
<text top="904" left="301" width="145" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref870">2011-2014. NCHS Data Brief. 2015:1</a></text>
<text top="903" left="446" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref870">–8</a></text>
<text top="904" left="455" width="3" height="9" font="4">.</text>
<text top="923" left="301" width="31" height="9" font="4">S10.1-2.</text>
<text top="923" left="335" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref871">Margolis KL, Piller LB, Ford CE, et al. Blood</a></text>
<text top="936" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref871">pressure control in Hispanics in the antihypertensive</a></text>
<text top="950" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref871">and lipid-lowering treatment to prevent heart attack</a></text>
<text top="963" left="301" width="134" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref871">trial. Hypertension. 2007;50:854</a></text>
<text top="961" left="435" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref871">–61</a></text>
<text top="963" left="448" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref871">.</a></text>
<text top="982" left="301" width="31" height="9" font="4">S10.1-3.</text>
<text top="982" left="335" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref872">Cooper-DeHoff RM, Aranda JM Jr., Gaxiola E,</a></text>
<text top="995" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref872">et al. Blood pressure control and cardiovascular</a></text>
<text top="1008" left="301" width="159" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref872">outcomes in high-risk Hispanic patients</a></text>
<text top="1007" left="460" width="58" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref872">–ﬁndings from</a></text>
<text top="1022" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref872">the International Verapamil SR/Trandolapril Study</a></text>
<text top="1035" left="301" width="151" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref872">(INVEST). Am Heart J. 2006;151:1072</a></text>
<text top="1034" left="452" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref872">–9</a></text>
<text top="1035" left="462" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref872">.</a></text>
<text top="1054" left="301" width="32" height="9" font="4">S10.1-4.</text>
<text top="1054" left="336" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref873">Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart</a></text>
<text top="1067" left="301" width="119" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref873">disease and stroke statistics</a></text>
<text top="1066" left="420" width="98" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref873">–2017 update: a report</a></text>
<text top="1081" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref873">from the American Heart Association. Circulation.</a></text>
<text top="1094" left="301" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref873">2017;135:e146</a></text>
<text top="1093" left="358" width="21" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref873">–603</a></text>
<text top="1094" left="379" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref873">.</a></text>
<text top="143" left="539" width="217" height="9" font="4">S10.1-5. Centers for Disease Control and Prevention.</text>
<text top="156" left="539" width="217" height="9" font="4">Compressed Mortality File: Underlying Cause-of-Death</text>
<text top="170" left="539" width="132" height="9" font="4">1999-2013. 2014. Available at:</text>
<text top="170" left="677" width="79" height="9" font="8"><a href="https://wonder.cdc.gov/mortsql.html">https://wonder.cdc.</a></text>
<text top="183" left="539" width="70" height="9" font="8"><a href="https://wonder.cdc.gov/mortsql.html">gov/mortsql.html</a></text>
<text top="183" left="610" width="121" height="9" font="4"><a href="https://wonder.cdc.gov/mortsql.html">. </a>Accessed November 2, 2017.</text>
<text top="204" left="539" width="32" height="9" font="4">S10.1-6.</text>
<text top="204" left="575" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref875">Guzman NJ. Epidemiology and management</a></text>
<text top="217" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref875">of hypertension in the Hispanic population: a review of</a></text>
<text top="231" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref875">the available literature. Am J Cardiovasc Drugs. Am J</a></text>
<text top="244" left="539" width="122" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref875">Cardiovasc Drugs. 2012;12:165</a></text>
<text top="243" left="661" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref875">–78</a></text>
<text top="244" left="675" width="3" height="9" font="4">.</text>
<text top="265" left="539" width="31" height="9" font="4">S10.1-7.</text>
<text top="265" left="574" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref876">Sorlie PD, Allison MA, Aviles-Santa ML, et al.</a></text>
<text top="278" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref876">Prevalence of hypertension, awareness, treatment,</a></text>
<text top="292" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref876">and control in the Hispanic Community Health Study/</a></text>
<text top="305" left="539" width="191" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref876">Study of Latinos. Am J Hypertens. 2014;27:793</a></text>
<text top="304" left="730" width="22" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref876">–800</a></text>
<text top="305" left="752" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref876">.</a></text>
<text top="326" left="539" width="32" height="9" font="4">S10.1-8.</text>
<text top="326" left="575" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref877">Rodriguez CJ, Allison M, Daviglus ML, et al.</a></text>
<text top="339" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref877">Status of cardiovascular disease and stroke in</a></text>
<text top="353" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref877">Hispanics/Latinos in the United States: a science</a></text>
<text top="366" left="539" width="33" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref877">advisory</a></text>
<text top="366" left="582" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref877">from</a></text>
<text top="366" left="610" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref877">the</a></text>
<text top="366" left="632" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref877">American</a></text>
<text top="366" left="678" width="22" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref877">Heart</a></text>
<text top="366" left="709" width="48" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref877">Association.</a></text>
<text top="380" left="539" width="103" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref877">Circulation. 2014;130:593</a></text>
<text top="378" left="642" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref877">–625</a></text>
<text top="380" left="662" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref877">.</a></text>
<text top="400" left="539" width="32" height="9" font="4">S10.1-9.</text>
<text top="400" left="575" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref878">Parsa A, Kao WHL, Xie D, et al. APOL1</a></text>
<text top="414" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref878">risk variants, race, and progression of chronic kidney</a></text>
<text top="427" left="539" width="154" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref878">disease. N Engl J Med. 2013;369:2183</a></text>
<text top="425" left="693" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref878">–96</a></text>
<text top="427" left="708" width="3" height="9" font="4">.</text>
<text top="448" left="539" width="36" height="9" font="4">S10.1-10.</text>
<text top="448" left="579" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref879">Lipkowitz MS, Freedman BI, Langefeld CD,</a></text>
<text top="461" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref879">et al. Apolipoprotein L1 gene variants associate with</a></text>
<text top="475" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref879">hypertension-attributed nephropathy and the rate of</a></text>
<text top="488" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref879">kidney function decline in African Americans. Kidney</a></text>
<text top="501" left="539" width="64" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref879">Int. 2013;83:114</a></text>
<text top="500" left="604" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref879">–20</a></text>
<text top="501" left="619" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref879">.</a></text>
<text top="522" left="539" width="34" height="9" font="4">S10.1-11.</text>
<text top="522" left="577" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref880">Langefeld CD, Divers J, Pajewski NM, et al.</a></text>
<text top="535" left="539" width="77" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref880">Apolipoprotein L1</a></text>
<text top="535" left="625" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref880">gene</a></text>
<text top="535" left="653" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref880">variants</a></text>
<text top="535" left="694" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref880">associate</a></text>
<text top="535" left="739" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref880">with</a></text>
<text top="549" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref880">prevalent kidney but not prevalent cardiovascular</a></text>
<text top="562" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref880">disease in the Systolic Blood Pressure Intervention</a></text>
<text top="576" left="539" width="119" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref880">Trial. Kidney Int. 2015;87:169</a></text>
<text top="574" left="659" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref880">–75</a></text>
<text top="576" left="672" width="3" height="9" font="4">.</text>
<text top="596" left="539" width="35" height="9" font="4">S10.1-12.</text>
<text top="596" left="578" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref881">Grams ME, Rebholz CM, Chen Y, et al.</a></text>
<text top="610" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref881">Race, APOL1 risk, and eGFR decline in the general</a></text>
<text top="623" left="539" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref881">population. J Am Soc Nephrol. 2016;27:2842</a></text>
<text top="622" left="721" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref881">–50</a></text>
<text top="623" left="736" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref881">.</a></text>
<text top="654" left="539" width="27" height="9" font="4">10.1.1.</text>
<text top="654" left="578" width="27" height="9" font="4">Racial</text>
<text top="654" left="617" width="17" height="9" font="4">and</text>
<text top="654" left="645" width="29" height="9" font="4">Ethnic</text>
<text top="654" left="685" width="51" height="9" font="4">Differences</text>
<text top="654" left="748" width="9" height="9" font="4">in</text>
<text top="667" left="539" width="47" height="9" font="4">Treatment</text>
<text top="683" left="539" width="37" height="9" font="4">S10.1.1-1.</text>
<text top="683" left="579" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref882">Leenen FHH, Nwachuku CE, Black HR, et al.</a></text>
<text top="697" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref882">Clinical events in high-risk hypertensive patients</a></text>
<text top="710" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref882">randomly assigned to calcium channel blocker versus</a></text>
<text top="724" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref882">angiotensin-converting enzyme inhibitor in the anti-</a></text>
<text top="737" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref882">hypertensive and lipid-lowering treatment to prevent</a></text>
<text top="750" left="539" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref882">heart attack trial. Hypertension. 2006;48:374</a></text>
<text top="749" left="724" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref882">–84</a></text>
<text top="750" left="739" width="3" height="9" font="4">.</text>
<text top="771" left="539" width="38" height="9" font="4">S10.1.1-2.</text>
<text top="771" left="580" width="85" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref883">Wright JT Jr., Probst</a></text>
<text top="769" left="665" width="91" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref883">ﬁeld JL, Cushman WC,</a></text>
<text top="784" left="539" width="61" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref883">et al. ALLHAT</a></text>
<text top="783" left="605" width="151" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref883">ﬁndings revisited in the context of</a></text>
<text top="798" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref883">subsequent analyses, other trials, and meta-analyses.</a></text>
<text top="811" left="539" width="129" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref883">Arch Intern Med. 2009;169:832</a></text>
<text top="810" left="668" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref883">–42</a></text>
<text top="811" left="682" width="3" height="9" font="4">.</text>
<text top="832" left="539" width="38" height="9" font="4">S10.1.1-3.</text>
<text top="832" left="580" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref884">Wright JT Jr., Dunn JK, Cutler JA, et al.</a></text>
<text top="845" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref884">Outcomes in hypertensive black and nonblack patients</a></text>
<text top="859" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref884">treated with chlorthalidone, amlodipine, and lisinopril.</a></text>
<text top="872" left="539" width="90" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref884">JAMA. 2005;293:1595</a></text>
<text top="871" left="629" width="21" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref884">–608</a></text>
<text top="872" left="650" width="3" height="9" font="4">.</text>
<text top="893" left="539" width="39" height="9" font="4">S10.1.1-4.</text>
<text top="893" left="581" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref885">Wright JT Jr., Harris-Haywood S, Pressel S,</a></text>
<text top="906" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref885">et al. Clinical outcomes by race in hypertensive pa-</a></text>
<text top="920" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref885">tients with and without the metabolic syndrome:</a></text>
<text top="933" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref885">Antihypertensive and Lipid-Lowering Treatment to</a></text>
<text top="947" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref885">Prevent Heart Attack Trial (ALLHAT). Arch Intern Med.</a></text>
<text top="960" left="539" width="58" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref885">2008;168:207</a></text>
<text top="958" left="598" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref885">–17</a></text>
<text top="960" left="610" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref885">.</a></text>
<text top="981" left="539" width="38" height="9" font="4">S10.1.1-5.</text>
<text top="981" left="580" width="46" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref886">ALLHAT Of</a></text>
<text top="979" left="626" width="130" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref886">ﬁcers and Coordinators for the</a></text>
<text top="994" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref886">ALLHAT Collaborative Research Group. Major out-</a></text>
<text top="1008" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref886">comes in high-risk hypertensive patients randomized</a></text>
<text top="1021" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref886">to angiotensin-converting enzyme inhibitor or calcium</a></text>
<text top="1034" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref886">channel blocker vs diuretic: The Antihypertensive and</a></text>
<text top="1048" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref886">Lipid-Lowering Treatment to Prevent Heart Attack</a></text>
<text top="1061" left="539" width="156" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref886">Trial (ALLHAT). JAMA. 2002;288:2981</a></text>
<text top="1060" left="695" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref886">–97</a></text>
<text top="1061" left="709" width="3" height="9" font="4">.</text>
<text top="1082" left="539" width="39" height="9" font="4">S10.1.1-6.</text>
<text top="1082" left="581" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref887">Wright JT Jr., Williamson JD, Whelton PK,</a></text>
<text top="1095" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref887">et al. A randomized trial of intensive versus standard</a></text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="790" width="18" height="9" font="4">e231</text>
</page>
<page number="106" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref887">blood-pressure control. SPRINT Research Group.</a></text>
<text top="156" left="108" width="118" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref887">N Engl J Med. 2015;373:2103</a></text>
<text top="155" left="226" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref887">–16</a></text>
<text top="156" left="239" width="3" height="9" font="4">.</text>
<text top="176" left="108" width="38" height="9" font="4">S10.1.1-7.</text>
<text top="176" left="148" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref888">Wright JT Jr., Bakris G, Greene T, et al.</a></text>
<text top="189" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref888">Effect of blood pressure lowering and antihypertensive</a></text>
<text top="203" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref888">drug class on progression of hypertensive kidney</a></text>
<text top="216" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref888">disease: results from the AASK trial. JAMA. 2002;288:</a></text>
<text top="230" left="108" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref888">2421</a></text>
<text top="228" left="126" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref888">–31</a></text>
<text top="230" left="139" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref888">.</a></text>
<text top="249" left="108" width="39" height="9" font="4">S10.1.1-8.</text>
<text top="249" left="149" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref889">Odedosu T, Schoenthaler A, Vieira DL, et al.</a></text>
<text top="263" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref889">Overcoming barriers to hypertension control in African</a></text>
<text top="276" left="108" width="165" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref889">Americans. Cleve Clin J Med. 2012;79:46</a></text>
<text top="275" left="273" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref889">–56</a></text>
<text top="276" left="287" width="3" height="9" font="4">.</text>
<text top="296" left="108" width="39" height="9" font="4">S10.1.1-9.</text>
<text top="296" left="149" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref890">Ferdinand KC. Management of high blood</a></text>
<text top="309" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref890">pressure in African Americans and the 2010 ISHIB</a></text>
<text top="323" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref890">consensus statement: meeting an unmet need. J Clin</a></text>
<text top="336" left="108" width="146" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref890">Hypertens (Greenwich). 2010;12:237</a></text>
<text top="335" left="254" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref890">–9</a></text>
<text top="336" left="263" width="3" height="9" font="4">.</text>
<text top="356" left="108" width="43" height="9" font="4">S10.1.1-10.</text>
<text top="356" left="153" width="171" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref891">Flack JM, Sica DA, Bakris G, et al. Man-</a></text>
<text top="369" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref891">agement of high blood pressure in blacks: an update of</a></text>
<text top="383" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref891">the International Society on Hypertension in Blacks</a></text>
<text top="396" left="108" width="213" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref891">consensus statement. Hypertension. 2010;56:780</a></text>
<text top="394" left="321" width="4" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref891">–</a></text>
<text top="410" left="108" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref891">800</a></text>
<text top="410" left="125" width="3" height="9" font="4">.</text>
<text top="429" left="108" width="41" height="9" font="4">S10.1.1-11.</text>
<text top="429" left="151" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref892">Jamerson K, DeQuattro V. The impact of</a></text>
<text top="443" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref892">ethnicity on response to antihypertensive therapy. Am</a></text>
<text top="456" left="108" width="84" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref892">J Med. 1996;101:22S</a></text>
<text top="454" left="191" width="18" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref892">–32S</a></text>
<text top="456" left="210" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref892">.</a></text>
<text top="477" left="108" width="42" height="9" font="4">S10.1.1-12.</text>
<text top="477" left="152" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref893">Saunders E, Weir MR, Kong BW, et al.</a></text>
<text top="491" left="108" width="99" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref893">A comparison of the ef</a></text>
<text top="489" left="206" width="118" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref893">ﬁcacy and safety of a beta-</a></text>
<text top="504" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref893">blocker, a calcium channel blocker, and a converting</a></text>
<text top="517" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref893">enzyme inhibitor in hypertensive blacks. Arch Intern</a></text>
<text top="531" left="108" width="83" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref893">Med. 1990;150:1707</a></text>
<text top="529" left="190" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref893">–13</a></text>
<text top="531" left="203" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref893">.</a></text>
<text top="550" left="108" width="42" height="9" font="4">S10.1.1-13.</text>
<text top="550" left="152" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref894">Cushman WC, Reda DJ, Perry HM, et al.</a></text>
<text top="564" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref894">Regional and racial differences in response to antihy-</a></text>
<text top="577" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref894">pertensive medication use in a randomized controlled</a></text>
<text top="591" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref894">trial of men with hypertension in the United States.</a></text>
<text top="604" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref894">Department of Veterans Affairs Cooperative Study</a></text>
<text top="618" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref894">Group on Antihypertensive Agents. Arch Intern Med.</a></text>
<text top="631" left="108" width="59" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref894">2000;160:825</a></text>
<text top="630" left="167" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref894">–31</a></text>
<text top="631" left="179" width="3" height="9" font="4">.</text>
<text top="651" left="108" width="43" height="9" font="4">S10.1.1-14.</text>
<text top="651" left="153" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref895">Brewster</a></text>
<text top="651" left="202" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref895">LM,</a></text>
<text top="651" left="229" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref895">van</a></text>
<text top="651" left="256" width="41" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref895">Montfrans</a></text>
<text top="651" left="310" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref895">GA,</a></text>
<text top="664" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref895">Kleijnen J. Systematic review: antihypertensive drug</a></text>
<text top="678" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref895">therapy in black patients. Ann Intern Med. 2004;141:</a></text>
<text top="691" left="108" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref895">614</a></text>
<text top="689" left="122" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref895">–27</a></text>
<text top="691" left="136" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref895">.</a></text>
<text top="711" left="108" width="42" height="9" font="4">S10.1.1-15.</text>
<text top="711" left="152" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref896">Zanchetti A, Julius S, Kjeldsen S, et al.</a></text>
<text top="724" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref896">Outcomes in subgroups of hypertensive patients</a></text>
<text top="738" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref896">treated with regimens based on valsartan and amlo-</a></text>
<text top="751" left="108" width="88" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref896">dipine: an analysis of</a></text>
<text top="749" left="199" width="125" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref896">ﬁndings from the VALUE trial.</a></text>
<text top="764" left="108" width="111" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref896">J Hypertens. 2006;24:2163</a></text>
<text top="763" left="218" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref896">–8</a></text>
<text top="764" left="228" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref896">.</a></text>
<text top="786" left="108" width="42" height="9" font="4">S10.1.1-16.</text>
<text top="786" left="153" width="172" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref897">Jamerson K, Weber MA, Bakris GL, et al.</a></text>
<text top="799" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref897">Benazepril plus amlodipine or hydrochlorothiazide for</a></text>
<text top="812" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref897">hypertension in high-risk patients. N Engl J Med.</a></text>
<text top="826" left="108" width="62" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref897">2008;359:2417</a></text>
<text top="824" left="169" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref897">–28</a></text>
<text top="826" left="184" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref897">.</a></text>
<text top="845" left="108" width="42" height="9" font="4">S10.1.1-17.</text>
<text top="845" left="152" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref898">Woo KS, Nicholls MG. High prevalence of</a></text>
<text top="859" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref898">persistent cough with angiotensin converting enzyme</a></text>
<text top="872" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref898">inhibitors in Chinese. Br J Clin Pharmacol. 1995;40:</a></text>
<text top="886" left="108" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref898">141</a></text>
<text top="884" left="120" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref898">–4</a></text>
<text top="886" left="130" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref898">.</a></text>
<text top="907" left="108" width="42" height="9" font="4">S10.1.1-18.</text>
<text top="907" left="153" width="172" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref899">Czernichow S, Zanchetti A, Turnbull F,</a></text>
<text top="920" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref899">et al. The effects of blood pressure reduction and of</a></text>
<text top="934" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref899">different blood pressure-lowering regimens on major</a></text>
<text top="947" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref899">cardiovascular events according to baseline blood</a></text>
<text top="961" left="108" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref899">pressure:</a></text>
<text top="961" left="156" width="55" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref899">meta-analysis</a></text>
<text top="961" left="223" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref899">of</a></text>
<text top="961" left="244" width="47" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref899">randomized</a></text>
<text top="961" left="302" width="22" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref899">trials.</a></text>
<text top="974" left="108" width="93" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref899">J Hypertens. 2011;29:4</a></text>
<text top="972" left="201" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref899">–16</a></text>
<text top="974" left="214" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref899">.</a></text>
<text top="995" left="108" width="42" height="9" font="4">S10.1.1-19.</text>
<text top="995" left="153" width="172" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref900">Fretheim A, Odgaard-Jensen J, Brors O,</a></text>
<text top="1009" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref900">et al. Comparative effectiveness of antihypertensive</a></text>
<text top="1022" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref900">medication for primary prevention of cardiovascular</a></text>
<text top="1035" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref900">disease: systematic review and multiple treatments</a></text>
<text top="1049" left="108" width="149" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref900">meta-analysis. BMC Med. 2012;10:33</a></text>
<text top="1049" left="256" width="3" height="9" font="4">.</text>
<text top="1068" left="108" width="44" height="9" font="4">S10.1.1-20.</text>
<text top="1068" left="154" width="170" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref901">Jafar TH, Stark PC, Schmid CH, et al. Pro-</a></text>
<text top="1082" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref901">gression of chronic kidney disease: the role of blood</a></text>
<text top="1095" left="108" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref901">pressure</a></text>
<text top="1095" left="152" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref901">control,</a></text>
<text top="1095" left="193" width="46" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref901">proteinuria,</a></text>
<text top="1095" left="250" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref901">and</a></text>
<text top="1095" left="275" width="50" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref901">angiotensin-</a></text>
<text top="143" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref901">converting enzyme inhibition: a patient-level meta-</a></text>
<text top="156" left="346" width="162" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref901">analysis. Ann Intern Med. 2003;139:244</a></text>
<text top="155" left="508" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref901">–52</a></text>
<text top="156" left="521" width="3" height="9" font="4">.</text>
<text top="175" left="346" width="42" height="9" font="4">S10.1.1-21.</text>
<text top="175" left="391" width="172" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref902">Law MR, Morris JK, Wald NJ. Use of blood</a></text>
<text top="188" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref902">pressure lowering drugs in the prevention of cardio-</a></text>
<text top="202" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref902">vascular disease: meta-analysis of 147 randomised</a></text>
<text top="215" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref902">trials in the context of expectations from prospective</a></text>
<text top="229" left="346" width="190" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref902">epidemiological studies. BMJ. 2009;338:b1665</a></text>
<text top="229" left="536" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref902">.</a></text>
<text top="250" left="346" width="109" height="9" font="23">10.2. Sex-Related Issues</text>
<text top="274" left="346" width="31" height="9" font="4">S10.2-1.</text>
<text top="274" left="380" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref903">Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart</a></text>
<text top="288" left="346" width="119" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref903">disease and stroke statistics</a></text>
<text top="286" left="465" width="98" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref903">–2017 update: a report</a></text>
<text top="301" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref903">from the American Heart Association. Circulation.</a></text>
<text top="315" left="346" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref903">2017;135:e146</a></text>
<text top="313" left="403" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref903">–603</a></text>
<text top="315" left="423" width="3" height="9" font="4">.</text>
<text top="333" left="346" width="32" height="9" font="4">S10.2-2.</text>
<text top="333" left="381" width="23" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref904">Gueyf</a></text>
<text top="331" left="405" width="158" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref904">ﬁer F, Boutitie F, Boissel JP, et al. Effect</a></text>
<text top="347" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref904">of antihypertensive drug treatment on cardiovascular</a></text>
<text top="360" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref904">outcomes in women and men. A meta-analysis of in-</a></text>
<text top="373" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref904">dividual patient data from randomized, controlled tri-</a></text>
<text top="387" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref904">als. The INDANA Investigators. Ann Intern Med. 1997;</a></text>
<text top="400" left="346" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref904">126:761</a></text>
<text top="399" left="377" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref904">–7</a></text>
<text top="400" left="385" width="3" height="9" font="4">.</text>
<text top="419" left="346" width="32" height="9" font="4">S10.2-3.</text>
<text top="419" left="381" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref905">Turnbull F, Woodward M, Neal B, et al. Do</a></text>
<text top="432" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref905">men and women respond differently to blood</a></text>
<text top="446" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref905">pressure-lowering treatment? Results of prospectively</a></text>
<text top="459" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref905">designed overviews of randomized trials. Eur Heart J.</a></text>
<text top="473" left="346" width="60" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref905">2008;29:2669</a></text>
<text top="471" left="406" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref905">–80</a></text>
<text top="473" left="421" width="3" height="9" font="4">.</text>
<text top="494" left="346" width="66" height="9" font="4">10.2.1. Women</text>
<text top="509" left="346" width="38" height="9" font="4">S10.2.1-1.</text>
<text top="509" left="387" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref906">Turnbull F, Woodward M, Neal B, et al. Do</a></text>
<text top="523" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref906">men and women respond differently to blood</a></text>
<text top="536" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref906">pressure-lowering treatment? Results of prospectively</a></text>
<text top="550" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref906">designed overviews of randomized trials. Eur Heart J.</a></text>
<text top="563" left="346" width="60" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref906">2008;29:2669</a></text>
<text top="561" left="406" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref906">–80</a></text>
<text top="563" left="421" width="3" height="9" font="4">.</text>
<text top="581" left="346" width="39" height="9" font="4">S10.2.1-2.</text>
<text top="581" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref907">Wenger NK, Ferdinand KC, Bairey Merz CN,</a></text>
<text top="595" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref907">et al. Women, hypertension, and the Systolic Blood</a></text>
<text top="608" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref907">Pressure Intervention Trial. Am J Med. 2016;129:</a></text>
<text top="622" left="346" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref907">1030</a></text>
<text top="620" left="367" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref907">–6</a></text>
<text top="622" left="376" width="3" height="9" font="4">.</text>
<text top="640" left="346" width="39" height="9" font="4">S10.2.1-3.</text>
<text top="640" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref908">Fletcher A, Beevers DG, Bulpitt C, et al.</a></text>
<text top="654" left="346" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref908">Beta</a></text>
<text top="654" left="373" width="53" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref908">adrenoceptor</a></text>
<text top="654" left="435" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref908">blockade</a></text>
<text top="654" left="480" width="6" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref908">is</a></text>
<text top="654" left="495" width="41" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref908">associated</a></text>
<text top="654" left="545" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref908">with</a></text>
<text top="667" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref908">increased survival in male but not female hyperten-</a></text>
<text top="681" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref908">sive patients: a report from the DHSS Hypertension</a></text>
<text top="694" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref908">Care Computing Project (DHCCP). J Hum Hypertens.</a></text>
<text top="708" left="346" width="45" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref908">1988;2:219</a></text>
<text top="706" left="391" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref908">–27</a></text>
<text top="708" left="404" width="3" height="9" font="4">.</text>
<text top="726" left="346" width="40" height="9" font="4">S10.2.1-4.</text>
<text top="726" left="388" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref909">Jansen J, Bonner C, McKinn S, et al. General</a></text>
<text top="740" left="346" width="50" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref909">practitioners</a></text>
<text top="738" left="396" width="167" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref909">’ use of absolute risk versus individual risk</a></text>
<text top="753" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref909">factors in cardiovascular disease prevention: an</a></text>
<text top="766" left="346" width="198" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref909">experimental study. BMJ OPEN. 2014;4:e004812</a></text>
<text top="766" left="544" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref909">.</a></text>
<text top="785" left="346" width="39" height="9" font="4">S10.2.1-5.</text>
<text top="785" left="388" width="153" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref910">Lewis CE, Grandits A, Flack J, et al. Ef</a></text>
<text top="783" left="540" width="23" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref910">ﬁcacy</a></text>
<text top="798" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref910">and tolerance of antihypertensive treatment in men</a></text>
<text top="812" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref910">and women with stage 1 diastolic hypertension. Re-</a></text>
<text top="825" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref910">sults of the Treatment of Mild Hypertension Study.</a></text>
<text top="839" left="346" width="125" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref910">Arch Intern Med. 1996;156:377</a></text>
<text top="837" left="471" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref910">–85</a></text>
<text top="839" left="485" width="3" height="9" font="4">.</text>
<text top="857" left="346" width="39" height="9" font="4">S10.2.1-6.</text>
<text top="857" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref911">Kloner RA, Sowers JR, DiBona GF, et al. Sex-</a></text>
<text top="871" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref911">and age-related antihypertensive effects of amlodi-</a></text>
<text top="884" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref911">pine. The Amlodipine Cardiovascular Community Trial</a></text>
<text top="898" left="346" width="160" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref911">Study Group. Am J Cardiol. 1996;77:713</a></text>
<text top="896" left="506" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref911">–22</a></text>
<text top="898" left="520" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref911">.</a></text>
<text top="916" left="346" width="39" height="9" font="4">S10.2.1-7.</text>
<text top="916" left="388" width="76" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref912">Igho Pemu P, O</a></text>
<text top="915" left="463" width="100" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref912">ﬁli E. Hypertension in</a></text>
<text top="930" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref912">women: part I. J Clin Hypertens (Greenwich). 2008;10:</a></text>
<text top="943" left="346" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref912">406</a></text>
<text top="941" left="363" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref912">–10</a></text>
<text top="943" left="377" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref912">.</a></text>
<text top="965" left="346" width="79" height="9" font="4">10.2.2. Pregnancy</text>
<text top="980" left="346" width="39" height="9" font="4">S10.2.2-1.</text>
<text top="980" left="388" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref913">James PR, Nelson-Piercy C. Management of</a></text>
<text top="993" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref913">hypertension before, during, and after pregnancy.</a></text>
<text top="1007" left="346" width="87" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref913">Heart. 2004;90:1499</a></text>
<text top="1005" left="433" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref913">–504</a></text>
<text top="1007" left="453" width="3" height="9" font="4">.</text>
<text top="1025" left="346" width="40" height="9" font="4">S10.2.2-2.</text>
<text top="1025" left="388" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref914">American College of Obstetricians and Gy-</a></text>
<text top="1039" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref914">necologists, Task Force on Hypertension in Pregnancy.</a></text>
<text top="1052" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref914">Hypertension in pregnancy. Report of the American</a></text>
<text top="1065" left="346" width="170" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref914">College of Obstetricians and Gynecologists</a></text>
<text top="1064" left="516" width="47" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref914">’ Task Force</a></text>
<text top="1079" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref914">on Hypertension in Pregnancy. Obstet Gynecol. 2013;</a></text>
<text top="1092" left="346" width="33" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref914">122:1122</a></text>
<text top="1091" left="379" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref914">–31</a></text>
<text top="1092" left="392" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref914">.</a></text>
<text top="143" left="584" width="40" height="9" font="4">S10.2.2-3.</text>
<text top="143" left="627" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref915">National Clinical Guideline Centre (UK).</a></text>
<text top="156" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref915">Hypertension: The Clinical Management of Primary</a></text>
<text top="170" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref915">Hypertension in Adults: Update of Clinical Guidelines</a></text>
<text top="183" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref915">18 and 34. London, UK: Royal College of Physicians</a></text>
<text top="197" left="584" width="42" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref915">(UK); 2011</a></text>
<text top="197" left="626" width="3" height="9" font="4">.</text>
<text top="215" left="584" width="40" height="9" font="4">S10.2.2-4.</text>
<text top="215" left="628" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref916">Pucci M, Sarween N, Knox E, et al. Angio-</a></text>
<text top="229" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref916">tensin-converting enzyme inhibitors and angiotensin</a></text>
<text top="242" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref916">receptor blockers in women of childbearing age: risks</a></text>
<text top="256" left="584" width="49" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref916">versus bene</a></text>
<text top="254" left="633" width="168" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref916">ﬁts. Expert Rev Clin Pharmacol. 2015;8:</a></text>
<text top="269" left="584" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref916">221</a></text>
<text top="268" left="598" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref916">–31</a></text>
<text top="269" left="610" width="3" height="9" font="4">.</text>
<text top="288" left="584" width="40" height="9" font="4">S10.2.2-5.</text>
<text top="288" left="627" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref917">Moretti ME, Caprara D, Drehuta I, et al.</a></text>
<text top="301" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref917">The fetal safety of angiotensin converting enzyme</a></text>
<text top="315" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref917">inhibitors and angiotensin II receptor blockers. Obstet</a></text>
<text top="328" left="584" width="126" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref917">Gynecol Int. 2012;2012:658310</a></text>
<text top="328" left="711" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref917">.</a></text>
<text top="347" left="584" width="40" height="9" font="4">S10.2.2-6.</text>
<text top="347" left="628" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref918">Ferrer RL, Sibai BM, Mulrow CD, et al.</a></text>
<text top="360" left="584" width="52" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref918">Management</a></text>
<text top="360" left="651" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref918">of</a></text>
<text top="360" left="674" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref918">mild</a></text>
<text top="360" left="706" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref918">chronic</a></text>
<text top="360" left="749" width="52" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref918">hypertension</a></text>
<text top="373" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref918">during pregnancy: a review. Obstet Gynecol. 2000;96:</a></text>
<text top="387" left="584" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref918">849</a></text>
<text top="385" left="601" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref918">–60</a></text>
<text top="387" left="616" width="3" height="9" font="4">.</text>
<text top="405" left="584" width="40" height="9" font="4">S10.2.2-7.</text>
<text top="405" left="627" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref919">Garovic VD, August P. Preeclampsia and</a></text>
<text top="419" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref919">the future risk of hypertension: the pregnant evidence.</a></text>
<text top="432" left="584" width="130" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref919">Curr Hypertens Rep. 2013;15:114</a></text>
<text top="431" left="715" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref919">–21</a></text>
<text top="432" left="727" width="3" height="9" font="4">.</text>
<text top="451" left="584" width="40" height="9" font="4">S10.2.2-8.</text>
<text top="451" left="628" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref920">Kessous R, Shoham-Vardi I, Pariente G,</a></text>
<text top="464" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref920">et al. Long-term maternal atherosclerotic morbidity in</a></text>
<text top="478" left="584" width="196" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref920">women with pre-eclampsia. Heart. 2015;101:442</a></text>
<text top="476" left="780" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref920">–6</a></text>
<text top="478" left="789" width="3" height="9" font="4">.</text>
<text top="496" left="584" width="40" height="9" font="4">S10.2.2-9.</text>
<text top="496" left="628" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref921">Veerbeek JHW, Hermes W, Breimer AY,</a></text>
<text top="510" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref921">et al. Cardiovascular disease risk factors after</a></text>
<text top="523" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref921">early-onset preeclampsia, late-onset preeclampsia,</a></text>
<text top="537" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref921">and pregnancy-induced hypertension. Hypertension.</a></text>
<text top="550" left="584" width="53" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref921">2015;65:600</a></text>
<text top="548" left="637" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref921">–6</a></text>
<text top="550" left="647" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref921">.</a></text>
<text top="569" left="584" width="45" height="9" font="4">S10.2.2-10.</text>
<text top="569" left="632" width="170" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref922">Abalos E, Duley L, Steyn DW. Antihyper-</a></text>
<text top="582" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref922">tensive drug therapy for mild to moderate hypertension</a></text>
<text top="596" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref922">during pregnancy. Cochrane Database Syst Rev. 2014;2:</a></text>
<text top="609" left="584" width="43" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref922">CD002252</a></text>
<text top="609" left="627" width="3" height="9" font="4">.</text>
<text top="628" left="584" width="43" height="9" font="4">S10.2.2-11.</text>
<text top="628" left="630" width="172" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref923">Nabhan AF, Elsedawy MM. Tight control</a></text>
<text top="641" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref923">of mild-moderate pre-existing or non-proteinuric</a></text>
<text top="654" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref923">gestational hypertension. Cochrane Database Syst</a></text>
<text top="668" left="584" width="87" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref923">Rev.. 2011CD006907</a></text>
<text top="668" left="671" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref923">.</a></text>
<text top="686" left="584" width="43" height="9" font="4">S10.2.2-12.</text>
<text top="686" left="631" width="171" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref924">Magee LA, Duley L. Oral beta-blockers for</a></text>
<text top="700" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref924">mild to moderate hypertension during pregnancy.</a></text>
<text top="713" left="584" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref924">Cochrane Database Syst Rev. 2003CD002863</a></text>
<text top="713" left="770" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref924">.</a></text>
<text top="732" left="584" width="43" height="9" font="4">S10.2.2-13.</text>
<text top="732" left="631" width="171" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref925">Magee LA, von Dadelszen P, Rey E, et al.</a></text>
<text top="745" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref925">Less-tight versus tight control of hypertension in</a></text>
<text top="759" left="584" width="162" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref925">pregnancy. N Engl J Med. 2015;372:407</a></text>
<text top="757" left="746" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref925">–17</a></text>
<text top="759" left="758" width="3" height="9" font="4">.</text>
<text top="777" left="584" width="44" height="9" font="4">S10.2.2-14.</text>
<text top="777" left="632" width="170" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref926">Duley L, Meher S, Jones L. Drugs for</a></text>
<text top="791" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref926">treatment of very high blood pressure during</a></text>
<text top="804" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref926">pregnancy. Cochrane Database Syst Rev. 2013;7:</a></text>
<text top="818" left="584" width="44" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref926">CD001449</a></text>
<text top="818" left="628" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref926">.</a></text>
<text top="836" left="584" width="43" height="9" font="4">S10.2.2-15.</text>
<text top="836" left="631" width="88" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref927">Gulati M. Early identi</a></text>
<text top="834" left="719" width="82" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref927">ﬁcation of pregnant</a></text>
<text top="850" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref927">women at risk for preeclampsia: USPSTF recommen-</a></text>
<text top="863" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref927">dations on screening for preeclampsia. JAMA Cardiol.</a></text>
<text top="876" left="584" width="45" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref927">2017;2:593</a></text>
<text top="875" left="629" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref927">–5</a></text>
<text top="876" left="638" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref927">.</a></text>
<text top="895" left="584" width="44" height="9" font="4">S10.2.2-16.</text>
<text top="895" left="632" width="170" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref928">Henderson JT, Thompson JH, Burda BU,</a></text>
<text top="908" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref928">et al. Preeclampsia screening: evidence report and</a></text>
<text top="922" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref928">systematic review for the US Preventive Services Task</a></text>
<text top="935" left="584" width="114" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref928">Force. JAMA. 2017;317:1668</a></text>
<text top="934" left="698" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref928">–83</a></text>
<text top="935" left="713" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref928">.</a></text>
<text top="954" left="584" width="43" height="9" font="4">S10.2.2-17.</text>
<text top="954" left="631" width="65" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref929">Regitz-Zagrosek</a></text>
<text top="954" left="709" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref929">V,</a></text>
<text top="954" left="731" width="44" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref929">Blomstrom</a></text>
<text top="954" left="789" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref929">LC,</a></text>
<text top="967" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref929">Borghi C, et al. ESC Guidelines on the management</a></text>
<text top="981" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref929">of cardiovascular diseases during pregnancy: the</a></text>
<text top="994" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref929">Task Force on the Management of Cardiovascular</a></text>
<text top="1008" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref929">Diseases during Pregnancy of the European Society of</a></text>
<text top="1021" left="584" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref929">Cardiology (ESC). Eur Heart J. 2011;32:3147</a></text>
<text top="1020" left="759" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref929">–97</a></text>
<text top="1021" left="774" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref929">.</a></text>
<text top="1040" left="584" width="44" height="9" font="4">S10.2.2-18.</text>
<text top="1040" left="632" width="44" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref930">Committee</a></text>
<text top="1040" left="690" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref930">on</a></text>
<text top="1040" left="716" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref930">Obstetric</a></text>
<text top="1040" left="767" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref930">Practice.</a></text>
<text top="1053" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref930">Committee Opinion No. 623: Emergent therapy for</a></text>
<text top="1067" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref930">acute-onset, severe hypertension during pregnancy</a></text>
<text top="1080" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref930">and the postpartum period. Obstet Gynecol. 2015;125:</a></text>
<text top="1093" left="584" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref930">521</a></text>
<text top="1092" left="598" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref930">–5</a></text>
<text top="1093" left="607" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref930">.</a></text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="19" height="9" font="4">e232</text>
</page>
<page number="107" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="44" height="9" font="4">S10.2.2-19.</text>
<text top="143" left="110" width="170" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref931">Shimada C, Akaishi R, Cho K, et al. Out-</a></text>
<text top="156" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref931">comes of 83 fetuses exposed to angiotensin receptor</a></text>
<text top="170" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref931">blockers during the second or third trimesters: a</a></text>
<text top="183" left="63" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref931">literature review. Hypertens Res. 2015;38:308</a></text>
<text top="182" left="249" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref931">–13</a></text>
<text top="183" left="262" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref931">.</a></text>
<text top="205" left="63" width="110" height="9" font="23">10.3. Age-Related Issues</text>
<text top="227" left="63" width="95" height="9" font="4">10.3.1. Older Persons</text>
<text top="243" left="63" width="38" height="9" font="4">S10.3.1-1.</text>
<text top="243" left="103" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref932">Williamson JD, Supiano MA, Applegate WB,</a></text>
<text top="256" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref932">et al. Intensive vs standard blood pressure control and</a></text>
<text top="270" left="63" width="196" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref932">cardiovascular disease outcomes in adults aged</a></text>
<text top="268" left="263" width="17" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref932">$75</a></text>
<text top="283" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref932">years: a randomized clinical trial. JAMA. 2016;315:</a></text>
<text top="297" left="63" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref932">2673</a></text>
<text top="295" left="83" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref932">–82</a></text>
<text top="297" left="97" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref932">.</a></text>
<text top="316" left="63" width="39" height="9" font="4">S10.3.1-2.</text>
<text top="316" left="104" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref933">Ettinger WH Jr., Fried LP, Harris T, et al. Self-</a></text>
<text top="329" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref933">reported causes of physical disability in older people:</a></text>
<text top="342" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref933">the Cardiovascular Health Study. CHS Collaborative</a></text>
<text top="356" left="63" width="192" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref933">Research Group. J Am Geriatr Soc. 1994;42:1035</a></text>
<text top="354" left="255" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref933">–44</a></text>
<text top="356" left="270" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref933">.</a></text>
<text top="375" left="63" width="39" height="9" font="4">S10.3.1-3.</text>
<text top="375" left="104" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref934">Ferrucci L, Guralnik JM, Pahor M, et al.</a></text>
<text top="388" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref934">Hospital diagnoses, Medicare charges, and nursing</a></text>
<text top="402" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref934">home admissions in the year when older persons</a></text>
<text top="415" left="63" width="191" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref934">become severely disabled. JAMA. 1997;277:728</a></text>
<text top="414" left="254" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref934">–34</a></text>
<text top="415" left="268" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref934">.</a></text>
<text top="434" left="63" width="40" height="9" font="4">S10.3.1-4.</text>
<text top="434" left="105" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref935">den Ouden MEM, Schuurmans MJ, Mueller-</a></text>
<text top="448" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref935">Schotte S, et al. Do subclinical vascular abnormalities</a></text>
<text top="461" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref935">precede impaired physical ability and ADL disability?</a></text>
<text top="475" left="63" width="98" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref935">Exp Gerontol. 2014;58:1</a></text>
<text top="473" left="160" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref935">–7</a></text>
<text top="475" left="169" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref935">.</a></text>
<text top="494" left="63" width="39" height="9" font="4">S10.3.1-5.</text>
<text top="494" left="104" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref936">Ezzati M, Lopez AD, Rodgers A, et al.</a></text>
<text top="507" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref936">Selected major risk factors and global and regional</a></text>
<text top="521" left="63" width="171" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref936">burden of disease. Lancet. 2002;360:1347</a></text>
<text top="519" left="234" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref936">–60</a></text>
<text top="521" left="249" width="3" height="9" font="4">.</text>
<text top="540" left="63" width="39" height="9" font="4">S10.3.1-6.</text>
<text top="540" left="105" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref937">Duprez DA. Systolic hypertension in the</a></text>
<text top="553" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref937">elderly: addressing an unmet need. Am J Med. 2008;</a></text>
<text top="567" left="63" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref937">121:179</a></text>
<text top="565" left="92" width="27" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref937">–84.e3</a></text>
<text top="567" left="119" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref937">.</a></text>
<text top="586" left="63" width="39" height="9" font="4">S10.3.1-7.</text>
<text top="586" left="104" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref938">Egan BM, Li J, Hutchison FN, et al. Hyper-</a></text>
<text top="599" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref938">tension in the United States, 1999 to 2012: progress</a></text>
<text top="612" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref938">toward Healthy People 2020 goals. Circulation. 2014;</a></text>
<text top="626" left="63" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref938">130:1692</a></text>
<text top="624" left="100" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref938">–9</a></text>
<text top="626" left="109" width="3" height="9" font="4">.</text>
<text top="645" left="63" width="39" height="9" font="4">S10.3.1-8.</text>
<text top="645" left="105" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref939">Liu X, Rodriguez CJ, Wang K. Prevalence</a></text>
<text top="658" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref939">and trends of isolated systolic hypertension among</a></text>
<text top="672" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref939">untreated adults in the United States. J Am Soc</a></text>
<text top="685" left="63" width="91" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref939">Hypertens. 2015;9:197</a></text>
<text top="684" left="153" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref939">–205</a></text>
<text top="685" left="173" width="3" height="9" font="4">.</text>
<text top="704" left="63" width="39" height="9" font="4">S10.3.1-9.</text>
<text top="704" left="105" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref940">Prevention of stroke by antihypertensive</a></text>
<text top="718" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref940">drug treatment in older persons with isolated systolic</a></text>
<text top="731" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref940">hypertension. Final results of the Systolic Hyperten-</a></text>
<text top="745" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref940">sion in the Elderly Program (SHEP). SHEP Cooperative</a></text>
<text top="758" left="63" width="156" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref940">Research Group. JAMA. 1991;265:3255</a></text>
<text top="756" left="218" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref940">–64</a></text>
<text top="758" left="233" width="3" height="9" font="4">.</text>
<text top="777" left="63" width="44" height="9" font="4">S10.3.1-10.</text>
<text top="777" left="109" width="170" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref941">Staessen JA, Fagard R, Thijs L, et al.</a></text>
<text top="791" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref941">Randomised double-blind comparison of placebo and</a></text>
<text top="804" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref941">active treatment for older patients with isolated sys-</a></text>
<text top="817" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref941">tolic hypertension. The Systolic Hypertension in</a></text>
<text top="831" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref941">Europe (Syst-Eur) Trial Investigators. Lancet. 1997;</a></text>
<text top="844" left="63" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref941">350:757</a></text>
<text top="843" left="95" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref941">–64</a></text>
<text top="844" left="110" width="3" height="9" font="4">.</text>
<text top="863" left="63" width="42" height="9" font="4">S10.3.1-11.</text>
<text top="863" left="107" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref942">Liu L, Wang JG, Gong L, et al. Comparison</a></text>
<text top="877" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref942">of active treatment and placebo in older Chinese pa-</a></text>
<text top="890" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref942">tients with isolated systolic hypertension. Systolic</a></text>
<text top="904" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref942">Hypertension in China (Syst-China) Collaborative</a></text>
<text top="917" left="63" width="137" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref942">Group. J Hypertens. 1998;16:1823</a></text>
<text top="916" left="200" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref942">–9</a></text>
<text top="917" left="210" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref942">.</a></text>
<text top="936" left="63" width="43" height="9" font="4">S10.3.1-12.</text>
<text top="936" left="108" width="172" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref943">Beckett NS, Peters R, Fletcher AE, et al.</a></text>
<text top="950" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref943">Treatment of hypertension in patients 80 years of age</a></text>
<text top="963" left="63" width="160" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref943">or older. N Engl J Med. 2008;358:1887</a></text>
<text top="962" left="223" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref943">–98</a></text>
<text top="963" left="238" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref943">.</a></text>
<text top="982" left="63" width="43" height="9" font="4">S10.3.1-13.</text>
<text top="982" left="108" width="172" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref944">Tinetti ME, Han L, Lee DSH, et al. Antihy-</a></text>
<text top="996" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref944">pertensive medications and serious fall injuries in a</a></text>
<text top="1009" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref944">nationally representative sample of older adults. JAMA</a></text>
<text top="1023" left="63" width="105" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref944">Intern Med. 2014;174:588</a></text>
<text top="1021" left="168" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref944">–95</a></text>
<text top="1023" left="182" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref944">.</a></text>
<text top="1042" left="63" width="43" height="9" font="4">S10.3.1-14.</text>
<text top="1042" left="109" width="171" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref945">Warwick J, Falaschetti E, Rockwood K,</a></text>
<text top="1055" left="63" width="150" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref945">et al. No evidence that frailty modi</a></text>
<text top="1053" left="213" width="67" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref945">ﬁes the positive</a></text>
<text top="1069" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref945">impact of antihypertensive treatment in very elderly</a></text>
<text top="1082" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref945">people: an investigation of the impact of frailty upon</a></text>
<text top="1095" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref945">treatment effect in the HYpertension in the Very</a></text>
<text top="143" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref945">Elderly Trial (HYVET) study, a double-blind, placebo-</a></text>
<text top="156" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref945">controlled study of antihypertensives in people with</a></text>
<text top="170" left="301" width="215" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref945">hypertension aged 80 and over. BMC Med. 2015;13:78</a></text>
<text top="170" left="516" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref945">.</a></text>
<text top="190" left="301" width="43" height="9" font="4">S10.3.1-15.</text>
<text top="190" left="347" width="172" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref946">Gangavati A, Hajjar I, Quach L, et al. Hy-</a></text>
<text top="204" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref946">pertension, orthostatic hypotension, and the risk of</a></text>
<text top="217" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref946">falls in a community-dwelling elderly population: the</a></text>
<text top="231" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref946">maintenance of balance, independent living, intellect,</a></text>
<text top="244" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref946">and zest in the elderly of Boston study. J Am Geriatr</a></text>
<text top="257" left="301" width="69" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref946">Soc. 2011;59:383</a></text>
<text top="256" left="370" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref946">–9</a></text>
<text top="257" left="379" width="3" height="9" font="4">.</text>
<text top="278" left="301" width="43" height="9" font="4">S10.3.1-16.</text>
<text top="278" left="347" width="171" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref947">Margolis KL, Palermo L, Vittinghoff E, et al.</a></text>
<text top="291" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref947">Intensive blood pressure control, falls, and fractures in</a></text>
<text top="305" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref947">patients with type 2 diabetes: the ACCORD trial. J Gen</a></text>
<text top="318" left="301" width="105" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref947">Intern Med. 2014;29:1599</a></text>
<text top="317" left="406" width="21" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref947">–606</a></text>
<text top="318" left="428" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref947">.</a></text>
<text top="339" left="301" width="43" height="9" font="4">S10.3.1-17.</text>
<text top="339" left="347" width="172" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref948">Bavishi C, Bangalore S, Messerli FH. Out-</a></text>
<text top="352" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref948">comes of intensive blood pressure lowering in older</a></text>
<text top="365" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref948">hypertensive patients. J Am Coll Cardiol. 2017;69:</a></text>
<text top="379" left="301" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref948">486</a></text>
<text top="377" left="318" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref948">–93</a></text>
<text top="379" left="332" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref948">.</a></text>
<text top="399" left="301" width="43" height="9" font="4">S10.3.1-18.</text>
<text top="399" left="347" width="171" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref949">Gibbons CH, Schmidt P, Biaggioni I, et al.</a></text>
<text top="413" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref949">The recommendations of a consensus panel for the</a></text>
<text top="426" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref949">screening, diagnosis, and treatment of neurogenic</a></text>
<text top="440" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref949">orthostatic hypotension and associated supine hyper-</a></text>
<text top="453" left="301" width="133" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref949">tension. J Neurol. 2017;264:1567</a></text>
<text top="451" left="434" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref949">–82</a></text>
<text top="453" left="449" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref949">.</a></text>
<text top="475" left="301" width="149" height="9" font="4">10.3.2. Children and Adolescents</text>
<text top="491" left="301" width="39" height="9" font="4">S10.3.2-1.</text>
<text top="491" left="343" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref950">Moser M, Roccella EJ. The treatment of</a></text>
<text top="505" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref950">hypertension: a remarkable success story. J Clin</a></text>
<text top="518" left="301" width="142" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref950">Hypertens (Greenwich). 2013;15:88</a></text>
<text top="517" left="443" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref950">–91</a></text>
<text top="518" left="456" width="3" height="9" font="4">.</text>
<text top="539" left="301" width="40" height="9" font="4">S10.3.2-2.</text>
<text top="539" left="344" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref951">Integrated Guidelines for Cardiovascular</a></text>
<text top="552" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref951">Health and Risk Reduction in Children and Adoles-</a></text>
<text top="566" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref951">cents: Summary Report. Bethesda, MD: National Heart,</a></text>
<text top="579" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref951">Lung, and Blood Institute, U.S. Department of Health</a></text>
<text top="592" left="301" width="117" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref951">and Human Services, 2012:S1</a></text>
<text top="591" left="418" width="100" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref951">–44. NIH Publication No.</a></text>
<text top="606" left="301" width="9" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref951">12</a></text>
<text top="604" left="310" width="25" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref951">–7486</a></text>
<text top="606" left="335" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref951">.</a></text>
<text top="626" left="301" width="40" height="9" font="4">S10.3.2-3.</text>
<text top="626" left="344" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref952">Expert Panel on Integrated Guidelines for</a></text>
<text top="640" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref952">Cardiovascular Health and Risk Reduction in Children</a></text>
<text top="653" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref952">and Adolescents, National Heart, Lung, and Blood</a></text>
<text top="667" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref952">Institute. Integrated guidelines for cardiovascular</a></text>
<text top="680" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref952">health and risk reduction in children and adolescents:</a></text>
<text top="694" left="301" width="200" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref952">summary report. Pediatrics. 2011;128 suppl 5:S213</a></text>
<text top="692" left="501" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref952">–56</a></text>
<text top="694" left="516" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref952">.</a></text>
<text top="714" left="301" width="40" height="9" font="4">S10.3.2-4.</text>
<text top="714" left="344" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref953">Chobanian AV, Bakris GL, Black HR, et al.,</a></text>
<text top="727" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref953">the National High Blood Pressure Education Program</a></text>
<text top="741" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref953">Coordinating Committee. Seventh Report of the Joint</a></text>
<text top="754" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref953">National Committee on Prevention, Detection, Evalu-</a></text>
<text top="768" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref953">ation, and Treatment of High Blood Pressure. Hyper-</a></text>
<text top="781" left="301" width="92" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref953">tension. 2003;42:1206</a></text>
<text top="780" left="393" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref953">–52</a></text>
<text top="781" left="407" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref953">.</a></text>
<text top="801" left="301" width="40" height="9" font="4">S10.3.2-5.</text>
<text top="801" left="344" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref954">Flynn JT, Daniels SR, Hayman LL, et al. Up-</a></text>
<text top="815" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref954">date: ambulatory blood pressure monitoring in children</a></text>
<text top="828" left="301" width="101" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref954">and adolescents: a scienti</a></text>
<text top="827" left="402" width="116" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref954">ﬁc statement from the Amer-</a></text>
<text top="842" left="301" width="199" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref954">ican Heart Association. Hypertension. 2014;63:1116</a></text>
<text top="840" left="500" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref954">–35</a></text>
<text top="842" left="513" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref954">.</a></text>
<text top="862" left="301" width="40" height="9" font="4">S10.3.2-6.</text>
<text top="862" left="344" width="6" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref955">O</a></text>
<text top="861" left="351" width="167" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref955">’Brien E, Parati G, Stergiou G, et al. Euro-</a></text>
<text top="876" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref955">pean Society of Hypertension position paper on</a></text>
<text top="889" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref955">ambulatory blood pressure monitoring. J Hypertens.</a></text>
<text top="903" left="301" width="50" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref955">2013;31:1731</a></text>
<text top="901" left="351" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref955">–68</a></text>
<text top="903" left="366" width="3" height="9" font="4">.</text>
<text top="923" left="301" width="40" height="9" font="4">S10.3.2-7.</text>
<text top="923" left="344" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref956">Flynn JT, Kaelber DC, Baker-Smith CM,</a></text>
<text top="936" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref956">et al. Clinical practice guideline for screening and</a></text>
<text top="950" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref956">management of high blood pressure in children and</a></text>
<text top="963" left="301" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref956">adolescents. Pediatrics. 2017;140:e20171904</a></text>
<text top="963" left="482" width="3" height="9" font="4">.</text>
<text top="1003" left="301" width="179" height="12" font="26">1 1 . O T H E R C O N S I D E R A T I O N S</text>
<text top="1029" left="301" width="129" height="9" font="23">11.1. Resistant Hypertension</text>
<text top="1055" left="301" width="28" height="9" font="4">S11.1-1.</text>
<text top="1055" left="333" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref957">Calhoun DA, Jones D, Textor S, et al. Resistant</a></text>
<text top="1068" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref957">hypertension: diagnosis, evaluation, and treatment: a</a></text>
<text top="1082" left="301" width="26" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref957">scienti</a></text>
<text top="1080" left="327" width="191" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref957">ﬁc statement from the American Heart Associ-</a></text>
<text top="1095" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref957">ation Professional Education Committee of the Council</a></text>
<text top="143" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref957">for High Blood Pressure Research. Hypertension.</a></text>
<text top="156" left="539" width="56" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref957">2008;51:1403</a></text>
<text top="155" left="596" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref957">–19</a></text>
<text top="156" left="609" width="3" height="9" font="4">.</text>
<text top="175" left="539" width="29" height="9" font="4">S11.1-2.</text>
<text top="175" left="572" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref958">Persell SD. Prevalence of resistant hyperten-</a></text>
<text top="189" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref958">sion in the United States, 2003-2008. Hypertension.</a></text>
<text top="202" left="539" width="53" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref958">2011;57:1076</a></text>
<text top="200" left="592" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref958">–80</a></text>
<text top="202" left="608" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref958">.</a></text>
<text top="221" left="539" width="29" height="9" font="4">S11.1-3.</text>
<text top="221" left="572" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref959">Achelrod D, Wenzel U, Frey S. Systematic</a></text>
<text top="234" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref959">review and meta-analysis of the prevalence of resis-</a></text>
<text top="248" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref959">tant hypertension in treated hypertensive populations.</a></text>
<text top="261" left="539" width="119" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref959">Am J Hypertens. 2015;28:355</a></text>
<text top="259" left="659" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref959">–61</a></text>
<text top="261" left="672" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref959">.</a></text>
<text top="280" left="539" width="30" height="9" font="4">S11.1-4.</text>
<text top="280" left="573" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref960">Smith SM, Huo T, Delia Johnson B, et al.</a></text>
<text top="293" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref960">Cardiovascular and mortality risk of apparent resistant</a></text>
<text top="307" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref960">hypertension in women with suspected myocardial</a></text>
<text top="320" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref960">ischemia: a report from the NHLBI-sponsored WISE</a></text>
<text top="334" left="539" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref960">Study. J Am Heart Assoc. 2014;3:e000660</a></text>
<text top="334" left="714" width="3" height="9" font="4">.</text>
<text top="352" left="539" width="29" height="9" font="4">S11.1-5.</text>
<text top="352" left="572" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref961">Tanner RM, Calhoun DA, Bell EK, et al. Incident</a></text>
<text top="366" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref961">ESRD and treatment-resistant hypertension: the rea-</a></text>
<text top="379" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref961">sons for geographic and racial differences in stroke</a></text>
<text top="393" left="539" width="191" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref961">(REGARDS) study. Am J Kidney Dis. 2014;63:781</a></text>
<text top="391" left="731" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref961">–8</a></text>
<text top="393" left="740" width="3" height="9" font="4">.</text>
<text top="411" left="539" width="30" height="9" font="4">S11.1-6.</text>
<text top="411" left="573" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref962">Bangalore S, Fayyad R, Laskey R, et al.</a></text>
<text top="425" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref962">Prevalence, predictors, and outcomes in treatment-</a></text>
<text top="438" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref962">resistant hypertension in patients with coronary</a></text>
<text top="451" left="539" width="127" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref962">disease. Am J Med. 2014;127:71</a></text>
<text top="450" left="667" width="24" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref962">–81.e1</a></text>
<text top="451" left="691" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref962">.</a></text>
<text top="470" left="539" width="29" height="9" font="4">S11.1-7.</text>
<text top="470" left="572" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref963">Calhoun DA, Booth JN 3rd, Oparil S, et al.</a></text>
<text top="484" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref963">Refractory hypertension: determination of prevalence,</a></text>
<text top="497" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref963">risk factors, and comorbidities in a large, population-</a></text>
<text top="510" left="539" width="166" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref963">based cohort. Hypertension. 2014;63:451</a></text>
<text top="509" left="705" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref963">–8</a></text>
<text top="510" left="715" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref963">.</a></text>
<text top="529" left="539" width="30" height="9" font="4">S11.1-8.</text>
<text top="529" left="573" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref964">Rosa J, Widimsky P, Waldauf P, et al. Role</a></text>
<text top="543" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref964">of adding spironolactone and renal denervation in</a></text>
<text top="556" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref964">true resistant hypertension: one-year outcomes of</a></text>
<text top="570" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref964">randomized PRAGUE-15 Study. Hypertension. 2016;</a></text>
<text top="583" left="539" width="28" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref964">67:397</a></text>
<text top="581" left="567" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref964">–403</a></text>
<text top="583" left="587" width="3" height="9" font="4">.</text>
<text top="602" left="539" width="30" height="9" font="4">S11.1-9.</text>
<text top="602" left="573" width="111" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref965">Bhatt DL, Kandzari DE, O</a></text>
<text top="600" left="684" width="73" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref965">’Neill WW, et al.</a></text>
<text top="615" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref965">A controlled trial of renal denervation for resistant</a></text>
<text top="629" left="539" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref965">hypertension. N Engl J Med. 2014;370:1393</a></text>
<text top="627" left="716" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref965">–401</a></text>
<text top="629" left="735" width="3" height="9" font="4">.</text>
<text top="647" left="539" width="34" height="9" font="4">S11.1-10.</text>
<text top="647" left="577" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref966">Bisognano JD, Bakris G, Nadim MK, et al.</a></text>
<text top="661" left="539" width="26" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref966">Barore</a></text>
<text top="659" left="566" width="191" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref966">ﬂex activation therapy lowers blood pressure in</a></text>
<text top="674" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref966">patients with resistant hypertension: results from the</a></text>
<text top="688" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref966">double-blind, randomized, placebo-controlled rheos</a></text>
<text top="701" left="539" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref966">pivotal trial. J Am Coll Cardiol. 2011;58:765</a></text>
<text top="699" left="716" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref966">–73</a></text>
<text top="701" left="729" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref966">.</a></text>
<text top="720" left="539" width="32" height="9" font="4">S11.1-11.</text>
<text top="720" left="575" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref967">Stergiou GS, Makris T, Papavasiliou M, et al.</a></text>
<text top="733" left="539" width="47" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref967">Comparison</a></text>
<text top="733" left="596" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref967">of</a></text>
<text top="733" left="615" width="66" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref967">antihypertensive</a></text>
<text top="733" left="691" width="27" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref967">effects</a></text>
<text top="733" left="729" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref967">of</a></text>
<text top="733" left="747" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref967">an</a></text>
<text top="747" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref967">angiotensin-converting enzyme inhibitor, a calcium</a></text>
<text top="760" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref967">antagonist and a diuretic in patients with hypertension</a></text>
<text top="773" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref967">not controlled by angiotensin receptor blocker</a></text>
<text top="787" left="539" width="165" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref967">monotherapy. J Hypertens. 2005;23:883</a></text>
<text top="785" left="704" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref967">–9</a></text>
<text top="787" left="714" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref967">.</a></text>
<text top="806" left="539" width="33" height="9" font="4">S11.1-12.</text>
<text top="806" left="576" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref968">Liu G, Zheng XX, Xu YL, et al. Effect of</a></text>
<text top="819" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref968">aldosterone antagonists on blood pressure in patients</a></text>
<text top="832" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref968">with resistant hypertension: a meta-analysis. J Hum</a></text>
<text top="846" left="539" width="96" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref968">Hypertens. 2015;29:159</a></text>
<text top="844" left="635" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref968">–66</a></text>
<text top="846" left="650" width="3" height="9" font="4">.</text>
<text top="865" left="539" width="33" height="9" font="4">S11.1-13.</text>
<text top="865" left="576" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref969">Williams B, MacDonald TM, Morant S, et al.</a></text>
<text top="878" left="539" width="60" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref969">Spironolactone</a></text>
<text top="878" left="609" width="25" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref969">versus</a></text>
<text top="878" left="645" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref969">placebo,</a></text>
<text top="878" left="689" width="42" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref969">bisoprolol,</a></text>
<text top="878" left="742" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref969">and</a></text>
<text top="891" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref969">doxazosin to determine the optimal treatment for</a></text>
<text top="905" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref969">drug-resistant hypertension (PATHWAY-2): a rando-</a></text>
<text top="918" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref969">mised, double-blind, crossover trial. Lancet. 2015;386:</a></text>
<text top="932" left="539" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref969">2059</a></text>
<text top="930" left="561" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref969">–68</a></text>
<text top="932" left="576" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref969">.</a></text>
<text top="950" left="539" width="34" height="9" font="4">S11.1-14.</text>
<text top="950" left="577" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref970">Rodilla E, Costa JA, Perez-Lahiguera F, et al.</a></text>
<text top="964" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref970">Spironolactone and doxazosin treatment in patients</a></text>
<text top="977" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref970">with resistant hypertension. Rev Esp Cardiol. 2009;62:</a></text>
<text top="991" left="539" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref970">158</a></text>
<text top="989" left="554" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref970">–66</a></text>
<text top="991" left="569" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref970">.</a></text>
<text top="1010" left="539" width="33" height="9" font="4">S11.1-15.</text>
<text top="1009" left="576" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref971">Dahal K, Kunwar S, Rijal J, et al. The effects</a></text>
<text top="1023" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref971">of aldosterone antagonists in patients with resistant</a></text>
<text top="1036" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref971">hypertension: a meta-analysis of randomized and</a></text>
<text top="1050" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref971">nonrandomized studies. Am J Hypertens. 2015;28:</a></text>
<text top="1063" left="539" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref971">1376</a></text>
<text top="1062" left="558" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref971">–85</a></text>
<text top="1063" left="572" width="3" height="9" font="4">.</text>
<text top="1082" left="539" width="34" height="9" font="4">S11.1-16.</text>
<text top="1082" left="576" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref972">Agodoa LY, Appel L, Bakris GL, et al. Effect of</a></text>
<text top="1095" left="539" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref972">ramipril</a></text>
<text top="1095" left="580" width="9" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref972">vs</a></text>
<text top="1095" left="598" width="44" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref972">amlodipine</a></text>
<text top="1095" left="651" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref972">on</a></text>
<text top="1095" left="671" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref972">renal</a></text>
<text top="1095" left="701" width="39" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref972">outcomes</a></text>
<text top="1095" left="749" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref972">in</a></text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="788" width="19" height="9" font="4">e233</text>
</page>
<page number="108" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref972">hypertensive nephrosclerosis: a randomized controlled</a></text>
<text top="156" left="108" width="110" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref972">trial. JAMA. 2001;285:2719</a></text>
<text top="155" left="217" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref972">–28</a></text>
<text top="156" left="232" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref972">.</a></text>
<text top="178" left="108" width="19" height="9" font="23">11.2.</text>
<text top="178" left="136" width="61" height="9" font="23">Hypertensive</text>
<text top="178" left="206" width="27" height="9" font="23">Crises</text>
<text top="177" left="234" width="91" height="12" font="23">—Emergencies and</text>
<text top="192" left="108" width="44" height="9" font="23">Urgencies</text>
<text top="206" left="108" width="29" height="9" font="4">S11.2-1.</text>
<text top="206" left="140" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref973">Farias S, Peacock WF, Gonzalez M, et al.</a></text>
<text top="219" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref973">Impact of initial blood pressure on antihypertensive</a></text>
<text top="233" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref973">response in patients with acute hypertension. Am J</a></text>
<text top="246" left="108" width="102" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref973">Emerg Med. 2014;32:833</a></text>
<text top="245" left="209" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref973">–6</a></text>
<text top="246" left="219" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref973">.</a></text>
<text top="265" left="108" width="30" height="9" font="4">S11.2-2.</text>
<text top="265" left="141" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref974">Peacock WF, Chandra A, Char D, et al. Clevi-</a></text>
<text top="279" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref974">dipine in acute heart failure: results of the A Study of</a></text>
<text top="292" left="108" width="186" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref974">Blood Pressure Control in Acute Heart Failure</a></text>
<text top="291" left="293" width="31" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref974">–A Pilot</a></text>
<text top="306" left="108" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref974">Study (PRONTO). Am Heart J. 2014;167:529</a></text>
<text top="304" left="285" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref974">–36</a></text>
<text top="306" left="299" width="3" height="9" font="4">.</text>
<text top="325" left="108" width="30" height="9" font="4">S11.2-3.</text>
<text top="325" left="141" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref975">Papadopoulos DP, Sanidas EA, Viniou NA,</a></text>
<text top="338" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref975">et al. Cardiovascular hypertensive emergencies. Curr</a></text>
<text top="352" left="108" width="103" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref975">Hypertens Rep. 2015;17:5</a></text>
<text top="352" left="210" width="3" height="9" font="4">.</text>
<text top="371" left="108" width="31" height="9" font="4">S11.2-4.</text>
<text top="371" left="142" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref976">Manning L, Robinson TG, Anderson CS. Con-</a></text>
<text top="384" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref976">trol of blood pressure in hypertensive neurological</a></text>
<text top="398" left="108" width="193" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref976">emergencies. Curr. Hypertens Rep. 2014;16:436</a></text>
<text top="398" left="300" width="3" height="9" font="4">.</text>
<text top="417" left="108" width="30" height="9" font="4">S11.2-5.</text>
<text top="417" left="141" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref977">Rhoney D, Peacock WF. Intravenous therapy</a></text>
<text top="430" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref977">for hypertensive emergencies, part 1. Am J Health Syst</a></text>
<text top="444" left="108" width="89" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref977">Pharm. 2009;66:1343</a></text>
<text top="442" left="196" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref977">–52</a></text>
<text top="444" left="210" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref977">.</a></text>
<text top="463" left="108" width="31" height="9" font="4">S11.2-6.</text>
<text top="463" left="142" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref978">Rhoney D, Peacock WF. Intravenous therapy</a></text>
<text top="476" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref978">for hypertensive emergencies, part 2. Am J Health Syst</a></text>
<text top="490" left="108" width="90" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref978">Pharm. 2009;66:1448</a></text>
<text top="488" left="198" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref978">–57</a></text>
<text top="490" left="211" width="3" height="9" font="4">.</text>
<text top="509" left="108" width="30" height="9" font="4">S11.2-7.</text>
<text top="509" left="141" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref979">Keith NM, Wagener HP, Barker NW. Some</a></text>
<text top="523" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref979">different types of essential hypertension: their course</a></text>
<text top="536" left="108" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref979">and prognosis. Am J Med Sci. 1974;268:336</a></text>
<text top="534" left="285" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref979">–45</a></text>
<text top="536" left="299" width="3" height="9" font="4">.</text>
<text top="555" left="108" width="31" height="9" font="4">S11.2-8.</text>
<text top="555" left="142" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref980">Perez MI, Musini VM. Pharmacological in-</a></text>
<text top="569" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref980">terventions for hypertensive emergencies: a Cochrane</a></text>
<text top="582" left="108" width="195" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref980">systematic review. J Hum Hypertens. 2008;22:596</a></text>
<text top="580" left="302" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref980">–607</a></text>
<text top="582" left="322" width="3" height="9" font="4">.</text>
<text top="601" left="108" width="31" height="9" font="4">S11.2-9.</text>
<text top="601" left="142" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref981">Gifford RW Jr. Current practices in general</a></text>
<text top="615" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref981">medicine. 7. Treatment of hypertensive emergencies</a></text>
<text top="628" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref981">including use of sodium nitroprusside. Proc Staff Meet</a></text>
<text top="642" left="108" width="95" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref981">Mayo Clin. 1959;34:387</a></text>
<text top="640" left="203" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref981">–94</a></text>
<text top="642" left="218" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref981">.</a></text>
<text top="661" left="108" width="35" height="9" font="4">S11.2-10.</text>
<text top="661" left="146" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref982">Peacock WF, Varon J, Baumann BM, et al.</a></text>
<text top="674" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref982">CLUE: a randomized comparative effectiveness trial of</a></text>
<text top="688" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref982">IV nicardipine versus labetalol use in the emergency</a></text>
<text top="701" left="108" width="143" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref982">department. Crit Care. 2011;15:R157</a></text>
<text top="701" left="251" width="3" height="9" font="4">.</text>
<text top="720" left="108" width="33" height="9" font="4">S11.2-11.</text>
<text top="720" left="144" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref983">Cannon CM, Levy P, Baumann BM, et al.</a></text>
<text top="734" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref983">Intravenous nicardipine and labetalol use in hyper-</a></text>
<text top="747" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref983">tensive patients with signs or symptoms suggestive of</a></text>
<text top="761" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref983">end-organ damage in the emergency department: a</a></text>
<text top="774" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref983">subgroup analysis of the CLUE trial. BMJ OPEN. 2013;</a></text>
<text top="787" left="108" width="44" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref983">3:e002338</a></text>
<text top="787" left="152" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref983">.</a></text>
<text top="807" left="108" width="34" height="9" font="4">S11.2-12.</text>
<text top="807" left="145" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref984">Varon J, Soto-Ruiz KM, Baumann BM, et al.</a></text>
<text top="820" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref984">The management of acute hypertension in patients</a></text>
<text top="833" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref984">with renal dysfunction: labetalol or nicardipine? Post-</a></text>
<text top="847" left="108" width="97" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref984">grad Med. 2014;126:124</a></text>
<text top="845" left="205" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref984">–30</a></text>
<text top="847" left="220" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref984">.</a></text>
<text top="866" left="108" width="34" height="9" font="4">S11.2-13.</text>
<text top="866" left="145" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref985">Anderson CS, Heeley E, Huang Y, et al. Rapid</a></text>
<text top="880" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref985">blood-pressure lowering in patients with acute intra-</a></text>
<text top="893" left="108" width="200" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref985">cerebral hemorrhage. N Engl J Med. 2013;368:2355</a></text>
<text top="891" left="308" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref985">–65</a></text>
<text top="893" left="322" width="3" height="9" font="4">.</text>
<text top="915" left="108" width="169" height="9" font="23">11.3. Cognitive Decline and Dementia</text>
<text top="936" left="108" width="29" height="9" font="4">S11.3-1.</text>
<text top="936" left="140" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref986">Applegate WB, Pressel S, Wittes J, et al.</a></text>
<text top="949" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref986">Impact of the treatment of isolated systolic hyper-</a></text>
<text top="963" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref986">tension on behavioral variables. Results from the sys-</a></text>
<text top="976" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref986">tolic hypertension in the elderly program. Arch Intern</a></text>
<text top="990" left="108" width="81" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref986">Med. 1994;154:2154</a></text>
<text top="988" left="189" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref986">–60</a></text>
<text top="990" left="204" width="3" height="9" font="4">.</text>
<text top="1009" left="108" width="30" height="9" font="4">S11.3-2.</text>
<text top="1009" left="141" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref987">Forette F, Seux ML, Staessen JA, et al. Pre-</a></text>
<text top="1022" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref987">vention of dementia in randomised double-blind pla-</a></text>
<text top="1036" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref987">cebo-controlled Systolic Hypertension in Europe (Syst-</a></text>
<text top="1049" left="108" width="132" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref987">Eur) trial. Lancet. 1998;352:1347</a></text>
<text top="1048" left="239" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref987">–51</a></text>
<text top="1049" left="252" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref987">.</a></text>
<text top="1068" left="108" width="30" height="9" font="4">S11.3-3.</text>
<text top="1068" left="141" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref988">Forette F, Seux M-L, Staessen JA, et al.</a></text>
<text top="1082" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref988">The prevention of dementia with antihypertensive</a></text>
<text top="1095" left="108" width="43" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref988">treatment:</a></text>
<text top="1095" left="162" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref988">new</a></text>
<text top="1095" left="191" width="35" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref988">evidence</a></text>
<text top="1095" left="238" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref988">from</a></text>
<text top="1095" left="269" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref988">the</a></text>
<text top="1095" left="294" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref988">Systolic</a></text>
<text top="143" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref988">Hypertension in Europe (Syst-Eur) study. Arch Intern</a></text>
<text top="156" left="346" width="86" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref988">Med. 2002;162:2046</a></text>
<text top="155" left="432" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref988">–52</a></text>
<text top="156" left="446" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref988">.</a></text>
<text top="175" left="346" width="31" height="9" font="4">S11.3-4.</text>
<text top="175" left="380" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref989">Lithell H, Hansson L, Skoog I, et al. The Study</a></text>
<text top="188" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref989">on Cognition and Prognosis in the Elderly (SCOPE):</a></text>
<text top="202" left="346" width="34" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref989">principal</a></text>
<text top="202" left="389" width="27" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref989">results</a></text>
<text top="202" left="425" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref989">of</a></text>
<text top="202" left="442" width="4" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref989">a</a></text>
<text top="202" left="456" width="47" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref989">randomized</a></text>
<text top="202" left="512" width="51" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref989">double-blind</a></text>
<text top="215" left="346" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref989">intervention trial. J Hypertens. 2003;21:875</a></text>
<text top="214" left="523" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref989">–86</a></text>
<text top="215" left="538" width="3" height="9" font="4">.</text>
<text top="234" left="346" width="30" height="9" font="4">S11.3-5.</text>
<text top="234" left="379" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref990">Tzourio C, Anderson C, Chapman N, et al.</a></text>
<text top="247" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref990">Effects of blood pressure lowering with perindopril</a></text>
<text top="261" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref990">and indapamide therapy on dementia and cognitive</a></text>
<text top="274" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref990">decline in patients with cerebrovascular disease. Arch</a></text>
<text top="288" left="346" width="112" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref990">Intern Med. 2003;163:1069</a></text>
<text top="286" left="458" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref990">–75</a></text>
<text top="288" left="471" width="3" height="9" font="4">.</text>
<text top="306" left="346" width="31" height="9" font="4">S11.3-6.</text>
<text top="306" left="380" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref991">Peters R, Beckett N, Forette F, et al.</a></text>
<text top="320" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref991">Incident dementia and blood pressure lowering in the</a></text>
<text top="333" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref991">Hypertension in the Very Elderly Trial cognitive func-</a></text>
<text top="347" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref991">tion assessment (HYVET-COG): a double-blind, pla-</a></text>
<text top="360" left="346" width="198" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref991">cebo controlled trial. Lancet Neurol. 2008;7:683</a></text>
<text top="358" left="543" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref991">–9</a></text>
<text top="360" left="553" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref991">.</a></text>
<text top="379" left="346" width="30" height="9" font="4">S11.3-7.</text>
<text top="379" left="379" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref992">Prince M, Wimo A, Guerchet M, et al. World</a></text>
<text top="392" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref992">Alzheimer Report 2015: The Global Impact of</a></text>
<text top="405" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref992">Dementia: An Analysis of Prevalence, Incidence, Cost</a></text>
<text top="419" left="346" width="143" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref992">and Trends. London, UK: Alzheimer</a></text>
<text top="417" left="489" width="74" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref992">’s Disease Interna-</a></text>
<text top="432" left="346" width="60" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref992">tional, 2015:10</a></text>
<text top="431" left="406" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref992">–27</a></text>
<text top="432" left="419" width="3" height="9" font="4">.</text>
<text top="451" left="346" width="31" height="9" font="4">S11.3-8.</text>
<text top="451" left="380" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref993">Brookmeyer R, Corrada MM, Curriero FC, et al.</a></text>
<text top="464" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref993">Survival following a diagnosis of Alzheimer disease.</a></text>
<text top="478" left="346" width="110" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref993">Arch Neurol. 2002;59:1764</a></text>
<text top="476" left="456" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref993">–7</a></text>
<text top="478" left="465" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref993">.</a></text>
<text top="496" left="346" width="31" height="9" font="4">S11.3-9.</text>
<text top="496" left="380" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref994">Qiu</a></text>
<text top="496" left="403" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref994">C,</a></text>
<text top="496" left="421" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref994">Winblad</a></text>
<text top="496" left="463" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref994">B,</a></text>
<text top="496" left="481" width="40" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref994">Fratiglioni</a></text>
<text top="496" left="531" width="7" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref994">L.</a></text>
<text top="496" left="548" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref994">The</a></text>
<text top="510" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref994">age-dependent relation of blood pressure to cognitive</a></text>
<text top="523" left="346" width="199" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref994">function and dementia. Lancet Neurol. 2005;4:487</a></text>
<text top="522" left="545" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref994">–99</a></text>
<text top="523" left="560" width="3" height="9" font="4">.</text>
<text top="542" left="346" width="35" height="9" font="4">S11.3-10.</text>
<text top="542" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref995">Kivipelto M, Helkala EL, Hanninen T, et al.</a></text>
<text top="555" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref995">Midlife vascular risk factors and late-life mild cognitive</a></text>
<text top="569" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref995">impairment: a population-based study. Neurology.</a></text>
<text top="582" left="346" width="56" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref995">2001;56:1683</a></text>
<text top="580" left="402" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref995">–9</a></text>
<text top="582" left="412" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref995">.</a></text>
<text top="601" left="346" width="33" height="9" font="4">S11.3-11.</text>
<text top="601" left="382" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref996">Kuller LH, Lopez OL, Jagust WJ, et al. De-</a></text>
<text top="614" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref996">terminants of vascular dementia in the Cardiovascular</a></text>
<text top="628" left="346" width="201" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref996">Health Cognition Study. Neurology. 2005;64:1548</a></text>
<text top="626" left="547" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref996">–52</a></text>
<text top="628" left="560" width="3" height="9" font="4">.</text>
<text top="646" left="346" width="34" height="9" font="4">S11.3-12.</text>
<text top="646" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref997">Liao D, Cooper L, Cai J, et al. Presence and</a></text>
<text top="659" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref997">severity of cerebral white matter lesions and hyper-</a></text>
<text top="673" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref997">tension, its treatment, and its control. The ARIC Study.</a></text>
<text top="686" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref997">Atherosclerosis Risk in Communities Study. Stroke.</a></text>
<text top="700" left="346" width="55" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref997">1996;27:2262</a></text>
<text top="698" left="401" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref997">–70</a></text>
<text top="700" left="416" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref997">.</a></text>
<text top="717" left="346" width="34" height="9" font="4">S11.3-13.</text>
<text top="717" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref998">Longstreth WT Jr., Manolio TA, Arnold A, et al.</a></text>
<text top="730" left="346" width="139" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref998">Clinical correlates of white matter</a></text>
<text top="729" left="488" width="75" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref998">ﬁndings on cranial</a></text>
<text top="744" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref998">magnetic resonance imaging of 3301 elderly people. The</a></text>
<text top="757" left="346" width="197" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref998">Cardiovascular Health Study. Stroke. 1996;27:1274</a></text>
<text top="756" left="542" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref998">–82</a></text>
<text top="757" left="557" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref998">.</a></text>
<text top="774" left="346" width="35" height="9" font="4">S11.3-14.</text>
<text top="774" left="384" width="6" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref999">O</a></text>
<text top="773" left="390" width="173" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref999">’Rourke MF, Safar ME. Relationship be-</a></text>
<text top="788" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref999">tween aortic stiffening and microvascular disease in</a></text>
<text top="801" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref999">brain and kidney: cause and logic of therapy. Hyper-</a></text>
<text top="815" left="346" width="90" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref999">tension. 2005;46:200</a></text>
<text top="813" left="436" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref999">–4</a></text>
<text top="815" left="445" width="3" height="9" font="4">.</text>
<text top="833" left="346" width="34" height="9" font="4">S11.3-15.</text>
<text top="833" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1000">Skoog I. A review on blood pressure and</a></text>
<text top="847" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1000">ischaemic white matter lesions. Dement Geriatr Cogn</a></text>
<text top="860" left="346" width="102" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1000">Disord. 1998;9 suppl 1:13</a></text>
<text top="858" left="448" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1000">–9</a></text>
<text top="860" left="458" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1000">.</a></text>
<text top="877" left="346" width="35" height="9" font="4">S11.3-16.</text>
<text top="877" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1001">Hughes TM, Sink KM. Hypertension and its</a></text>
<text top="891" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1001">role in cognitive function: current evidence and chal-</a></text>
<text top="904" left="346" width="201" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1001">lenges for the future. Am J Hypertens. 2016;29:149</a></text>
<text top="902" left="547" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1001">–57</a></text>
<text top="904" left="560" width="3" height="9" font="4">.</text>
<text top="923" left="346" width="34" height="9" font="4">S11.3-17.</text>
<text top="923" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1002">Staessen JA, Fagard R, Thijs L, et al. Rando-</a></text>
<text top="936" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1002">mised double-blind comparison of placebo and active</a></text>
<text top="949" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1002">treatment for older patients with isolated systolic hy-</a></text>
<text top="963" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1002">pertension. The Systolic Hypertension in Europe (Syst-</a></text>
<text top="976" left="346" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1002">Eur) Trial Investigators. Lancet. 1997;350:757</a></text>
<text top="975" left="526" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1002">–64</a></text>
<text top="976" left="542" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1002">.</a></text>
<text top="995" left="346" width="35" height="9" font="4">S11.3-18.</text>
<text top="995" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1003">Czernichow S, Ninomiya T, Huxley R, et al.</a></text>
<text top="1008" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1003">Impact of blood pressure lowering on cardiovascular</a></text>
<text top="1022" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1003">outcomes in normal weight, overweight, and obese</a></text>
<text top="1035" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1003">individuals: the Perindopril Protection Against Recur-</a></text>
<text top="1049" left="346" width="205" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1003">rent Stroke Study trial. Hypertension. 2010;55:1193</a></text>
<text top="1047" left="551" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1003">–8</a></text>
<text top="1049" left="560" width="3" height="9" font="4">.</text>
<text top="1067" left="346" width="35" height="9" font="4">S11.3-19.</text>
<text top="1067" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1004">Bosch J, Yusuf S, Pogue J, et al. Use of</a></text>
<text top="1081" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1004">ramipril in preventing stroke: double blind randomised</a></text>
<text top="1094" left="346" width="103" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1004">trial. BMJ. 2002;324:699</a></text>
<text top="1092" left="449" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1004">–702</a></text>
<text top="1094" left="468" width="3" height="9" font="4">.</text>
<text top="143" left="584" width="36" height="9" font="4">S11.3-20.</text>
<text top="143" left="623" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1005">Williamson JD, Launer LJ, Bryan RN, et al.</a></text>
<text top="156" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1005">Cognitive function and brain structure in persons with</a></text>
<text top="170" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1005">type 2 diabetes mellitus after intensive lowering of</a></text>
<text top="183" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1005">blood pressure and lipid levels: a randomized clinical</a></text>
<text top="197" left="584" width="151" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1005">trial. JAMA Intern Med. 2014;174:324</a></text>
<text top="195" left="735" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1005">–33</a></text>
<text top="197" left="749" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1005">.</a></text>
<text top="214" left="584" width="34" height="9" font="4">S11.3-21.</text>
<text top="214" left="621" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1006">Anderson C, Teo K, Gao P, et al. Renin-</a></text>
<text top="227" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1006">angiotensin system blockade and cognitive function in</a></text>
<text top="241" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1006">patients at high risk of cardiovascular disease: analysis</a></text>
<text top="254" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1006">of data from the ONTARGET and TRANSCEND studies.</a></text>
<text top="268" left="584" width="105" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1006">Lancet Neurol. 2011;10:43</a></text>
<text top="266" left="689" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1006">–53</a></text>
<text top="268" left="703" width="3" height="9" font="4">.</text>
<text top="285" left="584" width="35" height="9" font="4">S11.3-22.</text>
<text top="285" left="622" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1007">Diener H-C, Sacco RL, Yusuf S, et al. Effects</a></text>
<text top="298" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1007">of aspirin plus extended-release dipyridamole versus</a></text>
<text top="312" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1007">clopidogrel and telmisartan on disability and cognitive</a></text>
<text top="325" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1007">function after recurrent stroke in patients with</a></text>
<text top="339" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1007">ischaemic stroke in the Prevention Regimen for</a></text>
<text top="352" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1007">Effectively Avoiding Second Strokes (PRoFESS) trial: a</a></text>
<text top="365" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1007">double-blind, active and placebo-controlled study.</a></text>
<text top="379" left="584" width="109" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1007">Lancet Neurol. 2008;7:875</a></text>
<text top="377" left="693" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1007">–84</a></text>
<text top="379" left="708" width="3" height="9" font="4">.</text>
<text top="398" left="584" width="197" height="9" font="23">11.4. Sexual Dysfunction and Hypertension</text>
<text top="421" left="584" width="30" height="9" font="4">S11.4-1.</text>
<text top="421" left="617" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1008">Nunes KP, Labazi H, Webb RC. New insights</a></text>
<text top="435" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1008">into hypertension-associated erectile dysfunction. Curr</a></text>
<text top="448" left="584" width="150" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1008">Opin Nephrol Hypertens. 2012;21:163</a></text>
<text top="447" left="734" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1008">–70</a></text>
<text top="448" left="749" width="3" height="9" font="4">.</text>
<text top="465" left="584" width="31" height="9" font="4">S11.4-2.</text>
<text top="465" left="618" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1009">Johannes CB, Araujo AB, Feldman HA, et al.</a></text>
<text top="479" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1009">Incidence of erectile dysfunction in men 40 to 69</a></text>
<text top="492" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1009">years old: longitudinal results from the Massachusetts</a></text>
<text top="506" left="584" width="164" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1009">male aging study. J Urol. 2000;163:460</a></text>
<text top="504" left="748" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1009">–3</a></text>
<text top="506" left="757" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1009">.</a></text>
<text top="523" left="584" width="31" height="9" font="4">S11.4-3.</text>
<text top="523" left="618" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1010">Ayta IA, McKinlay JB, Krane RJ. The likely</a></text>
<text top="536" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1010">worldwide increase in erectile dysfunction between</a></text>
<text top="550" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1010">1995 and 2025 and some possible policy conse-</a></text>
<text top="563" left="584" width="121" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1010">quences. BJU Int. 1999;84:50</a></text>
<text top="562" left="705" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1010">–6</a></text>
<text top="563" left="715" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1010">.</a></text>
<text top="580" left="584" width="32" height="9" font="4">S11.4-4.</text>
<text top="580" left="619" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1011">Thompson IM, Tangen CM, Goodman PJ, et al.</a></text>
<text top="594" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1011">Erectile dysfunction and subsequent cardiovascular</a></text>
<text top="607" left="584" width="127" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1011">disease. JAMA. 2005;294:2996</a></text>
<text top="605" left="712" width="26" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1011">–3002</a></text>
<text top="607" left="737" width="3" height="9" font="4">.</text>
<text top="624" left="584" width="31" height="9" font="4">S11.4-5.</text>
<text top="624" left="618" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1012">Shin D, Pregenzer G Jr., Gardin JM. Erectile</a></text>
<text top="638" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1012">dysfunction: a disease marker for cardiovascular dis-</a></text>
<text top="651" left="584" width="112" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1012">ease. Cardiol Rev. 2011;19:5</a></text>
<text top="649" left="696" width="11" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1012">–11</a></text>
<text top="651" left="708" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1012">.</a></text>
<text top="670" left="584" width="32" height="9" font="4">S11.4-6.</text>
<text top="670" left="619" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1013">Martin SA, Atlantis E, Lange K, et al. Pre-</a></text>
<text top="683" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1013">dictors of sexual dysfunction incidence and remission</a></text>
<text top="696" left="584" width="130" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1013">in men. J Sex Med. 2014;11:1136</a></text>
<text top="695" left="714" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1013">–47</a></text>
<text top="696" left="728" width="3" height="9" font="4">.</text>
<text top="715" left="584" width="31" height="9" font="4">S11.4-7.</text>
<text top="715" left="618" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1014">Vasquez EC, Gava AL, Graceli JB, et al. Novel</a></text>
<text top="728" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1014">therapeutic targets for phosphodiesterase 5 inhibitors:</a></text>
<text top="742" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1014">current state-of-the-art on systemic arterial hyper-</a></text>
<text top="755" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1014">tension and atherosclerosis. Curr Pharm Biotechnol.</a></text>
<text top="769" left="584" width="49" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1014">2016;17:347</a></text>
<text top="767" left="633" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1014">–64</a></text>
<text top="769" left="648" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1014">.</a></text>
<text top="787" left="584" width="32" height="9" font="4">S11.4-8.</text>
<text top="787" left="619" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1015">Ghiadoni L, Versari D, Taddei S. Phosphodi-</a></text>
<text top="801" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1015">esterase 5 inhibition in essential hypertension. Curr</a></text>
<text top="814" left="584" width="112" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1015">Hypertens Rep. 2008;10:52</a></text>
<text top="813" left="696" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1015">–7</a></text>
<text top="814" left="705" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1015">.</a></text>
<text top="833" left="584" width="32" height="9" font="4">S11.4-9.</text>
<text top="833" left="619" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1016">Al Khaja KAJ, Sequeira RP, Alkhaja AK, et al.</a></text>
<text top="846" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1016">Antihypertensive drugs and male sexual dysfunction: a</a></text>
<text top="860" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1016">review of adult hypertension guideline recommenda-</a></text>
<text top="873" left="584" width="194" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1016">tions. J Cardiovasc Pharmacol Ther. 2016;21:233</a></text>
<text top="872" left="779" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1016">–44</a></text>
<text top="873" left="793" width="3" height="9" font="4">.</text>
<text top="895" left="584" width="209" height="9" font="23">11.5. Patients Undergoing Surgical Procedures</text>
<text top="919" left="584" width="29" height="9" font="4">S11.5-1.</text>
<text top="919" left="617" width="185" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1017">Lindenauer PK, Pekow P, Wang K, et al. Periop-</a></text>
<text top="932" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1017">erative beta-blocker therapy and mortality after major</a></text>
<text top="946" left="584" width="189" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1017">noncardiac surgery. N Engl J Med. 2005;353:349</a></text>
<text top="944" left="773" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1017">–61</a></text>
<text top="946" left="786" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1017">.</a></text>
<text top="964" left="584" width="30" height="9" font="4">S11.5-2.</text>
<text top="964" left="617" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1018">Shammash JB, Trost JC, Gold JM, et al.</a></text>
<text top="978" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1018">Perioperative beta-blocker withdrawal and mortality</a></text>
<text top="991" left="584" width="213" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1018">in vascular surgical patients. Am Heart J. 2001;141:148</a></text>
<text top="989" left="797" width="4" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1018">–</a></text>
<text top="1004" left="584" width="9" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1018">53</a></text>
<text top="1004" left="593" width="3" height="9" font="4">.</text>
<text top="1023" left="584" width="30" height="9" font="4">S11.5-3.</text>
<text top="1023" left="617" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1019">Wallace AW, Au S, Cason BA. Association of</a></text>
<text top="1036" left="584" width="149" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1019">the pattern of use of perioperative</a></text>
<text top="1034" left="738" width="5" height="13" font="7"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1019">b</a></text>
<text top="1036" left="742" width="59" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1019">-blockade and</a></text>
<text top="1050" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1019">postoperative mortality. Anesthesiology. 2010;113:</a></text>
<text top="1063" left="584" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1019">794</a></text>
<text top="1062" left="600" width="21" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1019">–805</a></text>
<text top="1063" left="620" width="3" height="9" font="4">.</text>
<text top="1082" left="584" width="31" height="9" font="4">S11.5-4.</text>
<text top="1082" left="618" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1020">Andersson C, Merie C, Jorgensen M, et al.</a></text>
<text top="1095" left="584" width="56" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1020">Association of</a></text>
<text top="1092" left="643" width="5" height="13" font="7"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1020">b</a></text>
<text top="1095" left="648" width="153" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1020">-blocker therapy with risks of adverse</a></text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="20" height="9" font="4">e234</text>
</page>
<page number="109" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1020">cardiovascular events and deaths in patients with</a></text>
<text top="156" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1020">ischemic heart disease undergoing noncardiac surgery:</a></text>
<text top="170" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1020">a Danish nationwide cohort study. JAMA Intern Med.</a></text>
<text top="183" left="63" width="54" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1020">2014;174:336</a></text>
<text top="182" left="117" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1020">–44</a></text>
<text top="183" left="132" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1020">.</a></text>
<text top="202" left="63" width="30" height="9" font="4">S11.5-5.</text>
<text top="202" left="96" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1021">Hoeks SE, Scholte Op Reimer WJM, van Urk H,</a></text>
<text top="215" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1021">et al. Increase of 1-year mortality after perioperative</a></text>
<text top="229" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1021">beta-blocker withdrawal in endovascular and vascular</a></text>
<text top="242" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1021">surgery patients. Eur J Vasc Endovasc Surg. 2007;33:</a></text>
<text top="256" left="63" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1021">13</a></text>
<text top="254" left="71" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1021">–9</a></text>
<text top="256" left="81" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1021">.</a></text>
<text top="274" left="63" width="31" height="9" font="4">S11.5-6.</text>
<text top="274" left="97" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1022">Barrett TW, Mori M, De Boer D. Association</a></text>
<text top="288" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1022">of ambulatory use of statins and beta-blockers with</a></text>
<text top="301" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1022">long-term mortality after vascular surgery. J Hosp</a></text>
<text top="315" left="63" width="68" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1022">Med. 2007;2:241</a></text>
<text top="313" left="131" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1022">–52</a></text>
<text top="315" left="145" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1022">.</a></text>
<text top="333" left="63" width="30" height="9" font="4">S11.5-7.</text>
<text top="333" left="96" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1023">London MJ, Hur K, Schwartz GG, et al.</a></text>
<text top="347" left="63" width="111" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1023">Association of perioperative</a></text>
<text top="344" left="176" width="5" height="13" font="7"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1023">b</a></text>
<text top="347" left="181" width="99" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1023">-blockade with mortality</a></text>
<text top="360" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1023">and cardiovascular morbidity following major noncar-</a></text>
<text top="373" left="63" width="144" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1023">diac surgery. JAMA. 2013;309:1704</a></text>
<text top="372" left="206" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1023">–13</a></text>
<text top="373" left="219" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1023">.</a></text>
<text top="392" left="63" width="31" height="9" font="4">S11.5-8.</text>
<text top="392" left="97" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1024">Turan A, You J, Shiba A, et al. Angiotensin</a></text>
<text top="405" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1024">converting enzyme inhibitors are not associated with</a></text>
<text top="419" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1024">respiratory complications or mortality after noncardiac</a></text>
<text top="432" left="63" width="147" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1024">surgery. Anesth Analg. 2012;114:552</a></text>
<text top="431" left="209" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1024">–60</a></text>
<text top="432" left="225" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1024">.</a></text>
<text top="451" left="63" width="31" height="9" font="4">S11.5-9.</text>
<text top="451" left="97" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1025">Rosenman DJ, McDonald FS, Ebbert JO, et al.</a></text>
<text top="464" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1025">Clinical consequences of withholding versus adminis-</a></text>
<text top="478" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1025">tering renin-angiotensin-aldosterone system antago-</a></text>
<text top="491" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1025">nists in the preoperative period. J Hosp Med. 2008;3:</a></text>
<text top="505" left="63" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1025">319</a></text>
<text top="503" left="77" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1025">–25</a></text>
<text top="505" left="91" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1025">.</a></text>
<text top="523" left="63" width="35" height="9" font="4">S11.5-10.</text>
<text top="523" left="101" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1026">Roshanov PS, Rochwerg B, Patel A, et al.</a></text>
<text top="537" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1026">Withholding versus continuing angiotensin-converting</a></text>
<text top="550" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1026">enzyme inhibitors or angiotensin II receptor blockers</a></text>
<text top="564" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1026">before noncardiac surgery: an analysis of the Vascular</a></text>
<text top="577" left="63" width="26" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1026">events</a></text>
<text top="577" left="99" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1026">In</a></text>
<text top="577" left="117" width="43" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1026">noncardiac</a></text>
<text top="577" left="169" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1026">Surgery</a></text>
<text top="577" left="210" width="33" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1026">patIents</a></text>
<text top="577" left="253" width="27" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1026">cOhort</a></text>
<text top="590" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1026">evaluatioN Prospective Cohort. Anesthesiology. 2017;</a></text>
<text top="604" left="63" width="26" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1026">126:16</a></text>
<text top="602" left="89" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1026">–27</a></text>
<text top="604" left="102" width="3" height="9" font="4">.</text>
<text top="622" left="63" width="33" height="9" font="4">S11.5-11.</text>
<text top="622" left="99" width="181" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1027">Fleisher LA. Preoperative evaluation of the</a></text>
<text top="636" left="63" width="201" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1027">patient with hypertension. JAMA. 2002;287:2043</a></text>
<text top="634" left="264" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1027">–6</a></text>
<text top="636" left="273" width="3" height="9" font="4">.</text>
<text top="654" left="63" width="34" height="9" font="4">S11.5-12.</text>
<text top="654" left="100" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1028">Howell SJ, Sear JW, Foex P. Hypertension,</a></text>
<text top="668" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1028">hypertensive heart disease and perioperative cardiac</a></text>
<text top="681" left="63" width="129" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1028">risk. Br J Anaesth. 2004;92:570</a></text>
<text top="680" left="192" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1028">–83</a></text>
<text top="681" left="206" width="3" height="9" font="4">.</text>
<text top="700" left="63" width="34" height="9" font="4">S11.5-13.</text>
<text top="700" left="100" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1029">Hart GR, Anderson RJ. Withdrawal syn-</a></text>
<text top="713" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1029">dromes and the cessation of antihypertensive therapy.</a></text>
<text top="727" left="63" width="125" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1029">Arch Intern Med. 1981;141:1125</a></text>
<text top="725" left="188" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1029">–7</a></text>
<text top="727" left="196" width="3" height="9" font="4">.</text>
<text top="745" left="63" width="35" height="9" font="4">S11.5-14.</text>
<text top="745" left="101" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1030">Devereaux PJ, Yang H, Yusuf S, et al. Effects</a></text>
<text top="759" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1030">of extended-release metoprolol succinate in patients</a></text>
<text top="772" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1030">undergoing non-cardiac surgery (POISE trial): a rand-</a></text>
<text top="786" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1030">omised controlled trial. POISE Study Group. Lancet.</a></text>
<text top="799" left="63" width="61" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1030">2008;371:1839</a></text>
<text top="797" left="123" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1030">–47</a></text>
<text top="799" left="137" width="3" height="9" font="4">.</text>
<text top="818" left="63" width="34" height="9" font="4">S11.5-15.</text>
<text top="818" left="100" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1031">Charlson ME, MacKenzie CR, Gold JP, et al.</a></text>
<text top="831" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1031">The preoperative and intraoperative hemodynamic</a></text>
<text top="845" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1031">predictors of postoperative myocardial infarction or</a></text>
<text top="858" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1031">ischemia in patients undergoing noncardiac surgery.</a></text>
<text top="871" left="63" width="98" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1031">Ann Surg. 1989;210:637</a></text>
<text top="870" left="160" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1031">–48</a></text>
<text top="871" left="175" width="3" height="9" font="4">.</text>
<text top="890" left="63" width="35" height="9" font="4">S11.5-16.</text>
<text top="890" left="101" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1032">Cheung AT. Exploring an optimum intra/</a></text>
<text top="903" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1032">postoperative management strategy for acute hyper-</a></text>
<text top="917" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1032">tension in the cardiac surgery patient. J Card Surg.</a></text>
<text top="930" left="63" width="78" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1032">2006;21 suppl 1:S8</a></text>
<text top="929" left="141" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1032">–14</a></text>
<text top="930" left="154" width="3" height="9" font="4">.</text>
<text top="949" left="63" width="34" height="9" font="4">S11.5-17.</text>
<text top="949" left="100" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1033">Dix P, Howell S. Survey of cancellation rate of</a></text>
<text top="962" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1033">hypertensive patients undergoing anaesthesia and</a></text>
<text top="976" left="63" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1033">elective surgery. Br J Anaesth. 2001;86:789</a></text>
<text top="974" left="241" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1033">–93</a></text>
<text top="976" left="256" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1033">.</a></text>
<text top="994" left="63" width="35" height="9" font="4">S11.5-18.</text>
<text top="994" left="101" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1034">Haas CE, LeBlanc JM. Acute postoperative</a></text>
<text top="1008" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1034">hypertension: a review of therapeutic options. Am J</a></text>
<text top="1021" left="63" width="136" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1034">Health Syst Pharm. 2004;61:1661</a></text>
<text top="1020" left="198" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1034">–73</a></text>
<text top="1021" left="212" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1034">.</a></text>
<text top="1040" left="63" width="35" height="9" font="4">S11.5-19.</text>
<text top="1040" left="101" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1035">Aronson S, Dyke CM, Stierer KA, et al. The</a></text>
<text top="1053" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1035">ECLIPSE trials: comparative studies of clevidipine to</a></text>
<text top="1067" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1035">nitroglycerin, sodium nitroprusside, and nicardipine</a></text>
<text top="1080" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1035">for acute hypertension treatment in cardiac surgery</a></text>
<text top="1093" left="63" width="156" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1035">patients. Anesth Analg. 2008;107:1110</a></text>
<text top="1092" left="219" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1035">–21</a></text>
<text top="1093" left="232" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1035">.</a></text>
<text top="143" left="301" width="36" height="9" font="4">S11.5-20.</text>
<text top="143" left="340" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1036">Espinosa A, Ripolles-Melchor J, Casans-</a></text>
<text top="156" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1036">Frances R, et al. Perioperative use of clevidipine: a</a></text>
<text top="170" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1036">systematic review and meta-analysis. PLoS ONE. 2016;</a></text>
<text top="183" left="301" width="51" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1036">11:e0150625</a></text>
<text top="183" left="352" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1036">.</a></text>
<text top="202" left="301" width="34" height="9" font="4">S11.5-21.</text>
<text top="202" left="338" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1037">Fleisher LA, Fleischmann KE, Auerbach AD,</a></text>
<text top="215" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1037">et al. 2014 ACC/AHA guideline on perioperative</a></text>
<text top="229" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1037">cardiovascular evaluation and management of patients</a></text>
<text top="242" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1037">undergoing noncardiac surgery: executive summary:</a></text>
<text top="256" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1037">a report of the American College of Cardiology/</a></text>
<text top="269" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1037">American Heart Association Task Force on Practice</a></text>
<text top="283" left="301" width="153" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1037">Guidelines. Circulation. 2014;130:2215</a></text>
<text top="281" left="454" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1037">–45</a></text>
<text top="283" left="468" width="3" height="9" font="4">.</text>
<text top="301" left="301" width="35" height="9" font="4">S11.5-22.</text>
<text top="301" left="339" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1038">Smith SC Jr., Benjamin EJ, Bonow RO, et al.</a></text>
<text top="315" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1038">AHA/ACCF secondary prevention and risk reduction</a></text>
<text top="328" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1038">therapy for patients with coronary and other athero-</a></text>
<text top="342" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1038">sclerotic vascular disease: 2011 update: a guideline</a></text>
<text top="355" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1038">from the American Heart Association and American</a></text>
<text top="368" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1038">College of Cardiology Foundation. J Am Coll Cardiol.</a></text>
<text top="382" left="301" width="54" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1038">2011;58:2432</a></text>
<text top="380" left="355" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1038">–46</a></text>
<text top="382" left="370" width="3" height="9" font="4">.</text>
<text top="400" left="301" width="35" height="9" font="4">S11.5-23.</text>
<text top="400" left="339" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1039">The sixth report of the Joint National</a></text>
<text top="414" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1039">Committee on prevention, detection, evaluation, and</a></text>
<text top="427" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1039">treatment of high blood pressure. Arch Intern Med.</a></text>
<text top="441" left="301" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1039">1997;157:2413</a></text>
<text top="439" left="358" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1039">–46</a></text>
<text top="441" left="373" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1039">.</a></text>
<text top="459" left="301" width="36" height="9" font="4">S11.5-24.</text>
<text top="459" left="340" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1040">Wolfsthal SD. Is blood pressure control</a></text>
<text top="473" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1040">necessary before surgery? Med Clin North Am. 1993;</a></text>
<text top="486" left="301" width="28" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1040">77:349</a></text>
<text top="485" left="329" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1040">–63</a></text>
<text top="486" left="343" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1040">.</a></text>
<text top="505" left="301" width="35" height="9" font="4">S11.5-25.</text>
<text top="505" left="339" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1041">Goldman L, Caldera DL. Risks of general</a></text>
<text top="518" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1041">anesthesia and elective operation in the hypertensive</a></text>
<text top="532" left="301" width="151" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1041">patient. Anesthesiology. 1979;50:285</a></text>
<text top="530" left="452" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1041">–92</a></text>
<text top="532" left="467" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1041">.</a></text>
<text top="550" left="301" width="36" height="9" font="4">S11.5-26.</text>
<text top="550" left="340" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1042">Towne JB, Bernhard VM. The relationship of</a></text>
<text top="564" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1042">postoperative hypertension to complications following</a></text>
<text top="577" left="301" width="187" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1042">carotid endarterectomy. Surgery. 1980;88:575</a></text>
<text top="575" left="488" width="16" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1042">–80</a></text>
<text top="577" left="504" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1042">.</a></text>
<text top="596" left="301" width="35" height="9" font="4">S11.5-27.</text>
<text top="596" left="339" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1043">Aronson S, Boisvert D, Lapp W. Isolated</a></text>
<text top="609" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1043">systolic hypertension is associated with adverse out-</a></text>
<text top="622" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1043">comes from coronary artery bypass grafting surgery.</a></text>
<text top="636" left="301" width="117" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1043">Anesth Analg. 2002;94:1079</a></text>
<text top="634" left="418" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1043">–84</a></text>
<text top="636" left="433" width="3" height="9" font="4">.</text>
<text top="654" left="301" width="36" height="9" font="4">S11.5-28.</text>
<text top="654" left="340" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1044">Foex P, Meloche R, Prys-Roberts C. Studies</a></text>
<text top="668" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1044">of anaesthesia in relation to hypertension. 3. Pulmo-</a></text>
<text top="681" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1044">nary gas exchange during spontaneous ventilation. Br</a></text>
<text top="695" left="301" width="94" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1044">J Anaesth. 1971;43:644</a></text>
<text top="693" left="395" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1044">–61</a></text>
<text top="695" left="409" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1044">.</a></text>
<text top="713" left="301" width="36" height="9" font="4">S11.5-29.</text>
<text top="713" left="340" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1045">Gerber JG, Nies AS. Abrupt withdrawal of</a></text>
<text top="727" left="301" width="206" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1045">cardiovascular drugs. N Engl J Med. 1979;301:1234</a></text>
<text top="725" left="507" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1045">–5</a></text>
<text top="727" left="515" width="3" height="9" font="4">.</text>
<text top="745" left="301" width="36" height="9" font="4">S11.5-30.</text>
<text top="745" left="340" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1046">Rangno RE, Langlois S. Comparison of</a></text>
<text top="759" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1046">withdrawal phenomena after propranolol, metoprolol,</a></text>
<text top="772" left="301" width="162" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1046">and pindolol. Am Heart J. 1982;104:473</a></text>
<text top="771" left="463" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1046">–8</a></text>
<text top="772" left="472" width="3" height="9" font="4">.</text>
<text top="791" left="301" width="34" height="9" font="4">S11.5-31.</text>
<text top="791" left="338" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1047">Walker PR, Marshall AJ, Farr S, et al. Abrupt</a></text>
<text top="804" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1047">withdrawal of atenolol in patients with severe angina.</a></text>
<text top="818" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1047">Comparison with the effects of treatment. Br Heart J.</a></text>
<text top="831" left="301" width="50" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1047">1985;53:276</a></text>
<text top="829" left="351" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1047">–82</a></text>
<text top="831" left="365" width="3" height="9" font="4">.</text>
<text top="871" left="301" width="181" height="12" font="26">1 2 . S T R A T E G I E S T O I M P R O V E</text>
<text top="885" left="301" width="209" height="12" font="26">H Y P E R T E N S I O N T R E A T M E N T A N D</text>
<text top="898" left="301" width="59" height="12" font="26">C O N T R O L</text>
<text top="930" left="301" width="217" height="9" font="23">12.1. Adherence Strategies for Treatment of</text>
<text top="943" left="301" width="62" height="9" font="23">Hypertension</text>
<text top="968" left="301" width="217" height="9" font="4">12.1.1. Antihypertensive Medication Adherence</text>
<text top="981" left="301" width="45" height="9" font="4">Strategies</text>
<text top="995" left="301" width="36" height="9" font="4">S12.1.1-1.</text>
<text top="995" left="340" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1048">Claxton AJ, Cramer J, Pierce C. A systematic</a></text>
<text top="1008" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1048">review of the associations between dose regimens and</a></text>
<text top="1022" left="301" width="194" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1048">medication compliance. Clin Ther. 2001;23:1296</a></text>
<text top="1020" left="495" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1048">–310</a></text>
<text top="1022" left="514" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1048">.</a></text>
<text top="1040" left="301" width="37" height="9" font="4">S12.1.1-2.</text>
<text top="1040" left="341" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1049">Iskedjian M, Einarson TR, MacKeigan LD,</a></text>
<text top="1054" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1049">et al. Relationship between daily dose frequency</a></text>
<text top="1067" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1049">and adherence to antihypertensive pharmacotherapy:</a></text>
<text top="1081" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1049">evidence from a meta-analysis. Clin Ther. 2002;24:</a></text>
<text top="1094" left="301" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1049">302</a></text>
<text top="1092" left="317" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1049">–16</a></text>
<text top="1094" left="330" width="3" height="9" font="4">.</text>
<text top="143" left="539" width="37" height="9" font="4">S12.1.1-3.</text>
<text top="143" left="579" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1050">Schroeder K, Fahey T, Ebrahim S. How can</a></text>
<text top="156" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1050">we improve adherence to blood pressure-lowering</a></text>
<text top="170" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1050">medication in ambulatory care? Systematic review of</a></text>
<text top="183" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1050">randomized controlled trials. Arch Intern Med. 2004;</a></text>
<text top="197" left="539" width="32" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1050">164:722</a></text>
<text top="195" left="571" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1050">–32</a></text>
<text top="197" left="585" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1050">.</a></text>
<text top="216" left="539" width="37" height="9" font="4">S12.1.1-4.</text>
<text top="216" left="580" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1051">Bangalore S, Kamalakkannan G, Parkar S,</a></text>
<text top="229" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1051">et al. Fixed-dose combinations improve medication</a></text>
<text top="243" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1051">compliance: a meta-analysis. Am J Med. 2007;120:</a></text>
<text top="256" left="539" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1051">713</a></text>
<text top="255" left="552" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1051">–9</a></text>
<text top="256" left="562" width="3" height="9" font="4">.</text>
<text top="275" left="539" width="37" height="9" font="4">S12.1.1-5.</text>
<text top="275" left="579" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1052">Gupta AK, Arshad S, Poulter NR. Compliance,</a></text>
<text top="289" left="539" width="114" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1052">safety, and effectiveness of</a></text>
<text top="287" left="657" width="99" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1052">ﬁxed-dose combinations</a></text>
<text top="302" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1052">of antihypertensive agents: a meta-analysis. Hyper-</a></text>
<text top="316" left="539" width="86" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1052">tension. 2010;55:399</a></text>
<text top="314" left="626" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1052">–407</a></text>
<text top="316" left="646" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1052">.</a></text>
<text top="335" left="539" width="37" height="9" font="4">S12.1.1-6.</text>
<text top="335" left="580" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1053">Sherrill B, Halpern M, Khan S, et al. Single-</a></text>
<text top="348" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1053">pill vs free-equivalent combination therapies for</a></text>
<text top="361" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1053">hypertension: a meta-analysis of health care costs and</a></text>
<text top="375" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1053">adherence. J Clin Hypertens (Greenwich). 2011;13:</a></text>
<text top="388" left="539" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1053">898</a></text>
<text top="387" left="556" width="21" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1053">–909</a></text>
<text top="388" left="577" width="3" height="9" font="4">.</text>
<text top="407" left="539" width="37" height="9" font="4">S12.1.1-7.</text>
<text top="407" left="579" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1054">Yang W, Chang J, Kahler KH, et al.</a></text>
<text top="421" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1054">Evaluation of compliance and health care utilization</a></text>
<text top="434" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1054">in patients treated with single pill vs. free combina-</a></text>
<text top="448" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1054">tion antihypertensives. Curr Med Res Opin. 2010;26:</a></text>
<text top="461" left="539" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1054">2065</a></text>
<text top="460" left="561" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1054">–76</a></text>
<text top="461" left="575" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1054">.</a></text>
<text top="480" left="539" width="37" height="9" font="4">S12.1.1-8.</text>
<text top="480" left="580" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1055">Franklin SS, Thijs L, Hansen TW, et al.</a></text>
<text top="494" left="539" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1055">Signi</a></text>
<text top="492" left="559" width="198" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1055">ﬁcance of white-coat hypertension in older</a></text>
<text top="507" left="539" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1055">persons</a></text>
<text top="507" left="580" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1055">with</a></text>
<text top="507" left="607" width="31" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1055">isolated</a></text>
<text top="507" left="648" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1055">systolic</a></text>
<text top="507" left="688" width="55" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1055">hypertension:</a></text>
<text top="507" left="752" width="4" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1055">a</a></text>
<text top="521" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1055">meta-analysis using the International Database on</a></text>
<text top="534" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1055">Ambulatory Blood Pressure Monitoring in Relation to</a></text>
<text top="547" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1055">Cardiovascular Outcomes population. Hypertension.</a></text>
<text top="561" left="539" width="51" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1055">2012;59:564</a></text>
<text top="559" left="590" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1055">–71</a></text>
<text top="561" left="603" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1055">.</a></text>
<text top="580" left="539" width="37" height="9" font="4">S12.1.1-9.</text>
<text top="580" left="580" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1056">Holland N, Segraves D, Nnadi VO, et al.</a></text>
<text top="593" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1056">Identifying barriers to hypertension care: implications</a></text>
<text top="607" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1056">for quality improvement initiatives. Dis Manag. 2008;</a></text>
<text top="620" left="539" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1056">11:71</a></text>
<text top="619" left="558" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1056">–7</a></text>
<text top="620" left="566" width="3" height="9" font="4">.</text>
<text top="639" left="539" width="42" height="9" font="4">S12.1.1-10.</text>
<text top="639" left="584" width="172" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1057">Berra E, Azizi M, Capron A, et al. Evaluation</a></text>
<text top="653" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1057">of adherence should become an integral part of</a></text>
<text top="666" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1057">assessment of patients with apparently treatment-</a></text>
<text top="680" left="539" width="213" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1057">resistant hypertension. Hypertension. 2016;68:297</a></text>
<text top="678" left="752" width="4" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1057">–</a></text>
<text top="693" left="539" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1057">306</a></text>
<text top="693" left="556" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1057">.</a></text>
<text top="712" left="539" width="40" height="9" font="4">S12.1.1-11.</text>
<text top="712" left="582" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1058">Gwadry-Sridhar FH, Manias E, Lal L, et al.</a></text>
<text top="726" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1058">Impact of interventions on medication adherence</a></text>
<text top="739" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1058">and blood pressure control in patients with essential</a></text>
<text top="753" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1058">hypertension: a systematic review by the ISPOR</a></text>
<text top="766" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1058">medication adherence and persistence special interest</a></text>
<text top="779" left="539" width="136" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1058">group. Value Health. 2013;16:863</a></text>
<text top="778" left="675" width="12" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1058">–71</a></text>
<text top="779" left="688" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1058">.</a></text>
<text top="799" left="539" width="40" height="9" font="4">S12.1.1-12.</text>
<text top="799" left="583" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1059">Petrilla AA, Benner JS, Battleman DS, et al.</a></text>
<text top="812" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1059">Evidence-based interventions to improve patient</a></text>
<text top="825" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1059">compliance with antihypertensive and lipid-lowering</a></text>
<text top="839" left="539" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1059">medications. Int J Clin Pract. 2005;59:1441</a></text>
<text top="837" left="713" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1059">–51</a></text>
<text top="839" left="726" width="3" height="9" font="4">.</text>
<text top="858" left="539" width="40" height="9" font="4">S12.1.1-13.</text>
<text top="858" left="583" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1060">Brown MT, Bussell JK. Medication adher-</a></text>
<text top="871" left="539" width="192" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1060">ence: WHO cares? Mayo Clin Proc. 2011;86:304</a></text>
<text top="870" left="731" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1060">–14</a></text>
<text top="871" left="744" width="3" height="9" font="4">.</text>
<text top="890" left="539" width="41" height="9" font="4">S12.1.1-14.</text>
<text top="890" left="584" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1061">Krousel-Wood MA, Muntner P, Islam T,</a></text>
<text top="904" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1061">et al. Barriers to and determinants of medication</a></text>
<text top="917" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1061">adherence in hypertension management: perspective</a></text>
<text top="931" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1061">of the cohort study of medication adherence among</a></text>
<text top="944" left="539" width="189" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1061">older adults. Med Clin North Am. 2009;93:753</a></text>
<text top="942" left="728" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1061">–69</a></text>
<text top="944" left="744" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1061">.</a></text>
<text top="963" left="539" width="40" height="9" font="4">S12.1.1-15.</text>
<text top="963" left="583" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1062">Nieuwlaat R, Wilczynski N, Navarro T, et al.</a></text>
<text top="977" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1062">Interventions for enhancing medication adherence.</a></text>
<text top="990" left="539" width="195" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1062">Cochrane Database Syst Rev. 2014;11:CD000011</a></text>
<text top="990" left="735" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1062">.</a></text>
<text top="1009" left="539" width="41" height="9" font="4">S12.1.1-16.</text>
<text top="1009" left="584" width="173" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1063">Viswanathan M, Golin CE, Jones CD, et al.</a></text>
<text top="1023" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1063">Closing the quality gap: revisiting the state of the</a></text>
<text top="1036" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1063">science (vol. 4: medication adherence interventions:</a></text>
<text top="1049" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1063">comparative effectiveness). Evid RepTechnol Assess</a></text>
<text top="1063" left="539" width="71" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1063">(Full Rep). 2012:1</a></text>
<text top="1061" left="610" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1063">–685</a></text>
<text top="1063" left="630" width="3" height="9" font="4">.</text>
<text top="1082" left="539" width="40" height="9" font="4">S12.1.1-17.</text>
<text top="1082" left="583" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1064">Kim MT, Hill MN, Bone LR, et al. Develop-</a></text>
<text top="1095" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1064">ment and testing of the Hill-Bone Compliance to High</a></text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="788" width="19" height="9" font="4">e235</text>
</page>
<page number="110" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1064">Blood Pressure Therapy Scale. Prog Cardiovasc Nurs.</a></text>
<text top="156" left="108" width="49" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1064">2000;15:90</a></text>
<text top="155" left="156" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1064">–6</a></text>
<text top="156" left="166" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1064">.</a></text>
<text top="178" left="108" width="27" height="9" font="4">12.1.2.</text>
<text top="178" left="149" width="45" height="9" font="4">Strategies</text>
<text top="178" left="209" width="9" height="9" font="4">to</text>
<text top="178" left="232" width="38" height="9" font="4">Promote</text>
<text top="178" left="285" width="39" height="9" font="4">Lifestyle</text>
<text top="192" left="108" width="23" height="9" font="4">Modi</text>
<text top="190" left="131" width="34" height="12" font="4">ﬁcation</text>
<text top="206" left="108" width="37" height="9" font="4">S12.1.2-1.</text>
<text top="206" left="147" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1065">Artinian NT, Fletcher GF, Mozaffarian D,</a></text>
<text top="219" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1065">et al. Interventions to promote physical activity and</a></text>
<text top="232" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1065">dietary lifestyle changes for cardiovascular risk factor</a></text>
<text top="246" left="108" width="121" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1065">reduction in adults: a scienti</a></text>
<text top="244" left="228" width="96" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1065">ﬁc statement from the</a></text>
<text top="259" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1065">American Heart Association. Circulation. 2010;122:</a></text>
<text top="273" left="108" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1065">406</a></text>
<text top="271" left="125" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1065">–41</a></text>
<text top="273" left="138" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1065">.</a></text>
<text top="292" left="108" width="37" height="9" font="4">S12.1.2-2.</text>
<text top="292" left="148" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1066">Eckel RH, Jakicic JM, Ard JD, et al. 2013</a></text>
<text top="305" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1066">AHA/ACC guideline on lifestyle management to reduce</a></text>
<text top="318" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1066">cardiovascular risk: a report of the American College of</a></text>
<text top="332" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1066">Cardiology/American Heart Association Task Force on</a></text>
<text top="345" left="108" width="213" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1066">Practice Guidelines. J Am Coll Cardiol. 2014;63:2960</a></text>
<text top="344" left="321" width="4" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1066">–</a></text>
<text top="359" left="108" width="11" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1066">84</a></text>
<text top="359" left="119" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1066">.</a></text>
<text top="380" left="108" width="217" height="9" font="4">12.1.3. Improving Quality of Care for Resource-</text>
<text top="394" left="108" width="112" height="9" font="4">Constrained Populations</text>
<text top="408" left="108" width="37" height="9" font="4">S12.1.3-1.</text>
<text top="408" left="147" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1067">Havranek EP, Mujahid MS, Barr DA, et al.</a></text>
<text top="421" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1067">Social determinants of risk and outcomes for cardio-</a></text>
<text top="435" left="108" width="114" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1067">vascular disease: a scienti</a></text>
<text top="433" left="222" width="103" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1067">ﬁc statement from the</a></text>
<text top="448" left="108" width="213" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1067">American Heart Association. Circulation. 2015;132:873</a></text>
<text top="447" left="321" width="4" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1067">–</a></text>
<text top="462" left="108" width="11" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1067">98</a></text>
<text top="462" left="119" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1067">.</a></text>
<text top="480" left="108" width="37" height="9" font="4">S12.1.3-2.</text>
<text top="480" left="148" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1068">Institute of Medicine (U.S.) Committee on</a></text>
<text top="494" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1068">Public Health Priorities to Reduce and Control Hyper-</a></text>
<text top="507" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1068">tension. A Population-Based Policy and Systems</a></text>
<text top="521" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1068">Change Approach to Prevent and Control Hyperten-</a></text>
<text top="534" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1068">sion. Washington, DC: National Academies Press;</a></text>
<text top="548" left="108" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1068">2010</a></text>
<text top="548" left="128" width="3" height="9" font="4">.</text>
<text top="567" left="108" width="37" height="9" font="4">S12.1.3-3.</text>
<text top="567" left="148" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1069">Margolius D, Bodenheimer T, Bennett H,</a></text>
<text top="580" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1069">et al. Health coaching to improve hypertension treat-</a></text>
<text top="593" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1069">ment in a low-income, minority population. Ann Fam</a></text>
<text top="607" left="108" width="72" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1069">Med. 2012;10:199</a></text>
<text top="605" left="180" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1069">–205</a></text>
<text top="607" left="200" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1069">.</a></text>
<text top="626" left="108" width="38" height="9" font="4">S12.1.3-4.</text>
<text top="626" left="149" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1070">Polgreen LA, Han J, Carter BL, et al. Cost-</a></text>
<text top="639" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1070">effectiveness of a physician-pharmacist collaboration</a></text>
<text top="653" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1070">intervention to improve blood pressure control. Hy-</a></text>
<text top="666" left="108" width="101" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1070">pertension. 2015;66:1145</a></text>
<text top="664" left="209" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1070">–51</a></text>
<text top="666" left="222" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1070">.</a></text>
<text top="685" left="108" width="37" height="9" font="4">S12.1.3-5.</text>
<text top="685" left="148" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1071">Brownstein JN, Chowdhury FM, Norris SL,</a></text>
<text top="698" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1071">et al. Effectiveness of community health workers in</a></text>
<text top="712" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1071">the care of people with hypertension. Am J Prev Med.</a></text>
<text top="725" left="108" width="51" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1071">2007;32:435</a></text>
<text top="724" left="159" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1071">–47</a></text>
<text top="725" left="173" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1071">.</a></text>
<text top="747" left="108" width="217" height="9" font="23">12.2. Structured, Team-Based Care Interventions</text>
<text top="760" left="108" width="111" height="9" font="23">for Hypertension Control</text>
<text top="783" left="108" width="30" height="9" font="4">S12.2-1.</text>
<text top="783" left="141" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1072">Carter BL, Rogers M, Daly J, et al. The potency</a></text>
<text top="797" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1072">of team-based care interventions for hypertension: a</a></text>
<text top="810" left="108" width="193" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1072">meta-analysis. Arch Intern Med. 2009;169:1748</a></text>
<text top="808" left="301" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1072">–55</a></text>
<text top="810" left="315" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1072">.</a></text>
<text top="829" left="108" width="31" height="9" font="4">S12.2-2.</text>
<text top="829" left="142" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1073">Clark CE, Smith LFP, Taylor RS, et al. Nurse</a></text>
<text top="842" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1073">led interventions to improve control of blood pressure</a></text>
<text top="856" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1073">in people with hypertension: systematic review and</a></text>
<text top="869" left="108" width="148" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1073">meta-analysis. BMJ. 2010;341:c3995</a></text>
<text top="869" left="256" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1073">.</a></text>
<text top="888" left="108" width="31" height="9" font="4">S12.2-3.</text>
<text top="888" left="142" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1074">Proia KK, Thota AB, Njie GJ, et al. Team-based</a></text>
<text top="902" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1074">care and improved blood pressure control: a commu-</a></text>
<text top="915" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1074">nity guide systematic review. Am J Prev Med. 2014;47:</a></text>
<text top="928" left="108" width="11" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1074">86</a></text>
<text top="927" left="119" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1074">–99</a></text>
<text top="928" left="134" width="3" height="9" font="4">.</text>
<text top="947" left="108" width="32" height="9" font="4">S12.2-4.</text>
<text top="947" left="143" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1075">Santschi V, Chiolero A, Colosimo AL, et al.</a></text>
<text top="961" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1075">Improving blood pressure control through pharmacist</a></text>
<text top="974" left="108" width="55" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1075">interventions:</a></text>
<text top="974" left="175" width="4" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1075">a</a></text>
<text top="974" left="191" width="55" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1075">meta-analysis</a></text>
<text top="974" left="258" width="8" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1075">of</a></text>
<text top="974" left="278" width="47" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1075">randomized</a></text>
<text top="988" left="108" width="213" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1075">controlled trials. J Am Heart Assoc. 2014;3:e000718</a></text>
<text top="988" left="320" width="3" height="9" font="4">.</text>
<text top="1006" left="108" width="31" height="9" font="4">S12.2-5.</text>
<text top="1006" left="142" width="66" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1076">Shaw RJ, McDuf</a></text>
<text top="1005" left="208" width="117" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1076">ﬁe JR, Hendrix CC, et al. Ef-</a></text>
<text top="1020" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1076">fects of nurse-managed protocols in the outpatient</a></text>
<text top="1033" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1076">management of adults with chronic conditions: a sys-</a></text>
<text top="1047" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1076">tematic review and meta-analysis. Ann Intern Med.</a></text>
<text top="1060" left="108" width="51" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1076">2014;161:113</a></text>
<text top="1058" left="158" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1076">–21</a></text>
<text top="1060" left="171" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1076">.</a></text>
<text top="1082" left="108" width="32" height="9" font="4">S12.2-6.</text>
<text top="1082" left="143" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1077">Thomas KL, Shah BR, Elliot-Bynum S, et al.</a></text>
<text top="1095" left="108" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1077">Check it, change it: a community-based, multifaceted</a></text>
<text top="143" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1077">intervention to improve blood pressure control. Circ</a></text>
<text top="156" left="346" width="158" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1077">Cardiovasc Qual Outcomes. 2014;7:828</a></text>
<text top="155" left="504" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1077">–34</a></text>
<text top="156" left="518" width="3" height="9" font="4">.</text>
<text top="178" left="346" width="31" height="9" font="4">S12.2-7.</text>
<text top="178" left="380" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1078">Carter BL, Coffey CS, Ardery G, et al. Cluster-</a></text>
<text top="192" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1078">randomized trial of a physician/pharmacist collabora-</a></text>
<text top="205" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1078">tive model to improve blood pressure control. Circ</a></text>
<text top="218" left="346" width="157" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1078">Cardiovasc Qual Outcomes. 2015;8:235</a></text>
<text top="217" left="503" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1078">–43</a></text>
<text top="218" left="517" width="3" height="9" font="4">.</text>
<text top="239" left="346" width="32" height="9" font="4">S12.2-8.</text>
<text top="239" left="381" width="182" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1079">Himmelfarb CRD, Commodore-Mensah Y,</a></text>
<text top="252" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1079">Hill MN. Expanding the role of nurses to improve hy-</a></text>
<text top="265" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1079">pertension care and control globally. Ann Glob Health.</a></text>
<text top="279" left="346" width="51" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1079">2016;82:243</a></text>
<text top="277" left="397" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1079">–53</a></text>
<text top="279" left="410" width="3" height="9" font="4">.</text>
<text top="297" left="346" width="217" height="9" font="4">S12.2-9. The Guide to Community Preventive Services</text>
<text top="311" left="346" width="217" height="9" font="4">(The Community Guide). Cardiovascular Disease:</text>
<text top="324" left="346" width="217" height="9" font="4">Team-Based Care to Improve Blood Pressure Control.</text>
<text top="338" left="346" width="77" height="9" font="4">2012. Available at:</text>
<text top="338" left="427" width="136" height="9" font="8"><a href="https://www.thecommunityguide.org/findings/cardiovascular-disease-team-based-care-improve-blood-pressure-control">https://www.thecommunityguide.</a></text>
<text top="351" left="346" width="17" height="9" font="8"><a href="https://www.thecommunityguide.org/findings/cardiovascular-disease-team-based-care-improve-blood-pressure-control">org/</a></text>
<text top="350" left="363" width="199" height="12" font="8"><a href="https://www.thecommunityguide.org/findings/cardiovascular-disease-team-based-care-improve-blood-pressure-control">ﬁndings/cardiovascular-disease-team-based-care-</a></text>
<text top="365" left="346" width="121" height="9" font="8"><a href="https://www.thecommunityguide.org/findings/cardiovascular-disease-team-based-care-improve-blood-pressure-control">improve-blood-pressure-control</a></text>
<text top="365" left="467" width="96" height="9" font="4"><a href="https://www.thecommunityguide.org/findings/cardiovascular-disease-team-based-care-improve-blood-pressure-control">. </a>Accessed June 1, 2017.</text>
<text top="383" left="346" width="217" height="9" font="4">S12.2-10. Centers for Disease Control and Prevention.</text>
<text top="397" left="346" width="18" height="9" font="4">Task</text>
<text top="397" left="374" width="22" height="9" font="4">Force</text>
<text top="397" left="406" width="51" height="9" font="4">recommends</text>
<text top="397" left="467" width="47" height="9" font="4">team-based</text>
<text top="397" left="525" width="17" height="9" font="4">care</text>
<text top="397" left="551" width="12" height="9" font="4">for</text>
<text top="410" left="346" width="217" height="9" font="4">improving blood pressure control. Press Release. May</text>
<text top="424" left="346" width="96" height="9" font="4">15, 2012. Available at:</text>
<text top="424" left="447" width="115" height="9" font="8"><a href="https://www.cdc.gov/media/releases/2012/p0515_bp_control.html">https://www.cdc.gov/media/</a></text>
<text top="437" left="346" width="149" height="9" font="8"><a href="https://www.cdc.gov/media/releases/2012/p0515_bp_control.html">releases/2012/p0515_bp_control.html</a></text>
<text top="437" left="495" width="3" height="9" font="4">.</text>
<text top="437" left="527" width="36" height="9" font="4">Accessed</text>
<text top="451" left="346" width="82" height="9" font="4">September 17, 2017.</text>
<text top="469" left="346" width="34" height="9" font="4">S12.2-11.</text>
<text top="469" left="383" width="180" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1082">Tsuyuki RT, Al Hamarneh YN, Jones CA, et al.</a></text>
<text top="483" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1082">The effectiveness of pharmacist interventions on car-</a></text>
<text top="496" left="346" width="45" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1082">diovascular</a></text>
<text top="496" left="402" width="16" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1082">risk:</a></text>
<text top="496" left="430" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1082">The</a></text>
<text top="496" left="457" width="46" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1082">Multicenter</a></text>
<text top="496" left="514" width="49" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1082">Randomized</a></text>
<text top="509" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1082">Controlled RxEACH Trial. J Am Coll Cardiol. 2016;67:</a></text>
<text top="523" left="346" width="21" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1082">2846</a></text>
<text top="521" left="367" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1082">–54</a></text>
<text top="523" left="382" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1082">.</a></text>
<text top="542" left="346" width="35" height="9" font="4">S12.2-12.</text>
<text top="542" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1083">Brownstein JN, Chowdhury FM, Norris SL,</a></text>
<text top="555" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1083">et al. Effectiveness of community health workers in</a></text>
<text top="568" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1083">the care of people with hypertension. Am J Prev Med.</a></text>
<text top="582" left="346" width="51" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1083">2007;32:435</a></text>
<text top="580" left="397" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1083">–47</a></text>
<text top="582" left="411" width="3" height="9" font="4">.</text>
<text top="600" left="346" width="35" height="9" font="4">S12.2-13.</text>
<text top="600" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1084">Brush JE Jr., Handberg EM, Biga C, et al.</a></text>
<text top="614" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1084">2015 ACC health policy statement on cardiovascular</a></text>
<text top="627" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1084">team-based care and the role of advanced practice</a></text>
<text top="641" left="346" width="171" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1084">providers. J Am Coll Cardiol. 2015;65:2118</a></text>
<text top="639" left="517" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1084">–36</a></text>
<text top="641" left="531" width="3" height="9" font="4">.</text>
<text top="659" left="346" width="217" height="9" font="4">S12.2-14. Patient-Centered Primary Care Collabora-</text>
<text top="673" left="346" width="217" height="9" font="4">tive. The Patient-Centered Medical Home: Integrating</text>
<text top="686" left="346" width="217" height="9" font="4">Comprehensive Medication Management to Optimize</text>
<text top="700" left="346" width="217" height="9" font="4">Patient Outcomes: Resource Guide. 2010. Available at:</text>
<text top="713" left="346" width="164" height="9" font="8"><a href="https://www.pcpcc.org/sites/default/files/media/medmanagement.pdf">https://www.pcpcc.org/sites/default/</a></text>
<text top="712" left="510" width="51" height="12" font="8"><a href="https://www.pcpcc.org/sites/default/files/media/medmanagement.pdf">ﬁles/media/</a></text>
<text top="727" left="346" width="92" height="9" font="8"><a href="https://www.pcpcc.org/sites/default/files/media/medmanagement.pdf">medmanagement.pdf</a></text>
<text top="727" left="438" width="102" height="9" font="4">. Accessed June 15, 2017.</text>
<text top="745" left="346" width="35" height="9" font="4">S12.2-15.</text>
<text top="745" left="384" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1086">Dunn SP, Birtcher KK, Beavers CJ, et al. The</a></text>
<text top="759" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1086">role of the clinical pharmacist in the care of patients</a></text>
<text top="772" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1086">with cardiovascular disease. J Am Coll Cardiol. 2015;</a></text>
<text top="786" left="346" width="33" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1086">66:2129</a></text>
<text top="784" left="379" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1086">–39</a></text>
<text top="786" left="393" width="3" height="9" font="4">.</text>
<text top="807" left="346" width="20" height="9" font="23">12.3.</text>
<text top="807" left="375" width="30" height="9" font="23">Health</text>
<text top="807" left="415" width="55" height="9" font="23">Information</text>
<text top="807" left="479" width="53" height="9" font="23">Technology</text>
<text top="806" left="532" width="31" height="12" font="23">–Based</text>
<text top="821" left="346" width="201" height="9" font="23">Strategies to Promote Hypertension Control</text>
<text top="847" left="346" width="154" height="9" font="4">12.3.1. EHR and Patient Registries</text>
<text top="861" left="346" width="37" height="9" font="4">S12.3.1-1.</text>
<text top="861" left="385" width="178" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1087">Rakotz MK, Ewigman BG, Sarav M, et al.</a></text>
<text top="875" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1087">A technology-based quality innovation to identify</a></text>
<text top="888" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1087">undiagnosed hypertension among active primary care</a></text>
<text top="902" left="346" width="147" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1087">patients. Ann Fam Med. 2014;12:352</a></text>
<text top="900" left="493" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1087">–8</a></text>
<text top="902" left="503" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1087">.</a></text>
<text top="920" left="346" width="37" height="9" font="4">S12.3.1-2.</text>
<text top="920" left="386" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1088">Borden WB, Maddox TM, Tang F, et al. Impact</a></text>
<text top="934" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1088">of the 2014 expert panel recommendations for man-</a></text>
<text top="947" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1088">agement of high blood pressure on contemporary car-</a></text>
<text top="961" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1088">diovascular practice: insights from the NCDR PINNACLE</a></text>
<text top="974" left="346" width="165" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1088">registry. J Am Coll Cardiol. 2014;64:2196</a></text>
<text top="973" left="511" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1088">–203</a></text>
<text top="974" left="530" width="3" height="9" font="4">.</text>
<text top="993" left="346" width="37" height="9" font="4">S12.3.1-3.</text>
<text top="993" left="386" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1089">Jaffe MG, Lee GA, Young JD, et al. Improved</a></text>
<text top="1006" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1089">blood pressure control associated with a large-scale</a></text>
<text top="1020" left="346" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1089">hypertension program. JAMA. 2013;310:699</a></text>
<text top="1018" left="525" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1089">–705</a></text>
<text top="1020" left="544" width="3" height="9" font="4">.</text>
<text top="1041" left="346" width="217" height="9" font="4">12.3.2. Telehealth Interventions to Improve</text>
<text top="1055" left="346" width="99" height="9" font="4">Hypertension Control</text>
<text top="1069" left="346" width="37" height="9" font="4">S12.3.2-1.</text>
<text top="1069" left="386" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1090">Omboni S, Gazzola T, Carabelli G, et al.</a></text>
<text top="1082" left="346" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1090">Clinical usefulness and cost effectiveness of home</a></text>
<text top="1095" left="346" width="23" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1090">blood</a></text>
<text top="1095" left="378" width="104" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1090">pressure telemonitoring:</a></text>
<text top="1095" left="491" width="72" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1090">meta-analysis of</a></text>
<text top="143" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1090">randomized controlled studies. J Hypertens. 2013;31:</a></text>
<text top="156" left="584" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1090">455</a></text>
<text top="155" left="599" width="88" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1090">–67; discussion 467–8</a></text>
<text top="156" left="688" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1090">.</a></text>
<text top="177" left="584" width="38" height="9" font="4">S12.3.2-2.</text>
<text top="177" left="626" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1091">Verberk WJ, Kessels AGH, Thien T. Telecare</a></text>
<text top="190" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1091">is a valuable tool for hypertension management, a</a></text>
<text top="204" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1091">systematic review and meta-analysis. Blood Press</a></text>
<text top="217" left="584" width="76" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1091">Monit. 2011;16:149</a></text>
<text top="216" left="661" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1091">–55</a></text>
<text top="217" left="674" width="3" height="9" font="4">.</text>
<text top="238" left="584" width="38" height="9" font="4">S12.3.2-3.</text>
<text top="238" left="626" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1092">Agarwal R, Bills JE, Hecht TJW, et al. Role</a></text>
<text top="251" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1092">of home blood pressure monitoring in overcoming</a></text>
<text top="264" left="584" width="45" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1092">therapeutic</a></text>
<text top="264" left="640" width="25" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1092">inertia</a></text>
<text top="264" left="675" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1092">and</a></text>
<text top="264" left="699" width="40" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1092">improving</a></text>
<text top="264" left="749" width="52" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1092">hypertension</a></text>
<text top="278" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1092">control: a systematic review and meta-analysis.</a></text>
<text top="291" left="584" width="102" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1092">Hypertension. 2011;57:29</a></text>
<text top="290" left="686" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1092">–38</a></text>
<text top="291" left="701" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1092">.</a></text>
<text top="312" left="584" width="39" height="9" font="4">S12.3.2-4.</text>
<text top="312" left="627" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1093">Liu S, Dunford SD, Leung YW, et al.</a></text>
<text top="325" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1093">Reducing blood pressure with Internet-based in-</a></text>
<text top="339" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1093">terventions: a meta-analysis. Can J Cardiol. 2013;29:</a></text>
<text top="352" left="584" width="14" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1093">613</a></text>
<text top="350" left="598" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1093">–21</a></text>
<text top="352" left="611" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1093">.</a></text>
<text top="371" left="584" width="38" height="9" font="4">S12.3.2-5.</text>
<text top="371" left="626" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1094">Burke LE, Ma J, Azar KMJ, et al. Current</a></text>
<text top="384" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1094">science on consumer use of mobile health for cardio-</a></text>
<text top="398" left="584" width="161" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1094">vascular disease prevention: a scienti</a></text>
<text top="396" left="745" width="56" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1094">ﬁc statement</a></text>
<text top="411" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1094">from the American Heart Association. Circulation.</a></text>
<text top="425" left="584" width="55" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1094">2015;132:1157</a></text>
<text top="423" left="639" width="17" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1094">–213</a></text>
<text top="425" left="656" width="3" height="9" font="4">.</text>
<text top="444" left="584" width="39" height="9" font="4">S12.3.2-6.</text>
<text top="444" left="626" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1095">Li JS, Barnett TA, Goodman E, et al.</a></text>
<text top="457" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1095">Approaches to the prevention and management of</a></text>
<text top="470" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1095">childhood obesity: the role of social networks and</a></text>
<text top="484" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1095">the use of social media and related electronic</a></text>
<text top="497" left="584" width="105" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1095">technologies: a scienti</a></text>
<text top="496" left="690" width="111" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1095">ﬁc statement from the</a></text>
<text top="511" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1095">American Heart Association. Circulation. 2013;127:</a></text>
<text top="524" left="584" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1095">260</a></text>
<text top="523" left="602" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1095">–7</a></text>
<text top="524" left="611" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1095">.</a></text>
<text top="543" left="584" width="38" height="9" font="4">S12.3.2-7.</text>
<text top="543" left="626" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1096">Omboni S, Ferrari R. The role of telemed-</a></text>
<text top="556" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1096">icine in hypertension management: focus on blood</a></text>
<text top="570" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1096">pressure telemonitoring. Curr Hypertens Rep. 2015;</a></text>
<text top="583" left="584" width="25" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1096">17:535</a></text>
<text top="583" left="610" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1096">.</a></text>
<text top="605" left="584" width="217" height="9" font="23">12.4. Improving Quality of Care for Patients</text>
<text top="619" left="584" width="87" height="9" font="23">With Hypertension</text>
<text top="644" left="584" width="135" height="9" font="4">12.4.1. Performance Measures</text>
<text top="659" left="584" width="37" height="9" font="4">S12.4.1-1.</text>
<text top="659" left="625" width="177" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1097">Svetkey LP, Pollak KI, Yancy WS Jr., et al.</a></text>
<text top="673" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1097">Hypertension improvement project: randomized trial</a></text>
<text top="686" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1097">of quality improvement for physicians and lifestyle</a></text>
<text top="700" left="584" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1097">modi</a></text>
<text top="698" left="604" width="197" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1097">ﬁcation for patients. Hypertension. 2009;54:</a></text>
<text top="713" left="584" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1097">1226</a></text>
<text top="712" left="603" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1097">–33</a></text>
<text top="713" left="617" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1097">.</a></text>
<text top="732" left="584" width="38" height="9" font="4">S12.4.1-2.</text>
<text top="732" left="626" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1098">de Lusignan S, Gallagher H, Jones S, et al.</a></text>
<text top="746" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1098">Audit-based education lowers systolic blood pressure</a></text>
<text top="759" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1098">in chronic kidney disease: the Quality Improvement</a></text>
<text top="772" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1098">in CKD (QICKD) trial results. Kidney Int. 2013;84:</a></text>
<text top="786" left="584" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1098">609</a></text>
<text top="784" left="601" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1098">–20</a></text>
<text top="786" left="616" width="3" height="9" font="4">.</text>
<text top="805" left="584" width="38" height="9" font="4">S12.4.1-3.</text>
<text top="805" left="626" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1099">Jaffe MG, Lee GA, Young JD, et al. Improved</a></text>
<text top="818" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1099">blood pressure control associated with a large-scale</a></text>
<text top="832" left="584" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1099">hypertension program. JAMA. 2013;310:699</a></text>
<text top="830" left="763" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1099">–705</a></text>
<text top="832" left="782" width="3" height="9" font="4">.</text>
<text top="850" left="584" width="217" height="9" font="4">S12.4.1-4. Performance Management and Measure-</text>
<text top="864" left="584" width="217" height="9" font="4">ment. U.S. Department of Health and Human Services,</text>
<text top="877" left="584" width="217" height="9" font="4">Health Resources and Services Administration; 2011.</text>
<text top="891" left="584" width="50" height="9" font="4">Available at:</text>
<text top="891" left="637" width="145" height="9" font="8"><a href="https://www.hrsa.gov/sites/default/files/quality/toolbox/508pdfs/performancemanagementandmeasurement.pdf">https://www.hrsa.gov/sites/default/</a></text>
<text top="889" left="781" width="20" height="12" font="8"><a href="https://www.hrsa.gov/sites/default/files/quality/toolbox/508pdfs/performancemanagementandmeasurement.pdf">ﬁles/</a></text>
<text top="904" left="584" width="217" height="9" font="8"><a href="https://www.hrsa.gov/sites/default/files/quality/toolbox/508pdfs/performancemanagementandmeasurement.pdf">quality/toolbox/508pdfs/performancemanagement</a></text>
<text top="918" left="584" width="89" height="9" font="8"><a href="https://www.hrsa.gov/sites/default/files/quality/toolbox/508pdfs/performancemanagementandmeasurement.pdf">andmeasurement.pdf</a></text>
<text top="918" left="674" width="118" height="9" font="4"><a href="https://www.hrsa.gov/sites/default/files/quality/toolbox/508pdfs/performancemanagementandmeasurement.pdf">. </a>Accessed October 30, 2017.</text>
<text top="937" left="584" width="38" height="9" font="4">S12.4.1-5.</text>
<text top="937" left="626" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1101">Bardach NS, Wang JJ, De Leon SF, et al.</a></text>
<text top="950" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1101">Effect of pay-for-performance incentives on quality of</a></text>
<text top="963" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1101">care in small practices with electronic health records: a</a></text>
<text top="977" left="584" width="157" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1101">randomized trial. JAMA. 2013;310:1051</a></text>
<text top="975" left="741" width="10" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1101">–9</a></text>
<text top="977" left="751" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1101">.</a></text>
<text top="996" left="584" width="39" height="9" font="4">S12.4.1-6.</text>
<text top="996" left="626" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1102">Navar-Boggan AM, Shah BR, Boggan JC,</a></text>
<text top="1009" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1102">et al. Variability in performance measures for assess-</a></text>
<text top="1023" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1102">ment of hypertension control. Am Heart J. 2013;165:</a></text>
<text top="1036" left="584" width="15" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1102">823</a></text>
<text top="1035" left="599" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1102">–7</a></text>
<text top="1036" left="608" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1102">.</a></text>
<text top="1055" left="584" width="38" height="9" font="4">S12.4.1-7.</text>
<text top="1055" left="626" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1103">Drozda J Jr., Messer JV, Spertus J, et al.</a></text>
<text top="1068" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1103">ACCF/AHA/AMA-PCPI 2011 performance measures for</a></text>
<text top="1082" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1103">adults with coronary artery disease and hypertension:</a></text>
<text top="1095" left="584" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1103">a report of the American College of Cardiology</a></text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="20" height="9" font="4">e236</text>
</page>
<page number="111" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1103">Foundation/American Heart Association Task Force</a></text>
<text top="156" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1103">on Performance Measures and the American Medical</a></text>
<text top="170" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1103">Association-Physician Consortium for Performance</a></text>
<text top="183" left="63" width="161" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1103">Improvement. Circulation. 2011;124:248</a></text>
<text top="182" left="223" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1103">–70</a></text>
<text top="183" left="238" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1103">.</a></text>
<text top="203" left="63" width="39" height="9" font="4">S12.4.1-8.</text>
<text top="203" left="105" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1104">Powers BJ, Olsen MK, Smith VA, et al.</a></text>
<text top="216" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1104">Measuring blood pressure for decision making and</a></text>
<text top="230" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1104">quality reporting: where and how many measures? Ann</a></text>
<text top="243" left="63" width="101" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1104">Intern Med. 2011;154:781</a></text>
<text top="241" left="164" width="58" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1104">–8. W-289–90</a></text>
<text top="243" left="222" width="3" height="9" font="4">.</text>
<text top="262" left="63" width="39" height="9" font="4">S12.4.1-9.</text>
<text top="262" left="105" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1105">Bonow RO, Douglas PS, Buxton AE, et al.</a></text>
<text top="276" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1105">ACCF/AHA methodology for the development of quality</a></text>
<text top="289" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1105">measures for cardiovascular technology: a report of the</a></text>
<text top="303" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1105">American College of Cardiology Foundation/American</a></text>
<text top="316" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1105">Heart Association Task Force on Performance Measures.</a></text>
<text top="330" left="63" width="123" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1105">J Am Coll Cardiol. 2011;58:1517</a></text>
<text top="328" left="186" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1105">–38</a></text>
<text top="330" left="200" width="3" height="9" font="4">.</text>
<text top="351" left="63" width="178" height="9" font="4">12.4.2. Quality Improvement Strategies</text>
<text top="367" left="63" width="38" height="9" font="4">S12.4.2-1.</text>
<text top="367" left="104" width="176" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1106">Walsh JME, McDonald KM, Shojania KG,</a></text>
<text top="380" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1106">et al. Quality improvement strategies for hypertension</a></text>
<text top="394" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1106">management: a systematic review. Med Care. 2006;</a></text>
<text top="407" left="63" width="30" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1106">44:646</a></text>
<text top="405" left="93" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1106">–57</a></text>
<text top="407" left="106" width="3" height="9" font="4">.</text>
<text top="426" left="63" width="39" height="9" font="4">S12.4.2-2.</text>
<text top="426" left="105" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1107">Carter BL, Rogers M, Daly J, et al. The po-</a></text>
<text top="440" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1107">tency of team-based care interventions for hyperten-</a></text>
<text top="453" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1107">sion: a meta-analysis. Arch Intern Med. 2009;169:</a></text>
<text top="467" left="63" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1107">1748</a></text>
<text top="465" left="82" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1107">–55</a></text>
<text top="467" left="96" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1107">.</a></text>
<text top="486" left="63" width="39" height="9" font="4">S12.4.2-3.</text>
<text top="486" left="105" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1108">Glynn LG, Murphy AW, Smith SM, et al. In-</a></text>
<text top="499" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1108">terventions used to improve control of blood pressure</a></text>
<text top="513" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1108">in patients with hypertension. Cochrane Database Syst</a></text>
<text top="526" left="63" width="86" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1108">Rev.. 2010CD005182</a></text>
<text top="526" left="149" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1108">.</a></text>
<text top="546" left="63" width="40" height="9" font="4">S12.4.2-4.</text>
<text top="546" left="106" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1109">Proia KK, Thota AB, Njie GJ, et al. Team-</a></text>
<text top="559" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1109">based care and improved blood pressure control: a</a></text>
<text top="572" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1109">community guide systematic review. Am J Prev Med.</a></text>
<text top="586" left="63" width="46" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1109">2014;47:86</a></text>
<text top="584" left="109" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1109">–99</a></text>
<text top="586" left="124" width="3" height="9" font="4">.</text>
<text top="605" left="63" width="39" height="9" font="4">S12.4.2-5.</text>
<text top="605" left="105" width="114" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1110">Anchala R, Pinto MP, Shrou</a></text>
<text top="604" left="219" width="61" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1110">ﬁ A, et al. The</a></text>
<text top="619" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1110">role of Decision Support System (DSS) in prevention of</a></text>
<text top="632" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1110">cardiovascular disease: a systematic review and meta-</a></text>
<text top="646" left="63" width="144" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1110">analysis. PLoS ONE. 2012;7:e47064</a></text>
<text top="646" left="206" width="3" height="9" font="4">.</text>
<text top="665" left="63" width="40" height="9" font="4">S12.4.2-6.</text>
<text top="665" left="106" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1111">Thomas KL, Shah BR, Elliot-Bynum S, et al.</a></text>
<text top="678" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1111">Check it, change it: a community-based, multifaceted</a></text>
<text top="692" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1111">intervention to improve blood pressure control. Circ</a></text>
<text top="705" left="63" width="158" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1111">Cardiovasc Qual Outcomes. 2014;7:828</a></text>
<text top="704" left="221" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1111">–34</a></text>
<text top="705" left="235" width="3" height="9" font="4">.</text>
<text top="724" left="63" width="39" height="9" font="4">S12.4.2-7.</text>
<text top="724" left="105" width="175" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1112">Jaffe MG, Lee GA, Young JD, et al. Improved</a></text>
<text top="738" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1112">blood pressure control associated with a large-scale</a></text>
<text top="751" left="63" width="179" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1112">hypertension program. JAMA. 2013;310:699</a></text>
<text top="750" left="241" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1112">–705</a></text>
<text top="751" left="261" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1112">.</a></text>
<text top="771" left="63" width="40" height="9" font="4">S12.4.2-8.</text>
<text top="771" left="106" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1113">Agarwal R, Bills JE, Hecht TJW, et al. Role</a></text>
<text top="784" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1113">of home blood pressure monitoring in overcoming</a></text>
<text top="797" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1113">therapeutic inertia and improving hypertension con-</a></text>
<text top="811" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1113">trol: a systematic review and meta-analysis. Hyper-</a></text>
<text top="824" left="63" width="78" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1113">tension. 2011;57:29</a></text>
<text top="823" left="141" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1113">–38</a></text>
<text top="824" left="155" width="3" height="9" font="4">.</text>
<text top="844" left="63" width="40" height="9" font="4">S12.4.2-9.</text>
<text top="844" left="106" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1114">Go AS, Bauman MA, Coleman King SM, et al.</a></text>
<text top="857" left="63" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1114">An effective approach to high blood pressure control:</a></text>
<text top="871" left="63" width="4" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1114">a</a></text>
<text top="871" left="77" width="29" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1114">science</a></text>
<text top="871" left="116" width="33" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1114">advisory</a></text>
<text top="871" left="159" width="19" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1114">from</a></text>
<text top="871" left="188" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1114">the</a></text>
<text top="871" left="211" width="37" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1114">American</a></text>
<text top="871" left="258" width="22" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1114">Heart</a></text>
<text top="143" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1114">Association, the American College of Cardiology, and</a></text>
<text top="156" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1114">the Centers for Disease Control and Prevention. Hy-</a></text>
<text top="170" left="301" width="99" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1114">pertension. 2014;63:878</a></text>
<text top="168" left="400" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1114">–85</a></text>
<text top="170" left="415" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1114">.</a></text>
<text top="190" left="301" width="44" height="9" font="4">S12.4.2-10.</text>
<text top="190" left="348" width="170" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1115">Walsh J, McDonald KM, Shojania KG, et al.</a></text>
<text top="203" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1115">Closing the Quality Gap: A Critical Analysis of Quality</a></text>
<text top="217" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1115">Improvement Strategies (Vol. 3: Hypertension Care).</a></text>
<text top="230" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1115">Rockville, MD: Agency for Healthcare Research and</a></text>
<text top="243" left="301" width="81" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1115">Quality (U.S.), 2005</a></text>
<text top="243" left="382" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1115">.</a></text>
<text top="263" left="301" width="217" height="9" font="4">S12.4.2-11. Center for Medicare and Medicaid Services.</text>
<text top="277" left="301" width="217" height="9" font="4">Million Hearts: Cardiovascular Disease Risk Reduction</text>
<text top="290" left="301" width="103" height="9" font="4">Model. 2016. Available at:</text>
<text top="290" left="407" width="112" height="9" font="8"><a href="https://innovation.cms.gov/initiatives/Million-Hearts-CVDRRM/">https://innovation.cms.gov/</a></text>
<text top="304" left="301" width="141" height="9" font="8"><a href="https://innovation.cms.gov/initiatives/Million-Hearts-CVDRRM/">initiatives/Million-Hearts-CVDRRM/</a></text>
<text top="304" left="442" width="76" height="9" font="4">. Accessed October</text>
<text top="317" left="301" width="38" height="9" font="4">30, 2017.</text>
<text top="339" left="301" width="115" height="9" font="23">12.5. Financial Incentives</text>
<text top="364" left="301" width="30" height="9" font="4">S12.5-1.</text>
<text top="364" left="334" width="184" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1117">Hysong SJ, Simpson K, Pietz K, et al. Financial</a></text>
<text top="377" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1117">incentives and physician commitment to guideline-</a></text>
<text top="391" left="301" width="57" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1117">recommended</a></text>
<text top="391" left="367" width="52" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1117">hypertension</a></text>
<text top="391" left="428" width="55" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1117">management.</a></text>
<text top="391" left="492" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1117">Am</a></text>
<text top="391" left="514" width="4" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1117">J</a></text>
<text top="404" left="301" width="106" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1117">Manag Care. 2012;18:e378</a></text>
<text top="402" left="408" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1117">–91</a></text>
<text top="404" left="421" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1117">.</a></text>
<text top="424" left="301" width="31" height="9" font="4">S12.5-2.</text>
<text top="424" left="335" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1118">Petersen LA, Simpson K, Pietz K, et al. Effects</a></text>
<text top="437" left="301" width="190" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1118">of individual physician-level and practice-level</a></text>
<text top="436" left="495" width="24" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1118">ﬁnan-</a></text>
<text top="451" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1118">cial incentives on hypertension care: a randomized</a></text>
<text top="464" left="301" width="109" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1118">trial. JAMA. 2013;310:1042</a></text>
<text top="463" left="410" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1118">–50</a></text>
<text top="464" left="425" width="3" height="9" font="4">.</text>
<text top="484" left="301" width="31" height="9" font="4">S12.5-3.</text>
<text top="484" left="335" width="183" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1119">Karunaratne K, Stevens P, Irving J, et al. The</a></text>
<text top="497" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1119">impact of pay for performance on the control of blood</a></text>
<text top="511" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1119">pressure in people with chronic kidney disease stage</a></text>
<text top="524" left="301" width="174" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1119">3-5. Nephrol Dial Transplant. 2013;28:2107</a></text>
<text top="523" left="475" width="13" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1119">–16</a></text>
<text top="524" left="489" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1119">.</a></text>
<text top="544" left="301" width="32" height="9" font="4">S12.5-4.</text>
<text top="544" left="336" width="167" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1120">Maimaris W, Paty J, Perel P, et al. The in</a></text>
<text top="542" left="504" width="14" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1120">ﬂu-</a></text>
<text top="558" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1120">ence of health systems on hypertension awareness,</a></text>
<text top="571" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1120">treatment, and control: a systematic literature review.</a></text>
<text top="584" left="301" width="121" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1120">PLoS Med. 2013;10:e1001490</a></text>
<text top="584" left="422" width="3" height="9" font="4">.</text>
<text top="604" left="301" width="217" height="9" font="4">S12.5-5. Center for Medicare and Medicaid Services.</text>
<text top="618" left="301" width="217" height="9" font="4">Million Hearts: Cardiovascular Disease Risk Reduction</text>
<text top="631" left="301" width="103" height="9" font="4">Model. 2016. Available at:</text>
<text top="631" left="407" width="112" height="9" font="8"><a href="https://innovation.cms.gov/initiatives/Million-Hearts-CVDRRM/">https://innovation.cms.gov/</a></text>
<text top="645" left="301" width="141" height="9" font="8"><a href="https://innovation.cms.gov/initiatives/Million-Hearts-CVDRRM/">initiatives/Million-Hearts-CVDRRM/</a></text>
<text top="645" left="442" width="76" height="9" font="4">. Accessed October</text>
<text top="658" left="301" width="38" height="9" font="4">30, 2017.</text>
<text top="698" left="301" width="169" height="12" font="26">1 3 . T H E P L A N O F C A R E F O R</text>
<text top="712" left="301" width="98" height="12" font="26">H Y P E R T E N S I O N</text>
<text top="743" left="301" width="23" height="9" font="4">S13-1.</text>
<text top="743" left="327" width="191" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1122">Jaffe MG, Young JD. The Kaiser Permanente</a></text>
<text top="757" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1122">Northern California story: improving hypertension</a></text>
<text top="770" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1122">control from 44% to 90% in 13 years (2000</a></text>
<text top="784" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1122">to 2013). J Clin Hypertens (Greenwich). 2016;18:</a></text>
<text top="797" left="301" width="17" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1122">260</a></text>
<text top="795" left="318" width="8" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1122">–1</a></text>
<text top="797" left="327" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1122">.</a></text>
<text top="817" left="301" width="24" height="9" font="4">S13-2.</text>
<text top="817" left="328" width="190" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1123">Smith SC Jr., Benjamin EJ, Bonow RO, et al.</a></text>
<text top="830" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1123">AHA/ACCF secondary prevention and risk reduction</a></text>
<text top="844" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1123">therapy for patients with coronary and other athero-</a></text>
<text top="857" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1123">sclerotic vascular disease: 2011 update: a guideline</a></text>
<text top="871" left="301" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1123">from the American Heart Association and American</a></text>
<text top="143" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1123">College of Cardiology Foundation. J Am Coll Cardiol.</a></text>
<text top="156" left="539" width="54" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1123">2011;58:2432</a></text>
<text top="155" left="593" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1123">–46</a></text>
<text top="156" left="608" width="3" height="9" font="4">.</text>
<text top="177" left="539" width="24" height="9" font="4">S13-3.</text>
<text top="177" left="566" width="190" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1124">Fihn SD, Blankenship JC, Alexander KP, et al.</a></text>
<text top="190" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1124">2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update</a></text>
<text top="203" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1124">of the guideline for the diagnosis and management of</a></text>
<text top="217" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1124">patients with stable ischemic heart disease: a report of</a></text>
<text top="230" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1124">the American College of Cardiology/American Heart</a></text>
<text top="244" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1124">Association Task Force on Practice Guidelines, and the</a></text>
<text top="257" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1124">American Association for Thoracic Surgery, Preventive</a></text>
<text top="271" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1124">Cardiovascular Nurses Association, Society for Cardio-</a></text>
<text top="284" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1124">vascular Angiography and Interventions, and Society</a></text>
<text top="298" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1124">of Thoracic Surgeons. J Am Coll Cardiol. 2014;64:</a></text>
<text top="311" left="539" width="20" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1124">1929</a></text>
<text top="309" left="559" width="15" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1124">–49</a></text>
<text top="311" left="574" width="3" height="9" font="4">.</text>
<text top="331" left="539" width="25" height="9" font="4">S13-4.</text>
<text top="331" left="567" width="189" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1125">Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/</a></text>
<text top="344" left="539" width="128" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1125">AHA/ACP/AATS/PCNA/SCAI/STS</a></text>
<text top="344" left="676" width="36" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1125">guideline</a></text>
<text top="344" left="722" width="12" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1125">for</a></text>
<text top="344" left="743" width="13" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1125">the</a></text>
<text top="358" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1125">diagnosis and management of patients with stable</a></text>
<text top="371" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1125">ischemic heart disease: a report of the American Col-</a></text>
<text top="385" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1125">lege of Cardiology Foundation/American Heart Asso-</a></text>
<text top="398" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1125">ciation Task Force on Practice Guidelines, and the</a></text>
<text top="412" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1125">American College of Physicians, American Association</a></text>
<text top="425" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1125">for Thoracic Surgery, Preventive Cardiovascular Nurses</a></text>
<text top="439" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1125">Association, Society for Cardiovascular Angiography</a></text>
<text top="452" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1125">and Interventions, and Society of Thoracic Surgeons.</a></text>
<text top="466" left="539" width="127" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1125">J Am Coll Cardiol. 2012;60:e44</a></text>
<text top="464" left="666" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1125">–164</a></text>
<text top="466" left="685" width="3" height="9" font="4">.</text>
<text top="486" left="539" width="24" height="9" font="4">S13-5.</text>
<text top="486" left="566" width="190" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1126">Yancy CW, Jessup M, Bozkurt B, et al. 2013</a></text>
<text top="499" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1126">ACCF/AHA guideline for the management of heart</a></text>
<text top="512" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1126">failure: a report of the American College of Cardiology</a></text>
<text top="526" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1126">Foundation/American Heart Association Task Force</a></text>
<text top="539" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1126">on Practice Guidelines. J Am Coll Cardiol. 2013;62:</a></text>
<text top="553" left="539" width="18" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1126">e147</a></text>
<text top="551" left="558" width="19" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1126">–239</a></text>
<text top="553" left="577" width="3" height="9" font="4"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1126">.</a></text>
<text top="571" left="539" width="25" height="9" font="4">S13-6.</text>
<text top="571" left="567" width="162" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1127">Standards of Medical Care in Diabetes</a></text>
<text top="570" left="730" width="27" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1127">–2016:</a></text>
<text top="585" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1127">Summary of Revisions. Diabetes Care. 2016;39 suppl 1:</a></text>
<text top="598" left="539" width="10" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1127">S4</a></text>
<text top="597" left="550" width="9" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1127">–5</a></text>
<text top="598" left="558" width="3" height="9" font="4">.</text>
<text top="638" left="539" width="206" height="12" font="26">1 5 . E V I D E N C E G A P S A N D F U T U R E</text>
<text top="652" left="539" width="77" height="12" font="26">D I R E C T I O N S</text>
<text top="684" left="539" width="23" height="9" font="4">S15-1.</text>
<text top="684" left="566" width="191" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1128">Moser M, Brown CM, Rose CH, et al. Hyper-</a></text>
<text top="697" left="539" width="217" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1128">tension in pregnancy: is it time for a new approach to</a></text>
<text top="710" left="539" width="156" height="9" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1128">treatment? J Hypertens. 2012;30:1092</a></text>
<text top="709" left="695" width="20" height="12" font="8"><a href="http://refhub.elsevier.com/S0735-1097(17)41519-1/sref1128">–100</a></text>
<text top="710" left="715" width="3" height="9" font="4">.</text>
<text top="761" left="539" width="62" height="12" font="23">KEY WORDS</text>
<text top="763" left="607" width="115" height="9" font="4">ACC/AHA Clinical Practice</text>
<text top="776" left="539" width="205" height="9" font="4">Guidelines, ambulatory care, antihypertensive</text>
<text top="790" left="539" width="99" height="9" font="4">agents, behavior modi</text>
<text top="788" left="639" width="108" height="12" font="4">ﬁcation, blood pressure,</text>
<text top="803" left="539" width="211" height="9" font="4">chronic kidney disease, diabetes, hypertension,</text>
<text top="817" left="539" width="200" height="9" font="4">hypertension emergency, lifestyle measures,</text>
<text top="830" left="539" width="198" height="9" font="4">measurement, nonpharmacologic treatment,</text>
<text top="844" left="539" width="217" height="9" font="4">resistant hypertension, risk reduction, secondary</text>
<text top="857" left="539" width="184" height="9" font="4">hypertension, systems of care, treatment</text>
<text top="870" left="539" width="142" height="9" font="4">adherence, treatment outcomes</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="789" width="19" height="9" font="4">e237</text>
</page>
<page number="112" position="absolute" top="0" left="0" height="1160" width="864">
<text top="251" left="108" width="50" height="9" font="13">Committee</text>
<text top="263" left="108" width="38" height="9" font="13">Member</text>
<text top="263" left="226" width="58" height="9" font="13">Employment</text>
<text top="263" left="331" width="50" height="9" font="13">Consultant</text>
<text top="251" left="401" width="42" height="9" font="13">Speakers</text>
<text top="263" left="406" width="32" height="9" font="13">Bureau</text>
<text top="239" left="471" width="53" height="9" font="13">Ownership/</text>
<text top="251" left="469" width="59" height="9" font="13">Partnership/</text>
<text top="263" left="478" width="41" height="9" font="13">Principal</text>
<text top="251" left="561" width="40" height="9" font="13">Personal</text>
<text top="263" left="560" width="42" height="9" font="13">Research</text>
<text top="227" left="643" width="60" height="9" font="13">Institutional,</text>
<text top="239" left="632" width="84" height="9" font="13">Organizational, or</text>
<text top="251" left="638" width="71" height="9" font="13">Other Financial</text>
<text top="263" left="657" width="23" height="9" font="13">Bene</text>
<text top="262" left="680" width="10" height="12" font="13">ﬁt</text>
<text top="251" left="730" width="31" height="9" font="13">Expert</text>
<text top="263" left="727" width="74" height="9" font="13">Witness Salary</text>
<text top="279" left="108" width="68" height="9" font="13">Paul K. Whelton</text>
<text top="291" left="123" width="28" height="9" font="13">(Chair)</text>
<text top="279" left="198" width="115" height="9" font="13">Tulane University School of</text>
<text top="291" left="188" width="129" height="9" font="13">Hygiene and Tropical Medicine</text>
<text top="290" left="316" width="7" height="12" font="13">—</text>
<text top="303" left="187" width="137" height="9" font="13">Show Chwan Professor of Global</text>
<text top="315" left="227" width="56" height="9" font="13">Public Health</text>
<text top="279" left="345" width="22" height="9" font="13">None</text>
<text top="279" left="411" width="22" height="9" font="13">None</text>
<text top="279" left="487" width="22" height="9" font="13">None</text>
<text top="279" left="570" width="22" height="9" font="13">None</text>
<text top="279" left="662" width="22" height="9" font="13">None</text>
<text top="279" left="735" width="22" height="9" font="13">None</text>
<text top="279" left="776" width="22" height="9" font="13">None</text>
<text top="335" left="108" width="68" height="9" font="13">Robert M. Carey</text>
<text top="347" left="123" width="47" height="9" font="13">(Vice Chair)</text>
<text top="335" left="190" width="130" height="9" font="13">University of Virginia School of</text>
<text top="347" left="191" width="37" height="9" font="13">Medicine</text>
<text top="345" left="228" width="91" height="12" font="13">—Dean, Emeritus, and</text>
<text top="358" left="210" width="91" height="9" font="13">Professor of Medicine</text>
<text top="335" left="345" width="22" height="9" font="13">None</text>
<text top="335" left="411" width="22" height="9" font="13">None</text>
<text top="335" left="487" width="22" height="9" font="13">None</text>
<text top="337" left="543" width="6" height="10" font="9">n</text>
<text top="337" left="557" width="66" height="9" font="13">Daiichi Sankyo,</text>
<text top="349" left="556" width="16" height="9" font="13"><a href="e127.full.html#113">Inc.</a></text>
<text top="348" left="572" width="5" height="12" font="17"><a href="e127.full.html#113">†</a></text>
<text top="335" left="662" width="22" height="9" font="13">None</text>
<text top="335" left="735" width="22" height="9" font="13">None</text>
<text top="335" left="776" width="22" height="9" font="13">None</text>
<text top="378" left="108" width="41" height="9" font="13">Wilbert S.</text>
<text top="390" left="123" width="32" height="9" font="13">Aronow</text>
<text top="378" left="188" width="135" height="9" font="13">Westchester Medical Center and</text>
<text top="390" left="197" width="110" height="9" font="13">New York Medical College</text>
<text top="388" left="307" width="7" height="12" font="13">—</text>
<text top="402" left="210" width="91" height="9" font="13">Professor of Medicine</text>
<text top="378" left="345" width="22" height="9" font="13">None</text>
<text top="378" left="411" width="22" height="9" font="13">None</text>
<text top="378" left="487" width="22" height="9" font="13">None</text>
<text top="378" left="570" width="22" height="9" font="13">None</text>
<text top="378" left="662" width="22" height="9" font="13">None</text>
<text top="378" left="735" width="22" height="9" font="13">None</text>
<text top="378" left="776" width="22" height="9" font="13">None</text>
<text top="421" left="108" width="70" height="9" font="13">Donald E. Casey,</text>
<text top="433" left="123" width="8" height="9" font="13">Jr</text>
<text top="421" left="195" width="120" height="9" font="13">Thomas Jefferson College of</text>
<text top="433" left="198" width="76" height="9" font="13">Population Health</text>
<text top="431" left="274" width="39" height="12" font="13">—Adjunct</text>
<text top="445" left="202" width="107" height="9" font="13">Faculty; Alvarez &amp; Marsal</text>
<text top="457" left="184" width="45" height="9" font="13">Ipo4health</text>
<text top="455" left="229" width="98" height="12" font="13">—Principal and Founder</text>
<text top="421" left="345" width="22" height="9" font="13">None</text>
<text top="421" left="411" width="22" height="9" font="13">None</text>
<text top="421" left="487" width="22" height="9" font="13">None</text>
<text top="421" left="570" width="22" height="9" font="13">None</text>
<text top="421" left="662" width="22" height="9" font="13">None</text>
<text top="421" left="735" width="22" height="9" font="13">None</text>
<text top="421" left="776" width="22" height="9" font="13">None</text>
<text top="476" left="108" width="65" height="9" font="13">Karen J. Collins</text>
<text top="476" left="189" width="87" height="9" font="13">Collins Collaboration</text>
<text top="474" left="276" width="46" height="12" font="13">—President</text>
<text top="476" left="345" width="22" height="9" font="13">None</text>
<text top="476" left="411" width="22" height="9" font="13">None</text>
<text top="476" left="487" width="22" height="9" font="13">None</text>
<text top="476" left="570" width="22" height="9" font="13">None</text>
<text top="476" left="662" width="22" height="9" font="13">None</text>
<text top="476" left="735" width="22" height="9" font="13">None</text>
<text top="476" left="776" width="22" height="9" font="13">None</text>
<text top="495" left="108" width="68" height="9" font="13">Cheryl Dennison</text>
<text top="507" left="123" width="49" height="9" font="13">Himmelfarb</text>
<text top="495" left="201" width="101" height="9" font="13">John Hopkins University</text>
<text top="493" left="302" width="7" height="12" font="13">—</text>
<text top="507" left="184" width="143" height="9" font="13">Professor of Nursing and Medicine,</text>
<text top="519" left="205" width="101" height="9" font="13">Institute for Clinical and</text>
<text top="531" left="208" width="94" height="9" font="13">Translational Research</text>
<text top="495" left="345" width="22" height="9" font="13">None</text>
<text top="495" left="411" width="22" height="9" font="13">None</text>
<text top="495" left="487" width="22" height="9" font="13">None</text>
<text top="495" left="570" width="22" height="9" font="13">None</text>
<text top="495" left="662" width="22" height="9" font="13">None</text>
<text top="495" left="735" width="22" height="9" font="13">None</text>
<text top="495" left="776" width="22" height="9" font="13">None</text>
<text top="550" left="108" width="42" height="9" font="13">Sondra M.</text>
<text top="562" left="123" width="37" height="9" font="13">DePalma</text>
<text top="550" left="192" width="127" height="9" font="13">PinnacleHealth CardioVascular</text>
<text top="562" left="194" width="35" height="9" font="13">Institute</text>
<text top="560" left="229" width="88" height="12" font="13">—Physician Assistant;</text>
<text top="574" left="197" width="110" height="9" font="13">American Academy of PAs</text>
<text top="572" left="307" width="7" height="12" font="13">—</text>
<text top="586" left="204" width="103" height="9" font="13">Director, Regulatory and</text>
<text top="598" left="212" width="87" height="9" font="13">Professional Practice</text>
<text top="550" left="345" width="22" height="9" font="13">None</text>
<text top="550" left="411" width="22" height="9" font="13">None</text>
<text top="550" left="487" width="22" height="9" font="13">None</text>
<text top="550" left="570" width="22" height="9" font="13">None</text>
<text top="550" left="662" width="22" height="9" font="13">None</text>
<text top="550" left="735" width="22" height="9" font="13">None</text>
<text top="550" left="776" width="22" height="9" font="13">None</text>
<text top="617" left="108" width="65" height="9" font="13">Samuel Gidding</text>
<text top="617" left="195" width="120" height="9" font="13">Alfred I. Dupont Hospital for</text>
<text top="629" left="199" width="35" height="9" font="13">Children</text>
<text top="627" left="234" width="78" height="12" font="13">—Chief, Division of</text>
<text top="641" left="192" width="127" height="9" font="13">Pediatric Cardiology, Nemours</text>
<text top="653" left="225" width="61" height="9" font="13">Cardiac Center</text>
<text top="617" left="345" width="22" height="9" font="13">None</text>
<text top="617" left="411" width="22" height="9" font="13">None</text>
<text top="617" left="487" width="22" height="9" font="13">None</text>
<text top="617" left="570" width="22" height="9" font="13">None</text>
<text top="617" left="662" width="22" height="9" font="13">None</text>
<text top="617" left="735" width="22" height="9" font="13">None</text>
<text top="617" left="776" width="22" height="9" font="13">None</text>
<text top="672" left="108" width="67" height="9" font="13">David C. Goff, <a href="e127.full.html#113">Jr</a></text>
<text top="672" left="175" width="4" height="9" font="17"><a href="e127.full.html#113">*</a></text>
<text top="672" left="184" width="137" height="9" font="13">Colorado School of Public Health</text>
<text top="671" left="320" width="7" height="12" font="13">—</text>
<text top="684" left="187" width="137" height="9" font="13">Professor and Dean, Department</text>
<text top="696" left="221" width="68" height="9" font="13">of Epidemiology</text>
<text top="672" left="345" width="22" height="9" font="13">None</text>
<text top="672" left="411" width="22" height="9" font="13">None</text>
<text top="672" left="487" width="22" height="9" font="13">None</text>
<text top="672" left="570" width="22" height="9" font="13">None</text>
<text top="672" left="662" width="22" height="9" font="13">None</text>
<text top="672" left="735" width="22" height="9" font="13">None</text>
<text top="672" left="776" width="22" height="9" font="13">None</text>
<text top="715" left="108" width="46" height="9" font="13">Kenneth A.</text>
<text top="727" left="123" width="40" height="9" font="13">Jamerson</text>
<text top="715" left="193" width="124" height="9" font="13">University of Michigan Health</text>
<text top="727" left="194" width="30" height="9" font="13">System</text>
<text top="726" left="224" width="93" height="12" font="13">—Professor of Internal</text>
<text top="739" left="197" width="116" height="9" font="13">Medicine and Frederick G.L.</text>
<text top="751" left="187" width="136" height="9" font="13">Huetwell Collegiate Professor of</text>
<text top="763" left="205" width="100" height="9" font="13">Cardiovascular Medicine</text>
<text top="715" left="345" width="22" height="9" font="13">None</text>
<text top="715" left="411" width="22" height="9" font="13">None</text>
<text top="715" left="487" width="22" height="9" font="13">None</text>
<text top="715" left="570" width="22" height="9" font="13">None</text>
<text top="715" left="662" width="22" height="9" font="13">None</text>
<text top="715" left="735" width="22" height="9" font="13">None</text>
<text top="715" left="776" width="22" height="9" font="13">None</text>
<text top="782" left="108" width="70" height="9" font="13">Danie W. l Jones</text>
<text top="782" left="188" width="135" height="9" font="13">University of Mississippi Medical</text>
<text top="794" left="184" width="27" height="9" font="13">Center</text>
<text top="793" left="211" width="116" height="12" font="13">—Professor of Medicine and</text>
<text top="806" left="190" width="130" height="9" font="13">Physiology; Metabolic Diseases</text>
<text top="818" left="203" width="56" height="9" font="13">and Nutrition</text>
<text top="817" left="259" width="48" height="12" font="13">—University</text>
<text top="830" left="199" width="112" height="9" font="13">Sanderson Chair in Obesity</text>
<text top="842" left="193" width="124" height="9" font="13">Mississippi Center for Obesity</text>
<text top="854" left="190" width="37" height="9" font="13">Research</text>
<text top="852" left="227" width="94" height="12" font="13">—Director, Clinical and</text>
<text top="866" left="216" width="79" height="9" font="13">Population Science</text>
<text top="782" left="345" width="22" height="9" font="13">None</text>
<text top="782" left="411" width="22" height="9" font="13">None</text>
<text top="782" left="487" width="22" height="9" font="13">None</text>
<text top="782" left="570" width="22" height="9" font="13">None</text>
<text top="782" left="662" width="22" height="9" font="13">None</text>
<text top="782" left="735" width="22" height="9" font="13">None</text>
<text top="782" left="776" width="22" height="9" font="13">None</text>
<text top="885" left="108" width="25" height="9" font="13">Eric J.</text>
<text top="897" left="123" width="52" height="9" font="13">MacLaughlin</text>
<text top="885" left="194" width="122" height="9" font="13">Texas Tech University Health</text>
<text top="897" left="190" width="66" height="9" font="13">Sciences Center</text>
<text top="896" left="256" width="64" height="12" font="13">—Professor and</text>
<text top="909" left="189" width="132" height="9" font="13">Chair, Department of Pharmacy</text>
<text top="921" left="194" width="122" height="9" font="13">Practice, School of Pharmacy</text>
<text top="885" left="345" width="22" height="9" font="13">None</text>
<text top="885" left="411" width="22" height="9" font="13">None</text>
<text top="885" left="487" width="22" height="9" font="13">None</text>
<text top="885" left="570" width="22" height="9" font="13">None</text>
<text top="885" left="662" width="22" height="9" font="13">None</text>
<text top="885" left="735" width="22" height="9" font="13">None</text>
<text top="885" left="776" width="22" height="9" font="13">None</text>
<text top="940" left="108" width="56" height="9" font="13">Paul Muntner</text>
<text top="940" left="204" width="104" height="9" font="13">University of Alabama at</text>
<text top="952" left="206" width="50" height="9" font="13">Birmingham</text>
<text top="951" left="256" width="49" height="12" font="13">—Professor,</text>
<text top="964" left="195" width="121" height="9" font="13">Department of Epidemiology</text>
<text top="940" left="345" width="22" height="9" font="13">None</text>
<text top="940" left="411" width="22" height="9" font="13">None</text>
<text top="940" left="487" width="22" height="9" font="13">None</text>
<text top="940" left="570" width="22" height="9" font="13">None</text>
<text top="940" left="662" width="22" height="9" font="13">None</text>
<text top="940" left="735" width="22" height="9" font="13">None</text>
<text top="940" left="776" width="22" height="9" font="13">None</text>
<text top="983" left="108" width="68" height="9" font="13">Bruce Ovbiagele</text>
<text top="983" left="197" width="116" height="9" font="13">Medical University of South</text>
<text top="995" left="197" width="34" height="9" font="13">Carolina</text>
<text top="994" left="231" width="83" height="12" font="13">—Pihl Professor and</text>
<text top="1007" left="207" width="97" height="9" font="13">Chairman of Neurology</text>
<text top="983" left="345" width="22" height="9" font="13">None</text>
<text top="985" left="390" width="6" height="10" font="9">n</text>
<text top="986" left="404" width="48" height="9" font="13">Boehringer</text>
<text top="998" left="404" width="43" height="9" font="13">Ingelheim</text>
<text top="1010" left="404" width="46" height="9" font="13">Korea Ltd.</text>
<text top="983" left="487" width="22" height="9" font="13">None</text>
<text top="983" left="570" width="22" height="9" font="13">None</text>
<text top="983" left="662" width="22" height="9" font="13">None</text>
<text top="983" left="735" width="22" height="9" font="13">None</text>
<text top="983" left="776" width="22" height="9" font="13">None</text>
<text top="1028" left="108" width="68" height="9" font="13">Sidney C. Smith,</text>
<text top="1040" left="123" width="8" height="9" font="13">Jr</text>
<text top="1028" left="191" width="129" height="9" font="13">University of North Carolina at</text>
<text top="1040" left="184" width="45" height="9" font="13">Chapel Hill</text>
<text top="1038" left="228" width="99" height="12" font="13">—Professor of Medicine;</text>
<text top="1052" left="185" width="140" height="9" font="13">Center for Cardiovascular Science</text>
<text top="1064" left="208" width="55" height="9" font="13">and Medicine</text>
<text top="1062" left="263" width="40" height="12" font="13">—Director</text>
<text top="1028" left="345" width="22" height="9" font="13">None</text>
<text top="1028" left="411" width="22" height="9" font="13">None</text>
<text top="1028" left="487" width="22" height="9" font="13">None</text>
<text top="1028" left="570" width="22" height="9" font="13">None</text>
<text top="1028" left="662" width="22" height="9" font="13">None</text>
<text top="1028" left="735" width="22" height="9" font="13">None</text>
<text top="1028" left="776" width="22" height="9" font="13">None</text>
<text top="1084" left="696" width="105" height="8" font="4">Continued on the next page</text>
<text top="142" left="108" width="657" height="16" font="14">APPENDIX 1. AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (RELEVANT)—2017</text>
<text top="160" left="108" width="673" height="16" font="14">ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA GUIDELINE FOR THE PREVENTION,</text>
<text top="178" left="108" width="694" height="16" font="14">DETECTION, EVALUATION, AND MANAGEMENT OF HIGH BLOOD PRESSURE IN ADULTS (OCTOBER 2017)</text>
<text top="53" left="108" width="60" height="9" font="13">Whelton et al.</text>
<text top="54" left="672" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="68" left="108" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="69" left="693" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="780" width="21" height="10" font="9">– 2 4 8</text>
<text top="53" left="57" width="20" height="9" font="4">e238</text>
</page>
<page number="113" position="absolute" top="0" left="0" height="1160" width="864">
<text top="207" left="63" width="50" height="9" font="13">Committee</text>
<text top="219" left="63" width="38" height="9" font="13">Member</text>
<text top="219" left="181" width="58" height="9" font="13">Employment</text>
<text top="219" left="287" width="50" height="9" font="13">Consultant</text>
<text top="207" left="356" width="42" height="9" font="13">Speakers</text>
<text top="219" left="361" width="32" height="9" font="13">Bureau</text>
<text top="195" left="427" width="53" height="9" font="13">Ownership/</text>
<text top="207" left="424" width="59" height="9" font="13">Partnership/</text>
<text top="219" left="433" width="40" height="9" font="13">Principal</text>
<text top="207" left="516" width="40" height="9" font="13">Personal</text>
<text top="219" left="516" width="42" height="9" font="13">Research</text>
<text top="183" left="598" width="60" height="9" font="13">Institutional,</text>
<text top="195" left="587" width="84" height="9" font="13">Organizational, or</text>
<text top="207" left="593" width="71" height="9" font="13">Other Financial</text>
<text top="219" left="612" width="23" height="9" font="13">Bene</text>
<text top="218" left="635" width="10" height="12" font="13">ﬁt</text>
<text top="207" left="685" width="31" height="9" font="13">Expert</text>
<text top="219" left="682" width="74" height="9" font="13">Witness Salary</text>
<text top="235" left="63" width="40" height="9" font="13">Crystal C.</text>
<text top="247" left="78" width="33" height="9" font="13">Spencer</text>
<text top="235" left="139" width="69" height="9" font="13">Spencer Law, PA</text>
<text top="234" left="208" width="74" height="12" font="13">—Attorney at Law</text>
<text top="235" left="301" width="22" height="9" font="13">None</text>
<text top="235" left="366" width="22" height="9" font="13">None</text>
<text top="235" left="442" width="22" height="9" font="13">None</text>
<text top="235" left="525" width="22" height="9" font="13">None</text>
<text top="235" left="618" width="22" height="9" font="13">None</text>
<text top="235" left="690" width="22" height="9" font="13">None</text>
<text top="235" left="731" width="22" height="9" font="13">None</text>
<text top="267" left="63" width="42" height="9" font="13">Randall S.</text>
<text top="279" left="78" width="34" height="9" font="13">Stafford</text>
<text top="267" left="148" width="124" height="9" font="13">Stanford Prevention Research</text>
<text top="279" left="147" width="27" height="9" font="13">Center</text>
<text top="277" left="174" width="100" height="12" font="13">—Professor of Medicine;</text>
<text top="291" left="162" width="97" height="9" font="13">Program on Prevention</text>
<text top="302" left="170" width="42" height="9" font="13">Outcomes</text>
<text top="301" left="211" width="40" height="12" font="13">—Director</text>
<text top="267" left="301" width="22" height="9" font="13">None</text>
<text top="267" left="366" width="22" height="9" font="13">None</text>
<text top="267" left="442" width="22" height="9" font="13">None</text>
<text top="267" left="525" width="22" height="9" font="13">None</text>
<text top="267" left="618" width="22" height="9" font="13">None</text>
<text top="267" left="690" width="22" height="9" font="13">None</text>
<text top="267" left="731" width="22" height="9" font="13">None</text>
<text top="322" left="63" width="62" height="9" font="13">Sandra J. Taler</text>
<text top="322" left="158" width="48" height="9" font="13">Mayo Clinic</text>
<text top="320" left="206" width="58" height="12" font="13">—Professor of</text>
<text top="334" left="148" width="126" height="9" font="13">Medicine, College of Medicine</text>
<text top="322" left="301" width="22" height="9" font="13">None</text>
<text top="322" left="366" width="22" height="9" font="13">None</text>
<text top="322" left="442" width="22" height="9" font="13">None</text>
<text top="322" left="525" width="22" height="9" font="13">None</text>
<text top="322" left="618" width="22" height="9" font="13">None</text>
<text top="322" left="690" width="22" height="9" font="13">None</text>
<text top="322" left="731" width="22" height="9" font="13">None</text>
<text top="353" left="63" width="38" height="9" font="13">Randal J.</text>
<text top="365" left="78" width="32" height="9" font="13">Thomas</text>
<text top="353" left="148" width="48" height="9" font="13">Mayo Clinic</text>
<text top="351" left="196" width="78" height="12" font="13">—Medical Director,</text>
<text top="365" left="146" width="129" height="9" font="13">Cardiac Rehabilitation Program</text>
<text top="353" left="301" width="22" height="9" font="13">None</text>
<text top="353" left="366" width="22" height="9" font="13">None</text>
<text top="353" left="442" width="22" height="9" font="13">None</text>
<text top="353" left="525" width="22" height="9" font="13">None</text>
<text top="353" left="618" width="22" height="9" font="13">None</text>
<text top="353" left="690" width="22" height="9" font="13">None</text>
<text top="353" left="731" width="22" height="9" font="13">None</text>
<text top="384" left="63" width="68" height="9" font="13">Kim A. Williams,</text>
<text top="396" left="78" width="8" height="9" font="13">Sr</text>
<text top="384" left="142" width="131" height="9" font="13">Rush University Medical Center</text>
<text top="382" left="272" width="7" height="12" font="13">—</text>
<text top="396" left="153" width="115" height="9" font="13">James B. Herrick Professor;</text>
<text top="408" left="151" width="92" height="9" font="13">Division of Cardiology</text>
<text top="406" left="242" width="28" height="12" font="13">—Chief</text>
<text top="384" left="301" width="22" height="9" font="13">None</text>
<text top="384" left="366" width="22" height="9" font="13">None</text>
<text top="384" left="442" width="22" height="9" font="13">None</text>
<text top="384" left="525" width="22" height="9" font="13">None</text>
<text top="384" left="618" width="22" height="9" font="13">None</text>
<text top="384" left="690" width="22" height="9" font="13">None</text>
<text top="384" left="731" width="22" height="9" font="13">None</text>
<text top="427" left="63" width="28" height="9" font="13">Jeff D.</text>
<text top="439" left="78" width="45" height="9" font="13">Williamson</text>
<text top="427" left="151" width="119" height="9" font="13">Wake Forest Baptist Medical</text>
<text top="439" left="150" width="27" height="9" font="13">Center</text>
<text top="437" left="178" width="93" height="12" font="13">—Professor of Internal</text>
<text top="451" left="140" width="142" height="9" font="13">Medicine; Section on Gerontology</text>
<text top="463" left="150" width="93" height="9" font="13">and Geriatric Medicine</text>
<text top="461" left="243" width="28" height="12" font="13">—Chief</text>
<text top="427" left="301" width="22" height="9" font="13">None</text>
<text top="427" left="366" width="22" height="9" font="13">None</text>
<text top="427" left="442" width="22" height="9" font="13">None</text>
<text top="427" left="525" width="22" height="9" font="13">None</text>
<text top="427" left="618" width="22" height="9" font="13">None</text>
<text top="427" left="690" width="22" height="9" font="13">None</text>
<text top="427" left="731" width="22" height="9" font="13">None</text>
<text top="482" left="63" width="44" height="9" font="13">Jackson T.</text>
<text top="494" left="78" width="41" height="9" font="13">Wright, Jr</text>
<text top="482" left="139" width="137" height="9" font="13">Case Western Reserve University</text>
<text top="481" left="275" width="7" height="12" font="13">—</text>
<text top="494" left="141" width="138" height="9" font="13">Professor of Medicine; William T.</text>
<text top="506" left="139" width="137" height="9" font="13">Dahms MD Clinical Research Unit</text>
<text top="504" left="275" width="7" height="12" font="13">—</text>
<text top="518" left="151" width="119" height="9" font="13">Program Director; University</text>
<text top="530" left="144" width="126" height="9" font="13">Hospitals Case Medical Center</text>
<text top="528" left="270" width="7" height="12" font="13">—</text>
<text top="542" left="147" width="127" height="9" font="13">Director, Clinical Hypertension</text>
<text top="554" left="193" width="35" height="9" font="13">Program</text>
<text top="482" left="301" width="22" height="9" font="13">None</text>
<text top="484" left="345" width="6" height="10" font="9">n</text>
<text top="485" left="359" width="30" height="9" font="13">Amgen</text>
<text top="485" left="390" width="4" height="9" font="17"><a href="e127.full.html#113">*</a></text>
<text top="482" left="442" width="22" height="9" font="13">None</text>
<text top="482" left="525" width="22" height="9" font="13">None</text>
<text top="482" left="618" width="22" height="9" font="13">None</text>
<text top="482" left="690" width="22" height="9" font="13">None</text>
<text top="482" left="731" width="22" height="9" font="13">None</text>
<text top="578" left="63" width="694" height="8" font="4">This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were</text>
<text top="590" left="63" width="694" height="8" font="4">reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily</text>
<text top="602" left="63" width="8" height="8" font="4">re</text>
<text top="600" left="70" width="686" height="11" font="4">ﬂect relationships with industry at the time of publication. A person is deemed to have a signiﬁcant interest in a business if the interest represents ownership of $5% of the voting</text>
<text top="613" left="63" width="202" height="8" font="4">stock or share of the business entity, or ownership of</text>
<text top="612" left="266" width="490" height="11" font="4">$$5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of</text>
<text top="625" left="63" width="41" height="8" font="4">the person</text>
<text top="624" left="104" width="652" height="11" font="4">’s gross income for the previous year. Relationships that exist with no ﬁnancial beneﬁt are also included for the purpose of transparency. Relationships in this table are</text>
<text top="637" left="63" width="694" height="8" font="4">modest unless otherwise noted. According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter,</text>
<text top="649" left="63" width="694" height="8" font="4">intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in</text>
<text top="661" left="63" width="487" height="8" font="4">the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person</text>
<text top="660" left="550" width="207" height="11" font="4">’s household, has a reasonable potential for ﬁnancial,</text>
<text top="673" left="63" width="612" height="8" font="4">professional or other personal gain or loss as a result of the issues/content addressed in the document. The complete ACC/AHA policy on RWI is available at</text>
<text top="673" left="678" width="79" height="8" font="8"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">http://www.acc.org/</a></text>
<text top="685" left="63" width="333" height="8" font="8"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy</a></text>
<text top="685" left="396" width="2" height="8" font="4"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">.</a></text>
<text top="697" left="63" width="632" height="8" font="4">We gratefully acknowledge the contributions of Dr. Lawrence Appel, who served as a member of the Writing Committee from November 2014 to September 2015.</text>
<text top="709" left="63" width="694" height="8" font="4">*Dr. David C. Goff resigned from the writing committee in December 2016 because of a change in employment before the recommendations were balloted. The writing committee</text>
<text top="721" left="63" width="235" height="8" font="4">thanks him for his contributions, which were extremely bene</text>
<text top="720" left="298" width="148" height="11" font="4">ﬁcial to the development of the draft.</text>
<text top="731" left="63" width="94" height="11" font="4">†Signiﬁcant relationship.</text>
<text top="747" left="71" width="686" height="8" font="4">AAPA indicates American Academy of Physician Assistants; ACC, American College of Cardiology; ACPM, American College of Preventive Medicine; AGS, American Geriatrics Society;</text>
<text top="759" left="63" width="694" height="8" font="4">AHA, American Heart Association; APhA, American Pharmacists Association; ASH, American Society of Hypertension; ASPC, American Society for Preventive Cardiology; ABC, Asso-</text>
<text top="771" left="63" width="476" height="8" font="4">ciation of Black Cardiologists; NMA, National Medical Association; and PCNA, Preventive Cardiovascular Nurses Association.</text>
<text top="141" left="63" width="156" height="16" font="14">APPENDIX 1. CONTINUED</text>
<text top="54" left="63" width="129" height="7" font="9">J A C C V O L . 7 1 , N O . 1 9 , 2 0 1 8</text>
<text top="54" left="697" width="60" height="9" font="13">Whelton et al.</text>
<text top="69" left="63" width="85" height="7" font="9">M A Y 1 5 , 2 0 1 8 : e 1 2 7</text>
<text top="67" left="149" width="21" height="10" font="9">– 2 4 8</text>
<text top="69" left="538" width="219" height="9" font="13">2017 High Blood Pressure Clinical Practice Guideline</text>
<text top="53" left="788" width="20" height="9" font="4">e239</text>
</page>
<page number="114" position="absolute" top="0" left="0" height="864" width="1160">
	<fontspec id="27" size="7" family="Times" color="#000000"/>
	<fontspec id="28" size="5" family="Times" color="#000000"/>
	<fontspec id="29" size="7" family="Times" color="#327eb1"/>
	<fontspec id="30" size="6" family="Times" color="#000000"/>
	<fontspec id="31" size="9" family="Times" color="#e3202b"/>
<text top="195" left="58" width="43" height="9" font="27">Reviewer</text>
<text top="195" left="153" width="71" height="9" font="27">Representation</text>
<text top="195" left="271" width="58" height="9" font="27">Employment</text>
<text top="195" left="387" width="50" height="9" font="27">Consultant</text>
<text top="183" left="476" width="42" height="9" font="27">Speakers</text>
<text top="195" left="481" width="32" height="9" font="27">Bureau</text>
<text top="171" left="546" width="53" height="9" font="27">Ownership/</text>
<text top="183" left="543" width="58" height="9" font="27">Partnership/</text>
<text top="195" left="553" width="41" height="9" font="27">Principal</text>
<text top="195" left="620" width="85" height="9" font="27">Personal Research</text>
<text top="171" left="744" width="60" height="9" font="27">Institutional,</text>
<text top="183" left="717" width="113" height="9" font="27">Organizational, or Other</text>
<text top="195" left="735" width="67" height="9" font="27">Financial Bene</text>
<text top="193" left="803" width="10" height="12" font="27">ﬁt</text>
<text top="195" left="842" width="71" height="9" font="27">Expert Witness</text>
<text top="195" left="957" width="28" height="9" font="27">Salary</text>
<text top="211" left="58" width="63" height="9" font="27">Kim K. Birtcher</text>
<text top="211" left="149" width="10" height="9" font="27">Of</text>
<text top="209" left="159" width="67" height="12" font="27">ﬁcial Reviewer—</text>
<text top="223" left="145" width="86" height="9" font="27">TFPG Lead Reviewer</text>
<text top="211" left="237" width="126" height="9" font="27">University of Houston College</text>
<text top="223" left="256" width="52" height="9" font="27">of Pharmacy</text>
<text top="221" left="308" width="36" height="12" font="27">—Clinical</text>
<text top="235" left="247" width="106" height="9" font="27">Professor, Department of</text>
<text top="247" left="253" width="95" height="9" font="27">Pharmacy Practice and</text>
<text top="259" left="253" width="94" height="9" font="27">Translational Research</text>
<text top="210" left="371" width="6" height="10" font="28">n</text>
<text top="211" left="386" width="71" height="9" font="27">Jones &amp; Bartlett</text>
<text top="223" left="385" width="38" height="9" font="27">Learning</text>
<text top="211" left="486" width="22" height="9" font="27">None</text>
<text top="211" left="562" width="22" height="9" font="27">None</text>
<text top="211" left="651" width="22" height="9" font="27">None</text>
<text top="210" left="720" width="6" height="10" font="28">n</text>
<text top="211" left="734" width="94" height="9" font="27">Accreditation Council</text>
<text top="223" left="734" width="48" height="9" font="27">for Clinical</text>
<text top="235" left="734" width="46" height="9" font="27">Lipidology</text>
<text top="233" left="780" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="211" left="866" width="22" height="9" font="27">None</text>
<text top="210" left="926" width="6" height="10" font="28">n</text>
<text top="211" left="940" width="46" height="9" font="27">Walgreens</text>
<text top="211" left="986" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="278" left="58" width="75" height="9" font="27">Roger Blumenthal</text>
<text top="278" left="149" width="10" height="9" font="27">Of</text>
<text top="276" left="159" width="67" height="12" font="27">ﬁcial Reviewer—</text>
<text top="290" left="166" width="45" height="9" font="27">Prevention</text>
<text top="302" left="158" width="60" height="9" font="27">Subcommittee</text>
<text top="278" left="248" width="98" height="9" font="27">Johns Hopkins Hospital</text>
<text top="276" left="346" width="7" height="12" font="27">—</text>
<text top="290" left="240" width="120" height="9" font="27">Kenneth Jay Pollin Professor</text>
<text top="302" left="249" width="102" height="9" font="27">of Cardiology; Ciccarone</text>
<text top="314" left="240" width="119" height="9" font="27">Center for the Prevention of</text>
<text top="326" left="251" width="57" height="9" font="27">Heart Disease</text>
<text top="324" left="308" width="40" height="12" font="27">—Director</text>
<text top="278" left="401" width="22" height="9" font="27">None</text>
<text top="278" left="486" width="22" height="9" font="27">None</text>
<text top="278" left="562" width="22" height="9" font="27">None</text>
<text top="278" left="651" width="22" height="9" font="27">None</text>
<text top="278" left="763" width="22" height="9" font="27">None</text>
<text top="278" left="866" width="22" height="9" font="27">None</text>
<text top="278" left="960" width="22" height="9" font="27">None</text>
<text top="345" left="58" width="71" height="9" font="27">Anna Dominiczak</text>
<text top="345" left="149" width="10" height="9" font="27">Of</text>
<text top="343" left="159" width="67" height="12" font="27">ﬁcial Reviewer—</text>
<text top="357" left="179" width="18" height="9" font="27">AHA</text>
<text top="345" left="237" width="91" height="9" font="27">University of Glasgow</text>
<text top="343" left="329" width="34" height="12" font="27">—Regius</text>
<text top="357" left="241" width="118" height="9" font="27">Professor of Medicine; Vice-</text>
<text top="369" left="238" width="124" height="9" font="27">Principal and Head of College</text>
<text top="381" left="237" width="126" height="9" font="27">of Medical, Veterinary and Life</text>
<text top="393" left="282" width="35" height="9" font="27">Sciences</text>
<text top="345" left="401" width="22" height="9" font="27">None</text>
<text top="345" left="486" width="22" height="9" font="27">None</text>
<text top="345" left="562" width="22" height="9" font="27">None</text>
<text top="345" left="651" width="22" height="9" font="27">None</text>
<text top="345" left="763" width="22" height="9" font="27">None</text>
<text top="345" left="866" width="22" height="9" font="27">None</text>
<text top="345" left="960" width="22" height="9" font="27">None</text>
<text top="412" left="58" width="75" height="9" font="27">Carlos M. Ferrario</text>
<text top="412" left="149" width="10" height="9" font="27">Of</text>
<text top="410" left="159" width="67" height="12" font="27">ﬁcial Reviewer—</text>
<text top="424" left="179" width="18" height="9" font="27">AHA</text>
<text top="412" left="253" width="94" height="9" font="27">Wake Forest School of</text>
<text top="424" left="251" width="37" height="9" font="27">Medicine</text>
<text top="422" left="288" width="60" height="12" font="27">—Professor, of</text>
<text top="436" left="268" width="63" height="9" font="27">Physiology and</text>
<text top="448" left="240" width="120" height="9" font="27">Pharmacology; Hypertension</text>
<text top="460" left="238" width="118" height="9" font="27">and Vascular Disease Center</text>
<text top="458" left="355" width="7" height="12" font="27">—</text>
<text top="472" left="283" width="33" height="9" font="27">Director</text>
<text top="412" left="401" width="22" height="9" font="27">None</text>
<text top="412" left="486" width="22" height="9" font="27">None</text>
<text top="412" left="562" width="22" height="9" font="27">None</text>
<text top="412" left="651" width="22" height="9" font="27">None</text>
<text top="412" left="763" width="22" height="9" font="27">None</text>
<text top="412" left="866" width="22" height="9" font="27">None</text>
<text top="412" left="960" width="22" height="9" font="27">None</text>
<text top="491" left="58" width="55" height="9" font="27">Eugene Yang</text>
<text top="491" left="149" width="10" height="9" font="27">Of</text>
<text top="489" left="159" width="67" height="12" font="27">ﬁcial Reviewer—</text>
<text top="503" left="168" width="39" height="9" font="27">ACC-BOG</text>
<text top="491" left="247" width="106" height="9" font="27">University of Washington</text>
<text top="503" left="237" width="80" height="9" font="27">School of Medicine</text>
<text top="501" left="317" width="46" height="12" font="27">—Associate</text>
<text top="515" left="237" width="126" height="9" font="27">Clinical Professor of Medicine;</text>
<text top="527" left="254" width="92" height="9" font="27">UW Medicine Eastside</text>
<text top="539" left="247" width="68" height="9" font="27">Specialty Center</text>
<text top="537" left="315" width="39" height="12" font="27">—Medical</text>
<text top="551" left="283" width="33" height="9" font="27">Director</text>
<text top="490" left="371" width="6" height="10" font="28">n</text>
<text top="491" left="386" width="50" height="9" font="27">RubiconMD</text>
<text top="491" left="436" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="503" left="371" width="6" height="10" font="28">n</text>
<text top="503" left="386" width="47" height="9" font="27">Regeneron</text>
<text top="503" left="433" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="491" left="486" width="22" height="9" font="27">None</text>
<text top="491" left="562" width="22" height="9" font="27">None</text>
<text top="490" left="617" width="6" height="10" font="28">n</text>
<text top="491" left="632" width="49" height="9" font="27">Amgen Inc.</text>
<text top="491" left="681" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="503" left="617" width="6" height="10" font="28">n</text>
<text top="503" left="632" width="71" height="9" font="27">Gilead Sciences,</text>
<text top="515" left="631" width="52" height="9" font="27">Inc. <a href="e127.full.html#122">(DSMB)</a></text>
<text top="515" left="683" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="491" left="763" width="22" height="9" font="27">None</text>
<text top="493" left="841" width="6" height="10" font="28">n</text>
<text top="494" left="855" width="52" height="9" font="27">Third party,</text>
<text top="506" left="855" width="46" height="9" font="27">CAD, 2016</text>
<text top="506" left="902" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="491" left="960" width="22" height="9" font="27">None</text>
<text top="570" left="58" width="78" height="9" font="27">Robert Jay Amrien</text>
<text top="570" left="158" width="60" height="9" font="27">Organizational</text>
<text top="582" left="154" width="38" height="9" font="27">Reviewer</text>
<text top="580" left="192" width="30" height="12" font="27">—AAPA</text>
<text top="570" left="252" width="95" height="9" font="27">Massachusetts General</text>
<text top="582" left="244" width="34" height="9" font="27">Hospital</text>
<text top="580" left="278" width="78" height="12" font="27">—Clinical Physician</text>
<text top="594" left="247" width="106" height="9" font="27">Assistant, Chelsea Health</text>
<text top="606" left="244" width="105" height="9" font="27">Center; Bryant University</text>
<text top="604" left="349" width="7" height="12" font="27">—</text>
<text top="618" left="241" width="117" height="9" font="27">Physician Assistant Program</text>
<text top="570" left="401" width="22" height="9" font="27">None</text>
<text top="570" left="486" width="22" height="9" font="27">None</text>
<text top="570" left="562" width="22" height="9" font="27">None</text>
<text top="570" left="651" width="22" height="9" font="27">None</text>
<text top="570" left="763" width="22" height="9" font="27">None</text>
<text top="572" left="841" width="6" height="10" font="28">n</text>
<text top="573" left="855" width="49" height="9" font="27">Defendant,</text>
<text top="585" left="855" width="59" height="9" font="27">aortic dissec-</text>
<text top="597" left="855" width="45" height="9" font="27">tion, 20<a href="e127.full.html#122">16</a></text>
<text top="597" left="900" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="570" left="960" width="22" height="9" font="27">None</text>
<text top="637" left="58" width="60" height="9" font="27">Greg Holzman</text>
<text top="637" left="158" width="60" height="9" font="27">Organizational</text>
<text top="649" left="153" width="38" height="9" font="27">Reviewer</text>
<text top="647" left="191" width="32" height="12" font="27">—ACPM</text>
<text top="637" left="249" width="101" height="9" font="27">Montana Department of</text>
<text top="649" left="247" width="107" height="9" font="27">Public Health and Human</text>
<text top="661" left="251" width="34" height="9" font="27">Services</text>
<text top="659" left="285" width="64" height="12" font="27">—State Medical</text>
<text top="673" left="286" width="10" height="9" font="27">Of</text>
<text top="671" left="296" width="18" height="12" font="27">ﬁcer</text>
<text top="637" left="401" width="22" height="9" font="27">None</text>
<text top="637" left="486" width="22" height="9" font="27">None</text>
<text top="637" left="562" width="22" height="9" font="27">None</text>
<text top="637" left="651" width="22" height="9" font="27">None</text>
<text top="639" left="720" width="6" height="10" font="28">n</text>
<text top="640" left="734" width="96" height="9" font="27">American Academy of</text>
<text top="652" left="734" width="71" height="9" font="27">Family Medicine</text>
<text top="650" left="805" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="663" left="720" width="6" height="10" font="28">n</text>
<text top="664" left="734" width="89" height="9" font="27">American College of</text>
<text top="676" left="734" width="89" height="9" font="27">Preventive Medicin<a href="e127.full.html#122">e</a></text>
<text top="674" left="823" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="637" left="866" width="22" height="9" font="27">None</text>
<text top="637" left="960" width="22" height="9" font="27">None</text>
<text top="696" left="58" width="57" height="9" font="27">Martha Gulati</text>
<text top="696" left="158" width="60" height="9" font="27">Organizational</text>
<text top="707" left="155" width="38" height="9" font="27">Reviewer</text>
<text top="706" left="193" width="29" height="12" font="27">—ASPC</text>
<text top="696" left="239" width="122" height="9" font="27">University of Arizona College</text>
<text top="707" left="247" width="49" height="9" font="27">of Medicine</text>
<text top="706" left="296" width="58" height="12" font="27">—Professor of</text>
<text top="719" left="243" width="114" height="9" font="27">Medicine; Chief, Division of</text>
<text top="731" left="254" width="92" height="9" font="27">Cardiology; University</text>
<text top="743" left="250" width="100" height="9" font="27">Medicine Cardiovascular</text>
<text top="755" left="237" width="80" height="9" font="27">Institute in Phoenix</text>
<text top="754" left="318" width="45" height="12" font="27">—Physician</text>
<text top="767" left="244" width="111" height="9" font="27">Executive Director, Banner</text>
<text top="696" left="401" width="22" height="9" font="27">None</text>
<text top="696" left="486" width="22" height="9" font="27">None</text>
<text top="696" left="562" width="22" height="9" font="27">None</text>
<text top="696" left="651" width="22" height="9" font="27">None</text>
<text top="698" left="720" width="6" height="10" font="28">n</text>
<text top="698" left="734" width="70" height="9" font="27">REATA (spouse)</text>
<text top="698" left="805" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="696" left="866" width="22" height="9" font="27">None</text>
<text top="696" left="960" width="22" height="9" font="27">None</text>
<text top="788" left="915" width="105" height="8" font="30">Continued on the next page</text>
<text top="93" left="58" width="959" height="16" font="31">APPENDIX 2. REVIEWER RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (COMPREHENSIVE)—2017 ACC/AHA/AAPA/ABC/ACPM/AGS/</text>
<text top="111" left="58" width="959" height="16" font="31">APhA/ASH/ASPC/NMA/PCNA GUIDELINE FOR THE PREVENTION, DETECTION, EVALUATION, AND MANAGEMENT OF HIGH BLOOD PRESSURE IN</text>
<text top="129" left="58" width="172" height="16" font="31">ADULTS (OCTOBER 2017)</text>
<text top="100" left="1100" width="0" height="9" font="13">Whelton</text>
<text top="139" left="1100" width="0" height="9" font="13">et</text>
<text top="150" left="1100" width="0" height="9" font="13">al</text>
<text top="158" left="1100" width="0" height="9" font="13">.</text>
<text top="667" left="1102" width="0" height="7" font="9">J</text>
<text top="672" left="1102" width="0" height="7" font="9">A</text>
<text top="679" left="1102" width="0" height="7" font="9">C</text>
<text top="685" left="1102" width="0" height="7" font="9">C</text>
<text top="695" left="1102" width="0" height="7" font="9">VO</text>
<text top="709" left="1102" width="0" height="7" font="9">L.</text>
<text top="721" left="1102" width="0" height="7" font="9">71,</text>
<text top="738" left="1102" width="0" height="7" font="9">N</text>
<text top="745" left="1102" width="0" height="7" font="9">O</text>
<text top="752" left="1102" width="0" height="7" font="9">.</text>
<text top="759" left="1102" width="0" height="7" font="9">19,</text>
<text top="776" left="1102" width="0" height="7" font="9">2</text>
<text top="781" left="1102" width="0" height="7" font="9">018</text>
<text top="100" left="1085" width="0" height="9" font="13">2017</text>
<text top="124" left="1085" width="0" height="9" font="13">High</text>
<text top="146" left="1085" width="0" height="9" font="13">Blood</text>
<text top="173" left="1085" width="0" height="9" font="13">Pressure</text>
<text top="212" left="1085" width="0" height="9" font="13">Clinical</text>
<text top="245" left="1085" width="0" height="9" font="13">Practice</text>
<text top="281" left="1085" width="0" height="9" font="13">Guideline</text>
<text top="688" left="1087" width="0" height="7" font="9">M</text>
<text top="695" left="1087" width="0" height="7" font="9">A</text>
<text top="702" left="1087" width="0" height="7" font="9">Y</text>
<text top="712" left="1087" width="0" height="7" font="9">1</text>
<text top="716" left="1087" width="0" height="7" font="9">5</text>
<text top="722" left="1087" width="0" height="7" font="9">,</text>
<text top="729" left="1087" width="0" height="7" font="9">20</text>
<text top="741" left="1087" width="0" height="7" font="9">18:</text>
<text top="754" left="1087" width="0" height="7" font="9">e</text>
<text top="760" left="1087" width="0" height="7" font="9">127</text>
<text top="773" left="1087" width="0" height="10" font="9">–</text>
<text top="780" left="1087" width="0" height="7" font="9">24</text>
<text top="792" left="1087" width="0" height="7" font="9">8</text>
<text top="50" left="1101" width="0" height="9" font="4">e240</text>
</page>
<page number="115" position="absolute" top="0" left="0" height="864" width="1160">
<text top="134" left="59" width="43" height="9" font="27">Reviewer</text>
<text top="134" left="153" width="71" height="9" font="27">Representation</text>
<text top="134" left="271" width="58" height="9" font="27">Employment</text>
<text top="134" left="387" width="50" height="9" font="27">Consultant</text>
<text top="122" left="476" width="42" height="9" font="27">Speakers</text>
<text top="134" left="481" width="32" height="9" font="27">Bureau</text>
<text top="110" left="546" width="53" height="9" font="27">Ownership/</text>
<text top="122" left="544" width="59" height="9" font="27">Partnership/</text>
<text top="134" left="553" width="41" height="9" font="27">Principal</text>
<text top="134" left="620" width="85" height="9" font="27">Personal Research</text>
<text top="110" left="744" width="60" height="9" font="27">Institutional,</text>
<text top="122" left="718" width="113" height="9" font="27">Organizational, or Other</text>
<text top="134" left="736" width="67" height="9" font="27">Financial Bene</text>
<text top="132" left="803" width="10" height="12" font="27">ﬁt</text>
<text top="134" left="842" width="71" height="9" font="27">Expert Witness</text>
<text top="134" left="957" width="28" height="9" font="27">Salary</text>
<text top="150" left="59" width="70" height="9" font="27">Wallace Johnson</text>
<text top="150" left="158" width="60" height="9" font="27">Organizational</text>
<text top="162" left="156" width="38" height="9" font="27">Reviewer</text>
<text top="160" left="194" width="27" height="12" font="27">—NMA</text>
<text top="150" left="253" width="95" height="9" font="27">University of Maryland</text>
<text top="162" left="247" width="63" height="9" font="27">Medical Center</text>
<text top="160" left="310" width="44" height="12" font="27">—Assistant</text>
<text top="174" left="255" width="91" height="9" font="27">Professor of Medicine</text>
<text top="150" left="401" width="22" height="9" font="27">None</text>
<text top="150" left="486" width="22" height="9" font="27">None</text>
<text top="150" left="562" width="22" height="9" font="27">None</text>
<text top="150" left="646" width="29" height="9" font="27">Amgen</text>
<text top="148" left="675" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="150" left="763" width="22" height="9" font="27">None</text>
<text top="150" left="866" width="22" height="9" font="27">None</text>
<text top="150" left="960" width="22" height="9" font="27">None</text>
<text top="193" left="59" width="64" height="9" font="27">Nancy Houston</text>
<text top="205" left="74" width="24" height="9" font="27">Miller</text>
<text top="193" left="158" width="60" height="9" font="27">Organizational</text>
<text top="205" left="154" width="38" height="9" font="27">Reviewer</text>
<text top="203" left="192" width="30" height="12" font="27">—PCNA</text>
<text top="193" left="251" width="93" height="9" font="27">The Lifecare Company</text>
<text top="191" left="343" width="7" height="12" font="27">—</text>
<text top="205" left="263" width="76" height="9" font="27">Associate Director</text>
<text top="192" left="372" width="6" height="10" font="28">n</text>
<text top="193" left="386" width="32" height="9" font="27">Moving</text>
<text top="205" left="386" width="40" height="9" font="27">Analytics</text>
<text top="205" left="426" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="193" left="486" width="22" height="9" font="27">None</text>
<text top="193" left="562" width="22" height="9" font="27">None</text>
<text top="193" left="652" width="22" height="9" font="27">None</text>
<text top="193" left="763" width="22" height="9" font="27">None</text>
<text top="193" left="866" width="22" height="9" font="27">None</text>
<text top="193" left="960" width="22" height="9" font="27">None</text>
<text top="224" left="59" width="64" height="9" font="27">Aldo J. Peixoto</text>
<text top="224" left="158" width="60" height="9" font="27">Organizational</text>
<text top="236" left="157" width="38" height="9" font="27">Reviewer</text>
<text top="235" left="195" width="24" height="12" font="27">—ASH</text>
<text top="224" left="248" width="105" height="9" font="27">Yale University School of</text>
<text top="236" left="253" width="37" height="9" font="27">Medicine</text>
<text top="235" left="290" width="58" height="12" font="27">—Professor of</text>
<text top="248" left="251" width="98" height="9" font="27">Medicine (Nephrology);</text>
<text top="260" left="261" width="78" height="9" font="27">Associate Chair for</text>
<text top="272" left="258" width="85" height="9" font="27">Ambulatory Services</text>
<text top="284" left="251" width="99" height="9" font="27">Operations and Quality,</text>
<text top="296" left="252" width="97" height="9" font="27">Department of Internal</text>
<text top="308" left="251" width="100" height="9" font="27">Medicine; Clinical Chief,</text>
<text top="320" left="253" width="94" height="9" font="27">Section of Nephrology</text>
<text top="223" left="372" width="6" height="10" font="28">n</text>
<text top="224" left="386" width="61" height="9" font="27">Lundbeck Inc.</text>
<text top="224" left="486" width="22" height="9" font="27">None</text>
<text top="224" left="562" width="22" height="9" font="27">None</text>
<text top="223" left="618" width="6" height="10" font="28">n</text>
<text top="224" left="632" width="75" height="9" font="27">Bayer Healthcare</text>
<text top="236" left="632" width="71" height="9" font="27">Pharmaceuticals</text>
<text top="234" left="703" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="223" left="721" width="6" height="10" font="28">n</text>
<text top="224" left="735" width="75" height="9" font="27">Bayer Healthcare</text>
<text top="236" left="734" width="71" height="9" font="27">Pharmaceuticals</text>
<text top="224" left="866" width="22" height="9" font="27">None</text>
<text top="224" left="960" width="22" height="9" font="27">None</text>
<text top="339" left="59" width="70" height="9" font="27">Carlos Rodriguez</text>
<text top="339" left="158" width="60" height="9" font="27">Organizational</text>
<text top="351" left="157" width="38" height="9" font="27">Reviewer</text>
<text top="349" left="196" width="24" height="12" font="27">—ABC</text>
<text top="339" left="249" width="96" height="9" font="27">Wake Forest University</text>
<text top="337" left="345" width="7" height="12" font="27">—</text>
<text top="351" left="240" width="120" height="9" font="27">Professor, Epidemiology and</text>
<text top="363" left="278" width="45" height="9" font="27">Prevention</text>
<text top="338" left="372" width="6" height="10" font="28">n</text>
<text top="339" left="386" width="49" height="9" font="27">Amgen Inc.</text>
<text top="339" left="486" width="22" height="9" font="27">None</text>
<text top="339" left="562" width="22" height="9" font="27">None</text>
<text top="339" left="652" width="22" height="9" font="27">None</text>
<text top="339" left="763" width="22" height="9" font="27">None</text>
<text top="339" left="866" width="22" height="9" font="27">None</text>
<text top="339" left="960" width="22" height="9" font="27">None</text>
<text top="382" left="59" width="61" height="9" font="27">Joseph Saseen</text>
<text top="382" left="158" width="60" height="9" font="27">Organizational</text>
<text top="394" left="155" width="38" height="9" font="27">Reviewer</text>
<text top="393" left="193" width="29" height="12" font="27">—APhA</text>
<text top="382" left="253" width="94" height="9" font="27">University of Colorado</text>
<text top="394" left="243" width="109" height="9" font="27">Anschutz Medical Campus</text>
<text top="393" left="351" width="7" height="12" font="27">—</text>
<text top="406" left="246" width="109" height="9" font="27">Vice-Chair, Department of</text>
<text top="418" left="246" width="108" height="9" font="27">Clinical Pharmacy, Skaggs</text>
<text top="430" left="250" width="101" height="9" font="27">School of Pharmacy and</text>
<text top="442" left="250" width="101" height="9" font="27">Pharmaceutical Sciences</text>
<text top="382" left="401" width="22" height="9" font="27">None</text>
<text top="382" left="486" width="22" height="9" font="27">None</text>
<text top="382" left="562" width="22" height="9" font="27">None</text>
<text top="382" left="652" width="22" height="9" font="27">None</text>
<text top="381" left="721" width="6" height="10" font="28">n</text>
<text top="382" left="735" width="61" height="9" font="27">National Lipid</text>
<text top="394" left="734" width="50" height="9" font="27">Associatio<a href="e127.full.html#122">n</a></text>
<text top="392" left="784" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="381" left="841" width="6" height="10" font="28">n</text>
<text top="382" left="856" width="49" height="9" font="27">Defendant,</text>
<text top="394" left="855" width="46" height="9" font="27">statin use,</text>
<text top="406" left="855" width="22" height="9" font="27">2016</text>
<text top="382" left="960" width="22" height="9" font="27">None</text>
<text top="461" left="59" width="56" height="9" font="27">Mark Supiano</text>
<text top="461" left="158" width="60" height="9" font="27">Organizational</text>
<text top="473" left="158" width="38" height="9" font="27">Reviewer</text>
<text top="472" left="196" width="24" height="12" font="27">—AGS</text>
<text top="461" left="241" width="119" height="9" font="27">University of Utah School of</text>
<text top="473" left="245" width="37" height="9" font="27">Medicine</text>
<text top="472" left="282" width="74" height="12" font="27">—D. Keith Barnes,</text>
<text top="485" left="253" width="95" height="9" font="27">MD, and Dottie Barnes</text>
<text top="497" left="238" width="125" height="9" font="27">Presidential Endowed Chair in</text>
<text top="509" left="243" width="114" height="9" font="27">Medicine; Chief, Division of</text>
<text top="521" left="242" width="117" height="9" font="27">Geriatrics; VA Salt Lake City</text>
<text top="533" left="241" width="75" height="9" font="27">Geriatric Research</text>
<text top="531" left="317" width="43" height="12" font="27">—Director,</text>
<text top="545" left="238" width="126" height="9" font="27">Education, and Clinical Center;</text>
<text top="557" left="240" width="121" height="9" font="27">University of Utah Center on</text>
<text top="569" left="247" width="67" height="9" font="27">Aging Executive</text>
<text top="567" left="314" width="40" height="12" font="27">—Director</text>
<text top="461" left="401" width="22" height="9" font="27">None</text>
<text top="461" left="486" width="22" height="9" font="27">None</text>
<text top="461" left="562" width="22" height="9" font="27">None</text>
<text top="461" left="652" width="22" height="9" font="27">None</text>
<text top="460" left="721" width="6" height="10" font="28">n</text>
<text top="461" left="735" width="85" height="9" font="27">American Geriatrics</text>
<text top="473" left="734" width="32" height="9" font="27">Societ<a href="e127.full.html#122">y</a></text>
<text top="471" left="766" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="484" left="721" width="6" height="10" font="28">n</text>
<text top="485" left="735" width="60" height="9" font="27">Division Chief</text>
<text top="483" left="795" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="497" left="721" width="6" height="10" font="28">n</text>
<text top="497" left="735" width="92" height="9" font="27">McGraw-Hill Medical</text>
<text top="461" left="866" width="22" height="9" font="27">None</text>
<text top="461" left="960" width="22" height="9" font="27">None</text>
<text top="588" left="59" width="76" height="9" font="27">Sana M. Al-Khatib</text>
<text top="588" left="148" width="74" height="9" font="27">Content Reviewer</text>
<text top="586" left="222" width="7" height="12" font="27">—</text>
<text top="600" left="145" width="87" height="9" font="27">ACC/AHA Task Force</text>
<text top="612" left="149" width="79" height="9" font="27">on Clinical Practice</text>
<text top="624" left="167" width="43" height="9" font="27">Guidelines</text>
<text top="588" left="253" width="94" height="9" font="27">Duke Clinical Research</text>
<text top="600" left="254" width="35" height="9" font="27">Institute</text>
<text top="598" left="289" width="58" height="12" font="27">—Professor of</text>
<text top="612" left="282" width="37" height="9" font="27">Medicine</text>
<text top="588" left="401" width="22" height="9" font="27">None</text>
<text top="588" left="486" width="22" height="9" font="27">None</text>
<text top="588" left="562" width="22" height="9" font="27">None</text>
<text top="587" left="618" width="6" height="10" font="28">n</text>
<text top="588" left="632" width="26" height="9" font="27">AHRQ</text>
<text top="588" left="658" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="600" left="618" width="6" height="10" font="28">n</text>
<text top="600" left="632" width="18" height="9" font="27">FDA</text>
<text top="600" left="650" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="612" left="618" width="6" height="10" font="28">n</text>
<text top="613" left="632" width="27" height="9" font="27">PCORI</text>
<text top="613" left="659" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="625" left="618" width="6" height="10" font="28">n</text>
<text top="626" left="632" width="79" height="9" font="27">VA Health System</text>
<text top="638" left="632" width="33" height="9" font="27">(DSMB)</text>
<text top="587" left="721" width="6" height="10" font="28">n</text>
<text top="588" left="735" width="34" height="9" font="27">Elsevi<a href="e127.full.html#122">er</a></text>
<text top="588" left="769" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="600" left="721" width="6" height="10" font="28">n</text>
<text top="600" left="735" width="50" height="9" font="27">NIH, NHLBI</text>
<text top="590" left="841" width="6" height="10" font="28">n</text>
<text top="591" left="856" width="52" height="9" font="27">Third party,</text>
<text top="603" left="855" width="52" height="9" font="27">implantable</text>
<text top="615" left="855" width="53" height="9" font="27">cardioverter</text>
<text top="627" left="855" width="10" height="9" font="27">de</text>
<text top="625" left="866" width="48" height="12" font="27">ﬁbrillators,</text>
<text top="639" left="855" width="21" height="9" font="27">2017</text>
<text top="588" left="960" width="22" height="9" font="27">None</text>
<text top="659" left="59" width="58" height="9" font="27">George Bakris</text>
<text top="659" left="151" width="74" height="9" font="27">Content Reviewer</text>
<text top="659" left="256" width="89" height="9" font="27">University of Chicago</text>
<text top="671" left="253" width="37" height="9" font="27">Medicine</text>
<text top="669" left="290" width="58" height="12" font="27">—Professor of</text>
<text top="683" left="261" width="79" height="9" font="27">Medicine; Director,</text>
<text top="695" left="244" width="113" height="9" font="27">Hypertensive Diseases Unit</text>
<text top="659" left="401" width="22" height="9" font="27">None</text>
<text top="659" left="486" width="22" height="9" font="27">None</text>
<text top="659" left="562" width="22" height="9" font="27">None</text>
<text top="657" left="618" width="6" height="10" font="28">n</text>
<text top="658" left="632" width="53" height="9" font="27">AbbVie, Inc.</text>
<text top="670" left="618" width="6" height="10" font="28">n</text>
<text top="671" left="632" width="68" height="9" font="27">Janssen, Bayer,</text>
<text top="683" left="632" width="34" height="9" font="27">Relypsa</text>
<text top="659" left="763" width="22" height="9" font="27">None</text>
<text top="659" left="866" width="22" height="9" font="27">None</text>
<text top="659" left="960" width="22" height="9" font="27">None</text>
<text top="715" left="915" width="105" height="8" font="30">Continued on the next page</text>
<text top="60" left="59" width="158" height="16" font="31">APPENDIX 2. CONTINUED</text>
<text top="57" left="1102" width="0" height="7" font="9">J</text>
<text top="63" left="1102" width="0" height="7" font="9">A</text>
<text top="69" left="1102" width="0" height="7" font="9">CC</text>
<text top="86" left="1102" width="0" height="7" font="9">VO</text>
<text top="99" left="1102" width="0" height="7" font="9">L.</text>
<text top="112" left="1102" width="0" height="7" font="9">7</text>
<text top="117" left="1102" width="0" height="7" font="9">1</text>
<text top="121" left="1102" width="0" height="7" font="9">,</text>
<text top="129" left="1102" width="0" height="7" font="9">N</text>
<text top="135" left="1102" width="0" height="7" font="9">O</text>
<text top="142" left="1102" width="0" height="7" font="9">.</text>
<text top="149" left="1102" width="0" height="7" font="9">1</text>
<text top="154" left="1102" width="0" height="7" font="9">9</text>
<text top="159" left="1102" width="0" height="7" font="9">,</text>
<text top="166" left="1102" width="0" height="7" font="9">2</text>
<text top="172" left="1102" width="0" height="7" font="9">01</text>
<text top="182" left="1102" width="0" height="7" font="9">8</text>
<text top="690" left="1100" width="0" height="9" font="13">Whelton</text>
<text top="728" left="1100" width="0" height="9" font="13">et</text>
<text top="739" left="1100" width="0" height="9" font="13">al</text>
<text top="747" left="1100" width="0" height="9" font="13">.</text>
<text top="57" left="1087" width="0" height="7" font="9">MA</text>
<text top="71" left="1087" width="0" height="7" font="9">Y</text>
<text top="81" left="1087" width="0" height="7" font="9">1</text>
<text top="86" left="1087" width="0" height="7" font="9">5,</text>
<text top="98" left="1087" width="0" height="7" font="9">2</text>
<text top="104" left="1087" width="0" height="7" font="9">0</text>
<text top="110" left="1087" width="0" height="7" font="9">1</text>
<text top="114" left="1087" width="0" height="7" font="9">8</text>
<text top="120" left="1087" width="0" height="7" font="9">:e</text>
<text top="129" left="1087" width="0" height="7" font="9">1</text>
<text top="133" left="1087" width="0" height="7" font="9">2</text>
<text top="139" left="1087" width="0" height="7" font="9">7</text>
<text top="142" left="1087" width="0" height="10" font="9">–</text>
<text top="149" left="1087" width="0" height="7" font="9">24</text>
<text top="161" left="1087" width="0" height="7" font="9">8</text>
<text top="531" left="1085" width="0" height="9" font="13">2017</text>
<text top="554" left="1085" width="0" height="9" font="13">High</text>
<text top="576" left="1085" width="0" height="9" font="13">Blood</text>
<text top="604" left="1085" width="0" height="9" font="13">Pressure</text>
<text top="642" left="1085" width="0" height="9" font="13">Clinical</text>
<text top="675" left="1085" width="0" height="9" font="13">Practice</text>
<text top="711" left="1085" width="0" height="9" font="13">Guideline</text>
<text top="782" left="1101" width="0" height="9" font="4">e241</text>
</page>
<page number="116" position="absolute" top="0" left="0" height="864" width="1160">
<text top="105" left="59" width="158" height="16" font="31">APPENDIX 2. CONTINUED</text>
<text top="174" left="58" width="43" height="9" font="27">Reviewer</text>
<text top="174" left="153" width="71" height="9" font="27">Representation</text>
<text top="174" left="271" width="58" height="9" font="27">Employment</text>
<text top="174" left="387" width="50" height="9" font="27">Consultant</text>
<text top="162" left="476" width="42" height="9" font="27">Speakers</text>
<text top="174" left="481" width="32" height="9" font="27">Bureau</text>
<text top="150" left="546" width="53" height="9" font="27">Ownership/</text>
<text top="162" left="544" width="58" height="9" font="27">Partnership/</text>
<text top="174" left="553" width="41" height="9" font="27">Principal</text>
<text top="174" left="620" width="85" height="9" font="27">Personal Research</text>
<text top="150" left="744" width="60" height="9" font="27">Institutional,</text>
<text top="162" left="717" width="113" height="9" font="27">Organizational, or Other</text>
<text top="174" left="735" width="67" height="9" font="27">Financial Bene</text>
<text top="173" left="803" width="10" height="12" font="27">ﬁt</text>
<text top="174" left="842" width="71" height="9" font="27">Expert Witness</text>
<text top="174" left="957" width="28" height="9" font="27">Salary</text>
<text top="190" left="58" width="42" height="9" font="27">Jan Basile</text>
<text top="190" left="151" width="74" height="9" font="27">Content Reviewer</text>
<text top="190" left="242" width="116" height="9" font="27">Medical University of South</text>
<text top="202" left="254" width="34" height="9" font="27">Carolina</text>
<text top="201" left="288" width="58" height="12" font="27">—Professor of</text>
<text top="214" left="254" width="93" height="9" font="27">Medicine, Seinsheimer</text>
<text top="226" left="255" width="91" height="9" font="27">Cardiovascular Health</text>
<text top="238" left="237" width="126" height="9" font="27">Program; Ralph H Johnson VA</text>
<text top="250" left="248" width="63" height="9" font="27">Medical Center</text>
<text top="249" left="310" width="42" height="12" font="27">—Internist</text>
<text top="190" left="401" width="22" height="9" font="27">None</text>
<text top="189" left="465" width="6" height="10" font="28">n</text>
<text top="190" left="480" width="49" height="9" font="27">Amgen Inc.</text>
<text top="202" left="465" width="6" height="10" font="28">n</text>
<text top="203" left="480" width="24" height="9" font="27">Arbor</text>
<text top="215" left="465" width="6" height="10" font="28">n</text>
<text top="216" left="480" width="34" height="9" font="27">Janssen</text>
<text top="227" left="479" width="52" height="9" font="27">Pharmaceu-</text>
<text top="239" left="479" width="42" height="9" font="27">ticals, Inc</text>
<text top="190" left="562" width="22" height="9" font="27">None</text>
<text top="192" left="617" width="6" height="10" font="28">n</text>
<text top="193" left="632" width="52" height="9" font="27">Eli Lilly and</text>
<text top="205" left="631" width="40" height="9" font="27">Company</text>
<text top="216" left="617" width="6" height="10" font="28">n</text>
<text top="217" left="632" width="27" height="9" font="27">NHLBI</text>
<text top="190" left="763" width="22" height="9" font="27">None</text>
<text top="190" left="866" width="22" height="9" font="27">None</text>
<text top="190" left="960" width="22" height="9" font="27">None</text>
<text top="269" left="58" width="164" height="9" font="27">Joshua A. Beckman Content Reviewer</text>
<text top="268" left="222" width="7" height="12" font="27">—</text>
<text top="281" left="145" width="87" height="9" font="27">ACC/AHA Task Force</text>
<text top="293" left="149" width="79" height="9" font="27">on Clinical Practice</text>
<text top="305" left="167" width="43" height="9" font="27">Guidelines</text>
<text top="269" left="239" width="123" height="9" font="27">Vanderbilt University Medical</text>
<text top="281" left="265" width="69" height="9" font="27">Center: Director,</text>
<text top="293" left="246" width="108" height="9" font="27">Cardiovascular Fellowship</text>
<text top="305" left="281" width="38" height="9" font="27">Program,</text>
<text top="268" left="372" width="6" height="10" font="28">n</text>
<text top="269" left="386" width="54" height="9" font="27">AstraZeneca</text>
<text top="269" left="440" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="281" left="372" width="6" height="10" font="28">n</text>
<text top="282" left="386" width="26" height="9" font="27">Merc<a href="e127.full.html#122">k</a></text>
<text top="282" left="412" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="294" left="372" width="6" height="10" font="28">n</text>
<text top="295" left="386" width="33" height="9" font="27">SANOFI</text>
<text top="295" left="419" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="269" left="486" width="22" height="9" font="27">None</text>
<text top="268" left="541" width="6" height="10" font="28">n</text>
<text top="269" left="556" width="20" height="9" font="27">EMX</text>
<text top="267" left="576" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="281" left="541" width="6" height="10" font="28">n</text>
<text top="282" left="556" width="39" height="9" font="27">JanaCare</text>
<text top="280" left="595" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="268" left="617" width="6" height="10" font="28">n</text>
<text top="269" left="632" width="58" height="9" font="27">Bristol Myers</text>
<text top="281" left="631" width="30" height="9" font="27">Squibb</text>
<text top="281" left="661" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="268" left="720" width="6" height="10" font="28">n</text>
<text top="269" left="734" width="81" height="9" font="27">Vascular Interven-</text>
<text top="281" left="734" width="70" height="9" font="27">tional Advances</text>
<text top="281" left="807" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="269" left="866" width="22" height="9" font="27">None</text>
<text top="268" left="926" width="6" height="10" font="28">n</text>
<text top="269" left="940" width="74" height="9" font="27">2015-Defendant;</text>
<text top="281" left="940" width="32" height="9" font="27">Venous</text>
<text top="293" left="940" width="75" height="9" font="27">thromboembolism</text>
<text top="293" left="1015" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="324" left="58" width="66" height="9" font="27">John Bisognano</text>
<text top="324" left="151" width="74" height="9" font="27">Content Reviewer</text>
<text top="324" left="251" width="98" height="9" font="27">University of Rochester</text>
<text top="336" left="240" width="63" height="9" font="27">Medical Center</text>
<text top="335" left="303" width="56" height="12" font="27">—Cardiologist</text>
<text top="323" left="372" width="6" height="10" font="28">n</text>
<text top="324" left="386" width="23" height="9" font="27">CVRx</text>
<text top="324" left="486" width="22" height="9" font="27">None</text>
<text top="324" left="562" width="22" height="9" font="27">None</text>
<text top="323" left="617" width="6" height="10" font="28">n</text>
<text top="324" left="632" width="23" height="9" font="27"><a href="e127.full.html#122">CVRx</a></text>
<text top="324" left="654" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="336" left="617" width="6" height="10" font="28">n</text>
<text top="337" left="632" width="16" height="9" font="27">NIH</text>
<text top="337" left="648" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="324" left="763" width="22" height="9" font="27">None</text>
<text top="324" left="866" width="22" height="9" font="27">None</text>
<text top="324" left="960" width="22" height="9" font="27">None</text>
<text top="357" left="58" width="65" height="9" font="27">Biykem Bozkurt</text>
<text top="357" left="148" width="74" height="9" font="27">Content Reviewer</text>
<text top="355" left="222" width="7" height="12" font="27">—</text>
<text top="369" left="145" width="87" height="9" font="27">ACC/AHA Task Force</text>
<text top="381" left="149" width="79" height="9" font="27">on Clinical Practice</text>
<text top="393" left="167" width="43" height="9" font="27">Guidelines</text>
<text top="357" left="240" width="113" height="9" font="27">Baylor College of Medicine</text>
<text top="355" left="353" width="7" height="12" font="27">—</text>
<text top="369" left="240" width="120" height="9" font="27">Medical Care Line Executive,</text>
<text top="381" left="237" width="126" height="9" font="27">Cardiology Chief, Gordon Cain</text>
<text top="393" left="240" width="120" height="9" font="27">Chair, Professor of Medicine,</text>
<text top="405" left="282" width="35" height="9" font="27">Debakey</text>
<text top="357" left="401" width="22" height="9" font="27">None</text>
<text top="357" left="486" width="22" height="9" font="27">None</text>
<text top="357" left="562" width="22" height="9" font="27">None</text>
<text top="356" left="617" width="6" height="10" font="28">n</text>
<text top="357" left="632" width="36" height="9" font="27">Novartis</text>
<text top="369" left="631" width="52" height="9" font="27">Corporation</text>
<text top="357" left="763" width="22" height="9" font="27">None</text>
<text top="357" left="866" width="22" height="9" font="27">None</text>
<text top="357" left="960" width="22" height="9" font="27">None</text>
<text top="424" left="58" width="60" height="9" font="27">David Calhoun</text>
<text top="424" left="151" width="74" height="9" font="27">Content Reviewer</text>
<text top="424" left="253" width="95" height="9" font="27">University of Alabama,</text>
<text top="436" left="254" width="92" height="9" font="27">Birmingham School of</text>
<text top="448" left="257" width="37" height="9" font="27">Medicine</text>
<text top="446" left="294" width="49" height="12" font="27">—Professor,</text>
<text top="460" left="238" width="125" height="9" font="27">Department of Cardiovascular</text>
<text top="472" left="284" width="31" height="9" font="27">Disease</text>
<text top="423" left="372" width="6" height="10" font="28">n</text>
<text top="424" left="386" width="37" height="9" font="27">Novartis</text>
<text top="436" left="372" width="6" height="10" font="28">n</text>
<text top="436" left="386" width="37" height="9" font="27">Valencia</text>
<text top="448" left="385" width="58" height="9" font="27">Technologie<a href="e127.full.html#122">s</a></text>
<text top="448" left="443" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="424" left="486" width="22" height="9" font="27">None</text>
<text top="424" left="562" width="22" height="9" font="27">None</text>
<text top="423" left="617" width="6" height="10" font="28">n</text>
<text top="424" left="632" width="54" height="9" font="27">MEDTRONIC</text>
<text top="424" left="686" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="436" left="617" width="6" height="10" font="28">n</text>
<text top="436" left="632" width="63" height="9" font="27">ReCor Medical</text>
<text top="436" left="695" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="424" left="763" width="22" height="9" font="27">None</text>
<text top="424" left="866" width="22" height="9" font="27">None</text>
<text top="424" left="960" width="22" height="9" font="27">None</text>
<text top="492" left="58" width="164" height="9" font="27">Joaquin E. Cigarroa Content Reviewer</text>
<text top="490" left="222" width="7" height="12" font="27">—</text>
<text top="504" left="145" width="87" height="9" font="27">ACC/AHA Task Force</text>
<text top="516" left="149" width="79" height="9" font="27">on Clinical Practice</text>
<text top="528" left="167" width="43" height="9" font="27">Guidelines</text>
<text top="492" left="243" width="113" height="9" font="27">Oregon Health and Science</text>
<text top="504" left="240" width="42" height="9" font="27">University</text>
<text top="502" left="281" width="79" height="12" font="27">—Clinical Professor</text>
<text top="516" left="276" width="49" height="9" font="27">of Medicine</text>
<text top="492" left="401" width="22" height="9" font="27">None</text>
<text top="492" left="486" width="22" height="9" font="27">None</text>
<text top="492" left="562" width="22" height="9" font="27">None</text>
<text top="494" left="617" width="6" height="10" font="28">n</text>
<text top="495" left="632" width="16" height="9" font="27">NIH</text>
<text top="494" left="720" width="6" height="10" font="28">n</text>
<text top="495" left="734" width="86" height="9" font="27">ACC/AHA Taskforce</text>
<text top="507" left="734" width="84" height="9" font="27">on Clinical Practice</text>
<text top="519" left="734" width="45" height="9" font="27">Guidelines</text>
<text top="517" left="780" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="529" left="720" width="6" height="10" font="28">n</text>
<text top="530" left="734" width="79" height="9" font="27">AHA, Board of Di-</text>
<text top="542" left="734" width="73" height="9" font="27">rectors, Western</text>
<text top="554" left="734" width="10" height="9" font="27">Af</text>
<text top="552" left="744" width="25" height="12" font="27">ﬁliate</text>
<text top="552" left="769" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="565" left="720" width="6" height="10" font="28">n</text>
<text top="566" left="734" width="90" height="9" font="27">American Stroke As-</text>
<text top="578" left="734" width="98" height="9" font="27">sociation, Cryptogenic</text>
<text top="590" left="734" width="97" height="9" font="27">Stroke Initiative Advi-</text>
<text top="602" left="734" width="70" height="9" font="27">sory Committee</text>
<text top="600" left="804" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="613" left="720" width="6" height="10" font="28">n</text>
<text top="614" left="734" width="86" height="9" font="27">Catheterization and</text>
<text top="626" left="734" width="64" height="9" font="27">Cardiovascular</text>
<text top="638" left="734" width="54" height="9" font="27">Interventio<a href="e127.full.html#122">n</a></text>
<text top="636" left="788" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="648" left="720" width="6" height="10" font="28">n</text>
<text top="649" left="734" width="83" height="9" font="27">SCAI Quality Inter-</text>
<text top="661" left="734" width="76" height="9" font="27">ventional Council</text>
<text top="660" left="811" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="494" left="841" width="6" height="10" font="28">n</text>
<text top="495" left="855" width="49" height="9" font="27">Defendant,</text>
<text top="507" left="855" width="45" height="9" font="27">CAD, 2011</text>
<text top="505" left="900" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="518" left="841" width="6" height="10" font="28">n</text>
<text top="518" left="855" width="49" height="9" font="27">Defendant,</text>
<text top="530" left="855" width="31" height="9" font="27">sudden</text>
<text top="542" left="855" width="50" height="9" font="27">death/CAD,</text>
<text top="554" left="855" width="22" height="9" font="27">2010</text>
<text top="552" left="878" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="492" left="960" width="22" height="9" font="27">None</text>
<text top="682" left="915" width="105" height="8" font="30">Continued on the next page</text>
<text top="100" left="1100" width="0" height="9" font="13">Whelton</text>
<text top="139" left="1100" width="0" height="9" font="13">et</text>
<text top="150" left="1100" width="0" height="9" font="13">al</text>
<text top="158" left="1100" width="0" height="9" font="13">.</text>
<text top="667" left="1102" width="0" height="7" font="9">J</text>
<text top="672" left="1102" width="0" height="7" font="9">A</text>
<text top="679" left="1102" width="0" height="7" font="9">C</text>
<text top="685" left="1102" width="0" height="7" font="9">C</text>
<text top="695" left="1102" width="0" height="7" font="9">VO</text>
<text top="709" left="1102" width="0" height="7" font="9">L.</text>
<text top="721" left="1102" width="0" height="7" font="9">71,</text>
<text top="738" left="1102" width="0" height="7" font="9">N</text>
<text top="745" left="1102" width="0" height="7" font="9">O</text>
<text top="752" left="1102" width="0" height="7" font="9">.</text>
<text top="759" left="1102" width="0" height="7" font="9">19,</text>
<text top="776" left="1102" width="0" height="7" font="9">2</text>
<text top="781" left="1102" width="0" height="7" font="9">018</text>
<text top="100" left="1085" width="0" height="9" font="13">2017</text>
<text top="124" left="1085" width="0" height="9" font="13">High</text>
<text top="146" left="1085" width="0" height="9" font="13">Blood</text>
<text top="173" left="1085" width="0" height="9" font="13">Pressure</text>
<text top="212" left="1085" width="0" height="9" font="13">Clinical</text>
<text top="245" left="1085" width="0" height="9" font="13">Practice</text>
<text top="281" left="1085" width="0" height="9" font="13">Guideline</text>
<text top="688" left="1087" width="0" height="7" font="9">M</text>
<text top="695" left="1087" width="0" height="7" font="9">A</text>
<text top="702" left="1087" width="0" height="7" font="9">Y</text>
<text top="712" left="1087" width="0" height="7" font="9">1</text>
<text top="716" left="1087" width="0" height="7" font="9">5</text>
<text top="722" left="1087" width="0" height="7" font="9">,</text>
<text top="729" left="1087" width="0" height="7" font="9">20</text>
<text top="741" left="1087" width="0" height="7" font="9">18:</text>
<text top="754" left="1087" width="0" height="7" font="9">e</text>
<text top="760" left="1087" width="0" height="7" font="9">127</text>
<text top="773" left="1087" width="0" height="10" font="9">–</text>
<text top="780" left="1087" width="0" height="7" font="9">24</text>
<text top="792" left="1087" width="0" height="7" font="9">8</text>
<text top="50" left="1101" width="0" height="9" font="4">e242</text>
</page>
<page number="117" position="absolute" top="0" left="0" height="864" width="1160">
<text top="134" left="59" width="42" height="9" font="27">Reviewer</text>
<text top="134" left="153" width="71" height="9" font="27">Representation</text>
<text top="134" left="271" width="58" height="9" font="27">Employment</text>
<text top="134" left="387" width="50" height="9" font="27">Consultant</text>
<text top="122" left="476" width="42" height="9" font="27">Speakers</text>
<text top="134" left="481" width="32" height="9" font="27">Bureau</text>
<text top="110" left="546" width="53" height="9" font="27">Ownership/</text>
<text top="122" left="544" width="58" height="9" font="27">Partnership/</text>
<text top="134" left="553" width="41" height="9" font="27">Principal</text>
<text top="134" left="620" width="85" height="9" font="27">Personal Research</text>
<text top="110" left="744" width="60" height="9" font="27">Institutional,</text>
<text top="122" left="718" width="113" height="9" font="27">Organizational, or Other</text>
<text top="134" left="736" width="67" height="9" font="27">Financial Bene</text>
<text top="132" left="803" width="10" height="12" font="27">ﬁt</text>
<text top="134" left="842" width="71" height="9" font="27">Expert Witness</text>
<text top="134" left="957" width="28" height="9" font="27">Salary</text>
<text top="150" left="59" width="71" height="9" font="27">William Cushman</text>
<text top="150" left="151" width="74" height="9" font="27">Content Reviewer</text>
<text top="150" left="238" width="118" height="9" font="27">Memphis VA Medical Center</text>
<text top="148" left="356" width="7" height="12" font="27">—</text>
<text top="162" left="245" width="111" height="9" font="27">Chief, Preventive Medicine</text>
<text top="174" left="256" width="90" height="9" font="27">Section; University of</text>
<text top="186" left="256" width="89" height="9" font="27">Tennessee College of</text>
<text top="198" left="258" width="37" height="9" font="27">Medicine</text>
<text top="196" left="295" width="49" height="12" font="27">—Professor,</text>
<text top="210" left="257" width="87" height="9" font="27">Medicine, Preventive</text>
<text top="222" left="247" width="106" height="9" font="27">Medicine, and Physiology</text>
<text top="150" left="401" width="22" height="9" font="27">None</text>
<text top="150" left="486" width="22" height="9" font="27">None</text>
<text top="150" left="562" width="22" height="9" font="27">None</text>
<text top="149" left="618" width="6" height="10" font="28">n</text>
<text top="150" left="632" width="19" height="9" font="27">Lilly</text>
<text top="149" left="721" width="6" height="10" font="28">n</text>
<text top="150" left="735" width="92" height="9" font="27">Novartis Corporation</text>
<text top="148" left="827" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="162" left="721" width="6" height="10" font="28">n</text>
<text top="162" left="735" width="31" height="9" font="27">Takeda</text>
<text top="161" left="766" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="150" left="866" width="22" height="9" font="27">None</text>
<text top="150" left="960" width="22" height="9" font="27">None</text>
<text top="241" left="59" width="55" height="9" font="27">Anita Deswal</text>
<text top="241" left="148" width="74" height="9" font="27">Content Reviewer</text>
<text top="239" left="222" width="7" height="12" font="27">—</text>
<text top="253" left="145" width="87" height="9" font="27">ACC/AHA Task Force</text>
<text top="265" left="149" width="79" height="9" font="27">on Clinical Practice</text>
<text top="277" left="167" width="43" height="9" font="27">Guidelines</text>
<text top="241" left="242" width="113" height="9" font="27">Baylor College of Medicine</text>
<text top="239" left="355" width="4" height="12" font="27">–</text>
<text top="253" left="254" width="93" height="9" font="27">Associate Professor of</text>
<text top="265" left="282" width="37" height="9" font="27">Medicine</text>
<text top="241" left="401" width="22" height="9" font="27">None</text>
<text top="241" left="486" width="22" height="9" font="27">None</text>
<text top="241" left="562" width="22" height="9" font="27">None</text>
<text top="243" left="618" width="6" height="10" font="28">n</text>
<text top="244" left="632" width="16" height="9" font="27"><a href="e127.full.html#122">NIH</a></text>
<text top="244" left="648" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="240" left="721" width="6" height="10" font="28">n</text>
<text top="241" left="735" width="90" height="9" font="27">bAurora Health Care</text>
<text top="253" left="734" width="16" height="9" font="27">Inc.</text>
<text top="263" left="721" width="6" height="10" font="28">n</text>
<text top="264" left="735" width="68" height="9" font="27">American Heart</text>
<text top="276" left="734" width="50" height="9" font="27">Associatio<a href="e127.full.html#122">n</a></text>
<text top="275" left="784" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="287" left="721" width="6" height="10" font="28">n</text>
<text top="288" left="735" width="84" height="9" font="27">AHA Committee on</text>
<text top="300" left="734" width="76" height="9" font="27">Heart Failure and</text>
<text top="312" left="734" width="69" height="9" font="27">Transplantation</text>
<text top="310" left="807" width="4" height="12" font="27">–</text>
<text top="324" left="734" width="22" height="9" font="27">Chair</text>
<text top="322" left="757" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="335" left="721" width="6" height="10" font="28">n</text>
<text top="336" left="735" width="92" height="9" font="27">Heart Failure Society</text>
<text top="348" left="734" width="47" height="9" font="27">of America</text>
<text top="346" left="782" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="241" left="866" width="22" height="9" font="27">None</text>
<text top="241" left="960" width="22" height="9" font="27">None</text>
<text top="367" left="59" width="47" height="9" font="27">Dave Dixon</text>
<text top="367" left="148" width="74" height="9" font="27">Content Reviewer</text>
<text top="365" left="222" width="7" height="12" font="27">—</text>
<text top="379" left="146" width="86" height="9" font="27">Cardiovascular Team</text>
<text top="367" left="251" width="99" height="9" font="27">Virginia Commonwealth</text>
<text top="379" left="258" width="84" height="9" font="27">University School of</text>
<text top="391" left="257" width="40" height="9" font="27">Pharmacy</text>
<text top="389" left="298" width="46" height="12" font="27">—Associate</text>
<text top="403" left="281" width="39" height="9" font="27">Professor</text>
<text top="367" left="401" width="22" height="9" font="27">None</text>
<text top="367" left="486" width="22" height="9" font="27">None</text>
<text top="367" left="562" width="22" height="9" font="27">None</text>
<text top="367" left="652" width="22" height="9" font="27">None</text>
<text top="367" left="763" width="22" height="9" font="27">None</text>
<text top="367" left="866" width="22" height="9" font="27">None</text>
<text top="367" left="960" width="22" height="9" font="27">None</text>
<text top="422" left="59" width="58" height="9" font="27">Ross Feldman</text>
<text top="422" left="151" width="74" height="9" font="27">Content Reviewer</text>
<text top="422" left="246" width="108" height="9" font="27">Winnipeg Regional Health</text>
<text top="434" left="242" width="39" height="9" font="27">Authority</text>
<text top="432" left="281" width="78" height="12" font="27">—Medical Director,</text>
<text top="446" left="246" width="109" height="9" font="27">Cardiac Sciences Program;</text>
<text top="458" left="249" width="95" height="9" font="27">University of Manitoba</text>
<text top="456" left="345" width="7" height="12" font="27">—</text>
<text top="470" left="255" width="91" height="9" font="27">Professor of Medicine</text>
<text top="421" left="372" width="6" height="10" font="28">n</text>
<text top="422" left="386" width="17" height="9" font="27">GSK</text>
<text top="422" left="404" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="433" left="372" width="6" height="10" font="28">n</text>
<text top="434" left="386" width="30" height="9" font="27">Servier</text>
<text top="434" left="417" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="446" left="372" width="6" height="10" font="28">n</text>
<text top="447" left="386" width="60" height="9" font="27">Valeant Phar-</text>
<text top="459" left="386" width="51" height="9" font="27">maceuticals</text>
<text top="471" left="386" width="57" height="9" font="27">International</text>
<text top="471" left="443" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="422" left="486" width="22" height="9" font="27">None</text>
<text top="422" left="562" width="22" height="9" font="27">None</text>
<text top="422" left="652" width="22" height="9" font="27">None</text>
<text top="422" left="763" width="22" height="9" font="27">None</text>
<text top="422" left="866" width="22" height="9" font="27">None</text>
<text top="422" left="960" width="22" height="9" font="27">None</text>
<text top="490" left="59" width="66" height="9" font="27">Keith Ferdinand</text>
<text top="490" left="151" width="74" height="9" font="27">Content Reviewer</text>
<text top="490" left="243" width="115" height="9" font="27">Tulane University School of</text>
<text top="502" left="253" width="37" height="9" font="27">Medicine</text>
<text top="500" left="290" width="58" height="12" font="27">—Professor of</text>
<text top="514" left="265" width="70" height="9" font="27">Clinical Medicine</text>
<text top="492" left="372" width="6" height="10" font="28">n</text>
<text top="493" left="386" width="49" height="9" font="27">Amgen Inc.</text>
<text top="493" left="436" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="505" left="372" width="6" height="10" font="28">n</text>
<text top="506" left="386" width="48" height="9" font="27">Boehringer</text>
<text top="518" left="386" width="43" height="9" font="27">Ingelheim</text>
<text top="518" left="429" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="528" left="372" width="6" height="10" font="28">n</text>
<text top="529" left="386" width="33" height="9" font="27">Eli Lilly</text>
<text top="529" left="419" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="541" left="372" width="6" height="10" font="28">n</text>
<text top="542" left="386" width="21" height="9" font="27">Sano</text>
<text top="540" left="407" width="42" height="12" font="27">ﬁ-Aventis</text>
<text top="542" left="450" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="554" left="372" width="6" height="10" font="28">n</text>
<text top="555" left="386" width="37" height="9" font="27">Novartis</text>
<text top="567" left="372" width="6" height="10" font="28">n</text>
<text top="567" left="386" width="40" height="9" font="27">Quantum</text>
<text top="579" left="386" width="42" height="9" font="27">Genomics</text>
<text top="590" left="372" width="6" height="10" font="28">n</text>
<text top="591" left="386" width="21" height="9" font="27">Sano</text>
<text top="589" left="407" width="42" height="12" font="27">ﬁ-Aventis</text>
<text top="591" left="450" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="490" left="486" width="22" height="9" font="27">None</text>
<text top="490" left="562" width="22" height="9" font="27">None</text>
<text top="490" left="652" width="22" height="9" font="27">None</text>
<text top="489" left="721" width="6" height="10" font="28">n</text>
<text top="490" left="735" width="37" height="9" font="27">Novartis</text>
<text top="490" left="866" width="22" height="9" font="27">None</text>
<text top="490" left="960" width="22" height="9" font="27">None</text>
<text top="612" left="59" width="55" height="9" font="27">Stephan Fihn</text>
<text top="612" left="151" width="74" height="9" font="27">Content Reviewer</text>
<text top="612" left="244" width="106" height="9" font="27">University of Washington</text>
<text top="610" left="350" width="7" height="12" font="27">—</text>
<text top="624" left="240" width="121" height="9" font="27">Professor of Medicine, Heath</text>
<text top="636" left="251" width="99" height="9" font="27">Services; Division Head,</text>
<text top="648" left="245" width="110" height="9" font="27">General Internal Medicine;</text>
<text top="660" left="242" width="49" height="9" font="27">Director, Of</text>
<text top="658" left="291" width="67" height="12" font="27">ﬁce of Analytics</text>
<text top="672" left="240" width="121" height="9" font="27">and Business Intelligence for</text>
<text top="684" left="258" width="84" height="9" font="27">the Veterans Health</text>
<text top="696" left="247" width="106" height="9" font="27">Administration; VA Puget</text>
<text top="708" left="241" width="111" height="9" font="27">Sound Health Care System</text>
<text top="706" left="353" width="7" height="12" font="27">—</text>
<text top="720" left="265" width="70" height="9" font="27">General Internist</text>
<text top="612" left="401" width="22" height="9" font="27">None</text>
<text top="612" left="486" width="22" height="9" font="27">None</text>
<text top="612" left="562" width="22" height="9" font="27">None</text>
<text top="612" left="652" width="22" height="9" font="27">None</text>
<text top="611" left="721" width="6" height="10" font="28">n</text>
<text top="612" left="735" width="56" height="9" font="27">University of</text>
<text top="624" left="734" width="52" height="9" font="27">Washington</text>
<text top="612" left="866" width="22" height="9" font="27">None</text>
<text top="612" left="960" width="22" height="9" font="27">None</text>
<text top="740" left="915" width="105" height="8" font="30">Continued on the next page</text>
<text top="60" left="59" width="158" height="16" font="31">APPENDIX 2. CONTINUED</text>
<text top="57" left="1102" width="0" height="7" font="9">J</text>
<text top="63" left="1102" width="0" height="7" font="9">A</text>
<text top="69" left="1102" width="0" height="7" font="9">CC</text>
<text top="86" left="1102" width="0" height="7" font="9">VO</text>
<text top="99" left="1102" width="0" height="7" font="9">L.</text>
<text top="112" left="1102" width="0" height="7" font="9">7</text>
<text top="117" left="1102" width="0" height="7" font="9">1</text>
<text top="121" left="1102" width="0" height="7" font="9">,</text>
<text top="129" left="1102" width="0" height="7" font="9">N</text>
<text top="135" left="1102" width="0" height="7" font="9">O</text>
<text top="142" left="1102" width="0" height="7" font="9">.</text>
<text top="149" left="1102" width="0" height="7" font="9">1</text>
<text top="154" left="1102" width="0" height="7" font="9">9</text>
<text top="159" left="1102" width="0" height="7" font="9">,</text>
<text top="166" left="1102" width="0" height="7" font="9">2</text>
<text top="172" left="1102" width="0" height="7" font="9">01</text>
<text top="182" left="1102" width="0" height="7" font="9">8</text>
<text top="690" left="1100" width="0" height="9" font="13">Whelton</text>
<text top="728" left="1100" width="0" height="9" font="13">et</text>
<text top="739" left="1100" width="0" height="9" font="13">al</text>
<text top="747" left="1100" width="0" height="9" font="13">.</text>
<text top="57" left="1087" width="0" height="7" font="9">MA</text>
<text top="71" left="1087" width="0" height="7" font="9">Y</text>
<text top="81" left="1087" width="0" height="7" font="9">1</text>
<text top="86" left="1087" width="0" height="7" font="9">5,</text>
<text top="98" left="1087" width="0" height="7" font="9">2</text>
<text top="104" left="1087" width="0" height="7" font="9">0</text>
<text top="110" left="1087" width="0" height="7" font="9">1</text>
<text top="114" left="1087" width="0" height="7" font="9">8</text>
<text top="120" left="1087" width="0" height="7" font="9">:e</text>
<text top="129" left="1087" width="0" height="7" font="9">1</text>
<text top="133" left="1087" width="0" height="7" font="9">2</text>
<text top="139" left="1087" width="0" height="7" font="9">7</text>
<text top="142" left="1087" width="0" height="10" font="9">–</text>
<text top="149" left="1087" width="0" height="7" font="9">24</text>
<text top="161" left="1087" width="0" height="7" font="9">8</text>
<text top="531" left="1085" width="0" height="9" font="13">2017</text>
<text top="554" left="1085" width="0" height="9" font="13">High</text>
<text top="576" left="1085" width="0" height="9" font="13">Blood</text>
<text top="604" left="1085" width="0" height="9" font="13">Pressure</text>
<text top="642" left="1085" width="0" height="9" font="13">Clinical</text>
<text top="675" left="1085" width="0" height="9" font="13">Practice</text>
<text top="711" left="1085" width="0" height="9" font="13">Guideline</text>
<text top="781" left="1101" width="0" height="9" font="4">e243</text>
</page>
<page number="118" position="absolute" top="0" left="0" height="864" width="1160">
<text top="171" left="59" width="43" height="9" font="27">Reviewer</text>
<text top="171" left="153" width="71" height="9" font="27">Representation</text>
<text top="171" left="272" width="58" height="9" font="27">Employment</text>
<text top="171" left="387" width="50" height="9" font="27">Consultant</text>
<text top="159" left="477" width="42" height="9" font="27">Speakers</text>
<text top="171" left="481" width="32" height="9" font="27">Bureau</text>
<text top="148" left="547" width="53" height="9" font="27">Ownership/</text>
<text top="159" left="544" width="58" height="9" font="27">Partnership/</text>
<text top="171" left="553" width="41" height="9" font="27">Principal</text>
<text top="171" left="620" width="85" height="9" font="27">Personal Research</text>
<text top="148" left="745" width="60" height="9" font="27">Institutional,</text>
<text top="159" left="718" width="113" height="9" font="27">Organizational, or Other</text>
<text top="171" left="736" width="67" height="9" font="27">Financial Bene</text>
<text top="170" left="803" width="10" height="12" font="27">ﬁt</text>
<text top="171" left="842" width="71" height="9" font="27">Expert Witness</text>
<text top="171" left="957" width="28" height="9" font="27">Salary</text>
<text top="188" left="59" width="60" height="9" font="27">Lawrence Fine</text>
<text top="188" left="152" width="74" height="9" font="27">Content Reviewer</text>
<text top="188" left="248" width="106" height="9" font="27">National Heart, Lung and</text>
<text top="200" left="238" width="62" height="9" font="27">Blood Institute</text>
<text top="198" left="300" width="63" height="12" font="27">—Chief, Clinical</text>
<text top="212" left="242" width="117" height="9" font="27">Applications and Prevention</text>
<text top="223" left="238" width="126" height="9" font="27">Branch, Division of Prevention</text>
<text top="235" left="250" width="101" height="9" font="27">and Population Sciences</text>
<text top="188" left="401" width="22" height="9" font="27">None</text>
<text top="188" left="486" width="22" height="9" font="27">None</text>
<text top="188" left="562" width="22" height="9" font="27">None</text>
<text top="188" left="652" width="22" height="9" font="27">None</text>
<text top="186" left="721" width="6" height="10" font="28">n</text>
<text top="187" left="735" width="16" height="9" font="27">NI<a href="e127.full.html#122">H</a></text>
<text top="187" left="751" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="188" left="867" width="22" height="9" font="27">None</text>
<text top="188" left="961" width="22" height="9" font="27">None</text>
<text top="255" left="59" width="45" height="9" font="27">John Flack</text>
<text top="255" left="152" width="74" height="9" font="27">Content Reviewer</text>
<text top="255" left="244" width="113" height="9" font="27">Southern Illinois University</text>
<text top="267" left="238" width="79" height="9" font="27">School of Medicine</text>
<text top="265" left="317" width="46" height="12" font="27">—Chair and</text>
<text top="279" left="249" width="104" height="9" font="27">Professor Department of</text>
<text top="291" left="250" width="102" height="9" font="27">Internal Medicine; Chief,</text>
<text top="302" left="253" width="96" height="9" font="27">Hypertension Specialty</text>
<text top="314" left="284" width="34" height="9" font="27">Services</text>
<text top="257" left="372" width="6" height="10" font="28">n</text>
<text top="257" left="386" width="47" height="9" font="27">Regeneron</text>
<text top="257" left="434" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="269" left="372" width="6" height="10" font="28">n</text>
<text top="270" left="386" width="27" height="9" font="27">NuSirt</text>
<text top="255" left="486" width="22" height="9" font="27">None</text>
<text top="255" left="562" width="22" height="9" font="27">None</text>
<text top="257" left="618" width="6" height="10" font="28">n</text>
<text top="257" left="632" width="75" height="9" font="27">Bayer Healthcare</text>
<text top="269" left="632" width="71" height="9" font="27">Pharmaceuticals</text>
<text top="268" left="703" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="283" left="618" width="6" height="10" font="28">n</text>
<text top="284" left="632" width="17" height="9" font="27">GSK</text>
<text top="282" left="650" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="253" left="721" width="6" height="10" font="28">n</text>
<text top="254" left="735" width="89" height="9" font="27">American Journal of</text>
<text top="266" left="735" width="58" height="9" font="27">Hypert<a href="e127.full.html#122">ension</a></text>
<text top="266" left="793" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="277" left="721" width="6" height="10" font="28">n</text>
<text top="278" left="735" width="52" height="9" font="27">CardioRenal</text>
<text top="290" left="735" width="39" height="9" font="27">Medicine</text>
<text top="288" left="774" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="301" left="721" width="6" height="10" font="28">n</text>
<text top="302" left="735" width="92" height="9" font="27">International Journal</text>
<text top="314" left="735" width="71" height="9" font="27">of Hypertension</text>
<text top="312" left="806" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="325" left="721" width="6" height="10" font="28">n</text>
<text top="325" left="735" width="94" height="9" font="27">Southern Illinois Uni-</text>
<text top="337" left="735" width="97" height="9" font="27">versity Department of</text>
<text top="349" left="735" width="39" height="9" font="27">Medicine</text>
<text top="349" left="774" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="255" left="867" width="22" height="9" font="27">None</text>
<text top="255" left="961" width="22" height="9" font="27">None</text>
<text top="369" left="59" width="55" height="9" font="27">Joseph Flynn</text>
<text top="369" left="152" width="74" height="9" font="27">Content Reviewer</text>
<text top="369" left="242" width="67" height="9" font="27">Seattle Children</text>
<text top="367" left="309" width="51" height="12" font="27">’s Hospital—</text>
<text top="381" left="252" width="97" height="9" font="27">Chief of the Division of</text>
<text top="393" left="247" width="108" height="9" font="27">Nephrology; University of</text>
<text top="404" left="255" width="92" height="9" font="27">Washington School of</text>
<text top="416" left="253" width="37" height="9" font="27">Medicine</text>
<text top="415" left="290" width="58" height="12" font="27">—Professor of</text>
<text top="428" left="280" width="40" height="9" font="27">Pediatrics</text>
<text top="367" left="372" width="6" height="10" font="28">n</text>
<text top="368" left="386" width="70" height="9" font="27">Ultragenyx, Inc.</text>
<text top="380" left="386" width="33" height="9" font="27">(DSMB)</text>
<text top="369" left="486" width="22" height="9" font="27">None</text>
<text top="369" left="562" width="22" height="9" font="27">None</text>
<text top="369" left="652" width="22" height="9" font="27">None</text>
<text top="367" left="721" width="6" height="10" font="28">n</text>
<text top="368" left="735" width="87" height="9" font="27">UpToDate, Springer</text>
<text top="368" left="822" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="369" left="867" width="22" height="9" font="27">None</text>
<text top="369" left="961" width="22" height="9" font="27">None</text>
<text top="448" left="59" width="68" height="9" font="27">Federico Gentile</text>
<text top="448" left="148" width="74" height="9" font="27">Content Reviewer</text>
<text top="446" left="222" width="7" height="12" font="27">—</text>
<text top="460" left="145" width="87" height="9" font="27">ACC/AHA Task Force</text>
<text top="472" left="149" width="79" height="9" font="27">on Clinical Practice</text>
<text top="483" left="167" width="43" height="9" font="27">Guidelines</text>
<text top="448" left="259" width="83" height="9" font="27">Centro Cardiologico</text>
<text top="448" left="401" width="22" height="9" font="27">None</text>
<text top="448" left="486" width="22" height="9" font="27">None</text>
<text top="448" left="562" width="22" height="9" font="27">None</text>
<text top="448" left="652" width="22" height="9" font="27">None</text>
<text top="448" left="764" width="22" height="9" font="27">None</text>
<text top="448" left="867" width="22" height="9" font="27">None</text>
<text top="448" left="961" width="22" height="9" font="27">None</text>
<text top="503" left="59" width="53" height="9" font="27">Joel Handler</text>
<text top="503" left="152" width="74" height="9" font="27">Content Reviewer</text>
<text top="503" left="238" width="78" height="9" font="27">Kaiser Permanente</text>
<text top="501" left="316" width="48" height="12" font="27">—Physician;</text>
<text top="515" left="243" width="116" height="9" font="27">National Kaiser Permanente</text>
<text top="527" left="239" width="55" height="9" font="27">Hypertension</text>
<text top="525" left="294" width="68" height="12" font="27">—Clinical Leader</text>
<text top="503" left="401" width="22" height="9" font="27">None</text>
<text top="503" left="486" width="22" height="9" font="27">None</text>
<text top="503" left="562" width="22" height="9" font="27">None</text>
<text top="503" left="652" width="22" height="9" font="27">None</text>
<text top="503" left="764" width="22" height="9" font="27">None</text>
<text top="503" left="867" width="22" height="9" font="27">None</text>
<text top="503" left="961" width="22" height="9" font="27">None</text>
<text top="546" left="59" width="44" height="9" font="27">Hani Jneid</text>
<text top="546" left="148" width="74" height="9" font="27">Content Reviewer</text>
<text top="544" left="222" width="7" height="12" font="27">—</text>
<text top="558" left="145" width="87" height="9" font="27">ACC/AHA Task Force</text>
<text top="570" left="156" width="66" height="9" font="27">on Clinical Data</text>
<text top="582" left="168" width="41" height="9" font="27">Standards</text>
<text top="546" left="241" width="113" height="9" font="27">Baylor College of Medicine</text>
<text top="544" left="354" width="7" height="12" font="27">—</text>
<text top="558" left="254" width="93" height="9" font="27">Associate Professor of</text>
<text top="570" left="257" width="87" height="9" font="27">Medicine, MEDVAMC</text>
<text top="546" left="401" width="22" height="9" font="27">None</text>
<text top="546" left="486" width="22" height="9" font="27">None</text>
<text top="546" left="562" width="22" height="9" font="27">None</text>
<text top="546" left="652" width="22" height="9" font="27">None</text>
<text top="546" left="764" width="22" height="9" font="27">None</text>
<text top="546" left="867" width="22" height="9" font="27">None</text>
<text top="546" left="961" width="22" height="9" font="27">None</text>
<text top="602" left="59" width="59" height="9" font="27">José A. Joglar</text>
<text top="602" left="148" width="74" height="9" font="27">Content Reviewer</text>
<text top="600" left="222" width="7" height="12" font="27">—</text>
<text top="614" left="145" width="87" height="9" font="27">ACC/AHA Task Force</text>
<text top="626" left="149" width="79" height="9" font="27">on Clinical Practice</text>
<text top="637" left="167" width="43" height="9" font="27">Guidelines</text>
<text top="602" left="247" width="107" height="9" font="27">UT Southwestern Medical</text>
<text top="614" left="240" width="27" height="9" font="27">Center</text>
<text top="612" left="268" width="93" height="12" font="27">—Professor of Internal</text>
<text top="626" left="249" width="103" height="9" font="27">Medicine; Cardiovascular</text>
<text top="637" left="247" width="101" height="9" font="27">Clinical Research Center</text>
<text top="636" left="347" width="7" height="12" font="27">—</text>
<text top="649" left="284" width="33" height="9" font="27">Director</text>
<text top="602" left="401" width="22" height="9" font="27">None</text>
<text top="602" left="486" width="22" height="9" font="27">None</text>
<text top="602" left="562" width="22" height="9" font="27">None</text>
<text top="602" left="652" width="22" height="9" font="27">None</text>
<text top="602" left="764" width="22" height="9" font="27">None</text>
<text top="602" left="867" width="22" height="9" font="27">None</text>
<text top="602" left="961" width="22" height="9" font="27">None</text>
<text top="670" left="915" width="105" height="8" font="30">Continued on the next page</text>
<text top="105" left="59" width="158" height="16" font="31">APPENDIX 2. CONTINUED</text>
<text top="100" left="1100" width="0" height="9" font="13">Whelton</text>
<text top="139" left="1100" width="0" height="9" font="13">et</text>
<text top="150" left="1100" width="0" height="9" font="13">al</text>
<text top="158" left="1100" width="0" height="9" font="13">.</text>
<text top="667" left="1102" width="0" height="7" font="9">J</text>
<text top="672" left="1102" width="0" height="7" font="9">A</text>
<text top="679" left="1102" width="0" height="7" font="9">C</text>
<text top="685" left="1102" width="0" height="7" font="9">C</text>
<text top="695" left="1102" width="0" height="7" font="9">VO</text>
<text top="709" left="1102" width="0" height="7" font="9">L.</text>
<text top="721" left="1102" width="0" height="7" font="9">71,</text>
<text top="738" left="1102" width="0" height="7" font="9">N</text>
<text top="745" left="1102" width="0" height="7" font="9">O</text>
<text top="752" left="1102" width="0" height="7" font="9">.</text>
<text top="759" left="1102" width="0" height="7" font="9">19,</text>
<text top="776" left="1102" width="0" height="7" font="9">2</text>
<text top="781" left="1102" width="0" height="7" font="9">018</text>
<text top="100" left="1085" width="0" height="9" font="13">2017</text>
<text top="124" left="1085" width="0" height="9" font="13">High</text>
<text top="146" left="1085" width="0" height="9" font="13">Blood</text>
<text top="173" left="1085" width="0" height="9" font="13">Pressure</text>
<text top="212" left="1085" width="0" height="9" font="13">Clinical</text>
<text top="245" left="1085" width="0" height="9" font="13">Practice</text>
<text top="281" left="1085" width="0" height="9" font="13">Guideline</text>
<text top="688" left="1087" width="0" height="7" font="9">M</text>
<text top="695" left="1087" width="0" height="7" font="9">A</text>
<text top="702" left="1087" width="0" height="7" font="9">Y</text>
<text top="712" left="1087" width="0" height="7" font="9">1</text>
<text top="716" left="1087" width="0" height="7" font="9">5</text>
<text top="722" left="1087" width="0" height="7" font="9">,</text>
<text top="729" left="1087" width="0" height="7" font="9">20</text>
<text top="741" left="1087" width="0" height="7" font="9">18:</text>
<text top="754" left="1087" width="0" height="7" font="9">e</text>
<text top="760" left="1087" width="0" height="7" font="9">127</text>
<text top="773" left="1087" width="0" height="10" font="9">–</text>
<text top="780" left="1087" width="0" height="7" font="9">24</text>
<text top="792" left="1087" width="0" height="7" font="9">8</text>
<text top="50" left="1101" width="0" height="9" font="4">e244</text>
</page>
<page number="119" position="absolute" top="0" left="0" height="864" width="1160">
<text top="131" left="59" width="43" height="9" font="27">Reviewer</text>
<text top="131" left="153" width="71" height="9" font="27">Representation</text>
<text top="131" left="271" width="58" height="9" font="27">Employment</text>
<text top="131" left="387" width="50" height="9" font="27">Consultant</text>
<text top="120" left="476" width="42" height="9" font="27">Speakers</text>
<text top="131" left="481" width="32" height="9" font="27">Bureau</text>
<text top="108" left="547" width="53" height="9" font="27">Ownership/</text>
<text top="120" left="544" width="58" height="9" font="27">Partnership/</text>
<text top="131" left="553" width="41" height="9" font="27">Principal</text>
<text top="131" left="620" width="85" height="9" font="27">Personal Research</text>
<text top="108" left="744" width="60" height="9" font="27">Institutional,</text>
<text top="120" left="718" width="113" height="9" font="27">Organizational, or Other</text>
<text top="131" left="736" width="67" height="9" font="27">Financial Bene</text>
<text top="130" left="803" width="10" height="12" font="27">ﬁt</text>
<text top="131" left="842" width="71" height="9" font="27">Expert Witness</text>
<text top="131" left="957" width="28" height="9" font="27">Salary</text>
<text top="148" left="59" width="47" height="9" font="27">Amit Khera</text>
<text top="148" left="151" width="74" height="9" font="27">Content Reviewer</text>
<text top="148" left="260" width="80" height="9" font="27">University of Texas</text>
<text top="160" left="254" width="92" height="9" font="27">Southwestern Medical</text>
<text top="172" left="238" width="27" height="9" font="27">Center</text>
<text top="170" left="265" width="98" height="12" font="27">—Assistant Professor of</text>
<text top="184" left="282" width="37" height="9" font="27">Medicine</text>
<text top="148" left="401" width="22" height="9" font="27">None</text>
<text top="148" left="486" width="22" height="9" font="27">None</text>
<text top="148" left="562" width="22" height="9" font="27">None</text>
<text top="148" left="652" width="22" height="9" font="27">None</text>
<text top="148" left="764" width="22" height="9" font="27">None</text>
<text top="148" left="866" width="22" height="9" font="27">None</text>
<text top="148" left="960" width="22" height="9" font="27">None</text>
<text top="203" left="59" width="67" height="9" font="27">Glenn N. Levine</text>
<text top="203" left="148" width="74" height="9" font="27">Content Reviewer</text>
<text top="201" left="222" width="7" height="12" font="27">—</text>
<text top="215" left="145" width="87" height="9" font="27">ACC/AHA Task Force</text>
<text top="227" left="149" width="79" height="9" font="27">on Clinical Practice</text>
<text top="239" left="167" width="43" height="9" font="27">Guidelines</text>
<text top="203" left="241" width="113" height="9" font="27">Baylor College of Medicine</text>
<text top="201" left="353" width="7" height="12" font="27">—</text>
<text top="215" left="254" width="94" height="9" font="27">Professor of Medicine;</text>
<text top="227" left="245" width="111" height="9" font="27">Director, Cardiac Care Unit</text>
<text top="203" left="401" width="22" height="9" font="27">None</text>
<text top="203" left="486" width="22" height="9" font="27">None</text>
<text top="203" left="562" width="22" height="9" font="27">None</text>
<text top="203" left="652" width="22" height="9" font="27">None</text>
<text top="203" left="764" width="22" height="9" font="27">None</text>
<text top="202" left="841" width="6" height="10" font="28">n</text>
<text top="202" left="856" width="46" height="9" font="27">Defendant,</text>
<text top="214" left="855" width="62" height="9" font="27">catheterization</text>
<text top="226" left="855" width="43" height="9" font="27">laboratory</text>
<text top="238" left="855" width="44" height="9" font="27">procedure,</text>
<text top="250" left="855" width="21" height="9" font="27">2016</text>
<text top="261" left="841" width="6" height="10" font="28">n</text>
<text top="262" left="856" width="49" height="9" font="27">Defendant,</text>
<text top="274" left="855" width="61" height="9" font="27">interpretation</text>
<text top="286" left="855" width="50" height="9" font="27">of ECG of a</text>
<text top="298" left="855" width="59" height="9" font="27">patient, 2014</text>
<text top="309" left="841" width="6" height="10" font="28">n</text>
<text top="310" left="856" width="49" height="9" font="27">Defendant,</text>
<text top="322" left="855" width="61" height="9" font="27">interpretation</text>
<text top="334" left="855" width="58" height="9" font="27">of angiogram</text>
<text top="345" left="855" width="48" height="9" font="27">(non-ACS),</text>
<text top="357" left="855" width="22" height="9" font="27">2014</text>
<text top="368" left="841" width="6" height="10" font="28">n</text>
<text top="369" left="856" width="49" height="9" font="27">Defendant,</text>
<text top="381" left="855" width="32" height="9" font="27">out-of-</text>
<text top="393" left="855" width="35" height="9" font="27">hospital</text>
<text top="405" left="855" width="53" height="9" font="27">death, 2016</text>
<text top="203" left="960" width="22" height="9" font="27">None</text>
<text top="424" left="59" width="70" height="9" font="27">Giuseppe Mancia</text>
<text top="424" left="151" width="74" height="9" font="27">Content Reviewer</text>
<text top="424" left="240" width="114" height="9" font="27">University of Milan-Bicocca</text>
<text top="423" left="354" width="7" height="12" font="27">—</text>
<text top="436" left="254" width="94" height="9" font="27">Professor of Medicine;</text>
<text top="448" left="247" width="106" height="9" font="27">Chairman, Department of</text>
<text top="460" left="240" width="120" height="9" font="27">Clinical Medicine, Prevention</text>
<text top="472" left="241" width="119" height="9" font="27">and Applied Biotechnologies</text>
<text top="423" left="372" width="6" height="10" font="28">n</text>
<text top="424" left="386" width="48" height="9" font="27">Boehringer</text>
<text top="436" left="386" width="43" height="9" font="27">Ingelheim</text>
<text top="436" left="429" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="447" left="372" width="6" height="10" font="28">n</text>
<text top="448" left="386" width="23" height="9" font="27">CVRx</text>
<text top="460" left="372" width="6" height="10" font="28">n</text>
<text top="460" left="386" width="26" height="9" font="27">Ferrer</text>
<text top="475" left="372" width="6" height="10" font="28">n</text>
<text top="476" left="386" width="54" height="9" font="27">MEDTRONIC</text>
<text top="488" left="372" width="6" height="10" font="28">n</text>
<text top="489" left="386" width="38" height="9" font="27">Menarini</text>
<text top="501" left="386" width="57" height="9" font="27">International</text>
<text top="501" left="443" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="512" left="372" width="6" height="10" font="28">n</text>
<text top="512" left="386" width="42" height="9" font="27">Recordati</text>
<text top="524" left="372" width="6" height="10" font="28">n</text>
<text top="525" left="386" width="30" height="9" font="27">Servier</text>
<text top="537" left="386" width="57" height="9" font="27">International</text>
<text top="537" left="443" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="548" left="372" width="6" height="10" font="28">n</text>
<text top="549" left="386" width="31" height="9" font="27">Actavis</text>
<text top="424" left="486" width="22" height="9" font="27">None</text>
<text top="424" left="562" width="22" height="9" font="27">None</text>
<text top="424" left="652" width="22" height="9" font="27">None</text>
<text top="423" left="721" width="6" height="10" font="28">n</text>
<text top="424" left="735" width="36" height="9" font="27">Novartis</text>
<text top="424" left="772" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="424" left="866" width="22" height="9" font="27">None</text>
<text top="424" left="960" width="22" height="9" font="27">None</text>
<text top="570" left="59" width="59" height="9" font="27">Andrew Miller</text>
<text top="570" left="148" width="74" height="9" font="27">Content Reviewer</text>
<text top="568" left="222" width="7" height="12" font="27">—</text>
<text top="582" left="147" width="83" height="9" font="27">Geriatric Cardiology</text>
<text top="594" left="173" width="31" height="9" font="27">Section</text>
<text top="570" left="244" width="107" height="9" font="27">Cardiovascular Associates</text>
<text top="568" left="350" width="7" height="12" font="27">—</text>
<text top="582" left="276" width="50" height="9" font="27">Cardiologist</text>
<text top="570" left="401" width="22" height="9" font="27">None</text>
<text top="570" left="486" width="22" height="9" font="27">None</text>
<text top="570" left="562" width="22" height="9" font="27">None</text>
<text top="569" left="618" width="6" height="10" font="28">n</text>
<text top="569" left="632" width="36" height="9" font="27">Novartis</text>
<text top="581" left="632" width="52" height="9" font="27">Corporation</text>
<text top="580" left="684" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="592" left="618" width="6" height="10" font="28">n</text>
<text top="593" left="632" width="5" height="9" font="27">P</text>
<text top="592" left="638" width="35" height="12" font="27">ﬁzer Inc</text>
<text top="592" left="673" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="569" left="721" width="6" height="10" font="28">n</text>
<text top="569" left="735" width="92" height="9" font="27">Bristol-Myers Squibb</text>
<text top="581" left="734" width="40" height="9" font="27">Company</text>
<text top="592" left="721" width="6" height="10" font="28">n</text>
<text top="593" left="735" width="96" height="9" font="27">Janssen Pharmaceuti-</text>
<text top="605" left="734" width="39" height="9" font="27">cals, Inc.</text>
<text top="616" left="721" width="6" height="10" font="28">n</text>
<text top="617" left="735" width="16" height="9" font="27">NIH</text>
<text top="570" left="866" width="22" height="9" font="27">None</text>
<text top="570" left="960" width="22" height="9" font="27">None</text>
<text top="638" left="915" width="105" height="8" font="30">Continued on the next page</text>
<text top="60" left="59" width="158" height="16" font="31">APPENDIX 2. CONTINUED</text>
<text top="57" left="1102" width="0" height="7" font="9">J</text>
<text top="63" left="1102" width="0" height="7" font="9">A</text>
<text top="69" left="1102" width="0" height="7" font="9">CC</text>
<text top="86" left="1102" width="0" height="7" font="9">VO</text>
<text top="99" left="1102" width="0" height="7" font="9">L.</text>
<text top="112" left="1102" width="0" height="7" font="9">7</text>
<text top="117" left="1102" width="0" height="7" font="9">1</text>
<text top="121" left="1102" width="0" height="7" font="9">,</text>
<text top="129" left="1102" width="0" height="7" font="9">N</text>
<text top="135" left="1102" width="0" height="7" font="9">O</text>
<text top="142" left="1102" width="0" height="7" font="9">.</text>
<text top="149" left="1102" width="0" height="7" font="9">1</text>
<text top="154" left="1102" width="0" height="7" font="9">9</text>
<text top="159" left="1102" width="0" height="7" font="9">,</text>
<text top="166" left="1102" width="0" height="7" font="9">2</text>
<text top="172" left="1102" width="0" height="7" font="9">01</text>
<text top="182" left="1102" width="0" height="7" font="9">8</text>
<text top="690" left="1100" width="0" height="9" font="13">Whelton</text>
<text top="728" left="1100" width="0" height="9" font="13">et</text>
<text top="739" left="1100" width="0" height="9" font="13">al</text>
<text top="747" left="1100" width="0" height="9" font="13">.</text>
<text top="57" left="1087" width="0" height="7" font="9">MA</text>
<text top="71" left="1087" width="0" height="7" font="9">Y</text>
<text top="81" left="1087" width="0" height="7" font="9">1</text>
<text top="86" left="1087" width="0" height="7" font="9">5,</text>
<text top="98" left="1087" width="0" height="7" font="9">2</text>
<text top="104" left="1087" width="0" height="7" font="9">0</text>
<text top="110" left="1087" width="0" height="7" font="9">1</text>
<text top="114" left="1087" width="0" height="7" font="9">8</text>
<text top="120" left="1087" width="0" height="7" font="9">:e</text>
<text top="129" left="1087" width="0" height="7" font="9">1</text>
<text top="133" left="1087" width="0" height="7" font="9">2</text>
<text top="139" left="1087" width="0" height="7" font="9">7</text>
<text top="142" left="1087" width="0" height="10" font="9">–</text>
<text top="149" left="1087" width="0" height="7" font="9">24</text>
<text top="161" left="1087" width="0" height="7" font="9">8</text>
<text top="531" left="1085" width="0" height="9" font="13">2017</text>
<text top="554" left="1085" width="0" height="9" font="13">High</text>
<text top="576" left="1085" width="0" height="9" font="13">Blood</text>
<text top="604" left="1085" width="0" height="9" font="13">Pressure</text>
<text top="642" left="1085" width="0" height="9" font="13">Clinical</text>
<text top="675" left="1085" width="0" height="9" font="13">Practice</text>
<text top="711" left="1085" width="0" height="9" font="13">Guideline</text>
<text top="781" left="1101" width="0" height="9" font="4">e245</text>
</page>
<page number="120" position="absolute" top="0" left="0" height="864" width="1160">
<text top="173" left="59" width="42" height="9" font="27">Reviewer</text>
<text top="173" left="153" width="71" height="9" font="27">Representation</text>
<text top="173" left="271" width="58" height="9" font="27">Employment</text>
<text top="173" left="387" width="50" height="9" font="27">Consultant</text>
<text top="161" left="476" width="42" height="9" font="27">Speakers</text>
<text top="173" left="481" width="32" height="9" font="27">Bureau</text>
<text top="149" left="547" width="53" height="9" font="27">Ownership/</text>
<text top="161" left="544" width="58" height="9" font="27">Partnership/</text>
<text top="173" left="553" width="41" height="9" font="27">Principal</text>
<text top="173" left="620" width="85" height="9" font="27">Personal Research</text>
<text top="149" left="744" width="60" height="9" font="27">Institutional,</text>
<text top="161" left="718" width="113" height="9" font="27">Organizational, or Other</text>
<text top="173" left="736" width="67" height="9" font="27">Financial Bene</text>
<text top="171" left="803" width="10" height="12" font="27">ﬁt</text>
<text top="173" left="842" width="71" height="9" font="27">Expert Witness</text>
<text top="173" left="957" width="28" height="9" font="27">Salary</text>
<text top="189" left="59" width="59" height="9" font="27">Pamela Morris</text>
<text top="189" left="148" width="74" height="9" font="27">Content Reviewer</text>
<text top="187" left="222" width="7" height="12" font="27">—</text>
<text top="201" left="148" width="81" height="9" font="27">Prevention Council,</text>
<text top="213" left="178" width="21" height="9" font="27">Chair</text>
<text top="189" left="244" width="113" height="9" font="27">Seinsheimer Cardiovascular</text>
<text top="201" left="244" width="66" height="9" font="27">Health Program</text>
<text top="199" left="310" width="46" height="12" font="27">— Director;</text>
<text top="213" left="250" width="31" height="9" font="27">Women</text>
<text top="211" left="282" width="54" height="12" font="27">’s Heart Care</text>
<text top="225" left="235" width="116" height="9" font="27">Medical University of South</text>
<text top="237" left="255" width="34" height="9" font="27">Carolina</text>
<text top="235" left="288" width="58" height="12" font="27">— Co-Director</text>
<text top="188" left="372" width="6" height="10" font="28">n</text>
<text top="189" left="386" width="49" height="9" font="27">Amgen Inc.</text>
<text top="201" left="372" width="6" height="10" font="28">n</text>
<text top="202" left="386" width="54" height="9" font="27">AstraZeneca</text>
<text top="213" left="372" width="6" height="10" font="28">n</text>
<text top="214" left="386" width="21" height="9" font="27">Sano</text>
<text top="213" left="407" width="5" height="12" font="27">ﬁ</text>
<text top="226" left="386" width="47" height="9" font="27">Regeneron</text>
<text top="189" left="486" width="22" height="9" font="27">None</text>
<text top="189" left="562" width="22" height="9" font="27">None</text>
<text top="188" left="618" width="6" height="10" font="28">n</text>
<text top="189" left="632" width="49" height="9" font="27">Amgen Inc.</text>
<text top="189" left="764" width="22" height="9" font="27">None</text>
<text top="189" left="866" width="22" height="9" font="27">None</text>
<text top="189" left="960" width="22" height="9" font="27">None</text>
<text top="256" left="59" width="55" height="9" font="27">Martin Myers</text>
<text top="256" left="151" width="74" height="9" font="27">Content Reviewer</text>
<text top="256" left="242" width="118" height="9" font="27">Sunnybrook Health Sciences</text>
<text top="268" left="246" width="27" height="9" font="27">Centre</text>
<text top="266" left="274" width="81" height="12" font="27">—Afﬁliate Scientist;</text>
<text top="280" left="252" width="90" height="9" font="27">University of Toronto</text>
<text top="278" left="342" width="7" height="12" font="27">—</text>
<text top="292" left="256" width="89" height="9" font="27">Professor, Cardiology</text>
<text top="255" left="372" width="6" height="10" font="28">n</text>
<text top="256" left="386" width="57" height="9" font="27">Ideal Life Inc</text>
<text top="256" left="444" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="256" left="486" width="22" height="9" font="27">None</text>
<text top="256" left="562" width="22" height="9" font="27">None</text>
<text top="256" left="652" width="22" height="9" font="27">None</text>
<text top="256" left="764" width="22" height="9" font="27">None</text>
<text top="256" left="866" width="22" height="9" font="27">None</text>
<text top="256" left="960" width="22" height="9" font="27">None</text>
<text top="311" left="59" width="61" height="9" font="27">Rick Nishimura</text>
<text top="311" left="151" width="74" height="9" font="27">Content Reviewer</text>
<text top="311" left="253" width="94" height="9" font="27">Mayo Clinic College of</text>
<text top="323" left="247" width="37" height="9" font="27">Medicine</text>
<text top="322" left="284" width="69" height="12" font="27">—Judd and Mary</text>
<text top="335" left="240" width="120" height="9" font="27">Morris Leighton Professor of</text>
<text top="347" left="281" width="40" height="9" font="27">Medicine;</text>
<text top="359" left="244" width="48" height="9" font="27">Mayo Clinic</text>
<text top="357" left="291" width="51" height="12" font="27">—Division of</text>
<text top="371" left="251" width="98" height="9" font="27">Cardiovascular Diseases</text>
<text top="311" left="401" width="22" height="9" font="27">None</text>
<text top="311" left="486" width="22" height="9" font="27">None</text>
<text top="311" left="562" width="22" height="9" font="27">None</text>
<text top="311" left="652" width="22" height="9" font="27">None</text>
<text top="311" left="764" width="22" height="9" font="27">None</text>
<text top="311" left="866" width="22" height="9" font="27">None</text>
<text top="311" left="960" width="22" height="9" font="27">None</text>
<text top="390" left="59" width="49" height="9" font="27">Patrick T. O</text>
<text top="389" left="108" width="21" height="12" font="27">’Gara</text>
<text top="390" left="148" width="74" height="9" font="27">Content Reviewer</text>
<text top="389" left="222" width="7" height="12" font="27">—</text>
<text top="402" left="145" width="87" height="9" font="27">ACC/AHA Task Force</text>
<text top="414" left="149" width="79" height="9" font="27">on Clinical Practice</text>
<text top="426" left="167" width="43" height="9" font="27">Guidelines</text>
<text top="390" left="248" width="99" height="9" font="27">Harvard Medical School</text>
<text top="389" left="346" width="7" height="12" font="27">—</text>
<text top="402" left="254" width="94" height="9" font="27">Professor of Medicine;</text>
<text top="414" left="254" width="87" height="9" font="27">Brigham and Women</text>
<text top="412" left="341" width="6" height="12" font="27">’s</text>
<text top="426" left="242" width="34" height="9" font="27">Hospital</text>
<text top="424" left="276" width="83" height="12" font="27">—Director, Strategic</text>
<text top="438" left="249" width="102" height="9" font="27">Planning, Cardiovascular</text>
<text top="450" left="284" width="32" height="9" font="27">Division</text>
<text top="390" left="401" width="22" height="9" font="27">None</text>
<text top="390" left="486" width="22" height="9" font="27">None</text>
<text top="390" left="562" width="22" height="9" font="27">None</text>
<text top="390" left="652" width="22" height="9" font="27">None</text>
<text top="389" left="721" width="6" height="10" font="28">n</text>
<text top="390" left="735" width="54" height="9" font="27">MEDTRONIC</text>
<text top="402" left="721" width="6" height="10" font="28">n</text>
<text top="403" left="735" width="16" height="9" font="27"><a href="e127.full.html#122">NIH</a></text>
<text top="403" left="751" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="390" left="866" width="22" height="9" font="27">None</text>
<text top="390" left="960" width="22" height="9" font="27">None</text>
<text top="469" left="59" width="62" height="9" font="27">Suzanne Oparil</text>
<text top="469" left="151" width="74" height="9" font="27">Content Reviewer</text>
<text top="469" left="249" width="104" height="9" font="27">University of Alabama at</text>
<text top="481" left="244" width="50" height="9" font="27">Birmingham</text>
<text top="480" left="294" width="63" height="12" font="27">—Distinguished</text>
<text top="493" left="254" width="94" height="9" font="27">Professor of Medicine;</text>
<text top="505" left="264" width="72" height="9" font="27">Professor of Cell,</text>
<text top="517" left="260" width="82" height="9" font="27">Developmental and</text>
<text top="529" left="242" width="118" height="9" font="27">Integrative Biology, Division</text>
<text top="541" left="272" width="56" height="9" font="27">of Cardiology</text>
<text top="468" left="372" width="6" height="10" font="28">n</text>
<text top="469" left="386" width="36" height="9" font="27">Actelion</text>
<text top="481" left="372" width="6" height="10" font="28">n</text>
<text top="482" left="386" width="42" height="9" font="27">Lundbeck</text>
<text top="494" left="372" width="6" height="10" font="28">n</text>
<text top="494" left="386" width="62" height="9" font="27">Novo Nordisk,</text>
<text top="506" left="386" width="16" height="9" font="27">Inc.</text>
<text top="469" left="486" width="22" height="9" font="27">None</text>
<text top="469" left="562" width="22" height="9" font="27">None</text>
<text top="468" left="618" width="6" height="10" font="28">n</text>
<text top="469" left="632" width="54" height="9" font="27">AstraZeneca</text>
<text top="481" left="632" width="76" height="9" font="27">(Duke University)</text>
<text top="481" left="708" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="492" left="618" width="6" height="10" font="28">n</text>
<text top="493" left="632" width="75" height="9" font="27">Bayer Healthcare</text>
<text top="505" left="632" width="74" height="9" font="27">Pharmaceuticals,</text>
<text top="517" left="632" width="16" height="9" font="27">Inc.</text>
<text top="517" left="648" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="528" left="618" width="6" height="10" font="28">n</text>
<text top="528" left="632" width="37" height="9" font="27">Novartis</text>
<text top="528" left="669" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="540" left="618" width="6" height="10" font="28">n</text>
<text top="541" left="632" width="16" height="9" font="27">NIH</text>
<text top="541" left="649" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="468" left="721" width="6" height="10" font="28">n</text>
<text top="469" left="735" width="51" height="9" font="27">NIH/NHLBI,</text>
<text top="481" left="721" width="6" height="10" font="28">n</text>
<text top="482" left="735" width="98" height="9" font="27">Takeda WHF/ESH/EPH</text>
<text top="469" left="866" width="22" height="9" font="27">None</text>
<text top="469" left="960" width="22" height="9" font="27">None</text>
<text top="561" left="59" width="47" height="9" font="27">Carl Pepine</text>
<text top="561" left="148" width="74" height="9" font="27">Content Reviewer</text>
<text top="559" left="222" width="7" height="12" font="27">—</text>
<text top="573" left="144" width="90" height="9" font="27">CV Disease in Women</text>
<text top="585" left="166" width="46" height="9" font="27">Committee</text>
<text top="561" left="239" width="123" height="9" font="27">Shands Hospital at University</text>
<text top="573" left="251" width="40" height="9" font="27">of Florida</text>
<text top="571" left="292" width="58" height="12" font="27">—Professor of</text>
<text top="585" left="263" width="76" height="9" font="27">Medicine, Chief of</text>
<text top="597" left="250" width="100" height="9" font="27">Cardiovascular Medicine</text>
<text top="561" left="401" width="22" height="9" font="27">None</text>
<text top="561" left="486" width="22" height="9" font="27">None</text>
<text top="561" left="562" width="22" height="9" font="27">None</text>
<text top="560" left="618" width="6" height="10" font="28">n</text>
<text top="561" left="632" width="58" height="9" font="27">Capricor, Inc.</text>
<text top="573" left="618" width="6" height="10" font="28">n</text>
<text top="574" left="632" width="16" height="9" font="27">NIH</text>
<text top="585" left="618" width="6" height="10" font="28">n</text>
<text top="586" left="632" width="74" height="9" font="27">Cytori Therapeu-</text>
<text top="598" left="632" width="37" height="9" font="27">tics, Inc.</text>
<text top="609" left="618" width="6" height="10" font="28">n</text>
<text top="610" left="632" width="21" height="9" font="27">Sano</text>
<text top="608" left="653" width="42" height="12" font="27">ﬁ-Aventis</text>
<text top="625" left="618" width="6" height="10" font="28">n</text>
<text top="626" left="632" width="74" height="9" font="27">InVentive Health</text>
<text top="638" left="632" width="54" height="9" font="27">Clinical. LLC</text>
<text top="561" left="764" width="22" height="9" font="27">None</text>
<text top="561" left="866" width="22" height="9" font="27">None</text>
<text top="561" left="960" width="22" height="9" font="27">None</text>
<text top="658" left="59" width="75" height="9" font="27">Mahboob Rahman</text>
<text top="658" left="151" width="74" height="9" font="27">Content Reviewer</text>
<text top="658" left="254" width="92" height="9" font="27">Case Western Reserve</text>
<text top="669" left="258" width="84" height="9" font="27">University School of</text>
<text top="681" left="253" width="37" height="9" font="27">Medicine</text>
<text top="680" left="290" width="58" height="12" font="27">—Professor of</text>
<text top="693" left="282" width="37" height="9" font="27">Medicine</text>
<text top="658" left="401" width="22" height="9" font="27">None</text>
<text top="658" left="486" width="22" height="9" font="27">None</text>
<text top="658" left="562" width="22" height="9" font="27">None</text>
<text top="658" left="652" width="22" height="9" font="27">None</text>
<text top="658" left="764" width="22" height="9" font="27">None</text>
<text top="658" left="866" width="22" height="9" font="27">None</text>
<text top="658" left="960" width="22" height="9" font="27">None</text>
<text top="714" left="915" width="105" height="8" font="30">Continued on the next page</text>
<text top="105" left="59" width="158" height="16" font="31">APPENDIX 2. CONTINUED</text>
<text top="100" left="1100" width="0" height="9" font="13">Whelton</text>
<text top="139" left="1100" width="0" height="9" font="13">et</text>
<text top="150" left="1100" width="0" height="9" font="13">al</text>
<text top="158" left="1100" width="0" height="9" font="13">.</text>
<text top="667" left="1102" width="0" height="7" font="9">J</text>
<text top="672" left="1102" width="0" height="7" font="9">A</text>
<text top="679" left="1102" width="0" height="7" font="9">C</text>
<text top="685" left="1102" width="0" height="7" font="9">C</text>
<text top="695" left="1102" width="0" height="7" font="9">VO</text>
<text top="709" left="1102" width="0" height="7" font="9">L.</text>
<text top="721" left="1102" width="0" height="7" font="9">71,</text>
<text top="738" left="1102" width="0" height="7" font="9">N</text>
<text top="745" left="1102" width="0" height="7" font="9">O</text>
<text top="752" left="1102" width="0" height="7" font="9">.</text>
<text top="759" left="1102" width="0" height="7" font="9">19,</text>
<text top="776" left="1102" width="0" height="7" font="9">2</text>
<text top="781" left="1102" width="0" height="7" font="9">018</text>
<text top="100" left="1085" width="0" height="9" font="13">2017</text>
<text top="124" left="1085" width="0" height="9" font="13">High</text>
<text top="146" left="1085" width="0" height="9" font="13">Blood</text>
<text top="173" left="1085" width="0" height="9" font="13">Pressure</text>
<text top="212" left="1085" width="0" height="9" font="13">Clinical</text>
<text top="245" left="1085" width="0" height="9" font="13">Practice</text>
<text top="281" left="1085" width="0" height="9" font="13">Guideline</text>
<text top="688" left="1087" width="0" height="7" font="9">M</text>
<text top="695" left="1087" width="0" height="7" font="9">A</text>
<text top="702" left="1087" width="0" height="7" font="9">Y</text>
<text top="712" left="1087" width="0" height="7" font="9">1</text>
<text top="716" left="1087" width="0" height="7" font="9">5</text>
<text top="722" left="1087" width="0" height="7" font="9">,</text>
<text top="729" left="1087" width="0" height="7" font="9">20</text>
<text top="741" left="1087" width="0" height="7" font="9">18:</text>
<text top="754" left="1087" width="0" height="7" font="9">e</text>
<text top="760" left="1087" width="0" height="7" font="9">127</text>
<text top="773" left="1087" width="0" height="10" font="9">–</text>
<text top="780" left="1087" width="0" height="7" font="9">24</text>
<text top="792" left="1087" width="0" height="7" font="9">8</text>
<text top="50" left="1101" width="0" height="9" font="4">e246</text>
</page>
<page number="121" position="absolute" top="0" left="0" height="864" width="1160">
<text top="136" left="59" width="42" height="9" font="27">Reviewer</text>
<text top="136" left="153" width="71" height="9" font="27">Representation</text>
<text top="136" left="271" width="58" height="9" font="27">Employment</text>
<text top="136" left="387" width="50" height="9" font="27">Consultant</text>
<text top="124" left="476" width="42" height="9" font="27">Speakers</text>
<text top="136" left="481" width="32" height="9" font="27">Bureau</text>
<text top="112" left="546" width="53" height="9" font="27">Ownership/</text>
<text top="124" left="544" width="59" height="9" font="27">Partnership/</text>
<text top="136" left="553" width="41" height="9" font="27">Principal</text>
<text top="136" left="620" width="85" height="9" font="27">Personal Research</text>
<text top="112" left="744" width="60" height="9" font="27">Institutional,</text>
<text top="124" left="718" width="113" height="9" font="27">Organizational, or Other</text>
<text top="136" left="736" width="67" height="9" font="27">Financial Bene</text>
<text top="134" left="803" width="10" height="12" font="27">ﬁt</text>
<text top="136" left="842" width="71" height="9" font="27">Expert Witness</text>
<text top="136" left="957" width="28" height="9" font="27">Salary</text>
<text top="152" left="59" width="55" height="9" font="27">Vankata Ram</text>
<text top="152" left="151" width="74" height="9" font="27">Content Reviewer</text>
<text top="152" left="247" width="107" height="9" font="27">UT Southwestern Medical</text>
<text top="164" left="243" width="114" height="9" font="27">Center; Apollo Institute for</text>
<text top="176" left="254" width="92" height="9" font="27">Blood Pressure Clinics</text>
<text top="152" left="401" width="22" height="9" font="27">None</text>
<text top="152" left="486" width="22" height="9" font="27">None</text>
<text top="152" left="562" width="22" height="9" font="27">None</text>
<text top="152" left="651" width="22" height="9" font="27">None</text>
<text top="152" left="763" width="22" height="9" font="27">None</text>
<text top="152" left="866" width="22" height="9" font="27">None</text>
<text top="152" left="960" width="22" height="9" font="27">None</text>
<text top="195" left="59" width="61" height="9" font="27">Barbara Riegel</text>
<text top="195" left="148" width="74" height="9" font="27">Content Reviewer</text>
<text top="194" left="222" width="7" height="12" font="27">—</text>
<text top="207" left="145" width="87" height="9" font="27">ACC/AHA Task Force</text>
<text top="219" left="149" width="79" height="9" font="27">on Clinical Practice</text>
<text top="231" left="167" width="43" height="9" font="27">Guidelines</text>
<text top="195" left="245" width="110" height="9" font="27">University of Pennsylvania</text>
<text top="207" left="240" width="121" height="9" font="27">School of Nursing- Professor</text>
<text top="195" left="401" width="22" height="9" font="27">None</text>
<text top="195" left="486" width="22" height="9" font="27">None</text>
<text top="195" left="562" width="22" height="9" font="27">None</text>
<text top="194" left="618" width="6" height="10" font="28">n</text>
<text top="195" left="632" width="72" height="9" font="27">Co-Investigator-</text>
<text top="207" left="631" width="32" height="9" font="27">mentor</text>
<text top="205" left="663" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="218" left="618" width="6" height="10" font="28">n</text>
<text top="219" left="632" width="68" height="9" font="27">Co-investigator</text>
<text top="231" left="631" width="16" height="9" font="27">NIH</text>
<text top="242" left="618" width="6" height="10" font="28">n</text>
<text top="242" left="632" width="43" height="9" font="27">NIH grant</text>
<text top="254" left="618" width="6" height="10" font="28">n</text>
<text top="255" left="632" width="27" height="9" font="27">PCORI</text>
<text top="197" left="720" width="6" height="10" font="28">n</text>
<text top="198" left="735" width="60" height="9" font="27">Novartis Corp</text>
<text top="196" left="795" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="195" left="866" width="22" height="9" font="27">None</text>
<text top="195" left="960" width="22" height="9" font="27">None</text>
<text top="275" left="59" width="69" height="9" font="27">Edward Roccella</text>
<text top="275" left="151" width="74" height="9" font="27">Content Reviewer</text>
<text top="275" left="246" width="108" height="9" font="27">National Heart, Lung, and</text>
<text top="287" left="273" width="62" height="9" font="27">Blood Institute</text>
<text top="286" left="335" width="7" height="12" font="27">—</text>
<text top="299" left="252" width="111" height="9" font="27">Coordinator, National High</text>
<text top="311" left="254" width="107" height="9" font="27">Blood Pressure Education</text>
<text top="323" left="290" width="35" height="9" font="27">Program</text>
<text top="274" left="372" width="6" height="10" font="28">n</text>
<text top="275" left="386" width="70" height="9" font="27">Medical Univer-</text>
<text top="287" left="385" width="56" height="9" font="27">sity of South</text>
<text top="299" left="385" width="36" height="9" font="27">Carolina</text>
<text top="275" left="486" width="22" height="9" font="27">None</text>
<text top="275" left="562" width="22" height="9" font="27">None</text>
<text top="275" left="651" width="22" height="9" font="27">None</text>
<text top="277" left="720" width="6" height="10" font="28">n</text>
<text top="278" left="735" width="88" height="9" font="27">American Society of</text>
<text top="290" left="734" width="58" height="9" font="27">Hypertension</text>
<text top="288" left="793" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="301" left="720" width="6" height="10" font="28">n</text>
<text top="302" left="735" width="66" height="9" font="27">Consortium for</text>
<text top="314" left="734" width="92" height="9" font="27">Southeast Hyperten-</text>
<text top="326" left="734" width="54" height="9" font="27">sion Control</text>
<text top="324" left="788" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="340" left="720" width="6" height="10" font="28">n</text>
<text top="341" left="735" width="97" height="9" font="27">Consortium Southeast</text>
<text top="353" left="734" width="94" height="9" font="27">Hypertension Control</text>
<text top="363" left="720" width="6" height="10" font="28">n</text>
<text top="364" left="735" width="90" height="9" font="27">Inter American Soci-</text>
<text top="376" left="734" width="88" height="9" font="27">ety of Hypertensio<a href="e127.full.html#122">n</a></text>
<text top="375" left="822" width="5" height="12" font="29"><a href="e127.full.html#122">†</a></text>
<text top="275" left="866" width="22" height="9" font="27">None</text>
<text top="275" left="960" width="22" height="9" font="27">None</text>
<text top="395" left="59" width="69" height="9" font="27">Ernesto Schiffrin</text>
<text top="395" left="151" width="74" height="9" font="27">Content Reviewer</text>
<text top="395" left="247" width="100" height="9" font="27">Jewish General Hospital</text>
<text top="394" left="347" width="7" height="12" font="27">—</text>
<text top="407" left="243" width="113" height="9" font="27">Physician-in-Chief, Chief of</text>
<text top="419" left="241" width="118" height="9" font="27">the Department of Medicine</text>
<text top="431" left="260" width="80" height="9" font="27">and Director of the</text>
<text top="443" left="246" width="108" height="9" font="27">Cardiovascular Prevention</text>
<text top="455" left="245" width="104" height="9" font="27">Centre; McGill University</text>
<text top="453" left="349" width="7" height="12" font="27">—</text>
<text top="467" left="247" width="106" height="9" font="27">Professor, Department of</text>
<text top="479" left="257" width="87" height="9" font="27">Medicine, Division of</text>
<text top="491" left="253" width="95" height="9" font="27">Experimental Medicine</text>
<text top="394" left="372" width="6" height="10" font="28">n</text>
<text top="395" left="386" width="36" height="9" font="27">Novartis</text>
<text top="407" left="372" width="6" height="10" font="28">n</text>
<text top="408" left="386" width="30" height="9" font="27">Servier</text>
<text top="394" left="466" width="6" height="10" font="28">n</text>
<text top="395" left="480" width="37" height="9" font="27">Novartis</text>
<text top="395" left="562" width="22" height="9" font="27">None</text>
<text top="394" left="618" width="6" height="10" font="28">n</text>
<text top="395" left="632" width="30" height="9" font="27">Servie<a href="e127.full.html#122">r</a></text>
<text top="395" left="662" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="407" left="618" width="6" height="10" font="28">n</text>
<text top="408" left="632" width="55" height="9" font="27">Canadian In-</text>
<text top="420" left="631" width="80" height="9" font="27">stitutes for Health</text>
<text top="432" left="631" width="39" height="9" font="27">Research</text>
<text top="432" left="671" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="394" left="720" width="6" height="10" font="28">n</text>
<text top="395" left="735" width="86" height="9" font="27">CME Medical Grand</text>
<text top="407" left="734" width="32" height="9" font="27">Rounds</text>
<text top="395" left="866" width="22" height="9" font="27">None</text>
<text top="395" left="960" width="22" height="9" font="27">None</text>
<text top="511" left="59" width="39" height="9" font="27">Raymond</text>
<text top="523" left="73" width="42" height="9" font="27">Townsend</text>
<text top="511" left="151" width="74" height="9" font="27">Content Reviewer</text>
<text top="511" left="245" width="110" height="9" font="27">University of Pennsylvania</text>
<text top="523" left="237" width="80" height="9" font="27">School of Medicine</text>
<text top="521" left="317" width="46" height="12" font="27">—Professor</text>
<text top="535" left="255" width="91" height="9" font="27">of Medicine; Director,</text>
<text top="547" left="254" width="92" height="9" font="27">Hypertension Section,</text>
<text top="559" left="252" width="97" height="9" font="27">Department of Internal</text>
<text top="571" left="240" width="120" height="9" font="27">Medicine/Renal; Institute for</text>
<text top="583" left="244" width="112" height="9" font="27">Translational Medicine and</text>
<text top="595" left="253" width="53" height="9" font="27">Therapeutics</text>
<text top="593" left="306" width="41" height="12" font="27">—Member</text>
<text top="510" left="372" width="6" height="10" font="28">n</text>
<text top="511" left="386" width="54" height="9" font="27">MEDTRONIC</text>
<text top="511" left="486" width="22" height="9" font="27">None</text>
<text top="511" left="562" width="22" height="9" font="27">None</text>
<text top="510" left="618" width="6" height="10" font="28">n</text>
<text top="511" left="632" width="16" height="9" font="27">NIH</text>
<text top="511" left="648" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="510" left="720" width="6" height="10" font="28">n</text>
<text top="511" left="735" width="18" height="9" font="27">ASN</text>
<text top="523" left="720" width="6" height="10" font="28">n</text>
<text top="523" left="735" width="44" height="9" font="27">UpToDate</text>
<text top="511" left="866" width="22" height="9" font="27">None</text>
<text top="511" left="960" width="22" height="9" font="27">None</text>
<text top="614" left="915" width="105" height="8" font="30">Continued on the next page</text>
<text top="60" left="59" width="158" height="16" font="31">APPENDIX 2. CONTINUED</text>
<text top="57" left="1102" width="0" height="7" font="9">J</text>
<text top="63" left="1102" width="0" height="7" font="9">A</text>
<text top="69" left="1102" width="0" height="7" font="9">CC</text>
<text top="86" left="1102" width="0" height="7" font="9">VO</text>
<text top="99" left="1102" width="0" height="7" font="9">L.</text>
<text top="112" left="1102" width="0" height="7" font="9">7</text>
<text top="117" left="1102" width="0" height="7" font="9">1</text>
<text top="121" left="1102" width="0" height="7" font="9">,</text>
<text top="129" left="1102" width="0" height="7" font="9">N</text>
<text top="135" left="1102" width="0" height="7" font="9">O</text>
<text top="142" left="1102" width="0" height="7" font="9">.</text>
<text top="149" left="1102" width="0" height="7" font="9">1</text>
<text top="154" left="1102" width="0" height="7" font="9">9</text>
<text top="159" left="1102" width="0" height="7" font="9">,</text>
<text top="166" left="1102" width="0" height="7" font="9">2</text>
<text top="172" left="1102" width="0" height="7" font="9">01</text>
<text top="182" left="1102" width="0" height="7" font="9">8</text>
<text top="690" left="1100" width="0" height="9" font="13">Whelton</text>
<text top="728" left="1100" width="0" height="9" font="13">et</text>
<text top="739" left="1100" width="0" height="9" font="13">al</text>
<text top="747" left="1100" width="0" height="9" font="13">.</text>
<text top="57" left="1087" width="0" height="7" font="9">MA</text>
<text top="71" left="1087" width="0" height="7" font="9">Y</text>
<text top="81" left="1087" width="0" height="7" font="9">1</text>
<text top="86" left="1087" width="0" height="7" font="9">5,</text>
<text top="98" left="1087" width="0" height="7" font="9">2</text>
<text top="104" left="1087" width="0" height="7" font="9">0</text>
<text top="110" left="1087" width="0" height="7" font="9">1</text>
<text top="114" left="1087" width="0" height="7" font="9">8</text>
<text top="120" left="1087" width="0" height="7" font="9">:e</text>
<text top="129" left="1087" width="0" height="7" font="9">1</text>
<text top="133" left="1087" width="0" height="7" font="9">2</text>
<text top="139" left="1087" width="0" height="7" font="9">7</text>
<text top="142" left="1087" width="0" height="10" font="9">–</text>
<text top="149" left="1087" width="0" height="7" font="9">24</text>
<text top="161" left="1087" width="0" height="7" font="9">8</text>
<text top="531" left="1085" width="0" height="9" font="13">2017</text>
<text top="554" left="1085" width="0" height="9" font="13">High</text>
<text top="576" left="1085" width="0" height="9" font="13">Blood</text>
<text top="604" left="1085" width="0" height="9" font="13">Pressure</text>
<text top="642" left="1085" width="0" height="9" font="13">Clinical</text>
<text top="675" left="1085" width="0" height="9" font="13">Practice</text>
<text top="711" left="1085" width="0" height="9" font="13">Guideline</text>
<text top="781" left="1101" width="0" height="9" font="4">e247</text>
</page>
<page number="122" position="absolute" top="0" left="0" height="864" width="1160">
	<fontspec id="32" size="6" family="Times" color="#327eb1"/>
<text top="179" left="60" width="43" height="9" font="27">Reviewer</text>
<text top="179" left="154" width="71" height="9" font="27">Representation</text>
<text top="179" left="272" width="58" height="9" font="27">Employment</text>
<text top="179" left="388" width="50" height="9" font="27">Consultant</text>
<text top="167" left="477" width="42" height="9" font="27">Speakers</text>
<text top="179" left="482" width="32" height="9" font="27">Bureau</text>
<text top="155" left="547" width="53" height="9" font="27">Ownership/</text>
<text top="167" left="545" width="58" height="9" font="27">Partnership/</text>
<text top="179" left="554" width="41" height="9" font="27">Principal</text>
<text top="179" left="621" width="85" height="9" font="27">Personal Research</text>
<text top="155" left="745" width="60" height="9" font="27">Institutional,</text>
<text top="167" left="719" width="113" height="9" font="27">Organizational, or Other</text>
<text top="179" left="737" width="67" height="9" font="27">Financial Bene</text>
<text top="177" left="804" width="10" height="12" font="27">ﬁt</text>
<text top="179" left="843" width="71" height="9" font="27">Expert Witness</text>
<text top="179" left="958" width="28" height="9" font="27">Salary</text>
<text top="197" left="60" width="62" height="9" font="27">Michael Weber</text>
<text top="197" left="152" width="74" height="9" font="27">Content Reviewer</text>
<text top="197" left="243" width="117" height="9" font="27">SUNY Downstate College of</text>
<text top="209" left="254" width="37" height="9" font="27">Medicine</text>
<text top="207" left="291" width="58" height="12" font="27">—Professor of</text>
<text top="221" left="283" width="37" height="9" font="27">Medicine</text>
<text top="198" left="373" width="6" height="10" font="28">n</text>
<text top="199" left="387" width="36" height="9" font="27">Ablative</text>
<text top="211" left="386" width="41" height="9" font="27">So<a href="e127.full.html#122">lutions</a></text>
<text top="211" left="427" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="222" left="373" width="6" height="10" font="28">n</text>
<text top="222" left="387" width="56" height="9" font="27">Allergan, Inc</text>
<text top="234" left="373" width="6" height="10" font="28">n</text>
<text top="235" left="387" width="71" height="9" font="27">Astellas Pharma</text>
<text top="247" left="386" width="12" height="9" font="27"><a href="e127.full.html#122">US</a></text>
<text top="247" left="398" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="258" left="373" width="6" height="10" font="28">n</text>
<text top="259" left="387" width="31" height="9" font="27">Boston</text>
<text top="271" left="386" width="29" height="9" font="27">Scienti</text>
<text top="269" left="416" width="10" height="12" font="27">ﬁc</text>
<text top="271" left="426" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="282" left="373" width="6" height="10" font="28">n</text>
<text top="283" left="387" width="52" height="9" font="27">Eli Lilly and</text>
<text top="295" left="386" width="40" height="9" font="27">Company</text>
<text top="305" left="373" width="6" height="10" font="28">n</text>
<text top="306" left="387" width="54" height="9" font="27">MEDTRONIC</text>
<text top="306" left="441" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="318" left="373" width="6" height="10" font="28">n</text>
<text top="319" left="387" width="37" height="9" font="27">Novartis</text>
<text top="331" left="373" width="6" height="10" font="28">n</text>
<text top="332" left="387" width="25" height="9" font="27">Recor</text>
<text top="196" left="467" width="6" height="10" font="28">n</text>
<text top="196" left="481" width="38" height="9" font="27">Menarini</text>
<text top="196" left="519" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="208" left="467" width="6" height="10" font="28">n</text>
<text top="209" left="481" width="36" height="9" font="27">Merck &amp;</text>
<text top="221" left="480" width="36" height="9" font="27">Co., Inc.</text>
<text top="221" left="517" width="4" height="9" font="29"><a href="e127.full.html#122">*</a></text>
<text top="197" left="563" width="22" height="9" font="27">None</text>
<text top="197" left="652" width="22" height="9" font="27">None</text>
<text top="197" left="764" width="22" height="9" font="27">None</text>
<text top="197" left="867" width="22" height="9" font="27">None</text>
<text top="197" left="961" width="22" height="9" font="27">None</text>
<text top="356" left="60" width="959" height="8" font="30">This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review, including those not deemed to be relevant to this document, at the time this document was under review. The table does</text>
<text top="368" left="60" width="68" height="8" font="30">not necessarily re</text>
<text top="367" left="127" width="891" height="11" font="30">ﬂect relationships with industry at the time of publication. A person is deemed to have a signiﬁcant interest in a business if the interest represents ownership of $5% of the voting stock or share of the business entity, or ownership</text>
<text top="380" left="60" width="8" height="8" font="30">of</text>
<text top="379" left="69" width="949" height="11" font="30">$$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no ﬁnancial beneﬁt are also included for the</text>
<text top="392" left="60" width="674" height="8" font="30">purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Please refer to</text>
<text top="392" left="737" width="281" height="8" font="32"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/</a></text>
<text top="404" left="60" width="130" height="8" font="32"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy">relationships-with-industry-policy</a></text>
<text top="404" left="192" width="23" height="8" font="30">for de</text>
<text top="403" left="216" width="466" height="11" font="30">ﬁnitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.</text>
<text top="416" left="60" width="22" height="8" font="30">*Signi</text>
<text top="414" left="82" width="72" height="11" font="30">ﬁcant relationship.</text>
<text top="426" left="60" width="82" height="11" font="30">†No ﬁnancial beneﬁt.</text>
<text top="442" left="68" width="951" height="8" font="30">AHRQ indicates Agency for Healthcare Research and Quality; AAPA, American Academy of Physician Assistants; ACC, American College of Cardiology; ACPM, American College of Preventive Medicine; AGS, American Geriatrics Society; AHA, American</text>
<text top="454" left="60" width="959" height="8" font="30">Heart Association; APhA, American Pharmacists Association; ASH, American Society of Hypertension; ASPC, American Society for Preventive Cardiology; ABC, Association of Black Cardiologists; BOG, Board of Governors; CME, continuing medical ed-</text>
<text top="466" left="60" width="959" height="8" font="30">ucation; DSMB, Data and Safety Monitoring Board; FDA, U.S. Food and Drug Administration; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; NMA, National Medical Association; PCNA, Preventive Cardiovascular Nurses</text>
<text top="478" left="60" width="924" height="8" font="30">Association; PCORI, Patient-Centered Outcomes Research Institute; SCAI, Society for Cardiovascular Angiography and Interventions; SUNY, State University of New York; TFPG, Task Force on Practice Guidelines; and UT, University of Texas.</text>
<text top="105" left="59" width="158" height="16" font="31">APPENDIX 2. CONTINUED</text>
<text top="100" left="1100" width="0" height="9" font="13">Whelton</text>
<text top="139" left="1100" width="0" height="9" font="13">et</text>
<text top="150" left="1100" width="0" height="9" font="13">al</text>
<text top="158" left="1100" width="0" height="9" font="13">.</text>
<text top="667" left="1102" width="0" height="7" font="9">J</text>
<text top="672" left="1102" width="0" height="7" font="9">A</text>
<text top="679" left="1102" width="0" height="7" font="9">C</text>
<text top="685" left="1102" width="0" height="7" font="9">C</text>
<text top="695" left="1102" width="0" height="7" font="9">VO</text>
<text top="709" left="1102" width="0" height="7" font="9">L.</text>
<text top="721" left="1102" width="0" height="7" font="9">71,</text>
<text top="738" left="1102" width="0" height="7" font="9">N</text>
<text top="745" left="1102" width="0" height="7" font="9">O</text>
<text top="752" left="1102" width="0" height="7" font="9">.</text>
<text top="759" left="1102" width="0" height="7" font="9">19,</text>
<text top="776" left="1102" width="0" height="7" font="9">2</text>
<text top="781" left="1102" width="0" height="7" font="9">018</text>
<text top="100" left="1085" width="0" height="9" font="13">2017</text>
<text top="124" left="1085" width="0" height="9" font="13">High</text>
<text top="146" left="1085" width="0" height="9" font="13">Blood</text>
<text top="173" left="1085" width="0" height="9" font="13">Pressure</text>
<text top="212" left="1085" width="0" height="9" font="13">Clinical</text>
<text top="245" left="1085" width="0" height="9" font="13">Practice</text>
<text top="281" left="1085" width="0" height="9" font="13">Guideline</text>
<text top="688" left="1087" width="0" height="7" font="9">M</text>
<text top="695" left="1087" width="0" height="7" font="9">A</text>
<text top="702" left="1087" width="0" height="7" font="9">Y</text>
<text top="712" left="1087" width="0" height="7" font="9">1</text>
<text top="716" left="1087" width="0" height="7" font="9">5</text>
<text top="722" left="1087" width="0" height="7" font="9">,</text>
<text top="729" left="1087" width="0" height="7" font="9">20</text>
<text top="741" left="1087" width="0" height="7" font="9">18:</text>
<text top="754" left="1087" width="0" height="7" font="9">e</text>
<text top="760" left="1087" width="0" height="7" font="9">127</text>
<text top="773" left="1087" width="0" height="10" font="9">–</text>
<text top="780" left="1087" width="0" height="7" font="9">24</text>
<text top="792" left="1087" width="0" height="7" font="9">8</text>
<text top="50" left="1101" width="0" height="9" font="4">e248</text>
</page>
<outline>
<item page="1">2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management o ...</item>
<outline>
<item page="2">Table of Contents</item>
<item page="4">Preamble</item>
<outline>
<item page="4">Intended Use</item>
<item page="4">Clinical Implementation</item>
<item page="4">Methodology and Modernization</item>
<item page="5">Selection of Writing Committee Members</item>
<item page="5">Relationships With Industry and Other Entities</item>
<item page="5">Evidence Review and Evidence Review Committees</item>
<item page="5">Guideline-Directed Management and Therapy</item>
<item page="5">Class of Recommendation and Level of Evidence</item>
</outline>
<item page="7">1. Introduction</item>
<outline>
<item page="7">1.1. Methodology and Evidence Review</item>
<item page="7">1.2. Organization of the Writing Committee</item>
<item page="8">1.3. Document Review and Approval</item>
<item page="8">1.4. Scope of the Guideline</item>
<item page="8">1.5. Abbreviations and Acronyms</item>
</outline>
<item page="8">2. BP and CVD Risk</item>
<outline>
<item page="8">2.1. Observational Relationship</item>
<item page="10">2.2. BP Components</item>
<item page="10">2.3. Population Risk</item>
<item page="10">2.4. Coexistence of Hypertension and Related Chronic Conditions</item>
</outline>
<item page="11">3. Classification of BP</item>
<outline>
<item page="11">3.1. Definition of High BP</item>
<item page="12">3.2. Lifetime Risk of Hypertension</item>
<item page="12">3.3. Prevalence of High BP</item>
<item page="13">3.4. Awareness, Treatment, and Control</item>
</outline>
<item page="14">4. Measurement of BP</item>
<outline>
<item page="14">4.1. Accurate Measurement of BP in the Office</item>
<item page="15">4.2. Out-of-Office and Self-Monitoring of BP</item>
<item page="16">4.3. Ambulatory BP Monitoring</item>
<item page="17">4.4. Masked and White Coat Hypertension</item>
</outline>
<item page="20">5. Causes of Hypertension</item>
<outline>
<item page="20">5.1. Genetic Predisposition</item>
<item page="20">5.2. Environmental Risk Factors</item>
<outline>
<item page="20">5.2.1. Overweight and Obesity</item>
<item page="21">5.2.2. Sodium Intake</item>
<item page="21">5.2.3. Potassium</item>
<item page="21">5.2.4. Physical Fitness</item>
<item page="21">5.2.5. Alcohol</item>
</outline>
<item page="21">5.3. Childhood Risk Factors and BP Tracking</item>
<item page="22">5.4. Secondary Forms of Hypertension</item>
<outline>
<item page="25">5.4.1. Drugs and Other Substances With Potential to Impair BP Control</item>
<item page="26">5.4.2. Primary Aldosteronism</item>
<item page="27">5.4.3. Renal Artery Stenosis</item>
<item page="28">5.4.4. Obstructive Sleep Apnea</item>
</outline>
</outline>
<item page="28">6. Nonpharmacological Interventions</item>
<outline>
<item page="28">6.1. Strategies</item>
<item page="29">6.2. Nonpharmacological Interventions</item>
</outline>
<item page="32">7. Patient Evaluation</item>
<outline>
<item page="33">7.1. Laboratory Tests and Other Diagnostic Procedures</item>
<item page="33">7.2. Cardiovascular Target Organ Damage</item>
</outline>
<item page="34">8. Treatment of High BP</item>
<outline>
<item page="34">8.1. Pharmacological Treatment</item>
<outline>
<item page="34">8.1.1. Initiation of Pharmacological BP Treatment in the Context of Overall CVD Risk</item>
<item page="34">8.1.2. BP Treatment Threshold and the Use of CVD Risk Estimation to Guide Drug Treatment of Hypertension</item>
<item page="37">8.1.3. Follow-Up After Initial BP Evaluation</item>
<item page="38">8.1.4. General Principles of Drug Therapy</item>
<item page="41">8.1.5. BP Goal for Patients With Hypertension</item>
<item page="42">8.1.6. Choice of Initial Medication</item>
<item page="43">8.1.6.1. Choice of Initial Monotherapy Versus Initial Combination Drug Therapy</item>
</outline>
<item page="43">8.2. Achieving BP Control in Individual Patients</item>
<item page="44">8.3. Follow-Up of BP During Antihypertensive Drug Therapy</item>
<outline>
<item page="44">8.3.1. Follow-Up After Initiating Antihypertensive Drug Therapy</item>
<item page="45">8.3.2. Monitoring Strategies to Improve Control of BP in Patients on Drug Therapy for High BP</item>
</outline>
</outline>
<item page="45">9. Hypertension in Patients With Comorbidities</item>
<outline>
<item page="46">9.1. Stable Ischemic Heart Disease</item>
<item page="47">9.2. Heart Failure</item>
<outline>
<item page="48">9.2.1. Heart Failure With Reduced Ejection Fraction</item>
<item page="48">9.2.2. Heart Failure With Preserved Ejection Fraction</item>
</outline>
<item page="49">9.3. Chronic Kidney Disease</item>
<outline>
<item page="51">9.3.1. Hypertension After Renal Transplantation</item>
</outline>
<item page="52">9.4. Cerebrovascular Disease</item>
<outline>
<item page="52">9.4.1. Acute Intracerebral Hemorrhage</item>
<item page="54">9.4.2. Acute Ischemic Stroke</item>
<item page="56">9.4.3. Secondary Stroke Prevention</item>
</outline>
<item page="58">9.5. Peripheral Artery Disease</item>
<item page="58">9.6. Diabetes Mellitus</item>
<item page="59">9.7. Metabolic Syndrome</item>
<item page="60">9.8. Atrial Fibrillation</item>
<item page="61">9.9. Valvular Heart Disease</item>
<item page="62">9.10. Aortic Disease</item>
</outline>
<item page="62">10. Special Patient Groups</item>
<outline>
<item page="62">10.1. Race and Ethnicity</item>
<outline>
<item page="63">10.1.1. Racial and Ethnic Differences in Treatment</item>
</outline>
<item page="63">10.2. Sex-Related Issues</item>
<outline>
<item page="64">10.2.1. Women</item>
<item page="64">10.2.2. Pregnancy</item>
</outline>
<item page="65">10.3. Age-Related Issues</item>
<outline>
<item page="65">10.3.1. Older Persons</item>
<item page="66">10.3.2. Children and Adolescents</item>
</outline>
</outline>
<item page="67">11. Other Considerations</item>
<outline>
<item page="67">11.1. Resistant Hypertension</item>
<item page="68">11.2. Hypertensive Crises—Emergencies and Urgencies</item>
<item page="71">11.3. Cognitive Decline and Dementia</item>
<item page="72">11.4. Sexual Dysfunction and Hypertension</item>
<item page="73">11.5. Patients Undergoing Surgical Procedures</item>
</outline>
<item page="74">12. Strategies to Improve Hypertension Treatment and Control</item>
<outline>
<item page="74">12.1. Adherence Strategies for Treatment of Hypertension</item>
<outline>
<item page="75">12.1.1. Antihypertensive Medication Adherence Strategies</item>
<item page="76">12.1.2. Strategies to Promote Lifestyle Modification</item>
<item page="76">12.1.3. Improving Quality of Care for Resource-Constrained Populations</item>
</outline>
<item page="77">12.2. Structured, Team-Based Care Interventions for Hypertension Control</item>
<item page="78">12.3. Health Information Technology–Based Strategies to Promote Hypertension Control</item>
<outline>
<item page="78">12.3.1. EHR and Patient Registries</item>
<item page="78">12.3.2. Telehealth Interventions to Improve Hypertension Control</item>
</outline>
<item page="79">12.4. Improving Quality of Care for Patients With Hypertension</item>
<outline>
<item page="79">12.4.1. Performance Measures</item>
<item page="79">12.4.2. Quality Improvement Strategies</item>
</outline>
<item page="80">12.5. Financial Incentives</item>
</outline>
<item page="81">13. The Plan of Care for Hypertension</item>
<outline>
<item page="81">13.1. Health Literacy</item>
<item page="81">13.2. Access to Health Insurance and Medication Assistance Plans</item>
<item page="81">13.3. Social and Community Services</item>
</outline>
<item page="82">14. Summary of BP Thresholds and Goals for Pharmacological Therapy</item>
<item page="82">15. Evidence Gaps and Future Directions</item>
<item page="84">Presidents and Staff</item>
<item page="85">References</item>
<item page="85">Preamble</item>
<item page="85">1. Introduction</item>
<item page="86">2. BP and CVD Risk</item>
<item page="87">3. Classification of BP</item>
<item page="88">4. Measurement of BP</item>
<item page="89">5. Causes of Hypertension</item>
<item page="92">6. Nonpharmacological Interventions</item>
<item page="95">7. Patient Evaluation</item>
<item page="95">8. Treatment of High BP</item>
<item page="99">9. Hypertension in Patients With Comorbidities</item>
<item page="105">10. Special Patient Groups</item>
<item page="107">11. Other Considerations</item>
<item page="109">12. Strategies to Improve Hypertension Treatment and Control</item>
<item page="111">13. The Plan of Care for Hypertension</item>
<item page="111">15. Evidence Gaps and Future Directions</item>
</outline>
</outline>
</pdf2xml>
